PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Krassioukov, AV; Ackery, A; Schwartz, G; Adamchik, Y; Liu, Y; Fehlings, MG				Krassioukov, AV; Ackery, A; Schwartz, G; Adamchik, Y; Liu, Y; Fehlings, MG			An in vitro model of neurotrauma in organotypic spinal cord cultures from adult mice	BRAIN RESEARCH PROTOCOLS			English	Article						trauma; spinal cord cultures; cell death; immunohistochemistry; neuroprotection	INJURY; NEURONS; TRAUMA; RAT	Cellular degeneration after spinal cord injury (SCI) involves numerous pathways. It is essential to use appropriate experimental models in order to understand the complex processes, which evolve after the initial trauma. The purpose of this study was to develop and assess an in vitro model of neurotrauma using organotypic slice culture of adult mice spinal cord. This model will facilitate the investigation of primary and secondary mechanisms of cell death that occurs after SCI We modified previously described methods for generating organotypic cultures of murine spinal cord. The viability of organotypic cultures was assessed by observing the outgrowth of neurites and by using a mitochondria dependent dye for live cells (tetrazolium dye; MTT). The morphological integrity of cultures was examined histologically by hematoxylin and eosin (H&E) staining for general morphology and with luxol fast blue (LFB) for myelin. Neuronal and glial (GFAP; CNPase) markers were used to identify neurons, astrocytes and oligodendroglia, respectively. Primary injury was achieved by using a weight drop (0.2 g) model of injury. Cell death after primary injury was attenuated by pre-treatment with two known neuroprotective agents: the AMPA/KA blocker CNQX and methylprednisolone. The nuclear markers Propidium iodide and Sytox-green, as well as the TUNEL (in situ terminal deoxytransferase-mediated dUTP nick end labeling) technique, were used as a quantitative indicators of cell death at 24, 48 and 72 h post-injury using a confocal microscope and image analysis software. This novel in vitro model of SCI is easy to reproduce, will facilitate the examination of post-trauma cell death mechanisms and the neuroprotective effects of pharmacological agents and aid in the study of transgenic murine models. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; Univ Toronto, Toronto Western Hosp, Hlth Network, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	Fehlings, MG (corresponding author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.		Ackery, Alun/B-6634-2016; Krassioukov, Andrei V/K-3131-2017	Fehlings, Michael/0000-0002-5722-6364			Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; BALENTINE JD, 1988, LAB INVEST, V58, P93; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BUNGE RP, 1993, ADV NEUROL, V59, P75; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; DELFS J, 1989, BRAIN RES, V488, P31, DOI 10.1016/0006-8993(89)90690-2; Kakulas B A, 1999, J Spinal Cord Med, V22, P119; KERKUT GA, 1995, PROG NEUROBIOL, V46, P1, DOI 10.1016/0301-0082(94)00055-M; KERKUT GA, 1965, COMP BIOCHEM PHYSIOL, V14, P167, DOI 10.1016/0010-406X(65)90017-4; Krassioukov AV, 1996, NEUROSCIENCE, V70, P211, DOI 10.1016/0306-4522(95)00294-S; Marsh DR, 2000, MOL THER, V1, P464, DOI 10.1006/mthe.2000.0061; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Van Westerlaak MGH, 2001, EXP NEUROL, V167, P393, DOI 10.1006/exnr.2000.7570; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219	15	65	67	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1385-299X			BRAIN RES PROTOC	Brain Res. Protoc.	OCT	2002	10	2					60	68	PII S1385-299X(02)00180-0	10.1016/S1385-299X(02)00180-0			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	625LW	WOS:000179818800002	12431704				2021-06-18	
J	Zausinger, S; Lumenta, DB; Pruneau, D; Schmid-Elsaesser, R; Plesnila, N; Baethmann, A				Zausinger, S; Lumenta, DB; Pruneau, D; Schmid-Elsaesser, R; Plesnila, N; Baethmann, A			Effects of LF 16-0687 Ms, a bradykinin B-2 receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia	BRAIN RESEARCH			English	Article						cerebral ischemia, focal; bradykinin; bradykinin B-2; receptor antagonization; laser-Doppler flowmetry; neuroprotection; brain edema	ARTERY OCCLUSION; BARRIER PERMEABILITY; SUBARACHNOID HEMORRHAGE; ACETYLCHOLINE-RELEASE; NERVOUS-SYSTEM; BINDING-SITES; SPINAL-CORD; INJURY; REPERFUSION; GLUTAMATE	Bradykinin, an endogenous nonapeptide produced by activation of the kallikrein-kinin system, promotes neuronal tissue damage as well as disturbances in blood-brain barrier function through activation of B-2 receptors. LF 16-0687 Ms, a non-peptide competitive bradykinin B-2 receptor antagonist, was recently found to decrease brain swelling in various models of traumatic brain injury. We have investigated the influence of LF 16-0687 Ms on the edema formation, neurological outcome, and infarct size in temporary focal cerebral ischemia in rats. Sprague-Dawley rats were subjected to MCA occlusion for 90 min by an intraluminal filament. Local CBF was bilaterally recorded by laser Doppler flowmetry. Study I: animals were assigned to one of three treatment arms (n=11 each): (a) vehicle, (b) LF 16-0687 Ms (12.0 mg/kg per day), or (c) LF 16-0687 Ms (36.0 mg/kg per day) given repetitively s.c. over 3 days. The neurological recovery was examined daily. The infarct volume was assessed histologically 7 days after ischemia. Study II: brain swelling and bilateral hemispheric water content were determined at 48 h post ischemia in eight rats, subjected to the low dose regimen as described above, and in eight vehicle-treated control animals. All treated animals showed tendency to exhibit improved neurological recovery throughout the observation period as compared to the vehicle-treated controls, while this improvement was only significant within the low dose group from postischemic days 3 to 4. Low dose LF 16-0687 Ms significantly attenuated the total and cortical infarct volume by 50 and 80%, respectively. Furthermore, postischemic swelling (-62%) and increase in water content of the infarcted brain hemisphere (-60.5%) was significantly inhibited. The present findings provide strong evidence for an involvement of bradykinin-mediated secondary brain damage following from focal cerebral ischemia. Accordingly, specific inhibition of bradykinin B-2 receptors by LF 16-0687 Ms attenuated postischemic brain swelling, improved the functional neurological recovery, and limited ischemic tissue damage, raising its potential for clinical evaluation in patients with acute stroke. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Munich, Klinikum Grosshadern, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81377 Munich, Germany; Ctr Rech, Lab Fournier, Daix, France	Zausinger, S (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurosurg, Marchioninistr 15, D-81377 Munich, Germany.		Plesnila, Nikolaus/T-7522-2019; Lumenta, David Benjamin/AAD-5935-2019	Lumenta, David Benjamin/0000-0003-0903-252X			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Ahluwalia A, 1999, TRENDS PHARMACOL SCI, V20, P100, DOI 10.1016/S0165-6147(99)01321-8; Alexandrov AV, 2001, CIRCULATION, V103, P2897, DOI 10.1161/01.CIR.103.24.2897; Araujo RC, 2001, BIOL CHEM, V382, P91, DOI 10.1515/BC.2001.014; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BERTRAND N, 1993, J CEREBR BLOOD F MET, V13, P789, DOI 10.1038/jcbfm.1993.100; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; Firlik AD, 1998, J NEUROSURG, V89, P243, DOI 10.3171/jns.1998.89.2.0243; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; FUJIWARA Y, 1989, LIFE SCI, V44, P1645, DOI 10.1016/0024-3205(89)90481-5; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; HOSLI L, 1992, NEUROSCI LETT, V148, P114, DOI 10.1016/0304-3940(92)90817-Q; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; KASUYA H, 1988, ACTA NEUROCHIR, V91, P120, DOI 10.1007/BF01424566; Krieger DW, 1999, STROKE, V30, P287, DOI 10.1161/01.STR.30.2.287; Kuroda S, 1997, CLIN NEUROSCI, V4, P199; Li FH, 1999, STROKE, V30, P2464, DOI 10.1161/01.STR.30.11.2464; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MAKEVNINA LG, 1994, BRAZ J MED BIOL RES, V27, P1955; Marceau F, 1998, PHARMACOL REV, V50, P357; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Mayhan WG, 2001, MICROCIRCULATION, V8, P89, DOI 10.1038/sj.mn.7300154; McLean PG, 2000, J EXP MED, V192, P367, DOI 10.1084/jem.192.3.367; Molina CA, 2001, STROKE, V32, P1079, DOI 10.1161/01.STR.32.5.1079; Murone C, 1996, EUR J PHARMACOL, V306, P237, DOI 10.1016/0014-2999(96)00190-2; Murone C, 1997, J COMP NEUROL, V381, P203, DOI 10.1002/(SICI)1096-9861(19970505)381:2<203::AID-CNE7>3.0.CO;2-7; ONOUE H, 1994, AM J PHYSIOL, V267, pH880; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Phillips LL, 1997, J NEUROSCI RES, V49, P197; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; PRIVITERA PJ, 1992, BRAIN RES, V577, P73, DOI 10.1016/0006-8993(92)90539-L; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V32, P39, DOI 10.1016/0162-3109(96)00007-0; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; RELTON JK, 1998, INFLAMMATORY CELLS M, P359; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; SIESJO BK, 1995, ANN THORAC SURG, V59, P1316, DOI 10.1016/0003-4975(95)00077-X; SIESJO BK, 1989, J CEREB BLOOD FLOW M, V9, P122; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; STEPHENS GJ, 1993, NEUROSCI LETT, V153, P223, DOI 10.1016/0304-3940(93)90327-H; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; XU J, 1992, J NEUROCHEM, V58, P1930, DOI 10.1111/j.1471-4159.1992.tb10071.x; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zausinger S, 2002, BRAIN RES PROTOC, V9, P112, DOI 10.1016/S1385-299X(02)00138-1; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	62	65	68	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 20	2002	950	1-2					268	278	PII S0006-8993(02)03053-6	10.1016/S0006-8993(02)03053-6			11	Neurosciences	Neurosciences & Neurology	601YU	WOS:000178477600031	12231253				2021-06-18	
J	Hammoud, DA; Wassennan, BA				Hammoud, DA; Wassennan, BA			Diffuse axonal injuries: pathophysiology and imaging	NEUROIMAGING CLINICS OF NORTH AMERICA			English	Article							TRAUMATIC BRAIN INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; INFLICTED HEAD-INJURY; FUNCTIONAL MRI; MILD; CT; NEUROPATHOLOGY; REHABILITATION; RECOVERY; FEATURES	Diffuse axonal injury (DAI) is the sequela of shear-strain injury to the brain, and occurs in almost half of serious traumatic brain injuries, both in adults and children. This article discusses the mechanism and pathophysiology of axonal shear injury as well as the clinical presentation and prognostic factors of DAI patients. The different imaging modalities are discussed, with emphasis on both classical and new modalities.	Johns Hopkins Univ, Div Neuroradiol, Sch Med, Baltimore, MD 21287 USA	Wassennan, BA (corresponding author), Johns Hopkins Univ, Div Neuroradiol, Sch Med, 600 N Wolfe St,Phipps B-100, Baltimore, MD 21287 USA.	bwasser@rad.jhu.edu	Hammoud, Dima A/C-2286-2015	Hammoud, Dima/0000-0001-7406-7871			Abo M, 2001, NEUROREPORT, V12, P1543, DOI 10.1097/00001756-200105250-00048; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cioni G, 2001, NEUROREPORT, V12, P1335, DOI 10.1097/00001756-200105250-00009; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; COTRAN R, 1999, ROBBINS PATHOLOGIC B, P1301; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 2001, MAGNETIC RESONANCE I, P1069; GOETZ CG, 1999, TXB CLIN NEUROLOGY, P1035; Graham DI, 2001, BRAIN, V124, P1261, DOI 10.1093/brain/124.7.1261; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama Y, 2000, FORENSIC SCI INT, V113, P245, DOI 10.1016/S0379-0738(00)00217-6; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; PRAYER L, 1993, ACTA RADIOL, V34, P593; TAVERAS J, 1996, NEURORADIOLOGY, P353; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	40	65	75	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1052-5149	1557-9867		NEUROIMAG CLIN N AM	Neuroimaging Clin. N. Am.	MAY	2002	12	2					205	+	PII S1052-5149(02)00011-4	10.1016/S1052-5149(02)00011-4			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	609GA	WOS:000178894200005	12391632				2021-06-18	
J	Hensler, T; Sauerland, S; Bouillon, B; Raum, A; Rixen, D; Helling, HJ; Andermahr, J; Neugebatter, EAM				Hensler, T; Sauerland, S; Bouillon, B; Raum, A; Rixen, D; Helling, HJ; Andermahr, J; Neugebatter, EAM			Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						human; multiple injuries; cytokine receptors; cytokines	FACTOR TNF RECEPTOR; ANTIINFLAMMATORY CYTOKINE; BRAIN INJURY; TRAUMA; RELEASE; SEPSIS; INDUCTION; RESPONSES; SEVERITY; PROTECT	Background. Our knowledge about the bidirectional interactions between brain and whole organism after trauma is still limited. It was the purpose of this prospective clinical study to determine the influence of severe head trauma (SHT) as well as trauma in different anatomic injury regions on posttraumatic inflammatory mediator levels from patients with multiple injuries. Methods: Thirty-five healthy controls, 33 patients with an isolated SHT, 47 patients with multiple injuries without SHT, and 45 patients with both SHT and multiple injuries were studied. The posttraumatic plasma levels of soluble tumor necrosis factor receptors p55 and p75, interleukin (IL)-6, IL-10, and polymorphonuclear neutrophil (ENIN) elastase were monitored using enzyme-linked immunosorbent assay technique. The influence of head injuries as well as thorax, abdomen, and extremity injuries on the mediator release from patients with multiple injuries was investigated by multivariate linear regression models. Results: The soluble tumor necrosis factor receptor p55/p75 ratio was significantly elevated within 3 hours of trauma in all three injury groups and returned to reference ratios after 12 hours. The lowest increase was found in patients suffering from an isolated SHT. Lowest mediator levels in this patient population were also found for IL-6, IL-10, and PININ elastase during the first 36 hours after trauma. Additional injuries to the head, thorax, abdomen, and extremity modulated mediator levels to a different degree. No specific effect was found for SHT when compared with other injury groups. Thorax injuries caused the quickest rise in mediator levels, whereas abdominal injuries significantly increased PMN elastase levels 12 to 24 hours after trauma. Conclusion: Traumatic injuries cause the liberation of various mediators, without any specific association between anatomic injury pattern and the pattern of mediator release.	Univ Cologne, Biochem & Exptl Div, Dept Surg 2, D-51109 Cologne, Germany; Univ Cologne, Clin & Policlin Trauma Hand & Reconstruct Surg, D-51109 Cologne, Germany	Neugebatter, EAM (corresponding author), Univ Cologne, Biochem & Exptl Div, Dept Surg 2, Ostmerheimer Str 200, D-51109 Cologne, Germany.			Sauerland, Stefan/0000-0003-1048-796X			ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Balogh Z, 2000, J TRAUMA, V48, P624, DOI 10.1097/00005373-200004000-00007; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Calvano SE, 1996, ARCH SURG-CHICAGO, V131, P434; CINAT ME, 1994, J AM COLL SURGEONS, V179, P529; COPE AP, 1995, IMMUNOLOGY, V84, P21; Davies MG, 1997, BRIT J SURG, V84, P920, DOI 10.1002/bjs.1800840707; DEITCH EA, 1990, J TRAUMA, V30, P184; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; ERTEL W, 1994, ARCH SURG-CHICAGO, V129, P1330; GUIRAO X, 1996, WORLD J SURG, V20, P443; Hart PH, 1996, J IMMUNOL, V157, P3672; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; LANTZ M, 1990, Cytokine, V2, P402, DOI 10.1016/1043-4666(90)90048-X; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; REGEL G, 1993, UNFALLCHIRURG, V96, P350; RUSH BF, 1988, ANN SURG, V207, P549, DOI 10.1097/00000658-198805000-00009; SAUERLAND S, 2001, CHIRURGISCHES FORUM, V30, P425; Selzman CH, 1998, SHOCK, V10, P309, DOI 10.1097/00024382-199811000-00001; *STAT BUND WIESB, 1999, GES RTOD DTSCH 1997, P1; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; STYLIANOS S, 1991, J TRAUMA, V31, P1063, DOI 10.1097/00005373-199131080-00003; TAN LR, 1993, J TRAUMA, V34, P634, DOI 10.1097/00005373-199305000-00004; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TILG H, 1994, BLOOD, V83, P113; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368	39	65	67	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2002	52	5					962	970		10.1097/00005373-200205000-00023			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	552DM	WOS:000175603600032	11988666				2021-06-18	
J	Ip, EYY; Giza, CC; Griesbach, GS; Hovda, DA				Ip, EYY; Giza, CC; Griesbach, GS; Hovda, DA			Effects of enriched environment and fluid percussion injury on dendritic arborization within the cerebral cortex of the developing rat	JOURNAL OF NEUROTRAUMA			English	Article						cortex; dendrite; development; enriched environment; fluid percussion injury; Golgi-Cox; plasticity	TRAUMATIC BRAIN-INJURY; VISUAL-CORTEX; DIFFERENTIAL EXPERIENCE; NEOCORTICAL DAMAGE; COGNITIVE FUNCTION; OCCIPITAL CORTEX; IMMATURE RAT; ADULT-RAT; COMPLEXITY; RECOVERY	We have recently demonstrated that fluid percussion injury (FPI) sustained early in life prevents the neural plasticity response associated with rearing in an enriched environment (EE). In order to determine if this reduction in plasticity capacity is reflected in alterations in dendritic arborization, the present study examined dendritic changes in response to EE, FPI, and FPI followed by EE. Twenty postnatal day 19-20 rat pups were subjected to FPI or sham injury and were subsequently housed in EE (17 days) or standard conditions. Brains were processed according to the Golgi-Cox method and were analyzed using dendritic density (Sholl) and dendritic branching analyses in frontal, parietal, and occipital cortices. Rearing in EE induced an increase in dendritic density, primarily within the occipital cortex. FPI induced an increase in dendritic density, primarily in regions remote from the injury site, namely contralateral parietal cortex and ipsilateral and contralateral occipital cortex. In injured animals subsequently housed in EE, FPI appeared to inhibit the experience-dependent dendritic density effects of EE. However, an unexpected enhancement of dendritic density was seen in the ipsilateral occipital cortex, indicating a unique response of this region based on its distance-specific sensitivity to injury-induced plasticity and its region-specific sensitivity to experience-dependent plasticity. These results suggest that dendritic changes mediate the anatomical and behavioral changes characteristic of impaired developmental plasticity following FPI, and that these changes are dependent on location within the cerebral cortex.	Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Neurosci Interdepartmental PHD Program, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA USA	Ip, EYY (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA.	eshieh@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; BLACK JE, 1987, NEUROSCI LETT, V83, P351, DOI 10.1016/0304-3940(87)90113-3; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; GLOBUS A, 1973, J COMP PHYSIOL PSYCH, V82, P175, DOI 10.1037/h0033910; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HOLLOWAY RALPH L., 1966, BRAIN RES, V2, P393, DOI 10.1016/0006-8993(66)90009-6; HYMOVITCH B, 1952, J COMP PHYSIOL PSYCH, V45, P313, DOI 10.1037/h0061535; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; JURASKA JM, 1984, DEV PSYCHOBIOL, V17, P209, DOI 10.1002/dev.420170302; JURASKA JM, 1984, BRAIN RES, V295, P27, DOI 10.1016/0006-8993(84)90812-6; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOLB B, 1987, BEHAV BRAIN RES, V26, P47, DOI 10.1016/0166-4328(87)90015-5; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; KRECH D, 1963, ARCH NEUROL-CHICAGO, V8, P403, DOI 10.1001/archneur.1963.00460040073007; Malkasian D R, 1971, Int J Neurosci, V2, P161, DOI 10.3109/00207457109146998; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Narayan RK, 1996, NEUROTRAUMA; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NYMAN AJ, 1967, J GENET PSYCHOL, V110, P31, DOI 10.1080/00221325.1967.10533713; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pascual R, 1996, BIOL NEONATE, V69, P399; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Ramon-Moliner E., 1970, CONT RES METHODS NEU, P32, DOI [10.1007/978-3-642-85986-1_3, DOI 10.1007/978-3-642-85986-1_3]; RAY OS, 1969, DEV PSYCHOL, V1, P311, DOI 10.1037/h0027661; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; ROSENZWEIG MR, 1969, BRAIN RES, V14, P427, DOI 10.1016/0006-8993(69)90120-6; Rosenzweig MR, 1996, ANNU REV PSYCHOL, V47, P1, DOI 10.1146/annurev.psych.47.1.1; ROSENZWEIG MR, 1972, MACROMOLECULES BEHAV, P205; SCHWARTZ S, 1964, J COMP PHYSIOL PSYCH, V57, P72, DOI 10.1037/h0045518; SIREVAAG AM, 1988, DEV BRAIN RES, V43, P299, DOI 10.1016/0165-3806(88)90107-1; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VOLKMAR FR, 1972, SCIENCE, V176, P1445, DOI 10.1126/science.176.4042.1445; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	48	65	68	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					573	585		10.1089/089771502753754055			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900003	12042093				2021-06-18	
J	Otani, N; Nawashiro, H; Fukui, S; Nomura, N; Yano, A; Miyazawa, T; Shima, K				Otani, N; Nawashiro, H; Fukui, S; Nomura, N; Yano, A; Miyazawa, T; Shima, K			Differential activation of mitogen-activated protein kinase pathways after traumatic brain injury in the rat hippocampus	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						MAPK; traumatic brain injury; ERK; JNK; lateral fluid percussion; hippocampus	TRANSIENT FOREBRAIN ISCHEMIA; SELECTIVE VULNERABILITY; REACTIVE ASTROCYTES; EXPRESSION; RECEPTORS; NEURONS; STRESS; APOPTOSIS; HYPOXIA	Mitogen-activated protein kinases, which play a crucial role in signal transduction, are activated by phosphorylation in response to a variety of mitogenic signals. In the present study, the authors used Western blot analysis and immunohistochemistry to show that phosphorylated extracellular signal-regulated protein kinase (p-ERK) and c-Jun NH(2)terminal kinase (p-JNK), but not p38 mitogen-activated protein kinase, significantly increased in both the neurons and astrocytes after traumatic brain injury in the rat hippocampus. Different immunoreactivities of p-ERK and p-JNK were observed in the pyramidal cell layers and dentate hilar cells immediately after traumatic brain injury. Immunoreactivity for p-JNK was uniformly induced but was only transiently induced throughout all pyramidal cell layers. However, strong immunoreactivity for p-ERK was observed in the dentate hilar cells and the damaged CA3 neurons, along with the appearance of pyknotic morphologic changes. In addition, immunoreactivity for p-ERK was seen in astrocytes surrounding dentate and CA3 pyramidal neurons 6 hours after traumatic brain injury. These findings suggest that ERK and JNK but not p38 cascades may be closely involved in signal transduction in the rat hippocampus after traumatic brain injury.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan	Otani, N (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KURINO M, 1995, J NEUROCHEM, V65, P1282; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SEGER R, 1995, FASEB J, V9, P726; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Toth Z, 1997, J NEUROSCI, V17, P8106; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	25	65	65	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2002	22	3					327	334		10.1097/00004647-200203000-00010			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	528YG	WOS:000174272800010	11891438	Bronze			2021-06-18	
J	Lewen, A; Fujimura, M; Sugawara, T; Matz, P; Copin, JC; Chan, PH				Lewen, A; Fujimura, M; Sugawara, T; Matz, P; Copin, JC; Chan, PH			Oxidative stress-dependent release of mitochondrial cytochrome c after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aconitase; cell death; head injury; outcome; reactive oxygen species; SOD2	FOCAL CEREBRAL-ISCHEMIA; COPPER/ZINC-SUPEROXIDE-DISMUTASE; PERMEABILITY TRANSITION PORE; DNA FRAGMENTATION; CASPASE ACTIVATION; MUTANT MICE; CELL-DEATH; APOPTOSIS; INDUCTION; PEROXYNITRITE	Mitochondrial cytochrome c translocation to the cytosol initiates the mitochondrial-dependent apoptotic pathway. This event has not been previously reported in traumatic; brain injury (TBI). The authors determined the expression of cytochrome c in cytosolic and mitochondrial fractions after severe TBI produced by the controlled cortical impact model in the mouse. One hour after trauma there was an increase in cytosolic cytochrome c immunoreactivity. The increases in cytosolic cytochrome c preceded DNA fragmentation, which started at 4 hours. Western blots of mitochondrial and cytosolic fractions confirmed that there was a translocation of cytochrome c from the mitochondria after TBI. Mice deficient in manganese superoxide dismutase (MnSOD) showed an increased loss of mitochondrial cytochrome c after trauma, but less apoptotic cell death 4 and 24 hours after injury compared with wild-type control mice. However, the overall cell death was increased in MnSOD mice, as illustrated by a larger cortical lesion in these animals. The results show that cytochrome c is released from the mitochondria after severe TBI partly by a free radical-dependent mechanism, and that massive mitochondrial cytochrome c release is a predictor of necrotic cell death rather than apoptosis.	Stanford Univ, Neurosurg Labs, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurosci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Neurosci Program, Sch Med, Stanford, CA 94305 USA	Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, Sch Med, Dept Neurosurg, 1201 Welch Rd,MSLS P304, Stanford, CA 94305 USA.		Lewen, Anders/A-5156-2013; Copin, Jean-Christophe/K-6890-2012	Lewen, Anders/0000-0003-4925-1348; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038653, P01NS014543, R01NS036147, R01NS025372, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 36147, NS 25372, NS 14543, NS 82386, NS 38653, NS 37530] Funding Source: Medline		Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Buki A, 2000, J NEUROSCI, V20, P2825; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Copin JC, 2000, FREE RADICAL BIO MED, V28, P1571, DOI 10.1016/S0891-5849(00)00280-X; Crapo J D, 1978, Methods Enzymol, V53, P382; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Enari M, 1998, NATURE, V391, P43; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 2000, J NEUROSCI, V20, P2817; Fujimura M, 1999, J NEUROSCI, V19, P3414; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hortelano S, 1999, FASEB J, V13, P2311; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LEIST M, 1998, BIOCHEMICA, V2, P25; LEWIN A, 2001, IN PRESS J CEREB BLO; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matz PG, 2001, STROKE, V32, P506, DOI 10.1161/01.STR.32.2.506; Matz PG, 2000, BRAIN RES, V858, P312, DOI 10.1016/S0006-8993(99)02454-3; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Murakami K, 1998, J NEUROSCI, V18, P205; Namura S, 1998, J NEUROSCI, V18, P3659; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicotera P, 1998, TOXICOL LETT, V103, P139; O'Dell DM, 2000, J NEUROSCI, V20, P4821; RINK A, 1995, AM J PATHOL, V147, P1575; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Sugawara T, 1999, J NEUROSCI, V19, part. no.; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5	38	65	67	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2001	21	8					914	920		10.1097/00004647-200108000-00003			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	459AQ	WOS:000170228000003	11487726	Bronze			2021-06-18	
J	Curtiss, G; Vanderploeg, RD; Spencer, J; Salazar, AM				Curtiss, G; Vanderploeg, RD; Spencer, J; Salazar, AM			Patterns of verbal learning and memory in traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; memory deficits; consolidation; retention; retrieval; CVLT	EPISODIC MEMORY; RETRIEVAL; COMA	CVLT and WMS-R Digit Span variables were used to calculate indexes of seven specific short- and long-term memory processes: working memory span and central executive functions, and long-term memory encoding, consolidation, retention. retrieval, control abilities. Scores on these indexes were then cluster-analyzed to determine whether subtypes of memory performance exist that correspond to deficits in these theoretical memory constructs. Parallel analyses were conducted with two large samples (N = 150 and N = 151) of individuals who had sustained a traumatic brain injury (TBI). Findings showed that TBI results in subgroups of memory disorders with specific deficits in consolidation, retention, and retrieval processes. Control problems (keeping track of list versus non-list items) only appeared in conjunction with retrieval deficits. Working memory span and central executive functioning (i.e., the ability to manipulate information in working memory) do not appear to be deficits characteristic of TBI as no such clusters emerged in the analyses. By using specific indexes of memory processes, and in contrast to previous studies, patterns of memory dysfunction were found that correspond to deficits in theoretically meaningful memory constructs.	James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; Univ S Florida, Tampa, FL USA; Henry M Jackson Fdn, Rockville, MD USA; Univ S Florida, Tampa, FL USA; Henry M Jackson Fdn, Rockville, MD USA	Curtiss, G (corresponding author), James A Haley Vet Adm Med Ctr, Phys Med & Rehabil 117,13000 N Bruce B Downs Blvd, Tampa, FL 33612 USA.		Curtiss, Glenn/ABB-5566-2020				ALBERT M S, 1981, Journal of Clinical Neuropsychology, V3, P1, DOI 10.1080/01688638108403109; Aldenderfer M.S., 1984, CLUSTER ANAL; Baddeley A.D, 1976, PSYCHOL MEMORY; BENTON AL, 1989, MULTINGUAL APHASIA; BUCKNER RL, 1995, J NEUROSCI, V15, P12; CATTELL RB, 1949, PSYCHOMETRIKA, V14, P279; CERMAK LS, 1972, NEUROPSYCHOLOGIA, V10, P89, DOI 10.1016/0028-3932(72)90045-0; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis D.C., 1991, CLIN NEUROPSYCHOL, V5, P154, DOI [DOI 10.1080/13854049108403299, 10.1080/13854049108403299]; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; FRIDLUND AJ, 1987, IBM USERS GUIDE CVTL; Golden C., 1978, STROOP COLOR WORD TE; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Harabasz, 1974, COMMUN STAT, V3, P1, DOI DOI 10.1080/03610927408827101; Hart, 1973, PATTERN CLASSIFICATI; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Heaton R., 1993, WISCONSIN CARD SORTI; KAPUR S, 1995, NEUROREPORT, V6, P1880, DOI 10.1097/00001756-199510020-00014; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Nyberg L, 1996, NATURE, V380, P715, DOI 10.1038/380715a0; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sarle W. S, 1983, A108 SAS; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	35	65	65	0	6	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-9863 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2001	7	5					574	585		10.1017/S1355617701755051			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	451XM	WOS:000169827900005	11459109				2021-06-18	
J	Statler, KD; Kochanek, PM; Dixon, CE; Alexander, HL; Warner, DS; Clark, RSB; Wisniewski, SR; Graham, SH; Jenkins, LW; Marion, DW; Safar, PJ				Statler, KD; Kochanek, PM; Dixon, CE; Alexander, HL; Warner, DS; Clark, RSB; Wisniewski, SR; Graham, SH; Jenkins, LW; Marion, DW; Safar, PJ			Isoflurane improves long-term neurologic outcome versus fentanyl after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						analgesia; anesthesia; head injury; narcotics; opioids; sedation	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; VOLATILE ANESTHETICS; FOREBRAIN ISCHEMIA; POTASSIUM CHANNELS; XENOPUS OOCYTES; RECEPTORS; AUTOREGULATION; CALCIUM; OPIATE	Despite routine nse of fentanyl in patients after traumatic brain injury (TBI), it is unclear if it is the optimal sedative/analgesic agent. Isoflurane is commonly used in experimental TBI. We hypothesized that isoflurane would be neuroprotective versus fentanyl after TBI. Rats underwent controlled cortical impact (CCI) and received 4 h of N2O/O-2 (2:1) and either fentanyl (10 mug/kg i.v. bolus, 50 mug/kg/h infusion) or isoflurane (1% by inhalation) with controlled ventilation. Shams underwent identical preparation, without CCI. Functional outcome (beam balance, beam walking, Morris water maze [MWM] tasks) was assessed over 20 days. Lesion volume and hippocampal neuron survival were quantified on day 21. Additional rats underwent identical CCI and anesthesia with intracranial pressure (ICP) monitoring, and brain water content was assessed. Motor and MWM performances were better in injured rats treated with isoflurane versus fentanyl (p < 0.05). CA1 hippocampal damage was attenuated in isoflurane-treated rats (p < 0.05). Fentanyl-treated rats had higher mean arterial blood pressure after injury (p < 0.05); however, ICP and brain water were similar between groups. Isoflurane improved functional outcome and attenuated damage to CA1 versus fentanyl in rats subjected to CCI. Isoflurane may be neuroprotective by augmenting cerebral blood flow and/or reducing excitotoxicity, not by reducing ICP or brain water content. Alternatively, fentanyl may be detrimental. Isoflurane may mask beneficial effects of novel agents tested in TBI models. Additionally, fentanyl may not be optimal early after TBI in humans.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Vet Adm Pittsburgh Hlth Ctr, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA; Duke Univ, Dept Anesthesia, Durham, NC USA	Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	kochanekpm@anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40686] Funding Source: Medline		ANTHONY BL, 1989, NEUROSCI LETT, V99, P191, DOI 10.1016/0304-3940(89)90288-7; BEAUMONT A, 1999, 11 INT S BRAIN OED M, P42; Bedell EA, 1998, J NEUROTRAUM, V15, P985, DOI 10.1089/neu.1998.15.985; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRADLEY PB, 1984, BRIT J PHARMACOL, V83, P763, DOI 10.1111/j.1476-5381.1984.tb16231.x; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1985, PEPTIDES, V6, P15, DOI 10.1016/0196-9781(85)90006-3; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; HOSSAIN MD, 1994, ANESTHESIOLOGY, V80, P1379, DOI 10.1097/00000542-199406000-00026; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kamatchi GL, 1999, BRAIN RES, V831, P85, DOI 10.1016/S0006-8993(99)01401-8; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; KISSIN I, 1983, CAN ANAESTH SOC J, V30, P623, DOI 10.1007/BF03015233; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1995, NEUROPEPTIDES, V29, P11, DOI 10.1016/0143-4179(95)90051-9; Mackensen GB, 1999, ANESTHESIOLOGY, V90, P873, DOI 10.1097/00000542-199903000-00031; Magyar J, 1996, MOL PHARMACOL, V50, P1520; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; McIntosh T K, 1986, NIDA Res Monogr, V75, P527; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Minami K, 1997, EUR J PHARMACOL, V339, P237, DOI 10.1016/S0014-2999(97)01354-X; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; MURR R, 1993, ANESTH ANALG, V77, P898; MURR R, 1995, ANESTH ANALG, V80, P1108, DOI 10.1097/00000539-199506000-00007; Neumaier J F, 1986, NIDA Res Monogr, V75, P101; NEUMAIER JF, 1988, J PHARMACOL EXP THER, V244, P564; Nietgen GW, 1998, BRIT J ANAESTH, V81, P569, DOI 10.1093/bja/81.4.569; Ohta S, 1995, Masui, V44, P1228; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; Patel PM, 1998, ANESTH ANALG, V86, P773, DOI 10.1097/00000539-199804000-00018; Rengasamy A, 1997, ANESTHESIOLOGY, V86, P689, DOI 10.1097/00000542-199703000-00022; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; STOVER J, 1999, 11 INT S BRAIN OEDEM, P141; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Tipps LB, 2000, NEUROSURGERY, V46, P596, DOI 10.1097/00006123-200003000-00015; VINK R, 1990, J NEUROSCI, V10, P3524; Winegar BD, 1996, ANESTHESIOLOGY, V85, P889, DOI 10.1097/00000542-199610000-00026; Zaharchuk G, 1999, STROKE, V30, P2197, DOI 10.1161/01.STR.30.10.2197; ZORN L, 1993, NEUROSCI LETT, V161, P81, DOI 10.1016/0304-3940(93)90145-B	57	65	66	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2000	17	12					1179	1189		10.1089/neu.2000.17.1179			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	379MB	WOS:000165644900006	11186231				2021-06-18	
J	Lu, J; Moochhala, S; Kaur, C; Ling, EA				Lu, J; Moochhala, S; Kaur, C; Ling, EA			Changes in apoptosis-related protein (p53, Bax, Bcl-2 and Fos) expression with DNA fragmentation in the central nervous system in rats after closed head injury	NEUROSCIENCE LETTERS			English	Article						closed head injury; apoptosis; transferase d-UTP nick-end labelling; Bax; Bl-2; p53; Fos; rat	CELL-DEATH; BRAIN INJURY; C-FOS; IN-VIVO; DAMAGE; INVOLVEMENT; NEURONS	This study aimed to examine the temporal profile of neuronal apoptosis in the central nervous system (CNS) following closed head injury in rat. Fos immunoreactivity was detected in neuronal nuclei in the cerebral cortex at 2 h after head injury. At 4 h, Bax protein expression was elevated with a concomitant down-regulation of Bcl-2 expression. Along with this, a marked immunoexpression of p53 was also observed in these cells. Double immunolabelling study has shown the colocalization of Bax immunoreactivity with Bcl-2 and p53. In rats killed 1 day after injury, a variable number of transferase d-UTP nick-end labelling positive cells were observed. Present findings suggest that the upregulation of p53 and a shift in the ratio of Bcl-2 to Bax may contribute to neuronal apoptosis in the CNS after closed head injury. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Def Med Res Inst, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 119260, Singapore	Lu, J (corresponding author), Def Med Res Inst, 18 Med Dr,01-06,MD2, Singapore 117597, Singapore.			MOOCHHALA, SHABBIR/0000-0003-4521-3192			Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morrison RS, 1996, J NEUROSCI, V16, P1337; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Rich KA, 1997, J NEUROBIOL, V32, P593, DOI 10.1002/(SICI)1097-4695(19970605)32:6<593::AID-NEU5>3.0.CO;2-V; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Xiang H, 1998, J NEUROSCI, V18, P1363	16	65	74	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 25	2000	290	2					89	92		10.1016/S0304-3940(00)01307-0			4	Neurosciences	Neurosciences & Neurology	347RL	WOS:000088942900002	10936684				2021-06-18	
J	Johanson, CE; Palm, DE; Primiano, MJ; McMillan, PN; Chan, P; Knuckey, NW; Stopa, EG				Johanson, CE; Palm, DE; Primiano, MJ; McMillan, PN; Chan, P; Knuckey, NW; Stopa, EG			Choroid plexus recovery after transient forebrain ischemia: Role of growth factors and other repair mechanisms	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						choroidal epithelium; lateral ventricle; cerebrospinal fluid (CSF); blood-CSF barrier; choroid plexus reperfusion injury; necrosis; epithelial restitution; growth factors and brain repair; autocrine; paracrine; CSF bulk flow; hippocampus	CEREBROSPINAL-FLUID FORMATION; RAT-BRAIN; MESSENGER-RNA; FACTOR-BETA; IMMUNOHISTOCHEMICAL LOCALIZATION; RECEPTOR IMMUNOREACTIVITY; INSITU HYBRIDIZATION; CEREBRAL-ISCHEMIA; CHLORIDE EFFLUX; ANGIOTENSIN-II	1. Transient forebrain ischemia in adult rats, induced by 10 min of bilateral carotid occlusion and an arterial hypotension of 40 mmHg, caused substantial damage not only to CA-1 neurons in hippocampus but also to epithelial cells in lateral ventricle choroid plexus. 2 When transient forebrain ischemia was followed by reperfusion (recovery) intervals of 0 to 12 hr, there was moderate to severe damage to many frond regions of the choroidal epithelium. In some areas, epithelial debris was sloughed into cerebrospinal fluid (CSF). Although some epithelial cells were disrupted and necrotic, their neighbors exhibited normal morphology. This patchy response to ischemia was probably due to regional differences in reperfusion or cellular metabolism. 3. Between 12 and 24 hr postischemia, there was marked restoration of the Na+, K+, water content, and ultrastructure of the choroid plexus epithelium. Since there was no microscopical evidence for mitosis, we postulate that healthy epithelial cells either were compressed together on the villus or migrated from the choroid plexus stalk to more distal regions, in order to "fill in gaps" along the basal lamina caused by necrotic epithelial cell disintegration. 4. Epithelial cells of mammalian choroid plexus synthesize and secrete many growth factors and other peptides that are of trophic benefit following injury to regions of the cerebroventricular system. For example, several growth factors are upregulated in choroid plexus after ischemic and traumatic insults to the central nervous system. 5. The presence of numerous types of growth factor receptors in choroid plexus allows growth factor mediation of recovery processes by autocrine and paracrine mechanisms. 6. The capability of choroid plexus after acute ischemia to recover its barrier and CSF formation functions is an important factor in stabilizing brain fluid balance. 7. Moreover, growth factors secreted by choroid plexus into CSF are distributed by diffusion and convection into brain tissue near the ventricular system, e.g., hippocampus. By this endocrine-like mechanism, growth factors are conveyed throughout the choroid plexus-CSF-brain nexus and can consequently promote repair of ischemia-damaged tissue in the ventricular wall and underlying brain.	Brown Univ, Rhode Isl Hosp, Dept Clin Neurosci, Providence, RI 02903 USA; Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA; Brown Univ, Rhode Isl Hosp, Dept Pathol, Providence, RI 02903 USA; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Neurosurg, Nedlands, WA 6009, Australia	Johanson, CE (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Clin Neurosci, 593 Eddy St, Providence, RI 02903 USA.	Conrad_Johanson@Brown.edu		Johanson, Conrad/0000-0002-1297-5484	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS/AG-91-03, NS 27601] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027601] Funding Source: NIH RePORTER		BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BASKIN DG, 1988, TRENDS NEUROSCI, V11, P107, DOI 10.1016/0166-2236(88)90155-5; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOHANNON NJ, 1988, BRAIN RES, V444, P205, DOI 10.1016/0006-8993(88)90931-6; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; Chodobski A, 1997, MOL BRAIN RES, V48, P67, DOI 10.1016/S0169-328X(97)00079-X; CHODOBSKI A, 1994, REGUL PEPTIDES, V53, P123, DOI 10.1016/0167-0115(94)90613-0; Cortez S., 1995, Society for Neuroscience Abstracts, V21, P741; CUEVAS P, 1994, NEUROL RES, V16, P310; DIAZRUIZ C, 1993, NEUROSCI LETT, V164, P44, DOI 10.1016/0304-3940(93)90853-D; ENDOH M, 1994, MOL BRAIN RES, V22, P76, DOI 10.1016/0169-328X(94)90034-5; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; GARNER C, 1992, BRAIN RES, V591, P137, DOI 10.1016/0006-8993(92)90988-L; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; GLAUMANN B, 1977, VIRCHOWS ARCH B, V24, P1; GOSPODAROWICZ D, 1975, J CELL BIOL, V66, P451, DOI 10.1083/jcb.66.2.451; HOLLOWAY LS, 1972, AM J PHYSIOL, V223, P499; HYNES MA, 1988, MOL ENDOCRINOL, V2, P47, DOI 10.1210/mend-2-1-47; IKEDA J, 1992, NEUROSCI LETT, V142, P257, DOI 10.1016/0304-3940(92)90386-L; Johanson C, 1993, PHARM BIOTECHNOLOGY, V5, P467; JOHANSON CE, 1990, AM J PHYSIOL, V258, pF1538; JOHANSON CE, 1978, J PHYSIOL-LONDON, V275, P167, DOI 10.1113/jphysiol.1978.sp012183; JOHANSON CE, 1974, J PHYSIOL-LONDON, V241, P359, DOI 10.1113/jphysiol.1974.sp010660; JOHANSON CE, 1995, NEUROSCIENCE MED, P171; JOHANSON CE, 1989, IMPLICATIONS BLOOD B, V1, P101; JOHANSON CE, 1998, INTRO BLOOD BRAIN BA, P259; JOHNSON NF, 1978, EXP EYE RES, V27, P45, DOI 10.1016/0014-4835(78)90052-0; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; KNUCKEY NW, 1995, STROKE, V26, P305, DOI 10.1161/01.STR.26.2.305; KNUCKEY NW, 1993, BRAIN RES, V618, P313, DOI 10.1016/0006-8993(93)91282-W; KOZLOWSKI GP, 1982, FRONTIERS HORMONE RE, V9, P105; LAFOND RE, 1995, TRANSGENIC RES, V4, P306, DOI 10.1007/BF01972527; LEE BCP, 1978, RADIOLOGY, V128, P647, DOI 10.1148/128.3.647; LEVINE S, 1987, LAB INVEST, V56, P231; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MAKTABI MA, 1994, STROKE, V25, P1489, DOI 10.1161/01.STR.25.7.1489; MARMOR MF, 1993, INVEST OPHTH VIS SCI, V34, P2570; MICHAEL DK, 1973, EXP NEUROL, V41, P769, DOI 10.1016/0014-4886(73)90067-8; MURPHY VA, 1985, J CEREBR BLOOD F MET, V5, P401, DOI 10.1038/jcbfm.1985.55; NAGAHIRO S, 1994, BRAIN RES, V633, P305, DOI 10.1016/0006-8993(94)91553-9; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P525, DOI 10.1038/jcbfm.1992.72; PALM D, 1995, AM J PHYSIOL-REG I, V269, pR73; PALM DE, 1995, BRAIN RES, V691, P1, DOI 10.1016/0006-8993(95)00520-Z; POLLAY M, 1974, FED PROC, V33, P2064; POLLAY M, 1985, NEUROSURGERY, V17, P768, DOI 10.1227/00006123-198511000-00007; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Riegler M, 1997, SCAND J GASTROENTERO, V32, P925, DOI 10.3109/00365529709011204; SCHREIBER G, 1990, FERNS FOUND SERIES, V14, P89; SMITH QR, 1991, BRAIN RES, V562, P306, DOI 10.1016/0006-8993(91)90636-A; SMITH QR, 1980, AM J PHYSIOL, V238, pF399; SOLEM M, 1990, BIOCHEM BIOPH RES CO, V172, P945, DOI 10.1016/0006-291X(90)90767-H; SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68; STOPA EG, 1990, ALZHEIMERS DIS BASIC, pCH37; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; VALENTINO KL, 1988, ENDOCRINOLOGY, V122, P2753, DOI 10.1210/endo-122-6-2753; VEGA JA, 1992, CELL MOL BIOL, V38, P145; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; Yanaka A, 1996, AM J PHYSIOL-GASTR L, V271, pG75	69	65	65	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	APR	2000	20	2					197	216		10.1023/A:1007097622590			20	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	283ET	WOS:000085263700006	10696510				2021-06-18	
J	Hibbard, MR; Gordon, WA; Flanagan, S; Haddad, L; Labinsky, E				Hibbard, MR; Gordon, WA; Flanagan, S; Haddad, L; Labinsky, E			Sexual dysfunction after traumatic brain injury	NEUROREHABILITATION			English	Article						traumatic brain injury; sexual dysfunction	INDIVIDUALS; MEN	Objective: The frequency of self reported sexual difficulties was examined in a group of 322 individuals with traumatic brain injury (TBI) (N = 193 men; 129 women) and contrasted with reports of sexual difficulties in 264 individuals without disability (152 men; 112 women) residing in the community. Physiological, physical, and body images problems impacting sexual functioning were examined individually and then summed into a sexual dysfunction score. Mood, quality of life, health status and presence of an endocrine disorder were examined as predictors of sexual difficulties post TBI. Study design: In this retrospective study, data about sexual difficulties were analyzed separately for men and women with TBI and without disability. ANOVAs with post hoc analysis for continuous variables, chi-square analyses for categorical variables, and ANCOVAs for predictors of sexual difficulties were utilized. Results: When contrasted to individuals without disability, individuals with TBI reported more frequent: (1) physiological difficulties influencing their energy for sex; sex drive, ability to initiate sexual activities and achieve orgasm; (2) physical difficulties influencing body positioning, body movement and sensation, and (3) body image difficulties influencing feelings of attractive and comfort with having a partner view one's body;during sexual activity. Additional gender specific TBI findings were observed. In comparison to gender matched groups without disability, men with TBI reported less frequent involvement in sexual activity and relationships, and more frequent difficulties in sustaining an erection; women with TBI reported more frequent difficulties in sexual arousal, pain with sex, masturbation and:vaginal lubrication. While groups differed in core demographic variables, age was the only demographic variable that was related to reports of sexual difficulties in individuals with TBI and men without disability. Age at onset and severity of injury were negatively related to reports of sexual difficulties in individuals with TBI. In men with TBI and without disability, the most sensitive predictor of sexual dysfunction was;level of depression. For women without disability, an endocrine disorder was the most sensitive predictor of sexual dysfunction. For women with TBI, an endocrine disorder and level depression combined were the most sensitive predictors of sexual difficulties. Conclusion: Individuals Post TBI report frequent physiological, physical and:body images difficulties which negatively impact sexual activity and interest. For men post TBI, predictors of sexual difficulties included age at interview, age at injury, and having milder injuries, however, depression was the most sensitive predictor of sexual dysfunctions. For women post TBI, predictors of their sexual difficulties included age at injury and having milder injuries, however, depression and Bn endocrine disorder combined were the most sensitive predictors of sexual dysfunction. implications of this study include the need for broad-based assessment of sexual dysfunction, and the implementation of treatment studies to enhance sexual functioning post TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Hibbard, MR (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, 1425 Madison Ave,Room L4-21, New York, NY 10029 USA.	mary.hibbard@mssm.edu	Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168			Aloni A, 1999, BRAIN INJURY, V13, P89, DOI 10.1080/026990599121755; *AM PSYCH ASS, 1994, DIAGN STAT MAN, P494; Andrews F. M., 1976, SOCIAL INDICATORS WE; BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; Bartlik B, 1999, PSYCHIAT ANN, V29, P27, DOI 10.3928/0048-5713-19990101-08; BASSON R, 1995, OBSTET GYNECOL, V4, pS54; Beck A.T., 1987, BECK DEPRESSION INVE; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Cernak I, 1999, BRAIN INJURY, V13, P1005; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Cole TM, 1990, KRUSENS HDB PHYSICAL, P988; DAVIS DL, 1990, J HEAD TRAUMA REHAB, V5, P31, DOI DOI 10.1097/00001199-199005020-00006; Dunn KM, 1999, J EPIDEMIOL COMMUN H, V53, P144, DOI 10.1136/jech.53.3.144; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Giuliano F, 1999, ANN NEUROL, V46, P15, DOI 10.1002/1531-8249(199907)46:1<15::AID-ANA5>3.0.CO;2-U; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hirschfeld RMA, 1999, J CLIN PSYCHIAT, V60, P32; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P163; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LABI MLC, 1996, MED REHAB TRAUMATIC; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; Maytom MC, 1999, SPINAL CORD, V37, P110, DOI 10.1038/sj.sc.3100803; McCarthy BW, 1998, J SEX EDUC THER, V23, P302; MCCLELLAND RJ, 1988, BRIT J PSYCHIAT, V153, P141, DOI 10.1192/bjp.153.2.141; MEYER J, 1971, J NEUROVISCERAL RE S, V10, P519; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; Porter S, 1989, PHY MED REHAB, P3143; Ravart M., 1996, CANADIAN J HUMAN SEX, V5, P279; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; SIPSKI M, 1991, SEX DISABIL, P45; SIPSKI ML, 1992, PHYS REHABIL CLIN N, V3, P811; SIPSKI ML, 1995, TOPICS SPINAL CORD I, V4, P1; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SOULAIRAC A, 1978, PSYCHONEUROENDOCRINO, V3, P17, DOI 10.1016/0306-4530(78)90038-0; *SPSS INC, 1998, SPSS WIND VERS 9 0 C; STEWARD DG, 1997, PHYS MED REHABIL CLI, V8, P827; Striar S, 1999, PSYCHIAT ANN, V29, P60, DOI 10.3928/0048-5713-19990101-13; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Ware JE., 1993, SF 36 HLTH SURVEY MA; ZEISS AM, 1999, HDB COUNSELING PSYCH, P294	45	65	66	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2000	15	2					109	120					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	406RN	WOS:000167229100004					2021-06-18	
J	Bank, U; Reinhold, D; Schneemilch, C; Kunz, D; Synowitz, HJ; Ansorge, S				Bank, U; Reinhold, D; Schneemilch, C; Kunz, D; Synowitz, HJ; Ansorge, S			Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation	JOURNAL OF INTERFERON AND CYTOKINE RESEARCH			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN INTERLEUKIN-2 RECEPTOR; TRAUMATIC BRAIN INJURY; CATHEPSIN-G; LEUKOCYTE ELASTASE; MOLECULAR-CLONING; TNF RECEPTOR; CELLS; EXPRESSION; GROWTH	Traumatic brain injuries induce a strong, locally restricted inflammatory response. Here we demonstrate that activated neutrophils infiltrate the site of tissue destruction and release large amounts of enzymatically active elastase, cathepsin G, and proteinase 3, High intracerebral protease concentrations were found to be accompanied by a reduced inhibitory potential at foci of inflammation. In 39 neurotrauma patients, a temporal correlation between the protease release from neutrophils and the solubilization of interleukin-2 (IL-2) receptor and IL-6 receptor ectodomains at sites of tissue destruction was observed, suggesting that neutrophil-derived proteases may play a crucial role in the cytokine receptor shedding at foci of inflammation. Under in vitro conditions, the cleavage of membrane-bound IL-2R alpha was found to be predominantly catalyzed by elastase and, to a lesser extent, by proteinase 3, Cathepsin G was found to be incapable of solubilizing this receptor. In contrast, the cleavage of the IL-6R 80 kDa chain was catalyzed by cathepsin G but not by elastase or proteinase 3, The receptor fragments released by the action of these enzymes were found to retain their ligand-binding capacity. These results strongly suggest a pathophysiologic role of neutrophil-derived serine proteases, particularly in regulation of the expression of functional IL-2 and IL-6 receptors at foci of inflammation.	Otto Von Guericke Univ, Inst Expt Internal Med, Ctr Internal Med, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Clin Anesthesiol & Intens Care Therapy, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Clin Chem, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Clin Neurosurg, D-39120 Magdeburg, Germany	Bank, U (corresponding author), Otto Von Guericke Univ, Inst Expt Internal Med, Ctr Internal Med, Leipziger Str 44, D-39120 Magdeburg, Germany.						Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BANGALORE N, 1994, BIOL CHEM H-S, V375, P659, DOI 10.1515/bchm3.1994.375.10.659; BANK U, 1995, INFLAMMATION, V19, P83, DOI 10.1007/BF01534383; BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BLOW AMJ, 1977, BIOCHEM J, V161, P13, DOI 10.1042/bj1610013; BORISH L, 1989, CELL IMMUNOL, V121, P280, DOI 10.1016/0008-8749(89)90026-9; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; DORING G, 1995, J IMMUNOL, V154, P4842; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; HANISCH UK, 1996, BRAIN RES REV, V21, P246; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; MCCLAIN C, 1991, J CLIN LAB MED, V118, P226; MIEDEL MC, 1989, J BIOL CHEM, V264, P21097; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NEEPER MP, 1987, J IMMUNOL, V138, P3532; NORTIER J, 1991, LIFE SCI, V49, P1879, DOI 10.1016/0024-3205(91)90288-M; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Reinhold D, 1997, IMMUNOLOGY, V91, P354, DOI 10.1046/j.1365-2567.1997.d01-2258.x; REMOLDODONNELL E, 1995, BLOOD, V86, P2395, DOI 10.1182/blood.V86.6.2395.bloodjournal8662395; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROSEN GM, 1995, FASEB J, V9, P200; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; TADA M, 1994, J NEUROSURG, V80, P1063, DOI 10.3171/jns.1994.80.6.1063; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vollmer P, 1996, INFECT IMMUN, V64, P3646, DOI 10.1128/IAI.64.9.3646-3651.1996; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	43	65	68	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	1079-9907			J INTERF CYTOK RES	J. Interferon Cytokine Res.	NOV	1999	19	11					1277	1287		10.1089/107999099312957			11	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	255RN	WOS:000083684100008	10574621				2021-06-18	
J	King, NS; Crawford, S; Wenden, FJ; Caldwell, FE; Wade, DT				King, NS; Crawford, S; Wenden, FJ; Caldwell, FE; Wade, DT			Early prediction of persisting post-concussion symptoms following mild and moderate head injuries	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							CONTROLLED TRIAL; SCALE; QUESTIONNAIRE; EPIDEMIOLOGY; SEQUELAE; RECOVERY	Objectives. King (1996) reported that a combination of emotional, organic and neuropsychological measures taken at 7-10 days following mild and moderate head injury may significantly help predict patients most likely to suffer persisting postconcussion symptoms (PCS) at three months post-injury. This study investigated a cross-validation sample (N = 57) to determine whether the results would be replicated for the early prediction of longer-term sufferers (i.e. those with persisting symptoms at 6 months post-injury). Design. Multiple regression analyses were used in which scores on the Hospital Anxiety and Depression Scale, Impact of Event Scale, Short Orientation Memory and Concentration Test, Rivermead Post-Concussion Symptoms Questionnaire and Post-Traumatic Amnesia taken at 7-10 days post-injury were the independent measures. Scoring on the Rivermead Post-Concussion Symptoms Questionnaire taken at 6 months post-injury was the dependent measure. Methods. Sixty-six consecutive patients admitted to any trauma ward in Oxfordshire with a mild or moderate head injury were recruited from a largescale randomized controlled sample. The assessment measures were administered at 7-10 days post-injury and the Rivermead Post-Concussion Symptoms Questionnaire at 6 months post-injury. Nine patients were unable to be followed up, leaving an active sample of 57. Results. The cross-validation data confirmed that a similar combination of measures to that found in the original study best predicted persisting PCS but that the strength of prediction diminished for the longer term prediction (i.e. 6 months post-injury). Conclusions. The Hospital Anxiety and Depression Scale, Impact of Event Scale and Post-Traumatic Amnesia in combination are recommended as useful prognostic screening instruments for predicting persisting PCS, but great caution is required if they are used to aid predictions beyond 3 months post-injury.	Warneford Hosp, Isis Educ Ctr, Oxford Reg Training Course Clin Psychol, Oxford OX3 7JX, England; Rivermead Rehabil Ctr, Oxford, England	King, NS (corresponding author), Warneford Hosp, Isis Educ Ctr, Oxford Reg Training Course Clin Psychol, Warneford Lane, Oxford OX3 7JX, England.			Wade, Derick/0000-0002-1188-8442			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; COUGHLAN AK, 1985, ADULT MEMORY INFORMA; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; EVANS RW, 1992, NEUROL CLIN, V10, P815; FOX DD, 1995, CLIN NEUROPSYCHOLOGI, V9, P78; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; INGEBRIGSTEN T, IN PRESS J NEUROLOGY; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACKAY R P, 1960, Ind Med Surg, V29, P200; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; TRENNERY MR, 1989, STROOP NEUROPSYCHOLO; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	65	65	0	5	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	MAR	1999	38		1				15	25		10.1348/014466599162638			11	Psychology, Clinical	Psychology	180FT	WOS:000079376000003	10212734				2021-06-18	
J	Hulsebosch, CE; DeWitt, DS; Jenkins, LW; Prough, DS				Hulsebosch, CE; DeWitt, DS; Jenkins, LW; Prough, DS			Traumatic brain injury in rats results in increased expression of Gap-43 that correlates with behavioral recovery	NEUROSCIENCE LETTERS			English	Article						GAP-43; rat; traumatic brain injury; neocortex; hippocampus	PROTEIN-KINASE-C; ADULT-RAT; REACTIVE SYNAPTOGENESIS; MODEL; MEMBRANE; LIGHT	Traumatic brain injury is associated with behavioral deficits, often in the absence of histopathological or ultrastructural changes. To determine whether membrane remodeling occurs, immunocytochemical techniques were used and the density and distribution of GAP-43 were measured. GAP-43 is a membrane-bound protein, which, when phosphorylated, is thought to regulate metabolic pathways involved in membrane remodeling and neurite growth. Moderate central fluid percussion injury (FPI, 1.9-2.2 atm.) was performed on anesthetized, spontaneously hypertensive Wistar rats (SHR). Behavioral reflex recovery was consistent with moderate levels of brain injury. One, 3, 5, 7 and 9 days after injury, both sham control (n = 4) and FPI (n = 4) animals were sacrificed, the brains were removed, cryosectioned and processed. Density measurements were taken from histological sections taken at interaural 6.20 mm and bregma -2.80 mm and were found to be statistically greater (P < 0.05) than background grey matter readings in the agranular cortices, the frontal, hindlimb, parietal 1 and 2 cortices, and the hippocampus and dentate gyrus, excluding the pyramidal and granular cell layers. Density measurements taken in forelimb and hindlimb cortical regions correlate with forelimb and hindlimb recovery in foot-fault and beam balance tests (P < 0.05). We interpret these data to indicate neuronal membrane remodeling as a result of the disruption of neuronal membranes due to the impact and shearing forces associated with the FPI. The disruption and remodeling of neuronal membranes are in areas that are consistent with the loss and recovery of locomotor and spatial behavior as a result of FPI. (C) 1998 Published by Elsevier Science Ireland Ltd. All rights reserved.	Dept Anat & Neurosci, Galveston, TX 77555 USA; Inst Marine Biomed, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Hulsebosch, CE (corresponding author), Dept Anat & Neurosci, Galveston, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 11255, NS 25450] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [S15NS025450, P01NS011255] Funding Source: NIH RePORTER		BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; COGGESHALL RE, 1991, NEUROSCI LETT, V131, P37, DOI 10.1016/0304-3940(91)90331-M; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P405; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; STROEMER RP, 1993, NEUROSCI LETT, V162, P51, DOI 10.1016/0304-3940(93)90557-2; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287	28	65	67	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 16	1998	255	2					83	86		10.1016/S0304-3940(98)00712-5			4	Neurosciences	Neurosciences & Neurology	134BT	WOS:000076723500006	9835220				2021-06-18	
J	Fisk, GD; Schneider, J; Novack, TA				Fisk, GD; Schneider, J; Novack, TA			Driving following traumatic brain injury: prevalence, exposure, advice and evaluations	BRAIN INJURY			English	Article							DAMAGE; PERFORMANCE; RECOVERY; DRIVER	Survivors of traumatic brain injury often have long-term sensory, cognitive and motor deficits that may impair vehicle operation. However, relatively little is known about the driving status and driving characteristics of brain injury survivors. To better understand driving following traumatic brain injury, a survey of driving status, driving exposure, advice received about driving and evaluations of driving competency was administered to a convenience sample of traumatic brain injury survivors (n = 83). The majority of survey participants had experienced either moderate or severe traumatic brain injuries based on the Glasgow Coma Scale. A total of 60% of the survey participants reported that they were currently active drivers. Most individuals (> 60%) who had returned to driving reported driving every day and more than 50 miles per week. Traumatic brain injury survivors frequently received advice about driving from family members, physicians or non-physician health care professionals, but over half (63%) had not been professionally evaluated for driving competency. The presence of high driving exposure, coupled with a lack of widespread driving fitness testing, suggests that some traumatic brain injury survivors have characteristics that may evaluate their risk for vehicle crashes. However, subsequent prospective studies that directly assess driver safety will be needed to confirm this possibility.	Gordon Coll, Dept Psychol, Div Business & Social Sci, Barnesville, GA 30204 USA; Birmingham So Coll, Dept Psychol, Birmingham, AL USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA	Fisk, GD (corresponding author), Gordon Coll, Dept Psychol, Div Business & Social Sci, 419 Coll Dr, Barnesville, GA 30204 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [D07420-06] Funding Source: Medline		BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; DANIEL W, 1995, BIOSTATISTICS FDN AN; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Devani Serio C., 1994, NEUROREHABILITATION, V4, P53; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DRESSER AC, 1973, ARCH NEUROL-CHICAGO, V29, P111, DOI 10.1001/archneur.1973.00490260055011; EVANS L, 1988, J GERONTOL, V43, pS186, DOI 10.1093/geronj/43.6.S186; Fisk GD, 1997, ARCH PHYS MED REHAB, V78, P1338, DOI 10.1016/S0003-9993(97)90307-5; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HANDLER BS, 1995, J REHABIL, V61, P43; HOPEWELL CA, 1990, NEUROPSYCHOLOGY EVER, P307; Johnson R, 1987, Int Disabil Stud, V9, P49; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KEITH RA, 1987, ADV CLIN REHABILITAT, P6; KIERNAN WE, 1988, VOCATIONAL REHABILIT, P221; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x; MAROTTOLI RA, 1993, J GERONTOL, V48, pS255, DOI 10.1093/geronj/48.5.S255; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; PIDIKITI RD, 1991, ARCH PHYS MED REHAB, V72, P109; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326	37	65	66	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1998	12	8					683	695					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800005	9724839				2021-06-18	
J	Pike, BR; Zhao, XR; Newcomb, JK; Wang, KKW; Posmantur, RM; Hayes, RL				Pike, BR; Zhao, XR; Newcomb, JK; Wang, KKW; Posmantur, RM; Hayes, RL			Temporal relationships between de novo protein synthesis, calpain and caspase 3-like protease activation, and DNA fragmentation during apoptosis in septo-hippocampal cultures	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						alpha-spectrin; fodrin; CPP32; cysteine proteases; brain; rat; trauma	KINASE INHIBITOR STAUROSPORINE; TRAUMATIC BRAIN INJURY; DELAYED NEURONAL DEATH; PROGRAMMED CELL-DEATH; CEREBRAL-ISCHEMIA; RAT-BRAIN; POLY(ADP-RIBOSE) POLYMERASE; GLOBAL-ISCHEMIA; NERVOUS-SYSTEM; ENDONUCLEASE	Caspase 3-like proteases are key executioners in mammalian apoptosis, and the calpain family of cysteine proteases has also been implicated as an effector of the apoptotic cascade, However, the influence of upstream events on calpain/caspase activation and the role of calpain/caspase activation on subsequent downstream events are poorly understood. This investigation examined the temporal profile of apoptosis-related events after staurosporine-induced apoptosis in mixed glial-neuronal septo-hippocampal cell cultures. Following 3 hr exposure to staurosporine (0.5 mu M), calpain and caspase 3-like proteases processed a-spectrin to their signature proteolytic fragments prior to endonuclease-mediated DNA fragmentation (not evident until 6 hr), indicating that endonuclease activation is downstream from calpain/ caspase activation, Cycloheximide, a general protein synthesis inhibitor, completely prevented processing of alpha-spectrin by calpains and caspase 3-like proteases, DNA fragmentation and cell death, indicating that de novo protein synthesis is an upstream event necessary for activation of calpains and caspase 3-like proteases, Calpain inhibitor II and the pan-caspase inhibitor Z-D-DCB each inhibited their respective protease-specific processing of alpha-spectrin and attenuated endonuclease DNA fragmentation and cell death. Thus, activation of calpains and caspase 3-like proteases is an early event in staurosporine-induced apoptosis, and synthesis of, as yet, unknown protein(s) is necessary for their activation. (C) 1998 Wiley-Liss, Inc.	Univ Texas, Dept Neurosurg, Hlth Sci Ctr, Viviam L Smith Ctr Neurol Res, Houston, TX 77030 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Ann Arbor, MI USA	Hayes, RL (corresponding author), Univ Texas, Dept Neurosurg, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Med Sch Bldg,Suite 7-154,6431 Fannin St, Houston, TX 77030 USA.	rhayes@heart.med.uth.tmc.edu		Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER		BEHRENS MM, 1995, CELL GROWTH DIFFER, V6, P1375; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Cagnoli CM, 1996, J MOL NEUROSCI, V7, P65, DOI 10.1007/BF02736849; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN JJ, 1984, J IMMUNOL, V132, P38; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CONTI AC, 1996, J NEUROTRAUM, V13, P595; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Linnik MD, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P33; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCCONKEY DJ, 1989, FASEB J, V3, P1843; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NELIPOVICH PA, 1988, INT J RADIAT BIOL, V53, P749, DOI 10.1080/09553008814551111; NEWCOMB JK, 1997, J NEUROTRAUM, V14, P763; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NITATORI T, 1995, J NEUROSCI, V15, P1001; OBERHAMMER F, 1993, J CELL SCI, V104, P317; PAPAS S, 1992, EUR J NEUROSCI, V4, P758, DOI 10.1111/j.1460-9568.1992.tb00185.x; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; SAIDO TC, 1994, FASEB J, V8, P814; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; Sloviter R S, 1996, Neurologia, V11 Suppl 4, P29; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	70	65	65	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN 1	1998	52	5					505	520		10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y			16	Neurosciences	Neurosciences & Neurology	ZQ760	WOS:000073900300003	9632307				2021-06-18	
J	Homayoun, P; deTurco, EBR; Parkins, NE; Lane, DC; Soblosky, J; Carey, ME; Bazan, NG				Homayoun, P; deTurco, EBR; Parkins, NE; Lane, DC; Soblosky, J; Carey, ME; Bazan, NG			Delayed phospholipid degradation in rat brain after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						free fatty acids; diacylglycerols; phospholipase A(2); phospholipase C; phospholipase D; traumatic brain injury	AMYLOID PROTEIN DEPOSITION; SEVERE HEAD-INJURY; FREE FATTY-ACIDS; NERVOUS-SYSTEM; PHOSPHATIDYLINOSITOL BISPHOSPHATE; CEREBRAL-CORTEX; MESSENGER-RNA; KINASE-C; ACTIVATION; ISCHEMIA	Lipid second messengers such as arachidonic acid and its metabolites and diacylglycerols (DAGs) are affected in brain injury. Therefore, changes in the pool size and the fatty acid composition of free fatty acids (FFAs) and DAGs were analyzed in different rat brain areas 4 and 35 days after traumatic injury. Cortical impact injury of low-grade severity was applied in the right frontal somatosensory cortex. Four days after injury, FFAs and DAGs were increased by three- and twofold, respectively, in the injured cortex and to a lesser extent in the contralateral cortex compared with sham-operated animals. Docosahexaenoic acid followed by stearic acid, and arachidonic acid, displayed the greatest changes in both FFAs and DAGs. By day 35, free stearic, oleic, and arachidonic acids remained elevated in the damaged cortex(1.5-fold each), DAGs showed the greatest change, reaching values 2.7-fold higher than sham in all frontal and occipital cortical areas, including brainstem. Oleoyl- and arachidonoyl-DAGs (four- and threefold increase, respectively) followed by docosahexaenoyl-DAGs (twofold) contributed to the DAG accumulation. These results reveal that traumatic brain injury triggers a sustained and time-dependent activation of phospholipase-mediated signaling pathways leading to membrane phospholipid degradation and targeting, early on, docosahexaenoyl phospholipid-enriched excitable membranes.	LOUISIANA STATE UNIV,MED CTR,DEPT NEUROSURG,NEW ORLEANS,LA 70112	Homayoun, P (corresponding author), LOUISIANA STATE UNIV,MED CTR,NEUROSCI CTR EXCELLENCE,2020 GRAVIER ST,NEW ORLEANS,LA 70112, USA.		Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Lane, Diane/0000-0001-7313-557X			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; BAZAN NG, 1993, PROG BRAIN RES, V96, P247; BAZAN NG, 1995, J NEUROTRAUM, V12, P789; BAZAN NG, 1980, ADV NEUROL, P197; BAZAN NG, 1990, LIPID MEDIATORS ISCH, P277; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN C, 1967, BIOCHEMISTRY-US, V3, P4606; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P405; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FADEN AI, 1989, UPDATE INTENSIVE CAR, V9, P14; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HAYES RL, 1991, CENTRAL NERVOUS SYST, P9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; MARCHESELLI VL, 1990, J NUTR BIOCHEM, V1, P382, DOI 10.1016/0955-2863(90)90009-A; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Pierce JES, 1996, J NEUROSCI, V16, P1083; PRASAD MR, 1994, J NEUROCHEM, V63, P773; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; SUN GY, 1972, BIOCHIM BIOPHYS ACTA, V280, P306, DOI 10.1016/0005-2760(72)90098-7; Tymianski M, 1996, NEUROSURGERY, V38, P1176; UMEMURA A, 1992, J NEUROSURG, V76, P648, DOI 10.3171/jns.1992.76.4.0648; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I	53	65	67	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	1997	69	1					199	205					7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	XF431	WOS:A1997XF43100024	9202311				2021-06-18	
J	Tavalin, SJ; Ellis, EF; Satin, LS				Tavalin, SJ; Ellis, EF; Satin, LS			Inhibition of the electrogenic Na pump underlies delayed depolarization of cortical neurons after mechanical injury or glutamate	JOURNAL OF NEUROPHYSIOLOGY			English	Article							EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; SODIUM-PUMP; EXTRACELLULAR POTASSIUM; HIPPOCAMPAL-NEURONS; PYRAMIDAL NEURONS; CELL-CULTURE; RAT; NEUROTOXICITY; INVITRO	We previously characterized the electrophysiological response of cortical neurons to a brief sublethal stretch-injury using an in vitro model of traumatic brain injury. This model revealed that cortical neurons undergo a stretch-induced delayed depolarization (SIDD) of their resting membrane potential (RMP) which is similar to 10 mV in magnitude. SIDD is dependent on N-methyl-D-aspartate (NIMDA) receptor activation, neuronal firing, and extracellular calcium for its induction but not its maintenance. SIDD was maximal 1 h after the insult and required incubation at 37 degrees C. The present study examined the mechanism mediating SIDD and its relation to glutamate receptor activation. The Na pump inhibitor ouabain was used to assess the contribution of the Na pump to the RMP of control and stretched neurons using whole cell patch-clamp techniques. The nitric oxide(NO) synthase inhibitor N omega-nitro-L-arginine and a polyethylene glycol conjugate of superoxide dismutase were used to assess whether NO or superoxide anion, respectively, were involved in the induction of SIDD. Neurons were exposed to exogenous glutamate in the absence of cell stretch to determine whether glutamate alone can mimic SIDD. We report that SIDD is mediated by Na pump inhibition and is likely to result from reduced energy levels since the RMP of neurons dialyzed with a pipette solution containing 5 mM ATP were identical to controls. NO, but not superoxide anion, also may contribute to SIDD. A 3-min exposure to 10 mu M glutamate produced a SIDD-like depolarization also associated with Na pump inhibition. The results suggest that Na pump inhibition secondary to alterations in cellular energetics underlies SIDD. Na pump inhibition due to glutamate exposure may contribute to traumatic brain injury or neurodegenerative diseases linked to glutamate receptor activation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYSIOL, RICHMOND, VA 23298 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-07027] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; BRINES ML, 1995, NEUROSCI LETT, V191, P145, DOI 10.1016/0304-3940(95)11577-J; BRINES ML, 1992, BRAIN RES, V591, P94, DOI 10.1016/0006-8993(92)90982-F; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; COULTER DA, 1992, J NEUROPHYSIOL, V68, P362; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DENHERTOG A, 1969, J PHYSIOL-LONDON, V204, P523, DOI 10.1113/jphysiol.1969.sp008929; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA A, 1992, DEV BRAIN RES, V65, P101, DOI 10.1016/0165-3806(92)90013-M; FUKUDA A, 1992, J NEUROPHYSIOL, V68, P28; GLYNN IM, 1975, ANNU REV PHYSIOL, V37, P13, DOI 10.1146/annurev.ph.37.030175.000305; HAGLUND MM, 1985, BRAIN RES, V343, P198, DOI 10.1016/0006-8993(85)91180-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES SW, 1989, NEURON, V3, P153, DOI 10.1016/0896-6273(89)90028-7; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCCORMICK DA, 1987, J PHYSIOL-LONDON, V393, P743, DOI 10.1113/jphysiol.1987.sp016851; NATHANSON JA, 1995, NEURON, V14, P781, DOI 10.1016/0896-6273(95)90222-8; Nilsson P, 1990, J CEREB BLOOD FLOW M, V10, P331; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; RETZ KC, 1982, J NEUROCHEM, V38, P196, DOI 10.1111/j.1471-4159.1982.tb10872.x; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; THOMAS RC, 1972, PHYSIOL REV, V52, P563; THOMPSON SM, 1985, J NEUROSCI, V5, P817; THOMPSON SM, 1986, J NEUROPHYSIOL, V56, P507; WANG GJ, 1994, J NEUROPHYSIOL, V72, P2563; WHITE RJ, 1995, J NEUROSCI, V15, P1318; WHITTAM R, 1962, BIOCHEM J, V82, P205, DOI 10.1042/bj0820205; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Zhang L., 1996, FASEB Journal, V10, pA281	46	65	66	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	FEB	1997	77	2					632	638					7	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	WK036	WOS:A1997WK03600011	9065836				2021-06-18	
J	Wilson, S; Smith, GA; Preisch, J; Casamassimo, PS				Wilson, S; Smith, GA; Preisch, J; Casamassimo, PS			Epidemiology of dental trauma treated in an urban pediatric emergency department	PEDIATRIC EMERGENCY CARE			English	Article							CHILDREN; INJURIES	Study objective: To describe the epidemiology of traumatic dental injuries to children treated in an urban pediatric emergency department (ED). Design: A descriptive study of a consecutive series of patients. Setting: The ED of a large, academic children's hospital. Participants: Children presenting to the ED with dental trauma from December 1992 to November 1993. Results: Of 1459 children treated for dental emergencies, 541 had dental trauma (37%) and were enrolled in this study. Patients ranged in age from five months to 18 years. Fifty-nine percent of patients were less than seven years of age, and 59% of patients were male. Falls caused 63% of injuries, followed by being struck (17%), and motor vehicle crashes (2%). Injuries to the soft tissues included lacerations (32%), swelling (8%), abrasions (7%), and contusions (6%). Injuries to hard dental structures included tooth fractures (33%), luxations (18%), concussions (12%), avulsions (8%), and jaw fractures (1%). Tooth luxation and concussion were more common among children less than seven years of age, and fractures to the tooth crown with dentin exposure (Ellis class II) were seen most often among children with permanent dentition (chi(2) = 41.4, P < 0.005). The central incisors were the teeth most frequently traumatized. Conclusion: Findings of this large consecutive series provide a useful description of the epidemiology of this common type of pediatric trauma for pediatric emergency care providers.	OHIO STATE UNIV,SCH DENT,COLUMBUS,OH 43210	Wilson, S (corresponding author), COLUMBUS CHILDRENS HOSP,DEPT PEDIAT DENT,COLUMBUS,OH 43205, USA.						Andreasen F M, 1991, Curr Opin Dent, V1, P535; Baker SP, 1992, THE INJURY FACT BOOK; BATTENHOUSE MR, 1988, J DENT CHILD     JAN, P68; BENAMAR A, 1977, ISRAEL J DENT MED, V26, P35; Berger J L, 1980, J Hosp Dent Pract, V14, P100; BERKOWITZ R, 1980, CLIN PEDIATR, V19, P166, DOI 10.1177/000992288001900302; Carter A P, 1972, J Public Health Dent, V32, P251, DOI 10.1111/j.1752-7325.1972.tb03982.x; FORSBERG CM, 1990, SWED DENT J, V14, P115; HARDWICK JL, 1954, J DENT RES, V33, P730; HARRINGTON MS, 1988, J DENT CHILD     SEP, P334; HAYRINENIMMONEN R, 1990, ENDOD DENT TRAUMATOL, V6, P208; Henry R J, 1991, Pediatr Nurs, V17, P162; Holland T, 1988, J Paediatr Dent, V4, P13; Judd P L, 1985, Ont Dent, V62, P19; JUDD PL, 1985, ONTARIO DENT, V62, P23; Lewis TE, 1959, ANGLE ORTHOD, V29, P128; MAJEWSKI RF, 1988, J DENT CHILD     SEP, P339; MEADOW D, 1984, Pediatric Dentistry, V6, P248; MUELLER W A, 1989, Pediatrician, V16, P147; NELSON L P, 1990, Pediatric Emergency Care, V6, P62, DOI 10.1097/00006565-199003000-00018; Nicholas N K, 1980, N Z Dent J, V76, P8; ONEIL DW, 1989, ORAL SURG ORAL MED O, V68, P691, DOI 10.1016/0030-4220(89)90157-6; PENNYCOOK A, 1993, J ROY SOC MED, V86, P702; PEREZ R, 1991, ENDOD DENT TRAUMATOL, V7, P212; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; SANCHEZ AV, 1990, ENDOD DENT TRAUMATOL, V6, P63; *SPSS, 1992, SPSS PC PLUS TM BAS; TOMS BV, 1976, BRIT DENT J, V140, P415, DOI 10.1038/sj.bdj.4803775; UJI T, 1988, ENDOD DENT TRAUMATOL, V4, P63; Widmer R P, 1992, Aust Fam Physician, V21, P1263; York A H, 1978, N Z Dent J, V74, P218; Zeng Yang, 1994, Pediatric Dentistry, V16, P419	32	65	67	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	1997	13	1					12	15		10.1097/00006565-199702000-00004			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	WK328	WOS:A1997WK32800004	9061727				2021-06-18	
J	Gorman, LK; Fu, K; Hovda, DA; Murray, M; Traystman, RJ				Gorman, LK; Fu, K; Hovda, DA; Murray, M; Traystman, RJ			Effects of traumatic brain injury on the cholinergic system in the rat	JOURNAL OF NEUROTRAUMA			English	Article						basal forebrain; hippocampus; fluid percussion; medial septal area; septohippocampal	RECEPTOR-BINDING; BASAL FOREBRAIN; NUCLEUS BASALIS; SPATIAL MEMORY; LONG-TERM; HIPPOCAMPAL; NEURONS; SEPTUM; PROJECTIONS; DEFICITS	Rats subjected to a mild to moderate fluid percussion injury exhibit memory deficits that are similar to rats that have received lesions of the septohippocampal system. Because the cholinergic system plays a major role in septohippocampal function, we studied the kinetics of the synthetic enzyme for acetylcholine, choline acetyltransferase (ChAT), at 1 h, 24 h, or 5 days after a fluid percussion injury. Decreases in ChAT activity were found in the dorsal hippocampus (25%), frontal (32%), and temporal (23%) cortices 1 h after injury. In the parietal cortex, a greater than 50% increase in ChAT activity was observed at all time intervals assessed. At 5 days after TBI, there was an 18% increase in ChAT activity in the medial septal area. These data provide evidence that a mild to moderate fluid percussion injury produces changes in the cholinergic system in brain areas related to memory.	UNIV CALIF LOS ANGELES,DEPT SURG,DIV NEUROSURG,LOS ANGELES,CA 90024	Gorman, LK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT ANESTHESIOL CRIT CARE MED,1404 BLALOCK,600 N WOLFE ST,BALTIMORE,MD 21287, USA.		Murray, Micah/A-8851-2008	Murray, Micah/0000-0002-7821-117X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308] Funding Source: Medline		BECKER DP, 1989, SOC NEUR ABSTR 1, P131; BIGL V, 1982, BRAIN RES BULL, V8, P727, DOI 10.1016/0361-9230(82)90101-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cooper JR, 1991, BIOCH BASIS NEUROPHA; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNETT SB, 1985, PSYCHOPHARMACOLOGY, V87, P357, DOI 10.1007/BF00432721; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; GALLAGHER M, 1990, NEUROBIOL AGING, V11, P507, DOI 10.1016/0197-4580(90)90111-C; GAYKEMA RPA, 1990, J COMP NEUROL, V293, P103, DOI 10.1002/cne.902930109; GAYKEMA RPA, 1991, J COMP NEUROL, V303, P563, DOI 10.1002/cne.903030405; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GORMANLK, 1995, SOC NEUR ABSTR, V21, P471; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; LAMOUR Y, 1984, BRAIN RES, V309, P227; LERANTH C, 1992, BRAIN RES, V583, P1, DOI 10.1016/S0006-8993(10)80004-6; LUINE V, 1990, BRAIN RES, V523, P321, DOI 10.1016/0006-8993(90)91507-D; LYETH B, 1988, BRAIN RES, V488, P88; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; OLTON DS, 1993, MEMORY ORG LOCUS CHA; ROBBINS TW, 1989, BEHAV BRAIN RES, V35, P221, DOI 10.1016/S0166-4328(89)80143-3; RYLETT RJ, 1993, J NEUROSCI, V13, P3956; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833	33	65	68	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1996	13	8					457	463		10.1089/neu.1996.13.457			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VH009	WOS:A1996VH00900003	8880609				2021-06-18	
J	Vink, R; Heath, DL; McIntosh, TK				Vink, R; Heath, DL; McIntosh, TK			Acute and prolonged alterations in brain free magnesium following fluid percussion-induced brain trauma in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						magnesium; magnetic resonance; injury; bioenergetics	MAGNETIC-RESONANCE SPECTROSCOPY; METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; INJURY; NEURONS; DAMAGE; HIPPOCAMPUS; METABOLISM; ENERGY; CELL	Several studies have reported declines in brain total and free magnesium concentration after a traumatic insult to the CNS. Although the evidence suggests that this magnesium decline is associated with eventual neurologic outcome after trauma, the duration of free magnesium decline and its impact on related bioenergetic variables are relatively unknown. The present study has therefore used phosphorus magnetic resonance spectroscopy to determine the length of time that free magnesium remains suppressed after traumatic brain injury in rats. Immediately after the traumatic event, brain intracellular free magnesium declined to <60% of preinjury values and remained significantly depressed (50 +/- 8%; p < 0.001) for 5 days before recovering to preinjury levels by day 8. Cytosolic phosphorylation ratio and mitochondrial oxidative capacity also significantly decreased (p = 0.008) and increased (p = 0.002), respectively, after trauma. However, unlike the time of maximum magnesium change, the maximum changes in these bioenergetic variables occurred at 16-24 h after trauma and thereafter remained stable until after the magnesium had recovered. We conclude that free magnesium decline after trauma precedes changes in bioenergetic variables. Furthermore, therapies targeted at reestablishing magnesium homeostasis after trauma may require administration over a 1-week period.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104	Vink, R (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803, R55NS026818, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS26818] Funding Source: Medline		ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; AVISON MJ, 1986, ANNU REV BIOPHYS BIO, V15, P377; Bara M, 1984, MAGNESIUM, V3, P212; BENYOSEPH O, 1990, J NEUROCHEM, V55, P1446, DOI 10.1111/j.1471-4159.1990.tb03160.x; BUCHLI R, 1994, MAGNET RESON MED, V32, P447, DOI 10.1002/mrm.1910320404; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; CHANCE B, 1986, FED PROC, V45, P2915; COHN M, 1962, J BIOL CHEM, V237, P176; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; EVELHOCH JL, 1984, J MAGN RESON, V56, P110, DOI 10.1016/0022-2364(84)90195-1; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GAWAZ M, 1994, THROMB HAEMOSTASIS, V72, P912; GORDON RE, 1982, J MAGN RESON, V46, P322, DOI 10.1016/0022-2364(82)90148-2; GUNTHER T, 1994, MAGNESIUM-B, V16, P38; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; JENKINS WT, 1994, ARCH BIOCHEM BIOPHYS, V313, P89, DOI 10.1006/abbi.1994.1363; KASS IS, 1988, ANESTHESIOLOGY, V69, P710, DOI 10.1097/00000542-198811000-00012; KWACK H, 1992, CURR TOP CELL REGUL, V33, P185; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Nelson KB, 1995, PEDIATRICS, V95, P1; NICOLETTI F, 1987, J NEUROCHEM, V48, P967, DOI 10.1111/j.1471-4159.1987.tb05611.x; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PRASAD MR, 1994, J NEUROCHEM, V63, P773; RAJDEV S, 1995, J NEUROPHYSIOL, V74, P942; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; RODRIGUEZ FD, 1992, J NEUROCHEM, V59, P467, DOI 10.1111/j.1471-4159.1992.tb09393.x; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; RUBIN H, 1977, J CELL PHYSIOL, V91, P449, DOI 10.1002/jcp.1040910315; SEELIG JM, 1983, AM J PHYSIOL, V245, P22; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, J NEUROTRAUMA, V5, P365; WOLF G, 1990, NEUROSCI LETT, V117, P207, DOI 10.1016/0304-3940(90)90145-Y; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	62	65	68	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	1996	66	6					2477	2483					7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	UL589	WOS:A1996UL58900030	8632172				2021-06-18	
J	Raghupathi, R; McIntosh, TK				Raghupathi, R; McIntosh, TK			Regionally and temporally distinct patterns of induction of c-fos, c-jun and junB mRNAs following experimental brain injury in the rat	MOLECULAR BRAIN RESEARCH			English	Article						immediate early genes; c-fos; c-jun; JunB; traumatic brain injury	DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; MAMMALIAN BRAIN; NMDA RECEPTORS; GROWTH-FACTORS; NERVE; ACCUMULATION; HIPPOCAMPUS; MODEL; PROMOTER	Lateral (parasagittal) fluid-percussion brain injury of mild (1.0-1.5 atm) and moderate (2.1-2.4 atm) severity induced expression of mRNAs for the immediate early genes (IEGs) c-fos, c-jun and junB. At 5 min following mild brain injury, c-fos and junB mRNA were co-induced in the cortex ipsilateral to the impact site. Expression remained elevated up to 2 h after injury and returned to control levels by 6 h. Levels of c-fos mRNA increased in the cells of the hippocampal dentate gyrus as early as 5 min after mild brain injury and additionally in the areas CA(1-3) by 30 min. By 2 h, no hippocampal c-fos mRNA was detectable. Induction of junB mRNA in the hippocampus was delayed, occurring at 30 min after injury, and remained elevated up to 2 h post injury. Increased levels of junB mRNA were also observed in the striatum ipsilateral to the injury. Increased expression of c-jun mRNA was restricted to the ipsilateral dentate gyrus and was observed at 5 min after injury and remained elevated up to 6 h. Although the temporal pattern of induction of individual IEGs after brain injury of moderate severity was similar to that observed after mild severity, moderate injury induced IEG mRNA in both injured and contralateral hemispheres. These data suggest that traumatic brain injury invokes a complex acute regional and cellular response which may involve the activation of multiple signal transduction pathways.		Raghupathi, R (corresponding author), UNIV PENN, SCH MED,DEPT SURG,DIV NEUROSURG,HAYDEN HALL, RM 7, 3320 SMITH WALK, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0-1 NS26818, P0-1 NS08803] Funding Source: Medline		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ARENANDER A, 1992, PROG BRAIN RES, V94, P177; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CURRAN T, 1987, ONCOGENE, V2, P79; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DRAGUNOW M, 1993, INT J DEV NEUROSCI, V11, P249, DOI 10.1016/0736-5748(93)90083-P; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; KINOUCHI H, 1994, NEUROSCI LETT, V179, P111, DOI 10.1016/0304-3940(94)90947-4; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEAH JD, 1993, NEUROSCIENCE, V57, P53, DOI 10.1016/0306-4522(93)90111-R; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORATALLA R, 1993, J NEUROSCI, V13, P423; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi Ramesh, 1994, Society for Neuroscience Abstracts, V20, P542; RINK A, 1995, AM J PATHOL, V147, P1575; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIMONATO M, 1991, MOL BRAIN RES, V11, P115, DOI 10.1016/0169-328X(91)90113-C; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH DH, 1993, J NEUROSCI, V13, P5383; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	46	65	68	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	APR	1996	37	1-2					134	144		10.1016/0169-328X(95)00289-5			11	Neurosciences	Neurosciences & Neurology	UL348	WOS:A1996UL34800015	8738144				2021-06-18	
J	Posmantur, RM; Kampfl, A; Liu, SJ; Heck, K; Taft, WC; Clifton, GL; Hayes, RL				Posmantur, RM; Kampfl, A; Liu, SJ; Heck, K; Taft, WC; Clifton, GL; Hayes, RL			Cytoskeletal derangements of cortical neuronal processes three hours after traumatic brain injury in rats: An immunofluorescence study	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						apical dendrites; axon; calpain; cortex; MAP2; neurofilament; trauma	PROTEINS FOLLOWING OCCLUSION; MIDDLE CEREBRAL-ARTERY; HIPPOCAMPAL SLICES; PROTEOLYSIS; CALCIUM; CALPAIN; DEGRADATION; PHOSPHORYLATION; DEGENERATION; HYPOXIA	Semiquantitative Western blot analyses have shown that traumatic brain injury (TBI) can produce significant loss of cytoskeletal proteins (neurofilament 68 [NF68], neurofilament 200 [NF200] and microtubule associated protein 2 [MAP2]) possibly by calpain-mediated proteolysis. Thus, we employed immunofluorescence (light and confocal microscopy) to study the histopathological correlates of acute neurofilament and MAP2 protein decreases observed 3 hours following unilateral cortical injury in rats. TBI induced dramatic alterations in NF68, NF200, and MAP2 immunolabeling in dendrites within and beyond contusion sites ipsilateral and contralateral to the injury site. Marked changes in immunolabeling were associated with but not exclusively restricted to regions of dark shrunken neurons labeled by hematoxylin and eosin staining, a morphopathological response to injury suggesting impending cell death. Light microscopic studies of NF200 immunofluorescence revealed a prominent fragmented appearance of apical dendrites of pyramidal neurons within layers 3 and 5, as well as a loss of fine dendritic arborization within layer 1. Confocal microscopy detected varying degrees of NF200 disassembly associated with these areas of neurofilament fragmentation. Light microscopic studies of NF68 immunofluorescence detected subtle and less severe structural changes including smaller breaks and focal vacuolization of apical dendrites. Light microscopic immunofluorescence of MAP2 revealed changes similar to those seen for NF200. Acute axonal alterations detected with NF68 were minimal compared to immunofluorescence changes seen in dendritic regions. Therefore, preferential dendritic cytoskeletal derangements may be an early morphological feature of experimental traumatic brain injury in vivo. In addition, these cytoskeletal derangements may not be exclusively restricted to sites of contusion and cell death.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,HOUSTON,TX 77030					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458, P01 NS31998] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARAI A, 1991, BRAIN RES, V555, P276, DOI 10.1016/0006-8993(91)90352-V; BARINAGA M, 1995, SCIENCE, V268, P2200; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; BRYAN RM, 1995, IN PRESS ANESTH ANAL; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GENNARELLI T, 1989, J NEUROSURG, V67, P244; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harris J.K, 1990, EPILEPSY CURRENT APP, P227; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKKS RR, 1994, SOC NEUR ABS; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; ISOKAWA M, 1991, NEUROSCI LETT, V132, P212, DOI 10.1016/0304-3940(91)90304-C; JOHNSON GVW, 1993, J NEUROSCI RES, V34, P642, DOI 10.1002/jnr.490340607; KAKULAS BA, 1992, HDB CLIN NEUROLOGY, P21; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A., 1995, Journal of Neurotrauma, V12, P491; KARST H, 1993, NEUROSCI LETT, V164, P154, DOI 10.1016/0304-3940(93)90880-T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI Z, 1995, IN PRESS NEUROCHEM I; LUDIN B, 1993, HIPPOCAMPUS, V3, P61; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; North M, 1989, PROTEOLYTIC ENZYMES, P105; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAATMAN KE, 1994, SOC NEUR ABS; SAATMAN KE, 1994, J NEUR ABS, P138; SCHLAEPFER WW, 1973, J CELL BIOL, V59, P456, DOI 10.1083/jcb.59.2.456; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SCHORMAIR C, 1993, BRAIN RES BULL, V32, P329, DOI 10.1016/0361-9230(93)90196-I; SHAW G, 1986, BIOESSAYS, V4, P161, DOI 10.1002/bies.950040406; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SUGIMOTO A, 1994, CEREBRAL ISCHEMIC BA, P201; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	54	65	73	0	0	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JAN	1996	55	1					68	80		10.1097/00005072-199601000-00007			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	TP445	WOS:A1996TP44500007	8558173	Bronze			2021-06-18	
J	GREENE, KA; MARCIANO, FF; JOHNSON, BA; JACOBOWITZ, R; SPETZLER, RF; HARRINGTON, TR				GREENE, KA; MARCIANO, FF; JOHNSON, BA; JACOBOWITZ, R; SPETZLER, RF; HARRINGTON, TR			IMPACT OF TRAUMATIC SUBARACHNOID HEMORRHAGE ON OUTCOME IN NONPENETRATING HEAD-INJURY .1. A PROPOSED COMPUTERIZED-TOMOGRAPHY GRADING SCALE	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC SUBARACHNOID HEMORRHAGE; NONPENETRATING HEAD INJURY; OUTCOME; GRADING SCALE	DIFFUSE AXONAL INJURY; TRANSCRANIAL DOPPLER ULTRASOUND; CEREBRAL BLOOD-FLOW; BRAIN INJURY; CT SCAN; INTRAVENTRICULAR HEMORRHAGE; VASOSPASM; SPASM; HUMANS; COMA	The presence of traumatic subarachnoid hemorrhage (tSAH) on admission computerized tomography (CT) scans obtained from patients suffering from severe, nonpenetrating head injury has been shown to be associated with a worse outcome than the injury alone would warrant. However, no previous study has provided a simple means of relating the amount of tSAH, its location, or other abnormal findings on initial head CT scans to outcome in patients with nonpenetrating head injury. In this study, admission head CT scans from 252 patients with tSAH, treated at a single institution, were reviewed to ascertain thickness of the tSAH; its location; evidence of mass lesion(s); shift of midline structures (less than or equal to 5 mm vs. > 5 mm); basal cistern effacement; and cortical sulcal effacement. The CT scans were then organized into Grades 1 to 4 with 1 indicating thin tSAH (less than or equal to 5 mm); 2, thick tSAH (> 5 mm); 3, thin tSAH with mass a lesion(s); and 4, thick tSAH with mass lesion(s). A stepwise regression analysis of CT features ranked them in descending order of contribution to Glasgow Outcome Scale (GOS) scores at the time of discharge from acute hospitalization as follows: basal cistern effacement, thickness of tSAH, cortical sulcal effacement, presence of mass lesion(s), and location of tSAH. A shift of midline structures was not found to be a significant variable. Further analysis comparing CT grades and admission postresuscitation Glasgow Coma Scale (GCS) scores was highly significant. Patients with lower CT grades had better admission GCS values and discharge GOS scores than those with higher CT grades. From their experience: the authors conclude that their CT grading scale is simple and reliable and relates significantly to outcome at the time of discharge from acute hospitalization.	ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEUROL SURG,EDITORIAL OFF,PHOENIX,AZ 85013; ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEURORADIOL,PHOENIX,AZ 85013; ARIZONA STATE UNIV,DEPT MATH,TEMPE,AZ 85287							ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; AWAD IA, 1987, STROKE, V18, P365, DOI 10.1161/01.STR.18.2.365; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRAAKMAN R, 1993, J NEUROTRAUMA S, V10, pS85; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; HILL AB, 1977, SHORT TXB MED STATIS, P118; HUNT WE, 1988, J NEUROSURG, V68, P985; JENNETT B, 1975, LANCET, V1, P480; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, J NEUROTRAUMA S, V10, pS84; RINKEL GJE, 1991, ANN NEUROL, V29, P463, DOI 10.1002/ana.410290503; RINKEL GJE, 1990, NEUROLOGY, V40, P1130, DOI 10.1212/WNL.40.7.1130; RINKEL GJE, 1991, AM J NEURORADIOL, V12, P829; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SHIGEMORI M, 1991, Neurologia Medico-Chirurgica, V31, P390, DOI 10.2176/nmc.31.390; SPETZLER RF, 1986, J NEUROSURG, V66, P476; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; The European Study Group on Nimodipine in Severe Head Injury, 1994, J NEUROSURG, V80, P797; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	47	65	67	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1995	83	3					445	452		10.3171/jns.1995.83.3.0445			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RR001	WOS:A1995RR00100010	7666221				2021-06-18	
J	SEN, S; GOLDMAN, H; MOREHEAD, M; MURPHY, S; PHILLIS, JW				SEN, S; GOLDMAN, H; MOREHEAD, M; MURPHY, S; PHILLIS, JW			ALPHA-PHENYL-TERT-BUTYL-NITRONE INHIBITS FREE-RADICAL RELEASE IN BRAIN CONCUSSION	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						BRAIN CONCUSSION; ESR; POBN; HYDROXYL RADICAL; PBN; FREE RADICALS	CEREBRAL ISCHEMIC-INJURY; PHENYLNITRONE PBN; HEAD-INJURY; REPERFUSION; GENERATION; MICRODIALYSIS; GERBILS	Traumatic brain injury (TBI) is one of the important causes of mortality and morbidity. The pathogenesis of the underlying brain dysfunction is poorly understood. Recent data have suggested that oxygen free radicals play a key role in the primary and secondary processes of acute TBI. We report direct electron spin resonance (ESR) evidence of hydroxyl ((OH)-O-.) radical generation in closed-head injury of rats. Moderate brain concussion was produced by controlled and reproducible mechanical, fixed, closed-head injury. A cortical cup was placed over one cerebral hemisphere within 20 min of the concussion, perfused with artificial cerebrospinal fluid (aCSF) containing the spin trap agent pyridyl-N-oxide-tert-butyl nitrone (POBN, 100 mM), and superfusate samples collected at 10 min intervals for a duration up to 130 min post brain trauma. In addition, POBN was administered systemically (50 mg/kg body wt.) 10 min pretrauma and 20 min posttrauma to improve our ability to detect free radicals. ESR analysis of the superfusate samples revealed six line spectra (alpha(N) = 15.4 G and alpha(H)(beta) = 2.5 G) characteristic of POBN-OH radical adducts, the intensity of which peaked 40 min posttrauma. The signal was undetectable after 120 min. Administration of alpha-phenyl-tert-butyl-nitrone (PBN), a spin adduct forming agent systemically (100 mg/kg body wt. IP 10 min prior to concussion) alone or along with topical PBN (100 mM PBN in aCSF), significantly (p < 0.001) attenuated the ESR signal, suggesting its possible role in the treatment of TBI.	WAYNE STATE UNIV,SCH MED,DEPT PHYSIOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026912] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26912-05] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [G0087C002, H133A20016] Funding Source: Medline		BRITIGAN BE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P213, DOI 10.1016/0304-4165(91)90269-M; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1988, OXYGEN RADICALS TISS, P92; HALLIWELL B, ACTA NEUROL SCAND S, V126; IKEDA Y, 1990, ACT NEUR S, V51, P74; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P33, DOI 10.1016/0003-9861(90)90514-Y; KIRSCH JR, 1987, FASEB J, V46, P799; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LAI EK, 1986, ARCH BIOCHEM BIOPHYS, V244, P156, DOI 10.1016/0003-9861(86)90104-9; LANGE D G, 1990, Free Radical Biology and Medicine, V9, P97; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; ORIOT D, 1990, FASEB J, V4, pA419; OZAWA T, 1990, BIOCH INT, V26, P477; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; SAKAMOTO A, 1991, FREE RADICAL BIO MED, V11, P385, DOI 10.1016/0891-5849(91)90155-V; Sano K, 1980, Neurol Res, V2, P253; Sen S., 1993, Society for Neuroscience Abstracts, V19, P636; TORBATI D, 1991, FASEB J, V5, pA891; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; ZINI I, 1992, NEUROSCI LETT, V138, P279, DOI 10.1016/0304-3940(92)90933-X	25	65	65	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUN	1994	16	6					685	691		10.1016/0891-5849(94)90183-X			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	NL951	WOS:A1994NL95100002	8070671				2021-06-18	
J	SHARMA, HS; OLSSON, Y; CERVOSNAVARRO, J				SHARMA, HS; OLSSON, Y; CERVOSNAVARRO, J			EARLY PERIFOCAL CELL CHANGES AND EDEMA IN TRAUMATIC INJURY OF THE SPINAL-CORD ARE REDUCED BY INDOMETHACIN, AN INHIBITOR OF PROSTAGLANDIN SYNTHESIS - EXPERIMENTAL-STUDY IN THE RAT	ACTA NEUROPATHOLOGICA			English	Article						SPINAL CORD TRAUMA; EDEMA; MYELIN BASIC PROTEIN; INDOMETHACIN; PROSTAGLANDINS	ARACHIDONIC-ACID METABOLISM; CENTRAL-NERVOUS-SYSTEM; BRAIN EDEMA; PARA-CHLOROPHENYLALANINE; BLOOD-FLOW; THROMBOXANE; NEUROTRANSMISSION; EICOSANOIDS; MECHANISMS; SEROTONIN	The possibility that prostaglandins participate in the formation of perifocal edema and cell changes following a localized trauma to the spinal cord was investigated in a rat model. A laminectomy was performed in urethane-anesthetized animals at the thoracic T10-11 segment. Using a scalpel blade a unilateral lesion, about 2 mm deep and 5 mm long was made 1 mm to the right of the midline. The deepest part of the injury occupied Rexed's lamina VII of the dorsal horn. Animals were pretreated with the prostaglandin synthesis inhibitor, indomethacin (10 mg/kg, i.p. 30 min prior to trauma). Five hours after the injury the water content was determined and cell changes in and around the primary lesion were examined by light and electron microscopy. Normal and injured rats without indomethacin pretreatment served as controls. Untreated injured rats showed a profound increase of water content in the traumatized T10-11, the rostral (T9) and caudal (T12) segments compared with normal rats. These segments also exhibited marked cell changes in ipsilateral and contralateral dorsal and ventral horns. The gray matter had a spongy appearance and some nerve cells were condensed and distorted. The white matter contained many distorted fibers. Immunostaining for myelin basic protein showed a marked reduction of reaction product in the injured animals compared with normal rats. Ultrastructurally widened extracellular spaces, cytoplasmic vacuolation, swollen and condensed neurons, swollen astrocytes and vesiculation of myelin were frequent findings. Pretreatment of rats with indomethacin significantly reduced the accumulation of water in the traumatized and in the rostral and caudal segments. The structural changes were less pronounced particularly in the cranial and caudal segments. The results indicate that prostaglandins somehow are involved in the pathophysiology of perifocal spinal cord injury and influence both the fluid microenvironment and the early cell changes.	FREE UNIV BERLIN, KLINIKUM STEGLITZ, INST NEUROPATHOL, W-1000 BERLIN 45, GERMANY	SHARMA, HS (corresponding author), UNIV HOSP UPPSALA, INST PATHOL, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN.		Sharma, Aruna/D-4430-2011				ABE K, 1989, ANN NY ACAD SCI, V559, P259; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BARKAI AI, 1989, ANN NY ACAD SCI, P559; BHATTACHARYA SK, 1989, INDIAN J EXP BIOL, V27, P393; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1983, ANN NEUROL, V13, P625, DOI 10.1002/ana.410130608; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; DEMEDIUK P, 1989, ANN NY ACAD SCI, V559, P433; DEMEDIUK P, 1989, ANN NY ACAD SCI, V559, P431; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DEY P K, 1984, Indian Journal of Physiology and Pharmacology, V28, P177; DEY PK, 1974, J PHYSIOL-LONDON, V241, P629, DOI 10.1113/jphysiol.1974.sp010675; DEY PK, 1983, INDIAN J MED RES, V77, P554; DEY PK, 1974, J PHYSIOL-LONDON, V239, pP102; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1988, BRAIN RES, V463, P63, DOI 10.1016/0006-8993(88)90527-6; FURLOW TW, 1978, STROKE, V9, P591, DOI 10.1161/01.STR.9.6.591; GUSTAFSSON LE, 1989, ANN NY ACAD SCI, V559, P178; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HALLENBECK JM, 1983, J NEUROSURG, V58, P749, DOI 10.3171/jns.1983.58.5.0749; HERTTING G, 1989, ANN NY ACAD SCI, V559, P84; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1989, ANN NY ACAD SCI, V559, P282; HSU CY, 1988, J NEUROL SCI, V83, P55, DOI 10.1016/0022-510X(88)90019-6; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; IANNOTTI F, 1981, STROKE, V12, P301, DOI 10.1161/01.STR.12.3.301; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; LANDS WEM, 1968, BIOCHIM BIOPHYS ACTA, V164, P426, DOI 10.1016/0005-2760(68)90168-9; MEANS ED, 1987, HDB SPINAL CORD, V5, P19; MONCADA S, 1978, PHARMACOL REV, V30, P293; OJEDA SR, 1989, ANN NY ACAD SCI, V559, P192; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; SALZMAN SK, 1991, ANN NEUROL, V30, P533, DOI 10.1002/ana.410300405; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SAMUELSSON B, 1979, ADV INFLAMMAT RES, V1, P405; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHARMA H S, 1991, Brain Dysfunction, V4, P104; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SIEGAL T, 1990, NEUROSURGERY, V26, P963, DOI 10.1227/00006123-199006000-00007; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Ting P, 1990, Adv Neurol, V52, P119; TSUBOKURA S, 1991, BRAIN RES, V543, P15, DOI 10.1016/0006-8993(91)91043-Z; WHITE RP, 1982, PHARMACOL THERAPEUT, V18, P313, DOI 10.1016/0163-7258(82)90035-3; WIELOCH T, 1990, CURR OPIN NEUROL NEU, V3, P944; WINKLER T, 1992, IN PRESS NEUROSCIENC; WOLFE LS, 1979, ANNU REV PHYSIOL, V41, P669, DOI 10.1146/annurev.ph.41.030179.003321; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; WOLFE LS, 1989, ANN NY ACAD SCI, V559, P74	59	65	66	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JAN	1993	85	2					145	153					9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	KJ618	WOS:A1993KJ61800005	8442406				2021-06-18	
J	LYETH, BG; RAY, M; HAMM, RJ; SCHNABEL, J; SAADY, JJ; POKLIS, A; JENKINS, LW; GUDEMAN, SK; HAYES, RL				LYETH, BG; RAY, M; HAMM, RJ; SCHNABEL, J; SAADY, JJ; POKLIS, A; JENKINS, LW; GUDEMAN, SK; HAYES, RL			POSTINJURY SCOPOLAMINE ADMINISTRATION IN EXPERIMENTAL TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						ACETYLCHOLINE; MUSCARINE; SCOPOLAMINE; TRAUMATIC BRAIN INJURY; BEHAVIOR; RAT; RADIORECEPTOR ASSAY	AMINO-ACIDS; RAT; BEHAVIOR; PLASMA; ASSAY; URINE	A single bolus dose of scopolamine (1.0 mg/kg) or saline (equal volume) was injected (i.p.) at 15-30 or 60 min after fluid percussion traumatic brain injury in the rat. Scopolamine administered at 15 min postinjury significantly reduced beam walking deficits and body weight loss assessed for 5 days after injury. Scopolamine treatment at 30 or 60 min postinjury had no effect on behavioral outcome assessed for 5 days after injury. Plasma concentrations of scopolamine were measured with a radioreceptor assay. The plasma half-life for scopolamine was 21.6 min in injured rats and 17.3 min in normal rats (P < 0.05). These results, along with evidence from previous studies, suggest that a brief period of excessive neuronal excitation can produce relatively long-lasting behavioral deficits. The temporal effectiveness of receptor antagonist intervention in this process appears to be brief.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,POB 693,MCV STN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PATHOL,RICHMOND,VA 23298; UNIV NORTH CAROLINA,DEPT SURG,DIV NEUROSURG,CHAPEL HILL,NC 27599; UNIV TEXAS,SCH MED,DEPT SURG,DIV NEUROSURG,HOUSTON,TX 77030				Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587, R01NS019950, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19950, NS 21458, NS 12587] Funding Source: Medline		BAYNE WF, 1975, J PHARM SCI, V64, P288, DOI 10.1002/jps.2600640220; CINTRON NM, 1987, J PHARM SCI, V76, P328, DOI 10.1002/jps.2600760413; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V	16	65	65	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 13	1992	569	2					281	286		10.1016/0006-8993(92)90640-U			6	Neurosciences	Neurosciences & Neurology	HC618	WOS:A1992HC61800012	1540831				2021-06-18	
J	HALL, ED				HALL, ED			NOVEL INHIBITORS OF IRON-DEPENDENT LIPID-PEROXIDATION FOR NEURODEGENERATIVE DISORDERS	ANNALS OF NEUROLOGY			English	Article; Proceedings Paper	SYMP ON THE ROLE OF IRON AND OXIDANT STRESS IN THE NORMAL AND PARKINSONIAN BRAIN	NOV 14-17, 1991	SARASOTA, FL	UNIV S FLORIDA			NERVOUS-SYSTEM TRAUMA; CEREBRAL-ARTERY OCCLUSION; EARLY DEGENERATION; BRAIN; ISCHEMIA; U74006F; INJURY; 21-AMINOSTEROIDS; PRESERVATION; RADICALS	A considerable body of information supports the occurrence and pathophysiological importance of oxygen radical-mediated lipid peroxidation in acute cerebral damage secondary to traumatic or ischemic injury. Moreover, peroxidative mechanisms have been implicated in chronic neurodegenerative (e.g., Alzheimer's and Parkinson's diseases) and demyelinating (e.g., multiple sclerosis) disorders. Consequently, there has been interest in identification of pharmacological agents with potent ability to interrupt oxygen radical formation or cell membrane lipid peroxidative mechanisms. Our laboratories have developed a novel series of potent lipid peroxidation inhibitors known as the 21-aminosteroids or "lazaroids." One of these compounds, U-74006F or tirilazad mesylate, has shown efficacy in animal models of brain injury and focal cerebral ischemia. In addition, the compound has been found to attenuate the increased lipid peroxidation observed in Alzheimer's brain tissue, to retard anterograde degeneration of motor nerve fibers, and to be effective in decreasing the clinical disease severity and blood-brain barrier disruption observed in the multiple sclerosis model of experimental allergic encephalomyelitis. Another series of antioxidants, the 2-methylaminochromans typified by the compound U-78517F, have been discovered that are even more potent and effective inhibitors of lipid peroxidation than the 21-aminosteroids.		HALL, ED (corresponding author), UPJOHN CO,CNS DIS RES,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				ALTHAUS J S, 1991, Society for Neuroscience Abstracts, V17, P164; ANDORN AC, 1990, NEUROBIOL AGING, V11, P316; ANDRUS P K, 1991, Society for Neuroscience Abstracts, V17, P1086; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V7, P125, DOI 10.1016/0891-5849(89)90003-8; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRAUGHLER JM, 1988, J PHARMACOL EXP THER, V244, P423; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Dimlich R V, 1990, Adv Neurol, V52, P365; GELB AW, 1990, J NEUROSURG ANESTHES, V2, P240; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1990, BRAIN RES, V513, P244, DOI 10.1016/0006-8993(90)90462-K; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1984, EXP NEUROL, V84, P715, DOI 10.1016/0014-4886(84)90219-X; HALL ED, 1987, BRAIN RES, V413, P175, DOI 10.1016/0006-8993(87)90166-1; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1991, STROKE, V22, P361, DOI 10.1161/01.STR.22.3.361; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALL ED, 1992, IN PRESS NEW DRUG ST; KARLIK SJ, 1991, NEUR ABSTR, V17, P1453; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LYTHGOE D J, 1990, British Journal of Pharmacology, V100, p454P; MCINTOSH L J, 1991, Society for Neuroscience Abstracts, V17, P1071; MCINTOSH T, 1991, ACTA NEUROCHIR S, V51, P329; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; MYERS RE, 1990, STROKE, V21, P179; PANETTA JA, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P351; SATO PH, 1992, J NEUROCHEM, V58, P2263, DOI 10.1111/j.1471-4159.1992.tb10972.x; SILVIA RC, 1987, NEUR ABST, V13, P1499; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; XUE D, 1990, Stroke, V21, P178; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013	37	65	68	0	1	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0364-5134			ANN NEUROL	Ann. Neurol.		1992	32			S			S137	S142		10.1002/ana.410320724			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JH405	WOS:A1992JH40500023	1510373				2021-06-18	
J	Mac Donald, CL; Barber, J; Jordan, M; Johnson, AM; Dikmen, S; Fann, JR; Temkin, N				Mac Donald, Christine L.; Barber, Jason; Jordan, Mary; Johnson, Ann M.; Dikmen, Sureyya; Fann, Jesse R.; Temkin, Nancy			Early Clinical Predictors of 5-Year Outcome After Concussive Blast Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; ADMINISTERED PTSD SCALE; POSTCONCUSSIVE SYMPTOMS; STRUCTURED INTERVIEWS; MILITARY PERSONNEL; OEF/OIF VETERANS; NATIONAL-GUARD; MENTAL-HEALTH; IRAQI FREEDOM	IMPORTANCE The long-term clinical effects of wartime traumatic brain injuries (TBIs), most of which are mild, remain incompletely described. Current medical disability cost estimates from world conflicts continually surpass projections. Additional information regarding long-term functional trajectory is needed to reduce this extensive public health burden. OBJECTIVES To examine 5-year clinical outcomes leveraging existing clinical data collected at 1 year after injury in the same patients and to identify early risk factors for long-term disability. DESIGN, SETTING, AND PARTICIPANTS This prospective, longitudinal study enrolled active-duty US military after concussive blast injury (n = 50) in the acute to subacute stage and combat-deployed control individuals (n = 44) in Afghanistan or after medical evacuation to Germany from November 1, 2008, through July 1, 2013. One-and 5-year clinical evaluations were completed in the United States. All concussive blast injuriesmet the Department of Defense definition of mild, uncomplicated TBI. In-person clinical evaluations included standardized evaluations for neurobehavior, neuropsychological performance, and mental health burden that were essentially identical to the evaluations completed at 1-year follow-up. Data were analyzed from October 1 through November 30, 2016. MAIN OUTCOMES AND MEASURES Changes in the in-person standardized evaluations for neurobehavior, neuropsychological performance, and mental health burden from the 1- to 5-year follow-up. Predictive modeling was used to identify early risk factors for long-term disability. RESULTS Among the 94 participants (87 men [93%] and 7 women [7%]; mean [SD] age, 34 [8] years), global disability, satisfaction with life, neurobehavioral symptom severity, psychiatric symptom severity, and sleep impairment were significantly worse in patients with concussive blast TBI compared with combat-deployed controls, whereas performance on cognitive measures was no different between groups at the 5-year evaluation. Logistic regression on the dichotomized Extended Glasgow Outcome Scale (GOS-E) at 5 years as a measure of overall disability identified brain injury diagnosis, preinjury intelligence, motor strength, verbal fluency, and neurobehavioral symptom severity at 1 year as risk factors for a poor outcome at 5 years, with an area under the curve of 0.92 indicating excellent prediction strength. Thirty-six of 50 patients with concussive blast TBI (72%) had a decline in the GOS-E from the 1- to 5-year evaluations, in contrast with only 5 of 44 combat-deployed controls (11%). Worsening of symptoms in concussive blast TBI was also observed on measures of posttraumatic stress disorder and depression. Service members with concussive blast TBI experienced evolution, not resolution, of symptoms from the 1- to 5-year outcomes. CONCLUSIONS AND RELEVANCE Considerable declinewas observed in military service members with concussive blast TBI when comparing 1- and 5-year clinical outcomes. These results advocate for new treatment strategies to combat the long-term and extremely costly effect of these wartime injuries.	[Mac Donald, Christine L.; Barber, Jason; Jordan, Mary; Temkin, Nancy] Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 359924, Seattle, WA 98104 USA; [Johnson, Ann M.] Washington Univ, Ctr Clin Studies, St Louis, MO USA; [Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98104 USA	Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 359924, Seattle, WA 98104 USA.	cmacd@uw.edu			Department of Defense grant through the Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095]; National Institute of Neurological and Communication Disorders and Stroke, National Institutes of Health [1R01NS091618-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091618] Funding Source: NIH RePORTER	This study was supported by Department of Defense grant W81XWH-13-2-0095 through the Chronic Effects of Neurotrauma Consortium and by grant 1R01NS091618-01 from the National Institute of Neurological and Communication Disorders and Stroke, National Institutes of Health.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Akaike H, 1973, P 2 INTERNTERNATIONA, P267, DOI 10.1007/978-1-4612-1694-0; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bell KR, 2017, J NEUROTRAUM, V34, P313, DOI 10.1089/neu.2016.4444; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Benton AL, 1983, MULTILINGUAL APHASIA; Bilmes L, 2011, ELGAR HDB EC CONFLIC; Bilmes L., 2007, SOLDIERS RETURNING I; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Centers for Disease Control and Prevention (CDC) NCfIPaC, 2003, REP C MILD TRAUM BRA; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; Defense and Veterans Brain Injury Center, 2016, DOD WORLDW TBI NUMB; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DVBIC, 2013, DOD NUMB TRAUM BRAIN; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mac Donald CL, 2016, J NEUROTRAUMA; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McCauley SR, 2010, J NEUROTRAUM, V27, P991, DOI 10.1089/neu.2009.1195; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Research IoMUCoSMa, 2006, SLEEP DISORDERS SLEE; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Storzbach D, 2015, J INT NEUROPSYCH SOC, V21, P353, DOI 10.1017/S1355617715000326; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Taniellian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; Vuletic S, 2016, J HEAD TRAUMA REHAB, V31, P147, DOI 10.1097/HTR.0000000000000221; Walker WC, 2015, BRAIN INJURY, V29, P1581, DOI 10.3109/02699052.2015.1075151; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 2001, WECHSLER TEST ADULT; Wilde EA, 2010, J NEUROTRAUM, V27, P13551; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Wilde EA, 2010, J NEUROTRAUM, V27, P983, DOI 10.1089/neu.2009.1194; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004	72	64	64	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JUL	2017	74	7					821	829		10.1001/jamaneurol.2017.0143			9	Clinical Neurology	Neurosciences & Neurology	EZ9VB	WOS:000405077100014	28459953	Bronze, Green Accepted			2021-06-18	
J	Herman, DC; Jones, D; Harrison, A; Moser, M; Tillman, S; Farmer, K; Pass, A; Clugston, JR; Hernandez, J; Chmielewski, TL				Herman, Daniel C.; Jones, Debi; Harrison, Ashley; Moser, Michael; Tillman, Susan; Farmer, Kevin; Pass, Anthony; Clugston, James R.; Hernandez, Jorge; Chmielewski, Terese L.			Concussion May Increase the Risk of Subsequent Lower Extremity Musculoskeletal Injury in Collegiate Athletes	SPORTS MEDICINE			English	Article							CRUCIATE LIGAMENT RECONSTRUCTION; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; NEUROMUSCULAR CONTROL; PERSISTENT INFLUENCE; COGNITIVE CONTROL; FOOTBALL PLAYERS; BALANCE CONTROL; GAIT; PREVENTION	Background Laboratory-based studies on neuromuscular control after concussion and epidemiological studies suggest that concussion may increase the risk of subsequent musculoskeletal injury. Objective The purpose of this study was to determine if athletes have an increased risk of lower extremity musculoskeletal injury after return to play from a concussion. Methods Injury data were collected from 2006 to 2013 for men's football and for women's basketball, soccer and lacrosse at a National Collegiate Athletic Association Division I university. Ninety cases of in-season concussion in 73 athletes (52 male, 21 female) with return to play at least 30 days prior to the end of the season were identified. A period of up to 90 days of in-season competition following return to play was reviewed for time-loss injury. The same period was studied in up to two control athletes who had no concussion within the prior year and were matched for sport, starting status and position. Results Lower extremity musculoskeletal injuries occurred at a higher rate in the concussed athletes (45/90 or 50 %) than in the non-concussed athletes (30/148 or 20 %; P < 0.01). The odds of sustaining a musculoskeletal injury were 3.39 times higher in the concussed athletes (95 % confidence interval 1.90-6.05; P < 0.01). Overall, the number of days lost because of injury was similar between concussed and non-concussed athletes (median 9 versus 15; P = 0.41). Conclusions The results of this study demonstrate a relationship between concussion and an increased risk of lower extremity musculoskeletal injury after return to play, and may have implications for current medical practice standards regarding evaluation and management of concussion injuries.	[Herman, Daniel C.; Moser, Michael; Farmer, Kevin] Univ Florida, Dept Orthopaed & Rehabil, POB 112727, Gainesville, FL 32611 USA; [Moser, Michael; Farmer, Kevin; Clugston, James R.] Univ Florida, Univ Florida Athlet Assoc, Gainesville, FL USA; [Jones, Debi; Tillman, Susan] Orthopaed & Sports Med Inst, UF Hlth Rehab Ctr, Gainesville, FL USA; [Harrison, Ashley] ProFormPT, Maitland, FL USA; [Pass, Anthony] Univ Texas Athlet, Austin, TX USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Student Hlth Care Ctr, Gainesville, FL USA; [Hernandez, Jorge] Univ Florida, Coll Vet Sci, Gainesville, FL USA; [Chmielewski, Terese L.] TRIA Orthoped Ctr, Bloomington, MN USA; [Chmielewski, Terese L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA	Herman, DC (corresponding author), Univ Florida, Dept Orthopaed & Rehabil, POB 112727, Gainesville, FL 32611 USA.	hermadc@ortho.ufl.edu		Clugston, James/0000-0002-2103-1039	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K12HD001097-17]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	This study was supported in part by National Institutes of Health Grant #5K12HD001097-17.	Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chiu SL, 2013, GAIT POSTURE, V38, P717, DOI 10.1016/j.gaitpost.2013.03.010; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Dai BY, 2012, RES SPORTS MED, V20, P198, DOI 10.1080/15438627.2012.680987; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Herman DC, 2015, CURR SPORT MED REP, V14, P194, DOI 10.1249/JSR.0000000000000157; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Kuenze CM, 2015, J ATHL TRAINING, V50, P303, DOI 10.4085/1062-6050-49.5.06; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Moore RD, 2015, BIOL PSYCHOL, V109, P93, DOI 10.1016/j.biopsycho.2015.04.008; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Pietrosimone BG, 2013, J SPORT REHABIL, V22, P1, DOI 10.1123/jsr.22.1.1; Pietrosimone BG, 2012, J ATHL TRAINING, V47, P621, DOI 10.4085/1062-6050-47.6.11; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Sadoghi P, 2012, J BONE JOINT SURG AM, V94A, P769, DOI 10.2106/JBJS.K.00467; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Tsao H, 2008, BRAIN, V131, P2161, DOI 10.1093/brain/awn154; Tsushima WT, 2016, APPL NEUROPSYCH-CHIL, V5, P9, DOI 10.1080/21622965.2014.902762; Verhagen EALM, 2010, BRIT J SPORT MED, V44, P1082, DOI 10.1136/bjsm.2010.076406; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Zazulak BT, 2007, AM J SPORT MED, V35, P1123, DOI 10.1177/0363546507301585	37	64	64	1	27	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	MAY	2017	47	5					1003	1010		10.1007/s40279-016-0607-9			8	Sport Sciences	Sport Sciences	EV7HA	WOS:000401945300013	27544666	Green Accepted			2021-06-18	
J	Anzalone, AJ; Blueitt, D; Case, T; McGuffin, T; Pollard, K; Garrison, JC; Jones, MT; Pavur, R; Turner, S; Oliver, JM				Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Jones, Margaret T.; Pavur, Robert; Turner, Stephanie; Oliver, Jonathan M.			A Positive Vestibular/Ocular Motor Screening (VOMS) Is Associated With Increased Recovery Time After Sports-Related Concussion in Youth and Adolescent Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; vestibular; ocular motor; symptoms	TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; POSTCONCUSSION SYNDROME; EMERGENCY-DEPARTMENT; BALANCE DISORDERS; FOOTBALL PLAYERS; HEAD TRAUMA; EPIDEMIOLOGY; CONVERGENCE; SYMPTOMS	Background: Vestibular and ocular motor impairments are routinely reported in patients with sports-related concussion (SRC) and may result in delayed return to play (RTP). The Vestibular/Ocular Motor Screening (VOMS) assessment has been shown to be consistent and sensitive in identifying concussion when used as part of a comprehensive examination. To what extent these impairments or symptoms are associated with length of recovery is unknown. Purpose: To examine whether symptom provocation or clinical abnormality in specific domains of the VOMS results in protracted recovery (time from SRC to commencement of RTP protocol). Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: A retrospective chart review was conducted of 167 patients (69 girls, 98 boys; mean SD age, 15 2 years [range, 11-19 years]) presenting with SRC in 2014. During the initial visit, VOMS was performed in which symptom provocation or clinical abnormality (eg, unsmooth eye movements) was documented by use of a dichotomous scale (0 = not present, 1 = present). The VOMS used in this clinic consisted of smooth pursuits (SMO_PUR), horizontal and vertical saccades (HOR_SAC and VER_SAC), horizontal and vertical vestibular ocular reflex (HOR_VOR and VER_VOR), near point of convergence (NPC), and accommodation (ACCOM). Domains were also categorized into ocular motor (SMO_PUR, HOR_SAC, VER_SAC, NPC, ACCOM) and vestibular (HOR_VOR, VER_VOR). Cox proportional hazard models were used to explore the relationship between the domains and recovery. Alpha was set at P .05. Results: Symptom provocation and/or clinical abnormality in all domains except NPC (P = .107) and ACCOM (P = .234) delayed recovery (domain, hazard ratio [95% CI]: SMO_PUR, 0.65 [0.47-0.90], P = .009; HOR_SAC, 0.68 [0.50-0.94], P = .018; VER_SAC, 0.55 [0.40-0.75], P < .001; HOR_VOR, 0.68 [0.49-0.94], P = .018; VER_VOR, 0.60 [0.44-0.83], P = .002). The lowest crude hazard ratio was for ocular motor category (0.45 [0.32-0.63], P < .001). Conclusion: These data suggest that symptom provocation/clinical abnormality associated with all domains except NPC and ACCOM can delay recovery after SRC in youth and adolescents. Thus, the VOMS not only may augment current diagnostic tools but also may serve as a predictor of recovery time in patients with SRC. The findings of this study may lead to more effective prognosis of concussion in youth and adolescents.	[Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Jones, Margaret T.; Pavur, Robert; Turner, Stephanie; Oliver, Jonathan M.] Texas Hlth Ben Hogan Sports Med Concuss Ctr, Ft Worth, TX USA; [Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Jones, Margaret T.; Pavur, Robert; Turner, Stephanie; Oliver, Jonathan M.] Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, POB 297730, Ft Worth, TX 76129 USA; [Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Turner, Stephanie; Oliver, Jonathan M.] Texas Hlth Ben Hogan Sports Med Concuss Ctr, Ft Worth, TX USA; [Anzalone, Anthony J.; Blueitt, Damond; Case, Tami; McGuffin, Tiffany; Pollard, Kalyssa; Garrison, J. Craig; Turner, Stephanie; Oliver, Jonathan M.] Texas Hlth Ben Hogan Sports Med, Ft Worth, TX USA; [Jones, Margaret T.] George Mason Univ, Sch Recreat Hlth & Tourism, Manassas, VA USA; [Pavur, Robert] Univ North Texas, Coll Business, Denton, TX USA	Oliver, JM (corresponding author), Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, POB 297730, Ft Worth, TX 76129 USA.	jonathan.oliver@tcu.edu					Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Naguib MB, 2012, J LARYNGOL OTOL, V126, P26, DOI 10.1017/S002221511100291X; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Stone S, 2017, SPORTS HEALTH, V9, P41, DOI 10.1177/1941738116672184; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	35	64	64	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2017	45	2					474	479		10.1177/0363546516668624			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EL7BU	WOS:000394776900028	27789472				2021-06-18	
J	Choi, YK; Maki, T; Mandeville, ET; Koh, SH; Hayakawa, K; Arai, K; Kim, YM; Whalen, MJ; Xing, CH; Wang, XY; Kim, KW; Lo, EH				Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Kim, Young-Myeong; Whalen, Michael J.; Xing, Changhong; Wang, Xiaoying; Kim, Kyu-Won; Lo, Eng H.			Dual effects of carbon monoxide on pericytes and neurogenesis in traumatic brain injury	NATURE MEDICINE			English	Article							ADULT BRAIN; DISEASE	At low levels, carbon monoxide (CO) has physiological roles as a second messenger and neuromodulator(1,2). Here we assess the effects of CO in a mouse model of traumatic brain injury (TBI). Treatment with CO-releasing molecule (CORM)-3 reduced pericyte death and ameliorated the progression of neurological deficits. In contrast, although treatment with the radical scavenger N-tert-butyl-a-phenylnitrone (PBN) also reduced pericyte death, neurological outcomes were not rescued. As compared to vehicle-treated control and PBN-treated mice, CORM-3-treated mice showed higher levels of phosphorylated neural nitric oxide synthase within neural stem cells (NSCs). Inhibition of nitric oxide synthase diminished the CORM-3-mediated increase in the number of cells that stained positive for both the neuronal marker NeuN and 5-bromo-2'-deoxyuridine (BrdU; a marker for proliferating cells) in vivo, consequently interfering with neurological recovery after TBI. Because NSCs seemed to be in close proximity to pericytes, we asked whether cross-talk between pericytes and NSCs was induced by CORM-3, thereby promoting neurogenesis. In pericyte cultures that were undergoing oxygen and glucose deprivation, conditioned cell culture medium collected after CORM-3 treatment enhanced the in vitro differentiation of NSCs into mature neurons. Taken together, these findings suggest that CO treatment may provide a therapeutic approach for TBI by preventing pericyte death, rescuing cross-talk with NSCs and promoting neurogenesis.	[Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA; [Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; [Koh, Seong-Ho] Hanyang Univ, Dept Neurol, Coll Med, Seoul, South Korea; [Kim, Young-Myeong] Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon, Gangwon Do, South Korea; [Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Boston, MA USA; [Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, SNU Harvard NeuroVasc Protect Res Ctr, Seoul, South Korea	Choi, YK; Lo, EH (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA.; Choi, YK; Lo, EH (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.	yoonkyung@kangwon.ac.kr; lo@helix.mgh.harvard.edu	Kim, Kyu Won/AAJ-7213-2020; 眞木, 崇州/AAO-1160-2020	Choi, Yoon Kyung/0000-0003-0242-9612; Koh, Seong-Ho/0000-0001-5419-5761	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Rappaport Foundation; National Research Foundation of KoreaNational Research Foundation of Korea; Global Research Laboratory Program of Korea	This work was supported in part by grants from the US National Institutes of Health (K.H., K.A., M.J.W., C.X., X.W. and E.H.L.), the Rappaport Foundation (E.H.L.), the Research Abroad grant from the National Research Foundation of Korea (Y.K.C., S.-H.K., Y.-M.K. and K.-W.K.) and the Global Research Laboratory Program of Korea (K.-WK.). The vector expressing the HIF-1 alpha double mutant was kindly provided by G.L. Semenza (Johns Hopkins University School of Medicine).	Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Chen JJ, 2004, DEV BIOL, V269, P165, DOI 10.1016/j.ydbio.2004.01.024; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Goldman SA, 2011, NAT NEUROSCI, V14, P1382, DOI 10.1038/nn.2963; Hu XM, 2014, PROG NEUROBIOL, V119, P60, DOI 10.1016/j.pneurobio.2014.06.002; Lo EH, 2014, VASCULAR MECH CNS TR; Lo EH, 2010, NAT MED, V16, P1205, DOI 10.1038/nm.2226; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Xing C., 2016, PROG NEUROBIOL; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022	17	64	67	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2016	22	11					1335	1341		10.1038/nm.4188			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EB3XK	WOS:000387302300027	27668935				2021-06-18	
J	Alluri, H; Wilson, RL; Shaji, CA; Wiggins-Dohlvik, K; Patel, S; Liu, Y; Peng, X; Beeram, MR; Davis, ML; Huang, JH; Tharakan, B				Alluri, Himakarnika; Wilson, Rickesha L.; Shaji, Chinchusha Anasooya; Wiggins-Dohlvik, Katie; Patel, Savan; Liu, Yang; Peng, Xu; Beeram, Madhava R.; Davis, Matthew L.; Huang, Jason H.; Tharakan, Binu			Melatonin Preserves Blood-Brain Barrier Integrity and Permeability via Matrix Metalloproteinase-9 Inhibition	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; CEREBROSPINAL-FLUID; IN-VITRO; INJURY; INTERLEUKIN-1; MICE; METALLOPROTEINASES; HYPERPERMEABILITY; DYSFUNCTION; OCCLUDIN	Microvascular hyperpermeability that occurs at the level of the blood-brain barrier (BBB) often leads to vasogenic brain edema and elevated intracranial pressure following traumatic brain injury (TBI). At a cellular level, tight junction proteins (TJPs) between neighboring endothelial cells maintain the integrity of the BBB via TJ associated proteins particularly, zonula occludens-1 (ZO-1) that binds to the transmembrane TJPs and actin cytoskeleton intracellularly. The pro-inflammatory cytokine, interleukin-1 beta (IL-1 beta) as well as the proteolytic enzymes, matrix metalloproteinase-9 (MMP-9) are key mediators of trauma-associated brain edema. Recent studies indicate that melatonin a pineal hormone directly binds to MMP-9 and also might act as its endogenous inhibitor. We hypothesized that melatonin treatment will provide protection against TBI-induced BBB hyperpermeability via MMP-9 inhibition. Rat brain microvascular endothelial cells grown as monolayers were used as an in vitro model of the BBB and a mouse model of TBI using a controlled cortical impactor was used for all in vivo studies. IL-1 beta (10 ng/mL; 2 hours)-induced endothelial monolayer hyperpermeability was significantly attenuated by melatonin (10 mu g/mL; 1 hour), GM6001 (broad spectrum MMP inhibitor; 10 mu M; 1 hour), MMP-9 inhibitor-1 (MMP-9 specific inhibitor; 5 nM; 1 hour) or MMP-9 siRNA transfection (48 hours) in vitro. Melatonin and MMP-9 inhibitor-1 pretreatment attenuated IL-1 beta-induced MMP-9 activity, loss of ZO-1 junctional integrity and f-actin stress fiber formation. IL-1 beta treatment neither affected ZO-1 protein or mRNA expression or cell viability. Acute melatonin treatment attenuated BBB hyperpermeability in a mouse controlled cortical impact model of TBI in vivo. In conclusion, one of the protective effects of melatonin against BBB hyperpermeability occurs due to enhanced BBB integrity via MMP-9 inhibition. In addition, acute melatonin treatment provides protection against BBB hyperpermeability in a mouse model of TBI indicating its potential as a therapeutic agent for brain edema when established in humans.	[Alluri, Himakarnika; Wilson, Rickesha L.; Shaji, Chinchusha Anasooya; Wiggins-Dohlvik, Katie; Patel, Savan; Tharakan, Binu] Texas A&M Univ, Coll Med, Dept Surg, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA; [Liu, Yang; Peng, Xu; Davis, Matthew L.] Texas A&M Univ, Coll Med, Dept Med Physiol, Hlth Sci Ctr, Temple, TX 76508 USA; [Beeram, Madhava R.] Texas A&M Univ, Coll Med, Dept Pediat, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA; [Huang, Jason H.] Texas A&M Univ, Coll Med, Dept Neurosurg, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA; [Wilson, Rickesha L.] Univ Connecticut, Sch Med, Dept Surg, Farmington, CT USA	Tharakan, B (corresponding author), Texas A&M Univ, Coll Med, Dept Surg, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA.	btharakan@medicine.tamhsc.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	Baylor Scott and White Health Academic Operations	We acknowledge the Baylor Scott and White Health Academic Operations for financial Support and Texas A&M University Health Science Center Integrated Microscopy and Imaging Laboratory for the use of Olympus confocal laser microscope. We also acknowledge Mr. Glen Cryer for his help with manuscript preparation.	Adderley SP, 2015, AM J PHYSIOL-CELL PH, V309, pC51, DOI 10.1152/ajpcell.00096.2015; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Amin ARMR, 2003, GENES CELLS, V8, P515, DOI 10.1046/j.1365-2443.2003.00652.x; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Blamire AM, 2000, J NEUROSCI, V20, P8153; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Breslin JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117970; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Chen F, 2009, HEPATOLOGY, V50, P1914, DOI 10.1002/hep.23203; Chen YC, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00100; Coisne C, 2011, ANTIOXID REDOX SIGN, V15, P1285, DOI 10.1089/ars.2011.3929; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Didier N, 2003, J NEUROCHEM, V86, P246, DOI 10.1046/j.1471-4159.2003.01829.x; Dong LP, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370804; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Rigor RR, 2012, AM J PHYSIOL-CELL PH, V302, pC1513, DOI 10.1152/ajpcell.00371.2011; Rudra DS, 2013, J PINEAL RES, V54, P398, DOI 10.1111/jpi.12034; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Simao F, 2012, J CEREBR BLOOD F MET, V32, P884, DOI 10.1038/jcbfm.2012.2; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Stagg HW, 2013, J TRAUMA ACUTE CARE, V75, P1040, DOI 10.1097/TA.0b013e3182aa9c79; Vermeer PD, 2009, AM J PHYSIOL-LUNG C, V296, pL751, DOI 10.1152/ajplung.90578.2008; Wiggins-Dohlvik K, 2014, AM J SURG, V208, P954, DOI 10.1016/j.amjsurg.2014.08.014; Wiggins-Dohlvik K, 2014, J TRAUMA ACUTE CARE, V77, P899, DOI 10.1097/TA.0000000000000346; Wu BH, 2010, TRANSL STROKE RES, V1, P57, DOI 10.1007/s12975-009-0002-z	28	64	68	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2016	11	5							e0154427	10.1371/journal.pone.0154427			18	Multidisciplinary Sciences	Science & Technology - Other Topics	DL5KX	WOS:000375677000020	27152411	DOAJ Gold, Green Published			2021-06-18	
J	Kulbe, JR; Geddes, JW				Kulbe, Jacqueline R.; Geddes, James W.			Current status of fluid biomarkers in mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Mild traumatic brain injury; Biomarkers; Serum; Cerebral spinal fluid; Biofluid; Novel; Discovery; Unbiased	NEURON-SPECIFIC-ENOLASE; MYELIN BASIC-PROTEIN; ALPHA-II-SPECTRIN; FIBRILLARY ACIDIC PROTEIN; MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; CONTROLLED CORTICAL IMPACT; POST-CONCUSSION SYMPTOMS; C-TERMINAL HYDROLASE-L1; SERUM S-100B PROTEIN	Mild traumatic brain injury (mTBI) affects millions of people annually and is difficult to diagnose. Mild injury is insensitive to conventional imaging techniques and diagnoses are often made using subjective criteria such as self-reported symptoms. Many people who sustain a mTBI develop persistent post-concussive symptoms. Athletes and military personnel are at great risk for repeat injury which can result in second impact syndrome or chronic traumatic encephalopathy. An objective and quantifiable measure, such as a serum biomarker, is needed to aid in mTBI diagnosis, prognosis, return to play/duty assessments, and would further elucidate mTBI pathophysiology. The majority of TBI biomarker research focuses on severe TBI with few studies specific to mild injury. Most studies use a hypothesis-driven approach, screening biofluids for markers known to be associated with TBI pathophysiology. This approach has yielded limited success in identifying markers that can be used clinically, additional candidate biomarkers are needed. Innovative and unbiased methods such as proteomics, microRNA arrays, urinary screens, autoantibody identification and phage display would complement more traditional approaches to aid in the discovery of novel mTBI biomarkers. (C) 2015 Elsevier Inc. All rights reserved.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA	Geddes, JW (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B483 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	jgeddes@uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS084088, RO1 NS062993]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, P01NS058484, R21NS084088, R01NS062993] Funding Source: NIH RePORTER	The author's research was supported by NIH grants R21 NS084088 and RO1 NS062993.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Alsaif M, 2012, PROTEOM CLIN APPL, V6, P297, DOI 10.1002/prca.201100061; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Babak T, 2004, RNA, V10, P1813, DOI 10.1261/rna.7119904; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Baker JG, 2014, INT J CLIN PRACT, V68, P1286, DOI 10.1111/ijcp.12517; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; BARBARESE E, 1988, J NEUROCHEM, V51, P1737, DOI 10.1111/j.1471-4159.1988.tb01153.x; Bay Esther, 2005, J Neurosci Nurs, V37, P4; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bradbury A.R., 2010, CURR PROTOC NEUROSCI; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cadosch D, 2010, ANZ J SURG, V80, P542, DOI 10.1111/j.1445-2197.2010.05268.x; Cai XY, 2011, ATHEROSCLEROSIS, V217, P536, DOI 10.1016/j.atherosclerosis.2011.05.023; Campbell LK, 2003, MODERN PATHOL, V16, P963, DOI 10.1097/01.MP.0000087088.88280.B0; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Caner H, 2004, ACTA NEUROCHIR, V146, P611, DOI 10.1007/s00701-003-0209-9; Canu N, 1998, J NEUROSCI, V18, P7061; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107; Chen JX, 2014, OTOLARYNG HEAD NECK, V151, P554, DOI 10.1177/0194599814542588; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Corcoran TB, 2011, ANTIOXID REDOX SIGN, V15, P2663, DOI 10.1089/ars.2011.4125; Cortes DF, 2012, ELECTROPHORESIS, V33, P3712, DOI 10.1002/elps.201200341; Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; De Guire V, 2013, CLIN BIOCHEM, V46, P846, DOI 10.1016/j.clinbiochem.2013.03.015; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Diamandis EP, 2004, J NATL CANCER I, V96, P353, DOI 10.1093/jnci/djh056; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Gogas H, 2009, ANN ONCOL, V20, pvi8, DOI DOI 10.1093/ANN0NC/MDP251; Good DM, 2007, J PROTEOME RES, V6, P4549, DOI 10.1021/pr070529w; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guingab-Cagmat JD, 2012, ELECTROPHORESIS, V33, P3786, DOI 10.1002/elps.201200326; Guzel A, 2010, AM J EMERG MED, V28, P399, DOI 10.1016/j.ajem.2008.12.025; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; HAIMOTO H, 1987, LAB INVEST, V57, P489; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hallen M, 2010, J TRAUMA, V69, P284, DOI 10.1097/TA.0b013e3181ca060b; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jeter CB, 2012, J NEUROTRAUM, V29, P119, DOI 10.1089/neu.2011.2029; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Kontogeorgis D, 2013, EMERG MED J, V30, P597, DOI 10.1136/emermed-2013-202853.3; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lash GE, 2006, J IMMUNOL METHODS, V309, P205, DOI 10.1016/j.jim.2005.12.007; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Lundblad R., 2003, INTERNET J GENOMICS, V1; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MAIR J, 1992, CRIT REV CL LAB SCI, V29, P31, DOI 10.3109/10408369209105245; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Martins TB, 2002, AM J CLIN PATHOL, V118, P346; Mazzini GS, 2005, LIFE SCI, V77, P882, DOI 10.1016/j.lfs.2004.12.035; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; O'Neal WK, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-9; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Ottens AK, 2014, J NEUROTRAUM, V31, P782, DOI 10.1089/neu.2013.3116; Ottens AK, 2010, J NEUROTRAUM, V27, P1837, DOI 10.1089/neu.2010.1374; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pogoda TK, 2014, J REHABIL RES DEV, V51, P363, DOI 10.1682/JRRD.2013.05.0115; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; RAND Corporation, 2008, INV WOUNDS MENT HLTH; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Romeo MJ, 2005, EXPERT REV PROTEOMIC, V2, P57, DOI 10.1586/14789450.2.1.57; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sakai K, 2003, J CLIN NEUROSCI, V10, P677, DOI 10.1016/S0967-5868(03)00073-0; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schroeter ML, 2013, CURR DRUG TARGETS, V14, P1237; SCHWAB C, 1994, HIPPOCAMPUS, V4, P210, DOI 10.1002/hipo.450040212; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R., 2014, J NEUROTRAU IN PRESS; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Somers V, 2008, J IMMUNOL, V180, P3957, DOI 10.4049/jimmunol.180.6.3957; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Takami Y, 2007, ARTERIOSCL THROM VAS, V27, P2184, DOI 10.1161/ATVBAHA.107.142505; Tandler N, 2012, AMINO ACIDS, V43, P2203, DOI 10.1007/s00726-012-1409-5; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; VINORES SA, 1984, J HISTOCHEM CYTOCHEM, V32, P1295, DOI 10.1177/32.12.6389693; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang M, 2011, RHEUMATOL INT, V31, P1009, DOI 10.1007/s00296-010-1403-8; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Weiss ES, 2009, ANN THORAC SURG, V88, P543, DOI 10.1016/j.athoracsur.2009.04.016; Weng XJ, 2012, CLIN BIOCHEM, V45, P303, DOI 10.1016/j.clinbiochem.2011.12.018; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang ZF, 2014, EURASIP J AUDIO SPEE, DOI 10.1186/1687-4722-2014-15; Zhang ZJ, 2011, J CLIN LAB ANAL, V25, P402, DOI 10.1002/jcla.20491; Zurbig P, 2012, ELECTROPHORESIS, V33, P3617, DOI 10.1002/elps.201200360	225	64	64	1	45	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2016	275		3		SI		334	352		10.1016/j.expneurol.2015.05.004			19	Neurosciences	Neurosciences & Neurology	DB2ED	WOS:000368320200005	25981889	Green Accepted			2021-06-18	
J	Skaper, SD; Facci, L; Barbierato, M; Zusso, M; Bruschetta, G; Impellizzeri, D; Cuzzocrea, S; Giusti, P				Skaper, Stephen D.; Facci, Laura; Barbierato, Massimo; Zusso, Morena; Bruschetta, Giuseppe; Impellizzeri, Daniela; Cuzzocrea, Salvatore; Giusti, Pietro			N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution	MOLECULAR NEUROBIOLOGY			English	Article						Microglia; Mast cells; Neuroinflammation; Neuropathic pain; Neurodegeneration; Palmitoylethanolamide; Luteolin; Ultramicronization; Neuroprotection	ACID AMIDE HYDROLASE; MAST-CELLS; SPINAL-CORD; IMMUNE-RESPONSES; OXIDATIVE STRESS; MICROGLIA; LUTEOLIN; RAT; ACTIVATION; MECHANISMS	Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process. However, when prolonged, it can override the bounds of physiological control and becomes destructive. Inflammation is a key element in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury, and neuropsychiatric disorders. Glia, key players in such nervous system disorders, are not only capable of expressing a pro-inflammatory phenotype but respond also to inflammatory signals released from cells of immune origin such as mast cells. Chronic inflammatory processes may be counteracted by a program of resolution that includes the production of lipid mediators endowed with the capacity to switch off inflammation. These naturally occurring lipid signaling molecules include the N-acylethanolamines, N-arachidonoylethanolamine (an endocannabinoid), and its congener N-palmitoylethanolamine (palmitoylethanolamide or PEA). PEA may play a role in maintaining cellular homeostasis when faced with external stressors provoking, for example, inflammation. PEA is efficacious in mast cell-mediated models of neurogenic inflammation and neuropathic pain and is neuroprotective in models of stroke, spinal cord injury, traumatic brain injury, and Parkinson disease. PEA in micronized/ultramicronized form shows superior oral efficacy in inflammatory pain models when compared to na < ve PEA. Intriguingly, while PEA has no antioxidant effects per se, its co-ultramicronization with the flavonoid luteolin is more efficacious than either molecule alone. Inhibiting or modulating the enzymatic breakdown of PEA represents a complementary therapeutic approach to treat neuroinflammation. This review is intended to discuss the role of mast cells and glia in neuroinflammation and strategies to modulate their activation based on leveraging natural mechanisms with the capacity for self-defense against inflammation.	[Skaper, Stephen D.; Facci, Laura; Barbierato, Massimo; Zusso, Morena; Giusti, Pietro] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy; [Bruschetta, Giuseppe; Impellizzeri, Daniela; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy	Skaper, SD (corresponding author), Univ Padua, Dept Pharmaceut & Pharmacol Sci, Largo Egidio Meneghetti 2, I-35131 Padua, Italy.	stephen.skaper@unipd.it		Cuzzocrea, Salvatore/0000-0001-6131-3690; Impellizzeri, Daniela/0000-0001-9492-3161; GIUSTi, Pietro/0000-0001-9352-4046	MIURMinistry of Education, Universities and Research (MIUR) [PON01_02512]	This study was supported in part by MIUR, PON "Ricerca e Competitivita 2007-2013" project PON01_02512.	Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; [Anonymous], 2013, Patent application WO, Patent No. [2013121449 A1, 2013121449]; BISRAT M, 1988, INT J PHARM, V47, P223, DOI 10.1016/0378-5173(88)90235-9; Bossers K, 2010, BRAIN, V133, P3699, DOI 10.1093/brain/awq258; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Buckley CD, 2013, NAT REV IMMUNOL, V13, P59, DOI 10.1038/nri3362; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Castellheim A, 2009, SCAND J IMMUNOL, V69, P479, DOI 10.1111/j.1365-3083.2009.02255.x; Cervellati C, 2013, CURR ALZHEIMER RES, V10, P365, DOI 10.2174/1567205011310040003; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; Coleta M, 2008, BEHAV BRAIN RES, V189, P75, DOI 10.1016/j.bbr.2007.12.010; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; Costanza M, 2012, INT J MOL SCI, V13, P15107, DOI 10.3390/ijms131115107; Crupi R, 2013, CNS NEUROL DISORD-DR, V12, P989, DOI 10.2174/18715273113129990084; Duranti A, 2012, J MED CHEM, V55, P4824, DOI 10.1021/jm300349j; Engler H, 2011, BRAIN BEHAV IMMUN, V25, P1384, DOI 10.1016/j.bbi.2011.04.005; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Fiala M, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-76; Frakes AE, 2014, NEURON, V81, P1009, DOI 10.1016/j.neuron.2014.01.013; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; Gasque P, 1997, AM J PATHOL, V150, P31; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Graves MC, 2004, AMYOTROPH LATERAL SC, V5, P213, DOI 10.1080/14660820410020286; Grosso C, 2013, CURR MED CHEM, V20, P4694, DOI 10.2174/09298673113209990155; Hoyer FF, 2014, J MOL CELL CARDIOL, V66, P126, DOI 10.1016/j.yjmcc.2013.11.013; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Impellizzeri D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0136-0; Joshi J.T., 2011, THE J, V3, P651; Kang HJ, 2012, NAT MED, V18, P1413, DOI 10.1038/nm.2886; Kim DY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-25; LAMBRACHTHALL M, 1990, DEV BRAIN RES, V56, P151, DOI 10.1016/0165-3806(90)90077-C; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Li Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042558; Lindsberg PJ, 2010, J CEREBR BLOOD F MET, V30, P689, DOI 10.1038/jcbfm.2009.282; McGeer PL, 2013, ACTA NEUROPATHOL, V126, P479, DOI 10.1007/s00401-013-1177-7; Morales I, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00112; Myers RR, 2006, DRUG DISCOV TODAY, V11, P8, DOI 10.1016/S1359-6446(05)03637-8; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Noriega DB, 2014, EUR J PEDIATR, V173, P33, DOI 10.1007/s00431-013-2183-4; Oh DM, 1995, ARCH PHARM RES, V18, P427, DOI 10.1007/BF02976347; Olusanmi D, 2014, POWDER TECHNOL, V258, P222, DOI 10.1016/j.powtec.2014.03.032; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Parra-Damas A, 2014, J NEUROSCI, V34, P5776, DOI 10.1523/JNEUROSCI.5288-13.2014; Paterniti I, 2014, CNS NEUROL DISORD-DR, V13, P1530, DOI 10.2174/1871527313666140806124322; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-91; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Pietrzak A, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/427473; Piomelli D, 2014, NAT NEUROSCI, V17, P164, DOI 10.1038/nn.3612; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Radi E, 2014, J ALZHEIMERS DIS, V42, pS125, DOI 10.3233/JAD-132738; Rasenack N, 2004, PHARM DEV TECHNOL, V9, P1, DOI 10.1081/PDT-120027417; Rivat C, 2010, PAIN, V150, P358, DOI 10.1016/j.pain.2010.05.031; Salim S, 2014, CURR NEUROPHARMACOL, V12, P140, DOI 10.2174/1570159X11666131120230309; Sasso O, 2013, PAIN, V154, P350, DOI 10.1016/j.pain.2012.10.018; Saturnino C, 2010, BIOORG MED CHEM LETT, V20, P1210, DOI 10.1016/j.bmcl.2009.11.134; Schafer T, 2010, ALLERGY, V65, P1242, DOI 10.1111/j.1398-9995.2010.02350.x; Siegmund SV, 2013, BIOCHEM BIOPH RES CO, V437, P48, DOI 10.1016/j.bbrc.2013.06.033; Silver R, 2013, TRENDS NEUROSCI, V36, P513, DOI 10.1016/j.tins.2013.06.001; Silverman AJ, 2000, J NEUROSCI, V20, P401, DOI 10.1523/JNEUROSCI.20-01-00401.2000; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Skaper SD, 2012, PHILOS T R SOC B, V367, P3312, DOI 10.1098/rstb.2011.0391; Skaper SD, 2012, FASEB J, V26, P3103, DOI 10.1096/fj.11-197194; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720; Ueda N, 2013, FEBS J, V280, P1874, DOI 10.1111/febs.12152; Vitale R, 2014, CHEMMEDCHEM, V9, P323, DOI 10.1002/cmdc.201300416; Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544; Xanthos DN, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-42; Xu B, 2010, EUR J PHARMACOL, V627, P99, DOI 10.1016/j.ejphar.2009.10.038; Yamano Y, 2012, BIOORGAN MED CHEM, V20, P3658, DOI 10.1016/j.bmc.2012.03.065	76	64	64	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	OCT	2015	52	2			SI		1034	1042		10.1007/s12035-015-9253-8			9	Neurosciences	Neurosciences & Neurology	CQ6AQ	WOS:000360687200022	26055231				2021-06-18	
J	Harrison, JL; Rowe, RK; Ellis, TW; Yee, NS; O'Hara, BF; Adelson, PD; Lifshitz, J				Harrison, Jordan L.; Rowe, Rachel K.; Ellis, Timothy W.; Yee, Nicole S.; O'Hara, Bruce F.; Adelson, P. David; Lifshitz, Jonathan			Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse	BRAIN BEHAVIOR AND IMMUNITY			English	Article						TBI; Inflammation; Resolvins; Protectins; Sleep; Mouse; Behavior; Aspirin-triggered resolvin	RAT MODEL; MICE; CYTOKINES; WAKE; WAKEFULNESS; PATHOPHYSIOLOGY; NEUROPROTECTION; INFLAMMATION; EXPRESSION; MEDIATORS	Traumatic brain injury (TBI) is induced by mechanical forces which initiate a cascade of secondary injury processes, including inflammation. Therapies which resolve the inflammatory response may promote neural repair without exacerbating the primary injury. Specific derivatives of omega-3 fatty acids loosely grouped as specialized pro-resolving lipid mediators (SPMs) and termed resolvins promote the active resolution of inflammation. In the current study, we investigate the effect of two resolvin molecules, RvE1 and AT-RvD1, on post-traumatic sleep and functional outcome following diffuse TBI through modulation of the inflammatory response. Adult, male C57BL/6 mice were injured using a midline fluid percussion injury (mFPI) model (6-10 min righting reflex time for brain-injured mice). Experimental groups included mFPI administered RvE1 (100 ng daily), AT-RvD1 (100 ng daily), or vehicle (sterile saline) and counterbalanced with uninjured sham mice. Resolvins or saline were administered daily for seven consecutive days beginning 3 days prior to TBI to evaluate proof-of-principle to improve outcome. Immediately following diffuse TBI, post-traumatic sleep was recorded for 24 h post-injury. For days 1-7 post-injury, motor outcome was assessed by rotarod. Cognitive function was measured at 6 days post-injury using novel object recognition (NOR). At 7 days post-injury, microglial activation was quantified using immunohistochemistry for Iba-1. In the diffuse brain-injured mouse, AT-RvD1 treatment, but not RvE1, mitigated motor and cognitive deficits. RvEl treatment significantly increased post-traumatic sleep in brain-injured mice compared to all other groups. RvEl treated mice displayed a higher proportion of ramified microglia and lower proportion of activated rod microglia in the cortex compared to saline or AT-RvD1 treated brain-injured mice. Thus, RvEl treatment modulated post-traumatic sleep and the inflammatory response to TB!, albeit independently of improvement in motor and cognitive outcome as seen in AT-RvD1-treated mice. This suggests AT-RvD1 may impart functional benefit through mechanisms other than resolution of inflammation alone. (C) 2015 Elsevier Inc. All rights reserved.	[Harrison, Jordan L.; Rowe, Rachel K.; Ellis, Timothy W.; Yee, Nicole S.; Adelson, P. David; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Harrison, Jordan L.; Rowe, Rachel K.; Ellis, Timothy W.; Yee, Nicole S.; Adelson, P. David; Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Harrison, Jordan L.; Adelson, P. David; Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Grad Program Neurosci, Tempe, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Ellis, Timothy W.] Midwestern Univ, Coll Osteopath Med, Glendale, AZ USA; [O'Hara, Bruce F.] Univ Kentucky, Dept Biol, Coll Arts & Sci, Lexington, KY USA; [O'Hara, Bruce F.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA	Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	jlifshitz@email.arizona.edu	Adelson, David/W-2083-2019	Rowe, Rachel/0000-0002-9034-3159	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS072611, RO1 NS-065052]; PCH Mission Support Funds; Kentucky Spinal Cord & Head Injury Research Trust [10-5A]; Diane and Bruce Halle Foundation; Science Foundation Arizona Bisgrove Scholarship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072611, R01NS065052] Funding Source: NIH RePORTER	Research reported in this manuscript was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award numbers R21 NS072611 and RO1 NS-065052, PCH Mission Support Funds, and Kentucky Spinal Cord & Head Injury Research Trust award 10-5A. The generosity of the Diane and Bruce Halle Foundation supported JLH during the conduct of these studies. RKR was supported by a Science Foundation Arizona Bisgrove Scholarship during the conduct of these studies.	Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bazan NG, 2012, EXP NEUROL, V236, P122, DOI 10.1016/j.expneurol.2012.04.007; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Donohue KD, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-14; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Harrison JL, 2014, EXP BRAIN RES, V232, P2709, DOI 10.1007/s00221-014-3948-3; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hazra A, 2014, J NEUROSCI RES, V92, P1434, DOI 10.1002/jnr.23430; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Hsu JC, 2003, CELLS TISSUES ORGANS, V173, P242, DOI 10.1159/000070380; Ingiosi AM, 2013, CURR OPIN NEUROBIOL, V23, P806, DOI 10.1016/j.conb.2013.02.003; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Klein CP, 2014, NEUROPHARMACOLOGY, V86, P57, DOI 10.1016/j.neuropharm.2014.05.043; Krueger JM, 2007, SLEEP MED CLIN, V2, P161, DOI 10.1016/j.jsmc.2007.03.003; KRUEGER JM, 1995, ADV NEUROIMMUNOL, V5, P171, DOI 10.1016/0960-5428(95)00007-O; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mang GM, 2014, SLEEP, V37, P1383, DOI 10.5665/sleep.3936; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McShane BB, 2010, J NEUROSCI METH, V193, P321, DOI 10.1016/j.jneumeth.2010.08.024; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mukherjee S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00028; Recchiuti A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00298; Rowe RK, 2014, SLEEP, V37, P743, DOI 10.5665/sleep.3582; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Tallarida RJ, 2012, J PHARMACOL EXP THER, V342, P2, DOI 10.1124/jpet.112.193474; Taylor SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097096; Tham SW, 2013, J PAIN, V14, P1242, DOI 10.1016/j.jpain.2013.05.007; Thomas KS, 2011, BRAIN BEHAV IMMUN, V25, P53, DOI 10.1016/j.bbi.2010.07.245; Wang L, 2014, CHINESE MED J-PEKING, V127, P803, DOI 10.3760/cma.j.issn.0366-6999.20131044; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404; Wirenfeldt M, 2009, NEUROBIOL DIS, V34, P432, DOI 10.1016/j.nbd.2009.02.015; Wisor JP, 2011, BRAIN BEHAV IMMUN, V25, P767, DOI 10.1016/j.bbi.2011.02.002; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	67	64	64	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JUL	2015	47				SI		131	140		10.1016/j.bbi.2015.01.001			10	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	CL8NM	WOS:000357231400015	25585137	Green Accepted			2021-06-18	
J	Scholten, AC; Haagsma, JA; Andriessen, TMJC; Vos, PE; Steyerberg, EW; van Beeck, EF; Polinder, S				Scholten, A. C.; Haagsma, J. A.; Andriessen, T. M. J. C.; Vos, P. E.; Steyerberg, E. W.; van Beeck, E. F.; Polinder, S.			Health-related quality of life after mild, moderate and severe traumatic brain injury: Patterns and predictors of suboptimal functioning during the first year after injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Follow-up studies; Glasgow outcome scale-extended; Health-related quality of life; SF-36	SEVERE HEAD-INJURY; GLASGOW OUTCOME SCALE; MULTIPLE TRAUMA; QOLIBRI; SATISFACTION; DISABILITY; RECOVERY; S100B; SF-36	Background: The Glasgow Outcome Scale Extended (GOSE) is the established functional outcome scale to assess disability following traumatic brain injury (TBI), however does not capture the patient's subjective perspective. Health-related quality of life (HRQL) does capture the individual's perception of disability after TBI, and has therefore been recognized as an important outcome in TBI. In contrast to GOSE, HRQL enables comparison of health outcome across various disease states and with healthy individuals. We aimed to assess functional outcome, HRQL, recovery, and predictors of 6 and 12-month outcome in a comprehensive sample of patients with mild, moderate or severe TBI, and to examine the relationship between functional impairment (GOSE) and HRQL. Methods: A prospective cohort study was conducted among a sample of 2066 adult TBI patients who attended the emergency department (ED). GOSE was determined through questionnaires or structured interviews. Questionnaires 6 and 12 months after ED treatment included socio-demographic information and HRQL measured with Short-Form Health Survey (SF-36; reflecting physical, mental and social functioning) and Perceived Quality of Life Scale (PQoL; measuring degree of satisfaction with functioning). Results: 996 TBI survivors with mild, moderate or severe TBI completed the 6-month questionnaire. Functional outcome and HRQL after moderate or severe TBI was significantly lower than after mild TBI. Patients with moderate TBI showed greatest improvement. After one year, the mild TBI group reached outcomes comparable to population norms. TBI of all severities highly affected SF-36 domains physical and social functioning, and physical and emotional role functioning. GOSE scores were highly related to all SF-36 domains and PQoL scores. Female gender, older age, co-morbidity and high ISS were strongest independent predictors of decreased HRQL at 6 and 12 months after TBI. Conclusions: HRQL and recovery patterns differ for mild, moderate and severe TBI. This study indicates that GOSE, although clinically relevant, fails to capture the subjective perspective of TBI patients, which endorses the use of HRQL as valuable addition to established instruments in assessing disability following TBI. Influence of TBI severity on recovery, together with female gender, older age, co-morbidity and high ISS should be considered in long-term follow-up and intervention programs. (C) 2014 Elsevier Ltd. All rights reserved.	[Scholten, A. C.; Haagsma, J. A.; Steyerberg, E. W.; van Beeck, E. F.; Polinder, S.] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Andriessen, T. M. J. C.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Vos, P. E.] Slingeland Hosp, Dept Neurol, NL-7000 AD Doetinchem, Netherlands	Scholten, AC (corresponding author), Erasmus MC, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.scholten@erasmusmc.nl					Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P825, DOI 10.3109/02699052.2012.655364; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Beseoglu K, 2013, BRIT J NEUROSURG, V27, P202, DOI 10.3109/02688697.2012.717984; Brain Injury Association of America, 2012, AB BRAIN INJ; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Forslund M.V., 2013, ACTA NEUROL SCAND; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Guyatt G. H, 1996, QUALITY LIFE PHARMAC, P41; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hu XB, 2012, BRAIN INJURY, V26, P183, DOI 10.3109/02699052.2011.648707; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Machamer J, 2013, J NEUROTRAUM, V30, P1845, DOI 10.1089/neu.2013.2920; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; McLean AM, 2014, DISABIL REHABIL, V36, P1409, DOI 10.3109/09638288.2013.834986; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Polinder S, 2013, LANCET, V381, P116; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Riemsma R P, 2001, Health Technol Assess, V5, P1; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Seattle Quality of Life Group, 2008, INF SHEET PERC QUAL; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; TEASDALE G, 1974, LANCET, V2, P81; Vittinghoff E, 2012, REGRESSION METHODS B, V2nd; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Ware JE., 1993, SF 36 HLTH SURVEY MA; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	57	64	65	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	APR	2015	46	4					616	624		10.1016/j.injury.2014.10.064			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CD7MZ	WOS:000351275900017	25476014				2021-06-18	
J	Imbach, LL; Valko, PO; Li, TZ; Maric, A; Symeonidou, ER; Stover, JF; Bassetti, CL; Mica, L; Werth, E; Baumann, CR				Imbach, Lukas L.; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Symeonidou, Evangelia-Regkina; Stover, John F.; Bassetti, Claudio L.; Mica, Ladislav; Werth, Esther; Baumann, Christian R.			Increased sleep need and daytime sleepiness 6 months after traumatic brain injury: a prospective controlled clinical trial	BRAIN			English	Article						traumatic brain injury; sleep; post-traumatic pleiosomnia; post-traumatic daytime sleepiness	NEURON-SPECIFIC ENOLASE; PERIODIC LEG MOVEMENTS; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; LESIONS; DISTURBANCES; ALERTNESS; PATTERNS; ADULTS; BLOOD	Post-traumatic sleep-wake disturbances are common after acute traumatic brain injury. Increased sleep need per 24 h and excessive daytime sleepiness are among the most prevalent post-traumatic sleep disorders and impair quality of life of trauma patients. Nevertheless, the relation between traumatic brain injury and sleep outcome, but also the link between post-traumatic sleep problems and clinical measures in the acute phase after traumatic brain injury has so far not been addressed in a controlled and prospective approach. We therefore performed a prospective controlled clinical study to examine (i) sleep-wake outcome after traumatic brain injury; and (ii) to screen for clinical and laboratory predictors of poor sleep-wake outcome after acute traumatic brain injury. Forty-two of 60 included patients with first-ever traumatic brain injury were available for follow-up examinations. Six months after trauma, the average sleep need per 24 h as assessed by actigraphy was markedly increased in patients as compared to controls (8.3 +/- 1.1 h versus 7.1 +/- 0.8 h, P < 0.0001). Objective daytime sleepiness was found in 57% of trauma patients and 19% of healthy subjects, and the average sleep latency in patients was reduced to 8.7 +/- 4.6 min (12.1 +/- 4.7 min in controls, P = 0.0009). Patients, but not controls, markedly underestimated both excessive sleep need and excessive daytime sleepiness when assessed only by subjective means, emphasizing the unreliability of self-assessment of increased sleep propensity in traumatic brain injury patients. At polysomnography, slow wave sleep after traumatic brain injury was more consolidated. The most important risk factor for developing increased sleep need after traumatic brain injury was the presence of an intracranial haemorrhage. In conclusion, we provide controlled and objective evidence for a direct relation between sleep-wake disturbances and traumatic brain injury, and for clinically significant underestimation of post-traumatic sleep-wake disturbances by trauma patients.	[Imbach, Lukas L.; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Symeonidou, Evangelia-Regkina; Werth, Esther; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Stover, John F.; Mica, Ladislav] Univ Zurich Hosp, Dept Traumatol, CH-8091 Zurich, Switzerland; [Bassetti, Claudio L.] Inselspital Bern, Dept Neurol, CH-3010 Bern, Switzerland	Baumann, CR (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	christian.baumann@usz.ch	Werth, E/AAN-7955-2021	Imbach, Lukas/0000-0002-6135-8642; Maric, Angelina/0000-0002-1416-6728; Werth, Esther/0000-0002-5099-3122; Bassetti, Claudio/0000-0002-4535-0245; Baumann, Christian/0000-0003-3417-1978	Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF) [32003B-125504]; Clinical Research Priority Program 'Sleep and Health' of the University of Zurich	This study was supported by the Swiss National Science Foundation (SNF, grant no. 32003B-125504), and by the Clinical Research Priority Program 'Sleep and Health' of the University of Zurich.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Cetas JS, 2009, NEUROSCIENCE, V163, P719, DOI 10.1016/j.neuroscience.2009.06.031; Chapotot F, 1998, J CLIN ENDOCR METAB, V83, P4263, DOI 10.1210/jc.83.12.4263; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Cippa MAT, 2013, J SLEEP RES, V22, P589, DOI 10.1111/jsr.12053; CROMPTON MR, 1971, LANCET, V1, P669; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Dijk DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030037; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Hautzinger M., 1993, ALLGEMEINE DEPRESSIO; King MA, 2005, SLEEP MED, V6, P507, DOI 10.1016/j.sleep.2004.12.010; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mignot E, 2006, BRAIN, V129, P1609, DOI 10.1093/brain/awl079; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Valko PO, ANN NEUROL; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	29	64	68	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR 1	2015	138		3				726	735		10.1093/brain/awu391			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CE0QY	WOS:000351510700027	25595147	Bronze, Green Published, Green Accepted			2021-06-18	
J	Patel, TP; Gullotti, DM; Hernandez, P; O'Brien, WT; Capehart, BP; Morrison, B; Bass, C; Eberwine, JE; Abel, T; Meaney, DF				Patel, Tapan P.; Gullotti, David M.; Hernandez, Pepe; O'Brien, W. Timothy; Capehart, Bruce P.; Morrison, Barclay, III; Bass, Cameron; Eberwine, James E.; Abel, Ted; Meaney, David F.			An open-source toolbox for automated phenotyping of mice in behavioral tasks	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						automated behavior; blast-induced traumatic brain injury; Elk-1 knockout; spatial object recognition; social interaction; Barnes maze	TRAUMATIC BRAIN-INJURY; LONG-TERM-MEMORY; HOME CAGE ACTIVITY; RECOGNITION MEMORY; TRANSCRIPTION FACTOR; C57BL/6J MICE; OPEN-FIELD; ELK-1; HIPPOCAMPUS; ANXIETY	Classifying behavior patterns in mouse models of neurological, psychiatric and neurodevelopmental disorders is critical for understanding disease causality and treatment. However, complete characterization of behavior is time-intensive, prone to subjective scoring, and often requires specialized equipment. Although several reports describe automated home-cage monitoring and individual task scoring methods, we report the first open source, comprehensive toolbox for automating the scoring of several common behavior tasks used by the neuroscience community. We show this new toolbox is robust and achieves equal or better consistency when compared to manual scoring methods. We use this toolbox to study the alterations in behavior that occur following blast-induced traumatic brain injury (bTBI), and study if these behavior patterns are altered following genetic deletion of the transcription factor Ets-like kinase 1 (Elk-1). Due to the role of Elk-1 in neuronal survival and proposed role in synaptic plasticity, we hypothesized that Elk-1 deletion would improve some neurobehavioral deficits, while impairing others, following blast exposure. In Elk-1 knockout (KO) animals, deficits in open field, spatial object recognition (SOR) and elevated zero maze performance after blast exposure disappeared, while new significant deficits appeared in spatial and associative memory. These are the first data suggesting a molecular mediator of anxiety deficits following bTBI, and represent the utility of the broad screening tool we developed. More broadly, we envision this open-source toolbox will provide a more consistent and rapid analysis of behavior across many neurological diseases, promoting the rapid discovery of novel pathways mediating disease progression and treatment.	[Patel, Tapan P.; Gullotti, David M.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Hernandez, Pepe; Abel, Ted] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [O'Brien, W. Timothy] Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; [Capehart, Bruce P.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA; [Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY USA; [Bass, Cameron] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Eberwine, James E.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Patel, Tapan/0000-0001-8959-6645; Abel, Ted/0000-0003-2423-4592; Meaney, David/0000-0002-0954-4122	Department of Army [W911F-10-1-0526]; Simon Foundation Autism Research Initiative [248429, R21MH099648-02]	Funding for this project was provided by the Department of Army grant W911F-10-1-0526, the Simon Foundation Autism Research Initiative 248429, and R21MH099648-02. We thank the Neurobehavior Testing Core of the Penn Medicine Neuroscience Center for providing some of the videos for software development.	Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Balderas I, 2008, LEARN MEMORY, V15, P618, DOI 10.1101/lm.1028008; Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Barrett LE, 2006, NAT METHODS, V3, P455, DOI 10.1038/NMETH885; Besnard A, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00035; Bonasera SJ, 2008, PSYCHOPHARMACOLOGY, V196, P591, DOI 10.1007/s00213-007-0994-6; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Casadesus G, 2001, MECH AGEING DEV, V122, P1887, DOI 10.1016/S0047-6374(01)00324-4; Cesari F, 2004, GENESIS, V38, P87, DOI 10.1002/gene.20003; Chen SA, 2006, NEUROPSYCHOPHARMACOL, V31, P2692, DOI 10.1038/sj.npp.1301008; Choleris E, 2001, NEUROSCI BIOBEHAV R, V25, P235, DOI 10.1016/S0149-7634(01)00011-2; Clifford S, 2007, J AUTISM DEV DISORD, V37, P301, DOI 10.1007/s10803-006-0160-8; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Defensor EB, 2011, BEHAV BRAIN RES, V217, P302, DOI 10.1016/j.bbr.2010.10.033; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goulding EH, 2008, P NATL ACAD SCI USA, V105, P20575, DOI 10.1073/pnas.0809053106; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Jacobson LH, 2007, PSYCHOPHARMACOLOGY, V190, P541, DOI 10.1007/s00213-006-0631-9; Jhuang H, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1064; Joachims T, 1999, ADVANCES IN KERNEL METHODS, P169; Kabra M, 2013, NAT METHODS, V10, P64, DOI [10.1038/NMETH.2281, 10.1038/nmeth.2281]; Karlsson RM, 2005, PHARMACOL BIOCHEM BE, V80, P427, DOI 10.1016/j.pbb.2004.12.009; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; MARKOW TA, 1981, P NATL ACAD SCI-BIOL, V78, P430, DOI 10.1073/pnas.78.1.430; Millecamps M, 2005, ARTHRITIS RHEUM-US, V52, P3470, DOI 10.1002/art.21403; Morris JF, 2013, HUM PATHOL, V44, P766, DOI 10.1016/j.humpath.2012.08.001; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rutten K, 2008, J NEUROSCI METH, V171, P72, DOI 10.1016/j.jneumeth.2008.02.006; Sananbenesi F, 2002, MOL CELL NEUROSCI, V21, P463, DOI 10.1006/mcne.2002.1188; Sharma A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009002; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; TAMBORINI P, 1989, ARCH TOXICOL, V63, P85, DOI 10.1007/BF00316429; Tang XD, 2005, PHYSIOL BEHAV, V84, P105, DOI 10.1016/j.physbeh.2004.10.017; Tang XD, 2002, BEHAV BRAIN RES, V136, P555, DOI 10.1016/S0166-4328(02)00228-0; Vekovischeva OY, 2007, BEHAV PROCESS, V75, P23, DOI 10.1016/j.beproc.2007.01.006; Vianna MRM, 2000, LEARN MEMORY, V7, P333, DOI 10.1101/lm.34600; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002	47	64	64	0	7	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	OCT 8	2014	8								349	10.3389/fnbeh.2014.00349			16	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AW0LQ	WOS:000345984200001	25339878	DOAJ Gold, Green Published			2021-06-18	
J	Xuan, WJ; Vatansever, F; Huang, LY; Hamblin, MR				Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Hamblin, Michael R.			Transcranial low-level laser therapy enhances learning, memory, and neuroprogenitor cells after traumatic brain injury in mice	JOURNAL OF BIOMEDICAL OPTICS			English	Article						traumatic brain injury; transcranial low level light therapy; Morris water maze; wire grip motion test; neurogenesis; BrdU; NeuN; double-cortin; TUJ-1; caspase-3; mitochondrial modulation	TERM NEUROLOGICAL DEFICITS; NEURON-SPECIFIC TUBULIN; ADULT NEUROGENESIS; LIGHT THERAPY; IMPACT; RAT; NEUROPROTECTION; DYSFUNCTION; EXPRESSION; DEPRESSION	The use of transcranial low-level laser (light) therapy (tLLLT) to treat stroke and traumatic brain injury (TBI) is attracting increasing attention. We previously showed that LLLT using an 810-nm laser 4 h after controlled cortical impact (CCI)-TBI in mice could significantly improve the neurological severity score, decrease lesion volume, and reduce Fluoro-Jade staining for degenerating neurons. We obtained some evidence for neurogenesis in the region of the lesion. We now tested the hypothesis that tLLLT can improve performance on the Morris water maze (MWM, learning, and memory) and increase neurogenesis in the hippocampus and subventricular zone (SVZ) after CCI-TBI in mice. One and (to a greater extent) three daily laser treatments commencing 4-h post-TBI improved neurological performance as measured by wire grip and motion test especially at 3 and 4 weeks post-TBI. Improvements in visible and hidden platform latency and probe tests in MWM were seen at 4 weeks. Caspase-3 expression was lower in the lesion region at 4 days post-TBI. Double-stained BrdU-NeuN (neuroprogenitor cells) was increased in the dentate gyrus and SVZ. Increases in double-cortin (DCX) and TUJ-1 were also seen. Our study results suggest that tLLLT may improve TBI both by reducing cell death in the lesion and by stimulating neurogenesis. (C) 2014 Society of Photo-Optical Instrumentation Engineers (SPIE)	[Xuan, Weijun] Guangxi Univ Chinese Med, Ruikang Hosp, Dept Otolaryngol, Nanning 530021, Peoples R China; [Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning 530021, Peoples R China; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605	US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550-13-1-0068]; US Army Medical Research Acquisition Activity Grant [W81XWH-09-1-0514]; US Army Medical Research and Materiel Command GrantU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0067]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by US NIH Grant No. R01AI050875, by Air Force Office of Scientific Research Grant No. FA9550-13-1-0068, by US Army Medical Research Acquisition Activity Grant No. W81XWH-09-1-0514 and by US Army Medical Research and Materiel Command Grant No. W81XWH-13-2-0067.	Acosta S, 2010, REJUV RES, V13, P581, DOI 10.1089/rej.2009.1011; Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; [Anonymous], 2011, REV NEUROSCI, V22, P457; Beukelaers P, 2012, CELL MOL LIFE SCI, V69, P1493, DOI 10.1007/s00018-011-0880-6; Bonfanti L, 2011, EUR J NEUROSCI, V34, P930, DOI 10.1111/j.1460-9568.2011.07832.x; Bovetti S, 2011, J CHEM NEUROANAT, V42, P304, DOI 10.1016/j.jchemneu.2011.05.006; Bromley-Brits K, 2011, JOVE-J VIS EXP, DOI 10.3791/2920; Brus M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00135; Chu JR, 2010, CANCER LETT, V297, P207, DOI 10.1016/j.canlet.2010.05.013; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Dubourg J, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11182; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Hanson ND, 2011, NEUROPSYCHOPHARMACOL, V36, P2589, DOI 10.1038/npp.2011.220; Huang YY, 2014, J BIOPHOTONICS, V7, P656, DOI 10.1002/jbio.201300125; Huang YY, 2013, J BIOPHOTONICS, V6, P829, DOI 10.1002/jbio.201200157; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Kaneko Y, 2012, CELL MED, V4, P55, DOI 10.3727/215517912X639306; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018472; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Masiulis I, 2011, MOL NEUROBIOL, V44, P287, DOI 10.1007/s12035-011-8207-z; MEMBERG SP, 1995, J NEUROBIOL, V27, P26, DOI 10.1002/neu.480270104; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; Meyer KS, 2010, PSYCHIAT CLIN N AM, V33, P783, DOI 10.1016/j.psc.2010.08.007; Mu YL, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-85; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xiao XL, 2010, NEUROL RES, V32, P547, DOI 10.1179/174313209X414533; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zhang L, 2013, INT J MOL MED, V32, P867, DOI 10.3892/ijmm.2013.1456	45	64	67	0	16	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668	1560-2281		J BIOMED OPT	J. Biomed. Opt.	OCT	2014	19	10							108003	10.1117/1.JBO.19.10.108003			15	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	AU8HM	WOS:000345837200036	25292167	Green Published			2021-06-18	
J	Howell, DR; Osternig, LR; Koester, MC; Chou, LS				Howell, David R.; Osternig, Louis R.; Koester, Michael C.; Chou, Li-Shan			The effect of cognitive task complexity on gait stability in adolescents following concussion	EXPERIMENTAL BRAIN RESEARCH			English	Article						Brain injury; Dual task; Gait; Balance; Recovery	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; POSITION STATEMENT; EXECUTIVE FUNCTION; BALANCE CONTROL; ATTENTION; PERFORMANCE; PARADIGM; LONG	Concussion has been reported to result in disturbances to motor and cognitive functions. One way to examine these disturbances is through a dual-task assessment. Many secondary cognitive tasks have been proposed as appropriate tools during concussion assessment; however, task complexity has not been compared within a dual-task investigation. The purpose of this study was to prospectively examine how gait balance control was affected by three secondary cognitive tasks of varying complexity following concussion. Forty-six adolescents completed a dual-task walking protocol which included walking without any cognitive task (WALK), walking while completing a single auditory Stroop (SAS), multiple auditory Stroop (MAS), and a question and answer task (Q&A). Those who sustained a concussion (n = 23, mean age 15.4 +/- A 1.3 years) reported to the laboratory within 72 h of injury and in the following time increments: 1 week, 2 weeks, 1 month, and 2 months post-injury. Twenty-three healthy control subjects (mean age 15.4 +/- A 1.3 years), individually matched to each concussion subject, completed the same protocol in similar time increments. The concussion group demonstrated greater total center of mass (COM) medial/lateral displacement in the MAS and Q&A conditions compared with the control group. The concussion group also displayed the greatest peak COM anterior velocity in the least complex condition (WALK), and a significant decrease was observed as task complexity increased (SAS > MAS > Q&A). These findings indicate that gait balance control may be affected by task complexity following concussion and represent a way to identify motor recovery following concussion.	[Howell, David R.; Osternig, Louis R.; Chou, Li-Shan] 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97401 USA; [Koester, Michael C.] Slocum Ctr Orthoped & Sports Med, Eugene, OR USA	Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97401 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Department of Defense-TATRCUnited States Department of Defense [W81XWH-11-1-0717]; University of Oregon; Peace Health Oregon Region	This work was supported by the Veterans Administration (Subcontract Awards Nos. A4842C8 and A4843C), the Department of Defense-TATRC (Award No. W81XWH-11-1-0717), and the translational research award from the University of Oregon and Peace Health Oregon Region.	Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bryer EJ, 2013, J INT NEUROPSYCH SOC, V19, P751, DOI 10.1017/S1355617713000490; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; Dreher JC, 2003, CEREB CORTEX, V13, P329, DOI 10.1093/cercor/13.4.329; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Katz-Leurer M, 2011, BRAIN INJURY, V25, P581, DOI 10.3109/02699052.2011.572943; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Purcell JJ, 2011, NEUROIMAGE, V55, P750, DOI 10.1016/j.neuroimage.2010.11.042; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170; Rickard TC, 2000, NEUROPSYCHOLOGIA, V38, P325, DOI 10.1016/S0028-3932(99)00068-8; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Teel EF, 2013, J SCI MED SPORT, V16, P190, DOI 10.1016/j.jsams.2012.09.007; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Winter D. A., 2009, BIOMECHANICS MOTOR C, P86, DOI 10.1002/9780470549148; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Yogev G, 2005, EUR J NEUROSCI, V22, P1248, DOI 10.1111/j.1460-9568.2005.04298.x; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	46	64	64	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JUN	2014	232	6					1773	1782		10.1007/s00221-014-3869-1			10	Neurosciences	Neurosciences & Neurology	AI3BC	WOS:000336732400017	24531643				2021-06-18	
J	Chrisman, SPD; Richardson, LP				Chrisman, Sara P. D.; Richardson, Laura P.			Prevalence of Diagnosed Depression in Adolescents With History of Concussion	JOURNAL OF ADOLESCENT HEALTH			English	Article						Adolescents; Concussion; Depression; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; MENTAL-DISORDERS; UNITED-STATES; ASSOCIATION; CHILDREN; SPORTS; RISK; PSYCHOPATHOLOGY; EPIDEMIOLOGY	Purpose: Previous studies in adults have suggested concussion and other brain injury presents a risk factor for depression. The goal of our study was to analyze the association between previous concussion and current depression diagnosis in a large nationally representative adolescent data set. Methods: Retrospective cohort study using the National Survey of Children's Health 2007-2008, a nationally representative survey conducted via random digit dialing. Data were obtained by parental report. We included youth 12-17 years old without a current concussion (N = 36,060), and evaluated the association between previous concussion (binary) and current depression diagnosis (binary) using multiple logistic regression to control for age, sex, parental mental health, and socioeconomic status. Results: After controlling for age, sex, parental mental health, and socioeconomic status, history of concussion was associated with a 3.3-fold greater risk for depression diagnosis (95% CI: 2.0-5.5). Other factors significantly associated with depression diagnosis included poor or fair parental mental health (OR: 3.7, 95% CI: 2.8-4.9), and older age (15-17 years vs. 12-14 years, OR: 1.4, 95% CI: 1.1-1.8). Sex of the subject was not significantly related to depression diagnosis. Being above 200% of the poverty level was associated with approximately a 50% decreased risk of depression diagnosis (95% CI: 35%-70%). Conclusions: History of concussion was associated with a higher prevalence of diagnosed depression in a large nationally representative adolescent data set. Clinicians should screen for depression in their adolescent patients with concussion. Future studies should confirm this association using prospective methodology and examine potential treatment approaches. (C) 2014 Society for Adolescent Health and Medicine. All rights reserved.	[Chrisman, Sara P. D.; Richardson, Laura P.] Univ Washington, Dept Pediat, Div Adolescent Med, Seattle, WA 98195 USA; [Chrisman, Sara P. D.; Richardson, Laura P.] Seattle Childrens Hosp, Ctr Child Hlth Behav & Dev, Seattle, WA 98104 USA	Chrisman, SPD (corresponding author), Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, MB 11-500-3,Seattle 4800 Sandpoint Way NE, Seattle, WA 98104 USA.	sara.chrisman@seattlechildrens.org		Chrisman, Sara/0000-0001-5373-7223	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This research was supported by a National Institutes of Health Loan Repayment Grant.	Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Birmaher B, 1998, J AM ACAD CHILD PSY, V37, P1234, DOI 10.1097/00004583-199811000-00029; Blumberg Stephen J, 2012, Vital Health Stat 1, P1; Centers for Disease Control and Prevention (CDC), REP C MILD TRAUM BRA; Child and Adolescent Health Measurement Initiative (CAHMI), 2007, NAT SURV CHILDR HLTH; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fewell Z, 2007, AM J EPIDEMIOL, V166, P646, DOI 10.1093/aje/kwm165; Fletcher JM, 2008, HEALTH ECON, V17, P1215, DOI 10.1002/hec.1319; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gureje O, 2011, MOL PSYCHIATR, V16, P1221, DOI 10.1038/mp.2010.111; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hirshfeld-Becker DR, 2012, AM J PSYCHIAT, V169, P1175, DOI 10.1176/appi.ajp.2012.11101514; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Krystal AD, 2012, NEUROL CLIN, V30, P1389, DOI 10.1016/j.ncl.2012.08.018; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P133, DOI 10.1037/0021-843X.102.4.517; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; MCGUINNESS TM, 2012, J PSYCHOSOC NURS MEN, V50, P17; McLaughlin KA, 2012, AM J PUBLIC HEALTH, V102, P1742, DOI 10.2105/AJPH.2011.300477; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Nordin JD, 2010, ANN FAM MED, V8, P511, DOI 10.1370/afm.1188; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Richardson LP, 2003, ARCH PEDIAT ADOL MED, V157, P739, DOI 10.1001/archpedi.157.8.739; Rushton JL, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e8; Saluja G, 2004, ARCH PEDIAT ADOL MED, V158, P760, DOI 10.1001/archpedi.158.8.760; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; StataCorp, 2011, STAT STAT SOFTW REL; Teychenne M, 2011, INT J BEHAV MED, V17, P246, DOI 10.1007/s12529-010-9075-z; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Witvliet M, 2010, J ABNORM CHILD PSYCH, V38, P1045, DOI 10.1007/s10802-010-9426-x; Zatzick DF, 2011, PSYCHIAT SERV, V62, P264, DOI 10.1176/ps.62.3.pss6203_0264	37	64	65	0	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	MAY	2014	54	5					582	586		10.1016/j.jadohealth.2013.10.006			5	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Psychology; Public, Environmental & Occupational Health; Pediatrics	AF1XG	WOS:000334506600013	24355628	Green Accepted			2021-06-18	
J	Verfaellie, M; Lafleche, G; Spiro, A; Bousquet, K				Verfaellie, Mieke; Lafleche, Ginette; Spiro, Avron, III; Bousquet, Kathryn			Neuropsychological Outcomes in OEF/OIF Veterans With Self-Report of Blast Exposure: Associations With Mental Health, but not mTBI	NEUROPSYCHOLOGY			English	Article						TBI; blast injuries; PTSD; depression; neuropsychological outcome	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; IRAQ-WAR; POSTCONCUSSIVE SYMPTOMS; PROCESSING SPEED; COMBAT VETERANS; PERFORMANCE; SOLDIERS; PTSD	Objective: To examine neuropsychological outcomes in veterans of Operations Enduring and Iraqi Freedom (OEF/OIF) with self-reported histories of blast exposure and determine the contribution of deployment-related mild traumatic brain injury (mTBI), and posttraumatic stress disorder (PTSD) and depression to performance. The effect of number of blast exposures and distance from the blast was also assessed. Method: OEF/OIF veterans who reported exposure to blast underwent structured interviews and were assigned to no-TBI (n = 39), mTBI without loss of consciousness (LOC; n = 53), or mTBI with LOC (n = 35) groups. They were administered tests of executive function, memory, and motor function at least 6 months after the index event. Results: Neuropsychological outcomes did not differ as a function of mTBI group. Blast load and distance from the blast also did not affect neuropsychological performance. Both PTSD and depression symptoms were significantly associated with neuropsychological outcomes. Conclusions: A history of mTBI with or without LOC during deployment does not contribute to objective cognitive impairment in the chronic phase post injury. In contrast, PTSD and depression symptoms are associated with cognitive performance decrements. This finding is thought to reflect at least in part the impact of psychiatric distress on neuropsychological performance.	[Verfaellie, Mieke; Lafleche, Ginette; Bousquet, Kathryn] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02130 USA; [Verfaellie, Mieke; Lafleche, Ginette; Spiro, Avron, III; Bousquet, Kathryn] Boston Univ, Sch Med, Boston, MA 02118 USA; [Spiro, Avron, III] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Boston, MA USA	Verfaellie, M (corresponding author), VA Boston Healthcare Syst, Memory Disorders Res Ctr 151A, 150 South Huntington Ave, Boston, MA 02130 USA.	verf@bu.edu		Verfaellie, Mieke/0000-0001-5535-4584; Spiro III, Avron/0000-0003-4080-8621	Clinical Science Research and Development; Rehabilitation Research and Development Services of the Department of Veterans AffairsUS Department of Veterans Affairs	This research was supported by the Clinical Science Research and Development and the Rehabilitation Research and Development Services of the Department of Veterans Affairs. The authors have no conflict of interest affecting this article.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Benedict R., 1997, BRIEF VISUOSPATIAL M; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Cooper DB, 2010, NEUROREHABILITATION, V26, P233, DOI 10.3233/NRE-2010-0559; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; First MB., 2002, STRUCTURED CLIN INTE; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Halstead WC, 1947, BRAIN INTELLIGENCE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrae M. A., 2008, MILD TRAUMATIC BRAIN; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Paniak C, 2000, BRAIN INJURY, V14, P219; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Porter RJ, 2007, AUST NZ J PSYCHIAT, V41, P115, DOI 10.1080/00048670601109881; Rao RP, 2009, POSTTRAUMATIC STRESS, P151, DOI DOI 10.1007/978-1-60327-329-9_7; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Southwick S. M., 2007, HDB PTSD SCI PRACTIC, P166; Tanielian T. L., 2008, INVISIBLE WOUNDS WAR, V1, DOI [10.1037/e527612010-001, DOI 10.1037/E527612010-001]; Tiffin J., 1968, PURDUE PEGBOARD EXAM; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P83; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Walter KH, 2010, J TRAUMA STRESS, V23, P292, DOI 10.1002/jts.20506; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wechsler D., 2001, WECHSLER TEST ADULT; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3	65	64	64	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2014	28	3					337	346		10.1037/neu0000027			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	AG3QH	WOS:000335334000002	24245929				2021-06-18	
J	Su, Y; Fan, W; Ma, Z; Wen, X; Wang, W; Wu, Q; Huang, H				Su, Y.; Fan, W.; Ma, Z.; Wen, X.; Wang, W.; Wu, Q.; Huang, H.			TAURINE IMPROVES FUNCTIONAL AND HISTOLOGICAL OUTCOMES AND REDUCES INFLAMMATION IN TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						taurine; traumatic brain injury; cytokine; inflammation; Luminex.	COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; IN-SITU DETECTION; BARRIER PERMEABILITY; CEREBROSPINAL-FLUID; CYTOKINE EXPRESSION; TEMPORAL PROFILE; LUNG INJURY; LEPTIN; PLASMA	We investigated the effect of taurine on inflammatory cytokine expression, on astrocyte activity and cerebral edema and functional outcomes, following traumatic brain injury (TBI) in rats. 72 rats were randomly divided into sham, TBI and Taurine groups. Rats subjected to moderate lateral fluid percussion injury were injected intravenously with taurine (200 mg/kg) or saline immediately after injury or daily for 7 days. Functional outcome was evaluated using Modified Neurological Severity Score (mNSS). Glial fibrillary acidic protein (GFAP) of the brain was measured using immunofluorescence. Concentration of 23 cytokines and chemokines in the injured cortex at 1 and 7 days after TBI was assessed by Luminex xMAP technology. The results showed that taurine significantly improved functional recovery except 1 day, reduced accumulation of GFAP and water content in the penumbral region at 7 days after TBI. Compared with the TBI group, taurine significantly suppressed growth-related oncogene (GRO/KC) and interleukin (IL)-1 beta levels while elevating the levels of regulated on activation, normal T cell expressed and secreted (RANTES) at 1 day. And taurine markedly decreased the level of 17 cytokine: eotaxin, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GMCSF), interferon-gamma (IFN-gamma), IL-1 alpha, IL-1 beta, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17, leptin, monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), vascular endothelial growth factor (VEGF), and only increased the level of MIP-1 alpha in a week. The results suggest that taurine effectively mitigates the severity of brain damage in TBI by attenuating the increase of astrocyte activity and edema as well as pro-inflammatory cytokines. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Su, Y.; Wen, X.] Tianjin Med Univ, Grad Sch, Tianjin 300070, Peoples R China; [Fan, W.; Wang, W.; Wu, Q.; Huang, H.] Tianjin Huanhu Hosp, Tianjin Neurosurg Inst, Tianjin 300060, Peoples R China; [Ma, Z.] Baoding 1 Hosp, Baoding 071000, Hebei, Peoples R China	Huang, H (corresponding author), Tianjin Huanhu Hosp, Tianjin Neurosurg Inst, Tianjin 300060, Peoples R China.	huanghuiling@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973089]; Tianjin Research Program of Application Foundation and Advanced Technology [10JCYBJC12200]; Tianjin Municipal Health Bureau of Science and Technology [2012KR09]	This work was supported by the National Natural Science Foundation of China (30973089), Tianjin Research Program of Application Foundation and Advanced Technology (10JCYBJC12200) and fund project of Tianjin Municipal Health Bureau of Science and Technology (2012KR09).	Abdih H, 2000, EUR SURG RES, V32, P347, DOI 10.1159/000052216; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chang X-L, 2012, TIANJIN MED J, V40, P493; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; El Idrissi A, 2008, AMINO ACIDS, V34, P321, DOI 10.1007/s00726-006-0396-9; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gurujeyalakshmi G, 2000, J PHARMACOL EXP THER, V293, P82; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; HUXTABLE RJ, 1989, PROG NEUROBIOL, V32, P471, DOI 10.1016/0301-0082(89)90019-1; Ivashkova Y, 2006, J TRAUMA, V61, P879, DOI 10.1097/01.ta.0000234722.98537.01; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lin C, 2012, PEPTIDES, V35, P166, DOI 10.1016/j.peptides.2012.03.024; Liu Y, 2002, IMMUNOL LETT, V80, P27, DOI 10.1016/S0165-2478(01)00291-7; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marcinkiewicz J, 1998, IMMUNOPHARMACOLOGY, V40, P27, DOI 10.1016/S0162-3109(98)00023-X; Messina SA, 2000, ADV EXP MED BIOL, V483, P355; Mo L-D, 2012, SHANDONG MED J, V52, P4; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nakajima Y, 2010, J NEUROTRAUM, V27, P403, DOI 10.1089/neu.2009.1044; Park E, 1998, ADV EXP MED BIOL, V442, P177; Park KW, 2005, J NEUROSCI RES, V81, P397, DOI 10.1002/jnr.20483; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Schaffer S, 2000, AMINO ACIDS, V19, P527, DOI 10.1007/s007260070004; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun M, 2012, AMINO ACIDS, V42, P1735, DOI 10.1007/s00726-011-0885-3; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Ward JL, 2011, J TRAUMA, V70, P1471, DOI 10.1097/TA.0b013e31821c38bd; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Xiao BG, 1998, NEUROREPORT, V9, P1487, DOI 10.1097/00001756-199805110-00044; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang F, 2010, AMINO ACIDS, V38, P237, DOI 10.1007/s00726-009-0233-z; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	55	64	68	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 25	2014	266						56	65		10.1016/j.neuroscience.2014.02.006			10	Neurosciences	Neurosciences & Neurology	AE8VO	WOS:000334281200006	24530657				2021-06-18	
J	Stoica, BA; Loane, DJ; Zhao, ZR; Kabadi, SV; Hanscom, M; Byrnes, KR; Faden, AI				Stoica, Bogdan A.; Loane, David J.; Zhao, Zaorui; Kabadi, Shruti V.; Hanscom, Marie; Byrnes, Kimberly R.; Faden, Alan I.			PARP-1 Inhibition Attenuates Neuronal Loss, Microglia Activation and Neurological Deficits after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						microglial activation; controlled cortical impact; neuroprotection; PJ34; PARP-1	APOPTOSIS-INDUCING FACTOR; POLYMERASE-1-DEPENDENT CELL-DEATH; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; POLY(ADP-RIBOSE) POLYMERASE-1; NAD(+) DEPLETION; NEUROPROTECTION; MICE; PJ34; IDENTIFICATION	Traumatic brain injury (TBI) causes neuronal cell death as well as microglial activation and related neurotoxicity that contribute to subsequent neurological dysfunction. Poly (ADP-ribose) polymerase (PARP-1) induces neuronal cell death through activation of caspase-independent mechanisms, including release of apoptosis inducing factor (AIF), and microglial activation. Administration of PJ34, a selective PARP-1 inhibitor, reduced cell death of primary cortical neurons exposed to N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG), a potent inducer of AIF-dependent cell death. PJ34 also attenuated lipopolysaccharide and interferon-gamma-induced activation of BV2 or primary microglia, limiting NF-kappa B activity and iNOS expression as well as decreasing generation of reactive oxygen species and TNF alpha. Systemic administration of PJ34 starting as late as 24 h after controlled cortical impact resulted in improved motor function recovery in mice with TBI. Stereological analysis demonstrated that PJ34 treatment reduced the lesion volume, attenuated neuronal cell loss in the cortex and thalamus, and reduced microglial activation in the TBI cortex. PJ34 treatment did not improve cognitive performance in a Morris water maze test or reduce neuronal cell loss in the hippocampus. Overall, our data indicate that PJ34 has a significant, albeit selective, neuroprotective effect after experimental TBI, and its therapeutic effect may be from multipotential actions on neuronal cell death and neuroinflammatory pathways.	[Stoica, Bogdan A.; Loane, David J.; Zhao, Zaorui; Kabadi, Shruti V.; Hanscom, Marie; Faden, Alan I.] Univ Maryland, Natl Study Ctr Trauma & EMS, Ctr Shock Trauma & Anesthesiol Res STAR, Dept Anesthesiol,Sch Med, Baltimore, MD 21201 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Stoica, BA (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Bressler Res Bldg 655 W Baltimore St,Room 6-015, Baltimore, MD 21201 USA.	bstoica@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348; Hanscom, Marie/0000-0001-8308-135X; Loane, David/0000-0003-0393-3503; Byrnes, Kimberly/0000-0002-7501-7734	 [RO1 NS061839]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER	We thank Titilola Akintola, Stephanie Custer, Vladimir Senatorov, and William Jeong for expert technical support. This work was supported by grant RO1 NS061839 to Alan Faden.	Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Antolin AA, 2012, ACS CHEM BIOL, V7, P1962, DOI 10.1021/cb300317y; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Cohen-Armon M, 2007, TRENDS PHARMACOL SCI, V28, P556, DOI 10.1016/j.tips.2007.08.005; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goebel DJ, 2006, J NEUROCHEM, V98, P1732, DOI 10.1111/j.1471-4159.2006.04065.x; Goldberg S, 2009, J NEUROCHEM, V111, P72, DOI 10.1111/j.1471-4159.2009.06296.x; Haddad M, 2008, EUR J PHARMACOL, V588, P52, DOI 10.1016/j.ejphar.2008.04.013; Hernandez AI, 2009, J NEUROSCI, V29, P9553, DOI 10.1523/JNEUROSCI.1512-09.2009; Iwashita A, 2004, J PHARMACOL EXP THER, V310, P425, DOI 10.1124/jpet.104.066944; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen TM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-152; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Lai Y, 2008, J NEUROCHEM, V104, P1700, DOI 10.1111/j.1471-4159.2007.05114.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Madison DL, 2011, DNA REPAIR, V10, P1003, DOI 10.1016/j.dnarep.2011.07.006; Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001; Phulwani NK, 2008, J NEUROCHEM, V106, P578, DOI 10.1111/j.1471-4159.2008.05403.x; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Poitras MF, 2007, NEUROSCIENCE, V148, P198, DOI 10.1016/j.neuroscience.2007.04.062; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wahlberg E, 2012, NAT BIOTECHNOL, V30, P283, DOI 10.1038/nbt.2121; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wang YF, 2009, J NEUROCHEM, V110, P687, DOI 10.1111/j.1471-4159.2009.06167.x; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhu DY, 2003, J NEUROSCI, V23, P223	51	64	66	0	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2014	31	8					758	772		10.1089/neu.2013.3194			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PX	WOS:000333457200007	24476502	Green Published			2021-06-18	
J	de la Cadena, SC; Hernandez-Fonseca, K; Camacho-Arroyo, I; Massieu, L				Garcia de la Cadena, Selene; Hernandez-Fonseca, Karla; Camacho-Arroyo, Ignacio; Massieu, Lourdes			Glucose deprivation induces reticulum stress by the PERK pathway and caspase-7-and calpain-mediated caspase-12 activation	APOPTOSIS			English	Article						Glucose deprivation; ER stress; PERK pathway; Caspase-12; Caspase-7; Calpain	ELECTRON-MICROSCOPIC FINDINGS; HYPOGLYCEMIC NEURONAL DEATH; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; ENDOPLASMIC-RETICULUM; CELL-DEATH; INCREASED EXPRESSION; TEMPORAL EVOLUTION; INDUCED APOPTOSIS; OXIDATIVE STRESS	Glucose is the main energy source in brain and it is critical for correct brain functioning. Type 1 diabetic patients might suffer from severe hypoglycemia if exceeding insulin administration, which can lead to acute brain injury if not opportunely corrected. The mechanisms leading to hypoglycemic brain damage are not completely understood and the role of endoplasmic reticulum (ER) stress has not been studied. ER stress resulting from the accumulation of unfolded or misfolded proteins in the ER is counteracted by the unfolded protein response (UPR). When the UPR is sustained, apoptotic death might take place. We have examined UPR activation during glucose deprivation (GD) in hippocampal cultured neurons and its role in the induction of apoptosis. Activation of the PERK pathway of the UPR was observed, as increased phosphorylation of eIF2 alpha and elevated levels of the transcription factor ATF4, occurred 30 min after GD and the levels of the chaperone protein, GRP78 and the transcription factor CHOP, increased after 2 h of GD. In addition, we observed an early activation of caspase-7 and 12 during GD, while caspase-3 activity increased only transiently during glucose reintroduction. Inhibition of caspase-3/7 and the calcium-dependent protease, calpain, significantly decreased caspase-12 activity. The ER stress inhibitor, salubrinal prevented neuronal death and caspase-12 activity. Results suggest that the PERK pathway of the UPR is involved in GD-induced apoptotic neuronal death through the activation of caspase-12, rather than the mitochondrial-dependent caspase pathway. In addition, we show that calpain and caspase-7 are soon activated after GD and mediate caspase-12 activation and neuronal death.	[Garcia de la Cadena, Selene; Massieu, Lourdes] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Div Neurociencias, Mexico City 04510, DF, Mexico; [Hernandez-Fonseca, Karla] Inst Nacl Psiquiatria Ramon de la Fuente Muniz, Dept Neuroquim, Mexico City, DF, Mexico; [Camacho-Arroyo, Ignacio] Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Mexico City 04510, DF, Mexico	Massieu, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Div Neurociencias, AP 70-253, Mexico City 04510, DF, Mexico.	lmassieu@ifc.unam.mx	Camacho-Arroyo, Ignacio/AAM-6757-2021; Hernandez-Fonseca, KARLA/AAG-1500-2020; Camacho-Arroyo, Ignacio/AAM-4654-2021	Camacho-Arroyo, Ignacio/0000-0003-2978-1253; Camacho-Arroyo, Ignacio/0000-0003-2978-1253; Hernandez-Fonseca, Karla/0000-0002-5932-8911	CONACyTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [S112179]; PAPIIT (UNAM)Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico [IN211710-3]; CONACyT fellowshipConsejo Nacional de Ciencia y Tecnologia (CONACyT) [221026]	This work was supported by S112179 CONACyT and IN211710-3 PAPIIT (UNAM) Grants to L.M. and 221026 CONACyT fellowship to S.G.C The authors thank Teresa Montiel for her technical assistance. This study was performed in partial fulfillment of the requirements for the PhD degree in Ciencias Bioquimicas of S. Garcia de la Cadena at the Universidad Nacional Autonoma de Mexico.	AUER RN, 1985, ACTA NEUROPATHOL, V67, P25, DOI 10.1007/BF00688121; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; Badiola N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.31; Benavides A, 2005, GLIA, V52, P261, DOI 10.1002/glia.20242; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BUTCHER SP, 1987, NEUROSCI LETT, V76, P296, DOI 10.1016/0304-3940(87)90418-6; Cryer PE, 2006, J CLIN INVEST, V116, P1470, DOI 10.1172/JCI28735; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Friberg H, 1998, J NEUROSCI, V18, P5151; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Hernandez-Fonseca K, 2012, NEUROENDOCRINOLOGY, V96, P41, DOI 10.1159/000334229; Ibuki T, 2012, NEUROSCI LETT, V518, P45, DOI 10.1016/j.neulet.2012.04.053; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Liu HJ, 2009, NEUROL SCI, V30, P227, DOI 10.1007/s10072-009-0086-y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malagelada C, 2005, NEUROBIOL DIS, V20, P27, DOI 10.1016/j.nbd.2005.01.028; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Mao WK, 2006, AM J PHYSIOL-CELL PH, V290, pC1373, DOI 10.1152/ajpcell.00369.2005; Martinez JA, 2010, APOPTOSIS, V15, P1480, DOI 10.1007/s10495-010-0526-4; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Merksamer PI, 2010, J CELL SCI, V123, P1003, DOI 10.1242/jcs.035832; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Minano A, 2008, J NEUROSCI RES, V86, P1734, DOI 10.1002/jnr.21633; Morimoto N, 2007, NEUROSCIENCE, V147, P957, DOI 10.1016/j.neuroscience.2007.04.017; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mouw G, 2002, J MOL NEUROSCI, V14, P183; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paramo B, 2010, NEUROSCIENCE, V167, P1057, DOI 10.1016/j.neuroscience.2010.02.074; Paramo B, 2013, INT J BIOCHEM CELL B, V45, P2596, DOI 10.1016/j.biocel.2013.08.013; Paschen W, 2003, J CEREBR BLOOD F MET, V23, P449, DOI 10.1097/01.WCB.0000054216.21675.AC; Raghubir R, 2011, METHOD ENZYMOL, V489, P259, DOI 10.1016/B978-0-12-385116-1.00015-7; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Rasheva VI, 2009, APOPTOSIS, V14, P996, DOI 10.1007/s10495-009-0341-y; Reijonen S, 2008, EXP CELL RES, V314, P950, DOI 10.1016/j.yexcr.2007.12.025; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; SANDBERG M, 1986, J NEUROCHEM, V47, P178; Saxena S, 2009, NAT NEUROSCI, V12, P627, DOI 10.1038/nn.2297; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2003, J NEUROSCI, V23, P10681; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tong L, 1998, J NEURAL TRANSM, V105, P905, DOI 10.1007/s007020050101; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; Xu YY, 2011, BRAIN RES, V1375, P49, DOI 10.1016/j.brainres.2010.12.029; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhang AL, 2010, NEUROSCI LETT, V478, P32, DOI 10.1016/j.neulet.2010.04.062; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	68	64	64	1	29	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1360-8185	1573-675X		APOPTOSIS	Apoptosis	MAR	2014	19	3					414	427		10.1007/s10495-013-0930-7			14	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	AB2QA	WOS:000331636000002	24185830				2021-06-18	
J	Soble, JR; Silva, MA; Vanderploeg, RD; Curtiss, G; Belanger, HG; Donnell, AJ; Scott, SG				Soble, Jason R.; Silva, Marc A.; Vanderploeg, Rodney D.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.			Normative Data for the Neurobehavioral Symptom Inventory (NSI) and Post-Concussion Symptom Profiles Among TBI, PTSD, and Nonclinical Samples	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neurobehavioral Symptom Inventory; Normative data; Post-Concussion Syndrome; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; METAANALYSIS; VETERANS; IRAQ; ASSOCIATIONS; EQUIVALENCE; VALIDATION	The Neurobehavioral Symptom Inventory (NSI) is a self-report measure of symptoms commonly associated with Post-Concussion Syndrome (PCS) that may emerge after mild traumatic brain injury (mTBI). Despite frequent clinical use, no NSI norms have been developed. Thus, the main objective of this study was to establish NSI normative data using the four NSI factors (i.e., vestibular, somatic, cognitive, and affective) identified by Vanderploeg, Silva, et al. (2014) among nonclinical epidemiological samples of deployed and non-deployed Florida National Guard members as well as a reference sample of Guard members with combat-related mTBI. In addition, NSI subscale profile patterns were compared across four distinct subgroups (i.e., non-deployed-nonclinical, deployed-nonclinical, deployed-mTBI, and deployed-PTSD). The deployed-nonclinical group endorsed greater PCS symptom severity than the non-deployed group, and the mTBI group uniformly endorsed more symptoms than both nonclinical groups. However, the PTSD group endorsed higher symptom severity relative to the other three subgroups. As such, this highlights the non-specificity of PCS symptoms and suggests that PTSD is associated with higher symptom endorsement than mTBI.	[Soble, Jason R.; Silva, Marc A.; Vanderploeg, Rodney D.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Soble, Jason R.; Vanderploeg, Rodney D.; Curtiss, Glenn; Belanger, Heather G.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Scott, Steven G.] James A Haley Vet Hosp, Hlth Serv Res & Dev HSR&D, Rehabil Res & Dev RR&D Ctr Excellence Maximizing, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Scott, Steven G.] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL 33612 USA; [Scott, Steven G.] Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020; Silva, Marc A./J-1874-2019	Silva, Marc A./0000-0002-3879-6054	Department of Veterans Affairs, Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; VA Grant SDR HSRD [08-411]; TBI Screening Instruments; VA HSRD Grant [CCN 06-164]; James A. Haley Veterans' HospitalUS Department of Veterans Affairs; HSR&D/RR&D Center of Excellence	This research was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), and Defense and Veterans Brain Injury Center (DVBIC), and by VA Grant SDR HSR&D #08-411, TBI Screening Instruments, processed to Rodney D. Vanderploeg, and VA HSR&D Grant CCN 06-164 processed to Steven G. Scott. Further support was provided by James A. Haley Veterans' Hospital, and its HSR&D/RR&D Center of Excellence, and the Defense and Veterans Brain Injury Center (DVBIC).	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Elhai JD, 2011, J ANXIETY DISORD, V25, P404, DOI 10.1016/j.janxdis.2010.11.003; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finger MS, 1999, PSYCHOL ASSESSMENT, V11, P58, DOI 10.1037/1040-3590.11.1.58; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Granacher R. P., 2008, TRAUMATIC BRAIN INJU, VSecond; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; National Center for PTSD, 2012, US PTSD CHECKL PCL; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schmitz N, 1999, PSYCHIAT RES, V87, P217, DOI 10.1016/S0165-1781(99)00060-8; Schmitz N, 2000, ACTA PSYCHIAT SCAND, V102, P147, DOI 10.1034/j.1600-0447.2000.102002147.x; Schulenberg SE, 2001, CURR PSYCHOL, V20, P216, DOI 10.1007/s12144-001-1008-1; Silva MA, 2013, CLIN NEUROPSYCHOL, V27, P601; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; STEER RA, 1993, J PERS ASSESS, V60, P532, DOI 10.1207/s15327752jpa6003_10; Trahan D. E., 1997, BEAUMONT POSTCONCUSS; Traub R.E., 1994, RELIABILITY SOCIAL S; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; World Health Organization, 1992, ICD 10 CLASS MENT BE	52	64	64	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	4			SI		614	632		10.1080/13854046.2014.894576			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AM8PH	WOS:000340138900006	24625213				2021-06-18	
J	Villapol, S; Byrnes, KR; Symes, AJ				Villapol, Sonia; Byrnes, Kimberly R.; Symes, Aviva J.			Temporal dynamics of cerebral blood flow, cortical damage, apoptosis, astrocyte vasculature interaction and astrogliosis in the pericontusional region after traumatic brain injury	FRONTIERS IN NEUROLOGY			English	Article						astrogliosis; cell death; cerebral blood flow; vasculature; glial scar		Traumatic brain injury (TBI) results in a loss of brain tissue at the moment of impact in the cerebral cortex. Subsequent secondary injury involves the release of molecular signals with dramatic consequences for the integrity of damaged tissue, leading to the evolution of a pericontusional-damaged area minutes to days after in the initial injury. The mechanisms behind the progression of tissue loss remain under investigation. In this study, we analyzed the spatial temporal profile of blood flow, apoptotic, and astrocytic vascular events in the cortical regions around the impact site at time points ranging from 5 h to 2 months after TBI. We performed a mild moderate controlled cortical impact injury in young adult mice and analyzed the glial and vascular response to injury. We observed a dramatic decrease in perilesional cerebral blood flow (CBF) immediately following the cortical impact that lasted until days later. CBF finally returned to baseline levels by 30 days post-injury (dpi). The initial impact also resulted in an immediate loss of tissue and cavity formation that gradually increased in size until 3 dpi. An increase in dying cells localized in the pericontusional region and a robust astrogliosis were also observed at 3 dpi. A strong vasculature interaction with astrocytes was established at 7 dpi. Glial scar formation began at 7 dpi and seemed to be compact by 60 dpi. Altogether, these results suggest that TBI results in a progression from acute neurodegeneration that precedes astrocytic activation, reformation of the neurovascular unit to glial scar formation. Understanding the multiple processes occurring after TBI is critical to the ability to develop neuroprotective therapeutics to ameliorate the short and long-term consequences of brain injury.	[Villapol, Sonia; Byrnes, Kimberly R.; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Road, Bethesda, MD 20814 USA; [Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Villapol, S (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Road, Bethesda, MD 20814 USA.	svilapol@gmail.com; aviva.symes@usuhs.edu	Symes, Aviva J/S-7471-2016; Villapol, Sonia/D-1949-2014	Symes, Aviva J/0000-0003-2557-9939; Byrnes, Kimberly/0000-0002-7501-7734; Villapol, Sonia/0000-0002-6174-4113	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense; CNRM post-doctoral fellowship	The authors thank M. Balarezo for her excellent technical assistance. This work was supported by grants from the Center for Neuroscience and Regenerative Medicine (CNRM). Sonia Villapol is supported by a CNRM post-doctoral fellowship. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences, the US Department of Defense or the Government of the United States.	Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Armstead WM, 2004, EXP TOXICOL PATHOL, V56, P75, DOI 10.1016/j.etp.2004.04.003; Badaut J, 2014, TRANSL STROKE RES, V5, P394, DOI 10.1007/s12975-013-0304-z; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bragin DE, 2011, J NEUROTRAUM, V28, P775, DOI 10.1089/neu.2010.1692; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Harris NG, 2010, J NEUROTRAUM, V27, P1971, DOI 10.1089/neu.2010.1470; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Hernandez MR, 2002, GLIA, V38, P45, DOI 10.1002/glia.10051; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Iadecola C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003; Jakovcevic D, 2007, CURR TOP DEV BIOL, V79, P75, DOI 10.1016/S0070-2153(06)79004-4; Karki P, 2014, MOL CELL ENDOCRINOL, V389, P58, DOI 10.1016/j.mce.2014.01.010; Katsel P, 2011, NEUROPSYCHOPHARMACOL, V36, P1171, DOI 10.1038/npp.2010.252; Leffler CW, 2006, AM J PHYSIOL-HEART C, V291, pH2897, DOI 10.1152/ajpheart.00722.2006; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Li AL, 2008, CHIN J TRAUMATOL, V11, P84, DOI 10.1016/S1008-1275(08)60018-8; Longhi L, 2003, Minerva Anestesiol, V69, P227; Martin-Lopez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074039; Massucci FA, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-103; Mitra S, 2013, TOXICOLOGY, V310, P39, DOI 10.1016/j.tox.2013.05.011; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nordal RA, 2005, INT J RADIAT ONCOL, V62, P279, DOI 10.1016/j.ijrobp.2005.01.039; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pekny M, 2007, INT REV NEUROBIOL, V82, P95, DOI 10.1016/S0074-7742(07)82005-8; Ragaisis V., 2002, MEDICINA, V38, P354; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Simard M, 2003, J NEUROSCI, V23, P9254; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sochocka M, 2013, CNS NEUROL DISORD-DR, V12, P870, DOI 10.2174/18715273113129990072; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Stichel CC, 1999, RESTOR NEUROL NEUROS, V15, P1; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Villapol S, 2008, NEUROSCIENTIST, V14, P339, DOI 10.1177/1073858408316003; Villapol S, 2011, PEDIATR RES, V69, P51, DOI 10.1203/PDR.0b013e3181fcb40b; Villapol S, 2009, AM J PATHOL, V175, P2111, DOI 10.2353/ajpath.2009.090257; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Wang JY, 2006, CURR PHARM DESIGN, V12, P3521, DOI 10.2174/138161206778343109; WESTERGREN H, 1991, ACTA NEUROCHIR, V113, P91, DOI 10.1007/BF01402121; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zou J, 2010, NEUROCHEM INT, V56, P577, DOI 10.1016/j.neuint.2009.12.021	51	64	64	1	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								82	10.3389/fneur.2014.00082			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300081	24926283	DOAJ Gold, Green Published			2021-06-18	
J	Brooks, JC; Strauss, DJ; Shavelle, RM; Paculdo, DR; Hammond, FM; Harrison-Felix, CL				Brooks, Jordan C.; Strauss, David J.; Shavelle, Robert M.; Paculdo, David R.; Hammond, Flora M.; Harrison-Felix, Cynthia L.			Long-Term Disability and Survival in Traumatic Brain Injury: Results From the National Institute on Disability and Rehabilitation Research Model Systems	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Mortality; Rehabilitation; Survival	MORTALITY TRENDS; LIFE EXPECTANCY	Objectives: To document long-term survival in 1-year survivors of traumatic brain injury (TBI); to compare the use of the Disability Rating Scale (DRS) and FIM as factors in the estimation of survival probabilities; and to investigate the effect of time since injury and secular trends in mortality. Design: Cohort study of 1-year survivors of TBI followed up to 20 years postinjury. Statistical methods include standardized mortality ratio, Kaplan-Meier survival curve, proportional hazards regression, and person-year logistic regression. Setting: Postdischarge from rehabilitation units. Participants: Population-based sample of persons (N=7228) who were admitted to a TBI Model Systems facility and survived at least 1 year postinjury. These persons contributed 32,505 person-years, with 537 deaths, over the 1989 to 2011 study period. Interventions: Not applicable. Main Outcome Measure: Survival. Results: Survival was poorer than that of the general population (standardized mortality ratio = 2.1; 95% confidence interval, 1.9-2.3). Age, sex, and functional disability were significant risk factors for mortality (P<.001). FIM- and DRS-based proportional hazards survival models had comparable predictive performance (C index: .80 vs .80; Akaike information criterion: 11,005 vs 11,015). Time since injury and current calendar year were not significant predictors of long-term survival (both P>.05). Conclusions: Long-term survival prognosis in TBI depends on age, sex, and disability. FIM and DRS are useful prognostic measures with comparable statistical performance. Age- and disability-specific mortality rates in TBI have not declined over the last 20 years. A survival prognosis calculator is available online (http://www.LifeExpectancy.org/tbims.shtml). (C) 2013 by the American Congress of Rehabilitation Medicine	[Brooks, Jordan C.; Strauss, David J.; Shavelle, Robert M.; Paculdo, David R.] Life Expectancy Project, San Francisco, CA 94122 USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Harrison-Felix, Cynthia L.] Craig Hosp, Englewood, CO USA; [Harrison-Felix, Cynthia L.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA	Brooks, JC (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.	Brooks@LifeExpectancy.org		Paculdo, David/0000-0002-2184-4603	U.S. Department of Education, National Institute on Disability and Rehabilitation ResearchUS Department of Education; Traumatic Brain Injury Model Systems Centers	The Traumatic Brain Injury Model Systems National Database is supported by the U.S. Department of Education, National Institute on Disability and Rehabilitation Research in collaboration with the Traumatic Brain Injury Model Systems Centers. However, these contents do not necessarily reflect the opinions or views of the Traumatic Brain Injury Model Systems Centers, the National Institute on Disability and Rehabilitation Research, or the U.S. Department of Education.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Arias E, 2002, NATL VITAL STAT REPO; Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Baguley IJ, 2008, BRAIN INJURY, V22, P919, DOI 10.1080/02699050802448578; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; COX DR, 1984, ANAL SURVIVAL DATA; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Harrison-Felix CL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P319; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; National Data and Statistical Center, TRAUM BRAIN INJ MOD; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shavelle RM, 2007, BRAIN INJURY MED PRI, P247; Shavelle RM, 2000, J INSUR MED, V32; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Strauss D, 2000, J Insur Med, V32, P217; Strauss D, 1999, J INSUR MED, V31, P104; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Uniform Data System for Medical Rehabilitation, 1997, GUID UN DAT SET MED; Zasler ND, 2009, PROG BRAIN RES, V177, P111, DOI 10.1016/S0079-6123(09)17709-9	29	64	64	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2013	94	11					2203	2209		10.1016/j.apmr.2013.07.005			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	250KV	WOS:000326852600023	23872079				2021-06-18	
J	Pu, HJ; Guo, YL; Zhang, WT; Huang, LT; Wang, GH; Liou, AK; Zhang, J; Zhang, PY; Leak, RK; Wang, Y; Chen, J; Gao, YQ				Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Liou, Anthony K.; Zhang, Jia; Zhang, Pengyue; Leak, Rehana K.; Wang, Yun; Chen, Jun; Gao, Yanqin			Omega-3 polyunsaturated fatty acid supplementation improves neurologic recovery and attenuates white matter injury after experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						behavior (rodent); brain trauma; inflammation; neurodegeneration; white matter/oligodendrocytes	SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; PARKINSONS-DISEASE; MODEL; RAT; OMEGA-3-FATTY-ACIDS; EXCITOTOXICITY; MECHANISMS; GLUTAMATE; VULNERABILITY	Dietary supplementation with omega-3 (omega-3) fatty acids is a safe, economical mean of preventive medicine that has shown protection against several neurologic disorders. The present study tested the hypothesis that this method is protective against controlled cortical impact (CCI). Indeed, mice fed with omega-3 polyunsaturated fatty acid (PUFA)-enriched diet for 2 months exhibited attenuated short and long-term behavioral deficits due to CCI. Although omega-3 PUFAs did not decrease cortical lesion volume, these fatty acids did protect against hippocampal neuronal loss after CCI and reduced pro-inflammatory response. Interestingly, omega-3 PUFAs prevented the loss of myelin basic protein (MPB), preserved the integrity of the myelin sheath, and maintained the nerve fiber conductivity in the CCI model. omega-3 PUFAs also directly protected oligodendrocyte cultures from excitotoxicity and blunted the microglial activation-induced death of oligodendrocytes in microglia/oligodendrocyte cocultures. In sum, omega-3 PUFAs elicit multifaceted protection against behavioral dysfunction, hippocampal neuronal loss, inflammation, and loss of myelination and impulse conductivity. The present report is the first demonstration that omega-3 PUFAs protect against white matter injury in vivo and in vitro. The protective impact of omega-3 PUFAs supports the clinical use of this dietary supplement as a prophylaxis against traumatic brain injury and other nervous system disorders.	[Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China; [Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA; [Liou, Anthony K.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA; [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA	Gao, YQ (corresponding author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.	chenj2@upmc.edu; yqgao@shmu.edu.cn	Pu, Hongjian/AAW-3322-2020; Leak, Rehana K/I-2607-2019; Gao, Yanqin/I-6790-2016	Leak, Rehana K/0000-0003-2817-7417; Gao, Yanqin/0000-0002-4915-9819	Chinese Ministry of Science and TechnologyMinistry of Science and Technology, China; National Institutes of Health/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36736, NS43802, NS45048, NS056118]; Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30870794, 81020108021, 81171149, 81150110494, 81000497]; VA Research Career Scientist Award; VA Merit Review grantUS Department of Veterans Affairs; UPMC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056118, R01NS043802, R01NS045048, R01NS036736] Funding Source: NIH RePORTER	This research is supported in part by the Special Research Funds from Chinese Ministry of Science and Technology to State Key laboratories (to YG and JC), National Institutes of Health/NINDS grants NS36736, NS43802, NS45048 and NS056118 (to JC), and Chinese Natural Science Foundation grants No 30870794, No 81020108021, No 81171149, No 81150110494, and No 81000497 (to YG). JC is a recipient of the VA Research Career Scientist Award, VA Merit Review grant, and the RK Mellon Endowed Chair from UPMC.	Allen NJ, 2009, NATURE, V457, P675, DOI 10.1038/457675a; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Bousquet M, 2011, AGEING RES REV, V10, P453, DOI 10.1016/j.arr.2011.03.001; Chen Y, 2007, NAT PROTOC, V2, P1044, DOI 10.1038/nprot.2007.149; Cole GM, 2010, NUTR REV, V68, pS102, DOI 10.1111/j.1753-4887.2010.00345.x; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Domercq M, 2011, J BIOL CHEM, V286, P11825, DOI 10.1074/jbc.M110.153049; Eady Tiffany N, 2012, Exp Transl Stroke Med, V4, P19, DOI 10.1186/2040-7378-4-19; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Ge YL, 2002, J NEUROCHEM, V82, P1360, DOI 10.1046/j.1471-4159.2002.01077.x; Hall JCE, 2012, J NEUROCHEM, V121, P738, DOI 10.1111/j.1471-4159.2012.07726.x; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Liu YQ, 2002, PEDIATR RES, V51, P25, DOI 10.1203/00006450-200201000-00007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Luchtman DW, 2012, BEHAV BRAIN RES, V226, P386, DOI 10.1016/j.bbr.2011.09.033; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Martin A, 2011, MOL IMAGING BIOL, V13, P10, DOI 10.1007/s11307-010-0324-y; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; Matute C, 2011, J ANAT, V219, P53, DOI 10.1111/j.1469-7580.2010.01339.x; Nguemeni C, 2010, PHARMACOL RES, V61, P226, DOI 10.1016/j.phrs.2009.12.007; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Okabe N, 2011, J STROKE CEREBROVASC, V20, P188, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.016; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pignier C, 2007, BASIC RES CARDIOL, V102, P553, DOI 10.1007/s00395-007-0676-x; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rosival V, 1990, Vnitr Lek, V36, P783; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shen HX, 2010, NEUROBIOL DIS, V37, P711, DOI 10.1016/j.nbd.2009.12.010; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	40	64	66	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2013	33	9					1474	1484		10.1038/jcbfm.2013.108			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	214IQ	WOS:000324126400020	23801244	Green Published, Bronze			2021-06-18	
J	Seichepine, DR; Stamm, JM; Daneshvar, DH; Riley, DO; Baugh, CM; Gavett, BE; Tripodis, Y; Martin, B; Chaisson, C; Mckee, AC; Cantu, RC; Nowinski, CJ; Stern, RA				Seichepine, Daniel R.; Stamm, Julie M.; Daneshvar, Daniel H.; Riley, David O.; Baugh, Christine M.; Gavett, Brandon E.; Tripodis, Yorghos; Martin, Brett; Chaisson, Christine; Mckee, Ann C.; Cantu, Robert C.; Nowinski, Christopher J.; Stern, Robert A.			Profile of Self-Reported Problems with Executive Functioning in College and Professional Football Players	JOURNAL OF NEUROTRAUMA			English	Article						chronic traumatic encephalopathy; executive function; football; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; BRAIN-FUNCTION; LEAGUE PLAYER; CONCUSSION; INJURY; EPIDEMIOLOGY; DISEASE; SPORTS; IMPACT	Repetitive mild traumatic brain injury (mTBI), such as that experienced by contact-sport athletes, has been associated with the development of chronic traumatic encephalopathy (CTE). Executive dysfunction is believed to be among the earliest symptoms of CTE, with these symptoms presenting in the fourth or fifth decade of life. The present study used a well-validated self-report measure to study executive functioning in football players, compared to healthy adults. Sixty-four college and professional football players were administered the Behavior Rating Inventory of Executive Function, adult version (BRIEF-A) to evaluate nine areas of executive functioning. Scores on the BRIEF-A were compared to published age-corrected normative scores for healthy adults Relative to healthy adults, the football players indicated significantly more problems overall and on seven of the nine clinical scales, including Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, and Task Monitor. These symptoms were greater in athletes 40 and older, relative to younger players. In sum, football players reported more-frequent problems with executive functioning and these symptoms may develop or worsen in the fifth decade of life. The findings are in accord with a growing body of evidence that participation in football is associated with the development of cognitive changes and dementia as observed in CTE.	[Seichepine, Daniel R.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Seichepine, Daniel R.; Stamm, Julie M.; Daneshvar, Daniel H.; Riley, David O.; Baugh, Christine M.; Mckee, Ann C.; Cantu, Robert C.; Nowinski, Christopher J.; Stern, Robert A.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Gavett, Brandon E.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Martin, Brett; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Mckee, Ann C.] Vet Affairs Boston Healthcare Syst, Neurol Serv, Jamaica Plain, MA USA; [Mckee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA	Stern, RA (corresponding author), Boston Univ, Ctr Study Traumat Encephalopathy, 72 East Concord St,Suite B7800, Boston, MA 02118 USA.	bobstern@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608; Daneshvar, Daniel/0000-0003-3691-9513; Seichepine, Daniel/0000-0002-2331-3072; Gavett, Brandon/0000-0003-1938-1854; Chaisson, Christine/0000-0002-3207-9257; Stern, Robert/0000-0002-5008-077X	Boston University Alzheimer's Disease Center [NIA P30 AG13846, 0572063345-5]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078337]; National Operating Committee on Standards for Athletic Equipment; Sports Legacy Institute; Center for the Integration of Medicine and Innovative Technology; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by the Boston University Alzheimer's Disease Center (NIA P30 AG13846, supplement 0572063345-5), the National Institutes of Health (R01NS078337), a grant from the National Operating Committee on Standards for Athletic Equipment, the Sports Legacy Institute, the Center for the Integration of Medicine and Innovative Technology, and an unrestricted gift from the National Football League. A portion of this research was presented at the 2012 Military Health System Research Symposium, in Fort Lauderdale, FL, August 13-16, 2012.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Control C.f.I.P.a, 2003, REP C MILD TRAUM BRA; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Council of Youth Sports, 2008, REP TRENDS PART ORG; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Promotion N.C.f.C.D.P.H, 2006, BEH RISK FACT SURV S; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Roth R., 2005, BRIEF A BEHAV RATING; Weir DR, 2009, NATL FOOTBALL LEAGUE, P1	24	64	64	4	52	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1299	1304		10.1089/neu.2012.2690			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100010	23421745	Green Published			2021-06-18	
J	Lange, RT; Brickell, TA; Ivins, B; Vanderploeg, RD; French, LM				Lange, Rael T.; Brickell, Tracey A.; Ivins, Brian; Vanderploeg, Rodney D.; French, Louis M.			Variable, Not Always Persistent, Postconcussion Symptoms after Mild TBI in U.S. Military Service Members: A Five-Year Cross-Sectional Outcome Study	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; military service members; postconcussion symptoms	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; MENTAL-HEALTH PROBLEMS; COMPLAINT BASE RATES; HEAD-INJURY; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; CHRONIC PAIN; IRAQ	This study examined postconcussion symptom reporting within the first 5 years after mild traumatic brain injury (mTBI). Participants were 167 U. S. military service members (mean age, 27.6 years; 74.3% blast; 96.4% male) who were evaluated subsequent to injuries sustained in theater during Operations Iraqi and Enduring Freedom (92.8%) or from other combat-related operations. Participants completed the Neurobehavioral Symptom Inventory and Post-Traumatic Stress Disorder Checklist within 3 months of injury and at least one follow-up telephone interview at 6 (n = 46), 12 (n = 89), 24 (n = 54), 36 (n = 42), 48 (n = 30), and/or 60 months (n = 25) postinjury. Approximately half of the sample (49.7%) met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) symptom criteria for postconcussion disorder (PCD) at baseline. At all six follow-ups, 46.1-72.0% met DSM-IV criteria for PCD. However, only 20.4-48.0% reported persistent PCD from baseline to follow-up. A substantial minority had also improved (4.0-24.1%) or "developed'' new symptoms (16.9-27.8%). Using regression analyses, baseline symptoms were somewhat predictive of PCD symptom reporting at follow-up, though this was not always reliable. Follow-up for all service members who sustain a combat-related mTBI in the context of polytrauma, regardless of the presence or absence of symptom reporting in the acute recovery stage, should be considered the rule, not the exception.	[Lange, Rael T.; Brickell, Tracey A.; Ivins, Brian; Vanderploeg, Rodney D.; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; Ivins, Brian; French, Louis M.] Walter Reed Natl Mil Med Ctr, Rockville, MD 20852 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Vanderploeg, Rodney D.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Psychol, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Rockville, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baker DG, 2009, MIL MED, V174, P773; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Defense and Veterans Brain Injury Center, 2012, DOD NUMB TRAUM BRAIN, V2012; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrier-Auerbach AG, 2010, J PSYCHIATR RES, V44, P470, DOI 10.1016/j.jpsychires.2009.10.010; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2012, BRAIN INJURY MED PRI; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Keane T., 1994, PTSD CHECKLIST CIVIL; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Uomoto JM, 2009, REHABIL PSYCHOL, V54, P259, DOI 10.1037/a0016907; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	85	64	64	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					958	969		10.1089/neu.2012.2743			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300006	23205671				2021-06-18	
J	Skop, NB; Calderon, F; Levison, SW; Gandhi, CD; Cho, CH				Skop, Nolan B.; Calderon, Frances; Levison, Steven W.; Gandhi, Chirag D.; Cho, Cheul H.			Heparin crosslinked chitosan microspheres for the delivery of neural stem cells and growth factors for central nervous system repair	ACTA BIOMATERIALIA			English	Article						Nerve tissue regeneration; Regenerative medicine; Multifunctional scaffold; Fibroblast growth factor-2; Cell transplantation	TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; IN-VIVO; CONTROLLED-RELEASE; GEL STIFFNESS; GLIAL-CELLS; GENIPIN; SURVIVAL; SCAFFOLDS; PROTEIN	An effective paradigm for transplanting large numbers of neural stem cells after central nervous system (CNS) injury has yet to be established. Biomaterial scaffolds have shown promise in cell transplantation and in regenerative medicine, but improved scaffolds are needed. In this study we designed and optimized multifunctional and biocompatible chitosan-based films and microspheres for the delivery of neural stem cells and growth factors for CNS injuries. The chitosan microspheres were fabricated by coaxial airflow techniques, with the sphere size controlled by varying the syringe needle gauge and the airflow rate. When applying a coaxial airflow at 30 standard cubic feet per hour, similar to 300 mu m diameter spheres were reproducibly generated that were physically stable yet susceptible to enzymatic degradation. Heparin was covalently crosslinked to the chitosan scaffolds using genipin, which bound fibroblast growth factor-2 (FGF-2) with high affinity while retaining its biological activity. At 1 mu g ml(-1) approximately 80% of the FGF-2 bound to the scaffold. A neural stem cell line, GFP + RG3.6 derived from embryonic rat cortex, was used to evaluate cytocompatibility, attachment and survival on the crosslinked chitosan-heparin complex surfaces. The MTT assay and microscopic analysis revealed that the scaffold containing tethered FGF-2 was superior in sustaining survival and growth of neural stem cells compared to standard culture conditions. Altogether, our results demonstrate that this multifunctional scaffold possesses good cytocompatibility and can be used as a growth factor delivery vehicle while supporting neural stem cell attachment and survival. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Skop, Nolan B.; Calderon, Frances; Levison, Steven W.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07102 USA; [Gandhi, Chirag D.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07102 USA; [Skop, Nolan B.; Cho, Cheul H.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA	Cho, CH (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	cho@njit.edu	Levison, Steven W./Q-6903-2019	Levison, Steven W./0000-0002-1264-7309	New Jersey Commission on Brain Injury Research [08.001.BIR2, CBIR12FEL025]; Wallace H. Coulter Foundation	This study was partially supported by the New Jersey Commission on Brain Injury Research grant number 08.001.BIR2 awarded to C.D.G. and S.W.L., fellowship grant number CBIR12FEL025 awarded to N.P.S. and the Wallace H. Coulter Foundation.	Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; Barbosa JN, 2010, J BIOMED MATER RES A, V93A, P20, DOI 10.1002/jbm.a.32499; Barbucci R, 2009, HYDROGELS BIOL PROPE, VXII, P200; Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019; Bottcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003-0040; Cervera A, 2004, J NEUROSCI RES, V77, P565, DOI 10.1002/jnr.20186; Chandy T, 2000, J MICROENCAPSUL, V17, P625; Cho CH, 2008, J BIOMED MATER RES A, V86A, P98, DOI 10.1002/jbm.a.31614; Cho Y, 2010, J EXP BIOL, V213, P1513, DOI 10.1242/jeb.035162; Crompton KE, 2007, BIOMATERIALS, V28, P441, DOI 10.1016/j.biomaterials.2006.08.044; Crompton KE, 2006, J MATER SCI-MATER M, V17, P633, DOI 10.1007/s10856-006-9226-6; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Eroglu H, 2010, CHEM PHARM BULL, V58, P1161, DOI 10.1248/cpb.58.1161; FOLKMAN J, 1983, CIBA F SYMP, V100, P132; Francesko A, 2011, ADV BIOCHEM ENG BIOT, V125, P1, DOI [10.1007/10_2010_93, 10.10007/10_2010_93]; Freier T, 2005, BIOMATERIALS, V26, P5872, DOI 10.1016/j.biomaterials.2005.02.033; Guo XD, 2012, CELL TRANSPLANT, V21, P1177, DOI 10.3727/096368911X612503; Guo XL, 2003, J BIOMAT SCI-POLYM E, V14, P551, DOI 10.1163/15685620360674245; Harris R, 2010, MAR DRUGS, V8, P1750, DOI 10.3390/md8061750; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hassan EE, 1993, J DRUG TARGET, V1, P7, DOI 10.3109/10611869308998759; Hidaka Y, 1999, J BIOMED MATER RES, V46, P418, DOI 10.1002/(SICI)1097-4636(19990905)46:3<418::AID-JBM15>3.0.CO;2-T; Hussain A, 2013, BIOTECHNOL BIOENG, V110, P637, DOI 10.1002/bit.24727; Jumaa M, 2002, EUR J PHARM BIOPHARM, V53, P115, DOI 10.1016/S0939-6411(01)00191-6; Kai D, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/9/095705; Khor E, 2003, BIOMATERIALS, V24, P2339, DOI 10.1016/S0142-9612(03)00026-7; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kim SE, 2003, J CONTROL RELEASE, V91, P365, DOI 10.1016/S0168-3659(03)00274-8; Kim S, 2009, BIOMATERIALS, V30, P4743, DOI 10.1016/j.biomaterials.2009.05.010; Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011; Koriyama Y, 2011, J NEUROCHEM, V119, P1232, DOI 10.1111/j.1471-4159.2011.07533.x; Kou JH, 1997, J CONTROL RELEASE, V43, P123, DOI 10.1016/S0168-3659(96)01477-0; LAMOUREUX P, 1989, NATURE, V340, P156, DOI 10.1038/340159a0; LEE KY, 1995, BIOMATERIALS, V16, P1211, DOI 10.1016/0142-9612(95)98126-Y; Leipzig ND, 2011, BIOMATERIALS, V32, P57, DOI 10.1016/j.biomaterials.2010.09.031; Li HD, 2004, DEV BIOL, V271, P225, DOI 10.1016/j.ydbio.2004.02.028; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142-9612(99)00011-3; Maysinger D, 1996, EXP NEUROL, V141, P47, DOI 10.1006/exnr.1996.0138; Mi FL, 2002, BIOMATERIALS, V23, P181, DOI 10.1016/S0142-9612(01)00094-1; Mo LH, 2010, BIOMATERIALS, V31, P2184, DOI 10.1016/j.biomaterials.2009.11.078; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nam KN, 2010, INT IMMUNOPHARMACOL, V10, P493, DOI 10.1016/j.intimp.2010.01.011; Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332; Nomura H, 2008, TISSUE ENG PT A, V14, P649, DOI 10.1089/tea.2007.0180; Onishi H, 1999, BIOMATERIALS, V20, P175, DOI 10.1016/S0142-9612(98)00159-8; PELUSO G, 1994, BIOMATERIALS, V15, P1215, DOI 10.1016/0142-9612(94)90272-0; RIBATTI D, 1987, ACTA ANAT, V130, P257; Seo MC, 2008, J NEUROSCI RES, V86, P1087, DOI 10.1002/jnr.21552; Shen H, 2011, BIOMATERIALS, V32, P3404, DOI 10.1016/j.biomaterials.2011.01.037; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sinha VR, 2004, INT J PHARMACEUT, V274, P1, DOI 10.1016/j.ijpharm.2003.12.026; Solorio L, 2010, J TISSUE ENG REGEN M, V4, P514, DOI 10.1002/term.267; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sung HW, 1999, J BIOMAT SCI-POLYM E, V10, P63, DOI 10.1163/156856299X00289; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thakur G, 2011, J MATER SCI-MATER M, V22, P115, DOI 10.1007/s10856-010-4185-3; Tolaimate A, 2000, POLYMER, V41, P2463, DOI 10.1016/S0032-3861(99)00400-0; Turkoglu OF, 2005, SURG NEUROL, V64, P11, DOI 10.1016/j.surneu.2005.07.041; Turkoglu OF, 2010, BRIT J NEUROSURG, V24, P578, DOI 10.3109/02688697.2010.487126; Vasavada VA, 2012, AM J OPHTHALMOL, V154, pe4; Vergano-Vera E, 2009, NEUROSCIENCE, V162, P39, DOI 10.1016/j.neuroscience.2009.03.033; Volpato FZ, 2012, ACTA BIOMATER, V8, P1551, DOI 10.1016/j.actbio.2011.12.023; Wang HB, 2000, AM J PHYSIOL-CELL PH, V279, pC1345; Willits RK, 2004, J BIOMAT SCI-POLYM E, V15, P1521, DOI 10.1163/1568562042459698; Wissink MJB, 2001, BIOMATERIALS, V22, P2291, DOI 10.1016/S0142-9612(00)00418-X; Wu JM, 2011, J MATER SCI-MATER M, V22, P107, DOI 10.1007/s10856-010-4176-4; Yamazaki M, 2004, EUR J PHARMACOL, V488, P35, DOI 10.1016/j.ejphar.2004.02.009; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yuan Y, 2007, CARBOHYD POLYM, V68, P561, DOI 10.1016/j.carbpol.2006.10.023; Zeng Y, 2011, MED HYPOTHESES, V77, P680, DOI 10.1016/j.mehy.2011.07.015; ZIELINSKI BA, 1994, BIOMATERIALS, V15, P1049	79	64	66	3	104	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JUN	2013	9	6					6834	6843		10.1016/j.actbio.2013.02.043			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	158EF	WOS:000319951500009	23467042				2021-06-18	
J	Dunisch, P; Walter, J; Sakr, Y; Kalff, R; Waschke, A; Ewald, C				Duenisch, Pedro; Walter, Jan; Sakr, Yasser; Kalff, Rolf; Waschke, Albrecht; Ewald, Christian			Risk factors of aseptic bone resorption: a study after autologous bone flap reinsertion due to decompressive craniotomy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						craniotomy; cranioplasty; bone flap; aseptic bone flap necrosis; bone resorption	SKIN FLAP; CRANIOPLASTY; CRANIECTOMY; COMPLICATIONS; HEMICRANIECTOMY; RECOVERY	Object. In patients who have undergone decompressive craniectomy, autologous bone flap reinsertion becomes necessary whenever the cerebral situation has consolidated. However, aseptic necrosis of the bone flap remains a concern. The aim of this study was to report possible perioperative complications in patients undergoing autologous bone flap reinsertion and to identify the risk factors that may predispose the bone flap to necrosis. Methods. All patients admitted to the authors' neurosurgical department between September 1994 and June 2011 and who received their own cryoconserved bone flap after decompressive craniectomy were studied. The grade of the bone flap necrosis was classified into 2 types. Type II bone necrosis was characterized by aseptic resorption with circumscribed or complete lysis of tabula interna and extema requiring surgical revision. To define predisposing factors, a multivariate analysis was performed using bone necrosis as the dependent variable. Results. Among the 372 patients (mean age 48.6 years, 57.4% males) who received 414 bone flaps during the observation period, 134 (36.0%) had a diffuse traumatic brain injury, 69 (18.5%) had subarachnoid hemorrhage, 58 (15.6%) had cerebral infarction, 56 (15.1%) had extraaxial bleeding, 43 (11.6%) had intracerebral bleeding, and 12 (3.2%) had a neoplasm. Surgical relevant Type II bone flap necrosis occurred in 85 patients (22.8%) and 91 bone flaps, after a median time of 15 months (interquartile range [IQR], 10-33 months). In a multivariate analysis with Type II necrosis as the dependent variable, bone flap fragmentation with 2 (OR 3.35, 95% CI 1.59-7.01, p < 0.002) or more fragments (OR 24.00, 95% CI 10.13-56.84, p < 0.001), shunt-dependent hydrocephalus (OR 1.76, 95% CI 0.99-3.12, p = 0.04), and a younger age (OR 0.98, 95% CI 0.96-0.99, p = 0.004) was associated with a higher risk for the development of an aseptic bone flap necrosis. Conclusions. In patients undergoing bone flap reinsertion after craniotomy, aseptic bone necrosis is an underestimated problem during long-term follow-up. Especially in younger patients with an expected good neurological recovery and a fragmented bone flap, an initial allograft should be considered because of an increased risk for aseptic bone flap necrosis. (http://thejns.org/doi/abs/10.3171/2013.1.JNS12860)	[Duenisch, Pedro; Walter, Jan; Kalff, Rolf; Waschke, Albrecht; Ewald, Christian] Univ Jena, Jena Univ Hosp, Dept Neurosurg, D-07745 Jena, Germany; [Sakr, Yasser] Univ Jena, Jena Univ Hosp, Dept Anaesthesiol, D-07745 Jena, Germany	Dunisch, P (corresponding author), Hosp Friedrich Schiller Univ, Dept Neurosurg, Erlanger Allee 101, D-07747 Jena, Germany.	pedro.duenisch@med.uni-jena.de	Walter, Jan/AAE-4536-2021; Sakr, Yasser/D-9802-2013				Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chieregato A, 2006, INTENS CARE MED, V32, P1668, DOI 10.1007/s00134-006-0302-7; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Kemmling A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-80; Meyer MJ, 2010, BRAIN INJURY, V24, P694, DOI 10.3109/02699051003692118; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Schorl M, 2009, CENT EUR NEUROSURG, V70, P68, DOI 10.1055/s-0028-1093355; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Yamaura A, 1977, No Shinkei Geka, V5, P345	23	64	67	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2013	118	5					1141	1147		10.3171/2013.1.JNS12860			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	131LT	WOS:000317995900041	23451904				2021-06-18	
J	King, D; Brughelli, M; Hume, P; Gissane, C				King, Doug; Brughelli, Matt; Hume, Patria; Gissane, Conor			Concussions in amateur rugby union identified with the use of a rapid visual screening tool	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Vision; Eye movements; Sports-related concussion; King-Devick test	INJURIES; EPIDEMIOLOGY; RELIABILITY; SPORTS; LEAGUE; HEAD	Aim: To use the King-Devick (KD) test and Sports Concussion Assessment Tool 2 (SCAT2) in amateur rugby union players to identify witnessed and unrecognised episodes of concussion that occurred from match participation. Methods: A prospective observational cohort study was conducted on a premier club level amateur rugby union team during the 2012 competition in New Zealand. Every player completed a pre-competition questionnaire on concussion history, a baseline PCSS and two trials of the KD before they participated in any match activities. Results: For players reporting a concussion in the previous three years there was an average of 4.0 +/- 2.8 concussions per player. There were 22 concussive incidents recorded over the duration of the competition (46 per 1000 match hours). Five concussive incidents were witnessed (11 per 1000 match hours) and 17 unrecognised concussive incidents were identified with the KD (37 per 1000 match hours). Witnessed concussions recorded, on average, a longer KD on the day of injury (5.5 +/- 2.4 s) than unrecognised concussions (4.4 +/- 0.9 s) when compared with their baseline KD. Discussion: The KD was able to identify players that had not shown, or reported, any signs or symptoms of a concussion but who had meaningful head injury. The current rate of concussion reported was a ten-fold increase in previously reported concussion injury rates. This makes the KD suitable for rapid assessment in a limited time frame on the sideline such as a five-minute window to assess and review suspected concussed players in rugby union. (c) 2013 Elsevier B.V. All rights reserved.	[King, Doug; Brughelli, Matt; Hume, Patria] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Sport & Recreat, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Gissane, Conor] St Marys Univ Coll, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England	King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Hume, Patria/AAN-5514-2021; Gissane, Conor/I-3661-2019	Hume, Patria/0000-0003-1847-8128; Gissane, Conor/0000-0003-4677-3853			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Borg G., 1998, BORGS PERCEIVED EXER; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Giza CC, 2001, J ATHL TRAINING, V36, P228; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King DA, 2009, J SCI MED SPORT, V12, P12, DOI 10.1016/j.jsams.2007.12.001; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Moriarity JM, 2012, BRIT J SPORT MED, V46, P1011, DOI 10.1136/bjsports-2011-090893; Mujika I, 2009, J SPORT SCI, V27, P1581, DOI 10.1080/02640410903350281; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Spencer M, 2006, J SCI MED SPORT, V9, P181, DOI 10.1016/j.jsams.2005.05.001; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019	27	64	64	0	32	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	MAR 15	2013	326	1-2					59	63		10.1016/j.jns.2013.01.012			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	128WA	WOS:000317799200010	23374885				2021-06-18	
J	Reis, PA; Estato, V; da Silva, TI; d'Avila, JC; Siqueira, LD; Assis, EF; Bozza, PT; Bozza, FA; Tibirica, EV; Zimmerman, GA; Castro-Faria-Neto, HC				Reis, Patricia A.; Estato, Vanessa; da Silva, Tathiany I.; d'Avila, Joana C.; Siqueira, Luciana D.; Assis, Edson F.; Bozza, Patricia T.; Bozza, Fernando A.; Tibirica, Eduardo V.; Zimmerman, Guy A.; Castro-Faria-Neto, Hugo C.			Statins Decrease Neuroinflammation and Prevent Cognitive Impairment after Cerebral Malaria	PLOS PATHOGENS			English	Article							SEVERE FALCIPARUM-MALARIA; TRAUMATIC BRAIN-INJURY; HEME OXYGENASE-1; IN-VIVO; CEREBROSPINAL-FLUID; MALAWIAN CHILDREN; SEPSIS; ATORVASTATIN; PATHOGENESIS; DYSFUNCTION	Cerebral malaria (CM) is the most severe manifestation of Plasmodium falciparum infection in children and non-immune adults. Previous work has documented a persistent cognitive impairment in children who survive an episode of CM that is mimicked in animal models of the disease. Potential therapeutic interventions for this complication have not been investigated, and are urgently needed. HMG-CoA reductase inhibitors (statins) are widely prescribed for cardiovascular diseases. In addition to their effects on the inhibition of cholesterol synthesis, statins have pleiotropic immunomodulatory activities. Here we tested if statins would prevent cognitive impairment in a murine model of cerebral malaria. Six days after infection with Plasmodium berghei ANKA (PbA) mice displayed clear signs of CM and were treated with chloroquine, or chloroquine and lovastatin. Intravital examination of pial vessels of infected animals demonstrated a decrease in functional capillary density and an increase in rolling and adhesion of leukocytes to inflamed endothelium that were reversed by treatment with lovastatin. In addition, oedema, ICAM-1, and CD11b mRNA levels were reduced in lovastatin-treated PbA-infected mice brains. Moreover, HMOX-1 mRNA levels are enhanced in lovastatin-treated healthy and infected brains. Oxidative stress and key inflammatory chemokines and cytokines were reduced to non-infected control levels in animals treated with lovastatin. Fifteen days post-infection cognitive dysfunction was detected by a battery of cognition tests in animals rescued from CM by chloroquine treatment. In contrast, it was absent in animals treated with lovastatin and chloroquine. The outcome was similar in experimental bacterial sepsis, suggesting that statins have neuroprotective effects in severe infectious syndromes in addition to CM. Statin treatment prevents neuroinflammation and blood brain barrier dysfunction in experimental CM and related conditions that are associated with cognitive sequelae, and may be a valuable adjuvant therapeutic agent for prevention of cognitive impairment in patients surviving an episode of CM.	[Reis, Patricia A.; da Silva, Tathiany I.; d'Avila, Joana C.; Siqueira, Luciana D.; Assis, Edson F.; Bozza, Patricia T.; Castro-Faria-Neto, Hugo C.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil; [Estato, Vanessa; Tibirica, Eduardo V.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Invest Cardiovasc, Rio De Janeiro, RJ, Brazil; [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil; [Zimmerman, Guy A.] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA	Reis, PA (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.	reispa@gmail.com; reispa@gmail.com	Bozza, Patricia T./AAE-2933-2021; d'Avila, Joana/L-8970-2013; Estato, Vanessa/AAJ-9060-2020; Bozza, Fernando A/A-2618-2013; Bozza, Patricia T./AAM-4537-2021	d'Avila, Joana/0000-0002-2045-0813; Bozza, Fernando A/0000-0003-4878-0256; Bozza, Patricia T./0000-0001-8349-9529	CNPq (National Counsel of Technological and Scientific Development)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Faperj (Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro)Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Pronex (Programa de Apoio a Nucleos de Excelencia); NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO3 NS04512]; NIHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37 HL044525]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL044525] Funding Source: NIH RePORTER	Financial support was provided by CNPq (National Counsel of Technological and Scientific Development), Faperj (Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro), Pronex (Programa de Apoio a Nucleos de Excelencia), NIH/NINDS RO3 NS04512 and NIHS R37 HL044525. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali F, 2009, J BIOL CHEM, V284, P18882, DOI 10.1074/jbc.M109.009886; Araujo CV, 2012, MICROVASC RES, V84, P218, DOI 10.1016/j.mvr.2012.05.006; Armah H, 2005, ANN TROP MED PARASIT, V99, P629, DOI 10.1179/136485905X51508; Barichello T, 2006, CRIT CARE MED, V34, P886, DOI 10.1097/01.CCM.0000201880.50116.12; Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96; Bienvenu AL, 2008, ANTIMICROB AGENTS CH, V52, P4203, DOI 10.1128/AAC.00513-08; Boivin MJ, 2007, PEDIATRICS, V119, pE360, DOI 10.1542/peds.2006-2027; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Brown H, 2001, AM J TROP MED HYG, V64, P207, DOI 10.4269/ajtmh.2001.64.207; Bu DX, 2011, CURR OPIN LIPIDOL, V22, P165, DOI 10.1097/MOL.0b013e3283453e41; Carter JA, 2006, DEV MED CHILD NEUROL, V48, P51, DOI 10.1017/S0012162206000107; Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893; Carvalho LJM, 2010, TRENDS PARASITOL, V26, P271, DOI 10.1016/j.pt.2010.03.001; Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141; Cordoliani YS, 1998, AM J NEURORADIOL, V19, P871; Craig AG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002401; de Souza JB, 2010, PARASITOLOGY, V137, P755, DOI 10.1017/S0031182009991715; Dobbie M, 2000, AM J TROP MED HYG, V62, P284, DOI 10.4269/ajtmh.2000.62.284; Dorovini-Zis K, 2011, AM J PATHOL, V178, P2146, DOI 10.1016/j.ajpath.2011.01.016; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2; Faille D, 2009, THROMB HAEMOSTASIS, V102, P1093, DOI 10.1160/TH09-05-0337; Golenser J, 2006, INT J PARASITOL, V36, P583, DOI 10.1016/j.ijpara.2006.02.009; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Hsu M, 2006, BIOCHEM BIOPH RES CO, V343, P738, DOI 10.1016/j.bbrc.2006.03.036; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Hunt NH, 2007, NAT MED, V13, P667, DOI 10.1038/nm0607-667; Hunt NH, 2010, TRENDS PARASITOL, V26, P272, DOI 10.1016/j.pt.2010.03.006; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709; John CC, 2008, AM J TROP MED HYG, V78, P198, DOI 10.4269/ajtmh.2008.78.198; Kappe SHI, 2010, SCIENCE, V328, P862, DOI 10.1126/science.1184785; Kouroumichakis I, 2011, EUR J INTERN MED, V22, P125, DOI 10.1016/j.ejim.2010.12.004; Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x; Langhorne J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-23; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; LOOAREESUWAN S, 1995, CLIN INFECT DIS, V21, P300, DOI 10.1093/clinids/21.2.300; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; McGown CC, 2010, BRIT J ANAESTH, V104, P183, DOI 10.1093/bja/aep361; MILLAN JM, 1993, AM J NEURORADIOL, V14, P493; Morandi A, 2011, CHEST, V140, P580, DOI 10.1378/chest.10-3065; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; Nie CQ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000369; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586; Papadopoulos G, 2002, EUR J ANAESTH, V19, P152, DOI 10.1017/S0265021502250267; Patankar TF, 2002, RADIOLOGY, V224, P811, DOI 10.1148/radiol.2243010588; Paul R, 2007, EXP NEUROL, V203, P158, DOI 10.1016/j.expneurol.2006.08.003; Penet MF, 2007, J BIOL CHEM, V282, P14505, DOI 10.1074/jbc.M608035200; Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005; Pino P, 2005, THROMB HAEMOSTASIS, V94, P336, DOI 10.1160/TH05-05-0354; PUHL H, 1994, METHOD ENZYMOL, V233, P425; Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963; Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050; Rozen S, 2000, Methods Mol Biol, V132, P365; Sabino B, 2008, J CARDIOVASC PHARM, V51, P402, DOI 10.1097/FJC.0b013e3181673bc5; Sacanella E, 2011, CRIT CARE, V15, DOI 10.1186/cc10121; Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38; Souraud JB, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-13; Stocker R, 2006, CIRCULATION, V114, P2178, DOI 10.1161/CIRCULATIONAHA.105.598698; Taoufiq Z, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-52; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Terblanche M, 2007, LANCET INFECT DIS, V7, P358, DOI 10.1016/S1473-3099(07)70111-1; van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; WILLIMANN K, 1995, J EXP MED, V182, P643, DOI 10.1084/jem.182.3.643; Wurtz N, 2010, J ANTIMICROB CHEMOTH, V65, P1387, DOI 10.1093/jac/dkq173; Yadava A, 1996, P NATL ACAD SCI USA, V93, P4595, DOI 10.1073/pnas.93.10.4595; Yoshimoto T, 1998, J IMMUNOL, V160, P5500; Zimmerman GA, 2010, EXPERT REV ANTI-INFE, V8, P1209, DOI 10.1586/ERI.10.117	78	64	66	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-7366	1553-7374		PLOS PATHOG	PLoS Pathog.	DEC	2012	8	12							e1003099	10.1371/journal.ppat.1003099			13	Microbiology; Parasitology; Virology	Microbiology; Parasitology; Virology	062GJ	WOS:000312907100046	23300448	DOAJ Gold, Green Published			2021-06-18	
J	Berry, C; Ley, EJ; Bukur, M; Malinoski, D; Margulies, DR; Mirocha, J; Salim, A				Berry, Cherisse; Ley, Eric J.; Bukur, Marko; Malinoski, Darren; Margulies, Daniel R.; Mirocha, James; Salim, Ali			Redefining hypotension in traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Hypotension; Traumatic brain injury; Mortality	SERUM ETHANOL LEVELS; CEREBRAL-BLOOD-FLOW; ACUTE HEAD-INJURY; PRESSURE; MODERATE; MORTALITY; OUTCOMES; GENDER	Background: Systemic hypotension is a well documented predictor of increased mortality following traumatic brain injury (TBI). Hypotension is traditionally defined as systolic blood pressure (SBP) < 90 mm Hg. Recent evidence defines hypotension by a higher SBP in injured (non-TBI) trauma patients. We hypothesize that hypotension threshold requires a higher SBP in isolated moderate to severe TBI. Patients and methods: A retrospective database review of all adults (>= 15 years) with isolated moderate to severe TBI (head abbreviated injury score (AIS) >= 3, all other AIS <= 3), admitted from five Level I and eight Level II trauma centres (Los Angeles County), between 1998 and 2005. Several fit statistic analyses were performed for each admission SBP from 60 to 180 mm Hg to identify the model that most accurately defined hypotension for three age groups: 15-49 years, 50-69 years, and >= 70 years. The main outcome variable was mortality, and the optimal definition of hypotension for each group was determined from the best fit model. Adjusted odds ratios (AOR) were then calculated to determine increased odds in mortality for the defined optimal SBP within each age group. Results: A total of 15,733 patients were analysed. The optimal threshold of hypotension according to the best fit model was SBP of 110 mm Hg for patients 15-49 years (AOR 1.98, CI 1.65-2.39, p < 0.0001), 100 mm Hg for patients 50-69 years (AOR 2.20, CI 1.46-3.31, p = 0.0002), and 110 mm Hg for patients >= 70 years (AOR 1.92, CI 1.35-2.74, p = 0.0003). Conclusions: Patients with isolated moderate to severe TBI should be considered hypotensive for SBP < 110 mm Hg. Further research should confirm this new definition of hypotension by correlation with indices of perfusion. (C) 2011 Elsevier Ltd. All rights reserved.	[Berry, Cherisse; Ley, Eric J.; Bukur, Marko; Malinoski, Darren; Margulies, Daniel R.; Mirocha, James; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020	Bukur, Marko/0000-0002-1850-7147			Alban RF, 2010, AM SURGEON, V76, P1108; Berry C, 2011, AM J SURG, V201, P429, DOI 10.1016/j.amjsurg.2010.10.008; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Berry C, 2010, AM SURGEON, V76, P1067; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; Brain Trauma Foundation Guidelines, MAN PROGN SEV TRAUM; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis JW, 2003, J TRAUMA, V55, P860, DOI 10.1097/01.TA.0000092686.91877.DE; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Edelman DA, 2007, SHOCK, V27, P134, DOI 10.1097/01.shk.0000239772.18151.18; Edwards M, 2010, AM SURGEON, V76, P1035; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; GENTLEMAN D, 1992, INT SURG, V77, P297; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JEFFREYS RV, 1981, LANCET, V2, P459; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; WO CCJ, 1993, CRIT CARE MED, V21, P218, DOI 10.1097/00003246-199302000-00012	31	64	65	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	NOV	2012	43	11					1833	1837		10.1016/j.injury.2011.08.014			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014VR	WOS:000309404300010	21939970				2021-06-18	
J	Collen, J; Orr, N; Lettieri, CJ; Carter, K; Holley, AB				Collen, Jacob; Orr, Nicholas; Lettieri, Christopher J.; Carter, Kevin; Holley, Aaron B.			Sleep Disturbances Among Soldiers With Combat-Related Traumatic Brain Injury	CHEST			English	Article							LONG-TERM DISABILITY; BREATHING DISORDERS; OBJECTIVE MEASURES; UNITED-STATES; HEAD-INJURY; INSOMNIA; APNEA; AFGHANISTAN; PREVALENCE; DEPLOYMENT	Background: Sleep complaints are common among patients with traumatic brain injury. Evaluation of this population is confounded by polypharmacy and comorbid disease, with few studies addressing combat-related injuries. The aim of this study was to assess the prevalence of sleep disorders among soldiers who sustained combat-related traumatic brain injury. Methods: The study design was a retrospective review of soldiers returning from combat with mild to moderate traumatic brain injury. All underwent comprehensive sleep evaluations. We determined the prevalence of sleep complaints and disorders in this population and assessed demographics, mechanism of injury, medication use, comorbid psychiatric disease, and polysomnographic findings to identify variables that correlated with the development of specific sleep disorders. Results: Of 116 consecutive patients, 96.6% were men (mean age, 31.1 +/- 9.8 years; mean BMI, 27.8 +/- 4.1 kg/m(2)), and 29.5% and 70.5% sustained blunt and blast injuries, respectively. Nearly all (97.4%) reported sleep complaints. Hypersomnia and sleep fragmentation were reported in 85.2% and 54.3%, respectively. Obstructive sleep apnea syndrome (OSAS) was found in 34.5%, and 55.2% had insomnia. Patients with blast injuries developed more anxiety (50.6% vs 20.0%, P = .002) and insomnia (63% vs 40%, P = .02), whereas patients with blunt trauma had significantly more OSAS (54.3% vs 25.9%, P = .003). In multivariate analysis, blunt trauma was a significant predictor of OSAS (OR, 3.09; 95% CI, 1.02-9.38; P = .047). Conclusions: Sleep disruption is common following traumatic brain injury, and the majority of patients develop a chronic sleep disorder. It appears that sleep disturbances may be influenced by the mechanism of injury in those with combat-related traumatic brain injury, with blunt injury potentially predicting the development of OSAS. CHEST 2012; 142(3):622-630	[Collen, Jacob; Lettieri, Christopher J.; Carter, Kevin; Holley, Aaron B.] Walter Reed Natl Mil Med Ctr, Dept Pulm Crit Care & Sleep Med, Bethesda, MD 20889 USA; [Orr, Nicholas] Walter Reed Natl Mil Med Ctr, Dept Med, Bethesda, MD 20889 USA; [Lettieri, Christopher J.; Holley, Aaron B.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA	Collen, J (corresponding author), Walter Reed Natl Mil Med Ctr, Dept Pulm Crit Care & Sleep Med, 8901 Rockville Pike, Bethesda, MD 20889 USA.	jacob.collen@us.army.mil		Lettieri, Christopher/0000-0001-7950-2908			American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, P51; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; American Sleep Disorders Association, 1990, INT CLASS SLEEP DIS; Nguyen ATD, 2006, J CLIN SLEEP MED, V2, P170; [Anonymous], 2010, MED SURVEILLANCE MON, V17, P12; Armed Forces Health Surveillance Center, 2010, MSMR, V17, P8; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Beneto A, 2009, SLEEP MED REV, V13, P287, DOI 10.1016/j.smrv.2008.09.006; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fischer H, 2010, US MILITARY CASUALTY; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Iber C, 2007, AASM MANUAL SCORING; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kanbayashi T, 2009, SLEEP, V32, P181, DOI 10.1093/sleep/32.2.181; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kennedy K., 2010, ARMY TIMES; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lavie P, 2007, SLEEP MED, V8, pS21, DOI 10.1016/S1389-9457(08)70005-4; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; O'Hara R, 2009, J REHABIL RES DEV, V46, P837, DOI 10.1682/JRRD.2008.10.0140; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Oyefeso A, 1997, DRUG ALCOHOL DEPEN, V48, P9, DOI 10.1016/S0376-8716(97)00097-5; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rishi MA, 2010, CLIN NEUROPHARMACOL, V33, P109, DOI 10.1097/WNF.0b013e3181db8040; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sateia MJ, 2009, CHEST, V135, P1370, DOI 10.1378/chest.08-1834; Schwab KA, 2006, NEUROLOGY, V66, pA235; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Smith S, 2004, SLEEP MED, V5, P449, DOI 10.1016/j.sleep.2004.03.005; Stein MD, 2004, J SUBST ABUSE TREAT, V26, P175, DOI 10.1016/S0740-5472(03)00191-0; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Wickwire EM, 2010, SLEEP MED, V11, P772, DOI 10.1016/j.sleep.2010.03.012; Wickwire EM, 2010, CHEST, V137, P1449, DOI 10.1378/chest.09-1485; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	61	64	64	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0012-3692			CHEST	Chest	SEP	2012	142	3					622	630		10.1378/chest.11-1603			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	003PE	WOS:000308623000014	22459784				2021-06-18	
J	Hart, T; Hoffman, JM; Pretz, C; Kennedy, R; Clark, AN; Brenner, LA				Hart, Tessa; Hoffman, Jeanne M.; Pretz, Christopher; Kennedy, Richard; Clark, Allison N.; Brenner, Lisa A.			A Longitudinal Study of Major and Minor Depression Following Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Mental health; Rehabilitation	PATIENT HEALTH QUESTIONNAIRE-9; SOCIAL SUPPORT; SERVICE UTILIZATION; SYSTEMATIC BIAS; DISORDERS; OUTCOMES; ADULTS; REHABILITATION; PREVALENCE; MORBIDITY	Objective: To examine patterns of change and factors associated with change in depression, both major (major depressive disorder [MDD]) and minor, between 1 and 2 years after traumatic brain injury (TBI). Design: Observational prospective longitudinal study. Setting: Inpatient rehabilitation centers, with 1- and 2-year follow-up) conducted primarily by telephone. Participants: Persons with TBI (N = 1089) enrolled in the Traumatic Brain Injury Model Systems database, followed at 1 and 2 years postinjury. Interventions: Not applicable. Main Outcome Measure: Patient Health Questionnaire-9. Results: Among participants not depressed at I year, close to three fourths remained so at 2-year follow-up. However, 26% developed MDD or minor depression between the first and second years postinjury. Over half of participants with MDD at year 1 also reported MDD the following year, with another 22% reporting minor depression; thus three fourths of those with MDD at year I experienced clinically significant symptoms at year 2. Almost one third of those with minor depression at year I traversed to MDD at year 2. Polytomous logistic regression confirmed that worse depression at year 1 was associated with higher odds of depression a year later. For those without depression at year 1, symptom worsening over time was related to year 2 problematic substance use and lower FIM motor and cognitive scores. For those with depression at year 1, worsening was associated with lower cognitive FIM, poor social support, and preinjury mental health issues including subslance abuse. Conclusion: Major and minor depression exist on a continuum along which individuals with TBI may traverse over time. Predictors of change differ according to symptom onset. Results highlight importance of long-term monitoring for depression, treating minor as well as major depression, and developing interventions for comorbid depression and substance abuse.	Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Pretz, Christopher; Brenner, Lisa A.] Craig Hosp, Englewood, CO USA; [Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Kennedy, Richard] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA; [Clark, Allison N.] TIRR Mem Hermann, Houston, TX USA; [Clark, Allison N.] Baylor Coll Med, Houston, TX 77030 USA; [Brenner, Lisa A.] VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Aurora, CO USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu	Brenner, Lisa A./AAG-2442-2019		National Institute on Disability and Rehabilitation Research [H133A070040, H133A070032, H133A070022, H133A070043, H133A070039, H133A 110016]	Supported by the National Institute on Disability and Rehabilitation Research (grant nos. H133A070040, H133A070032, H133A070022, H133A070043. H133A070039, and H133A 110016).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cuijpers P, 2004, J AFFECT DISORDERS, V79, P71, DOI 10.1016/S0165-0327(02)00348-8; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Granger CV, 1987, UNIFORM DATA SET MED; Graves DE, 1999, ARCH PHYS MED REHAB, V80, P1464, DOI 10.1016/S0003-9993(99)90259-9; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Howland RH, 2008, PSYCHOTHER PSYCHOSOM, V77, P384, DOI 10.1159/000151519; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Judd LL, 1997, J AFFECT DISORDERS, V45, P5, DOI 10.1016/S0165-0327(97)00055-4; JUDD LL, 1997, J AFFECT DISORDERS, V45, P17; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kessler RC, 1997, J AFFECT DISORDERS, V45, P19, DOI 10.1016/S0165-0327(97)00056-6; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCDANIEL JS, 2000, PSYCHIAT CARE MED PA, P149; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rapaport MH, 2002, AM J PSYCHIAT, V159, P637, DOI 10.1176/appi.ajp.159.4.637; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; SKODOL AE, 1994, ARCH GEN PSYCHIAT, V51, P542; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; United States Department of Health and Human Services, 1998, NAT HOUS SURV DRUG A; Wagner HR, 2000, PSYCHOL MED, V30, P1377, DOI 10.1017/S0033291799002998; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002	49	64	65	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1343	1349		10.1016/j.apmr.2012.03.036			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700008	22840833				2021-06-18	
J	Stein, NR; McArthur, DL; Etchepare, M; Vespa, PM				Stein, Nathan R.; McArthur, David L.; Etchepare, Maria; Vespa, Paul M.			Early Cerebral Metabolic Crisis After TBI Influences Outcome Despite Adequate Hemodynamic Resuscitation	NEUROCRITICAL CARE			English	Article						Brain trauma; Glucose; Lactate; Lactate/pyruvate ratio; Microdialysis; Resuscitation	TRAUMATIC BRAIN-INJURY; MICRODIALYSIS; SEIZURES; LACTATE; ATROPHY	Optimal resuscitation after traumatic brain injury (TBI) remains uncertain. We hypothesize that cerebral metabolic crisis is frequent despite adequate resuscitation of the TBI patient and that metabolic crisis negatively influences outcome. We assessed the effectiveness of a standardized trauma resuscitation protocol in 89 patients with moderate to severe TBI, and determined the frequency of adequate resuscitation. Prospective hourly values of heart rate, blood pressure, pulse oximetry, intracranial pressure (ICP), respiratory rate, jugular venous oximetry, and brain extracellular values of glucose, lactate, pyruvate, glycerol, and glutamate were obtained. The incidence during the initial 72 h after injury of low brain glucose < 0.8 mmol/L, elevated lactate/pyruvate ratio (LPR) > 25, and metabolic crisis, defined as the simultaneous occurrence of both low glucose and high LPR, were determined for the group. 5 patients were inadequately resuscitated and eight patients had intractable ICP. In patients with successful resuscitation and controlled ICP (n = 76), within 72 h of trauma, 76 % had low glucose, 93 % had elevated LPR, and 74 % were in metabolic crisis. The duration of metabolic crisis was longer in those patients with unfavorable (GOSe a parts per thousand currency sign 6) versus favorable (GOSe a parts per thousand yen 7) outcome at 6 months (P = 0.011). In four multivariate models the burden of metabolic crisis was a powerful independent predictor of poor outcome. Metabolic crisis occurs frequently after TBI despite adequate resuscitation and controlled ICP, and is a strong independent predictor of poor outcome at 6 months.	[Stein, Nathan R.; McArthur, David L.; Etchepare, Maria; Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	Vespa, PM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 757 Westwood Blvd,RR 6236A, Los Angeles, CA 90095 USA.	pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	 [NS-058489]	UCLA Brain Injury Research Center, supported by NS-058489.	Agostinelli C, 2010, WLE WEIGHTED LIKELIH; Bhardwaj A, 2011, HDB NEUROCRITICAL CA, DOI [10.1007/978-1-4419-6842-5_18, DOI 10.1007/978-1-4419-6842-5_18]; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Dries DJ, 2011, INITIAL EVALUATION T; Fletcher JJ, 2010, NEUROCRIT CARE, V13, P47, DOI 10.1007/s12028-010-9345-2; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sander A., 2002, EXTENDED GLASGOW OUT; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Ts L., 2006, HONG KONG J EMERG ME, V13, P24; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wilcox R, 2012, ROBUST STAT; Wilcox R. R., 2005, INTRO ROBUST ESTIMAT; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	27	64	65	1	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2012	17	1					49	57		10.1007/s12028-012-9708-y			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	976NG	WOS:000306591000007	22528283				2021-06-18	
J	Bressan, S; Romanato, S; Mion, T; Zanconato, S; Da Dalt, L				Bressan, Silvia; Romanato, Sabrina; Mion, Teresa; Zanconato, Stefania; Da Dalt, Liviana			Implementation of Adapted PECARN Decision Rule for Children With Minor Head Injury in the Pediatric Emergency Department	ACADEMIC EMERGENCY MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; PREDICTION; IMPACT	ACADEMIC EMERGENCY MEDICINE 2012; 19:801807 (c) 2012 by the Society for Academic Emergency Medicine Abstract Objectives: Of the currently published clinical decision rules for the management of minor head injury (MHI) in children, the Pediatric Emergency Care Applied Research Network (PECARN) rule, derived and validated in a large multicenter prospective study cohort, with high methodologic standards, appears to be the best clinical decision rule to accurately identify children at very low risk of clinically important traumatic brain injuries (ciTBI) in the pediatric emergency department (PED). This study describes the implementation of an adapted version of the PECARN rule in a tertiary care academic PED in Italy and evaluates implementation success, in terms of medical staff adherence and satisfaction, as well as its effects on clinical practice. Methods: The adapted PECARN decision rule algorithms for children (one for those younger than 2 years and one for those older than 2 years) were actively implemented in the PED of Padova, Italy, for a 6-month testing period. Adherence and satisfaction of medical staff to the new rule were calculated. Data from 356 visits for MHI during PECARN rule implementation and those of 288 patients attending the PED for MHI in the previous 6 months were compared for changes in computed tomography (CT) scan rate, ciTBI rate (defined as death, neurosurgery, intubation for longer than 24 hours, or hospital admission at least for two nights associated with TBI) and return visits for symptoms or signs potentially related to MHI. The safety and efficacy of the adapted PECARN rule in clinical practice were also calculated. Results: Adherence to the adapted PECARN rule was 93.5%. The percentage of medical staff satisfied with the new rule, in terms of usefulness and ease of use for rapid decision-making, was significantly higher (96% vs. 51%, p < 0.0001) compared to the previous, more complex, internal guideline. CT scan was performed in 30 patients (8.4%, 95% confidence interval [CI] = 6% to 11.8%) in the implementation period versus 21 patients (7.3%, 95% CI = 4.8% to 10.9%) before implementation. A ciTBI occurred in three children (0.8%, 95% CI = 0.3 to 2.5) during the implementation period and in two children (0.7%, 95% CI = 0.2 to 2.5) in the prior 6 months. There were five return visits (1.4%) postimplementation and seven (2.4%) before implementation (p = 0.506). The safety of use of the adapted PECARN rule in clinical practice was 100% (95% CI = 36.8 to 100; three of three patients with ciTBI who received CT scan at first evaluation), while efficacy was 92.3% (95% CI = 89 to 95; 326 of 353 patients without ciTBI who did not receive a CT scan). Conclusions: The adapted PECARN rule was successfully implemented in an Italian tertiary care academic PED, achieving high adherence and satisfaction of medical staff. Its use determined a low CT scan rate that was unchanged compared to previous clinical practice and showed an optimal safety and high efficacy profile. Strict monitoring is mandatory to evaluate the long-lasting benefit in patient care and/or resource utilization.	[Bressan, Silvia; Romanato, Sabrina; Mion, Teresa; Zanconato, Stefania; Da Dalt, Liviana] Univ Padua, Dept Pediat, Padua, Italy	Bressan, S (corresponding author), Univ Padua, Dept Pediat, Padua, Italy.	silvia.bressan.1@unipd.it					Armon K, 2004, ARCH DIS CHILD, V89, P159, DOI 10.1136/adc.2002.024406; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner David J., 2010, Reviews on Environmental Health, V25, P63; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Callegaro S, 2009, PEDIATR NEUROL, V40, P78, DOI 10.1016/j.pediatrneurol.2008.09.008; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; Da Dalt L, 2007, J PEDIATR-US, V150, P274, DOI 10.1016/j.jpeds.2006.11.060; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Norton SP, 2007, ARCH DIS CHILD, V92, P60, DOI 10.1136/adc.2006.097287; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Parkin PC, 2009, LANCET, V374, P1127, DOI 10.1016/S0140-6736(09)61634-2; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009	18	64	65	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JUL	2012	19	7					801	807		10.1111/j.1553-2712.2012.01384.x			7	Emergency Medicine	Emergency Medicine	974CL	WOS:000306407300005	22724450				2021-06-18	
J	Slobounov, S; Gay, M; Johnson, B; Zhang, K				Slobounov, Semyon; Gay, Michael; Johnson, Brian; Zhang, Kai			Concussion in athletics: ongoing clinical and brain imaging research controversies	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild TBI; Neuroimaging; Clinical outcome	MAGNETIC-RESONANCE-SPECTROSCOPY; COMPENSATORY CORTICAL ACTIVATION; WORKING-MEMORY DYSFUNCTION; SELF-REPORTED CONCUSSIONS; RESTING-STATE NETWORKS; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; WHITE-MATTER; FUNCTIONAL CONNECTIVITY; DEFAULT-MODE	Concussion, the most common form of traumatic brain injury, proves to be increasingly complex and not mild in nature as its synonymous term mild traumatic brain injury (mTBI) would imply. Despite the increasing occurrence and prevalence of mTBI there is no universally accepted definition and conventional brain imaging techniques lack the sensitivity to detect subtle changes it causes. Moreover, clinical management of sports induced mild traumatic brain injury has not changed much over the past decade. Advances in neuroimaging that include electroencephalography (EEG), functional magnetic resonance imaging (fMRI), resting-state functional connectivity, diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS) offer promise in aiding research into understanding the complexities and nuances of mTBI which may ultimately influence clinical management of the condition. In this paper the authors review the major findings from these advanced neuroimaging methods along with current controversy within this field of research. As mTBI is frequently associated with youth and sports injury this review focuses on sportsaEurorelated mTBI in the younger population.	[Slobounov, Semyon; Gay, Michael; Johnson, Brian; Zhang, Kai] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Slobounov, Semyon] NINDS, NIH, Bethesda, MD USA; [Slobounov, Semyon] Penn State Univ, Dept Orthopaed & Med Rehabil, HMC, University Pk, PA 16802 USA; [Johnson, Brian] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreation Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150			Alves W., 1989, MILD HEAD INJURY; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Barwick F, 2012, CLIN NEUROPHYSIOL, V123, P278, DOI 10.1016/j.clinph.2011.06.027; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler E. D, 2012, BRAIN IMAGING BEHAV; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cao C, 2011, CLIN NEUROPHYSIOL, V122, P1314, DOI 10.1016/j.clinph.2010.12.042; CAoSMC C, 2000, CLIN J SPORT MED, V10, P209; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chang L, 2004, ANN NEUROL, V56, P259, DOI 10.1002/ana.20190; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chiaravalloti ND, 2005, J CLIN EXP NEUROPSYC, V27, P33, DOI 10.1080/138033990513609; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Courtney Susan M., 2004, Cognitive Affective & Behavioral Neuroscience, V4, P501, DOI 10.3758/CABN.4.4.501; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; FAAS FH, 1968, J NEUROSURG, V28, P137, DOI 10.3171/jns.1968.28.2.0137; Flamm E S, 1966, Surg Forum, V17, P414; Forn C, 2006, NEUROIMAGE, V31, P686, DOI 10.1016/j.neuroimage.2005.12.030; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Gardner A, 2010, ARCH CLIN NEUROPSYCH, V25, P174, DOI 10.1093/arclin/acq007; Gasparovic C., 2009, J NEUROTRAUM; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geets W, 1985, Rev Electroencephalogr Neurophysiol Clin, V14, P333; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glaser MA, 1940, W SURG, V48, P6989; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Helgeson S. R, 2011, BRAIN INJURY PROFESS, V7; Henry L. C., 2011, J NEUROTRAUM; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horowitz AL, 1995, MRI PHYS RADIOLOGIST; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; Jaeggi SM, 2003, NEUROIMAGE, V19, P210, DOI 10.1016/S1053-8119(03)00098-3; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Jasper HH, 1940, ARCH NEURO PSYCHIATR, V44, P328, DOI 10.1001/archneurpsyc.1940.02280080088005; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; JUEPTNER M, 1995, NEUROIMAGE, V2, P148, DOI 10.1006/nimg.1995.1017; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Landau SM, 2004, NEUROIMAGE, V22, P211, DOI 10.1016/j.neuroimage.2004.01.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; LopesdaSilva F, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI [10.1016/0013-4694(91)90044-5, DOI 10.1016/0013-4694(91)90044-5]; Lutzenberger W., 1987, J PSYCHOPHYSIOL, V1, P81; Mainero C, 2006, J NEUROL SCI, V245, P93, DOI 10.1016/j.jns.2005.08.024; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; Olejniczak P, 2006, J CLIN NEUROPHYSIOL, V23, P186, DOI 10.1097/01.wnp.0000220079.61973.6c; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pantano P, 2006, J NEUROIMAGING, V16, P104, DOI 10.1111/j.1552-6569.2006.00029.x; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Schwarz A, 2010, NY TIMES; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shekdar K, 2011, SEMIN ULTRASOUND CT, V32, P510, DOI 10.1053/j.sult.2011.08.001; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S., 2012, CLIN NEUROPHYSIOLOGY; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Slobounov S, 2011, IEEE ENG MED BIO, P1383, DOI 10.1109/IEMBS.2011.6090325; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhu T, 2011, NEUROIMAGE, V56, P1398, DOI 10.1016/j.neuroimage.2011.02.010	170	64	64	1	49	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		224	243		10.1007/s11682-012-9167-2			20	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900006	22669496				2021-06-18	
J	Mailles, A; De Broucker, T; Costanzo, P; Martinez-Almoyna, L; Vaillant, V; Stahl, JP				Mailles, Alexandra; De Broucker, Thomas; Costanzo, Pascale; Martinez-Almoyna, Laurent; Vaillant, Veronique; Stahl, Jean-Paul		Steering Comm Investigators Grp	Long-term Outcome of Patients Presenting With Acute Infectious Encephalitis of Various Causes in France	CLINICAL INFECTIOUS DISEASES			English	Article							HERPES-SIMPLEX ENCEPHALITIS; TRAUMATIC BRAIN-INJURY; VIRAL ENCEPHALITIS; MULTICENTER; ACYCLOVIR; RECOVERY; QUESTIONNAIRE; VALIDATION; CHILDHOOD; PROGNOSIS	Background. A prospective study of infectious encephalitis was conducted in France in 2007. In total, 253 patients were enrolled with a proven etiological diagnosis for 52%. The cohort of surviving patients with encephalitis was assessed for sequelae and impairment 3 years after enrollment. Methods. Patients, their family, and general practitioners (GPs) were interviewed by phone to document persisting symptoms, return to work, and past and current leisure activities, with standardized questionnaires. The IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) was completed with relatives. The global outcome was determined in all patients with the Glasgow outcome scale. Results. In 2010, 20 patients (10%) were unavailable for follow-up, 2 (1%) were excluded, and 18 (9%) had died since hospital discharge. Data were available for 167 survivors and 9 patients whose death was related to the encephalitis. The outcome was favorable in 108 of 176 patients (61%) (71 with complete resolution), 31 (18%) were mildly impaired, 25 (14%) were severely impaired, and 3 (1%) were in a vegetative state. The most frequent symptoms were difficulty concentrating (42%), behavioral disorders (27%), speech disorders (20%), and memory loss (19%). Fifteen of 63 patients (24%) previously employed were still unable to resume work. Long-term outcome was significantly associated with comorbid conditions, age, level of education, and the causative agent of encephalitis. Conclusions. Most patients with encephalitis experienced a favorable outcome 3 years after hospital discharge. However, minor to severe disability persists in a high number of cases with consequences for everyday life. Physical and mental impairment should be evaluated in all patients with encephalitis, and neuropsychological rehabilitation implemented whenever needed.	[Mailles, Alexandra; Vaillant, Veronique] French Inst Publ Hlth Surveillance, St Maurice, France; [De Broucker, Thomas] Hop Delafontaine, Dept Neurol, St Denis, Reunion, France; [Costanzo, Pascale] Hosp Civils Lyon, Neuro Psychol Dept, Lyon, France; [Martinez-Almoyna, Laurent] Univ Joseph Fourier, Ctr Hosp, Dept Neurol, Grenoble, France; [Stahl, Jean-Paul] Univ Joseph Fourier, Grenoble, France; [Stahl, Jean-Paul] Univ Hosp, Grenoble, France	Mailles, A (corresponding author), Inst Veille Sanit, 12 Rue Val dOsne, F-94415 St Maurice, France.	a.mailles@invs.sante.fr	Boutolleau, David/D-9610-2014; Rogez, Sylvie/O-8891-2016; Lecuit, Marc/M-4126-2019; Stahl, Jean Paul/AAM-6425-2020; Lecuit, Marc/J-4073-2013; Dinh, Aurelien/AAI-5355-2021; GOZLAN, Joel/P-6014-2017; Guery, Benoit/D-8089-2017	Boutolleau, David/0000-0001-9401-4662; Rogez, Sylvie/0000-0002-4092-7164; Lecuit, Marc/0000-0002-4491-1063; Lecuit, Marc/0000-0002-4491-1063; Herrmann, Jean-Louis/0000-0003-2347-6418; Stahl, Jean Paul/0000-0002-0086-3557; Mailles, Alexandra/0000-0002-8739-1168; Prendki, Virginie/0000-0003-1315-2938; Bebear, Cecile/0000-0001-6065-2332; lina, bruno/0000-0002-8959-2123; Terral, Daniel/0000-0003-3706-6786; POZZETTO, Bruno/0000-0002-2603-8467; Guery, Benoit/0000-0002-6526-0714			BERLIT P, 1988, J NEUROIMMUNOL, V20, P117, DOI 10.1016/0165-5728(88)90142-7; Daxboeck F, 2004, J CHILD NEUROL, V19, P865, DOI 10.1177/08830738040190110401; Ebaugh FG, 2007, J ATTEN DISORD, V11, P339; Ebaugh Franklin G, 2007, J Atten Disord, V11, P336, DOI 10.1177/1087054707305340; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Fowler A, 2010, PEDIATRICS, V126, pE828, DOI 10.1542/peds.2009-3188; Glaser CA, 2006, CLIN INFECT DIS, V43, P1565, DOI 10.1086/509330; GORDON B, 1990, ARCH NEUROL-CHICAGO, V47, P646, DOI 10.1001/archneur.1990.00530060054017; Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X; Haaland KY, 2006, EMERG INFECT DIS, V12, P1260, DOI 10.3201/eid1708.060097; Hokkanen L, 1997, J NEUROL NEUROSUR PS, V63, P222, DOI 10.1136/jnnp.63.2.222; JENNETT B, 1975, LANCET, V1, P480; Jeon IC, 2008, J KOREAN NEUROSURG S, V44, P295, DOI 10.3340/jkns.2008.44.5.295; JORM AF, 1995, PSYCHOL MED, V25, P437; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LAW S, 1995, BRIT J PSYCHIAT, V167, P541, DOI 10.1192/bjp.167.4.541; Lee WT, 2007, EUR J PAEDIATR NEURO, V11, P302, DOI 10.1016/j.ejpn.2007.02.011; Lefebvre C, 2005, J NEUROL, V252, P1504, DOI 10.1007/s00415-005-0900-2; Liu XD, 2007, CLIN NEUROL NEUROSUR, V109, P571, DOI 10.1016/j.clineuro.2007.05.008; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Mailles A, 2009, CLIN INFECT DIS, V49, P1838, DOI 10.1086/648419; McGrath N, 1997, J NEUROL NEUROSUR PS, V63, P321, DOI 10.1136/jnnp.63.3.321; Michel J A, 2006, Eura Medicophys, V42, P59; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Raschilas F, 2002, CLIN INFECT DIS, V35, P254, DOI 10.1086/341405; Schmidt A, 2011, CLIN MICROBIOL INFEC, V17, P621, DOI 10.1111/j.1469-0691.2010.03276.x; SKOLDENBERG B, 1991, SCAND J INFECT DIS, P40; Stahl JP, 2012, EPIDEMIOL INFECT, V140, P372, DOI 10.1017/S0950268811000483; Stahl JP, 2011, MED MALADIES INFECT, V41, P453, DOI 10.1016/j.medmal.2011.05.015; THOMAS NH, 1993, ARCH DIS CHILD, V69, P573, DOI 10.1136/adc.69.5.573; Utley TFM, 1997, NEUROPSY NEUROPSY BE, V10, P180; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; World Health Organization, 2004, INT STAT CLASS DIS R, V2	34	64	65	2	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1058-4838	1537-6591		CLIN INFECT DIS	Clin. Infect. Dis.	MAY 15	2012	54	10					1455	1464		10.1093/cid/cis226			10	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	942MW	WOS:000304049300017	22460967	Bronze			2021-06-18	
J	Fernandez-Ortega, JF; Prieto-Palomino, MA; Garcia-Caballero, M; Galeas-Lopez, JL; Quesada-Garcia, G; Baguley, IJ				Francisco Fernandez-Ortega, Juan; Angel Prieto-Palomino, Miguel; Garcia-Caballero, Manuel; Luis Galeas-Lopez, Juan; Quesada-Garcia, Guillermo; Baguley, Ian J.			Paroxysmal Sympathetic Hyperactivity after Traumatic Brain Injury: Clinical and Prognostic Implications	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; intensive care unit; paroxysmal sympathetic hyperactivity; prognosis; traumatic brain injury	SEVERE HEAD-INJURY; INTENSIVE-CARE-UNIT; AUTONOMIC INSTABILITY; DIENCEPHALIC SEIZURES; DYSAUTONOMIA; DYSTONIA; BROMOCRIPTINE; MANAGEMENT; PRESSURE	A proportion of patients surviving severe traumatic brain injury (TBI) have symptoms suggestive of excessive sympathetic discharge, here termed paroxysmal sympathetic hyperactivity (PSH). The goals of this study were: (1) to describe the clinical associations and radiological findings of PSH, its incidence, and features in subjects with severe TBI in the intensive care unit (ICU); (2) to investigate the potential role of increased intracranial pressure in the pathogenesis of PSH; and (3) to determine the prognostic influence of PSH during the ICU stay, on discharge from the ICU, and at 12 months post-injury. A prospective cohort study was undertaken of all ICU admissions with severe TBI older than 14 years over an 18-month period. The PSH symptoms consisted of paroxysmal increases in blood pressure, respiratory rate, and heart rate; worsening level of consciousness; muscle rigidity; and hyperhidrosis. Subjects demonstrating PSH episodes were compared with a group of non-PSH consecutive subjects studied over the first 6 months of the study period. Data were recorded on the clinical variables associated with PSH episodes, early post-injury cerebral CT findings, and neurological status at 1 year. Of 179 severe TBI patients admitted over the study period, 18 (10.1%) experienced PSH. Injury severity-related variables (e. g., initial APACHE II score, admission coma level, and proportion with intracranial hypertension) were similar between the two groups. The PSH group had a longer ICU stay and a greater incidence of infectious complications. At 1 year post-injury, 20% of this group demonstrated ongoing PSH episodes. Over 18 months, 10.1% of admissions following severe TBI demonstrated PSH features in ICU. Subjects with PSH had a longer ICU stay and higher rate of complications, although this did not appear to compromise their long-term neurological recovery.	[Francisco Fernandez-Ortega, Juan; Angel Prieto-Palomino, Miguel; Garcia-Caballero, Manuel; Luis Galeas-Lopez, Juan; Quesada-Garcia, Guillermo] Univ Hosp Carlos Haya, ICU Serv, Malaga, Spain; [Baguley, Ian J.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia	Fernandez-Ortega, JF (corresponding author), C Mirador Candado 1, Malaga 29018, Spain.	patferon@gmail.com	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Fernandez Ortega, Juan F/0000-0003-2130-1331; Galeas Lopez, Juan Luis/0000-0002-1612-7730			Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BHIGJEE AI, 1985, J NEUROL SCI, V71, P77, DOI 10.1016/0022-510X(85)90038-3; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fernandez-Ortega JF, 2004, REV NEUROLOGIA, V39, P715, DOI 10.33588/rn.3908.2004034; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goddeau RP, 2007, NEUROCRIT CARE, V7, P217, DOI 10.1007/s12028-007-0066-0; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KLUG N, 1984, ACTA NEUROCHIR, V72, P219, DOI 10.1007/BF01406872; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; Perkes I.E., BRAIN INJ IN PRESS; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; SUAREZALVAREZ JR, 1995, INTENS CARE MED, V21, P729, DOI 10.1007/BF01704740; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Wang VY, 2008, J TRAUMA, V64, P500, DOI 10.1097/TA.0b013e31804a5738; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	39	64	72	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1364	1370		10.1089/neu.2011.2033			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600010	22150061				2021-06-18	
J	Cruse, D; Chennu, S; Chatelle, C; Fernandez-Espejo, D; Bekinschtein, TA; Pickard, JD; Laureys, S; Owen, AM				Cruse, D.; Chennu, S.; Chatelle, C.; Fernandez-Espejo, D.; Bekinschtein, T. A.; Pickard, J. D.; Laureys, S.; Owen, A. M.			Relationship between etiology and covert cognition in the minimally conscious state	NEUROLOGY			English	Article							PERSISTENT VEGETATIVE STATE; DIFFUSE AXONAL INJURY; BRAIN-INJURY; HEAD-INJURY; LATE RECOVERY; DISORDERS; NEUROPATHOLOGY; AWARENESS; REHABILITATION; DIAGNOSIS	Objectives: Functional neuroimaging has shown that the absence of externally observable signs of consciousness and cognition in severely brain-injured patients does not necessarily indicate the true absence of such abilities. However, relative to traumatic brain injury, nontraumatic injury is known to be associated with a reduced likelihood of regaining overtly measurable levels of consciousness. We investigated the relationships between etiology and both overt and covert cognitive abilities in a group of patients in the minimally conscious state (MCS). Methods: Twenty-three MCS patients (15 traumatic and 8 nontraumatic) completed a motor imagery EEG task in which they were required to imagine movements of their right-hand and toes to command. When successfully performed, these imagined movements appear as distinct sensorimotor modulations, which can be used to determine the presence of reliable command-following. The utility of this task has been demonstrated previously in a group of vegetative state patients. Results: Consistent and robust responses to command were observed in the EEG of 22% of the MCS patients (5 of 23). Etiology had a significant impact on the ability to successfully complete this task, with 33% of traumatic patients (5 of 15) returning positive EEG outcomes compared with none of the nontraumatic patients (0 of 8). Conclusions: The overt behavioral signs of awareness (measured with the Coma Recovery Scale-Revised) exhibited by nontraumatic MCS patients appear to be an accurate reflection of their covert cognitive abilities. In contrast, one-third of a group of traumatically injured patients in the MCS possess a range of high-level cognitive faculties that are not evident from their overt behavior. Neurology (R) 2012;78:816-822	[Cruse, D.; Fernandez-Espejo, D.; Owen, A. M.] Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada; [Cruse, D.; Bekinschtein, T. A.; Owen, A. M.] MRC, Cognit & Brain Sci Unit, Cambridge, England; [Chennu, S.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 1TN, England; Univ Hosp Liege, Liege, Belgium; [Chatelle, C.; Laureys, S.] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Chatelle, C.; Laureys, S.] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Pickard, J. D.] Addenbrookes Hosp, Div Acad Neurosurg, Cambridge, England	Cruse, D (corresponding author), Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada.	dcruse@uwo.ca	Owen, Adrian M/B-4997-2015; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Chatelle, Camille/0000-0002-7526-2107; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Chennu, Srivas/0000-0002-6840-2941	Medical Research Council UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Canada Excellence Research Chair Program; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); McDonnell Foundation; James S. McDonnell Foundation; Guarantors of Brain	Dr. Cruse has received research support from Medical Research Council UK and the Canada Excellence Research Chair Program. Dr. Chennu receives research support from Medical Research Council UK, Visiting Worker, James S. McDonnell Foundation, and Guarantors of Brain. Dr. Chatelle, Dr. Fernandez-Espejo, and Dr. Bekinschtein report no disclosures. Dr. Pickard serves on scientific advisory boards for Codman and Johnson & Johnson; serves as Chief Editor for Advances and Technical Standards in Neurosurgery; receives publishing royalties for Pseudotumor Cerebro Syndrome (Cambridge University Press, 2008); and receives research support from MRC Translational Grant and the McDonnell Foundation. Dr. Laureys reports no disclosures. Dr. Owen serves as an Associate Editor for Journal of Neuroscience and on the editorial advisory board of Annals of the New York Academy of Sciences; receives publishing royalties for Cognitive Deficits in Neurological Disorders (Dunitz, 2001); and receives research support from Medical Research Council UK and the James S. McDonnell Foundation.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adams JH, 1992, GREENFIELDS NEUROPAT; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Fins JJ, 2007, NEUROLOGY, V68, P304, DOI 10.1212/01.wnl.0000252376.43779.96; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Monti MM, 2010, J PSYCHOPHY IN PRESS; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3	31	64	67	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAR	2012	78	11					816	822		10.1212/WNL.0b013e318249f764			7	Clinical Neurology	Neurosciences & Neurology	907VW	WOS:000301448300011	22377810	Green Published, Green Accepted			2021-06-18	
J	Kerr, ZY; Marshall, SW; Guskiewicz, KM				Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Reliability of Concussion History in Former Professional Football Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; HEAD INJURY; TRAUMATIC BRAIN INJURY	LIFE COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; SPORTS CONCUSSION; AGREEMENT; ASSOCIATION; RISK	KERR, Z. Y., S. W. MARSHALL, and K. M. GUSKIEWICZ. Reliability of Concussion History in Former Professional Football Players. Med. Sci. Sports Exerc., Vol. 44, No. 3, pp. 377-382, 2012. Purpose: The reliability of athletes to recall and self-report a concussion history has never been quantified. This study examined the reliability of the self-report concussion history measure and explored determinants of recall in the number of self-reported concussions in a group of retired professional football players. Methods: In 2001, a short questionnaire was administered to a cohort of former professional football players to ascertain the number of self-reported concussions they sustained during their professional playing careers. In 2010, the same instrument was readministered to a subset (n = 899) of the original cohort to assess reliability. Results: Overall reliability was moderate (weighted Cohen kappa = 0.48). The majority (62.1%) reported the same number of concussions in both administrations (2001 and 2010); 31.4% reported more concussions in the second administration. Compared with the "same number reported" group, the "greater number reported" group had more deficits in the second administration in their Short Form 36 physical health (composite score combining physical functioning, role physical, bodily pain, general health) and mental health (e. g., composite score combining vitality, social functioning, role emotional) scales. Conclusions: The self-reported concussion history had moderate reliability in former professional football players, on the basis of two administrations of the same instrument, 9 yr apart. However, changes in health status may be differentially associated with recall of concussions.	[Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Ctr Study Retired Athletes, Chapel Hill, NC 27599 USA	Marshall, SW (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, 2101 McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.	smarshall@unc.edu		Kerr, Zachary/0000-0003-1423-1259; Marshall, Stephen/0000-0002-2664-9233; Guskiewicz, Kevin/0000-0002-8682-2130	NFL Players Association; Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research; Center for the Study of Retired Athletes	The authors also thank the support of the NFL Players Association. The Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research and the Center for the Study of Retired Athletes are funded by private donations and various grant funding agencies interested in understanding the late-life consequences and benefits of playing sports.	Bandura A., 1986, SOCIAL FDN THOUGHT A, P544; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Gerbner G., 1986, PERSPECTIVES MEDIA E, P17; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MCCOMBS ME, 1972, PUBLIC OPIN QUART, V36, P176, DOI 10.1086/267990; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; Valadka AB, 2005, NEUROSURGERY, V57, P725; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1167, DOI 10.1016/S0895-4356(98)00108-5	15	64	64	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	MAR	2012	44	3					377	382		10.1249/MSS.0b013e31823240f2			6	Sport Sciences	Sport Sciences	897HR	WOS:000300639500002	21857370				2021-06-18	
J	Gupta, A; Elgammal, FS; Proddutur, A; Shah, S; Santhakumar, V				Gupta, Akshay; Elgammal, Fatima S.; Proddutur, Archana; Shah, Samik; Santhakumar, Vijayalakshmi			Decrease in Tonic Inhibition Contributes to Increase in Dentate Semilunar Granule Cell Excitability after Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							TEMPORAL-LOBE EPILEPSY; CONTAINING GABA(A) RECEPTORS; PRINCIPAL NEURON SYNAPSE; POSTTRAUMATIC EPILEPSY; DELTA-SUBUNIT; SEIZURE SUSCEPTIBILITY; MOSSY CELLS; HEAD TRAUMA; MOUSE MODEL; GYRUS	Brain injury is an etiological factor for temporal lobe epilepsy and can lead to memory and cognitive impairments. A recently characterized excitatory neuronal class in the dentate molecular layer, semilunar granule cell (SGC), has been proposed to regulate dentate network activity patterns and working memory formation. Although SGCs, like granule cells, project to CA3, their typical sustained firing and associational axon collaterals suggest that they are functionally distinct from granule cells. We find that brain injury results in an enhancement of SGC excitability associated with an increase in input resistance 1 week after trauma. In addition to prolonging miniature and spontaneous IPSC interevent intervals, brain injury significantly reduces the amplitude of tonic GABA currents in SGCs. The postinjury decrease in SGC tonic GABA currents is in direct contrast to the increase observed in granule cells after trauma. Although our observation that SGCs express Prox1 indicates a shared lineage with granule cells, data from control rats show that SGC tonic GABA currents are larger and sIPSC interevent intervals shorter than in granule cells, demonstrating inherent differences in inhibition between these cell types. GABA(A) receptor antagonists selectively augmented SGC input resistance in controls but not in head-injured rats. Moreover, post-traumatic differences in SGC firing were abolished in GABAA receptor blockers. Our data show that cell-type-specific post-traumatic decreases in tonic GABA currents boost SGC excitability after brain injury. Hyperexcitable SGCs could augment dentate throughput to CA3 and contribute substantively to the enhanced risk for epilepsy and memory dysfunction after traumatic brain injury.	[Gupta, Akshay; Elgammal, Fatima S.; Proddutur, Archana; Shah, Samik; Santhakumar, Vijayalakshmi] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA; [Santhakumar, Vijayalakshmi] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Santhakumar, V (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, MSB-H-512,185 S Orange Ave, Newark, NJ 07103 USA.	santhavi@umdnj.edu	Santhakumar, Vijayalakshmi/M-4192-2013; Santhakumar, Viji/K-4856-2019	Santhakumar, Viji/0000-0001-6278-4187	New Jersey Commission for Brain Injury Research [09.003-BIR1, 11-3223-BIR-E-0]	This work was supported by New Jersey Commission for Brain Injury Research Grants 09.003-BIR1 (to V.S.) and 11-3223-BIR-E-0 (to A.G.). We thank Takahiro Ito for technical assistance and Drs. Stella Elkabes and Robert F. Heary for equipment and discussions.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Brown N, 2002, BRIT J PHARMACOL, V136, P965, DOI 10.1038/sj.bjp.0704795; Cajal SR, 1995, HISTOLOGY NERVOUS SY; Chadderton P, 2004, NATURE, V428, P856, DOI 10.1038/nature02442; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cooper DC, 2003, J NEUROSCI, V23, P9937; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Foldy C, 2007, NAT NEUROSCI, V10, P1128, DOI 10.1038/nn1952; Glykys J, 2007, J PHYSIOL-LONDON, V582, P1163, DOI 10.1113/jphysiol.2007.134460; Golarai G, 2001, J NEUROSCI, V21, P8523; Hefft S, 2005, NAT NEUROSCI, V8, P1319, DOI 10.1038/nn1542; HEINEMANN U, 1992, EPILEPSY RES, P273; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Jessberger S, 2008, NAT NEUROSCI, V11, P888, DOI 10.1038/nn.2148; Karalay O, 2011, CELL CYCLE, V10, P2239, DOI 10.4161/cc.10.14.15850; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kraushaar U, 2000, J NEUROSCI, V20, P5594; Larimer P, 2010, NAT NEUROSCI, V13, P213, DOI 10.1038/nn.2458; Lavado A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000460; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lubke J, 1998, J NEUROPHYSIOL, V79, P1518, DOI 10.1152/jn.1998.79.3.1518; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maguire JL, 2005, NAT NEUROSCI, V8, P797, DOI 10.1038/nn1469; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mitchell SJ, 2003, NEURON, V38, P433, DOI 10.1016/S0896-6273(03)00200-9; Morgan RJ, 2008, P NATL ACAD SCI USA, V105, P6179, DOI 10.1073/pnas.0801372105; Mtchedlishvili Z, 2006, MOL PHARMACOL, V69, P564, DOI 10.1124/mol.105.016683; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Pathak HR, 2007, J NEUROSCI, V27, P14012, DOI 10.1523/JNEUROSCI.4390-07.2007; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Rajasekaran K, 2010, NEUROBIOL DIS, V40, P490, DOI 10.1016/j.nbd.2010.07.016; Ratzliff ADH, 2004, J NEUROSCI, V24, P2259, DOI 10.1523/JNEUROSCI.5191-03.2004; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Ruiz A, 2003, NEURON, V39, P961, DOI 10.1016/S0896-6273(03)00559-2; Santhakumar V, 2006, J NEUROSCI, V26, P3357, DOI 10.1523/JNEUROSCI.4799-05.2006; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2010, NEUROSCIENCE, V167, P644, DOI 10.1016/j.neuroscience.2010.02.048; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Silver RA, 2010, NAT REV NEUROSCI, V11, P474, DOI 10.1038/nrn2864; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Szabadics J, 2010, J NEUROSCI, V30, P8296, DOI 10.1523/JNEUROSCI.5602-09.2010; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Walker MC, 2010, NAT NEUROSCI, V13, P145, DOI 10.1038/nn0210-146; Wei WZ, 2003, J NEUROSCI, V23, P10650; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Williams PA, 2007, J NEUROSCI, V27, P13756, DOI 10.1523/JNEUROSCI.4053-07.2007; Zhan RZ, 2009, J NEUROPHYSIOL, V102, P670, DOI 10.1152/jn.00147.2009; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007	64	64	64	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 15	2012	32	7					2523	2537		10.1523/JNEUROSCI.4141-11.2012			15	Neurosciences	Neurosciences & Neurology	895ZO	WOS:000300535400028	22396425	Green Published, Bronze			2021-06-18	
J	Mayes, SD; Calhoun, SL; Aggarwal, R; Baker, C; Mathapati, S; Anderson, R; Petersen, C				Mayes, Susan Dickerson; Calhoun, Susan L.; Aggarwal, Richa; Baker, Courtney; Mathapati, Santoshkumar; Anderson, Robert; Petersen, Christopher			Explosive, oppositional, and aggressive behavior in children with autism compared to other clinical disorders and typical children	RESEARCH IN AUTISM SPECTRUM DISORDERS			English	Article						Explosive; Oppositional; Aggressive; Autism; ADHD	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; DEFIANT DISORDER; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME; PROCESSING SPEED; GENDER-DIFFERENCES; SPECTRUM DISORDER	Maternal ratings of explosiveness, opposition, and aggression were analyzed in 1609 children 6-16 years of age. Behavior problems were common in autism, ADHD-Combined type, and depression, whereas children with ADHD-Inattentive type, anxiety disorder, and acquired brain injury did not differ from typical controls. More than 40% of children with autism, ADHD-Combined type, and depression met criteria for oppositional-defiant disorder (ODD), and less than 15% did in the other groups. Male gender and low SES increased the risk of behavior problems, but correlations were small between behavior problems and age and IQ. Our findings have implications for new DSM-V diagnostic categories and criteria. The DSM-V needs to clarify whether or not an additional diagnosis of ODD should be made in children with autism who meet ODD criteria. The proposed DSM-V states that ADHD and temper dysregulation disorder with dysphoria not be diagnosed in autism, but does not mention ODD. Our study also suggests that diagnoses of temper dysregulation disorder with dysphoria and prepubertal bipolar disorder may be redundant to a diagnosis of ODD. (C) 2011 Elsevier Ltd. All rights reserved.	[Mayes, Susan Dickerson; Calhoun, Susan L.; Aggarwal, Richa; Baker, Courtney; Mathapati, Santoshkumar; Anderson, Robert; Petersen, Christopher] Penn State Coll Med, Dept Psychiat, Hershey, PA USA	Mayes, SD (corresponding author), Hershey Med Ctr, Dept Psychiat H073, 500 Univ Dr, Hershey, PA 17033 USA.	smayes@psu.edu					Abikoff H, 2004, J AM ACAD CHILD PSY, V43, P802, DOI 10.1097/01.chi.0000128791.10014.ac; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barkley R. A., 2006, ATTENTION DEFICIT HY, V3rd ed, P184; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; Bellini S., 2004, FOCUS AUTISM DEV DIS, V19, P78, DOI DOI 10.1177/10883576040190020201; Biederman J, 2001, J AM ACAD CHILD PSY, V40, P871, DOI 10.1097/00004583-200108000-00007; Bimbrauer J. S., 1993, BEHAV CHANGE, V10, P63, DOI DOI 10.1017/S0813483900005556; Bixler EO, 2009, SLEEP, V32, P731, DOI 10.1093/sleep/32.6.731; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Boylan K, 2010, J AM ACAD CHILD PSY, V49, P152, DOI 10.1016/j.jaac.2009.09.007; Brereton AV, 2006, J AUTISM DEV DISORD, V36, P863, DOI 10.1007/s10803-006-0125-y; Brosnan J, 2011, RES DEV DISABIL, V32, P437, DOI 10.1016/j.ridd.2010.12.023; Calhoun SL, 2005, PSYCHOL SCHOOLS, V42, P333, DOI 10.1002/pits.20067; Card NA, 2008, CHILD DEV, V79, P1185, DOI 10.1111/j.1467-8624.2008.01184.x; Carlson CL, 1997, J AM ACAD CHILD PSY, V36, P1706, DOI 10.1097/00004583-199712000-00019; Chacko A, 2005, J AM ACAD CHILD PSY, V44, P249, DOI 10.1097/00004583-200503000-00009; Clark T, 1999, EUR CHILD ADOLES PSY, V8, P50, DOI 10.1007/s007870050083; Connor DF, 2010, J DEV BEHAV PEDIATR, V31, P427, DOI 10.1097/DBP.0b013e3181e121bd; Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958; Efron D, 2010, J PAEDIATR CHILD H, V46, P392, DOI 10.1111/j.1440-1754.2010.01750.x; Eikeseth S, 2002, BEHAV MODIF, V26, P49, DOI 10.1177/0145445502026001004; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Fabiano GA, 2007, SCHOOL PSYCHOL REV, V36, P195; Fabiano GA, 2009, CLIN PSYCHOL REV, V29, P129, DOI 10.1016/j.cpr.2008.11.001; Faraone SV, 1998, J AM ACAD CHILD PSY, V37, P185, DOI 10.1097/00004583-199802000-00011; FENSKE EC, 1985, ANAL INTERVEN DEVEL, V5, P49, DOI 10.1016/S0270-4684(85)80005-7; Frazier TW, 2010, J CHILD ADOL PSYCHOP, V20, P167, DOI 10.1089/cap.2009.0048; Gadow KD, 2005, AUTISM, V9, P392, DOI 10.1177/1362361305056079; Gadow KD, 2008, J AUTISM DEV DISORD, V38, P1710, DOI 10.1007/s10803-008-0556-8; Green G., 1998, BEHAV INTERVENT, V13, P201, DOI [3.0.co;2-r, DOI 10.1002/(SICI)1099-078X(199811)13:4]; Green J, 2000, J AUTISM DEV DISORD, V30, P279, DOI 10.1023/A:1005523232106; Greene RW, 2002, J EMOT BEHAV DISORD, V10, P79, DOI 10.1177/10634266020100020201; Gross-Tsur V, 2006, DEV MED CHILD NEUROL, V48, P901, DOI 10.1017/S0012162206001976; Guttmann-Steinmetz S, 2009, J AUTISM DEV DISORD, V39, P976, DOI 10.1007/s10803-009-0706-7; Harris SL, 2000, J AUTISM DEV DISORD, V30, P137, DOI 10.1023/A:1005459606120; Howard JS, 2005, RES DEV DISABIL, V26, P359, DOI 10.1016/j.ridd.2004.09.005; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Hurtig T, 2009, AUTISM, V13, P583, DOI 10.1177/1362361309335719; Jensen PS, 1997, J AM ACAD CHILD PSY, V36, P1065, DOI 10.1097/00004583-199708000-00014; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1088, DOI 10.1001/archpsyc.56.12.1088; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Kanne SM, 2009, J AUTISM DEV DISORD, V39, P827, DOI 10.1007/s10803-008-0688-x; Kaplan Stuart L., 2011, YOUR CHILD DOES NOT; Kim J.A., 2000, AUTISM INT J RES PRA, V4, P117, DOI DOI 10.1177/1362361300004002002; King S, 2010, EXPERT REV NEUROTHER, V10, P1581, DOI [10.1586/ern.10.146, 10.1586/ERN.10.146]; Krug D. A., 1993, AUTISM BEHAV CHECKLI; Lalonde J, 1998, CAN J PSYCHIAT, V43, P623, DOI 10.1177/070674379804300612; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Lindgren S. D., 1987, ADV BEHAV ASSESSMENT, P57; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; MANJIVIONA J, 1995, J AUTISM DEV DISORD, V25, P23, DOI 10.1007/BF02178165; Matson JL, 1996, RES DEV DISABIL, V17, P433, DOI 10.1016/S0891-4222(96)00030-3; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; Maughan B, 2004, J CHILD PSYCHOL PSYC, V45, P609, DOI 10.1111/j.1469-7610.2004.00250.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes SD, 2004, CLIN NEUROPSYCHOL, V18, P559, DOI 10.1080/13854040490888530; Mayes SD, 2004, J DEV PHYS DISABIL, V16, P257, DOI 10.1023/B:JODD.0000032301.07550.0e; Mayes SD, 2001, J ABNORM CHILD PSYCH, V29, P263, DOI 10.1023/A:1010337916636; Mayes SD, 1999, INFANT YOUNG CHILD, V12, P90, DOI 10.1097/00001163-199910000-00011; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; Mayes SD, 2008, J AUTISM DEV DISORD, V38, P428, DOI 10.1007/s10803-007-0410-4; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes SD, 2006, LEARN INDIVID DIFFER, V16, P145, DOI 10.1016/j.lindif.2005.07.004; Mayes SD, 2012, RES AUTISM SPECT DIS, V6, P277, DOI 10.1016/j.rasd.2011.05.009; Mayes SD, 2011, J DEV PHYS DISABIL, V23, P325, DOI 10.1007/s10882-011-9231-7; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P749, DOI 10.1016/j.rasd.2010.09.002; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P474, DOI 10.1016/j.rasd.2010.06.012; Mayes SD, 2009, J ATTEN DISORD, V12, P540, DOI 10.1177/1087054708320402; Mayes SD, 2009, J AUTISM DEV DISORD, V39, P1682, DOI 10.1007/s10803-009-0812-6; Mayes SD, 2009, SLEEP MED CLIN, V4, P19, DOI 10.1016/j.jsmc.2008.12.004; Mayes SD, 2009, RES AUTISM SPECT DIS, V3, P931, DOI 10.1016/j.rasd.2009.04.002; Mayes SD, 2009, J PEDIATR PSYCHOL, V34, P328, DOI 10.1093/jpepsy/jsn083; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; MCEACHIN JJ, 1993, AM J MENT RETARD, V97, P359; Milich R, 2001, CLIN PSYCHOL-SCI PR, V8, P463, DOI 10.1093/clipsy/8.4.463; Miller JN, 2000, J ABNORM PSYCHOL, V109, P227, DOI 10.1037/0021-843X.109.2.227; Miller JN, 1997, J CHILD PSYCHOL PSYC, V38, P247; Murphy O, 2009, RES AUTISM SPECT DIS, V3, P474, DOI 10.1016/j.rasd.2008.09.008; Murray MJ, 2011, J AUTISM DEV DISORD, V41, P1586, DOI 10.1007/s10803-011-1178-0; Nagaraj R, 2006, J CHILD NEUROL, V21, P450, DOI 10.1177/08830738060210060801; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; Ozonoff S., 2000, AUTISM, V4, P29, DOI [DOI 10.1177/1362361300041003, 10.1177/1362361300041003]; Pandina GJ, 2007, J AUTISM DEV DISORD, V37, P367, DOI 10.1007/s10803-006-0234-7; Posner K, 2007, J CHILD ADOL PSYCHOP, V17, P547, DOI 10.1089/cap.2007.0075; Russell E, 2005, AUST NZ J PSYCHIAT, V39, P633, DOI 10.1111/j.1440-1614.2005.01637.x; Schopler E., 1986, CHILDHOOD AUTISM RAT; Sheinkopf SJ, 1998, J AUTISM DEV DISORD, V28, P15, DOI 10.1023/A:1026054701472; Smith T, 2000, AM J MENT RETARD, V105, P269, DOI 10.1352/0895-8017(2000)105<0269:RTOIEI>2.0.CO;2; So CYC, 2008, BEHAV RES THER, V46, P983, DOI 10.1016/j.brat.2008.06.007; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; SZATMARI P, 1995, J AM ACAD CHILD PSY, V34, P1662, DOI 10.1097/00004583-199512000-00017; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Tryon P. A., 2006, FOCUS AUTISM OTHER D, V21, P2, DOI [10.1177/10883576060210010101, DOI 10.1177/10883576060210010101]; van der Oord S, 2007, EUR CHILD ADOLES PSY, V16, P48, DOI 10.1007/s00787-006-0574-z; Waxmonsky J, 2008, J CHILD ADOL PSYCHOP, V18, P573, DOI 10.1089/cap.2008.065; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 1991, WECHSLER INTELLIGENC; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501	102	64	64	0	40	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-9467	1878-0237		RES AUTISM SPECT DIS	Res. Autism Spectr. Disord.	JAN-MAR	2012	6	1					1	10		10.1016/j.rasd.2011.08.001			10	Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation	Education & Educational Research; Psychology; Psychiatry; Rehabilitation	858TU	WOS:000297826400001					2021-06-18	
J	Meehan, WP; d'Hemecourt, P; Collins, CL; Taylor, AM; Comstock, RD				Meehan, William P., III; d'Hemecourt, Pierre; Collins, Christy L.; Taylor, Alex M.; Comstock, R. Dawn			Computerized Neurocognitive Testing for the Management of Sport-Related Concussions	PEDIATRICS			English	Article						concussion; injuries; high school; neuropsychological testing	HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE ASSESSMENT; RECOVERY; IMPACT; SENSITIVITY; PERFORMANCE; STATEMENT; INJURIES; PLAY	OBJECTIVES: To describe the prevalence of computerized neurocognitive testing for the assessment of high school athletes who sustain concussions, and to describe associations between using computerized neurocognitive tests, timing of return-to-play, and medical provider managing the athlete. METHODS: Concussions recorded in the High School Reporting Information Online injury surveillance system during the 2009-2010 academic year were included. Measures of association between use of computerized neurocognitive testing and outcomes were analyzed. A questionnaire was sent to athletic trainers (ATs) querying the use of computerized neurocognitive testing. chi(2) analyses were conducted for categorical variables. Logistic regression analyses were used to adjust for potential confounders. Statistical significance was set at P < .05. RESULTS: High School Reporting Information Online recorded 1056 concussions. Athletes who underwent computerized neurocognitive testing were less likely to be returned to play within 10 days of injury (38.5% vs 55.7%, P < .001) and more likely to be returned to play by a physician (60.9% vs 45.6%, P < .001). We had a response rate of 97.3% for the survey. Of respondents, 39.9% used computerized neurocognitive testing; 93.0% of those used ImPACT. Tests were most often interpreted by ATs (78.9%) and/or physicians (78.8%), as opposed to neuropsychologists (16.9%). CONCLUSIONS: Approximately 40% of US high schools that employ an AT use computerized neurocognitive tests when managing sport-related concussions. Tests are most often interpreted by ATs and physicians, as opposed to neuropsychologists. Computerized neurocognitive tests are significantly associated with the timing of return-to-play. Pediatrics 2012;129:38-44	[Meehan, William P., III; d'Hemecourt, Pierre; Taylor, Alex M.] Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III; d'Hemecourt, Pierre; Taylor, Alex M.] Childrens Hosp Boston, Brain Injury Ctr, Boston, MA 02115 USA; [Taylor, Alex M.] Childrens Hosp Boston, Dept Neurol, Boston, MA 02115 USA; [Collins, Christy L.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA	Meehan, WP (corresponding author), Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; National Operating Committee on Standards for Athletic Equipment, EyeBlack, and DonJoy Orthotics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health T32 award to Dr Meehan (T32 HD040128-06A1). In addition, the content of this report was funded in part by the Centers for Disease Control and Prevention grants R49/CE000674-01 and R49/CE001172-01. We would also like to acknowledge the generous research funding contributions of the National Federation of State High School Associations, the National Operating Committee on Standards for Athletic Equipment, EyeBlack, and DonJoy Orthotics.	[Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brooks DA, 2007, NEUROREHABILITATION, V22, P169; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; FACKELMANN K, 2003, US TODAY        1118; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 2006, J ATHL TRAINING, V41, P138; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACMULLAN J, 2007, BOSTON GLOBE    0202; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rickerson J., 2011, CONCUSSION LAWS; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; SCHWARZ A, 2007, NY TIMES        0915, pA1; Schwarz A, 2009, NY TIMES        1220; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WAXENBERG R, 2009, ATHLETIC TRAINERS FI	39	64	64	0	10	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2012	129	1					38	44		10.1542/peds.2011-1972			7	Pediatrics	Pediatrics	870BT	WOS:000298644800040	22129538	Green Published			2021-06-18	
J	Koepsell, TD; Rivara, FP; Vavilala, MS; Wang, J; Temkin, N; Jaffe, KM; Durbin, DR				Koepsell, Thomas D.; Rivara, Frederick P.; Vavilala, Monica S.; Wang, Jin; Temkin, Nancy; Jaffe, Kenneth M.; Durbin, Dennis R.			Incidence and Descriptive Epidemiologic Features of Traumatic Brain Injury in King County, Washington	PEDIATRICS			English	Article						brain injury; epidemiology; population surveillance	UNITED-STATES; OUTCOMES; CHILDREN; MILD	OBJECTIVE: Traumatic brain injury (TBI) is a major cause of disability among US children. Our goal was to obtain population-based data on TBI incidence rates. METHODS: We conducted surveillance through a stratified random sample of hospital emergency departments in King County, Washington, to identify children 0 to 17 years of age with medically treated TBIs during an 18-month study period in 2007-2008. Additional cases were identified through hospital admission logs and the medical examiner's office. For a sample of nonfatal cases, parents were interviewed to verify TBIs, and medical record data on severity and mechanisms were obtained. RESULTS: The estimated incidence of TBIs in this setting was 304 cases per 100 000 child-years. The incidence was highest for preschool-aged children and lowest for children aged 5 to 9 years. Rates were uniformly higher for boys than for girls; there was a larger gender gap at older ages. Falls were the main mechanism of injury, especially among preschool-aged children, whereas being struck by or against an object and motor vehicle-related trauma were important contributors for older children. Approximately 97% of TBI cases were mild, although moderate/severe TBI incidence increased with age. CONCLUSIONS: TBIs led to many emergency department visits involving children, but a large majority of the cases were clinically mild. Incidence rates for King County were well below recent national estimates but within the range reported in previous US studies. Because mechanisms of injury varied greatly according to age, prevention strategies almost certainly must be customized to each age group for greatest impact. Pediatrics 2011;128:946-954	[Koepsell, Thomas D.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Koepsell, Thomas D.; Rivara, Frederick P.; Vavilala, Monica S.; Wang, Jin; Jaffe, Kenneth M.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA; [Durbin, Dennis R.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA	Koepsell, TD (corresponding author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA.	koepsell@u.washington.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014] Funding Source: NIH RePORTER	This work was supported by Centers for Disease Control and Prevention grant R49 CE 001021.	Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Atabaki SM, 2007, PEDIATR REV, V28, P215, DOI 10.1542/pir.28-6-215; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Day Heather, 2006, Minn Med, V89, P40; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; Ebel BE, 2003, JAMA-J AM MED ASSOC, V289, P879, DOI 10.1001/jama.289.7.879; Eisele JA, 2006, J HEAD TRAUMA REHAB, V21, P537, DOI 10.1097/00001199-200611000-00008; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleiss Joseph L., 2003, STAT METHODS RATES P; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Koepsell TD, 2003, EPIDEMIOLOGIC METHOD; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levy P.S., 1999, WILEY S PRO STAT SUR, V3rd; Minnesota Department of Health Injury and Violence Prevention Unit, 2005, EM DEP TREAT TRAUM B; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; R Development Core Team, 2010, R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP R LANG ENV STAT COMP; Rodriguez SR, 2006, PUBLIC HEALTH REP, V121, P282, DOI 10.1177/003335490612100310; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Washington State Office of Financial Management, 2008, RAC CAT PERC COUNT P; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034	31	64	64	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2011	128	5					946	954		10.1542/peds.2010-2259			9	Pediatrics	Pediatrics	843YO	WOS:000296714000062	21969286				2021-06-18	
J	Shrey, DW; Griesbach, GS; Giza, CC				Shrey, Daniel W.; Griesbach, Grace S.; Giza, Christopher C.			The Pathophysiology of Concussions in Youth	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Metabolic cascade; Activation; Plasticity; Pediatrics	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; LATERAL FLUID PERCUSSION; NEUROTROPHIC FACTOR EXPRESSION; CEREBRAL GLUCOSE-METABOLISM; CAVUM-SEPTUM-PELLUCIDUM; LONG-TERM ACCUMULATION; FACTOR MESSENGER-RNA; AXONAL INJURY; HEAD-INJURY	Mild traumatic brain injury, especially sport-related concussion, is common among young persons. Consequences of transient pathophysiologic dysfunction must be considered in the context of a developing or immature brain, as must the potential for an accumulation of damage with repeated exposure. This review summarizes the underlying neurometabolic cascade of concussion, with emphasis on the young brain in terms of acute pathophysiology, vulnerability, alterations in plasticity and activation, axonal injury, and cumulative risk from chronic, repetitive damage, and discusses their implications in the context of clinical care for the concussed youth, highlighting areas for future investigation.	[Shrey, Daniel W.; Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, David Geffen Sch Med, Div Pediat Neurol,Dept Pediat, Los Angeles, CA 90095 USA; [Griesbach, Grace S.; Giza, Christopher C.] Univ Calif Los Angeles, Dept Neurosurg, Brain Injury Res Ctr, Semel Inst,David Geffen Sch Med, Los Angeles, CA 90095 USA	Shrey, DW (corresponding author), Univ Calif Los Angeles, Mattel Childrens Hosp, David Geffen Sch Med, Div Pediat Neurol,Dept Pediat, Room 22-474 MDCC,10833 Le Conte Blvd, Los Angeles, CA 90095 USA.	dshrey@mednet.ucla.edu		Shrey, Daniel/0000-0002-3163-4773	Child Neurology Foundation/Winokur Family Foundation; Today's and Tomorrow's Children Fund; UCLA Brain Injury Research Center;  [NS27544];  [NS057420];  [NS06190]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061960, K02NS057420, R01NS027544] Funding Source: NIH RePORTER	This work was supported by: NS27544, NS057420, NS06190, the Child Neurology Foundation/Winokur Family Foundation, the Today's and Tomorrow's Children Fund, and the UCLA Brain Injury Research Center.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Appel SH, 2010, MUSCLE NERVE, V42, P851, DOI 10.1002/mus.21939; Armon C, 2011, J NEUROPATH EXP NEUR, V70, P97, DOI 10.1097/01.JNEN.0000392910.86750.32; Ashman TA, 2006, MT SINAI J MED, V73, P999; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Avital A, 2005, INT J NEUROPSYCHOPH, V8, P163, DOI 10.1017/S1461145704004808; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Carro E, 2001, J NEUROSCI, V21, P5678; Castelli DM, 2007, J SPORT EXERCISE PSY, V29, P239, DOI 10.1123/jsep.29.2.239; CATSICAS S, 1987, P NATL ACAD SCI USA, V84, P8165, DOI 10.1073/pnas.84.22.8165; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chaddock L, 2011, MED SCI SPORT EXER, V43, P344, DOI 10.1249/MSS.0b013e3181e9af48; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; Dalsgaard MK, 2004, J APPL PHYSIOL, V97, P1733, DOI 10.1152/japplphysiol.00450.2004; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Davis CL, 2007, RES Q EXERCISE SPORT, V78, P510, DOI 10.5641/193250307X13082512817660; Desmurget M, 2007, BRAIN, V130, P898, DOI 10.1093/brain/awl300; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; Dinner Dudley S., 1993, P654; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Ekeland E, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003683.PUB2; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Field AS, 2003, AM J NEURORADIOL, V24, P1461; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hansson AC, 2000, EUR J NEUROSCI, V12, P2918, DOI 10.1046/j.1460-9568.2000.00185.x; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hillman CH, 2009, NEUROSCIENCE, V159, P1044, DOI 10.1016/j.neuroscience.2009.01.057; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; HOVDA DA, 1996, NEUROTRAUMA, P1459; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Ivanco TL, 2000, NEUROPHARMACOLOGY, V39, P765, DOI 10.1016/S0028-3908(00)00004-6; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Johnson KL, 2006, AACN ADV CRIT CARE, V17, P39, DOI 10.1097/00044067-200601000-00006; Johnson MH, 2005, DEV PSYCHOBIOL, V46, P287, DOI 10.1002/dev.20057; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Koseoglu E, 2003, CEPHALALGIA, V23, P972, DOI 10.1046/j.1468-2982.2003.00624.x; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lein ES, 2000, J NEUROSCI, V20, P1470; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LOCKETT DMC, 1992, HEADACHE, V32, P50, DOI 10.1111/j.1526-4610.1992.hed3201050.x; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; Merom D, 2008, J ANXIETY DISORD, V22, P959, DOI 10.1016/j.janxdis.2007.09.010; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Pryce CR, 2005, NEUROSCI BIOBEHAV R, V29, P649, DOI 10.1016/j.neubiorev.2005.03.011; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; Salin P, 1995, J NEUROSCI, V15, P8234; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; SCHOUPS AA, 1995, DEV BRAIN RES, V86, P326, DOI 10.1016/0165-3806(95)00043-D; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; SILBERT PL, 1993, J NEUROL NEUROSUR PS, V56, P820, DOI 10.1136/jnnp.56.7.820; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Smits JAJ, 2008, DEPRESS ANXIETY, V25, P689, DOI 10.1002/da.20411; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Takei N, 1997, J NEUROCHEM, V68, P370; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; ZAFRA F, 1992, J NEUROSCI, V12, P4793; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399; Zhou JW, 1996, DEV BRAIN RES, V97, P297, DOI 10.1016/S0165-3806(96)00159-9	217	64	68	1	30	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	NOV	2011	22	4					577	+		10.1016/j.pmr.2011.08.002			27	Rehabilitation	Rehabilitation	858SI	WOS:000297822600003	22050937	Green Accepted			2021-06-18	
J	Dash, PK; Johnson, D; Clark, J; Orsi, SA; Zhang, M; Zhao, J; Grill, RJ; Moore, AN; Pati, S				Dash, Pramod K.; Johnson, Daniel; Clark, Jordan; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Grill, Raymond J.; Moore, Anthony N.; Pati, Shibani			Involvement of the Glycogen Synthase Kinase-3 Signaling Pathway in TBI Pathology and Neurocognitive Outcome	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY DEFICITS; N-ACETYL-ASPARTATE; INCREASED PHOSPHORYLATION; CHRONIC LITHIUM; NEURONAL DEATH; VALPROIC ACID; GRANULE CELLS; IN-VIVO	Background: Traumatic brain injury (TBI) sets in motion cascades of biochemical changes that result in delayed cell death and altered neuronal architecture. Studies have demonstrated that inhibition of glycogen synthase kinase-3 (GSK-3) effectively reduces apoptosis following a number of stimuli. The Wnt family of proteins, and growth factors are two major factors that regulate GSK-3 activity. In the absence of stimuli, GSK-3 is constitutively active and is complexed with Axin, adenomatous polyposis coli (APC), and casein kinase I alpha (CK1 alpha) and phosphorylates ss-Catenin leading to its degradation. Binding of Wnt to Frizzled receptors causes the translocation of GSK-3 to the plasma membrane, where it phosphorylates and inactivates the Frizzled co-receptor lipoprotein-related protein 6 (LRP6). Furthermore, the translocation of GSK-3 reduces ss-Catenin phosphorylation and degradation, leading to ss-Catenin accumulation and gene expression. Growth factors activate Akt, which in turn inhibits GSK-3 activity by direct phosphorylation, leading to a reduction in apoptosis. Methodology/Principal Findings: Using a rodent model, we found that TBI caused a rapid, but transient, increase in LRP6 phosphorylation that is followed by a modest decrease in ss-Catenin phosphorylation. Phospho-GSK-3 beta immunoreactivity was found to increase three days post injury, a time point at which increased Akt activity following TBI has been observed. Lithium influences several neurochemical cascades, including inhibiting GSK-3. When the efficacy of daily lithium was assessed, reduced hippocampal neuronal cell loss and learning and memory improvements were observed. These influences were partially mimicked by administration of the GSK-3-selective inhibitor SB-216763, as this drug resulted in improved motor function, but only a modest improvement in memory retention and no overt neuroprotection. Conclusion/Significance: Taken together, our findings suggest that selective inhibition of GSK-3 may offer partial cognitive improvement. As a broad spectrum inhibitor of GSK-3, lithium offers neuroprotection and robust cognitive improvement, supporting its clinical testing as a treatment for TBI.	[Dash, Pramod K.; Johnson, Daniel; Clark, Jordan; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrated Biol & Pharmacol, Houston, TX USA; [Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA.	P.Dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0134, W81XWH-08-2-0150]	This research was made possible by funding support from the Department of Defense (W81XWH-08-2-0134 and W81XWH-08-2-0150). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghdam SY, 2007, CURR ALZHEIMER RES, V4, P21; ATACK JR, 1992, J NEUROCHEM, V59, P1946, DOI 10.1111/j.1471-4159.1992.tb11031.x; Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006; Castro AA, 2009, PEPTIDES, V30, P1914, DOI 10.1016/j.peptides.2009.07.004; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Davidson G, 2010, TRENDS CELL BIOL, V20, P453, DOI 10.1016/j.tcb.2010.05.002; de Sousa RT, 2011, NEUROSCI LETT, V494, P54, DOI 10.1016/j.neulet.2011.02.054; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; Facci L, 2003, NEUROREPORT, V14, P1467, DOI 10.1097/00001756-200308060-00012; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Feng HL, 2008, NEUROSCIENCE, V155, P567, DOI 10.1016/j.neuroscience.2008.06.040; Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871; Grandjean EM, 2009, CNS DRUGS, V23, P397, DOI 10.2165/00023210-200923050-00004; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Haddad PM, 2009, EXPERT OPIN DRUG MET, V5, P539, DOI [10.1517/17425250902911455 , 10.1517/17425250902911455]; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022-3042.2001.00728.x; Hayes RL, 1998, DRUG NEWS PERSPECT, V11, P215; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hu SX, 2009, NEUROBIOL DIS, V33, P193, DOI 10.1016/j.nbd.2008.10.007; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Lin D, 2006, CNS DRUGS, V20, P29, DOI 10.2165/00023210-200620010-00003; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Miller JS, 2010, BRAIN RES BULL, V82, P184, DOI 10.1016/j.brainresbull.2010.03.005; Moore GJ, 2000, LANCET, V356, P1241, DOI 10.1016/S0140-6736(00)02793-8; Moore GJ, 2000, BIOL PSYCHIAT, V48, P1, DOI 10.1016/S0006-3223(00)00252-3; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; Neary JT, 2006, J NEUROSCI RES, V84, P515, DOI 10.1002/jnr.20969; Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018-010-0329-3; Perez M, 2003, BIOCHEM J, V372, P129, DOI 10.1042/BJ20021596; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Silverstone PH, 2003, INT CLIN PSYCHOPHARM, V18, P73, DOI 10.1097/00004850-200303000-00002; Soutar MPM, 2010, J NEUROCHEM, V115, P974, DOI 10.1111/j.1471-4159.2010.06988.x; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takadera T, 2004, EUR J PHARMACOL, V499, P239, DOI 10.1016/j.ejphar.2004.07.115; Takadera T, 2004, BRAIN RES, V1020, P196, DOI 10.1016/j.brainres.2004.06.035; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; WRAAE O, 1978, BRIT J PHARMACOL, V64, P273, DOI 10.1111/j.1476-5381.1978.tb17300.x; Wu G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004926; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	70	64	67	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2011	6	9							e24648	10.1371/journal.pone.0024648			11	Multidisciplinary Sciences	Science & Technology - Other Topics	822JR	WOS:000295041700046	21935433	DOAJ Gold, Green Published			2021-06-18	
J	Bembea, MM; Savage, W; Strouse, JJ; Schwartz, JM; Graham, E; Thompson, CB; Everett, A				Bembea, Melania M.; Savage, William; Strouse, John J.; Schwartz, Jamie McElrath; Graham, Ernest; Thompson, Carol B.; Everett, Allen			Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						biochemical marker; ECMO; extracorporeal membrane oxygenation; GFAP; glial fibrillary acidic protein; intracranial hemorrhage	PEDIATRIC INTENSIVE-CARE; LIFE-SUPPORT; FOLLOW-UP; CARDIOPULMONARY-RESUSCITATION; RESPIRATORY-FAILURE; TRAUMATIC BRAIN; ACUTE STROKE; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; ISCHEMIC-INJURY	Objective: To determine whether, in children, plasma glial fibrillary acidic protein is associated with brain injury during extracorporeal membrane oxygenation and with mortality. Design: Prospective, observational study. Setting: Pediatric intensive care unit in an urban tertiary care academic center. Patients: Neonatal and pediatric patients on extracorporeal membrane oxygenation (n = 22). Interventions: Serial blood sampling for glial fibrillary acidic protein measurements. Measurements and Main Results: Prospective patients age 1 day to 18 yrs who required extracorporeal membrane oxygenation from April 2008 to August 2009 were studied. Glial fibrillary acidic protein was measured using an electrochemiluminescent immunoassay developed at Johns Hopkins. Control samples were collected from 99 healthy children (0.5-16 yrs) and 59 neonatal intensive care unit infants without neurologic injury. In controls, the median glial fibrillary acidic protein concentration was 0.055 ng/mL (interquartile range, 0-0.092 ng/mL) and the 95th percentile of glial fibrillary acidic protein was 0.436 ng/mL. In patients on extracorporeal membrane oxygenation, plasma glial fibrillary acidic protein was measured at 6, 12, and every 24 hrs after cannulation. We enrolled 22 children who underwent extracorporeal membrane oxygenation. Median age was 7 days (interquartile range, 2 days to 9 yrs), and primary extracorporeal membrane oxygenation indication was: cardiac failure, six of 22 (27.3%); respiratory failure, 12 of 22 (54.5%); extracorporeal cardiopulmonary resuscitation, three of 22 (13.6%); and sepsis, one of 22 (4.6%). Seven of 22 (32%) patients developed acute neurologic injury ( intracranial hemorrhage, brain death, or cerebral edema diagnosed by imaging). Fifteen of 22 (68%) survived to hospital discharge. In the extracorporeal membrane oxygenation group, peak glial fibrillary acidic protein levels were higher in children with brain injury than those without (median, 5.9 vs. 0.09 ng/mL, p = .04) and in nonsurvivors compared with survivors to discharge (median, 5.9 vs. 0.09 ng/mL, p = .04). The odds ratio for brain injury for glial fibrillary acidic protein >0.436 ng/mL vs. normal was 11.5 (95% confidence interval, 1.3-98.3) and the odds ratio for mortality was 13.6 (95% confidence interval, 1.7-108.5). Conclusions: High glial fibrillary acidic protein during extracorporeal membrane oxygenation is significantly associated with acute brain injury and death. Brain injury biomarkers may aid in outcome prediction and neurologic monitoring of patients on extracorporeal membrane oxygenation to improve outcomes and benchmark new therapies. (Pediatr Crit Care Med 2011; 12:572-579)	[Bembea, Melania M.; Schwartz, Jamie McElrath] Johns Hopkins Univ, Dept Anesthesiol & Crit Care, Baltimore, MD 21205 USA; [Bembea, Melania M.; Savage, William; Strouse, John J.; Schwartz, Jamie McElrath; Everett, Allen] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; [Savage, William] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA; [Graham, Ernest] Johns Hopkins Univ, Dept Gynecol & Obstet, Baltimore, MD 21218 USA; [Thompson, Carol B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA	Bembea, MM (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care, Baltimore, MD 21205 USA.	mbembea1@jhmi.edu	Strouse, J/A-2690-2008	Strouse, J/0000-0003-0341-1457; Bembea, Melania/0000-0003-4984-520X	National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR 025005, 1KL2RR025006-01]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Johns Hopkins Clinical Hematology Development Program [5K12HL087169, 5R01HL091759]; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5T15HL086386]; Basic and Translational Research Program in Sickle Cell Disease [1U54HL090515]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025005, KL2RR025006] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T15HL086386, R01HL091759, K23HL078819, K12HL087169, U54HL090515] Funding Source: NIH RePORTER	The project described was supported by Grants Number UL1 RR 025005 and 1KL2RR025006-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at www.ncrr.nih.gov. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap. nih. gov/clinicalresearch/overview-translational.asp M.M.B.). Dr. Savage acknowledges support from the Johns Hopkins Clinical Hematology Development Program 5K12HL087169, 5R01HL091759; the National Heart, Lung and Blood Institute Proteomics and Genomics Hands-on Workshop 5T15HL086386; and Basic and Translational Research Program in Sickle Cell Disease, 1U54HL090515.	ADOLPH V, 1990, J PEDIATR SURG, V25, P43, DOI 10.1016/S0022-3468(05)80162-9; Alsoufi B, 2007, J THORAC CARDIOV SUR, V134, P952, DOI 10.1016/j.jtcvs.2007.05.054; Amigoni A, 2005, PEDIATR NEUROL, V32, P173, DOI 10.1016/j.pediatrneurol.2004.10.002; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Barrett CS, 2009, PEDIATR CRIT CARE ME, V10, P445, DOI 10.1097/PCC.0b013e318198bd85; CAMPBELL LR, 1991, J PEDIATR-US, V119, P789, DOI 10.1016/S0022-3476(05)80304-X; Cengiz P, 2005, CRIT CARE MED, V33, P2817, DOI 10.1097/01.CCM.0000189940.70617.C3; CILLEY RE, 1986, PEDIATRICS, V78, P699; Conrad SA, 2005, ASAIO J, V51, P4, DOI 10.1097/01.mat.0000151922.67540.E9; Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632; Field D, 1996, LANCET, V348, P75; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Fraser DD, 2010, PEDIAT CRIT CAR 0709; Gazzolo D, 2002, ACTA PAEDIATR, V91, P218, DOI 10.1080/080352502317285243; GLASS P, 1995, J PEDIATR-US, V127, P447, DOI 10.1016/S0022-3476(95)70082-X; GLASS P, 1989, PEDIATRICS, V83, P72; GRAZIANI LJ, 1994, J PEDIATR-US, V125, P969, DOI 10.1016/S0022-3476(05)82017-7; GREEN TP, 1995, CRIT CARE MED, V23, P1132, DOI 10.1097/00003246-199506000-00021; Gupta M, 2008, PEDIATR CRIT CARE ME, V9, P380, DOI 10.1097/PCC.0b013e318172d54d; Haines NM, 2009, ASAIO J, V55, P111, DOI 10.1097/MAT.0b013e318190b6f7; Hanekamp MN, 2006, CRIT CARE, V10, DOI 10.1186/cc5039; HAYASHIDA H, 2009, NEUROCRIT CARE  1222; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; HOFKOSH D, 1991, PEDIATRICS, V87, P549; Hunter Christian J, 2004, Pediatr Crit Care Med, V5, P475, DOI 10.1097/01.PCC.0000130992.73123.BC; Ibrahim AE, 2000, ANN THORAC SURG, V69, P186, DOI 10.1016/S0003-4975(99)01194-7; Jonsson H, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-24; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; KORINTHENBERG R, 1993, DEV MED CHILD NEUROL, V35, P249; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; LAZAR EL, 1994, J PEDIATR SURG, V29, P186, DOI 10.1016/0022-3468(94)90315-8; Lequier L, 2008, J THORAC CARDIOV SUR, V136, P976, DOI 10.1016/j.jtcvs.2008.02.009; Morris Marilyn C, 2004, Pediatr Crit Care Med, V5, P440, DOI 10.1097/01.PCC.0000137356.58150.2E; Niebroj-Dobosz I, 1994, Folia Neuropathol, V32, P129; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2004, J IMMUNOL METHODS, V287, P169, DOI 10.1016/j.jim.2004.01.015; Prodhan P, 2009, RESUSCITATION, V80, P1124, DOI 10.1016/j.resuscitation.2009.07.004; RAJAGOPAL SK, 2009, CRIT CARE MED   0928; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; SCHUMACHER RE, 1991, PEDIATRICS, V87, P451; SHORT BL, 1994, CRIT CARE MED, V22, P1262, DOI 10.1097/00003246-199408000-00010; Taylor Anna K, 2007, Crit Care Resusc, V9, P172; TAYLOR GA, 1989, INVEST RADIOL, V24, P511, DOI 10.1097/00004424-198907000-00001; Thiagarajan RR, 2007, CIRCULATION, V116, P1693, DOI 10.1161/CIRCULATIONAHA.106.680678; Unden J, 2009, J NEUROL, V256, P72, DOI 10.1007/s00415-009-0054-8; van Heijst A, 2004, J PEDIATR-US, V144, P223, DOI 10.1016/j.jpeds.2003.11.006; Vaucher YE, 1996, J PEDIATR-US, V128, P109, DOI 10.1016/S0022-3476(96)70439-0; WIESMANN M, 2009, ACTA NEUROL SCA 1005	53	64	68	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2011	12	5					572	579		10.1097/PCC.0b013e3181fe3ec7			8	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	816KP	WOS:000294598400021	21057367	Green Accepted			2021-06-18	
J	Sakellaridis, N; Pavlou, E; Karatzas, S; Chroni, D; Vlachos, K; Chatzopoulos, K; Dimopoulou, E; Kelesis, C; Karaouli, V				Sakellaridis, Nikolaos; Pavlou, Elias; Karatzas, Stylianos; Chroni, Despina; Vlachos, Konstantinos; Chatzopoulos, Konstantinos; Dimopoulou, Eleni; Kelesis, Christos; Karaouli, Vasiliki			Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries	JOURNAL OF NEUROSURGERY			English	Article						mannitol; hypertonic saline; trauma; brain injury; intracranial hypertension; osmotic burden		Object. The purpose of this study was to compare the effects of mannitol and hypertonic saline in doses of similar osmotic burden for the treatment of intracranial hypertension in patients with severe traumatic brain injury. Methods. The authors used an alternating treatment protocol to compare the effect of hypertonic saline with that of mannitol given for episodes of increased intracranial pressure in patients treated for severe head injury at their hospital during 2006-2008. Standard guidelines for the management of severe traumatic brain injury were followed. Elevated intracranial pressure (ICP) was treated either with mannitol or hypertonic saline. Doses of similar osmotic burden (mannitol 20%, 2 ml/kg, infused over 20 minutes, or saline 15%, 0.42 ml/kg, administered as a bolus via a central venous catheter) were given alternately to the individual patient with severe brain injury during episodes of increased pressure. The dependent variables were the extent and duration of reduction of increased ICP. The choice of agent for treatment of the initial hypertensive event was determined on a randomized basis; treatment was alternated for every subsequent event in each individual patient. Reduction of ICP and duration of action were recorded after each event. Results obtained after mannitol administration were statistically compared with those obtained after hypertonic saline administration. Results. Data pertaining to 199 hypertensive events in 29 patients were collected. The mean decrease in ICP obtained with mannitol was 7.96 mm Hg and that obtained with hypertonic saline was 8.43 mm Hg (p = 0.586, equal variances assumed). The mean duration of effect was 3 hours 33 minutes for mannitol and 4 hours 17 minutes for hypertonic saline (p = 0.40, equal variances assumed). Conclusions. No difference between the 2 medications could be found with respect to the extent of reduction of ICP or duration of action. (DOI: 10.3171/2010.5.JNS091685)	[Sakellaridis, Nikolaos; Vlachos, Konstantinos; Kelesis, Christos] Dept Neurosurg, Attica, Greece; [Pavlou, Elias; Chatzopoulos, Konstantinos] Intens Care Unit 1, Attica, Greece; [Karatzas, Stylianos; Karaouli, Vasiliki] Univ Athens, Dept Intens Care, Attica, Greece; [Chroni, Despina; Dimopoulou, Eleni] KAT Natl Hosp, Intens Care Unit 2, Attica, Greece	Sakellaridis, N (corresponding author), Karaiskaki 23, Neo Psychiko 15451, Attica, Greece.	nicksac2@hotmail.com					Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; LEHR R, 1992, STAT MED, V11, P1099, DOI 10.1002/sim.4780110811; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Thomas L, 1997, CONSERV BIOL, V11, P276, DOI 10.1046/j.1523-1739.1997.96102.x; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Yilmaz N, 2007, BRAIN RES, V1164, P132, DOI 10.1016/j.brainres.2007.06.017	11	64	70	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2011	114	2					545	548		10.3171/2010.5.JNS091685			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	710WU	WOS:000286548500043	21087203				2021-06-18	
J	McCrory, P				McCrory, Paul			Sports Concussion and the Risk of Chronic Neurological Impairment	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sports concussion; neurological impairment	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; AMATEUR BOXING LEAD; AMYOTROPHIC-LATERAL-SCLEROSIS; APOLIPOPROTEIN-E EPSILON-4; REPETITIVE HEAD-INJURY; DEMENTIA-PUGILISTICA; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; RECURRENT CONCUSSION	Intense recent media focus on long-term outcomes from sports concussion has highlighted concerns on both cognitive deterioration and mental health issues, such as depression and suicide. At this time, the scientific evidence to support these views is limited, with only a handful of cases thus far reported. Based on the literature on this topic that extends back over 50 years, it is clear that only a small percentage of athletes suffer such sequelae presumably due to recurrent concussive or subconcussive head impacts. At this stage, determining which athletes are at future risk is not possible; however, following existing concussion guidelines (eg, Zurich guidelines) is likely to be the safest option based on current evidence.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Aotsuka A, 1990, Rinsho Shinkeigaku, V30, P1243; Bouras C, 1997, EUR NEUROL, V38, P53, DOI 10.1159/000112903; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CANTU R, 1995, BOXING MED; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Critchley M, 1937, MED ANN, P318; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; Iqbal K, CURR ALZHEIMER RES; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; Jordan B. D., 1998, SPORTS NEUROLOGY, P351; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; JORDAN BD, 1993, MED ASPECTS BOXING; KASTE M, 1982, LANCET, V2, P1186; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LACAVA G, 1963, J Sports Med Phys Fitness, V3, P87; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; LEVIN HS, 1993, MED ASPECTS BOXING, P197; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAWDSLEY C, 1963, LANCET, V2, P795; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millspaugh J., 1937, US NAVAL MED B, V35, P297; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; ROBERTS GW, 1988, LANCET, V2, P1456; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; Ross RT, 1999, MIL MED, V164, P68; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Sironi V A, 1982, J Neurosurg Sci, V26, P165; SPILLANE J D, 1962, Br Med J, V2, P1205; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F J, 1972, Scand J Rehabil Med, V4, P77; Vandrovcova J, CURR ALZHEIMER RES; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; Zazryn T, 2007, SPORTS MED, V37, P467; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518; Zimmerman RD, 1993, MED ASPECTS BOXING, P188	85	64	64	0	62	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2011	21	1					6	12		10.1097/JSM.0b013e318204db50			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	702AM	WOS:000285866300011	21200164				2021-06-18	
J	Sarkamo, T; Pihko, E; Laitinen, S; Forsblom, A; Soinila, S; Mikkonen, M; Autti, T; Silvennoinen, HM; Erkkila, J; Laine, M; Peretz, I; Hietanen, M; Tervaniemi, M				Sarkamo, Teppo; Pihko, Elina; Laitinen, Sari; Forsblom, Anita; Soinila, Seppo; Mikkonen, Mikko; Autti, Taina; Silvennoinen, Heli M.; Erkkila, Jaakko; Laine, Matti; Peretz, Isabelle; Hietanen, Marja; Tervaniemi, Mari			Music and Speech Listening Enhance the Recovery of Early Sensory Processing after Stroke	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							NMDA-RECEPTOR ANTAGONIST; MISMATCH NEGATIVITY MMN; AUDITORY CHANGE-DETECTION; EVENT-RELATED POTENTIALS; EARLY-ONSET STIMULATION; TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL ENRICHMENT; NEUROTROPHIC FACTOR; NEURAL CHANGES; DURATION	Our surrounding auditory environment has a dramatic influence on the development of basic auditory and cognitive skills, but little is known about how it influences the recovery of these skills after neural damage. Here, we studied the long-term effects of daily music and speech listening on auditory sensory memory after middle cerebral artery (MCA) stroke. In the acute recovery phase, 60 patients who had middle cerebral artery stroke were randomly assigned to a music listening group, an audio book listening group, or a control group. Auditory sensory memory, as indexed by the magnetic MMN (MMNm) response to changes in sound frequency and duration, was measured 1 week (baseline), 3 months, and 6 months after the stroke with whole-head magnetoencephalography recordings. Fifty-four patients completed the study. Results showed that the amplitude of the frequency MMNm increased significantly more in both music and audio book groups than in the control group during the 6-month poststroke period. In contrast, the duration MMNm amplitude increased more in the audio book group than in the other groups. Moreover, changes in the frequency MMNm amplitude correlated significantly with the behavioral improvement of verbal memory and focused attention induced by music listening. These findings demonstrate that merely listening to music and speech after neural damage can induce long-term plastic changes in early sensory processing, which, in turn, may facilitate the recovery of higher cognitive functions. The neural mechanisms potentially underlying this effect are discussed.	[Sarkamo, Teppo] Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, FIN-00014 Helsinki, Finland; [Pihko, Elina] BioMag Lab, Helsinki, Finland; [Laitinen, Sari; Forsblom, Anita; Erkkila, Jaakko] Univ Jyvaskyla, SF-40351 Jyvaskyla, Finland; [Soinila, Seppo; Autti, Taina; Silvennoinen, Heli M.; Hietanen, Marja] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; [Peretz, Isabelle] Univ Montreal, Montreal, PQ H3C 3J7, Canada	Sarkamo, T (corresponding author), Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, POB 9,Siltavuorenpenger 20 C, FIN-00014 Helsinki, Finland.	teppo.sarkamo@helsinki.fi	Pihko, Elina/J-6026-2012	Tervaniemi, Mari/0000-0002-9651-2929; Sarkamo, Teppo/0000-0002-1470-4530; Erkkila, Jaakko/0000-0003-1130-837X	Academy of FinlandAcademy of FinlandEuropean Commission [77322]; Jenny and Antti Wihuri Foundation (Helsinki, Finland); National Graduate School of Psychology; Neurology Foundation (Helsinki, Finland)	This work was supported by the Academy of Finland (project no. 77322), the Jenny and Antti Wihuri Foundation (Helsinki, Finland), the National Graduate School of Psychology, and the Neurology Foundation (Helsinki, Finland). The authors thank the staff of the HUCH Department of Neurology and other rehabilitation hospitals in the Helsinki metropolitan area for their collaboration, the patient subjects and their families for their participation and effort, and Minna Huotilainen, Anna Shestakova, Irina Anourova, Suvi Heikkila, Jyrki Makela, and Jussi Nurminen for their technical assistance.	AHLFORS S, 1989, P 7 INT C BIOM, P693; Ahveninen J, 1999, ALCOHOL CLIN EXP RES, V23, P1507, DOI 10.1097/00000374-199909000-00013; ALHO K, 1995, EAR HEARING, V16, P38, DOI 10.1097/00003446-199502000-00004; ALHO K, 1989, PSYCHOPHYSIOLOGY, V26, P514, DOI 10.1111/j.1469-8986.1989.tb00704.x; Amenedo E, 2000, EUR J NEUROSCI, V12, P2570, DOI 10.1046/j.1460-9568.2000.00114.x; Angelucci F, 2007, NEUROSCI LETT, V429, P152, DOI 10.1016/j.neulet.2007.10.005; Angelucci F, 2007, BEHAV PHARMACOL, V18, P491, DOI 10.1097/FBP.0b013e3282d28f50; Atienza M, 2002, LEARN MEMORY, V9, P138, DOI 10.1101/lm.46502; Baldeweg T, 2004, SCHIZOPHR RES, V69, P203, DOI 10.1016/j.schres.2003.09.009; Bi CX, 2006, BRAIN RES, V1110, P30, DOI 10.1016/j.brainres.2006.06.056; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; Centonze D, 2007, NEUROBIOL DIS, V27, P44, DOI 10.1016/j.nbd.2007.03.012; Chikahisa S, 2006, BEHAV BRAIN RES, V169, P312, DOI 10.1016/j.bbr.2006.01.021; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; COWAN N, 1988, PSYCHOL BULL, V104, P163, DOI 10.1037/0033-2909.104.2.163; Csepe V, 2001, NEUROPSYCHOLOGIA, V39, P1194, DOI 10.1016/S0028-3932(01)00052-5; Deouell LY, 2000, BRAIN, V123, P353, DOI 10.1093/brain/123.2.353; Ehrlichman RS, 2008, J COGNITIVE NEUROSCI, V20, P1403, DOI 10.1162/jocn.2008.20097; Engineer ND, 2004, J NEUROPHYSIOL, V92, P73, DOI 10.1152/jn.00059.2004; Flores-Gutierrez EO, 2007, INT J PSYCHOPHYSIOL, V65, P69, DOI 10.1016/j.ijpsycho.2007.03.004; Garrido MI, 2009, CLIN NEUROPHYSIOL, V120, P453, DOI 10.1016/j.clinph.2008.11.029; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; Griffiths TD, 1999, NEUROREPORT, V10, P3825, DOI 10.1097/00001756-199912160-00019; Ilvonen TM, 2003, STROKE, V34, P1746, DOI 10.1161/01.STR.0000078836.26328.3B; Jaaskelainen IP, 2007, TRENDS NEUROSCI, V30, P653, DOI 10.1016/j.tins.2007.09.003; Janata P, 2002, COGN AFFECT BEHAV NE, V2, P121, DOI 10.3758/CABN.2.2.121; Jansson-Verkasalo E, 2004, CLIN NEUROPHYSIOL, V115, P179, DOI 10.1016/S1388-2457(03)00319-5; Jaramillo M, 2000, NEUROSCI LETT, V290, P101, DOI 10.1016/S0304-3940(00)01344-6; Javitt DC, 1996, P NATL ACAD SCI USA, V93, P11962, DOI 10.1073/pnas.93.21.11962; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Kawakubo Y, 2006, NEUROREPORT, V17, P1043, DOI 10.1097/01.wnr.0000221828.10846.ba; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Kiang M, 2007, J INT NEUROPSYCH SOC, V13, P653, DOI 10.1017/S1355617707070816; Kim H, 2006, BRAIN DEV-JPN, V28, P109, DOI 10.1016/j.braindev.2005.05.008; Korostenskaja M, 2007, BRAIN RES BULL, V72, P275, DOI 10.1016/j.brainresbull.2007.01.007; Kreisel SH, 2006, CEREBROVASC DIS, V21, P6, DOI 10.1159/000089588; Kreitschmann-Andermahr I, 2001, COGNITIVE BRAIN RES, V12, P109, DOI 10.1016/S0926-6410(01)00043-X; Kujala T, 2001, P NATL ACAD SCI USA, V98, P10509, DOI 10.1073/pnas.181589198; Kujala T, 2007, BIOL PSYCHOL, V74, P1, DOI 10.1016/j.biopsycho.2006.06.001; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; Light GA, 2005, ARCH GEN PSYCHIAT, V62, P127, DOI 10.1001/archpsyc.62.2.127; Light GA, 2007, J COGNITIVE NEUROSCI, V19, P1624, DOI 10.1162/jocn.2007.19.10.1624; Lindenberg R, 2007, NEUROPSYCHOLOGIA, V45, P2407, DOI 10.1016/j.neuropsychologia.2007.02.008; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/jocn.1993.5.4.467; Menning H, 2002, LEARN MEMORY, V9, P253, DOI 10.1101/lm.49402; Mikkola K, 2007, CLIN NEUROPHYSIOL, V118, P1494, DOI 10.1016/j.clinph.2007.04.012; Molholm S, 2005, CEREB CORTEX, V15, P545, DOI 10.1093/cercor/bhh155; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; NAATANEN R, 1991, PSYCHOPHYSIOLOGY, V28, P478, DOI 10.1111/j.1469-8986.1991.tb00735.x; Nenadic I, 2003, EXP BRAIN RES, V148, P238, DOI 10.1007/s00221-002-1188-4; Nichols JA, 2007, NEUROSCIENCE, V145, P832, DOI 10.1016/j.neuroscience.2006.12.061; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Novitski N, 2004, COGNITIVE BRAIN RES, V20, P26, DOI 10.1016/j.cogbrainres.2003.12.011; Opitz B, 2002, NEUROIMAGE, V15, P167, DOI 10.1006/nimg.2001.0970; PAAVILAINEN P, 1991, ELECTROEN CLIN NEURO, V78, P466, DOI 10.1016/0013-4694(91)90064-B; Papathanassiou D, 2000, NEUROIMAGE, V11, P347, DOI 10.1006/nimg.2000.0546; Pekkonen E, 2000, AUDIOL NEURO-OTOL, V5, P216, DOI 10.1159/000013883; Percaccio CR, 2005, J NEUROPHYSIOL, V94, P3590, DOI 10.1152/jn.00433.2005; Pettigrew CM, 2005, APHASIOLOGY, V19, P131, DOI 10.1080/02687030444000642; Reiterer SM, 2005, NEUROREPORT, V16, P239, DOI 10.1097/00001756-200502280-00007; Restuccia D, 2005, COGNITIVE BRAIN RES, V25, P891, DOI 10.1016/j.cogbrainres.2005.09.023; Rinne T, 2000, NEUROIMAGE, V12, P14, DOI 10.1006/nimg.2000.0591; Santos Marco Aurelio Rocha, 2006, Braz J Otorhinolaryngol, V72, P800; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Schmithorst VJ, 2006, NEUROIMAGE, V29, P254, DOI 10.1016/j.neuroimage.2005.07.020; Srinivasan N, 2007, NEUROREPORT, V18, P1709, DOI 10.1097/WNR.0b013e3282f0d2d8; Tallal P, 2006, TRENDS NEUROSCI, V29, P382, DOI 10.1016/j.tins.2006.06.003; Tervaniemi M, 2005, CLIN NEUROPHYSIOL, V116, P1897, DOI 10.1016/j.clinph.2005.03.025; Tervaniemi M, 1999, CLIN NEUROPHYSIOL, V110, P1388, DOI 10.1016/S1388-2457(99)00108-X; Tervaniemi M, 2006, EUR J NEUROSCI, V23, P2538, DOI 10.1111/j.1460-9568.2006.04752.x; TIITINEN H, 1994, NATURE, V372, P90, DOI 10.1038/372090a0; Tikhonravov D, 2008, BRAIN RES, V1203, P97, DOI 10.1016/j.brainres.2008.02.006; Toyomaki A, 2008, PROG NEURO-PSYCHOPH, V32, P95, DOI 10.1016/j.pnpbp.2007.07.020; Turetsky BI, 2007, SCHIZOPHRENIA BULL, V33, P69, DOI 10.1093/schbul/sbl060; Tzourio-Mazoyer N, 2004, NEUROIMAGE, V21, P422, DOI 10.1016/j.neuroimage.2003.08.032; Umbricht D, 2002, BIOL PSYCHIAT, V51, P400, DOI 10.1016/S0006-3223(01)01242-2; Uutela K, 1999, NEUROIMAGE, V10, P173, DOI 10.1006/nimg.1999.0454; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Xu F, 2007, NEUROSCI LETT, V420, P179, DOI 10.1016/j.neulet.2007.05.005	84	64	69	1	28	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0898-929X	1530-8898		J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	DEC	2010	22	12					2716	2727		10.1162/jocn.2009.21376			12	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	641MB	WOS:000281129400004	19925203				2021-06-18	
J	Eckner, JT; Kutcher, JS; Richardson, JK				Eckner, James T.; Kutcher, Jeffrey S.; Richardson, James K.			Pilot Evaluation of a Novel Clinical Test of Reaction Time in National Collegiate Athletic Association Division I Football Players	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; mild traumatic brain injuries; neuropsychological tests; athletes; assessment; motivation	SPORTS; CONCUSSION; PERFORMANCE; IMPACT	Context: Evidence suggests that concussion prolongs reaction time (RT). We have developed a simple, reliable clinical tool for measuring reaction time that may be of value in the assessment of concussion in athletes. Objective: To compare baseline values of clinical AT (RTclin) obtained using the new clinical reaction time apparatus with computerized AT (RTcomp) obtained using a validated computerized neuropsychological test battery. Design: Cross-sectional study. Setting: Data were collected during a National Collegiate Athletic Association Division I collegiate football team's preparticipation physical examination session. Patients or Other Participants: Ninety-four Division I collegiate football players. Main Outcome Measure(s): The RTclin was measured using a 1.3-m measuring stick embedded in a weighted rubber disk that was released and caught as quickly as possible. The RTcomp was measured using the simple AT component of Cog State Sport. Results: For the 68 athletes whose CogState Sport tests passed the program's integrity check, RTclin and RTcomp were correlated (r = 0.445, P < .001). Overall, mean RTclin was shorter and less variable than mean RTcomp (203 +/- 20 milliseconds versus 268 +/- 44 milliseconds; P <.001). When RTclin and RTcomp were compared between those athletes with (n = 68) and those without (n = 26) valid CogState Sport test sessions, mean RTcli, was similar (202 +/- 19 milliseconds versus 207 +/- 23 milliseconds; P = .390), but mean RTclin was different (258 +/- 35 milliseconds versus 290 55 milliseconds; P = .009). Conclusions: The RTclin was positively correlated with RTclin and yielded more consistent reaction time values during baseline testing. Given that RTclin is easy to measure using simple, inexpensive equipment, further prospective study is warranted to determine its clinical utility in the assessment of concussion in athletes.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48108 USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 100A, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			Foundation for Physical Medicine and Rehabilitation (Chicago, IL)	We thank Dr David Darby, chief medical officer for CogState Ltd, for the advice and assistance he provided relating to the CogState Sport program, and Steve Nordwall, MA, ATC, and his athletic training staff for their support in organizing and conducting this project. We also thank Dr Sri Krishna Chandran for his assistance with data imputation and organization. We acknowledge the support of our sponsors: The Foundation for Physical Medicine and Rehabilitation (Chicago, IL), which gave the 2007 New Investigator Award to J.T.E., and the University of Michigan Bone & Joint Injury Prevention & Rehabilitation Center (Ann Arbor, MI) for a pilot grant awarded to J.T.E. and J.K.R.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT., 1989, MILD HEAD INJURY, P257; *CDCP, 2005, MMWR-MORBID MORTAL W, V56, P733; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; CHANDRAN S, 2008, ARCH PHYS MED REHAB, V89, pE85; Chudler E. H., NEUROSCIENCE KIDS; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dane S, 2003, INT J NEUROSCI, V113, P923, DOI 10.1080/00207450390220367; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Eckner J. T., 2006, ARCH PHYS MED REHAB, V87, pe10; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Fredrickson J, 2010, NEUROEPIDEMIOLOGY, V34, P65, DOI 10.1159/000264823; Goodman D, 2001, BRIT J SPORT MED, V35, P371; Grindel Scott H, 2006, Curr Sports Med Rep, V5, P9; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Lovell M., 2001, BRIT J SPORT MED, V35, P373; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	29	64	67	1	16	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2010	45	4					327	332		10.4085/1062-6050-45.4.327			6	Sport Sciences	Sport Sciences	627FY	WOS:000280026100003	20617905	Green Published			2021-06-18	
J	Emery, CA; Hagel, B; Decloe, M; Carly, M				Emery, Carolyn A.; Hagel, Brent; Decloe, Melissa; Carly, McKay			Risk factors for injury and severe injury in youth ice hockey: a systematic review of the literature	INJURY PREVENTION			English	Article							DATA-COLLECTION PROCEDURES; CONSENSUS STATEMENT; BODY CHECKING; RATES; SPORT; BODYCHECKING; DEFINITIONS; PLAYERS	Objective To identify risk factors for injury in youth ice hockey (ie, body checking, age, player position, player experience and level of play). Study design Systematic review and meta-analysis. Methods A systematic review of the literature, including a meta-analysis component was completed. Ten electronic databases and the American Society for Testing and Materials Safety in Ice Hockey series (volumes 1-4) were systematically searched with strict inclusion and exclusion criteria to identify articles examining risk factors for injury in youth ice hockey. Results Participation in games, compared with practices, was associated with an increased risk of injury in all studies examined. Age, level of play and player position produced inconsistent findings. Body checking was identified as a significant risk factor for all injuries (summary rate ratio: 2.45; 95% CI 1.7 to 3.6) and concussion (summary odds ratio: 1.71; 95% CI 1.2 to 2.44). Conclusions Findings regarding most risk factors for injury remain inconclusive; however, body checking was found to be associated with an increased risk of injury. Policy implications regarding delaying body checking to older age groups and to only the most elite levels requires further rigorous investigation.	[Emery, Carolyn A.] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Carly, McKay] Univ Western Ontario, London, ON N6A 3K7, Canada	Emery, CA (corresponding author), Univ Calgary, Sport Med Ctr, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	caemery@ucalgary.ca	Hagel, Brent/AAK-3319-2020; Emery, Carolyn/AAI-2761-2020	McKay, Carly/0000-0001-7664-3211	Alberta Heritage Foundation for Medical ResearchAlberta Heritage Foundation for Medical Research; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Paediatric Rehabilitation through the Alberta Children's Hospital Foundation; Canadian National Railway Company; Social Sciences and Humanities Research Council of Canada (SSHRCC)Social Sciences and Humanities Research Council of Canada (SSHRC); Department of Paediatrics Child Health Research Group Scholarship; Alberta Centre for Injury Control	Dr Emery and Dr Hagel are supported by a Population Health Investigator Award from the Alberta Heritage Foundation for Medical Research. Dr Emery also holds and a New Investigator Award from the Canadian Institutes of Health Research and a Professorship in Paediatric Rehabilitation funded through the Alberta Children's Hospital Foundation. Dr Hagel holds a Professorship in Child Health and Wellness funded by the Alberta Children's Hospital Foundation, through the support of an anonymous donor and Canadian National Railway Company. Melissa Decloe's MSc was supported by the Social Sciences and Humanities Research Council of Canada (SSHRCC), a Department of Paediatrics Child Health Research Group Scholarship and the Joanne A. Vincenten Scholarship from the Alberta Centre for Injury Control. Carly McKay is supported by SSHRCC.	Benson Brian W, 2005, Med Sport Sci, V49, P86, DOI 10.1159/000085393; BERNARD D, 1993, AM SOC TESTING MAT S, P44; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Egger M., 2001, SYSTEMATIC REV HLTH; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Emery CA, 2008, BRIT J SPORT MED, V42, P491; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; FINKE R C, 1988, Journal of Orthopaedic and Sports Physical Therapy, V10, P54; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2006, SCAND J MED SCI SPOR, V16, P83, DOI 10.1111/j.1600-0838.2006.00528.x; Hagel BE, 2006, CAN MED ASSOC J, V175, P155, DOI 10.1503/cmaj.051531; HockeyCanada, HOCK CAN ANN REP 200; *INT HOCKEYFEDERAT, 2009, INT IC HOCK FED SURV; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCKAY C, 2008, BRIT J SPORT MED, V42, P533; McKay C, 2008, BRIT J SPORT MED, V42, P532; Molsa J, 2003, AM J SPORT MED, V31, P751; MONTELPARE WJ, 2004, J ASTM INT, V1, P70; REGNIER G, 1989, SAF ICE HOCKEY; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; *USAHOCKEY, 2009, US HOCK ANN C REG RE; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Wattie N, 2007, PEDIATRICS, V120, P142, DOI 10.1542/peds.2006-2672; WIGGINS W, 1999, IMPLICATION INTRO BO; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06; WILLIAMSON IJS, 2006, EPIDEMIOLOGICAL INVE	37	64	65	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	APR	2010	16	2					113	118		10.1136/ip.2009.022764			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	577FW	WOS:000276208800009	20363818				2021-06-18	
J	DeMatteo, CA; Hanna, SE; Mahoney, WJ; Hollenberg, RD; Scott, LA; Law, MC; Newman, A; Lin, CYA; Xu, LQ				DeMatteo, Carol A.; Hanna, Steven E.; Mahoney, William J.; Hollenberg, Robert D.; Scott, Louise A.; Law, Mary C.; Newman, Anne; Lin, Chia-Yu A.; Xu, Liqin			"My Child Doesn't Have a Brain Injury, He Only Has a Concussion"	PEDIATRICS			English	Article						adolescent; brain concussion; brain injuries; child; pediatric hospitals	SPORT-RELATED CONCUSSION; DECISION-TREE ANALYSIS; GLASGOW COMA SCALE; IMPAIRED CONSCIOUSNESS; MANAGEMENT; CLASSIFICATION; ADOLESCENTS; POPULATION; PREDICTION; STATEMENT	OBJECTIVE: The term "concussion" is frequently used in clinical records to describe a traumatic head injury; however, there are no standard definitions of this term, particularly in how it is used with children. The goals of this study were to examine the clinical correlates of the concussion diagnosis and to identify the factors that lead to the use of this term in a regional pediatric center. METHODS: Medical data were prospectively collected from 434 children with traumatic brain injury who were admitted to a Canadian children's hospital. A proportional hazards regression was used to examine the association of the concussion diagnosis and the times until discharge and school return. A classification-tree analysis modeled the clinical correlates of patients who received a concussion diagnosis. RESULTS: The concussion label was significantly more likely to be applied to children with mild Glasgow Coma Scale scores of 13 to 15 (P = .03). The concussion label was strongly predictive of earlier hospital discharge (odds ratio [OR]: 1.5; 95% confidence interval [CI]: 1.2-1.9; P = .003) and earlier return to school (OR: 2.4 [95% CI: 1.6-3.7]; P < .001). A diagnosis of a concussion was significantly more likely when the computed-tomography results were normal and the child had lost consciousness. CONCLUSIONS: Children with mild traumatic brain injuries have an increased frequency of receiving the concussion label, although the label may also be applied to children with more-severe injuries. The concussion diagnosis is associated with important clinical outcomes. Its typical use in hospital settings likely refers to an impact-related mild brain injury, in the absence of indicators other than a loss of consciousness. Clinicians may use the concussion label because it is less alarming to parents than the term mild brain injury, with the intent of implying that the injury is transient with no significant long-term health consequences. Pediatrics 2010; 125: 327-334	[DeMatteo, Carol A.] McMaster Univ, Sch Rehabil Sci, Inst Appl Hlth Sci, Hamilton, ON L8S 1C7, Canada; [Hanna, Steven E.] McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; [Mahoney, William J.; Hollenberg, Robert D.] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Hollenberg, Robert D.] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada; [DeMatteo, Carol A.; Hollenberg, Robert D.; Newman, Anne] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada; [DeMatteo, Carol A.; Hanna, Steven E.; Law, Mary C.; Lin, Chia-Yu A.] McMaster Univ, CanChild Ctr Childhood Disabil Res, Hamilton, ON L8S 1C7, Canada; [DeMatteo, Carol A.; Hollenberg, Robert D.; Newman, Anne] McMaster Childrens Hosp, Hamilton, ON, Canada	DeMatteo, CA (corresponding author), McMaster Univ, Sch Rehabil Sci, Inst Appl Hlth Sci, Room 433,1400 Main St W, Hamilton, ON L8S 1C7, Canada.	dematteo@mcmaster.ca		Hanna, Steven/0000-0003-3120-9600	Ontario Neurotrauma Foundation, Canada [2004-ABI-MTBI-305]; Ontario Ministry of Health and Long-term CareMinistry of Health and Long-Term Care, Ontario	This research was funded by a research grant from the Ontario Neurotrauma Foundation, Canada (2004-ABI-MTBI-305). The CanChild Centre for Childhood Disability Research is supported by the Ontario Ministry of Health and Long-term Care.	Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Cantu RC, 2007, NEW ENGL J MED, V356, P1787; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CHAPMAN SB, 1999, ADV SPEECH LANGUAGE, V1, P19; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Falk AC, 2005, CHILD NERV SYST, V21, P430, DOI 10.1007/s00381-005-1142-4; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hall KM, 1997, ARCH PHYS MED REHAB, V78, pS5, DOI 10.1016/S0003-9993(97)90149-0; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Olshen RA, 1984, CLASSIFICATION REGRE; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thompson Matthew D, 2003, Semin Pediatr Neurol, V10, P130, DOI 10.1016/S1071-9091(03)00021-4; Wade DT, 1992, MEASUREMENT NEUROLOG; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; World Health Organization, 1992, ICD 10 INT STAT CLAS; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	39	64	66	1	25	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2010	125	2					327	334		10.1542/peds.2008-2720			8	Pediatrics	Pediatrics	573VH	WOS:000275942900018	20083526				2021-06-18	
J	Halamek, J; Bocharova, V; Chinnapareddy, S; Windmiller, JR; Strack, G; Chuang, MC; Zhou, J; Santhosh, P; Ramirez, GV; Arugula, MA; Wang, J; Katz, E				Halamek, Jan; Bocharova, Vera; Chinnapareddy, Soujanya; Windmiller, Joshua Ray; Strack, Guinevere; Chuang, Min-Chieh; Zhou, Jian; Santhosh, Padmanabhan; Ramirez, Gabriela V.; Arugula, Mary A.; Wang, Joseph; Katz, Evgeny			Multi-enzyme logic network architectures for assessing injuries: digital processing of biomarkers	MOLECULAR BIOSYSTEMS			English	Article							TRAUMATIC BRAIN-INJURY; MOLECULAR LOGIC; BIOCHEMICAL LOGIC; GATES; ENZYME; INFORMATION; NAND; NOR; NOREPINEPHRINE; FLUORESCENCE	A multi-enzyme biocatalytic cascade processing simultaneously five biomarkers characteristic of traumatic brain injury (TBI) and soft tissue injury (STI) was developed. The system operates as a digital biosensor based on concerted function of 8 Boolean AND logic gates, resulting in the decision about the physiological conditions based on the logic analysis of complex patterns of the biomarkers. The system represents the first example of a multi-step/multi-enzyme biosensor with the built-in logic for the analysis of complex combinations of biochemical inputs. The approach is based on recent advances in enzyme-based biocomputing systems and the present paper demonstrates the potential applicability of biocomputing for developing novel digital biosensor networks.	[Windmiller, Joshua Ray; Chuang, Min-Chieh; Santhosh, Padmanabhan; Ramirez, Gabriela V.; Wang, Joseph] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA; [Halamek, Jan; Bocharova, Vera; Chinnapareddy, Soujanya; Strack, Guinevere; Zhou, Jian; Arugula, Mary A.; Katz, Evgeny] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA	Wang, J (corresponding author), Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA.	josephwang@ucsd.edu; ekatz@clarkson.edu	Wang, Joseph/C-6175-2011; Valdes-Ramirez, Gabriela/D-2053-2012; Padmanabhan, Santhosh/A-6930-2009	Padmanabhan, Santhosh/0000-0003-2418-5284; Valdes Ramirez, Gabriela/0000-0002-9566-930X	Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]	This work was supported by the Office of Naval Research (Award # N00014-08-1-1202).	Adamatzky A., 2007, UNCONVENTIONAL COMPU; Andreasson J, 2010, CHEM SOC REV, V39, P174, DOI 10.1039/b820280j; Arugula MA, 2009, 2009 SECOND INTERNATIONAL CONFERENCE ON ADVANCES IN CIRCUITS, ELECTRONICS AND MICRO-ELECTRONICS, P1, DOI 10.1109/CENICS.2009.8; Ashkenasy G, 2004, J AM CHEM SOC, V126, P11140, DOI 10.1021/ja046745c; Ashkenazi G, 1997, BIOSENS BIOELECTRON, V12, P85, DOI 10.1016/S0956-5663(97)87054-6; Baron R, 2006, J PHYS CHEM A, V110, P8548, DOI 10.1021/jp0568327; Baytekin HT, 2000, ORG LETT, V2, P1725, DOI 10.1021/ol005873c; Benenson Y, 2004, NATURE, V429, P423, DOI 10.1038/nature02551; Benenson Y, 2009, CURR OPIN BIOTECH, V20, P471, DOI 10.1016/j.copbio.2009.08.002; Benenson Y, 2009, MOL BIOSYST, V5, P675, DOI 10.1039/b902484k; Berger RP, 2006, CLIN PEDIATR EMERG M, V7, P186, DOI 10.1016/j.cpem.2006.06.001; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, V4, P2066; Calude C.S., 2009, LECT NOTES COMPUTER, V5715; Ciosek P, 2007, ANALYST, V132, P963, DOI 10.1039/b705107g; Credi A, 2007, ANGEW CHEM INT EDIT, V46, P5472, DOI 10.1002/anie.200700879; Darehmiraki M, 2007, APPL MATH COMPUT, V187, P1033, DOI 10.1016/j.amc.2006.09.020; de Silva AP, 2007, COORDIN CHEM REV, V251, P1623, DOI 10.1016/j.ccr.2007.03.001; de Silva AP, 2007, NAT NANOTECHNOL, V2, P399, DOI 10.1038/nnano.2007.188; DE SILVA AP, 1993, NATURE, V364, P42, DOI 10.1038/364042a0; de Silva AP, 1997, J AM CHEM SOC, V119, P7891, DOI 10.1021/ja9712229; DE SILVA AP, 1994, J CHEM SOC CHEM COMM, P1213, DOI 10.1039/c39940001213; de Silva AP, 2002, CHEM-EUR J, V8, P4935, DOI 10.1002/1521-3765(20021104)8:21<4935::AID-CHEM4935>3.0.CO;2-2; de Silva AP, 1999, J AM CHEM SOC, V121, P1393, DOI 10.1021/ja982909b; de Sousa M, 2006, CHEM COMMUN, P2051, DOI 10.1039/b600932h; Deonarine AS, 2003, FUTURE GENER COMP SY, V19, P87, DOI 10.1016/S0167-739X(02)00110-3; Ezziane Z, 2006, NANOTECHNOLOGY, V17, pR27, DOI 10.1088/0957-4484/17/2/R01; Fu L, 2004, ADV COLLOID INTERFAC, V111, P133, DOI 10.1016/j.cis.2004.09.004; Gunnlaugsson T, 2000, CHEM COMMUN, P93, DOI 10.1039/a908951i; Gunnlaugsson T, 2001, J AM CHEM SOC, V123, P12866, DOI 10.1021/ja004316i; Halamek J, 2010, ANALYST, V135, P2249, DOI 10.1039/c0an00270d; Ji S, 1999, BIOSYSTEMS, V52, P123, DOI 10.1016/S0303-2647(99)00039-8; JOSEPHY PD, 1982, J BIOL CHEM, V257, P3669; Kahan M, 2008, PHYSICA D, V237, P1165, DOI 10.1016/j.physd.2008.01.027; Katz E, 2010, CHEM SOC REV, V39, P1835, DOI 10.1039/b806038j; Kim KJ, 2006, ARTIF LIFE, V12, P153, DOI 10.1162/106454606775186455; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; Lee JY, 2005, LECT NOTES COMPUT SC, V3384, P215; Li L, 2007, COLLOID SURFACE A, V304, P49, DOI 10.1016/j.colsurfa.2007.04.020; Liberman EA, 1996, BIOSYSTEMS, V38, P173, DOI 10.1016/0303-2647(95)01588-4; Luxami V, 2008, NEW J CHEM, V32, P2074, DOI 10.1039/b805558k; Manesh KM, 2009, BIOSENS BIOELECTRON, V24, P3569, DOI 10.1016/j.bios.2009.05.019; Maojo V, 2010, PEDIATR RES, V67, P481, DOI 10.1203/PDR.0b013e3181d6245e; Margulies D, 2009, J AM CHEM SOC, V131, P9142, DOI 10.1021/ja900848t; May EE, 2008, IEEE SENS J, V8, P1011, DOI 10.1109/JSEN.2008.923945; Munoz YJ, 2009, J EXP THEOR ARTIF IN, V21, P273, DOI 10.1080/09528130902823649; Niazov T, 2006, P NATL ACAD SCI USA, V103, P17160, DOI 10.1073/pnas.0608319103; Ogawa A, 2009, CHEM COMMUN, P4666, DOI 10.1039/b910288d; OLERUD JE, 1976, ARCH INTERN MED, V136, P692, DOI 10.1001/archinte.136.6.692; Pischel U, 2007, ANGEW CHEM INT EDIT, V46, P4026, DOI 10.1002/anie.200603990; Pischel U, 2010, AUST J CHEM, V63, P148, DOI 10.1071/CH09460; Pita M, 2008, J AM CHEM SOC, V130, P36, DOI 10.1021/ja077908a; Pita M, 2009, SENSOR ACTUAT B-CHEM, V139, P631, DOI 10.1016/j.snb.2009.03.001; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Privman V, 2008, J PHYS CHEM B, V112, P11777, DOI 10.1021/jp802673q; Qian JH, 2008, CHEM COMMUN, P4141, DOI 10.1039/b805876h; Reif JH, 2009, THEOR COMPUT SCI, V410, P1428, DOI 10.1016/j.tcs.2008.12.003; Rinaudo K, 2007, NAT BIOTECHNOL, V25, P795, DOI 10.1038/nbt1307; ROSENBERG J, 1961, ANN SURG, V154, P611, DOI 10.1097/00000658-196110000-00011; Saghatelian A, 2003, J AM CHEM SOC, V125, P346, DOI 10.1021/ja029009m; Seminario JM, 1998, ANN NY ACAD SCI, V852, P68, DOI 10.1111/j.1749-6632.1998.tb09865.x; Simmel FC, 2007, NANOMEDICINE-UK, V2, P817, DOI 10.2217/17435889.2.6.817; Sivan S, 2003, BIOSYSTEMS, V70, P21, DOI 10.1016/S0303-2647(03)00039-X; Sivan S, 1999, BIOTECHNOL PROGR, V15, P964, DOI 10.1021/bp990075a; Staiano M, 2005, MOL BIOSYST, V1, P354, DOI 10.1039/b513385h; Stojanovic MN, 2005, BIOELECTRONICS: FROM THEORY TO APPLICATIONS, P427, DOI 10.1002/352760376X.ch14; Stojanovic MN, 2002, J AM CHEM SOC, V124, P3555, DOI 10.1021/ja016756v; Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862; Strack G, 2008, CHEMBIOCHEM, V9, P1260, DOI 10.1002/cbic.200700762; Strack G, 2008, J AM CHEM SOC, V130, P4234, DOI 10.1021/ja7114713; Strack G, 2010, J PHYS CHEM LETT, V1, P839, DOI 10.1021/jz100070u; Straight SD, 2007, ADV FUNCT MATER, V17, P777, DOI 10.1002/adfm.200600802; Szacilowski K, 2008, CHEM REV, V108, P3481, DOI 10.1021/cr068403q; Tokarev I, 2009, ACS APPL MATER INTER, V1, P532, DOI 10.1021/am800251a; Turfan B, 2002, ORG LETT, V4, P2857, DOI 10.1021/ol026245t; Unger R, 2006, PROTEINS, V63, P53, DOI 10.1002/prot.20886; van Noort D, 2005, LECT NOTES COMPUT SC, V3384, P365; von Maltzahn G, 2007, J AM CHEM SOC, V129, P6064, DOI 10.1021/ja070461l; Wagner N, 2009, CHEM-EUR J, V15, P1765, DOI 10.1002/chem.200801850; Wang J, 2001, ELECTROANAL, V13, P13, DOI 10.1002/1521-4109(200101)13:1<13::AID-ELAN13>3.0.CO;2-F; Wang J, 2010, ANAL BIOANAL CHEM, V398, P1591, DOI 10.1007/s00216-010-3746-0; Wang ZX, 2005, ORG LETT, V7, P3669, DOI 10.1021/ol051211h; Win MN, 2008, SCIENCE, V322, P456, DOI 10.1126/science.1160311; Zauner KP, 2005, CRIT REV SOLID STATE, V30, P33, DOI 10.1080/10408430590918387; Zhou J, 2009, J PHYS CHEM B, V113, P16065, DOI 10.1021/jp9079052; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zong GQ, 2007, TETRAHEDRON LETT, V48, P3891, DOI 10.1016/j.tetlet.2007.03.139	86	64	64	1	23	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1742-206X	1742-2051		MOL BIOSYST	Mol. Biosyst.		2010	6	12					2554	2560		10.1039/c0mb00153h			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	676SD	WOS:000283937800023	20953502				2021-06-18	
J	Dobscha, SK; Clark, ME; Morasco, BJ; Freeman, M; Campbell, R; Helfand, M				Dobscha, Steven K.; Clark, Michael E.; Morasco, Benjamin J.; Freeman, Michele; Campbell, Rose; Helfand, Mark			Systematic Review of the Literature on Pain in Patients with Polytrauma Including Traumatic Brain Injury	PAIN MEDICINE			English	Article						Pain; Multiple Trauma; Blast Injuries; Traumatic Brain Injury; Veterans	PERIPHERAL-NERVE LESIONS; LONG-TERM OUTCOMES; INTRATHECAL BACLOFEN THERAPY; HEAD-INJURY; MULTIPLE TRAUMA; MAJOR TRAUMA; FOLLOW-UP; FUNCTIONAL CONSEQUENCES; SPASTIC HYPERTONIA; RISK-FACTORS	Objective. To review the literature addressing the assessment and management of pain in patients with polytraumatic injuries including traumatic brain injury (TBI) and blast-related headache, and to identify patient, clinician and systems factors associated with pain-related outcomes. Design. Systematic review. Methods. We conducted searches in MEDLINE of literature published from 1950 through July 2008. Due to a limited number of studies using controls or comparators, we included observational and rigorous qualitative studies. We systematically rated the quality of systematic reviews, cohort, and case-control design studies. Results. One systematic review, 93 observational studies, and one qualitative research study met inclusion criteria. The literature search yielded no published studies that assessed measures of pain intensity or pain-related functional interference among patients with cognitive deficits due to TBI, that compared patients with blast-related headache with patients with other types of headache, or that assessed treatments for blast-related headache pain. Studies on the association between TBI severity and pain reported mixed findings. There was limited evidence that the following factors are associated with pain among TBI patients: severity, location, and multiplicity of injuries; insomnia; fatigue; depression; and post-traumatic stress disorder. Conclusions. Very little evidence is currently available to guide pain assessment and treatment approaches in patients with polytrauma. Further research employing systematic observational as well as controlled intervention designs is clearly indicated.	[Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA; [Dobscha, Steven K.; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Dobscha, Steven K.; Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97207 USA; [Clark, Michael E.] James A Haley Vet Affairs Hosp, Psychol Serv, Tampa, FL USA; [Clark, Michael E.] Univ S Florida, Coll Med, Dept Psychol, Jacksonville, FL USA; [Clark, Michael E.] Univ S Florida, Coll Med, Dept Neurol, Jacksonville, FL USA; [Freeman, Michele; Campbell, Rose] Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR 97201 USA; [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Helfand, Mark] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA	Dobscha, SK (corresponding author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Box 1034 P3MHADM, Portland, OR 97207 USA.	steven.dobscha@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration, Health Services Research and Development ServiceUS Department of Veterans Affairs [RCD 04129]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23DA023467-01A1]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K23DA023467] Funding Source: NIH RePORTER	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Project RCD 04129 (Dobscha), National Institutes of Health K23DA023467-01A1 (Morasco) and Evidence-based Practice Center funding which is supported by the Agency for Healthcare Research and Quality. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.	ADELOYE A, 1971, PRACTITIONER, V206, P517; ANDY OJ, 1989, CLIN ELECTROENCEPHAL, V20, P24, DOI 10.1177/155005948902000107; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bergfeldt U, 2006, J REHABIL MED, V38, P166, DOI 10.1080/16501970500415348; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Brenneman FD, 1997, J TRAUMA, V42, P773, DOI 10.1097/00005373-199705000-00003; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Chen KW, 2004, J ALTERN COMPLEM MED, V10, P159, DOI 10.1089/107555304322849075; Childers MK, 1997, BRAIN INJURY, V11, P537, DOI 10.1080/713802187; CONCALVES J, 1994, STEREOT FUNCT NEUROS, V62, P108, DOI 10.1159/000098605; COSGROVE JL, 1989, AM J PHYS MED REHAB, V68, P15, DOI 10.1097/00002060-198902000-00005; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Denys P, 1996, BRAIN INJURY, V10, P149, DOI 10.1080/026990596124656; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Donnellan Clare P, 2006, Acupunct Med, V24, P129; Dougherty PJ, 1999, J BONE JOINT SURG AM, V81A, P1384, DOI 10.2106/00004623-199910000-00003; Dougherty PJ, 2001, J BONE JOINT SURG AM, V83A, P383, DOI 10.2106/00004623-200103000-00010; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fischer Hannah, 2009, US MILITARY CASUALTY; Fitzharris Michael, 2007, Traffic Inj Prev, V8, P309, DOI 10.1080/15389580701216533; Francisco GE, 2005, BRAIN INJURY, V19, P359, DOI 10.1080/02699050400003999; Francisco GE, 2007, BRAIN INJURY, V21, P335, DOI 10.1080/02699050701311018; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Frink M, 2007, INJURY, V38, P607, DOI 10.1016/j.injury.2006.12.021; Gallagher R, 2006, J AM MED DIR ASSOC, V7, P432, DOI 10.1016/j.jamda.2006.04.010; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; Guttmann E, 1943, LANCET, V1, P10; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hebert JS, 2000, SPINE, V25, P55, DOI 10.1097/00007632-200001010-00011; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Jang SH, 2000, YONSEI MED J, V41, P536, DOI 10.3349/ymj.2000.41.4.536; KAY DWK, 1971, LANCET, V2, P1052; Lacoux PA, 2002, PAIN, V99, P309, DOI 10.1016/S0304-3959(02)00154-9; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Leung J, 2007, CLIN REHABIL, V21, P171, DOI 10.1177/0269215506070254; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; LEYTON N, 1951, Med Press, V226, P46; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Mkandawire NC, 2002, INJURY, V33, P111, DOI 10.1016/S0020-1383(01)00047-X; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; Ribbers GM, 2001, ARCH PHYS MED REHAB, V82, P851, DOI 10.1053/apmr.2001.21911; Roganovic Z, 2006, NEUROSURGERY, V59, P1238, DOI 10.1227/01.NEU.0000245618.16979.32; Roganovic Z, 2006, NEUROSURGERY, V59, P1226, DOI 10.1227/01.NEU.0000245610.01732.32; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Shah RV, 2004, ARCH PHYS MED REHAB, V85, P1013, DOI 10.1016/j.apmr.2003.07.017; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; Tran T, 2002, FOOT ANKLE INT, V23, P340, DOI 10.1177/107110070202300409; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; Turchin DC, 1999, J ORTHOP TRAUMA, V13, P1, DOI 10.1097/00005131-199901000-00001; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Urquhart DM, 2006, ANZ J SURG, V76, P600, DOI 10.1111/j.1445-2197.2006.03785.x; Verdolin MH, 2007, ANESTH ANALG, V104, P1557, DOI 10.1213/01.ane.0000264087.93163.bf; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wardell DW, 2006, J HOLIST NURS, V24, P231, DOI 10.1177/0898010106289840; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WARDEN DL, 2005, 23 ANN NAT NEUR SOC; WILKINSON M, 1980, UPSALA J MED SCI, P48; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; ZACHARIAH SB, 1994, AM J MED SCI, V308, P38, DOI 10.1097/00000441-199407000-00009; Zelle BA, 2005, INJURY, V36, P169, DOI 10.1016/j.injury.2004.06.004	90	64	66	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	OCT	2009	10	7					1200	1217		10.1111/j.1526-4637.2009.00721.x			18	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	504BT	WOS:000270589100006	19818031	Green Accepted, Bronze			2021-06-18	
J	Abrahamson, EE; Ikonomovic, MD; Dixon, CE; DeKosky, ST				Abrahamson, Eric E.; Ikonomovic, Milos D.; Dixon, C. Edward; DeKosky, Steven T.			Simvastatin Therapy Prevents Brain Trauma-Induced Increases in beta-Amyloid Peptide Levels	ANNALS OF NEUROLOGY			English	Article							A REDUCTASE INHIBITORS; GENE-TARGETED MICE; SEVERE HEAD-INJURY; PRECURSOR PROTEIN; IN-VIVO; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; NEURONAL SURVIVAL; CORTICAL-NEURONS; ATORVASTATIN	Elevations in beta-amyloid peptide (A beta) levels after traumatic brain injury (TBI) may confer risk for developing Alzheimer's disease in head trauma patients. We investigated the effects of simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, on hippocampal A beta burden in a clinically relevant head injury/intervention model using mice expressing human A beta. Simvastatin therapy blunted TBI-induced increases in A beta, reduced hippocampal tissue damage and microglial activation, and improved behavioral outcome. The ability of statins to reduce post-injury A beta load and ameliorate pathological sequelae of brain injury makes them potentially effective in reducing the risk of developing Alzheimer's disease in TBI patients.	[DeKosky, Steven T.] Univ Virginia, Off Dean, Sch Med, Charlottesville, VA 22908 USA; [Abrahamson, Eric E.; Ikonomovic, Milos D.; DeKosky, Steven T.] Univ Pittsburgh, Sch Med, Dept Neurol, Brain Trauma Res Ctr, Pittsburgh, PA 15261 USA; [Ikonomovic, Milos D.; DeKosky, Steven T.] Univ Pittsburgh, Sch Med, Dept Psychiat, Brain Trauma Res Ctr, Pittsburgh, PA USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15261 USA	DeKosky, ST (corresponding author), Univ Virginia, Off Dean, Sch Med, POB 800793, Charlottesville, VA 22908 USA.	dekosky@virginia.edu		DeKosky, Steven/0000-0003-3743-2758	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS30318]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060672, P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER	This work was supported by the NIH (National Institute of Neurological Disorders and Stroke, NS30318) (S.D., M.I., E.D.).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burns M, 2003, J NEUROSCI, V23, P5645; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clarke RM, 2007, NEUROPHARMACOLOGY, V52, P136, DOI 10.1016/j.neuropharm.2006.07.031; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Cotman CW, 1996, NEUROBIOL AGING, V17, P723; Cotman CW, 1997, ANN NY ACAD SCI, V814, P1, DOI 10.1111/j.1749-6632.1997.tb46140.x; DeKosky ST, 2005, AM J MED, V118, p48S, DOI 10.1016/j.amjmed.2005.09.006; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Flood DG, 2002, NEUROBIOL AGING, V23, P335, DOI 10.1016/S0197-4580(01)00330-X; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; He X, 2006, J NEUROPATH EXP NEUR, V65, P652, DOI 10.1097/01.jnen.0000225906.82428.69; HOEG JM, 1987, JAMA-J AM MED ASSOC, V258, P3532, DOI 10.1001/jama.258.24.3532; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Li L, 2006, ANN NEUROL, V60, P729, DOI 10.1002/ana.21053; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Mattson MP, 1997, PHYSIOL REV, V77, P1081; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miida T, 2007, PHARMACOL THERAPEUT, V113, P378, DOI 10.1016/j.pharmthera.2006.09.003; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Parvathy S, 2009, NEUROBIOL AGING, V30, P1792, DOI 10.1016/j.neurobiolaging.2008.01.011; Pedrini S, 2005, PLOS MED, V2, P69, DOI 10.1371/journal.pmed.0020018; Petanceska SS, 2003, J MOL NEUROSCI, V20, P395, DOI 10.1385/JMN:20:3:395; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Shabanzadeh AP, 2005, BRAIN RES, V1042, P1, DOI 10.1016/j.brainres.2005.01.105; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Sparks DL, 2006, ACTA NEUROL SCAND, V114, P78, DOI 10.1111/j.1600-0404.2006.00689.x; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Xie ZC, 2008, ANN NEUROL, V64, P618, DOI 10.1002/ana.21548; Zacco A, 2003, J NEUROSCI, V23, P11104	63	64	64	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	SEP	2009	66	3					407	414		10.1002/ana.21731			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	503WX	WOS:000270573700022	19798641				2021-06-18	
J	von Elm, E; Schoettker, P; Henzi, I; Osterwalder, J; Walder, B				von Elm, E.; Schoettker, P.; Henzi, I.; Osterwalder, J.; Walder, B.			Pre-hospital tracheal intubation in patients with traumatic brain injury: systematic review of current evidence	BRITISH JOURNAL OF ANAESTHESIA			English	Article						airway; brain, injury; complications, intubation tracheal; ventilation, mechanical	RAPID-SEQUENCE INTUBATION; ADVANCED LIFE-SUPPORT; ENDOTRACHEAL INTUBATION; SURVIVAL; FIELD; VENTILATION; MANAGEMENT; MODERATE; IMPACT; GUIDELINES	Background. We reviewed the current evidence on the benefit and harm of pre-hospital tracheal intubation and mechanical ventilation after traumatic brain injury (TBI). Methods. We conducted a systematic literature search up to December 2007 without language restriction to identify interventional and observational studies comparing pre-hospital intubation with other airway management (e. g. bag-valve-mask or oxygen administration) in patients with TBI. Information on study design, population, interventions, and outcomes was abstracted by two investigators and cross-checked by two others. Seventeen studies were included with data for 15 335 patients collected from 1985 to 2004. There were 12 retrospective analyses of trauma registries or hospital databases, three cohort studies, one case-control study, and one controlled trial. Using Brain Trauma Foundation classification of evidence, there were 14 class 3 studies, three class 2 studies, and no class 1 study. Six studies were of adults, five of children, and three of both; age groups were unclear in three studies. Maximum follow-up was up to 6 months or hospital discharge. Results. In 13 studies, the unadjusted odds ratios (ORs) for an effect of pre-hospital intubation on in-hospital mortality ranged from 0.17 (favouring control interventions) to 2.43 (favouring pre-hospital intubation); adjusted ORs ranged from 0.24 to 1.42. Estimates for functional outcomes after TBI were equivocal. Three studies indicated higher risk of pneumonia associated with pre-hospital (when compared with in-hospital) intubation. Conclusions. Overall, the available evidence did not support any benefit from pre-hospital intubation and mechanical ventilation after TBI. Additional arguments need to be taken into account, including medical and procedural aspects.	[von Elm, E.] Univ Med Ctr Freiburg, Dept Med Biometry & Stat, German Cochrane Ctr, D-79104 Freiburg, Germany; [von Elm, E.] Swiss Paraplegia Res, Nottwil, Switzerland; [Schoettker, P.] Univ Hosp Vaud, Dept Anaesthesiol, Lausanne, Switzerland; [Henzi, I.; Walder, B.] Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland; [Osterwalder, J.] St Gallen Cantonal Hosp, Emergency Dept, St Gallen, Switzerland	von Elm, E (corresponding author), Univ Med Ctr Freiburg, Dept Med Biometry & Stat, German Cochrane Ctr, Stefan Meier Str 26, D-79104 Freiburg, Germany.	vonelm@cochrane.de	Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; von Elm, Erik/0000-0002-7412-0406			ADELSON PD, 2003, PEDIATR CRIT CARE ME, V4, P9; Arozullah AM, 2001, ANN INTERN MED, V135, P847, DOI 10.7326/0003-4819-135-10-200111200-00005; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Baker CC, 2005, J TRAUMA, V58, P723; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christensen EF, 2003, BRIT MED J, V327, P533, DOI 10.1136/bmj.327.7414.533; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; Davis D P, 2001, Prehosp Emerg Care, V5, P163, DOI 10.1080/10903120190940065; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Deitch Sean, 2003, Prehosp Emerg Care, V7, P380, DOI 10.1080/10903120390936617; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; DiRusso SM, 2005, J TRAUMA, V59, P84, DOI 10.1097/01.TA.0000171462.28379.F3; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckert MJ, 2004, J TRAUMA, V57, P750, DOI 10.1097/01.TA.0000147499.73570.12; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; ERLER C, 1993, AIR MED J, V7, P223; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Grmec S, 2004, EMERG MED J, V21, P518, DOI 10.1136/emj.2002.001974; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; KOENIG KL, 1992, ANN EMERG MED, V21, P929, DOI 10.1016/S0196-0644(05)82930-0; Konrad C, 1998, ANESTH ANALG, V86, P635; Lenartova L, 2007, WIEN KLIN WOCHENSCHR, V119, P35, DOI 10.1007/s00508-006-0762-3; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Mackway-Jones K, 2005, Emerg Med J, V22, P887, DOI 10.1136/emj.2005.031708; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; ROSE DK, 1994, CAN J ANAESTH, V41, P372, DOI 10.1007/BF03009858; Salomone JP, 2005, J TRAUMA, V58, P509, DOI 10.1097/01.TA.0000152807.63559.2E; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shatz DV, 2005, J TRAUMA, V58, P515; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stanic-Canji D, 2006, Acta Chir Iugosl, V53, P45; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Suominen P, 2000, Eur J Emerg Med, V7, P3; von Elm E, 2008, SWISS MED WKLY, V138, P327, DOI 2008/23/smw-12025; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2006, ANN EMERG MED, V47, P532, DOI 10.1016/j.annemergmed.2006.01.016; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	59	64	66	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	SEP	2009	103	3					371	386		10.1093/bja/aep202			16	Anesthesiology	Anesthesiology	483ZV	WOS:000269013300008	19648153	Green Published, Bronze			2021-06-18	
J	Gilmer, LK; Roberts, KN; Joy, K; Sullivan, PG; Scheff, SW				Gilmer, Lesley K.; Roberts, Kelly N.; Joy, Kelly; Sullivan, Patrick G.; Scheff, Stephen W.			Early Mitochondrial Dysfunction after Cortical Contusion Injury	JOURNAL OF NEUROTRAUMA			English	Article						Clark-type electrode; cortical contusion injury; mitochondrial bioenergetics; total mitochondria; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; FOREBRAIN MITOCHONDRIA; CELL-DEATH; RATS; PROTECTION; MEMBRANE; HIPPOCAMPUS	Following traumatic brain injury, mitochondria sustain structural and functional impairment, which contributes to secondary damage that can continue for days after the initial injury. The present study investigated mitochondrial bioenergetic changes in the rat neocortex at 1 and 3 h after mild, moderate, and severe injuries. Brains from young adult Sprague-Dawley rats were harvested from the injured and contralateral cortex to assess possible changes in mitochondrial respiration abilities following a unilateral cortical contusion injury. Differential centrifugation was used to isolate synaptic and extrasynaptic mitochondria from cortical tissue. Bioenergetics was assessed using a Clark-type electrode and results were graphed as a function of injury severity and time post-injury. Respiration was significantly affected by all injury severity levels compared to uninjured tissue. Complex 1- and complex 2-driven respirations were affected proportionally to the severity of the injury, indicating that damage to mitochondria may occur on a gradient. Total oxygen utilization, respiratory control ratio, ATP production, and maximal respiration capabilities were all significantly decreased in the injured cortex at both 1 and 3 h post-trauma. Although mitochondria displayed bioenergetic deficits at 1 h following injury, damage was not exacerbated by 3 h. This study stresses the importance of early therapeutic intervention and suggests a window of approximately 1-3 h before greater dysfunction occurs.	[Gilmer, Lesley K.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Sullivan, Patrick G.; Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Sullivan, Patrick G.; Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown Bldg, Lexington, KY 40536 USA.	sscheff@email.uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981, T32 DA022738-01]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	We thank Paula Thomason for carefully reading the manuscript. This work was supported by NIH grant AG21981 and training grant T32 DA022738-01.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Baldwin SA, 1996, GLIA, V16, P266; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Finsterer J, 2008, J NEUROL SCI, V272, P20, DOI 10.1016/j.jns.2008.05.011; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hino K, 2005, BRAIN RES, V1053, P77, DOI 10.1016/j.brainres.2005.06.062; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Khodorov B, 1996, FEBS LETT, V393, P135, DOI 10.1016/0014-5793(96)00873-3; Kovesdi E, 2007, PROG BRAIN RES, V161, P81, DOI 10.1016/S0079-6123(06)61006-6; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Long JG, 2006, LIFE SCI, V79, P1466, DOI 10.1016/j.lfs.2006.04.024; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sugden Mary C, 2003, Biochem J, V374, pe1, DOI 10.1042/BJ20031105; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Vergun O, 2003, BIOPHYS J, V85, P3358, DOI 10.1016/S0006-3495(03)74755-9; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001	43	64	67	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1271	1280		10.1089/neu.2008.0857			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900010	19637966	Green Published			2021-06-18	
J	Slemmer, JE; Zhu, C; Landshamer, S; Trabold, R; Grohm, J; Ardeshiri, A; Wagner, E; Sweeney, MI; Blomgren, K; Culmsee, C; Weber, JT; Plesnila, N				Slemmer, Jennifer E.; Zhu, Changlian; Landshamer, Stefan; Trabold, Raimund; Grohm, Julia; Ardeshiri, Ardavan; Wagner, Ernst; Sweeney, Marva I.; Blomgren, Klas; Culmsee, Carsten; Weber, John T.; Plesnila, Nikolaus			Causal Role of Apoptosis-Inducing Factor for Neuronal Cell Death Following Traumatic Brain Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FOCAL CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION; CONTROLLED CORTICAL IMPACT; STRETCH-INDUCED INJURY; CNS INJURY; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; HIPPOCAMPAL CELLS; HYPOXIA-ISCHEMIA	Traumatic brain injury (TBI) consists of two phases: an immediate phase in which damage is caused as a direct result of the mechanical impact; and a late phase of altered biochemical events that results in delayed tissue damage and is therefore amenable to therapeutic treatment. Because the molecular mechanisms of delayed post-traumatic neuronal cell death are stiff poorly understood, we investigated whether apoptosis-inducing factor (AIF), a pro-apoptotic mitochondrial molecule and the key factor in the caspase-independent, cell death signaling pathway, plays a causal role in neuronal death following TBI. Using an in vitro model of neuronal stretch injury, we demonstrated that AN translocated from mitochondria to the nucleus of neurons displaying axonal disruption, chromatin condensation, and nuclear pyknosis in a caspase-independent manner, whereas astrocytes remained unaffected. Similar findings were observed following experimental TBI in mice, where AN translocation to die nucleus coincided with delayed neuronal cell death in both cortical and hippocampal neurons. Down-regulation of AIF in vitro by siRNA significantly reduced stretch-induced neuronal cell death by 67%, a finding corroborated in vivo using AIF-deficient harlequin mutant mice, where secondary contusion expansion was significantly reduced by 44%. Hence, our current findings demonstrate that caspase-independent, ALF-mediated signaling pathways significantly contribute to post-traumatic neuronal cell death and may therefore represent novel therapeutic targets for the treatment of TBI. (Am J Pathol 2008,173:1795-1805, DOI: 10.2353/ajpath.2008.080168)	[Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dept Physiol & Neurodegenerat, Dublin 2, Ireland; [Slemmer, Jennifer E.; Sweeney, Marva I.] Univ Prince Edward Isl, Dept Biol, Charlottetown, PE C1A 4P3, Canada; [Slemmer, Jennifer E.; Weber, John T.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Zhu, Changlian; Blomgren, Klas] Gothenburg Univ, Inst Neurosci & Physiol, Ctr Brain Repair & Rehab, S-41124 Gothenburg, Sweden; [Landshamer, Stefan; Wagner, Ernst; Culmsee, Carsten] Univ Munich, Dept Pharm, D-80539 Munich, Germany; [Trabold, Raimund; Ardeshiri, Ardavan; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, D-80539 Munich, Germany; [Trabold, Raimund; Ardeshiri, Ardavan; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Inst Surg Res, D-80539 Munich, Germany; [Grohm, Julia; Blomgren, Klas] Gothenburg Univ, Queen Silvia Childrens Hosp, Dept Pediat Oncol, S-41124 Gothenburg, Sweden; [Culmsee, Carsten] Univ Marburg, Inst Pharmacol & Toxicol, D-35032 Marburg, Germany; [Weber, John T.] Mem Univ Newfoundland, Sch Pharm, St John, NF, Canada	Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Neurodegenerat, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Wagner, Ernst/ABB-5976-2020; Plesnila, Nikolaus/T-7522-2019; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Zhu, Changlian/0000-0002-5029-6730; Blomgren, Klas/0000-0002-0476-7271; Culmsee, Carsten/0000-0002-5121-5015	Fakultatsforderprogramm fur Forschung und Lehre (FoFoLe) of the University of Munich; Erasmus MC; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Childhood Cancer FoundationEuropean Commission; Hersenstichting Nederland	Supported by the Fakultatsforderprogramm fur Forschung und Lehre (FoFoLe) of the University of Munich, a Breedtestrategie subsidie from Erasmus MC, the Swedish Research Council, the Swedish Childhood Cancer Foundation and Hersenstichting Nederland.	BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Chu CT, 2005, J NEUROCHEM, V94, P1685, DOI 10.1111/j.1471-4159.2005.03329.x; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Katayama Y, 1998, ACT NEUR S, V71, P289; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhu C, 2007, CELL DEATH DIFFER, V14, P775, DOI 10.1038/sj.cdd.4402053; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P320, DOI 10.1007/BF00395288; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	54	64	70	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2008	173	6					1795	1805		10.2353/ajpath.2008.080168			11	Pathology	Pathology	377LU	WOS:000261253500020	18988795	Green Published			2021-06-18	
J	Ziai, WC; Toung, TJK; Bhardwaj, A				Ziai, Wendy C.; Toung, Thomas J. K.; Bhardwaj, Anish			Hypertonic saline: First-line therapy for cerebral edema?	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						cerebral edema; hypertonic saline; intracranial hemorrhage	ELEVATED INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; SODIUM-CHLORIDE; CELL-VOLUME; RAT-BRAIN; INTRACEREBRAL HEMORRHAGE; FLUID RESUSCITATION; 20-PERCENT MANNITOL; 7.5-PERCENT SALINE	This article highlights the experimental and clinical data, controversies and postulated mechanisms surrounding osmotherapy with hypertonic saline (HS) solutions in the neurocritical care arena and builds on previous reviews on the subject. Special attention is focused on HS therapy on commonly encountered clinical paradigms of acute brain injury including traumatic brain injury (TBI), post-operative "retraction edema", intracranial hemorrhage (ICH), tumor-associated cerebral edema, and ischemia associated with ischemic stroke. (C) 2007 Elsevier B.V. All rights reserved.	Johns Hopkins Univ, Sch Med, Dept Neurol, Neurosci Crit Care Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Surg, Neurosci Crit Care Div, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Neurosci Crit Care Div, Baltimore, MD USA	Bhardwaj, A (corresponding author), Oregon Hlth & Sci Univ, Neurosci Crit Care Program, 3181 SW Sam Jackson Pk Rd,L-226, Portland, OR 97239 USA.	bhardwaj@ohsu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046379] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS046379] Funding Source: Medline		Angle N, 2000, SHOCK, V14, P503, DOI 10.1097/00024382-200014050-00002; Arbabi S, 1999, J SURG RES, V83, P141, DOI 10.1006/jsre.1999.5583; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bhardwaj, 1999, Curr Treat Options Neurol, V1, P179, DOI 10.1007/s11940-999-0002-z; Bhardwaj A, 2000, STROKE, V31, P1694, DOI 10.1161/01.STR.31.7.1694; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P21; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V6, P449; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Ciesla DJ, 2000, J TRAUMA, V48, P388, DOI 10.1097/00005373-200003000-00004; COTE CJ, 1979, ANESTHESIOLOGY, V50, P30, DOI 10.1097/00000542-197901000-00007; Cruz J, 2001, NEUROSURGERY, V49, P864; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Fremont-Smith F, 1927, ARCH NEURO PSYCHIATR, V18, P550, DOI 10.1001/archneurpsyc.1927.02210040057002; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; Gemma M, 1996, J NEUROSURG ANESTH, V8, P137, DOI 10.1097/00008506-199604000-00007; Hartl R, 1997, ZBL CHIR, V122, P181; Hartl R, 1997, ACT NEUR S, V70, P126; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; Himmelseher S, 2001, J NEUROSURG ANESTH, V13, P120, DOI 10.1097/00008506-200104000-00009; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912; Hughes J, 1938, ARCH NEURO PSYCHIATR, V39, P1277, DOI 10.1001/archneurpsyc.1938.02270060167009; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; JAVID M, 1961, J NEUROSURG, V18, P51, DOI 10.3171/jns.1961.18.1.0051; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; KRAUSZ MM, 1995, SHOCK, V4, P56, DOI 10.1097/00024382-199507000-00009; Krep H, 2004, RESUSCITATION, V63, P73, DOI 10.1016/j.resuscitation.2004.03.023; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Oreopoulos GD, 2000, SHOCK, V14, P409, DOI 10.1097/00024382-200014030-00029; OREOPOULOS GD, 2001, SURGERY, P57; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Phillis JW, 1999, BRAIN RES, V828, P1, DOI 10.1016/S0006-8993(99)01235-4; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2002, J NEUROSURG ANESTH, V14, P22, DOI 10.1097/00008506-200201000-00005; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RAICHLE ME, 1983, ACTA NEUROPATHOL, P75; ROPPER AH, 2003, TREATMENT INTRACRANI, P26; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Schrot RJ, 2005, CRIT CARE MED, V33, P257, DOI 10.1097/01.CCM.0000150761.07904.A4; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SCHWARZ S, 1998, STROKE, V29, P1055; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1988, SURGERY, V104, P553; SHENKIN HA, 1962, J NEUROSURG, V19, P897, DOI 10.3171/jns.1962.19.10.0897; Silva MRE, 1998, MEDICINA-BUENOS AIRE, V58, P393; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P106, DOI 10.1097/00005072-199601000-00011; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; SUZUKI J, 1985, STROKE, V16, P695, DOI 10.1161/01.STR.16.4.695; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Toung TJK, 2002, J NEUROSURG ANESTH, V14, P187, DOI 10.1097/00008506-200207000-00003; Toung TJK, 2002, CRIT CARE MED, V30, P644, DOI 10.1097/00003246-200203000-00025; TRUMBLE ER, 1995, J NEUROSURG, V82, P44, DOI 10.3171/jns.1995.82.1.0044; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V128, P1003; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Weed LH, 1919, AM J PHYSIOL, V48, P531; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; WILLERSON JT, 1975, CIRCULATION, V51, P1095, DOI 10.1161/01.CIR.51.6.1095; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Zausinger S, 2004, NEUROSURGERY, V55, P679, DOI 10.1227/01.NEU.0000134558.28977.EE; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	90	64	69	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2007	261	1-2					157	166		10.1016/j.jns.2007.04.048			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	216JO	WOS:000249874500019	17585941				2021-06-18	
J	Sperry, JL; Frankel, HL; Vanek, SL; Nathens, AB; Moore, EE; Maier, RV; Minei, JP				Sperry, Jason L.; Frankel, Heidi L.; Vanek, Sue L.; Nathens, Avery B.; Moore, Ernest E.; Maier, Ronald V.; Minei, Jospeh P.			Early hyperglycemia predicts multiple organ failure and mortality but not infection	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		early hyperglycemia; strict glycemic control; multiple organ failure; nosocomial infection	STANDARD OPERATING PROCEDURES; SCALE COLLABORATIVE PROJECT; ORIENTED RESEARCH CORE; INTENSIVE INSULIN THERAPY; CONFOUNDER SELECTION CRITERIA; CLINICAL CARE; TRAUMA PATIENTS; CRITICALLY-ILL; HOST RESPONSE; ADMISSION HYPERGLYCEMIA	Background: Previous studies attempting to characterize the association between early hyperglycemia (EH) and subsequent outcome have been performed without utilization of a strict glycemic control protocol. We sought to characterize the clinical outcomes associated with EH in a cohort of severely injured trauma patients, when a strict glycemic control protocol was used. Methods: Data were obtained from a multicenter prospective cohort study evaluating clinical outcomes in blunt injured adults with hemorrhagic shock. Known diabetics and patients with isolated traumatic brain injury were excluded from the analysis. A strict glycemic protocol (target glucose, 80-110 mg/dL) was employed. Cox proportional hazard regression was used to evaluate the effects of EH on multiple organ failure (MOF), nosocomial infection (NI), and mortality, after adjusting for the effects of early death on subsequent infection rates. Results: Overall mortality, MOF, and NI rates for the entire cohort were 19.6%, 37.5%, and 42.2%, respectively, with a mean Injury Severity Score of 31.6 +/- 14. Cox proportional hazard regression confirmed that EH was independently associated with almost a twofold higher mortality rate and a 30% higher incidence of MOF, but was not an independent risk factor for NI, after control-ling for all important confounders. There continued to be no independent association between ER and NI, even when stratified by infection type (pneumonia, catheter-related blood stream infection, or urinary tract infection). Conclusion: These results suggest that EH is a marker of severe physiologic insult after injury, and that strict glycemic control may reduce or prevent the infectious complications previously shown to be associated with hyperglycemia early after injury.	Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Crit Care, Dallas, TX 75390 USA; Univ Toronto, Dept Surg, Toronto, ON, Canada; St Michaels Hosp, Div Gen Surg & Trauma, Toronto, ON M5B 1W8, Canada; Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Div Gen Surg & Trauma, Seattle, WA 98104 USA	Minei, JP (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Crit Care, 5323 Harry Hines Blvd,Mail Stop 9158, Dallas, TX 75390 USA.	joseph.minei@utsouthwestem.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54 GM062119-1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119] Funding Source: NIH RePORTER		ANAND KJS, 1986, PROG FOOD NUTR SCI, V10, P67; Angus DC, 2005, AM J RESP CRIT CARE, V172, P1358, DOI 10.1164/rccm.2508009; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Brandt C A, 2003, AMIA Annu Symp Proc, P794; CAREY LC, 1970, ANN SURG, V172, P342, DOI 10.1097/00000658-197009000-00004; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; CHERNOW B, 1987, ARCH INTERN MED, V147, P1273, DOI 10.1001/archinte.147.7.1273; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Epstein J, 1999, CRIT CARE CLIN, V15, P17, DOI 10.1016/S0749-0704(05)70037-3; GREENLAND S, 1989, AM J EPIDEMIOL, V130, P1066, DOI 10.1093/oxfordjournals.aje.a115409; Hirsch IB, 2002, J CLIN ENDOCR METAB, V87, P975, DOI 10.1210/jc.87.3.975; Khoury W, 2004, J TRAUMA, V57, P1132, DOI 10.1097/01.TA.0000141889.31903.9C; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LINDSEY A, 1974, JAMA-J AM MED ASSOC, V227, P757, DOI 10.1001/jama.227.7.757; Maier RV, 2005, J TRAUMA, V59, P762, DOI 10.1097/01.ta.0000177656.85206.cd; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Marshall JC, 1999, EUR J SURG, V163, P62; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Minei JP, 2006, J TRAUMA, V60, P1106, DOI 10.1097/01.ta.0000220424.34835.f1; Moore FA, 2006, J TRAUMA, V61, P82, DOI 10.1097/01.ta.0000225933.08478.65; Nathens AB, 2005, J TRAUMA, V59, P764, DOI 10.1097/01.ta.0000177759.17704.35; SKILLMAN JJ, 1971, ANN SURG, V174, P911, DOI 10.1097/00000658-197112000-00006; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; West MA, 2006, J TRAUMA, V61, P436, DOI 10.1097/01.ta.0000232517.83039.c4; Whitcomb BW, 2005, CRIT CARE MED, V33, P2772, DOI 10.1097/01.CCM.0000189741.44071.25; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72	30	64	64	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					487	494		10.1097/TA.0b013e31812e51fc			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	211DA	WOS:000249503300001	18073591				2021-06-18	
J	Kurpius, D; Nolley, EP; Dailey, ME				Kurpius, Dana; Nolley, Eric P.; Dailey, Michael E.			Purines induce directed migration and rapid homing of microglia to injured pyramidal neurons in developing hippocampus	GLIA			English	Article						brain slice; ATP; time-lapse; motility; migration; CNS trauma	RAT-BRAIN; IN-VITRO; EXTRACELLULAR NUCLEOTIDES; P2Y(12) RECEPTOR; NERVOUS-SYSTEM; CELL-MIGRATION; SLICE CULTURES; GLIAL-CELLS; ACTIVATION; EXPRESSION	Traumatic CNS injury activates and mobilizes resident parenchymal microglia (MG), which rapidly accumulate near injured neurons where they transform into phagocytes. The mechanisms underlying this rapid 'homing' in situ are unknown. Using time-lapse confocal imaging in acutely excised neonatal hippocampal slices, we show that rapid accumulation of MG near somata of injured pyramidal neurons in the stratum pyramidale (SP) results from directed migration from tissue regions immediately adjacent to (< 200 mu m from) the SP. Time-lapse sequences also reveal a 'spreading activation wave' wherein MG situated progressively farther from the SP begin to migrate later and exhibit less directional migration toward the SP Because purines have been implicated in MG activation and chemotaxis, we tested whether ATP/ADP released from injured pyramidal neurons might account for these patterns of MG behavior. Indeed, application of apyrase, which degrades extracellular ATP/ADP, inhibits MG motility and homing to injured neurons in the SP Moreover, bath application of exogenous ATP/ADP disrupts MG homing by inducing directional migration toward the slice exterior and away from injured neurons. These results indicate that extracellular ATP/ADP is both necessary and sufficient to induce directional migration and rapid homing of neonatal MG to injured neurons in situ. Rapid, ATP/ADP-dependent MG homing may promote clearance of dead and dying cells and help limit secondary damage during the critical first few hours after neuronal injury. (c) 2007 Wiley-Liss, Inc.	Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA	Dailey, ME (corresponding author), Univ Iowa, Dept Biol Sci, 369 Biol Bldg, Iowa City, IA 52242 USA.	Michael-e-dailey@uiowa.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10 RR017941] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS043468, NS43468] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043468] Funding Source: NIH RePORTER		Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; Bianco F, 2005, BRAIN RES REV, V48, P144, DOI 10.1016/j.brainresrev.2004.12.004; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Boucsein C, 2003, EUR J NEUROSCI, V17, P2267, DOI 10.1046/j.1460-9568.2003.02663.x; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Carbonell WS, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-5; Carbonell WS, 2005, J NEUROSCI, V25, P7040, DOI 10.1523/JNEUROSCI.5171-04.2005; Cross AK, 1999, J NEUROSCI RES, V55, P17, DOI 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J; DAILEY ME, 2005, IMAGING NEUROSCIENCE, P1; Dalmau I, 1998, J COMP NEUROL, V398, P333, DOI 10.1002/(SICI)1096-9861(19980831)398:3<333::AID-CNE3>3.0.CO;2-0; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Duan YL, 2003, J NEUROBIOL, V57, P183, DOI 10.1002/neu.10262; DUBYAK GR, 1993, AM J PHYSIOL, V265, P577; Elkabes S, 1996, J NEUROSCI, V16, P2508; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Franklin A, 2003, EUR J PHARMACOL, V474, P195, DOI 10.1016/S0014-2999(03)02074-0; Haas S, 1996, NEUROSCIENCE, V75, P257, DOI 10.1016/0306-4522(96)00270-9; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Kim JV, 2006, J IMMUNOL, V177, P5269, DOI 10.4049/jimmunol.177.8.5269; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KURPIUS D, 2005, IMAGING NEUROSCIENCE, P425; Kurpius D, 2006, GLIA, V54, P58, DOI 10.1002/glia.20355; Maciejewski-Lenoir D, 1999, J IMMUNOL, V163, P1628; Marella M, 2004, J NEUROSCI, V24, P620, DOI 10.1523/JNEUROSCI.4303-03.2004; MCGLADEMCCULLOH E, 1989, P NATL ACAD SCI USA, V86, P1093, DOI 10.1073/pnas.86.3.1093; McLarnon JG, 2005, J NEUROSCI RES, V81, P349, DOI 10.1002/jnr.20475; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Nicholas RA, 2001, MOL PHARMACOL, V60, P416; Nolte C, 1997, EUR J NEUROSCI, V9, P1690, DOI 10.1111/j.1460-9568.1997.tb01526.x; NORENBERG W, 1994, BRIT J PHARMACOL, V111, P942; Petersen MA, 2004, GLIA, V46, P195, DOI 10.1002/glia.10362; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rappert A, 2002, J IMMUNOL, V168, P3221, DOI 10.4049/jimmunol.168.7.3221; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; Sasaki Y, 2003, GLIA, V44, P242, DOI 10.1002/glia.10293; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Walter L, 2003, J NEUROSCI, V23, P1398; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101; Xiang ZH, 2005, GLIA, V52, P119, DOI 10.1002/glia.20227; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	54	64	66	0	3	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0894-1491			GLIA	Glia	JUN	2007	55	8					873	884		10.1002/glia.20509			12	Neurosciences	Neurosciences & Neurology	164IY	WOS:000246228300009	17405148				2021-06-18	
J	Parvizi, J; Joseph, J; Press, DZ; Schmahmann, JD				Parvizi, Josef; Joseph, Jeffrey; Press, Daniel Z.; Schmahmann, Jeremy D.			Pathological laughter and crying in patients with multiple system atrophy-cerebellar type	MOVEMENT DISORDERS			English	Article						olivopontocerebellar atrophy; disinhibition; emotion; behavior; pseudobulbar affect	SPORADIC OLIVOPONTOCEREBELLAR ATROPHY; TRAUMATIC BRAIN-INJURY; PSEUDOBULBAR AFFECT; SCLEROSIS; PREVALENCE; DISORDERS; DIAGNOSIS; STROKE	In the cerebellar type of multiple system atrophy (MSA-C), the burden of pathological changes involves the cerebellum and its associated brainstem structures in the basis pontis and the inferior olivary nucleus, and as a result, the clinical phenotype is dominated early on by the cerebellar dysfunction. We report our clinical and post mortem findings in a patient with MSA-C who exhibited pathological laughter in the absence of any congruent changes of mood. A review of the clinical notes of 27 other patients with MSA-C revealed a problem with pathological laughter, or crying, or both in 9 more patients. Our finding of about 36% occurrence suggests that the problem of dysregulation of emotional expression is more prevalent in MSA-C than the paucity of reports in the literature suggests. Our findings are consistent with the view that the cerebellum and its interconnected structures may be involved in the regulation of emotional expression. (c) 2007 Movement Disorder Society.	Harvard Univ, Sch Med, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA	Parvizi, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	jparvizi@ucla.edu					ASFORA WT, 1989, J NEUROL NEUROSUR PS, V52, P523, DOI 10.1136/jnnp.52.4.523; BLACK DW, 1982, J NERV MENT DIS, V170, P67, DOI 10.1097/00005053-198202000-00001; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Feinstein A, 1999, MULT SCLER, V5, P69, DOI 10.1177/135245859900500201; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; Geser F, 2006, MOVEMENT DISORD, V21, P179, DOI 10.1002/mds.20678; Gilman S, 2000, NEUROLOGY, V55, P527, DOI 10.1212/WNL.55.4.527; Gilman S, 1999, J NEUROL SCI, V163, P94, DOI 10.1016/S0022-510X(98)00304-9; Gilman S, 1996, NEUROLOGY, V46, P1197, DOI 10.1212/WNL.46.5.1197; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Jellinger KA, 2005, MOVEMENT DISORD, V20, pS29, DOI 10.1002/mds.20537; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Oppenheim H, 1886, BERL KLI WOCH, V46; Ozawa T, 2004, BRAIN, V127, P2657, DOI 10.1093/brain/awh303; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; Parvizi J, 2006, MAYO CLIN PROC, V81, P1482, DOI 10.4065/81.11.1482; POECK K, 1985, CLIN NEUROPSYCHOLOGY, P219; POECK K, 1985, DISORDERS HIGHER NER, P343; Quinn NP, 2005, MOVEMENT DISORD, V20, pS5, DOI 10.1002/mds.20534; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; Siddiqui MS, 2006, NEUROLOGY, V66, pA369; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Wenning GK, 2004, LANCET NEUROL, V3, P93, DOI 10.1016/S1474-4422(03)00662-8; Wild B, 2003, BRAIN, V126, P2121, DOI 10.1093/brain/awg226; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160	30	64	66	0	7	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0885-3185			MOVEMENT DISORD	Mov. Disord.	APR 30	2007	22	6					798	803		10.1002/mds.21348			6	Clinical Neurology	Neurosciences & Neurology	163KQ	WOS:000246159000006	17290465				2021-06-18	
J	Shimono, H; Okada, M; Kanda, E; Arakawa, I				Shimono, Hiroyuki; Okada, Masumi; Kanda, Eiji; Arakawa, Ichiro			Low temperature-induced sterility in rice: Evidence for the effects of temperature before panicle initiation	FIELD CROPS RESEARCH			English	Article						cool damage; panicle development; simulation model; spikelet sterility; rice	YOUNG MICROSPORE STAGE; SPIKELET STERILITY; WATER TEMPERATURE; COOLING TREATMENT; INJURY; PLANTS; TOLERANCE; RESPONSES; GROWTH; YIELD	Spikelet sterility of rice (Oryza sativa L.) results from low temperatures during particle development. However, this temperature alone cannot fully explain the fluctuations in sterility observed in the field, since the susceptibility of rice plants to low temperature often changes according to its physiological status during sensitive stages. In the present study, we examined whether temperatures before the particle initiation stage (PI) influence the plant's susceptibility to sterility during panicle development. To test this, we conducted a 2-year pot study and an analysis of field data using a model of cooling degree-days (CDD). In the pot study, the air temperature (T-a) and water temperature (T-w) were controlled independently for 3 weeks during the vegetative growth stage before PI. After PI, the plants were submerged in a cool water bath at a critical temperature of 19.5 degrees C to induce floral sterility. We found that low T-w during vegetative growth significantly increased the sterility. Low T-a during vegetative growth also significantly increased the sterility, but this effect was diminished by warm T-w even at low T-a. There was a close and negative correlation between sterility and T-w during vegetative growth. In the analysis of field data, we introduced CDD using temperatures below a threshold level of 20 degrees C to represent the magnitude of the exposure to low temperature from PI to the heading stage. Data of T-a was used for this analysis because data of T-w was scare. The CDD model was applied to 77 independent data sets collected at nine Agricultural Research Centers during four typical cool summers (1980, 1988, 1993, and 2003) in northern Japan. Year-to-year variations in sterility at one site were roughly accounted for by the variations in CDD, but large deviations were observed among the years. The deviations were related to T-a averaged over the 30-day period before PI. For a similar level of CDD, the lower the T-a before PI, the greater the sterility. Similar deviations were observed in the between-site relationships between sterility and CDD, and these deviations were related with the T-a before PI. These results suggest that temperatures before PI, and especially T-w change the susceptibility of a rice plant to low temperatures during panicle development. (c) 2006 Elsevier B.V. All rights reserved.	Natl Agr Res Ctr, Shimokuriyagawa, Iwate 0200198, Japan; Fukushima Agr Technol Ctr, Fukushima 9696506, Japan	Shimono, H (corresponding author), USDA ARS, Beltsville Agr Res Ctr, Crop Syst & Global Change Lab, 10300 Baltimore Ave, Beltsville, MD 20705 USA.	shimn@affrc.go.jp		Shimono, Hiroyuki/0000-0002-7328-0483	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [05J02945] Funding Source: KAKEN		AMANO T, 1984, JPN J CROP SCI, V53, P7, DOI 10.1626/jcs.53.7; AMANO T, 1984, JPN J CROP SCI, V53; BOARD JE, 1980, AGRON J, V72, P483, DOI 10.2134/agronj1980.00021962007200030019x; COLLINSON ST, 1995, EXP AGR, V31, P151, DOI 10.1017/S0014479700025230; DINGKUHN M, 1995, AGR SYST, V48, P385, DOI 10.1016/0308-521X(94)00027-I; Farrell TC, 2006, FIELD CROP RES, V98, P178, DOI 10.1016/j.fcr.2006.01.003; GODWIN DC, 1994, AUST J EXP AGR, V34, P921, DOI 10.1071/EA9940921; Gunawardena TA, 2003, AUST J AGR RES, V54, P947, DOI 10.1071/AR03076; HAYASE H, 1969, P CROP SCI SOC JPN, V38, P706, DOI DOI 10.1626/JCS.38.706; IRRI (International Rice Research Institute), 2002, RIC ALM SOURC BOOK M; Ito N., 1976, Proceedings of the Crop Science Society of Japan, V45, P558; Kanda E, 2000, JPN J CROP SCI, V69, P540, DOI 10.1626/jcs.69.540; Kaneda C., 1974, SABRAO Journal, V6, P17; KONDO Y, 1952, B NATL I AGR SCI D, V3, P114; MATSUZAKI A, 1971, P CROP SCI SOC JPN, V40, P519; Nagano K., 1999, BREED RES, V1, P33; NAKAGAWA H, 1995, JPN J CROP SCI, V64, P33, DOI 10.1626/jcs.64.33; Okada M., 2000, Biotronics, V29, P43; Okada M., 2005, J AGROMETEOROL, V60, P589; OZAWA K, 1994, SOL ENERGY, V20, P23; Sameshima Ryoji, 2004, Journal of Agricultural Meteorology, V60, P67, DOI 10.2480/agrmet.60.67; SATAKE T, 1987, JPN J CROP SCI, V56, P404; SATAKE T, 1988, JPN J CROP SCI, V57, P234, DOI 10.1626/jcs.57.234; Satake T., 1976, RES B HOKKAIDO NATL, V113; SHIMAZAKI Y., 1963, Research Bulletin. Hokkaido National Agricultural Experiment Station, V80, P1; Shimono H, 2005, AGRON J, V97, P1524, DOI 10.2134/agronj2005.0043; Shimono H, 2002, FIELD CROP RES, V73, P67, DOI 10.1016/S0378-4290(01)00184-8; Shimono H, 2004, FIELD CROP RES, V89, P71, DOI 10.1016/j.fcr.2004.01.025; Shimono H, 2007, AGR ECOSYST ENVIRON, V118, P223, DOI 10.1016/j.agee.2006.05.015; Uchijima T, 1976, J AGROMETEOROL, V31, P199, DOI DOI 10.2480/AGRMET.31.199; Wada S., 1972, Proceedings of the Crop Science Society of Japan (Nihon Sakumotsugakki Kiji), V41, P340; Yajima M., 1989, ANN M AGR MET SOC JA, P58; YAMAMOTO T, 1986, JPN J BREED, V36, P147; Zhang ZJ, 2001, JPN J CROP SCI, V70, P84, DOI 10.1626/jcs.70.84	34	64	79	2	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-4290	1872-6852		FIELD CROP RES	Field Crop. Res.	MAR 5	2007	101	2					221	231		10.1016/j.fcr.2006.11.010			11	Agronomy	Agriculture	135KY	WOS:000244153700010					2021-06-18	
J	Lifshitz, J; Kelley, BJ; Povlishock, JT				Lifshitz, Jonathan; Kelley, Brian Joseph; Povlishock, John Theodore			Perisomatic thalamic Axotomy after diffuse traumatic brain injury is associated with atrophy rather than cell death	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						disector; fractionator; head injury; nucleator; stereology; thalamus; traumatic brain injury	FLUID PERCUSSION INJURY; AXONAL INJURY; TOTAL NUMBER; NEURONS; DAMAGE; RESPONSES; CORTEX; FRACTIONATOR; HIPPOCAMPUS; ACTIVATION	Morbidity and mortality associated with traumatic brain injury (TBI) stem from diffuse axonal injury (DAI) throughout subcortical and brainstem white matter and subcortical nuclei. After midline fluid percussion brain injury, DAI in the thalamus includes perisomatic axotomy and resembles human post-traumatic pathology where the degree of morbidity correlates with thalamic damage. After axotomy, acute somatic perturbations resolve and appear compatible with cell survival; however, the long-term fate of neurons in an area with perisomatic axotomy is unknown. From brain-injured and uninjured rats at 1, 7 and 28 days after injury (injury, n = 5/group; sham, n =.4), alternate sections were immunostained for amyloid precursor protein (APP) to detect perisomatic axotomy or Giemsa stained for quantification of neuronal number, neuronal density, regional volume, and neuronal nuclear volume using design-based stercology. One day postinjury, APP-immunoreactive axons were identified consistently within the perisomatic domains of thalamic neurons of the ventral basal complex. Bilateral systematic-random quantification of the ventral basal complex indicated a significant reduction in neuronal density (number per mm 3, but not number alone) at 1 week after injury, compared with sham and 1 day postinjury. Furthermore, by I day and persisting through I week after injury, the mean neuronal nuclear volume was atrophied significantly compared with sham. Therefore, diffuse TBI results in early perisomatic axonal injury followed by neuronal atrophy in the ventral basal complex, without gross degeneration. Enduring atrophy in thalamic relays could underlie circuit disruption responsible for post-traumatic morbidity.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Hlth Syst, Richmond, VA USA	Lifshitz, J (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA.	jlifshitz@uky.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045824, R01NS020193, P30NS047463] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD049343, F32-HD049343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS020193, 5P30-NS047463, R01-NS045824] Funding Source: Medline		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Ahmed FAKM, 2001, EXP NEUROL, V167, P451, DOI 10.1006/exnr.2000.7562; Andersen BB, 2004, BRAIN RES, V1007, P10, DOI 10.1016/j.brainres.2004.01.058; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; BARRON KD, 1983, SPINAL CORD RECONSTR, P7; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bothwell S, 2001, J NEUROSCI, V21, P4789, DOI 10.1523/JNEUROSCI.21-13-04789.2001; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; EMERY DG, 1987, EXP BRAIN RES, V67, P41, DOI 10.1007/BF00269451; EMERY DG, 1991, EXP BRAIN RES, V86, P60; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1988, J MICROSC-OXFORD, V151, P3, DOI 10.1111/j.1365-2818.1988.tb04609.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley B, 2006, J NEUROTRAUM, V23, P1031; Kreutzberg Georg W., 1995, P355; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; LAND PW, 1995, J COMP NEUROL, V355, P573, DOI 10.1002/cne.903550407; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; NYENGAARD JR, 1992, J MICROSC-OXFORD, V165, P427, DOI 10.1111/j.1365-2818.1992.tb01497.x; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PETERSON DA, 1994, J NEUROSCI, V14, P6872; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Price Joseph L., 1995, P629; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Sa MJ, 2000, ACTA NEUROPATHOL, V99, P643, DOI 10.1007/s004010051175; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOFRONIEW MV, 1993, J NEUROSCI, V13, P5263; Stamatakis EA, 2002, J NUCL MED, V43, P476; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Waite Phil M. E., 1995, P705; West MJ, 1998, HIPPOCAMPUS, V8, P69; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	73	64	64	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2007	66	3					218	229		10.1097/01.jnen.0000248558.75950.4d			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	173DB	WOS:000246852600006	17356383	Bronze			2021-06-18	
J	Guilmette, TJ; Malia, LA; Mcquiggan, MD				Guilmette, Thomas J.; Malia, Laurie A.; Mcquiggan, Michael D.			Concussion understanding and management among New England high school football coaches	BRAIN INJURY			English	Article						concussion; football; football coaches	TRAUMATIC BRAIN-INJURY; MISCONCEPTIONS	Primary objective: To determine high school football coaches' understanding, management and sources of information of concussion at schools without a certified athletic trainer (ATC) or without one at practice. Research design: Anonymous survey of head football coaches at New England high schools. Methods and procedures: Surveys were mailed to 254 New England high school head football coaches. One hundred and nine ( 43%) surveys were returned, of which 62 respondents indicated there was no ATC either at the school or at practice. These 62 respondents were used for data analysis. Main outcomes and results: Coaching associations and conferences were the two most common sources of information received about concussion. Coaches were significantly more knowledgeable about concussion than a general public sample, from which data were available from a prior study. When given potential symptoms of concussion, 70 - 95% of coaches reported that they would consult a healthcare professional before allowing a player to return to action, consistent with most return-to-play guidelines. Conclusions: Participants demonstrated greater knowledge about concussions than the general public and most, but not all, coaches reported taking a conservative approach to concussion management. Ramifications of the results are discussed.	Providence Coll, Dept Psychol, Providence, RI 02918 USA; Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA; So New England Rehabil Ctr, Providence, RI USA	Guilmette, TJ (corresponding author), Providence Coll, Dept Psychol, Providence, RI 02918 USA.	tguilmet@providence.edu					BELL K, 2006, INTERNET J HLTH; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carek P J, 1999, J S C Med Assoc, V95, P420; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Macciocchi S, 2006, SPORTS NEUROPSYCHOLO, P71; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McKeag DB, 2003, JAMA-J AM MED ASSOC, V290, P2604, DOI 10.1001/jama.290.19.2604; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; *NAT FED STAT HIGH, GUID MAN HEAD TRAUM; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Tonino PM, 2004, PHYSICIAN SPORTSMED, V32, P37, DOI 10.3810/psm.2004.02.123; *US DEP HHS CDCP, 2005, 0998262 US DEP HHS C; VANGSNESS C, 1994, AM J SPORT MED, V22, P719, DOI 10.1177/036354659402200524; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	23	64	64	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	10					1039	1047		10.1080/02699050701633080			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600006	17891566				2021-06-18	
J	Rivera, P; Elliott, TR; Berry, JW; Grant, JS; Oswald, K				Rivera, Patricia; Elliott, Timothy R.; Berry, Jack W.; Grant, Joan S.; Oswald, Kimberly			Predictors of caregiver depression among community-residing families living with traumatic brain injury	NEUROREHABILITATION			English	Article						caregivers; depression; traumatic brain injury	PROBLEM-SOLVING ABILITIES; PHYSICAL HEALTH; STROKE SURVIVORS; SOCIAL SUPPORT; ADJUSTMENT; DISTRESS; THERAPY; RISK	Objective: To test the hypothesis that ineffective problem-solving abilities would be significantly predictive of risk for depression in caregivers of persons with traumatic brain injury (TBI) after controlling for caregiver burden, caregiver health and demographic characteristics. Design: Correlational and logistic regression analyses of cross-sectional data. Participants: 57 women and 3 men (M age of caregivers=51.4, SD=10.1) caring for a relative with a TBI. Main outcome measure: Centers for Epidemiologic Studies - Depression scale (CES-D). Results: Twenty-nine caregivers (48.3%) had CES-D scores that met the criteria for risk of depression. An ineffective approach to problem solving, characterized by negative, avoidant, and careless/impulsive styles, and self-reported caregiver physical symptoms were significantly predictive of caregiver depression regardless of length of time caregiving, perceived burden, or demographic variables. Conclusions: Caregivers of persons with TBI who report physical health problems and who exhibit ineffective problem solving area at greater risk for depression, regardless of the time they have spent in their role as a caregiver.	Univ Alabama Birmingham, Injury Control Res Ctr, Dept Med Immunol Rheumatol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; Texas A&M Univ, College Stn, TX USA	Rivera, P (corresponding author), Univ Alabama Birmingham, Injury Control Res Ctr, Dept Med Immunol Rheumatol, CH19-401,1530 3rd Ave S, Birmingham, AL 35294 USA.	rivera@uab.edu	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714; Grant, Joan/0000-0001-6000-4060	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR412718-01, R49/CCR403641] Funding Source: Medline		Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Carey P J, 1991, Oncol Nurs Forum, V18, P1341; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Dzurilla T.J., 2004, SOCIAL PROBLEM SOLVI, P11, DOI DOI 10.1037/10805-001; DZurilla T. J., 2002, SOCIAL PROBLEM SOLVI; Elliott T, 2004, SOCIAL PROBLEM SOLVI, P117, DOI DOI 10.1037/10805-007; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Elliott TR, 2000, HDB HOPE THEORY MEAS, P373; ERGH T, PREDICTORS CAREGIVER; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grant JS, 2004, REHABIL PSYCHOL, V49, P172, DOI 10.1037/0090-5550.49.2.172; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HOOKER K, 1992, PSYCHOL AGING, V7, P367, DOI 10.1037/0882-7974.7.3.367; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Livingston MG., 1990, REHABILITATION ADULT, P225; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; Nezu AM, 2004, BEHAV THER, V35, P1, DOI 10.1016/S0005-7894(04)80002-9; Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036; NEZU AM, 1989, J CONSULT CLIN PSYCH, V57, P408, DOI 10.1037/0022-006X.57.3.408; Pennebaker J.W., 1982, PSYCHOL PHYS SYMPTOM; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Shewchuk RM, 1998, HEALTH PSYCHOL, V17, P125, DOI 10.1037/0278-6133.17.2.125; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062	36	64	64	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	1					3	8					6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600002	17379944				2021-06-18	
J	Browne, KD; Iwata, A; Putt, ME; Smith, DH				Browne, Kevin D.; Iwata, Akira; Putt, M. E.; Smith, Douglas H.			Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						ibuprofen; NSAIDs; cognitive function; traumatic brain injury; COX inhibition	ALZHEIMERS-DISEASE; HEAD-INJURY; CYCLOOXYGENASE INHIBITION; PROGRESSIVE ATROPHY; NEURONAL INJURY; PATHOLOGY; INFLAMMATION; ISCHEMIA; RISK; DEFICITS	Traumatic brain injury (TBI) can induce progressive neurodegeneration in association with chronic inflammation. Since chronic treatment with the non-steroidal anti-inflammatory drug (NSAID), ibuprofen, improves functional and histopathologic outcome in a mouse model of Alzheimer's disease (AD), we investigated whether it would also improve long-term outcome following TBI. Anesthetized adult rats were subjected to fluid percussion brain injury. Over the following 4 months the injured animals received ibuprofen per os (formulated in feed) at the approximate doses of 20 mg/kg body wt/day (it = 13), 40 mg/kg body wt/day (n = 13), or control (feed only, n = 12). Sham animals underwent surgery without injury or ibuprofen treatment (n = 9). At 4 months post-injury, a Morris water maze task revealed a profound learning dysfunction in all three injured groups compared to the sham group. Surprisingly, the learning ability of injured animals treated with either chronic ibuprofen regimen was significantly worsened compared to non-treated injured animals. However, there was no difference in the extent of progressive atrophy of the cortex or hippocampus between treated and non-treated injured animals. These data may have important implications for TBI patients who are often prescribed NSAIDs for chronic pain. (c) 2006 Elsevier Inc. All rights reserved.	Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; Univ Penn, Dept Biostat & Clin Epidemiol, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	kbrowne@mail.med.upenn.edu; iwata-nsu@umin.ac.jp; mputt@cceb.upenn.edu; smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS038104, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD026979-16] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline		Antezana DF, 2003, J NEUROSURG, V98, P860, DOI 10.3171/jns.2003.98.4.0860; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Browne KD, 2004, J NEUROSCI RES, V77, P878, DOI 10.1002/jnr.20215; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; COLE DJ, 1993, J PHARMACOL EXP THER, V266, P1713; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Etminan M, 2003, BMJ-BRIT MED J, V327, P128, DOI 10.1136/bmj.327.7407.128; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Holscher C, 1995, EUR J PHARMACOL, V294, P253, DOI 10.1016/0014-2999(95)00541-2; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; Lim GP, 2000, J NEUROSCI, V20, P5709; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morihara T, 2005, NEUROPSYCHOPHARMACOL, V30, P1111, DOI 10.1038/sj.npp.1300668; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Park EM, 2005, NEUROSCIENCE, V132, P625, DOI 10.1016/j.neuroscience.2005.01.021; PATEL PM, 1993, BRAIN RES, V614, P315, DOI 10.1016/0006-8993(93)91050-3; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Richardson RL, 2005, BEHAV PHARMACOL, V16, P531, DOI 10.1097/01.fbp.0000179278.03868.96; Richardson RL, 2002, BRAIN RES, V954, P1, DOI 10.1016/S0006-8993(02)03006-8; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shaw KN, 2005, BRAIN RES, V1038, P231, DOI 10.1016/j.brainres.2005.01.035; Shaw KN, 2003, EUR J NEUROSCI, V17, P2438, DOI 10.1046/j.1460-9568.2003.02643.x; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Teather LA, 2002, LEARN MEMORY, V9, P41, DOI 10.1101/lm.43602; Therneau TM, 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev; Veld BAIT, 2002, EPIDEMIOL REV, V24, P248, DOI 10.1093/epirev/mxf001	48	64	67	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2006	201	2					301	307		10.1016/j.expneurol.2006.04.008			7	Neurosciences	Neurosciences & Neurology	096RG	WOS:000241393900004	16764859				2021-06-18	
J	Wang, MC; Linnau, KF; Tirschwell, DL; Hollingworth, W				Wang, Marjorie C.; Linnau, Ken F.; Tirschwell, David L.; Hollingworth, William			Utility of repeat head computed tomography after blunt head trauma: A systematic review	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress of Neurological Surgeons Cerebrovascular Section/American-Society-of-Interventional-and-Therapeutic-Neuroradiology	APR 16-21, 2005	New Orleans, LA	Amer Assoc Neurol Surg		repeat head CT; systematic review	PROGRESSIVE BRAIN INJURY; SUBARACHNOID HEMORRHAGE; EXTRADURAL HEMATOMA; IONIZING-RADIATION; PEDIATRIC CT; CANCER-RISKS; FOLLOW-UP; MANAGEMENT; MODERATE; CHILDREN	Background: Repeat head computed tomography (CT) is standard practice for head-injured patients at many trauma centers. Utilization of CT has increased over time, yet effects on outcome and associated risks are unknown. We systematically reviewed the literature to determine the incidence of progression of injury on repeat CT and resulting treatment changes. Methods: Studies were included from Medline, Embase, and a hand search of citations in reviewed articles. Main outcome measures were progression of injury on repeat CT and resulting intervention. Data were abstracted from 30 eligible studies and discrepancies were settled by consensus. Results: Progression of injury on repeat CT was evident in 8 to 67% of patients in the included studies. Neurosurgical intervention resulting subsequent to a repeat CT occurred in 0 to 54% of patients. More severe traumatic brain injury, defined by Glasgow Coma Scale, was associated with a higher proportion of patients with progression of injury on CT and subsequent neurosurgical interventions. Risk factors associated with progression of injury on CT or resulting intervention were inconsistently reported, but coagulopathy and injury severity were most commonly reported. Few studies reported changes in nonsurgical management, in-hospital disposition, or adverse events associated with obtaining repeat CTs. Conclusion:. Indications for repeat head CT after traumatic brain injury are unclear. The wide range of reported injury progression on CT and resulting surgical and medical treatment changes suggest there may be a subset of patients who benefit from repeat CT. Further research should stratify by severity of traumatic brain injury, clearly define inclusion and exclusion criteria, address selection bias, quantify progression of injury on CT, determine factors predictive of injury progression and intervention, and assess risks associated with repeat CT.	Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; Univ Washington, Harborview Med Ctr, Dept Radiol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Neurol, Seattle, WA 98104 USA	Wang, MC (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	mcwang@u.washington.edu		Tirschwell, David/0000-0002-8059-2901; Hollingworth, William/0000-0002-0840-6254			BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Etzel RA, 1998, PEDIATRICS, V101, P717; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; FRENCH BN, 1977, SURG NEUROL, V7, P171; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Glasziou P., 2001, SYSTEMATIC REV HLTH; Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; HUNEIDI AHS, 1992, ANN ROY COLL SURG, V74, P345; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LUND E, 1982, NEURORADIOLOGY, V22, P181, DOI 10.1007/BF00341246; MACPHERSON P, 1990, CLIN RADIOL, V42, P85, DOI 10.1016/S0009-9260(05)82072-0; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Mettler Fred A. Jr., 2000, Journal of Radiological Protection, V20, P353, DOI 10.1088/0952-4746/20/4/301; Muszynski CA, 1999, NEURORADIOLOGY, V41, P875, DOI 10.1007/s002340050859; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Stearley H E, 1998, Am J Crit Care, V7, P282; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Subramanian SK, 2002, NEUROL RES, V24, P125, DOI 10.1179/016164102101199657; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; *US COCHR CTR, 2005, COCHR CENTR REG CONT; *US COCHR CTR, 2004, COCHR CENTR REG SYST; Vano E, 1998, BRIT J RADIOL, V71, P728, DOI 10.1259/bjr.71.847.9771383; Zahari M., 1996, Singapore Medical Journal, V37, P285; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	48	64	64	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2006	61	1					226	233		10.1097/01.ta.0000197385.18452.89			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	065TV	WOS:000239183600051	16832279				2021-06-18	
J	Giza, CC; Maria, NS; Hovda, DA				Giza, Christopher C.; Santa Maria, Naomi S.; Hovda, David A.			N-methyl-D-aspartate receptor subunit changes after traumatic injury to the developing brain	JOURNAL OF NEUROTRAUMA			English	Article						glutamate; immature; pediatric; plasticity; synapse; synaptoneurosomes; traumatic brain injury	FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; DEVELOPMENTAL LEAD-EXPOSURE; RAT HIPPOCAMPAL SLICES; MORRIS WATER MAZE; NMDA RECEPTORS; ADULT-RAT; GLUCOSE-UTILIZATION; SYNAPTIC CURRENTS; VISUAL-CORTEX	Traumatic brain injury (TBI) is a major cause of disability in the pediatric population and can result in abnormal development. Experimental studies conducted in animals have revealed impaired plasticity following developmental TBI, even in the absence of significant anatomical damage. The N-methyl-D-aspartate receptor (NMDAR) is clearly involved in both normal development and in the pathophysiology of TBI. Following lateral fluid percussion injury in postnatal day (PND) 19 rats, we tested the hypothesis that TBI sustained at an early age would result in impaired NMDAR expression. Using immunoblotting and reverse transcriptase-polymerase chain reaction (RT-PCR), protein and RNA levels of NMDAR subunits were measured in the cerebral cortex and hippocampus on post-injury days (PID) 1, 2, 4, and 7 (though the PID7 analysis was only for protein) and compared with age-matched shams. Significant effects of hemisphere (analysis of variance [ANOVA], p < 0.01), and interactions between hemisphere and injury (ANOVA,p < 0.05) and hemisphere and PID (ANOVA, p < 0.05) were found for synaptic protein levels of the NR2A subunit in hippocampus. Specifically, within the ipsilateral hippocampus, NR2A was reduced by 9.9%, 47.9%, 40.8%, and 6.3% on PID1, PID2, PID4, and PID7, respectively. Within the cortex, there was a significant effect of injury (ANOVA,p < 0.05) without any hemispheric differences. These bilateral cortical reductions measured 30.5%, 3.2%, 5.7%, and 13.4% at the same timepoints after injury. Injury had no significant main effect on NR1 or NR2B protein levels. RT-PCR analysis showed no significant changes in NR1, NR2A, or NR2B gene expression; however, as a positive control, hsp70 was induced more than twofold in ipsilateral cortex and hippocampus on PID1. It is known that NR2A expression levels increase during normal development, and in response to environmental stimuli. Our data suggest that injury-induced reduction in the expression of NR2A is one likely mechanism for the impaired experience-dependent neuroplasticity seen following traumatic injury to the immature brain.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurol, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA	Giza, CC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Room 18-218B NPI,Mail Code 703919, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu		Sta Maria, Naomi/0000-0001-9710-2908	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, K08NS002197] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS02197, R01 NS027544, K08 NS002197-02, K08 NS002197, NS27544, K08 NS002197-03, K08 NS002197-01A1, K08 NS002197-04, K08 NS002197-05] Funding Source: Medline		Bellinger FP, 2002, SYNAPSE, V43, P95, DOI 10.1002/syn.10020; Berggren KN, 2002, PROTEOMICS, V2, P486, DOI 10.1002/1615-9861(200205)2:5<486::AID-PROT486>3.0.CO;2-X; *BIORAD, 2005, INSTR MAN DISC SER Q; *BIORAD, INSTR MAN SYPR RUB P; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Conti AC, 1998, J NEUROSCI, V18, P5663; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Flint AC, 1997, J NEUROSCI, V17, P2469; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GORTER JA, 1992, BRAIN RES, V572, P176, DOI 10.1016/0006-8993(92)90467-N; Gottmann K, 1997, J NEUROSCI, V17, P2766; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hughes PD, 1998, ALCOHOL CLIN EXP RES, V22, P1255, DOI 10.1097/00000374-199809000-00010; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; JABLONSKA B, 1995, BEHAV BRAIN RES, V66, P207, DOI 10.1016/0166-4328(94)00141-2; Jett DA, 1997, PHARMACOL BIOCHEM BE, V57, P271, DOI 10.1016/S0091-3057(96)00350-4; Johnson MW, 1997, J NEUROSCI METH, V77, P151, DOI 10.1016/S0165-0270(97)00120-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kew JNC, 1998, J NEUROSCI, V18, P1935; Kind PC, 2001, TRENDS NEUROSCI, V24, P553, DOI 10.1016/S0166-2236(00)01921-4; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; Kuhlmann AC, 1997, NEUROSCI LETT, V233, P101, DOI 10.1016/S0304-3940(97)00633-2; Lavezzari G, 2004, J NEUROSCI, V24, P6383, DOI 10.1523/JNEUROSCI.1890-04.2004; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Liu D, 2000, NAT NEUROSCI, V3, P799; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Max JE, 1997, BRAIN INJURY, V11, P699; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Nihei MK, 1999, MOL BRAIN RES, V66, P42, DOI 10.1016/S0169-328X(99)00005-4; Perez-Otano I, 2005, TRENDS NEUROSCI, V28, P229, DOI 10.1016/j.tins.2005.03.004; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Quinlan EM, 1999, P NATL ACAD SCI USA, V96, P12876, DOI 10.1073/pnas.96.22.12876; Quinlan EM, 1999, NAT NEUROSCI, V2, P352; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Roberts EB, 1999, J NEUROPHYSIOL, V81, P2587; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; SCHEETZ AJ, 1994, FASEB J, V8, P745; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Small DL, 1997, NEUROSCI LETT, V232, P87, DOI 10.1016/S0304-3940(97)00592-2; Takahashi T, 1996, J NEUROSCI, V16, P4376; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Weiner H. L., 2000, HEAD INJURY, P419; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	60	64	71	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2006	23	6					950	961		10.1089/neu.2006.23.950			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	056TW	WOS:000238549000011	16774479	Green Accepted			2021-06-18	
J	Herrmann, BL; Rehder, J; Kahlke, S; Wiedemayer, H; Doerfler, A; Ischebeck, W; Laumer, R; Forsting, M; Stolke, D; Mann, K				Herrmann, B. L.; Rehder, J.; Kahlke, S.; Wiedemayer, H.; Doerfler, A.; Ischebeck, W.; Laumer, R.; Forsting, M.; Stolke, D.; Mann, K.			Hypopituitarism following severe traumatic brain injury	EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES			English	Article						severe traumatic brain injury; hypopituitarism	GROWTH-HORMONE; PITUITARY DYSFUNCTION; POSTTRAUMATIC HYPOPITUITARISM; NEUROENDOCRINE DYSFUNCTION; TSH RESPONSE; REHABILITATION; INVOLVEMENT; DEFICIENCY; METABOLISM; GLUCOSE	Although hypopituitarism is a known complication of traumatic head injury, it may be under-recognized due to its subtle clinical manifestations. To address this issue, we determine the prevalence of neuroendocrine abnormalities in patients rehabilitating from severe traumatic brain injury (Glasgow Coma Scale <= 8). 76 patients (mean age 39 +/- 14 yr; range 18-65; 53 males and 23 females; BMI 25.8 +/- 4.2 kg/m(2); mean +/- SD) with a severe traumatic brain injury, an average of 22 10 months before this study (median, 20 months), underwent a series of standard endocrine tests, including TSH, free T4, T4, T3, prolactin, testosterone (males), estradiol (females), cortisol, ACTH, GH, and IGF-I. All subjects also underwent GH response to GHRH + arginine. Growth hormone deficiency (GHD) was defined as a GH response < 9 mu g/L to GHRH + arginine and was confirmed by ITT (< 3 mu g/L). Pituitary deficiency was shown in 24 % of the patients (18/76). 8 % (n = 6) had GHD (GH-peak range [GHRH + arginine]: 2.8 - 6.3 mu g/L; GH-peak range [ITT]: 1.5 - 2.2 mu g/L; IGF-I range: 62 - 174 mu g/L). 17 % (n = 13) had hypogonadism (total testosterone < 9.5 nmol/L and low gonadotropins in 12 males; low estradiol, and low gonadotropins in 1 female). Total testosterone levels did not correlate with BMI or age. 2 males with hypogonadism also showed a mild hyperprolactinemia (33 and 41 ng/ml). 3 % (n = 2) patients had partial ACTH-deficiency (cortisol-peak [ITT] 392 and 417 nmol/L) and 3 % (n = 2) had TSH-deficiency. In summary, we have found hypopituitarism in one-fourth of patients with predominantly secondary hypogonadism and GHD. These findings strongly suggest that patients who suffer head trauma must routinely include neuroendocrine evaluations.	Technol Ctr Bochum, Inst Cardiodiabet, D-44799 Bochum, Germany; Univ Hosp Essen, Dept Endocrinol, Essen, Germany; Univ Hosp Essen, Dept Neurosurg, Essen, Germany; Univ Hosp Essen, Dept Neuroradiol, Essen, Germany; Univ Witten Herdecke, Clin Neurosurg Rehabil, D-5810 Witten, Germany; Univ Essen Gesamthsch, Dept Neurosurg, Alfried Krupp Clin, Essen, Germany	Herrmann, BL (corresponding author), Technol Ctr Bochum, Inst Cardiodiabet, Univ Str 142, D-44799 Bochum, Germany.	herrmann@kardio-diabetes.biz	Forsting, Michael/C-6925-2013				Abs R, 2003, EUR J ENDOCRINOL, V148, pS3, DOI 10.1530/eje.0.148S003; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BENGTSSON BA, 1990, HORM RES, V33, P19, DOI 10.1159/000181579; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Coiro V, 2000, J INVEST MED, V48, P133; EDWARDS OM, 1986, MEDICINE, V65, P281; Goni MJ, 1997, METABOLISM, V46, P1305, DOI 10.1016/S0026-0495(97)90235-3; Herrmann BL, 2004, HORM METAB RES, V36, P54, DOI 10.1055/s-2004-814199; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P727, DOI 10.1210/jc.82.3.727; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MULLER EE, 1987, PHYSIOL REV, V67, P962; Radetti G, 2000, J ENDOCRINOL INVEST, V23, P744, DOI 10.1007/BF03345064; Rees P, 2001, LANCET, V358, P1812, DOI 10.1016/S0140-6736(01)06814-3; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; Seidell JC, 2000, EUR J CLIN NUTR, V54, pS33, DOI 10.1038/sj.ejcn.1601023; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; Webster JB, 1997, ARCH PHYS MED REHAB, V78, P314, DOI 10.1016/S0003-9993(97)90040-X	30	64	65	0	4	JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH	STUTTGART	RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY	0947-7349	1439-3646		EXP CLIN ENDOCR DIAB	Exp. Clin. Endocrinol. Diabet.	JUN	2006	114	6					316	321		10.1055/s-2006-924254			6	Endocrinology & Metabolism	Endocrinology & Metabolism	068GA	WOS:000239359500006	16868891				2021-06-18	
J	Dubreuil, CI; Marklund, N; Deschamps, K; McIntosh, TK; McKerracher, L				Dubreuil, CI; Marklund, N; Deschamps, K; McIntosh, TK; McKerracher, L			Activation of Rho after traumatic brain injury and seizure in rats	EXPERIMENTAL NEUROLOGY			English	Article						Rho; TBI; kainic acid; seisure; cortex; hippocampus	FLUID-PERCUSSION INJURY; RECEPTOR FAMILY-MEMBER; CORTICAL IMPACT INJURY; NECROSIS-FACTOR-ALPHA; NEURONAL DEATH; CELL-DEATH; NEUTROPHIL INFILTRATION; HIPPOCAMPAL-NEURONS; AXONAL REGENERATION; ACTIN CYTOSKELETON	Traumatic brain injury (TBI) is characterized by a progressive cell loss and a lack of axonal regeneration. In the central nervous system (CNS), the Rho signaling pathway regulates the neuronal response to growth inhibitory proteins and regeneration of damaged axons, and Rho activation is also correlated with an increased susceptibility to apoptosis. To evaluate whether traumatic brain injury (TBI) results in changes in Rho activation in vulnerable regions of the brain, GTP-RhoA pull down assays were performed on rat cortical and hippocampal tissue homogenates obtained from 24 h to 3 days following lateral fluid percussion brain injury (FPI). Following FPI, a significantly increased RhoA activation was observed from 24 h to 3 days post-injury in the cortex and by 3 days in the hippocampus ipsilateral to the injury. We also detected activated RhoA in the cortex and hippocampus contralateral to the injury, without concomitant changes in total RhoA levels. To determine if immediate post-traumatic events such as seizures may activate Rho, we examined RhoA activation in the brains of rats with kainic acid-induced seizures. Severe seizures resulted in bilateral RhoA activation in the cortex and hippocampus. Together, these results indicate that RhoA is activated in vulnerable brain regions following traumatic and epileptic insults to the CNS. (C) 2005 Elsevier Inc. All rights reserved.	Univ Montreal, Fac Med, Dept Pathol & Biol Cellulaire, Montreal, PQ H3T 1J4, Canada; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Pittsburgh, PA 15261 USA	McKerracher, L (corresponding author), Univ Montreal, Fac Med, Dept Pathol & Biol Cellulaire, 2900 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	c.dubreuil@umontreal.ca; niklas.marklund@neurokir.uu.se; kathleen7deschamps@hotmail.com; tkm53@comcast.net; lisa.mckerracher@bioaxone.com		Marklund, Niklas/0000-0002-9797-5626	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS40978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER		Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dergham P, 2002, J NEUROSCI, V22, P6570; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fournier AE, 2003, J NEUROSCI, V23, P1416; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jourquin J, 2003, EUR J NEUROSCI, V18, P1507, DOI 10.1046/j.1460-9568.2003.02876.x; Kim SW, 2004, BRAIN RES, V1007, P188, DOI 10.1016/j.brainres.2004.02.009; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kinouchi T, 2002, BIOL GROW ANIM, V1, P203, DOI 10.1016/S1877-1823(09)70123-7; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marklund N, 2005, RESTOR NEUROL NEUROS, V23, P31; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Niederost B, 2002, J NEUROSCI, V22, P10368; O'Kane EM, 2004, NEUROPHARMACOLOGY, V46, P879, DOI 10.1016/j.neuropharm.2003.11.020; O'Kane EM, 2003, J NEUROCHEM, V87, P1309, DOI 10.1046/j.1471-4159.2003.02102.x; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Peterson S, 2003, J BIOL CHEM, V278, P33943, DOI 10.1074/jbc.M302376200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Wu KY, 2005, NATURE, V436, P1020, DOI 10.1038/nature03885; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yi JS, 2003, NEUROSCI LETT, V347, P126, DOI 10.1016/S0304-3940(03)00656-6; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x	62	64	66	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2006	198	2					361	369		10.1016/j.expneurol.2005.12.002			9	Neurosciences	Neurosciences & Neurology	033RJ	WOS:000236866400009	16448651				2021-06-18	
J	Delaney, JS; Puni, V; Rouah, F				Delaney, JS; Puni, V; Rouah, F			Mechanisms of injury for concussions in university football, ice hockey, and soccer - A pilot study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; football; ice hockey; mechanisms; soccer	IMPACTS	Objective: To examine the mechanisms of injury for concussions in university football, ice hockey, and soccer. Design: Prospective analysis. Setting: McGill University. Patients: All athletes participating in varsity football, ice hockey, and soccer. Main Outcome Measures: Athletes participating in university varsity football, ice hockey, and soccer were followed prospectively to determine the mechanisms of injury for concussions, whether certain mechanisms of injury causing concussions were more common in any of the three sports, whether different areas of the body seem to be more vulnerable to a concussion after contact, and whether these areas might be predisposed to higher grades of concussion after contact. Results: There were 69 concussions in 60 athletes over a 3-year period. Being hit in the head or helmet was the most common mechanism of injury for all 3 sports. The side/temporal area of the head or helmet was the most probable area to be struck, resulting in concussion for both football and soccer. When examining the body part or object delivering the concussive blow, contact with another player's helmet was the most probable mechanism in football. Conclusion: The mechanisms of injury for concussions in football are similar to previously published research on professional football players. The mechanisms of injury for concussions in soccer are similar to past research on Australian rules football and rugby.	McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; McGill Univ, Dept Emergency Med, Hlth Ctr 2, Montreal, PQ H3A 2T5, Canada; McGill Univ, Fac Management, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5	10	64	64	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2006	16	2					162	165		10.1097/00042752-200603000-00013			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	029KC	WOS:000236560200013	16603887				2021-06-18	
J	Seyfried, D; Ding, J; Han, YX; Li, Y; Chen, JL; Chopp, M				Seyfried, D; Ding, J; Han, YX; Li, Y; Chen, JL; Chopp, M			Effects of intravenous administration of human bone marrow stromal cells after intracerebral hemorrhage in rats	JOURNAL OF NEUROSURGERY			English	Article						bone marrow stromal cell; intracerebral hemorrhage; neural regeneration; rat	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; NONHEMATOPOIETIC TISSUES; PROGENITOR CELLS; STROKE; TRANSPLANTATION; SYNAPTOGENESIS; MOUSE; MICE	Object. The goal of this study was to investigate whether human bone marrow stromal cells (hBMSCs) administered by intravenous injection have a beneficial effect on outcome after intracerebral hemorrhage (ICH) in rats. Methods. An ICH was induced in 54 adult male Wistar rats by a stereotactically guided injection of autologous blood into the right striatum. Intravenous infusion of the hBMSCs (3, 5, or 8 million cells) was performed I day after ICH, and for each dose group there was a control group that received injections of vehicle. Neurological function, which was evaluated using the Neurological Severity Score (NSS) and the corner turn test, was tested before and at 1, 7, and 14 days after ICH. After 14 days of survival, the area of encephalomalacia was calculated and histochemical labeling was performed. For all three groups, there were no statistical differences in either the NSS or corner turn tests after I day. After 7 and 14 days, however, the three groups that received the hBMSCs showed significant improvement in functional scores compared with the control group. In addition, after 14 days there was significantly more striatal tissue loss in the placebo groups compared with each of the three treatment groups. The region of injury in the treated animals demonstrated a significantly increased presence of hBMSCs, immature neurons, neuronal migration, synaptogenesis, and newly formed DNA. Conclusions. Intravenous administration of hBMSCs significantly improves neurological function in rats subjected to ICH. This improvement in the treated animals is associated with reduced tissue loss and increased local presence of the hBMSCs, mitotic activity, immature neurons, synaptogenesis, and neuronal migration.	Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA	Seyfried, D (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsdos@neuro.hfh.edu					ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; BENNETT JH, 1991, J CELL SCI, V99, P131; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; Fernandes HM, 2000, STROKE, V31, P2511, DOI 10.1161/01.STR.31.10.2511; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gong C, 2001, NEUROSURGERY, V48, P875, DOI 10.1097/00006123-200104000-00037; Hua Y, 2002, J CEREBR BLOOD F MET, V22, P55, DOI 10.1097/00004647-200201000-00007; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1999, OSTEOARTHR CARTILAGE, V7, P364, DOI 10.1053/joca.1998.0213; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Ujike H, 2002, ANN NY ACAD SCI, V965, P55; Villars F, 2000, J CELL BIOCHEM, V79, P672, DOI 10.1002/1097-4644(20001215)79:4<672::AID-JCB150>3.0.CO;2-2; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang ZG, 2004, NEUROIMAGE, V23, P281, DOI 10.1016/j.neuroimage.2004.05.019; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	31	64	73	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2006	104	2					313	318		10.3171/jns.2006.104.2.313			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	009CY	WOS:000235090000021	16509507				2021-06-18	
J	Bayly, PV; Black, EE; Pedersen, RC; Leister, EP; Genin, GM				Bayly, PV; Black, EE; Pedersen, RC; Leister, EP; Genin, GM			In vivo imaging of rapid deformation and strain in an animal model of traumatic brain injury	JOURNAL OF BIOMECHANICS			English	Article						brain injury; concussion; strain; deformation; HARP; MRI	DIFFUSE AXONAL INJURY; SPATIAL MODULATION; MECHANICAL STRETCH; MOTION; RAT; HEART; MRI; MAGNETIZATION; IMPACT	In traumatic brain injury (TBI) rapid deformation of brain tissue leads to axonal injury and cell death. In vivo quantification of such fast deformations is extremely difficult, but important for understanding the mechanisms of degeneration post-trauma and for development of numerical models of injury biomechanics. In this paper, strain fields in the brain of the perinatal rat were estimated from data obtained in vivo during rapid indentation. Tagged magnetic resonance (MR) images were obtained with high spatial (0.2 mm) and temporal (3.9 ms) resolution by gated image acquisition during and after impact. Impacts were repeated either 64 or 128 times to obtain images of horizontal and vertical tag lines in coronal and sagittal planes. Strain fields were estimated by harmonic phase (HARP) analysis of the tagged images. The original MR data was filtered and Fourier-transformed to obtain HARP images, following a method originally developed by Osman et al. (IEEE Trans. Med. Imaging 19(3) (2000) 186). The displacements of material points were estimated from intersections of HARP contours and used to generate estimates of the deformation gradient and Lagrangian strain tensors. Maximum principal Lagrangian strains of > 0.20 at strain rates > 40/s were observed during indentations of 2 mm depth and 21 ms duration. (c) 2005 Elsevier Ltd. All rights reserved.	Washington Univ, St Louis, MO 63130 USA	Bayly, PV (corresponding author), Washington Univ, 1 Brookings Dr,Box 1185, St Louis, MO 63130 USA.	pvb@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA083060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045237] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24-CA83060, R24 CA083060] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS045237, NS45237] Funding Source: Medline		Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; AXEL L, 1989, RADIOLOGY, V172, P349, DOI 10.1148/radiology.172.2.2748813; AXEL L, 1989, RADIOLOGY, V171, P841, DOI 10.1148/radiology.171.3.2717762; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2004, J BIOMECH ENG-T ASME, V126, P523, DOI 10.1115/1.1785811; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Black EE, 2004, J NEUROTRAUM, V21, P1276; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy W.N., 1997, ASME PUBLICATION AMD, V225, P241; Holbourn AHS, 1943, LANCET, V2, P438; Kraitchman DL, 2003, CIRCULATION, V107, P2025, DOI 10.1161/01.CIR.0000062684.47526.47; Kuijer JPA, 2001, MAGN RESON MED, V46, P993; Liu W, 2004, MAGN RESON MED, V52, P1282, DOI 10.1002/mrm.20276; MARGULIES SS, 1990, J BIOMECH, V23, P832, DOI DOI 10.1016/0021-9290(90)90029-3; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; PRANGE MT, 2001, P 2001 ASME BIOENG C, V50, P833; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Sampath S, 2003, MAGN RESON MED, V50, P154, DOI 10.1002/mrm.10509; Smith DH, 1999, J NEUROSCI, V19, P4263; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283; ZHANG L, 2001, P ASME BIOENG C BED, V50, P831	28	64	66	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.		2006	39	6					1086	1095		10.1016/j.jbiomech.2005.02.014			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	033GL	WOS:000236834900012	16549098	Green Accepted			2021-06-18	
J	Duhaime, AC				Duhaime, Ann-Christine			Large animal models of traumatic injury to the immature brain	DEVELOPMENTAL NEUROSCIENCE			English	Article						injury forces; large animal models; traumatic brain injury	CEREBRAL-BLOOD-FLOW; NONACCIDENTAL HEAD-INJURY; AXONAL INJURY; PROFESSIONAL FOOTBALL; DEVELOPMENTAL-CHANGES; OXYGEN-SATURATION; HYPOXIA-ISCHEMIA; NEONATAL BRAIN; AGE; NEWBORN	Large animal models have been used much less frequently than rodent models to study traumatic brain injury. However, large animal models offer distinct advantages in replicating specific mechanisms, morphology and maturational stages relevant to age-dependent injury responses. This paper reviews how each of these features is relevant in matching a model to a particular scientific question and discusses various scaling strategies, advantages and disadvantages of large animal models for studying traumatic brain injury in infants and children. Progress to date and future directions are outlined. Copyright (c) 2006 S. Karger AG, Basel.	Dartmouth Hitchcock Med Ctr, Childrens Hosp Dartmouth, Lebanon, NH 03756 USA	Duhaime, AC (corresponding author), Dartmouth Hitchcock Med Ctr, Childrens Hosp Dartmouth, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	acd@hitchcock.org	Dilger, Ryan N./E-7031-2010	Dilger, Ryan N./0000-0003-2538-2845			Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; BARKS JDE, 1992, BRAIN PATHOL, V2, P235, DOI 10.1111/j.1750-3639.1992.tb00697.x; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; Bauer R, 2004, PEDIATR RES, V56, P639, DOI 10.1203/01.PDR.0000139425.94975.77; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bittigau P, 1998, RESTOR NEUROL NEUROS, V13, P11; BUCKLEY NM, 1986, COMP BIOCHEM PHYS A, V83, P1, DOI 10.1016/0300-9629(86)90080-0; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; DIGIACOMO JE, 1992, BIOL NEONATE, V61, P25, DOI 10.1159/000243527; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 2006, J NEUROSURG, V104, P259, DOI 10.3171/ped.2006.104.4.259; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; DURHAM SR, 2004, 33 ANN M AM ASS NEUR; Finnie JW, 2003, AUST VET J, V81, P153, DOI 10.1111/j.1751-0813.2003.tb11078.x; Finnie JW, 1999, VET PATHOL, V36, P256, DOI 10.1354/vp.36-3-256; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Finnie JW, 2001, J COMP PATHOL, V124, P159, DOI 10.1053/jcpa.2000.0446; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Gavilanes AWD, 2001, CLIN NEUROPHYSIOL, V112, P52, DOI 10.1016/S1388-2457(00)00499-5; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1985, NEUROSURGERY, P1531; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; HARADA J, 1991, J NEUROSURG, V75, P103, DOI 10.3171/jns.1991.75.1.0103; Inder T, 2004, SEMIN PERINATOL, V28, P396, DOI 10.1053/j.semperi.2004.10.002; Ioroi T, 2002, EXP BRAIN RES, V144, P172, DOI 10.1007/s00221-002-1030-z; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; Loepke AW, 2005, ANESTH ANALG, V101, P340, DOI 10.1213/01.ANE.0000154199.67104.6A; Luerssen T G, 1991, Neurosurg Clin N Am, V2, P399; MADSEN FF, 1987, ACTA NEUROCHIR, V88, P65, DOI 10.1007/BF01400517; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Roohey T, 1997, EARLY HUM DEV, V47, P115, DOI 10.1016/S0378-3782(96)01773-2; Saito T, 2005, PHYSIOL BEHAV, V84, P725, DOI 10.1016/j.physbeh.2005.02.018; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Takahashi T, 1999, AM J NEURORADIOL, V20, P917; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; WAGERLE LC, 1986, PEDIATR RES, V20, P131, DOI 10.1203/00006450-198602000-00007; WOOTTON R, 1982, BIOL NEONATE, V41, P209; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	64	64	69	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					380	387		10.1159/000094164			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600015	16943661				2021-06-18	
J	Rapport, L; Hanks, RA; Bryer, RC				Rapport, L; Hanks, RA; Bryer, RC			Barriers to driving and community integration after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; driving; traumatic brain injury	OLDER DRIVERS; STROKE; DAMAGE; CONSEQUENCES; RESTRICTIONS; VALIDATION; PREDICTORS; AWARENESS; DOCTORS; FITNESS	Objective: To examine the relations among driving status, perceptions of barriers to the resumption of driving, and community integration outcomes after traumatic brain injury (17131). Design: Correlational research using logistic and multiple regression analyses, analyses of variance, and covariance. Participants: Fifty-one survivors of TBI, 6 months to 10 years postinjury. Main outcome measures: Driving status postinjury, Community Integration Measure, and Craig Hospital Assessment and Reporting Technique. Results: Perceptions of barriers to driving provided unique information in predicting Subjective and objective indices of community integration, even after accounting for other potentially pertinent variables (eg, injury severity social support, negative affectivity, and use of alternative transportation). Moreover, survivors who had not resumed driving showed poorer community integration than did those who had resumed driving. Social barriers such as directives against driving from significant others accounted for the most variance in survivor driving status. Decisions to cease driving were more common among those with no formal driving evaluation than among survivors who had been evaluated. Conclusions: Significant others have substantial influence on post-TBI driving outcome. The findings highlight the importance of independent driving to community integration, as well as psychoeducation of survivors and their families.	Wayne State Univ, Dept Psychol, Detroit, MI 48226 USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48226 USA	Rapport, L (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave,5057 Woodward Ave,7th Floor, Detroit, MI 48226 USA.	rapport@sun.science.wayne.edu					Anderson CJ, 2002, ARCH PHYS MED REHAB, V83, P791, DOI 10.1053/apmr.2002.32742; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Coleman BR., 2005, DRIVER REHABILITATIO, P165; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; FINN P, 1986, ACCIDENT ANAL PREV, V18, P289, DOI 10.1016/0001-4575(86)90043-6; Fisk GD, 1998, BRAIN INJURY, V12, P683; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Glass TA, 1999, BRIT MED J, V319, P478, DOI 10.1136/bmj.319.7208.478; Goodyear K, 2003, CLIN MED, V3, P86, DOI 10.7861/clinmedicine.3-1-86; Groeger JA, 1996, BRIT J PSYCHOL, V87, P61, DOI 10.1111/j.2044-8295.1996.tb02577.x; GROEGER JA, 1989, ACCIDENT ANAL PREV, V21, P155, DOI 10.1016/0001-4575(89)90083-3; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hopewell CA, 2002, J HEAD TRAUMA REHAB, V17, P48, DOI 10.1097/00001199-200202000-00007; Jewkes R, 1996, SOC SCI MED, V43, P555, DOI 10.1016/0277-9536(95)00439-4; Johnson J E, 1999, J Gerontol Nurs, V25, P12; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Kelly R, 1999, POSTGRAD MED J, V75, P537, DOI 10.1136/pgmj.75.887.537; Kiyono Y, 2001, ARCH PHYS MED REHAB, V82, P1389, DOI 10.1053/apmr.2001.26089; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Mackenzie C, 2003, APHASIOLOGY, V17, P107, DOI 10.1080/729255215; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; Marottoli RA, 2000, J GERONTOL B-PSYCHOL, V55, pS334, DOI 10.1093/geronb/55.6.S334; Marottoli RA, 1998, ACCIDENT ANAL PREV, V30, P331, DOI 10.1016/S0001-4575(97)00100-0; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; MCKENNA FP, 1991, ACCIDENT ANAL PREV, V23, P45, DOI 10.1016/0001-4575(91)90034-3; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RAPPORT LJ, 2004, M INT NEUR SOC JUL B; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P481; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SVENSON O, 1981, ACTA PSYCHOL, V47, P143, DOI 10.1016/0001-6918(81)90005-6; Taylor J, 2002, CLIN PSYCHOL REV, V22, P631, DOI 10.1016/S0272-7358(01)00114-3; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WHITENECK GG, 1997, HANDICAP ASSESSMENT	46	64	64	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					34	44		10.1097/00001199-200601000-00004			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300004	16456390				2021-06-18	
J	Cutler, SM; Pettus, EH; Hoffman, SW; Stein, DG				Cutler, SM; Pettus, EH; Hoffman, SW; Stein, DG			Tapered progesterone withdrawal enhances behavioral and molecular recovery after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						progesterone; withdrawal; traumatic brain injury (TBI); apoptosis; inflammation; anxiety	TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVITY; HORMONE REPLACEMENT; CORTICAL CONTUSION; GABA(A) RECEPTOR; ACTIVATION; PROTECTS; ANXIETY; MECHANISM; DURATION	Systemic injections of the neurosteroid progesterone improve cognitive recovery after traumatic brain injury (TBI) and stroke, and decrease molecular indicators of neuronal damage. Suddenly withdrawing progesterone after repeated dosing (PW) exacerbates ischemia and causes increased anxiety, seizure susceptibility, and excitotoxicity. Adult male Sprague-Dawley rats received either bilateral medial frontal cortex contusions or sham surgery. Injections were administered at 1 and 6 h post-injury, then every 24 h for 7 days. Vehicle-treated rats received 2-hydroxypropyl-beta-cyclodextrin (HBC). Acute PW (AW) rats received a full 16 mg/ml of progesterone for 7 days, and tapered PW (TW) rats received 5 days at full dosage, then 2 days with progressively halved dosages. Anxiety behaviors were observed pre- and post-surgery, and compared to levels at the peak of withdrawal. AW rats with lesions exhibited significantly more anxiety than any other treatment group, while both lesion- and sham-operated TW rats were indistinguishable from vehicle-treated intact animals. After behavioral tests were complete, the brains were extracted and prepared for Western blotting. TNF alpha, cFos, Caspase-3, and NF kappa B, among others, were investigated. While all progesterone treatments resulted in improved molecular recovery, TW animals had significantly fewer active markers for apoptosis and inflammation than AW animals. In conclusion, although progesterone treatment decreases inflammation and apoptosis, acute withdrawal increases activity in some apoptotic and inflammatory pathways and increases anxiety behavior during the acute healing phase. A tapered withdrawal of the hormone further enhances short-term recovery after TBI. (c) 2005 Elsevier Inc. All rights reserved.	Dept Emergency Med, Clin B, Atlanta, GA 30322 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA	Cutler, SM (corresponding author), Dept Emergency Med, Clin B, B5-301,1365 Clifton Rd, Atlanta, GA 30322 USA.	gt7812c@mail.gatech.edu	Stein, Donald/AAJ-5139-2020		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N540825, 1R01N538664] Funding Source: Medline		Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Brenner RM, 2002, ANN NY ACAD SCI, V955, P60, DOI 10.1111/j.1749-6632.2002.tb02766.x; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burleson MH, 1998, PSYCHOSOM MED, V60, P17, DOI 10.1097/00006842-199801000-00004; Challis JRG, 1999, J PERINAT MED, V27, P26, DOI 10.1515/JPM.1999.003; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Choi SH, 2001, PSYCHOSOM MED, V63, P822, DOI 10.1097/00006842-200109000-00016; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; DAVIS WW, 1968, J BIOL CHEM, V243, P5153; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; GALLO MA, 1993, PHARMACOL BIOCHEM BE, V46, P897, DOI 10.1016/0091-3057(93)90219-J; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gulinello M, 2003, EUR J NEUROSCI, V17, P641, DOI 10.1046/j.1460-9568.2003.02479.x; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Kulkarni S. K., 1995, Drugs of Today, V31, P433; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; NAKAMURA T, 1974, ACTA ENDOCRINOL-COP, V75, P410, DOI 10.1530/acta.0.0750410; Oinonen KA, 2002, J AFFECT DISORDERS, V70, P229, DOI 10.1016/S0165-0327(01)00356-1; Pan B S, 1997, Sheng Li Ke Xue Jin Zhan, V28, P101; Rodgers RJ, 1997, BRAZ J MED BIOL RES, V30, P289, DOI 10.1590/S0100-879X1997000300002; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, 21 ANN M SOC NEUR MI, P191; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Smith SS, 2002, STEROIDS, V67, P519, DOI 10.1016/S0039-128X(01)00170-2; Tremollieres FA, 2001, OSTEOPOROSIS INT, V12, P385, DOI 10.1007/s001980170107; Wallace AE, 1999, RESTOR NEUROL NEUROS, V14, P35; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355	37	64	66	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2005	195	2					423	429		10.1016/j.expneurol.2005.06.003			7	Neurosciences	Neurosciences & Neurology	968VI	WOS:000232190600016	16039652				2021-06-18	
J	Schwab, JM; Monnier, PP; Schluesener, HJ; Conrad, S; Beschorner, R; Chen, L; Meyermann, R; Mueller, BK				Schwab, JM; Monnier, PP; Schluesener, HJ; Conrad, S; Beschorner, R; Chen, L; Meyermann, R; Mueller, BK			Central nervous system injury-induced repulsive guidance molecule expression in the adult human brain	ARCHIVES OF NEUROLOGY			English	Article							OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCANS; CNS GLIAL SCAR; NEURITE GROWTH; AXONAL REGENERATION; REACTIVE ASTROCYTES; VISUAL-SYSTEM; SPINAL-CORD; INHIBITOR; OUTGROWTH	Background: The repulsive guidance molecule (RGM) is involved in formation of the central nervous system during development by moderating the repulsion of growing axons. However, the role of RGM in adult central nervous system lesions remains to be clarified. Objective: To identify and determine RGM expression in adult brains with focal cerebral ischemia or traumatic brain injury and in neuropathologically unaffected control brains. Patients: Twenty-one brains of patients with focal cerebral ischemia, 25 brains after traumatic brain injury, and 4 control brains. Main Outcome Measure: Expression of RGM as assessed by immunohistochemical analysis. Results: In normal brains, RGM expression was detected on the perikarya of some neurons, choroid plexus, smooth muscle and endothelial cells, oligodendrocytes, and myelinated white matter fibers. After focal cerebral ischemia and traumatic brain injury, RGM-mummopositive cells accumulated in lesional and perilesional areas. In hemorrhagic lesions, a massive accumulation of RGM-immunopositive cells was observed. During the first week after insult, RGM expression remained confined to neurons, smooth muscle and endothelial cells, and leukocytes infiltrating the lesion. Thereafter, with maturation of the lesion, we observed RGM expression by components of the developing scar tissue, such as fibroblastoid cells, reactive astrocytes, and a pronounced extracellular RGM deposition resembling neo-laminae. Conclusions: This is the first study of RGM in the human central nervous system. Following central nervous system injury, RGM, a novel, potent axonal growth inhibitor, is present in axonal growth impediments: the mature myelin, choroid plexus, and components of the developing scar.	Univ Tubingen, Brain Res Inst, Sch Med, Tubingen, Germany; Univ Tubingen, Inst Anat, Tubingen, Germany; Univ Paris 06, CNRS, UMR 7102, Equipe Dev Neuronal, Paris, France; Univ Toronto, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON, Canada; Kafides GmbH, Dusslingen, Germany	Schwab, JM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut, Thorn Bldg 724,75 Francis St, Boston, MA 02115 USA.	Jschwab@.zeus.bwh.harvard.edu	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; Schwab, Jan/0000-0001-6784-4919; monnier, philippe/0000-0002-6221-4130			Buffo A, 2000, J NEUROSCI, V20, P2275; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; DOU CL, 1994, J NEUROSCI, V14, P7616; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; KALIMO H, 1996, GREENFIELDS NEUROPAT, P315; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; McKeon RJ, 1999, J NEUROSCI, V19, P10778; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Pasterkamp RJ, 2001, BRAIN RES REV, V35, P36, DOI 10.1016/S0165-0173(00)00050-3; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schwab JM, 2001, J NEUROIMMUNOL, V114, P232, DOI 10.1016/S0165-5728(00)00433-1; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Schwab ME, 1996, PHYSIOL REV, V76, P319; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; WIZENMANN A, 1993, NEURON, V11, P975, DOI 10.1016/0896-6273(93)90126-C	32	64	68	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	2005	62	10					1561	1568		10.1001/archneur.62.10.1561			8	Clinical Neurology	Neurosciences & Neurology	973DK	WOS:000232502900009	16216939	Bronze			2021-06-18	
J	Borgaro, SR; Baker, J; Wethe, JV; Prigatano, GP; Kwasnica, C				Borgaro, SR; Baker, J; Wethe, JV; Prigatano, GP; Kwasnica, C			Subjective reports of fatigue during early recovery from traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; fatigue; traumatic brain injury	MINOR HEAD-INJURY; MULTIPLE-SCLEROSIS; VITAL EXHAUSTION; MENTAL FATIGUE; DEPRESSION; EXPERIENCE; SEVERITY; SEQUELAE; IMPACT; DISORDERS	Objective: To determine whether patients with traumatic brain injury (TBI) report higher levels of fatigue than do normal controls and to identify demographic and cognitive correlates of self-reported fatigue. Design: Prospective study. Setting: Inpatient neurorehabilitation unit in a medical center and neurological institute. Participants: Forty-seven neurorehabilitation inpatients with TBI. Main Outcome Measures: Barrow Neurological Institute (BNI) Fatigue Scale and BNI Screen for Higher Cerebral Functions. Results: Patients reported significantly greater levels of fatigue compared to the levels reported by normal controls, although fatigue was found to be unrelated to injury severity, number of days from injury to assessment, cognitive impairment, and gender. Inspection of individual items revealed no significant differences between severe versus moderate versus mild TBI groups. However, being able to last the day without taking a nap (ie, item 10) was found to be the most sensitive item associated with fatigue in the TBI group, Conclusions: Results of this study suggest the need to integrate activities and interventions to increase endurance in patients with TBI during early rehabilitation. Accommodating regular rest breaks and increasing restful sleep should be a focus of inpatient neurorehabilitation units.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA	Borgaro, SR (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	sborgar@chu.edu					BELZA BL, 1993, NURS RES, V42, P93; BINDER LM, 1987, REHABIL PSYCHOL, P65; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Busek P, 2000, Sb Lek, V101, P233; CARDENAS DD, 1982, NEPHRON, V30, P336, DOI 10.1159/000182512; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chervin R., 2002, CHEST, V118, P372; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EVANS RW, 1992, NEUROL CLIN, V10, P815; FISK JD, 1994, CAN J NEUROL SCI, V21, P9, DOI 10.1017/S0317167100048691; FISK JD, 1994, CLIN INFECT DIS   S1, V18, P79; GROBARMURRAY ME, 1998, J NEUROSCI NURS, V30, P191; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Halstead WC., 1947, BRAIN INTELLIGENCE Q; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; JENNETT B, 1974, MANAGEMENT HEAD INJU; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; Khan AA, 2002, AM J PSYCHIAT, V159, P1427, DOI 10.1176/appi.ajp.159.8.1427; Kop WJ, 1996, J PSYCHOSOM RES, V40, P397, DOI 10.1016/0022-3999(95)00613-3; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; Krupp LB, 1996, CURR OPIN NEUROL, V9, P456, DOI 10.1097/00019052-199612000-00011; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVITT MA, 1994, AM J EMERG MED, V12, P172, DOI 10.1016/0735-6757(94)90240-2; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; Lou JS, 2001, MOVEMENT DISORD, V16, P190, DOI 10.1002/mds.1042; Luria A.R., 1948, RESTORATION FUNCTION; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PARAMENTER BA, 2001, MULT SCLER, V9, P111; Pater JL, 1997, SUPPORT CARE CANCER, V5, P410, DOI 10.1007/s005200050100; PAUL R, 2002, MUSCLE NERVE, V23, P1402; Paul RH, 2002, J CLIN NEUROSCI, V9, P243, DOI 10.1054/jocn.2001.1016; Pedersen SS, 2001, J PSYCHOSOM RES, V51, P443, DOI 10.1016/S0022-3999(01)00203-3; Poynard T, 2002, J VIRAL HEPATITIS, V9, P295, DOI 10.1046/j.1365-2893.2002.00364.x; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1993, BNI Q, V9, P2; Prigatano GP, 1995, ADM SCORING MANUAL B; Ross S, 2001, Appl Neuropsychol, V8, P4, DOI 10.1207/S15324826AN0801_2; Schenkman M, 2001, PARKINSONISM RELAT D, V8, P41, DOI 10.1016/S1353-8020(00)00079-1; Short K, 2002, J PSYCHOSOM RES, V52, P475, DOI 10.1016/S0022-3999(02)00290-8; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Smets EMA, 1998, BRIT J CANCER, V78, P907, DOI 10.1038/bjc.1998.600; Torres-Harding SR, 2002, J BEHAV MED, V25, P99, DOI 10.1023/A:1014850819995; Uuskula M, 1996, PSYCHOTHER PSYCHOSOM, V65, P327, DOI 10.1159/000289092; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Van Zomeren A. H., 1981, REACTION TIME ATTENT; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469	54	64	64	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					416	425		10.1097/00001199-200509000-00003			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600004	16170250				2021-06-18	
J	Bandyopadhyay, S; Hennes, H; Gorelick, MH; Wells, RG; Walsh-Kelly, CM				Bandyopadhyay, S; Hennes, H; Gorelick, MH; Wells, RG; Walsh-Kelly, CM			Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	MAY 01-04, 2004	San Francisco, CA	Pediat Acad Soc		neuron-specific enolase; enolase; prediction; pediatrics; children; disability; outcomes	SEVERE HEAD-INJURY; CREATINE-KINASE BB; S-100 PROTEIN; CEREBROSPINAL-FLUID; FOLLOW-UP; DAMAGE; MILD; MARKER; SCALE; MODERATE	Background: Closed traumatic brain injury (cTBI) is a significant cause of mortality and morbidity in children. The natural course and extent of recovery from cTBI in children are poorly understood. Neuron-specific enolase (NSE), an enzyme detected in serum following structural damage of neuronal brain cells, appears to be a good marker for intracranial injury. However, to the best of the authors' knowledge, the usefulness of NSE as a predictor of disability in children with cTBI has not been reported. Objectives: To examine the association between posttraumatic serum NSE level and short-term physical disability in children with cTBI. Methods: This was a retrospective analysis of a prospectively enrolled cohort of children aged 0-18 years with isolated cTBI presenting to the emergency department (ED) within 24 hours of injury, and having a cranial computed tomography (CT) scan as part of the evaluation. The NSE level was obtained at the time of ED evaluation. Physical disability was measured using the Glasgow Outcome Scale (GOS). The GOS score was assigned retrospectively for enrolled patients by a single investigator blinded to NSE level. Patient outcomes were categorized as good (GOS = 5) or poor (GOS < 5). A single radiologist reviewed all cranial CT scans. Results: Ninety eligible subjects with NSE levels were identified; 86 met the enrollment criteria. Seven subjects (8%) had poor outcome. There was a significant difference in NSE levels between the poor and good outcome groups, even within high-risk subgroups. The area under the curve (AUC) for NSE prediction of poor vs. good outcome was 0.83. A serum NSE level of 21.2 ng/dL was 86% sensitive and 74% specific in predicting poor outcome. Conclusions: It appears that the serum NSE level can be used as a predictor of global short-term physical disability in children following cTBI.	Emory Univ, Sch Med, Dept Pediat, Emergency Med Div, Atlanta, GA 30329 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Childrens Hosp Wisconsin, Dept Radiol, Milwaukee, WI 53201 USA	Bandyopadhyay, S (corresponding author), Emory Univ, Sch Med, Dept Pediat, Emergency Med Div, 1645 Tullie Circle, Atlanta, GA 30329 USA.	sbandy2@emory.edu	Hennes, Halim/H-6592-2019	Hennes, Halim/0000-0002-1230-7371			Abdul-Khaliq H, 2000, CLIN CHEM LAB MED, V38, P1173, DOI 10.1515/CCLM.2000.181; Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Beaudeux JL, 1999, ANN BIOL CLIN-PARIS, V57, P261; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Ergun R, 1998, NEUROL RES, V20, P418; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FISHER DH, 1992, J PEDIATR, V121, P68; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; HANS P, 1993, J NEUROSURG ANESTH, V5, P111; Hellawell DJ, 2000, SCAND J REHABIL MED, V32, P25; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Khan NE, 2001, ANN THORAC SURG, V72, P666, DOI 10.1016/S0003-4975(01)02605-4; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; KRUSE A, 1991, ACTA NEUROCHIR, V110, P106, DOI 10.1007/BF01400675; Kusch B, 2001, THORAC CARDIOV SURG, V49, P179, DOI 10.1055/s-2001-14297; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Linstedt U, 2000, ANAESTHESIST, V49, P887, DOI 10.1007/s001010070042; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Robertson Charlene M T, 2002, Pediatr Crit Care Med, V3, P345, DOI 10.1097/00130478-200210000-00003; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Sosin DM, 1996, BRAIN INJURY, V10, P47; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woischneck D, 1998, ACT NEUR S, V71, P138; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	50	64	72	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2005	12	8					732	738		10.1197/j.aem.2005.02.017			7	Emergency Medicine	Emergency Medicine	951TL	WOS:000230953800007	16079426	Bronze			2021-06-18	
J	Hutchinson, PJ; O'Connell, MT; Nortje, J; Smith, P; Al-Rawi, PG; Gupta, AK; Menon, DK; Pickard, JD				Hutchinson, PJ; O'Connell, MT; Nortje, J; Smith, P; Al-Rawi, PG; Gupta, AK; Menon, DK; Pickard, JD			Cerebral microdialysis methodology - evaluation of 20 kDa and 100 kDa catheters	PHYSIOLOGICAL MEASUREMENT			English	Article						cerebral metabolism; brain injury; microdialysis; cytokines; lactate/pyruvate ratio	BRAIN; INJURY	Microdialysis monitoring of cerebral metabolism is now performed in several neuro-intensive care units. Conventional microdialysis utilizes CMA70 catheters with 20 kDa molecular weight cut-off membranes enabling the measurement of small molecules such as glucose, lactate, pyruvate and glutamate. The CMA71 100 kDa molecular weight cut-off microdialysis catheter has recently been introduced to allow detection of larger molecules such as cytokines. The objective of this study was to perform in vitro and in vivo testing of the CMA71 microdialysis catheter, comparing its performance with the CMA70. In vitro comparison studies of three of each catheter using reference analyte solutions, demonstrated equivalent recovery for glucose, lactate, pyruvate and glutamate (range 94-97% for CMA70 and 88-103% for CMA71). In vivo comparison involved intracranial placement of paired CMA70 and CMA71 catheters (through the same cranial access device) in six patients with severe traumatic brain injury. Both catheters were perfused with CNS Perfusion Fluid without dextran at 0.3 mu l min(-1) with hourly sampling and bedside analysis on a CMA600 microdialysis analyser. The two catheters yielded equivalent results for glucose, lactate, pyruvate, glutamate and lactate/pyruvate ratio. CMA71 microdialysis catheters can, therefore, be used for routine clinical monitoring of extracellular substances, as well as for their intended research role of larger molecular weight protein sampling.	Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England	Hutchinson, PJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Hills Rd, Cambridge CB2 2QQ, England.	pjah2@cam.ac.uk		O'Connell, Mark/0000-0001-6272-8767	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Ungerstedt U, 1997, Acta Anaesthesiol Scand Suppl, V110, P123; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	11	64	65	0	6	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0967-3334	1361-6579		PHYSIOL MEAS	Physiol. Meas.	AUG	2005	26	4					423	428		10.1088/0967-3334/26/4/008			6	Biophysics; Engineering, Biomedical; Physiology	Biophysics; Engineering; Physiology	956SC	WOS:000231319100011	15886437				2021-06-18	
J	Keren, O; Yupatov, S; Radai, MM; Elad-Yarum, R; Faraggi, D; Abboud, S; Ring, H; Groswasser, Z				Keren, O; Yupatov, S; Radai, MM; Elad-Yarum, R; Faraggi, D; Abboud, S; Ring, H; Groswasser, Z			Heart rate variability (HRV) of patients with traumatic brain injury (TBI) during the post-insult sub-acute period	BRAIN INJURY			English	Article						autonomic nervous system; heart rate variability (HRV); traumatic brain injury (TBI)	AUTONOMIC DYSFUNCTION; REHABILITATION	Objective: To evaluate heart rate variability (HRV) of patients with traumatic brain injury (TBI). Methods: By a prospective study, the HRV was assessed in 20 patients with TBI during the sub-acute period post-injury (the first test was performed at a mean time post-insult of 38 days) and a matched control. The patients were examined twice, 1 month apart. The assessment included HRV (both in time and frequency domains), GCS, length of coma, brain CT, FIM and FAM. Results: A significant difference was found between patients and controls concerning HRV total power, i.e. frequencies between 0.01-0.6 Hz ( high frequency p = 0.003, low frequency p = 0.013, total power p = 0.034) and for standard deviation of RR interval p = 0.011. HRV changes were related more to the timing of the evaluation than to the severity of the brain damage. Conclusion: HRV differed of patients with TBI and in the control group. Tendency to HRV normalization changes was detected during the first 3 months after the injury, which suggests recovery of the autonomic nervous system.	Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, IL-43100 Raanana, Israel; Tel Aviv Univ, Fac Engn, Dept Biomed Engn, IL-69978 Tel Aviv, Israel; Univ Haifa, Dept Stat, IL-31999 Haifa, Israel	Keren, O (corresponding author), Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.	ofkeren@internet-zahav.net					ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Andersson S, 1998, J PSYCHOSOM RES, V44, P645, DOI 10.1016/S0022-3999(97)00305-X; Ansakorpi H, 2000, EPILEPSIA, V41, P42, DOI 10.1111/j.1528-1157.2000.tb01503.x; Arad M, 2002, AM J PHYS MED REHAB, V81, P590, DOI 10.1097/00002060-200208000-00006; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Druschky A, 2001, BRAIN, V124, P2372, DOI 10.1093/brain/124.12.2372; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; GOLDSTEIN B, 1998, AM J PHYSIOL, V275, P1287; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; Groswasser Z, 1998, J HEAD TRAUMA REHAB, V13, P69, DOI 10.1097/00001199-199802000-00009; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; King ML, 1997, BRAIN INJURY, V11, P445; Korpelainen JT, 1996, ACTA NEUROL SCAND, V94, P337, DOI 10.1111/j.1600-0404.1996.tb07076.x; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; LOWENSOHN RI, 1977, LANCET, V1, P626; Maschke M, 2002, J NEUROL NEUROSUR PS, V72, P116, DOI 10.1136/jnnp.72.1.116; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sinson G, 2001, AM J NEURORADIOL, V22, P143; TEASDALE G, 1974, LANCET, V2, P81; Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850; YAMOUR BJ, 1980, AM HEART J, V99, P294, DOI 10.1016/0002-8703(80)90343-9	30	64	65	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	8					605	611		10.1080/02699050400024946			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700005	16175814				2021-06-18	
J	Wade, SL; Wolfe, C; Brown, TM; Pestian, JP				Wade, SL; Wolfe, C; Brown, TM; Pestian, JP			Putting the pieces together: Preliminary efficacy of a web-based family intervention for children with traumatic brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	112th Annual Convention of the American-Psychological-Association	JUL 28-AUG 01, 2004	Honolulu, HI	Amer Psychol Assoc		telehealth; acquired brain injury; intervention; problem-solving; online	PROBLEM-SOLVING SKILLS; PREDICTORS; ADOLESCENTS	Objective To report preliminary efficacy data from a Web-based family problem-solving intervention to improve parent and child adaptation. Method Eight parents and six children with moderate to severe traumatic brain injury (TBI) who were injured more than 15 months earlier (M = 16 months) participated in the intervention. Families were given computers, Web cameras, and high-speed Internet access. Weekly videoconferences with the therapist were conducted after they completed self-guided Web exercises on problem-solving, communication, and antecedent behavior management strategies. Results Paired t tests comparing pre- and post-intervention scores revealed significant improvements in injury-related burden, parental psychiatric symptoms, depression, and parenting stress. There were also significant reductions in antisocial behaviors in the injured child, but not in self-reported depressive symptoms. Conclusions These findings suggest that a computer-based intervention may successfully be used to improve both parent and child outcomes following TBI in children.	Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40942-02] Funding Source: Medline		Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; LOYD BH, 1985, J PEDIATR PSYCHOL, V10, P169, DOI 10.1093/jpepsy/10.2.169; Marks I, 1998, CLIN PSYCHOL-SCI PR, V5, P151, DOI 10.1111/j.1468-2850.1998.tb00141.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; PATTERSON GR, 1988, STRESS COPING DEV CH, P235; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Sitarenios G., 1999, USE PSYCHOL TESTING, P267; Speilberger C.D., 1983, STATE TRAIT ANXIETY; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WADE SL, 2004, UNPUB PUTTING PIECES; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; YLVSAKER M, 1998, COLLABORATIVE BRAIN	27	64	64	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUL-AUG	2005	30	5					437	442		10.1093/jpepsy/jsi067			6	Psychology, Developmental	Psychology	938KT	WOS:000230003000007	15944171	Bronze			2021-06-18	
J	Trommer, BL; Shah, C; Yun, SH; Gamkrelidze, G; Pasternak, ES; Stine, WB; Manelli, A; Sullivan, P; Pasternak, JF; LaDu, MJ				Trommer, BL; Shah, C; Yun, SH; Gamkrelidze, G; Pasternak, ES; Stine, WB; Manelli, A; Sullivan, P; Pasternak, JF; LaDu, MJ			ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta 1-42	NEUROBIOLOGY OF DISEASE			English	Article						ApoE; amyloid-beta; long-term potentiation (LTP); dentate gyrus; Alzheimer disease; ApoE transgenic mice; A beta oligomers; neuroplasticity; hippocampal slices	AMYLOID-BETA-PEPTIDE; LONG-TERM POTENTIATION; HUMAN APOLIPOPROTEIN E4; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; TRANSGENIC MICE; DENTATE GYRUS; PRECURSOR PROTEIN; CHOLINERGIC DEFICITS; SYNAPTIC PLASTICITY	Amyloid-beta1-42 (Abeta1-42) is crucial to Alzheimer disease (AD) pathogenesis but the conformation of the toxic A species remains uncertain. AD risk is increased by apolipoprotein E4 (apoE4) and decreased by apoE2 compared with the apoE3 isoform, but whether inheritance of apoE4 represents a gain of negative or a loss of protective function is also unresolved. Using hippocampal slices from apoE knockout (apoE-KO) and human apoE2, E3, and E4 targeted replacement (apoE-TR) mice, we found that oligomeric Abeta1-42 inhibited long-term potentiation (LTP) with a hierarchy of susceptibility mirroring clinical AD risk (apoE4-TR > apoE3-TR = apoE-KO > apoE2-TR), and that comparable doses of unaggregated Abeta1-42 did not affect LTP. These data provide a novel link among apoE isoform, Abeta1-42, and a functional cellular model of memory. In this model, apoE4 confers a gain of negative function synergistic with Abeta1-42, apoE2 is protective, and the apoE-Abeta interaction is specific to oligomeric Abeta1-42. (C) 2004 Elsevier Inc. All rights reserved.	Evanston Northwestern Healthcare, Div Neurol, Dept Pediat, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60614 USA; ENH Res Inst, Evanston, IL 60202 USA; Duke Univ, Dept Med, Div Neurol & Bryan ARDC, Durham, NC 27710 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Geriatr, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Core Ctr, Chicago, IL 60614 USA; Evanston Northwestern Healthcare, Div Geriatr, Dept Med, Evanston, IL 60201 USA	Trommer, BL (corresponding author), Evanston Northwestern Healthcare, Div Neurol, Dept Pediat, 2650 Ridge Ave, Evanston, IL 60201 USA.	btrommer@northwestern.edu		LaDu, Mary Jo/0000-0003-2141-1450	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG18121] Funding Source: Medline		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Barger SW, 1997, J NEUROCHEM, V69, P60; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; Cambon K, 2000, NEUROSCIENCE, V97, P685, DOI 10.1016/S0306-4522(00)00065-8; Carter DB, 2001, ANN NEUROL, V50, P468, DOI 10.1002/ana.1134; Chapman PF, 1999, NAT NEUROSCI, V2, P271; Chen QS, 2000, J NEUROSCI RES, V60, P65, DOI 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deb S, 2000, BRIT J PSYCHIAT, V176, P468, DOI 10.1192/bjp.176.5.468; Drouet B, 2001, J NEUROCHEM, V76, P117, DOI 10.1046/j.1471-4159.2001.00047.x; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; Grehan S, 2001, J NEUROSCI, V21, P812; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartman RE, 2002, J NEUROSCI, V22, P10083; HOFFER MJV, 1993, GENOMICS, V15, P62, DOI 10.1006/geno.1993.1010; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; Irizarry MC, 2000, ANN NY ACAD SCI, V920, P171; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan J, 1998, J NEUROSCI, V18, P195; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lanz TA, 2003, NEUROBIOL DIS, V13, P246, DOI 10.1016/S0969-9961(03)00079-2; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Manelli AM, 2004, J MOL NEUROSCI, V23, P235, DOI 10.1385/JMN:23:3:235; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raymond CR, 2003, BRAIN RES, V968, P263, DOI 10.1016/S0006-8993(03)02269-8; Rebeck GW, 2002, J ALZHEIMERS DIS, V4, P145, DOI 10.3233/JAD-2002-4304; REBECK GW, 1993, NEURON, V11, P575; Saunders AM, 2000, J NEUROPATH EXP NEUR, V59, P751, DOI 10.1093/jnen/59.9.751; Scheff SW, 2003, NEUROBIOL AGING, V24, P1029, DOI 10.1016/j.neurobiolaging.2003.08.002; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Small D H, 1998, Amyloid, V5, P301, DOI 10.3109/13506129809007304; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sun YL, 1998, J NEUROSCI, V18, P3261; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Teter B, 2002, J ALZHEIMERS DIS, V4, P155, DOI 10.3233/JAD-2002-4305; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Wang XS, 1997, J CELL PHYSIOL, V173, P73, DOI 10.1002/(SICI)1097-4652(199710)173:1<73::AID-JCP9>3.0.CO;2-G; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Zhu YJ, 2003, J BIOL CHEM, V278, P36257, DOI 10.1074/jbc.M303171200	71	64	66	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2005	18	1					75	82		10.1016/j.nbd.2004.08.011			8	Neurosciences	Neurosciences & Neurology	889OO	WOS:000226452500006	15649697				2021-06-18	
J	Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Feuer, H				Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Feuer, H			Concussion in professional football: Players returning to the same game - Part 7	NEUROSURGERY			English	Article						concussion; concussion guidelines; epidemiology; injury surveillance; sport injury; traumatic brain injury	NCAA CONCUSSION; INJURIES; IMPACTS	OBJECTIVE: A 6-year study was conducted to determine the signs, symptoms, and outcome of players who were concussed and either returned immediately or were rested and returned to the same game in the National Football League (NFL). METHODS: From 1996 to 2001, concussions were recorded by NFL teams by use of a special standardized reporting form filled out by team physicians. Signs and symptoms were grouped by general symptoms, somatic complaints, cranial nerve effects, cognition problems, memory problems, and unconsciousness. Action taken after concussion was recorded for 887 patients. RESULTS: There were 135 players (15.2%) who returned immediately and 304 (34.3%) who rested and returned to the same game after concussion. There were few differences by player position or team activity about the injury or action taken. However, the mean number of signs and symptoms progressively increased from those who returned immediately (1.52), rested and returned to play (2.07), were removed from play (3.51), or were hospitalized (6.55). Immediate recall problems (odds ratio [OR], 1.93; confidence interval [01, 1.26-2.94], memory problems (OR, 1.52; Cl, 1.06-2.19), and the number of signs and symptoms (OR, 1.39; Cl, 1.25-1.55) were predictive of removal from play or hospitalization. There was no statistical association between return to play in the same game and a subsequent concussion or a more serious concussion involving 7+ days out. CONCLUSION: Players who are concussed and return to the same game have fewer initial signs and symptoms than those removed from play. Return to play does not involve a significant risk of a second injury either in the same game or during the season. The current decision-making of NFL team physicians seems appropriate for return to the game after a concussion, when the player has become asymptomatic and does not have memory or cognitive problems.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA; ProHLTH Care Assoc LLP, Lake Success, NY USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Wayne State Univ, Ctr Healthcare Effect Res, Dept Psychiat & Behav Neurosci, Detroit, MI USA; Indianapolis Neurosurg Grp, Indianapolis, IN USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; *COL MED SOC, 1991, REPORT SPORTS MED CO; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POLIN R, 1996, NEUROLOGY TRAUMA, P166; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958	18	64	65	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2005	56	1					79	90		10.1227/01.NEU.0000150180.16552.8D			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	884FD	WOS:000226069300029	28184620				2021-06-18	
J	Reiter, ER; DiNardo, LJ; Costanzo, RM				Reiter, ER; DiNardo, LJ; Costanzo, RM			Effects of head injury on olfaction and taste	OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA			English	Article							SMELL IDENTIFICATION TEST; POST-TRAUMATIC ANOSMIA; OF-PENNSYLVANIA SMELL; BRAIN INJURY; DYSFUNCTION; DISORDERS; NERVE; UNIVERSITY; AGEUSIA; BULB	Reports of olfactory or gustatory disturbances date back to the 1800s. Today, head injuries are sustained from traumatic events such as motor vehicle accidents, falls, and assault. A significant percentage of head-injured patients will experience changes in olfaction, or, less commonly, gustation. An understanding of the mechanisms of posttraumatic olfactory and gustatory dysfunction will help physicians better detect patients with such deficits, determine their prognosis for recovery, and provide appropriate treatment and counseling. Such measures may be important to patients in limiting the impact of their sensory loss on their quality of life and rehabilitation.	Virginia Commonwealth Univ, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Otolaryngol Head & Neck Surg, Richmond, VA 23298 USA	Costanzo, RM (corresponding author), Virginia Commonwealth Univ, Dept Physiol, 1101 E Marshall St, Richmond, VA 23298 USA.	rcostanz@mail.2.vcu.edu		Costanzo, Richard/0000-0002-6839-3520	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000165] Funding Source: NIH RePORTER		Aiba T, 1998, ACTA OTO-LARYNGOL, P202; ALHADY MRA, 1990, J LARYNGOL OTOL, V104, P927, DOI 10.1017/S0022215100114410; ANDERSSON BGJ, 2002, GUIDES EVALUATION PE; Auerbach SH, 1989, TRAUMATIC BRAIN INJU; Bartoshuk L, 1989, Ear Nose Throat J, V68, P331; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; CAIN WS, 1987, AM IND HYG ASSOC J, V48, P47; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Cerf B, 1998, ANN NY ACAD SCI, V855, P575, DOI 10.1111/j.1749-6632.1998.tb10627.x; COMBARROS O, 1994, EUR NEUROL, V34, P344, DOI 10.1159/000117076; CONE JE, 1991, ENVIRON HEALTH PERSP, V95, P53, DOI 10.2307/3431106; Costanzo RM, 1986, CLIN MEASUREMENTS TA, P565; Costanzo RM, 1991, SMELL TASTE HLTH DIS, P711; Costanzo RM, 1995, NEUROL DIS, P493; Costanzo RM, 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; Darrouzet V, 2001, OTOLARYNG HEAD NECK, V125, P77, DOI 10.1067/mhn.2001.116182; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Delank K.-W., 1998, Rhinology (Utrecht), V36, P15; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Doty RL, 1995, CHEM SENSES, V20, P645, DOI 10.1093/chemse/20.6.645; DUFFY V B, 1989, Ear Nose and Throat Journal, V68, P395; EBY TL, 1988, LARYNGOSCOPE, V98, P717; Formaker BK, 1998, ANN NY ACAD SCI, V855, P776, DOI 10.1111/j.1749-6632.1998.tb10657.x; FRANK ME, 1991, SMELL TASTE HLTH DIS, P503; Fujii M, 2002, AURIS NASUS LARYNX, V29, P35, DOI 10.1016/S0385-8146(01)00118-3; Fujikane M, 1999, Rinsho Shinkeigaku, V39, P771; Green P, 2001, NEUROREHABILITATION, V16, P237; HENKIN RI, 1971, J AMER MED ASSOC, V217, P434, DOI 10.1001/jama.217.4.434; HERBERHOLD C, 1980, LARYNG RHINOL OTOL V, V59, P570, DOI 10.1055/s-2007-1008898; HEYWOOD PG, 1986, AM J OTOLARYNG, V7, P194, DOI 10.1016/S0196-0709(86)80006-0; Ikeda K, 1995, TOHOKU J EXP MED, V177, P343, DOI 10.1620/tjem.177.343; Ikeda K, 1999, Auris Nasus Larynx, V26, P435, DOI 10.1016/S0385-8146(99)00023-1; INAMITSU M, 1990, J LARYNGOL OTOL, V104, P959, DOI 10.1017/S0022215100114483; Kalavrezos ND, 2000, J ROY COLL SURG EDIN, V45, P359; KEMINK JL, 1989, ARCH OTOLARYNGOL, V115, P661; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; Koster NL, 1996, BRAIN RES, V724, P117, DOI 10.1016/0006-8993(96)00281-8; Lawless H, 1983, Trans Pa Acad Ophthalmol Otolaryngol, V36, P190; LEGG JW, 1873, LANCET, V2, P659, DOI DOI 10.1016/S0140-6736(02)66313-5; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MATTES RD, 1994, J AM DIET ASSOC, V94, P50, DOI 10.1016/0002-8223(94)92041-9; MAY M, 1981, LARYNGOSCOPE, V91, P2092; MILLER IJ, 1990, PHYSIOL BEHAV, V47, P1213, DOI 10.1016/0031-9384(90)90374-D; Miwa T, 2001, ARCH OTOLARYNGOL, V127, P497, DOI 10.1001/archotol.127.5.497; MORAN DT, 1985, ARCH OTOLARYNGOL, V111, P122; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; Obrebowski A, 1976, Otolaryngol Pol, V30, P391; Obrebowski A, 1977, Czas Stomatol, V30, P343; Renzi G, 2002, ANN PLAS SURG, V48, P355, DOI 10.1097/00000637-200204000-00003; ROTCH TM, 1878, BOSTON MED SURG J, V99, P130; Rousseaux M, 1996, STROKE, V27, P2328, DOI 10.1161/01.STR.27.12.2328; Saito T, 2001, ORL-J OTO-RHIN-LARYN, V63, P359, DOI 10.1159/000055774; Saito T, 2001, LARYNGOSCOPE, V111, P2064, DOI 10.1097/00005537-200111000-00037; SAKAI SC, 1984, SEMIN HEAR, V5, P157; Santos DV, 2004, ARCH OTOLARYNGOL, V130, P317, DOI 10.1001/archotol.130.3.317; Scrivani SJ, 2000, J ORAL MAXIL SURG, V58, P3, DOI 10.1016/S0278-2391(00)80003-8; Seiden AM, 2001, LARYNGOSCOPE, V111, P9, DOI 10.1097/00005537-200101000-00002; SEMIRA C, 1957, MINERVA OTORINOLARIN, V7, P3; Sofferman PA, 1993, SURG EAR TEMPORAL BO, P329; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SUMNER D, 1967, BRAIN, V90, P187, DOI 10.1093/brain/90.1.187; Sumner D, 1975, HDB CLIN NEUROLOGY, P1; Sunada I, 1995, NEURORADIOLOGY, V37, P659; TAKAGI SF, 1987, ANN NY ACAD SCI, V510, P113; Temmel AFP, 2002, ARCH OTOLARYNGOL, V128, P635, DOI 10.1001/archotol.128.6.635; Van Toller S, 1999, CHEM SENSES, V24, P705, DOI 10.1093/chemse/24.6.705; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Yamauchi Y, 1995, Nihon Jibiinkoka Gakkai Kaiho, V98, P119; Yee KK, 1998, CHEM SENSES, V23, P513, DOI 10.1093/chemse/23.5.513; YEE KK, 1995, PHYSIOL BEHAV, V58, P959, DOI 10.1016/0031-9384(95)00159-G; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	75	64	65	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0030-6665	1557-8259		OTOLARYNG CLIN N AM	Otolaryngol. Clin. N. Am.	DEC	2004	37	6					1167	+		10.1016/j.otc.2004.06.005			19	Otorhinolaryngology	Otorhinolaryngology	881KW	WOS:000225867400006	15563909				2021-06-18	
J	Zygun, DA; Steiner, LA; Johnston, AJ; Hutchinson, PJ; Al-Rawi, PG; Chatfield, D; Kirkpatrick, PJ; Menon, DK; Gupta, AK				Zygun, DA; Steiner, LA; Johnston, AJ; Hutchinson, PJ; Al-Rawi, PG; Chatfield, D; Kirkpatrick, PJ; Menon, DK; Gupta, AK			Hyperglycemia and brain tissue pH after traumatic brain injury	NEUROSURGERY			English	Article						generalized estimating equation; head injury; hyperglycemia; insulin; neuromonitoring; pH	SEVERE HEAD-INJURY; FOCAL CEREBRAL-ISCHEMIA; BLOOD-GLUCOSE; ADMISSION HYPERGLYCEMIA; DEPRESSIONS; ACIDOSIS; RATS	OBJECTIVE: Hyperglycemia occurring after head injury is associated with poor neurological outcome. We tested the hypothesis that blood glucose levels are associated with brain tissue pH (pH(b)) and that the correction of hyperglycemia would result in an improvement in pH(b). METHODS: This is a retrospective analysis of a prospectively collected database. Thirty-four patients in a tertiary care neuroscience critical care unit with major traumatic brain injury underwent pHb monitoring. RESULTS: A total of 428 glucose measurements were recorded during pHb monitoring. Mean glucose level was 7.1 mmol/L (range, 2.8-21.7 mmol/L) and median (interquartile range) pHb was 7.11 mmol/L (7.00-7.19 mmol/L). To account for the correlated, unbalanced nature of the data, a linear generalized estimating equation model was created. This model predicted that for each 1 mmol/L increase in blood glucose, pHb changed by -0.011 mmol/L (95% confidence interval, -0.016 to -0.005 mmol/L; P < 0.001). This relationship remained significant in a multivariable model that included cerebral perfusion pressure, brain tissue oxygen and carbon dioxide tension, and brain temperature. Twenty-one episodes of significant hyperglycemia (&GE;11.1 mmol/L) treated with intravenous insulin were identified. Insulin therapy significantly reduced blood glucose concentration from a median (interquartile range) of 11.9 mmol/L (range, 11.4-13.6 mmol/L) to 8.8 mmol/L (range, 7.3-9.6 mmol/L; P < 0.001). Baseline pHb was not significantly different from pHb associated with the subsequent glucose reading of less than 11.1 mmol/L (P = 0.29), but there was a suggestion of improvement if the change in blood glucose was large. CONCLUSION: Blood glucose is associated with brain tissue acidosis in patients with major head injury. Prospective studies are required to confirm these results and to determine whether treatment of hyperglycemia improves outcome.	Univ Calgary, Dept Crit Care Med, Foothills Med Ctr, Calgary Hlth Reg, Calgary, AB T2N 2T9, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Cambridge, Neurosci Crit Care Unit, Cambridge, England; Univ Cambridge, Dept Anaesthesia, Cambridge, England; Addenbrookes Hosp, Cambridge, England; Univ Cambridge, Neurosci Crit Care Unit, Cambridge, England	Zygun, DA (corresponding author), Univ Calgary, Dept Crit Care Med, Foothills Med Ctr, Calgary Hlth Reg, Room EG23,1403 29th St NW, Calgary, AB T2N 2T9, Canada.	david.zygun@calgaryhealthregion.ca	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019				Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Deloof T, 1979, Acta Neurochir Suppl (Wien), V28, P113; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSH WR, 1986, J NEUROSURG, V65, P693, DOI 10.3171/jns.1986.65.5.0693; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; PENTELENYI T, 1977, INJURY, V8, P264, DOI 10.1016/0020-1383(77)90099-7; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Schurr A, 2002, CRIT CARE, V6, P330; SHIMAZU T, 1966, NATURE, V210, P1178, DOI 10.1038/2101178a0; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2000, STROKE, V31, P214, DOI 10.1161/01.STR.31.1.214; VOLL CL, 1988, ANN NEUROL, V24, P638, DOI 10.1002/ana.410240508; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	33	64	74	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	OCT	2004	55	4					877	881		10.1227/01.NEU.0000137658.14906.E4			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100031	15458595				2021-06-18	
J	Shore, PM; Thomas, NJ; Clark, RSB; Adelson, PD; Wisniewski, SR; Janesko, KL; Bayir, H; Jackson, EK; Kochanek, PM				Shore, PM; Thomas, NJ; Clark, RSB; Adelson, PD; Wisniewski, SR; Janesko, KL; Bayir, H; Jackson, EK; Kochanek, PM			Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: Effect on biochemical markers	JOURNAL OF NEUROTRAUMA			English	Article						head injury; interleukin-6; neuron-specific enolase; pediatrics; s100B; vascular endothelial growth factor; ventriculostomy	ENDOTHELIAL GROWTH-FACTOR; INTERLEUKIN-6; GLUTAMATE	Drainage of cerebrospinal fluid (CSF) is routinely used in the treatment of severe traumatic brain injury (TBI), either continuously or intermittently in response to increases in intracranial pressure (ICP). There has been little study of the effect of CSF drainage method on the biochemistry, pathophysiology or outcome of TBI in adults or children. Having previously reported that a variety of markers of injury or repair increase in CSF after severe TBI, we chose to evaluate directly the effect of CSF drainage method on the biochemistry and volume of CSF drained as well as ICP. We hypothesized that concentrations of these markers would be similar in CSF drained continuously vs intermittently. We compared CSF levels of markers of neuronal injury (neuron specific enolase, [NSE]), glial injury (s100B), inflammation (interleukin-6 [IL-6]), and regeneration (vascular endothelial growth factor [VEGF]) (measured by ELISA) in 80 CSF samples from 19 severely injured children whose CSF was drained continuously (n = 13) versus intermittently (n = 6) as part of standard care in two institutions. Compared to continuous CSF drainage, intermittent drainage of CSF was associated with twofold greater CSF concentrations of NSE, s100B, IL-6 and VEGF (P < 0.05) and with about half the volume of CSF removal than continuous drainage (P = 0.002). The resulting elimination (concentration x volume) of these biochemicals, however, was not influenced by drainage method. Patients treated with continuous drainage had lower mean ICPs than those with intermittent drainage (13.6 +/- 0.69 vs. 21.8 +/- 0.95 mm Hg,p < 0.0001). We conclude that the method of CSF drainage greatly affects concentrations of CSF markers after TBI and may influence ICP. The influence of method on CSF marker concentration must be kept in mind when interpreting studies of CSF biomarkers. The striking difference in biomarker concentration, CSF volume drained, and ICP suggests the need for a randomized trial directly comparing these two approaches in infants and children with severe TBI.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Penn State Univ, Coll Med, Penn State Childrens Hosp, Div Pediat Crit Care Med, Hershey, PA USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol & Med, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Wisniewski, Stephen/0000-0002-3877-9860; Thomas, Neal/0000-0002-7991-7510	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32 HD 40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38087, NS 30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038087, P01NS030318, P20NS030318] Funding Source: NIH RePORTER		BAYIR H, 2001, MO CL BI CC, V2, P115; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bergsneider M, 2001, NEUROSURG CLIN N AM, V12, P631, DOI 10.1016/S1042-3680(18)30021-4; CUTLER RWP, 1968, BRAIN, V91, P707, DOI 10.1093/brain/91.4.707; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; MORGANTIKOSSMANN MC, 2001, MO CL BI CC, V2, P99; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Yamamoto T, 1999, ACT NEUR S, V75, P17	13	64	65	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1113	1122					10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900001	15453982				2021-06-18	
J	Robertson, CL				Robertson, CL			Mitochondrial dysfunction contributes to cell death following traumatic brain injury in adult and immature animals	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article; Proceedings Paper	Mitochondria and Neuroprotection Symposium	APR 16-19, 2004	Ft Lauderdale, FL			brain mitochondria; development; pediatric; cytochrome c; bcl-2; membrane permeability transition; apoptosis	CYTOCHROME-C RELEASE; DEVELOPING RAT-BRAIN; CYCLOSPORINE-A; OXIDATIVE-PHOSPHORYLATION; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; CASPASE ACTIVATION; AXONAL INJURY; HEAD-INJURY; DAMAGE	Secondary injury following traumatic brain injury (TBI) is characterized by a variety of pathophysiologic cascades. Many of these cascades can have significant detrimental effects on cerebral mitochondria. These include exposure of neurons to excitotoxic levels of excitatory neurotransmitters with intracellular calcium influx, generation of reactive oxygen species, and production of peptides that participate in apoptotic cell death. Both experimental and clinical TBI studies have documented mitochondrial dysfunction, and animal studies suggest this dysfunction begins early and may persist for days following injury. Furthermore, interventions targeting mitochondrial mechanisms have shown neuroprotection after TBI. Continued evaluation and understanding of mitochondrial mechanisms contributing to neuronal cell death and survival after TBI is indicated. In addition, important underlying factors, such as brain maturation, that influence mitochondrial function should be studied. The ability to identify, target, and manipulate mitochondrial dysfunction may lead to the development of novel therapies for the treatment of adult and pediatric TBI.	Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA	Robertson, CL (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 22 S Greene St,S5D18, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS 42805] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER		AEESSANDRI B, 2002, J NEUROTRAUM, V19, P829; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; CDC, 1999, TRAUM BRAIN INJ US R; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DIENEL G, 1977, BIOCHIM BIOPHYS ACTA, V496, P484, DOI 10.1016/0304-4165(77)90330-0; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HOLTZMAN D, 1975, J NEUROCHEM, V24, P1011, DOI 10.1111/j.1471-4159.1975.tb03670.x; HOLTZMAN D, 1973, BIOL NEONATE, V22, P230; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lai YC, 2003, CRIT CARE MED, V31, pA12; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; McDonald RPA, 1999, NEUROREPORT, V10, P1875, DOI 10.1097/00001756-199906230-00014; MILSTEIN JM, 1968, J NEUROCHEM, V15, P411, DOI 10.1111/j.1471-4159.1968.tb11627.x; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; MURTHY M R, 1963, Biochim Biophys Acta, V74, P51, DOI 10.1016/0006-3002(63)91328-3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PETTUS EH, 1996, BRAIN RES, V25, P1; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; SITKIEWICZ D, 1982, J NEUROCHEM, V39, P1308, DOI 10.1111/j.1471-4159.1982.tb12571.x; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STRANGE CJ, 2003, CRIT CARE MED, V31, pA12; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Thurman DJ, 2001, HEAD TRAUMA THERAPEU; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	48	64	65	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	AUG	2004	36	4					363	368		10.1023/B:JOBB.0000041769.06954.e4			6	Biophysics; Cell Biology	Biophysics; Cell Biology	854PR	WOS:000223916300018	15377873				2021-06-18	
J	Song, S; Kamath, S; Mosquera, D; Zigova, T; Sanberg, P; Vesely, DL; Sanchez-Ramos, J				Song, S; Kamath, S; Mosquera, D; Zigova, T; Sanberg, P; Vesely, DL; Sanchez-Ramos, J			Expression of brain natriuretic peptide by human bone marrow stromal cells	EXPERIMENTAL NEUROLOGY			English	Article						bone marrow stromal cells; brain natriuretic factor; stroke	GROWTH-FACTOR PRODUCTION; FUNCTIONAL RECOVERY; INTRACEREBRAL TRANSPLANTATION; STEM-CELLS; ADULT RATS; INJURY; EXTRACTS; STROKE; EDEMA	Bone marrow stromal cells (BMSC) have been shown to generate neural cells under experimental conditions in vitro and following transplantation into animal models of stroke and traumatic CNS injury. Hastened recovery from the neurological deficit has not correlated with structural repair of the lesion in the stroke model. Secretory functions of BMSC, such as the elaboration of growth factors and cytokines, have been hypothesized to play a role in the enhanced recovery of neurological function. Using gene expression arrays, real time RT-PCR and radioimmunoassay, we have found that brain natriuretic peptide (BNP) is synthesized and released by BMSC at physiologically relevant levels in vitro. BNP, like its close homolog atrial natriuretic peptide (ANP), exerts powerful natriuretic, diuretic and vasodilatory effects. We speculate that transplanted BMSCs facilitate recovery from brain and spinal cord lesions by releasing BNP and other vasoactive factors that reduce edema, decrease intracranial pressure and improve cerebral perfusion. (C) 2003 Elsevier Inc. All rights reserved.	Univ S Florida, Dept Neurol, Ctr Aging & Brain Repair, Tampa, FL 33612 USA; James A Haley VA Hosp, Tampa, FL 33612 USA; Univ S Florida, Dept Med, Ctr Aging & Brain Repair, Tampa, FL 33612 USA; Univ S Florida, Dept Neurosurg, Ctr Aging & Brain Repair, Tampa, FL 33612 USA	Sanchez-Ramos, J (corresponding author), Univ S Florida, Dept Neurol, Ctr Aging & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Sanchez-Ramos, Juan/O-7870-2014; Sanberg, Paul/A-6753-2009; Sanchez-Ramos, Juan/A-1188-2009	Sanchez-Ramos, Juan/0000-0002-3391-7857			Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; DOCZI TP, 1995, ACTA NEUROCHIR, V132, P87, DOI 10.1007/BF01404853; Jensen KT, 1997, SCAND J CLIN LAB INV, V57, P529, DOI 10.3109/00365519709084604; KANEKO T, 1993, BRAIN RES, V612, P104, DOI 10.1016/0006-8993(93)91649-D; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; NAKAO N, 1990, NEUROSURGERY, V27, P39, DOI 10.1227/00006123-199007000-00005; NARUSE S, 1990, ACT NEUR S, V51, P118; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; SONG S, 2002, PROTOCOLS NEURAL STE, P79; SUDOH T, 1988, BIOCHEM BIOPH RES CO, V155, P726, DOI 10.1016/S0006-291X(88)80555-2; VESELY DL, 1992, RENAL PHYSIOL BIOCH, V15, P23; VESELY DL, 1992, MOL CELL BIOCHEM, V109, P43	24	64	79	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2004	185	1					191	197		10.1016/j.expneurol.2003.09.003			7	Neurosciences	Neurosciences & Neurology	760JM	WOS:000187807900018	14697330				2021-06-18	
J	Chiaretti, A; Piastra, M; Polidori, G; Di Rocco, C; Caresta, E; Antonelli, A; Amendola, T; Aloe, L				Chiaretti, A; Piastra, M; Polidori, G; Di Rocco, C; Caresta, E; Antonelli, A; Amendola, T; Aloe, L			Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						nerve growth factor; brain-derived neurotrophic factor; glia-derived neurotrophic factor; traumatic brain injury; Glasgow Coma Scale; Glasgow Outcome Score	NERVE GROWTH-FACTOR; CEREBROSPINAL-FLUID; HEAD-INJURY; ALZHEIMER PATIENT; RAT HIPPOCAMPUS; FACTOR PROTECTS; MESSENGER-RNA; ADULT-RAT; NEURONS; RECEPTORS	Objectives: We evaluated the neurotrophic factors [nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glia-derived neurotrophic factor (GDNF)] expression and their association with the severity and outcome of children with traumatic brain injury. Design: Prospective observational clinical study. Setting: Pediatric intensive care unit. Patients: Fourteen children with severe head injury; 12 controls with obstructive hydrocephalus. Measurement: Cerebrospinal fluid (CSF) and plasma samples were collected 2 h (T1) and 24 h (T2) after head injury. Neurotrophic factor levels were measured using an immunoenzymatic assay. Main results: In patients, neurotrophic factor mean levels were significantly different in both CSF and plasma, showing high levels of BDNF compared to NGF and GDNF. Considering T1 and T2 expression, in the CSF the level of NGF increased from 3.5 +/- 0.4 pg/ml to 48.2 +/- 11.7 pg/ml (p<0.001); BDNF decreased from 4854.0 +/- 1303.7 pg/ml to 593.0 +/- 114.8 pg/ml (p<0.001), while GDNF did not undergo significant variations. In plasma, no significant changes were observed. Regarding severity and outcome, BDNF levels showed a sharp peak after head injury, but the only significant association was between NGF expression in the CSF and a good outcome versus a poor outcome (p=0.007). Conclusions: The variations in neurotrophic factor levels reflect an endogenous attempt at neuroprotection against biochemical and molecular changes after traumatic head injury. BDNF represents an early marker of brain injury, while NGF expression in the CSF was indicative of a good outcome and the role of this neurotrophin in the treatment of children with severe head injury may be hypothesized.	Univ Sacred Heart, Sch Med, Pediat Intens Care Unit, Policlin Gemelli, I-00168 Rome, Italy; CNR, Inst Neurobiol, I-00137 Rome, Italy	Chiaretti, A (corresponding author), Univ Sacred Heart, Sch Med, Pediat Intens Care Unit, Policlin Gemelli, Largo Gemelli 1, I-00168 Rome, Italy.						Abe K, 2000, J CEREBR BLOOD F MET, V20, P1393, DOI 10.1097/00004647-200010000-00001; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Aronica E, 2001, ACTA NEUROPATHOL, V101, P383; Azmitia EC, 2001, BRAIN DEV-JPN, V23, pS1, DOI 10.1016/S0387-7604(01)00368-0; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Barde Y. A., 1994, PROG CLIN BIOL RES, V390, P1855; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; FISHER W, 1987, NATURE, V329, P65; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; HASHIMOTO Y, 1992, NEUROSCI LETT, V139, P45, DOI 10.1016/0304-3940(92)90853-Y; HEFTI F, 1986, J NEUROSCI, V6, P2155; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Ikeda T, 2000, ACTA NEUROPATHOL, V100, P161, DOI 10.1007/s004019900162; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; Kanai M, 2002, TOHOKU J EXP MED, V196, P241, DOI 10.1620/tjem.196.241; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; Kim JY, 2002, EPILEPSIA, V43, P220, DOI 10.1046/j.1528-1157.43.s.5.33.x; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Lappalainen R, 1996, J CHILD NEUROL, V11, P296, DOI 10.1177/088307389601100407; LAUTERBORN JC, 1993, NEUROREPORT, V5, P273, DOI 10.1097/00001756-199312000-00023; Lee TH, 1998, STROKE, V29, P1687, DOI 10.1161/01.STR.29.8.1687; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; Lui VCH, 2002, LAB INVEST, V82, P703, DOI 10.1097/01.LAB.0000017364.13014.AE; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nelson KB, 2001, ANN NEUROL, V49, P597, DOI 10.1002/ana.1024.abs; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Seguier-Lipszyc E, 2001, J UROLOGY, V165, P2269, DOI 10.1016/S0022-5347(05)66182-4; SEIGER A, 1993, BEHAV BRAIN RES, V57, P255, DOI 10.1016/0166-4328(93)90141-C; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; Siegel GJ, 2000, BRAIN RES REV, V33, P199, DOI 10.1016/S0165-0173(00)00030-8; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Tokunaga Y, 2002, PEDIATR NEUROL, V27, P102, DOI 10.1016/S0887-8994(02)00387-9	54	64	66	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	AUG	2003	29	8					1329	1338		10.1007/s00134-003-1852-6			10	Critical Care Medicine	General & Internal Medicine	720HQ	WOS:000185255700020	12845427				2021-06-18	
J	O'Connor, CA; Cernak, I; Vink, R				O'Connor, CA; Cernak, I; Vink, R			Interaction between anesthesia, gender, and functional outcome task following diffuse traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						anesthesia; female; gender; male; neurotrauma; outcome; TBI	FOREBRAIN ISCHEMIA; ESTROGEN-TREATMENT; AXONAL INJURY; HEAD-INJURY; BLOOD-FLOW; ISOFLURANE; PROGESTERONE; HALOTHANE; FENTANYL; RABBITS	A number of experimental and clinical studies have demonstrated that functional outcome following traumatic brain injury differs between males and females. Some studies report that females have a better outcome than males following trauma while others report the opposite. In experimental studies, some of the contradictory results may be due to the different experimental conditions, including type of anesthesia and the outcome measures employed. In the present study we have used three different anesthetic protocols and four different outcome measures to determine how these parameters interact and affect functional outcome following traumatic brain injury in male and female rats. Diffuse traumatic brain injury was induced in adult male and female animals using the impact-acceleration brain injury model. Mortality in female animals was no different than males when using halothane anesthesia, slightly better than males when using isoflurane anesthesia, but significantly worse than males under pentobarbital anesthesia. Female animals always performed better than males on rotarod tests of motor outcome, with this effect being unrelated to anesthetic effects. Conversely, in cognitive tests using the Barnes Maze, only isoflurane-anesthetized females performed better than their male counterparts. Similarly, in an open field activity task, females always performed better than males after trauma, with isoflurane-anesthetized females also performing significantly better than the halothane-anesthetized female group after injury. Our results suggest that female animals do better than males after diffuse traumatic brain injury, although this observation is dependent upon the type of anesthesia and the functional task employed. Isoflurane is particularly protective in females, pentobarbital is deleterious to female outcome, while halothane anesthesia has the least influence on gender-related outcome.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Georgetown Univ, Dept Neurosci, Washington, DC USA	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Alexiou T, 2000, NEUROSCI RES COMMUN, V26, P1, DOI 10.1002/(SICI)1520-6769(200001/02)26:1<1::AID-NRC1>3.0.CO;2-Q; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; EMERSON CS, 1992, NEUROREPORT, V4, P957; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; GIULIAN D, 1975, PHYSIOL BEHAV, V14, P109, DOI 10.1016/0031-9384(75)90150-X; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HATTORI T, 1986, Neurological Research, V8, P33; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heikkinen T, 2002, HORM BEHAV, V41, P22, DOI 10.1006/hbeh.2001.1738; HOFFMAN A, 1989, PHARM RES-DORDR, V6, P976, DOI 10.1023/A:1015953715346; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P571, DOI 10.1097/00000542-198910000-00016; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDERMOTT JL, 1994, HORM BEHAV, V28, P16, DOI 10.1006/hbeh.1994.1002; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MURR R, 1993, ANESTH ANALG, V77, P898; Nellgard B, 2000, ANESTHESIOLOGY, V93, P431, DOI 10.1097/00000542-200008000-00022; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Steen P A, 1991, Agressologie, V32, P323; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; Torbati D, 1999, CRIT CARE MED, V27, P1878, DOI 10.1097/00003246-199909000-00028; Vallee M, 1997, J NEUROSCI, V17, P2626; VERHAEGEN MJ, 1992, ANESTHESIOLOGY, V76, P743, DOI 10.1097/00000542-199205000-00013; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wise-Faberowski L, 2001, ANESTH ANALG, V93, P1281, DOI 10.1097/00000539-200111000-00051	38	64	64	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2003	20	6					533	541		10.1089/089771503767168465			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	697DL	WOS:000183926900002	12906738				2021-06-18	
J	Mattioli, C; Beretta, L; Gerevini, S; Veglia, F; Citerio, G; Cormio, M; Stocchetti, N				Mattioli, C; Beretta, L; Gerevini, S; Veglia, F; Citerio, G; Cormio, M; Stocchetti, N			Traumatic subarachnoid hemorrhage on the computerized tomography scan obtained at admission: a multicenter assessment of the accuracy of diagnosis and the potential impact on patient outcome	JOURNAL OF NEUROSURGERY			English	Article						head injury; subarachnoid hemorrhage; computerized tomography; outcome	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; CT SCAN; VASOSPASM; COMA	Object. The goal of this study was fourfold: 1) to determine the incidence of traumatic subarachnoid hemorrhage (tSAH) in patients with traumatic brain injury (TBI); 2) to verify agreement in the diagnosis of tSAH in a multicenter study; 3) to assess the incidence of tSAH on the outcome of the patient; and 4) to establish whether tSAH itself leads to an unfavorable outcome or whether it is a sign of major brain trauma associated with severe posttraumatic lesions. Methods. Computerized tomography (CT) scans obtained in 169 head-injured patients on admission to 12 Italian intensive care units during a 3-month period were examined. The scans were collected for neuroradiological review and were used for the analysis together with data from a multicenter database (Neurolink). A review committee found a high incidence of tSAH (61%) in patients with TBI and a moderate agreement among centers (K = 0.57). Significant associations were observed between the presence and grading of tSAH and patient outcomes, and between the presence of tSAH and the severity of the CT findings. Logistic regression analysis showed that the presence of tSAH and its grading alone do not assume statistical significance in the prediction of unfavorable outcome. Conclusions. Traumatic SAH frequently occurs in patients with TBI, but it is difficult to detect and grade. Traumatic SAH is associated with more severe CT findings and a worse patient outcome.	IRCCS H San Raffaele, Dept Neuroradiol, Neurointens Care Unit, Milan, Italy; Inst Sci Interchange Fdn, ISI, Turin, Italy; H S Gerardo, Intens Care Unit, Monza, Italy; IRCCS H Policlin, Milan, Italy	Mattioli, C (corresponding author), Osped San Raffaele, Via Olgettina 60, Milan, Italy.		Veglia, Fabrizio/K-1958-2016; Citerio, Giuseppe/B-1839-2015; gerevini, simonetta/AAL-9594-2020; Stocchetti, Nino/O-7444-2017	Veglia, Fabrizio/0000-0002-9378-8874; Citerio, Giuseppe/0000-0002-5374-3161; gerevini, simonetta/0000-0002-2374-194X; Stocchetti, Nino/0000-0003-3250-6834			BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ESKESEN V, 1987, ACTA NEUROCHIR, V87, P54, DOI 10.1007/BF02076017; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FREYTAG E, 1963, ARCH PATHOL, V75, P402; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; JENNETT B, 1975, LANCET, V1, P480; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KAKARIEKA A, 1995, CEREBROVASC DIS, V5, P403, DOI 10.1159/000107892; KAKARIEKA A, 1994, J NEURAL TRANSM-SUPP, P13; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; SIMONSEN J, 1963, J Forensic Sci, V8, P97; Svensson E, 1996, NEUROL RES, V18, P487; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; TEASDALE G, 1974, LANCET, V2, P81; VANGIJN J, 1982, NEURORADIOLOGY, V23, P153, DOI 10.1007/BF00347559; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	32	64	68	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2003	98	1					37	42		10.3171/jns.2003.98.1.0037			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	636NY	WOS:000180463700008	12546350				2021-06-18	
J	Schick, DM; Meeuwisse, WH				Schick, DM; Meeuwisse, WH			Injury rates and profiles in female ice hockey players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	Canadian-Academy-of-Sport-Medicine Symposium	MAY, 2000	TORONTO, CANADA	Canadian Acad Sport Med				Background: Little data exist on injury rates and profiles in female ice hockey players. Objective: To examine the incidence of injury in female ice hockey players and compare injury rates with those of male players. Study Design: Prospective cohort study. Methods: Six male and six female teams from the Canada West Universities Athletic Association were followed prospectively for one varsity season. Preseason medical history forms were completed by each player. Injury report forms and attendance records for each team session were submitted by team therapists. Results: Male players reported 161 injuries, whereas female players reported 66 injuries. However, the overall injury rates for male (9.19 injuries per 1000 athlete-exposures) and female (7.77 injuries per 1000 athlete-exposures) players did not differ significantly. Ninety-six percent of injuries in female players and 79% in male players were related to contact mechanisms, even though intentional body checking is not allowed in female ice hockey. Women were more likely than men to be injured by contacting the boards or their opponent. Men sustained more severe injuries than women and missed about twice as many sessions (exposures) because of injury. Concussions were the most common injury in female players, followed by ankle sprains, adductor muscle strains, and sacroiliac dysfunction. Conclusion: Although the injury rate in female ice hockey players was expected to be lower than that in male players because of the lack of intentional body checking, the injury rates were found to be similar. (C) 2003 American Orthopaedic Society for Sports Medicine.	Univ Calgary, Fac Kinesiol, Sport Med Ctr, Calgary, AB T2N 1N4, Canada	Meeuwisse, WH (corresponding author), Univ Calgary, Fac Kinesiol, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.						AVERY J, 1997, TOO MANY MEN ICE WOM; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; *CAN HOCK ASS, 2001, ONL STAT; DICK RW, 1994, ASTM STP, V1229; Dryden DM, 2000, MED SCI SPORT EXER, V32, P1378, DOI 10.1097/00005768-200008000-00004; FALCONER T, 1994, EQUINOX          JAN; FINKE R C, 1988, Journal of Orthopaedic and Sports Physical Therapy, V10, P54; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; McKnight Cynthia M., 1992, Journal of Athletic Training, V27, P342; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; MEEUWISSE WH, 1999, J INFORMATICS PR JUN; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; RIELLY MF, 1982, ATHLETIC TRAINING, V17, P88; TATOR C, 1994, ASTM STP, V1229; Tegner Y, 1991, Br J Sports Med, V25, P87	15	64	64	1	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	2003	31	1					47	52		10.1177/03635465030310011901			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	636TP	WOS:000180473300008	12531756				2021-06-18	
J	Blanchard, R; Christensen, BK; Strong, SM; Cantor, JM; Kuban, ME; Klassen, P; Dickey, R; Blak, T				Blanchard, R; Christensen, BK; Strong, SM; Cantor, JM; Kuban, ME; Klassen, P; Dickey, R; Blak, T			Retrospective self-reports of childhood accidents causing unconsciousness in phallometrically diagnosed pedophiles	ARCHIVES OF SEXUAL BEHAVIOR			English	Article						childhood accidents; head injury; neuropsychology; pedophilia; phallometry; sex offenders	TRAUMATIC BRAIN INJURY; LEFT-HANDEDNESS; HEAD-INJURY; MENTAL-RETARDATION; SEXUAL ORIENTATION; PREFRONTAL CORTEX; INCREASED RISK; FOLLOW-UP; CHILDREN; AGE	The present study investigated whether head injuries in childhood might increase the risk of pedophilia in males. The subjects were 1206 patients referred to a clinical sexology service for assessment of their erotic preferences. These were classified, on the basis of phallometric test results, as pedophilic (n = 413) or nonpedophilic (n = 793). Information regarding early head injuries, other signs of possible neurodevelopmental problems, and parental histories of psychiatric treatment were collected with self-administered questionnaires. The results showed that childhood accidents that resulted in unconsciousness were associated with pedophilia and with lower levels of intelligence and education. These associations were statistically significant for accidents that occurred before the age of 6, but not for accidents that occurred between the ages of 6 and 12. These results are compatible with the hypothesis that neurodevelopmental perturbations in early childhood may increase the risk of pedophilia. They are also, however, compatible with the alternative explanation that prior neurodevelopmental problems lead to accident-proneness and head injury, on the one hand, and to pedophilia, on the other, and that head injury has no causal influence on pedophilia. A secondary finding was that the pedophiles were more likely to report that their mothers had undergone psychiatric treatment. This finding suggests that pedophilia may be influenced by genetic factors, which are manifested in women as an increased risk of psychiatric problems, and in their sons, as an increased risk of erotic interest in children.	Ctr Addict & Mental Hlth, Law & Mental Hlth Program, Toronto, ON M5T 1R8, Canada; Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON M5S 1A1, Canada; Ctr Addict & Mental Hlth, Schizophrenia & Continuing Care Program, Toronto, ON, Canada	Blanchard, R (corresponding author), Ctr Addict & Mental Hlth, Law & Mental Hlth Program, Clarke Site,250 Coll St, Toronto, ON M5T 1R8, Canada.		Cantor, James M/P-8796-2014				ALMLI CR, 1984, EARLY BRAIN DAMAGE, V1; ANDERSON SA, 1995, NEUROSCIENCE, V67, P7, DOI 10.1016/0306-4522(95)00051-J; Aram DM, 1992, HDB NEUROPSYCHOLOGY, P73; Barbaree Howard E., 1997, P175; Barkley Russell A., 1996, P63; Bates E, 2001, BRAIN LANG, V79, P223, DOI 10.1006/brln.2001.2482; BIRO V, 1995, STUD PSYCHOL, V37, P81; Blanchard R, 2001, HORM BEHAV, V40, P105, DOI 10.1006/hbeh.2001.1681; Blanchard R, 1999, ARCH SEX BEHAV, V28, P111, DOI 10.1023/A:1018754004962; Blanchard R, 2002, HORM BEHAV, V41, P321, DOI 10.1006/hbeh.2002.1765; BLANCHARD R, 1989, J NERV MENT DIS, V177, P616, DOI 10.1097/00005053-198910000-00004; Blanchard R, 2001, PSYCHOL ASSESSMENT, V13, P118, DOI 10.1037/1040-3590.13.1.118; Blanchard R, 2001, J BIOSOC SCI, V33, P451, DOI 10.1017/S0021932001004515; BLANCHARD R, 1998, HDB SEXUALITY RELATE, P581; Bogaert AF, 2001, NEUROPSYCHOLOGIA, V39, P465, DOI 10.1016/S0028-3932(00)00134-2; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cantor JM, 2002, ARCH SEX BEHAV, V31, P63, DOI 10.1023/A:1014031201935; CANTOR JM, 2001, DIAGNOSIS PROGNOSIS; CAVINESS VS, 1989, DEV NEUROBIOL, P1; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; COREN S, 1991, PSYCHOL BULL, V109, P90, DOI 10.1037/0033-2909.109.1.90; COREN S, 1994, EARLY HUM DEV, V40, P23, DOI 10.1016/0378-3782(94)90096-5; DENNIS M, 1994, J DEV BEHAV PEDIATR, V15, P124; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; EARLS CM, 1987, ARCH SEX BEHAV, V16, P493, DOI 10.1007/BF01541713; ELLIS A, 1951, INT J SEXOLOGY, V4, P127; FINGER S, 1984, EARLY BRAIN DAMAGE, V2; Fisch GS, 1996, AM J MED GENET, V64, P356, DOI 10.1002/(SICI)1096-8628(19960809)64:2<356::AID-AJMG24>3.0.CO;2-D; FREUND K, 1967, BEHAV RES THER, V5, P209, DOI 10.1016/0005-7967(67)90036-8; FREUND K, 1989, J CONSULT CLIN PSYCH, V57, P100, DOI 10.1037/0022-006X.57.1.100; FREUND K, 1983, ARCH SEX BEHAV, V12, P369, DOI 10.1007/BF01542881; FREUND K, 1983, J HOMOSEXUAL, V9, P7, DOI 10.1300/J082v09n01_02; FREUND K., 1981, ADULT SEXUAL INTERES, P139; FREUND K, 1998, HDB SEXUALITY RELATE, P454; Freund K, 1991, PSYCHOL ASSESSMENT J, V3, P254, DOI DOI 10.1037/1040-3590.3.2.254; Frosch J, 1939, AM J ORTHOPSYCHIAT, V9, P761, DOI 10.1111/j.1939-0025.1939.tb05646.x; Frydman Marcel, 1996, Journal of Environmental Pathology Toxicology and Oncology, V15, P169; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GOTTFRIED AW, 1973, PSYCHOL BULL, V80, P231, DOI 10.1037/h0034914; HAMBRIDGE JA, 1994, J FORENSIC SCI, V39, P456; Harris G. T., 1992, PSYCHOL ASSESSMENT, V4, P502, DOI DOI 10.1037/1040-3590.4.4.502; HAYES A, 1993, PEDIATR CLIN N AM, V40, P523; HENN FA, 1976, AM J PSYCHIAT, V133, P694; Henry P C, 1992, J Neurosci Nurs, V24, P311; HEPPER PG, 1991, NEUROPSYCHOLOGIA, V29, P1107, DOI 10.1016/0028-3932(91)90080-R; Hucker S, 1988, ANN SEX RES, V1, P33; Jernigan T. L., 1997, NEURODEVELOPMENT ADU, P63; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; Kieler H, 2001, EPIDEMIOLOGY, V12, P618, DOI 10.1097/00001648-200111000-00007; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kozma C, 1998, AM J MED GENET, V81, P269, DOI 10.1002/(SICI)1096-8628(19980508)81:3<269::AID-AJMG12>3.0.CO;2-D; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kuban M, 1999, ARCH SEX BEHAV, V28, P345, DOI 10.1023/A:1018700813140; LANGEVIN R, 1989, ANN SEX RES, V2, P163, DOI DOI 10.1007/BF00851321; LANGEVIN R, 1985, EROTIC PREFERENCE GE, P1; LANGEVIN R, 1988, ANN SEX RES, V1, P401; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEWIS DA, 1997, NEURODEVELOPMENT ADU, P12; LUND JS, 1993, J COMP NEUROL, V328, P282, DOI 10.1002/cne.903280209; LUND JS, 1997, NEURODEVELOPMENT ADU, P3; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARLOW N, 1989, ARCH DIS CHILD, V64, P1713, DOI 10.1136/adc.64.12.1713; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; Neyens LGJ, 1999, EPILEPSY RES, V34, P85, DOI 10.1016/S0920-1211(98)00118-1; Olson HC, 1998, ALCOHOL CLIN EXP RES, V22, P1998, DOI 10.1111/j.1530-0277.1998.tb05909.x; OVERGAARD J, 1973, LANCET, V2, P631; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; PLANT TM, 1988, FRONT NEUROENDOCRIN, V10, P215; QUINSEY VL, 1980, J CLIN PSYCHOL, V36, P410, DOI 10.1002/jclp.6120360204; RADCLIFFE J, 1994, INT J DEV NEUROSCI, V12, P327, DOI 10.1016/0736-5748(94)90081-7; SAIGAL S, 1992, DEV MED CHILD NEUROL, V34, P425; SCOTT ML, 1984, J FORENSIC SCI, V29, P1114; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wesseling J, 2001, THROMB HAEMOSTASIS, V85, P609; WILLIAMS CS, 1992, AM J EPIDEMIOL, V136, P277, DOI 10.1093/oxfordjournals.aje.a116493	76	64	66	1	20	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0004-0002			ARCH SEX BEHAV	Arch. Sex. Behav.	DEC	2002	31	6					511	526		10.1023/A:1020659331965			16	Psychology, Clinical; Social Sciences, Interdisciplinary	Psychology; Social Sciences - Other Topics	603CK	WOS:000178541100007	12462478				2021-06-18	
J	Slemmer, JE; Matser, EJT; De Zeeuw, CI; Weber, JT				Slemmer, JE; Matser, EJT; De Zeeuw, CI; Weber, JT			Repeated mild injury causes cumulative damage to hippocampal cells	BRAIN			English	Article						brain trauma; hippocampal neurones; in vitro; neurone-specific enolase; S-100 beta	TRAUMATIC BRAIN INJURY; CONTROLLED CORTICAL IMPACT; NEURON-SPECIFIC ENOLASE; AMATEUR SOCCER PLAYERS; STRETCH-INDUCED INJURY; HEAD-INJURY; S-100 PROTEIN; SERUM LEVELS; RAT; VULNERABILITY	An interesting hypothesis in the study of neurotrauma is that repeated traumatic brain injury may result in cumulative damage to cells of the brain. However, post-injury sequelae are difficult to address at the cellular level in vivo. Therefore, it is necessary to complement these studies with experiments conducted in vitro. In this report, the effects of single and repeated traumatic injury in vitro were investigated in cultured mouse hippocampal cells using a well characterized model of stretch-induced injury. Cell damage was assessed by the level of propidium iodide (PrI) uptake and retention of fluorescein diacetate (FDA). Uninjured control wells displayed minimal PrI uptake and high levels of FDA retention. Mild, moderate and severe levels of stretch caused increasing amounts of PrI uptake, respectively, when measured at 15 min and 24 h post-injury, indicating increased cellular damage with increasing amounts of stretch. For repeated injury studies, cultures received a second injury 1 h after the initial insult. Repeated mild injury caused a slight increase in PrI uptake compared with single injury at 15 min and 24 h post-injury, which was evident primarily in glial cells. However, the neurites of neurones in cultures that received repeated insults showed signs of damage that were not evident after a single mild injury. The release of neurone-specific enolase (NSE) and S-100beta protein, two common clinical markers of CNS damage, was also measured following the repeated injuries paradigm. When measured at 6 h post-injury, both NSE and S-100beta were found to be elevated after repeated mild injuries when compared with the single injury group. These results suggest that cells of the hippocampus may be susceptible to cumulative damage following repeated mild traumatic insults. Both glial cells and neurones appear to exhibit increased signs of damage after repetitive injury. To our knowledge, this study represents the first report on the effects of repeated mechanical insults on specific cells of the brain using an in vitro model system. The biochemical pathways of cellular degradation following repeated mild injuries may differ considerably from those that are activated by a single mild insult. Therefore, we hope to use this model in order to investigate secondary pathways of cellular damage after repeated mild traumatic injury, and as a rapid and economical means of screening possibilities for treatment strategies, including pharmaceutical intervention.	Erasmus Med Ctr, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands; St Anna Hosp, Dept Neuropsychol & Sports Neurol, Geldrop, Netherlands	Weber, JT (corresponding author), Erasmus Med Ctr, Dept Neurosci, Dr Molenwaterplein 50, NL-3000 DR Rotterdam, Netherlands.						Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Babbs CF, 2000, JAMA-J AM MED ASSOC, V283, P882, DOI 10.1001/jama.283.7.882; BAILES JE, 1998, SPORTS NEUROLOGY, P215; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Mattson MP, 1999, J NEUROSCI RES, V58, P152, DOI 10.1002/(SICI)1097-4547(19991001)58:1<152::AID-JNR15>3.0.CO;2-V; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; OLSSON Y, 1971, ACTA NEUROPATHOL, V19, P225, DOI 10.1007/BF00684599; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHREIBER D, 1995, INT RES COMMITTEE BI, P233; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	50	64	67	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	DEC	2002	125		12				2699	2709		10.1093/brain/awf271			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	615MT	WOS:000179250400010	12429597	Bronze			2021-06-18	
J	Whyte, J; Vaccaro, M; Grieb-Neff, P; Hail, T				Whyte, J; Vaccaro, M; Grieb-Neff, P; Hail, T			Psychostimulant use in the rehabilitation of individuals with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						amphetamine; attention; brain injury; dextroamphetamine; memory; methylphenidate	DEFICIT HYPERACTIVITY DISORDER; SUSTAINED-RELEASE METHYLPHENIDATE; CLOSED-HEAD-INJURY; DOUBLE-BLIND; CHILDREN; RECOVERY; AMPHETAMINE; TRIALS	Background: Psychostimulants are used commonly in the rehabilitation of individuals with traumatic brain injury (TBI), despite the dearth of well-controlled studies of their effects. The available literature suggests that these drugs predominantly affect the speed of cognitive processing and certain observational ratings of mood and behavior. Effects on sustained attention, distractibility, and memory are less clear. Objective: This article reviews the controlled research literature on the use of these drugs in TBI and presents preliminary data from the authors' laboratory that extends these findings. Some of the common research pitfalls that have limited progress in research on these drugs are discussed.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd,Korman Bldg,Suite 211, Philadelphia, PA 19141 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R24 HD 39621-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS 39163] Funding Source: Medline		BIRMAHER B, 1989, J AM ACAD CHILD PSY, V28, P768, DOI 10.1097/00004583-198909000-00020; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Braha RED, 1999, NEUROREHABILITATION, V12, P201; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Dhillon HS, 1998, BRAIN RES, V804, P231, DOI 10.1016/S0006-8993(98)00639-8; Dougherty DD, 1999, LANCET, V354, P2132, DOI 10.1016/S0140-6736(99)04030-1; Efron D, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e6; Efron D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/peds.100.4.662; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hinkin CH, 2001, J NEUROPSYCH CLIN N, V13, P248, DOI 10.1176/appi.neuropsych.13.2.248; HOFFMAN BB, 2001, PHARM BASIS THERAPEU; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Jansen IHM, 2001, J AM GERIATR SOC, V49, P474, DOI 10.1046/j.1532-5415.2001.49092.x; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Laborde A, 1997, J HEAD TRAUMA REHAB, V12, P90, DOI 10.1097/00001199-199708000-00009; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; Mehta MA, 2000, J NEUROSCI, V20; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PELHAM WE, 1990, PEDIATRICS, V86, P226; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Pliszka SR, 1998, PEDIATR CLIN N AM, V45, P1085, DOI 10.1016/S0031-3955(05)70063-8; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Thompson SJ, 2001, J CLIN ONCOL, V19, P1802, DOI 10.1200/JCO.2001.19.6.1802; Tiberti C, 1998, EUR J NEUROL, V5, P297, DOI 10.1046/j.1468-1331.1998.530297.x; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VASTAG V, 2001, JAMA-J AM MED ASSOC, V285, P905; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Wax PM, 1997, J TOXICOL-CLIN TOXIC, V35, P203, DOI 10.3109/15563659709001195; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P59; Whyte J., 1997, PROMISE OUTCOMES RES, P43; WHYTE J, 1998, INT PERSPECTIVES TRA, P154; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Worzniak M, 1997, J FAM PRACTICE, V44, P495	44	64	66	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2002	17	4					284	299		10.1097/00001199-200208000-00003			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	578UY	WOS:000177140200003	12105998				2021-06-18	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			Delayed-onset posttraumatic stress disorder: a prospective evaluation	AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY			English	Article						delayed onset; diagnosis; posttraumatic stress disorder	MOTOR-VEHICLE ACCIDENTS; 2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN INJURY; PTSD; WAR; PREDICTORS; INTERVIEW; SURVIVORS; SYMPTOMS; VETERANS	Objective: Delayed onset posttraumatic stress disorder (PTSD) refers to PTSD that develops at least 6 months after the traumatic event. This study aimed to index the features of patients who develop delayed-onset PTSD. Method: This study investigated delayed onset PTSD by prospectively assessing 103 motor vehicle accident survivors within 1 month of the motor vehicle accident for acute stress disorder, and subsequently assessing them for PTSD 6 months post-accident, and 2 years post-accident. Patients were initially assessed for symptoms of traumatic stress, anxiety, depression, and resting heart rate. Results: Five patients displayed PTSD 2 years post-trauma without meeting PTSD criteria 6 months posttrauma. Delayed onset cases were characterized by elevated psycho-pathology scores and resting heart rate levels within the initial month and elevated psychopathology 6 months posttrauma. Conclusions: These findings suggest that cases of delayed onset PTSD suffer subsyndromal levels of posttraumatic stress prior to the diagnosis of PTSD. These findings challenge the notion of PTSD developing after a period without symptoms.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Oxford, Oxford, England	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			*ASS ADV AUT MED, 1990, ABBR INJ SCAL; BECK AT, 1979, COGNITIVE THERAPY DE; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; EPSTEIN RS, 1993, J TRAUMA STRESS, V6, P451, DOI 10.1002/jts.2490060404; GREEN BL, 1990, AM J ORTHOPSYCHIAT, V60, P43, DOI 10.1037/h0079168; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HERRMANN N, 1994, CAN J PSYCHIAT, V39, P439, DOI 10.1177/070674379403900710; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P30, DOI 10.1097/00005053-198801000-00004; MCFARLANE AC, 1997, PSYCHOBIOLOGY POSTTR, P433; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; PITMAN RK, 1989, BIOL PSYCHIAT, V26, P221, DOI 10.1016/0006-3223(89)90033-4; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; SIMON RI, 1995, POSTTRAUMATIC STRESS; SOLOMON Z, 1989, PSYCHIATRY, V52, P428, DOI 10.1080/00332747.1989.11024467; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; VANDYKE C, 1985, AM J PSYCHIAT, V142, P1070	26	64	64	0	5	BLACKWELL PUBLISHING ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0004-8674			AUST NZ J PSYCHIAT	Aust. N. Z. J. Psych.	APR	2002	36	2					205	209		10.1046/j.1440-1614.2002.01009.x			5	Psychiatry	Psychiatry	554XR	WOS:000175762900007	11982541				2021-06-18	
J	von Oettingen, G; Bergholt, B; Gyldensted, C; Astrup, J				von Oettingen, G; Bergholt, B; Gyldensted, C; Astrup, J			Blood flow and ischemia within traumatic cerebral contusions	NEUROSURGERY			English	Article						contusion; head injury; ischemia; regional cerebral blood flow; xenon-enhanced computed tomography	HEAD-INJURY; XENON-CT; INTRACRANIAL HYPERTENSION; FOCAL ISCHEMIA; PRESSURE; PATHOPHYSIOLOGY; TOMOGRAPHY; METABOLISM; INHALATION	OBJECTIVE: To provide evidence of irreversible ischemia in cerebral contusions among patients with severe traumatic brain injuries and to clarify the potential viability of tissue in the pericontusional zone, quantitative regional cerebral blood flow (rCBF) measurements obtained with the xenon-enhanced computed tomographic method were correlated with the areas of contusions, by using image fusion. METHODS: rCBF measurements obtained during the acute phase (mean, 2 d after injury; range, 0-10 d) were statistically correlated with the extent of tissue necrosis identified as focal atrophy on late follow-up computed tomographic scans (mean time after the xenon-enhanced computed tomographic cerebral blood flow investigation, 265 d; range, 30-1047 d). RESULTS: Seventeen patients exhibited 26 traumatic contusions. All contusions progressed to late focal atrophic areas on the follow-up computed tomographic scans. The rCBF values within the traumatic contusions ranged from 0.5 to 22.0 ml/100 g/min, with a mean of 5.9 +/- 5.9 ml/100 g/min. The contusions exhibited a specific rCBF profile, presenting as a core of severe lethal ischemia surrounded by variable but gradually increasing perfusion with increasing distance from the ischemic core. CONCLUSION: The ischemic profile of the contusions, with a pericontusional zone of low rCBF, presents the potential risk of secondary ischemic insults, similar to the risk in the ischemic penumbral zones surrounding areas of acute ischemic stroke.	Aarhus Univ Hosp, Dept Neurosurg, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Neuroradiol, DK-8000 Aarhus C, Denmark	von Oettingen, G (corresponding author), Aarhus Univ Hosp, Dept Neurosurg, Noerebrogade 44, DK-8000 Aarhus C, Denmark.	von_oettingen@dadlnet.dk					ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bullock RM, 2000, J NEUROTRAUM, V17, P449; FATOUROS PP, 1995, QUANTITATIVE CEREBRAL BLOOD FLOW MEASUREMENTS USING STABLE XENON/CT: CLINICAL APPLICATIONS, P73; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HOLL K, 1995, QUANTITATIVE CEREBRAL BLOOD FLOW MEASUREMENTS USING STABLE XENON/CT: CLINICAL APPLICATIONS, P41; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KASHIWAGI S, 1986, Electromedica (English Edition), V54, P136; KETY SS, 1951, PHARMACOL REV, V3, P1; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MEYER JS, 1980, AM J ROENTGENOL, V135, P239, DOI 10.2214/ajr.135.2.239; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; OBRIST WD, 1990, CEREBROVAS BRAIN MET, V2, P283; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Obrist WD, 1998, J CEREBR BLOOD F MET, V18, P1192, DOI 10.1097/00004647-199811000-00005; OBRIST WD, 1967, CIRC RES, V20, P124, DOI 10.1161/01.RES.20.1.124; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; POLACIN A, 1991, MED PHYS, V18, P1025, DOI 10.1118/1.596738; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; von Oettingen G, 2000, J NEUROSCI METH, V95, P159, DOI 10.1016/S0165-0270(99)00179-X; von Oettingen G, 2000, NEURORADIOLOGY, V42, P168, DOI 10.1007/s002340050039; YONAS H, 1988, STROKE, V19, P228, DOI 10.1161/01.STR.19.2.228; YONAS H, 1989, NEUROSURGERY, V24, P368, DOI 10.1227/00006123-198903000-00010	34	64	64	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2002	50	4					781	788		10.1097/00006123-200204000-00019			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	539DQ	WOS:000174855100027	11904029				2021-06-18	
J	Gottesfeld, Z; Moore, AN; Dash, PK				Gottesfeld, Z; Moore, AN; Dash, PK			Acute ethanol intake attenuates inflammatory cytokines after brain injury in rats: A possible role for corticosterone	JOURNAL OF NEUROTRAUMA			English	Article						corticosterone; ethanol; interleukin-1 beta; traumatic brain injury; tumor necrosis factor-alpha	TUMOR-NECROSIS-FACTOR; CORTICOTROPIN-RELEASING-FACTOR; BLOOD-ALCOHOL LEVEL; CONTROLLED CORTICAL IMPACT; FACTOR-ALPHA; TNF-ALPHA; HEAD-INJURY; NERVOUS-SYSTEM; INFARCT VOLUME; EXPRESSION	It has been reported that acute ethanol intoxication exerts dose-dependent effects, both beneficial and detrimental, on the outcome of traumatic brain injury (TBI), although the mechanism(s) has not been determined. Given that pro-inflammatory cytokines are either neuroprotective or neurotoxic, depending on their tissue levels, ethanol-induced alterations in brain cytokine production may be involved in determining the recovery after TBI. The present study was undertaken to examine the effect of acute ethanol pretreatments (producing blood alcohol concentrations of 100 +/- 16 mg/dL, and 220 +/- 10 mg/dL, considered low and intoxicating doses, respectively) on interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) levels in discrete brain regions. In addition, serum corticosterone levels were also examined because the hormone is a modulator of cytokine production, its secretion is stimulated by ethanol, and it has been associated with the severity of post-injury neurologic dysfunction. The data presented in this report demonstrate that moderate cortical impact brain injury elicits a marked increase in IL-1beta and TNF-alpha in the injured cortex as well as in the hippocampus ipsilateral to the injury. Ethanol pretreatment lowered cytokine levels in the cortex, hippocampus and hypothalamus in a dose-dependent manner after TBI compared to the untreated injured rats. Serum corticosterone levels were markedly increased in the injured rats, and were further augmented in the ethanol-pretreated injured animals in a dose-dependent manner. Our findings suggest that ethanol-induced decrease in pro,inflarnmatory cytokine production may be linked to increased circulating corticosterone, both of which may contribute to the outcome of brain injury.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327, R01NS035457] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, P50NS23327] Funding Source: Medline		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; BRADBURY A, 1991, INJURY, V22, P132, DOI 10.1016/0020-1383(91)90074-O; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Cernak I, 1999, BRAIN INJURY, V13, P1005; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Craighead MW, 2000, BRAIN RES, V881, P139, DOI 10.1016/S0006-8993(00)02759-1; CROSBY WH, 1956, BLOOD, V11, P380, DOI 10.1182/blood.V11.4.380.380; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; DUNN AJ, 1993, CIBA F SYMP, V172, P226; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hallenbeck JM, 1997, NEUROLOGY, V49, pS5, DOI 10.1212/WNL.49.5_Suppl_4.S5; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kapcala LP, 1995, ANN NY ACAD SCI, V771, P419, DOI 10.1111/j.1749-6632.1995.tb44699.x; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MARWAY JS, 1994, BIOCHEM SOC T, V22, pS351, DOI 10.1042/bst022351s; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIVIER C, 1984, ENDOCRINOLOGY, V115, P882, DOI 10.1210/endo-115-3-882; Rivier C, 1999, ALCOHOL CLIN EXP RES, V23, P673, DOI 10.1097/00000374-199904001-00014; RIVIER CL, 1986, ANNU REV PHYSIOL, V48, P475, DOI 10.1146/annurev.ph.48.030186.002355; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STERNBERG EM, 1995, HORM RES, V43, P159, DOI 10.1159/000184268; STRUBELT O, 1974, ARCH TOXICOL, V32, P83, DOI 10.1007/BF00316229; SULLIVAN P, 1997, J NEUROTRAUM, V14, P770; SZABO G, 1994, J CLIN IMMUNOL, V14, P340, DOI 10.1007/BF01546318; Tate PS, 1999, BRAIN INJURY, V13, P767; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	67	64	70	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					317	326		10.1089/089771502753594882			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900003	11939499				2021-06-18	
J	Dash, PK; Mach, SA; Moore, AN				Dash, PK; Mach, SA; Moore, AN			The role of extracellular signal-regulated kinase in cognitive and motor deficits following experimental traumatic brain injury	NEUROSCIENCE			English	Article						spatial memory; plasticity; hippocampus; conditioned emotional response; mitogen-activated protein kinase; brain injury	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY; CELL-DEATH; RAT HIPPOCAMPUS; IN-VIVO; ACTIVATION; NEUROPROTECTION; INHIBITION; CASCADE	Traumatic brain injury (TBI) causes neuronal death and alters the plasticity (e.g. morphology) of surviving neurons. Both of these events contribute to TBI-associated neurological deficits, such as memory dysfunction. Although a majority of current research is directed towards identifying biochemical cascades responsible for cell death, little is known about mechanisms of altered neuronal plasticity following TBI. Extracellular signal-regulated kinases (Erk1 and 2) play a critical role in growth and have been implicated in long-lasting neuronal plasticity and memory storage. The activation of Erk following TBI was investigated utilizing an antibody that specifically binds to dually phosphorylated Erk. Using this antibody, we report that lateral cortical impact injury in rats increases Erk phosphorylation both in the cortex and the hippocampus as early as 10 min post-injury. Double immunostaining experiments using either a neuron-specific or an astroglial-specific marker show that the active Erk is localized almost exclusively in neuronal cells. Furthermore, the increase in phospho-Erk immunoreactivity was initially localized to axons and at later time points was observed to be predominantly in the cell soma. This suggests that Erk redistributed over time and may play a role in retrograde signaling. Administration of inhibitors of the Erk cascade worsened retrograde amnesia, impaired performances in hippocampus- and amygdala-dependent memory tasks, and exacerbated motor deficits following TBI. Furthermore, inhibition of this cascade did not have any overt effects on cell survival, but altered neuronal morphology as detected by a dendritic-specific marker. These findings suggest that the Erk cascade plays an essential role for the maintenance of neuronal function and plasticity following TBI. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, POB 20708, Houston, TX 77225 USA.				NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS3545, P50NS23327] Funding Source: Medline		Alberini CM, 1999, J EXP BIOL, V202, P2887; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BARNES CA, 1994, J NEUROSCI, V14, P5793; Blum S, 1999, J NEUROSCI, V19, P3535; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; D'Onofrio M, 2001, J NEUROCHEM, V78, P435, DOI 10.1046/j.1471-4159.2001.00435.x; DASH PK, 1995, J NEUROSCI, V15, P2030; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KLANN E, 1991, J BIOL CHEM, V266, P24253; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NEWLON PG, 1991, BRAIN RES, V544, P320, DOI 10.1016/0006-8993(91)90072-4; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Satoh T, 2000, NEUROSCI LETT, V288, P163, DOI 10.1016/S0304-3940(00)01229-5; Schafe GE, 2000, J NEUROSCI, V20, P8177; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Sung YJ, 2001, J NEUROBIOL, V47, P67, DOI 10.1002/neu.1016; SUZUKI WA, 1993, J NEUROSCI, V13, P2430; Valjent E, 2000, J NEUROSCI, V20, P8701; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	47	64	66	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	114	3					755	767	PII S0306-4522(02)00277-4	10.1016/S0306-4522(02)00277-4			13	Neurosciences	Neurosciences & Neurology	601GZ	WOS:000178439300022	12220576				2021-06-18	
J	Hiott, DW; Labbate, L				Hiott, DW; Labbate, L			Anxiety disorders associated with traumatic brain injuries	NEUROREHABILITATION			English	Article						traumatic brain injury; obsessive compulsive disorder; posttraumatic stress disorder; panic disorder; generalized anxiety disorder	OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; PSYCHIATRIC-DISORDERS; PANIC DISORDER; CONSEQUENCES; INDIVIDUALS; DEPRESSION; TOMOGRAPHY; LESIONS	Anxiety disorders are common in the general population and may be even more common in people with traumatic brain injuries. This article presents a review of the literature on anxiety disorders as a result of traumatic brain injury, specifically post-traumatic stress disorder, generalized anxiety disorder, obsessive compulsive disorder, and panic disorder. Our current understanding suggests that the increased frequency of anxiety disorders after TBI may reflect an overlap between brain regions vulnerable to traumatic brain injury, and the neural circuitry of these disorders. Issues regarding treatment are largely anecdotal, and much remains unsettled. More research is needed, both in terms of diagnosis and treatment.	Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson VAMC, Charleston, SC 29425 USA	Hiott, DW (corresponding author), Med Univ S Carolina, Dept Psychiat, 67 President St,5 South, Charleston, SC 29412 USA.	hiottdw@musc.edu					Adler A, 1943, J AMER MED ASSOC, V123, P1098, DOI 10.1001/jama.1943.02840520014004; American Psychiatric Association, 1994, DIAGN STAT MAN, V4th; Berthier ML, 1996, NEUROLOGY, V47, P353, DOI 10.1212/WNL.47.2.353; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Bisaga A, 1998, AM J PSYCHIAT, V155, P1178, DOI 10.1176/ajp.155.9.1178; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Childers MK, 1998, BRAIN INJURY, V12, P613; Coplan JD, 1998, BIOL PSYCHIAT, V44, P1264, DOI 10.1016/S0006-3223(98)00300-X; Deb S, 1999, AM J PSYCHIAT, V156, P374; DICESARE A, 1990, COGNITIVE REHABILITA, V8, P14; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; Epstein Richard S., 1994, P285; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fischer H, 1998, NEUROSCI LETT, V251, P137, DOI 10.1016/S0304-3940(98)00503-5; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; Griffith J P, 1998, W V Med J, V94, P198; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Javanmard M, 1999, BIOL PSYCHIAT, V45, P872, DOI 10.1016/S0006-3223(98)00348-5; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kant R, 1996, BRAIN INJURY, V10, P55; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Khouzam HR, 1998, GEN HOSP PSYCHIAT, V20, P62, DOI 10.1016/S0163-8343(97)00097-2; KLONOFF H, 1971, PERCEPT MOTOR SKILL, V32, P603, DOI 10.2466/pms.1971.32.2.603; LEWIS A, 2001, P ROY SOC MED, V35, P607; Malizia AL, 1998, ARCH GEN PSYCHIAT, V55, P715, DOI 10.1001/archpsyc.55.8.715; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; MELTZER H, 1995, REPORTS OFFICE POPUL, V1; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Saxena S, 1998, BRIT J PSYCHIAT, V173, P26; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SooMeng K, 1997, INT J CLIN PRACT, V51, P336; Van der Linden G, 2000, PROG NEURO-PSYCHOPH, V24, P419, DOI 10.1016/S0278-5846(99)00109-8; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Villarreal G, 2001, Semin Clin Neuropsychiatry, V6, P131, DOI 10.1053/scnp.2001.21840; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; YUDOFSKY SC, APA ANN REV, V4, P142; Zohar J, 2000, ACTA PSYCHIAT SCAND, V101, P39, DOI 10.1111/j.1600-0447.2000.tb10947.x	44	64	66	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2002	17	4					345	355					11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	636GA	WOS:000180445200008	12547982				2021-06-18	
J	McCrory, PR; Berkovic, SF				McCrory, PR; Berkovic, SF			Concussion - The history of clinical and pathophysiological concepts and misconceptions	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; HEAD-INJURY; DAMAGE; TRAUMA	Concussion is a well-recognized clinical entity; however, its pathophysiologic basis remains a mystery. One unresolved issue is whether concussion is associated with lesser degrees of diffuse structural change seen in severe traumatic brain injury, or is the mechanism entirely caused by reversible functional changes. This issue is clouded not only by the lack of critical data, but also by confusion in terminology, even in contemporary literature. This confusion began in ancient times when no distinction was made between the transient effects of concussion and severe traumatic brain injury. The first clear separate recognition of concussion was made by the Persian physician, Rhazes, in the 10th century. Lanfrancus subsequently expanded this concept as brain "commotion" in the 13th century, although other Renaissance physicians continued to obscure this concept. By the 18th century, a variety of hypotheses for concussion had emerged. The 19th century discovery of petechial hemorrhagic lesions in severe traumatic brain injury led to these being posited as the basis of concussion, and a similar logic was used later to suggest diffuse axonal injury was responsible. The neuropathology and pathophysiology of concussion has important implications in neurology, sports medicine, medicolegal medicine, and in the understanding of consciousness. Fresh approaches to these questions are needed and modern research tools, including functional imaging and experimental studies of ion-channel function, could help elucidate this puzzle that has evolved over the past 3,000 years.	Univ Melbourne, Austin & Repatriat Med Ctr, Brain Res Inst, Heidelberg, Vic 3084, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Epilepsy Res Inst, Heidelberg, Vic 3084, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Ctr Sports Med Res & Educ, Heidelberg, Vic 3084, Australia	McCrory, PR (corresponding author), 31 Grosvenor Parade, Balwyn, Vic 3103, Australia.		McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			ABBOTT K, 1961, B LA NEUROL SCI, V26, P97; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBUCASIS, 1532, OCTAVII HORATIANI RU; ALRODHAN NRF, 1986, SURG NEUROL, V26, P92, DOI 10.1016/0090-3019(86)90070-4; AVICENA, 1479, CANON MED; BAUDNES M, 1836, CLIN PLAIES ARMES FE; BELL B, 1786, SYSTEM SURG; BELL J, 1807, DISCOURSES NATURE CU; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Boirel A, 1674, TRITE PLAYES TESTE; Breasted JH, 1930, E SMITH SURG PAPYRUS; Bright R., 1831, REPORTS MED CASES SE; Brunschwig H, 1497, IST BUCH CIRURGIE; BRYANT T, 1888, LANCET, V2, P405; BRYANT T, 1888, LANCET, V2, P507; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CELSUS A, 1493, MEDICINA; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; Clevenger S. V., 1889, SPINAL CONCUSSION; COITIER V, 1573, EXTERNARUM INTERNARU; Conrad LI N. M., 1995, W MED TRADITION; COOPER A, 1824, LECT SIR A COOPER PR; Courville C. B., 1967, INJURIES SKULL BRAIN; COURVILLE CB, 1944, B LOS ANGELES NEUROL, V9, P1; DACARPI B, 1535, TRACTATUS PERUTILIS; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DESAULT P, 1830, OEUVRES CHIRURG EXPO; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; Dixon KC, 1940, LANCET, V2, P360; du Chauliac G, 1499, CYRURGIA GUIDONIS CA; DURET H, 1920, REV NEUROL, V27, P888; EBIED R, 1971, BIBLIO MEDIEVAL ARAB; Elsberg Charles A, 1931, Ann Med Hist, V3, P271; ERICHSEN JE, 1882, CONCUSSION SPINE NER; FABRICIUS H, 1578, OPERE CHIAUGICHE SIG; Fano S., 1853, MEM SOC CHIR PARIS, V3, P163; Flamm E., 1996, HIST NEUROSURGERY, P65; Gabriel Richard A, 1992, HIST MILITARY MED, V1; GALEN C, 1856, OUVRES ANATOMIQUES P; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GOODRICH J, 1996, HIST NEUROSURGERY, P37; Gurdjian ES., 1973, HEAD INJURY ANTIQUIT; HEISSE K, 1929, MONATSCHR UNFALH, V36, P120; HEISTER L, 1739, I CHIRURG; Heister L., 1750, I CHIRURG; HIPPOCRATES, 1525, HIPPOCRATIS COI MEDI; Hippocrates, 1950, HIPPOCRATIC WRITINGS; Hippocrates, 1849, GENUINE WORKS HIPPOC; Hitti Philip Khuri, 1937, HIST ARABS; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; JANE JA, 1985, TRAUMA CENTRAL NERVO, P27; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kontos H.A., 1980, CLIN ASS T, V92, P111; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; KRIKLAND T, 1792, COMMENTARY APOPLECTI; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Littre M., 1705, HIST ACAD ROYALE SCI; Lyons A.S., 1987, MED ILLUSTRATED HIST; Majno G, 1975, HEALING HAND MAN WOU; Marchetti P., 1665, OBSERVATIONUM MED CH; McHenry L.C., 1969, GARRISONS HIST NEURO; Mettler C., 1947, HIST MED; METTLER FA, 1945, RES PUBL ASSOC RES N, V24, P1; Neuburger Max, 1910, HIST MED; Nunn J.F., 1996, ANCIENT EGYPTIAN MED; OPPENHEIMER D, 1968, J EXP NEUROL, V26, P77; Page Herbert, 1883, INJURIES SPINE SPINA; PARE A, 1579, WORKES FAMOUS CHIRUR; PAULUS, 1844, 7 BOOKS PAULUS AEGIN; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Petit J-L, 1774, TRAITE MALADIES CHIR; Polis A, 1894, REV CHIR, V14, P273; Pott P., 1768, OBSERVATIONS NATURE; Quesnay Francois, 1744, RECHERCHES CRITIQUES; QUEYRAT L, 1657, TRACTATUS VULNERABLI; READ A, 1687, CHIRURGORUM COMES WH; RHAZES A, 1548, LUTETIAE EX OFFICINA; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SARMA P, 1931, ANN MED HIST, V3, P320; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; SYME JT, 1856, PRINCIPLES SURG; SYMONDS C, 1962, LANCET, V1, P1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Trotter W, 1924, LANCET, V1, P935; WILKINS RH, 1964, J NEUROSURG, V21, P240, DOI 10.3171/jns.1964.21.3.0240; Witkowski L., 1877, ARCH PATH ANAT, V69, P498	91	64	65	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	DEC 26	2001	57	12					2283	2289		10.1212/WNL.57.12.2283			7	Clinical Neurology	Neurosciences & Neurology	505BP	WOS:000172891500023	11756611				2021-06-18	
J	Boddeke, EWGM				Boddeke, EWGM			Involvement of chemokines in pain	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article; Proceedings Paper	Spring Meeting of the European-Journal-of-Pharmacology	JUN 08-10, 2001	ZEIST, NETHERLANDS	European Journal Pharmacol		chemokine; nociception; hyperalgesia; inflammation	RECEPTOR EXPRESSION; CNS; HYPERALGESIA; INFLAMMATION; ACTIVATION; NOCICEPTIN; CYTOKINES; CELLS; NEUROINFLAMMATION; INTERLEUKIN-8	It is well established that neuroinflammation plays an important role in neurodegenerative diseases like Alzheimer's disease, stroke, traumatic brain- and spinal cord injury and demyelinating diseases. Likewise, it has been suggested that neuroinflammation plays an important role in nociception and hyperalgesia. Most research concerning inflammatory aspects of pain has concerned the effects of proinflammatory cytokines, prostaglandins and growth factors. Recently, it has been suggested that chemokines play a role in inflammatory pain. Chemokines do not only attract blood leukocytes to the site of injury but also contribute directly to nociception. (C) 2001 Published by Elsevier Science B.V.	Univ Groningen, Dept Med Physiol, NL-9713 AV Groningen, Netherlands	Boddeke, EWGM (corresponding author), Univ Groningen, Dept Med Physiol, A Deusinglaan 1,Bld 3125, NL-9713 AV Groningen, Netherlands.	h.w.g.m.boddeke@med.rug.nl					ANTONY VB, 1985, J CLIN INVEST, V76, P1514, DOI 10.1172/JCI112131; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bacon KB, 2000, J NEUROIMMUNOL, V104, P92, DOI 10.1016/S0165-5728(99)00266-0; Boom A, 1999, NEUROSCIENCE, V91, P991, DOI 10.1016/S0306-4522(98)00683-6; CLATWORTHY AL, 1995, NEUROSCI LETT, V184, P5, DOI 10.1016/0304-3940(94)11154-B; CUNHA FQ, 1991, BRIT J PHARMACOL, V107, P660; DEGROOT CJA, 2001, PROG BRAIN RES, V132, P543; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; Gazvani MR, 1998, HUM REPROD, V13, P1957, DOI 10.1093/humrep/13.7.1957; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hochreiter WW, 2000, UROLOGY, V56, P1025, DOI 10.1016/S0090-4295(00)00844-X; Huber JD, 2001, AM J PHYSIOL-HEART C, V280, pH1241; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laughlin TM, 2000, PAIN, V84, P159, DOI 10.1016/S0304-3959(99)00195-5; Limatola C, 2000, EUR J NEUROSCI, V12, P2497, DOI 10.1046/j.1460-9568.2000.00139.x; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Miller DW, 1999, J NEUROVIROL, V5, P570, DOI 10.3109/13550289909021286; Mizumura K, 1996, PROG BRAIN RES, V113, P115, DOI 10.1016/S0079-6123(08)61084-5; Murphy PM, 2000, PHARMACOL REV, V52, P145; Noda Y, 1998, J BIOL CHEM, V273, P18047, DOI 10.1074/jbc.273.29.18047; Oh SB, 2001, J NEUROSCI, V21, P5027, DOI 10.1523/JNEUROSCI.21-14-05027.2001; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Ramer MS, 1997, PAIN, V72, P71, DOI 10.1016/S0304-3959(97)00019-5; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Ribeiro RA, 2000, EUR J PHARMACOL, V387, P111, DOI 10.1016/S0014-2999(99)00790-6; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Serhan CN, 2001, J IMMUNOL, V166, P3650, DOI 10.4049/jimmunol.166.6.3650; Sommer C, 1998, PAIN, V74, P83, DOI 10.1016/S0304-3959(97)00154-1; SOUZA GEP, 1988, AGENTS ACTIONS, V24, P377, DOI 10.1007/BF02028296; Sweitzer SM, 1999, BRAIN RES, V829, P209, DOI 10.1016/S0006-8993(99)01326-8; TAIWO YO, 1990, BRAIN RES, V537, P372, DOI 10.1016/0006-8993(90)90389-S; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Wagner G, 1998, INT J IMPOT RES, V10, P74, DOI 10.1038/sj.ijir.3900335; WAGNER R, 1995, EXP NEUROL, V133, P256, DOI 10.1006/exnr.1995.1028; Wagner R, 1996, NEUROSCIENCE, V73, P625, DOI 10.1016/0306-4522(96)00127-3; Wagner R, 1996, NEUROREPORT, V7, P2897, DOI 10.1097/00001756-199611250-00018; Watkins LR, 1997, PAIN, V71, P225, DOI 10.1016/S0304-3959(97)03369-1; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; Wong D, 1999, J NEUROPATH EXP NEUR, V58, P138, DOI 10.1097/00005072-199902000-00004; Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038/sj.bjp.0701148; Wu DT, 2000, J NEUROVIROL, V6, pS82	53	64	65	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	OCT 19	2001	429	1-3			SI		115	119		10.1016/S0014-2999(01)01311-5			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	495UP	WOS:000172359000012	11698032				2021-06-18	
J	Glenn, MB; O'Neil-Pirozzi, T; Goldstein, R; Burke, D; Jacob, L				Glenn, MB; O'Neil-Pirozzi, T; Goldstein, R; Burke, D; Jacob, L			Depression amongst outpatients with traumatic brain injury	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; HEAD-INJURY; INDIVIDUALS; INVENTORY; RECOVERY	The incidence of depression and its association with subject characteristics in outpatients with traumatic brain injury (TBI) were investigated. Logistic regression was estimated with depressed/not-depressed as the dependent variable in 41 outpatients with TBI who filled out the Beck Depression Inventory-II (BDI-II). Twenty-four of 41 subjects (59%) scored in the depressed categories based on BDI-II scores >13. Fourteen (34%) scored in the moderate or severe depression categories (BDI >19). Logistic regression demonstrated a positive relationship amongst depression and age, female gender, mild TBI, and use of antidepressant and stimulant drugs; and a negative relationship between depression and violent aetiology of injury. ANOVA demonstrated that individuals with mild TBI were significantly older than those with moderate or severe TBI, which might account for the association between depression and age. The implications of these results are discussed.	Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Boston, MA 02114 USA	Glenn, MB (corresponding author), Spaulding Rehabil Hosp, 125 Nashua St, Boston, MA 02114 USA.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXOPOULOS GS, 2000, KAPLAN SADOCKS COMPR, P3060; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P317; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GOLDSTEIN MZ, 2000, KAPLAIN SADOCKS COMP, P3174; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1984, MNAGEMENT HEAD INJUR, P317; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vollmer DG, 1991, J NEUROSURG S, V75, P37	27	64	71	0	13	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					811	818		10.1080/02699050010025777			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400006	11516349				2021-06-18	
J	Goldstein, FC; Levin, HS; Goldman, WP; Clark, AN; Altonen, TK				Goldstein, FC; Levin, HS; Goldman, WP; Clark, AN; Altonen, TK			Cognitive and neurobehavioral functioning after mild versus moderate traumatic brain injury in older adults	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; aging; cognitive functioning; depression	CLOSED-HEAD INJURY; BEHAVIORAL SEQUELAE; PRACTICAL SCALE; FOLLOW-UP; RECOVERY; AGE; CONSEQUENCES; COMA; CLASSIFICATION; PREDICTORS	This study evaluated the early cognitive and neurobehavioral outcomes of older adults with mild versus moderate traumatic brain injury (TBI). Thirty-five patients who were age 50 years and older and sustained mild or moderate TBI were prospectively recruited from acute care hospitals. Patients were administered cognitive and neurobehavioral measures up to 2 months post-injury. Demographically comparable control participants received the same measures. Patients and controls did not have previous histories of substance abuse, neuropsychiatric disturbance, dementia, or neurologic illness. Moderate TBI patients performed significantly poorer than mild TBI patients and controls on most cognitive measures, whereas the mild patients performed comparably to controls. In contrast, both mild and moderate patients exhibited significantly greater depression and anxiety/somatic concern than controls. The results indicate that the classification of TBI as mild versus moderate is prognostically meaningful as applied to older adults. The findings extend previous investigations in young adults by demonstrating a relatively good cognitive outcome on objective measures, but subjective complaints after a single, uncomplicated mild TBI in older persons.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA; Emory Univ, Wesley Woods Ctr, Atlanta, GA USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX USA	Goldstein, FC (corresponding author), Emory Univ, Sch Med, Dept Neurol, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133G30051, R49/CCR612707-01] Funding Source: Medline		AharonPeretz J, 1997, BRAIN INJURY, V11, P871; BALTES PB, 1996, LIFESPAN DEV INDIVID, P427; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Benton A., 1976, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HANNAY HJ, 1988, CONTINUOUS RECOGNITI; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1987, HEAD INJURY, P1; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Libon DJ, 1996, CLIN NEUROPSYCHOL, V10, P237, DOI 10.1080/13854049608406686; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PRIGATANO GP, 1987, NEUROPSYCHOLOGICAL R, P335; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; United States War Department, 1944, ARM IND TEST BATT MA; *US BUR CENS, 1997, STAT ABSTR US 1997; Verhaeghen P, 1997, PSYCHOL BULL, V122, P231, DOI 10.1037/0033-2909.122.3.231; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson BA, 1998, CURR OPIN NEUROBIOL, V8, P281, DOI 10.1016/S0959-4388(98)80152-9; YSEVAGE JA, 1983, J PSYCHIAT RES, V17, P37; ZASLER ND, 1997, ARCH PHYSICAL MED RE, V78, P512	67	64	66	0	13	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-4930 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2001	7	3					373	383		10.1017/S1355617701733115			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	427VA	WOS:000168425100011	11311038				2021-06-18	
J	Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; McLarty, JW				Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; McLarty, JW			A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							MOLECULAR-WEIGHT HEPARIN; CAVA FILTER INSERTION; LOW-DOSE HEPARIN; PULMONARY-EMBOLISM; MAJOR TRAUMA; COMPRESSION STOCKINGS; PROPHYLAXIS; THROMBOSIS; NEUROSURGERY; PLACEMENT	BACKGROUND: Venous thromboembolism (VTE) is a frequent and potentially life-threatening complication after trauma. The purpose of this study is to investigate the effectiveness of enoxaparin in preventing deep venous thrombosis (DVT) and pulmonary embolism (PE) after injury in patients who are at high risk for developing VTE. STUDY DESIGN: A prospective single-cohort observational study was initiated for seriously injured blunt trauma patients admitted to a Level I trauma center during a 7-month period. Patients were eligible for the study if time hospitalized was greater than or equal to 72 hours, Injury Severity Score (ISS) was greater than or equal to 9, enoxaparin was started within 24 hours after admission, and one or more of the following high risk criteria were met: age > 50 years, ISS greater than or equal to 16, presence of a femoral vein catheter, Abbreviated Injury Score (AIS) greater than or equal to 3 for any body region, Glasgow Coma Scale (GCS) Score less than or equal to 8, presence of major pelvic, femur, or tibia fracture, and presence of direct blunt mechanism venous injury. Patients with closed head injuries and nonoperatively treated solid abdominal organ injuries were also potential participants. The primary outcomes measured were thromboembolic events-either a documented lower extremity DVT by duplex color-flow doppler ultrasonography or a PE documented by rapid infusion CT pulmonary angiography or conventional pulmonary angiography. RESULTS: There were 118 patients enrolled in the study. Two patients (2%) developed DVT, one of which was proximal to the calf (95% confidence interval, 0% to 6%). Two of 12 patients (17%) with splenic injuries who received enoxaparin failed initial nonoperative management. There were no other bleeding complications, and no clinical evidence or documented episodes of PE. One patient died from multiple system organ failure. CONCLUSIONS: Enoxaparin is a practical and effective method for reducing the incidence of VTE in high risk, seriously injured patients. This study supports further investigation into the safety of enoxaparin prophylaxis in patients with closed head injuries and nonoperatively treated solid abdominal organ injuries. (J Am Coll Surg 2001;192:161-167. (C) 2001 by the American College of Surgeons).	E Texas Med Ctr, Trauma Serv, Tyler, TX USA; E Texas Med Ctr, Neurosurg Serv, Tyler, TX USA; Univ Texas, Ctr Hlth, Tyler, TX USA	Norwood, SH (corresponding author), 1020 E Idel St, Tyler, TX 75701 USA.						Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; Greenfield LJ, 1997, J TRAUMA, V42, P100, DOI 10.1097/00005373-199701000-00017; Headrick JR, 1997, AM SURGEON, V63, P1; Horlocker TT, 1997, ANESTH ANALG, V85, P874, DOI 10.1097/00000539-199710000-00031; KHANSARINIA S, 1995, J VASC SURG, V22, P231, DOI 10.1016/S0741-5214(95)70135-4; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; McMurtry AL, 1999, J AM COLL SURGEONS, V189, P314, DOI 10.1016/S1072-7515(99)00137-4; *MED EC CO INC, 1998, PHYS DESK REF, P2369; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Peitzman AB, 2000, J TRAUMA, V49, P177, DOI 10.1097/00005373-200008000-00002; Quader MA, 1998, J AM COLL SURGEONS, V187, P641, DOI 10.1016/S1072-7515(98)00255-5; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; ROGERS FB, 1995, SURG CLIN N AM, V75, P279, DOI 10.1016/S0039-6109(16)46588-6; ROTONDO MF, 2000, TRAUMA, P1267; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; Spain DA, 1997, J TRAUMA, V42, P463, DOI 10.1097/00005373-199703000-00014; TuttleNewhall JE, 1997, J TRAUMA, V42, P90, DOI 10.1097/00005373-199701000-00016; Velmahos GC, 1998, J AM COLL SURGEONS, V187, P529, DOI 10.1016/S1072-7515(98)00223-3; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020	31	64	65	0	3	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	FEB	2001	192	2					161	167		10.1016/S1072-7515(00)00802-4			7	Surgery	Surgery	401BA	WOS:000166906000003	11220715				2021-06-18	
J	Berger, MM; Reymond, MJ; Shenkin, A; Rey, F; Wardle, C; Cayeux, C; Schindler, C; Chiolero, RL				Berger, MM; Reymond, MJ; Shenkin, A; Rey, F; Wardle, C; Cayeux, C; Schindler, C; Chiolero, RL			Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial	INTENSIVE CARE MEDICINE			English	Article						trauma; critically ill; selenium; supplementation; thyroid hormone; non-thyroidal illness	EUTHYROID SICK SYNDROME; CRITICALLY ILL PATIENTS; FREE-RADICALS; HEAD-INJURY; HORMONE METABOLISM; MAJOR TRAUMA; BRAIN INJURY; THYROXINE; ILLNESS; SERUM	Objective:To investigate whether early selenium (Se) supplementation can modify the post-traumatic alterations of thyroid hormone metabolism, since the first week after trauma is characterised by low plasma Se and negative Se balances. Design: Prospective, placebo-controlled randomised supplementation trial. Setting: Surgical ICU in a tertiary university hospital. Patients: Thirty-one critically ill trauma patients aged 42 +/- 16 years (mean +/- SD), with severe multiple injury (Injury Severity Score 30 +/- 7). Intervention: Supplementation during the first 5 days after injury with either Se or placebo. The selenium group was further randomised to receive daily 500 mug Se, with or without 150 mg alpha -tocopherol (AT) and 13 mg zinc supplements. The placebo group received the vehicle. Circulating Se, AT, zinc, and thyroid hormones were determined on D0 (= day 0, admission), D1, D2, D5, D10, and D20. Results: Plasma Se, low on DO, normalised from D1 in the selenium group; total T4 and T3 increased more and faster after D2 (P = 0.04 and 0.08), reverse T3 rising less between D0 and D2 (P = 0.05). Conclusions: Selenium supplements increased the circulating Se levels. Supplementation was associated with modest changes in thyroid hormones, with an earlier normalisation of T4 and reverse T3 plasma levels. The addition of AT and zinc did not produce any additional change.	CHU Vaudois, CH-1011 Lausanne, Switzerland; Royal Liverpool Univ Hosp, Liverpool, Merseyside, England	Berger, MM (corresponding author), CHU Vaudois, BH08-660, CH-1011 Lausanne, Switzerland.						BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; Berger MM, 1998, AM J CLIN NUTR, V68, P365; Berger MM, 1996, J TRAUMA, V40, P103, DOI 10.1097/00005373-199601000-00019; Berger MM, 1996, INTENS CARE MED, V22, P575, DOI 10.1007/BF01708099; Bertin-Maghit M, 2000, INTENS CARE MED, V26, P800, DOI 10.1007/s001340051250; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bratter P, 1996, J TRACE ELEM MED BIO, V10, P163; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Chopra IJ, 1997, J CLIN ENDOCR METAB, V82, P329, DOI 10.1210/jc.82.2.329; CONTEMPRE B, 1992, CLIN ENDOCRINOL, V36, P579, DOI 10.1111/j.1365-2265.1992.tb02268.x; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; De Groot LJ, 1999, J CLIN ENDOCR METAB, V84, P151, DOI 10.1210/jc.84.1.151; DOCTER R, 1993, CLIN ENDOCRINOL, V39, P499, DOI 10.1111/j.1365-2265.1993.tb02401.x; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Forceville X, 1998, CRIT CARE MED, V26, P1536, DOI 10.1097/00003246-199809000-00021; HAWKER FH, 1990, CRIT CARE MED, V18, P442, DOI 10.1097/00003246-199004000-00020; HUANG TS, 1987, ENDOCRINOLOGY, V121, P498, DOI 10.1210/endo-121-2-498; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kohrle J, 2000, Rev Endocr Metab Disord, V1, P49, DOI 10.1023/A:1010012419869; Kohrle J, 1996, ACTA MED AUST, V23, P17; KOHRLE J, 1994, EXP CLIN ENDOCRINOL, V102, P63; LEHMANN J, 1982, CLIN CHEM, V28, P1784; MCLARTY DG, 1975, LANCET, V2, P275; NOVITZKY D, 1992, J HEART LUNG TRANSPL, V11, pS196; SLAG MF, 1981, JAMA-J AM MED ASSOC, V245, P43, DOI 10.1001/jama.245.1.43; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; VANELLA A, 1993, NEUROCHEM RES, V18, P1337, DOI 10.1007/BF00975056; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; YANG G, 1994, J TRACE ELEM ELECT H, V8, P159; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25	35	64	65	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JAN	2001	27	1					91	100		10.1007/s001340000757			10	Critical Care Medicine	General & Internal Medicine	400XJ	WOS:000166897700016	11280679				2021-06-18	
J	Biberthaler, P; Mussack, T; Wiedemann, E; Kanz, KG; Koelsch, M; Gippner-Steppert, C; Jochum, M				Biberthaler, P; Mussack, T; Wiedemann, E; Kanz, KG; Koelsch, M; Gippner-Steppert, C; Jochum, M			Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma	WORLD JOURNAL OF SURGERY			English	Article; Proceedings Paper	38th World Congress of the International-Society-of-Surgery/Societe-Internationale-de-Chirurgie (ISS/SIC)	AUG 15-20, 1999	VIENNA, AUSTRIA	Int Soc Surg, Soc Int Chirurg			INTRACRANIAL INJURY; SERUM LEVELS; PROTEIN; PREDICTORS; INDICATORS; MANAGEMENT; SCANS; GFAP	Management of patients with minor head trauma (MHT) continues to be debated in the literature. Measurement of S-100b in serum has been introduced into the discussion as an additional screening tool far intracerebral injuries because routine cranial computed tomography (CCT) of a large number of patients causes logistic difficulties, and the neurologic examination is often impaired by a high frequency of coincidental intoxication. The aim of our study was to determine the diagnostic value of measuring S-100b in the serum of MHT patients to identify risk groups. Additional validity should be aquired by a comparison with plasma levels of polymorphonuclear neutrophil (PMN) elastase an established general trauma marker. A series of 52 patients with MHT were included in the prospective study. At admission the patients underwent a routine CCT scan to detect intracerebral lesions, and blood samples were drawn to investigate circulating levels of S-100b and PMN elastase. For comparison, data for a positive control group of 10 severe head trauma patients (initial Glasgow Coma Scale score < 8) and for a negative control group with 20 healthy volunteers were obtained. The interval between MHT and admission to our hospital was 73.4 +/- 47.0 minutes. The initial S-100b serum levels of MHT patients were 0.470 +/- 0.099 ng/ml, those of the positive control group were 7.16 +/- 3.77 ng/ml, and those of the negative control group were 0.05 +/- 0.01 ng/ml. Relevant pathologic CCT scans were detected in 28.8% of MHT patients; one patient of that group was subjected to immediate surgical intervention (1.9%). At a cut-off point of 0.1 ng/ml, the sensitivity of positive S-100b levels reached 100% and the specificity 40.5%. Plasma levels of PMN elastase reached 60.52 +/- 10.75 ng/ml in the MHT group, 66.4 +/- 14.92 ng/ml in the severely head-injured group, and 23.26 +/- 1.53 ng/ml in the negative control group. Serum levels of S-100b seem to be a highly sensitive but not very specific marker for isolated neurotrauma. Measurement of this parameter may be helpful as an additional screening tool to identify high risk groups in the cohort of MHT patients.	Univ Munich, Chirurg Klin & Poliklin Standort Innenstadt, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany	Biberthaler, P (corresponding author), Univ Munich, Chirurg Klin & Poliklin Standort Innenstadt, Klin Chem & Klin Biochem Abt, Nussbaumstr 20, D-80336 Munich, Germany.						Bianchi R, 1996, BBA-MOL CELL RES, V1313, P258, DOI 10.1016/0167-4889(96)00098-5; BIANCHI R, 1995, BIOCHEM BIOPH RES CO, V208, P910, DOI 10.1006/bbrc.1995.1421; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; HERRMANN M, 1998, ZENTRALBL NEUROCHIR, V59, P208; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KRAUS JF, 1987, HEAD INJURY, P1; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; NastKolb D, 1997, J TRAUMA, V42, P446, DOI 10.1097/00005373-199703000-00012; NASTKOLB D, 1997, J TRAUMA, V42, P454; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SACKETT DL, 1995, CLIN EPIDEMIOLOGY, P59; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012	22	64	68	1	4	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	JAN	2001	25	1					93	97		10.1007/s002680020370			5	Surgery	Surgery	396KR	WOS:000166636000014	11213162				2021-06-18	
J	Yu, CG; Marcillo, AE; Fairbanks, CA; Wilcox, GL; Yezierski, RP				Yu, CG; Marcillo, AE; Fairbanks, CA; Wilcox, GL; Yezierski, RP			Agmatine improves locomotor function and reduces tissue damage following spinal cord injury	NEUROREPORT			English	Article						agmatine; locomotor function; neuroprotection; nitric oxide; NMDA	NITRIC-OXIDE SYNTHASE; RATS; RECEPTORS; INHIBITION; EXPRESSION; DEFICITS; NEURONS; TRAUMA; BRAIN; NMDA	Clinically effective drug treatments for spinal cord injury (SCI) remain unavailable. Agmatine, an NMDA receptor antagonist and inhibitor of nitric oxide synthase (NOS), is an endogenous neuromodulator found in the brain and spinal cord. Evidence is presented that agmatine significantly improves locomotor function and reduces tissue damage following traumatic SCI in rats. The results suggest the importance of future therapeutic strategies encompassing the use of single drugs with multiple targets for the treatment of acute SCI. The therapeutic targets of agmatine (NMDA receptor and NOS) have been shown to be critically linked to the pathophysiological sequelae of CNS injury and this, combined with the non-toxic profile, lends support to agmatine being considered as a potential candidate for future clinical applications; NeuroReport 11:3203-3207 (C) 2000 Lippincott Williams & Wilkins.	Univ Miami, Sch Med, Miami Project, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33136 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA	Yezierski, RP (corresponding author), Univ Miami, Sch Med, Miami Project, 1600 NW 10th Ave,R-48, Miami, FL 33136 USA.		Yu, Chen Guang/C-6176-2011				Agrawal SK, 1997, J NEUROSCI, V17, P1055; AUGUET M, 1995, JPN J PHARMACOL, V69, P285, DOI 10.1254/jjp.69.285; Barinaga M, 1996, SCIENCE, V274, P1466; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Fairbanks CA, 1997, J PHARMACOL EXP THER, V282, P1408; FAIRBANKS CA, 2000, IN PRESS P NATL ACAD; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; GILAD GM, 1996, LIFE SCI, V58, P141; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Horvath G, 1999, EUR J PHARMACOL, V368, P197, DOI 10.1016/S0014-2999(99)00060-6; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; McAdoo DJ, 1997, J NEUROTRAUM, V14, P507, DOI 10.1089/neu.1997.14.507; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085	25	64	67	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	SEP 28	2000	11	14					3203	3207		10.1097/00001756-200009280-00031			5	Neurosciences	Neurosciences & Neurology	363JX	WOS:000089833500032	11043549				2021-06-18	
J	Huang, ME; Cifu, DX; Keyser-Marcus, L				Huang, ME; Cifu, DX; Keyser-Marcus, L			Functional outcomes in patients with brain tumor after inpatient rehabilitation - Comparison with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						rehabilitation; function; outcome; brain tumor; traumatic brain injury	STROKE REHABILITATION; CANCER-PATIENT; EFFICACY	Objective: To compare the functional outcome, length of stay, and discharge disposition of individuals with brain tumor versus those with acute traumatic brain injury. Design: In this study, 78 brain tumor patients were one-to-one matched by location of lesion and age with 78 acute traumatic brain injury patients. Outcome was measured by using the Functional Independence Measure (FIM 228) on admission and discharge. The FIM change and FIM efficiency were also calculated. FIM data were analyzed in three subsets, i.e., activities of daily living, mobility, and cognition. Discharge disposition and rehabilitation length of stay were also compared. Results: Demographic variables of race, marital status, and payer source were comparable for the two groups. No significant difference was found between the brain tumor and the traumatic brain injury populations with respect to total admission FIM, total discharge FIM, and FIM efficiency. The brain injury population had a significantly greater change in FIM. The tumor group had a significantly shorter rehabilitation length of stay and a greater discharge to community rate. Conclusions: Thus, individuals with brain tumor can achieve comparable functional outcome and have a shorter rehabilitation length of stay and greater discharge to community rate than individuals with brain injury.	Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Rehabil & Res Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia Hosp, Rehabil & Res Training Ctr Support Employment, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Huang, ME (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Rehabil & Res Ctr, POB 980661, Richmond, VA 23298 USA.			Cifu, David/0000-0003-1600-9387; Keyser-Marcus, Lori/0000-0001-6014-2500			ALEXANDER MP, 1994, STROKE, V25, P128, DOI 10.1161/01.STR.25.1.128; ANDERSON TP, 1974, ARCH PHYS MED REHAB, V55, P545; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS37, DOI 10.1016/S0003-9993(98)90120-4; BONTKE CF, 1996, PHYS MED REHABILITAT, P1027; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; CIFU DX, 1994, ARCH PHYS MED REHAB, V75, P56; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Garden FH, 1996, PHYSICAL MED REHABIL, P1199; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Haut MW, 1991, NEUROREHABILITATION, V1, P39; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Huang ME, 1998, ARCH PHYS MED REHAB, V79, P1386, DOI 10.1016/S0003-9993(98)90232-5; IMPERATO JP, 1990, ANN NEUROL, V28, P818, DOI 10.1002/ana.410280614; Karnofsky DA., 1949, EVALUATION CHEMOTHER, P191; KEITH RA, 1987, ADV CLIN REHABILITAT, V2, P6; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEHMANN JF, 1975, ARCH PHYS MED REHAB, V56, P375; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Marciniak CM, 1996, ARCH PHYS MED REHAB, V77, P54, DOI 10.1016/S0003-9993(96)90220-8; McKinley WO, 1996, ARCH PHYS MED REHAB, V77, P892, DOI 10.1016/S0003-9993(96)90276-2; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Patchell RA, 1998, JAMA-J AM MED ASSOC, V280, P1485, DOI 10.1001/jama.280.17.1485; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; YOSHIOKA H, 1994, AM J PHYS MED REHAB, V73, P199, DOI 10.1097/00002060-199406000-00009; 1995, GUIDE UNIFORM DATA S	29	64	64	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	2000	79	4					327	335		10.1097/00002060-200007000-00003			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	329HY	WOS:000087902600003	10892618				2021-06-18	
J	Mattson, AJ; Levin, HS; Grafman, J				Mattson, AJ; Levin, HS; Grafman, J			A case of prosopagnosia following moderate closed head injury with left hemisphere focal lesion	CORTEX			English	Article							FACE RECOGNITION; OBJECT; PATHWAYS; DISSOCIATION; AGNOSIA; PET	This study describes a left handed woman with prosopagnosia following traumatic brain injury with a focal lesion confined to the left-posterior hemisphere. Few cases of prosopagnosia following unilateral left hemisphere lesions have previously been reported in the literature. Corrected visual acuity was 20/70 (binocular), color vision was intact on screening, and shape detection was borderline. Impairments in higher order visual perception were evident to varying degrees on nonfacial tasks. Matching of unfamiliar faces was very slow but accurate. A marked impairment in the ability to recognize familiar faces and learn new face-name associations was evident on experimental tasks relative to the performance of healthy control subjects. In contrast, identification of characteristics of faces (gender, age) and identification and matching of facial expressions were relatively preserved. We discuss the cognitive processing stages that appear to be disrupted using Bruce and Young's (1986) model of facial recognition and perception as a framework.	Western State Hosp, Neuropsychol Serv, Steilacoom, WA USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; NIH, Cognit Neurosci Sect, Med Neurol Branch, Bethesda, MD 20892 USA	Levin, HS (corresponding author), PM&R Res Off, 1333 Moursund Ave,Room A205, Houston, TX 77003 USA.			Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, Z01NS002792] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		BENKE T, 1988, EUR NEUROL, V28, P236, DOI 10.1159/000116274; BENTON A, 1990, CORTEX, V26, P491, DOI 10.1016/S0010-9452(13)80299-7; Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; Benton A. L., 1969, EMBEDDED FIGURES TES; BOERI R, 1994, CURR OPIN NEUROL, V7, P61, DOI 10.1097/00019052-199402000-00011; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; BRUYER R, 1986, NEUROPSYCHOLOGY FACE, P63; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CARLESIMO GA, 1995, J CLIN EXP NEUROPSYC, V17, P691, DOI 10.1080/01688639508405159; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1986, NEUROPSYCHOLOGY FACE, P31; De Renzi E, 1998, CORTEX, V34, P403, DOI 10.1016/S0010-9452(08)70763-9; DERENZI E, 1994, NEUROPSYCHOLOGIA, V32, P893, DOI 10.1016/0028-3932(94)90041-8; DERENZI E, 1986, NEUROPSYCHOLOGIA, V24, P385; DERENZI E, 1991, CORTEX, V27, P213, DOI 10.1016/S0010-9452(13)80125-6; EKMAN P, 1976, CONSULTING PSYCHOL P, V21, P98; Farah M, 1990, VISUAL AGNOSIA; GRADY CL, 1994, J NEUROSCI, V14, P1450; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; Hooper, 1983, HOOPER VISUAL ORG TE; LEVIN HS, 1976, DIS NERV SYST, V37, P68; LEVINE DN, 1989, BRAIN COGNITION, V10, P149, DOI 10.1016/0278-2626(89)90051-1; MATTSON AJ, 1994, J NEUROL NEUROSUR PS, V57, P818, DOI 10.1136/jnnp.57.7.818; MCINTOSH AR, 1994, J NEUROSCI, V14, P655; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; READ DE, 1988, J CLIN EXP NEUROPSYC, V10, P451, DOI 10.1080/01688638808408252; RHODES G, 1985, BRIT J PSYCHOL, V76, P249, DOI 10.1111/j.2044-8295.1985.tb01949.x; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SERGENT J, 1990, BRAIN, V113, P989, DOI 10.1093/brain/113.4.989; TAKAHASHI N, 1995, CORTEX, V31, P317, DOI 10.1016/S0010-9452(13)80365-6; TEASDALE G, 1974, LANCET, V2, P81; Tzavaras A, 1973, Encephale, V62, P382; Warrington E., 1991, VISUAL OBJECT SPACE; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson BA, 1997, CORTEX, V33, P529, DOI 10.1016/S0010-9452(08)70234-X; YOUNG AW, 1993, BRAIN, V116, P941, DOI 10.1093/brain/116.4.941	36	64	65	1	6	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	FEB	2000	36	1					125	137		10.1016/S0010-9452(08)70841-4			13	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	291MN	WOS:000085740800010	10728902				2021-06-18	
J	Morrison, B; Eberwine, JH; Meaney, DF; McIntosh, TK				Morrison, B; Eberwine, JH; Meaney, DF; McIntosh, TK			Traumatic injury induces differential expression of cell death genes in organotypic brain slice cultures determined by complementary DNA array hybridization	NEUROSCIENCE			English	Article						genomic expression; in vitro model; traumatic brain injury; organotypic culture; stretch injury; cDNA array	NERVE GROWTH-FACTOR; DIFFUSE AXONAL INJURY; PROTEIN-KINASE-C; CORTICAL IMPACT INJURY; TRANSCRIPTION FACTOR CREB; MESSENGER-RNA EXPRESSION; HIPPOCAMPAL CA1 NEURONS; RAT-BRAIN; ENDOTHELIAL-CELLS; HEAD-INJURY	The expression of a large panel of selected genes hypothesized to play a central role in post-traumatic cell death was shown to be differentially altered in response to a precisely controlled, mechanical injury applied to an organotypic slice culture of the rat brain. Within 48 h of injury, the expression of nerve growth factor messenger RNA was significantly increased whereas the levels of bcl-2, alpha-subunit of calcium/calmodulin-dependent protein kinase II, cAMP response element binding protein, 65,000 mel. wt isoform of glutamate decarboxylase, 1 beta isoform of protein kinase C, and ubiquitin messenger RNA were significantly decreased. Because the expression levels of a number of other messenger RNAs such as the neuron-specific amyloid precursor protein, beta(2) microglobulin, bax, bcl(xl), brain-derived neurotrophic factor, cyclooxygenase-2, interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, receptor tyrosine kinase A, and receptor tyrosine kinase B were unaffected, these selective changes may represent components of an active and directed response of the brain initiated by mechanical trauma. Interpretation of these co-ordinated alterations suggests that mechanical injury to the central nervous system may lead to disruption of calcium homeostasis resulting in altered gene expression, an impairment of intracellular cascades responsible for trophic factor signaling, and initiation of apoptosis via multiple pathways. An understanding of these transcriptional changes may contribute to the development of novel therapeutic strategies to enhance beneficial and blunt detrimental, endogenous, post-injury response mechanisms. (C) 2000 IBRO. Published by Elsevier Science Ltd.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), 3320 Smith Walk,Hayden Hall Room 105C, Philadelphia, PA 19104 USA.		Morrison, Barclay/B-7132-2008; Eberwine, James/B-2247-2010	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BAYER SA, 1980, J COMP NEUROL, V190, P115, DOI 10.1002/cne.901900108; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; CARGILL RS, 1996, J NEUROTRAUM, V13, P396; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chow N, 1998, P NATL ACAD SCI USA, V95, P9620, DOI 10.1073/pnas.95.16.9620; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DASH PK, 1995, J NEUROSCI, V15, P2030; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FREIDIN M, 1992, P NATL ACAD SCI USA, V89, P10440, DOI 10.1073/pnas.89.21.10440; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HIESTAND DM, 1992, NEUROSCI LETT, V144, P75, DOI 10.1016/0304-3940(92)90719-N; HIESTAND DM, 1992, J NEUROL SCI, V113, P31, DOI 10.1016/0022-510X(92)90261-I; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; HUMPEL C, 1993, NEUROSCIENCE, V57, P913, DOI 10.1016/0306-4522(93)90037-G; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Llanos S, 1998, J NEUROCHEM, V70, P2315; MACKLER SA, 1993, MOL PHARMACOL, V44, P308; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; Morimoto T, 1996, AM J PATHOL, V148, P249; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; OBLINGER MM, 1993, INT J DEV NEUROSCI, V11, P149, DOI 10.1016/0736-5748(93)90075-O; Oh YJ, 1997, MOL BRAIN RES, V51, P133, DOI 10.1016/S0169-328X(97)00229-5; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RINK A, 1995, AM J PATHOL, V147, P1575; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yang SY, 1998, J NEUROSURG, V89, P297, DOI 10.3171/jns.1998.89.2.0297	74	64	68	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	96	1					131	139		10.1016/S0306-4522(99)00537-0			9	Neurosciences	Neurosciences & Neurology	283XG	WOS:000085300900016	10683418	Green Published			2021-06-18	
J	Cohen, IR; Schwartz, M				Cohen, IR; Schwartz, M			Autoimmune maintenance and neuroprotection of the central nervous system	JOURNAL OF NEUROIMMUNOLOGY			English	Article						central nervous system; central nervous system injury; autoimmune maintenance	TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; GROWTH-FACTOR; BASIC-PROTEIN; ENCEPHALOMYELITIS; LYMPHOCYTES; RECEPTOR; REGENERATION; MECHANISMS; EXPRESSION	The genesis of immune privilege high in the evolutionary tree suggests that immune privilege is necessary, if not advantageous for the progressive development of the CNS. Upon reaching a certain degree of complexity, it seems as if the CNS was obliged to restrain the immune system from penetrating the blood-brain barrier. CNS autoimmunity against myelin proteins is known to be a contributory factor in the pathophysiology of multiple sclerosis and in the animal model of experimental autoimmune encephalomyelitis (EAE) (Wekerle, 1993). Such autoimmunity has therefore been regarded as detrimental and hence obviously undesirable. However, recent findings in our laboratory suggest that T-cell autoimmunity to CNS self-antigens (Moalem et al., 1999), if expressed at the right time and the right place, can do much good in the CNS. We shall review the experiments briefly, and then discuss their implications for our understanding of immune privilege and CNS maintenance after injury. (C) 1999 Elsevier Science B.V. All rights reserved.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Cohen, Irun R/B-3542-2009				Agrawal SK, 1996, J NEUROSCI, V16, P545; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BIRK O, 1999, IN PRESS P NATL ACA; BURNET M, 1959, CLONAL SELECTION THE; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1999, IN PRESS TENDING ADA; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; GILLIS S, 1978, J IMMUNOL, V120, P2027; HAUBEN E, 1999, IN PRESS LANCET; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; LazarovSpiegler O, 1996, FASEB J, V10, P1296; LIU DX, 1994, J NEUROCHEM, V62, P37; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207; MOALEM G, 1999, UNPUB AUTOIMMUNE T C; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1998, NEUROSCIENTIST, V4, P71, DOI 10.1177/107385849800400203; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RANSOM BR, 1990, STROKE, V21, P52; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; SANNER CA, 1994, J NEUROSCI, V14, P6472; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; Schwab ME, 1996, PHYSIOL REV, V76, P319; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Wekerle H, 1993, Curr Opin Neurobiol, V3, P779, DOI 10.1016/0959-4388(93)90153-P; YAROM Y, 1983, NATURE, V303, P246, DOI 10.1038/303246a0; Yoles E, 1998, SURV OPHTHALMOL, V42, P367, DOI 10.1016/S0039-6257(97)00123-9; Young W, 1996, SCIENCE, V273, P451, DOI 10.1126/science.273.5274.451	37	64	66	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	DEC	1999	100	1-2					111	114		10.1016/S0165-5728(99)00190-3			4	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	284XE	WOS:000085357500013	10695721				2021-06-18	
J	Simpson, G; Blaszczynski, A; Hodgkinson, A				Simpson, G; Blaszczynski, A; Hodgkinson, A			Sex offending as a psychosocial sequela of traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article								Objective: To describe the nature and extent of sexual offending after traumatic brain injury (TBI). Design: Retrospective file review. Setting: A brain injury unit providing inpatient and outpatient rehabilitation services. Participants: A review of five years of admissions to the Brain Injury Rehabilitation Unit (N = 477) identified a sample of 29 males who committed 128 incidents of sex offending, Main Outcome Measures: A protocol to record data on demographic, injury, radiological, and psychosocial variables and offending behaviors. Results: Of the total population of 445 clients with TBI, 6.5% (n = 29) were identified as having committed some form of sexual offense. Alcohol was a factor in only three (2.3%) of the incidents, and only two clients had a preinjury history of sexual offending. The most com mon offenses were the "touching" offenses, followed by exhibitionism and overt sexual aggression. Staff members were the most common targets of the offenses, followed by members of the general public, other people with TBI, and family members. Conclusions: Sex offending is a significant clinical problem among a small minority of men after TBI. The absence of alcohol and preinjury histories of sexual offending suggest that the brain injury and contingent sequelae were a significant etiological factor underlying the offenses. A. number of implications for the clinical management of clients with sexually aberrant behaviors is identified and discussed.	Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool BC, NSW 1871, Australia; Univ New S Wales, Sch Psychiat, Kensington, NSW 2033, Australia	Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool BC, NSW 1871, Australia.		Simpson, Grahame K/W-1074-2019; Blaszczynski, Alexander/G-2713-2013	Simpson, Grahame K/0000-0001-8156-9060; Blaszczynski, Alexander/0000-0003-1476-0791			American Psychiatric Association, 1995, DIAGN STAT MAN MENT; Arieff AJ, 1942, J NERV MENT DIS, V96, P523, DOI 10.1097/00005053-194211000-00004; BERLIN FS, 1981, AM J PSYCHIAT, V138, P601; BLAIR CD, 1981, PSYCHOL BULL, V89, P439, DOI 10.1037/0033-2909.89.3.439; BLUMER D, 1967, ARCH NEUROL-CHICAGO, V16, P37, DOI 10.1001/archneur.1967.00470190041005; BLUMER D, 1970, AM J PSYCHIAT, V126, P83; DEMETRAL GD, 1994, MENT RETARD, V32, P141; EMORY LE, 1995, J HEAD TRAUMA REHAB, V10, P47; Goldberg R L, 1982, Int J Psychiatry Med, V12, P275; GRABER B, 1982, J FORENSIC SCI, V27, P125; HAWK GL, 1993, HOSP COMMUNITY PSYCH, V44, P784; HENN FA, 1976, AM J PSYCHIAT, V133, P694; HUCKER SJ, 1990, HDB SEXUAL ASSAULT; JENNET WB, 1962, EPILEPSY BLUNT HEAD; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LEHNE G, 1986, SEX DISABIL, V7, P145; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; MONEY J, 1990, AM J PSYCHOTHER, V44, P26; MURREY GJ, 1992, MED SCI LAW, V32, P331, DOI 10.1177/002580249203200408; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; REGESTEIN QR, 1978, J NERV MENT DIS, V166, P794, DOI 10.1097/00005053-197811000-00007; ROSENTHAL M, 1990, REHABILITATION ADULT; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; WEINSTEIN EA, 1961, PSYCHIATR, V24, P69; WESOLOWSKI MD, 1993, BEHAV RESIDENTI 0408, P89; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	30	64	64	0	9	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					567	580		10.1097/00001199-199912000-00005			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300004	10671702				2021-06-18	
J	Ishikawa, M; Sekizuka, E; Sato, S; Yamaguchi, N; Inamasu, J; Bertalanffy, H; Kawase, T				Ishikawa, M; Sekizuka, E; Sato, S; Yamaguchi, N; Inamasu, J; Bertalanffy, H; Kawase, T			Effects of moderate hypothermia on leukocyte-endothelium interaction in the rat pial microvasculature after transient middle cerebral artery occlusion	STROKE			English	Article						hypothermia; leukocytes; middle cerebral artery; occlusion; reperfusion injury	ISCHEMIC CELL-DAMAGE; TRAUMATIC BRAIN INJURY; INTRAISCHEMIC HYPOTHERMIA; REPERFUSION INJURY; MESENTERIC VENULES; MILD HYPOTHERMIA; FOCAL ISCHEMIA; NEUTROPHIL; ADHESION; MICROCIRCULATION	Background and Purpose-It has been demonstrated that moderate hypothermia attenuates brain damage, but the mechanism whereby this is achieved has not been clearly shown. Recently, the role of leukocytes as mediators of secondary brain damage after brain ischemia has been discussed. The aim of this study is to examine the effects of moderate hypothermia on leukocyte-endothelium interaction in the rat pial microvasculature after transient middle cerebral artery occlusion (MCAO). Methods-Rhodamine 6G-labeled leukocytes in brain surface were visualized with intravital fluorescence videomicroscopy through a closed cranial window. We analyzed the number of leukocytes adhering to the venular and arteriolar endothelium before ischemic insult and up to 3 hours after reperfusion. Rats were divided into 4 experimental groups. Group I (n=6) consisted of sham-operated animals. Groups II (n=6) and III (n=6) received left MCAO for 1 hour under normothermia (36 degrees C to 37 degrees C, group II) and under moderate hypothermia (30 degrees C to 32 degrees C, group III). Group IV (n=4) received left common carotid artery occlusion for 1 hour under normothermia. Results-The number of adhering leukocytes in venules in groups II and IV increased significantly (P<0.001) after reperfusion compared with the group I, but that in group III did not increase significantly (P>0.05). The number of adhering leukocytes in arterioles in group II increased significantly (P<0.01) compared with the other groups, although the adhering leukocytes were not as numerous as those seen in venules. Conclusions-It is demonstrated that hypothermia attenuates adhering leukocytes in venules and arterioles after reperfusion of MCAO. The inhibition of the leukocyte function may be an important factor in the neuroprotective effect of hypothermia.	Saitama Natl Hosp, Dept Neurosurg, Moroyama, Saitama, Japan; Saitama Natl Hosp, Dept Internal Med, Moroyama, Saitama, Japan; Keio Univ, Sch Med, Dept Neurosurg, Tokyo 160, Japan; Univ Marburg, Dept Neurosurg, Marburg, Germany	Ishikawa, M (corresponding author), Philipps Univ Hosp, Dept Neurosurg, Baldingerstr, D-35033 Marbury, Germany.		Inamasu, Joji/R-7314-2019				AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK WM, 1994, STROKE, V25, P1411, DOI 10.1161/01.STR.25.7.1411; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DELZOPPO GJ, 1995, PHYSL PATHOPHYSIOLOG, P408; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIRNAGL U, 1994, STROKE, V25, P1028, DOI 10.1161/01.STR.25.5.1028; GOTO Y, 1993, NEUROSURGERY, V32, P980, DOI 10.1227/00006123-199306000-00017; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662; GUTE D, 1995, PHYSL PATHOPHYSIOLOG, P359; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Iigo Y, 1997, AM J PHYSIOL-HEART C, V273, pH138; INAMASU J, 1997, J CEREB BLOOD FLOW M, V17, pS702; Ishikawa M, 1998, MICROVASC RES, V56, P166, DOI 10.1006/mvre.1998.2100; Ishikawa M, 1999, NEUROSURGERY, V44, P156, DOI 10.1097/00006123-199901000-00096; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MAYROVITZ HN, 1980, MICROVASC RES, V20, P264, DOI 10.1016/0026-2862(80)90028-X; MEMEZAWA H, 1992, EXP BRAIN RES, V89, P67; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; MORII S, 1986, J CEREBR BLOOD F MET, V6, P34, DOI 10.1038/jcbfm.1986.5; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MOYER DJ, 1992, STROKE, V23, P1812, DOI 10.1161/01.STR.23.12.1812; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NAZZIOLA E, 1992, MICROVASC RES, V44, P127, DOI 10.1016/0026-2862(92)90076-2; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; SEKIZUKA E, 1991, GASTROINTESTINAL FUN, V9, P93; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SIEMIONOW M, 1993, J HAND SURG-AM, V18A, P963, DOI 10.1016/0363-5023(93)90384-F; Tomita M, 1996, ACT NEUR S, V66, P32; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; VILLRINGER A, 1991, MICROVASC RES, V42, P305, DOI 10.1016/0026-2862(91)90064-I; Wass CT, 1996, INT ANESTHESIOL CLIN, V34, P95, DOI 10.1097/00004311-199603440-00008; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	47	64	71	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	AUG	1999	30	8					1679	1685		10.1161/01.STR.30.8.1679			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	224JM	WOS:000081894300035	10436121	Bronze			2021-06-18	
J	Berge, J; Marque, B; Vital, JM; Senegas, J; Caille, JM				Berge, J; Marque, B; Vital, JM; Senegas, J; Caille, JM			Age-related changes in the cervical spines of front-line rugby players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							DEGENERATIVE DISK DISEASE; MR SIGNAL INTENSITY; MAGNETIC-RESONANCE; INTERVERTEBRAL-DISK; HYPEREXTENSION INJURIES; SPONDYLOTIC MYELOPATHY; FOOTBALL PLAYERS; CORD CONCUSSION; FACET JOINTS; BONE-MARROW	Cervical spine trauma occurs frequently in front-line rugby players. To evaluate the accumulative effects of this trauma, magnetic resonance imaging scans of the cervical spine were performed on 47 rugby players and 40 age-matched control subjects. The aim of this study was to compare the changes in the cervical spine of players at different points in their careers. A study of cervical spine changes, including spinal curve, spinal constituents, posttraumatic deformities, and degenerative modifications, was completed by a study of cervical measurements. Front-line rugby players showed more early degenerative alterations on magnetic resonance imaging scans than did the control subjects of the same age. These changes correlated with age and were probably linked with repetitive cervical trauma throughout the players' careers. Particular attention should be paid to the data confirming cervical spine canal stenosis in front-line players, which may place these athletes at risk for acute neurapraxia while playing this collision sport.	Hop Pellegrin, Dept Neuroradiol, F-33076 Bordeaux, France; Hop Pellegrin, Spine Unit, F-33076 Bordeaux, France	Berge, J (corresponding author), Hop Pellegrin, Dept Neuroradiol, F-33076 Bordeaux, France.						AOKI J, 1987, RADIOLOGY, V164, P411, DOI 10.1148/radiology.164.2.3602378; AUDIGEY I, 1992, THESIS BORDEAUX 2 U; BARNES MP, 1984, J NEUROL NEUROSUR PS, V47, P17, DOI 10.1136/jnnp.47.1.17; BEERS GJ, 1988, J COMPUT ASSIST TOMO, V12, P755, DOI 10.1097/00004728-198809010-00007; BERNADET E, 1984, THESIS BORDEAUX 2 U, V410; BERQUIST T, 1992, IMAGING SPORTS INJUR, P1; BLUMBERG ML, 1991, RADIOLOGY, V179, P584, DOI 10.1148/radiology.179.2.1826566; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; BOHRER SP, 1990, SKELETAL RADIOL, V19, P521; BOYE JB, 1975, THESIS BORDEAUX 2 U; CHAKERES DW, 1987, AM J NEURORADIOL, V8, P5; CHIROSSEL JP, 1992, TRAUMATISMES CRANE R, P149; CZERVIONKE LF, 1988, RADIOL CLIN N AM, V26, P921; CZERVIONKE LF, 1988, RADIOLOGY, V169, P753, DOI 10.1148/radiology.169.3.3186997; Daniel M, 1992, J Radiol, V73, P695; DAVIS SJ, 1991, RADIOLOGY, V180, P245, DOI 10.1148/radiology.180.1.2052703; DELBIGIO MR, 1989, SPINE, V14, P37, DOI 10.1097/00007632-198901000-00007; DEROOS A, 1987, AM J ROENTGENOL, V149, P531, DOI 10.2214/ajr.149.3.531; DOOMS GC, 1985, RADIOLOGY, V155, P429, DOI 10.1148/radiology.155.2.3983394; DUSSAULT RG, 1990, RADIOL CLIN N AM, V28, P1033; EDWARDS WC, 1983, SPINE, V8, P20, DOI 10.1097/00007632-198301000-00003; EPSTEIN N, 1980, SPINE, V5, P489, DOI 10.1097/00007632-198011000-00001; FLANNIGAN BD, 1987, AM J ROENTGENOL, V148, P785, DOI 10.2214/ajr.148.4.785; FLETCHER G, 1990, AM J NEURORADIOL, V11, P27; FORSBERG DA, 1990, AM J ROENTGENOL, V154, P751, DOI 10.2214/ajr.154.4.2107670; FUJIWARA K, 1988, SPINE, V13, P1212, DOI 10.1097/00007632-198811000-00002; GERHART KA, 1991, J TRAUMA, V31, P1529, DOI 10.1097/00005373-199111000-00012; GOLDBERG AL, 1989, SKELETAL RADIOL, V18, P283, DOI 10.1007/BF00361208; GRENIER N, 1987, RADIOLOGY, V165, P517, DOI 10.1148/radiology.165.2.3659376; GRENIER N, 1989, RADIOLOGY, V171, P197, DOI 10.1148/radiology.171.1.2928526; GRENIER N, 1990, J COMPUT ASSIST TOMO, V14, P243, DOI 10.1097/00004728-199003000-00016; GRENIER N, 1992, IRM MOELLA RACHIS; HAJEK PC, 1987, RADIOLOGY, V162, P245, DOI 10.1148/radiology.162.1.3786770; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; HO PSP, 1988, RADIOLOGY, V168, P469, DOI 10.1148/radiology.168.2.3393666; ISU T, 1986, NEURORADIOLOGY, V28, P215, DOI 10.1007/BF00548195; JAHNKE RW, 1991, RADIOL CLIN N AM, V29, P777; KUBINETSKY A, 1969, THESIS PARIS 6 U PAR; KUROSAWA H, 1991, SKELETAL RADIOL, V20, P437; LADD AL, 1986, J BONE JOINT SURG AM, V68A, P1371, DOI 10.2106/00004623-198668090-00009; LAISSY JP, 1990, AM J NEURORADIOL, V11, P394; LOUAIL C, 1992, J NEURORADIOLOGY, V19, P177; MAILLOT C, 1992, RIV NEURORADIOLOG S2, V5, P59; MANELFE C, 1989, REV IMAGERIE MED, V1, P7; Manelfe C., 1989, IMAGERIE RACHIS MOEL; MODIC MT, 1988, RADIOLOGY, V168, P177, DOI 10.1148/radiology.168.1.3289089; MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678; MODIC MT, 1990, RADIOLOGY, V177, P332, DOI 10.1148/radiology.177.2.2217764; MOMBET J, 1980, MED RUGBY; MURPHEY MD, 1989, RADIOL CLIN N AM, V27, P855; NAKSTAD PH, 1989, NEURORADIOLOGY, V31, P382, DOI 10.1007/BF00343860; NEUHOLD A, 1991, NEURORADIOLOGY, V33, P422, DOI 10.1007/BF00598617; NGUYEN CM, 1989, INVEST RADIOL, V24, P407, DOI 10.1097/00004424-198905000-00014; ODOR JM, 1990, AM J SPORT MED, V18, P507, DOI 10.1177/036354659001800510; OGINO H, 1983, SPINE, V8, P1, DOI 10.1097/00007632-198301000-00001; PAN G, 1988, J NEUROSURG, V68, P798, DOI 10.3171/jns.1988.68.5.0798; PAVLOV H, 1987, RADIOLOGY, V164, P771, DOI 10.1148/radiology.164.3.3615879; PAYOT M, 1977, THESIS BORDEAUX 2 U; PERE JP, 1980, THESIS POITIERS U; PRERE J, 1989, IMAGERIE RACHIS MOEL; RESNICK D, 1978, RADIOLOGY, V126, P57, DOI 10.1148/126.1.57; ROBINSON MD, 1990, SPINE, V15, P1003, DOI 10.1097/00007632-199015100-00004; ROSS JS, 1989, AM J NEURORADIOL, V10, P1243; RUSSELL EJ, 1990, RADIOLOGY, V177, P313, DOI 10.1148/radiology.177.2.2217760; SCHELLINGER D, 1990, RADIOLOGY, V175, P831, DOI 10.1148/radiology.175.3.2343133; SCHER AT, 1991, AM J SPORT MED, V19, P485, DOI 10.1177/036354659101900511; SCOTTI G, 1992, RIV NEURORADIOL, V5, P43; SENEGAS X, 1991, THESIS BORDEAUX 2 U; SETHER LA, 1990, RADIOLOGY, V177, P385, DOI 10.1148/radiology.177.2.2217773; Sortland O, 1982, Br J Sports Med, V16, P80; TERESI LM, 1987, RADIOLOGY, V164, P83, DOI 10.1148/radiology.164.1.3588931; THANGUY A, 1992, RIV NEURORADIOL, V5, P5; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; VANDYKE C, 1989, AM J NEURORADIOL, V10, P627; WILLIAMS JPR, 1978, BRIT MED J, V2, P1747, DOI 10.1136/bmj.2.6154.1747; YU SW, 1991, RADIOL CLIN N AM, V29, P691; YU SW, 1989, AM J NEURORADIOL, V10, P1105; YU SW, 1988, RADIOLOGY, V169, P761, DOI 10.1148/radiology.169.3.3186998	78	64	65	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL-AUG	1999	27	4					422	429		10.1177/03635465990270040401			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	218NE	WOS:000081558000004	10424210				2021-06-18	
J	Czosnyka, M; Smielewski, P; Piechnik, S; Al-Rawi, PG; Kirkpatrick, PJ; Matta, BF; Pickard, JD				Czosnyka, M; Smielewski, P; Piechnik, S; Al-Rawi, PG; Kirkpatrick, PJ; Matta, BF; Pickard, JD			Critical closing pressure in cerebrovascular circulation	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						critical closing pressure; cerebral autoregulation; head injury; transcranial Doppler	CEREBRAL BLOOD-FLOW; VELOCITY-MEASUREMENTS; TRANSCRANIAL DOPPLER; HEAD-INJURY; MODEL; VASOREACTIVITY; AUTOREGULATION; IMPEDANCE	Objective-Cerebral critical closing pressure (CCP) has been defined as an arterial pressure threshold below which arterial vessels collapse. Hypothetically this is equal to intracranial pressure (ICP) plus the contribution from the active tone of cerebral arterial smooth muscle. The correlation of CCP with ICP, cerebral autoregulation, and other clinical and haemodynamic modalities in patients with head injury was evaluated. Method-intracranial pressure, arterial blood pressure (ABP) and middle cerebral artery blood flow velocity were recorded daily in ventilated patients. Waveforms were processed to calculate CCP, the transcranial Doppler-derived cerebral autoregulation index (Mx), mean arterial pressure (ABP), intracranial pressure (ICP), and cerebral perfusion pressure (CPP). Results-Critical closing pressure reflected the time related changes in ICP during plateau and B waves. Overall correlation between CCP and ICP was mild but significant (R=0.41; p<0.0002). The mean difference between ABP and CCP correlated with CPP (R=0.57, 95% confidence interval (95% CI) for prediction 25 mm Hg). The difference between CCP and ICP, described previously as proportional to arterial wall tension, correlated with the index of cerebral autoregulation Mx (p<0.0002) and CPP (p<0.0001). However, by contrast with the Mx index, CCP-ICP was not significantly correlated with outcome after head injury. Conclusion-Critical closing pressure, although sensitive to variations in ICP and CPP, cannot be used as an accurate estimator of these modalities with acceptable confidence intervals. The difference CCP-ICP significantly correlates with cerebral autoregulation, but it lacks the power to predict outcome after head injury.	Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, MRC, Cambridge Ctr Brain Repair, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England	Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, POB 167, Cambridge CB2 2QQ, England.			Piechnik, Stefan K./0000-0002-0268-5221; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Aaslid R, 1992, TRANSCRANIAL DOPPLER, P49; BURTON AC, 1951, AM J PHYSIOL, V164, P319; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CZOSNYKA M, 1994, ULTRASOUND MED BIOL, V20, P391, DOI 10.1016/0301-5629(94)90008-6; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; CZOSNYKA M, 1996, STROKE, V27, P829; DAHL A, 1992, J CEREBR BLOOD F MET, V12, P1049, DOI 10.1038/jcbfm.1992.142; DAHL A, 1992, STROKE, V23, P15, DOI 10.1161/01.STR.23.1.15; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Giller CA, 1996, ULTRASOUND MED BIOL, V22, P373, DOI 10.1016/0301-5629(96)00024-5; KONTOS HA, 1989, STROKE, V20, P1; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; MICHEL E, 1995, NEUROL RES, V17, P149, DOI 10.1080/01616412.1995.11740304; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; PANERAI RB, 1995, NEUROPEDIATRICS, V26, P168, DOI 10.1055/s-2007-979748; PANERAI RB, 1993, PHYSIOL MEAS, V14, P411, DOI 10.1088/0967-3334/14/4/002; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236	21	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1999	66	5					606	611		10.1136/jnnp.66.5.606			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	189QD	WOS:000079915300010	10209171	Green Published, Bronze			2021-06-18	
J	Lee, TT; Green, BA; Dietrich, WD; Yezierski, RP				Lee, TT; Green, BA; Dietrich, WD; Yezierski, RP			Neuroprotective effects of basic fibroblast growth factor following spinal cord contusion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						ciliary neurotrophic factor; cytokine; interleukin-4; nerve growth factor; neurotrophic factor	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; NEUROTROPHIC FACTOR; FACTOR PROTECTS; NERVOUS-SYSTEM; MESSENGER-RNA; IN-VIVO; EXPRESSION; CELLS; INTERLEUKIN-6	Cytokines and neurotrophic factors have been implicated in the pathophysiology of injury to the central nervous system. While some cytokines are considered pro-inflammatory, other factors promote neuronal growth and survival. The present study investigated the neuroprotective effects of interleukins 1 (IL-1), 4 (IL-4), and 6 (IL-6), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), and basic fibroblast growth factor (bFGF) in a contusion model of spinal cord injury. Female Sprague-Dawley rats (n = 55) sustained a 10-g weight-drop injury to the lower thoracic spinal cord (T10) from a height of 12.5 mm using the NYU impactor. A micro-infusion system (Alzet minipump) was used to continuously deliver drugs or vehicle directly into the epicenter of the contused spinal cord starting 1 or three h postinjury. At the end of 7 days, animals were perfused and the cords removed for histopathological analysis. Longitudinal serial sections were cut on a freezing microtome and stained with cresyl violet. Areas of central necrosis, partial preservation, and total zone of tissue injury were identified and traced by an independent reviewer using a computer based imaging system. The mean total zone of injury in five animals receiving vehicle infusion was 18.04 +/- 4.20 mm(3). The mean zone of partial preservation in these animals was 16.46 +/- 3.32 mm. Basic fibroblast growth factor reduced the total zone of injury by 33% [p < 0.01, least significant difference (LSD) of Fisher] in five animals and the zone of partial preservation by 32% (p < 0.01, LSD of Fisher) when compared to controls. There were trends toward reduction in total zone of injury and zone of partial preservation in rats treated with IL-4, CNTF, and NGF versus vehicle; however, none of these reached statistical significance. No significant differences were observed between animals receiving vehicle versus bFGF treatment commencing 3 h after injury. These data demonstrate that the continuous intramedullary infusion of bFGF initiated one hour after moderate contusion injury of the spinal cord significantly reduces the total zone of injury and the zone of partial preservation. These results support the further investigation and possible future clinical application of bFGF in the treatment of acute spinal cord contusion injury.	Miami Univ, Dept Neurol Surg, Sch Med, Miami, FL 33101 USA; Miami Univ, Miami Project Cure Paralysis, Sch Med, Miami, FL 33101 USA	Lee, TT (corresponding author), Miami Univ, Dept Neurol Surg, Sch Med, POB 016960 M813, Miami, FL 33101 USA.						Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696; AY I, 1998, NEUROPROTECTIVE SIGN, P111; BAFOUR R, 1995, J NEUROSURG, V83, P103; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; BLOTTNER D, 1994, ACTA ANAT, V150, P235; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; GIULIAN D, 1988, J NEUROSCI RES, V21, P487, DOI 10.1002/jnr.490210240; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HEFTI F, 1997, NEUROPROTECTION CNS, P243; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; JIMENEZ O, 1997, J NEUROTRAUM, V14, P772; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; KOSHINAGA M, 1993, EXP NEUROL, V120, P32, DOI 10.1006/exnr.1993.1038; KRUSHEL LA, 1995, P NATL ACAD SCI USA, V92, P4323, DOI 10.1073/pnas.92.10.4323; KUSHIMA Y, 1992, NEUROSCI LETT, V143, P110, DOI 10.1016/0304-3940(92)90244-2; LEE SC, 1993, J IMMUNOL, V150, P2659; LEE TT, 1993, GLIA, V8, P51, DOI 10.1002/glia.440080107; Lugering N, 1997, IMMUNOLOGY, V91, P130, DOI 10.1046/j.1365-2567.1997.00221.x; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; MURPHY M, 1994, DEVELOPMENT, V120, P3519; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; OLSON L, 1994, J NEUROL, V242, P12; Oudega M, 1996, EXP NEUROL, V140, P218, DOI 10.1006/exnr.1996.0131; Peterson DA, 1996, J NEUROSCI, V16, P886; QUIRION R, 1991, CAN J NEUROL SCI, V18, P390, DOI 10.1017/S0317167100032510; RELTON JK, 1997, NEUROPROTECTION CNS, P225; SAAD B, 1991, J CELL BIOL, V115, P473, DOI 10.1083/jcb.115.2.473; SARIOLA H, 1994, ANN MED, V26, P355, DOI 10.3109/07853899409148351; Teng Y. D., 1997, Society for Neuroscience Abstracts, V23, P1382; Teng YD, 1998, EUR J NEUROSCI, V10, P798, DOI 10.1046/j.1460-9568.1998.00100.x; Toulmond S, 1996, TRENDS NEUROSCI, V19, P409; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; YABUUCHI K, 1994, MOL BRAIN RES, V27, P27, DOI 10.1016/0169-328X(94)90180-5; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; YUEN EC, 1996, NEURAL NOTES, V1, P3	51	64	76	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					347	356		10.1089/neu.1999.16.347			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200001	10369555				2021-06-18	
J	Ruffolo, CF; Friedland, JF; Dawson, DR; Colantonio, A; Lindsay, PH				Ruffolo, CF; Friedland, JF; Dawson, DR; Colantonio, A; Lindsay, PH			Mild traumatic brain injury from motor vehicle accidents: Factors associated with return to work	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MINOR HEAD-INJURY; SOCIAL SUPPORT; SYMPTOMS; PERFORMANCE; SEVERITY; IMPACT; TIME	Objectives: To describe return to work (RTW) for motor vehicle accident (MVA) survivors with mild traumatic brain injury (MTBI) and to examine relationships between RTW and injury severity, cognitive impairment, social interaction, discharge disposition, and sociodemographics. Design: Inception cohort assessed within 1 month of injury and at follow-up 6 to 9 months (mean = 7.4) after injury, for comparisons on outcome of RTW. Setting: Tertiary care center in Toronto (time 1); at home for follow-up. Participants: Fifty patients with MTBI resulting from MVA who were consecutively admitted during a 20-month period ending April 1994. Thirteen of 63 eligible patients refused consent or were lost to follow-up. Mean age was 31; 62% were men. Eligibility criteria: (1)patients had been working; (2) they had no history of head injury, neurologic disease, or psychiatric illness requiring hospitalization; and (3) they had no catastrophic impairment from accident. Main Outcome Measure: Return to work (at premorbid or modified level). Results: Of the 42% who returned to work, 12% resumed their premorbid level of employment and 30% returned to modified work. There were significant differences (p <.05) between the groups in level of social interaction, premorbid occupation, and discharge disposition. On one test of cognitive functioning the difference was at p =.06. Conclusion: Social interaction, jobs with greater decisionmaking latitude, and discharge home were positively related to RTW for this population. Cognitive impairment within the first month was not a reliable indicator of RTW potential. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Toronto, Fac Med, Dept Occupat Therapy, Toronto, ON M5T 1W5, Canada; Univ Toronto, Ontario Inst Studies Educ, Dept Human Dev & Appl Psychol, Toronto, ON, Canada	Friedland, JF (corresponding author), Univ Toronto, Fac Med, Dept Occupat Therapy, 256 McCaul St, Toronto, ON M5T 1W5, Canada.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121; Colantonio, Angela/0000-0003-2094-4765			*AM ASS ADV AUT ME, 1990, ABB INJ SCAL 1990 RE; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Baker J E, 1990, J Neurosci Nurs, V22, P232; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barth JT., 1989, MILD HEAD INJURY, P257; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P159, DOI 10.2307/2136512; COOK JV, 1990, REHABILITATION ADULT, P236; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; FRIEDLAND J, 1987, ARCH PHYS MED REHAB, V68, P475; GRAY JM, 1990, COGNITIVE REHABILITA, P29; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRONWALL DMA, 1974, LANCET, V14, P605; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Karasek R.A., 1990, HLTH WORK STRESS PRO; KIRSCH NL, 1989, MILD MODERATE HEAD I, P145; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; Ocampo S, 1997, OCCUP THER INT, V4, P161; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTLEDGE R, 1995, J TRAUMA, V38, P590, DOI 10.1097/00005373-199504000-00022; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SCHAPIRO SR, 1993, MINOR HEAD TRAUMA AS, P86; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; VanDongen S, 1993, Rehabil Nurs, V18, P76; WANG P, 1991, CAN PSYCHOL 2A, V32, P216; WANG PL, 1992, NEW VERSION PASATR R; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	51	64	65	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1999	80	4					392	398		10.1016/S0003-9993(99)90275-7			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	184TG	WOS:000079629100006	10206600				2021-06-18	
J	Whalen, MJ; Carlos, TM; Dixon, CE; Schiding, JK; Clark, RSB; Baum, E; Yan, HQ; Marion, DW; Kochanek, PM				Whalen, MJ; Carlos, TM; Dixon, CE; Schiding, JK; Clark, RSB; Baum, E; Yan, HQ; Marion, DW; Kochanek, PM			Effect of traumatic brain injury in mice deficient in intercellular adhesion molecule-1: Assessment of histopathologic and functional outcome	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	16th Annual National Neurotrauma-Society Meeting	NOV 06-07, 1998	LOS ANGELES, CA	Natl Neurotrauma Soc		brain vascular endothelium; ICAM-I; neutrophil accumulation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; ACUTE LUNG INJURY; RAT-BRAIN; PULMONARY INFLAMMATION; BACTERIAL-MENINGITIS; CEREBROSPINAL-FLUID; VASCULAR INJURY	Intercellular adhesion molecule-1 (ICAM-1) is an adhesion molecule of the immunoglobulin family expressed on endothelial cells that is upregulated in brain as part of the acute inflammatory response to traumatic brain injury (TBI). ICAM-1 mediates neurologic injury in experimental meningitis and stroke; however, its role in the pathogenesis of TBI is unknown. We hypothesized that mutant mice deficient in ICAM-1 (-/-) would have decreased neutrophil accumulation, diminished histologic injury, and improved functional neurologic outcome versus ICAM-1 +/+ wild type control mice after TBI. Anesthetized ICAM-1 -/- mice and wild-type controls were subjected to controlled cortical impact (CCI, 6 m/sec, 1.2 mm depth). Neutrophils in brain parenchyma and ICAM-1 on vascular endothelium were assessed by immunohistochemistry in cryostat brain sections from the center of the contusion 24 h after TBI (n = 4/group). Separate groups of wild-type and ICAM-1-deficient mice (n = 9-10/group) underwent motor (wire grip test, days 1-5) and cognitive (Morris water maze [MWM], days 14-20) testing. Lesion volume was determined by image analysis 21 days following TBI. Robust expression of ICAM-1 was readily detected in choroid plexus and cerebral endothelium at 24 h in ICAM-1 +/+ mice but not in ICAM-1 -/- mice, No differences between groups were observed in brain neutrophil accumulation (9.4 +/- 2.2 versus 11.1 +/- 3.0 per x 100 field, -/- versus +/+), wire grip score, MWM latency, or lesion volume (7.24 +/- 0.63 versus 7.21 +/- 0.45 mm(3), -/- versus +/+). These studies fail to support a role for ICAM-1 in the pathogenesis of TBI.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	Kochanek@smtp.anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; ALOISI F, 1992, J NEUROSCI RES, V32, P494, DOI 10.1002/jnr.490320405; BANBURY POT, 1997, NEURON, V19, P755; BELL M, 1998, CRIT CARE MED, V26, pA86; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; Bullard DC, 1996, J IMMUNOL, V157, P3153; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Doerschuk CM, 1996, J IMMUNOL, V157, P4609; Eppihimer MJ, 1997, AM J PHYSIOL-HEART C, V273, pH1903; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; Hallahan DE, 1997, P NATL ACAD SCI USA, V94, P6432, DOI 10.1073/pnas.94.12.6432; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hatfield CA, 1997, AM J PHYSIOL-LUNG C, V273, pL513; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HORGAN MJ, 1991, AM J PHYSIOL, V261, pH1578; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; KING PD, 1995, J IMMUNOL, V154, P6080; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lloyd CM, 1997, J CLIN INVEST, V100, P963, DOI 10.1172/JCI119647; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOSSINSKY AS, 1995, BRAIN PATHOL, V5, P339, DOI 10.1111/j.1750-3639.1995.tb00614.x; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MULLIGAN MS, 1994, AM J PATHOL, V144, P1008; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; Mulligan MS, 1996, P ASSOC AM PHYSICIAN, V108, P198; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Que LG, 1998, SHOCK, V9, P304, DOI 10.1097/00024382-199804000-00011; SARMAN G, 1995, J INFECT DIS, V172, P1001, DOI 10.1093/infdis/172.4.1001; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SHERMAN DG, 1997, NEUROLOGY, V48, pA270; Shibayama M, 1996, J NEUROTRAUM, V13, P801, DOI 10.1089/neu.1996.13.801; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SINZ EH, 1997, 10 INT S INTR PRESS; SINZ EH, 1997, J NEUROTRAUM, V14, P769; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soriano SG, 1998, BRAIN RES, V780, P337, DOI 10.1016/S0006-8993(97)01298-5; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; TAN TQ, 1995, J INFECT DIS, V171, P342, DOI 10.1093/infdis/171.2.342; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Vougioukas VI, 1998, AM J PATHOL, V152, P241; Wang CY, 1998, CIRC RES, V82, P762, DOI 10.1161/01.RES.82.7.762; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6; ZU H, 1994, J EXP MED, V180, P95	57	64	64	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1999	16	4					299	309		10.1089/neu.1999.16.299			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	190AM	WOS:000079939400003	10225216				2021-06-18	
J	Horsburgh, K; Kelly, S; McCulloch, J; Higgins, GA; Roses, AD; Nicoll, JAR				Horsburgh, K; Kelly, S; McCulloch, J; Higgins, GA; Roses, AD; Nicoll, JAR			Increased neuronal damage in apolipoprotein E-deficient mice following global ischaemia	NEUROREPORT			English	Article						apolipoprotein E; brain; cerebrovascular anatomy; ischaemia; mouse; neuronal damage	TRANSIENT FOREBRAIN ISCHEMIA; CLOSED-HEAD INJURY; CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; E IMMUNOREACTIVITY; SUSCEPTIBILITY; ASSOCIATION; EPSILON-4; STRAIN; CELLS	THERE is accumulating evidence that apolipoprotein E (apoE) plays a role in regulating the response to and outcome following brain injury. The present study compared the histological outcome and recovery following an episode of global ischaemia in apoE-deficient mice and wild-type littermates (12-week-old males, n=8 per group). Transient global ischaemia was induced for ii period of 17 min and the animals were allowed to recover for 72 h, Transient global ischaemia induced selective neuronal degeneration in several brain regions in wild-type mice. There was statistically significant increased ischaemic neuronal damage in apoE-deficient mice compared with wild-type mice in six of the seven regions examined (hippocampal regions CA1, CA3/CA4 and dentate gyrus; thalamus; cortex and caudate nucleus; P < 0.05). The data substantiate a role for apoE in modifying the response of the CNS to acute injury. NeuroReport 10:837-841 (C); 1999 Lippincott Williams & Wilkins.	Univ Glasgow, Hugh Fraser Neurosci Labs, Dept Neuropathol, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Hugh Fraser Neurosci Labs, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland; Glaxo Wellcome Res & Dev Ltd, Res Triangle Pk, NC USA	Horsburgh, K (corresponding author), Univ Glasgow, Hugh Fraser Neurosci Labs, Dept Neuropathol, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.		Kelly, Stephen/A-8307-2010; Nicoll, James/I-9253-2017	Kelly, Stephen/0000-0001-7618-1328; Horsburgh, Karen/0000-0002-9620-3691; Nicoll, James/0000-0002-9444-7246	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Anderson R, 1998, NEUROSCIENCE, V85, P93, DOI 10.1016/S0306-4522(97)00598-8; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570, DOI 10.1097/00004647-199805000-00012; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Masliah E, 1996, APOLIPOPROTEIN E ALZ, P59; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	24	64	68	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	MAR 17	1999	10	4					837	841		10.1097/00001756-199903170-00031			5	Neurosciences	Neurosciences & Neurology	180PA	WOS:000079393300033	10208557				2021-06-18	
J	Iida, H; Tachibana, S; Kitahara, T; Horiike, S; Ohwada, T; Fujii, K				Iida, H; Tachibana, S; Kitahara, T; Horiike, S; Ohwada, T; Fujii, K			Association of head trauma with cervical spine injury, spinal cord injury, or both	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article								Background: Links between cervical spine and/or spinal cord injuries and head trauma have not been reported in detail. Methods: 188 patients with cervical spine and/or spinal cord injury were divided into two groups, i.e,, with upper cervical and mid-lower cervical injury, and compared for head injury. Results: Associated head trauma was investigated in 188 patients with cervical spine and/or spinal cord injuries; 35% had moderate or severe injuries. Brain damage was more frequently observed in patients with upper cervical injury than in those with mid to lower cervical injury. Those patients with upper cervical injury appeared to have an elevated risk of suffering skull base fractures, traumatic subarachnoid hemorrhage, and contusional hemotoma. Conclusions: Approximately one third of patients with cervical spine and/or spinal card injuries had moderate or severe head injuries, Brain damage was more frequently associated with upper cervical injury. Those patients with upper cervical injury are at greater risk of suffering from skull base fractures and severe intracranial hematomas than those with mid to lower cervical injury.	Kitasato Univ, Sch Med, Dept Neurosurg, Kanagawa, Japan; Kitasato Univ, Sch Med, Dept Crit Care Med, Kanagawa, Japan	Iida, H (corresponding author), 245 0006 Int Goodwill Hosp, 1-28-1 Nishigaoka, Kanagawa, Japan.						BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIS D, 1971, J NEUROSURG, V34, P603, DOI 10.3171/jns.1971.34.5.0603; Harris P., 1967, PARAPLEGIA, V5, P215; MEINECKE FW, 1967, PARAPLEGIA, V5, P196; REISS SJ, 1986, NEUROSURGERY, V18, P327, DOI 10.1227/00006123-198603000-00012; SHRAGO GG, 1973, AM J ROENTGENOL, V118, P670, DOI 10.2214/ajr.118.3.670; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Steudel W I, 1988, Acta Neurochir Suppl (Wien), V43, P85; TEASDALE G, 1974, LANCET, V2, P81; Tricot D A, 1968, Paraplegia, V5, P211	12	64	68	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1999	46	3					450	452		10.1097/00005373-199903000-00018			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	175TP	WOS:000079111600020	10088849				2021-06-18	
J	Agrawal, SK; Theriault, E; Fehlings, MG				Agrawal, SK; Theriault, E; Fehlings, MG			Role of group I metabotropic glutamate receptors in traumatic spinal cord white matter injury	JOURNAL OF NEUROTRAUMA			English	Article						axons; glia; group I; immunocytochemistry; mGluR; rat; spinal cord injury	OXYGEN-GLUCOSE DEPRIVATION; DEPENDENT PROTEIN-KINASE; EXCITATORY AMINO-ACIDS; IONOTROPIC GLUTAMATE; CORTICAL CULTURES; ARACHIDONIC-ACID; BRAIN INJURY; GLIAL-CELLS; PHENYLGLYCINE DERIVATIVES; HIPPOCAMPAL-NEURONS	Metabotropic glutamate receptors (mGluRs) participate in glutamate neural transmission, but their role in the pathophysiology of spinal cord injury (SCI) has not been explored. Accordingly, we examined the role of group I mGluRs, which are linked to phospholipase C, in mediating SCI using an in vitro model. A dorsal column segment was isolated from the spinal cord of adult rats, maintained in vitro, and injured by compression for 15 sec with a clip having a 2g closing force. Under control conditions after SCI, the compound action potential (CAP) amplitude was reduced to 69.1 +/- 5.4% of baseline. Blockade of group I mGluR receptors with MCPG, 4CPG, or AIDA resulted in improved recovery of CAP amplitude (82.2 +/- 2.0%, 86.2 +/- 3.9%, and 86.0 +/- 2.5% of baseline, respectively). The group I/II agonist trans-ACPD and selective group I agonist DHPG exacerbated the posttraumatic reduction of CAP amplitude. The phospholipase C inhibitor U-73122 improved recovery of CAP amplitude after traumatic spinal cord axonal injury. Western blotting and immunocytochemistry demonstrated the presence of mGluR1 alpha-immunopositive astrocytes and the absence of mGluR5 in spinal cord white matter. These studies are consistent with the hypothesis that activation of group I mGluR receptors after SCI exacerbates posttraumatic axonal injury through a phospholipase C dependent mechanism, The presence of mGluR1 alpha labeling on astrocytes suggests a role for these cells in the pathophysiology of SCI. Additional studies in vivo, are required to further clarify the role of mGluRs in acute traumatic SCI.	Toronto Hosp, Western Div, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada; Univ Toronto, Div Neurosurg, Toronto, ON, Canada	Fehlings, MG (corresponding author), Toronto Hosp, Western Div, Playfair Neurosci Unit, Mclaughlin Pavil,Room 12-411,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364			Agrawal S. K., 1997, Society for Neuroscience Abstracts, V23, P2189; Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; ANIKSZTEJN L, 1991, EUR J PHARMACOL, V205, P327, DOI 10.1016/0014-2999(91)90921-C; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARRES BA, 1991, J NEUROSCI, V11, P3685; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BARRES BA, 1988, GLIA, V1, P1; BIRRELL GJ, 1993, NEUROPHARMACOLOGY, V32, P1351, DOI 10.1016/0028-3908(93)90030-7; BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHARLES AC, 1993, GLIA, V7, P134, DOI 10.1002/glia.440070203; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; Choi S, 1996, J NEUROSCI, V16, P36; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dalby NO, 1996, J PHARMACOL EXP THER, V276, P516; DOLAN EJ, 1979, J NEUROSURG, V51, P229, DOI 10.3171/jns.1979.51.2.0229; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/0006-8993(96)00667-1; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GALLO V, 1991, GLIA, V4, P245, DOI 10.1002/glia.440040302; GLAUM SR, 1993, J NEUROSCI, V13, P1636; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HARVEY J, 1993, BRIT J PHARMACOL, V109, P1085, DOI 10.1111/j.1476-5381.1993.tb13733.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JENSEN AM, 1993, J NEUROSCI, V13, P1664; KINGSTON AE, 1995, NEUROPHARMACOLOGY, V34, P887, DOI 10.1016/0028-3908(95)00069-I; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; MACVICAR BA, 1988, NEUROSCIENCE, V25, P721, DOI 10.1016/0306-4522(88)90272-2; Maiese K, 1996, J NEUROCHEM, V66, P2419; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MITANI A, 1993, BRAIN RES, V601, P103, DOI 10.1016/0006-8993(93)91700-3; Mukhin A, 1996, J NEUROSCI, V16, P6012; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NAKANISHI S, 1994, EXS, V71, P71; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; OPTIZ T, 1994, NEUROPHARMACOLOGY, V33, P715; OPTIZ T, 1993, NEUROPHARMACOLOGY, V32, P103; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; QUANDT FN, 1986, NEUROSCIENCE, V19, P29, DOI 10.1016/0306-4522(86)90003-5; ROSS SM, 1994, NEUROSCI LETT, V173, P139, DOI 10.1016/0304-3940(94)90168-6; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHOEPP DD, 1994, NEUROCHEM INT, V24, P439, DOI 10.1016/0197-0186(94)90092-2; SILIPRANDI R, 1992, EUR J PHARMACOL, V219, P173, DOI 10.1016/0014-2999(92)90598-X; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tang E, 1997, EUR J PHARMACOL, V327, P109, DOI 10.1016/S0014-2999(97)89649-5; Teng YD, 1997, J NEUROSCI, V17, P4359; Theriault E, 1997, J COMP NEUROL, V382, P199; Theriault E., 1995, Journal of Neurotrauma, V12, P365; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1994, J NEUROSCI, V14, P6598	74	64	65	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1998	15	11					929	941		10.1089/neu.1998.15.929			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	139RN	WOS:000077043400002	9840766				2021-06-18	
J	Juneja, G; Czyrny, JJ; Linn, RT				Juneja, G; Czyrny, JJ; Linn, RT			Admission balance and outcomes of patients admitted for acute inpatient rehabilitation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						balance; rehabilitation; functional outcomes; length of stay	ELDERLY PATIENTS; ACUTE STROKE; PROGNOSIS	The objective of the study contained herein was to evaluate the clinical use of the Berg Balance Scale in a heterogeneous acute inpatient rehabilitation population and to assess the relationship between balance scores at admission and rehabilitation outcomes, including functional gain and length of stay. This was a prospective study of 45 patients with diagnoses including stroke (n = 15), traumatic brain injury (n = 19), and other impairments (n = 11) who were admitted for acute inpatient rehabilitation. Functional ability was evaluated with the Functional Independence Measure (FIM(TM)) instrument, and balance was measured using the 14-item Berg Balance Scale. These measures were assessed both at admission to and discharge from inpatient rehabilitation. Correlation and multiple regression analyses were used to determine the relationship between balance and functional ability scores at admission and rehabilitation outcomes at discharge, including length of stay, functional gain, and efficiency. Analyses of variance comparing impairment groups indicated that patients with traumatic brain injury were younger than the stroke and other groups, but there were no group differences on FIM or balance scores at admission or discharge. There were no significant group differences for any of the outcome measures. When the impairment groups were collapsed into a single heterogeneous group, multiple regression analyses demonstrated that the sitting unsupported item score at admission accounted for 27% of the variation in length of stay, once demographic influences were controlled. The FIM efficiency score was predicted best by the total Berg Balance Scale score, with 22% of the variance accounted for. In contrast, balance scores did not provide predictive information about the FIM gain score beyond that already provided by the FIM-Total score at admission, which accounted for 10% of the variance once demographics were controlled. Balance scores collected at admission to inpatient rehabilitation, in whole and in part, were shown to account for moderate amounts of variation in length of stay and the FIM efficiency score. For several of the rehabilitation outcomes, balance scores at admission accounted for more variation than scores on the FIM instrument. These findings suggest that routine assessment of balance at admission to inpatient rehabilitation may enhance the ability to predict rehabilitation outcomes beyond that provided by assessment of functional status alone.	SUNY Buffalo, Dept Rehabil Med, Sch Med & Biomed Sci, Buffalo, NY 14260 USA	Czyrny, JJ (corresponding author), Erie Cty Med Ctr & Labs, 462 Grider St, Buffalo, NY 14215 USA.						BERG K, 1989, Physiotherapy Canada, V41, P240; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; BOBATH B, 1965, ABNORMAL POSTURAL RE; BOHANNON RW, 1995, ARCH PHYS MED REHAB, V76, P994, DOI 10.1016/S0003-9993(95)81035-8; Brunnstrom S., 1970, MOVEMENT THERAPY HEM; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; FUGLMEYER AR, 1976, P INT REH ASS MEX CI, P683; Gabell A, 1982, Physiotherapy, V68, P286; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; SANDIN KJ, 1990, STROKE, V21, P82, DOI 10.1161/01.STR.21.1.82; *SPSS INC, 1996, SPSS WIND REL 7 0; *STAT U NY BUFF, 1996, GUID UN DAT SET MED; Stineman MG, 1997, ARCH PHYS MED REHAB, V78, P980, DOI 10.1016/S0003-9993(97)90061-7; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; WADE DT, 1983, ARCH PHYS MED REHAB, V64, P24; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WING AM, 1993, ARCH PHYS MED REHAB, V74, P292	22	64	73	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP-OCT	1998	77	5					388	393		10.1097/00002060-199809000-00005			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	132DA	WOS:000076613900005	9798829				2021-06-18	
J	Strauss, DJ; Shavelle, RM; Anderson, TW				Strauss, DJ; Shavelle, RM; Anderson, TW			Long-term survival of children and adolescents after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL-CORD INJURY; SEVERE MENTAL-RETARDATION; LIFE EXPECTANCY; MORTALITY; PEOPLE	Objective: To obtain information on long-term mortality risk and life expectancy after traumatic brain injury (TBI), to improve planning and for counseling patients and their families. In contrast to the literature for spinal cord injury and other disabilities, there have been few such reports for TBI. Design: Records were reviewed on 946 persons aged 5 to 21 years who had sustained TBI. All were patients who subsequently received disability services in California, 1987 to 1995. Results: The chief predictors of mortality were basic functional skills such as mobility and self-feeding. After the initial high-risk period, mortality risk for TBI was much lower than for similarly functioning persons with cerebral palsy (a comparison group), although after 10 years the two sets of mortality rates had largely converged. For high-functioning persons, life expectancies were only 3 to 5 years shorter than for the general population. By contrast, the remaining life expectancy for those without mobility 6 months after injury was only 15 years. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA; Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC V5Z 1M9, Canada	Strauss, DJ (corresponding author), Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA.						Agresti A., 1990, CATEGORICAL DATA ANA; ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; ASHWAL S, 1994, PEDIATR NEUROL, V10, P27, DOI 10.1016/0887-8994(94)90063-9; *CAL DEP DEV SERV, 1978, CLIENT DEV EV REP; Collett D., 1994, MODELING SURVIVAL DA; *CONT SOFTW SYST I, 1995, INT CLASS DIS; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; EYMAN RK, 1993, AM J DIS CHILD, V147, P329, DOI 10.1001/archpedi.1993.02160270091029; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; GEISLER WO, 1977, PARAPLEGIA, V14, P262, DOI 10.1038/sc.1976.44; HARRIS CW, 1982, UCLA MENTAL RETARDAT; Hartkopp A, 1997, SPINAL CORD, V35, P76, DOI 10.1038/sj.sc.3100351; HUTTON JL, 1994, BRIT MED J, V309, P431, DOI 10.1136/bmj.309.6952.431; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MacKenzie E J, 1989, Md Med J, V38, P725; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; Schoen R., 1988, MODELING MULTIGROUP; Strauss D, 1997, J PEDIATR-US, V131, P712, DOI 10.1016/S0022-3476(97)70098-2; Strauss D, 1996, AM J PUBLIC HEALTH, V86, P1422, DOI 10.2105/AJPH.86.10.1422; Strauss D, 1996, AM J MENT RETARD, V101, P26; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; WIDAMAN KF, 1984, 92 ANN M AM PSYCH AS; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN	30	64	64	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1998	79	9					1095	1100		10.1016/S0003-9993(98)90177-0			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	118FX	WOS:000075828700013	9749690				2021-06-18	
J	Christman, CW; Salvant, JB; Walker, SA; Povlishock, JT				Christman, CW; Salvant, JB; Walker, SA; Povlishock, JT			Characterization of a prolonged regenerative attempt by diffusely injured axons following traumatic brain injury in adult cat: a light and electron microscopic immunocytochemical study	ACTA NEUROPATHOLOGICA			English	Article						regeneration; diffuse axonal injury; GAP43; neurofilament; ultrastructure	RAT SPINAL-CORD; NERVE GROWTH-FACTOR; HEAD-INJURY; NEUROFILAMENT SUBUNITS; CNS NEURONS; GAP-43; ANTIBODIES; LESIONS; HUMANS; EXPRESSION	Traumatic brain injury in animals and humans is well known to cause axonal damage diffusely scattered throughout the brain without evidence of other brain parenchymal change. This observation has prompted some to posit that such damaged axons are well positioned to mount a regenerative attempt. The present study uses an immunocytochemical marker specific for regenerating neurites to explore this issue. Further, in an attempt to expedite and enhance any potential regenerative effort, this study evaluates the efficacy of intrathecally applied nerve growth factor. Three sets of experiments were performed in adult cats. One group of animals was subjected to moderate fluid percussion brain injury and followed for 7 or 14 days post injury, with the continuous intraventricular infusion of nerve growth factor delivered by implanted osmotic pumps. These animals were compared to a second group of time-matched, sham-operated animals receiving artificial cerebrospinal fluid infusion. To assess axonal damage immunohistochemical staining for the low molecular weight neurofilament subunit (NF-L) was carried out using an NR4 monoclonal antibody. To localize axons exhibiting a regenerative response immunohistochemical staining for the growth associated protein GAP43 was employed. In sham controls, at the light microscopic level NF-L-immunoreactive axonal swellings were numerous at 7 days, but by 14 days post injury their frequency declined markedly. In contrast, GAP43-immunoreactive, disconnected reactive axonal swellings were rarely observed at 7 days but were numerous at 14 days. Ultrastructural analysis at 14 days post injury of carefully matched sections revealed reactive axons demonstrating sprouting consistent with a regenerative effort. Analysis of tissue from animals of 14 days of survival indicated that supplementation with nerve growth factor did not appear to enhance the capacity of damaged brain axons to mount a regenerative attempt. Rather, it appears that regenerative efforts seen reflect a spontaneous response. A third group of adult cats, subjected to the same injury but not subjected to osmotic pump implantation was allowed to survive for 22-28 days. Animals in this group also demonstrated GAP43 immunoreactivity in reactive axonal swellings in the brain stem. This study demonstrates that diffusely injured axons can mount a sustained regenerative attempt that is associated with a reorganization of their cytoskeleton and accompanied by an up-regulation of growth-associated proteins.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT SURG, DIV NEUROL SURG, RICHMOND, VA 23298 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BARRON KD, 1989, J NEUROSCI RES, V22, P331, DOI 10.1002/jnr.490220313; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; BURRY RW, 1992, J NEUROCYTOL, V21, P413, DOI 10.1007/BF01191506; CAMPBELL G, 1992, J NEUROCYTOL, V21, P755, DOI 10.1007/BF01237903; CAMPBELL G, 1991, EXP BRAIN RES, V87, P67; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; COGGESHALL RE, 1991, NEUROSCI LETT, V131, P37, DOI 10.1016/0304-3940(91)90331-M; CURTIS R, 1993, J NEUROCYTOL, V22, P51, DOI 10.1007/BF01183975; GILSON BC, 1974, CELL TISSUE RES, V149, P1; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; LAMPERT P, 1964, LAB INVEST, V13, P825; LAMPERT PW, 1967, J NEUROPATH EXP NEUR, V26, P345, DOI 10.1097/00005072-196707000-00001; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LI Y, 1994, J NEUROSCI, V14, P4050; MCHALE MK, 1995, J COMP NEUROL, V353, P25, DOI 10.1002/cne.903530105; OESTREICHER AB, 1988, BRAIN RES BULL, V21, P713, DOI 10.1016/0361-9230(88)90037-8; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; PEREZPOLO JR, 1990, MOL NEUROBIOL, V4, P57, DOI 10.1007/BF02935585; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Reier P J, 1988, Adv Neurol, V47, P87; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SORENSEN JC, 1992, EXP BRAIN RES, V92, P299; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TONDER N, 1990, PROG BRAIN RES, V83, P391; VANDENPOL AN, 1994, J COMP NEUROL, V349, P244, DOI 10.1002/cne.903490207; WILLIAMS DK, 1994, DEV BRAIN RES, V81, P89, DOI 10.1016/0165-3806(94)90071-X; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	39	64	64	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	OCT	1997	94	4					329	337		10.1007/s004010050715			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	XZ298	WOS:A1997XZ29800005	9341933				2021-06-18	
J	Gemma, M; Cozzi, S; Tommasino, C; Mungo, M; Calvi, MR; Cipriani, A; Garancini, MP				Gemma, M; Cozzi, S; Tommasino, C; Mungo, M; Calvi, MR; Cipriani, A; Garancini, MP			7.5% hypertonic saline versus 20% mannitol during elective neurosurgical supratentorial procedures	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Society-of-Neurosurgical-Anesthesia-and-Critical-Care	OCT, 1995	ATLANTA, GA	Soc Neurosurg Anesthesia & Crit Care		intracranial pressure; neuroanesthesia; hypertonic saline; mannitol; elective neurosurgery; intraoperative brain bulk	CENTRAL PONTINE MYELINOLYSIS; CEREBRAL OXYGEN DELIVERY; TRAUMATIC BRAIN INJURY; HEMORRHAGIC-SHOCK; INTRACRANIAL-PRESSURE; ISOVOLEMIC HEMODILUTION; FLUID RESUSCITATION; CEREBROSPINAL-FLUID; 3-PERCENT SALINE; RENAL-FAILURE	This prospective randomized clinical study was designed to compare the effects of equal volumes of 7.5% hypertonic saline solution (HS) or 20% mannitol (M) on brain bulk and lumbar cerebrospinal fluid pressure (CSFP) during elective neurosurgical procedures (aneurysm, arteriovenous malformation, or tumor). After informed consent, 50 American Society of Anesthesiologists physical Status I (ASA I) patients were randomly assigned to M (n = 25) or HS (n = 25) groups. Anesthesia protocol was identical for both, and variables monitored included mean arterial blood pressure (MAP), heart rate (HR), central venous pressure(CVP), CSF pressure (CSFP), arterial blood gases (PaCO2 30-35 mm Hg), serum sodium, potassium, and osmolality, and diuresis. The study period started before hypertonic solution administration (To) and ended at the opening of the dura mater or 60 min after T-0. Data were assessed with repeated measures analysis of variance and Student t test with Bonferroni correction (p less than or equal to 0.05). MAP and CVP were the same in the two groups. After treatment, osmolality increased, and the increase at T-15 was higher in HS treated patients [316.6 +/- 9.3 vs. 304.0 +/- 12.0 (SD) mOsmol/kg; p < 0.001]. Sodium decreased after M and increased after HS. During the study, brain bulk was always considered satisfactory. CSFP was not different between M and I-IS groups and significantly decreased over time (p = 0.0056) with no difference between treatments. The results of the present study demonstrate that hypertonic saline is as effective as mannitol in reducing the brain bulk and the CSFP during elective neu rosurgical procedures under general anesthesia.	UNIV MILAN,IRCCS H SAN RAFFAELE ANESTHESIA,DEPT ANESTHESIOL,SECT NEUROANESTHESIA & INTENS CARE,I-20132 MILAN,ITALY				Tommasino, Concezione/0000-0001-8856-6866; Gemma, Marco/0000-0002-9543-3831			AVIRAM A, 1967, AM J MED, V42, P648, DOI 10.1016/0002-9343(67)90066-6; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BORGES HF, 1982, ARCH INTERN MED, V142, P63, DOI 10.1001/archinte.142.1.63; DIMATTIO J, 1975, PFLUG ARCH EUR J PHY, V359, P253, DOI 10.1007/BF00587383; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; Earley L E, 1972, CLIN DISORDERS FLUID, P95; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; FOXWORTHY JC, 1990, J NEUROSURG ANESTH, V2, P256, DOI 10.1097/00008506-199012000-00002; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GOTO T, 1993, CLIN ANESTHESIA PROC, P368; GUNNAR W, 1988, SURGERY, V103, P398; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; HASAN D, 1990, ANN NEUROL, V27, P106, DOI 10.1002/ana.410270118; LAURENO R, 1983, ANN NEUROL, V13, P232, DOI 10.1002/ana.410130303; LAYON J, 1987, ANESTH ANALG, V66, P154; NORENBERG MD, 1982, ANN NEUROL, V11, P128, DOI 10.1002/ana.410110204; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; RAPOPORT SI, 1972, AM J PHYSIOL, V223, P323; RAVUSSIN P, 1988, J NEUROSURG, V69, P869, DOI 10.3171/jns.1988.69.6.0869; SAHAR A, 1978, EXP NEUROL, V60, P584, DOI 10.1016/0014-4886(78)90012-2; SCHACKFORD SR, 1987, SURG GYNECOL OBSTET, V164, P127; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SCHELLER MS, 1991, J NEUROSURG ANESTH, V3, P291, DOI 10.1097/00008506-199112000-00009; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1988, SURGERY, V104, P553; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Tommasino C, 1992, Minerva Anestesiol, V58, P35; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; TOMMASINO C, 1995, FUNDAMENTALS NEUROAN, P133; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; WHELAN TV, 1984, ARCH INTERN MED, V144, P2053, DOI 10.1001/archinte.144.10.2053; WHITLEY JM, 1991, J NEUROSURG ANESTH, V3, P47, DOI 10.1097/00008506-199103000-00008; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	39	64	67	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	1997	9	4					329	334		10.1097/00008506-199710000-00007			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	YC944	WOS:A1997YC94400007	9339405				2021-06-18	
J	Selladurai, BM; Vickneswaran, M; Duraisamy, S; Atan, M				Selladurai, BM; Vickneswaran, M; Duraisamy, S; Atan, M			Coagulopathy in acute head injury - a study of its role as a prognostic indicator	BRITISH JOURNAL OF NEUROSURGERY			English	Article						coagulopathy; disseminated intravascular coagulation; head injury; outcome	DISSEMINATED INTRAVASCULAR COAGULATION; ABNORMALITIES; FIBRINOLYSIS; CT	The aim of this investigation was to determine the prognostic value of coagulation abnormalities in a defined subset of patients with acute head injury. Prothrombin time, accelerated partial thromboplastin time (APTT), thrombin clotting time, fibrinogen assay, platelet count, fibrin degradation products (FDP) were assayed in 204 patients with acute closed head injury. Their values were graded on a score 0-3 and the sum score for each patient regarded as the disseminated intravascular coagulation (DIG) score. Moderate to severe DIC scores were evident in 38% of the cohort. At least one parameter was abnormal in 71% of patients. The DIC score correlated inversely with the Glasgow coma score (GCS) (p<0.0001). In the GCS 13-15 subset, FDP scores were significant predictors of poor outcome (p<0.001). In the GCS 6-12 subset, the APTT score (p<0.001), and DIC score (p<0.0001) predicted an adverse outcome. The DIC scores were significantly abnormal in most patients who had a poor outcome, without evidence of adverse predictors on CT. Logistic regression analysis confirmed the independent predictive capacity of APTT, FDP and DIC scores when values for GCS were fixed. Abnormal haemostatic parameters may enhance the predictive ability in subsets of patients with acute head injury defined by clinical or CT predictors.	UNIV KEBANGSAAN MALAYSIA, DIV NEUROSURG, KUALA LUMPUR, MALAYSIA; UNIV KEBANGSAAN MALAYSIA, DEPT RADIOL, KUALA LUMPUR, MALAYSIA; HOSP KUALA LUMPUR, DEPT NEUROSURG, KUALA LUMPUR, MALAYSIA; HOSP KUALA LUMPUR, DEPT HAEMATOL, KUALA LUMPUR, MALAYSIA			Mathaneswaran, Vickneswaran/A-1228-2011; Mathaneswaran, Vickneswaran/E-5180-2010				BICK RL, 1978, AM J HEMATOL, V5, P265, DOI 10.1002/ajh.2830050311; COOPER PR, 1986, NEUROSURGERY, V19, P531; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; MELLION BT, 1992, COMPLICATIONS SEQUEL, P51; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; SPERO JA, 1980, THROMB HAEMOSTASIS, V43, P28; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718	19	64	74	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	1997	11	5					398	404					7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	YB241	WOS:A1997YB24100005	9474270				2021-06-18	
J	Whalen, MJ; Carlos, TM; Clark, RSB; Marion, DW; DeKosky, ST; Heineman, S; Schiding, JK; Memarzadeh, F; Kochanek, PM				Whalen, MJ; Carlos, TM; Clark, RSB; Marion, DW; DeKosky, ST; Heineman, S; Schiding, JK; Memarzadeh, F; Kochanek, PM			The effect of brain temperature on acute inflammation after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	13th Annual Houston Conference on Biomedical Engineering Research	FEB09, 1996	HOUSTON, TX			brain injury; cell adhesion; controlled cortical impact; hypothermia; inflammation; rat	CONTROLLED CORTICAL IMPACT; ANTI-CD18 MONOCLONAL-ANTIBODIES; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; NEUTROPHIL ACCUMULATION; MYELOPEROXIDASE ACTIVITY; ADHESION MOLECULE-1; CEREBRAL-ISCHEMIA; PROTECTION; EDEMA	The effect of varying brain temperature on neutrophil accumulation in brain and the expression of E-selectin and intercellular adhesion molecule-1 (ICAM-1) on cerebrovascular endothelium after controlled cortical impact (CCI) was studied in rats. Sprague Dawley rats were anesthetized and subjected to CCI to the left parietal cortex. Ten minutes after CCI, brain temperature was modulated and maintained at 32 degrees C, 37 degrees C, or 39 degrees C (n = 8 per group) for 4 h. Rats were then decapitated and immunohistochemistry on brain sections was performed using monoclonal antibodies (MoAb) that recognize neutrophils (RP-3), ICAM-1 (TM-8, Athena Neurosciences), or MoAb that react with E-selectin (La-Roche). Each of these markers was quantified in 100 x fields. Neutrophil accumulation was also quantified with myeloperoxidase (MPO) assay. Absolute neutrophil count (ANC) was measured in blood samples before and 1 h and 4 h after CCI. Neutrophil accumulation in injured brain was decreased in rats maintained at 32 degrees C vs 39 degrees C (4-fold difference as assessed by immunohistochemistry, p < 0.05; 8-fold difference as assessed by MPO assay, p < 0.05). Peripheral blood ANC was not affected by temperature. E-selectin was induced on cerebrovascular endothelium after CCI (p < 0.05), but was only decreased modestly at 32 degrees C versus 39 degrees C (p = 0.11). ICAM-1 was not upregulated on cerebrovascular endothelium at this early time following CCI. Neutrophil accumulation is directly dependent on brain temperature during the initial 4 h after CCI. This appears to be mediated by mechanisms other than effects of temperature on E-selectin or ICAM-1 expression or systemic ANC.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT PEDIAT, PITTSBURGH, PA USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT NEUROL SURG, PITTSBURGH, PA USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT PSYCHIAT, PITTSBURGH, PA USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA USA			Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51; BALCH HH, 1955, SURGERY, V38, P1036; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Brooks B, 1941, ANN SURG, V114, P1069, DOI 10.1097/00000658-194112000-00013; Brundeau J, 1944, ANN SURG, V120, P716, DOI 10.1097/00000658-194411000-00004; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DELAUNAY A, 1954, ANN I PASTEUR PARIS, V86, P520; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; Duerschner DR, 1943, J INFECT DIS, V72, P183, DOI 10.1093/infdis/72.3.183; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; Hartl R, 1996, J NEUROSURG, V84, P845; HINES D, 1983, SOC NEUR ABSTR, V19, P1875; HORNER HC, 1992, SOC NEUR ABSTR, V8, P173; JANSSEN CW, 1967, ACTA PATHOL MIC SC, V69, P557; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; KUBES P, 1994, J IMMUNOL, V152, P3570; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; SAEZLLORENS X, 1991, J CLIN INVEST, V88, P2003, DOI 10.1172/JCI115527; SANDERS F, 1959, SURG FORUM, V10, P92; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Soares HD, 1995, J NEUROSCI, V15, P8223; SVANES K, 1965, ACTA PATHOL MIC SC, V65, P1; SVANES K, 1964, ACTA ANAESTH SCAND, V8, P143, DOI 10.1111/j.1399-6576.1964.tb00236.x; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAUBER MG, 1988, J INFECT DIS, V157, P456, DOI 10.1093/infdis/157.3.456; THOMAS G, 1986, J PHARM PHARMACOL, V38, P936, DOI 10.1111/j.2042-7158.1986.tb03390.x; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VANEEDEN S, 1995, AM J RESP CRIT CARE, V151, P500, DOI 10.1164/ajrccm.151.2.7531098; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; ZHANG ZG, 1995, BRAIN RES, V698, P79, DOI 10.1016/0006-8993(95)00830-J	70	64	65	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1997	14	8					561	572		10.1089/neu.1997.14.561			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XU894	WOS:A1997XU89400007	9300566				2021-06-18	
J	Bramlett, HM; Green, EJ; Dietrich, WD				Bramlett, HM; Green, EJ; Dietrich, WD			Hippocampally dependent and independent chronic spatial navigational deficits following parasagittal fluid percussion brain injury in the rat	BRAIN RESEARCH			English	Article						head injury; hippocampus; learning and memory; Morris water maze; rat	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; VENTRICULAR DILATION; LONG-TERM; MEMORY; PLACE; RECOVERY; LESIONS; DAMAGE; IMPAIRMENTS	Previous reports have documented spatial navigational deficits following experimental traumatic brain injury (TBI), although the majority of the work to date has involved assessment at acute intervals following TBI, and has focused on tasks sensitive to hippocampal dysfunction. The present experiments were designed to investigate the chronic consequences of TBI, and the possible contribution of extrahippocampal dysfunction to TBI-induced spatial navigational deficits, in a moderate parasagittal fluid percussion TBI model. In Experiment 1, animals were pre-trained in a water maze, subjected to TBI or sham procedures, and re-evaluated in the water maze 48 h following the insult. Six to 8 weeks following TBI, the same animals were required to navigate to a different platform location. TBI animals exhibited significant deficits in retention of previously learned spatial information at the 48 h interval, and marginally impaired acquisition of a novel platform location during the chronic test sessions. In Experiment 2, animals were required to navigate to novel spatial locations using cued (to evaluate extrahippocampal function) as well as non-cued variants of the water maze task during the 8 week period following the insult. Injured animals exhibited deficits in both tasks which gradually diminished over the course of testing. The results of these experiments indicate that moderate TBI is accompanied by both retention and acquisition deficits, and that some of the navigational deficits observed in the water maze can be attributed to extrahippocampal damage. The possible recovery of spatial navigational ability following parasagittal TBI at moderate intensities is also discussed. (C) 1997 Elsevier Science B.V.	UNIV MIAMI,DEPT PSYCHOL,CORAL GABLES,FL 33124; UNIV MIAMI,NEUROTRAUMA RES CTR,MIAMI,FL 33136; UNIV MIAMI,DEPT NEUROL,MIAMI,FL 33136					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRAMLETT HM, 1996, SOC NEUR ABSTR, P231; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS HR, 1993, J NEUROTRAUM, V10, P405; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P176; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; MARMAROU A, 1985, BRAIN EDEMA, P88; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; POVLISHOCK JT, 1990, ADV NEUROTRAUMA RES, V2, P1; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SUTHERLAND RJ, 1988, PSYCHOBIOLOGY, V16, P157; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; WHISHAW IQ, 1985, PHYSIOL BEHAV, V35, P139, DOI 10.1016/0031-9384(85)90186-6; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZILLES L, 1985, CORTEX RAT STEREOTAX	43	64	65	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 11	1997	762	1-2					195	202		10.1016/S0006-8993(97)00387-9			8	Neurosciences	Neurosciences & Neurology	XL775	WOS:A1997XL77500022	9262173				2021-06-18	
J	King, ML; Lichtman, SW; Seliger, G; Ehert, FA; Steinberg, JS				King, ML; Lichtman, SW; Seliger, G; Ehert, FA; Steinberg, JS			Heart-rate variability in chronic traumatic brain injury	BRAIN INJURY			English	Article							MYOCARDIAL-INFARCTION	Heart-rate variability (HRV), a measure of fluctuation around the mean heart rate, reflects the sympathetic and parasympathetic balance of the autonomic nervous system, and is an excellent technique to study cardiovascular tone in patients with neurological injuries. The purpose of this study was to determine whether abnormal HRV is present in patients with traumatic brain injury (TBI) during the post-acute recovery phase. Using a prospective, case/control design, we performed 24-h ambulatory ECG monitoring in seven TBI patients and in seven controls (C). There was a significant difference in root mean squared successive difference of RR intervals (C 40.4 +/- 10.3, TBI 23.3 +/- 16.5, p = 0.04) between TBI and C. Four patients with TBI (compared to one control) had abnormal standard deviation of the RR interval. When these four patients were compared to their matched controls, significant differences were found in frequency domain measure (In total po TBI 4.4 +/- 0.9 ms(2), C 7.1 +/- 1.4 ms(2). In low frequency: TBI 3.3 +/- 1.1 ms(2), C 6.4 +/- 1.4 ms(2); In high frequency TBI 2.0 +/- 1.0 ms(2), C 4.8 +/- 1.3 ms(2), all p < 0.05). Thus, abnormalities in both time and frequency domains of HRV are present in TBI during the pose-acute recovery phase.	HELEN HAYES HOSP, DEPT NEUROL, W HAVERSTRAW, NY 10993 USA; ST LUKES ROOSEVELT HOSP, DIV CARDIOL, ARRHYTHMIA SERV, NEW YORK, NY USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10027 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10027 USA	King, ML (corresponding author), HELEN HAYES HOSP, DEPT INTERNAL MED, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.						ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; BIGGER JT, 1993, J AM COLL CARDIOL, V21, P729, DOI 10.1016/0735-1097(93)90106-B; BINKLEY PF, 1993, J AM COLL CARDIOL, V21, P655, DOI 10.1016/0735-1097(93)90098-L; FRANK JI, 1992, ARCH NEUROL-CHICAGO, V49, P1200, DOI 10.1001/archneur.1992.00530350122028; GOLDSMITH RL, 1992, J AM COLL CARDIOL, V20, P552, DOI 10.1016/0735-1097(92)90007-A; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LATHERS CM, 1987, J CLIN PHARMACOL, V27, P346, DOI 10.1002/j.1552-4604.1987.tb03030.x; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; LOWENSOHN RI, 1977, LANCET, V1, P626; NIEMELA MJ, 1994, J AM COLL CARDIOL, V23, P1370, DOI 10.1016/0735-1097(94)90379-4; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; TEASDALE G, 1974, LANCET, V2, P81; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008	14	64	64	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	1997	11	6					445	453					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WZ726	WOS:A1997WZ72600005	9171929				2021-06-18	
J	Ghirnikar, RS; Lee, YL; He, TR; Eng, LF				Ghirnikar, RS; Lee, YL; He, TR; Eng, LF			Chemokine expression in rat stab wound brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						mechanical injury; gliosis; GFAP; astrocyte	FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; LOCALIZATION; ASTROCYTES; CYTOKINES; INCREASE; DISEASE	A traumatic injury to the adult mammalian central nervous system (CNS) results in reactive astrogliosis and the migration of hematogenous cells into the damaged neural tissue. Chemokines, a novel class of chemoattractant cytokines, are now being recognized as mediators of the inflammatory changes that occur following injury. The expression of MCP-1 (macrophage chemotactic peptide-1), a member of the beta family of chemokines, has recently been demonstrated in trauma in the rat brain (Berman et al.: J Immunol 156:3017-3023, 1996). Using a stab wound model for mechanical injury, we studied the expression of two other beta chemokines: RANTES (Regulated on Activation, Normal T cell Expressed and Secreted) and MIP-1 beta (macrophage inflammatory protein-1 beta) in the rat brain. The stab wound injury was characterized by widespread gliosis and infiltration of hematogenous cells. Immunohistochemical staining revealed the presence of RANTES and MIP-1 beta in the injured brain, RANTES and MIP-1 beta were both diffusely expressed in the necrotic tissue and were detected as early as 1 day post-injury (dpi). Double-labeling studies showed that MIP-1 beta, but not RANTES, was expressed by reactive astrocytes near the lesion site. In addition, MIP-1 beta staining was also detected on macrophages at the site of injury. The initial expression of the chemokines closely correlated with the appearance of inflammatory cells in the injured CNS, suggesting that RANTES and MIP-1 beta may play a role in the inflammatory events of traumatic brain injury. This study also demonstrates for the first time MIP-1 beta expression in reactive astrocytes following trauma to the rat CNS. (C) 1996 Wiley-Liss, Inc.	VAPA HLTH CARE SYST, PATHOL RES 113R, DEPT PATHOL, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, STANFORD, CA 94305 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-11632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS011632] Funding Source: NIH RePORTER		Benveniste EN, 1995, FASEB J, V9, P1577; Benveniste EN., 1993, ASTROCYTES PHARM FUN, P355; Berman JW, 1996, J IMMUNOL, V156, P3017; BROSNAN CF, 1993, ADV NEUROL, V59, P349; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Eng LF, 1996, NEUROCHEM RES, V21, P511, DOI 10.1007/BF02527717; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; GLABINSKI AR, 1995, INT J DEV NEUROSCI, V13, P153, DOI 10.1016/0736-5748(95)00017-B; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Hopkins Stephen J., 1995, Trends in Neurosciences, V18, P83, DOI 10.1016/0166-2236(95)93881-W; HULKOWER K, 1993, J IMMUNOL, V150, P2525; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KUNA P, 1993, J IMMUNOL, V150, P1932; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LOTAN M, 1994, FASEB J, V8, P1026; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; NEUGARTEN J, 1995, J AM SOC NEPHROL, V5, P1903; NOE KH, 1996, J NEUROCHEM S, V66, pSD71; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; RANSOHOFF RM, 1993, FASEB J, V7, P592; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHMOUDER RL, 1993, KIDNEY INT, V44, P43, DOI 10.1038/ki.1993.211; SEEBACH J, 1995, J IMMUNOL, V155, P4367; TANI M, 1994, BRAIN PATHOL, V4, P135, DOI 10.1111/j.1750-3639.1994.tb00824.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; VANOTTEREN GM, 1995, J IMMUNOL, V154, P1900; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; WILSON SD, 1990, J EXP MED, V171, P1301, DOI 10.1084/jem.171.4.1301; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOODWARD WR, 1992, J NEUROSCI, V12, P142	36	64	64	3	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	1996	46	6					727	733					7	Neurosciences	Neurosciences & Neurology	VY927	WOS:A1996VY92700010	8978507				2021-06-18	
J	Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO				Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO			Childhood traumatic brain injury: Initial impact on the family	JOURNAL OF LEARNING DISABILITIES			English	Article							CLOSED HEAD-INJURY; ASSESSMENT DEVICE; CHILDREN; SEQUELAE; RELIABILITY; VALIDITY	Traumatic brain injury (TBI) is a significant source of morbidity and mortality in children, resulting in a wide range of cognitive and behavioral sequelae. However, little is known about the effects of pediatric TBI and its aftermath on families. The current investigation examined the impact of TBI on families during the first month following injury. Children with orthopedic injuries requiring hospitalization served as a control group. The sample consisted of 44 families of children of severe TBI, 52 families of children with moderate TBI, and 69 families of children with orthopedic injuries not involving the central nervous system (CNS). Families of children with severe TBI experienced significantly more injury-related stress than the other two groups of families. Parents of children with TBI also reported higher levels of psychological symptoms than parents of children with orthopedic injuries. Findings from regression analyses suggested that families facing multiple stressors in addition to the injury and those who cope poorly may be at greatest risk for adverse consequences. Future interventions could provide anticipatory guidance and support to at-risk families.	RAINBOW BABIES & CHILDRENS HOSP,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PSYCHOL,SCH MED,CLEVELAND,OH 44106; METROHLTH MED CTR,DEPT PSYCHIAT,CLEVELAND,OH 44109; OHIO STATE UNIV,COLUMBUS,OH 43210; COLUMBUS CHILDRENS HOSP,COLUMBUS,OH 43205			Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Derogatis L. R., 1982, ADM PROCEDURES BSI M; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DROTAR S, 1996, FAMILY BURDEN INJURY; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; JENNETT B, 1975, LANCET, V1, P480; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos RH, 1988, J SUBSTANCE ABUSE, V1, P135, DOI DOI 10.1016/S0899-3289(88)80017-8; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; ROLLAND JS, 1987, FAM PROCESS, V26, P203, DOI 10.1111/j.1545-5300.1987.00203.x; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Stein R, 1985, PACTS PAPERS AECOM T; TAYLOR HG, IN PRESS TRAUMATIC B; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737	30	64	66	0	3	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1996	29	6					652	661		10.1177/002221949602900609			10	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	VU234	WOS:A1996VU23400009	8942309				2021-06-18	
J	Lewis, SB; Finnie, JW; Blumbergs, PC; Scott, G; Manavis, J; Brown, C; Reilly, PL; Jones, NR; McLean, AJ				Lewis, SB; Finnie, JW; Blumbergs, PC; Scott, G; Manavis, J; Brown, C; Reilly, PL; Jones, NR; McLean, AJ			A head impact model of early axonal injury in the sheep	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; axonal injury; head injury model; pathophysiological correlation; sheep	AMYLOID PRECURSOR PROTEIN; BRAIN INJURY; TRAUMA	Axonal injury (AI), one of the principal determinants of clinical outcome after head injury, may evolve over several hours after injury, raising the future possibility of therapeutic intervention during this period. A new head impact model of AI in sheep was developed to examine pathological and physiological changes in the brain resulting from a graded traumatic insult. In this preliminary study 10 anesthetized and ventilated Merino ewes were used. Head injury was produced by impact from a humane stunner to the temporal region of an unrestrained head. Eight sheep were studied for 1, 2, 4, or 6 h after impact. Two sham animals (no impact, 6 h survival) were also examined. Arterial blood pressure, intracranial pressure, and cerebral blood flow were monitored continuously. A physiological index of injury severity was calculated by weighting the percentage shift from preinjury values for each monitored parameter over the first hour after injury. Immunostaining with amyloid precursor protein (APP) was used as a marker of axonal damage and the distribution of APP positive axons was recorded according to a sector scoring method (APPS). Widespread AI was identified in 7 of the 8 impacted animals, around cerebral contusions and in hemispheric white matter, central gray matter, brain stem, and cerebellum, and was detected as early as 1 h after injury. The degree of axonal injury (APPS) correlated well with an index of physiological response to injury (r = 0.83, p = 0.005).	ROYAL ADELAIDE HOSP,DEPT NEUROSURG,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,INST MED & VET SCI,NEUROPATHOL LAB,ADELAIDE,SA 5005,AUSTRALIA; UNIV ADELAIDE,DEPT NEUROSURG,ADELAIDE,SA 5005,AUSTRALIA; UNIV ADELAIDE,NHMRC ROAD ACCID RES UNIT,ADELAIDE,SA 5005,AUSTRALIA							ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTLEMAN SM, 1993, PATHOLOGY DOMESTIC A, V1, P323; JUBB KVF, 1933, PATHOLOGY DOMESTIC A, V1, P323; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRKPATRICK JB, 1988, FORENSIC NEUROPATHOL, P276; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; May NDS., 1964, ANATOMY SHEEP; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1966, HEAD INJURY, P260; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROBERTS GW, 1993, NEUROSCI LETT, V160, P139; RYAN GA, 1994, J TRAUMA, V36, P469; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHIGEMATSU K, 1992, BRAIN RES, V592, P353, DOI 10.1016/0006-8993(92)91697-D; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; UPTON R, 1994, J CEREBR BLOOD F MET, V14, P680, DOI 10.1038/jcbfm.1994.85; Yoshikawa T., 1967, ATLAS BRAINS DOMESTI	26	64	66	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					505	514		10.1089/neu.1996.13.505			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600003	8913967				2021-06-18	
J	Posmantur, RM; Kampfl, A; Taft, WC; Bhattacharjee, M; Dixon, CE; Bao, J; Hayes, RL				Posmantur, RM; Kampfl, A; Taft, WC; Bhattacharjee, M; Dixon, CE; Bao, J; Hayes, RL			Diminished microtubule-associated protein 2 (MAP2) immunoreactivity following cortical impact brain injury	JOURNAL OF NEUROTRAUMA			English	Article						microtubule-associated protein 2; Western blotting; immunocytochemistry; dendritic change; rat	FLUID-PERCUSSION MODEL; MIDDLE CEREBRAL-ARTERY; HIPPOCAMPAL SLICES; CALPAIN-I; HEAD-INJURY; RAT; NEURONS; PROTEOLYSIS; OCCLUSION; HYPOXIA	This study employed Western blotting and qualitative immunohistochemistry to analyze the effects of cortical impact traumatic brain injury (TBI) on acute changes in MAP2 immunoreactivity in the rat cortex, We employed a lateral cortical impact injury device to induce severe TBI, which is associated with focal cortical contusion and neuronal death at the impact site, Three hours following TBI, Western blotting detected substantial MAP2 loss only in the cortex ipsilateral to the site of injury, Light microscopic studies of MAP2 revealed a prominent loss of MAP2 immunofluorescence in apical dendrites of pyramidal neurons within layers 3 and 5, as well as a loss of fine dendritic arborization within layer 1, These changes in MAP2 immunolabeling were associated with, but not exclusively restricted to, the presence of dark shrunken neurons labeled by hematoxylin and eosin staining, suggesting impending cell death, Alterations in MAP2 immunofluorescence were found both within and beyond areas of focal contusion and necrosis in the ipsilateral cortex, Thus, traumatic brain injury in rats can produce rapid and significant dendritic pathology within sites of contusion, However, immunohistochemical changes in MAP2 labeling outside of contused regions suggests that TBI-induced dendritic damage may not be exclusively associated with acute cell death.	UNIV TEXAS, HOUSTON HLTH SCI CTR, DEPT NEUROSURG, HOUSTON, TX 77030 USA; UNIV TEXAS, HOUSTON HLTH SCI CTR, DEPT PATHOL, HOUSTON, TX 77030 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, R01 NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARAI A, 1991, BRAIN RES, V555, P276, DOI 10.1016/0006-8993(91)90352-V; BARINAGA M, 1995, SCIENCE, V268, P200, DOI 10.1126/science.7536341; BERKOWITZ SA, 1977, BIOCHEMISTRY-US, V16, P5610, DOI 10.1021/bi00644a035; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; CROALL DE, 1990, INTRACELLULAR CALCIU, P103; DASH PK, 1995, J NEUROSCI, V15, P2030; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1995, IN PRESS CATASTROPHI; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; ISOKAWA M, 1991, NEUROSCI LETT, V132, P212, DOI 10.1016/0304-3940(91)90304-C; KAMPFL A, 1995, NEUROSCI LETT, V194, P149, DOI 10.1016/0304-3940(95)11745-I; KAMPFL A, 1995, IN PRESS EUR J NEURO; KAMPFL AW, 1994, SOC NEUR ABSTR, V20; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; LI Z, 1995, IN PRESS NEUROCHEM I; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELLOR GW, 1989, BIOCHEM J, V290, P75; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; North M, 1989, PROTEOLYTIC ENZYMES, P105; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POSMANTUR RM, 1995, UNPUB J NEUROSCI; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAATMAN KE, 1994, IN PRESS J NEUR ABST; SCHORMAIR C, 1993, BRAIN RES BULL, V32, P329, DOI 10.1016/0361-9230(93)90196-I; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALDIVIA MM, 1982, BIOCHEM BIOPH RES CO, V105, P1241, DOI 10.1016/0006-291X(82)90920-2; WHITSON JS, 1995, NEUROSCI LETT, V197, P159, DOI 10.1016/0304-3940(95)11921-I; WHITSON JS, 1995, BRAIN RES, V948, P213; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	60	64	64	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1996	13	3					125	137		10.1089/neu.1996.13.125			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UD469	WOS:A1996UD46900002	8965322				2021-06-18	
J	Ommaya, AK; Ommaya, AK; Dannenberg, AL; Salazar, AM				Ommaya, AK; Ommaya, AK; Dannenberg, AL; Salazar, AM			Causation, incidence, and costs of traumatic brain injury in the US military medical system	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; epidemiology; costs; causes	CARE	Hospital discharge records from military facilities and private facilities reimbursed by Civilian Health and Medical Program of the Uniformed Services for fiscal year 1992 were reviewed to identify head injury admissions. Incidence rates, case fatality rates, causes of head injuries, and direct cost for hospital admissions were computed in this well-defined population. For fiscal year 1992, there were 5,568 hospitalized cases of noncombat head injury in the military medical system. The age-adjusted head injury rates for ages 15-44 years are higher in active-duty individuals compared with other beneficiaries (1.6 times greater for men and 2.5 times greater for women). The total cost for hospitalization in this population was $43 million. Private facility rehabilitation accounted for 26% of all private facility costs but only 6% of head injury cases. Firearms and motor vehicle crashes caused the most severe injuries for cases admitted to military facilities. Motor vehicle crashes, falls, and fighting accounted for 80% of the total military facility cost for head injuries, Military active-duty individuals are at increased risk for noncombat head injury. Prevention of head injury in military settings should focus on motor vehicle crashes, fist fights (assault), and falls.	GEORGE WASHINGTON UNIV,DEPT NEUROSURG,WASHINGTON,DC; JOHNS HOPKINS UNIV,SCH PUBL HLTH,INJURY PREVENT CTR,BALTIMORE,MD; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	Ommaya, AK (corresponding author), WALTER REED ARMY MED CTR,DEF & VET HEAD INJURY PROGRAM,BLDG 7,ROOM 240,WASHINGTON,DC 20307, USA.				AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R03 HS08414-01] Funding Source: Medline		ARMITAGE P, 1987, STATISTICAL METHODS, P459; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; *COMM GOV OP, 1992, FRAUD AB HEAD INJ RE; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; *DEF MED INF MAN, 1993, CENTR RCMAS OSE US M; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; JOY SA, 1994, J TRAUMA, V37, P303, DOI 10.1097/00005373-199408000-00024; Kraus JF, 1993, HEAD INJURY, P1; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MacKenzie E J, 1989, Md Med J, V38, P725; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; OMMAYA AK, 1983, HEAD NECK INJURY CRI, P248; RICE DH, 1989, CURRENT CONCEPTS HEA, P1; RIVARA FP, 1988, JAMA-J AM MED ASSOC, V260, P221; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251	16	64	64	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	1996	40	2					211	217		10.1097/00005373-199602000-00007			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	TW081	WOS:A1996TW08100007	8637068				2021-06-18	
J	Memon, ZI; Altura, BT; Benjamin, JL; Cracco, RQ; Altura, BM				Memon, ZI; Altura, BT; Benjamin, JL; Cracco, RQ; Altura, BM			Predictive value of serum ionized but not total magnesium levels in head injuries	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article						brain injury; head injury; ion-selective electrodes; ionized calcium; ionized magnesium	BRAIN INJURY; HYPOMAGNESEMIA; GLUTAMATE; ISCHEMIA	Despite a wealth of recent literature and research on traumatic brain injury, very little has been applicable to diagnosing and treating this syndrome at a tissue level. Part of this problem is the inability to assess rapidly and early in the syndrome the degree or progression of brain injury at a tissue level using simple biochemical analytes. With this in mind, we designed a study in 66 human subjects, who presented with acute blunt head trauma, to determine whether free, ionized serum magnesium (IMg2+) and/or free, ionized serum calcium (ICa2+) levels correlated with the severity of head trauma (HT) and whether any predictive reliable patterns emerge. By using a new ion-selective electrode (ISE) for IMg2+, we have been able to determine IMg2+ and ICa2+ within minutes after sampling in the serum of patients early (1-8 h) after HT. These studies reveal that acute HT is associated with graded deficits (up to 62%, mean=25%) in serum IMg2+, but not in total serum Mg, which are related to severity of injury based on CT scans and other diagnostic parameters. The greater the degree of injury, the greater the ICa2+/IMg2+ ratio. These ionic findings are compatible with the idea that early ischaemia after head trauma may be important in determining neurological outcome. Our findings provide the first evidence for divalent cation changes in blood after traumatic brain injury, which could be of both diagnostic and prognostic value in patients with traumatic brain injury.	SUNY HLTH SCI CTR,DEPT PHYSIOL,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT NEUROL,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT MED,BROOKLYN,NY 11203					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA008674] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA-08674] Funding Source: Medline		Aikawa J., 1981, MAGNESIUM ITS BIOL S; ALLGROVE J, 1984, CLIN ENDOCRINOL, V21, P435, DOI 10.1111/j.1365-2265.1984.tb03230.x; Altura B. M., 1992, Magnesium and Trace Elements, V10, P122; Altura B T, 1984, Magnesium, V3, P195; Altura B. T., 1992, Magnesium and Trace Elements, V10, P90; ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; ALTURA BM, 1987, MAGNESIUM CELLULAR P; ALTURA BT, 1992, METHOD FIND EXP CLIN, V14, P297; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P21, DOI 10.3109/00365519409095208; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P77, DOI 10.3109/00365519409095213; ALTURA BT, 1980, NEUROSCI LETT, V20, P323, DOI 10.1016/0304-3940(80)90168-8; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BECKER DP, 1985, CENTRAL NERVOUS SYST; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Dubey S N, 1975, Neurol India, V23, P17; FAGG GL, 1985, TRENDS NEUROSCI, P207; FLINK EB, 1981, ARCH INTERN MED, V141, P441, DOI 10.1001/archinte.141.4.441; HUANG Q, 1989, FASEB Journal, V3, pA845; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JANE JA, 1991, CENTRAL NERVOUS SYST; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; JUAN D, 1982, SURGERY, V91, P510; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KING LR, 1973, ANN SURG, V177, P126, DOI 10.1097/00000658-197301000-00022; Mangal B D, 1975, J Assoc Physicians India, V23, P339; MARSHALL LF, 1990, CURR OPIN NEUROL NEU, V3, P4; MAUSKOP A, 1993, HEADACHE, V33, P135, DOI 10.1111/j.1526-4610.1993.hed3303135.x; MCLAURIN RL, 1976, HDB CLIN NEUROLOGY, V23, P109; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUDE RK, 1987, MAGNESIUM CELLULAR P, P183; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6	35	64	66	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5513			SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.	DEC	1995	55	8					671	677		10.3109/00365519509075397			7	Medicine, Research & Experimental	Research & Experimental Medicine	TM055	WOS:A1995TM05500003	8903837				2021-06-18	
J	KAY, T; CAVALLO, MM; EZRACHI, O; VAVAGIAKIS, P				KAY, T; CAVALLO, MM; EZRACHI, O; VAVAGIAKIS, P			THE HEAD-INJURY FAMILY INTERVIEW - A CLINICAL AND RESEARCH TOOL	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						FAMILY ASSESSMENT; TRAUMATIC BRAIN INJURY	RATING-SCALE	This article describes the Head Injury Family Interview (HI-FI), a five-part structured interview designed to gather clinical and research data on persons with head injury and their family members. The HI-FI was developed over a 10-year period at the Research and Training Center on Head Injury and Stroke of New York University Medical Center to track outcomes of persons recovering from traumatic brain injury, with input from both the injured person and significant others, and to document the impact of the injury on the family system. The structure, contents, rationale, and development of the interviews are described, as well as its clinical utility and research potential. In addition, the statistical properties of one particular instrument within the interview, the Problem Checklist, are detailed and data presented from a multi-center study.	ASSOC HELP RETARDED CHILDREN,TRAUMAT BRAIN INJURY SERV,NEW YORK,NY; ASSOC HELP RETARDED CHILDREN,TRAUMAT BRAIN INJURY COMMUNITY SUPPORT SERV,NEW YORK,NY; NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013	KAY, T (corresponding author), NYU MED CTR,RUSK INST REHABIL MED,NEW YORK,NY 10016, USA.						BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BISHOP D, 1989, J HEAD TRAUMA REHABI, V3, P16; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; DEPOMPEI R, 1991, HEAD INJURY FAMILY M; HARVEY R, 1981, ARCH PHYS MED REHAB, V62, P109; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1991, HEAD INJURY FAMILY M; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; 1990, FUNCTIONAL INDEPENDE	13	64	64	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1995	10	2					12	31		10.1097/00001199-199504000-00004			20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QR039	WOS:A1995QR03900004					2021-06-18	
J	KARZMARK, P; HALL, K; ENGLANDER, J				KARZMARK, P; HALL, K; ENGLANDER, J			LATE-ONSET POST-CONCUSSION SYMPTOMS AFTER MILD BRAIN INJURY - THE ROLE OF PREMORBID, INJURY-RELATED, ENVIRONMENTAL, AND PERSONALITY FACTORS	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; POSTCONCUSSIONAL SYNDROME; SEQUELAE; TRAUMA; IMPACT; TIME	The present study investigated the possible role of a number of pre- peri-, and post-traumatic factors in the experience of post-concussion syndrome (PCS). These factors included: (1) history of premorbid risk factors, (2) severity of injury, and (3) post-morbid functioning and environmental factors. Subjects were 55 persons with mild brain injury. PCS was defined in terms of the severity and impact of 'late-onset' symptoms. Pre- and peri-traumatic factors were not associated with level of PCS symptom impact. Among post-traumatic factors, only level of psychological distress was strongly associated with impact level. The results suggest the importance of psychological factors in prolonged PCS.		KARZMARK, P (corresponding author), SANTA CLARA VALLEY MED CTR,PSYCHOL SERV,751 S BASCOM AVE,SAN JOSE,CA 95128, USA.						ADLER A, 1945, ARCH NEURO PSYCHIATR, V53, P34, DOI 10.1001/archneurpsyc.1945.02300010044003; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALFANO PP, 1992, J CLIN EXPT NEUROPSY, V14, P77; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN SS, 1989, MILD HEAD INJURY, P229; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; KAY DWK, 1971, LANCET, V2, P1052; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; Mahon D, 1989, J Neurosci Nurs, V21, P382; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER H, 1961, BRIT MED J, V1, P991; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Ruff RM, 1986, J HEAD TRAUMA REHAB, V1, P43; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1978, INJURY, V10, P225; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	28	64	64	1	8	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					21	26		10.3109/02699059509004567			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200003	7874092				2021-06-18	
J	FRESTA, M; PUGLISI, G; DIGIACOMO, C; RUSSO, A				FRESTA, M; PUGLISI, G; DIGIACOMO, C; RUSSO, A			LIPOSOMES AS IN-VIVO CARRIERS FOR CITICOLINE - EFFECTS ON RAT CEREBRAL POSTISCHEMIC REPERFUSION	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article							REVERSE-PHASE EVAPORATION; PHOSPHOLIPID-VESICLES; ENCAPSULATION EFFICIENCY; CDP-CHOLINE; DELIVERY; RELEASE; BRAIN; DRUG; MICRODIALYSIS; MULTILAMELLAR	Citicoline is a therapeutic agent widely used in the treatment of brain injury, for example in cerebrovascular disease or traumatic accidents. Unfortunately, the strong polar nature of this drug prevents it crossing the blood-brain barrier. In this paper, the possibility of efficiently trapping citicoline in liposomes to improve its therapeutic effects is reported. The citicoline-encapsulation efficiency, drug leakage and size analysis of various liposome systems were studied. The real therapeutic effectiveness of these citicoline liposome formulations was evaluated by biological assay. The effects of free and liposome encapsulated citicoline on survival rate of ischaemic reperfused male Wistar rats (80-100g) were investigated, Of the phospholipid mixtures used in citicoline liposome formulation the best in terms of delivery and therapeutic effects was 1,2-dipalmitoyl-sn-glycero-phosphocholine : dipalmitoyl-DL-alpha-phosphatidyl-L-serine: cholesterol (7:4:7 molar ratio). This phospholipid mixture was also assayed for brain conjugated diene levels in rats, since this parameter is an index of lipid peroxidation in rat cerebral cortex during post-ischaemic reperfusion. A citicoline-loaded phospholipid mixture has produced an increase in rat survival rate of about 24% and a reduction in diene levels of 60%, compared to the free drug.	UNIV CATANIA,IST CHIM FARMACEUT & TOSSICOL,I-95125 CATANIA,ITALY; ETH ZURICH,INST POLYMERE,CH-8092 ZURICH,SWITZERLAND; UNIV CATANIA,IST CHIM BIOL,I-95125 CATANIA,ITALY			Fresta, Massimo/K-8859-2016	Fresta, Massimo/0000-0001-8062-817X; Russo, Alessandra/0000-0003-2925-6600; Di Giacomo, Claudia/0000-0002-2665-0007			AGUT J, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1045; ALLEN TM, 1981, BIOCHIM BIOPHYS ACTA, V640, P385, DOI 10.1016/0005-2736(81)90464-8; ALLEN TM, 1983, J PHARMACOL EXP THER, V226, P539; AMSELEM S, 1990, J PHARM SCI, V79, P1045, DOI 10.1002/jps.2600791202; ARIENTI G, 1979, J BIOCH, V28, P39; BAETHMANN A, 1991, ARZNEIMITTEL-FORSCH, V41-1, P310; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENITA S, 1984, J PHARM SCI, V73, P1751, DOI 10.1002/jps.2600731223; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Berne BJ., 1976, DYNAMIC LIGHT SCATTE; Chu B., 1974, LASER LIGHT SCATTERI; FRESTA M, 1993, DRUG DEV IND PHARM, V19, P559, DOI 10.3109/03639049309062967; FRESTA M, 1993, INT J PHARM, V99, P145, DOI 10.1016/0378-5173(93)90356-K; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; GINSBERG MD, 1991, ARZNEIMITTEL-FORSCH, V41-1, P334; GORDON K, 1990, J NEUROCHEM, V54, P605, DOI 10.1111/j.1471-4159.1990.tb01914.x; GREENBERG JH, 1991, ARZNEIMITTEL-FORSCH, V41-1, P324; HENRY RJ, 1964, CLIN CHEM PRINCIPLES, P834; HILLERED L, 1990, J CEREB BLOOD FLOW M, V9, P607; HOGAN M, 1991, ARZNEIMITTEL-FORSCH, V41-1, P332; HOPE MJ, 1986, CHEM PHYS LIPIDS, V40, P89, DOI 10.1016/0009-3084(86)90065-4; Ito U, 1992, MATURATION PHENOMENO, P1; JULIANO RL, 1975, BIOCHEM BIOPH RES CO, V63, P651, DOI 10.1016/S0006-291X(75)80433-5; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591; KRIEGLSTEIN J, 1991, ARZNEIMITTEL-FORSCH, V41-1, P303; KUSCHINSKY W, 1991, ARZNEIMITTEL-FORSCH, V41-1, P284; LAROSA C, 1992, THERMOCHIM ACTA, V195, P139, DOI 10.1016/0040-6031(92)80056-3; LAROSA C, 1992, THERMOCHIM ACTA, V198, P181, DOI 10.1016/0040-6031(92)85072-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANEV H, 1990, FASEB J, V4, P2789; MARUYAMA K, 1993, BIOCHIM BIOPHYS ACTA, V1149, P209, DOI 10.1016/0005-2736(93)90203-C; MAYHEW E, 1984, LIPOSOME TECHNOLOGY, V2, P19; MCCULLOCH J, 1991, ARZNEIMITTEL-FORSCH, V41-1, P319; NOLL F, 1984, METHOD ENZYMAT AN, V6, P582; PALMER C, 1990, J CEREBR BLOOD F MET, V10, P227, DOI 10.1038/jcbfm.1990.39; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PUGLISI G, 1992, PHARMAZIE, V47, P212; RECKNAGEL RO, 1984, METHOD ENZYMOL, V105, P331; SHIMAMOTO K, 1975, TAKEDA KENKYUSHO HO, V34, P189; SIESJO BK, 1991, ARZNEIMITTELFORSCH, V41-1, P288; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TALL AR, 1980, J LIPID RES, V21, P354; VANELLA A, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P311; VANELLA A, 1992, INT J DEV NEUROSCI, V10, P75, DOI 10.1016/0736-5748(92)90008-N; WHEELER KP, 1970, NATURE, V225, P449, DOI 10.1038/225449a0; WIDDER KJ, 1982, J PHARM SCI, V71, P379, DOI 10.1002/jps.2600710403; YASUHARA M, 1974, CURR THER RES CLIN E, V16, P346	48	64	69	1	2	ROYAL PHARMACEUTICAL SOC GREAT BRITAIN	LONDON	1 LAMBETH HIGH ST, LONDON, ENGLAND SE1 7JN	0022-3573			J PHARM PHARMACOL	J. Pharm. Pharmacol.	DEC	1994	46	12					974	981		10.1111/j.2042-7158.1994.tb03252.x			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	PY734	WOS:A1994PY73400006	7714721				2021-06-18	
J	MILLIS, SR; RICKER, JH				MILLIS, SR; RICKER, JH			VERBAL-LEARNING PATTERNS IN MODERATE AND SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							PARKINSONS-DISEASE; HEAD-INJURY; COMA	Previous studies that have examined performances on the California Verbal Learning Test (CVLT) among individuals with traumatic brain injury (TBI) have found differing levels of performance. Differential patterns of performance, however, have only been inferred. The present investigation sought to determine empirically if differential patterns of performance could be discerned in a TBI sample of 65 subjects with CVLT variables. The CVLT variables were selected based on the instrument's factor structure. Cluster analysis yielded four distinct subtypes of brain-injured individuals. The Active subtype demonstrated impaired unassisted retrieval, but used active encoding strategies and showed relatively intact ability to store novel information. The Disorganized subtype demonstrated an inconsistent, haphazard learning style along with deficits in encoding. The Passive subtype was marked by an overreliance on a serial clustering strategy as well as impaired encoding and/or consolidation. The Deficient subtype was the most impaired of all groups, exhibiting a slowed rate of acquisition, passive learning style, and significant impairment in encoding. Implications for rehabilitation are discussed.		MILLIS, SR (corresponding author), WAYNE STATE UNIV,SCH MED,REHABIL INST MICHIGAN,DEPT REHABIL PSYCHOL & NEUROPSYCHOL,261 MACK BLVD,DETROIT,MI 48201, USA.			Ricker, Joseph/0000-0003-3415-991X			Afifi A. A., 1990, COMPUTER AIDED MULTI; BROWN RG, 1988, BRAIN, V111, P323, DOI 10.1093/brain/111.2.323; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; Crosson B., 1992, SUBCORTICAL FUNCTION; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; DELIS DC, 1991, PSYCHOL ASSESSMENT, V3, P19, DOI DOI 10.1037/1040-3590.3.1.19; FRIDLUND AJ, 1987, IBM USER GUIDE CLVT; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; HUMMEL TJ, 1971, PSYCHOL BULL, V76, P49, DOI 10.1037/h0031323; Kramer J. H., 1991, PSYCHOL ASSESSMENT J, V3, P299; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; STEVENS J, 1992, APPLIED MULTIVARIATE; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223	21	64	64	1	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1994	16	4					498	507		10.1080/01688639408402661			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	NW682	WOS:A1994NW68200002	7962354				2021-06-18	
J	NEWCOMBE, F; RABBITT, P; BRIGGS, M				NEWCOMBE, F; RABBITT, P; BRIGGS, M			MINOR HEAD-INJURY - PATHOPHYSIOLOGICAL OR IATROGENIC SEQUELAE	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; MILD CONCUSSION; REACTION-TIME; RECOVERY; LONG	This study addresses the possibility that cognitive sequelae-albeit of a transient or minor character-can be associated with mild head injury. Twenty men (aged 16-30 years of age), whose post-traumatic amnesia did not exceed eight hours, were examined within 48 hours of their accident and again one month later. This unselected sample had no previous history of head injury. A control group of 20 men of similar socioeconomic background, was selected from medical wards (where they had been admitted for orthopaedic treatment or a minor operation). They were also retested one month after the first examination. Neuropsychological tests were selected to measure abilities often compromised after significant head injury, namely memory and attention. The experimental component consisted of the fractionation of a complex skill (paced addition) to probe for deficits at different stages of information processing: perception and input into storage; search for and retrieval of information from working memory; and paced and unpaced addition. In general, no significant difference was found between the experimental and control groups, with the possible exception of an initial decrement on two working memory tasks: probe digits and a keeping track task (where the subject has to keep in mind and update a number of variables at the same time). The keeping track paradigm, ostensibly of ecological relevance, may well be worth further exploration in memory research, and in studies of more severely head-injured patients. It is further suggested that the appropriate management and counselling of mildly head-injured patients may help to avert symptoms that are of psychological rather than pathophysiological origin.	UNIV MANCHESTER,AGE & COGNIT PERFORMANCE RES CTR,MANCHESTER,ENGLAND	NEWCOMBE, F (corresponding author), RADCLIFFE INFIRM,DEPT NEUROSURG,OXFORD OX2 6HE,ENGLAND.						[Anonymous], 1942, Proc R Soc Med, V35, P601; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BADDELEY AD, 1982, AGING-US, V19, P141; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOWER GH, 1976, Q J EXP PSYCHOL, V28, P511, DOI 10.1080/14640747608400579; BROOKS D N, 1975, Cortex, V11, P329; Brooks N., 1984, CLOSED HEAD INJURY P; CURRY H, 1981, 7TH INT C NEUR SURG; DEELMAN BG, 1990, TRAUMATIC BRAIN INJU; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENKINS A, 1986, LANCET, V2, P445; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LIDVALL JHF, 1974, ACTA NEUROL SCAN S56, V50, P1; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; ODDY MJ, THESIS U LONDON LOND; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Panting A., 1972, REHABILITATION, V38, P33; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENBAUM M, 1978, SCAND J REHABIL MED, V10, P1; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SAMPSON H, 1956, CAN J PSYCHOLOGY, V10, P219, DOI 10.1037/h0083679; SAMPSON H, 1958, CAN J PSYCHOLOGY, V12, P7, DOI 10.1037/h0083724; SHEPARD RN, 1961, J EXP PSYCHOL, V62, P302, DOI 10.1037/h0048606; SHORES EA, 1986, MED J AUSTRALIA, V144, P596; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1984, CLOSED HEAD INJURY P, P4; THOMAS CM, 1977, THESIS OXFORD U OXFO; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, NEUROBEHAVIOURAL REC, P398; WAUGH NC, 1965, PSYCHOL REV, V72, P89, DOI 10.1037/h0021797; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; YNTEMA DB, 1960, J EXP PSYCHOL, V60, P18, DOI 10.1037/h0040055	50	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1994	57	6					709	716		10.1136/jnnp.57.6.709			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	NP425	WOS:A1994NP42500009	8006652	Green Published, Other Gold			2021-06-18	
J	SLICK, D; HOPP, G; STRAUSS, E; HUNTER, M; PINCH, D				SLICK, D; HOPP, G; STRAUSS, E; HUNTER, M; PINCH, D			DETECTING DISSIMULATION - PROFILES OF SIMULATED MALINGERERS, TRAUMATIC BRAIN-INJURY PATIENTS, AND NORMAL CONTROLS ON A REVISED VERSION OF HISCOCK AND HISCOCKS FORCED-CHOICE MEMORY TEST	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD TRAUMA; BELIEVABLE DEFICITS; TASK; PERFORMANCE; INDIVIDUALS; COMPLAINTS; PROSPECTS; VALIDITY	A computer-administered memory test was given to normal subjects instructed to feign brain damage, normal controls, and traumatic brain-injured (TBI) patients with complaints of memory dysfunction. The test, a revised version of an instrument developed by Hiscock and Hiscock(1989), employed forced, two-choice recognition of previously presented five-digit numbers. Two levels of item difficulty and three retention intervals were used. Control and TBI subjects performed at near ceiling level on easy items and items with short retention intervals. Feigning subjects performed worse than TBI and control subjects at all levels of item difficulty and all retention intervals. Subject groups were maximally distinguishable from one another by performance on difficult items and items with the longest retention interval. All TBI patients performed at or above chance level. Only 15% of the feigning subjects performed below chance level on any section of the test. Jack-knifed discriminant function analysis correctly classified 83% of all subjects into their respective groups. Although evaluation of patient performance relative to chance probability is useful for indicating the presence of extremely exaggerated memory deficits, criteria derived from sample distributions of group scores were superior for evaluation of motivation in less obvious cases. The Victoria Revision may be useful for detecting true memory deficit as well as dissimulation.		SLICK, D (corresponding author), UNIV VICTORIA, DEPT PSYCHOL, POB 3050, VICTORIA V8W 3P5, BC, CANADA.						BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1990, J CLIN PSYCHOL, V46, P432, DOI 10.1002/1097-4679(199007)46:4<432::AID-JCLP2270460410>3.0.CO;2-0; BICKART WT, 1991, J FORENSIC PSYCHOL, V9, P3; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1987, J CLIN EXP NEUROPSYC, V9, P167, DOI 10.1080/01688638708405357; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; DAVIDSON H, 1991, ANN M INT NEUROPSYCH; FAUST D, 1990, J CONSULT CLIN PSYCH, V58, P248, DOI 10.1037/0022-006X.58.2.248; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; GOLDBERG JO, 1986, J CLIN PSYCHOL, V42, P792, DOI 10.1002/1097-4679(198609)42:5<792::AID-JCLP2270420519>3.0.CO;2-8; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK CK, 1993, ANN M INT NEUROPSYCH; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; Puri ML., 1971, NONPARAMETRIC METHOD; Rey A, 1964, EXAMEN CLIN PSYCHOL; SCHRETLEN D, 1991, PSYCHOL ASSESSMENT, V3, P67; SLICK DJ, 1992, UNPUB VICTORIA REVIS; Spreen O., 1991, COMPENDIUM NEUROPSYC; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; WILKINSON L, 1990, SYSTAT SYSTEM STATIS	30	64	65	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1994	16	3					472	481		10.1080/01688639408402657			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	NR764	WOS:A1994NR76400015	7929714				2021-06-18	
J	GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D				GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D			FORTNIGHTLY REVIEW - GUIDELINES FOR RESUSCITATION AND TRANSFER OF PATIENTS WITH SERIOUS HEAD-INJURY	BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN INJURY; CRITICALLY ILL PATIENTS; HEMATOMA		WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; LAW HOSP,CARLUKE ML8 5ER,LANARK,SCOTLAND	GENTLEMAN, D (corresponding author), DUNDEE ROYAL INFIRM,DUNDEE DD1 9ND,SCOTLAND.						ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GENTLEMAN D, 1992, INT SURG, V77, P297; GENTLEMAN D, 1990, LANCET, V335, P327; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LAMBERT SM, 1993, INJURY, V24, P333, DOI 10.1016/0020-1383(93)90058-E; McLaren C A, 1983, J R Coll Surg Edinb, V28, P399; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUNRO HM, 1993, BR J INTENSIVE CARE, V3, P210; REEVE WG, 1990, BRIT MED J, V300, P85, DOI 10.1136/bmj.300.6717.85; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; RUNCIE CJ, 1992, ANAESTHESIA, V47, P327, DOI 10.1111/j.1365-2044.1992.tb02175.x; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; VYVYAN HAL, 1991, ANAESTHESIA, V46, P395; 1988, RECOMMENDATIONS STAN; 1984, BMJ, V288, P983; 1993, ATLS COURSE MANUAL	25	64	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					547	552		10.1136/bmj.307.6903.547			6	Medicine, General & Internal	General & Internal Medicine	LV180	WOS:A1993LV18000025	8400978	Bronze, Green Published			2021-06-18	
J	TOULMOND, S; DUVAL, D; SERRANO, A; SCATTON, B; BENAVIDES, J				TOULMOND, S; DUVAL, D; SERRANO, A; SCATTON, B; BENAVIDES, J			BIOCHEMICAL AND HISTOLOGICAL ALTERATIONS INDUCED BY FLUID PERCUSSION BRAIN INJURY IN THE RAT	BRAIN RESEARCH			English	Article						FLUID PERCUSSION; BRAIN TRAUMA; LESION VOLUME; NEURONAL ALTERATION; GLIAL ACTIVATION	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; MAGNETIC-RESONANCE; MODEL; QUANTIFICATION; RESPONSES; ISCHEMIA; DAMAGE; TRAUMA; PH	In the present study we have characterized the time-course of the histopathological and biochemical alterations resulting from mechanical brain injury caused by lateral fluid percussion centered over the parietal cortex in the rat. The injury device used was an HPLC pump coupled to a solenoid valve which delivered a constant and short lasting (10 ms) impact pressure (1.6 atm). This traumatic procedure resulted in an accumulation of blood in the subarachnoid space and cortical edema art 4-24 h post-trauma. From 4 h after injury, cortical neurons exhibited a pathologic appearance and phagocytic cells invaded the brain parenchyma. At 3 and 7 days post-injury, complete neuronal loss was observed in the parietal cortex around the impact site. In the ipsilateral cortex, the time-course of histologically assessed neuronal loss and phagocytic/glial activation paralleled the time-course of the loss of omega1-2 (benzodiazepine) sites (a neuronal marker) and of the increase in p sites (peripheral-type benzodiazepine binding sites; a glial/macrophage marker). Neuronal loss and increase in the density of the glial/macrophage biochemical marker were also observed in the hippocampus but not in the contralateral cortex or in other subcortical structures, suggesting a selective vulnerability of the hippocampus to this traumatic procedure. There was a very good spatial correlation between the histological alterations and the changes in the density of the neuronal and glial/macrophage biochemical markers (as assessed by autoradiography). The volume of the lesion, integrated from the surface of the lesion measured at 10 coronal levels cut at a 1 mm interval and stained with haemalum and eosin, represented 32.9 +/- 1.7 mm3. There was a very small inter-experimental variation in this volume. These results demonstrate the feasibility of monitoring the extent of traumatic brain damage induced by fluid percussion by measuring the volume of the lesion.	SYNTHELAB RECH LERS,DEPT BIOL,31 AV PAUL VAILLANT COUTURIER,F-92220 BAGNEUX,FRANCE							BENAVIDES J, 1990, BRAIN RES, V522, P275, DOI 10.1016/0006-8993(90)91472-S; BENAVIDES J, 1988, J PHARMACOL EXP THER, V245, P1033; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMEDIUK P, 1988, Journal of Neurotrauma, V5, P105, DOI 10.1089/neu.1988.5.105; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lindgren S., 1965, BIOPHYSIK, V2, P20; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757	26	64	65	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	1993	620	1					24	31		10.1016/0006-8993(93)90266-P			8	Neurosciences	Neurosciences & Neurology	LR731	WOS:A1993LR73100004	7691381				2021-06-18	
J	JIANG, MH; HOOG, A; MA, KC; NIE, XJ; OLSSON, Y; ZHANG, WW				JIANG, MH; HOOG, A; MA, KC; NIE, XJ; OLSSON, Y; ZHANG, WW			ENDOTHELIN-1-LIKE IMMUNOREACTIVITY IS EXPRESSED IN HUMAN REACTIVE ASTROCYTES	NEUROREPORT			English	Article						CEREBROVASCULAR DISEASE; LACUNES; TRAUMA; HUMAN BRAIN; ALZHEIMERS DISEASE; ENDOTHELIN-1; ASTROCYTES	BINDING-SITES; RAT-BRAIN; CEREBROSPINAL-FLUID; CEREBRAL-ARTERIES; RECEPTORS; PEPTIDE; LOCALIZATION; NEURONS; CELLS; FAMILY	THE expression of endothelin-1-like immunoreactivity in astrocytes of the human brain was investigated by the avidin-biotin-peroxidase complex method in post mortem material. A marked immunoreaction was present in reactive astrocytes around infarcts, lacunes, traumatic injuries, the lesions of progressive multifocal leucoencephalopathy and in the cerebral cortex and white matter of Alzheimer's disease. The brains of patients who had neither history nor signs of cerebral disease exhibited only occasional immunoreactive astrocytes. A hypothesis is presented that endothelin-1 may be released from reactive astrocytes in many organic diseases of the human brain with considerable pathogenic consequences. It is known from experimental investigations that endothelin-1 may for instance cause severe vasoconstriction resulting in cell injury and that it may act as a growth factor for glial cells.	UNIV HOSP UPPSALA, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN; KAROLINSKA HOSP, DEPT PATHOL, S-10401 STOCKHOLM 60, SWEDEN							CINTRA A, 1989, ACTA PHYSIOL SCAND, V137, P557, DOI 10.1111/j.1748-1716.1989.tb08799.x; FUXE K, 1989, ACTA PHYSIOL SCAND, V137, P563, DOI 10.1111/j.1748-1716.1989.tb08802.x; FUXE K, 1991, METHODS NEUROSCIENCE, V7, P256; GIAID A, 1991, HISTOCHEMISTRY, V95, P303; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; HIRATA Y, 1990, BIOCHEM BIOPH RES CO, V166, P1274, DOI 10.1016/0006-291X(90)91003-B; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JANSEN I, 1989, J CEREBR BLOOD F MET, V9, P743, DOI 10.1038/jcbfm.1989.106; JONES CR, 1989, NEUROSCI LETT, V97, P276, DOI 10.1016/0304-3940(89)90610-1; KOBAYASHI H, 1990, NEUROSURGERY, V27, P357, DOI 10.1227/00006123-199009000-00003; KOSEKI C, 1989, AM J PHYSIOL, V256, pR858; KOSEKI C, 1989, NEUROSCI RES, V6, P581, DOI 10.1016/0168-0102(89)90047-3; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MILLER RC, 1993, TRENDS PHARMACOL SCI, V14, P54, DOI 10.1016/0165-6147(93)90031-E; NAMBI P, 1990, NEUROPEPTIDES, V16, P195, DOI 10.1016/0143-4179(90)90062-4; SAITO A, 1989, EUR J PHARMACOL, V162, P353, DOI 10.1016/0014-2999(89)90299-9; SCHIFFRIN EL, 1991, AM J PHYSIOL, V260, pH58; SHIGENO T, 1989, J CARDIOVASC PHARM, V13, pS174, DOI 10.1097/00005344-198900135-00047; TAKAHASHI K, 1991, J CLIN ENDOCR METAB, V72, P693, DOI 10.1210/jcem-72-3-693; YAMAJI T, 1990, J CLIN ENDOCR METAB, V71, P1611, DOI 10.1210/jcem-71-6-1611; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X	24	64	64	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JUL	1993	4	7					935	937		10.1097/00001756-199307000-00024			3	Neurosciences	Neurosciences & Neurology	LM114	WOS:A1993LM11400024	8369484				2021-06-18	
J	MENDELSOHN, D; LEVIN, HS; BRUCE, D; LILLY, M; HARWARD, H; CULHANE, KA; EISENBERG, HM				MENDELSOHN, D; LEVIN, HS; BRUCE, D; LILLY, M; HARWARD, H; CULHANE, KA; EISENBERG, HM			LATE MRI AFTER HEAD-INJURY IN CHILDREN - RELATIONSHIP TO CLINICAL-FEATURES AND OUTCOME	CHILDS NERVOUS SYSTEM			English	Article						HEAD INJURY; OUTCOME; MAGNETIC RESONANCE IMAGING; FRONTAL LOBES; CHILDREN	MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; BRAIN INJURIES; TRAUMA; LESIONS; MILD; CT	To characterize the brain pathology in relation to long-term outcome after pediatric head injury, 55 children were studied by magnetic resonance imaging (MRI) at least 3 months after sustaining moderate to severe closed head injury (CHI). Thirty-nine of the patients had abnormal signal intensity consistent with residual brain lesions, including 28 children with lesions involving the frontal lobes. The clinical features of children with frontal lesions, extrafrontal lesions, and diffuse injury were compared. The analysis disclosed that children with frontal lobe lesions were more frequently disabled than children who sustained diffuse injury. Our MRI findings indicate that residual brain lesions are more common after moderate to severe CHI in children than previously thought and that the frontal lobes are most frequently involved. Further investigation is indicated to elucidate whether distinctive cognitive and behavioral sequelae are associated with frontal lobe lesions in children.	UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D-73,GALVESTON,TX 77550; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75230; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75230					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUCE DA, 1978, J NEUROSURG, V48, P688; Damasio H., 1989, LESION ANAL NEUROPSY; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; EBISU T, 1989, SURG NEUROL, V31, P261, DOI 10.1016/0090-3019(89)90049-9; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1909, NEUROSURGERY, V24, P223; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TEASDALE G, 1974, LANCET, V2, P81; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	25	64	64	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	DEC	1992	8	8					445	452		10.1007/BF00274405			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	KH026	WOS:A1992KH02600004	1288853				2021-06-18	
J	Broglio, SP; Katz, BP; Zhao, S; McCrea, M; McAllister, T				Broglio, Steven P.; Katz, Barry P.; Zhao, Shi; McCrea, Michael; McAllister, Thomas		CARE Consortium Investigators	Test-Retest Reliability and Interpretation of Common Concussion Assessment Tools: Findings from the NCAA-DoD CARE Consortium	SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; HIGH-SCHOOL; TEST-PERFORMANCE; REACTION-TIME; VALIDITY; MANAGEMENT; STATEMENT; RECOVERY; SIDELINE; IMPACT	Background Concussion diagnosis is typically made through clinical examination and supported by performance on clinical assessment tools. Performance on commonly implemented and emerging assessment tools is known to vary between administrations, in the absence of concussion. Objective To evaluate the test-retest reliability of commonly implemented and emerging concussion assessment tools across a large nationally representative sample of student-athletes. Methods Participants (n = 4874) from the Concussion Assessment, Research, and Education Consortium completed annual baseline assessments on two or three occasions. Each assessment included measures of self-reported concussion symptoms, motor control, brief and extended neurocognitive function, reaction time, oculomotor/oculovestibular function, and quality of life. Consistency between years 1 and 2 and 1 and 3 were estimated using intraclass correlation coefficients or Kappa and effect sizes (Cohen's d). Clinical interpretation guidelines were also generated using confidence intervals to account for non-normally distributed data. Results Reliability for the self-reported concussion symptoms, motor control, and brief and extended neurocognitive assessments from year 1 to 2 ranged from 0.30 to 0.72 while effect sizes ranged from 0.01 to 0.28 (i.e., small). The reliability for these same measures ranged from 0.34 to 0.66 for the year 1-3 interval with effect sizes ranging from 0.05 to 0.42 (i.e., small to less than medium). The year 1-2 reliability for the reaction time, oculomotor/oculovestibular function, and quality-of-life measures ranged from 0.28 to 0.74 with effect sizes from 0.01 to 0.38 (i.e., small to less than medium effects). Conclusions This investigation noted less than optimal reliability for most common and emerging concussion assessment tools. Despite this finding, their use is still necessitated by the absence of a gold standard diagnostic measure, with the ultimate goal of developing more refined and sound tools for clinical use. Clinical interpretation guidelines are provided for the clinician to apply with a degree of certainty in application.	[Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA; [Katz, Barry P.; Zhao, Shi] Indiana Univ, Dept Biostat, Indianapolis, IN 46204 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA	Broglio, SP (corresponding author), Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu		Kontos, Anthony/0000-0002-3749-4310; Clugston, James/0000-0002-2103-1039; Chrisman, Sara/0000-0001-5373-7223; Master, Christina/0000-0002-6717-4270	Grand Alliance Concussion Assessment, Research, and Education Consortium; National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense; US Army Medical Research Acquisition Activity, Fort Detrick, MD, USA; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education Consortium, funded by the National Collegiate Athletic Association and the Department of Defense. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, USA is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award no. W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (Defense Health Program funds).	[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Byron K, 2011, PERS SOC PSYCHOL B, V37, P269, DOI 10.1177/0146167210392788; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Doros G., 2010, AM J BIOSTATISTICS, V1, P1, DOI DOI 10.3844/AMJBSP.2010.1.8; Eckner JT, 2015, PERCEPT MOTOR SKILL, V120, P841, DOI 10.2466/25.15.PMS.120v19x6; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Fischer KW, 1997, DEV NEUROIMAGING MAP, P263; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Katz BP, SPORTS MED IN PRESS; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Kutcher Jeffrey S, 2014, Continuum (Minneap Minn), V20, P1552, DOI 10.1212/01.CON.0000458974.78766.58; Lancaster MA, 2016, CLIN NEUROPSYCHOL, V30, P321, DOI 10.1080/13854046.2016.1138504; Leahy S., 2011, US TODAY; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Lim J, 2010, PSYCHOL BULL, V136, P375, DOI 10.1037/a0018883; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Masson M, 2016, NEUROPSYCHOLOGY, V30, P143, DOI 10.1037/neu0000228; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; National Collegiate Athletic Association (NCAA), 2016, INT CONS DIAGN MAN S; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Portney LG, 2009, FDN CLIN RES APPL PR; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2005, J ATHL TRAINING, V40, P139; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, P000012, DOI [10.1136/bmjsem-2015-000012, DOI 10.1136/BMJSEM-2015-000012]; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Stocker RPJ, 2017, ARCH CLIN NEUROPSYCH, V32, P349, DOI 10.1093/arclin/acx003; van der Vaart A.W., 1998, ASYMPTOTIC STAT; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3	59	63	63	0	8	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	MAY	2018	48	5					1255	1268		10.1007/s40279-017-0813-0			14	Sport Sciences	Sport Sciences	GM4RT	WOS:000438111000013	29138991	Green Published, Other Gold			2021-06-18	
J	Xu, X; Gao, WW; Cheng, SQ; Yin, DP; Li, F; Wu, YG; Sun, DD; Zhou, S; Wang, D; Zhang, YQ; Jiang, RC; Zhang, JN				Xu, Xin; Gao, Weiwei; Cheng, Shiqi; Yin, Dongpei; Li, Fei; Wu, Yingang; Sun, Dongdong; Zhou, Shuai; Wang, Dong; Zhang, Yongqiang; Jiang, Rongcai; Zhang, Jianning			Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Atorvastatin; Immunomodulation; Anti-inflammation; Leukocyte; Microglia/macrophage subtype	NATURAL-KILLER-CELLS; T-CELLS; INTRACEREBRAL HEMORRHAGE; MICROGLIA/MACROPHAGE POLARIZATION; MACROPHAGE INFILTRATION; INFLAMMATORY REACTION; NEUROPROTECTION; STATINS; TARGET; SYNAPTOGENESIS	Background: Neuroinflammation is an important secondary injury mechanism that has dual beneficial and detrimental roles in the pathophysiology of traumatic brain injury (TBI). Compelling data indicate that statins, a group of lipid-lowering drugs, also have extensive immunomodulatory and anti-inflammatory properties. Among statins, atorvastatin has been demonstrated as a neuroprotective agent in experimental TBI; however, there is a lack of evidence regarding its effects on neuroinflammation during the acute phase of TBI. The current study aimed to evaluate the effects of atorvastatin therapy on modulating the immune reaction, and to explore the possible involvement of peripheral leukocyte invasion and microglia/macrophage polarization in the acute period post-TBI. Methods: C57BL/6 mice were subjected to TBI using a controlled cortical impact (CCI) device. Either atorvastatin or vehicle saline was administered orally starting 1 h post-TBI for three consecutive days. Short-term neurological deficits were evaluated using the modified neurological severity score (mNSS) and Rota-rod. Brain-invading leukocyte subpopulations were analyzed by flow cytometry and immunohistochemistry. Pro-and anti-inflammatory cytokines and chemokines were examined using enzyme-linked immunosorbent assay (ELISA). Markers of classically activated (M1) and alternatively activated (M2) microglia/macrophages were then determined by quantitative real-time PCR (qRT-PCR) and flow cytometry. Neuronal apoptosis was identified by double staining of terminal deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL) staining and immunofluorescence labeling for neuronal nuclei (NeuN). Results: Acute treatment with atorvastatin at doses of 1 mg/kg/day significantly reduced neuronal apoptosis and improved behavioral deficits. Invasions of T cells, neutrophils and natural killer (NK) cells were attenuated profoundly after atorvastatin therapy, as was the production of pro-inflammatory cytokines (IFN-gamma and IL-6) and chemokines (RANTES and IP-10). Notably, atorvastatin treatment significantly increased the proportion of regulatory T cells (Tregs) in both the peripheral spleen and brain, and at the same time, increased their main effector cytokines IL-10 and TGF-beta 1. We also found that atorvastatin significantly attenuated total microglia/macrophage activation but augmented the M2/M1 ratio by both inhibiting M1 polarization and enhancing M2 polarization. Conclusions: Our data demonstrated that acute atorvastatin administration could modulate post-TBI neuroinflammation effectively, via a mechanism that involves altering peripheral leukocyte invasion and the alternative polarization of )microglia/macrophages.	[Xu, Xin; Gao, Weiwei; Yin, Dongpei; Li, Fei; Wu, Yingang; Sun, Dongdong; Zhou, Shuai; Wang, Dong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin, Peoples R China; [Xu, Xin; Gao, Weiwei; Yin, Dongpei; Li, Fei; Wu, Yingang; Sun, Dongdong; Zhou, Shuai; Wang, Dong; Jiang, Rongcai; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, 154 Anshan Rd, Tianjin, Peoples R China; [Gao, Weiwei] Tianjin Huan Hu Hosp, Dept Neurol, 6 Jizhao Rd, Tianjin, Peoples R China; [Cheng, Shiqi] Nanchang Univ, Affiliated Hosp 2, Dept Neurosurg, 1 Minde Rd, Nanchang, Jiangxi, Peoples R China; [Zhang, Yongqiang] Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin, Peoples R China	Jiang, RC; Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin, Peoples R China.; Jiang, RC; Zhang, JN (corresponding author), Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, 154 Anshan Rd, Tianjin, Peoples R China.	jiang116216@163.com; zhangjntjmu@163.com		Xu, Xin/0000-0003-3395-9923; Dongpei, Yin/0000-0003-2572-3689	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81671380, 81502173, 81501055]; Tianjin Research Program of Application Foundation and Advanced Technology [16JCYBJC27200]	This work was supported by grants from the National Natural Science Foundation of China (grant 81330029, 81671380, 81502173, and 81501055), and the Tianjin Research Program of Application Foundation and Advanced Technology (grant 16JCYBJC27200).	Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; de Oliveira DM, 2015, INFLAMMOPHARMACOLOGY, V23, P343, DOI 10.1007/s10787-015-0252-1; Dong TT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0663-y; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Gan Y, 2014, P NATL ACAD SCI USA, V111, P2704, DOI 10.1073/pnas.1315943111; Gao Chuang, 2017, Mol Neurobiol, V54, P8348, DOI 10.1007/s12035-016-0318-0; Gao WW, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00281; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85; Kong XD, 2014, NEUROSCI BULL, V30, P903, DOI 10.1007/s12264-014-1481-9; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee J, 2014, J TRAUMA ACUTE CARE, V77, P709, DOI 10.1097/TA.0000000000000445; Li M, 2015, CHINESE MED J-PEKING, V128, P1072, DOI 10.4103/0366-6999.155094; Li MS, 2017, P NATL ACAD SCI USA, V114, pE396, DOI 10.1073/pnas.1612930114; Liu GW, 2011, IMMUNOL CELL BIOL, V89, P130, DOI 10.1038/icb.2010.70; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-44; Rodriguez-Perea AL, 2017, J NEUROIMMUNE PHARM, V12, P152, DOI 10.1007/s11481-016-9706-5; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; MAY MJ, 1992, EUR J IMMUNOL, V22, P219, DOI 10.1002/eji.1830220132; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mishra SK, 2017, MOL CELL NEUROSCI, V78, P25, DOI 10.1016/j.mcn.2016.11.008; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Potey C, 2015, BRIT J PHARMACOL, V172, P5188, DOI 10.1111/bph.13285; Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Shi H. P., 2015, ELECT J DIFFERENTIAL, V2015, P1, DOI DOI 10.1089/CELL.2015.0039; Simon-O'Brien E, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0687-3; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Strowig T, 2008, J IMMUNOL, V180, P7785, DOI 10.4049/jimmunol.180.12.7785; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wang D, 2014, J NEUROL SCI, V336, P237, DOI 10.1016/j.jns.2013.11.005; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang ZQ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9875298; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Xie LK, 2015, EUR J IMMUNOL, V45, P180, DOI 10.1002/eji.201444823; Xing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20040; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-79; Zhou K, 2017, J CEREBR BLOOD F MET, V37, P967, DOI 10.1177/0271678X16648712; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zouggari Y, 2009, CIRCULATION, V120, P1415, DOI 10.1161/CIRCULATIONAHA.109.875583	59	63	72	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 23	2017	14								167	10.1186/s12974-017-0934-2			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FE5QX	WOS:000408267100001	28835272	DOAJ Gold, Green Published			2021-06-18	
J	Zhang, L; Wang, HD; Fan, YW; Gao, YY; Li, X; Hu, ZG; Ding, K; Wang, YJ; Wang, XL				Zhang, Li; Wang, Handong; Fan, Youwu; Gao, Yongyue; Li, Xiang; Hu, Zhigang; Ding, Ke; Wang, Yujie; Wang, Xiaoliang			Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE and Nrf2-autophagy pathways	SCIENTIFIC REPORTS			English	Article							IN-VITRO; OXIDATIVE STRESS; NEURONAL APOPTOSIS; AUTOPHAGY; MICE; ANTIOXIDANT; ACTIVATION; EXPRESSION; DAMAGE; SYSTEM	Fucoxanthin is abundant in seaweed and is considered as a powerful antioxidant. It has been proposed to possess anti-cancer, anti-obesity and anti-diabetes effects. However, its roles in brain injury models have not been fully understood. The objective of this study was to investigate the neuroprotection of fucoxanthin in models of traumatic brain injury (TBI) and the role of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant-response element (ARE) and Nrf2-autophagy pathways in the putative neuroprotection. We found that fucoxanthin alleviated TBI-induced secondary brain injury, including neurological deficits, cerebral edema, brain lesion and neuronal apoptosis. Moreover, the upregulation of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were reversed by fucoxanthin treatment. Furthermore, our in vitro studies demonstrated that fucoxanthin increased the neuron survival and reduced the reactive oxygen species (ROS) level. In addition, fucoxanthin activated the Nrf2-ARE pathway and autophagy both in vivo and in vitro, which was proven by the results of immunohistochemistry, western blot and electrophoretic mobility shift assay (EMSA). However, fucoxanthin failed to provide neuroprotection and activated autophagy following TBI in Nrf2/mice. In conclusion, our studies indicated that fucoxanthin provided neuroprotective effects in models of TBI, potentially via regulation of the Nrf2-ARE and Nrf2-autophagy pathways.	[Zhang, Li; Wang, Handong; Fan, Youwu; Gao, Yongyue; Li, Xiang; Hu, Zhigang; Ding, Ke; Wang, Yujie; Wang, Xiaoliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81672503, 81401026]; Key Medical Subjects of Jiangsu Province [X4200722]	This work was supported by Grants from the National Natural Science Foundation of China (No. 81672503 and 81401026) and the Key Medical Subjects of Jiangsu Province (no. X4200722).	Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Fan WL, 2010, AUTOPHAGY, V6, P614, DOI 10.4161/auto.6.5.12189; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gammone MA, 2015, MAR DRUGS, V13, P2196, DOI 10.3390/md13042196; GEACINTOV NE, 1984, BIOPHYS CHEM, V20, P121, DOI 10.1016/0301-4622(84)80012-5; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Larsen KB, 2010, AUTOPHAGY, V6, P784, DOI 10.4161/auto.6.6.12510; Lei S, 2014, ASN NEURO, V6, DOI 10.1177/1759091414558417; Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x; Lin JJ, 2016, MAR DRUGS, V14, DOI 10.3390/md14040067; Liu CL, 2011, J AGR FOOD CHEM, V59, P11344, DOI 10.1021/jf2029785; Liu Y, 2016, INT J OPHTHALMOL-CHI, V9, P9, DOI 10.18240/ijo.2016.01.02; Liu YX, 2016, J AGR FOOD CHEM, V64, P416, DOI 10.1021/acs.jafc.5b05436; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Noda NN, 2008, GENES CELLS, V13, P1211, DOI 10.1111/j.1365-2443.2008.01238.x; Ovey IS, 2015, NEUROSCIENCE, V284, P225, DOI 10.1016/j.neuroscience.2014.09.078; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Puissant A, 2012, AM J CANCER RES, V2, P397; Rodriguez KJ, 2013, J DERMATOL SCI, V72, P304, DOI 10.1016/j.jdermsci.2013.08.004; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Sugawara T, 2002, J NUTR, V132, P946; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu KC, 2012, TOXICOL APPL PHARM, V263, P14, DOI 10.1016/j.taap.2012.05.017; Xu JG, 2014, BRAIN RES, V1582, P237, DOI 10.1016/j.brainres.2014.07.042; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yan XJ, 1999, BIOSCI BIOTECH BIOCH, V63, P605, DOI 10.1271/bbb.63.605; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zheng J, 2014, MAR DRUGS, V12, P4214, DOI 10.3390/md12074214	43	63	66	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	APR 21	2017	7								46763	10.1038/srep46763			15	Multidisciplinary Sciences	Science & Technology - Other Topics	ET0UU	WOS:000399980400001	28429775	DOAJ Gold, Green Published			2021-06-18	
J	Dikmen, S; Machamer, J; Temkin, N				Dikmen, Sureyya; Machamer, Joan; Temkin, Nancy			Mild Traumatic Brain Injury: Longitudinal Study of Cognition, Functional Status, and Post-Traumatic Symptoms	JOURNAL OF NEUROTRAUMA			English	Article						cognition; control group; Glasgow Outcome Scale; mild traumatic brain injury; post-traumatic symptoms	HEAD-INJURY; RECOVERY; OUTCOMES; PREVENTION; CONCUSSION; PHENYTOIN; VALPROATE; ACCURACY; MEMORY	More than 75% of traumatic brain injuries (TBIs) seeking medical attention are mild, and outcome in that group is heterogeneous. Until sensitive and valid biomarkers are identified, methods are needed to classify mild TBI into more homogeneous subgroups. Four hundred twenty-one adults with mild TBI were divided into groups based on Glasgow Coma Scale (GCS) 13-15 without computed tomography (CT) abnormalities, GCS 15 with CT abnormalities, and GCS 13-14 with CT abnormalities, and were compared with 120 trauma controls on 1-month and 1-year outcomes. At 1 month post-injury, almost all neuropsychological variables differed significantly among the groups. Compared with trauma controls, the GCS 13-15 CT normal group showed no significant differences on any neuropsychological measure or Glasgow Outcome Scale (GOS). The GCS 15 CT abnormal group performed significantly worse on only a measure of episodic memory and learning (Selective Reminding Recall [SRCL]) and GOS, and the GCS 13-14 CT abnormal group performed significantly worse on most neuropsychological measures and GOS. At 1 year post-injury, except for an isolated difficulty on SRCL in the GCS 13-14 CT abnormal group, no differences were observed on any neuropsychological measures nor on GOS. Mean percent of total post-traumatic symptoms endorsed as new or worse and percent endorsing three or more symptoms differed significantly (p < 0.001), with each TBI subgroup reporting significantly more symptoms than the trauma controls at both 1 month and 1 year. In conclusion, this subgrouping improves granularity within mild TBI. While most neuropsychological and functional differences abate by 1 year, reporting three or more posttraumatic symptoms remain for about half of individuals.	[Dikmen, Sureyya; Machamer, Joan; Temkin, Nancy] Univ Washington, Dept Rehabil Med, Box 359612,325 Ninth Ave, Seattle, WA 98104 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Machamer, J (corresponding author), Univ Washington, Dept Rehabil Med, Box 359612,325 Ninth Ave, Seattle, WA 98104 USA.	machamer@u.washington.edu			NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643]; DoDUnited States Department of Defense [W81XWH-14-2-0176]; NIDILRRUnited States Department of Health & Human Services [90-DP-0031];  [U01NS086090];  [HS04146];  [HS05304]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, R01NS019643] Funding Source: NIH RePORTER	This work was supported by grants U01NS086090, HS04146, HS05304, NIH-NINDS R01NS19643, DoD W81XWH-14-2-0176, and NIDILRR 90-DP-0031.	Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Jaiswal MK, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00148; JENNETT B, 1975, LANCET, V1, P480; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus JF, 2014, BRAIN INJURY, V28, P1248, DOI 10.3109/02699052.2014.916420; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Papoutsis J, 2014, DEV NEUROPSYCHOL, V39, P638, DOI 10.1080/87565641.2014.979926; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Wechsler D., 1955, MANUAL WECHSLER ADUL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfson D., 1993, HALSTEAD REITAN NEUR	39	63	64	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1524	1530		10.1089/neu.2016.4618			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500003	27785968	Green Published			2021-06-18	
J	Tanaka, Y; Suzuki, G; Matsuwaki, T; Hosokawa, M; Serrano, G; Beach, TG; Yamanouchi, K; Hasegawa, M; Nishihara, M				Tanaka, Yoshinori; Suzuki, Genjiro; Matsuwaki, Takashi; Hosokawa, Masato; Serrano, Geidy; Beach, Thomas G.; Yamanouchi, Keitaro; Hasegawa, Masato; Nishihara, Masugi			Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes	HUMAN MOLECULAR GENETICS			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; ACTIVATED MICROGLIA; DEFICIENT MICE; KNOCKOUT MICE; CATHEPSIN-D; TDP-43; GENE; MUTATIONS	Progranulin (PGRN) haploinsufficiency resulting from loss-of-function mutations in the PGRN gene causes frontotemporal lobar degeneration accompanied by TDP-43 accumulation, and patients with homozygous mutations in the PGRN gene present with neuronal ceroid lipofuscinosis. Although it remains unknown why PGRN deficiency causes neurodegenerative diseases, there is increasing evidence that PGRN is implicated in lysosomal functions. Here, we show PGRN is a secretory lysosomal protein that regulates lysosomal function and biogenesis by controlling the acidification of lysosomes. PGRN gene expression and protein levels increased concomitantly with the increase of lysosomal biogenesis induced by lysosome alkalizers or serum starvation. Down-regulation or insufficiency of PGRN led to the increased lysosomal gene expression and protein levels, while PGRN overexpression led to the decreased lysosomal gene expression and protein levels. In particular, the level of mature cathepsin D (CTSDmat) dramatically changed depending upon PGRN levels. The acidification of lysosomes was facilitated in cells transfected with PGRN. Then, this caused degradation of CTSDmat by cathepsin B. Secreted PGRN is incorporated into cells via sortilin or cation-independent mannose 6-phosphate receptor, and facilitated the acidification of lysosomes and degradation of CTSDmat. Moreover, the change of PGRN levels led to a cell-type-specific increase of insoluble TDP-43. In the brain tissue of FTLD-TDP patients with PGRN deficiency, CTSD and phosphorylated TDP-43 accumulated in neurons. Our study provides new insights into the physiological function of PGRN and the role of PGRN insufficiency in the pathogenesis of neurodegenerative diseases.	[Tanaka, Yoshinori; Suzuki, Genjiro; Hosokawa, Masato; Hasegawa, Masato] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Dementia Res Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan; [Tanaka, Yoshinori; Matsuwaki, Takashi; Yamanouchi, Keitaro; Nishihara, Masugi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan; [Serrano, Geidy; Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, 10515 West Santa Fe Dr, Sun City, AZ 85351 USA	Nishihara, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amnishi@mail.ecc.u-tokyo.ac.jp	Yamanouchi, Keitaro/R-5003-2019	Tanaka, Yoshinori/0000-0003-1428-0683	Japan Society for the Promotion of Science KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP15K18370, JP14J03307, JP23228004, JP15H02356]; Ministry of Education, Culture, Sports, Science and Technology KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP26117005, JP23240050]; Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan [12946221]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16K21650, 14J03307, 15K18370] Funding Source: KAKEN	This work was supported by Japan Society for the Promotion of Science KAKENHI [Grant Numbers JP15K18370, JP14J03307 to Y.T., JP23228004 to M.N., JP15H02356 to M.H.]; Ministry of Education, Culture, Sports, Science and Technology KAKENHI [Grant Numbers JP26117005, JP23240050 to M.H.]; and Ministry of Health, Labour and Welfare [Grant ID Number 12946221 to M.H.].	Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Beach TG, 2015, NEUROPATHOLOGY, V35, P354, DOI 10.1111/neup.12189; Benussi L, 2016, NEUROBIOL AGING, V40, P41, DOI 10.1016/j.neurobiolaging.2016.01.001; Birdsill AC, 2011, CELL TISSUE BANK, V12, P311, DOI 10.1007/s10561-010-9210-8; Breton S, 2013, PHYSIOLOGY, V28, P318, DOI 10.1152/physiol.00007.2013; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; Gowrishankar S, 2015, P NATL ACAD SCI USA, V112, pE3699, DOI 10.1073/pnas.1510329112; Han JY, 2010, CHEM REV, V110, P2709, DOI 10.1021/cr900249z; Hasegawa M, 2008, ANN NEUROL, V64, P60, DOI 10.1002/ana.21425; He ZH, 2002, CANCER RES, V62, P5590; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Inukai Y, 2008, FEBS LETT, V582, P2899, DOI 10.1016/j.febslet.2008.07.027; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; Lee AY, 1998, NAT STRUCT BIOL, V5, P866, DOI 10.1038/2306; Lu YY, 2013, J BIOL CHEM, V288, P24247, DOI 10.1074/jbc.M113.484253; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Mackenzie IRA, 2006, BRAIN, V129, P3081, DOI 10.1093/brain/awl271; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Nakamichi K, 2006, NEUROSCI LETT, V407, P205, DOI 10.1016/j.neulet.2006.08.044; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Sargeant TJ, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00011; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Takenouchi T, 2005, BBA-GEN SUBJECTS, V1726, P177, DOI 10.1016/j.bbagen.2005.08.001; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tanaka Y, 2016, PRION, V10, P283, DOI 10.1080/19336896.2016.1207033; Tanaka Y, 2016, HUM MOL GENET, V25, P1420, DOI 10.1093/hmg/ddw024; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Wang K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131789; Wils H, 2012, J PATHOL, V228, P67, DOI 10.1002/path.4043; Zhou XL, 2015, J CELL BIOL, V210, P991, DOI 10.1083/jcb.201502029	46	63	63	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	MAR 1	2017	26	5					969	988		10.1093/hmg/ddx011			20	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	EQ3UZ	WOS:000398000100011	28073925	Bronze			2021-06-18	
J	Raina, GB; Cersosimo, MG; Folgar, SS; Giugni, JC; Calandra, C; Paviolo, JP; Tkachuk, VA; Ramirez, CZ; Tschopp, AL; Calvo, DS; Pellene, LA; Roca, MCU; Velez, M; Giannaula, RJ; Pardal, MMF; Micheli, FE				Raina, Gabriela B.; Cersosimo, Maria G.; Folgar, Silvia S.; Giugni, Juan C.; Calandra, Cristian; Paviolo, Juan P.; Tkachuk, Veronica A.; Zuniga Ramirez, Carlos; Tschopp, Andrea L.; Calvo, Daniela S.; Pellene, Luis A.; Uribe Roca, Marcela C.; Velez, Miriam; Giannaula, Rolando J.; Fernandez Pardal, Manuel M.; Micheli, Federico E.			Holmes tremor Clinical description, lesion localization, and treatment in a series of 29 cases	NEUROLOGY			English	Article							HYPERTROPHIC OLIVARY DEGENERATION; MIDBRAIN TOXOPLASMA ABSCESS; BRAIN-STEM HEMORRHAGE; RUBRAL TREMOR; LEVODOPA; STIMULATION; SUPPRESSION; PET; CAVERNOMA; PATIENT	Objective:To describe the clinical features, etiology, findings from neuroimaging, and treatment results in a series of 29 patients with Holmes tremor (HT).Methods:A retrospective study was performed based on review of medical records and videos of patients with HT diagnosis.Results:A total of 16 women and 13 men were included. The mean age at the moment of CNS insult was 33.9 20.1 years (range 8-76 years). The most common causes were vascular (48.3%), ischemic, or hemorrhagic. Traumatic brain injury only represented 17.24%; other causes represented 34.5%. The median latency from lesion to tremor onset was 2 months (range 7 days-228 months). The most common symptoms/signs associated with HT were hemiparesis (62%), ataxia (51.7%), hypoesthesia (27.58%), dystonia (24.1%), cranial nerve involvement (24.1%), and dysarthria (24.1%). Other symptoms/signs were vertical gaze disorders (6.8%), bradykinesia/rigidity (6.8%), myoclonus (3.4%), and seizures (3.4%). Most of the patients had lesions involving more than one area. MRI showed lesions in thalamus or midbrain or cerebellum in 82.7% of the patients. Levodopa treatment was effective in 13 out of 24 treated patients (54.16%) and in 3 patients unilateral thalamotomy provided excellent results.Conclusions:The most common causes of HT in our series were vascular lesions. The most common lesion topography was mesencephalic, thalamic, or both. Treatment with levodopa and thalamic stereotactic lesional surgery seems to be effective.	[Raina, Gabriela B.; Cersosimo, Maria G.; Folgar, Silvia S.; Giugni, Juan C.; Calandra, Cristian; Paviolo, Juan P.; Tkachuk, Veronica A.; Tschopp, Andrea L.; Calvo, Daniela S.; Pellene, Luis A.; Micheli, Federico E.] Hosp Clin Jose San Martin, Caba, Buenos Aires, Argentina; [Uribe Roca, Marcela C.; Fernandez Pardal, Manuel M.] Hosp Britan, Caba, Buenos Aires, Argentina; [Giannaula, Rolando J.] Hosp Espanol, Caba, Buenos Aires, Argentina; [Zuniga Ramirez, Carlos] Hosp Civil Guadalajara Fray Antonio Alcalde, Movement Disorders & Neurodegenerat Dis Unit, Guadalajara, Jalisco, Mexico; [Velez, Miriam] Inst Ciencias Neurol Luis Trelles Montes, Lima, Peru	Micheli, FE (corresponding author), Hosp Clin Jose San Martin, Caba, Buenos Aires, Argentina.	fmicheli@fibertel.com.ar		Tschopp, Andrea Lorena/0000-0003-0838-8188; Zuniga-Ramirez, Carlos/0000-0003-4319-5875			ANDREW J, 1982, J NEUROL NEUROSUR PS, V45, P815, DOI 10.1136/jnnp.45.9.815; Aydin S, 2013, J NEUROL SURG PART A, V74, P271, DOI 10.1055/s-0032-1322549; Benedikt M., 1889, B MED, V3, P547; BIARY N, 1989, NEUROLOGY, V39, P103, DOI 10.1212/WNL.39.1.103; Boelmans K, 2012, MOVEMENT DISORD, V27, P1097, DOI 10.1002/mds.24005; Bolen RD, 2014, J NEUROL SCI, V347, P411, DOI 10.1016/j.jns.2014.10.039; Castrop F, 2013, MOVEMENT DISORD, V28, P1456, DOI 10.1002/mds.25398; Coumou AD, 2012, MOVEMENT DISORD, V27, P964, DOI 10.1002/mds.25039; de Mattos JP, 2002, ARQ NEURO-PSIQUIAT, V60, P525, DOI 10.1590/S0004-282X2002000400002; DEFER GL, 1994, J NEUROL NEUROSUR PS, V57, P987, DOI 10.1136/jnnp.57.8.987; DERECONDO A, 1993, REV NEUROL, V149, P46; Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303; Fahn S, 1986, MOVEMENT DISORD, V1, P299; FINDLEY LJ, 1980, BRIT MED J, V281, P1043, DOI 10.1136/bmj.281.6247.1043; Follett MA, 2014, NEUROMODULATION, V17, P289, DOI 10.1111/ner.12096; FUJIEDA T, 1974, BMJ-BRIT MED J, V1, P456, DOI 10.1136/bmj.1.5905.456-b; Gajos A, 2010, ACTA NEUROL SCAND, V122, P360, DOI 10.1111/j.1600-0404.2009.01319.x; HARMON R L, 1991, Brain Injury, V5, P213, DOI 10.3109/02699059109008092; Holmes G, 1904, BRAIN, V27, P327, DOI 10.1093/brain/27.3.327; Kim DG, 2009, MOVEMENT DISORD, V24, P463, DOI 10.1002/mds.22394; Kipfer S, 2013, MOVEMENT DISORD, V28, P1347, DOI 10.1002/mds.25621; KOPPEL BS, 1990, MOVEMENT DISORD, V5, P254, DOI 10.1002/mds.870050314; KREMER M, 1947, J NEUROL NEUROSUR PS, V10, P49, DOI 10.1136/jnnp.10.2.49; Lekoubou A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-37; Menon B, 2014, J MOV DISORD, V7, P22, DOI 10.14802/jmd.14005; MOSSUTOAGATIELLO L, 1993, J NEUROL, V241, P27, DOI 10.1007/BF00870668; Paviour DC, 2006, MOVEMENT DISORD, V21, P2260, DOI 10.1002/mds.20981; Pezzini A, 2002, PARKINSONISM RELAT D, V8, P177, DOI 10.1016/S1353-8020(01)00013-X; Raina GB, 2007, CLIN NEUROPHARMACOL, V30, P95, DOI 10.1097/01.WNF.0000240957.56939.E6; REMY P, 1995, NEUROLOGY, V45, P472, DOI 10.1212/WNL.45.3.472; Rieder CRM, 2003, ARQ NEURO-PSIQUIAT, V61, P473, DOI 10.1590/S0004-282X2003000300028; SAMIE MR, 1990, NEUROLOGY, V40, P62, DOI 10.1212/WNL.40.1.62; Shepherd GMG, 1997, MOVEMENT DISORD, V12, P432, DOI 10.1002/mds.870120327; Strecker K, 2007, EUR J NEUROL, V14, pE9, DOI 10.1111/j.1468-1331.2006.01665.x; Velez Miriam, 2002, Mov Disord, V17, P741, DOI 10.1002/mds.10224; Vidailhet M, 1998, MOVEMENT DISORD, V13, P49; Walker M, 2007, MOVEMENT DISORD, V22, P272, DOI 10.1002/mds.21271; Woo JH, 2013, ANN REHABIL MED-ARM, V37, P591, DOI 10.5535/arm.2013.37.4.591; YUILL GM, 1980, BRIT MED J, V281, P1428, DOI 10.1136/bmj.281.6252.1428-b; Zhong J, 2007, CHINESE MED J-PEKING, V120, P2059, DOI 10.1097/00029330-200711020-00025	40	63	68	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 8	2016	86	10					931	938		10.1212/WNL.0000000000002440			8	Clinical Neurology	Neurosciences & Neurology	DG1NA	WOS:000371833600009	26865524	Green Published			2021-06-18	
J	LaRoche, AA; Nelson, LD; Connelly, PK; Walter, KD; McCrea, MA				LaRoche, Ashley A.; Nelson, Lindsay D.; Connelly, Peter K.; Walter, Kevin D.; McCrea, Michael A.			Sport-Related Concussion Reporting and State Legislative Effects	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sport concussion; head injury; mild traumatic brain injury; legislation; reporting	HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; HEAD-INJURY; EPIDEMIOLOGY; COLLEGIATE; KNOWLEDGE; RECOVERY; RECOMMENDATIONS	Objective:To investigate concussion rates and reporting frequencies in high school and collegiate athletes in 2013, compare results to those obtained from 1999 to 2002, and examine to what extent the 2012 Wisconsin state concussion law affected reporting in 2013.Design:Retrospective 2013 survey compared with prior survey.Setting:High schools and colleges in the Milwaukee, Wisconsin, area.Participants:Athletes (N = 784) from multiple sports were surveyed in 2013. Football players (N = 1532) from 1999 to 2002 completed the same measure.Main Outcome Measures:Both surveys assessed concussion history, concussion incidence during the current season, whether incident concussions were reported, who concussions were reported to, and reasons for not reporting. The 2013 survey also assessed awareness of the Wisconsin state law and its effect on reporting.Results:Rates of concussion in the surveyed season were comparable to previous findings from 1999 to 2002 (16.6% vs 15.3%, P = 0.558). Notably, athletes were significantly more likely to report their concussions in 2013 (70.6% vs 47.3% previously, P = 0.011). Among high school athletes surveyed, 59.5% were aware of the Wisconsin state law, with 55.1% stating it would make them more likely to report a concussion.Conclusions:Rates of concussion for 1 sport season have not changed significantly over the past 14 years. The percentage of concussions that are reported to someone has increased significantly. Awareness of the Wisconsin state law does not fully account for the increase in concussion reporting.	[LaRoche, Ashley A.; Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Connelly, Peter K.] Med Coll Wisconsin, Phys Med & Rehabil, Milwaukee, WI 53226 USA; [Walter, Kevin D.] Childrens Hosp Wisconsin, Dept Orthoped Surg, Milwaukee, WI 53201 USA	LaRoche, AA (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	alaroche@mcw.edu			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 (-01)]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	Supported by the US Army Medical Research and Materiel Command under Award No. W81XWH-12-1-0004 and the Clinical and Translational Science Institute Grant No. 1UL1-RR031973 (-01). Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the US Army. This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant No. 8UL1TR000055. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Armstrong C, 2014, AM FAM PHYSICIAN, V89, P585; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Converse PD, 2008, AM J EVAL, V29, P99, DOI 10.1177/1098214007313228; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; LaRoche A., 2014, END OF SEASON SURVEY; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Metzl JD, 2006, PEDIATRICS, V117, P1813, DOI 10.1542/peds.2006-0480; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; WIAA, 2011, WIAA CONCUSSION POLI	36	63	63	1	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2016	26	1					33	39		10.1097/JSM.0000000000000192			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DA2JB	WOS:000367620000005	25894530	Green Accepted			2021-06-18	
J	Xu, LY; Nguyen, JV; Lehar, M; Menon, A; Rha, E; Arena, J; Ryu, J; Marsh-Armstrong, N; Marmarou, CR; Koliatsos, VE				Xu, Leyan; Nguyen, Judy V.; Lehar, Mohamed; Menon, Adarsh; Rha, Elizabeth; Arena, John; Ryu, Jiwon; Marsh-Armstrong, Nicholas; Marmarou, Christina R.; Koliatsos, Vassilis E.			Repetitive mild traumatic brain injury with impact acceleration in the mouse: Multifocal axonopathy, neuroinflammation, and neurodegeneration in the visual system	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic axonal injury; Diffuse axonal injury; Concussion; CTE; Retinal ganglion cell; Optic nerve; Tau	FLUORO-JADE-C; FOOTBALL-LEAGUE PLAYER; DIFFUSE AXONAL INJURY; SPINAL-CORD-INJURY; OPTIC-NERVE; HEAD-INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; DEGENERATING NEURONS; APOLIPOPROTEIN-E	Repetitive mild traumatic brain injury (mTBI) is implicated in chronic neurological illness. The development of animal models of repetitive mTBI in mice is essential for exploring mechanisms of these chronic diseases, including genetic vulnerability by using transgenic backgrounds. In this study, the rat model of impact acceleration (IA) was redesigned for the mouse cranium and used in two clinically relevant repetitive mTBI paradigms. We first determined, by using increments of weight dropped from 1 m that the 40 g weight was most representative of mTBI and was not associated with fractures, brain contusions, anoxic-ischemic injury, mortality, or significant neurological impairments. Quantitative evaluation of traumatic axonal injury (TAI) in the optic nerve/tract, cerebellum and corpus callosum confirmed that weight increase produced a graded injury. We next evaluated two novel repetitive mTBI paradigms (1 time per day or 3 times per day at days 0, 1, 3, and 7) and compared the resulting TAI, neuronal cell death, and neuroinflammation to single hit mTBI at sub-acute (7 days) and chronic time points (10 weeks) post-injury. Both single and repetitive mTBI caused TAI in the optic nerve/tract, cerebellum, corticospinal tract, lateral lemniscus and corpus callosum. Reactive microglia with phagocytic phenotypes were present at injury sites. Severity of axonal injury corresponded to impact load and frequency in the optic nerve/tract and cerebellum. Both single and repeat injury protocols were associated with retinal ganglion cell loss and optic nerve degeneration; these outcomes correlated with impact load and number/frequency. No phosphorylated tau immunoreactivity was detected in the brains of animals subjected to repetitive mTBI. Our findings establish a new model of repetitive mTBI model featured by TAI in discrete CNS tracts, especially the visual system and cerebellum. Injury in retina and optic nerve provides a sensitive measure of severity of mTBI, thus enabling further studies on mechanisms and experimental therapeutics. Our model can also be useful in exploring mechanisms of chronic neurological disease caused by repetitive mTBI in wild-type and transgenic mice. (C) 2014 Elsevier Inc. All rights reserved.	[Xu, Leyan; Menon, Adarsh; Rha, Elizabeth; Arena, John; Ryu, Jiwon; Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Nguyen, Judy V.; Marsh-Armstrong, Nicholas] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Lehar, Mohamed] Johns Hopkins Univ, Sch Med, Dept Otolaryngol HNS, Baltimore, MD 21205 USA; [Marsh-Armstrong, Nicholas] Johns Hopkins Univ, Sch Med, Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Marmarou, Christina R.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Xu, LY (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, 720 Rutland Ave,Ross Res Bldg 558, Baltimore, MD 21205 USA.	lxu9@jhmi.edu; judy.v.nguyen@gmail.com; mlehar@jhmi.edu; amen692@gmail.com; lizrha@gmail.com; jarena2@jhu.edu; jryu4@jhmi.edu; Marsh-Armstrong@Kennedykrieger.Org; crmarmar@vcu.edu; koliat@jhmi.edu		Ryu, Jiwon/0000-0003-0251-7858; Arena, John/0000-0002-4322-4472	Maryland Technology Development Corporation funds; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY019960] Funding Source: NIH RePORTER	This work was supported by Maryland Technology Development Corporation funds to VEK.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Barth J.T., 2011, SPORTS CONCUSSION CO; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481; Bian GL, 2007, BRAIN RES, V1150, P55, DOI 10.1016/j.brainres.2007.02.078; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Carter SF, 2012, J NUCL MED, V53, P37, DOI 10.2967/jnumed.110.087031; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chidlow G, 2009, EXP EYE RES, V88, P426, DOI 10.1016/j.exer.2008.10.015; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dratviman-Storobinsky O, 2008, MOL VIS, V14, P2171; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Ferrari R, 2011, J MOL NEUROSCI, V45, P500, DOI 10.1007/s12031-011-9635-y; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hartman RE, 2005, J NEUROSCI, V25, P6213, DOI 10.1523/JNEUROSCI.0664-05.2005; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jefferson SC, 2011, J NEUROSCI, V31, P5710, DOI 10.1523/JNEUROSCI.4459-10.2011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4898, DOI 10.1167/iovs.07-1447; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McPhail LT, 2004, EUR J NEUROSCI, V20, P1984, DOI 10.1111/j.1460-9568.2004.03662.x; Millspaugh, 1937, US NAV MED B, V35, P297; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pohl HBF, 2011, J NEUROSCI, V31, P1069, DOI 10.1523/JNEUROSCI.5035-10.2011; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Soto I, 2008, J NEUROSCI, V28, P548, DOI 10.1523/JNEUROSCI.3714-07.2008; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Summers MJ, 2006, BRAIN INJURY, V20, P51, DOI 10.1080/02699050500309742; Turgut M, 2010, J BRACHIAL PLEX PERI, V5, DOI 10.1186/1749-7221-5-10; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vandrovcova J, 2010, CURR ALZHEIMER RES, V7, P726, DOI 10.2174/156720510793611619; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wang YP, 2007, P NATL ACAD SCI USA, V104, P10252, DOI 10.1073/pnas.0703676104; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110; Xu H, 2014, NEUROPATH APPL NEURO, V40, P833, DOI 10.1111/nan.12160; Xu LY, 2009, J COMP NEUROL, V514, P297, DOI 10.1002/cne.22022; Yamada J, 2013, J COMP NEUROL, V521, P1184, DOI 10.1002/cne.23228	90	63	63	3	34	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2016	275		3		SI		436	449		10.1016/j.expneurol.2014.11.004			14	Neurosciences	Neurosciences & Neurology	DB2ED	WOS:000368320200013	25450468				2021-06-18	
J	Vatansever, D; Menon, DK; Manktelow, AE; Sahakian, BJ; Stamatakis, EA				Vatansever, D.; Menon, D. K.; Manktelow, A. E.; Sahakian, B. J.; Stamatakis, E. A.			Default mode network connectivity during task execution	NEUROIMAGE			English	Article						Default mode network; Finger opposition task; Functional connectivity; Graph theory; Hierarchical clustering	INTRINSIC FUNCTIONAL CONNECTIVITY; GLOBAL SIGNAL REGRESSION; CONSCIOUS RESTING STATE; HUMAN CORTICAL NETWORKS; TRAUMATIC BRAIN-INJURY; PREFRONTAL CORTEX; STRUCTURAL CONNECTIVITY; CINGULATE CORTEX; WORKING-MEMORY; ORGANIZATION	Initially described as task-induced deactivations during goal-directed paradigms of high attentional load, the unresolved functionality of default mode regions has long been assumed to interfere with task performance. However, recent evidence suggests a potential default mode network involvement in fulfilling cognitive demands. We tested this hypothesis in a finger opposition paradigm with task and fixation periods which we compared with an independent resting state scan using functional magnetic resonance imaging and a comprehensive analysis pipeline including activation, functional connectivity, behavioural and graph theoretical assessments. The results indicate task specific changes in the default mode network topography. Behaviourally, we show that increased connectivity of the posterior cingulate cortex with the left superior frontal gyrus predicts faster reaction times. Moreover, interactive and dynamic reconfiguration of the default mode network regions' functional connections illustrates their involvement with the task at hand with higher-level global parallel processing power, yet preserved small-world architecture in comparison with rest. These findings demonstrate that the default mode network does not disengage during this paradigm, but instead may be involved in task relevant processing. (C) 2015 The Authors. Published by Elsevier Inc.	[Vatansever, D.; Menon, D. K.; Manktelow, A. E.; Stamatakis, E. A.] Univ Cambridge, Div Anaesthesia, Sch Clin Med, Cambridge CB2 0QQ, England; [Vatansever, D.; Menon, D. K.; Manktelow, A. E.; Stamatakis, E. A.] Univ Cambridge, Dept Clin Neurosci, Sch Clin Med, Cambridge CB2 0QQ, England; [Vatansever, D.; Menon, D. K.; Manktelow, A. E.; Stamatakis, E. A.] Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England; [Sahakian, B. J.] Univ Cambridge, Dept Psychiat, Sch Clin Med, Cambridge CB2 0QQ, England	Vatansever, D (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Anaesthesia, Addenbrookes Hosp, Box 93,Hills Rd, Cambridge CB2 0QQ, England.	ddsv2@cam.ac.uk	Vatansever, Deniz/AAE-9766-2020; Sahakian, Barbara/AAW-1198-2020	Vatansever, Deniz/0000-0002-2494-9945; Sahakian, Barbara/0000-0001-7352-1745; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601	Evelyn Trust [RUAG/018]; Yousef Jameel Academic Program; NIHR Cambridge Biomedical Centre [RCZB/004]; NIHR Senior Investigator Award [RCZB/014]; Stephen Erskine Fellowship Queens' College Cambridge; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	The Evelyn Trust (RUAG/018) provided the required funding for this research. Additionally, D Vatansever is funded by the Yousef Jameel Academic Program administered via the Cambridge Commonwealth, European and International Trust; DK Menon is supported by funding from the NIHR Cambridge Biomedical Centre (RCZB/004), and an NIHR Senior Investigator Award (RCZB/014), and EA Stamatakis is funded by the Stephen Erskine Fellowship Queens' College Cambridge. We would also like to thank Sanja Abbott for programming the stimulus delivery, Dr. Guy Williams and Victoria Lupson and the rest of the staff in the Wolfson Brain Imaging Centre (WBIC) at Addenbrooke's Hospital for their assistance in scanning. Last but not least, we thank all the participants for their contribution to this study.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Andrews-Hanna JR, 2010, J NEUROPHYSIOL, V104, P322, DOI 10.1152/jn.00830.2009; Arbabshirani MR, 2013, HUM BRAIN MAPP, V34, P2959, DOI 10.1002/hbm.22118; Bartels A, 2005, NEUROIMAGE, V24, P339, DOI 10.1016/j.neuroimage.2004.08.044; Bassett DS, 2008, J NEUROSCI, V28, P9239, DOI 10.1523/JNEUROSCI.1929-08.2008; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Bassettt DS, 2006, P NATL ACAD SCI USA, V103, P19518, DOI 10.1073/pnas.0606005103; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009; Bullmore ET, 2012, NAT REV NEUROSCI, V13, P336, DOI 10.1038/nrn3214; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; du Boisgueheneuc F, 2006, BRAIN, V129, P3315, DOI 10.1093/brain/awl244; Fair DA, 2007, NEUROIMAGE, V35, P396, DOI 10.1016/j.neuroimage.2006.11.051; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Fransson P, 2006, NEUROPSYCHOLOGIA, V44, P2836, DOI 10.1016/j.neuropsychologia.2006.06.017; Gilbert SJ, 2006, J EXP PSYCHOL HUMAN, V32, P45, DOI 10.1037/0096-1523.32.1.45; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Habas C, 2009, J NEUROSCI, V29, P8586, DOI 10.1523/JNEUROSCI.1868-09.2009; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; Harrison BJ, 2008, P NATL ACAD SCI USA, V105, P9781, DOI 10.1073/pnas.0711791105; Hasson U, 2009, P NATL ACAD SCI USA, V106, P10841, DOI 10.1073/pnas.0903253106; Hosseini SMH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040709; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kitzbichler MG, 2011, J NEUROSCI, V31, P8259, DOI 10.1523/JNEUROSCI.0440-11.2011; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Leech R, 2011, J NEUROSCI, V31, P3217, DOI 10.1523/JNEUROSCI.5626-10.2011; Margulies DS, 2009, P NATL ACAD SCI USA, V106, P20069, DOI 10.1073/pnas.0905314106; Mazoyer B, 2001, BRAIN RES BULL, V54, P287, DOI 10.1016/S0361-9230(00)00437-8; McKiernan KA, 2006, NEUROIMAGE, V29, P1185, DOI 10.1016/j.neuroimage.2005.09.030; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Newton AT, 2011, HUM BRAIN MAPP, V32, P1649, DOI 10.1002/hbm.21138; Pasupathy A, 2005, NATURE, V433, P873, DOI 10.1038/nature03287; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schacter DL, 2012, NEURON, V76, P677, DOI 10.1016/j.neuron.2012.11.001; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Spreng RN, 2013, J COGNITIVE NEUROSCI, V25, P74, DOI 10.1162/jocn_a_00281; Spreng RN, 2010, NEUROIMAGE, V53, P303, DOI 10.1016/j.neuroimage.2010.06.016; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; Stoodley CJ, 2012, CEREBELLUM, V11, P352, DOI 10.1007/s12311-011-0260-7; Tomson SN, 2013, J NEUROSCI, V33, P14098, DOI 10.1523/JNEUROSCI.5131-12.2013; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Wang JH, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00016; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	62	63	63	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	NOV 15	2015	122						96	104		10.1016/j.neuroimage.2015.07.053			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CT9GO	WOS:000363125200011	26220743	Other Gold, Green Published			2021-06-18	
J	Phang, I; Werndle, MC; Saadoun, S; Varsos, G; Czosnyka, M; Zoumprouli, A; Papadopoulos, MC				Phang, Isaac; Werndle, Melissa C.; Saadoun, Samira; Varsos, Georgios; Czosnyka, Marek; Zoumprouli, Argyro; Papadopoulos, Marios C.			Expansion Duroplasty Improves Intraspinal Pressure, Spinal Cord Perfusion Pressure, and Vascular Pressure Reactivity Index in Patients with Traumatic Spinal Cord Injury: Injured Spinal Cord Pressure Evaluation Study	JOURNAL OF NEUROTRAUMA			English	Article						decompression; duroplasty; perfusion pressure; spinal cord injury	BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; ANIMAL-MODEL; COMPENSATION; MULTICENTER; REPAIR	We recently showed that, after traumatic spinal cord injury (TSCI), laminectomy does not improve intraspinal pressure (ISP), spinal cord perfusion pressure (SCPP), or the vascular pressure reactivity index (sPRx) at the injury site sufficiently because of dural compression. This is an open label, prospective trial comparing combined bony and dural decompression versus laminectomy. Twenty-one patients with acute severe TSCI had re-alignment of the fracture and surgical fixation; 11 had laminectomy alone (laminectomy group) and 10 had laminectomy and duroplasty (laminectomy+duroplasty group). Primary outcomes were magnetic resonance imaging evidence of spinal cord decompression (increase in intradural space, cerebrospinal fluid around the injured cord) and spinal cord physiology (ISP, SCPP, sPRx). The laminectomy and laminectomy+duroplasty groups were well matched. Compared with the laminectomy group, the laminectomy+duroplasty group had greater increase in intradural space at the injury site and more effective decompression of the injured cord. In the laminectomy+duroplasty group, ISP was lower, SCPP higher, and sPRx lower, (i.e., improved vascular pressure reactivity), compared with the laminectomy group. Laminectomy+duroplasty caused cerebrospinal fluid leak that settled with lumbar drain in one patient and pseudomeningocele that resolved completely in five patients. We conclude that, after TSCI, laminectomy+duroplasty improves spinal cord radiological and physiological parameters more effectively than laminectomy alone.	[Phang, Isaac; Werndle, Melissa C.; Saadoun, Samira; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, London SW17 0RE, England; [Varsos, Georgios; Czosnyka, Marek] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Zoumprouli, Argyro] St George Hosp, Dept Anaesthesia, London, England	Papadopoulos, MC (corresponding author), St Georges Univ London, Dept Neurosurg, Room 0-136 Jenner Wing,Cranmer Terrace, London SW17 0RE, England.	mpapadop@sgul.ac.uk		czosnyka, marek/0000-0003-2446-8006; Saadoun, Samira/0000-0002-5480-5678; Zoumprouli, Argyro/0000-0003-0890-690X; Papadopoulos, Marios/0000-0001-9174-4176	Neurosciences Research Foundation; London Deanery; Royal College of Surgeons of England; Housham Fund; Fletcher Fund; Guthy Jackson Foundation; Wings for Life Spinal Cord Research Foundation; A. G. Leventis Foundation Scholarship; Charter Studentship from St. Edmund's College, Cambridge	Financial support was provided by the Neurosciences Research Foundation (MCP, MCW, IP), London Deanery (IP, MCW), the Royal College of Surgeons of England (MCW), the Housham Fund (MCW), and the Fletcher Fund (MCP). MCP is supported by the Guthy Jackson Foundation and by the Wings for Life Spinal Cord Research Foundation. MC is National Institute for Health Research principal investigator on cerebrospinal dynamics. GV is supported by an A. G. Leventis Foundation Scholarship and a Charter Studentship from St. Edmund's College, Cambridge. The funders had no input at any stage of this research.	Ackerman P, 2010, SPINAL CORD, V48, P380, DOI 10.1038/sc.2009.140; Awwad Waleed, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS261, DOI 10.1007/s00590-013-1409-5; Cao Y., 2011, TOP SPINAL CORD INJ, V16, P10, DOI DOI 10.1310/SCI1604-10; Cripps RA, 2011, SPINAL CORD, V49, P493, DOI 10.1038/sc.2010.146; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Ditunno JF, 2000, SPINAL CORD, V38, P234, DOI 10.1038/sj.sc.3100993; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Fehlings MG, 2010, SPINE, V35, pS166, DOI 10.1097/BRS.0b013e3181f386f6; FERNANDEZ E, 1985, ACTA NEUROCHIR, V76, P145, DOI 10.1007/BF01418478; Huang X, 2010, INT J MED SCI, V7, P385; Iannotti C, 2006, J NEUROTRAUM, V23, P853, DOI 10.1089/neu.2006.23.853; Jones CF, 2012, SPINE, V37, pE1422, DOI 10.1097/BRS.0b013e31826ba7cd; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Kornblith LZ, 2013, J TRAUMA ACUTE CARE, V75, P1060, DOI 10.1097/TA.0b013e3182a74a5b; Martirosyan NL, 2011, J NEUROSURG-SPINE, V15, P238, DOI 10.3171/2011.4.SPINE10543; Papadopoulos MC, 2012, LANCET NEUROL, V11, P535, DOI 10.1016/S1474-4422(12)70133-3; Perkins P., 1998, INJURY, V19, P397; Ropper Allan H, 2014, Pract Neurol, V14, P152, DOI 10.1136/practneurol-2014-000811; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Smith JS, 2010, J BONE JOINT SURG AM, V92A, P1206, DOI 10.2106/JBJS.I.00740; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Walters B, 2013, SIGHT SOUND, V23, P82; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	27	63	66	2	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 15	2015	32	12					865	874		10.1089/neu.2014.3668			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0NZ	WOS:000363948800001	25705999	Green Accepted, Green Published			2021-06-18	
J	Vanderploeg, RD; Silva, MA; Soble, JR; Curtiss, G; Belanger, HG; Donnell, AJ; Scott, SG				Vanderploeg, Rodney D.; Silva, Marc A.; Soble, Jason R.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.			The Structure of Postconcussion Symptoms on the Neurobehavioral Symptom Inventory: A Comparison of Alternative Models	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; mild traumatic brain injury; postconcussion syndrome; structural equation modeling	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; SERVICE MEMBERS; ASSOCIATIONS; RATES	Objective: To evaluate and compare the existing Neurobehavioral Symptom Inventory factor structure models to determine which model provides the best overall fit for postconcussion symptoms and determine which model is useful across different samples (eg, with and without mild traumatic brain injury [TBI] history). Setting: N/A. Participants: A Florida National Guard sample (N = 3098) and a national Department of Veterans Affairs sample (N = 48 175). Design: Retrospective structural equation modeling was used to compare 16 alternative factor structure models. First, these 16 possible models were examined separately in both samples. Then, to determine whether the same factor structures applied across subsamples within these samples, the models were compared for those deployed and those not deployed in the Florida National Guard sample and between those with TBI confirmed on clinical evaluation and those who were determined not to have sustained a TBI within the Department of Veterans Affairs sample. Main Measures: Neurobehavioral Symptom Inventory. Results: A 4-factor model-vestibular, somatic, cognitive, and affective-had the best overall fit, after elimination of 2 items (ie, hearing problems and appetite disturbance), and was most applicable across samples. Conclusions: These findings extend the findings of Meterko et al to other samples. Because findings were consistent across sample and subsamples, the current findings are applicable to both Department of Veteran Affairs and Department of Defense postdeployment medical evaluation settings.	[Vanderploeg, Rodney D.; Silva, Marc A.; Soble, Jason R.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Scott, Steven G.] James A Haley Vet Hosp, HSR&D, RR&D, Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL 33612 USA; [Scott, Steven G.] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Silva, Marc A.; Curtiss, Glenn; Belanger, Heather G.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.] Def & Vet Brain Injury Ctr, Tampa, FL USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020; Silva, Marc A./J-1874-2019	Silva, Marc A./0000-0002-3879-6054	Department of Veterans Affairs (VA)US Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; VA grant SDR HSRD [08-411-TBI]; VA HSRD [CCN 06-164]; James A. Haley Veterans' HospitalUS Department of Veterans Affairs; HSR&D/RR&D Center of Excellence; DVBICUS Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs (VA), Veterans Health Administration, and Defense and Veterans Brain Injury Center (DVBIC) and by VA grant SDR HSR&D #08-411-TBI Screening Instruments and Processes to Rodney D. Vanderploeg, PhD, and VA HSR&D grant CCN 06-164 to Steven G. Scott, DO. Further support was provided by the James A. Haley Veterans' Hospital and its HSR&D/RR&D Center of Excellence and the DVBIC. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Army, Department of Defense, VA, or US Government. No potential conflict of interest relevant to this article was reported.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411; Arbuckle J. L., 2007, AMOS 16 USERS GUIDE; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Belanger HG, 2006, J INT NEUROPSYCH SOC, V16, P194; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Browne M. W., 1992, SOCIOL METHOD RES, V21, P136; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Burnham K. P., 2002, MODEL SELECTION INFE; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gizzi M, 2003, J HEAD TRAUMA REHAB, V18, P398, DOI 10.1097/00001199-200309000-00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Joreskog K.G., 1989, LISREL 7 GUIDE PROGR; Kelloway E. K., 1998, USING LISREL STRUCTU; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Silva MA, 2003, CLIN NEUROPSYCHOL, V27, P201; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; STEIGER JH, 1990, MULTIVAR BEHAV RES, V25, P173, DOI 10.1207/s15327906mbr2502_4; Tabachnick B., 2001, USING MULTIVARIATE S; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Weathers F., 1996, MEASUREMENT STRESS T, P250; Weathers F. W., 1993, ANN M INT SOC TRAUM; World Health Organization, 1992, ICD 10 CLASS MENT BE	46	63	63	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					1	11		10.1097/HTR.0000000000000009			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400009	24263177				2021-06-18	
J	Cheng, JS; Craft, R; Yu, GQ; Ho, K; Wang, X; Mohan, G; Mangnitsky, S; Ponnusamy, R; Mucke, L				Cheng, Jason S.; Craft, Ryan; Yu, Gui-Qiu; Ho, Kaitlyn; Wang, Xin; Mohan, Geetha; Mangnitsky, Sergey; Ponnusamy, Ravikumar; Mucke, Lennart			Tau Reduction Diminishes Spatial Learning and Memory Deficits after Mild Repetitive Traumatic Brain Injury in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; MOUSE MODELS; NETWORK	Objective: Because reduction of the microtubule-associated protein Tau has beneficial effects in mouse models of Alzheimer's disease and epilepsy, we wanted to determine whether this strategy can also improve the outcome of mild traumatic brain injury (TBI). Methods: We adapted a mild frontal impact model of TBI for wildtype C57Bl/6J mice and characterized the behavioral deficits it causes in these animals. The Barnes maze, Y maze, contextual and cued fear conditioning, elevated plus maze, open field, balance beam, and forced swim test were used to assess different behavioral functions. Magnetic resonance imaging (MRI, 7 Tesla) and histological analysis of brain sections were used to look for neuropathological alterations. We also compared the functional effects of this TBI model and of controlled cortical impact in mice with two, one or no Tau alleles. Results: Repeated (2-hit), but not single (1-hit), mild frontal impact impaired spatial learning and memory in wildtype mice as determined by testing of mice in the Barnes maze one month after the injury. Locomotor activity, anxiety, depression and fear related behaviors did not differ between injured and sham-injured mice. MRI imaging did not reveal focal injury or mass lesions shortly after the injury. Complete ablation or partial reduction of tau prevented deficits in spatial learning and memory after repeated mild frontal impact. Complete tau ablation also showed a trend towards protection after a single controlled cortical impact. Complete or partial reduction of tau also reduced the level of axonopathy in the corpus callosum after repeated mild frontal impact. Interpretation: Tau promotes or enables the development of learning and memory deficits and of axonopathy after mild TBI, and tau reduction counteracts these adverse effects.	[Cheng, Jason S.; Craft, Ryan; Yu, Gui-Qiu; Ho, Kaitlyn; Wang, Xin; Ponnusamy, Ravikumar; Mucke, Lennart] Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Cheng, Jason S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Mucke, Lennart] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Mohan, Geetha; Mangnitsky, Sergey] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA	Mucke, L (corresponding author), Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.	lmucke@gladstone.ucsf.edu		Mohan, Geetha/0000-0002-4192-5785	National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS041787, NS065780]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041787, P30NS065780] Funding Source: NIH RePORTER	LM received grants NS041787 and NS065780 from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). http://www.ninds.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crawley J.N., 2007, WHATS WRONG MY MOUSE; Dawson HN, 2001, J CELL SCI, V114, P1179; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Devos SL, 2013, J NEUROSCI, V33, P12887, DOI 10.1523/JNEUROSCI.2107-13.2013; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Durazzo TC, 2013, J NEUROTRAUM, V30, P1013, DOI 10.1089/neu.2012.2676; Freire MAM, 2012, W INDIAN MED J, V61, P751; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gheyara AL, 2014, ANN NEUROL, V76, P443, DOI 10.1002/ana.24230; Holth JK, 2013, J NEUROSCI, V33, P1651, DOI 10.1523/JNEUROSCI.3191-12.2013; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Lei P, 2012, NAT MED, V18, P291, DOI 10.1038/nm.2613; Li Z, 2014, NEUROBIOL AGING; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mauri M, 2006, FUNCT NEUROL, V21, P223; Morris M, 2013, NEUROBIOL AGING, V34, P1523, DOI 10.1016/j.neurobiolaging.2012.12.003; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Pape TLB, 2013, PM&R, V5, P856, DOI 10.1016/j.pmrj.2013.06.007; Petraglia AL, 2014, J NEUROTRAUMA; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Roberson ED, 2011, J NEUROSCI, V31, P700, DOI 10.1523/JNEUROSCI.4152-10.2011; Sanchez PE, 2012, P NATL ACAD SCI USA, V109, pE2895, DOI 10.1073/pnas.1121081109; Sanders MJ, 2005, NEUROBIOL LEARN MEM, V84, P33, DOI 10.1016/j.nlm.2005.03.001; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Ullmann JF, 2013, BRAIN STRUCT FUNCT; Vossel KA, 2010, SCIENCE, V330, P198, DOI 10.1126/science.1194653; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zempel H, 2013, EMBO J, V32, P2920, DOI 10.1038/emboj.2013.207	42	63	64	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2014	9	12							e115765	10.1371/journal.pone.0115765			17	Multidisciplinary Sciences	Science & Technology - Other Topics	AX7UC	WOS:000347119100059	25551452	DOAJ Gold, Green Published			2021-06-18	
J	Johnson, B; Neuberger, T; Gay, M; Hallett, M; Slobounov, S				Johnson, Brian; Neuberger, Thomas; Gay, Michael; Hallett, Mark; Slobounov, Semyon			Effects of Subconcussive Head Trauma on the Default Mode Network of the Brain	JOURNAL OF NEUROTRAUMA			English	Article						default mode network; concussion; subconcussive head trauma; resting-state	RECURRENT CONCUSSION; IMPACT; MILD; ENCEPHALOPATHY; CONNECTIVITY; INJURY; ACTIVATION; PLAYERS; CORTEX; SCHOOL	Although they are less severe than a full blown concussive episodes, subconcussive impacts happen much more frequently and current research has suggested this form of head trauma may have an accumulative effect and lead to neurological impairment later in life. To investigate the acute effects that subconcussive head trauma may have on the default mode network of the brain resting-state, functional magnetic resonance was performed. Twenty-four current collegiate rugby players were recruited and all subjects underwent initial scanning 24 h prior to a scheduled full contact game to provide a baseline. Follow-up scanning of the rugby players occurred within 24 h following that game to assess acute effects from subconcussive head trauma. Differences between pre-game and post-game scans showed both increased connectivity from the left supramarginal gyrus to bilateral orbitofrontal cortex and decreased connectivity from the retrosplenial cortex and dorsal posterior cingulate cortex. To assess whether or not a history of previous concussion may lead to a differential response following subconcussive impacts, subjects were further divided into two subgroups based upon history of previous concussion. Individuals with a prior history of concussion exhibited only decreased functional connectivity following exposure to subconcussive head trauma, while those with no history showed increased connectivity. Even acute exposure to subconcussive head trauma demonstrates the ability to alter functional connectivity and there is possible evidence of a differential response in the brain for those with and without a history of concussion.	[Johnson, Brian; Gay, Michael; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Neuberger, Thomas] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Neuberger, Thomas] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA; [Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA; [Slobounov, Semyon] Penn State Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA	Johnson, B (corresponding author), Penn State Univ, Dept Kinesiol, Ctr Sport Concuss Res, 19 Recreat Bldg, University Pk, PA 16802 USA.	bdj5039@psu.edu			American Society of Radiological Technologists Education and Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002667] Funding Source: NIH RePORTER	This research was partly supported by The American Society of Radiological Technologists Education and Research Foundation.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Gabbett TJ, 2011, J SCI MED SPORT, V14, P210, DOI 10.1016/j.jsams.2011.01.002; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Horovitz SG, 2008, HUM BRAIN MAPP, V29, P671, DOI 10.1002/hbm.20428; Jacobs AH, 2012, J CEREBR BLOOD F MET, V32, P1393, DOI 10.1038/jcbfm.2012.53; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Noble RL, 1942, Q J EXP PHYSIOL CMS, V31, P187, DOI 10.1113/expphysiol.1942.sp000856; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rushworth MFS, 2001, J COGNITIVE NEUROSCI, V13, P698, DOI 10.1162/089892901750363244; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seghier ML, 2013, NEUROSCIENTIST, V19, P43, DOI 10.1177/1073858412440596; Seitz JA, 2000, NEW IDEAS PSYCHOL, V18, P23, DOI 10.1016/S0732-118X(99)00035-5; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Wolf RC, 2011, J PSYCHIATR NEUROSCI, V36, P402, DOI 10.1503/jpn.100150; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	45	63	63	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1907	1913		10.1089/neu.2014.3415			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500002	25010992	Green Published			2021-06-18	
J	Okuma, Y; Liu, KY; Wake, H; Liu, R; Nishimura, Y; Hui, Z; Teshigawara, K; Haruma, J; Yamamoto, Y; Yamamoto, H; Date, I; Takahashi, HK; Mori, S; Nishibori, M				Okuma, Yu; Liu, Keyue; Wake, Hidenori; Liu, Rui; Nishimura, Yoshito; Hui, Zhong; Teshigawara, Kiyoshi; Haruma, Jun; Yamamoto, Yasuhiko; Yamamoto, Hiroshi; Date, Isao; Takahashi, Hideo K.; Mori, Shuji; Nishibori, Masahiro			Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction	NEUROPHARMACOLOGY			English	Article						Traumatic brain injury; Glycyrrhizin; HMGB1; RAGE; Brain edema	MOBILITY GROUP BOX-1; CHRONIC HEPATITIS-C; FACTOR-KAPPA-B; THERAPEUTIC TARGET; ISCHEMIA; RATS; ACTIVATION; RECEPTOR; PROTEIN; CELLS	Glycyrrhizin (GL) is a major constituent of licorice root and has been suggested to inhibit the release of high mobility group box-1 (HMGB1), a protein considered representative of damage-associated molecular patterns. We found that GL bound HMGB1 but not RAGE with a moderate equilibrium dissociation constant value based on surface plasmon resonance analysis. This complex formation prevented HMGB1 from binding to RAGE in vitro. The effects of glycyrrhizin on traumatic brain injury (TBI) induced by fluid percussion were examined in rats or mice in the present study. GL was administered intravenously after TBI. Treatment of rats with GL dose-dependently suppressed the increase in BBB permeability and impairment of motor functions, in association with the inhibition of HMGB1 translocation in neurons in injured sites. The beneficial effects of GL on motor and cognitive functions persisted for 7 days after injury. The expression of TNF-alpha, IL-1 beta and IL-6 in injured sites was completely inhibited by GL treatment. In RAGE-/- mice, the effects of GL were not observed. These results suggested that GL may be a novel therapeutic agent for TBI through its interference with HMGB1 and RAGE interaction. (C) 2014 Elsevier Ltd. All rights reserved.	[Okuma, Yu; Liu, Keyue; Wake, Hidenori; Liu, Rui; Nishimura, Yoshito; Hui, Zhong; Teshigawara, Kiyoshi; Haruma, Jun; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Kita Ku, Okayama 7008558, Japan; [Okuma, Yu; Haruma, Jun; Date, Isao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurosurg, Kita Ku, Okayama 7008558, Japan; [Yamamoto, Yasuhiko; Yamamoto, Hiroshi] Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa 9208640, Japan; [Takahashi, Hideo K.] Kinki Univ, Dept Pharmacol, Osakasayama 5898511, Japan; [Mori, Shuji] Shujitsu Univ, Sch Pharm, Dept Pharmacol, Okayama 7038516, Japan	Nishibori, M (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	yakuri@md.okayama-u.ac.jp	Nishimura, Yoshito/ABF-6713-2020	Nishimura, Yoshito/0000-0003-0224-7501; Okuma, Yu/0000-0003-4769-8111; Takahashi, Hideo/0000-0001-9444-9746	Scientific Research from the Ministry of Health, Labor and Welfare of JapanMinistry of Health, Labour and Welfare, Japan; Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [23659687, 24390061]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24590375, 25461947, 24590658, 25460649, 25461335] Funding Source: KAKEN	This work was supported by grants from the Scientific Research from the Ministry of Health, Labor and Welfare of Japan, from the Japan Society for the Promotion of Science (JSPS No. 23659687, 24390061).	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Arase Y, 1997, CANCER, V79, P1494, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B; Cherng JM, 2006, EUR J PHARMACOL, V547, P10, DOI 10.1016/j.ejphar.2006.06.080; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; He M, 2011, EMBO REP, V12, P358, DOI 10.1038/embor.2011.28; Hidaka I, 2007, LIVER INT, V27, P845, DOI 10.1111/j.1478-3231.2007.01492.x; Hwang IK, 2006, ACTA PHARMACOL SIN, V27, P959, DOI 10.1111/j.1745-7254.2006.00346.x; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Kumada H, 2002, ONCOLOGY-BASEL, V62, P94, DOI 10.1159/000048283; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Liu R, 2009, ACTA MED OKAYAMA, V63, P203; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mabuchi A, 2009, MICROCIRCULATION, V16, P364, DOI 10.1080/10739680902796917; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Miyaji C, 2002, INT IMMUNOPHARMACOL, V2, P1079, DOI 10.1016/S1567-5769(02)00033-4; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Myint KM, 2006, DIABETES, V55, P2510, DOI 10.2337/db06-0221; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Ohshima T, 2005, J NEUROCHEM, V94, P917, DOI 10.1111/j.1471-4159.2005.03233.x; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739; Shamsa F., 2010, Journal of Medicinal Plants, V9, P1; Sharifzadeh M, 2008, PLANTA MED, V74, P485, DOI 10.1055/s-2008-1074494; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Takei H, 2008, J PHARMACOL SCI, V106, P460, DOI 10.1254/jphs.FP0072378; van Rossum TGJ, 1999, CLIN THER, V21, P2080, DOI 10.1016/S0149-2918(00)87239-2; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zurolo E, 2011, BRAIN, V134, P1015, DOI 10.1093/brain/awr032	33	63	69	3	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	OCT	2014	85						18	26		10.1016/j.neuropharm.2014.05.007			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AN8KR	WOS:000340853600003	24859607				2021-06-18	
J	Lerner, A; Mogensen, MA; Kim, PE; Shiroishi, MS; Hwang, DH; Law, M				Lerner, Alexander; Mogensen, Monique A.; Kim, Paul E.; Shiroishi, Mark S.; Hwang, Darryl H.; Law, Meng			Clinical Applications of Diffusion Tensor Imaging	WORLD NEUROSURGERY			English	Article						Advanced MR imaging; Clinical applications; Diffusion tensor imaging, DTI	NORMAL-APPEARING WHITE; TEMPORAL-LOBE EPILEPSY; MILD COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS LESIONS; TRAUMATIC BRAIN-INJURY; PARTIAL STATUS EPILEPTICUS; MAGNETIC-RESONANCE; WATER DIFFUSION; FIBER TRACTOGRAPHY; SPINAL-CORD	Advancements in diffusion-weighted imaging during the past decade have led to the use of diffusion tensor imaging to further characterize the structural integrity of neural tissue and to noninvasively trace neuronal tracts in the brain and spine. This has led to many clinical applications that have aided in surgical planning for brain and spinal cord tumors and has increased the diagnostic potential of magnetic resonance imaging in disorders such as multiple sclerosis, Alzheimer disease, and traumatic brain injury.	[Lerner, Alexander; Mogensen, Monique A.; Kim, Paul E.; Shiroishi, Mark S.; Hwang, Darryl H.; Law, Meng] Univ So Calif, Keck Sch Med, Dept Radiol, Neuroradiol Div, Los Angeles, CA 90033 USA	Lerner, A (corresponding author), Univ So Calif, Keck Sch Med, Dept Radiol, Neuroradiol Div, Los Angeles, CA 90033 USA.	lernera@med.usc.edu	Hwang, Darryl/M-7221-2019; Mogensen, Monique/Y-1870-2019		Prism Medical Imaging; Seimens Medical Solutions; Bayer HealthcareBayer AGBayer Healthcare Pharmaceuticals	Dr. Meng Law's financial disclosures include Prism Medical Imaging (consultant), Seimens Medical Solutions (Speakers' Bureau), and Bayer Healthcare (Speakers' Bureau). The remaining authors have no conflicts to report.	Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf BA, 2003, AM J NEURORADIOL, V24, P1857; Bammer R, 2002, MAGNET RESON MED, V48, P128, DOI 10.1002/mrm.10184; Bammer R, 2000, MAGNET RESON MED, V44, P583, DOI 10.1002/1522-2594(200010)44:4<583::AID-MRM12>3.0.CO;2-O; Bammer R, 2001, MAGN RESON MED, V46, P548, DOI 10.1002/mrm.1226; Bammer R, 2009, MAGN RESON IMAGING C, V17, P175, DOI 10.1016/j.mric.2009.01.011; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bello L, 2008, NEUROIMAGE, V39, P369, DOI 10.1016/j.neuroimage.2007.08.031; Bello L, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09240; Berman J, 2009, MAGN RESON IMAGING C, V17, P205, DOI 10.1016/j.mric.2009.02.002; Berman JI, 2007, J NEUROSURG, V107, P488, DOI 10.3171/JNS-07/09/0488; Berman JI, 2004, J NEUROSURG, V101, P66, DOI 10.3171/jns.2004.101.1.0066; Bozzali M, 2002, AM J NEURORADIOL, V23, P985; Bozzali M, 2002, J NEUROL NEUROSUR PS, V72, P742, DOI 10.1136/jnnp.72.6.742; Buchmann N, 2011, ACTA NEUROCHIR, V153, P68, DOI 10.1007/s00701-010-0817-0; Burgel U, 2009, CENT EUR NEUROSURG, V70, P27, DOI 10.1055/s-0028-1087212; Calabrese M, 2011, RADIOLOGY, V261, P891, DOI 10.1148/radiol.11110195; Carlesimo GA, 2010, NEUROLOGY, V74, P194, DOI 10.1212/WNL.0b013e3181cb3e39; Castriota-Scanderbeg A, 2003, AM J NEURORADIOL, V24, P663; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; Cercignani M, 2000, NEUROLOGY, V54, P1139, DOI 10.1212/WNL.54.5.1139; Cercignani M, 2001, J NEUROL NEUROSUR PS, V70, P311, DOI 10.1136/jnnp.70.3.311; CHRISTIANSEN P, 1993, ACTA NEUROL SCAND, V87, P195; Clark CA, 2000, MAGN RESON MED, V43, P133; Coenen VA, 2001, NEUROSURGERY, V49, P86, DOI 10.1097/00006123-200107000-00013; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; de la Roque AD, 2005, EUR RADIOL, V15, P279, DOI 10.1007/s00330-004-2578-8; Droogan AG, 1999, MAGN RESON IMAGING, V17, P653, DOI 10.1016/S0730-725X(99)00011-9; Ducreux D, 2007, NEUROIMAG CLIN N AM, V17, P137, DOI 10.1016/j.nic.2006.11.005; El-Koussy M, 2002, EUR RADIOL, V12, P568, DOI 10.1007/s003300100999; Farber RS, 2009, J MAGN RESON IMAGING, V30, P732, DOI 10.1002/jmri.21922; Farina L, 2004, NEURORADIOLOGY, V46, P251, DOI 10.1007/s00234-003-1122-x; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; FARZANEH F, 1990, MAGNET RESON MED, V14, P123, DOI 10.1002/mrm.1910140112; Fellgiebel A, 2004, DEMENT GERIATR COGN, V18, P101, DOI 10.1159/000077817; Field AS, 2004, J MAGN RESON IMAGING, V20, P555, DOI 10.1002/jmri.20169; Filippi M, 2000, ARCH NEUROL-CHICAGO, V57, P1017, DOI 10.1001/archneur.57.7.1017; Filippi M, 1999, NEUROLOGY, V52, P845, DOI 10.1212/WNL.52.4.845; FILIPPI M, 1995, NEUROLOGY, V45, P478, DOI 10.1212/WNL.45.3.478; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Fischer FU, 2012, J MAGN RESON IMAGING, V36, P84, DOI 10.1002/jmri.23621; Frank LR, 2002, MAGN RESON MED, V47, P1083, DOI 10.1002/mrm.10156; Frank LR, 2001, MAGN RESON MED, V45, P935, DOI 10.1002/mrm.1125; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; Ge YL, 2004, J MAGN RESON IMAGING, V20, P1, DOI 10.1002/jmri.20083; GEANMARTON AD, 1991, RADIOLOGY, V180, P215, DOI 10.1148/radiology.180.1.2052698; Gold BT, 2012, J ALZHEIMERS DIS, V31, pS19, DOI 10.3233/JAD-2012-112165; Guye M, 2007, NEUROIMAGE, V35, P28, DOI 10.1016/j.neuroimage.2006.11.049; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Haselgrove JC, 1996, MAGNET RESON MED, V36, P960, DOI 10.1002/mrm.1910360620; Hendler T, 2003, J NEUROSURG, V99, P1018, DOI 10.3171/jns.2003.99.6.1018; Hesseltine SM, 2006, AM J NEURORADIOL, V27, P1189; Holodny AI, 2001, J NEUROSURG, V95, P1082, DOI 10.3171/jns.2001.95.6.1082; Holodny AI, 2001, AM J NEURORADIOL, V22, P83; Horsfield MA, 1996, MAGN RESON MED, V36, P393, DOI 10.1002/mrm.1910360310; Hosomi A, 2009, NEURORADIOLOGY, V51, P549, DOI 10.1007/s00234-009-0534-7; Huang JB, 2007, ANN NY ACAD SCI, V1097, P259, DOI 10.1196/annals.1379.021; HUSTED CA, 1994, ANN NEUROL, V36, P157, DOI 10.1002/ana.410360207; Hutchinson E, 2010, EPILEPSY RES, V88, P208, DOI 10.1016/j.eplepsyres.2009.11.011; Inoue T, 2005, CLIN NEUROL NEUROSUR, V107, P174, DOI 10.1016/j.clineuro.2004.06.011; Jellison BJ, 2004, AM J NEURORADIOL, V25, P356; Jones JGA, 2013, AM J NEURORADIOL, V34, P471, DOI 10.3174/ajnr.A3199; Kamada K, 2005, J NEUROSURG, V102, P664, DOI 10.3171/jns.2005.102.4.0664; Kantarci K, 2005, NEUROLOGY, V64, P902, DOI 10.1212/01.WNL.0000153076.46126.E9; Kimiwada T, 2006, EPILEPSIA, V47, P167, DOI 10.1111/j.1528-1167.2006.00383.x; Kinoshita M, 2005, NEUROIMAGE, V25, P424, DOI 10.1016/j.neuroimage.2004.07.076; Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021; LARSSON HBW, 1992, MAGN RESON IMAGING, V10, P7, DOI 10.1016/0730-725X(92)90367-9; Le Bihan D, 2006, J MAGN RESON IMAGING, V24, P478, DOI 10.1002/jmri.20683; Leclercq D, 2011, NEUROSURG CLIN N AM, V22, P253, DOI 10.1016/j.nec.2010.11.004; Leclercq D, 2010, J NEUROSURG, V112, P503, DOI 10.3171/2009.8.JNS09558; Lehmann TN, 2000, EPILEPSIA, V41, pS190, DOI 10.1111/j.1528-1157.2000.tb01580.x; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu CL, 2004, MAGN RESON MED, V51, P924, DOI 10.1002/mrm.20071; Londono A, 2003, AM J NEURORADIOL, V24, P1582; Lu S, 2004, RADIOLOGY, V232, P221, DOI 10.1148/radiol.2321030653; Luat AF, 2008, EPILEPSIA, V49, P15, DOI 10.1111/j.1528-1167.2008.01506.x; Lui YW, NEUROSURGERY, V61, P1199; Maesawa S, 2010, WORLD NEUROSURG, V74, P153, DOI 10.1016/j.wneu.2010.03.022; Maier SE, 2005, ANN NY ACAD SCI, V1064, P50, DOI 10.1196/annals.1340.011; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; Medina David A, 2008, Neuropsychiatr Dis Treat, V4, P737; Mikuni N, J NEUROL NEUROSURG P; Mikuni N, 2007, J NEUROSURG, V106, P128, DOI 10.3171/jns.2007.106.1.128; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Muller MJ, 2007, NEUROBIOL AGING, V28, P398, DOI 10.1016/j.neurobiolaging.2006.01.009; Mukherjee P, 2005, NEUROIMAG CLIN N AM, V15, P655, DOI 10.1016/j.nic.2005.08.010; Mukherjee P, 2000, RADIOLOGY, V215, P211, DOI 10.1148/radiology.215.1.r00ap29211; Nimsky C, 2005, ZBL NEUROCHIR, V66, P133, DOI 10.1055/s-2005-836606; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NITSCH C, 1983, J NEUROL SCI, V59, P305, DOI 10.1016/0022-510X(83)90016-3; Nusbaum AO, 2000, NEUROLOGY, V54, P1421, DOI 10.1212/WNL.54.7.1421; Ozsunar Y, 2004, AM J NEURORADIOL, V25, P699; Pipe JG, 1999, MAGNET RESON MED, V42, P963, DOI 10.1002/(SICI)1522-2594(199911)42:5<963::AID-MRM17>3.0.CO;2-L; Powell HWR, 2008, J NEUROL NEUROSUR PS, V79, P327, DOI 10.1136/jnnp.2007.126078; Powell HWR, 2007, NEUROIMAGE, V36, P209, DOI 10.1016/j.neuroimage.2007.02.028; Rashid W, 2004, MULT SCLER J, V10, P9, DOI 10.1191/1352458504ms985oa; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; RIGHINI A, 1994, MAGN RESON IMAGING, V12, P865, DOI 10.1016/0730-725X(94)92027-3; Romano A, 2011, NEUROSURGERY, V69, P696, DOI 10.1227/NEU.0b013e31821a8555; Rovaris M, 2009, NEUROIMAG CLIN N AM, V19, P37, DOI 10.1016/j.nic.2008.08.001; Roychowdhury S, 2000, AM J NEURORADIOL, V21, P869; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Schonberg T, 2006, NEUROIMAGE, V30, P1100, DOI 10.1016/j.neuroimage.2005.11.015; Sigal T, 2012, J NEUROIMAGING, V22, P33, DOI 10.1111/j.1552-6569.2010.00556.x; Singh M, 2010, MAGN RESON MED, V64, P1676, DOI 10.1002/mrm.22509; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Sinha S, 2002, AM J NEURORADIOL, V23, P520; Sjobeck M, 2010, ARCH GERONTOL GERIAT, V50, P260, DOI 10.1016/j.archger.2009.03.014; Smits M, 2007, AM J NEURORADIOL, V28, P1354, DOI 10.3174/ajnr.A0538; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; Stadlbauer A, 2006, RADIOLOGY, V240, P803, DOI 10.1148/radiol.2403050937; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Takahashi S, 2002, NEUROSCI LETT, V332, P45, DOI 10.1016/S0304-3940(02)00914-X; Takao H, 2012, HUM BRAIN MAPP, V33, P466, DOI 10.1002/hbm.21225; Takao H, 2011, NEUROIMAGE, V54, P1053, DOI 10.1016/j.neuroimage.2010.09.023; TANAKA T, 1992, PROG NEUROBIOL, V38, P317, DOI 10.1016/0301-0082(92)90023-8; Thivard L, 2005, NEUROIMAGE, V28, P682, DOI 10.1016/j.neuroimage.2005.06.045; Thurnher MM, 2009, MAGN RESON IMAGING C, V17, P225, DOI 10.1016/j.mric.2009.02.004; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Valsasina P, 2005, NEUROIMAGE, V26, P822, DOI 10.1016/j.neuroimage.2005.02.033; Van Petten C, 2004, NEUROPSYCHOLOGIA, V42, P1394, DOI 10.1016/j.neuropsychologia.2004.04.006; von Oertzen J, 2002, J NEUROL NEUROSUR PS, V73, P643, DOI 10.1136/jnnp.73.6.643; Wang FN, 2005, MAGN RESON MED, V54, P1232, DOI 10.1002/mrm.20677; Wang Y, 1996, EPILEPSIA, V37, P1000, DOI 10.1111/j.1528-1157.1996.tb00539.x; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Winston GP, 2011, EPILEPSIA, V52, P1430, DOI 10.1111/j.1528-1167.2011.03088.x; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511; Wu JS, 2007, NEUROSURGERY, V61, P935, DOI 10.1227/01.neu.0000303189.80049.ab; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165	137	63	68	1	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUL-AUG	2014	82	1-2					96	109		10.1016/j.wneu.2013.07.083			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AQ6HM	WOS:000342911400128	23916498				2021-06-18	
J	Ryan, NP; Anderson, V; Godfrey, C; Beauchamp, MH; Coleman, L; Eren, S; Rosema, S; Taylor, K; Catroppa, C				Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Beauchamp, Miriam H.; Coleman, Lee; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy			Predictors of Very-Long-Term Sociocognitive Function after Pediatric Traumatic Brain Injury: Evidence for the Vulnerability of the Immature "Social Brain"	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; emotion perception; sociocognitive function; childhood	EMOTION RECOGNITION; CORPUS-CALLOSUM; FAMILY ENVIRONMENT; FACIAL EXPRESSION; HEAD-INJURY; PERCEPTION; CHILDHOOD; CHILDREN; DEFICITS; OUTCOMES	Emotion perception (EP) forms an integral part of social communication and is critical to attain developmentally appropriate goals. This skill, which emerges relatively early in development, is driven by increasing connectivity among regions of a distributed sociocognitive neural network and may be vulnerable to disruption from early-childhood traumatic brain injury (TBI). The present study aimed to evaluate the very-long-term effect of childhood TBI on EP, as well as examine the contribution of injury- and non-injury-related risk and resilience factors to variability in sociocognitive outcomes. Thirty-four young adult survivors of early-childhood TBI (mean [M], 20.62 years; M time since injury, 16.55 years) and 16 typically developing controls matched for age, gender, and socioeconomic status were assessed using tasks that required recognition and interpretation of facial and prosodic emotional cues. Survivors of severe childhood TBI were found to have significantly poorer emotion perception than controls and young adults with mild-to-moderate injuries. Further, poorer emotion perception was associated with reduced volume of the posterior corpus callosum, presence of frontal pathology, lower SES, and a less-intimate family environment. Our findings lend support to the vulnerability of the immature "social brain" network to early disruption and underscore the need for context-sensitive rehabilitation that optimizes early family environments to enhance recovery of EP skills after childhood TBI.	[Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Parkville, Vic 3052, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Anderson, Vicki; Taylor, Kaitlyn; Catroppa, Cathy] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada; [Coleman, Lee] Royal Childrens Hosp, Dept Radiol, Melbourne, Vic, Australia; [Godfrey, Celia; Rosema, Stefanie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Ryan, Nicholas/K-5445-2019	Ryan, Nicholas/0000-0002-0878-8889	Victorian Neurotrauma Initiative; National Health and Medical Research Council (NHMRC) FellowshipNational Health and Medical Research Council of Australia; NHMRC Career Development AwardNational Health and Medical Research Council of Australia; Victorian Government Operational Infrastructure Scheme	This work was supprted by the Victorian Neurotrauma Initiative, a National Health and Medical Research Council (NHMRC) Fellowship (to V. A.), a NHMRC Career Development Award (to C. C.), and the Victorian Government Operational Infrastructure Scheme.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Beauchamp MH, 2011, BRAIN INJURY, V25, P950, DOI 10.3109/02699052.2011.589791; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Daniel A. E., 1983, POWER PRIVILEGE PRES; DEMOREST A, 1984, CHILD DEV, V55, P1527, DOI 10.2307/1130022; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gilliam M, 2011, BIOL PSYCHIAT, V69, P839, DOI 10.1016/j.biopsych.2010.11.024; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Holdnack J, 2011, ASSESSMENT, V18, P192, DOI 10.1177/1073191110394771; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Johnson MH, 2001, NAT REV NEUROSCI, V2, P475, DOI 10.1038/35081509; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S., 2012, DEV SOCIAL NEUROSCIE, P325; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; National Scientific Council on the Developing Child, 2007, 5 NAT SCI COUNC DEV; NOLLER P, 1992, J ADOLESCENCE, V15, P101, DOI 10.1016/0140-1971(92)90041-3; Noller P, 1988, ICPS FAMILY FUNCTION; Pearson, 2009, ADV CLIN SOLUTIONS W; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Schmidt AT, 2010, BRAIN INJURY, V24, P1550, DOI 10.3109/02699052.2010.523047; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Sengpiel F, 2007, CURR BIOL, V17, pR742, DOI 10.1016/j.cub.2007.06.017; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Tabachnick B., 2001, USING MULTIVARIATE S; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tonks J., 2007, BRAIN IMPAIR, V18, P458; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Woods D, 2012, DEV SOCIAL NEUROSCIE, P350; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2009, PEDIAT NEUROPSYCHOLO	60	63	63	0	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					649	657		10.1089/neu.2013.3153			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000006	24147615				2021-06-18	
J	Wang, J; Pang, T; Hafko, R; Benicky, J; Sanchez-Lemus, E; Saavedra, JM				Wang, Juan; Pang, Tao; Hafko, Roman; Benicky, Julius; Sanchez-Lemus, Enrique; Saavedra, Juan M.			Telmisartan ameliorates glutamate-induced neurotoxicity: Roles of AT(1) receptor blockade and PPAR gamma activation	NEUROPHARMACOLOGY			English	Article						Angiotensin II AT(1) Receptor Blockers; Telmisartan; PPAR gamma; Neuroprotection; Glutamate neurotoxicity; Apoptosis	II TYPE-1 RECEPTOR; TRAUMATIC BRAIN-INJURY; INNATE IMMUNE-RESPONSE; FACTOR-KAPPA-B; ANGIOTENSIN-II; VASCULAR INFLAMMATION; HYPERTENSIVE-RATS; DOWN-REGULATION; BLOOD-PRESSURE; VALPROIC ACID	Sartans (Angiotensin II AT(1) Receptor Blockers, ARBs) are powerful neuroprotective agents in vivo and protect against IL-1 beta neurotoxicity in vitro. The purpose of this research was to determine the extent of sartan neuroprotection against glutamate excitotoxicity, a common cause of neuronal injury and apoptosis. The results show that sartans are neuroprotective, significantly reducing glutamate-induced neuronal injury and apoptosis in cultured rat primary cerebellar granule cells (CGCs). Telmisartan was the most potent sartan studied, with an order of potency telmisartan > candesartan > losartan > valsartan. Mechanisms involved reduction of pro-apoptotic caspase-3 activation, protection of the survival PI3K/Akt/GSK-3 beta pathway and prevention of glutamate-induced ERK1/2 activation. NMDA receptor stimulation was essential for glutamate-induced cell injury and apoptosis. Participation of AT(1A) receptor was supported by glutamate-induced upregulation of AT(1A) gene expression and AT(1) receptor binding. Conversely, AT(1B) or AT(2) receptors played no role. Glutamate-induced neuronal injury and the neuroprotective effect of telmisartan were decreased, but not abolished, in CGCs obtained from AT(1A), knock-out mice. This indicates that although AT(1) receptors are necessary for glutamate to exert its full neurotoxic potential, part of the neuroprotective effect of telmisartan is independent of AT(1) receptor blockade. PPAR gamma activation was also involved in the neuroprotective effects of telmisartan, as telmisartan enhanced PPAR gamma nuclear translocation and the PPAR gamma antagonist GW9662 partially reversed the neuroprotective effects of telmisartan. The present results substantiate the therapeutic use of sartans, in particular telmisartan, in neurodegenerative diseases and traumatic brain disorders where glutamate neurotoxicity plays a significant role. Published by Elsevier Ltd.	[Wang, Juan; Pang, Tao; Hafko, Roman; Benicky, Julius; Sanchez-Lemus, Enrique; Saavedra, Juan M.] NIMH, Sect Pharmacol, Div Intramural Res Programs, NIH,US Dept HHS, Bethesda, MD 20892 USA; [Pang, Tao] China Pharmaceut Univ, New Drug Screening Ctr, Nanjing 210009, Jiangsu, Peoples R China; [Saavedra, Juan M.] Georgetown Univ, Dept Physiol & Pharmacol, Med Ctr, Washington, DC 20057 USA	Saavedra, JM (corresponding author), Georgetown Univ, Dept Physiol & Pharmacol, Med Ctr, Bldg D,Room 287,3970 Reservoir Rd NW, Washington, DC 20057 USA.	jw543@georgetown.edu; jb2304@georgetown.edu; scientificsupport@mesoscale.com; jms522@georgetown.edu	Saavedra, Juan/AAO-7149-2020		Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department Of Health and Human Services, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 002762-16]; Natural Science Foundation of Jiangsu Province, P.R.ChinaNatural Science Foundation of Jiangsu Province [BK 20130653]; Fundamental Research Funds for the Central Universities, P.R.ChinaFundamental Research Funds for the Central Universities [JKZD 2013006]; China Pharmaceutical University; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH002762] Funding Source: NIH RePORTER	This study was supported by the Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department Of Health and Human Services, USA (MH 002762-16), the Natural Science Foundation of Jiangsu Province, P.R.China (BK 20130653), the Fundamental Research Funds for the Central Universities, P.R.China (JKZD 2013006), and the Initial Fund of China Pharmaceutical University.	Anderson C, 2011, LANCET NEUROL, V10, P43, DOI 10.1016/S1474-4422(10)70250-7; Anderson C, 2010, J HYPERTENS, V28, P429, DOI 10.1097/HJH.0b013e3283371355; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; Armando I, 2001, ENDOCRINOLOGY, V142, P3880, DOI 10.1210/en.142.9.3880; Bakris G, 2010, AM J CARDIOL, V105, p21A; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; CHIU AT, 1993, BIOCHEM BIOPH RES CO, V197, P440, DOI 10.1006/bbrc.1993.2499; Chrysant SG, 2010, CURR CLIN PHARMACOL, V5, P89, DOI 10.2174/157488410791110742; Cisneros IE, 2012, CURR HIV RES, V10, P392, DOI 10.2174/157016212802138832; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dandona P, 2003, J CLIN ENDOCR METAB, V88, P4496, DOI 10.1210/jc.2002-021836; Danielyan L, 2010, REJUV RES, V13, P195, DOI 10.1089/rej.2009.0944; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Duan SZ, 2009, CURR OPIN NEPHROL HY, V18, P128, DOI 10.1097/MNH.0b013e328325803b; Erbe DV, 2006, VASC PHARMACOL, V45, P154, DOI 10.1016/j.vph.2006.05.002; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Fogari R, 2004, EUR J CLIN PHARMACOL, V59, P863, DOI 10.1007/s00228-003-0717-9; Fujino M, 2010, HYPERTENS RES, V33, P1044, DOI 10.1038/hr.2010.135; Gao XM, 1995, BRAIN RES, V703, P63, DOI 10.1016/0006-8993(95)01066-1; Heemskerk FMJ, 1999, CELL MOL NEUROBIOL, V19, P277, DOI 10.1023/A:1006985329240; Hodgkinson CP, 2003, BIOCHEM BIOPH RES CO, V308, P505, DOI 10.1016/S0006-291X(03)01416-5; Hu SQ, 2013, NEUROCHEM INT, V62, P468, DOI 10.1016/j.neuint.2013.01.022; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Jezova D, 1998, J NEUROENDOCRINOL, V10, P67, DOI 10.1046/j.1365-2826.1998.00182.x; Ji YY, 2009, LAB INVEST, V89, P887, DOI 10.1038/labinvest.2009.45; KAISER FC, 1992, NEUROREPORT, V3, P922, DOI 10.1097/00001756-199210000-00026; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Koh EJ, 2013, BRIT J PHARMACOL, V169, P1404, DOI 10.1111/bph.12229; Konstam MA, 2009, LANCET, V374, P1840, DOI 10.1016/S0140-6736(09)61913-9; Kramer D, 2010, METHODS MOL BIOL, V633, P233, DOI 10.1007/978-1-59745-019-5_17; Kung J, 2012, EXPERT OPIN DRUG SAF, V11, P565, DOI 10.1517/14740338.2012.691963; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Leng Y, 2006, J NEUROSCI, V26, P7502, DOI 10.1523/JNEUROSCI.0096-06.2006; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Liu Z, 2012, CELL MOL NEUROBIOL, V32, P191, DOI 10.1007/s10571-011-9746-6; Min LJ, 2012, HYPERTENSION, V59, P1079, DOI 10.1161/HYPERTENSIONAHA.112.192401; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Miura S, 2011, J RENIN-ANGIO-ALDO S, V12, P1, DOI 10.1177/1470320310370852; Miyoshi M, 2008, EUR J NEUROSCI, V27, P343, DOI 10.1111/j.1460-9568.2007.06014.x; Mogi M, 2006, HYPERTENSION, V48, P141, DOI 10.1161/01.HYP.0000229648.67883.f9; Nakajima T., 2010, HYPERTENS RES, V33, P831; Nishimoto T, 2008, J NEUROSCI RES, V86, P1096, DOI 10.1002/jnr.21567; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Pang T, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-102; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Phillips MI, 2008, J MOL MED, V86, P715, DOI 10.1007/s00109-008-0331-5; Qi L, 2010, INT J CLIN EXP MED, V3, P283; Rotman N, 2010, PHYSIOLOGY, V25, P176, DOI 10.1152/physiol.00018.2010; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Savoia C, 2007, CLIN SCI, V112, P375, DOI 10.1042/CS20060247; Stangier J, 2000, J INT MED RES, V28, P149, DOI 10.1177/147323000002800401; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Suksomboon N, 2012, J CLIN PHARM THER, V37, P319, DOI 10.1111/j.1365-2710.2011.01295.x; Takaki J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-275; Tham DM, 2002, PHYSIOL GENOMICS, V11, P21, DOI 10.1152/physiolgenomics.00062.2002; Tian CH, 2008, J NEUROCHEM, V105, P994, DOI 10.1111/j.1471-4159.2007.05197.x; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Viviani B, 2003, J NEUROSCI, V23, P8692; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Yamakawa H, 2003, J CEREBR BLOOD F MET, V23, P371, DOI 10.1097/01.WCB.0000047369.05600.03; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao SM, 2008, CHINESE J PHYSIOL, V51, P357; Zhao Y, 2005, J NEUROCHEM, V94, P1395, DOI 10.1111/j.1471-4159.2005.03275.x; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082; Zhu D., 2011, PLOS ONE, V6; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062	83	63	67	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2014	79						249	261		10.1016/j.neuropharm.2013.11.022			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AE1ZX	WOS:000333774200026	24316465	Green Accepted			2021-06-18	
J	Qin, LY; Jing, DQ; Parauda, S; Carmel, J; Ratan, RR; Lee, FS; Cho, S				Qin, Luye; Jing, Deqiang; Parauda, Sarah; Carmel, Jason; Ratan, Rajiv R.; Lee, Francis S.; Cho, Sunghee			An Adaptive Role for BDNF Val66Met Polymorphism in Motor Recovery in Chronic Stroke	JOURNAL OF NEUROSCIENCE			English	Article						BDNF; cerebral ischemia; gait; motor function; striatum; Val66Met polymorphism	ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; GENETIC VARIANT; MOUSE MODEL; MET ALLELE; PLASTICITY; CORTEX; INHIBITION; RECEPTOR	Little is known about the influence of genetic diversity on stroke recovery. One exception is the polymorphism in brain derived neurotrophic factor (BDNF), a critical neurotrophin for brain repair and plasticity. Humans have a high-frequency single nucleotide polymorphism (SNP) in the prodomain of the BDNF gene. Previous studies show that the BDNF Val66Met variant negatively affects motor learning and severity of acute stroke. To investigate the impact of this common BDNF SNP on stroke recovery, we used a mouse model that contains the human BDNF Val66Met variant in both alleles (BDNFM/M). Male BDNF+/+ and BDNFM/M littermates received sham or transient middle cerebral artery occlusion. We assessed motor function regularly for 6 months after stroke and then performed anatomical analyses. Despite reported negative association of the SNP with motor learning and acute deficits, we unexpectedly found that BDNFM/M mice displayed significantly enhanced motor/kinematic performance in the chronic phase of motor recovery, especially in ipsilesional hindlimb. The enhanced recovery was associated with significant increases in striatum volume, dendritic arbor, and elevated excitatory synaptic markers in the contralesional striatum. Transient inactivation of the contralateral striatum during recovery transiently abolished the enhanced function. This study showed an unexpected benefit of the BDNFVal66Met carriers for functional recovery, involving structural and molecular plasticity in the nonstroked hemisphere. Clinically, this study suggests a role for BDNF genotype in predicting stroke recovery and identifies a novel systems-level mechanism for enhanced motor recovery.	[Qin, Luye; Parauda, Sarah; Carmel, Jason; Ratan, Rajiv R.; Cho, Sunghee] Burke Med Res Inst, Weill Cornell Med Coll, White Plains, NY 10605 USA; [Jing, Deqiang; Lee, Francis S.] Weill Cornell Med Coll, New York, NY 10021 USA	Cho, S (corresponding author), Burke Med Res Inst, Weill Cornell Med Coll, Dept Neurosci, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	suc2002@med.cornell.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1RR024996, NS077897, HL082511, NS073796]; Dr. Miriam and Sheldon G. Adelson Foundation; Burke Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000457] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077897, K08NS073796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG014930] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health under award numbers UL1RR024996 (to S. C. and F. L.), NS077897 and HL082511 (to S. C.), and NS073796 (to J.C.), Dr. Miriam and Sheldon G. Adelson Foundation (to R. R.), and the Burke Foundation (to S. C.). We thank C. Beltran and S. Bhosle for technical assistance and Dr. E. Shipp and N. Geibel for editorial assistance.	BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; Bateup HS, 2010, P NATL ACAD SCI USA, V107, P14845, DOI 10.1073/pnas.1009874107; Bejot Y, 2008, STROKE, V39, P1945, DOI 10.1161/STROKEAHA.107.510933; Brown P, 1996, BRAIN, V119, P309, DOI 10.1093/brain/119.1.309; Calautti C, 2001, STROKE, V32, P2534, DOI 10.1161/hs1101.097401; Carmichael S Thomas, 2005, NeuroRx, V2, P396; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Clarkson AN, 2011, J NEUROSCI, V31, P3766, DOI 10.1523/JNEUROSCI.5780-10.2011; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Cline H, 2005, CURR BIOL, V15, pR203, DOI 10.1016/j.cub.2005.03.010; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Dang MT, 2006, P NATL ACAD SCI USA, V103, P15254, DOI 10.1073/pnas.0601758103; Darling WG, 2011, EXP NEUROL, V231, P56, DOI 10.1016/j.expneurol.2011.05.015; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gerasimenko Y, 2008, EXP NEUROL, V209, P417, DOI 10.1016/j.expneurol.2007.07.015; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Gonzalez CLR, 2004, EUR J NEUROSCI, V20, P3442, DOI 10.1111/j.1460-9568.2004.03751.x; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Harris Jocelyn E, 2004, Physiother Can, V56, P171, DOI 10.2310/6640.2004.00017; He XM, 2007, NEUROPSYCHOBIOLOGY, V55, P151, DOI 10.1159/000106473; Hong EJ, 2008, NEURON, V60, P610, DOI 10.1016/j.neuron.2008.09.024; Kermani P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655; Kim E, 2008, J NEUROSCI, V28, P4661, DOI 10.1523/JNEUROSCI.0982-08.2008; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Kline DD, 2010, J NEUROSCI, V30, P5303, DOI 10.1523/JNEUROSCI.5503-09.2010; Kozorovitskiy Y, 2012, NATURE, V485, P646, DOI 10.1038/nature11052; Kreitzer AC, 2008, NEURON, V60, P543, DOI 10.1016/j.neuron.2008.11.005; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P1217, DOI 10.1001/archneur.55.9.1217; Martin JH, 1999, J NEUROSCI METH, V86, P145, DOI 10.1016/S0165-0270(98)00163-0; McHughen SA, 2010, CEREB CORTEX, V20, P1254, DOI 10.1093/cercor/bhp189; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Mirowska-Guzel D, 2012, J NEUROIMMUNOL, V249, P71, DOI 10.1016/j.jneuroim.2012.04.011; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Pandian S, 2013, J BODYW MOV THER, V17, P495, DOI 10.1016/j.jbmt.2013.03.008; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Qin LY, 2011, J NEUROSCI, V31, P775, DOI 10.1523/JNEUROSCI.4547-10.2011; Rossignol S, 2006, PHILOS T R SOC B, V361, P1647, DOI 10.1098/rstb.2006.1889; Schaefer SY, 2009, NEUROPSYCHOLOGIA, V47, P2953, DOI 10.1016/j.neuropsychologia.2009.06.025; Seil FJ, 2000, J NEUROSCI, V20, P5367, DOI 10.1523/JNEUROSCI.20-14-05367.2000; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; SWANSON LW, 1995, TRENDS NEUROSCI, V18, P471, DOI 10.1016/0166-2236(95)92766-J; van Meer MPA, 2010, J NEUROSCI, V30, P3964, DOI 10.1523/JNEUROSCI.5709-09.2010; Vilkki J, 2008, NEUROSURGERY, V63, P198, DOI 10.1227/01.NEU.0000320382.21577.8E; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Xie YX, 2010, J NEUROSCI, V30, P14708, DOI 10.1523/JNEUROSCI.1637-10.2010; Zeiler SR, 2013, STROKE, V44, P483, DOI 10.1161/STROKEAHA.112.676940; Zhang JY, 2010, NEUROIMAGE, V49, P2340, DOI 10.1016/j.neuroimage.2009.10.027	55	63	64	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 12	2014	34	7					2493	2502		10.1523/JNEUROSCI.4140-13.2014			10	Neurosciences	Neurosciences & Neurology	AB2HV	WOS:000331614700012	24523540	Green Published, Bronze			2021-06-18	
J	Pugh, MJV; Finley, EP; Copeland, LA; Wang, CP; Noel, PH; Amuan, ME; Parsons, HM; Wells, M; Elizondo, B; Pugh, JA				Pugh, Mary Jo V.; Finley, Erin P.; Copeland, Laurel A.; Wang, Chen-Pin; Noel, Polly H.; Amuan, Megan E.; Parsons, Helen M.; Wells, Margaret; Elizondo, Barbara; Pugh, Jacqueline A.			Complex Comorbidity Clusters in OEF/OIF Veterans The Polytrauma Clinical Triad and Beyond	MEDICAL CARE			English	Article						Afghan Campaign 2001 (Operation Enduring Freedom); comorbidity; Iraq War 2003 (Operation Iraqi Freedom); veterans	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH DISORDERS; OPERATION-IRAQI-FREEDOM; ENDURING FREEDOM; US VETERANS; WAR; AFGHANISTAN; PAIN; CARE	Background:A growing body of research on US Veterans from Afghanistan and Iraq [Operations Enduring and Iraqi Freedom, and Operation New Dawn (OEF/OIF)] has described the polytrauma clinical triad (PCT): traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and pain. Extant research has not explored comorbidity clusters in this population more broadly, particularly co-occurring chronic diseases.Objectives:The aim of the study was to identify comorbidity clusters among diagnoses of deployment-specific (TBI, PTSD, pain) and chronic (eg, hypertension, diabetes) conditions, and to examine the association of these clusters with health care utilization and adverse outcomes.Research Design:This was a retrospective cohort study.Subjects:The cohort comprised OEF/OIF Veterans who received care in the Veterans Health Administration in fiscal years (FY) 2008-2010.Measures:We identified comorbidity using validated ICD-9-CM code-based algorithms and FY08-09 data, followed by which we applied latent class analysis to identify the most statistically distinct and clinically meaningful patterns of comorbidity. We examined the association of these clusters with process measures/outcomes using logistic regression to correlate medication use, acute health care utilization, and adverse outcomes in FY10.Results:In this cohort (N=191,797), we found 6 comorbidity clusters. Cluster 1: PCT+Chronic Disease (5%); Cluster 2: PCT (9%); Cluster 3: Mental Health+Substance Abuse (24%); Cluster 4: Sleep, Amputation, Chronic Disease (4%); Cluster 5: Pain, Moderate PTSD (6%); and Cluster 6: Relatively Healthy (53%). Subsequent health care utilization patterns and adverse events were consistent with disease patterns.Conclusions:These comorbidity clusters extend beyond the PCT and may be used as a foundation to examine coordination/quality of care and outcomes for OEF/OIF Veterans with different patterns of comorbidity.	[Pugh, Mary Jo V.; Finley, Erin P.; Wang, Chen-Pin; Noel, Polly H.; Wells, Margaret; Elizondo, Barbara; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; [Pugh, Mary Jo V.; Wang, Chen-Pin; Parsons, Helen M.; Wells, Margaret; Elizondo, Barbara] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Pugh, Mary Jo V.; Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Bryan, TX USA; [Finley, Erin P.; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA; [Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA; [Copeland, Laurel A.] Scott & White Healthcare Syst, Temple, TX USA; [Amuan, Megan E.] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA; [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA	Pugh, MJV (corresponding author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	Maryjo.pughm@uthscsa.edu	Copeland, Laurel A/C-3763-2017; Pugh, Mary Jo/K-5336-2019; Pugh, Jacqueline/I-6199-2013	Copeland, Laurel A/0000-0002-9478-0209; Pugh, Mary Jo/0000-0003-4196-7763; Noel, Polly/0000-0002-1519-7489; Finley, Erin/0000-0003-4497-7721; Pugh, Jacqueline/0000-0003-4933-141X	Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; Veterans AffairsUS Department of Veterans Affairs [I01HX000329] Funding Source: NIH RePORTER	Funded by the Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237).	Agency for Healthcare Research and Quality, MULT CHRON COND; Bandeen-Roche K, 1997, J AM STAT ASSOC, V92, P1375, DOI 10.2307/2965407; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carter AC, 2011, J DUAL DIAGN, V7, P285, DOI 10.1080/15504263.2011.620453; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Cohen BE, 2009, JAMA-J AM MED ASSOC, V302, P489, DOI 10.1001/jama.2009.1084; Defense Science Board Task Force, 2007, DEPL MEMB NAT GUARD; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Frayne SM, 2011, J GEN INTERN MED, V26, P33, DOI 10.1007/s11606-010-1497-4; Gailey R, 2010, J REHABIL RES DEV, V47, P317, DOI 10.1682/JRRD.2009.04.0039; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Morgan RO, 2005, HEALTH SERV RES, V40, P1573, DOI 10.1111/j.1475-6773.2005.00448.x; Nazarian D, 2012, J TRAUMA STRESS, V25, P220, DOI 10.1002/jts.21690; Petrakis IL, 2011, AM J ADDICTION, V20, P185, DOI 10.1111/j.1521-0391.2011.00126.x; Pietrzak RH, 2011, J PSYCHIATR RES, V45, P1579, DOI 10.1016/j.jpsychires.2011.07.010; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Shepperd S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000086; Sullenberger L, 2008, MIL MED, V173, P193, DOI 10.7205/MILMED.173.2.193; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Whitty JA, 2011, APPL HEALTH ECON HEA, V9, P73, DOI [10.1097/SLA.0b013e31820752e3, 10.2165/11537150-000000000-00000]; Zouris JM, 2008, MIL MED, V173, P247, DOI 10.7205/MILMED.173.3.247	34	63	63	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079	1537-1948		MED CARE	Med. Care	FEB	2014	52	2					172	181		10.1097/MLR.0000000000000059			10	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	AA4SS	WOS:000331087100014	24374417				2021-06-18	
J	Powers, KC; Kalmar, JM; Cinelli, ME				Powers, Kaley C.; Kalmar, Jayne M.; Cinelli, Michael E.			Recovery of static stability following a concussion	GAIT & POSTURE			English	Article						Concussion; Static balance; Return-to-play; Centre of pressure	ADAPTATION; BALANCE; STANCE; SPORT	The purpose of this study was to use centre of pressure (COP) measurements to determine if static balance deficits had recovered when concussed athletes were cleared to return to play. Nine concussed varsity football players were matched with nine teammates who served as controls. Static balance in the anterior-posterior (A/P) and medial-lateral (M/L) directions was assessed during quiet stance with eyes open and eyes closed. Results showed that concussed football players displayed greater A/P COP displacements in the acute phase, which recovered by RTP; however, COP velocity remained elevated compared to controls even at RTP, particularly in the A/P direction. This balance control deficit in the A/P direction may suggest vestibular impairment, likely due to poor sensorimotor integration of the lateral vestibulospinal tract. The observed persistence of balance control deficits in concussed football players at RTP are usually undetected by traditional assessments because the current study used higher-order COP analysis. Future RTP balance measures may want to incorporate higher-order measures of balance. (C) 2013 Elsevier B. V. All rights reserved.	[Powers, Kaley C.; Kalmar, Jayne M.; Cinelli, Michael E.] Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, Waterloo, ON N2L 3C5, Canada	Cinelli, ME (corresponding author), Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, 75 Univ Ave,W Rm 501, Waterloo, ON N2L 3C5, Canada.	mcinelli@wlu.ca	Cinelli, Michael/ABE-7625-2020	Cinelli, Michael/0000-0002-5802-2590	NSERC DiscoveryNatural Sciences and Engineering Research Council of Canada (NSERC) [386601]	This project was funded through an NSERC Discovery Grant (386601).	Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Highstein SM, 2012, ANAT REC, V295, P2000, DOI 10.1002/ar.22582; Masani K, 2003, J NEUROPHYSIOL, V90, P3774, DOI 10.1152/jn.00730.2002; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; WINTER DA, 1990, MED PROG TECHNOL, V16, P31	14	63	63	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	JAN	2014	39	1					611	614		10.1016/j.gaitpost.2013.05.026			4	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	259QS	WOS:000327542000104	23810088				2021-06-18	
J	Zuckerman, SL; Apple, RP; Odom, MJ; Lee, YM; Solomon, GS; Sills, AK				Zuckerman, Scott L.; Apple, Rachel P.; Odom, Mitchell J.; Lee, Young M.; Solomon, Gary S.; Sills, Allen K.			Effect of sex on symptoms and return to baseline in sport-related concussion Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; sports; sex; mild traumatic brain injury; symptoms; return to baseline; trauma	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; GENDER; SPECIFICITY; SENSITIVITY; PERFORMANCE; ZURICH	Object. Sport-related concussions (SRCs) among youth athletes represent a significant public health concern. Prior research suggests that females fare worse symptomatically after an SRC. The authors aimed to assess sex differences in number, severity, and resolution of postconcussive symptoms using reliable change index (RCI) methodology applied to days to return to symptom baseline. Methods. Between 2009 and 2011, 740 youth athletes completed valid neurocognitive and symptom testing before and after an SRC using Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT). A total of 122 female and 122 male athletes were matched on number of prior concussions, age, and number of days to first postconcussion test. At baseline and postconcussion, the authors compared each of the individual 22 symptoms on ImPACT to calculate individual symptom severity and aggregate symptom severity, or the Total Symptom Score (TSS). When comparing individual symptoms, the significance level for the comparison of each symptom was set at 0.05/22 = 0.0023. When comparing aggregate symptom severity, or TSS, a single value was compared, requiring an alpha set to 0.05. The number of days to return to baseline TSS was compared using RCI methods set at the 80% confidence interval, equal to a raw score point value of 9.18 on the TSS. Results. At baseline, females reported a greater severity for the symptom, "sleeping less than usual," compared with males (0.88 +/- 1.49 vs 0.31 +/- 0.86, p < 0.001). However, no other individual symptom severity differences were noted before or after SRC. At baseline, females exhibited a statistically significant greater aggregate symptom severity than males (7.24 +/- 10.22 vs 4.10 +/- 6.52, p = 0.005). Greater aggregate symptom severity for females was also found postconcussion (21.38 +/- 19.02 vs 16.80 +/- 17.07, p = 0.049). Females took longer to return to baseline TSS (9.1 +/- 7.1 days vs 7.0 +/- 5.1 days, p = 0.013). Conclusions. The results of this retrospective study indicate that females endorse a greater severity of symptoms at baseline and postconcussion than males without significantly different symptom profiles. Furthermore, after suffering an SRC, females take longer to return to their baseline symptom level.	[Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN USA; [Apple, Rachel P.] Vanderbilt Univ, Sch Med, Dept Med & Pediat, Nashville, TN 37232 USA; [Odom, Mitchell J.; Lee, Young M.] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA	Zuckerman, SL (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, T-4224 Med Ctr N, Nashville, TN 37232 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019; Meijer, Anna/K-5118-2016				ADLER A, 1945, ARCH NEURO PSYCHIATR, V53, P34, DOI 10.1001/archneurpsyc.1945.02300010044003; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; BROSHEK DK, 2012, J CHILD NEUROL; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Granito VJ., 2002, J SPORT BEHAV, V25, P243; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; *NAT COLL ATHL ASS, 2010, 1981 82 2008 09 NCAA; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RUTHERFORD WH, 1977, LANCET, V1, P1; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Weiss E, 2003, NEUROSCI LETT, V344, P169, DOI 10.1016/S0304-3940(03)00406-3; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	44	63	63	0	21	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JAN	2014	13	1					72	81		10.3171/2013.9.PEDS13257			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	281GM	WOS:000329088000013	24206343				2021-06-18	
J	Risbud, RM; Porter, BE				Risbud, Rashmi M.; Porter, Brenda E.			Changes in MicroRNA Expression in the Whole Hippocampus and Hippocampal Synaptoneurosome Fraction following Pilocarpine Induced Status Epilepticus	PLOS ONE			English	Article							KINASE-II ACTIVITY; CONTROLS DENDRITIC PLASTICITY; ACTIVITY-REGULATED MICRORNA; TRAUMATIC BRAIN-INJURY; NEURONAL CULTURE MODEL; TEMPORAL-LOBE EPILEPSY; IN-VIVO; SEIZURES; MORPHOGENESIS; DECREASE	MicroRNAs regulate protein synthesis by binding non-translated regions of mRNAs and suppressing translation and/or increasing mRNA degradation. MicroRNAs play an important role in the nervous system including controlling synaptic plasticity. Their expression is altered in disease states including stroke, head injury and epilepsy. To better understand microRNA expression changes that might contribute to the development of epilepsy, microRNA arrays were performed on rat hippocampus 4 hours, 48 hours and 3 weeks following an episode of pilocarpine induced status epilepticus. Eighty microRNAs increased at one or more of the time points. No microRNAs decreased at 4 hours, and only a few decreased at 3 weeks, but 188 decreased 48 hours after status epilepticus. The large number of microRNAs with altered expression following status epilepticus suggests that microRNA regulation of translation has the potential to contribute to changes in protein expression during epileptogenesis. We carried out a second set of array's comparing microRNA expression at 48 hours in synaptoneurosome and nuclear fractions of the hippocampus. In control rat hippocampi multiple microRNAs were enriched in the synaptoneurosomal fraction as compared to the nuclear fraction. In contrast, 48 hours after status epilepticus only one microRNA was enriched in the synaptoneurosome fraction. The loss of microRNAs enriched in the synaptoneurosomal fraction implies a dramatic change in translational regulation in synapses 48 hours after status epilepticus.	[Risbud, Rashmi M.; Porter, Brenda E.] Childrens Hosp Philadelphia, Dept Pediat, Div Pediat Neurol, Philadelphia, PA 19104 USA; [Porter, Brenda E.] Univ Penn, Perelman Sch Med, Dept Neurol, Div Pediat Neurol, Philadelphia, PA 19104 USA	Porter, BE (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Pediat Neurol, Philadelphia, PA 19104 USA.	Brenda2@stanford.edu			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)	NINDS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman Naomi, 2005, Appl Bioinformatics, V4, P33, DOI 10.2165/00822942-200504010-00004; Aronica E, 2010, EUR J NEUROSCI, V31, P1100, DOI 10.1111/j.1460-9568.2010.07122.x; Bail S, 2010, RNA, V16, P1032, DOI 10.1261/rna.1851510; Blair RE, 1999, BRAIN RES, V851, P54, DOI 10.1016/S0006-8993(99)02100-9; Blair RE, 2008, EUR J PHARMACOL, V588, P64, DOI 10.1016/j.ejphar.2008.04.021; Booth RFG, 1978, BIOCHEM SOC T, V6, P128, DOI 10.1042/bst0060128; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Ceman S, 2011, PHARMACOL THERAPEUT, V130, P26, DOI 10.1016/j.pharmthera.2011.01.004; Churn SB, 2000, BRAIN RES, V875, P66, DOI 10.1016/S0006-8993(00)02623-8; Cougot N, 2008, J NEUROSCI, V28, P13793, DOI 10.1523/JNEUROSCI.4155-08.2008; Glanzer J, 2005, P NATL ACAD SCI USA, V102, P16859, DOI 10.1073/pnas.0503783102; Guo DJ, 2012, NEUROBIOL DIS, V45, P348, DOI 10.1016/j.nbd.2011.08.020; Hu K, 2011, NEUROSCI LETT, V488, P252, DOI 10.1016/j.neulet.2010.11.040; Huang YF, 2002, J NEUROSCI, V22, P8422; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Kim YK, 2011, MOL CELL, V43, P1005, DOI 10.1016/j.molcel.2011.07.031; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039; Kye MJ, 2007, RNA, V13, P1224, DOI 10.1261/rna.480407; Lambert TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015182; Lee K, 2012, J NEUROSCI, V32, P5678, DOI 10.1523/JNEUROSCI.6471-11.2012; Lippi G, 2011, J CELL BIOL, V194, P889, DOI 10.1083/jcb.201103006; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lugli G, 2008, J NEUROCHEM, V106, P650, DOI 10.1111/j.1471-4159.2008.05413.x; McKiernan RC, 2012, EXP NEUROL, V237, P346, DOI 10.1016/j.expneurol.2012.06.029; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; Pichardo-Casas I, 2012, BRAIN RES, V1436, P20, DOI 10.1016/j.brainres.2011.12.001; Poon MM, 2006, J NEUROSCI, V26, P13390, DOI 10.1523/JNEUROSCI.3432-06.2006; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raol YH, 2006, J NEUROSCI, V26, P11342, DOI 10.1523/JNEUROSCI.3329-06.2006; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rensing N, 2005, ANN NEUROL, V58, P888, DOI 10.1002/ana.20658; Risbud RM, 2011, BRAIN RES, V1424, P53, DOI 10.1016/j.brainres.2011.09.039; Ross JR, 2011, J NEUROCHEM, V117, P812, DOI 10.1111/j.1471-4159.2011.07233.x; Sano T, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.23; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Siegel G, 2009, NAT CELL BIOL, V11, P705, DOI 10.1038/ncb1876; Song YJ, 2011, BRAIN RES, V1387, P134, DOI 10.1016/j.brainres.2011.02.073; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; Tsai CA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng052; Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102; Wayman GA, 2008, P NATL ACAD SCI USA, V105, P9093, DOI 10.1073/pnas.0803072105; Wong M, 2012, NEUROSCIENCE; Zeng LH, 2007, J NEUROSCI, V27, P11604, DOI 10.1523/JNEUROSCI.0983-07.2007	47	63	65	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2013	8	1							e53464	10.1371/journal.pone.0053464			16	Multidisciplinary Sciences	Science & Technology - Other Topics	069IS	WOS:000313429100071	23308228	DOAJ Gold, Green Published			2021-06-18	
J	Hosp, JA; Luft, AR				Hosp, Jonas A.; Luft, Andreas R.			Dopaminergic meso-cortical projections to M1: role in motor learning and motor cortex plasticity	FRONTIERS IN NEUROLOGY			English	Article						dopamine; motor cortex; motor learning; cortical plasticity; memory		Although the architecture of a dopaminergic (DA) system within the primary motor cortex (M1) was well characterized anatomically, its functional significance remained obscure for a long time. Recent studies in rats revealed that the integrity of DA fibers in M1 is a prerequisite for successful acquisition of motor skills. This essential contribution of DA for motor learning is plausible as it modulates M1 circuitry at multiple levels thereby promoting plastic changes that are required for information storage: at the network level, DA increases cortical excitability and enhances the stability of motor maps. At the cellular level, DA induces the expression of learning-related genes via the transcription factor c-Fos. At the level of synapses, DA is required for the formation of long-term potentiation, a mechanism that likely is a fingerprint of a motor memory trace within M1. DA fibers innervating M1 originate within the midbrain, precisely the ventral tegmental area (VTA) and the medial portion of substantia nigra (SN). Thus, they could be part of the meso-cortico-limbic pathway a network that provides information about saliency and motivational value of an external stimulus and is commonly referred as "reward system." However, the behavioral triggers of the release of dopamine in M1 are not yet identified. As alterations in DA transmission within M1 occur under various pathological conditions such as Parkinson disease or ischemic and traumatic brain injury, a deeper understanding of the interaction of VTA/SN and M1 may reveal a deeper insight into a large spectrum of neurological disorders.	[Hosp, Jonas A.; Luft, Andreas R.] Univ Zurich, Dept Neurol, Clin Neurorehabil, CH-8091 Zurich, Switzerland; [Hosp, Jonas A.; Luft, Andreas R.] RITZ, Rehabil Initiat & Technol Ctr Zurich, Zurich, Switzerland; [Luft, Andreas R.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA	Luft, AR (corresponding author), Univ Zurich, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	andreas.luft@usz.ch					ARIANO MA, 1993, BRAIN RES, V609, P71, DOI 10.1016/0006-8993(93)90857-J; Asanuma H, 1997, NEUROREPORT, V8, pR1; Awenowicz PW, 2002, J NEUROPHYSIOL, V88, P3439, DOI 10.1152/jn.00078.2002; Berardelli A, 1996, BRAIN, V119, P71, DOI 10.1093/brain/119.1.71; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BERGER B, 1985, NEUROSCIENCE, V15, P983, DOI 10.1016/0306-4522(85)90248-9; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Boroojerdi B, 2002, J CLIN NEUROPHYSIOL, V19, P255, DOI 10.1097/00004691-200208000-00002; Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022; Buitrago MM, 2004, BEHAV BRAIN RES, V155, P249, DOI 10.1016/j.bbr.2004.04.025; Chudasama Y, 2004, NEUROPSYCHOPHARMACOL, V29, P1628, DOI 10.1038/sj.npp.1300490; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DEUTCH AY, 1988, ANN NY ACAD SCI, V537, P27, DOI 10.1111/j.1749-6632.1988.tb42095.x; FALLON JH, 1981, J NEUROSCI, V1, P1361; Floel A, 2005, NEUROLOGY, V65, P472, DOI 10.1212/01.wnl.0000172340.56307.5e; Floel A, 2005, ANN NEUROL, V58, P121, DOI 10.1002/ana.20536; Floel A, 2008, EUR J NEUROSCI, V27, P1301, DOI 10.1111/j.1460-9568.2008.06079.x; Floresco SB, 2006, PSYCHOPHARMACOLOGY, V188, P567, DOI 10.1007/s00213-006-0404-5; FOOTE SL, 1987, CURR TOP DEV BIOL, V21, P391; FRITH CD, 1986, PSYCHIATRY, V49, P661, DOI DOI 10.1136/JNNP.49.6.661; GARRIS PA, 1994, J NEUROSCI, V14, P442; GASPAR P, 1991, ANN NEUROL, V30, P365, DOI 10.1002/ana.410300308; GASPAR P, 1989, J COMP NEUROL, V279, P249, DOI 10.1002/cne.902790208; GERMAN DC, 1993, J COMP NEUROL, V331, P297, DOI 10.1002/cne.903310302; Hikosaka O, 2002, CURR OPIN NEUROBIOL, V12, P217, DOI 10.1016/S0959-4388(02)00307-0; Hosp JA, 2009, NEUROSCIENCE, V159, P692, DOI 10.1016/j.neuroscience.2008.12.056; Hosp JA, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/871296; Hosp JA, 2011, J NEUROSCI, V31, P2481, DOI 10.1523/JNEUROSCI.5411-10.2011; Hosp JA, 2011, NEUROIMAGE, V54, P154, DOI 10.1016/j.neuroimage.2010.07.029; IRIKI A, 1989, SCIENCE, V245, P1385, DOI 10.1126/science.2551038; Kishore A, 2012, BRAIN, V135, P2074, DOI 10.1093/brain/aws124; Kishore A, 2012, CLIN NEUROPHYSIOL, V123, P822, DOI 10.1016/j.clinph.2011.06.034; Kleim JA, 2004, J NEUROSCI, V24, P628, DOI 10.1523/JNEUROSCI.3440-03.2004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Kleim JA, 1996, J NEUROSCI, V16, P4529; Lammel S, 2008, NEURON, V57, P760, DOI 10.1016/j.neuron.2008.01.022; LEPORE F, 1986, 2 HEMISPHERES ONE BR; LEWIS DA, 1987, J NEUROSCI, V7, P279; Lokk J, 2011, ACTA NEUROL SCAND, V123, P266, DOI 10.1111/j.1600-0404.2010.01395.x; LOUGHLIN SE, 1984, NEUROSCIENCE, V11, P425, DOI 10.1016/0306-4522(84)90034-4; Luft AR, 2005, MOL NEUROBIOL, V32, P205, DOI 10.1385/MN:32:3:205; Luft AR, 2004, J NEUROSCI, V24, P6515, DOI 10.1523/JNEUROSCI.1034-04.2004; McRitchie DA, 1997, EXP NEUROL, V144, P202, DOI 10.1006/exnr.1997.6418; Meintzschel F, 2006, CEREB CORTEX, V16, P1106, DOI 10.1093/cercor/bhj052; Molina-Luna K, 2008, NEUROIMAGE, V40, P1748, DOI 10.1016/j.neuroimage.2007.11.018; Molina-Luna K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007082; Monfils MH, 2005, NEUROSCIENTIST, V11, P471, DOI 10.1177/1073858405278015; Moore RY, 2008, NEUROBIOL DIS, V29, P381, DOI 10.1016/j.nbd.2007.09.004; Morgante F, 2006, BRAIN, V129, P1059, DOI 10.1093/brain/awl031; Mundorf ML, 2001, J NEUROCHEM, V79, P130, DOI 10.1046/j.1471-4159.2001.00554.x; Nudo RJ, 1996, J NEUROSCI, V16, P785; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037; Pearson-Fuhrhop KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061197; Raghanti MA, 2008, NEUROSCIENCE, V155, P203, DOI 10.1016/j.neuroscience.2008.05.008; Rioult-Pedotti MS, 2007, J NEUROPHYSIOL, V98, P3688, DOI 10.1152/jn.00164.2007; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; SAKAMOTO T, 1989, BRAIN RES, V503, P258, DOI 10.1016/0006-8993(89)91672-7; SAVASTA M, 1986, BRAIN RES, V375, P291, DOI 10.1016/0006-8993(86)90749-3; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722; Schultz W, 2007, TRENDS NEUROSCI, V30, P203, DOI 10.1016/j.tins.2007.03.007; Seamans JK, 2004, PROG NEUROBIOL, V74, P1, DOI 10.1016/j.pneurobio.2004.05.006; Suppa A, 2011, EXP NEUROL, V227, P296, DOI 10.1016/j.expneurol.2010.11.020; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; Ueki Y, 2006, ANN NEUROL, V59, P60, DOI 10.1002/ana.20692; Verschueren SMP, 1997, EXP BRAIN RES, V113, P497, DOI 10.1007/PL00005602; Wang JQ, 1997, J PHARMACOL EXP THER, V281, P972; Williams SM, 1998, CEREB CORTEX, V8, P321, DOI 10.1093/cercor/8.4.321; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Ziemann U, 1997, ELECTROMYOGR MOTOR C, V105, P430, DOI 10.1016/S0924-980X(97)00050-7	74	63	63	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								145	10.3389/fneur.2013.00145			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QT	WOS:000209629000144	24109472	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Wright, RM; Post, A; Hoshizaki, B; Ramesh, KT				Wright, Rika M.; Post, Andrew; Hoshizaki, Blaine; Ramesh, Kaliat T.			A Multiscale Computational Approach to Estimating Axonal Damage under Inertial Loading of the Head	JOURNAL OF NEUROTRAUMA			English	Article						axonal strain; DAI; FE model; traumatic brain injury	IN-VITRO; BRAIN RESPONSES; INJURY; MODELS; FOOTBALL; CRITERIA; IMPACTS; TRAUMA	A computational modeling framework is developed to estimate the location and degree of diffuse axonal injury (DAI) under inertial loading of the head. DAI is one of the most common pathological features of traumatic brain injury and is characterized by damage to the neural axons in the white matter regions of the brain. We incorporate the microstructure of the white matter (i.e., the fiber orientations and fiber dispersion) through the use of diffusion tensor imaging (DTI), and model the white matter with an anisotropic, hyper-viscoelastic constitutive model. The extent of DAI is estimated using an axonal strain injury criterion. A novel injury analysis method is developed to quantify the degree of axonal damage in the fiber tracts of the brain and identify the tracts that are at the greatest risk for functional failure. Our modeling framework is applied to analyze DAI in a real-life ice hockey incident that resulted in concussive injury. To simulate the impact, two-dimensional finite element (FE) models of the head were constructed from detailed MRI and DTI data and validated using available human head experimental data. Acceleration loading curves from accident reconstruction data were then applied to the FE models. The rotational (rather than translational) accelerations were shown to dominate the injury response, which is consistent with previous studies. Through this accident reconstruction, we demonstrate a conceptual framework to estimate the degree of axonal injury in the fiber tracts of the human brain, enabling the future development of relationships between computational simulation and neurocognitive impairment.	[Wright, Rika M.; Ramesh, Kaliat T.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; [Post, Andrew; Hoshizaki, Blaine] Univ Ottawa, Dept Human Kinet, Neurotrauma Impact Sci Lab, Ottawa, ON, Canada	Wright, RM (corresponding author), Johns Hopkins Univ, Dept Mech Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	rika@jhu.edu		Post, Andrew/0000-0002-5960-5552	National Science FoundationNational Science Foundation (NSF); Center for Advanced Metallic and Ceramic Systems	We gratefully acknowledge Dr. Susumu Mori at the Johns Hopkins University School of Medicine for providing the medical imaging data used in this study, and Dr. Reuben Kraft at the Army Research Laboratory (ARL) for providing access to ARL's High Performance Computing Systems. This work was supported by a National Science Foundation Graduate Research Fellowship and by the Center for Advanced Metallic and Ceramic Systems. Dr. Wright developed the modeling framework, conducted the computational analysis, and prepared the manuscript, with assistance and advice on formulation from her doctoral advisor, Dr. Ramesh. Mr. Post provided the accelerometer data and provided clarification on the accident reconstruction procedure, and Dr. Hoshizaki provided insight on applications.	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bammer R, 2003, EUR J RADIOL, V45, P223, DOI 10.1016/S0720-048X(02)00311-X; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BOTTINI G, 1994, BRAIN, V117, P1241, DOI 10.1093/brain/117.6.1241; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cloots RJH, 2012, J MECH BEHAV BIOMED, V5, P41, DOI 10.1016/j.jmbbm.2011.09.012; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Feist F., 2009, 21 INT C ENH SAF VEH, P1; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Goldberg II, 2006, NEURON, V50, P329, DOI 10.1016/j.neuron.2006.03.015; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Itoh S., 2002, 12 INT DET S SAN DIE; Karnath HO, 2001, NATURE, V411, P950, DOI 10.1038/35082075; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Merodio J, 2005, INT J NONLIN MECH, V40, P213, DOI 10.1016/j.ijnontinmec.2004.05.003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nahum AM, 1977, INTRACRANIAL PRESSUR; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Post A., 2011, COMPUT METHODS BIOME; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Tamura A., 2006, J BIOMECH SCI ENG, V1, P304; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; van Dommelen J.A., 2012, BIOMECH MODEL MECHAN; van Dommelen J.A.W., 2008, J BIOMECH ENG, V130, P663; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Voo L, 1996, MED BIOL ENG COMPUT, V34, P375, DOI 10.1007/BF02520009; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Wittek A, 2003, JSME INT J C-MECH SY, V46, P1388, DOI 10.1299/jsmec.46.1388; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	60	63	65	1	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					102	118		10.1089/neu.2012.2418			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000006	22992118				2021-06-18	
J	Goodman, J; Leong, KC; Packard, MG				Goodman, Jarid; Leong, Kah-Chung; Packard, Mark G.			Emotional modulation of multiple memory systems: implications for the neurobiology of post-traumatic stress disorder	REVIEWS IN THE NEUROSCIENCES			English	Article						anxiety; brain; memory; stress; posttraumatic stress disorder	CEREBRAL-BLOOD-FLOW; OBSESSIVE-COMPULSIVE DISORDER; RESPONSE LEARNING-STRATEGIES; TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL VOLUME; CAUDATE-NUCLEUS; DORSAL STRIATUM; NEUROGENIC AMNESIA; DRUG-ADDICTION; LIFE EVENTS	In lower animals and humans, stress/anxiety can enhance dorsal striatal-dependent habit memory, at the expense of hippocampal-dependent cognitive memory. The present review considers the potential for this 'stress/anxiety-induced habit bias' to explain some aspects of post-traumatic stress disorder (PTSD). In rats, anxiety induced by peripheral or intra-amygdala infusions of anxiogenic drugs can enhance habit memory and impair cognitive memory. In tasks in which both habit and cognitive memory processes may provide a learned solution, stress and drug-induced anxiety favors the use of habit memory. The effect of stress and anxiety on the use of multiple memory systems in rats depends on the functional integrity of the basolateral amygdala. Thus, under robust emotional arousal, amygdala activation can modulate the relative use of memory systems in a manner that favors habit memory. We propose a similar mechanism may underlie the development and persistence of some PTSD symptoms. The traumatic memories of PTSD patients can be deficient in hippocampus-dependent contextual or autobiographical aspects, and enhanced in responding to trauma related cues, which we suggest may reflect increased involvement of the dorsal striatum. We briefly consider the potential role of a stress/anxiety-induced habit bias with regard to other psychopathologies, including obsessive-compulsive disorder and drug addiction.	[Goodman, Jarid; Leong, Kah-Chung; Packard, Mark G.] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA	Packard, MG (corresponding author), Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.	mgp@psyc.tamu.edu					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armony JL, 2005, AM J PSYCHIAT, V162, P1961, DOI 10.1176/appi.ajp.162.10.1961; Astur RS, 2006, CYBERPSYCHOL BEHAV, V9, P234, DOI 10.1089/cpb.2006.9.234; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Berardi A, 2012, REV NEUROSCIENCE, V23, P645, DOI 10.1515/revneuro-2012-0054; Bohbot VD, 2007, J NEUROSCI, V27, P10078, DOI 10.1523/JNEUROSCI.1763-07.2007; Bohbot VD, 2011, NEUROBIOL LEARN MEM, V96, P173, DOI 10.1016/j.nlm.2011.04.007; Bonne O, 2001, AM J PSYCHIAT, V158, P1248, DOI 10.1176/appi.ajp.158.8.1248; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Bremner JD, 2006, ANN NY ACAD SCI, V1071, P80, DOI 10.1196/annals.1364.008; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 2001, HIPPOCAMPUS, V11, P75, DOI 10.1002/hipo.1023; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 2003, CLIN PSYCHOL REV, V23, P339, DOI 10.1016/S0272-7358(03)00033-3; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Britton JC, 2005, BIOL PSYCHIAT, V57, P832, DOI 10.1016/j.biopsych.2004.12.025; Brunet A, 2008, J PSYCHIATR RES, V42, P503, DOI 10.1016/j.jpsychires.2007.05.006; Brunetti M, 2010, NEUROSCIENCE, V168, P670, DOI 10.1016/j.neuroscience.2010.04.024; Bryant RA, 2005, CNS SPECTRUMS, V10, P116, DOI 10.1017/S1092852900019453; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; Carrion VG, 2001, BIOL PSYCHIAT, V50, P943, DOI 10.1016/S0006-3223(01)01218-5; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Cromer KR, 2007, BEHAV RES THER, V45, P2581, DOI 10.1016/j.brat.2007.06.005; Cromer KR, 2007, BEHAV RES THER, V45, P1683, DOI 10.1016/j.brat.2006.08.018; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.ne.15.030192.002033; De Bellis MD, 2001, BIOL PSYCHIAT, V50, P305, DOI 10.1016/S0006-3223(01)01105-2; Del Casale A, 2011, NEUROPSYCHOBIOLOGY, V64, P61, DOI 10.1159/000325223; Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6; Dickie EW, 2008, NEUROPSYCHOLOGIA, V46, P1522, DOI 10.1016/j.neuropsychologia.2008.01.007; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 2010, INT J PSYCHOPHYSIOL, V78, P27, DOI 10.1016/j.ijpsycho.2010.04.009; Elliott AE, 2008, NEUROBIOL LEARN MEM, V90, P616, DOI 10.1016/j.nlm.2008.06.012; Evans C, 2007, J CONSULT CLIN PSYCH, V75, P134, DOI 10.1037/0022-006X.75.1.134; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; EYSENCK HJ, 1976, BEHAV RES THER, V14, P251, DOI 10.1016/0005-7967(76)90001-2; FAMULARO R, 1988, AM J DIS CHILD, V142, P1244, DOI 10.1001/archpedi.1988.02150110122036; Fennema-Notestine C, 2002, BIOL PSYCHIAT, V52, P1089, DOI 10.1016/S0006-3223(02)01413-0; Ferragud A, 2010, BEHAV BRAIN RES, V210, P134, DOI 10.1016/j.bbr.2010.02.013; Ferreira TL, 2008, NEUROSCIENCE, V153, P84, DOI 10.1016/j.neuroscience.2008.02.013; Ferreira TL, 2003, BRAIN RES, V987, P17, DOI 10.1016/S0006-8993(03)03217-7; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; FOA EB, 1992, PSYCHOL BULL, V112, P218, DOI 10.1037/0033-2909.112.2.218; Francati V, 2007, DEPRESS ANXIETY, V24, P202, DOI 10.1002/da.20208; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Gillan CM, 2011, AM J PSYCHIAT, V168, P718, DOI 10.1176/appi.ajp.2011.10071062; Glantz M., 1992, VULNERABILITY DRUG A, P200; Golier JA, 2005, PSYCHIAT RES-NEUROIM, V139, P53, DOI 10.1016/j.pscychresns.2005.02.007; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; GUY AP, 1985, NEUROPSYCHOBIOLOGY, V13, P194, DOI 10.1159/000118187; Halligan SL, 2002, J BEHAV THER EXP PSY, V33, P73, DOI 10.1016/S0005-7916(02)00014-9; HANDLEY SL, 1984, N-S ARCH PHARMACOL, V327, P1, DOI 10.1007/BF00504983; Happle R, 2005, J AM ACAD DERMATOL, V52, P157, DOI 10.1016/j.jaad.2004.07.060; Harrison PA, 1997, CHILD ABUSE NEGLECT, V21, P529, DOI 10.1016/S0145-2134(97)00013-6; Hawley WR, 2011, BEHAV BRAIN RES, V216, P525, DOI 10.1016/j.bbr.2010.08.028; HIGGINS RL, 1975, J ABNORM PSYCHOL, V84, P644, DOI 10.1037/0021-843X.84.6.644; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; Horton A.M., 1991, ARCH CLIN NEUROPSYCH, V6, P195; Hughes KC, 2011, EXPERT REV NEUROTHER, V11, P275, DOI [10.1586/ern.10.198, 10.1586/ERN.10.198]; Hull C. L., 1943, PRINCIPLES BEHAV; KESNER RP, 1998, NEUROBIOLOGY LEARNIN, P361; Kim JJ, 2001, J NEUROSCI, V21, P5222, DOI 10.1523/JNEUROSCI.21-14-05222.2001; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Kindt M, 2008, J BEHAV THER EXP PSY, V39, P546, DOI 10.1016/j.jbtep.2007.12.003; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Koss MP, 1996, J ABNORM PSYCHOL, V105, P421, DOI 10.1037/0021-843X.105.3.421; Krauseneck T, 2010, PSYCHOL MED, V40, P861, DOI 10.1017/S0033291709990614; Krikorian R, 1998, J NEUROPSYCH CLIN N, V10, P359, DOI 10.1176/jnp.10.3.359; Landau D, 2011, J ANXIETY DISORD, V25, P192, DOI 10.1016/j.janxdis.2010.09.002; Laposa JM, 2012, J BEHAV THER EXP PSY, V43, P877, DOI 10.1016/j.jbtep.2011.12.007; Layton B, 2002, J NEUROPSYCH CLIN N, V14, P254, DOI 10.1176/appi.neuropsych.14.3.254; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LeDoux J, 2003, CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629; Lee T, 2009, NEUROREPORT, V20, P1554, DOI 10.1097/WNR.0b013e328332bb09; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Lindauer RJL, 2004, BIOL PSYCHIAT, V56, P853, DOI 10.1016/j.biopsych.2004.08.003; Linnman C, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-8; Lucey JV, 1997, BRIT J PSYCHIAT, V171, P346, DOI 10.1192/bjp.171.4.346; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Marlatt G, 1980, BEHAV MED CHANGING H, P410; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; McDonald RJ, 2004, NEUROBIOL LEARN MEM, V82, P333, DOI 10.1016/j.nlm.2004.05.009; McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI 10.1146/annurev.neuro.27.070203.144157; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; McKinnon AC, 2008, BEHAV RES THER, V46, P766, DOI 10.1016/j.brat.2008.02.008; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Mechanic MB, 1998, J CONSULT CLIN PSYCH, V66, P948, DOI 10.1037/0022-006X.66.6.948; Merz CJ, 2010, BEHAV NEUROSCI, V124, P288, DOI 10.1037/a0018942; Mickleborough MJS, 2011, J PSYCHIATR NEUROSCI, V36, P6, DOI 10.1503/jpn.080188; Milad MR, 2012, TRENDS COGN SCI, V16, P43, DOI 10.1016/j.tics.2011.11.003; Mishkin M., 1984, NE UR OPS YCHOL MEMO, P287; Mowrer O., 1960, LEARNING THEORY BEHA; Mowrer OH, 1947, HARVARD EDUC REV, V17, P102; Nadel L, 1998, CURR DIR PSYCHOL SCI, V7, P154, DOI 10.1111/1467-8721.ep10836842; NAGY J, 1979, NEUROPHARMACOLOGY, V18, P573, DOI 10.1016/0028-3908(79)90104-7; Nardo D, 2011, PSYCHOL MED, V41, P2549, DOI 10.1017/S0033291711000912; NEWCOMB MD, 1988, J ABNORM PSYCHOL, V97, P64, DOI 10.1037/0021-843X.97.1.64; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Osuch EA, 2001, BIOL PSYCHIAT, V50, P246, DOI 10.1016/S0006-3223(01)01107-6; Osuch EA, 2008, BIOL PSYCHIAT, V64, P327, DOI 10.1016/j.biopsych.2008.03.010; Packard MG, 2009, NEUROSCIENCE, V164, P457, DOI 10.1016/j.neuroscience.2009.07.054; Packard MG, 2010, HBK BEHAV NEUROSCI, V20, P561; Packard MG, 2009, BRAIN RES, V1293, P121, DOI 10.1016/j.brainres.2009.03.029; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; PACKARD MG, 1994, P NATL ACAD SCI USA, V91, P8477, DOI 10.1073/pnas.91.18.8477; Packard MG, 2004, NEUROBIOL LEARN MEM, V82, P243, DOI 10.1016/j.nlm.2004.06.008; PACKARD MG, 1989, J NEUROSCI, V9, P1465; PACKARD MG, 1991, BEHAV NEUROSCI, V105, P295, DOI 10.1037/0735-7044.105.2.295; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Packard MG, 2001, CURR OPIN NEUROBIOL, V11, P752, DOI 10.1016/S0959-4388(01)00280-X; Packard MG, 1997, BEHAV NEUROSCI, V111, P543, DOI 10.1037/0735-7044.111.3.543; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P278, DOI 10.1006/nlme.1996.0033; Packard MG, 1998, NEUROBIOL LEARN MEM, V69, P163, DOI 10.1006/nlme.1997.3815; Papagni SA, 2011, STRESS, V14, P227, DOI 10.3109/10253890.2010.522279; Pederson CL, 2004, J TRAUMA STRESS, V17, P37, DOI 10.1023/B:JOTS.0000014674.84517.46; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; Pitman RK, 2005, CNS SPECTRUMS, V10, P99, DOI 10.1017/S109285290001943X; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Pitman RK, 2001, HIPPOCAMPUS, V11, P73, DOI 10.1002/hipo.1022; PITMAN RK, 1989, BIOL PSYCHIAT, V26, P221, DOI 10.1016/0006-3223(89)90033-4; Pitman RK, 2000, NEW COGNITIVE NEUROS, P1133; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Podoll K, 2000, FORTSCHR NEUROL PSYC, V68, P458, DOI 10.1055/s-2000-7736; Podoll K, 2000, NEUROL PSYCHIAT BR, V8, P33; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; Protopopescu X, 2005, BIOL PSYCHIAT, V57, P464, DOI 10.1016/j.biopsych.2004.12.026; Rasmusson AM, 1997, ANN NY ACAD SCI, V821, P332, DOI 10.1111/j.1749-6632.1997.tb48290.x; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Regambal MJ, 2012, J BEHAV THER EXP PSY, V43, P947, DOI 10.1016/j.jbtep.2012.02.003; Roozendaal B, 1996, BRAIN RES, V709, P243, DOI 10.1016/0006-8993(95)01305-9; Roozendaal B, 1997, EUR J NEUROSCI, V9, P76, DOI 10.1111/j.1460-9568.1997.tb01355.x; SANDERS SK, 1991, BRAIN RES, V567, P101, DOI 10.1016/0006-8993(91)91441-3; Sasson Y, 2005, PSYCHIAT RES, V135, P145, DOI 10.1016/j.psychres.2004.05.026; SCHEELKRUGER J, 1982, EUR J PHARMACOL, V82, P115, DOI 10.1016/0014-2999(82)90564-7; Schroeder JP, 2002, HIPPOCAMPUS, V12, P280, DOI 10.1002/hipo.10024; Schwabe L, 2008, NEUROBIOL LEARN MEM, V90, P495, DOI 10.1016/j.nlm.2008.07.015; Schwabe L, 2007, LEARN MEMORY, V14, P109, DOI 10.1101/lm.435807; Schwabe L, 2011, EXP CLIN PSYCHOPHARM, V19, P53, DOI 10.1037/a0022212; Schwabe L, 2010, NEUROBIOL LEARN MEM, V93, P183, DOI 10.1016/j.nlm.2009.09.009; Schwabe L, 2009, J NEUROSCI, V29, P7191, DOI 10.1523/JNEUROSCI.0979-09.2009; Schwabe L, 2009, LEARN MEMORY, V16, P110, DOI 10.1101/lm.1257509; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; SHIFFMAN S, 1982, J CONSULT CLIN PSYCH, V50, P71, DOI 10.1037/0022-006X.50.1.71; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Siegmund A, 2006, ANN NY ACAD SCI, V1071, P324, DOI 10.1196/annals.1364.025; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Steidl S, 2006, LEARN MEMORY, V13, P650, DOI 10.1101/lm.324406; Steidl S, 2011, EMOTION, V11, P12, DOI 10.1037/a0020288; Strawn JR, 2008, DEPRESS ANXIETY, V25, P260, DOI 10.1002/da.20292; Thomas KGF, 2010, S AFR J PSYCHOL, V40, P32, DOI 10.1177/008124631004000104; Tichenor V, 1996, J CONSULT CLIN PSYCH, V64, P1054, DOI 10.1037/0022-006X.64.5.1054; Tolin DF, 2010, DEPRESS ANXIETY, V27, P829, DOI 10.1002/da.20684; Tolman E. C., 1932, PURPOSIVE BEHAV ANIM; Tricomi E, 2009, EUR J NEUROSCI, V29, P2225, DOI 10.1111/j.1460-9568.2009.06796.x; Vaiva G, 2003, BIOL PSYCHIAT, V54, P947, DOI 10.1016/S0006-3223(03)00412-8; VANDERKOLK BA, 1995, J TRAUMA STRESS, V8, P505, DOI 10.1002/jts.2490080402; Vermetten E, 2007, PSYCHOPHARMACOL BULL, V40, P8; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Werner NS, 2008, J PSYCHIATR RES, V43, P309, DOI 10.1016/j.jpsychires.2008.03.011; Whalley MG, 2009, BRAIN COGNITION, V69, P98, DOI 10.1016/j.bandc.2008.05.008; White DA, 2001, PSYCHOPHARMACOLOGY, V154, P169, DOI 10.1007/s002130000649; White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x; White NM, 2003, BEHAV BRAIN RES, V142, P99, DOI 10.1016/S0166-4328(02)00402-3; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; Wingard JC, 2008, BEHAV BRAIN RES, V193, P126, DOI 10.1016/j.bbr.2008.05.002; Wolpe J, 1952, B J PSYCHOL-GEN SECT, V43, P243, DOI 10.1111/j.2044-8295.1952.tb00347.x; Yovell Y, 2003, CNS SPECTRUMS, V8, P676, DOI 10.1017/S1092852900008865	179	63	64	0	35	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	NOV	2012	23	5-6			SI		627	643		10.1515/revneuro-2012-0049			17	Neurosciences	Neurosciences & Neurology	083IM	WOS:000314456900014	23001314				2021-06-18	
J	Hayashida, K; Sano, M; Kamimura, N; Yokota, T; Suzuki, M; Maekawa, Y; Kawamura, A; Abe, T; Ohta, S; Fukuda, K; Hori, S				Hayashida, Kei; Sano, Motoaki; Kamimura, Naomi; Yokota, Takashi; Suzuki, Masaru; Maekawa, Yuichiro; Kawamura, Akio; Abe, Takayuki; Ohta, Shigeo; Fukuda, Keiichi; Hori, Shingo			H-2 Gas Improves Functional Outcome After Cardiac Arrest to an Extent Comparable to Therapeutic Hypothermia in a Rat Model	JOURNAL OF THE AMERICAN HEART ASSOCIATION			English	Article						cardiac arrest; cardiopulmonary resuscitation; hydrogen gas; therapeutic hypothermia; ventricular fibrillation	HYDROGEN-RICH WATER; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; MOLECULAR-HYDROGEN; CARDIOPULMONARY-RESUSCITATION; OXIDATIVE STRESS; MODERATE HYPOTHERMIA; ANTIOXIDANT; MITOCHONDRIAL; METABOLISM	Background-All clinical and biological manifestations related to postcardiac arrest (CA) syndrome are attributed to ischemia-reperfusion injury in various organs including brain and heart. Molecular hydrogen (H-2) has potential as a novel antioxidant. This study tested the hypothesis that inhalation of H-2 gas starting at the beginning of cardiopulmonary resuscitation (CPR) could improve the outcome of CA. Methods and Results-Ventricular fibrillation was induced by transcutaneous electrical epicardial stimulation in rats. After 5 minutes of the subsequent CA, rats were randomly assigned to 1 of 4 experimental groups at the beginning of CPR: mechanical ventilation (MV) with 2% N-2 and 98% O-2 under normothermia (37 degrees C), the control group; MV with 2% H-2 and 98% O-2 under normothermia; MV with 2% N-2 and 98% O-2 under therapeutic hypothermia (TH), 33 degrees C; and MV with 2% H-2 and 98% O-2 under TH. Mixed gas inhalation and TH continued until 2 hours after the return of spontaneous circulation (ROSC). H-2 gas inhalation yielded better improvement in survival and neurological deficit score (NDS) after ROSC to an extent comparable to TH. H-2 gas inhalation, but not TH, prevented a rise in left ventricular end-diastolic pressure and increase in serum IL-6 level after ROSC. The salutary impact of H-2 gas was at least partially attributed to the radical-scavenging effects of H-2 gas, because both 8-OHdG- and 4-HNE-positive cardiomyocytes were markedly suppressed by H-2 gas inhalation after ROSC. Conclusions-Inhalation of H-2 gas is a favorable strategy to mitigate mortality and functional outcome of post-CA syndrome in a rat model, either alone or in combination with TH.	[Hayashida, Kei; Suzuki, Masaru; Hori, Shingo] Keio Univ, Sch Med, Dept Emergency & Crit Care Med, Tokyo, Japan; [Sano, Motoaki; Maekawa, Yuichiro; Kawamura, Akio; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan; [Abe, Takayuki] Keio Univ, Sch Med, Clin Res Ctr, Tokyo, Japan; [Kamimura, Naomi; Yokota, Takashi; Ohta, Shigeo] Nippon Med Sch, Grad Sch Med, Inst Dev & Aging Sci, Dept Biochem & Cell Biol, Kanagawa, Japan	Sano, M (corresponding author), 35 Shinanomachi, Tokyo 1608582, Japan.	msano@a8.keio.jp	Sano, Motoaki/L-3405-2013; Fukuda, Keiichi/L-3777-2013		KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI); Marumo Research Foundation of the Japanese Society of Acute Medicine; Research Foundation of the General Insurance Association of Japan; Graduate School Doctoral Student Aid Program, Keio University; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24500871, 24651055, 23300257, 23500971] Funding Source: KAKEN	This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI; to S. H.), the Marumo Research Foundation of the Japanese Society of Acute Medicine (to K. H.), the Research Foundation of the General Insurance Association of Japan (to K. H.), and Graduate School Doctoral Student Aid Program, Keio University (to K.H.).	Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Aoki K, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-12; Buchholz BM, 2008, AM J TRANSPLANT, V8, P2015, DOI 10.1111/j.1600-6143.2008.02359.x; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; CARDEN DL, 1987, ANN EMERG MED, V16, P1317, DOI 10.1016/S0196-0644(87)80408-0; Che DF, 2011, CRIT CARE MED, V39, P1423, DOI 10.1097/CCM.0b013e318212020a; Chen CW, 2010, NEUROCHEM RES, V35, P1111, DOI 10.1007/s11064-010-0162-y; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Fujita K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007247; Hayashida K, 2008, BIOCHEM BIOPH RES CO, V373, P30, DOI 10.1016/j.bbrc.2008.05.165; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; Ito M, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-24; Kajiyama S, 2008, NUTR RES, V28, P137, DOI 10.1016/j.nutres.2008.01.008; Kamimura N, 2011, OBESITY, V19, P1396, DOI 10.1038/oby.2011.6; Kang KM, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-11; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; Li J, 2010, BRAIN RES, V1328, P152, DOI 10.1016/j.brainres.2010.02.046; Lin JY, 2010, RESUSCITATION, V81, P1197, DOI 10.1016/j.resuscitation.2010.05.019; Liu Q, 2010, LIVER INT, V30, P958, DOI 10.1111/j.1478-3231.2010.02254.x; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Merchant RM, 2006, CRIT CARE MED, V34, P1935, DOI 10.1097/01.CCM.0000220494.90290.92; Nakao A, 2010, J CLIN BIOCHEM NUTR, V46, P140, DOI 10.3164/jcbn.09-100; Nakayama M, 2010, NEPHROL DIAL TRANSPL, V25, P3026, DOI 10.1093/ndt/gfq196; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; NEUMAR RW, 1995, RESUSCITATION, V29, P249, DOI 10.1016/0300-9572(94)00827-3; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ohta S, 2012, BBA-GEN SUBJECTS, V1820, P586, DOI 10.1016/j.bbagen.2011.05.006; Ohta S, 2011, CURR PHARM DESIGN, V17, P2241, DOI 10.2174/138161211797052664; Ono H, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-14; Ono H, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-12; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Schneider A, 2012, RESUSCITATION, V83, P232, DOI 10.1016/j.resuscitation.2011.07.023; Shimouchi A, 2012, ADV EXP MED BIOL, V737, P245, DOI 10.1007/978-1-4614-1566-4_36; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; VONPLANTA I, 1988, J APPL PHYSIOL, V65, P2641; Walters JH, 2011, RESUSCITATION, V82, P508, DOI 10.1016/j.resuscitation.2011.01.021; Xie KL, 2010, SHOCK, V34, P495, DOI 10.1097/SHK.0b013e3181def9aa; Xie KL, 2010, SHOCK, V34, P90, DOI 10.1097/SHK.0b013e3181cdc4ae; Ye S, 2012, CIRCULATION, V125, P123, DOI 10.1161/CIRCULATIONAHA.111.062257	41	63	69	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2047-9980			J AM HEART ASSOC	J. Am. Heart Assoc.	OCT	2012	1	5							e003459	10.1161/JAHA.112.003459			13	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	243RU	WOS:000326335500012	23316300	DOAJ Gold, Green Published			2021-06-18	
J	Bagley, AF; Daneshvar, DH; Schanker, BD; Zurakowski, D; d'Hemecourt, CA; Nowinski, CJ; Cantu, RC; Goulet, K				Bagley, Alexander F.; Daneshvar, Daniel H.; Schanker, Benjamin D.; Zurakowski, David; d'Hemecourt, Charles A.; Nowinski, Christopher J.; Cantu, Robert C.; Goulet, Kristian			Effectiveness of the SLICE Program for Youth Concussion Education	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion education; student-athletes; SLICE; concussion; injury prevention	CHRONIC TRAUMATIC ENCEPHALOPATHY; FOOTBALL-LEAGUE; HIGH-SCHOOL; ICE HOCKEY; INJURY; EPIDEMIOLOGY; ACHIEVEMENT; SPORTS; BRAIN	Objective: To analyze the effectiveness of the Sports Legacy Institute Community Educators (SLICE) curriculum for student-athletes on recognition and appropriate responses to concussions. Design: Prospective cohort study, level II. Setting: The SLICE concussion workshop. Participants: All students ranging from 9 to 18 years (n = 636) taking the SLICE concussion education program. Intervention: The SLICE concussion education program featuring interactive demonstrations, discussion, and case studies of athletes delivered by medical students and others in health-related fields. Main Outcome Measures: Evaluations assessing knowledge of concussion recognition and appropriate response were administered before and after participating in the SLICE concussion education program. Results: Students displayed significant improvements in absolute mean score on the concussion knowledge quiz between prepresentation and postpresentation (P < 0.0001). Significant improvements in mean score were observed among both male and female students within each age group. The proportion of students who passed the quiz increased from 34% prepresentation to 80% postpresentation (P < 0.0001). However, the percentage who passed the quiz postpresentation was significantly higher among female students compared with male students (P < 0.0001) and among students 13 years of age or older compared with students less than 13 years (P < 0.0001). Using multivariable logistic regression, we identified age group and gender as the most significant factors associated with passing the quiz postpresentation. Conclusion: The SLICE program promotes effective learning and knowledge about concussion recognition and response among students ranging from 9 to 18 years. Lessons from the SLICE program may be broadly applicable to youth concussion education.	[Bagley, Alexander F.] Harvard Univ, Sch Med, MD PhD Program, Cambridge, MA 02138 USA; [Bagley, Alexander F.; Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Boston, MA USA; [Daneshvar, Daniel H.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Schanker, Benjamin D.; Zurakowski, David] Harvard Univ, Biophys Program, Boston, MA 02115 USA; [Zurakowski, David; d'Hemecourt, Charles A.; Goulet, Kristian] Boston Childrens Hosp, Dept Orthoped Surg, Div Sports Med, Boston, MA USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Goulet, Kristian] ActiveCare Med Ctr, Eastern Ontario Concuss Clin, Kanata, ON, Canada	Bagley, AF (corresponding author), Harvard Univ, Sch Med, MD PhD Program, 550 Winthrop Mail Ctr, Cambridge, MA 02138 USA.	abagley@mit.edu		Daneshvar, Daniel/0000-0003-3691-9513	Boston Bruins Foundation	The Boston Bruins Foundation provided a grant to Sports Legacy Institute to support and expand SLICE chapters.	Anderson AJ, 2000, PEDIATRICS, V105, P657; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Centers for Disease Control, CDC FACT SHEET ATHL; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Dale E., 1946, AUDIO VISUAL METHODS, V1; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; KIMBALL MM, 1989, PSYCHOL BULL, V105, P198, DOI 10.1037/0033-2909.105.2.198; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Council of Youth Sports, NCYS REP TRENDS PART; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Stumpf H, 1998, CURR DIR PSYCHOL SCI, V7, P192, DOI 10.1111/1467-8721.ep10836927; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Zazryn T, 2007, SPORTS MED, V37, P467	24	63	63	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2012	22	5					385	389		10.1097/JSM.0b013e3182639bb4			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	004PU	WOS:000308694400002	22929042				2021-06-18	
J	Leitgeb, J; Mauritz, W; Brazinova, A; Janciak, I; Majdan, M; Wilbacher, I; Rusnak, M				Leitgeb, Johannes; Mauritz, Walter; Brazinova, Alexandra; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Rusnak, Martin			Outcome after severe brain trauma due to acute subdural hematoma Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; acute subdural hematoma; outcome; prognostic score	GLASGOW COMA SCALE; HEAD-INJURY; CLASSIFICATION; PREDICTION; MANAGEMENT; MORTALITY; ADMISSION; SYSTEM; IMPACT; SCORE	Object. In this paper, the authors' goal was to identify factors contributing to outcomes after severe traumatic brain injury (TBI) due to acute subdural hematoma (SDH). Methods. Between February 2002 and April 2010, 17 Austrian centers prospectively enrolled 863 patients with moderate and severe TBI into observational studies. Data regarding accident, treatment, and outcomes were collected. Data sets from patients who had severe TBI (Glasgow Coma Scale score <9) and acute SDH were selected. Six-month outcomes were classified as "favorable" if the Glasgow Outcome Scale (GOS) scores were 5 or 4, and they were classified as "unfavorable" if GOS scores were 3 or less. The Rotterdam score was used to classify CT findings, and the scores published by Hukkelhoven et al. were used to estimate the predicted rates of death and of unfavorable outcomes. Univariate (Fisher exact test, t-test, chi-square test) and multivariate (logistic regression) statistics were used to identify factors associated with hospital mortality and favorable outcome. Results. Of the 738 patients with severe TBI, 360 (49%) had acute SDH. Of these, 168 (46.7%) died in the hospital, 67(18.6%) survived with unfavorable outcome, and 116(32.2%) survived with favorable outcome. Long-term outcome was unknown in 9 survivors (2.5%). Mortality rates predicted by the Rotterdam CT score showed good correlation with observed mortality rates. According to the Hukkelhoven scores, observed/predicted ratios for mortality and unfavorable outcome were 1.09 and 1.02, respectively. Conclusions. Age, severity of TBI, and neurological status were the main factors influencing outcomes after severe TBI due to acute SDH. Nonoperative management was associated with significantly higher mortality. (http://thejns.org/doi/abs/10.3171/2012.4.JNS111448)	[Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria; [Mauritz, Walter] Trauma Hosp Lorenz Boehler, Dept Anesthesiol & Intens Care Med, Vienna, Austria; [Mauritz, Walter; Brazinova, Alexandra; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Rusnak, Martin] Int Neurotrauma Res Org, Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek; Rusnak, Martin] Trnava Univ, Dept Publ Hlth, Fac Hlth & Social Serv, Trnava, Slovakia	Leitgeb, J (corresponding author), Med Univ Vienna, Dept Traumatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	johannes.leitgeb@meduniwien.ac.at	Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016; Brazinova, Alexandra/C-4265-2016	Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042; Brazinova, Alexandra/0000-0003-0625-256X; Mauritz, Walter/0000-0001-9043-3712	Austrian Workers' Compensation Board (AUVA) [FK 33/2003]; Austrian National Bank [8987]; Ministry of Health; AUVA [FK 11/2008, FK 11/2010]	The data used for this study were collected for a project funded by the Austrian Workers' Compensation Board (AUVA; FK 33/2003) and by the "Jubilee Fund" of the Austrian National Bank (Project 8987), and for a project funded by the Ministry of Health (Contract October 15, 2008) and the AUVA (FK 11/2008 and FK 11/2010). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources.	Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	29	63	64	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2012	117	2					324	333		10.3171/2012.4.JNS111448			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	978ST	WOS:000306766800025	22631691				2021-06-18	
J	Wood, JN; Medina, SP; Feudtner, C; Luan, XQ; Localio, R; Fieldston, ES; Rubin, DM				Wood, Joanne N.; Medina, Sheyla P.; Feudtner, Chris; Luan, Xianqun; Localio, Russell; Fieldston, Evan S.; Rubin, David M.			Local Macroeconomic Trends and Hospital Admissions for Child Abuse, 2000-2009	PEDIATRICS			English	Article						child safety; maltreatment; abuse; head trauma; head injuries	TRAUMATIC BRAIN-INJURY; UNITED-STATES; COMPUTED-TOMOGRAPHY; PHYSICAL ABUSE; HEAD TRAUMA; EMERGENCY-DEPARTMENTS; MALTREATMENT; UNEMPLOYMENT; RECESSION; INFANTS	OBJECTIVE: To examine the relationship between local macroeconomic indicators and physical abuse admission rates to pediatric hospitals over time. METHODS: Retrospective study of children admitted to 38 hospitals in the Pediatric Hospital Information System database. Hospital data were linked to unemployment, mortgage delinquency, and foreclosure data for the associated metropolitan statistical areas. Primary outcomes were admission rates for (1) physical abuse in children <6 years old, (2) non-birth, non-motor vehicle crash-related traumatic brain injury (TBI) in infants <1 year old (which carry high risk for abuse), and (3) all-cause injuries. Poisson fixed-effects regression estimated trends in admission rates and associations between those rates and trends in unemployment, mortgage delinquency, and foreclosure. RESULTS: Between 2000 and 2009, rates of physical abuse and high-risk TBI admissions increased by 0.79% and 3.1% per year, respectively (P <= .02), whereas all-cause injury rates declined by 0.80% per year (P < .001). Abuse and high-risk TBI admission rates were associated with the current mortgage delinquency rate and with the change in delinquency and foreclosure rates from the previous year (P <= .03). Neither abuse nor high-risk TBI rates were associated with the current unemployment rate. The all-cause injury rate was negatively associated with unemployment, delinquency, and foreclosure rates (P <= .007). CONCLUSIONS: Multicenter hospital data show an increase in pediatric admissions for physical abuse and high-risk TBI during a time of declining all-cause injury rate. Abuse and high-risk TBI admission rates increased in relationship to local mortgage delinquency and foreclosure trends. Pediatrics 2012;130:e358-e364	[Wood, Joanne N.; Medina, Sheyla P.; Feudtner, Chris; Luan, Xianqun; Fieldston, Evan S.; Rubin, David M.] Childrens Hosp Philadelphia, PolicyLab, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Fieldston, Evan S.; Rubin, David M.] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Fieldston, Evan S.; Rubin, David M.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Localio, Russell] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA	Wood, JN (corresponding author), Childrens Hosp Philadelphia, PolicyLab, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434; Wood, Joanne/0000-0001-6431-8024			[Anonymous], 2011, STAT NAT HOUS; [Anonymous], 2010, GROW CRIS CHILD PROT; BAUM K, 2005, JUVENILE VICTIMIZATI; Berger LM, 2004, CHILD YOUTH SERV REV, V26, P725, DOI 10.1016/j.childyouth.2004.02.017; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; CATALANO R, 1991, AM J PUBLIC HEALTH, V81, P1148, DOI 10.2105/AJPH.81.9.1148; Child Welfare Information Gateway, 2008, DIFF RESP REP CHILD; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cohen R., 2011, SHOULD I STAY SHOULD; Currie J, 2011, NATL BUREAU EC RES W, P17310; Differential Response in Child Protective Services, 2011, LIT REV VERS 2; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Federal Interagency Forum on Child and Family Statistics, 2011, AM CHILDR KEY NAT IN; Finkelhor D, 2003, CHILD ABUSE NEGLECT, V27, P77, DOI 10.1016/S0145-2134(02)00508-2; Finkelhor D, 2009, UPDATED TRENDS CHILD; Finkelhor D, 2011, UPDATED TRENDS CHILD; Finkelhor D, 2010, ARCH PEDIAT ADOL MED, V164, P238, DOI 10.1001/archpediatrics.2009.283; Freisthler B, 2007, SOC WORK, V52, P7, DOI 10.1093/sw/52.1.7; Gallup Organization, 1995, DISC CHILDR AM GALL; GIL DG, 1969, PEDIATRICS, V44, P857; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; Gilbert R, 2009, LANCET, V373, P167, DOI 10.1016/S0140-6736(08)61707-9; Huang MI, 2011, J NEUROSURG-PEDIATR, V8, P171, DOI 10.3171/2011.5.PEDS1139; Hughes S, 2009, CBS NEWS; Kan J, 2008, MBA RES DATANOTES; KRUGMAN RD, 1986, CHILD ABUSE NEGLECT, V10, P415, DOI 10.1016/0145-2134(86)90018-9; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; Leventhal JM, 2012, PEDIATRICS, V129, P458, DOI 10.1542/peds.2011-1277; Lovell P., 2008, IMPACT MORTGAGE CRIS; Madan AK, 2007, WORLD J SURG, V31, P1930, DOI 10.1007/s00268-007-9190-4; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Menoch MJA, 2012, PEDIATRICS, V129, pE690, DOI 10.1542/peds.2011-2548; Mersky JP, 2009, CHILD MALTREATMENT, V14, P73, DOI 10.1177/1077559508318399; Millett L, 2011, CHILD YOUTH SERV REV, V33, P1280, DOI 10.1016/j.childyouth.2011.03.001; Minnesota Departments of Education Health Human Services & Public Safety, 2010, MINN STUD SURV 1992; MULLER A, 1989, AM J PUBLIC HEALTH, V79, P1366, DOI 10.2105/AJPH.79.10.1366; Pare J, 1992, 8 NAT S CHILD VICT M; Sedlak A. J., 2010, 4 NATL INCIDENCE STU; SEDLAK AJ, 1996, 3 NAT INC STUD CHILD; Sermons MW, 2011, STATE HOMELESSNESS A; Shattuck A., 2010, UPDATED TRENDS CHILD; STEINBERG LD, 1981, CHILD DEV, V52, P975; Stuckler D, 2011, LANCET, V378, P124, DOI 10.1016/S0140-6736(11)61079-9; Stuckler D, 2009, LANCET, V374, P315, DOI 10.1016/S0140-6736(09)61124-7; Szep J, 2009, REUTERS NEWS SERVICE; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; U.S. Census Bureau, METR MICR STAT AR; U.S. Department of Health and Human Services Administration on Children Youth and Families, 2009, CHILD MALTR 2007; U. S. Department of Health & Human Services (USDHHS) Administration for Children Youth and Families & Children's Bureau, 2011, CHILD MALTR 2010; *US ADM CHILDR YOU, 2008, CHILD MALTR 2006; US Bureau of Labor Statistics, LOC AR UNEMPL STAT D; US Department of Health and Human Services Administration for Children Youth and Families, 2010, CHILD MALTR 2009; US Department of Health and Human Services Administration on Children Youth and Families, 2002, CHILD MALTR 2000; US Department of Health and Human Services Administration on Children Youth and Families, 2010, CHILD MALTR 2008; US Department of Health and Human Services Administration on Children Youth and Families, 2005, CHILD MALTR 2005; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	59	63	63	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2012	130	2					E358	E364		10.1542/peds.2011-3755			7	Pediatrics	Pediatrics	983MI	WOS:000307123000015	22802600				2021-06-18	
J	Jin, G; deMoya, MA; Duggan, M; Knightly, T; Mejaddam, AY; Hwabejire, J; Lu, J; Smith, WM; Kasotakis, G; Velmahos, GC; Socrate, S; Alam, HB				Jin, Guang; deMoya, Marc A.; Duggan, Michael; Knightly, Thomas; Mejaddam, Ali Y.; Hwabejire, John; Lu, Jennifer; Smith, William Michael; Kasotakis, Georgios; Velmahos, George C.; Socrate, Simona; Alam, Hasan B.			TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK: EVALUATION OF DIFFERENT RESUSCITATION STRATEGIES IN A LARGE ANIMAL MODEL OF COMBINED INSULTS	SHOCK			English	Article						Traumatic brain injury; hemorrhage; edema; swine; shock	FOCAL CEREBRAL-ISCHEMIA; FRESH-FROZEN PLASMA; HEAD-INJURY; FLUID RESUSCITATION; POLYTRAUMA; HEMODILUTION; COAGULATION; IMPACT; TISSUE; SWINE	Traumatic brain injury (TBI) and hemorrhagic shock (HS) are the leading causes of trauma-related mortality and morbidity. Combination of TBI and HS (TBI + HS) is highly lethal, and the optimal resuscitation strategy for this combined insult remains unclear. A critical limitation is the lack of suitable large animal models to test different treatment strategies. We have developed a clinically relevant large animal model of TBI + HS, which was used to evaluate the impact of different treatments on brain lesion size and associated edema. Yorkshire swine (42-50 kg) were instrumented to measure hemodynamic parameters and intracranial pressure. A computer-controlled cortical impact device was used to create a TBI through a 20-mm craniotomy: 15-mm cylindrical tip impactor at 4 m/s velocity, 100-ms dwell time, and 12-mm penetration depth. Volume-controlled hemorrhage was started (40% blood volume) concurrent with the TBI. After 2 h of shock, animals were randomized to one of three resuscitation groups (n = 5/group): (a) normal saline (NS); (b) 6% hetastarch, Hextend (Hex); and (c) fresh frozen plasma (FFP). Volumes of Hex and FFP matched the shed blood, whereas NS was three times the volume. After 6 h of postresuscitation monitoring, brains were sectioned into 5-mm slices and stained with TIC (2,3,5-triphenyltetrazolium chloride) to quantify the lesion size and brain swelling. Combination of 40% blood loss with cortical impact and a period of shock (2 h) resulted in a highly reproducible brain injury. Total fluid requirements were lower in the Hex and FFP groups. Lesion size and brain swelling in the FFP group (2,160 +/- 202.6 mm(3) and 22% +/- 1.0%, respectively) were significantly smaller than those in the NS group (3,285 +/- 130.8 mm(3) and 37% +/- 1.6%, respectively) (P < 0.05). Hex treatment decreased the swelling (29% +/- 1.6%) without reducing the lesion size. Early administration of FFP reduces the size of brain lesion and associated swelling in a large animal model of TBI + HS. In contrast, artificial colloid (Hex) decreases swelling without reducing the actual size of the brain lesion.	[Jin, Guang; deMoya, Marc A.; Duggan, Michael; Knightly, Thomas; Mejaddam, Ali Y.; Hwabejire, John; Lu, Jennifer; Smith, William Michael; Kasotakis, Georgios; Velmahos, George C.; Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA; [Socrate, Simona] MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA	Alam, HB (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.	hbalam@partners.org		Kasotakis, George/0000-0002-7630-0742	US Army Medical Research Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; U.S. Army Research Office [W911NF-07-D-0004]	This study was funded by a pant from the US Army Medical Research Material Command GRANTT00521959 (to H.B.A.) and by the U.S. Army Research Office under contract number W911NF-07-D-0004 (to SS).	Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, J TRAUMA, V67, P856, DOI 10.1097/TA.0b013e3181b5ae75; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Baker AJ, 2008, J TRAUMA, V64, P348, DOI 10.1097/01.ta.0000245973.71929.db; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bilotta F, 2007, NEW ENGL J MED, V357, P2635; Bourguignon PR, 1998, ARCH SURG-CHICAGO, V133, P390, DOI 10.1001/archsurg.133.4.390; Brown LM, 2011, J TRAUMA, V71, pS358, DOI 10.1097/TA.0b013e318227f152; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Earle SA, 2007, J AM COLL SURGEONS, V204, P261, DOI 10.1016/j.jamcollsurg.2006.11.014; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jin G, 2010, TRANSL STROKE RES, V1, P65, DOI 10.1007/s12975-009-0009-5; Jin G, 2009, EXP NEUROL, V217, P165, DOI 10.1016/j.expneurol.2009.02.004; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Myburgh J, 2007, NEW ENGL J MED, V357, P874; OHTAKI M, 1993, SURG NEUROL, V40, P196, DOI 10.1016/0090-3019(93)90068-C; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Sambasivan CN, 2009, AM J SURG, V197, P576, DOI 10.1016/j.amjsurg.2008.12.011; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Shuja F, 2008, J TRAUMA, V65, P975, DOI 10.1097/TA.0b013e3181801cd9; Takano K, 1997, STROKE, V28, P1255, DOI 10.1161/01.STR.28.6.1255; TU YK, 1988, J NEUROSURG, V69, P72, DOI 10.3171/jns.1988.69.1.0072; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	34	63	64	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUL	2012	38	1					49	56		10.1097/SHK.0b013e3182574778			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	961WV	WOS:000305501100009	22575994				2021-06-18	
J	Mao, SS; Hua, R; Zhao, XP; Qin, X; Sun, ZQ; Zhang, Y; Wu, YQ; Jia, MX; Cao, JL; Zhang, YM				Mao, Shan-Shan; Hua, Rong; Zhao, Xiao-Ping; Qin, Xia; Sun, Zhen-Quan; Zhang, Yang; Wu, Yu-Qing; Jia, Meng-Xing; Cao, Jun-Li; Zhang, Yong-Mei			Exogenous Administration of PACAP Alleviates Traumatic Brain Injury in Rats through a Mechanism Involving the TLR4/MyD88/NF-kappa B Pathway	JOURNAL OF NEUROTRAUMA			English	Article						inflammatory cytokines; MyD88; PACAP; toll-like receptor 4; traumatic brain injury	CYCLASE-ACTIVATING POLYPEPTIDE; TOLL-LIKE RECEPTORS; FOCAL CEREBRAL-ISCHEMIA; INNATE IMMUNE-RESPONSE; CENTRAL-NERVOUS-SYSTEM; ADENYLATE-CYCLASE; HEAD-INJURY; CELL-DEATH; PARAVENTRICULAR NUCLEUS; PATHOGEN RECOGNITION	Pituitary adenylate cyclase-activating polypeptide (PACAP) is effective in reducing axonal damage associated with traumatic brain injury (TBI), and has immunomodulatory properties. Toll-like receptor 4 (TLR4) is an important mediator of the innate immune response. It significantly contributes to neuroinflammation induced by brain injury. However, it remains unknown whether exogenous PACAP can modulate TBI through the TLR4/adapter protein myeloid differentiation factor 88 (MyD88)/nuclear factor-kappa B (NF-kappa B) signaling pathway. In this study, we investigated the potential neuroprotective mechanisms of PACAP pretreatment in a weight-drop model of TBI. PACAP38 was microinjected intracerebroventricularly before TBI. Brain samples were extracted from the pericontusional area in the cortex and hippocampus. We found that TBI induced significant upregulation of TLR4, with peak expression occurring 24 h post-trauma, and that pretreatment with PACAP significantly improved motor and cognitive dysfunction, attenuated neuronal apoptosis, and decreased brain edema. Pretreatment with PACAP inhibited upregulation of TLR4 and its downstream signaling molecules MyD88, p-I kappa B, and NF-kappa B, and suppressed increases in the levels of the downstream inflammatory agents interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), in the brain tissue around the injured cortex and in the hippocampus. Administration of PACAP both in vitro and in vivo attenuated the ability of the TLR4 agonist lipopolysaccharide (LPS) to increase TLR4 protein levels. Therefore, PACAP exerts a neuroprotective effect in this rat model of TBI, by inhibiting a secondary inflammatory response mediated by the TLR4/MyD88/NF-kappa B signaling pathway in microglia and neurons, thereby reducing neuronal death and improving the outcome following TBI.	[Cao, Jun-Li; Zhang, Yong-Mei] Xuzhou Med Coll, Affiliated Hosp, Dept Anesthesiol, Jiangsu Prov Key Lab Anesthesiol, Xuzhou 221002, Jiangsu, Peoples R China; [Zhang, Yong-Mei] Xuzhou Med Coll, Jiangsu Key Lab Brain Dis Bioinformat, Xuzhou 221002, Jiangsu, Peoples R China; [Hua, Rong] PLA, Hosp 97, Dept Emergency Med, Xuzhou, Jiangsu, Peoples R China	Zhang, YM (corresponding author), Xuzhou Med Coll, Affiliated Hosp, Dept Anesthesiol, Jiangsu Prov Key Lab Anesthesiol, 84 W Huaihai Rd, Xuzhou 221002, Jiangsu, Peoples R China.	caojl0310@yahoo.com.cn; zhangym700@163.com		Cao, Jun-Li/0000-0002-8932-4743	National Natural Science of ChinaNational Natural Science Foundation of China (NSFC) [81171041, 81171013]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK2011197]; Educational Department Science Research Foundation of Jiangsu Province [09KJD310009]; Jiangsu Key Laboratory of Brain Disease Bioinformation [JSBL0804]; Innovation Project of Nanjing Military Region [09MA036]; Research Foundation of President of Xuzhou Medical College [09KJZ17]; Priority Academic Program Development of Jiangsu Higher Education Institutions of Jiangsu Province	This project was supported by grants from the National Natural Science of China (81171041 and 81171013), the Natural Science Foundation of Jiangsu Province (BK2011197), the Educational Department Science Research Foundation of Jiangsu Province (09KJD310009), a project from the Jiangsu Key Laboratory of Brain Disease Bioinformation (JSBL0804), the Innovation Project of Nanjing Military Region (09MA036), the Research Foundation of President of Xuzhou Medical College (no. 09KJZ17), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions of Jiangsu Province.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Allais A, 2010, J NEUROCHEM, V113, P329, DOI 10.1111/j.1471-4159.2009.06555.x; Aravalli RN, 2008, J NEUROIMMUNE PHARM, V3, P5, DOI 10.1007/s11481-007-9097-8; Aravalli RN, 2007, J NEUROIMMUNE PHARM, V2, P297, DOI 10.1007/s11481-007-9071-5; Armant MA, 2002, GENOME BIOL, V3; Armstrong BD, 2008, NEUROSCIENCE, V151, P63, DOI 10.1016/j.neuroscience.2007.09.084; Arslan F, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/704202; Arumugam TV, 2009, SHOCK, V32, P4, DOI 10.1097/SHK.0b013e318193e333; Autret A, 2009, MOL CELL, V36, P355, DOI 10.1016/j.molcel.2009.10.011; Barichello T, 2011, NEUROCHEM RES, V36, P1922, DOI 10.1007/s11064-011-0514-2; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Brea D, 2011, REV NEUROLOGIA, V52, P12, DOI 10.33588/rn.5201.2010494; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Choi DC, 2008, ENDOCRINOLOGY, V149, P818, DOI 10.1210/en.2007-0883; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Das M, 2007, J COMP NEUROL, V500, P761, DOI 10.1002/cne.21212; Ding BJ, 2011, INT J DEV NEUROSCI, V29, P537, DOI 10.1016/j.ijdevneu.2011.04.002; Dong XQ, 2011, INFLAMM RES, V60, P533, DOI 10.1007/s00011-010-0300-7; Du J, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-3; Fang KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015299; Farina C, 2005, J NEUROIMMUNOL, V159, P12, DOI 10.1016/j.jneuroim.2004.09.009; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fletcher JI, 2008, CELL CYCLE, V7, P39, DOI 10.4161/cc.7.1.5178; Gomariz RP, 2007, PEPTIDES, V28, P1825, DOI 10.1016/j.peptides.2007.07.005; Gressens P, 2000, J NEUROPATH EXP NEUR, V59, P1051, DOI 10.1093/jnen/59.12.1051; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hyakkoku K, 2010, NEUROSCIENCE, V171, P258, DOI 10.1016/j.neuroscience.2010.08.054; Jang HR, 2009, CLIN IMMUNOL, V130, P41, DOI 10.1016/j.clim.2008.08.016; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Jung DY, 2005, J IMMUNOL, V174, P6467, DOI 10.4049/jimmunol.174.10.6467; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kojro E, 2006, FASEB J, V20, P512, DOI 10.1096/fj.05-4812fje; Kovesdi E, 2008, NEUROTOX RES, V13, P71, DOI 10.1007/BF03033558; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mack WJ, 2006, J NEUROSCI RES, V83, P883, DOI 10.1002/jnr.20775; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matsttzaki S, 2008, EXPERT OPIN THER TAR, V12, P1097, DOI [10.1517/14728222.12.9.1097 , 10.1517/14728220802321783]; Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nakamachi T, 2010, ACTA NEUROCHIR SUPPL, V106, P43, DOI 10.1007/978-3-211-98811-4_6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Norrholm SD, 2005, REGUL PEPTIDES, V128, P33, DOI 10.1016/j.regpep.2004.12.023; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; Panaro MA, 2008, IMMUNOPHARM IMMUNOT, V30, P729, DOI 10.1080/08923970802278557 ; Pulskens WP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003596; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reglodi D, 2006, NEUROPEPTIDES, V40, P265, DOI 10.1016/j.npep.2006.06.001; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Rock RB, 2006, J NEUROIMMUNE PHARM, V1, P117, DOI 10.1007/s11481-006-9012-8; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Stetler RA, 2010, P NATL ACAD SCI USA, V107, P3204, DOI 10.1073/pnas.1000030107; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; Tanaka K, 2006, J NEUROSCI, V26, P5091, DOI 10.1523/JNEUROSCI.4376-05.2006; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; van Landeghem FKH, 2007, ACTA NEUROPATHOL, V113, P683, DOI 10.1007/s00401-007-0208-7; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Vollmar P, 2010, J IMMUNOL, V185, P6338, DOI 10.4049/jimmunol.1001765; Waak J, 2009, FASEB J, V23, P2478, DOI 10.1096/fj.08-125153; Watanabe J, 2007, PEPTIDES, V28, P1713, DOI 10.1016/j.peptides.2007.06.029; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Xia Y, 2006, BRAIN RES, V1095, P85, DOI 10.1016/j.brainres.2006.03.112; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yu JW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-141; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	88	63	70	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1941	1959		10.1089/neu.2011.2244			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400397	22583372				2021-06-18	
J	Griesbach, GS; Tio, DL; Vincelli, J; McArthur, DL; Taylor, AN				Griesbach, Grace S.; Tio, Delia L.; Vincelli, Jennifer; McArthur, David L.; Taylor, Anna N.			Differential Effects of Voluntary and Forced Exercise on Stress Responses after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adrenocorticotropic hormone; corticosterone; brain-derived neurotrophic factor; exercise; glucocorticoid receptors	LATERAL FLUID PERCUSSION; ADRENOCORTICAL AXIS; TEMPORAL WINDOW; MESSENGER-RNA; UP-REGULATION; MILD; CORTICOSTERONE; HIPPOCAMPUS; DYSFUNCTION; SEVERITY	Voluntary exercise increases levels of brain-derived neurotrophic factor (BDNF) after traumatic brain injury (TBI) when it occurs during a delayed time window. In contrast, acute post-TBI exercise does not increase BDNF. It is well known that increases in glucocorticoids suppress levels of BDNF. Moreover, recent work from our laboratory showed that there is a heightened stress response after fluid percussion injury (FPI). In order to determine if a heightened stress response is also observed with acute exercise, at post-injury days 0-4 and 7-11, corticosterone (CORT) and adrenocorticotropic hormone (ACTH) release were measured in rats running voluntarily or exposed to two daily 20-min periods of forced running wheel exercise. Forced, but not voluntary exercise, continuously elevated CORT. ACTH levels were initially elevated with forced exercise, but decreased by post-injury day 7 in the control, but not the FPI animals. As previously reported, voluntary exercise did not increase BDNF in the FPI group as it did in the control animals. Forced exercise did not increase levels of BDNF in any group. It did, however, decrease hippocampal glucocorticoid receptors in the control group. The results suggest that exercise regimens with strong stress responses may not be beneficial during the early post-injury period.	[Griesbach, Grace S.; Vincelli, Jennifer; McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Tio, Delia L.; Taylor, Anna N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957030, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS06190]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061960] Funding Source: NIH RePORTER	We thank David Garfinkel and Shyama Nair for their excellent technical assistance. This research was supported by NIH grant NS06190 to G. S. G., and the UCLA Brain Injury Research Center.	Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Dallman MF, 2004, ANN NY ACAD SCI, V1018, P141, DOI 10.1196/annals.1296.017; Droste SK, 2007, NEUROENDOCRINOLOGY, V86, P26, DOI 10.1159/000104770; ENGELAND WC, 1977, ENDOCRINOLOGY, V100, P138, DOI 10.1210/endo-100-1-138; Furay AR, 2008, ENDOCRINOLOGY, V149, P5482, DOI 10.1210/en.2008-0642; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Johnson KL, 2006, AACN ADV CRIT CARE, V17, P39, DOI 10.1097/00044067-200601000-00006; Kwon MS, 2006, NEUROSCIENCE, V142, P1281, DOI 10.1016/j.neuroscience.2006.07.027; Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Neigh GN, 2009, J CEREBR BLOOD F MET, V29, P1673, DOI 10.1038/jcbfm.2009.85; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Callaghan RM, 2009, HIPPOCAMPUS, V19, P1019, DOI 10.1002/hipo.20591; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pinheiro J., 2000, MIXED EFFECTS MODELS; R Development Core Team, 2011, R LANG ENV STAT COMP; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x	40	63	65	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1426	1433		10.1089/neu.2011.2229			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600016	22233388	Green Published			2021-06-18	
J	Yeates, KO; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M				Yeates, Keith Owen; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha			Premorbid child and family functioning as predictors of post-concussive symptoms in children with mild traumatic brain injuries	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Post-concussive; Mild head injury; Children; Premorbid; Moderator	HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RELIABILITY; ADOLESCENTS; BEHAVIOR	Study aim: This study sought to determine whether premorbid child and family functioning accounts for or moderates group differences in post-concussive symptoms following mild traumatic brain injury (TBI) in childhood. Methods: This prospective, longitudinal cohort study recruited 8- to 15-year-old children, 186 with mild TBI and 99 with orthopedic injuries (OI), from consecutive emergency department admissions. Parents and children rated post-concussive symptoms within 3 weeks of injury and at 1, 3, and 12 months post injury. Parents also provided retrospective ratings of pre-injury symptoms, as well as of premorbid child behavioral adjustment, overall family functioning, and other stressors and resources in the family environment. Results: Children with mild TBI reported more post-concussive symptoms than those with OI, as did their parents, although premorbid child behavioral adjustment and symptoms also were significant predictors of post-concussive symptoms. Group differences in somatic symptoms as reported by parents were more pronounced among children from families that were higher functioning and had more environmental resources. Discussion: Mild TBI during childhood results in more post-concussive symptoms than OI, even after children's premorbid adjustment is taken into account. Counter to expectations, post-concussive symptoms following mild TBI may actually be more apparent among children from higher-functioning families with greater resources. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Wright, Martha] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	This work was supported by grants HD44099 and HD39834 from the National Institutes of Health to the first author.	ACHENBACH TM, 2001, MANUAL ASEBA SCHOOL; Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Ashwal S., 2010, PEDIAT TRAUMATIC BRA, P68; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Giza CC, 2001, J ATHL TRAINING, V36, P228; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moos R, 1994, LIFE STRESSORS SOCIA; Moos RH, 1988, J SUBSTANCE ABUSE, V1, P135, DOI DOI 10.1016/S0899-3289(88)80017-8; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	48	63	63	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		231	237		10.1016/j.ijdevneu.2011.05.008			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800009	21651973	Green Accepted			2021-06-18	
J	Hinzman, JM; Thomas, TC; Quintero, JE; Gerhardt, GA; Lifshitz, J				Hinzman, Jason M.; Thomas, Theresa Currier; Quintero, Jorge E.; Gerhardt, Greg A.; Lifshitz, Jonathan			Disruptions in the Regulation of Extracellular Glutamate by Neurons and Glia in the Rat Striatum Two Days after Diffuse Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						LY 379268; DL-threo-beta-benzyloxyaspartate; omega-conotoxin; (S)-4-carboxyphenylglycine	EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION INJURY; CENTRAL-NERVOUS-SYSTEM; HUMAN HEAD-INJURY; RECEPTOR AGONIST; TRANSPORTER GLT-1; IN-VIVO; PREFRONTAL CORTEX; NEUROLOGICAL DISORDERS; MICRODIALYSIS PROBES	Disrupted regulation of extracellular glutamate in the central nervous system contributes to and can exacerbate the acute pathophysiology of traumatic brain injury (TBI). Previously, we reported increased extracellular glutamate in the striatum of anesthetized rats 2 days after diffuse brain injury. To determine the mechanism(s) responsible for increased extracellular glutamate, we used enzyme-based microelectrode arrays (MEAs) coupled with specific pharmacological agents targeted at in vivo neuronal and glial regulation of extracellular glutamate. After TBI, extracellular glutamate was significantly increased in the striatum by (similar to 90%) averaging 4.1 +/- 0.6 mu M compared with sham 2.2 +/- 0.4 mu M. Calcium-dependent neuronal glutamate release, investigated by local application of an N-type calcium channel blocker, was no longer a significant source of extracellular glutamate after TBI, compared with sham. In brain-injured animals, inhibition of glutamate uptake with local application of an excitatory amino acid transporter inhibitor produced significantly greater increase in glutamate spillover (similar to 65%) from the synapses compared with sham. Furthermore, glutamate clearance measured by locally applying glutamate into the extracellular space revealed significant reductions in glutamate clearance parameters in brain-injured animals compared with sham. Taken together, these data indicate that disruptions in calcium-mediated glutamate release and glial regulation of extracellular glutamate contribute to increased extracellular glutamate in the striatum 2 days after diffuse brain injury. Overall, these data suggest that therapeutic strategies used to regulate glutamate release and uptake may improve excitatory circuit function and, possibly, outcomes following TBI.	[Hinzman, Jason M.; Thomas, Theresa Currier; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Chandler Med Ctr, Morris K Udall Parkinsons Dis Res Ctr Excellence, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Chandler Med Ctr, Ctr Microelectrode Technol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, B463 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	JLifshitz@uky.edu	Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666	USPHSUnited States Department of Health & Human ServicesUnited States Public Health Service [DA017186, NS3978, AG013494]; NSF (ERC)European Research Council (ERC)National Science Foundation (NSF) [EEC-0310723]; DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N6601-09-2080]; Kentucky Spinal Cord and Head Injury Research Trust [7-11];  [F31NS067899]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS067899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG013494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA017186] Funding Source: NIH RePORTER	The authors thank Francois Pomerleau and Peter Huettl for technical assistance on the glutamate recordings, and Amanda Bolton for assistance on the rtPCR. Support provided by F31NS067899, USPHS DA017186, USPHS NS3978, AG013494, NSF (ERC) EEC-0310723 DARPA N6601-09-2080, and Kentucky Spinal Cord and Head Injury Research Trust Grant 7-11.	Albrecht P, 2010, CNS NEUROL DISORD-DR, V9, P373, DOI 10.2174/187152710791292567; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Baker DA, 2002, J NEUROSCI, V22, P9134; Battaglia G, 1997, NEUROSCI LETT, V229, P161, DOI 10.1016/S0304-3940(97)00442-4; Bond A, 1999, NEUROSCI LETT, V273, P191, DOI 10.1016/S0304-3940(99)00663-1; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; Borland LM, 2005, J NEUROSCI METH, V146, P149, DOI 10.1016/j.jneumeth.2005.02.002; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Day BK, 2006, J NEUROCHEM, V96, P1626, DOI 10.1111/j.1471-4159.2006.03673.x; Diamond JS, 2005, J NEUROSCI, V25, P2906, DOI 10.1523/JNEUROSCI.5125-04.2005; DiIorio P, 1996, J NEUROCHEM, V67, P302; Domercq M, 2007, J IMMUNOL, V178, P6549, DOI 10.4049/jimmunol.178.10.6549; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRIEDEMANN MN, 1992, NEUROBIOL AGING, V13, P325, DOI 10.1016/0197-4580(92)90046-Z; GEMBA T, 1994, NEUROSCIENCE, V63, P789, DOI 10.1016/0306-4522(94)90523-1; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hamann M, 2002, EUR J NEUROSCI, V15, P308, DOI 10.1046/j.0953-816x.2001.01861.x; Harvey BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022135; Hascup ER, 2010, J NEUROCHEM, V115, P1608, DOI 10.1111/j.1471-4159.2010.07066.x; Hascup ER, 2009, BRAIN RES, V1291, P12, DOI 10.1016/j.brainres.2009.06.084; Hascup KN, 2007, ELECTROCHEMICAL METH; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jaquins-Gerstl A, 2009, J NEUROSCI METH, V183, P127, DOI 10.1016/j.jneumeth.2009.06.023; Jensen JB, 2000, INT J DEV NEUROSCI, V18, P309, DOI 10.1016/S0736-5748(99)00099-4; Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Koura SS, 1998, ACT NEUR S, V71, P244; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lupinsky D, 2010, J NEUROSCI, V30, P7624, DOI 10.1523/JNEUROSCI.1187-10.2010; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntosh TK, 1996, LAB INVEST, V74, P315; Melendez RI, 2005, J PHARMACOL EXP THER, V314, P139, DOI 10.1124/jpet.104.081521; Montiel T, 2005, NEUROSCIENCE, V133, P667, DOI 10.1016/j.neuroscience.2004.11.020; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Neher E, 2008, NEURON, V59, P861, DOI 10.1016/j.neuron.2008.08.019; Nicholson C, 2000, PROG BRAIN RES, V125, P129; Nickell J, 2007, NEUROBIOL AGING, V28, P1737, DOI 10.1016/j.neurobiolaging.2006.07.015; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Phillis JW, 2000, BRAIN RES, V880, P224, DOI 10.1016/S0006-8993(00)02755-4; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reinert M, 2000, Neurosurg Focus, V8, pe10; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rutherford EC, 2007, J NEUROCHEM, V102, P712, DOI 10.1111/j.1471-4159.2007.04596.x; Ryglewski S, 2007, PLOS BIOL, V5, P818, DOI 10.1371/journal.pbio.0050066; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; Stephens ML, 2011, NEUROBIOL AGING, V32, P811, DOI 10.1016/j.neurobiolaging.2009.05.009; Stoffel M, 1997, ACT NEUR S, V70, P91; Stoffel M, 2002, J NEUROTRAUM, V19, P467, DOI 10.1089/08977150252932415; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Thomas TC, 2012, J NEUROTRAUM, V29, P187, DOI 10.1089/neu.2011.2091; Thomas TC, 2009, NEUROPSYCHOPHARMACOL, V34, P436, DOI 10.1038/npp.2008.74; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tovar Y.R. L.B., 2009, NEUROCHEM INT, V54, P186; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099	88	63	66	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1197	1208		10.1089/neu.2011.2261			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100020	22233432	Green Published			2021-06-18	
J	Nigrovic, LE; Lee, LK; Hoyle, J; Stanley, RM; Gorelick, MH; Miskin, M; Atabaki, SM; Dayan, PS; Holmes, JF; Kuppermann, N				Nigrovic, Lise E.; Lee, Lois K.; Hoyle, John; Stanley, Rachel M.; Gorelick, Marc H.; Miskin, Michelle; Atabaki, Shireen M.; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		Pediat Emergency Care Appl Res Ne	Prevalence of Clinically Important Traumatic Brain Injuries in Children With Minor Blunt Head Trauma and Isolated Severe Injury Mechanisms	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; DECISION RULE; INTRACRANIAL INJURY; PREDICTION; RADIATION; CT	Objective: To determine the prevalence of clinically important traumatic brain injuries (TBIs) with severe injury mechanisms in children with minor blunt head trauma but with no other risk factors from the Pediatric Emergency Care Applied Research Network (PECARN) TBI prediction rules (defined as isolated severe injury mechanisms). Design: Secondary analysis of a large prospective observational cohort study. Setting: Twenty-five emergency departments participating in the PECARN. Patients: Children with minor blunt head trauma and Glasgow Coma Scale scores of at least 14. Intervention: Treating clinicians completed a structured data form that included injury mechanism (severity categories defined a priori). Main Outcome Measures: Clinically important TBIs were defined as intracranial injuries resulting in death, neurosurgical intervention, intubation for more than 24 hours, or hospital admission for at least 2 nights. We investigated the rate of clinically important TBIs in children with either severe injury mechanisms or isolated severe injury mechanisms. Results: Of the 42 412 patients enrolled in the overall study, 42 099 (99%) had injury mechanisms recorded, and their data were included for analysis. Of all study patients, 5869 (14%) had severe injury mechanisms, and 3302 (8%) had isolated severe injury mechanisms. Overall, 367 children had clinically important TBIs (0.9%; 95% CI, 0.8%-1.0%). Of the 1327 children younger than 2 years with isolated severe injury mechanisms, 4 (0.3%; 95% CI, 0.1%-0.8%) had clinically important TBIs, as did 12 of the 1975 children 2 years or older (0.6%; 95% CI, 0.3%-1.1%). Conclusion: Children with isolated severe injury mechanisms are at low risk of clinically important TBI, and many do not require emergent neuroimaging.	[Nigrovic, Lise E.; Lee, Lois K.] Harvard Univ, Childrens Hosp, Div Emergency Med, Sch Med, Boston, MA 02115 USA; [Hoyle, John] Michigan State Univ, Sch Med, Div Emergency Med, Helen DeVos Childrens Hosp, Grand Rapids, MI USA; [Stanley, Rachel M.] Univ Michigan, Univ Michigan Hlth Syst, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Gorelick, Marc H.] Med Coll Wisconsin, Childrens Hosp Wisconsin, Div Emergency Med, Milwaukee, WI 53226 USA; [Miskin, Michelle] Univ Utah, Sch Med, Salt Lake City, UT USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Pediat, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Emergency Med, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Pediat, Morgan Stanley Childrens Hosp New York Presbyteri, New York, NY 10032 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Dept Emergency Med, Sch Med, Davis, CA 95616 USA; [Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Dept Pediat, Sch Med, Davis, CA 95616 USA	Nigrovic, LE (corresponding author), Harvard Univ, Childrens Hosp, Div Emergency Med, Sch Med, 300 Longwood Ave, Boston, MA 02115 USA.	lise.nigrovic@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997; Tsung, James/0000-0002-4718-8325	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Division of Research, Training and Education (DRTE); Emergency Medical Services of Children (EMSC) [R40MC02461]; MCHB/HRSA [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]	This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Training and Education (DRTE), and the Emergency Medical Services of Children (EMSC) Program (R40MC02461). The Pediatric Emergency Care Applied Research Network (PECARN) is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 from the EMSC program of the MCHB/HRSA.	Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Dorfman AL, 2011, ARCH PEDIAT ADOL MED, V165, P458, DOI 10.1001/archpediatrics.2010.270; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Frush DP, 2009, RADIOLOGY, V252, P4, DOI 10.1148/radiol.2521090661; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2004, ARCH DIS CHILD, V89, P593, DOI 10.1136/adc.2003.046821; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6	17	63	63	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	APR	2012	166	4					356	361					6	Pediatrics	Pediatrics	918UU	WOS:000302277500009	22147762	Bronze			2021-06-18	
J	Siopi, E; Llufriu-Daben, G; Fanucchi, F; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehrani, M				Siopi, Eleni; Llufriu-Daben, Gemma; Fanucchi, Francesca; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz			Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: The effect of minocycline	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Memory impairment; Anxiety; Minocycline; Neuroprotection	CLINICAL NEUROPSYCHOLOGY; OBJECT RECOGNITION; MEMORY; SEVERITY; DEFICITS; MODEL; MODULATION; RECOVERY; BEHAVIOR; IMPACT	Comorbidity of cognitive and stress disorders is a common clinical sequel of traumatic brain injury (TBI) that is essentially determined by the site and severity of the insult, but also by the extent of the ensuing neuroinflammatory response. The present study sought to examine the late effects of closed-head TBI on memory function and anxiety in mice, in order to further examine the potential efficacy of an acute anti-inflammatory treatment with minocycline. The mouse model of closed-head injury by mechanical percussion was applied on anesthetized Swiss mice. The treatment protocol included three injections of minocycline (i.p.) at 5 min (90 mg/kg), 3 h and 9 h (45 mg/kg) post-TBI. The Novel Object Recognition Test as well as the Elevated Plus Maze (EPM) and Elevated Zero Maze (EZM) tasks were employed to assess post-TBI memory and anxiety respectively. Our results revealed a recognition memory deficit that was significant up to at least 13 weeks post-TBI. However, neither EPM nor EZM revealed any alteration in post-TBI anxiety levels albeit some mild disinhibition. Most importantly, minocycline was able to attenuate the memory impairment in an effective and lasting manner, highlighting its therapeutic potential in TBI. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Siopi, Eleni; Llufriu-Daben, Gemma; Fanucchi, Francesca; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA 4475, F-75006 Paris, France	Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA 4475, 4 Ave Observ, F-75006 Paris, France.	eleni.siopi@etu.parisdescartes.fr; gemmaldaben@hotmail.com; fanucchifrancesca@yahoo.it; michel.plotkine@parisdescartes.fr; catherine.marchand@parisdescartes.fr; mehrnaz.jafarian@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856	nonprofit organization "Fondation des Gueules Cassees"	This work was supported by the nonprofit organization "Fondation des Gueules Cassees" (Grants to ES and MJT). The authors would like to thank Dr. Florence Noble and Dr. Laurent Naudon for their kind contribution in the project.	Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Cook MN, 2002, BEHAV GENET, V32, P113, DOI 10.1023/A:1015249706579; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kondo K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-147; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mechan AO, 2009, J NEUROSCI METH, V180, P43, DOI 10.1016/j.jneumeth.2009.02.018; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nicholl J, 2009, SEMIN NEUROL, V29, P247, DOI 10.1055/s-0029-1223878; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	37	63	65	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 9	2012	511	2					110	115		10.1016/j.neulet.2012.01.051			6	Neurosciences	Neurosciences & Neurology	912AD	WOS:000301764900011	22314279				2021-06-18	
J	Viano, DC; Withnall, C; Halstead, D				Viano, David C.; Withnall, Chris; Halstead, David			Impact Performance of Modern Football Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Protective headgear; Recreation and sport; Concussion; Helmets; Sport equipment	PROFESSIONAL FOOTBALL; GAME IMPACTS; CONCUSSION; BIOMECHANICS; INJURIES; PLAYER	Linear impact tests were conducted on 17 modern football helmets. The helmets were placed on the Hybrid III head with the neck attached to a sliding table. The head was instrumented with an array of 3-2-2-2 accelerometers to determine translational acceleration, rotational acceleration, and HIC. Twenty-three (23) different impacts were conducted on four identical helmets of each model at eight sites on the shell and facemask, four speeds (5.5, 7.4, 9.3, and 11.2 m/s) and two temperatures (22.2 and 37.8 degrees C). There were 1,850 tests in total; 276 established the 1990s helmet performance (baseline) and 1,564 were on the 17 different helmet models. Differences from the 1990s baseline were evaluated using the Student t test (p < 0.05 as significant). Four of the helmets had significantly lower HICs and head accelerations than the 1990s baseline with average reductions of 14.6-21.9% in HIC, 7.3-14.0% in translational acceleration, and 8.4-15.9% in rotational acceleration. Four other helmets showed some improvements. Eight were not statistically different from the 1990s baseline and one had significantly poorer performance. Of the 17 helmet models, four provided a significant reduction in head responses compared to 1990s helmets.	[Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Withnall, Chris] Biokinet & Associates Ltd, Ottawa, ON K1H 1E1, Canada; [Halstead, David] Univ Tennessee, Coll Engn, Sports Biomech Impact Res Lab, Knoxville, TN 37996 USA; [Halstead, David] So Impact Res Ctr LLC, Rockford, TN 37853 USA	Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd,Hills, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net			NFL	The testing reported here was completed while the lead author was a member of the NFL's MTBI Committee and oversaw the evaluation program. The test plan was developed in mid-2009. The testing at Biokinetics and Associates Ltd. and Southern Impact Research Center, LLC was commissioned and the raw data was verified and accepted by ProBiomechanics LLC. The testing was funded by the NFL. The cooperation of Riddell, Schutt Sports, Adams USA, PSE (Protective Sport Equipment) and Xenith for supplying helmets for testing at Biokinetics and SIRC is appreciated. Both laboratories have previous and ongoing relationships with some of the helmet manufacturers. These were acknowledged at the onset. Xenith withdrew from participation in the program after receiving their test results. All manufacturers received a copy of their verified and analyzed data as well as the raw transducer responses and test video of their helmets. Identical helmet testing was conducted at each laboratory and the results were not shared between them. The merging of data and analysis was done by ProBiomechanics LLC without the involvement of the two laboratories, which were blinded from the others test results. The views presented here are those of the authors and not necessarily those of the NFL or any helmet manufacturer. Many individuals contributed to this helmet testing program and their assistance is greatly appreciated. Mr. Michael Wonnacott ran the impact tests and processed the raw data at Biokinetics and Associates, Ltd. Ms. Elizabeth McCalley ran the impact tests and processed the raw data at SIRC. Dr. Chantal Parenteau merged, tabulated and analyzed the combined data at ProBiomechanics LLC. All of the analyzed data, tables and figures were developed by ProBiomechanics LLC. Two independent researchers reviewed the data and subjected a subset to ANOVA analysis. Those results were shared with the NFL teams and players, and were included in a press release by the league about the helmet testing on July 23, 2010. The ANOVA analysis reached similar but not identical results to those presented here.	[Anonymous], 1998, 00298M03 NOCSAE; [Anonymous], 1998, 02198M05 NOCSAE; [Anonymous], 2004, 00104M05 NOCSAE; Bland M., 2000, INTRO MED STAT; Craig M. J., 2007, THESIS WAYNE STATE U; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Horsch J. D., 1987, 870222 SAE INT; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S., 2009, J BIOMECH ENG, V131, P610; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; *SAE, 1980, J855 SAE; Society of Automotive Engineers (SAE), 1995, J2111 SAE; Society of Automotive Engineers (SAE), 1994, J1733 SAE; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	21	63	63	0	36	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964			ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		160	174		10.1007/s10439-011-0384-4			15	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700015	22012079				2021-06-18	
J	Kuehn, R; Simard, PF; Driscoll, I; Keledjian, K; Ivanova, S; Tosun, C; Williams, A; Bochicchio, G; Gerzanich, V; Simard, JM				Kuehn, Reed; Simard, Philippe F.; Driscoll, Ian; Keledjian, Kaspar; Ivanova, Svetlana; Tosun, Cigdem; Williams, Alicia; Bochicchio, Grant; Gerzanich, Volodymyr; Simard, J. Marc			Rodent Model of Direct Cranial Blast Injury	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid precursor protein; caspase-3; primary blast injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; RAT-BRAIN; INTRACRANIAL-PRESSURE; COGNITIVE FUNCTION; CIVILIAN INJURIES; EXPLOSIVE BLAST; AXONAL INJURY	Traumatic brain injury resulting from an explosive blast is one of the most serious wounds suffered by war-fighters, yet the effects of explosive blast overpressure directly impacting the head are poorly understood. We developed a rodent model of direct cranial blast injury (dcBI), in which a blast overpressure could be delivered exclusively to the head, precluding indirect brain injury via thoracic transmission of the blast wave. We constructed and validated a Cranium Only Blast Injury Apparatus (COBIA) to deliver blast overpressures generated by detonating .22 caliber cartridges of smokeless powder. Blast waveforms generated by COBIA replicated those recorded within armored vehicles penetrated by munitions. Lethal dcBI (LD(50) similar to 515 kPa) was associated with: (1) apparent brainstem failure, characterized by immediate opisthotonus and apnea leading to cardiac arrest that could not be overcome by cardiopulmonary resuscitation; (2) widespread subarachnoid hemorrhages without cortical contusions or intracerebral or intraventricular hemorrhages; and (3) no pulmonary abnormalities. Sublethal dcBI was associated with: (1) apnea lasting up to 15 sec, with transient abnormalities in oxygen saturation; (2) very few delayed deaths; (3) subarachnoid hemorrhages, especially in the path of the blast wave; (4) abnormal immunolabeling for IgG, cleaved caspase-3, and beta-amyloid precursor protein (beta-APP), and staining for Fluoro-Jade C, all in deep brain regions away from the subarachnoid hemorrhages, but in the path of the blast wave; and (5) abnormalities on the accelerating Rotarod that persisted for the 1 week period of observation. We conclude that exposure of the head alone to severe explosive blast predisposes to significant neurological dysfunction.	[Simard, Philippe F.; Keledjian, Kaspar; Ivanova, Svetlana; Tosun, Cigdem; Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Bochicchio, Grant] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Kuehn, Reed; Driscoll, Ian; Williams, Alicia] Walter Reed Army Med Ctr, Dept Surg, Washington, DC 20307 USA; [Bochicchio, Grant] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Shaheen, Ahmed/AAP-4054-2021; Tosun, Cigdem/AAG-4026-2020	Shaheen, Ahmed/0000-0002-2216-1951; 	Department of the Army (U.S. Army Medical Research Acquisition Activity) [PT074766, MD 21702-5014]	This work was supported by a grant to J.M.S. from the Department of the Army (PT074766; the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering acquisition office). The information in this article does not necessarily reflect the position or the policy of the United States Government, and no official endorsement should be inferred.	Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 1997, TOXICOLOGY, V121, P65, DOI 10.1016/S0300-483X(97)03656-1; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bochicchio GV, 2008, AM SURGEON, V74, P267; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Clemedson J. C., 1956, PHYSIOL REV, V36, P336; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HARVEY J, 1984, PRAMANA, V22, P447, DOI 10.1007/BF02847111; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; RICHMOND R, 1961, AEROSPACE MED, V32, P997; RICHMOND R, 1962, AEROSPACE MED, V33, P1; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Zajtchuk R, 1991, CONVENTIONAL WARFARE, P241; Zel'dovich Y.B., 1966, PHYS SHOCK WAVES HIG	49	63	64	0	20	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2155	2169		10.1089/neu.2010.1532			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500016	21639724	Bronze			2021-06-18	
J	Brien, M; Sveistrup, H				Brien, Marie; Sveistrup, Heidi			An Intensive Virtual Reality Program Improves Functional Balance and Mobility of Adolescents With Cerebral Palsy	PEDIATRIC PHYSICAL THERAPY			English	Article						adolescent; cerebral palsy; computer simulation; computer-user interface; motor activity; postural balance; psychomotor performance; walking	GROSS MOTOR FUNCTION; TRAUMATIC BRAIN-INJURY; SCHOOL-AGED CHILDREN; 6-MINUTE WALK TEST; COMMUNITY BALANCE; CLASSIFICATION; FEASIBILITY; RELIABILITY; STABILITY; EXERCISE	Purpose: To examine functional balance and mobility in adolescents with cerebral palsy classified at Gross Motor Function Classification System (GMFCS) level I following an intensive short-duration virtual reality (VR) intervention. Methods: Single-subject, multiple-baseline design with 4 adolescents. Outcomes included the Community Balance and Mobility Scale (CB&M), the 6-Minute Walk Test (6MWT), the Timed Up and Down Stairs, and the Gross Motor Function Measure Dimension E. Assessments were recorded 3 to 6 times at baseline, 5 times during intervention, and 4 times at follow-up. Daily 90-minute VR intervention was completed for 5 consecutive days. Visual, statistical, and clinical significance analyses were used. Results: Statistically significant improvements were shown in all adolescents on CB&M and 6MWT. True change was recorded in all for the CB&M and in 3 for the 6MWT. Conclusions: Functional balance and mobility in adolescents with cerebral palsy classified at GMFCS level I improve with intense, short duration VR intervention, and changes are maintained at 1-month posttraining. (Pediatr Phys Ther 2011;23:258-266)	[Brien, Marie] Univ Ottawa, Ottawa Childrens Treatment Ctr, Fac Hlth Sci, Ottawa, ON, Canada; [Sveistrup, Heidi] Univ Ottawa, Sch Rehabil Sci, Fac Hlth Sci, Ottawa, ON, Canada	Brien, M (corresponding author), 395 Smyth Rd, Ottawa, ON K1H 8L2, Canada.	mbrien@octc.ca			TD Bank Financial Group	This project was funded by the TD Bank Financial Group, which provided a TD grant in medical excellence.	Bjornson KF, 2007, PHYS THER, V87, P248, DOI 10.2522/ptj.20060157; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Burtner P A, 2007, Dev Neurorehabil, V10, P249, DOI 10.1080/17518420701303066; Chen YP, 2007, PHYS THER, V87, P1441, DOI 10.2522/ptj.20060062; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Damiano DL, 2006, PHYS THER, V86, P1534, DOI 10.2522/ptj.20050397; Damiano DL, 2009, J CHILD NEUROL, V24, P1200, DOI 10.1177/0883073809337919; Hanna SE, 2009, DEV MED CHILD NEUROL, V51, P295, DOI 10.1111/j.1469-8749.2008.03196.x; Howe JA, 2006, CLIN REHABIL, V20, P885, DOI 10.1177/0269215506072183; Logan LR, 2008, DEV MED CHILD NEUROL, V50, P99, DOI 10.1111/j.1469-8749.2007.02005.x; Maher CA, 2008, INT J REHABIL RES, V31, P185, DOI 10.1097/MRR.0b013e32830150f9; Oeffinger D, 2007, DEV MED CHILD NEUROL, V49, P172, DOI 10.1111/j.1469-8749.2007.00172.x; Ottenbacher KJ, 1986, EVALUATING CLIN CHAN; Palisano RJ, 2008, DEV MED CHILD NEUROL, V50, P744, DOI 10.1111/j.1469-8749.2008.03089.x; Penn PR, 2009, DEV NEUROREHABIL, V12, P32, DOI 10.1080/17518420902739365; Portney LG, 2009, FDN CLIN RES APPL PR; Provost Beth, 2007, Pediatr Phys Ther, V19, P2, DOI 10.1097/01.pep.0000249418.25913.a3; Reid D., 2002, TECHNOL DISABIL, V14, P53, DOI [10.3233/TAD-2002-14202, DOI 10.3233/TAD-2002-14202]; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Rosenbaum PL, 2002, JAMA-J AM MED ASSOC, V288, P1357, DOI 10.1001/jama.288.11.1357; Russell D., 2002, CLIN DEV MED; Sandstrom K, 2004, DISABIL REHABIL, V26, P1023, DOI 10.1080/09638280410001703503; Thompson P, 2008, DEV MED CHILD NEUROL, V50, P370, DOI 10.1111/j.1469-8749.2008.02048.x; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Wilson A, 2011, PHYS OCCUP THER PEDI, V31, P135, DOI 10.3109/01942638.2010.489543; Woollacott M, 2005, DEV MED CHILD NEUROL, V47, P455, DOI 10.1017/S0012162205000885; Wright FV, 2010, BRAIN INJURY, V24, P1585, DOI 10.3109/02699052.2010.523045; You SH, 2005, DEV MED CHILD NEUROL, V47, P628, DOI 10.1017/S0012162205001234; Zaino Christopher A, 2004, Pediatr Phys Ther, V16, P90, DOI 10.1097/01.PEP.0000127564.08922.6A	29	63	66	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-5669	1538-005X		PEDIATR PHYS THER	Pediatr. Phys. Ther.	FAL	2011	23	3					258	266		10.1097/PEP.0b013e318227ca0f			9	Pediatrics; Rehabilitation	Pediatrics; Rehabilitation	896HO	WOS:000300556500010	21829120				2021-06-18	
J	Samuels, O; Webb, A; Culler, S; Martin, K; Barrow, D				Samuels, Owen; Webb, Adam; Culler, Steve; Martin, Kathleen; Barrow, Daniel			Impact of a Dedicated Neurocritical Care Team in Treating Patients with Aneurysmal Subarachnoid Hemorrhage	NEUROCRITICAL CARE			English	Article						Subarachnoid hemorrhage; Neurocritical care; Discharge outcomes; Cerebral aneurysm; Neurointensivist	INTENSIVE-CARE; INTRACRANIAL ANEURYSMS; ILL PATIENTS; UNIT; OUTCOMES; MORTALITY; LENGTH; TIME	Background Intensivist staffing of intensive care units (ICUs) has been associated with a reduction in in-hospital mortality. These improvements in patient outcomes have been extended to neurointensivist staffing of neuroscience ICUs for patients with intracranial hemorrhage and traumatic brain injury. Objective The primary objective of this study is to determine if hospital outcomes (measured by discharge status) for patients admitted with aneurysmal subarachnoid hemorrhage changed after the introduction of a neurointensivist-led multidisciplinary neurocritical care team. Methods The authors retrospectively identified 703 patients admitted to the neuroscience ICU with a diagnosis of aneurysmal subarachnoid hemorrhage at a single academic tertiary care hospital between January 1, 1995 and December 31, 2002. It was compared with discharge outcomes for those patients treated prior to and following the development of a multidisciplinary neurocritical care team. Results Patients treated after the introduction of a neurocritical care team were significantly more likely to be discharged to home (25.2% vs. 36.5%) and less likely to be discharged to a rehab facility (25.2% vs. 36.5%). Patients treated after introduction of a neurocritical care team were also more likely to receive definitive aneurysm treatment (10.9% vs. 18%). Conclusion The implementation of a neurointensivist-led neurocritical care team is associated with improved hospital discharge disposition for patients with aneurysmal subarachnoid hemorrhage.	[Samuels, Owen; Webb, Adam; Martin, Kathleen; Barrow, Daniel] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA; [Samuels, Owen; Webb, Adam] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Samuels, Owen; Webb, Adam; Culler, Steve; Martin, Kathleen; Barrow, Daniel] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA	Samuels, O (corresponding author), Emory Univ, Sch Med, Dept Neurosurg, 1365 Clifton Rd NE, Atlanta, GA 30322 USA.	obsamue@emory.edu		Culler, Steven/0000-0002-6905-1186; Barrow, Daniel/0000-0003-0413-7883			Andaluz N, 2008, J NEUROSURG, V108, P1163, DOI 10.3171/JNS/2008/108/6/1163; Blunt MC, 2000, LANCET, V356, P735, DOI 10.1016/S0140-6736(00)02634-9; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Dimick JB, 2000, CRIT CARE MED, V28, pA77; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Krishnamurthy S, 2007, NEUROSURGERY, V61, P475, DOI 10.1227/01.NEU.0000290892.46954.12; *LEAPF GROUP PAT S, 2004, FACT SHEET ICU PHYS; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Milstein A, 2000, Eff Clin Pract, V3, P313; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Rosenfeld BA, 2000, CRIT CARE MED, V28, P3925, DOI 10.1097/00003246-200012000-00034; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713	21	63	67	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	JUN	2011	14	3					334	340		10.1007/s12028-011-9505-z			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	759FT	WOS:000290226800002	21424884				2021-06-18	
J	Cuthbert, JP; Corrigan, JD; Harrison-Felix, C; Coronado, V; Dijkers, MP; Heinemann, AW; Whiteneck, GG				Cuthbert, Jeffrey P.; Corrigan, John D.; Harrison-Felix, Cynthia; Coronado, Victor; Dijkers, Marcel P.; Heinemann, Allen W.; Whiteneck, Gale G.			Factors That Predict Acute Hospitalization Discharge Disposition for Adults With Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Healthcare disparities; Hospitalization; Nursing homes, Patient discharge; Rehabilitation; Rehabilitation centers	MODEL SYSTEMS; ACUTE-CARE; OUTCOMES; MORTALITY; OLDER; INSURANCE; ACCESS; HEALTH; AGE; DISABILITY	Objective: To identify factors predicting acute hospital discharge disposition after moderate to severe traumatic brain injury (TBI). Design: Secondary analysis of existing datasets. Setting: Acute care hospitals. Participants: Adults hospitalized with moderate to severe TBI included in 3 large sets of archival data: (1) Centers for Disease Control and Prevention Central Nervous System Injury Surveillance database (n=15,646); (2) the National Trauma Data Bank (n=52,012); and (3) the National Study on the Costs and Outcomes of Trauma (n=1286). Interventions: None. Main Outcome Measure: Discharge disposition from acute hospitalization to 1 of 3 postacute settings: (1) home, (2) inpatient rehabilitation, or (3) subacute settings, including nursing homes and similar facilities. Results: The Glasgow Coma Scale (GCS) score and length of acute hospital length of stay (LOS) accounted for 35% to 44% of the variance in discharges to home versus not home, while age and sex added from 5% to 8%, and race/ethnicity and hospitalization payment source added another 2% to 5%. When predicting discharge to rehabilitation versus subacute care for those not going home, GCS and LOS accounted for 2% to 4% of the variance, while age and sex added 7% to 31%, and race/ethnicity and payment source added 4% to 5%. Across the datasets, longer LOS, older age, and white race increased the likelihood of not being discharged home; the most consistent predictor of discharge to rehabilitation was younger age. Conclusions: The decision to discharge to home a person with moderate to severe TBI appears to be based primarily on severity-related factors. In contrast, the decision to discharge to rehabilitation rather than to subacute care appears to reflect sociobiologic and socioeconomic factors; however, generalizability of these results is limited by the restricted range of potentially important variables available for analysis.	[Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Coronado, Victor] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA	Cuthbert, JP (corresponding author), 3425 S Clarkson St, Englewood, CO 80113 USA.	JCuthbert@Craighospital.org	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012; Corrigan, John D./E-2921-2011	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, U.S. Department of EducationUS Department of Education [H133A060038]; Traumatic Brain Injury Model System Centers [H133A070022]; Ohio State UniversityOhio State University [H133A070029]; Mount Sinai Medical Center [H133A070033]; Rehabilitation Institute of Chicago [H133A080045]	Supported by a supplemental grant to the Traumatic Brain Injury Model Systems National Data and Statistical Center from the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, U.S. Department of Education (grant no. H133A060038): and Traumatic Brain Injury Model System Centers grants to Craig Hospital (grant no. H133A070022), Ohio State University (grant no. H133A070029), Mount Sinai Medical Center (grant no. H133A070033), and the Rehabilitation Institute of Chicago (grant no. H133A080045).	Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BODOFSKY E, 2010, INT BRAIN INJ ASS 8; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; CROSS J, 2003, MMWR-MORBID MORTAL W, V52, P276; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; GOLEBURN CR, 2001, J CLIN GEROPSYCHOLOG, V7, P161; Hadley J, 2006, HEALTH AFFAIR, V25, P1679, DOI 10.1377/hlthaff.25.6.1679; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Labi MLC, 2003, BRAIN INJURY, V17, P265, DOI 10.1080/0269905021000038410; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Malec JF, 2009, BRAIN INJURY, V23, P22, DOI 10.1080/02699050802590320; Marr AL., 2004, CENTRAL NERVOUS SYST; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Okoro CA, 2005, J HEALTH CARE POOR U, V16, P453, DOI 10.1353/hpu.2005.0058; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Richardson LD, 2010, MT SINAI J MED, V77, P166, DOI 10.1002/msj.20174; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; Sentell T, 2007, J GEN INTERN MED, V22, P289, DOI 10.1007/s11606-007-0345-7; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shahian DM, 2007, CIRCULATION, V115, P1518, DOI 10.1161/CIRCULATIONAHA.106.633008; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; *US DEP HHS, 2004, INT CLASS DIS 9 REV; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	40	63	65	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2011	92	5					721	730		10.1016/j.apmr.2010.12.023			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	759YO	WOS:000290288000005	21530719				2021-06-18	
J	Kilbaugh, TJ; Bhandare, S; Lorom, DH; Saraswati, M; Robertson, CL; Margulies, SS				Kilbaugh, Todd J.; Bhandare, Sunita; Lorom, David H.; Saraswati, Manda; Robertson, Courtney L.; Margulies, Susan S.			Cyclosporin A Preserves Mitochondrial Function after Traumatic Brain Injury in the Immature Rat and Piglet	JOURNAL OF NEUROTRAUMA			English	Article						cerebral microdialysis; cyclosporin A; mitochondrial bioenergetics; neuroprotection; pediatric brain injury	MATURATION-DEPENDENT RESPONSE; DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; OXIDATIVE STRESS; PERMEABILITY TRANSITION; CYTOCHROME-C; CEREBRAL METABOLISM; DAMAGE; DYSFUNCTION; CALCIUM	Cyclosporin A (CsA) has been shown to be neuroprotective in mature animal models of traumatic brain injury (TBI), but its effects on immature animal models of TBI are unknown. In mature animal models, CsA inhibits the opening of the mitochondrial permeability transition pore (MPTP), thereby maintaining mitochondrial homeostasis following injury by inhibiting calcium influx and preserving mitochondrial membrane potential. The aim of the present study was to evaluate CsA's ability to preserve mitochondrial bioenergetic function following TBI (as measured by mitochondrial respiration and cerebral microdialysis), in two immature models (focal and diffuse), and in two different species (rat and piglet). Three groups were studied: injured + CsA, injured + saline vehicle, and uninjured shams. In addition, we evaluated CsA's effects on cerebral hemodynamics as measured by a novel thermal diffusion probe. The results demonstrate that post-injury administration of CsA ameliorates mitochondrial dysfunction, preserves cerebral blood flow (CBF), and limits neuropathology in immature animals 24 h post-TBI. Mitochondria were isolated 24 h after controlled cortical impact (CCI) in rats and rapid non-impact rotational injury (RNR) in piglets, and CsA ameliorated cerebral bioenergetic crisis with preservation of the respiratory control ratio (RCR) to sham levels. Results were more dramatic in RNR piglets than in CCI rats. In piglets, CsA also preserved lactate pyruvate ratios (LPR), as measured by cerebral microdialysis and CBF at sham levels 24 h after injury, in contrast to the significant alterations seen in injured piglets compared to shams (p<0.01). The administration of CsA to piglets following RNR promoted a 42% decrease in injured brain volume (p<0.01). We conclude that CsA exhibits significant neuroprotective activity in immature models of focal and diffuse TBI, and has exciting translational potential as a therapeutic agent for neuroprotection in children.	[Lorom, David H.; Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Kilbaugh, Todd J.] Univ Penn, Sch Med Anesthesiol & Crit Care Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Bhandare, Sunita] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Saraswati, Manda; Robertson, Courtney L.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Margulies, SS (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu		Kilbaugh, Todd/0000-0002-4959-3092	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679]; Endowed Chair of Anesthesiology and Critical Care Medicine at the Children's Hospital of Philadelphia; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545, R01NS039679] Funding Source: NIH RePORTER	These studies were supported by NIH/NINDS grant R01NS039679 and the Endowed Chair of Anesthesiology and Critical Care Medicine at the Children's Hospital of Philadelphia. We are thankful for the technical and scientific assistance of Trupti Akella, Stuart Friess, Jill Ralston, and Gary Fiskum.	Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BATES TE, 1994, DEV NEUROSCI-BASEL, V16, P321, DOI 10.1159/000112126; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; de Gatta MDF, 2002, CLIN PHARMACOKINET, V41, P115; DELMAESTRO R, 1987, MECH AGEING DEV, V41, P29, DOI 10.1016/0047-6374(87)90051-0; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Eliseev RA, 2007, NEUROBIOL AGING, V28, P1532, DOI 10.1016/j.neurobiolaging.2006.06.022; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fukui S, 2003, ACT NEUR S, V86, P301; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Ghafari A, 2007, TRANSPL P, V39, P1219, DOI 10.1016/j.transproceed.2007.03.014; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hoyert Donna L, 2006, Natl Vital Stat Rep, V54, P1; Hutchinson PJ, 2005, ACTA NEUROCHIR SUPPL, V95, P441; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hwang JH, 2010, BRAIN RES, V1359, P208, DOI 10.1016/j.brainres.2010.08.047; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Leger PL, 2010, EXP NEUROL; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Lie RH, 2010, ACTA ANAESTH SCAND, V54, P804, DOI 10.1111/j.1399-6576.2010.02241.x; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Nakai A, 2004, PEDIATR NEUROL, V30, P247, DOI 10.1016/j.pediatrneurol.2003.09.006; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nishiyama A, 2003, HYPERTENSION, V42, P754, DOI 10.1161/01.HYP.0000085195.38870.44; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Patrick PD, 2006, J CHILD NEUROL, V21, P879, DOI 10.1177/08830738060210100901; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; Setkowicz Z, 2004, EPILEPSY RES, V61, P63, DOI 10.1016/j.eplepsyres.2004.06.001; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Turner MS, 2003, ACT NEUR S, V87, P81; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3	94	63	64	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					763	774		10.1089/neu.2010.1635			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100277	21250918	Green Published			2021-06-18	
J	Khuman, J; Meehan, WP; Zhu, XX; Qiu, JH; Hoffmann, U; Zhang, J; Giovannone, E; Lo, EH; Whalen, MJ				Khuman, Jugta; Meehan, William P., III; Zhu, Xiaoxia; Qiu, Jianhua; Hoffmann, Ulrike; Zhang, Jimmy; Giovannone, Eric; Lo, Eng H.; Whalen, Michael J.			Tumor necrosis factor alpha and Fas receptor contribute to cognitive deficits independent of cell death after concussive traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cognition; concussion; inflammation; mice; traumatic brain injury; tumor necrosis factor	CLOSED-HEAD INJURY; HIPPOCAMPAL SYNAPTIC PLASTICITY; NEURONAL LOSS; TNF-ALPHA; RAT; MEMORY; INVOLVEMENT; IMPAIRMENT; EXPRESSION; MODEL	Tumor necrosis factor alpha (TNF alpha) and Fas receptor contribute to cell death and cognitive dysfunction after focal traumatic brain injury (TBI). We examined the role of TNF alpha/Fas in postinjury functional outcome independent of cell death in a novel closed head injury (CHI) model produced with weight drop and free rotational head movement in the anterior-posterior plane. The CHI produced no cerebral edema or blood-brain barrier damage at 24 to 48 hours, no detectable cell death, occasional axonal injury (24 hours), and no brain atrophy or hippocampal cell loss (day 60). Microglia and astrocytes were activated (48 to 72 hours). Tumor necrosis factor-alpha mRNA, Fas mRNA, and TNF alpha protein were increased in the brain at 3 to 6 hours after injury (P < 0.001 versus sham injured). In wild-type (WT) mice, CHI produced hidden platform (P = 0.009) and probe deficits (P = 0.001) in the Morris water maze versus sham. Surprisingly, injured TNF alpha/Fas knockout (KO) mice performed worse in hidden platform trials (P = 0.036) but better in probe trials than did WT mice (P = 0.0001). Administration of recombinant TNF alpha to injured TNF alpha/Fas KO mice reduced probe trial performance to that of WT. Thus, TNF alpha/Fas influence cognitive deficits independent of cell death after CHI. Therapies targeting TNF alpha/Fas together may be inappropriate for patients with concussive TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 778-789; doi:10.1038/jcbfm.2010.172; published online 13 October 2010	[Khuman, Jugta; Zhang, Jimmy; Giovannone, Eric; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Khuman, Jugta; Meehan, William P., III; Zhu, Xiaoxia; Qiu, Jianhua; Hoffmann, Ulrike; Zhang, Jimmy; Giovannone, Eric; Lo, Eng H.; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Meehan, William P., III] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med,Dept Med, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Sports Med,Dept Orthoped,Sports Concuss Clin, Boston, MA USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [Qiu, Jianhua; Hoffmann, Ulrike; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA.	mwhalen@partners.org			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040128-06]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447]; MGH Center for the Integration of Medicine and Technology (CIMIT); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, R01NS064545] Funding Source: NIH RePORTER	This work was supported by grants from NICHD T32 HD040128-06 (WM), NINDS 5RO1NS047447 (MJW), and MGH Center for the Integration of Medicine and Technology (CIMIT) (MJW).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Albensi BC, 2000, SYNAPSE, V35, P151; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Corsini NS, 2009, CELL STEM CELL, V5, P178, DOI 10.1016/j.stem.2009.05.004; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gerlai R, 2001, BEHAV BRAIN RES, V125, P269, DOI 10.1016/S0166-4328(01)00296-0; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Qiu JH, 2002, J NEUROSCI, V22, P3504; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	37	63	65	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2011	31	2					778	789		10.1038/jcbfm.2010.172			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	715XY	WOS:000286930100038	20940727	Bronze, Green Published			2021-06-18	
J	Eucker, SA; Smith, C; Ralston, J; Friess, SH; Margulies, SS				Eucker, Stephanie A.; Smith, Colin; Ralston, Jill; Friess, Stuart H.; Margulies, Susan S.			Physiological and histopathological responses following closed rotational head injury depend on direction of head motion	EXPERIMENTAL NEUROLOGY			English	Article						Animal models; Brain ischemia; Brain trauma; Cerebral blood flow; Neuropathology; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; AXONAL INJURY; YOUNG-CHILDREN; WHITE-MATTER; BETA-APP; DAMAGE; TIME; AGE; MECHANISMS	Rotational inertial forces are thought to be the underlying mechanism for most severe brain injuries. However, little is known about the effect of head rotation direction on injury outcomes, particularly in the pediatric population. Neonatal piglets were subjected to a single non-impact head rotation in the horizontal, coronal, or sagittal direction, and physiological and histopathological responses were observed. Sagittal rotation produced the longest duration of unconsciousness, highest incidence of apnea, and largest intracranial pressure increase, while coronal rotation produced little change, and horizontal rotation produced intermediate and variable derangements. Significant cerebral blood flow reductions were observed following sagittal but not coronal or horizontal injury compared to sham. Subarachnoid hemorrhage, ischemia, and brainstem pathology were observed in the sagittal and horizontal groups but not in a single coronal animal. Significant axonal injury occurred following both horizontal and sagittal rotations. For both groups, the distribution of injury was greater in the frontal and parietotemporal lobes than in the occipital lobes, frequently occurred in the absence of ischemia, and did not correlate with regional cerebral blood flow reductions. We postulate that these direction-dependent differences in injury outcomes are due to differences in tissue mechanical loading produced during head rotation. (C) 2010 Elsevier Inc. All rights reserved.	[Eucker, Stephanie A.; Ralston, Jill; Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Smith, Colin] Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland; [Friess, Stuart H.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Eucker, Stephanie/AAL-1828-2021	Eucker, Stephanie/0000-0001-9986-5773	American Heart AssociationAmerican Heart Association; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	The authors would like to thank Dr. Nicole Ibrahim, Dr. Brittany Coats, Rahul Natesh, Sarah Casey, and Alison Agres for their valuable technical expertise. This research was funded by the American Heart Association and NIH R01 NS39679.	ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Arbogast KB, 2005, PEDIATRICS, V116, P180, DOI 10.1542/peds.2004-2671; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Baiden-Amissah K, 1998, NEUROPATH APPL NEURO, V24, P346; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Chieregato A, 2004, J NEUROTRAUM, V21, P655, DOI 10.1089/0897715041269669; Cotran RS, 1999, ROBBINS PATHOLOGIC B; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Eucker SA, 2010, BRAIN RES, V1326, P128, DOI 10.1016/j.brainres.2010.02.059; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1987, STAPP CAR CRASH C, P49; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LAPTOOK AR, 1983, BRAIN RES, V276, P51, DOI 10.1016/0006-8993(83)90547-4; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Maxwell WL, 1991, J NEUROTRAUM, V8, P271, DOI 10.1089/neu.1991.8.271; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; Shiina G, 1998, AM J NEURORADIOL, V19, P297; SISSON S, 1975, J NEUROSURG, V93, P315; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; Tanaka Y, 1998, EUR J PHARMACOL, V356, P225, DOI 10.1016/S0014-2999(98)00547-0; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; THIBAULT LE, 1991, STRAIN DEPENDENT ISC, P101; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410	41	63	65	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2011	227	1					79	88		10.1016/j.expneurol.2010.09.015			10	Neurosciences	Neurosciences & Neurology	708NF	WOS:000286367800012	20875409	Green Accepted			2021-06-18	
S	Lok, J; Leung, W; Murphy, S; Butler, W; Noviski, N; Lo, EH		Zhang, JH; Colohan, A		Lok, Josephine; Leung, Wendy; Murphy, Sarah; Butler, William; Noviski, Natan; Lo, Eng H.			Intracranial Hemorrhage: Mechanisms of Secondary Brain Injury	INTRACEREBRAL HEMORRHAGE RESEARCH: FROM BENCH TO BEDSIDE	Acta Neurochirurgica Supplementum		English	Article; Book Chapter						Intracranial hemorrhage; Heme toxicity; Iron toxicity; Coagulation; Inflammation; Vascular response	TRAUMATIC INTRACEREBRAL HEMORRHAGE; CEREBRAL-ARTERY OCCLUSION; SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; RAT MODEL; INFLAMMATION; HEME; HAPTOGLOBIN; HEMOGLOBIN	ICH is a disease with high rates of mortality and morbidity, with a substantial public health impact. Spontaneous ICH (sICH) has been extensively studied, and a large body of data has been accumulated on its pathophysiology. However, the literature on traumatic ICH (tICH) is limited, and further investigations of this important topic are needed. This review will highlight some of the cellular pathways in ICH with an emphasis on the mechanisms of secondary injury due to heme toxicity and to events in the coagulation process that are common to both sICH and tICH.	[Lok, Josephine; Leung, Wendy; Lo, Eng H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Boston, MA 02114 USA; [Lok, Josephine; Leung, Wendy; Murphy, Sarah; Noviski, Natan] Massachusetts Gen Hosp, Dept Pediat Pediat Crit Care Med, Boston, MA 02114 USA; [Butler, William] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA	Lok, J (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Boston, MA 02114 USA.	jlok1@partners.org			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37 NS037074, K08 NS057339, R01 NS076694, K08NS057339, R01 NS053560-05, P01 NS055104, K08 NS057339-02, R01 NS053560, P01 NS055104-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076694, R01NS053560, K08NS057339, R37NS037074, P01NS055104] Funding Source: NIH RePORTER		Akopov S, 1996, CEREBROVAS BRAIN MET, V8, P11; ALLISON AC, 1957, BRIT MED J, V2, P1137, DOI 10.1136/bmj.2.5054.1137; Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; AUER LM, 1985, J CEREBR BLOOD F MET, V5, P517, DOI 10.1038/jcbfm.1985.78; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Bhasin RR, 2002, ACTA NEUROCHIR SUPPL, V81, P249; Buehler PW, 2009, BLOOD, V113, P2578, DOI 10.1182/blood-2008-08-174466; Canolle B, 2004, J NEUROCHEM, V88, P1521, DOI 10.1046/j.1471-4159.2003.02301.x; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; FEIN JM, 1974, J NEUROSURG, V41, P49, DOI 10.3171/jns.1974.41.1.0049; Ferris CD, 1999, NAT CELL BIOL, V1, P152; Gecse A, 1999, INT ARCH ALLERGY IMM, V118, P166, DOI 10.1159/000024057; Gomis P, 2000, HISTOCHEM J, V32, P673, DOI 10.1023/A:1004115432660; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Ishikawa M, 2004, FRONT BIOSCI-LANDMRK, V9, P1339, DOI 10.2741/1330; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Kai Y, 2008, J PHARMACOL SCI, V108, P426, DOI 10.1254/jphs.08R11FM; Keep RF, 2008, ACT NEUR S, V105, P73; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; KHALIL Z, 1990, BRAIN RES, V527, P292, DOI 10.1016/0006-8993(90)91149-B; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; LEE PY, 1990, AGENTS ACTIONS, V30, P67, DOI 10.1007/BF01969000; Mander P, 2005, J NEUROSCI RES, V79, P208, DOI 10.1002/jnr.20285; MAYBERG MR, 1990, J NEUROSURG, V72, P626, DOI 10.3171/jns.1990.72.4.0626; Min KJ, 2006, J NEUROSCI, V26, P1880, DOI 10.1523/JNEUROSCI.3696-05.2006; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Morel O, 2008, PLATELETS, V19, P9, DOI 10.1080/09537100701817232; Muhonen MG, 1997, J NEUROSURG, V87, P301, DOI 10.3171/jns.1997.87.2.0301; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P493, DOI 10.1139/o69-077; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Schrieber M, 2007, J TRAUMA, V63, P1261; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stern M, 1996, AM J PATHOL, V149, P911; Stoll G, 2004, BRAIN PATHOL, V14, P51, DOI 10.1111/j.1750-3639.2004.tb00497.x; Sugawara T, 2009, STROKE, V40, P1530, DOI 10.1161/STROKEAHA.108.531699; Thiex Ruth, 2007, Neurosurg Focus, V22, pE6; UEMURA Y, 1987, J NEUROSURG, V66, P741, DOI 10.3171/jns.1987.66.5.0741; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Vergouwen MDI, 2008, J CEREBR BLOOD F MET, V28, P1761, DOI 10.1038/jcbfm.2008.74; WADA T, 1970, J RETICULOENDOTH SOC, V8, P185; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Wang YP, 2001, REDOX REP, V6, P379, DOI 10.1179/135100001101536580; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; YAMAMOTO Y, 1990, NEUROSURGERY, V27, P921, DOI 10.1227/00006123-199012000-00010; Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009	66	63	67	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, A-1201 VIENNA, AUSTRIA	0065-1419		978-3-7091-0692-1	ACTA NEUROCHIR SUPPL	Acta Neurochir. Suppl.		2011	111						63	69		10.1007/978-3-7091-0693-8_11	10.1007/978-3-7091-0693-8		7	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	BGT35	WOS:000324076300011	21725733	Green Accepted			2021-06-18	
J	Schonberger, M; Ponsford, J				Schoenberger, Michael; Ponsford, Jennie			The factor structure of the Hospital Anxiety and Depression Scale in individuals with traumatic brain injury	PSYCHIATRY RESEARCH			English	Article						Hospital Anxiety and Depression Scale (HADS); Traumatic Brain Injury (TBI); Confirmatory Factor Analysis; Multi-Trait Multi-Method/Correlated; Trait-Correlated Method approach; Diagnosis	SELF-ESTEEM SCALE; MOOD DISORDERS; MODEL; DIMENSIONALITY; VALIDATION; INVARIANCE; VALIDITY	There is a lack of validated scales for screening for anxiety and depression in individuals with traumatic brain injury (TB!). The purpose of this study was to examine the factor structure of the Hospital Anxiety and Depression Scale (HADS) in individuals with TBI. A total of 294 individuals with TBI (72.1% male; mean age 37.1 years, S.D. 17.5, median post-traumatic amnesia (PTA) duration 17 days) completed the HADS 1 year post-injury. A series of confirmatory factor analyses was conducted to examine the fit of a one-, two- and three-factor solution, with and without controlling for item wording effects (Multi-Trait Multi-Method approach). The one-, two- or three-factor model fit the data only when controlling for negative item wording. The results are in support of the validity of the original anxiety and depression subscales of the HADS and demonstrate the importance of evaluating item wording effects when examining the factor structure of a questionnaire. The results would also justify the use of the HADS as a single scale of emotional distress. However, even though the three-factor solution fit the data, alternative scales should be used if the purpose of the assessment is to measure stress symptoms separately from anxiety and depression. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia; [Schoenberger, Michael; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Schonberger, M (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	michael_schoenberger@web.de					Abbott RA, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-76; Aluja A, 2007, J PERS ASSESS, V88, P246, DOI 10.1080/00223890701268116; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Desmond DM, 2005, INT J GERIATR PSYCH, V20, P344, DOI 10.1002/gps.1289; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DiStefano C, 2009, STRUCT EQU MODELING, V16, P134, DOI 10.1080/10705510802565403; DiStefano C, 2009, PERS INDIV DIFFER, V46, P309, DOI 10.1016/j.paid.2008.10.020; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Dunbar M, 2000, BRIT J CLIN PSYCHOL, V39, P79, DOI 10.1348/014466500163121; Eid M, 2000, PSYCHOMETRIKA, V65, P241, DOI 10.1007/BF02294377; Graham JM, 2006, EDUC PSYCHOL MEAS, V66, P930, DOI 10.1177/0013164406288165; Greenberger E, 2003, PERS INDIV DIFFER, V35, P1241, DOI 10.1016/S0191-8869(02)00331-8; HANCOCK GR, 2001, EQUATION MODELING PR; Haslam N, 2003, AUST NZ J PSYCHIAT, V37, P696, DOI 10.1111/j.1440-1614.2003.01258.x; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Horan PM, 2003, STRUCT EQU MODELING, V10, P435, DOI 10.1207/S15328007SEM1003_6; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kaufman J, 2000, DEPRESS ANXIETY, V12, P69, DOI 10.1002/1520-6394(2000)12:1+<69::AID-DA9>3.0.CO;2-K; Lance CE, 2002, PSYCHOL METHODS, V7, P228, DOI 10.1037//1082-989X.7.2.228; Lord F., 1968, STAT THEORIES MENTAL; Marsh H.W., 1995, STRUCTURAL EQUATION, P177; Marsh HW, 1996, J PERS SOC PSYCHOL, V70, P810, DOI 10.1037/0022-3514.70.4.810; MARSH HW, 1989, APPL PSYCH MEAS, V13, P335, DOI 10.1177/014662168901300402; Martin CR, 2005, CURR PSYCHIATRY REV, V1, P69, DOI 10.2174/1573400052953510; Martin CR, 2004, PSYCHIAT RES, V129, P279, DOI 10.1016/j.psychres.2004.06.012; Martin CR, 2004, BRIT J CLIN PSYCHOL, V43, P51, DOI 10.1348/014466504772812968; MARTIN CR, 2004, PSYCHOL HEALTH MED, V9, P327, DOI DOI 10.1080/13548500410001721891; Motl RW, 2002, STRUCT EQU MODELING, V9, P562, DOI 10.1207/S15328007SEM0904_6; Muthen B., 1997, ROBUST INFERENCE USI; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Quilty LC, 2006, STRUCT EQU MODELING, V13, P99, DOI 10.1207/s15328007sem1301_5; RAZAVI D, 1990, BRIT J PSYCHIAT, V156, P79, DOI 10.1192/bjp.156.1.79; SCHRIESHEIM CA, 1981, EDUC PSYCHOL MEAS, V41, P1101, DOI 10.1177/001316448104100420; SNAITH RP, 1983, HOSP ANXIETY DEPRESS; Tomas JM, 1999, STRUCT EQU MODELING, V6, P84, DOI 10.1080/10705519909540120; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Wu CH, 2008, J SOC PSYCHOL, V148, P535, DOI 10.3200/SOCP.148.5.535-552	52	63	64	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	OCT 30	2010	179	3					342	349		10.1016/j.psychres.2009.07.003			8	Psychiatry	Psychiatry	676FV	WOS:000283897300018	20483471				2021-06-18	
J	Krahulik, D; Zapletalova, J; Frysak, Z; Vaverka, M				Krahulik, David; Zapletalova, Jirina; Frysak, Zdenek; Vaverka, Miroslav			Dysfunction of hypothalamic-hypophysial axis after traumatic brain injury in adults	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypopituitarism; hypothalamic-hypophysial axis	SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; NATURAL-HISTORY; HYPOPITUITARISM; DEPRESSION; PREVALENCE; RISK	Object. Traumatic brain injury (TBI) is a major cause of serious morbidity and mortality. The incidence is 100-500/100,000 inhabitants/year. Chronic pituitary dysfunction is increasingly recognized after TBI. To define the incidence of endocrine dysfunction and risk factors, the authors describe a prospectively assessed group of patients in whom they documented hormonal functions, early diagnosis, and treatment of neuroendocrine dysfunction after TBI. Methods. Patients aged 18-65 years were prospectively observed from the time of injury to 1 year postinjury; the Glasgow Coma Scale score ranged from 3 to 14. Patients underwent evaluation of hormonal function at the time of injury and at 3, 6, and 12 months postinjury. Magnetic resonance imaging was also conducted at 1 year postinjury. Results. During the study period, 89 patients were observed. The mean age of the patients was 36 years, there were 23 women, and the median Glasgow Coma Scale score was 7. Nineteen patients (21%) had primary hormonal dysfunction. Major deficits included growth hormone dysfunction, hypogonadism, and diabetes insipidus. Patients in whom the deficiency was major had a worse Glasgow Outcome Scale score, and MR imaging demonstrated empty sella syndrome more often than in patients without a deficit. Conclusions. To the authors' knowledge, this is the third largest study of its kind worldwide. The incidence of chronic hypopituitarism after TBI was higher than the authors expected. After TBI, patients are usually observed on the neurological and rehabilitative wards, and endocrine dysfunction can be overlooked. This dysfunction can be life threatening and other clinical symptoms can worsen the neurological deficit, extend the duration of physiotherapy, and lead to mental illness. The authors recommend routine pituitary hormone testing after moderate or severe TBI within 6 months and 1 year of injury. (DOI: 10.3171/2009.10.JNS09930)	[Krahulik, David; Vaverka, Miroslav] Fac Hosp, Neurosurg Clin, Olomouc, Czech Republic; [Zapletalova, Jirina] Fac Hosp, Dept Paediat, Olomouc, Czech Republic; [Frysak, Zdenek] Fac Hosp, Internal Clin 3, Olomouc, Czech Republic	Krahulik, D (corresponding author), IP Pavlova 6, Olomouc 77900, Czech Republic.	david.krahulik@fnol.cz		David, Krahulik/0000-0002-4907-7960			Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2001, Pituitary, V4, P129, DOI 10.1023/A:1015306705154; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; DANIEL PM, 1959, LANCET, V2, P927; DANIEL PM, 1963, SCI BASIS MED ANN, V84, P83; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308	22	63	65	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					581	584		10.3171/2009.10.JNS09930			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100022	19929195				2021-06-18	
J	Geary, EK; Kraus, MF; Pliskin, NH; Little, DM				Geary, Elizabeth K.; Kraus, Marilyn F.; Pliskin, Neil H.; Little, Deborah M.			Verbal learning differences in chronic mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Concussion; Diffusion tensor imaging; Single trial learning	POST-CONCUSSIONAL SYNDROME; DIFFUSION-TENSOR; WHITE-MATTER; HEAD-INJURY; COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL ASSESSMENT; ECOLOGICAL VALIDITY; SYMPTOMS; DEFICITS; MEMORY	Following mild traumatic brain injury (TBI), a percentage of individuals report chronic memory and attention difficulties. Traditional neuropsychological assessments often fail to find evidence for such complaints. We hypothesized that mild TB! patients may, in fact, experience subtle cognitive deficits that reflect diminished initial acquisition that can be explained by changes in cerebral white matter microstructure. In the data presented here, a sample of nonlitigating and gainfully employed mild TBI patients demonstrated statistically significant differences from age and education matched control participants in performance on the first trial of a verbal learning task. Performance on this trial was associated with reduced fractional anisotropy in the uncinate fasciculus and the superior longitudinal fasciculus providing an anatomical correlate for the cognitive findings. Mild TBI patients were not impaired relative to control participants on total learning or memory composite variables. Performance on the first learning trial was not related to any psychological variables including mood. We concluded that patients with mild TBI demonstrate diminished verbal learning that is not often interpreted in standard neuropsychological assessment. (ENS, 2010, 16, 506-516.)	[Geary, Elizabeth K.; Kraus, Marilyn F.; Pliskin, Neil H.; Little, Deborah M.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL 60612 USA; [Geary, Elizabeth K.; Little, Deborah M.] Univ Illinois, Coll Med, Ctr Stroke Res, Chicago, IL 60612 USA; [Kraus, Marilyn F.; Pliskin, Neil H.] Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA; [Kraus, Marilyn F.; Pliskin, Neil H.; Little, Deborah M.] Univ Illinois, Coll Med, Ctr Cognit Med, Chicago, IL 60612 USA; [Little, Deborah M.] Univ Illinois, Coll Med, Dept Anat, Chicago, IL 60612 USA; [Little, Deborah M.] Univ Illinois, Coll Med, Dept Ophthalmol, Chicago, IL 60612 USA; [Little, Deborah M.] Univ Illinois, Coll Med, Dept Psychol, Chicago, IL 60612 USA	Little, DM (corresponding author), Univ Illinois, Coll Med, Dept Neurol, MC 796,912 S Wood St 855 N, Chicago, IL 60612 USA.	little@uic.edu			NIH, National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH068787]; Marshall Goldberg Traumatic Brain Injury Fund; Department of Defense/Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT 075675]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH068787] Funding Source: NIH RePORTER	This work is supported in part by NIH grant K23 MH068787 from the National Institute of Mental Health (MFK), the Marshall Goldberg Traumatic Brain Injury Fund (DML), and a grant from the Department of Defense/Congressionally Directed Medical Research Program grant PT 075675. The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the University of Illinois at Chicago. Department of Defense, or the National Institute of Mental Health. We thank Dr. Xiaohong Joe Zhou for providing the pulse sequence used to collect the DT1 data.	ANDERSON JR, 1982, PSYCHOL REV, V89, P369, DOI 10.1037/0033-295X.89.4.369; BAUER R, 2003, AMNESIC DISORDERS; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Breier JI, 2008, AM J NEURORADIOL, V29, P483, DOI 10.3174/ajnr.A0846; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chan AS, 2000, SCHIZOPHR RES, V41, P431, DOI 10.1016/S0920-9964(99)00078-X; Cho H, 2008, J KOREAN MED SCI, V23, P477, DOI 10.3346/jkms.2008.23.3.477; Delis D, 2000, CALIFORNIA VERBAL LE; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gold BT, 2007, NEUROPSYCHOLOGIA, V45, P2439, DOI 10.1016/j.neuropsychologia.2007.04.011; Gongvatana A, 2007, J NEUROPSYCH CLIN N, V19, P36, DOI 10.1176/appi.neuropsych.19.1.36; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Ivory SJ, 1999, NEUROPSYCHOLOGIA, V37, P817, DOI 10.1016/S0028-3932(98)00131-6; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; LOGAN GD, 1988, PSYCHOL REV, V95, P492, DOI 10.1037/0033-295X.95.4.492; LUEK SP, 1976, MEM COGNITION, V4, P476, DOI 10.3758/BF03213207; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Medina D, 2006, NEUROBIOL AGING, V27, P663, DOI 10.1016/j.neurobiolaging.2005.03.026; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Poonawalla AH, 2004, J MAGN RESON IMAGING, V19, P489, DOI 10.1002/jmri.20020; Rao SL, 1997, NIMHANS J, V15, P157; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ribeiro F, 2007, J CLIN EXP NEUROPSYC, V29, P187, DOI 10.1080/13803390600629775; Ropper AH, 2005, ADAMS VICTORS PRINCI; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Silverberg ND, 2009, J INT NEUROPSYCH SOC, V15, P94, DOI 10.1017/S1355617708090139; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Teasdale TW, 1997, BRIT MED J, V315, P569; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; WILLIAMS CW, 1993, PSYCHOL REP, V72, P483, DOI 10.2466/pr0.1993.72.2.483; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wood RL, 2009, J HEAD TRAUMA REHAB, V24, P88, DOI 10.1097/HTR.0b013e31819b118a; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	77	63	65	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2010	16	3					506	516		10.1017/S135561771000010X			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	594ZA	WOS:000277579000011	20188015				2021-06-18	
J	Senathi-Raja, D; Ponsford, J; Schonberger, M				Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael			Impact of Age on Long-Term Cognitive Function After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						aging; neuropsychology; traumatic brain injury; brain plasticity; long-term outcome	PENETRATING HEAD-INJURY; CEREBRAL ATROPHY; DECLINE	Objective: To examine the association of age and time postinjury with cognitive outcome 5-22 years following traumatic brain injury (TBI), in relation to matched uninjured controls. Methods: One hundred twelve participants with mild to very severe TBI, aged 16-81 years at the time of injury, were cognitively assessed on measures of processing speed and attention, verbal and visual memory, executive function, and working memory. Results were compared with those of 112 healthy controls individually matched for current age, gender, education, and estimated IQ. Results: Older injured individuals performed worse than did younger injured individuals across all cognitive domains, after controlling for the performance of controls. In relation to matched controls, long-time survivors performed disproportionately worse than did more recently injured individuals, irrespective of age. Conclusions: After maximum spontaneous recovery from TBI, poorer cognitive functioning appears to be associated with both older age at the time of injury and increased time postinjury. These findings have implications for prognosis, early treatment recommendations, and long-term issues of differential diagnosis and management planning.	[Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia.	Jennie.Ponsford@med.monash.edu.au					AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Baddeley A, 1994, DOORS PEOPLE; Barnet V, 1978, OUTLIERS STAT DATA; Benton A., 1994, MULTILINGUAL APHASIA; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CORKIN S, 1989, J NEUROSCI, V9, P3876; GOLEBURN CR, 2001, J CLIN GEROPSYCHOLOG, V7, P161; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kolb B., 1995, BRAIN PLASTICITY BEH; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Luebke JI, 2003, J COMP NEUROL, V460, P573, DOI 10.1002/cne.10668; OCONNOR P, 1999, TRAUMATIC BRAIN INJU; PORTEUS SD, 1933, PORTEUS MAZES SCORIN; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; REITAN RM, 1988, HALTEADREITAN NEUROP; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Shallice, 1997, HAYLING BRIXTON TEST; Shimada A, 1999, NEUROBIOL AGING, V20, P125, DOI 10.1016/S0197-4580(99)00044-5; SHORES A, 1986, MED J AUSTRALIA, V144, P569; Smith A., 1973, SYMBOL DIGIT MODALIT; Terry RD, 2001, NEUROBIOL AGING, V22, P347, DOI 10.1016/S0197-4580(00)00250-5; TEUBER H-L, 1975, P159; Volkow ND, 1998, ANN NEUROL, V44, P143, DOI 10.1002/ana.410440125; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553	32	63	65	1	17	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2010	24	3					336	344		10.1037/a0018239			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	587IW	WOS:000276985500006	20438211				2021-06-18	
J	Tanriverdi, F; De Bellis, A; Battaglia, M; Bellastella, G; Bizzarro, A; Sinisi, AA; Bellastella, A; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; De Bellis, Annamaria; Battaglia, Marina; Bellastella, Giuseppe; Bizzarro, Antonio; Sinisi, Antonio A.; Bellastella, Antonio; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity?	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							BRAIN-INJURY; GH DEFICIENCY; HYPOPITUITARISM; HORMONE; AUTOANTIBODIES; INSUFFICIENCY; EPIDEMIOLOGY; HYPOPHYSITIS; AUSTRALIA; CHILDREN	Objective: Current data clearly demonstrate that sports-related chronic repetitive head trauma due to boxing might result in hypopituitarism. However, the mechanism of sports-related traumatic brain injury-induced pituitary dysfunction is still unclear. In order to understand whether autoimmune mechanisms could play a role in the pituitary dysfunction due to sports-related head trauma, we investigated the presence of antipituitary antibodies (APAs) and antihypothalamus antibodies (AHAs) in amateur boxers. Patients and design: Sixty-one actively competing (n = 44) or retired (n = 17) male boxers (mean age, 26 years; range, 17-53) who had been evaluated regarding pituitary functions previously were included in the study. In all boxers and in 60 age/sex-similar normal controls, AHAs and APAs were investigated by an indirect immunofluorescence method. Results: AHAs were detected in 13 of 61 boxers (21.3%), and APAs were detected in 14 of 61 boxers (22.9%), but in none of the normal controls. Pituitary dysfunction was significantly higher in AHA-positive boxers (46.2%) than in AHA-negative boxers (10.4%) (P = 0.003). There was a significant association between AHA positivity and hypopituitarism due to boxing (odds ratio: 7.37, 95% confidence interval 1.8-30.8). There was no significant association between APA positivity and hypopituitarism. Conclusions: This study demonstrates for the first time the presence of AHAs and APAs in boxers who were exposed to sports-related head trauma. Moreover, the present investigation provides preliminary evidence that AHAs are associated with the development of pituitary dysfunction in boxers, thus suggesting that autoimmunity may have a role in the pathogenesis.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Dept Endocrinol, Sch Med, TR-38039 Kayseri, Turkey; [De Bellis, Annamaria; Battaglia, Marina; Bellastella, Giuseppe; Sinisi, Antonio A.; Bellastella, Antonio] Univ Naples 2, Chair Endocrinol, I-80131 Naples, Italy; [Bizzarro, Antonio] Univ Naples 2, Chair Immunol, I-80131 Naples, Italy; [Selcuklu, Ahmet] Erciyes Univ, Dept Neurosurg, Sch Med, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Dept Med, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Dept Endocrinol, Sch Med, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr		DE BELLIS, Annamaria/0000-0002-0611-4506			Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Bensing S, 2007, P NATL ACAD SCI USA, V104, P949, DOI 10.1073/pnas.0610070104; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; De Bellis A, 2005, BEST PRACT RES CL EN, V19, P67, DOI 10.1016/j.beem.2004.11.007; De Bellis A, 2003, J CLIN ENDOCR METAB, V88, P650, DOI 10.1210/jc.2002-021054; De Bellis A, 1999, J CLIN ENDOCR METAB, V84, P3047, DOI 10.1210/jc.84.9.3047; De Bellis A, 2008, EUR J ENDOCRINOL, V158, P147, DOI 10.1530/EJE-07-0647; De Bellis A, 2006, J CLIN ENDOCR METAB, V91, P2484, DOI 10.1210/jc.2006-0040; Falorni A, 2004, J CLIN ENDOCR METAB, V89, P1598, DOI 10.1210/jc.2003-030954; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gionis D, 2003, J PEDIATR ENDOCR MET, V16, P49; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Hillier SL, 1997, BRAIN INJURY, V11, P649; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Manetti L, 2007, J CLIN ENDOCR METAB, V92, P2176, DOI 10.1210/jc.2006-2748; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Powell JW, 2001, J ATHL TRAINING, V36, P307; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Salehi F, 2007, BRAIN INJURY, V21, P651, DOI 10.1080/02699050701426956; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448	34	63	64	0	4	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	MAY	2010	162	5					861	867		10.1530/EJE-09-1024			7	Endocrinology & Metabolism	Endocrinology & Metabolism	587YH	WOS:000277032100005	20176736	Bronze			2021-06-18	
J	Cao, C; Slobounov, S				Cao, C.; Slobounov, S.			Alteration of Cortical Functional Connectivity as a Result of Traumatic Brain Injury Revealed by Graph Theory, ICA, and sLORETA Analyses of EEG Signals	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Connectivity; electroencephalographic (EEG); independent component analysis (ICA); mild traumatic brain injury (MTBI); standardize low resolution brain electromagnetic (sLORETA); small-world network	ALZHEIMERS-DISEASE; LOW-FREQUENCY; DEFAULT MODE; SCALP EEG; MILD; CONCUSSION; SYNCHRONIZATION; NETWORK; ORGANIZATION; FLUCTUATIONS	In this paper, a novel approach to examine the cortical functional connectivity using multichannel electroencephalographic (EEG) signals is proposed. First we utilized independent component analysis (ICA) to transform multichannel EEG recordings into independent processes and then applied source reconstruction algorithm [i.e., standardize low resolution brain electromagnetic (sLORETA)] to identify the cortical regions of interest (ROIs). Second, we performed a graph theory analysis of the bipartite network composite of ROIs and independent processes to assess the connectivity between ROIs. We applied this proposed algorithm and compared the functional connectivity network properties under resting state condition using 29 student-athletes prior to and shortly after sport-related mild traumatic brain injury (MTBI). The major findings of interest are the following. There was 1) alterations in vertex degree at frontal and occipital regions in subjects suffering from MTBI, (p < 0.05); 2) a significant decrease in the long-distance connectivity and significant increase in the short-distance connectivity as a result of MTBI, (p < 0.05); 3) a departure from small-world network configuration in MTBI subjects. These major findings are discussed in relation to current debates regarding the brain functional connectivity within and between local and distal regions both in normal controls in pathological subjects.	[Cao, C.; Slobounov, S.] Penn State Univ, Dept Kinesiol, State Coll, PA 16801 USA	Cao, C (corresponding author), Penn State Univ, Dept Kinesiol, State Coll, PA 16801 USA.	cxc687@psu.edu; sms18@psu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	Manuscript received November 13, 2008; revised April 09, 2009; accepted April 09, 2009. First published July 17, 2009; current version published February 24, 2010. This work of S. Slobounov was supported by the National Institutes of Health under Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury."	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; BATUEV AS, 1979, ACTA PHYSIOL HUNG, V53, P345; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; Breakspear M, 2003, NEUROIMAGE, V20, P466, DOI 10.1016/S1053-8119(03)00332-X; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Ciaramella A., 2006, INT MATH FORUM, V1, P769; Cohen AL, 2008, NEUROIMAGE, V41, P45, DOI 10.1016/j.neuroimage.2008.01.066; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; ELBERT T, 1992, BIOL PSYCHIAT, V32, P595, DOI 10.1016/0006-3223(92)90072-8; Ferri R, 2007, CLIN NEUROPHYSIOL, V118, P449, DOI 10.1016/j.clinph.2006.10.021; FOSTER JK, 1994, COGNITIVE NEUROPSYCH, V11, P133, DOI 10.1080/02643299408251971; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Fuchs M, 1998, IEEE T BIO-MED ENG, V45, P980, DOI 10.1109/10.704867; Funahashi S, 2006, NEUROSCIENCE, V139, P251, DOI 10.1016/j.neuroscience.2005.07.003; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guntekin B, 2008, BRAIN RES, V1235, P109, DOI 10.1016/j.brainres.2008.06.028; Horwitz B, 2003, NEUROIMAGE, V19, P466, DOI 10.1016/S1053-8119(03)00112-5; Hyvarinen A, 1997, NEURAL COMPUT, V9, P1483, DOI 10.1162/neco.1997.9.7.1483; Iwaki S, 1998, J APPL PHYS, V83, P6441, DOI 10.1063/1.367732; Jeong J, 1998, ELECTROEN CLIN NEURO, V106, P220, DOI 10.1016/S0013-4694(97)00079-5; Jung TP, 2000, PSYCHOPHYSIOLOGY, V37, P163, DOI 10.1017/S0048577200980259; Klein M, 2003, ANN NEUROL, V54, P514, DOI 10.1002/ana.10712; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Koles ZJ, 1998, ELECTROEN CLIN NEURO, V106, P127, DOI 10.1016/S0013-4694(97)00115-6; Locatelli T, 1998, ELECTROEN CLIN NEURO, V106, P229, DOI 10.1016/S0013-4694(97)00129-6; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lycke C, 2008, SCAND J PSYCHOL, V49, P393, DOI 10.1111/j.1467-9450.2008.00672.x; Marchal B, 2005, PHYS LIFE REV, V2, P251, DOI 10.1016/j.plrev.2005.07.001; MARZETTI L, 2008, NEUROIMAGE, V36, P68; Marzetti L, 2008, NEUROIMAGE, V42, P87, DOI 10.1016/j.neuroimage.2008.04.250; Murias M, 2007, BIOL PSYCHIAT, V62, P270, DOI 10.1016/j.biopsych.2006.11.012; Newman MEJ, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.056131; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Olthoff A, 2008, LARYNGOSCOPE, V118, P2091, DOI 10.1097/MLG.0b013e31817fd40f; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Pascual-Marqui RD, 1999, PSYCHIAT RES-NEUROIM, V90, P169, DOI 10.1016/S0925-4927(99)00013-X; Purves D., NEUROSCIENCE, Vsecond edition,; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; ROSENBAUM RS, 2008, NEUROBIOL AGING  JUL; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Salvador R, 2005, PHILOS T R SOC B, V360, P937, DOI 10.1098/rstb.2005.1645; SARVAS J, 1987, PHYS MED BIOL, V32, P11, DOI 10.1088/0031-9155/32/1/004; Sekihara K, 2005, NEUROIMAGE, V25, P1056, DOI 10.1016/j.neuroimage.2004.11.051; Silberstein RB, 2004, BRAIN TOPOGR, V16, P249; Slobounov S, 2000, MOTOR CONTROL, V4, P350, DOI 10.1123/mcj.4.3.350; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 1998, EXP BRAIN RES, V123, P461, DOI 10.1007/s002210050590; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2002, PHYSICA D, V163, P236, DOI 10.1016/S0167-2789(01)00386-4; Thatcher RW, 2007, CLIN EEG NEUROSCI, V38, P35, DOI 10.1177/155005940703800109; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; TRIMBLE MR, 1990, SEMIN NEUROL, V10, P287, DOI 10.1055/s-2008-1041280; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Wagner M, 2004, BRAIN TOPOGR, V16, P277; Yao DZ, 2001, PHYSIOL MEAS, V22, P693, DOI 10.1088/0967-3334/22/4/305; Zhou YX, 2008, ALZHEIMERS DEMENT, V4, P265, DOI 10.1016/j.jalz.2008.04.006; Zhukov L, 2000, IEEE ENG MED BIOL, V19, P87, DOI 10.1109/51.844386	68	63	67	3	21	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	FEB	2010	18	1					11	19		10.1109/TNSRE.2009.2027704			9	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	562KP	WOS:000275049400002	20064767	Green Accepted			2021-06-18	
S	Atlasz, T; Szabadfi, K; Kiss, P; Racz, B; Gallyas, F; Tamas, A; Gaal, V; Marton, Z; Gabriel, R; Reglodi, D		Vaudry, H; Shioda, S		Atlasz, T.; Szabadfi, K.; Kiss, P.; Racz, B.; Gallyas, F.; Tamas, A.; Gaal, V.; Marton, Zs.; Gabriel, R.; Reglodi, D.			Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects	PHYLOGENETIC ASPECTS OF NEUROPEPTIDES: FROM INVERTEBRATES TO HUMANS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	9th International Symposium on VIP, PACAP and Related Peptides	OCT 02-03, 2009	Yakushima Island, JAPAN			retinal injury; retinoprotection; neuropeptide; PACAP	MONOSODIUM GLUTAMATE TREATMENT; VASOACTIVE-INTESTINAL-PEPTIDE; CHICKEN PINEAL-GLAND; RAT MULLER CELLS; MESSENGER-RNA; GANGLION-CELLS; SIGNALING PATHWAYS; ULTRASTRUCTURAL-LOCALIZATION; INDUCED NEUROTOXICITY; MELATONIN RELEASE	Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophic and neuroprotective peptide that has been shown to exert protective effects against different neuronal injuries, such as traumatic brain and spinal cord injury, models of neurodegenerative diseases, and cerebral ischemia. PACAP and its receptors are present in the retina. In this study, we summarize the current knowledge on retinal PACAP with focus on the retinoprotective effects. Results of histological, immunohistochemical, and molecular biological analysis are reviewed. In vitro, PACAP shows protection against glutamate, thapsigargin, anisomycin, and anoxia. In vivo, the protective effects of intravitreal PACAP treatment have been shown in the following models of retinal degeneration in rats: excitotoxic injury induced by glutamate and kainate, ischemic injury, degeneration caused by UV-A light, optic nerve transection, and streptozotocin-induced diabetic retinopathy. Studying the molecular mechanism has revealed that PACAP acts by activating antiapoptotic and inhibiting proapoptotic signaling pathways in the retina in vivo. These studies strongly suggest that PACAP is an excellent candidate retinoprotective agent that could be a potential therapeutic substance in various retinal diseases.	[Reglodi, D.] Univ Pecs, Dept Anat, Sch Med, H-7624 Pecs, Hungary; [Atlasz, T.] Univ Pecs, Dept Sportbiol, H-7624 Pecs, Hungary; [Szabadfi, K.; Gabriel, R.] Univ Pecs, Dept Expt Zool & Neurobiol, H-7624 Pecs, Hungary; [Racz, B.; Gallyas, F.] Univ Pecs, Dept Biochem & Med Chem, H-7624 Pecs, Hungary; [Gaal, V.] Univ Pecs, Dept Ophthalmol, H-7624 Pecs, Hungary; [Marton, Zs.] Univ Pecs, Dept Environm & Laser Spect, H-7624 Pecs, Hungary	Reglodi, D (corresponding author), Univ Pecs, Dept Anat, Sch Med, Szigeti U 12, H-7624 Pecs, Hungary.	dora.reglodi@aok.pte.hu	Racz, Boglarka/M-2160-2015; Gallyas, Ferenc/AAY-5343-2020; Marton, Zsuzsanna/A-5158-2012; Gallyas, Ferenc/C-2272-2012; Szabadfi, Krisztina/K-5955-2012	Szabadfi, Krisztina/0000-0002-8390-5408; Gallyas, Ferenc/0000-0002-1906-4333; Atlasz, Tamas/0000-0002-8112-8633	Hungarian National Scientific Grants OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [T061766, K72592, F67830, CNK 78480, ETT278-04/2009]; Richter Gedeon Centenary Foundation; Bolyai ScholarshipHungarian Academy of Sciences; University of Pecs Medical School;  [GVOP-3.2.1-2004-04-0172/3.0]	This work was supported by Hungarian National Scientific Grants OTKA T061766, K72592, F67830, CNK 78480, ETT278-04/2009, Richter Gedeon Centenary Foundation, GVOP-3.2.1-2004-04-0172/3.0, Bolyai Scholarship, University of Pecs Medical School Research Grant 2009.	Arimura A, 2007, PEPTIDES, V28, P1617, DOI 10.1016/j.peptides.2007.06.006; ATLASZ T, 2009, SAT S 9 INT S VIP PA; Atlasz T, 2007, GEN COMP ENDOCR, V153, P108, DOI 10.1016/j.ygcen.2006.12.022; Atlasz T, 2010, BRAIN RES BULL, V81, P497, DOI 10.1016/j.brainresbull.2009.09.004; Atlasz T, 2008, J MOL NEUROSCI, V36, P97, DOI 10.1007/s12031-008-9059-5; Atlasz T, 2009, ANN NY ACAD SCI, V1163, P348, DOI 10.1111/j.1749-6632.2008.03650.x; Babai N, 2005, NEUROTOX RES, V8, P227, DOI 10.1007/BF03033976; Babai N, 2006, ANN NY ACAD SCI, V1070, P149, DOI 10.1196/annals.1317.003; Bagnoli P, 2003, HISTOL HISTOPATHOL, V18, P1219, DOI 10.14670/HH-18.1219; Beaule C, 2009, J BIOL RHYTHM, V24, P126, DOI 10.1177/0748730409332037; Borba JC, 2005, DEV BRAIN RES, V156, P193, DOI 10.1016/j.devbrainres.2005.02.016; Csernus V, 2004, GEN COMP ENDOCR, V135, P62, DOI 10.1016/S0016-6480(03)00284-3; D'Agata V, 1998, MOL BRAIN RES, V54, P161, DOI 10.1016/S0169-328X(97)00335-5; Elsas T, 1996, GRAEF ARCH CLIN EXP, V234, P573, DOI 10.1007/BF00448802; Falluel-Morel A, 2007, J NEUROENDOCRINOL, V19, P321, DOI 10.1111/j.1365-2826.2007.01537.x; Faluhelyi N, 2004, REGUL PEPTIDES, V123, P23, DOI 10.1016/j.regpep.2004.05.009; Fukiage C, 2007, AM J OPHTHALMOL, V143, P255, DOI 10.1016/j.ajo.2006.10.034; Gaal V, 2008, J MOL NEUROSCI, V36, P321, DOI 10.1007/s12031-008-9067-5; Grone BP, 2007, J BIOL RHYTHM, V22, P558, DOI 10.1177/0748730407308285; Hannibal J, 2004, CELL TISSUE RES, V316, P99, DOI 10.1007/s00441-004-0858-x; ITOH H, 2009, SAT S 9 INT S VIP PA; Izumi S, 2000, ANN NY ACAD SCI, V921, P317; Jarkman S, 1998, OPHTHALMIC RES, V30, P199, DOI 10.1159/000055476; Jozsa R, 2001, PEPTIDES, V22, P1371, DOI 10.1016/S0196-9781(01)00477-6; Kiss P, 2006, ANN NY ACAD SCI, V1070, P365, DOI 10.1196/annals.1317.046; Koves K, 2000, ANN NY ACAD SCI, V921, P321; Kubrusly RCC, 2005, BRAIN RES, V1038, P141, DOI 10.1016/j.brainres.2005.01.031; Lang B, 2010, NEUROPHARMACOLOGY, V58, P215, DOI 10.1016/j.neuropharm.2009.07.003; Markhotina N, 2007, IET NANOBIOTECHNOL, V1, P44, DOI 10.1049/iet-nbt:20060019; Mathieu M, 2005, EUR J HISTOCHEM, V49, P167; Mathieu M, 2004, DEV BRAIN RES, V151, P169, DOI 10.1016/j.devbrainres.2004.05.003; Mathis U, 2007, GRAEF ARCH CLIN EXP, V245, P267, DOI 10.1007/s00417-006-0282-x; Mester L, 2009, NEUROTOX RES, V16, P68, DOI 10.1007/s12640-009-9049-6; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Nagy AD, 2007, PEPTIDES, V28, P1767, DOI 10.1016/j.peptides.2007.07.013; Nakatani M, 2006, PEPTIDES, V27, P1871, DOI 10.1016/j.peptides.2005.12.011; NILSSON SFE, 1994, EUR J PHARMACOL, V253, P17, DOI 10.1016/0014-2999(94)90752-8; NILSSON SFE, 1994, EXP EYE RES, V58, P459, DOI 10.1006/exer.1994.1039; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Olianas MC, 1997, J NEUROCHEM, V69, P1213; Olianas MC, 1996, J NEUROCHEM, V67, P1293; ONALI P, 1994, BRAIN RES, V641, P132, DOI 10.1016/0006-8993(94)91825-2; Pucci S, 2008, PROG BRAIN RES, V173, P555, DOI 10.1016/S0079-6123(08)01138-2; Rabl K, 2002, REGUL PEPTIDES, V109, P71, DOI 10.1016/S0167-0115(02)00189-1; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Racz B, 2007, NEUROTOX RES, V12, P95, DOI 10.1007/BF03033918; Racz B, 2006, ANN NY ACAD SCI, V1070, P507, DOI 10.1196/annals.1317.070; Racz B, 2008, J MOL NEUROSCI, V36, P220, DOI 10.1007/s12031-008-9112-4; Reglodi D, 2001, PEPTIDES, V22, P873, DOI 10.1016/S0196-9781(01)00412-0; Rekasi Z, 2002, J MOL ENDOCRINOL, V28, P19, DOI 10.1677/jme.0.0280019; Sakamoto K, 2005, EUR J NEUROSCI, V22, P3129, DOI 10.1111/j.1460-9568.2005.04512.x; Seki M, 2004, DIABETES, V53, P2412, DOI 10.2337/diabetes.53.9.2412; Seki T, 2006, ANN NY ACAD SCI, V1070, P535, DOI 10.1196/annals.1317.043; Seki T, 2000, ANN NY ACAD SCI, V921, P366; Seki T, 1997, NEUROSCI LETT, V238, P127, DOI 10.1016/S0304-3940(97)00869-0; Seki T, 2000, PEPTIDES, V21, P109, DOI 10.1016/S0196-9781(99)00180-1; Seki T, 2006, ANN NY ACAD SCI, V1070, P531, DOI 10.1196/annals.1317.074; Seki T, 2008, J MOL NEUROSCI, V36, P57, DOI 10.1007/s12031-008-9091-5; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Shoge K, 1998, BRAIN RES, V809, P127, DOI 10.1016/S0006-8993(98)00789-6; Silveira MS, 2002, J BIOL CHEM, V277, P16075, DOI 10.1074/jbc.M110106200; Skoglosa Y, 1999, MOL BRAIN RES, V65, P1, DOI 10.1016/S0169-328X(98)00294-0; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Son YJ, 2007, MOL CELLS, V23, P215; Szabadfi K, 2009, BRAIN RES, V1259, P107, DOI 10.1016/j.brainres.2009.01.004; Tamas A, 2004, NEUROSCI LETT, V372, P110, DOI 10.1016/j.neulet.2004.09.021; Tuncel N, 1996, ANN NY ACAD SCI, V805, P489; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Vereczki V, 2006, NEUROSCIENCE, V140, P1089, DOI 10.1016/j.neuroscience.2006.02.081; Wan J, 2006, NEUROSCI LETT, V400, P48, DOI 10.1016/j.neulet.2006.02.084; WANG ZY, 1995, NEUROSCIENCE, V69, P297, DOI 10.1016/0306-4522(95)00258-K; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Yamaji K, 2005, EXP EYE RES, V80, P815, DOI 10.1016/j.exer.2004.12.020; Yoshitomi T, 2002, INVEST OPHTH VIS SCI, V43, P780; ZHANG D, 1995, NEUROSCIENCE, V67, P177, DOI 10.1016/0306-4522(94)00627-H; Zhang XY, 2005, CURR EYE RES, V30, P1105, DOI 10.1080/02713680500421444	77	63	64	0	12	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-798-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1200						128	139		10.1111/j.1749-6632.2010.05512.x			12	Multidisciplinary Sciences	Science & Technology - Other Topics	BRJ61	WOS:000282839600013	20633141				2021-06-18	
J	Wilde, EA; Ramos, MA; Yallampalli, R; Bigler, ED; McCauley, SR; Chu, ZL; Wu, TC; Hanten, G; Scheibel, RS; Li, XQ; Vasquez, AC; Hunter, JV; Levin, HS				Wilde, Elisabeth A.; Ramos, Marco A.; Yallampalli, Ragini; Bigler, Erin D.; McCauley, Stephen R.; Chu, Zili; Wu, Trevor C.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Vasquez, Ana C.; Hunter, Jill V.; Levin, Harvey S.			Diffusion Tensor Imaging of the Cingulum Bundle in Children After Traumatic Brain Injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							WHITE-MATTER INJURY; AXONAL INJURY; SPATIAL ATTENTION; COGNITIVE-CONTROL; CORPUS-CALLOSUM; HEAD TRAUMA; CORTEX; MILD; MRI; SEVERITY	Structural damage to the prefrontal-cingulate network has been implicated in cognitive and neurobehavioral deficits associated with traumatic brain injury (TBI). Forty-six children who had sustained moderate-to-severe TBI and 43 children with extracranial injury were imaged using diffusion tensor imaging (DTI). Decreased fractional anisotropy (FA) and increased apparent diffusion coefficient (ADC) values were found in the cingulum bundles bilaterally in the TBI group. Cingulum ADC was related to frontal lesion volume, injury severity, and injury mechanism. Finally, cingulum DTI parameters were related to cognitive control measures. DTI detects TBI-related injury to the cingulum, which may facilitate advances in assessment and treatment.	[Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Yallampalli, Ragini; McCauley, Stephen R.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Vasquez, Ana C.; Levin, Harvey S.] Univ Texas Houston Med Sch, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Hematol Oncol Sect, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Scheibel, Randall S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Ramos, Marco A.; Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu		Ramos, Marco/0000-0002-1649-7547	National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; TIRR Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by the National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). The authors also acknowledge the generous contribution of Mission Connect of the TIRR Foundation.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GEAN A, 1994, IMAGING HEAD; GENNARELLI TA, 1993, J EMERG MED, V1, P5; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gong GL, 2005, NEUROREPORT, V16, P1701, DOI 10.1097/01.wnr.0000183327.98370.6a; Gong GL, 2005, HUM BRAIN MAPP, V24, P92, DOI 10.1002/hbm.20072; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; HOOGENRAAD F, 2002, MULTICENTER EVALUATI; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Huster RJ, 2007, NEUROIMAGE, V34, P888, DOI 10.1016/j.neuroimage.2006.10.023; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kadosh RC, 2008, NEUROPSYCHOLOGIA, V46, P2872, DOI 10.1016/j.neuropsychologia.2008.05.025; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Mesulam MM, 2001, NEUROIMAGE, V13, P1065, DOI 10.1006/nimg.2001.0768; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2001, INT C COMP VIS VANC; Nielson KA, 2005, NEUROBIOL LEARN MEM, V84, P42, DOI 10.1016/j.nlm.2005.03.004; Park HJ, 2004, NEUROIMAGE, V23, P213, DOI 10.1016/j.neuroimage.2004.04.036; PAUS T, 1993, J NEUROPHYSIOL, V70, P453; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Small DM, 2003, NEUROIMAGE, V18, P633, DOI 10.1016/S1053-8119(02)00012-5; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yucel M, 2001, CEREB CORTEX, V11, P17, DOI 10.1093/cercor/11.1.17	77	63	66	0	11	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2010	35	3					333	351	PII 921879186	10.1080/87565641003696940			19	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	594EX	WOS:000277518100007	20446136	Green Accepted			2021-06-18	
J	Mayer, AR; Mannell, MV; Ling, J; Elgie, R; Gasparovic, C; Phillips, JP; Doezema, D; Yeo, RA				Mayer, Andrew R.; Mannell, Maggie V.; Ling, Josef; Elgie, Robert; Gasparovic, Charles; Phillips, John P.; Doezema, David; Yeo, Ronald A.			Auditory Orienting and Inhibition of Return in Mild Traumatic Brain Injury: A FMRI Study	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; attention; auditory; bottom-up; orienting; FMRI	EVENT-RELATED FMRI; DIFFUSE AXONAL INJURY; VISUOSPATIAL ATTENTION DEFICITS; VISUAL-ATTENTION; FUNCTIONAL MRI; WORKING-MEMORY; SPATIAL ATTENTION; HEAD-INJURY; CONCUSSION; DYSFUNCTION	The semiacute phase of mild traumatic brain injury (mTBI) is associated with deficits in the cognitive domains of attention, memory, and executive function, which previous work suggests may be related to a specific deficit in disengaging attentional focus. However, to date, there have only been a few studies that have employed dynamic imaging techniques to investigate the potential neurological basis of these cognitive deficits during the semiacute stage of injury. Therefore, event-related functional magnetic resonance imaging was used to investigate the neurological correlates of attentional dysfunction in a clinically homogeneous sample of 16 patients with mTBI during the semiacute phase of injury (<3 weeks). Behaviorally, patients with mTBI exhibited deficits in disengaging and reorienting auditory attention following invalid cues as well as a failure to inhibit attentional allocation to a cued spatial location compared to a group of matched controls. Accordingly, patients with mTBI also exhibited hypoactivation within thalamus, striatum, midbrain nuclei, and cerebellum across all trials as well as hypoactivation in the right posterior parietal cortex, presupplementary motor area, bilateral frontal eye fields, and right ventrolateral prefrontal cortex during attentional disengagement. Finally, the hemodynamic response within several regions of the attentional network predicted response times better for controls than for patients with mTBI. These objective neurological findings represent a potential biomarker for the behavioral deficits in spatial attention.that characterize the initial recovery phase of mTBI. Hum Brain Mapp 30:4152-4166, 2009. (C) 2009 Wiley-Liss, Inc.	[Mayer, Andrew R.; Mannell, Maggie V.; Ling, Josef; Gasparovic, Charles; Phillips, John P.; Yeo, Ronald A.] Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.; Phillips, John P.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Elgie, Robert; Doezema, David] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Gasparovic, Charles; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Gasparovic, Charles/E-7289-2010		Department of EnergyUnited States Department of Energy (DOE) [DE-FG02-99ER62764]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21NS064464-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	Contract grant sponsor: Department of Energy; Contract grant number: DE-FG02-99ER62764; Contract grant sponsor: National Institutes of Health; Contract grant number: R24-HD050836, R21NS064464-01A1.	AREND I, 2008, REV NEUROL, V131, P2140; Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Belin P, 2002, NEUROPSYCHOLOGIA, V40, P1956, DOI 10.1016/S0028-3932(02)00062-3; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Corbetta M, 2000, NAT NEUROSCI, V3, P292, DOI 10.1038/73009; Corbetta M, 1998, PHILOS T ROY SOC B, V353, P1353, DOI 10.1098/rstb.1998.0289; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; GASPAROVIC C, 2009, J NEUROTRAU IN PRESS; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Harris NS, 1999, COGNITIVE BRAIN RES, V8, P61, DOI 10.1016/S0926-6410(99)00006-3; Hesselmann V, 2001, HEARING RES, V158, P160, DOI 10.1016/S0378-5955(01)00307-0; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lepsien J, 2002, J COGNITIVE NEUROSCI, V14, P127, DOI 10.1162/089892902317236795; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Mayer AR, 2009, NEUROIMAGE, V44, P182, DOI 10.1016/j.neuroimage.2008.08.025; Mayer AR, 2007, J COGNITIVE NEUROSCI, V19, P455, DOI 10.1162/jocn.2007.19.3.455; Mayer AR, 2004, NEUROIMAGE, V23, P534, DOI 10.1016/j.neuroimage.2004.06.027; Mayer AR, 2004, J COGNITIVE NEUROSCI, V16, P1262, DOI 10.1162/0898929041920531; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; POSNER MI, 1985, COGNITIVE NEUROPSYCH, V2, P211, DOI 10.1080/02643298508252866; RAFAL RD, 1987, P NATL ACAD SCI USA, V84, P7349, DOI 10.1073/pnas.84.20.7349; Salmi J, 2007, BRAIN STRUCT FUNCT, V212, P181, DOI 10.1007/s00429-007-0152-2; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SMITS M, 2008, HUM BRAIN M IN PRESS; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Talairach J, 1988, COPLANAR STERIOTAXIC; Thiel CM, 2004, NEUROIMAGE, V21, P318, DOI 10.1016/j.neuroimage.2003.08.044; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Zatorre RJ, 2002, NAT NEUROSCI, V5, P905, DOI 10.1038/nn904	71	63	63	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	DEC	2009	30	12					4152	4166		10.1002/hbm.20836			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	530IW	WOS:000272584000025	19554558	Green Published, Green Accepted			2021-06-18	
J	Mazzeo, AT; Brophy, GM; Gilman, CB; Alves, OL; Robles, JR; Hayes, RL; Povlishock, JT; Bullock, MR				Mazzeo, Anna Teresa; Brophy, Gretchen M.; Gilman, Charlotte B.; Alves, Oscar Luis; Robles, Jaime R.; Hayes, Ronald L.; Povlishock, John T.; Bullock, M. Ross			Safety and Tolerability of Cyclosporin A in Severe Traumatic Brain Injury Patients: Results from a Prospective Randomized Trial	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporin A; neurological outcome; neuroprotection; safety; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; SEVERE HEAD-INJURY; TRANSIENT FOREBRAIN ISCHEMIA; INDUCED AXONAL DAMAGE; CYTOCHROME-C RELEASE; CELL-DEATH; IMMUNOSUPPRESSIVE THERAPY; REPERFUSION INJURY; CASPASE ACTIVATION; OXIDATIVE STRESS	Cyclosporin A (CsA) has recently been proposed for use in the early phase after traumatic brain injury (TBI), for its ability to preserve mitochondrial integrity in experimental brain injury models, and thereby provide improved behavioral outcomes as well as significant histological protection. The aim of this prospective, randomized, double-blind, dual-center, placebo-controlled trial was to evaluate the safety, tolerability, and pharmacokinetics of a single intravenous infusion of CsA in patients with severe TBI. Fifty adult severe TBI patients were enrolled over a 22-month period. Within 12 h of the injury patients received 5mg/kg of CsA infused over 24 h, or placebo. Blood urea nitrogen ( BUN), creatinine, hemoglobin, platelets, white blood cell count (WBC), and a hepatic panel were monitored on admission, and at 12, 24, 36, and 48 h, and on days 4 and 7. Potential adverse events (AEs) were also recorded. Neurological outcome was recorded at 3 and 6 months after injury. This study revealed only transient differences in BUN levels at 24 and 48 h and for WBC counts at 24 h between the CsA and placebo patients. These modest differences were not clinically significant in that they did not negatively impact on patient course. Both BUN and creatinine values, markers of renal function, remained within their normal limits over the entire monitoring period. There were no significant differences in other mean laboratory values, or in the incidence of AEs at any other measured time point. Also, no significant difference was demonstrated for neurological outcome. Based on these results, we report a good safety profile of CsA infusion when given at the chosen dose of 5mg/kg, infused over 24 h, during the early phase after severe head injury in humans, with the aim of neuroprotection.	[Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr, Miami, FL 33136 USA; [Mazzeo, Anna Teresa] Univ Messina, Dept Neurosci, Messina, Italy; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Richmond, VA USA; [Robles, Jaime R.] Virginia Commonwealth Univ, Dept Pharm, Sch Pharm, Richmond, VA USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Gilman, Charlotte B.] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Alves, Oscar Luis] Univ Porto, Serv Neurocirurgia, Ctr Hosp Vila Nova Gaia, Fac Med, P-4100 Oporto, Portugal; [Hayes, Ronald L.] Univ Florida, Dept Neurosurg, Ctr Innovat Res, Banyan Biomarkers Inc, Alachua, FL USA	Bullock, MR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr, 1095 NW 14th Terrace,Suite 3-20 R-48, Miami, FL 33136 USA.	rbullock@med.miami.edu		Mazzeo, Anna Teresa/0000-0002-8454-7243; Brophy, Gretchen/0000-0002-4749-2693	NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587]; Lind-Lawrence Foundation; Reynolds Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER	This study was funded by the NIH-NINDS as part of project grant no. NS12587 to M.R.B. (the primary investigator), and by the Lind-Lawrence Foundation and the Reynolds Foundation.	Al Aly Z, 2005, CLIN TRANSPLANT, V19, P683, DOI 10.1111/j.1399-0012.2005.00408.x; Aleo MD, 2008, TOXICOL APPL PHARM, V230, P126, DOI 10.1016/j.taap.2008.02.011; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Benigni A, 1999, KIDNEY INT, V55, P674, DOI 10.1046/j.1523-1755.1999.00288.x; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Buki A, 2000, J NEUROSCI, V20, P2825; Cattaneo D, 2004, TRANSPL P, V36, p234S, DOI 10.1016/j.transproceed.2004.01.011; Danovitch GM, 2005, HDB KIDNEY TRANSPLAN, P72; Fellstrom B, 2004, TRANSPLANT P, V36, p220S, DOI 10.1016/j.transproceed.2004.01.028; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friberg H, 1998, J NEUROSCI, V18, P5151; Gardiner SM, 2004, BRIT J PHARMACOL, V141, P634, DOI 10.1038/sj.bjp.0705659; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; JENNETT B, 1975, LANCET, V1, P480; Kapturczak MH, 2004, TRANSPL P, V36, p25S, DOI 10.1016/j.transproceed.2004.01.018; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Miller LW, 1996, CIRCULATION, V94, P1209, DOI 10.1161/01.CIR.94.6.1209; MIN DI, 1991, PHARMACOTHERAPY, V11, pS119; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Paul LC, 2004, TRANSPL P, V36, p224S, DOI 10.1016/j.transproceed.2004.01.005; Piot C, 2008, NEW ENGL J MED, V359, P473, DOI 10.1056/NEJMoa071142; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; REMUZZI G, 1995, KIDNEY INT, V48, pS70; Rezzani R, 2004, PROG HISTOCHEM CYTO, V39, P85, DOI 10.1016/j.proghi.2004.04.001; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; Schiff J, 2007, CLIN J AM SOC NEPHRO, V2, P374, DOI 10.2215/CJN.03791106; Shaltout HA, 2003, J PHARMACOL EXP THER, V305, P966, DOI 10.1124/jpet.102.048447; Shaw LM, 1996, CLIN CHEM, V42, P1316; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SZABO I, 1991, J BIOL CHEM, V266, P3376; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang XD, 2001, GENE DEV, V15, P2922; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	64	63	65	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2195	2206		10.1089/neu.2009.1012			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200007	19621985	Green Published			2021-06-18	
J	Downey, DM; Monson, B; Butler, KL; Fortuna, GR; Saxe, JM; Dolan, JP; Markert, RJ; McCarthy, MC				Downey, Douglas M.; Monson, Benjamin; Butler, Karyn L.; Fortuna, Gerald R., Jr.; Saxe, Jonathan M.; Dolan, James P.; Markert, Ronald J.; McCarthy, Mary C.			Does Platelet Administration Affect Mortality in Elderly Head-Injured Patients Taking Antiplatelet Medications?	AMERICAN SURGEON			English	Article							TRAUMATIC INTRACRANIAL HEMORRHAGE	A significant portion of patients sustaining traumatic brain injury (TBI) take antiplatelet medications (aspirin or clopidogrel), which have been associated with increased morbidity and mortality. In an attempt to alleviate the risk of increased bleeding, platelet transfusion has become standard practice in some institutions. This study was designed to determine if platelet transfusion reduces mortality in patients with TBI on antiplatelet medications. Databases from two Level I trauma centers were reviewed. Patients with TBI 50 years of age or older with documented preinjury use of clopidogrel or aspirin were included in our cohort. Patients who received platelet transfusions were compared with those who did not to assess outcome differences between them. Demographics and other patient characteristics abstracted included Injury Severity Score, Glasgow Coma Scale, hospital length of stay, and warfarin use. Three hundred twenty-eight patients comprised the study group. Of these patients, 166 received platelet transfusion and 162 patients did not. Patients who received platelets had a mortality rate of 17.5 per cent (29 of 166), whereas those who did not receive platelets had a mortality rate of 16.7 per cent (27 of 162) (P = 0.85). Transfusion of platelets in patients with TBI using antiplatelet therapy did not reduce mortality.	[Saxe, Jonathan M.; McCarthy, Mary C.] Wright State Univ, Boonshoft Sch Med, Dept Surg, Div Trauma, Dayton, OH 45409 USA; [Butler, Karyn L.] Hartford Hosp, Dept Surg, Hartford, CT 06115 USA; [Fortuna, Gerald R., Jr.] Univ Cincinnati, Sch Med, Dept Surg, Cincinnati, OH USA; [Dolan, James P.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA	Saxe, JM (corresponding author), Wright State Univ, Boonshoft Sch Med, Dept Surg, Weber Ctr Hlth Educ,Miami Valley Hosp, Suite 7000,1 Wyoming St, Dayton, OH 45409 USA.	jonathan.m.saxe@wright.edu					Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Santa-Cruz Richard A, 2004, Curr Cardiol Rep, V6, P264, DOI 10.1007/s11886-004-0074-z; Seegmiller A, 2007, HEMATOL ONCOL CLIN N, V21, P731, DOI 10.1016/j.hoc.2007.06.008; Stuart G, 1998, J CLIN NEUROSCI, V5, P402, DOI 10.1016/S0967-5868(98)90271-5; Vane JR, 2003, THROMB RES, V110, P255, DOI 10.1016/S0049-3848(03)00379-7; Vilahur G, 2007, J THROMB HAEMOST, V5, P82, DOI 10.1111/j.1538-7836.2006.02245.x	12	63	65	0	2	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	NOV	2009	75	11					1100	1103					4	Surgery	Surgery	513PZ	WOS:000271336600015	19927514				2021-06-18	
J	Broglio, SP; Sosnoff, JJ; Ferrara, MS				Broglio, Steven P.; Sosnoff, Jacob J.; Ferrara, Michael S.			The Relationship of Athlete-Reported Concussion Symptoms and Objective Measures of Neurocognitive Function and Postural Control	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sport concussion; symptoms; balance; cognitive function	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; RECOVERY; SPORTS; SENSITIVITY; PERFORMANCE; VALIDITY; INJURY	Objective: Concussed athlete evaluations often include symptoms, balance, and neurocognitive assessments. We sought to identify the relationship between subjective symptom reports and objective clinical measures. Design: A retrospective assessment. Setting: A research laboratory. Patients: Concussed collegiate-level athletes (N = 32, 19.7 years) evaluated pre- and postinjury (less than 48 hours). Intervention: Each athlete completed an inventory of concussion-related symptoms, the NeuroCom Sensory Organization Test (SOT), and ImPACT neurocognitive assessment. Spearman correlations between balance symptoms and SOT scores and cognitive symptoms and ImPACT scores were completed. Main Outcome Measures: Symptoms related to balance and cognitive deficits, SOT composite balance and visual, vestibular, and somatosensory ratios, and ImPACT output scores. Results: Significant Spearman correlations were noted between reports of "dizziness" and the SOT composite balance (r(s) = -0.55) and vestibular ratio (r(s) = -0.50). Similarly, "balance problems" were significantly correlated with composite balance (r(s) = -0.52) and the somatosensory (r(s) = -0.41), visual (r(s) = -0.39), and vestibular ratios (r(s) = -0.57). The cognitive symptom of "feeling mentally foggy" and ImPACT variables of reaction time (r(s) = 0.36) and "difficulty concentrating" and verbal memory score (r(s) = -0.41) were significantly related. Finally, reports of "difficultly remembering" were significantly related to the verbal memory score (r(s) = -0.48) and reaction time (r(s) = 0.36). Conclusions: These findings indicate self-report symptoms are associated with athlete deficits in postural control and cognitive function. The moderate relationship between the symptom reports and the objective measures warrants the continued use of all measures. A reduction in the number of symptoms concussed athletes respond to may be justified to reduce redundancy.	[Broglio, Steven P.; Sosnoff, Jacob J.] Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, Urbana, IL 61801 USA; [Ferrara, Michael S.] Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu	Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; DELATORRE JC, 2002, STROKE, V33, P1; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Karatas M, 2008, NEUROLOGIST, V14, P355, DOI 10.1097/NRL.0b013e31817533a3; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; VANKAMPEN DA, 2006, AM J SPORT MED, V30, P1	35	63	63	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2009	19	5					377	382		10.1097/JSM.0b013e3181b625fe			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	493DS	WOS:000269714200005	19741309				2021-06-18	
J	Kraft, AD; McPherson, CA; Harry, GJ				Kraft, Andrew D.; McPherson, Christopher A.; Harry, G. Jean			Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival	NEUROTOXICOLOGY			English	Article; Proceedings Paper	25th International Neurotoxicology Conference	OCT 12-16, 2008	Rochester, NY			Microglia; Neuroinflammation; Hippocampus; Trimethyltin; TNF alpha; TNF receptors	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE NEURITIS; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; FACTOR RECEPTOR P75; KAPPA-B ACTIVATION; FACTOR-ALPHA; MOUSE MODEL; MESSENGER-RNA	Microglia do not constitute a single, uniform cell population, but rather comprise cells with varied phenotypes, some which are beneficial and others that may require active regulatory control. Thus, gaining a better understanding of the heterogeneity of resident microglia responses will contribute to any interpretation regarding the impact of any such response in the brain. Microglia are the primary source of the pro-inflammatory cytokine, tumor necrosis factor (TNF) that can initiate various effects through the activation of membrane receptors. The TNF p55 receptor contains a death domain and activation normally leads to cellular apoptosis; however, under specific conditions, receptor activation can also lead to the activation of NF-kappa B and contribute to cell survival. These divergent outcomes have been linked to receptor localization with receptor internalization leading to cell death and membrane localization supporting cell survival. A second TNF receptor, TNF p75 receptor, is normally linked to cell growth and survival, however, it can cooperate with the p55 receptor and contribute to cell death. Thus, while an elevation in TNF alpha in the brain is often considered an indicator of microglia activation and neuroinflammation, a number of factors come into play to determine the final outcome. Data are reviewed demonstrating that heterogeneity in morphological response of microglia and the expression of TNF alpha and TNF receptors are critical in identifying and characterizing neurotoxic events as they relate to neuroinflammation, neuronal damage and in stimulating neuroprotection. Published by Elsevier Inc.	[Kraft, Andrew D.; McPherson, Christopher A.; Harry, G. Jean] NIEHS, Neurotoxicol Grp, Mol Toxicol Lab, NIH,Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	Harry, GJ (corresponding author), NIEHS, Neurotoxicol Grp, Mol Toxicol Lab, NIH,Dept Hlth & Human Serv, POB 12233,MD C1-04, Res Triangle Pk, NC 27709 USA.	harry@niehs.nih.gov			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA ES101623-08, ZIA ES021164-14] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ZIAES021164, ZIAES101623] Funding Source: NIH RePORTER		Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Akassoglou K, 2003, P NATL ACAD SCI USA, V100, P709, DOI 10.1073/pnas.0236046100; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Badie B, 2000, EXP NEUROL, V162, P290, DOI 10.1006/exnr.1999.7345; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; Bohatschek M, 2004, J COMP NEUROL, V470, P382, DOI 10.1002/cne.20017; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Brochard V, 2009, J CLIN INVEST, V119, P182, DOI 10.1172/JCI36470; Bruccoleri A, 2000, J NEUROSCI RES, V62, P146, DOI 10.1002/1097-4547(20001001)62:1<146::AID-JNR15>3.0.CO;2-L; Bruccoleri A, 1998, J NEUROCHEM, V71, P1577; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Carson MJ, 2007, NEUROTHERAPEUTICS, V4, P571, DOI 10.1016/j.nurt.2007.07.002; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; CORSARO A, 2009, NEUROTOX RES, V15, P102; Cunningham O, 2009, GLIA, V57, P1802, DOI 10.1002/glia.20892; d'Hellencourt CL, 2005, J NEUROCHEM, V93, P206, DOI 10.1111/j.1471-4159.2004.03017.x; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Declercq W, 1998, J IMMUNOL, V161, P390; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Eskes C, 2003, J NEUROSCI RES, V71, P583, DOI 10.1002/jnr.10508; Fiedorowicz A, 2001, BRAIN RES, V912, P116, DOI 10.1016/S0006-8993(01)02675-0; Fiers W, 1996, J INFLAMM, V47, P67; Figiel I, 2007, BRAIN RES, V1131, P17, DOI 10.1016/j.brainres.2006.10.095; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P1; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Gendelman HE, 1999, J LEUKOCYTE BIOL, V65, P407; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; Haddad EB, 2002, J IMMUNOL, V169, P974, DOI 10.4049/jimmunol.169.2.974; Haga S, 2002, ACTA NEUROPATHOL, V103, P575, DOI 10.1007/s00401-001-0505-5; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Harry GJ, 2008, J NEUROCHEM, V106, P281, DOI 10.1111/j.1471-4159.2008.05382.x; Harry GJ, 2008, BRAIN RES, V1194, P8, DOI 10.1016/j.brainres.2007.11.076; Harry GJ, 2003, J NEUROSCI RES, V73, P526, DOI 10.1002/jnr.10653; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Harry GJ, 2002, TOXICOL APPL PHARM, V180, P205, DOI 10.1006/taap.2002.9390; Henshall DC, 2005, J CEREBR BLOOD F MET, V25, P1557, DOI 10.1038/sj.jcbfm.9600149; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; KIMOTO H, 2009, CELL MOL NEUROBIOL, DOI DOI 10.1007/S10571-009-9412A; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; KODA T, 2009, CELL MOL NEUROBIOL, DOI DOI 10.1007/SL0571-008-9344-4; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lambertsen KL, 2007, NEUROSCIENCE, V144, P934, DOI 10.1016/j.neuroscience.2006.10.046; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu MO, 2007, J NEUROIMMUNOL, V186, P19, DOI 10.1016/j.jneuroim.2007.02.004; Maier WE, 1997, NEUROCHEM INT, V30, P385, DOI 10.1016/S0197-0186(96)00073-3; Malm TM, 2008, GLIA, V56, P1767, DOI 10.1002/glia.20726; Mao HY, 2007, BRAIN RES, V1186, P267, DOI 10.1016/j.brainres.2007.10.020; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4; McGeer PL, 2001, ADV NEUROL, V86, P83; MEAGER A, 1993, CYTOKINE, V5, P556, DOI 10.1016/S1043-4666(05)80004-3; MEDVEDEV AE, 1994, EUR J IMMUNOL, V24, P2842, DOI 10.1002/eji.1830241139; Medvedev AE, 1996, SCAND J IMMUNOL, V43, P439, DOI 10.1046/j.1365-3083.1996.d01-58.x; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MONNETTSCHUDI F, 1995, BRAIN RES, V690, P8, DOI 10.1016/0006-8993(95)00509-O; Namura S, 2001, STROKE, V32, P1906, DOI 10.1161/01.STR.32.8.1906; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Qiu JH, 2002, J NEUROSCI, V22, P3504; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; RENNO T, 1995, J IMMUNOL, V154, P944; Rohl C, 2009, TOXICOL IN VITRO, V23, P1541, DOI 10.1016/j.tiv.2009.04.013; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Rousselet E, 2002, EXP NEUROL, V177, P183, DOI 10.1006/exnr.2002.7960; Sairanen TR, 2001, J NEUROL SCI, V186, P87, DOI 10.1016/S0022-510X(01)00508-1; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sawada M, 2006, J NEURAL TRANSM-SUPP, P373; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/S1074-7613(04)00234-1; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sriram K, 2006, J NEUROCHEM, V96, P706, DOI 10.1111/j.1471-4159.2005.03566.x; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Suvannavejh GC, 2000, CELL IMMUNOL, V205, P24, DOI 10.1006/cimm.2000.1706; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Taylor DL, 2005, J NEUROSCI, V25, P2952, DOI 10.1523/JNEUROSCI.4456-04.2005; Tchelingerian JL, 1996, J NEUROSCI RES, V43, P99, DOI 10.1002/jnr.490430113; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Viviani B, 1998, TOXICOL APPL PHARM, V150, P271, DOI 10.1006/taap.1998.8406; Wajant H, 1999, CYTOKINE GROWTH F R, V10, P15, DOI 10.1016/S1359-6101(98)00023-9; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Weishaupt A, 2000, J NEUROPATH EXP NEUR, V59, P368, DOI 10.1093/jnen/59.5.368; Weiss T, 1997, J IMMUNOL, V158, P2398; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167; WINE RN, 2009, NEUROTOX RES, V20; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yang RN, 2001, CHIN J STRUCT CHEM, V20, P4; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	132	63	69	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	SEP	2009	30	5			SI		785	793		10.1016/j.neuro.2009.07.001			9	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	513AC	WOS:000271292900008	19596372	Green Accepted			2021-06-18	
J	Krajewska, M; Smith, LH; Rong, J; Huang, XS; Hyer, ML; Zeps, N; Iacopetta, B; Linke, SP; Olson, AH; Reed, JC; Krajewski, S				Krajewska, Maryla; Smith, Layton H.; Rong, Juan; Huang, Xianshu; Hyer, Marc L.; Zeps, Nikolajs; Iacopetta, Barry; Linke, Steven P.; Olson, Allen H.; Reed, John C.; Krajewski, Stan			Image Analysis Algorithms for Immunohistochemical Assessment of Cell Death Events and Fibrosis in Tissue Sections	JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY			English	Article						cell death; automated image analysis; algorithm; autoscore; virtual pathology	POLY(ADP-RIBOSE) POLYMERASE; HISTONE H2AX; DNA-DAMAGE; APOPTOSIS; EXPRESSION; HISTOPATHOLOGY; QUANTIFICATION; STRATEGIES; PROTEINS; CLEAVAGE	Cell death is of broad physiological and pathological importance, making quantification of biochemical events associated with cell demise a high priority for experimental pathology. Fibrosis is a common consequence of tissue injury involving necrotic cell death. Using tissue specimens from experimental mouse models of traumatic brain injury, cardiac fibrosis, and cancer, as well as human tumor specimens assembled in tissue microarray (TMA) format, we undertook computer-assisted quantification of specific immunohistochemical and histological parameters that characterize processes associated with cell death. In this study, we demonstrated the utility of image analysis algorithms for color deconvolution, colocalization, and nuclear morphometry to characterize cell death events in tissue specimens: (a) subjected to immunostaining for detecting cleaved caspase-3, cleaved poly(ADP-ribose)polymerase, cleaved lamin-A, phosphorylated histone H2AX, and Bcl-2; (b) analyzed by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay to detect DNA fragmentation; and (c) evaluated with Masson's trichrome staining. We developed novel algorithm-based scoring methods and validated them using TMAs as a high-throughput format. The proposed computer-assisted scoring methods for digital images by brightfield microscopy permit linear quantification of immunohistochemical and histochemical stainings. Examples are provided of digital image analysis performed in automated or semiautomated fashion for successful quantification of molecular events associated with cell death in tissue sections. (J Histochem Cytochem 57:649-663, 2009)	[Krajewska, Maryla; Rong, Juan; Huang, Xianshu; Hyer, Marc L.; Reed, John C.; Krajewski, Stan] Burnham Inst Med Res, La Jolla, CA 92037 USA; [Smith, Layton H.] Lake Nona Orlando, Orlando, FL USA; [Zeps, Nikolajs] Bendat Family Comprehens Canc Ctr, Subiaco, WA, Australia; [Iacopetta, Barry] Univ Western Australia, Nedlands, WA 6009, Australia; [Olson, Allen H.] Aperio Technol Inc, Vista, CA USA	Krajewski, S (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stan@burnham.org	Zeps, Nikolajs/C-4180-2013; Zeps, Nikolajs/AAF-3186-2021	Zeps, Nikolajs/0000-0002-6404-6839; Zeps, Nikolajs/0000-0002-6404-6839; Linke, Steven/0000-0001-8584-4947; Smith, Layton/0000-0003-2621-9740	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [036821, U01-CA113318]; California Breast Cancer Research Program [10WB-0194]; Florida Department of Health [06-NIR-09]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R44CA-117001]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R44CA117001, U19CA113318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036821] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) Grant NS-036821 (to SK), the California Breast Cancer Research Program (grant 10WB-0194) and NIH Grant U01-CA113318 (to JCR) and Florida Department of Health (grant 06-NIR-09 to LS). The TMA project was supported by National Cancer Institute Grant R44CA-117001 (to SPL). We thank Lisa Spalding for high-quality TMA preparation and Jessica Groos and Judy Wade for excellent animal care assistance.	BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Billet S, 2007, J CLIN INVEST, V117, P1914, DOI 10.1172/JCI28764; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Brennan DJ, 2008, CLIN CANCER RES, V14, P2681, DOI 10.1158/1078-0432.CCR-07-1760; Fine JL, 2008, HUM PATHOL, V39, P564, DOI 10.1016/j.humpath.2007.08.007; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Rojo MG, 2006, INT J SURG PATHOL, V14, P285, DOI 10.1177/1066896906292274; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Jonker A, 1997, HISTOCHEM J, V29, P347, DOI 10.1023/A:1026434816947; Kivinen K, 2005, EXP CELL RES, V311, P62, DOI 10.1016/j.yexcr.2005.08.006; Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094; Krajewska M, 2008, CLIN CANCER RES, V14, P3011, DOI 10.1158/1078-0432.CCR-07-1955; Krajewska M, 2007, PROSTATE, V67, P907, DOI 10.1002/pros.20578; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kumar S, 1997, INT J BIOCHEM CELL B, V29, P393, DOI 10.1016/S1357-2725(96)00146-X; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Meier P, 2007, MOL CELL, V28, P746, DOI 10.1016/j.molcel.2007.11.016; Mulrane L, 2008, EXPERT REV MOL DIAGN, V8, P707, DOI 10.1586/14737159.8.6.707; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Plesca D, 2008, METHOD ENZYMOL, V446, P107, DOI 10.1016/S0076-6879(08)01606-6; Ramires FJA, 1998, J MOL CELL CARDIOL, V30, P475, DOI 10.1006/jmcc.1997.0612; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Reed WP, 2004, SURG ENDOSC, V18, P11, DOI 10.1007/s00464-003-8913-3; Rexhepaj E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2187; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; ROSENTHAL WD, 1990, J PROD AGRIC, V3, P124, DOI 10.2134/jpa1990.0124; Rubin MA, 2004, AM J PATHOL, V164, P831, DOI 10.1016/S0002-9440(10)63171-9; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Takemura G, 2004, PHARMACOL THERAPEUT, V104, P1, DOI 10.1016/j.pharmthera.2004.07.005; Taylor CR, 2006, HISTOPATHOLOGY, V49, P411, DOI 10.1111/j.1365-2559.2006.02513.x; Tewari M, 2008, SURG ONCOL, V17, P301, DOI 10.1016/j.suronc.2008.03.003; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Weber KT, 2004, HYPERTENSION, V43, P716, DOI 10.1161/01.HYP.0000118586.38323.5b; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307	41	63	64	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0022-1554	1551-5044		J HISTOCHEM CYTOCHEM	J. Histochem. Cytochem.	JUL	2009	57	7					649	663		10.1369/jhc.2009.952812			15	Cell Biology	Cell Biology	457PZ	WOS:000266945800005	19289554	Bronze, Green Published			2021-06-18	
J	Fadyl, JK; McPherson, KM				Fadyl, Joanna Kristin; McPherson, Kathryn M.			Approaches to Vocational Rehabilitation After Traumatic Brain Injury: A Review of the Evidence	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						review; traumatic brain injury; vocational rehabilitation; work reentry	MILIEU-BASED NEUROREHABILITATION; QUALITY-OF-LIFE; SUPPORTED EMPLOYMENT; WORK; RETURN; OUTCOMES; MODEL; INDIVIDUALS; PROGRAM; INTEGRATION	Background: Return to work after traumatic brain injury (TBI) is an important outcome but frequently problematic to achieve. Vocational rehabilitation is commonly recommended as a means of facilitating return to work after TBI. However, there are several different approaches to vocational rehabilitation after TBI and little guidance regarding how to identify the best option for a particular context. Objectives: To (1) identify approaches most commonly underpinning vocational Interventions in TBI and (2) evaluate the evidence for effectiveness, strengths and weaknesses, and application of each approach for the TBI population. Methods: Principles of systematic review were used for searching and critiquing articles. Findings are expressed as descriptive synthesis owing to heterogeneity of designs and outcome measures. Results: Three broad categories of vocational rehabilitation for people with TBI were identified on the basis of models that underpin them-program-based vocational rehabilitation, supported employment, and case coordinated. The characteristics, similarities, differences, and applications of each approach are described, as are their strengths and limitations. Conclusions: There is little clear evidence to suggest what should be considered the "best practice" approach to vocational rehabilitation,	[Fadyl, Joanna Kristin; McPherson, Kathryn M.] AUT Univ, Sch Rehabil & Occupat Studies, Auckland 1142, New Zealand	Fadyl, JK (corresponding author), AUT Univ, Sch Rehabil & Occupat Studies, Private Bag 92006, Auckland 1142, New Zealand.	jfadyl@aut.ac.nz		McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882			*ACC COMP CORP, 2007, ACC INJ STAT 2006; Babineau J L, 1998, Work, V10, P137, DOI 10.3233/WOR-1998-10205; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BREIL L, 1996, J VOCAT REHABIL, V7, P151; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CRISP R, 1992, J REHABIL, V58, P27; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; ELLERD DA, 1992, J APPL REHABILITATIO, V23, P48; EVANS RW, 1990, COMMUNITY INTEGRATIO, P125; Fineout-Overholt E, 2005, NURSE LEAD, V3, P26, DOI 10.1016/j.mnl.2005.09.007; Gamble D, 2003, J REHABIL, V69, P31; Gamble D, 2003, J VOCATIONAL REHABIL, V19, P47; GOLDEN TP, 1993, J REHABIL, V59, P55; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HOARE R, 2004, NZ STAT ASS 2004 C J; Johansson U, 2006, AM J OCCUP THER, V60, P60, DOI 10.5014/ajot.60.1.60; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 2006, NEUROREHABILITATION, V21, P335; Kendall E, 2006, J VOCAT REHABIL, V25, P149; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; LAMARCHE JA, 1995, J HEAD TRAUMA REHAB, V10, P81, DOI 10.1097/00001199-199508000-00008; Lawthers AG, 2003, INT J QUAL HEALTH C, V15, P287, DOI 10.1093/intqhc/mzg048; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; MALEC J, 1995, PRACTICAL SOLUTIONS, P89; Malec JF, 2006, BRAIN INJURY, V20, P227, DOI 10.1080/02699050500488124; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Murphy L, 2006, BRAIN INJURY, V20, P1119, DOI 10.1080/02699050600664335; Murrey GJ, 2004, BRAIN INJURY, V18, P519, DOI 10.1080/02699050310001646125; O'Brien L, 2007, BRAIN INJURY, V21, P465, DOI 10.1080/02699050701315134; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; O'Neill JH, 2004, ARCH PHYS MED REHAB, V85, pS68, DOI 10.1016/j.apmr.2003.08.114; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; PARENTE R, 1991, J HEAD TRAUMA REHAB, V6, P35; Petticrew M, 2006, SYSTEMATIC REVIEWS IN THE SOCIAL SCIENCES: A PRACTICAL GUIDE, P1, DOI 10.1002/9780470754887; PRESTON B, 1992, REHABIL COUNS BULL, V35, P230; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Schonbrun SL, 2007, J REHABIL, V73, P26; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; THOMAS DF, 1993, COMMUNITY BASED EMPL; Turner-Stokes L, 2006, CLIN MED, V6, P91, DOI 10.7861/clinmedicine.6-1-91; Vandiver VL, 2003, J HEAD TRAUMA REHAB, V18, P457, DOI 10.1097/00001199-200309000-00007; Wall JR, 1998, NEUROREHABILITATION, V10, P39, DOI 10.3233/NRE-1998-10105; Wall JR, 1998, BRAIN INJURY, V12, P215; Wehman P, 2000, NEUROREHABILITATION, V15, P71; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN P, 2000, TRAUMATIC BRAIN INJU, P201; Wehman P, 1996, J VOCATIONAL REHABIL, V7, P205; Wehman P, 2007, J HEAD TRAUMA REHAB, V22, P95, DOI 10.1097/01.HTR.0000265097.44683.22; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; World Health Organization, 2001, INT CLASS FUNCT DIS; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	69	63	64	3	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					195	212		10.1097/HTR.0b013e3181a0d458			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800006	19461367				2021-06-18	
J	Ngo, QN; Ranger, A; Singh, RN; Kornecki, A; Seabrook, JA; Fraser, DD				Ngo, Quang N.; Ranger, Adrianna; Singh, Ram N.; Kornecki, Alik; Seabrook, Jamie A.; Fraser, Douglas D.			External ventricular drains in pediatric patients	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						ventriculostomy; cerebrospinal fluid; traumatic brain injury; hydrocephalus	CEREBROSPINAL-FLUID; INFECTIONS; COMPLICATIONS; CATHETERS; DURATION; HYDROCEPHALUS; HYPONATREMIA; MANAGEMENT; CHILDREN; RATES	Objective: To determine the indications and complications of external ventricular drain (EVD) placement in pediatric patients. Design: Retrospective chart review. Setting., University associated, tertiary-level Children's Hospital. Patients: Sixty-six [median age, 10.1 years (interquartile range, 5.9)] patients between 1994 and 2006 with 96 EVDs. Measurements and Results: Clinical indications for EVD insertion include traumatic brain injury (TBI; 36%), acute hydrocephalus (35%), and ventriculoperitoneal shunt failure (29%). Of the 96 EVDs, 65% were inserted at the bedside in the pediatric critical care unit (PCCU) and 33% in the operating room (OR). Median duration of EVD insertion was 7.0 days (interquartile range, 8.8). Complications occurred with 26% of EVD insertions and included infection (9.4%), misplacement (6.3%), hemorrhage (4.2%), obstruction (3.1%), and malfunction (3.1%). The primary infectious etiology was coagulase-negative Staphylococcus (67% of infections). Despite patients with TBI having significantly smaller lateral ventricles than hydrocephalus patients (p < 0.05), EVD complications were similar (risk ratios 1.41; 95% confidence interval 0.68-2.72). Furthermore, the complication rate was the same for EVDs inserted in either the PCCU or OR (risk ratios 1.10; 95% confidence interval 0.55-2.29). Conclusion. EVDs were placed for TBI, ventriculoperitoneal shunt failure and new-onset hydrocephalus. The overall complication rate was 26%. Complication rates were similar in TBI and hydrocephalus patients, and with EVDs inserted in either the PCCU or OR. Prophylactic antibiotics or antimicrobial-impregnated catheters directed against coagulase-negative Staphylococcus may reduce EVD infections. (Pediatr Crit Care Med 2009; 10:346-351)	[Ngo, Quang N.; Singh, Ram N.; Kornecki, Alik; Seabrook, Jamie A.; Fraser, Douglas D.] Univ Western Ontario, Dept Paediat, London, ON, Canada; [Ranger, Adrianna; Fraser, Douglas D.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Singh, Ram N.; Kornecki, Alik; Seabrook, Jamie A.; Fraser, Douglas D.] Childrens Hlth Res Inst, London, ON, Canada; [Singh, Ram N.; Kornecki, Alik; Fraser, Douglas D.] Ctr Crit Illness Res, London, ON, Canada	Ngo, QN (corresponding author), Univ Western Ontario, Dept Paediat, London, ON, Canada.	fraserd@lhsc.on.ca		Ngo, Quang N./0000-0002-8244-4208			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Berger A, 2000, CHILD NERV SYST, V16, P103, DOI 10.1007/s003810050022; BREIMAN RS, 1982, AM J ROENTGENOL, V138, P329, DOI 10.2214/ajr.138.2.329; Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901; DIAS MS, 1989, PEDIATR NEUROSCI, V15, P283; EDDY VA, 1995, AM SURGEON, V61, P24; Hader WJ, 2000, NEUROSURGERY, V46, P1149, DOI 10.1097/00006123-200005000-00025; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JAMES HE, 1982, NEUROSURGERY, V10, P50, DOI 10.1227/00006123-198201000-00009; KANTER RK, 1984, NEW ENGL J MED, V311, P987; Khalil BA, 2005, CHILD NERV SYST, V21, P355, DOI 10.1007/s00381-004-1080-6; Khan SH, 1998, ACT NEUR S, V71, P50; KIM DK, 1995, J NEUROL NEUROSUR PS, V58, P444, DOI 10.1136/jnnp.58.4.444; Korinek AM, 2005, ACTA NEUROCHIR, V147, P39, DOI 10.1007/s00701-004-0416-z; Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378; Lucey M A, 2003, Crit Care Resusc, V5, P182; MACMAHON P, 1983, ARCH DIS CHILD, V58, P385, DOI 10.1136/adc.58.5.385; Maniker AH, 2006, NEUROSURGERY, V59, P419, DOI 10.1227/01.NEU.0000222817.99752.E6; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; PAPO I, 1982, NEUROSURGERY, V10, P13, DOI 10.1227/00006123-198201000-00002; Pfisterer W, 2003, J NEUROL NEUROSUR PS, V74, P929, DOI 10.1136/jnnp.74.7.929; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; RHODES TT, 1987, PEDIATR NEUROSCI, V13, P255, DOI 10.1159/000120339; Roitberg BZ, 2001, BRIT J NEUROSURG, V15, P324; Rossi S, 1998, ACT NEUR S, V71, P91; SCARFF TB, 1978, CHILD BRAIN, V4, P129; Schade RP, 2005, J NEUROSURG, V102, P229, DOI 10.3171/jns.2005.102.2.0229; Simpson S, 2006, ANAESTH INTENS CARE, V34, P659, DOI 10.1177/0310057X0603400502; Sloffer CA, 2005, NEUROSURGERY, V56, P1041, DOI 10.1227/01.NEU.0000158193.99783.35; SMITH RW, 1976, J NEUROSURG, V44, P567, DOI 10.3171/jns.1976.44.5.0567; STENAGER E, 1986, ACTA NEUROCHIR, V83, P20, DOI 10.1007/BF01420503; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497; TOBIAS JD, 1991, SOUTHERN MED J, V84, P279, DOI 10.1097/00007611-199102000-00035; WENINGER M, 1992, NEUROSURGERY, V31, P52, DOI 10.1227/00006123-199207000-00008; Whitehead WE, 2001, PEDIATR NEUROSURG, V35, P205, DOI 10.1159/000050422; WINFIELD JA, 1993, NEUROSURGERY, V33, P424; Wong GKC, 2006, J CLIN PHARM THER, V31, P231, DOI 10.1111/j.1365-2710.2006.00729.x; WYLER AR, 1972, J NEUROSURG, V37, P185, DOI 10.3171/jns.1972.37.2.0185; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	41	63	64	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2009	10	3					346	351		10.1097/PCC.0b013e3181a320cd			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	444YG	WOS:000266016200011	19325503				2021-06-18	
J	McPherson, KM; Kayes, N; Weatherall, M				McPherson, Kathryn M.; Kayes, Nicola; Weatherall, Mark		Goals SR Res Grp	A pilot study of self-regulation informed goal setting in people with traumatic brain injury	CLINICAL REHABILITATION			English	Article							REHABILITATION; ATTAINMENT; MOTIVATION	Objective: To determine the acceptability and clinical application of two recently developed goal-setting interventions (Goal Management Training and Identity Oriented Goal Training) in people with traumatic brain injury. Design: A three parallel group, randomized controlled pilot study. Setting: Inpatient and community rehabilitation facilities. Subjects: Thirty-four people with moderate to severe traumatic brain injury (Goal Management Training, n = 12; Identity Oriented Goal Training, n = 10; usual care, n = 12) and their rehabilitation clinicians. Interventions: For both Goal Management Training and Identity Oriented Goal Training participants met face to face with their key worker weekly over a period of 6-8 weeks, during which time the key worker worked to engage them in goal setting and goal performance using the strategy prescribed by their group allocation. Usual care was provided to the other participants. Main measures: Largely qualitative using observation, individual interviews and focus groups. Participants also completed a Goal Attainment Scale at baseline, post intervention and at three months follow-up. Results: Both approaches were acceptable to the majority of participants with many reporting improved mood and goal attainment. Clinicians found working in a different way with patients both challenging and rewarding, with both experimental approaches enhancing a focus on the person's own goals. Identity Oriented Goal Training seemed particularly helpful in engaging people in the goal-setting process while Goal Management Training appeared particularly helpful in providing a structured framework for error prevention in attempting goal performance. Conclusion: These theoretically informed approaches to goal setting showed promise but were time intensive and at times difficult for practitioners to utilize.	[McPherson, Kathryn M.; Kayes, Nicola; Weatherall, Mark; Goals SR Res Grp] Natl Res Ctr Stroke, Appl Neurosci & Neurorehabil & Hlth & Rehabil Res, Sch Rehabil & Occupat Studies, Auckland, New Zealand	McPherson, KM (corresponding author), Natl Res Ctr Stroke, Appl Neurosci & Neurorehabil & Hlth & Rehabil Res, Sch Rehabil & Occupat Studies, Akoranga Dr Campus,AA Bldg,Room 263,Private Bag, Auckland, New Zealand.	Kathryn.McPherson@aut.ac.nz	Weatherall, Mark/Y-6824-2019	Weatherall, Mark/0000-0002-0051-9107; McPherson, Kath/0000-0003-0487-8497	Health Research Council of New ZealandHealth Research Council of New Zealand	This study was supported by the Health Research Council of New Zealand.	Ashford S, 2006, PHYSIOTHER RES INT, V11, P24, DOI 10.1002/pri.36; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; Carver C. S., 1998, SELF REGULATION BEHA; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CYTRYNBAUM S, 1979, EVALUATION QUART, V3, P5, DOI 10.1177/0193841X7900300102; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Feigin V. L., 2007, HDB CLIN NEUROEPIDEM, P197; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; Hellawell DJ, 1997, INT J REHABIL RES, V20, P345, DOI 10.1097/00004356-199712000-00001; JANE JA, 1982, CLIN NEUR, V29, P346; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; Khan F, 2008, ARCH PHYS MED REHAB, V89, P652, DOI 10.1016/j.apmr.2007.09.049; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; Levack WMM, 2006, DISABIL REHABIL, V28, P741, DOI 10.1080/09638280500265961; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Locke E.A., 1990, THEORY GOAL SETTING; Locke EA, 2002, AM PSYCHOL, V57, P705, DOI 10.1037//0003-066X.57.9.705; Maclean N, 2000, SOC SCI MED, V50, P495; MRC (Med. Res. Counc.), 2000, FRAM DEV EV RCTS COM; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Siegert RJ, 2005, DISABIL REHABIL, V27, P1493, DOI 10.1080/09638280500288401; Siegert RJ, 2004, DISABIL REHABIL, V26, P1175, DOI 10.1080/09638280410001724834; Tennant A, 2007, DISABIL REHABIL, V29, P1583, DOI 10.1080/09638280701618828; TORNER JC, 1996, EPIDEMIOLOGY CLOSED; Wade DT, 1998, CLIN REHABIL, V12, P273, DOI 10.1191/026921598678166365; World Health Organization, 2005, 55 SESS WHO REG COMM; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; Ylvisaker M, 2008, NEUROPSYCHOL REHABIL, V18, P713, DOI 10.1080/09602010802201832	31	63	64	0	15	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	APR	2009	23	4					296	309		10.1177/0269215509102980			14	Rehabilitation	Rehabilitation	427YC	WOS:000264814000002	19293290				2021-06-18	
J	Wagner, AK; Drewencki, LL; Chen, X; Santos, FR; Khan, AS; Harun, R; Torres, GE; Michael, AC; Dixon, CE				Wagner, Amy K.; Drewencki, Laura L.; Chen, Xiangbai; Santos, F. Ryan; Khan, Amina S.; Harun, Rashed; Torres, Gonzalo E.; Michael, Adrian C.; Dixon, C. Edward			Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						dopamine; methylphenidate; neurotransmission; striatum; transcription factor; traumatic brain injury; voltammetry	TYROSINE-HYDROXYLASE ACTIVITY; CORTICAL IMPACT INJURY; PROTEIN-KINASE-A; C-FOS; RAT STRIATUM; DYNAMIC REGULATION; GENE-EXPRESSION; TRANSPORTER; RELEASE; TRAFFICKING	Traumatic brain injury (TBI) results in functional deficits that often are effectively treated clinically with the neurostimulant, methylphenidate (MPH). We hypothesized that daily MPH administration would reverse striatal neurotransmission deficits observed in the controlled cortical impact (CCI) model of TBI. CCI or naive rats received daily injections of MPH (5 mg/kg) or saline for 14 days and were assessed on day 15 using fast scan cyclic voltammetry. Dopamine (DA) transporter (DAT) localization, DA-related proteins, and transcription factor (c-fos) expression were also assessed. CCI resulted in reduced electrically evoked overflow of DA and maximal velocity of DA clearance (V-max). In contrast, CCI was associated with a decrease in the apparent K-M of DAT. Daily dose of MPH after CCI resulted in robust increases in evoked DA overflow and V-max as well as increased apparent K-M. Reductions in total striatal DAT expression occurred after CCI and were not further affected by MPH. In contrast, membrane-bound striatal DAT levels were increased in both CCI groups. MPH post-CCI significantly increased striatal c-fos levels compared with saline. These results support the hypothesis that daily MPH improves striatal DA neurotransmission after CCI. DAT expression and transcriptional changes affecting DA protein function may underlie the injury and MPH-induced alterations in neurotransmission observed.	[Wagner, Amy K.; Drewencki, Laura L.; Chen, Xiangbai; Santos, F. Ryan; Khan, Amina S.; Harun, Rashed; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Drewencki, Laura L.; Chen, Xiangbai; Santos, F. Ryan; Harun, Rashed; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Harun, Rashed; Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15213 USA; [Michael, Adrian C.] Univ Pittsburgh, Sch Arts & Sci, Dept Chem, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	Wagnerak@upmc.edu		Harun, Rashed/0000-0003-1843-6710	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08HD40833, R01NS40125]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER	This work was supported by NIH K08HD40833 (AKW) and R01NS40125 (CED). Special thanks to Xiecheng Ma and Scott Kunkel for their technical support on this project.	Batchelor M, 1998, J NEUROSCI, V18, P10304; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; Borland LM, 2004, J NEUROCHEM, V91, P220, DOI 10.1111/j.1471-4159.2004.02708.x; Brandon CL, 2003, EUR J NEUROSCI, V18, P1584, DOI 10.1046/j.1460-9568.2003.02892.x; Bungay PM, 2003, J NEUROCHEM, V86, P932, DOI 10.1046/j.1471-4159.2003.01904.x; Canales JJ, 2000, ANN NEUROL, V47, pS53; Chase TD, 2003, NEUROREPORT, V14, P769, DOI 10.1097/00001756-200304150-00022; Crawford CA, 1998, PSYCHOPHARMACOLOGY, V136, P34, DOI 10.1007/s002130050536; DASH PK, 1995, J NEUROSCI, V15, P2030; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DONNEMILLER E, 2001, EUR J NUCL MED, V27, P1410; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fleckenstein AE, 2009, NEUROPHARMACOLOGY, V56, P133, DOI 10.1016/j.neuropharm.2008.07.002; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; GARRIS PA, 1994, J NEUROSCI, V14, P442; Garris PA, 1997, BRAIN RES, V753, P225, DOI 10.1016/S0006-8993(97)00003-6; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Greco PG, 2003, EUR J PHARMACOL, V479, P117, DOI 10.1016/j.ejphar.2003.08.062; Hawken CM, 2004, NEUROREPORT, V15, P1045, DOI 10.1097/00001756-200404290-00022; Hersch SM, 1997, J COMP NEUROL, V388, P211; Hoffman BJ, 1998, FRONT NEUROENDOCRIN, V19, P187, DOI 10.1006/frne.1998.0168; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; Jones SR, 1999, J NEUROCHEM, V73, P2406, DOI 10.1046/j.1471-4159.1999.0732406.x; Kilbourn MR, 1996, NUCL MED BIOL, V23, P467, DOI 10.1016/0969-8051(96)00023-6; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kulagina NV, 2001, NEUROSCIENCE, V102, P121, DOI 10.1016/S0306-4522(00)00480-2; Kumer SC, 1996, J NEUROCHEM, V67, P443; Lee KH, 2004, NEUROCHEM RES, V29, P1405, DOI 10.1023/B:NERE.0000026404.08779.43; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Lin JS, 1996, P NATL ACAD SCI USA, V93, P14128, DOI 10.1073/pnas.93.24.14128; Lindgren N, 2001, EUR J NEUROSCI, V13, P773, DOI 10.1046/j.0953-816x.2000.01443.x; Lindgren N, 2000, J NEUROCHEM, V74, P2470, DOI 10.1046/j.1471-4159.2000.0742470.x; MAY LJ, 1989, BRAIN RES, V487, P311, DOI 10.1016/0006-8993(89)90835-4; Michael DJ, 1999, J PHARMACEUT BIOMED, V19, P33, DOI 10.1016/S0731-7085(98)00145-9; Miranda M, 2007, MOL BIOL CELL, V18, P313, DOI 10.1091/mbc.E06-08-0704; Moll GH, 2001, J CHILD ADOL PSYCHOP, V11, P15, DOI 10.1089/104454601750143366; Mortensen OV, 2003, EUR J PHARMACOL, V479, P159, DOI 10.1016/j.ejphar.2003.08.066; Munir M, 2000, NEUROCHEM INT, V37, P147, DOI 10.1016/S0197-0186(00)00018-8; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.0.CO;2-K; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Robinson DL, 2004, J NEUROCHEM, V90, P894, DOI 10.1111/j.1471-4159.2004.02559.x; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; VanderBorght T, 1995, EUR J PHARMACOL, V294, P577; Venton BJ, 2003, J NEUROCHEM, V87, P1284, DOI 10.1046/j.1471-4159.2003.02109.x; Volz TJ, 2008, J PHARMACOL EXP THER, V327, P161, DOI 10.1124/jpet.108.139386; Volz TJ, 2007, J PHARMACOL EXP THER, V323, P738, DOI 10.1124/jpet.107.126888; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wightman RM, 2007, EUR J NEUROSCI, V26, P2046, DOI 10.1111/j.1460-9568.2007.05772.x; WIGHTMAN RM, 1990, BRAIN RES REV, V15, P135, DOI 10.1016/0165-0173(90)90015-G; Williams JM, 2006, HANDB EXP PHARM, V175, P215; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Wu Q, 2001, J NEUROSCI METH, V112, P119, DOI 10.1016/S0165-0270(01)00459-9; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Yang H, 1998, J NEUROCHEM, V71, P684; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yatin SM, 2005, J NEUROSCI METH, V143, P69, DOI 10.1016/j.jneumeth.2004.09.016; Yatin SM, 2002, SYNAPSE, V45, P52, DOI 10.1002/syn.10084; Yi JJ, 2005, NEURON, V47, P629, DOI 10.1016/j.neuron.2005.07.008; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhu J, 2005, J NEUROCHEM, V93, P1434, DOI 10.1111/j.1471-4159.2005.03130.x; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982	70	63	64	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2009	108	4					986	997		10.1111/j.1471-4159.2008.05840.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	395IF	WOS:000262517100013	19077052	Green Accepted			2021-06-18	
J	Vassallo, S; Cooper, SL; Douglas, JM				Vassallo, Suzane; Cooper, Sian L.; Douglas, Jacinta M.			Visual scanning in the recognition of facial affect: Is there an observer sex difference?	JOURNAL OF VISION			English	Article						reaction time; facial expression; eye movements; ocular fixation; nonverbal communication; emotions	TRAUMATIC BRAIN-INJURY; EXPLORATORY EYE-MOVEMENTS; GENDER-DIFFERENCES; EMOTION PERCEPTION; FACE RECOGNITION; LIFE-SPAN; EXPRESSIONS; SCHIZOPHRENIA; IDENTIFICATION; COMMUNICATION	This investigation assessed whether differences exist in the way males and females overtly orient their visual attention to salient facial features while viewing static emotional facial expressions. Eye movements were recorded while fifty healthy participants (23 males, 27 females) viewed a series of six universal facial expressions. Groups were compared with respect to accuracy and reaction time in emotional labeling. The number and duration of foveal fixations to four predefined facial areas of interest (AOIs)-each eye, nose, mouth-were also recorded. There were no significant group differences with respect to accuracy (p = 0.997), though females were significantly faster than males in correctly identifying expressions (p = 0.047). Analysis of the visual scan path revealed that while both groups spent more time and looked more frequently at the eye region, males spent significantly more time viewing the nose and mouth. The duration and number of fixations made to the nose were significantly greater in males (p < 0.05). This study is the first to show reaction time differences between the sexes across a range of universal emotions. Further, this is the first work to suggest the orienting of attention to the lower part of the face, especially the nose, appears to differentiate the sexes.	[Vassallo, Suzane; Cooper, Sian L.] La Trobe Univ, Dept Clin Vis Sci, Bundoora, Vic 3086, Australia; [Douglas, Jacinta M.] La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia	Vassallo, S (corresponding author), La Trobe Univ, Dept Clin Vis Sci, Bundoora, Vic 3086, Australia.	S.Vassallo@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Vassallo, Suzane/0000-0003-1259-5905			Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Biele C, 2006, EXP BRAIN RES, V171, P1, DOI 10.1007/s00221-005-0254-0; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bourne VJ, 2005, NEUROPSYCHOLOGIA, V43, P953, DOI 10.1016/j.neuropsychologia.2004.08.007; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; Calder AJ, 2003, NEUROPSYCHOLOGIA, V41, P195, DOI 10.1016/S0028-3932(02)00149-5; Calvo MG, 2008, BEHAV RES METHODS, V40, P109, DOI 10.3758/BRM.40.1.109; Campbell R, 2002, NEUROPSYCHOLOGIA, V40, P575, DOI 10.1016/S0028-3932(01)00164-6; Canli T, 2002, P NATL ACAD SCI USA, V99, P10789, DOI 10.1073/pnas.162356599; Dyer AG, 2006, J FORENSIC SCI, V51, P1397, DOI 10.1111/j.1556-4029.2006.00269.x; Goos LM, 2002, J NONVERBAL BEHAV, V26, P27, DOI 10.1023/A:1014418503754; Green MJ, 2005, CURR PSYCHIATRY REV, V1, P11, DOI 10.2174/1573400052953529; Grimshaw GM, 2004, BRAIN COGNITION, V54, P248, DOI 10.1016/j.bandc.2004.02.029; Hall JA, 2004, EMOTION, V4, P201, DOI 10.1037/1528-3542.4.2.201; Hargrave R, 2002, J NEUROPSYCH CLIN N, V14, P64, DOI 10.1176/jnp.14.1.64; Henderson JM, 2005, MEM COGNITION, V33, P98, DOI 10.3758/BF03195300; Hooker C, 2002, PSYCHIAT RES, V112, P41, DOI 10.1016/S0165-1781(02)00177-4; Horley K, 2004, PSYCHIAT RES, V127, P43, DOI 10.1016/j.psychres.2004.02.016; KIROUAC G, 1985, J NONVERBAL BEHAV, V9, P3, DOI 10.1007/BF00987555; KIROUAC G, 1984, PERCEPT MOTOR SKILL, V59, P147, DOI 10.2466/pms.1984.59.1.147; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Lee TMC, 2002, NEUROSCI LETT, V333, P13, DOI 10.1016/S0304-3940(02)00965-5; Leigh R.J., 1999, NEUROLOGY EYE MOVEME, V3rd ed.; Loughland CM, 2004, SCHIZOPHR RES, V67, P11, DOI 10.1016/S0920-9964(03)00094-X; Loughland CM, 2002, SCHIZOPHR RES, V55, P159, DOI 10.1016/S0920-9964(01)00186-4; Loughland CM, 2002, BIOL PSYCHIAT, V52, P338, DOI 10.1016/S0006-3223(02)01356-2; MANDAL MK, 1985, PERCEPT MOTOR SKILL, V60, P96, DOI 10.2466/pms.1985.60.1.96; Matsumoto D, 2004, JAPANESE CAUCASIAN F; Miyahira A, 2000, LIFE SCI, V68, P569, DOI 10.1016/S0024-3205(00)00963-2; Miyahira A, 2000, PSYCHIAT CLIN NEUROS, V54, P31, DOI 10.1046/j.1440-1819.2000.00632.x; Montagne Barbara, 2005, Cogn Process, V6, P136, DOI 10.1007/s10339-005-0050-6; NOTON D, 1971, SCI AM, V224, P34; NOWICKI S, 1988, J SOC PSYCHOL, V128, P363, DOI 10.1080/00224545.1988.9713753; Ogrocki PK, 2000, NEUROPSY NEUROPSY BE, V13, P271; Palermo R, 2004, BEHAV RES METH INS C, V36, P634, DOI 10.3758/BF03206544; Pelphrey KA, 2002, J AUTISM DEV DISORD, V32, P249, DOI 10.1023/A:1016374617369; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Rahman Q, 2004, BRAIN COGNITION, V54, P179, DOI 10.1016/j.bandc.2004.01.002; ROTTER NG, 1988, J NONVERBAL BEHAV, V12, P139, DOI 10.1007/BF00986931; Rutherford MD, 2008, J AUTISM DEV DISORD, V38, P1371, DOI 10.1007/s10803-007-0525-7; Scholten MRM, 2005, SCHIZOPHR RES, V78, P61, DOI 10.1016/j.schres.2005.06.019; Sullivan S, 2007, J GERONTOL B-PSYCHOL, V62, pP53, DOI 10.1093/geronb/62.1.P53; Thayer JF, 2000, SCAND J PSYCHOL, V41, P243, DOI 10.1111/1467-9450.00193; *TOB TECHN, 2006, US MAN TOB EYE TRACK; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; WAGNER HL, 1986, J PERS SOC PSYCHOL, V50, P737, DOI 10.1037/0022-3514.50.4.737; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Williams LM, 1999, SCHIZOPHR RES, V40, P189, DOI 10.1016/S0920-9964(99)00056-0	50	63	65	0	24	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	1534-7362			J VISION	J. Vision		2009	9	3							11	10.1167/9.3.11			10	Ophthalmology	Ophthalmology	461RJ	WOS:000267287800011	19757950	DOAJ Gold			2021-06-18	
J	Kline, AE; Hoffman, AN; Cheng, JP; Zafonte, RD; Massucci, JL				Kline, Anthony E.; Hoffman, Ann N.; Cheng, Jeffrey P.; Zafonte, Ross D.; Massucci, Jaime L.			Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Antipsychotics; Beam-walk; Controlled cortical impact; Functional recovery; Haloperidol; Learning and memory; Morris water maze; Neurobehavior; Risperidone; Traumatic brain injury	5-HT1A RECEPTOR AGONIST; CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; ATYPICAL ANTIPSYCHOTICS; CORTEX INJURY; RATS; HALOPERIDOL; SENSORIMOTOR; HYPOTHERMIA; EXPERIENCE	Antipsychotics are often administered to traumatic brain injured (TBI) patients as a means of controlling agitation, albeit the rehabilitative consequences of this intervention are not well known. Hence. the goal of this study was to evaluate the effects of risperidone (RISP) and haloperidol (HAL) on behavioral outcome after experimental TBI. Anesthetized rats received either a cortical impact or sham injury and then were randomly assigned to five TBI (RISP 0.045 mg/kg, RISP 0.45 mg/kg, RISP 4.5 mg/kg, HAL 0.5 mg/kg and VEHicle 1 ml/kg) and three Sham (RISP 4.5 mg/kg, HAL 0.5 mg/kg and VEH 1 mL/kg) groups. Treatments began 24 h after surgery and were provided once daily for 19 days. Behavior was assessed with established motor (beam-balance/walk) and cognitive (spatial learning/memory in a water maze) tasks on post-operative days 1-5 and 14-19, respectively. RISP and HAL delayed motor recovery, impaired the acquisition of spatial learning, and slowed swim speed relative to VEH in both TBI and sham groups. These data indicate that chronic administration of RISP and HAL impede behavioral recovery after TBI and impair performance in uninjured controls. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Massucci, Jaime L.] Christiana Care Hlth Syst, Emergency Med, Newark, DE 19718 USA; [Kline, Anthony E.; Hoffman, Ann N.; Cheng, Jeffrey P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basic Cognit, Pittsburgh, PA 15213 USA; [Zafonte, Ross D.] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA 02114 USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700, R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported by NIH grants HD043851 and HD046700 (AEK).	Bayir H, 2005, CRIT CARE MED, V33, pS498, DOI 10.1097/01.CCM.0000186787.64500.12; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Levine A M, 1988, Brain Inj, V2, P165, DOI 10.3109/02699058809150940; Levy M, 2005, NEUROREHABILITATION, V20, P279; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Olsen AS, 2007, J NEUROTRAUM, V24, P1245; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	25	63	63	1	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	DEC 31	2008	448	3					263	267		10.1016/j.neulet.2008.10.076			5	Neurosciences	Neurosciences & Neurology	385CM	WOS:000261790700008	18983891	Green Accepted			2021-06-18	
J	Gong, YS; Liu, LG; Xie, BJ; Liao, YC; Yang, EL; Sun, ZD				Gong, Yushi; Liu, Liegang; Xie, Bijun; Liao, Yongcheng; Yang, Erling; Sun, Zhida			Ameliorative effects of lotus seedpod proanthocyanidins on cognitive deficits and oxidative damage in senescence-accelerated mice	BEHAVIOURAL BRAIN RESEARCH			English	Article						LSPC (lotus seedpod proanthocyanidins); aging; oxidative stress; brain; serum; senescence-accelerated mouse (SAM); antioxidants	TRAUMATIC BRAIN-INJURY; ALPHA-LIPOIC ACID; NITRIC-OXIDE; LIPID-PEROXIDATION; FREE-RADICALS; MOUSE SAM; ALZHEIMERS-DISEASE; MURINE MODEL; MEMORY; STRESS	We investigated the effects of lotus seedpod proanthocyanidins (LSPC) administration by oral gavage for 3 months on body weight, learning and memory deficits using Y-maze test, oxidative stress and antioxidative enzyme activity in brain and serum of the senescence-accelerated mice (SAMP8) and the senescence-resistant mice (SAMR1). Mice of each group were weighed weekly. Brain was obtained from SAMP8 and SAMR1 (the control mouse for SAMP8) at 6 months of age and serum was available from SAMP8 and SAMR1 at 3, 4, 5 and 6 months of age. The results of body weight showed that 90 mg/kg LSPC administration significantly increased body weight at 5.5 and 6 months of age in SAMP8 when compared with control SAMP8 of the same age. Y-maze test indicated that learning and memory abilities of mice were deteriorated significantly at 6 months of age in SAMP8 compared with age-matched SAMR1, but were remarkably improved after LSPC (60, 90,120 mg/kg body weight) administration beginning at 3 months of ages. Malondialdehyde (MDA), nitric oxide (NO) and nitric oxide synthase (NOS) exhibited significant increases mostly at 5 and 6 months of age in SAMPS. Glutathione (GSH). glutathione peroxidase (GPx) and Superoxide dismutase (SOD) activities decreased significantly mostly at 5 and 6 months of age in SAMP8. LSPC (60, 90, 120 mg/kg body weight) administration beginning at 3 months of ages decreased MDA, NO content and lowered NOS activity in the brain and serum of SAMP8. Furthermore, LSPC significantly increased GSH level and augmented GPx, SOD activity in the brain and serum of SAMP8. These results suggest that an age-related increase in brain tissue vulnerability to oxidation and deterioration in learning and memory abilities in SAM that can be modified by LSPC, most likely through the ability of LSPC to scavenge oxygen free radicals and to stimulate antioxidant enzyme activity. (C) 2008 Elsevier B.V. All rights reserved.	[Gong, Yushi; Xie, Bijun; Liao, Yongcheng; Yang, Erling; Sun, Zhida] Huazhong Agr Univ, Dept Food Sci & Technol, Nat Prod Lab, Wuhan 430070, Peoples R China; [Liu, Liegang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Food Hyg & Nutr, Wuhan 430030, Peoples R China	Xie, BJ (corresponding author), Huazhong Agr Univ, Dept Food Sci & Technol, Nat Prod Lab, Wuhan 430070, Peoples R China.	tortoise39@163.com; bijunxie@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30270938, u0731005]; National Key Technology RD programNational Key Technology R&D Program [2006BAD27B08]; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China; Ministry of Education of ChinaMinistry of Education, China [20040504013]	This work was supported by grants from the National Natural Science Foundation of China (NSFC, No. 30270938), National Natural Science Foundation of China (NSFC, No. u0731005), and the National Key Technology R&D program (No. 2006BAD27B08) of the Ministry of Science and Technology of China and the Doctoral Fund (20040504013) of the Ministry of Education of China.	Bagchi D, 2000, TOXICOLOGY, V148, P187, DOI 10.1016/S0300-483X(00)00210-9; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; Biesalski HK, 2002, CURR OPIN CLIN NUTR, V5, P5, DOI 10.1097/00075197-200201000-00002; CINI M, 1994, NEUROCHEM RES, V19, P283, DOI 10.1007/BF00971576; Colas D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-81; Devasagayam T P A, 2004, J Assoc Physicians India, V52, P794; Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x; Duan YuQing, 2003, Acta Nutrimenta Sinica, V25, P306; Duan YuQing, 2005, Acta Nutrimenta Sinica, V27, P30; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Erickson CA, 2003, EXP GERONTOL, V38, P61, DOI 10.1016/S0531-5565(02)00160-2; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Grady CL, 2000, CURR OPIN NEUROBIOL, V10, P224, DOI 10.1016/S0959-4388(00)00073-8; Gutierrez-Cuesta J, 2007, J PINEAL RES, V42, P394, DOI 10.1111/j.1600-079X.2007.00433.x; Hua XD, 2007, LIFE SCI, V80, P1897, DOI 10.1016/j.lfs.2007.02.030; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; [凌智群 Ling Zhiqun], 2002, [营养学报, Acta Nutrimenta Sinica], V24, P121; [凌智群 Ling Zhiqun], 2002, [食品科学, Food Science], V23, P98; Ling ZQ, 2005, J AGR FOOD CHEM, V53, P2441, DOI 10.1021/jf040325p; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luth HJ, 2001, BRAIN RES, V913, P57, DOI 10.1016/S0006-8993(01)02758-5; Markesbery WR, 2005, ANN NEUROL, V58, P730, DOI 10.1002/ana.20629; Markowska AL, 1998, PHYSIOL BEHAV, V64, P15, DOI 10.1016/S0031-9384(98)00011-0; Matsugo S, 2004, INT CONGR SER, V1260, P251, DOI 10.1016/S0531-5131(03)01571-1; Mishra OP, 2002, NEUROSCI LETT, V318, P93, DOI 10.1016/S0304-3940(01)02484-3; MIYAMOTO M, 1992, PHYSIOL BEHAV, V51, P979, DOI 10.1016/0031-9384(92)90081-C; Moriguchi T, 1996, BIOL PHARM BULL, V19, P305, DOI 10.1248/bpb.19.305; Morley JE, 2002, BIOGERONTOLOGY, V3, P57, DOI 10.1023/A:1015207429786; Nishikawa T, 1998, NEUROSCI LETT, V254, P69, DOI 10.1016/S0304-3940(98)00646-6; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pang KCH, 2006, AGE, V28, P283, DOI 10.1007/s11357-006-9013-9; Poon HF, 2004, CLIN GERIATR MED, V20, P329, DOI 10.1016/j.cger.2004.02.005; Poona HF, 2005, NEUROCHEM INT, V46, P159, DOI 10.1016/j.neuint.2004.07.008; Porter L., 1986, PHYTOCHEMISTRY, V36, P523; Rebrin I, 2005, FREE RADICAL BIO MED, V39, P549, DOI 10.1016/j.freeradbiomed.2005.04.008; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; REITER RJ, 1995, FASEB J, V9, P526; RONALD LP, 2005, PHYTOCHEMISTRY, V66, P2264; Rubaj A, 2003, BEHAV BRAIN RES, V141, P11, DOI 10.1016/S0166-4328(02)00314-5; SCHROEDER RA, 1995, ANESTH ANALG, V81, P1052, DOI 10.1097/00000539-199511000-00027; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Suganuma H, 2004, INT CONGR SER, V1260, P129, DOI 10.1016/S0531-5131(03)01601-7; TAKEDA T, 1991, J AM GERIATR SOC, V39, P911, DOI 10.1111/j.1532-5415.1991.tb04460.x; TAKEDA T, 1981, MECH AGEING DEV, V17, P183, DOI 10.1016/0047-6374(81)90084-1; THOMAS BLK, 2005, MECH AGEING DEV, V126, P1011; Thorns V, 1998, EXP NEUROL, V150, P14, DOI 10.1006/exnr.1997.6751; Unno K, 2004, INT CONGR SER, V1260, P409, DOI 10.1016/S0531-5131(03)01429-8; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Williams TI, 2006, NEUROBIOL AGING, V27, P1094, DOI 10.1016/j.neurobiolaging.2005.06.004; WU ZQ, 2007, NEURAL REGEN RES, V2, P355; Yamada K, 1999, NEUROSCIENCE, V88, P281, DOI 10.1016/S0306-4522(98)00237-1; YAMADA K, 1995, BRIT J PHARMACOL, V115, P852, DOI 10.1111/j.1476-5381.1995.tb15011.x; Yasui F, 2003, NEUROSCI LETT, V350, P66, DOI 10.1016/S0304-3940(03)00827-9; ZHENG JX, 1999, FUNCTIONAL FOOD, P294	58	63	71	2	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 1	2008	194	1					100	107		10.1016/j.bbr.2008.06.029			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	355MM	WOS:000259713000014	18652848				2021-06-18	
J	Avants, B; Duda, JT; Kim, J; Zhang, H; Pluta, J; Gee, JC; Whyte, J				Avants, Brian; Duda, Jeffrey T.; Kim, Junghoon; Zhang, Hui; Pluta, John; Gee, James C.; Whyte, John			Multivariate Analysis of Structural and Diffusion Imaging in Traumatic Brain Injury	ACADEMIC RADIOLOGY			English	Article						Diffeomorphism; unbiased; traumatic brain injury; diffusion; morphometry	MILD COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; AXONAL INJURY; THALAMIC NUCLEI; HEAD-INJURY; CORTICOSPINAL TRACT; FIBER TRACTOGRAPHY; VEGETATIVE STATE; TEMPORAL-LOBE; TENSOR	Rationale and Objectives. Diffusion tensor (DT) and T1 structural magnetic resonance images provide unique and complementary tools for quantifying the living brain. We leverage both modalities in a diffeomorphic normalization method that unifies analysis of clinical datasets in a consistent and inherently multivariate (MV) statistical framework. We use this technique to study MV effects of traumatic brain injury (TBI). Materials and Methods. We contrast T1 and DT image-based measurements in the thalamus and hippocampus of 12 TBI survivors and nine matched controls normalized to a combined DT and T1 template space. The normalization method uses maps that are topology-preserving and unbiased. Normalization is based on the full tensor of information at each voxel and simultaneously, the similarity between high-resolution features derived from T1 data. The technique is termed symmetric normalization for MV neuroanatomy (SyNMN). Voxel-wise MV statistics on the local volume and mean diffusion are assessed with Hotelling's T-2 test with correction for multiple comparisons. Results. TBI significantly (false discovery rate P < .05) reduces volume and increases mean diffusion at coincident locations in the mediodorsal thalamus and anterior hippocampus. Conclusions: SyNMN reveals evidence that TBI compromises the limbic system. This TBI morphometry study and an additional performance evaluation contrasting SyNMN with other methods suggest that the DT component may aid normalization quality.	[Avants, Brian; Duda, Jeffrey T.; Zhang, Hui; Gee, James C.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Pluta, John] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Kim, Junghoon; Whyte, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA USA	Duda, JT (corresponding author), Univ Penn, Dept Radiol, 3600 Market St,Suite 320, Philadelphia, PA 19104 USA.	stnava@gmail.com	Kim, Junghoon/A-6669-2012; Kim, Junghoon John/I-6702-2019; Kennedy, Kristen M/B-4699-2008	Kim, Junghoon John/0000-0001-5729-8993; Kennedy, Kristen M/0000-0001-5373-9026; Zhang, Hui/0000-0002-5426-2140; avants, brian/0000-0002-4212-3362; Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA074781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32 CA74781, T32 CA074781] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD39621, R24 HD039621] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [L40 DA025520] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS045839] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; Ardekani BA, 2005, NEUROREPORT, V16, P1455, DOI 10.1097/01.wnr.0000177001.27569.06; Arsigny V, 2006, MAGN RESON MED, V56, P411, DOI 10.1002/mrm.20965; Avants B, 2003, LECT NOTES COMPUT SC, V2717, P21; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; AVANTS BB, 2006, MATH METHODS BIOMEDI; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beg MF, 2007, IEEE T MED IMAGING, V26, P1179, DOI 10.1109/TMI.2007.898813; CHAPPELL MH, 2006, J MAGN RESON IMAGING; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Duan Y, 2007, INT J BIOMED IMAGING, V2007, DOI 10.1155/2007/90216; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; FURLOW B, 2006, RADIOL TECHNOL, V78, P157; Furlow Bryant, 2006, Radiol Technol, V78, P145; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Hammers A, 2007, NEUROIMAGE, V36, P38, DOI 10.1016/j.neuroimage.2007.02.031; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hashimoto K, 2007, J REHABIL MED, V39, P418, DOI 10.2340/16501977-0065; Hermosillo G, 2002, INT J COMPUT VISION, V50, P329, DOI 10.1023/A:1020830525823; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kantarci K, 2001, RADIOLOGY, V219, P101, DOI 10.1148/radiology.219.1.r01ap14101; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kindlmann G, 2007, LECT NOTES COMPUT SC, V4791, P1; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langers DRM, 2007, NEUROIMAGE, V38, P43, DOI 10.1016/j.neuroimage.2007.07.031; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mangin JF, 2002, MED IMAGE ANAL, V6, P191, DOI 10.1016/S1361-8415(02)00079-8; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; McAllister TW, 1998, SEMIN CLIN NEUROPSYC, V3, P211; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Miller MI, 2005, P NATL ACAD SCI USA, V102, P9685, DOI 10.1073/pnas.0503892102; MILLER MI, 1993, P NATL ACAD SCI USA, V90, P11944, DOI 10.1073/pnas.90.24.11944; Miller MI, 2002, ANNU REV BIOMED ENG, V4, P375, DOI 10.1146/annurev.bioeng.4.092101.125733; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; O'Sullivan M, 2004, NEUROLOGY, V62, P702, DOI 10.1212/01.WNL.0000113760.72706.D2; Park HJ, 2003, NEUROIMAGE, V20, P1995, DOI 10.1016/j.neuroimage.2003.08.008; Ray KM, 2006, RADIOLOGY, V241, P197, DOI 10.1148/radiol.2411051051; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; STUDHOLME C, 2008, MED IMAGE ANAL  0416; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Sydykova D, 2007, CEREB CORTEX, V17, P2276, DOI 10.1093/cercor/bhl136; Thirion JP, 1996, PROC CVPR IEEE, P245, DOI 10.1109/CVPR.1996.517081; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wiegell MR, 2003, NEUROIMAGE, V19, P391, DOI 10.1016/S1053-8119(03)00044-2; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; YAN C, 2005, TMI, V24, P1216; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Yushkevich PA, 2007, NEUROIMAGE, V35, P1516, DOI 10.1016/j.neuroimage.2007.01.029; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784; Zhang H, 2006, MED IMAGE ANAL, V10, P764, DOI 10.1016/j.media.2006.06.004; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	71	63	63	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	NOV	2008	15	11					1360	1375		10.1016/j.acra.2008.07.007			16	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	369PY	WOS:000260707600004	18995188	Green Accepted			2021-06-18	
J	Jagannathan, J; Okonkwo, DO; Yeoh, HK; Dumont, AS; Saulle, D; Raizlip, J; Barth, JT; Jane, JA; Jane, JA				Jagannathan, Jay; Okonkwo, David O.; Yeoh, Hian Kwang; Dumont, Aaron S.; Saulle, Dwight; Raizlip, Julie; Barth, Jeffrey T.; Jane, John A., Sr.; Jane, John A., Jr.			Long-term outcomes and prognostic factors in pediatric patients with severe traumatic brain injury and elevated intracranial pressure	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						intracranial pressure; management strategy; outcomes; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SOMATOSENSORY-EVOKED POTENTIALS; SEVERE HEAD-INJURY; COMA DATA-BANK; BLOOD-FLOW; CHILDREN; HYPERTENSION; EXPERIENCE; VENTRICULOSTOMY; CRANIECTOMY	Object. The management strategics and outcomes in pediatric patients with elevated intracranial pressure (ICP) following severe traumatic brain injury (TBI) are examined in this study. Methods. This study was a retrospective review of a prospectively acquired pediatric trauma database. More than 750 pediatric patients with brain injury were seen over a 10-year period. Records were retrospectively reviewed to determine interventions for correcting ICP, and surviving patients were contacted prospectively to determine functional status and quality of life. Only patients with 2 years of follow-up were included in the study. Results. Ninety-six pediatric patients (age range 3-18 years) were identified with a Glasgow Coma Scale score < 8 and elevated ICP > 20 mm Hg on presentation. The mean injury severity score was 65 (range 30-100). All patients were treated using a standardized head injury protocol. The mean time course until peak ICP was 69 hours postinjury (range 2-196 hours). Intracranial pressure control was achieved in 82 patients (85%). Methods employed to achieve ICP control included maximal medical therapy (sedation, hyperosmolar therapy, and paralysis) in 34 patients (35%), ventriculostomy in 23 patients (24%). and surgery in 39 patients (41%). Fourteen patients (15%) had refractory ICP despite all interventions, and all of these patients died. Seventy-two patients (75%) were discharged from the hospital, whereas 24 (25%) died during hospitalization. Univariate and multivariate analysis revealed that the presence of vascular injury, refractory ICP, and cisternal effacement at presentation had the highest correlation with subsequent death (p < 0.05). Mean follow-up was 53 months (range 11-126 months). Three patients died during the follow-up period (2 due to infections and I committed Suicide). The mean 2-year Glasgow Outcome Scale score was 4 (median 4, range 1-5). The mean patient competency rating at follow-up was 4.13 out of 5 (median 4.5, range 1-4.8). Univariate analysis revealed that the extent of intracranial and Systemic injuries had the highest correlation with long-term quality of life (p < 0.05). Conclusions. Controlling elevated ICP is an important factor in patient survival following severe pediatric TBI. The modality used for ICP control appears to be less important. Long-term follow-up is essential to determine neurocognitive sequelae associated with TBI.	[Jagannathan, Jay; Yeoh, Hian Kwang; Dumont, Aaron S.; Saulle, Dwight; Jane, John A., Sr.; Jane, John A., Jr.] Univ Virginia Hlth Syst, Dept Neurosurg, Charlottesville, VA 22908 USA; [Raizlip, Julie; Jane, John A., Jr.] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; [Barth, Jeffrey T.] Univ Virginia Hlth Syst, Dept Psychiat Med, Charlottesville, VA 22908 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA	Jane, JA (corresponding author), Univ Virginia Hlth Syst, Dept Neurosurg, POB 800212, Charlottesville, VA 22908 USA.	jaj2k@virginia.edu					Adelson P D, 2000, Clin Neurosurg, V47, P319; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Artru F, 1990, Agressologie, V31, P367; BADER MK, 1995, HEART LUNG, V24, P166, DOI 10.1016/S0147-9563(05)80012-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chugani H T, 1999, Adv Neurol, V81, P241; Chugani HT, 1996, BRAIN DEV-JPN, V18, P347, DOI 10.1016/0387-7604(96)00032-0; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Hamilton KL, 2002, EXP PHYSIOL, V87, P437, DOI 10.1111/j.1469-445X.2002.tb00056.x; Hammer MD, 2006, SURG CLIN N AM, V86, P1541, DOI 10.1016/j.suc.2006.08.002; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Jones PA, 2005, ACT NEUR S, V95, P29; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LEROUX PD, 1991, CHILD NERV SYST, V7, P34, DOI 10.1007/BF00263831; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; MARSHALL LF, 1975, J NEUROSURG, V43, P308, DOI 10.3171/jns.1975.43.3.0308; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Moraine JJ, 2000, J NEUROSURG, V92, P606, DOI 10.3171/jns.2000.92.4.0606; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; OBRIEN JF, 1991, ANN EMERG MED, V20, P644, DOI 10.1016/S0196-0644(05)82384-4; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Pople IK, 1996, PEDIATR NEUROSURG, V25, P1, DOI 10.1159/000121088; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Savitsky EA, 2000, AM J EMERG MED, V18, P96, DOI 10.1016/S0735-6757(00)90060-3; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; Vigue B, 2000, INTENS CARE MED, V26, P722, DOI 10.1007/s001340051238; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	49	63	68	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2008	2	4					240	249		10.3171/PED.2008.2.10.240			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	353ET	WOS:000259549600004	18831656				2021-06-18	
J	Morgalla, MH; Will, BE; Roser, F; Tatagiba, M				Morgalla, Matthias H.; Will, Bernd E.; Roser, Florian; Tatagiba, Marcos			Do long-term results justify decompressive craniectomy after severe traumatic brain injury?	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; intracranial pressure; intracranial pressure monitoring; neuromonitoring; transcranial Doppler ultrasonography	SURGICAL DECOMPRESSION; CEREBRAL EDEMA; HEAD-INJURY; MANAGEMENT; CHILDREN; ICP	Object. A decompressive craniectomy can be a life-saving procedure to relieve critically increased intracranial pressure. The survival of a patient is important as well as the subsequent and long-term quality of life. In this paper the authors' goal was to investigate whether long-term clinical results justify the use of a decompressive craniectomy. Methods. Thirty-three patient,, (20 males and 13 females) with a mean age of 36.3 years (range 13-60 years) with severe traumatic brain injury (Grades III and IV) and subsequent massive brain swelling were examined. For postoperative assessment the Barthel Index was used. A Surgical intervention was based on the following criteria: I) The intracranial pressure Could not be controlled by conservative treatment and constantly exceeded 30 rum Hg (cerebral perfusion pressure < 50 mm Hg). 2) Transcranial Doppler ultrasonography revealed only a systolic flow pattern or systolic peaks. 3) There were no other major injuries. 4) The patient was not older than 60 years. Results. One-fifth of all patients died and one-fifth remained in a vegetative state. Mild deficits were seen in 6 of 33 patients. A full rehabilitation (Barthel Index 90-100) was achieved in 13 patients (39.4%). Five patients could resume their former occupation, and another 4 had to change jobs. Conclusions. Age remains to be one of the most important exclusion factors. Decompressive craniectomy provided good clinical results in nearly 40% of patients who were otherwise most likely to die. Therefore, long-term results justify the use of decompressive craniectomy in this case series.	[Morgalla, Matthias H.; Will, Bernd E.; Roser, Florian; Tatagiba, Marcos] Univ Tubingen, Dept Neurosurg, D-72076 Tubingen, Germany	Morgalla, MH (corresponding author), Univ Tubingen, Dept Neurosurg, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	matthias.morgalla@med.uni-tuebingen.de		Roser, Florian/0000-0002-7854-6789			Carmelo A, 2002, ACT NEUR S, V81, P109; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; Kunze E, 1998, ACT NEUR S, V71, P16; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schaller B, 2002, Swiss Surg, V8, P145, DOI 10.1024/1023-9332.8.4.145; Schneider GH, 2002, ACT NEUR S, V81, P77; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Spagnuolo E, 2004, NEUROCIRUGIA, V15, P36; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	25	63	66	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					685	690		10.3171/JNS/2008/109/10/0685			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100014	18826356				2021-06-18	
J	Wu, HT; Lu, DY; Jiang, H; Xiong, Y; Qu, CS; Li, B; Mahmood, A; Zhou, D; Chopp, M				Wu, Hongtao; Lu, Dunyue; Jiang, Hao; Xiong, Ye; Qu, Changsheng; Li, Bo; Mahmood, Asim; Zhou, Dong; Chopp, Michael			Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						Akt; apoptosis; FOXO1; I kappa B; rat; simvastatin; traumatic brain injury	NF-KAPPA-B; REDUCES NEUROLOGICAL DEFICIT; GLUCOSE-INDUCED APOPTOSIS; NITRIC-OXIDE SYNTHASE; TRANSCRIPTION FACTOR; NEURONAL DEATH; IN-VIVO; MORPHOLOGICAL CONSEQUENCES; PI3K/AKT/ENOS PATHWAY; ENDOTHELIAL-CELLS	Object. In their previous Studies, the authors found that simvastatin treatment of traumatic brain injury (TBI) in rats had beneficial effects oil spatial learning functions. In the Current study they wanted to determine whether simvastatin Suppressed neuronal cell apoptosis after TBI, and if so, they wanted to examine the underlying mechanisms of this process. Methods. Saline or simvastatin (1 mg/kg) was administered orally to rats starting oil Day I after TBI and then daily for 14 days. Modified Neurological Severity Scores were used to evaluate the sensory motor functional recovery. Rats were killed at 1, 3, 7, 14, and 35 clays after treatment, and brain tissue was harvested for terminal deoxynucleotidyl nick-end labeling (TUNEL) staining, caspase-3 activity assay, and Western blot analysis. Results. Simvastatin significantly decreased the modified Neurological Severity Scores from Days 7 to 35 after TBI, significantly reduced the number of TUNEL-positive cells at Day 3, suppressed the caspase-3 activity at Days I and 3 after TBI, and increased phosphorylation of Akt as well as Forkhead transcription factor 1, inhibitory-kappa B, and enclothelial nitric oxide synthase, which are the downstream targets of the prosurvival Akt signaling protein. Conclusions. These data suggested that simvastatin reduces the apoptosis in neuronal cells and improves the sensory motor function recovery after TBI. These beneficial effects of simvastatin may be mediated through activation of Akt, Forkhead transcription factor 1 and nuclear factor-kappa 13 signaling pathways, which suppress the activation of caspase-3 and apoptotic cell death, and thereby, lead to neuronal function recovery after TBI.	[Chopp, Michael] Henry Ford Hosp, Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Wu, Hongtao; Xiong, Ye; Qu, Changsheng; Li, Bo; Mahmood, Asim; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Wu, Hongtao; Zhou, Dong] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China; [Lu, Dunyue] SUNY, Dept Psychiat, Brooklyn, NY USA	Chopp, M (corresponding author), Henry Ford Hosp, Henry Ford Hlth Syst, Dept Neurol, E&R Bldg 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	Wu, Hongtao/A-8602-2011	Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NS052280-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER	This Study Was Supported by National Institutes of Health Grant No. RO1NS052280-01A1.	Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Balduini W, 2001, STROKE, V32, P2185, DOI 10.1161/hs0901.094287; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Carloni S, 2006, NEUROBIOL DIS, V21, P119, DOI 10.1016/j.nbd.2005.06.014; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fukunaga K, 2005, J PHARMACOL SCI, V98, P205, DOI 10.1254/jphs.FMJ05001X3; Ho FM, 2006, CELL SIGNAL, V18, P391, DOI 10.1016/j.cellsig.2005.05.009; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Murohara T, 2002, ANTIOXID REDOX SIGN, V4, P825, DOI 10.1089/152308602760598981; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vaughan CJ, 2001, CURR OPIN CARDIOL, V16, P219, DOI 10.1097/00001573-200107000-00001; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Wolfrum S, 2004, J CARDIOVASC PHARM, V44, P348, DOI 10.1097/01.fjc.0000137162.14735.30; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhang W, 2007, NUTRITION, V23, P762, DOI 10.1016/j.nut.2007.07.003	36	63	65	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					691	698		10.3171/JNS/2008/109/10/0691			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100015	18826357	Green Accepted			2021-06-18	
J	Zlotnik, A; Gurevich, B; Cherniavsky, E; Tkachov, S; Matuzani-Ruban, A; Leon, A; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Gurevich, Boris; Cherniavsky, Evgenia; Tkachov, Sergei; Matuzani-Ruban, Angela; Leon, Avner; Shapira, Yoram; Teichberg, Vivian I.			The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury	NEUROCHEMICAL RESEARCH			English	Article						glutamate; excitotoxicity; blood glutamate levels; blood glutamate scavenging; oxaloacetate; pyruvate; glutamate-pyruvate transaminase; closed head injury; stroke; neuroprotection; brain to blood glutamate efflux; neurological outcome; antioxidant activity; intravenous injection	TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; NERVOUS-SYSTEM NEURONS; CEREBROSPINAL-FLUID; CORTICAL CONTUSION; HYDROGEN-PEROXIDE; PROTECTS NEURONS; CEREBRAL-CORTEX; BARRIER CHANGES; CELL-DEATH	The removal of excess glutamate from brain fluids after acute insults such as closed head injury (CHI) and stroke is expected to prevent excitotoxicity and the ensuing long lasting neurological deficits. Since blood glutamate scavenging accelerates the removal of excess glutamate from brain into blood and causes neuroprotection, we have evaluated here whether the neuroprotective properties of pyruvate could be partly accounted to its blood glutamate scavenging activity. The neurological outcome of rats after CHI improved significantly when treated with intravenous pyruvate (0.9 mmoles/100 g) but not with pyruvate administered together with glutamate. Pyruvate, at 5 mu mole/100 g rat was neither protective not able to decrease blood glutamate but displayed the latter two properties when combined with 60 mu g/100 g of glutamate-pyruvate transaminase. Since the neurological recovery from CHI was correlated with the decrease of blood glutamate levels, we conclude that pyruvate blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms.	[Matuzani-Ruban, Angela; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Cherniavsky, Evgenia] Ben Gurion Univ Negev, Soroka Med Ctr, Dept Radiol, IL-84105 Beer Sheva, Israel; [Zlotnik, Alexander; Gurevich, Boris; Tkachov, Sergei; Leon, Avner; Shapira, Yoram] Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel	Teichberg, VI (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	vivian.teichberg@weizman.ac.il		Ruban, Angela/0000-0003-1091-8854			BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; BERL S, 1962, J BIOL CHEM, V237, P2562; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; CAVALLINI L, 1990, J MOL CELL CARDIOL, V22, P143, DOI 10.1016/0022-2828(90)91111-J; CONN AR, 1982, AM J PHYSIOL, V243, pE272; Crestanello JA, 1998, SURGERY, V124, P92, DOI 10.1016/S0039-6060(98)70080-7; Desagher S, 1997, J NEUROSCI, V17, P9060; Dobsak P, 1999, J CARDIOVASC PHARM, V34, P651, DOI 10.1097/00005344-199911000-00005; EIMERL S, 1995, J NEUROCHEM, V65, P739; FACCI L, 1985, J NEUROSCI RES, V14, P293, DOI 10.1002/jnr.490140302; GOODWIN TW, 1952, BIOCHEM J, V51, P708, DOI 10.1042/bj0510708; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hosoya K, 1999, J NEUROCHEM, V73, P1206, DOI 10.1046/j.1471-4159.1999.0731206.x; Koura SS, 1998, ACT NEUR S, V71, P244; Lee JY, 2001, J NEUROSCI, V21; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Mongan PD, 2001, AM J PHYSIOL-HEART C, V281, pH854; Nakamichi N, 2005, J NEUROCHEM, V93, P84, DOI 10.1111/j.1471-4159.2005.02999.x; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; OLDENDORF WH, 1973, AM J PHYSIOL, V224, P1450; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Ruiz F, 1998, NEUROREPORT, V9, P1277; SELAK I, 1985, J NEUROSCI, V5, P23; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sharma P, 2003, BRAIN RES, V992, P104, DOI 10.1016/j.brainres.2003.08.043; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Suh SW, 2005, DIABETES, V54, P1452, DOI 10.2337/diabetes.54.5.1452; Varma SD, 1998, FREE RADICAL RES, V28, P131, DOI 10.3109/10715769809065799; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wada M, 2006, BRAIN RES, V1081, P92, DOI 10.1016/j.brainres.2006.01.084; Wang XF, 2001, J NEUROSCI, V21, P3322, DOI 10.1523/JNEUROSCI.21-10-03322.2001; Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007; Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	45	63	63	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	JUN	2008	33	6					1044	1050		10.1007/s11064-007-9548-x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	288CW	WOS:000254964800011	18080187				2021-06-18	
J	Goel, RS; Goyal, NK; Dharap, SB; Kumar, M; Gore, MA				Goel, Ravishankar S.; Goyal, Navin K.; Dharap, Satish B.; Kumar, Meena; Gore, Madhuri A.			Utility of optic nerve ultrasonography in head injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						optic nerve ultrasonography; optic nerve sheath diameter; raised intracranial pressure	ELEVATED INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID PRESSURE; EMERGENCY ULTRASONOGRAPHY; OCULAR ULTRASONOGRAPHY; SONOGRAPHIC EVALUATION; SHEATH DIAMETER; ULTRASOUND; PATIENT	Background: CT has evolved as the gold standard for evaluation of head injury, but early CT is not always possible. Bedside ultrasonography is available in most trauma units and optic nerve ultrasound (ONUS) examination should be feasible. Objective: To evaluate the role of ONUS for people with head injury. Setting: Tertiary care trauma service in a teaching hospital in a large metropolitan city in India. Design: Prospective, blinded, observational study. Methods: From April 2006 to January 2007, all adult patients with head injury but without obvious ocular trauma, for whom it was possible to perform CT, were enrolled. Using a 7.5-MHz ultrasonographic probe on the closed eyelids, optic nerve sheath diameter (ONSD) was measured on either side. A mean binocular ONSD Less than 5.00 mm was considered normal. Cranial CT findings were used as a reference standard to evaluate ONUS. Results: The study included 100 participants (72 men, 28 women, median age 28 years, median Glasgow Coma Scale score 11). Clinical features did not correlate with CT for signs of raised intracranial pressure (ICP). The mean binocular ONSD (5.8 +/- 0.57 mm) was significantly increased among individuals with signs of raised ICP on CT compared with the mean ONSD (3.5 +/- 0.75 mm) among those without such signs. ONUS revealed evidence of raised ICP in 74 cases (confirmed by CT in 72 cases), 59 of whom had significant intracranial haematoma needing surgical evacuation. Of the 26 cases with negative ONUS, confirmed by CT in 25 cases, only 1 needed surgical intervention for drainage of intracranial haematoma. ONUS was false positive for two and false negative for one person. The sensitivity of ONUS in detecting elevated ICP was 98.6%, specificity 92.8%, positive predictive value 97.26% and negative predictive value 96.3%. Conclusion: ONUS has potential as a sensitive bedside screening test for detecting raised ICP and the presence of intracranial haematoma needing surgical intervention in adult head injury. This can be of immense help for unstable patients, in mass casualty situations and in remote locations. (C) 2007 Elsevier Ltd. All rights reserved.	[Goel, Ravishankar S.] LTM Med Coll, Dept Surg, Trauma Serv, Bombay 400022, Maharashtra, India; LTMG Hosp, Bombay 400022, Maharashtra, India	Goel, RS (corresponding author), LTM Med Coll, Dept Surg, Trauma Serv, Bombay 400022, Maharashtra, India.	docravishankar@yahoo.co.in	Dharap, Satish/AAE-8565-2020	Dharap, Satish/0000-0002-9304-9617			Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Blaivas M, 2002, ACAD EMERG MED, V9, P791, DOI 10.1197/aemj.9.8.791; Czarnik T, 2007, J TRAUMA, V62, P207, DOI 10.1097/01.ta.0000219128.29515.d5; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GALETTA S, 1989, J CLIN NEURO-OPHTHAL, V9, P79; Girisgin AS, 2007, EMERG MED J, V24, P251, DOI 10.1136/emj.2006.040931; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; HAYREH SS, 1968, DOC OPHTHALMOL, V24, P289, DOI 10.1007/BF02550944; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Jang T, 2005, ANN EMERG MED, V45, P336, DOI 10.1016/j.annemergmed.2004.09.031; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Malayeri AA, 2005, J ULTRAS MED, V24, P143, DOI 10.7863/jum.2005.24.2.143; MATEER J, 1994, ANN EMERG MED, V23, P95, DOI 10.1016/S0196-0644(94)70014-1; OSSOINIG KC, 1993, DOC OPHTH P, V55, P3; Romagnuolo L, 2005, AM J EMERG MED, V23, P686, DOI 10.1016/j.ajem.2004.11.004; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; Tsung JW, 2005, PEDIATR EMERG CARE, V21, P94, DOI 10.1097/01.pec.0000159052.64930.64	19	63	66	1	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2008	39	5					519	524		10.1016/j.injury.2007.09.029			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	298OZ	WOS:000255698300004	18325519				2021-06-18	
J	Taylor, AN; Rahman, SU; Sanders, NC; Tio, DL; Prolo, P; Sutton, RL				Taylor, Anna N.; Rahman, Shayan U.; Sanders, Nicole C.; Tio, Delia L.; Prolo, Paolo; Sutton, Richard L.			Injury severity differentially affects short- and long-term neuroendocrine outcomes of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						allostasis; controlled cortical impact; corticosterone; rat; stress	CONTROLLED CORTICAL IMPACT; CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; HIPPOCAMPAL-NEURONS; HEAD-INJURY; CELL-DEATH; RAT-BRAIN; STRESS SENSITIVITY; SPATIAL MEMORY; RECEPTOR	Having reported that traumatic brain injury (TBI), produced by moderate lateral controlled cortical impact (CCI), causes long-term dysregulation of the neuroendocrine stress response, the aim of this study was to assess short- and long-term effects of both moderate and mild CCI on stress-induced hypothalamic-pituitary-adrenal (HPA) function. TBI was induced to the left parietal cortex in adult male rats with a pneumatic piston, at two different impact velocities and compression depths to produce either a moderate or mild CCI. Controls underwent sham surgery without injury. Commencing at one week after recovery from surgery, rats were exposed to stressors: 30-min restraint (days 7, 34, and 70) or 15-min forced swim (days 21 and 54). Tail vein blood was analyzed for corticosterone (CORT) content by radioimmunoassay. On days 7 and 21, the stress-induced HPA responses were significantly attenuated by both mild and moderate CCI. Significant attenuation of the CORT response to stress persisted through day 70 after moderate CCI. In contrast, stress-induced CORT levels on days 34, 54, and 70 were significantly enhanced after mild CCI. Differential effects of injury severity were also observed on motor function in a forelimb test on post-injury day 12 and on cortical lesion volume and hippocampal cell loss at day 70, but not on working memory in a radial maze on day 15. The differing short- and long-term stress-induced HPA responses may be mediated by differential effects of moderate and mild CCI on the efficiency of glucocorticoid negative feedback or signaling among hypothalamic and extrahypothalamic components of the neuroendocrine stress-response system.	[Taylor, Anna N.; Tio, Delia L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, Los Angeles, CA 90095 USA; [Taylor, Anna N.; Tio, Delia L.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Rahman, Shayan U.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA 90095 USA; [Sanders, Nicole C.] Williams Coll, Williamstown, MA 01267 USA; [Prolo, Paolo] Univ Calif Los Angeles, Sch Dent, Div Oral Biol, Los Angeles, CA 90024 USA	Taylor, AN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, 10833 Conte Ave,Box 951763, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu					Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bale TL, 2000, NAT GENET, V24, P410; Bale TL, 2006, HORM BEHAV, V50, P529, DOI 10.1016/j.yhbeh.2006.06.033; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bhatnagar S, 1998, NEUROSCIENCE, V84, P1025, DOI 10.1016/S0306-4522(97)00577-0; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHILDERS MK, 1998, BRAIN INJURY, V12, P547; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conrad CD, 1999, NEUROBIOL LEARN MEM, V72, P39, DOI 10.1006/nlme.1998.3898; Coste SC, 2000, NAT GENET, V24, P403; DEKOSKY ST, 1984, NEUROENDOCRINOLOGY, V38, P33, DOI 10.1159/000123862; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Goel N, 2007, ENDOCRINOLOGY, V148, P4585, DOI 10.1210/en.2007-0479; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P875, DOI 10.1046/j.1365-2826.2001.00714.x; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; LEVIN BE, 1994, RESTOR NEUROL NEUROS, V7, P5, DOI 10.3233/RNN-1994-7102; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Masera RG, 2002, PSYCHONEUROENDOCRINO, V27, P447, DOI 10.1016/S0306-4530(01)00062-2; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2004, ANN NY ACAD SCI, V1032, P1, DOI 10.1196/annals.1314.001; McIntosh LJ, 1996, EXP NEUROL, V141, P201, DOI 10.1006/exnr.1996.0154; McNay EC, 2001, NEUROBIOL LEARN MEM, V75, P325, DOI 10.1006/nlme.2000.3976; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; SCHALLERT T, 2005, BEHAV LAB RATS HDB T, V1, P129; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH MA, 1995, J NEUROSCI, V15, P1768; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TAYLOR AN, 2004, 7 INT NEUR S AD AUST; TAYLOR AN, 2007, SOC NEUR ABST, V33; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Wei Q, 2007, J NEUROSCI, V27, P8836, DOI 10.1523/JNEUROSCI.0910-07.2007; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	79	63	64	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2008	25	4					311	323		10.1089/neu.2007.0486			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	282PL	WOS:000254579600004	18373481				2021-06-18	
J	Raymont, V; Greathouse, A; Reding, K; Lipsky, R; Salazar, A; Grafman, J				Raymont, Vanessa; Greathouse, Amanda; Reding, Katherine; Lipsky, Robert; Salazar, Andres; Grafman, Jordan			Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury	BRAIN			English	Article						cognitive decline; brain injury; penetrating brain injury; genetics; predictors	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E EPSILON-4; AMYLOID BETA-PROTEIN; MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; RISK-FACTOR; VAL(158)MET POLYMORPHISM; FUNCTIONAL POLYMORPHISM; GENOTYPE PREDICTS; APOE GENOTYPE	We examined the relationship of pre-injury intelligence, demographic variables, lesion location, brain tissue volume loss and a number of genetic markers to long-term cognitive decline in a group of Vietnam veterans with predominantly penetrating head injury (PHI) suffered more than 30 years ago. Using linear and stepwise regression procedures, we found that those with PHI demonstrated a greater degree of cognitive decline overall during the years following recovery from injury compared with a control group of uninjured Vietnam veterans. This became increasingly significant later in life. We also found that pre-injury intelligence was the most consistent predictor of cognitive outcome across all phases of potential recovery and decline after such injuries. While laterality of lesion was not a factor, we did find some associations between atrophy and specific regions of tissue loss and long-term cognitive functioning. Finally, we found evidence for an association between level of cognitive decline following PHI and the possession of certain genetic markers that have been linked with brain injury and neurodegeneration. Thus exacerbated decline does occur in Vietnam veterans with PHI and it is apparently unrelated to dementia and is determined by multiple factors (most notably pre-injury intelligence).	[Raymont, Vanessa; Greathouse, Amanda; Reding, Katherine; Salazar, Andres; Grafman, Jordan] Natl Naval Med Ctr, Vietnam Head Injury Study, Henry M Jackson Fdn, Bethesda, MD 20889 USA; [Lipsky, Robert] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA	Grafman, J (corresponding author), NINDS, Cognit Neurosci Sect, NIH, Bldg 10,Room 7D43,MSC 1440, Bethesda, MD 20892 USA.	grafmanj@ninds.nih.gov		Lipsky, Robert/0000-0001-7753-1473; Cole, Katherine/0000-0002-1910-127X; Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS003024, ZIANS003024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [Z01AA000325] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA Funding Source: Medline		Aalto S, 2005, J NEUROSCI, V25, P2471, DOI 10.1523/JNEUROSCI.2097-04.2005; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Arning L, 2005, NEUROGENETICS, V6, P25, DOI 10.1007/s10048-004-0198-8; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Brooks N, 2003, J NEUROL NEUROSUR PS, V74, P1014, DOI 10.1136/jnnp.74.8.1014; CAREY ME, 1987, MIL MED, V152, P6; Cervilla J, 2004, J NEUROL NEUROSUR PS, V75, P1100, DOI 10.1136/jnnp.2003.028076; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; CHUNN MM, 2007, CURR OPIN NEUROBIOL; Chuu JYJ, 2006, J ALZHEIMERS DIS, V9, P43; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORKIN S, 1989, J NEUROSCI, V9, P3876; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DAMAASIO H, 1983, LESION NEUROPSYCHOLO; de Frias CM, 2005, J COGNITIVE NEUROSCI, V17, P1018, DOI 10.1162/0898929054475136; *DEP DEF, 1960, AFQT7A; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Ekstrom AD, 2003, NATURE, V425, P184, DOI 10.1038/nature01964; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Giubilei F, 2004, DEMENT GERIATR COGN, V18, P338, DOI 10.1159/000080128; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Gothelf D, 2005, NAT NEUROSCI, V8, P1500, DOI 10.1038/nn1572; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Grossman M, 2002, HUM BRAIN MAPP, V15, P124, DOI 10.1002/hbm.10117; HAMMOND W, 1986, J NEUROSURG, V34, P127; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007; Laske C, 2006, J NEURAL TRANSM, V113, P1217, DOI 10.1007/s00702-005-0397-y; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Marczynski TJ, 1998, BRAIN RES BULL, V45, P341, DOI 10.1016/S0361-9230(97)00347-X; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mayeux R, 1996, NEUROLOGY, V46, P891; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1992, NEUROLOGY, V42, P1689, DOI 10.1212/WNL.42.9.1689; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Newcombe F, 1996, J CLIN EXP NEUROPSYC, V18, P1, DOI 10.1080/01688639608408258; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramsey MM, 2004, NEUROSCIENCE, V129, P119, DOI 10.1016/j.neuroscience.2004.08.001; RAPOPORT M, 2004, CAN ALZHEIMERS DIS R, V1, P4; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; Richardson MP, 2003, NEUROIMAGE, V20, pS112, DOI 10.1016/j.neuroimage.2003.09.008; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Robert PH, 2006, DEMENT GERIATR COGN, V21, P192, DOI 10.1159/000090766; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Robinson S, 2006, J NEUROSURG, V104, P396, DOI 10.3171/ped.2006.104.6.396; SACK AT, 2007, CEREB CORTEX; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stefanis NC, 2005, AM J PSYCHIAT, V162, P1752, DOI 10.1176/appi.ajp.162.9.1752; STERN Y, 1995, ANN NEUROL, V37, P590, DOI 10.1002/ana.410370508; STERN Y, 2006, COGNITIVE RESERVE TH; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Talairach J., 1988, COPLANAR STEREOTAXIC, P122; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Tariq SH, 2006, AM J GERIAT PSYCHIAT, V14, P900, DOI 10.1097/01.JGP.0000221510.33817.86; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	88	63	64	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2008	131		2				543	558		10.1093/brain/awm300			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	258XO	WOS:000252903900024	18094019	Bronze			2021-06-18	
J	Serbest, G; Burkhardt, MF; Siman, R; Raghupathi, R; Saatman, KE				Serbest, Gulyeter; Burkhardt, Matthew F.; Siman, Robert; Raghupathi, Ramesh; Saatman, Kathryn E.			Temporal profiles of cytoskeletal protein loss following traumatic axonal injury in mice	NEUROCHEMICAL RESEARCH			English	Article						calpain; cytoskeleton; neurofilament; optic nerve; spectrin; tubulin; white matter	SPINAL-CORD-INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; EXPERIMENTAL BRAIN-INJURY; CALPAIN I ACTIVATION; CLOSED-HEAD INJURY; NEUROFILAMENT PROTEINS; CATHEPSIN-D; SPECTRIN DEGRADATION; MEDIATED PROTEOLYSIS; BREAKDOWN PRODUCTS	To examine the time course and relative extent of proteolysis of neurofilament and tubulin proteins after traumatic axonal injury (TAI), anesthetized mice were subjected to optic nerve stretch injury. Immunohistochemistry confirmed neurofilament accumulation within axonal swellings at 4, 24, and 72 h postinjury (n = 4 injured and 2 sham per time point). Immunoblotting of optic nerve homogenates (n = 5 injured and 1 sham at 0.5, 4, 24 or 72 h) revealed calpain-mediated spectrin proteolytic fragments after injury. Protein levels for NF68 progressively decreased from 0.5 h to 24 h postinjury, while NF200 and alpha-tubulin levels decreased acutely (0.5-4 h), with a secondary decline at 72 h postinjury. These data demonstrate that diffusely distributed TAI is associated not only with a localized accumulation of neurofilament proteins, but also significant decreases in total cytoskeletal protein levels which may be mediated, in part, by calpains. Protection of the axonal cytoskeleton represents a potential therapeutic target for axonal damage associated with injury or neurodegenerative diseases.	Univ Kentucky, Dept Physiol Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA	Saatman, KE (corresponding author), Univ Kentucky, Dept Physiol Spinal Cord & Brain Injury Res Ctr, B367 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	k.saatman@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, T32NS043126, R01NS045131, P50NS008803, R01NS048234] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS41561, R01 NS048234, R01 NS048234-01A2, T32-NS043126, R01-NS45131] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BANAYSCHWARTZ M, 1983, NEUROCHEM RES, V8, P51, DOI 10.1007/BF00965653; BANAYSCHWARTZ M, 1987, NEUROCHEM RES, V12, P361, DOI 10.1007/BF00993246; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; Ellis RC, 2004, J NEUROCHEM, V88, P689, DOI 10.1046/j.1471-4159.2003.02197.x; Fournier AE, 1995, BIOCHEM CELL BIOL, V73, P659, DOI 10.1139/o95-073; GEDDES JW, 1995, NEUROBIOL AGING, V16, P651, DOI 10.1016/0197-4580(95)00062-J; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Haranishi Y, 2005, EUR J ANAESTH, V22, P140, DOI 10.1017/S0265021505000268; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; Irving EA, 1997, MOL CHEM NEUROPATHOL, V30, P253, DOI 10.1007/BF02815102; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MOSKOWITZ PF, 1993, J NEUROSCI RES, V34, P129, DOI 10.1002/jnr.490340113; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAATMAN KE, 2007, HDB NEUROCHEMISTRY M; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SCHWAB C, 1994, HIPPOCAMPUS, V4, P210, DOI 10.1002/hipo.450040212; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STEPHENS RE, 1976, PHYSIOL REV, V56, P709; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	66	63	65	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	DEC	2007	32	12					2006	2014		10.1007/s11064-007-9318-9			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	226ZK	WOS:000250626800002	17401646				2021-06-18	
J	Vannatta, K; Gerhardt, CA; Wells, RJ; Noll, RB				Vannatta, Kathryn; Gerhardt, Cynthia A.; Wells, Robert J.; Noll, Robert B.			Intensity of CNS treatment for pediatric cancer: Prediction of social outcomes in survivors	PEDIATRIC BLOOD & CANCER			English	Article						late effects; methotrexate; pediatric oncology; psychosocial; radiation therapy	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVORS; CHILDHOOD-CANCER; LEARNING-DISABILITIES; PEER RELATIONSHIPS; PSYCHOLOGICAL ADJUSTMENT; CRANIAL IRRADIATION; WHOLE-BRAIN; CHILDREN	Purpose. To evaluate the association of central nervous system (CNS) treatment intensity and the social functioning of children who have completed treatment for leukemia, lymphoma, and solid tumors outside the CNS. Furthermore, we expected that these associations would be moderated by child age at diagnosis and gender. Method. Peer, teacher, and self-report data were obtained for 82 cancer survivors (age 9-17 years) using classroom rating and nomination procedures that are widely used in research on social development. Information regarding cranial radiation therapy (CRT), intrathecal chemotherapy (ITC), and systemic methotrexate were obtained from medical records and used to create a composite index of CNS treatment intensity. Results. Higher scores on the index of CNS treatment intensity were associated with poorer peer acceptance, fewer friendships, greater social sensitivity-isolation, and diminished leadership-popularity based on peer-report. These associations were stronger for boys and children who were younger (<10 years old) at diagnosis. In contrast, CNS treatment intensity was only predictive of teacher-perceptions of aggressive-disruptive behavior and it was unrelated to social self-perceptions. Conclusion. These results suggest that children who receive CRT and ITC are at risk for problematic peer relations, particularly if they are male or younger at diagnosis. Given the stability of poor peer relationships and documented linkages between peer problems and subsequent academic and psychiatric difficulties, clinical services should address these issues. Research is needed to identify mechanisms that account for these outcomes and provide direction for prevention and treatment efforts.	Columbus Childrens Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Texas, MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA; Childrens Hosp Pittsburgh, Child Dev Unit, Pittsburgh, PA 15213 USA	Vannatta, K (corresponding author), Columbus Childrens Res Inst, Ctr Biobehav Hlth, Rm G361,700 Childrens Dr, Columbus, OH 43205 USA.	vannattk@pediatrics.ohio-state.edu	Gerhardt, Cynthia/E-3109-2011; Vannatta, Kathryn/E-4237-2011				Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Armstrong FD, 2005, J PEDIATR PSYCHOL, V30, P89, DOI 10.1093/jpepsy/jsi020; Armstrong FD, 1999, SCHOOL PSYCHOL REV, V28, P194; ASHER SR, 1979, DEV PSYCHOL, V15, P443, DOI 10.1037/0012-1649.15.4.443; Bleyer WA, 1997, EUR J CANCER, V33, P1439, DOI 10.1016/S0959-8049(97)00249-9; Brown RT, 1998, J PEDIATR PSYCHOL, V23, P333, DOI 10.1093/jpepsy/23.5.333; Bukowski W. M., 1989, CONTRIBUTIONS PEER R, P15; BUTLER RW, 1994, J CLIN ONCOL, V12, P2621, DOI 10.1200/JCO.1994.12.12.2621; Copeland DR, 1996, J CLIN ONCOL, V14, P2826, DOI 10.1200/JCO.1996.14.10.2826; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Deater-Deckard K, 2001, J CHILD PSYCHOL PSYC, V42, P565, DOI 10.1111/1469-7610.00753; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Fuemmeler BF, 2002, CLIN PSYCHOL REV, V22, P547, DOI 10.1016/S0272-7358(01)00120-9; Fuss M, 2000, STRAHLENTHER ONKOL, V176, P573, DOI 10.1007/PL00002327; Guralnick MJ, 1999, MENT RETARD DEV D R, V5, P21; HAUPT R, 1994, JAMA-J AM MED ASSOC, V272, P1427, DOI 10.1001/jama.272.18.1427; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kavale KA, 1996, J LEARN DISABIL, V29, P226, DOI 10.1177/002221949602900301; KUPST MJ, 1995, J PEDIATR PSYCHOL, V20, P601, DOI 10.1093/jpepsy/20.5.601; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; MASTEN AS, 1985, DEV PSYCHOL, V21, P523, DOI 10.1037/0012-1649.21.3.523; MORISON P, 1991, CHILD DEV, V62, P991, DOI 10.2307/1131148; Mulhern Raymond K, 2004, Pediatr Rehabil, V7, P1, DOI 10.1080/13638490310001655528; MULHERN RK, 1991, J CLIN ONCOL, V9, P1348, DOI 10.1200/JCO.1991.9.8.1348; MULHERN RK, 1989, PEDIATRICS, V83, P18; Mulhern RK, 2004, PEDIAT REHABIL, V7, P15; Nassau JH, 1997, J PEDIATR PSYCHOL, V22, P771, DOI 10.1093/jpepsy/22.6.771; Newby WL, 2000, PSYCHO-ONCOL, V9, P113; NOLL RB, 1991, J PEDIATR PSYCHOL, V16, P307, DOI 10.1093/jpepsy/16.3.307; NOLL RB, 1993, J PEDIATR PSYCHOL, V18, P351, DOI 10.1093/jpepsy/18.3.351; Noll RB, 1999, PEDIATRICS, V103, P71, DOI 10.1542/peds.103.1.71; Nowicki EA, 2003, LEARN DISABILITY Q, V26, P171, DOI 10.2307/1593650; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Parker JG, 1995, DEV PSYCHOPATHOL, V2, P96; Patel SK, 2005, J PEDIATR PSYCHOL, V30, P85, DOI 10.1093/jpepsy/jsi019; PERRIN EC, 1991, J PEDIATR PSYCHOL, V16, P411, DOI 10.1093/jpepsy/16.4.411; Reaman Gregory H, 2005, Clin Adv Hematol Oncol, V3, P133; Reiter-Purtill J, 2003, J PEDIATR PSYCHOL, V28, P17, DOI 10.1093/jpepsy/28.1.17; Sawyer M, 2000, J PEDIAT HEMATOL ONC, V22, P214, DOI 10.1097/00043426-200005000-00006; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; SPIRITO A, 1990, J PEDIATR PSYCHOL, V15, P359, DOI 10.1093/jpepsy/15.3.359; Vance YH, 2002, CHILD CARE HLTH DEV, V28, P5, DOI 10.1046/j.1365-2214.2002.00227.x; Vannatta K, 1998, J PEDIATR PSYCHOL, V23, P279, DOI 10.1093/jpepsy/23.5.279; Vannatta K, 1998, J PEDIATR PSYCHOL, V23, P169, DOI 10.1093/jpepsy/23.3.169; VARNI JW, 1993, J PEDIATR PSYCHOL, V18, P751, DOI 10.1093/jpepsy/18.6.751; Waber DP, 2004, J CLIN ONCOL, V22, P2701, DOI 10.1200/JCO.2004.10.173; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; Wiener J, 2002, J ABNORM CHILD PSYCH, V30, P127, DOI 10.1023/A:1014701215315; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zeller M, 2003, DEV PSYCHOL, V39, P129, DOI 10.1037//0012-1649.39.1.129	50	63	63	0	9	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1545-5009			PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	OCT 15	2007	49	5					716	722		10.1002/pbc.21062			7	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	205AO	WOS:000249085300020	17096410				2021-06-18	
J	Molcanyi, M; Riess, P; Bentz, K; Maegele, M; Hescheler, J; Schafke, B; Trapp, T; Neugebauer, E; Klug, N; Schafer, U				Molcanyi, Marek; Riess, Peter; Bentz, Kristine; Maegele, Marc; Hescheler, Juergen; Schaefke, Bernhard; Trapp, Thorsten; Neugebauer, Edmund; Klug, Norfrid; Schaefer, Ute			Trauma-associated inflammatory response impairs embryonic stem cell survival and integration after implantation into injured rat brain	JOURNAL OF NEUROTRAUMA			English	Article						cell therapy; fluid percussion injury; macrophages; Sprague-Dawley rats	CENTRAL-NERVOUS-SYSTEM; MARROW STROMAL CELLS; GROWTH-FACTOR; IN-VIVO; NEURAL TRANSPLANTATION; EXPERIMENTAL STROKE; COMPLEMENT-SYSTEM; STAB WOUNDS; ADULT-RAT; FLUID	Pluripotent embryonic stem cells were shown to survive and differentiate into mature neuronal cells after implantation in experimental models of Parkinson disease and cerebral ischemia. Embryonic stem cell transplantation has also been proposed as a potential therapy for cerebral trauma, characteristic of massive loss of multiple cell types due to primary insult and secondary sequelae. Green fluorescent protein (GFP)-transfected murine embryonic stem cells were implanted into the ipsi or contralateral cortex of male Sprague-Dawley rats 72 h after fluid-percussion injury. Animals were sacrificed at day 5 or week 7 postimplantation. Brain sections were examined using conventional and fluorescent double-labelling immunohistochemistry. Five days after implantation, clusters of GFP-positive cells undergoing partial differentiation along neuronal pathway, were detected at the implantation site. However, after 7 weeks, only a few GFP-positive cells were found, indicating an extensive loss of stem cells during this time period. For the first time, we proved the observed cell loss to be mediated via phagocytosis of implanted cells by activated macrophages. Cerebral trauma, induced 3 days prior to implantation, has activated the inflammatory potential of otherwise immunologically privileged tissue. Subsequent cell implantation was accompanied by reactive astrogliosis, activation of microglia, as well as a massive invasion of macrophages into transplantation sites even if the grafts were placed into contralateral healthy hemispheres, remote from the traumatic lesion. Our results demonstrate a significant post-traumatic inflammatory response, which impairs survival and integration of implanted stem cells and has generally not been taken into account in designs of previous transplantation studies.	Univ Witten Herdecke, IFOM, Fac Med, D-51109 Cologne, Germany; Univ Witten Herdecke, Hosp Merheim, Fac Med, Dept Trauma & Orthoped Surg, Cologne, Germany; Univ Cologne, Clin Neurosurg, Fac Med, Cologne, Germany; Univ Cologne, Dept Neurophysiol, Fac Med, Cologne, Germany; Natl Res Ctr Environm & Hlth, Inst Dev Genet, Munich, Germany; Max Planck Inst Neurol Res, Cologne, Germany; Univ Dusseldorf, Fac Med, Inst Transplantat Diagnost & Cell Therapeut, D-4000 Dusseldorf, Germany	Schafer, U (corresponding author), Univ Witten Herdecke, IFOM, Fac Med, Ostmerheimerstr 200, D-51109 Cologne, Germany.	u.schaefer@uni-koeln.de					Arnhold S, 2000, J NEUROSURG, V93, P1026, DOI 10.3171/jns.2000.93.6.1026; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Erdo Franciska, 2004, Orvosi Hetilap, V145, P1307; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kleinschnitz C, 2003, J CEREBR BLOOD F MET, V23, P1356, DOI 10.1097/01.WCB.0000090505.76664.DB; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Li PY, 2005, ARCH NEUROL-CHICAGO, V62, P223, DOI 10.1001/archneur.62.2.223; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Prasad ML, 1999, AM J SURG PATHOL, V23, P176, DOI 10.1097/00000478-199902000-00006; Rausch M, 2001, MAGNET RESON MED, V46, P1018, DOI 10.1002/mrm.1290.abs; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Saleh A, 2004, NMR BIOMED, V17, P163, DOI 10.1002/nbm.881; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schroeter M, 2003, MOL BRAIN RES, V117, P1, DOI 10.1016/S0169-328X(03)00255-9; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Wang X, 2004, ACTA NEUROCHIR SUPPL, V89, P49; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009	45	63	66	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					625	637		10.1089/neu.2006.0180			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000005	17439346				2021-06-18	
J	Stuke, L; Diaz-Arrastia, R; Gentilello, LM; Shafi, S				Stuke, Lance; Diaz-Arrastia, Ramon; Gentilello, Larry M.; Shafi, Shahid			Effect of alcohol on Glasgow Coma Scale in head-injured patients	ANNALS OF SURGERY			English	Article; Proceedings Paper	58th Annual Meeting of the Southwestern-Surgical-Congress	APR 03-07, 2006	Kauai, HI	SW Surg Congress			TRAUMA CENTER; INTOXICATION; INTERVENTION; SCORE	Objective: Almost 50% of traumatic brain-injured (TBI) patients are alcohol intoxicated. The Glasgow Coma Scale (GCS) is frequently used to direct diagnostic and therapeutic decisions in these patients. It is commonly assumed that alcohol intoxication reduces GCS, thus limiting its utility in intoxicated patients. The purpose of this study was to test the hypothesis that the presence of blood alcohol has a clinically significant impact on GCS in TBI patients. Methods: The National Trauma Data Bank of the American College of Surgeons was queried (1994-2003). Patients 18 to 45 years of age with blunt injury mechanism, whose GCS in the emergency department, survival status, anatomic severity of TBI (Head Abbreviated Injury Score [AIS]), and blood alcohol testing status were known, were included. GCS of patients who tested positive for alcohol (n = 55,732) was compared with GCS of patients who tested negative (n = 53,197), stratified by head AIS. Results: Groups were similar in age (31 8 vs. 30 8 years), Injury Severity Score (ISS; 12 +/- 11 vs. 12 +/- 11), systolic blood pressure in the ED (131 +/- 25 vs. 134 +/- 25 mm Hg), TRISS (Trauma Injury Severity Score; probability of survival (94% +/- 16% vs. 95% +/- 15%), and actual survival (96% vs. 96%). When stratified by anatomic severity of TBI, the presence of alcohol did not lower GCS by more than I point in any head AIS group (GCS in alcohol-positive vs. alcohol-negative patients; AIS 1 = 13.9 +/- 2.8 vs. 14.3 +/- 2.3; AIS 2 = 13.4 +/- 3.2 vs. 14.1 +/- 2.4; AIS 3 = 11.1 +/- 4.7 vs. 11.6 +/- 4.6; AIS 4 = 9.8 +/- 4.9 vs. 10.4 +/- 4.9; AIS 5 = 5.5 +/- 3.8 vs. 5.9 +/- 4.1, NIS 6: 3.4 +/- 1.1 vs. 3.8 +/- 2.8). Conclusion: Alcohol use does not result in a clinically significant reduction in GCS in trauma patients. Attributing low GCS to alcohol intoxication in TBI patients may delay necessary diagnostic and therapeutic interventions.	Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Surg Crit Care, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA	Shafi, S (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Surg Crit Care, 5323 Harry Hines Blvd,Mail Code 9158, Dallas, TX 75390 USA.	shahid.shafi@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594			*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP; American College of Surgeons Committee on Trauma, 2006, RES OPT CAR INJ PAT; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Cherpitel C, 2005, EMERG MED J, V22, P689, DOI 10.1136/emj.2004.016865; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Dunne JR, 2005, J TRAUMA, V58, P959, DOI 10.1097/01.TA.0000158508.84009.49; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; Gentilello LM, 2005, J TRAUMA, V59, P624, DOI 10.1097/01.ta.0000179309.34613.27; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gentilello LM, 1999, J TRAUMA, V47, P1131, DOI 10.1097/00005373-199912000-00027; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; MINION GE, 1989, J TOXICOL-CLIN TOXIC, V27, P375, DOI 10.3109/15563658909000358; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Schermer CR, 2003, J TRAUMA, V55, P849, DOI 10.1097/01.TA.0000091110.83692.38; Soderstrom C A, 1988, Md Med J, V37, P541; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SPERRY J, 2006, J TRAUMA, V60, P252; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; VALADKA AB, 2000, TRAUMA, P377; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170	21	63	66	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	APR	2007	245	4					651	655		10.1097/01.sla.0000250413.41265.d3			5	Surgery	Surgery	150RB	WOS:000245232900023	17414616	Green Published			2021-06-18	
J	Chafetz, MD; Abrahams, JP; Kohlmaier, J				Chafetz, Michael D.; Abrahams, Joel P.; Kohlmaier, Joy			Malingering on the social security disability consultative exam: A new rating scale	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; disability; social security; mental retardation	ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; MENTAL-RETARDATION; PERFORMANCE; VALIDATION; TESTS	In disability examinations, benefits may depend on the findings of a psychological consultative examination (PCE), which in Louisiana usually involves a mental status examination and a Wechsler Scale. The disability determinations service (DDS) requires a warning that failure to do one's best may result in an unfavorable decision on the claim, but psychologists are officially discouraged from determining effort by the use of formal effort tests. Consequently, there is a need for internal indicators of effort. Formal testing of effort was undertaken in order to identify indicators of effort within the PCE in WAIS-age and WISC-age claimants. Our findings indicated that the total score of indicators was more predictive of effort than any single indicator. Regression equations yielded information on how much effort contributes to IQ. Classification accuracy for the new rating scale was described for a "dose-response" of effort. Disincentives for malingering detection in the PCE were identified. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	River Oaks Hosp, Harahan, LA 70123 USA	Chafetz, MD (corresponding author), 3520 Gen DeGaulle Dr 4098, New Orleans, LA 70114 USA.	mikechaf@yahoo.com	Chafetz, Michael/AAC-2579-2020				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; CHAFETZ MD, 2005, ANN M AM AC CLIN NEU; CHAFETZ MD, 2005, ANN M NAT AC NEUR; Cohen J., 1983, APPL MULTIPLE REGRES; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; DROB SL, 2000, AM J FORENSIC PSYCH, V18, P57; Evans S., 1984, J GEN PSYCHOL, V111, P12; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2004, MED SYMPTOM VALIDITY; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Hayes J S, 1998, Appl Neuropsychol, V5, P33, DOI 10.1207/s15324826an0501_4; Hayes JS, 1997, J PSYCHOL, V131, P575, DOI 10.1080/00223989709603549; Hurley KE, 2006, MENT RETARD, V44, P112, DOI 10.1352/0047-6765(2006)44[112:AIMMUW]2.0.CO;2; Kim J.O., 1978, FACTOR ANAL STAT MET; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2000, J CLIN EXP NEUROPSYC, V22, P702, DOI 10.1076/1380-3395(200010)22:5;1-9;FT702; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; MILLER LS, 2006, ANN M INT NEUR SOC; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rogers R, 1990, Bull Am Acad Psychiatry Law, V18, P323; Rohling M. L., 2004, NEWSLETTER, V22, P1; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; *SOC SEC ADM, 2003, SOC SEC ADM BUDG REQ; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; *US DEH HHS SOC SE, 2006, SSA PUBL; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009	33	63	63	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					1	14		10.1016/j.acn.2006.10.003			14	Psychology, Clinical; Psychology	Psychology	144RV	WOS:000244814700001	17097263	Bronze			2021-06-18	
J	Ratcliff, JJ; Greenspan, AI; Goldstein, FC; Stringer, AY; Bushnik, T; Hammond, FM; Novack, TA; Whyte, J; Wright, DW				Ratcliff, Jonathan J.; Greenspan, Arlene I.; Goldstein, Felicia C.; Stringer, Anthony Y.; Bushnik, Tamara; Hammond, Flora M.; Novack, Thomas A.; Whyte, John; Wright, David W.			Gender and traumatic brain injury: Do the sexes fare differently?	BRAIN INJURY			English	Article						traumatic brain injury; closed head injury; gender; outcome	HEAD-INJURY; TBI; PROGESTERONE; METAANALYSIS; ABILITIES; VARIABLES; SEVERITY; DAMAGE; TASK; AGE	Objective: To examine the relationship between gender and cognitive recovery 1 year following traumatic brain injury (TBI). Methods: Patients with blunt TBI were identified from the TBI Model Systems of Care National Database, multi-centre cohort study. The included patients ( n = 325) were 16 - 45 years at injury, admitted to an acute care facility within 24 hours, received inpatient rehabilitation, had documented admission Glasgow Coma Scale (GCS) scores, completed neuropsychological follow-up 1 year post-injury and did not report pre-morbid learning problems. Multivariate analyses of variance examined the unadjusted association between gender and six cognitive domains examining attention/working memory, verbal memory, language, visual analytic skills, problem-solving and motor functioning. Analyses of covariance models were constructed to determine if confounding factors biased the observed associations. Results: Females performed significantly better than males on tests of attention/working memory and language. Males outperformed females in visual analytic skills. Gender remained significantly associated with performance in these areas when controlling for confounding variables. Conclusions: These results suggest a better cognitive recovery of females than males following TBI. However, future studies need to include non-TBI patients to control for possible pre-injury gender-related differences, as well as to conduct extended follow-ups to determine the stability of the observed differences.	Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA; Emory Univ, Sch Med, Dept Rehabil Med, Atlanta, GA USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Santa Clara Valley Med Ctr, No CA TBI Model Syst Care, Rehabil Res Ctr, San Jose, CA 95128 USA; Carolinas Rehabil, Charlotte, NC USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA; Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA USA	Wright, DW (corresponding author), 49 Jessie Hill Jr Dr, Atlanta, GA 30303 USA.	david.wright@emory.edu	Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105; Bushnik, Tamara/0000-0003-3328-257X; Whyte, John/0000-0002-4381-1474			Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BECHTOLDT HP, 1962, PSYCHOL REC, V12, P147, DOI 10.1007/BF03393452; BENTON AL, 1994, CONTRIBUTION NEUROPS; Benton AL, 1978, MULTILINGUAL APHASIA; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; DABNER EF, 1993, J HEAD TRAUMA REHAB, V8, P12; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Georgopoulos AP, 2001, J COGNITIVE NEUROSCI, V13, P72, DOI 10.1162/089892901564180; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Heaton R.K., 1991, COMPREHENSIVE NORMS; Jorm AF, 2004, INTELLIGENCE, V32, P7, DOI 10.1016/j.intell.2003.08.001; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KRAUS JF, 2000, NEUROSURGERY FOCUS, V8; MITRUSHINA MN, 1999, HANDBOOD NORMATIVE D; *PSYCH CORP, 1999, WAIS 3 WMS 3 TECHN M; *PSYCH CORP, 1997, WECHSL ADULT INT SCA; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; VOYER D, 1995, PSYCHOL BULL, V117, P250, DOI 10.1037/0033-2909.117.2.250; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WALDMANN BW, 1992, J CLIN PSYCHOL, V48, P360, DOI 10.1002/1097-4679(199205)48:3<360::AID-JCLP2270480314>3.0.CO;2-P; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; Weiss E, 2003, NEUROSCI LETT, V344, P169, DOI 10.1016/S0304-3940(03)00406-3; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	36	63	63	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1023	1030		10.1080/02699050701633072			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600004	17891564				2021-06-18	
J	Tomberg, T; Toomela, A; Ennok, M; Tikk, A				Tomberg, T.; Toomela, A.; Ennok, M.; Tikk, A.			Changes in coping strategies, social support, optimism and health-related quality of life following traumatic brain injury: A longitudinal study	BRAIN INJURY			English	Article						coping strategies; social support; optimism; health-related quality of life; longitudinal changes; traumatic brain injury	ADJUSTMENT; DEPRESSION; RECOVERY; STRESS; DISABILITY; FAMILIES; MODERATE; OUTCOMES; STYLE; WORK	Primary objective: To study longitudinal changes in psychological coping strategies, social support, life orientation and health-related quality of life in the late period after traumatic brain injury ( TBI). Subjects: Thirty-one patients with TBI who were first investigated on average 2.3 years after injury and were prospectively followed on average 5.7 years later. Methods: Estonian versions of the COPE-D Test, the Brief Social Support Questionnaire, the Life Orientation Test and the RAND-36 questionnaire. Results: During the late follow-up period health-related quality of life and resuming work did not improve significantly. Persons with TBI reported an increase in seeking social/emotional support ( p < 0.05), frequent use of avoidance-oriented styles and reduced use of task-oriented styles. This was accompanied by low social support and low satisfaction with support, both of which were associated with health-related quality of life and resuming work after TBI. Although the patients had become more optimistic ( p < 0.05), this did not correlate with their health status and social well-being. Conclusions: This prospective study revealed maladaptive changes in the profile of coping strategies and an increase in optimism. As social support, satisfaction with support and health-related quality of life did not improve, then rehabilitation, social and psychological support are continuously needed.	Univ Tartu, Dept Neurol & Neurosurg, EE-51014 Tartu, Estonia; Univ Tartu, Dept Special Educ, EE-51014 Tartu, Estonia	Tomberg, T (corresponding author), Univ Tartu, Dept Neurol & Neurosurg, 2 L Puusepp St, EE-51014 Tartu, Estonia.	tiiu.tomberg@kliinikum.ee	Toomela, Aaro/H-6033-2018	Toomela, Aaro/0000-0002-8520-9676			Bedi G, 2005, BRIT J HEALTH PSYCH, V10, P57, DOI 10.1348/135910704X15266; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; CARVER CS, 1992, HOSTILITY, COPING & HEALTH, P167, DOI 10.1037/10105-012; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2006, BRAIN COGNITION, V60, P214; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Finset A, 2000, BRAIN INJURY, V14, P887; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Herodes M, 2001, EPILEPSIA, V42, P1061, DOI 10.1046/j.1528-1157.2001.0420081061.x; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Kallasmaa T, 2000, PERS INDIV DIFFER, V29, P881, DOI 10.1016/S0191-8869(99)00240-8; KAPLAN SP, 1993, REHABIL COUNS BULL, V36, P151; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Power PW, 2003, BRAIN INJURY, V17, P1021, DOI 10.1080/0269905031000110526; *RAND HLTH SCI PRO, 1992, RAND 36 IT HLTH SURV; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SCHEIER MF, 1986, J PERS SOC PSYCHOL, V51, P1257, DOI 10.1037/0022-3514.51.6.1257; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; Shen BJ, 2004, J BEHAV MED, V27, P39, DOI 10.1023/B:JOBM.0000013643.36767.22; SVELNIKAS K, 1998, THESIS U TARTU TARTU; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; THOITS PA, 1995, J HEALTH SOC BEHAV, V35, P53, DOI 10.2307/2626957; TINA A, 1998, THESIS U TARTU TARTU; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Toomela A, 2004, J REHABIL MED, V36, P63, DOI 10.1080/16501970310017414; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	48	63	63	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	5					479	488		10.1080/02699050701311737			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175FI	WOS:000246998000004	17522987				2021-06-18	
J	Zhang, L; Heier, LA; Zimmerman, RD; Jordan, B; Ulug, AM				Zhang, L.; Heier, L. A.; Zimmerman, R. D.; Jordan, B.; Ulug, A. M.			Diffusion anisotropy changes in the brains of professional boxers	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLOSED-HEAD INJURY; WHITE-MATTER; FIBER TRACKING; TENSOR; DAMAGE; TRACT	BACKGROUND AND PURPOSE: Professional boxing may result in brain injury. We hypothesize that quantitative MR diffusion imaging may be useful in determining early white matter changes. METHODS: Forty-nine professional boxers (age 30 +/- 4.5 years) and 19 healthy control subjects (age 32 +/- 9.5 years) were imaged on a clinical 1.5T scanner. None of the subjects had neurologic disorder or deficit. The average diffusion constant (D-av) and diffusion anisotropy (FA) were determined pixel by pixel. Regional diffusion measurements were done in the corpus callosum (CC) and internal capsule (IC). The whole brain diffusion constant (BDav) was also determined. Student t test was used to analyze the diffusion difference between boxers and the healthy control subjects. P < .05 was considered statistically significant. RESULTS: Of the 49 professional boxers, 42 had normal conventional MRIs. The remaining 7 boxers had abnormal MR imaging findings dominated by nonspecific white matter disease. There was a significant difference in diffusion and anisotropy measurements in all the boxers compared with the healthy control subjects. In the boxer group, BDav increased and FA decreased significantly in the CC and posterior limb of IC. The measured FA and D-av inversely correlated in regions of CC and IC in boxers but not in healthy control subjects. BDav also robustly correlated with both FA and D-av in the splenium of CC in boxers. CONCLUSION: Increased BID., and the decreased FA in the CC and IC may represent preclinical signs of subtle brain injury in professional boxers.	Cornell Univ, Weill Med Coll, Dept Radiol, New York, NY 10021 USA; New York State Athlet Commiss, New York, NY USA; Burke Rehabil Hosp, White Plains, NY USA	Ulug, AM (corresponding author), Cornell Univ, Weill Med Coll, Dept Radiol, Box 141,1300 York Ave, New York, NY 10021 USA.	ulug@ieee.org	Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322			Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Chun T, 2000, AM J NEURORADIOL, V21, P1078; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BMJ-BRIT MED J, P105; Fernando MS, 2004, NEUROPATH APPL NEURO, V30, P385, DOI 10.1111/j.1365-2990.2004.00550.x; Higano S, 2001, AM J NEURORADIOL, V22, P456; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; LeBihan D, 1995, NMR BIOMED, V8, P375; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; Lee SK, 2004, NEUROIMAGE, V22, P1826, DOI 10.1016/j.neuroimage.2004.04.028; Mamata H, 2004, NEUROCHEM INT, V45, P553, DOI 10.1016/j.neuint.2003.11.014; MOODY DM, 1988, AM J NEURORADIOL, V9, P1051; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Nicholl JP, 1995, BRIT J SPORT MED, V29, P232, DOI 10.1136/bjsm.29.4.232; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; Ross J, 2000, HAEMOPHILIA, V6, P41; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sotak CH, 2004, NEUROCHEM INT, V45, P569, DOI 10.1016/j.neuint.2003.11.010; Spriggs M, 2004, J MED ETHICS, V30, P515, DOI 10.1136/jme.2003.003541; Ulug AM, 1999, AM J NEURORADIOL, V20, P1044; Ulug AM, 2004, J MAGN RESON IMAGING, V19, P34, DOI 10.1002/jmri.10433; Ulug AM, 1999, JMRI-J MAGN RESON IM, V9, P804; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; WAKANA S, 2004, RADIOLOGY, P230; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Yamada K, 2003, STROKE, V34, DOI 10.1161/01.STR.0000085827.54986.89; Yamada K, 2003, RADIOLOGY, V227, P295, DOI 10.1148/radiol.2271020313; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	40	63	64	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	OCT	2006	27	9					2000	2004					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	095OE	WOS:000241316400043	17032883				2021-06-18	
J	af Geijerstam, JL; Oredsson, S; Britton, M				af Geijerstam, Jean-Luc; Oredsson, Sven; Britton, Mona		OCTOPUS Study Investigators	Medical outcome after immediate computed tomography or admission for observation in patients with mild head injury: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; RAY TECHNIQUE FACTORS; EMERGENCY-DEPARTMENT; RADIATION; MANAGEMENT; DISCHARGE; MORTALITY; COHORT; SCALE; SIZE	Objective To compare immediate computed tomography during triage for admission with observation in hospital in patients with mild head injury. Design Multicentre, pragmatic, non-inferiority randomised trial. Setting 39 acute hospitals in Sweden. Participants 2602 patients (aged >= 6) with mild head injury. Interventions Immediate computed tomography or admission for observation. Main outcome measure Dichotomised extended Glasgow outcome scale (1-7 v 8). The non-inferiority margin was 5 percentage points. Results At three months, 275 patients (21.4%) in the computed tomography group had not recovered completely compared with 300 (24.2%) admitted for observation. The difference was - 2.8 percentage points, non-significantly in favour of computed tomography (95% confidence interval - 6.1% to 0.6%). The worst outcomes (mortality and more severe loss of function) were similar between the groups. In the patients admitted for observation, there was a considerable delay in time to treatment in those who required surgery. None of the patients with normal findings on immediate computed tomography had complications later. Patients' satisfaction with the two strategies was similar. Conclusions The use of computed tomography in the management of patients with mild head injury is feasible and leads to similar clinical outcomes compared with observation in hospital.	Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden; Helsingborg Hosp, Emergency Dept, Helsingborg, Sweden; Swedish Council Technol Assessement Hlth Care, Stockholm, Sweden	af Geijerstam, JL (corresponding author), Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden.	jean-luc.af.geijerstam@ki.se					Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Geijerstam JL, 2005, EMERG MED J, V22, P103; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; GEIJERSTAM JLA, 2004, EMERG MED J, V21, P54; Griffiths PD, 2004, BRIT MED J, V329, P930, DOI 10.1136/bmj.329.7472.930; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Huda W, 2004, MED PHYS, V31, P595, DOI 10.1118/1.1646233; Huda W, 2004, MED PHYS, V31, P588, DOI 10.1118/1.1646232; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; *NAT I CLIN EXC, 2003, HEAD INJ TRIAG ASS I; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; *SWED COUNC TECHN, 2000, MILD HEAD INJ OBS CT; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	25	63	63	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2006	333	7566					465	468		10.1136/bmj.38918.669317.4F			4	Medicine, General & Internal	General & Internal Medicine	085QP	WOS:000240618900013	16895944	Bronze, Green Published			2021-06-18	
J	McCarthy, ML; Dikmen, SS; Langlois, JA; Selassie, AW; Gu, JK; Horner, MD				McCarthy, Melissa L.; Dikmen, Sureyya S.; Langlois, Jean A.; Selassie, Anbesaw W.; Gu, Ja K.; Horner, Michael D.			Self-reported psychosocial health among adults with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation	QUALITY-OF-LIFE; HEAD-INJURY; PSYCHIATRIC-DISORDERS; SURVEY SF-36; SOCIOECONOMIC-STATUS; DEPRESSION; VALIDITY; 1-YEAR; PRODUCTIVITY; INDIVIDUALS	Objective: To measure the subjective psychosocial health of a population-based sample of adults with traumatic brain injury (TBI). Design: Retrospective, cohort study involving a 1-year postinjury interview. Setting: Sixty-two acute care, nonfederal hospitals in South Carolina. Participants: Persons (>= 15y) hospitalized with TBI. Interventions: Not applicable. Main Outcome Measure: The psychosocial health scales of the Medical Outcomes Study 36-Item Short-Form Health Survey. Results: Of the 7612 participants, 29% reported poor psychosocial health. Factors associated with poor psychosocial well-being included younger age, female sex, Medicaid coverage, no health insurance, inadequate or moderate social support, comorbidities (eg, a preinjury substance abuse problem), cognitive complaints, and some or a lot of limitation with activities of daily living. Only 36% of participants who reported poor psychosocial health reported receiving any mental health services. Conclusions: A substantial proportion of persons hospitalized with TBI reported poor psychosocial health at 1 year postinjury. To optimize recovery, clinicians need to ensure that patients' psychosocial health needs are addressed during the postacute period.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21209 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA	McCarthy, ML (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 5801 Smith Ave,Davis Bldg,Ste 3220, Baltimore, MD 21209 USA.	mmccarth@jhmi.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Adler NE, 1999, ANN NY ACAD SCI, V896, P3, DOI 10.1111/j.1749-6632.1999.tb08101.x; Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARRERA M, 1981, AM J COMMUN PSYCHOL, V9, P435, DOI 10.1007/BF00918174; BARRERA M, 1983, AM J COMMUN PSYCHOL, V11, P133; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Calsyn DA, 2004, DRUG ALCOHOL DEPEN, V76, P165, DOI 10.1016/j.drugalcdep.2004.04.018; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Damiano AM, 1996, SICKNESS IMPACT PROF; de Zwaan M, 2002, OBES SURG, V12, P773, DOI 10.1381/096089202320995547; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Green CA, 1999, SOC SCI MED, V48, P1363, DOI 10.1016/S0277-9536(98)00440-7; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KANDRACK MA, 1991, SOC SCI MED, V32, P579, DOI 10.1016/0277-9536(91)90293-L; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; Machamer JE, 2003, J HEAD TRAUMA REHAB, V18, P387, DOI 10.1097/00001199-200309000-00001; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Marmot M, 1997, SOC SCI MED, V44, P901, DOI 10.1016/S0277-9536(96)00194-3; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; McCarthy ML, 2003, J BONE JOINT SURG AM, V85A, P1689, DOI 10.2106/00004623-200309000-00006; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MCLEAN A, 2002, ARCH PHYS MED REH S2, V74, P1041; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Myrdal G, 2003, THORAX, V58, P194, DOI 10.1136/thorax.58.3.194; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P29, DOI 10.1016/0001-4575(81)90040-3; Revicki DA, 1998, MED CARE, V36, P126, DOI 10.1097/00005650-199802000-00003; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Selassie A, 2004, S CAROLINA TRAUMATIC; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thurman DJ., 1995, GUIDELINES SURVEILLA; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VERBRUGGE L M, 1979, Women and Health, V4, P61; Ware J.E., 1994, SF 36 PHYS MENTAL SU; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1993, SF 36 HLTH SURVEY MA; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; 1993, INT CLASSIFICATION D	76	63	63	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2006	87	7					953	961		10.1016/j.apmr.2006.03.007			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	059MY	WOS:000238738100011	16813783				2021-06-18	
J	Pappachan, B; Alexander, M				Pappachan, Biju; Alexander, Mohan			Correlating facial fractures and cranial injuries	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							CERVICAL-SPINE INJURY; CLOSED-HEAD INJURIES; MAXILLOFACIAL TRAUMA; SKELETON; PATTERN; IMPACT; FACE	Purpose: This study retrospectively evaluated individuals with traumatic injuries from different mechanisms and tried to determine if there is any relationship between various isolated or combined fractures of facial skeleton and cranial injuries. Materials and Methods: We retrospectively studied hospital charts of all patients who reported to the trauma center at Kasturba Hospital in Manipal with facial fractures and suspected cranial injuries during a 5-year period (January 1, 1995 to December 31, 1999). These patients were admitted to the Department of Neurosurgery or the Maxillofacial Unit of Kasturba Hospital, Manipal. The complete medical record of each patient was reviewed, recording the following in a standard format: age, gender, cause of injury, type of facial fractures, type of cranial bone fracture, concussion, intracranial injury, cerebrospinal fluid (CSF) rhinorrhea, CSF otorrhea, and the Glasgow coma scale. Results: The study data were collected as part of retrospective analysis. A total of 12,329 patients reported to the trauma center of the study hospital during a 5-year period with various injuries. A total of 772 patients had facial fractures (6%). A total of 108 patients with a combination of cranial injuries and facial fractures were identified within this group (14%). Gender predilection was seen to favor males (90%) more than females (10%). The ratio was seen to be nearly 9: 1. The ages of the patients ranged from 7 to 70 years with mean age being 32 years (standard deviation [SD] = +/- 12). Central midfacial bone involvement was found to be more commonly associated with head injury. Conclusions: There is a correlation between midfacial injuries and CNS trauma. A more exhaustive multicentric case-control study with a larger sample and additional parameters will be essential to reach definite conclusions regarding the spectrum of head injuries associated with facial fractures. (C) 2006 American Association of Oral and Maxillofacial Surgeons.	Radhika Meghe Mem Med Trust, Sharad Pawar Dent Coll, Dept Maxillofacial Surg, Wardha, Maharashtra, India; Mahatma Gandhi Dent Coll, Pondicherry, India	Pappachan, B (corresponding author), Care of Kedar S, Snehal Nagar, Wardha, Maharashtra, India.	biju_pappachan@yahoo.com	Pappachan, Biju/AAA-2344-2020				ADEKEYE EO, 1980, ORAL SURG ORAL MED O, V49, P491, DOI 10.1016/0030-4220(80)90068-7; BECK RA, 1989, ARCH OTOLARYNGOL, V115, P826; BERTOLAMI CN, 1982, ORAL SURG ORAL MED O, V53, P122, DOI 10.1016/0030-4220(82)90274-2; BRANDT KE, 1991, J TRAUMA, V31, P15, DOI 10.1097/00005373-199101000-00003; CHANG CJ, 1994, J TRAUMA, V37, P807, DOI 10.1097/00005373-199411000-00017; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; DAWSON RLG, 1953, BRIT J SURG, V41, P254, DOI 10.1002/bjs.18004116707; DAWSON RLG, 1962, BR DENT J, V113, P345; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; HAUG RH, 1991, J ORAL MAXIL SURG, V49, P725, DOI 10.1016/S0278-2391(10)80236-8; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HAYTER JP, 1991, BRIT J ORAL MAX SURG, V29, P370, DOI 10.1016/0266-4356(91)90003-N; HUESTON JT, 1956, MED J AUSTRALIA, V2, P141; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; MCCABE JB, 1984, AM J EMERG MED, V2, P333, DOI 10.1016/0735-6757(84)90130-X; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; Murray J F, 1975, Clin Plast Surg, V2, P131; NORUSIS MJ, 1986, SPSS IBM PC AT VERSI; O'Sullivan ST, 1999, BRIT J PLAST SURG, V52, P519, DOI 10.1054/bjps.1999.3159; ROWE NL, 1968, FRACTURES FACIAL SKE, P857; SCHULTZ RC, 1967, PLAST RECONSTR SURG, V40, P415, DOI 10.1097/00006534-196711000-00001; SINCLAIR D, 1988, Journal of Emergency Medicine, V6, P109, DOI 10.1016/0736-4679(88)90148-5; SLUPCHYNSKYJ OS, 1992, LARYNGOSCOPE, V102, P1247, DOI 10.1288/00005537-199211000-00008; TEASDALE G, 1974, LANCET, V2, P81; Tessier P, 1972, Plast Reconstr Surg, V50, P600; TURVEY TA, 1977, J ORAL SURG, V35, P887; Ugboko VI, 1998, INT J ORAL MAX SURG, V27, P286, DOI 10.1016/S0901-5027(05)80616-2; UNGER JM, 1990, RADIOLOGY, V175, P175, DOI 10.1148/radiology.175.1.2315477; van Beek GJ, 1999, INT J ORAL MAX SURG, V28, P424, DOI 10.1016/S0901-5027(99)80055-1; VANHOOF RF, 1977, INT J ORAL MAXILLOF, V6, P3, DOI 10.1016/S0300-9785(77)80066-5	34	63	64	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUL	2006	64	7					1023	1029		10.1016/j.joms.2006.03.021			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	057OQ	WOS:000238605500006	16781334				2021-06-18	
J	Davis, DP; Serrano, JA; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, Daniel P.; Serrano, Jennifer A.; Vilke, Gaty M.; Sise, Michael J.; Kennedy, Frank; Eastman, A. Brent; Velky, Thomas; Hoyt, David B.			The predictive value of field versus arrival Glasgow coma scale score and TRISS calculations in moderate-to-severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma		Glasgow Coma Scale; traumatic brain injury; TRISS; paramedic; predictive value	RAPID-SEQUENCE INTUBATION; EMERGENCY CARE; MORTALITY; IMPACT; PATIENT; TEAM; AIR	Background: Glasgow Coma Scale (GCS) scores are widely used to quantify level of consciousness in the prehospital environment. The predictive value of field versus arrival GCS is not well defined but has tremendous implications with regard to triage and therapeutic decisions as well as the use of various predictive scoring systems, such as Trauma Score and Injury Severity Score (TRISS). This study explores the predictive value of field GCS (fGCS) and arrival GCS (aGCS) as well as TRISS calculations using field (fTRISS) and arrival (aTRISS) data in patients with moderate-to-severe traumatic brain injury (TBI). Methods: Major trauma victims with head Abbreviated Injury Scores of 3 or greater were identified from our county trauma registry over a 16-year period. The predictive ability of fGCS with regard to aGCS was explored using univariate statistics and linear regression modeling. The difference between aGCS and fGCS was also modeled against mortality and the composite endpoint using logistic regression, adjusting for fGCS. The predictive value of preadmission GCS (pGCS), defined as either fGCS or aGCS in nonintubated patients without a documented fGCS, with regard to mortality and a composite endpoint representing the need for neurosurgical care (death, craniotomy, invasive intracranial pressure monitoring, or intensive care unit care > 48 hours) was determined using receiver-operator curve (ROC) analysis. Finally, fTRISS and aTRISS predicted survival values were compared with each other and to observed survival. Results: A total of 12,882 patients were included. Mean values for fGCS and aGCS were similar (11.4 and 11.5, respectively, p = 0.336), and a strong correlation (r(2) = 0.67, 95 % CI 0.66-0.69, p < 0.0001) was observed between them. The difference between fGCS and aGCS was also predictive of outcome after adjusting for fGCS. Good predictive ability was observed for pGCS with regard to both mortality and neurosurgical intervention. Both fTRISS and aTRISS predicted survival values were nearly identical to observed survival. Observed and fTRISS predicted survival were nearly identical in patients undergoing prehospital intubation. Conclusions: Values for fGCS are highly predictive of aGCS, and both are associated with outcome from TBI. A change in GCS from the field to arrival is highly predictive of outcome. The use of field data for TRISS calculations appears to be a valid methodological approach, even in severely injured TBI patients undergoing prehospital intubation.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; Mercy Air Med Serv, San Diego, CA USA; Scripps Mercy Hosp, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA; Scripps La Jolla Hosp, La Jolla, CA USA; Palomar Hosp, Escondido, CA USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr 8676, San Diego, CA 92103 USA.	davismd@cox.net					Amin AP, 2000, SURGERY, V127, P245, DOI 10.1067/msy.2000.104296; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; BAXT WG, 1983, JAMA-J AM MED ASSOC, V249, P3047, DOI 10.1001/jama.249.22.3047; BAXT WG, 1985, ANN EMERG MED, V14, P859, DOI 10.1016/S0196-0644(85)80634-X; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; BOYD CR, 1989, J TRAUMA, V29, P789, DOI 10.1097/00005373-198906000-00015; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Jacobs L M, 1999, Conn Med, V63, P677; Larson JT, 2004, J TRAUMA, V56, P89, DOI 10.1097/01.TA.0000061163.35582.A5; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; TEASDALE G, 1982, SCOT MED J, V27, P7, DOI 10.1177/003693308202700103; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2000, INTENS CARE MED, V26, P153, DOI 10.1007/s001340050037; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X	33	63	64	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2006	60	5					985	990		10.1097/01.ta.0000205860.96209.1c			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	044NB	WOS:000237678100017	16688059				2021-06-18	
J	Marmarou, CR; Povlishock, JT				Marmarou, CR; Povlishock, JT			Administration of the immunophilin ligand FK506 differentially attenuates neurofilament compaction and impaired axonal transport in injured axons following diffuse traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; axonal damage; amyloid precursor protein (APP); immunophilin ligands; FK506; neurofilament compaction (NFC)	TRANSIENT FOCAL ISCHEMIA; CYCLOSPORINE-A; POSTTRAUMATIC HYPOTHERMIA; IMMUNOSUPPRESSANT FK506; CYTOSKELETAL CHANGES; DAMAGE; RAT; PROTEOLYSIS; MODEL; BETA	Traumatic axonal injury (TAI) following traumatic brain injury (TBI) remains a clinical problem for which no effective treatment exists. TAI was thought to involve intraaxonal changes that universally led to impaired axonal transport (IAT), disconnection and axonal bulb formation. However, recent, immunocytochemical studies employing antibodies to amyloid precursor protein (APP), a marker of IAT and antibodies to neurofilament compaction (NFC), RM014, demonstrated that NFC typically occurs independent of IAT, indicating the existence of different populations of damaged axons. FK506 administration has been shown to attenuate IAT. However, in light of the above, the ability of FK506 to attenuate axonal damage demonstrating NFC requires evaluation. The Current study explored the potential of FK506 to attenuate both populations of damaged axons. Rats were administered FK506 (3 mg/kg) or vehicle 30 min preinjury. Three hours post-TBI, tissue was prepared for the visualization of TAI using antibodies targeting IAT (APP) or NFC (RM014) or a combined labeling strategy. Confirming previous reports, FK506 treatment reduced the number of axons demonstrating IAT in the CSpT, from 411 +/- 54.70 to 91.00 +/- 33.87 (P <= 0.05) and in the ML from 78.62 +/- 16.87 to 41.00 +/- 5.80 (P <= 0.05). FK506 treatment failed to reduce the number of axons demonstrating NFC in either the CSpT or ML. FK506's failure to attenuate NFC suggests that additional therapeutic agents may be necessary to blunt the full burden of TAL Because FK506 targets IAT, calcineurin appears to be a major target for neuroprotection in damaged axons demonstrating IAT. (c) 2005 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jpovlish@hse.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS7288, NS-20193] Funding Source: Medline		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; Arii T, 2001, NEUROL RES, V23, P755, DOI 10.1179/016164101101199135; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BUKI A, 2001, J NEUROTRAUM, V18, P1171; Butcher SP, 1997, J NEUROSCI, V17, P6939; Drake M, 1996, ACTA PHYSIOL SCAND, V158, P155, DOI 10.1046/j.1365-201X.1996.535298000.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lofvenberg L, 1999, FEBS LETT, V443, P89, DOI 10.1016/S0014-5793(98)01697-4; MALBOUISSON AMB, 1985, ANAT EMBRYOL, V171, P339, DOI 10.1007/BF00347022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; Nito C, 2004, BRAIN RES, V1008, P179, DOI 10.1016/j.brainres.2004.02.031; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OKONKWO DO, 2002, IMMUNOSUPPRESSANT AN, P263; PANNESE E, 1984, ACTA ANAT, V118, P193; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Shields DC, 1997, EXP EYE RES, V65, P15, DOI 10.1006/exer.1997.0286; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Stys PK, 2002, NEUROSCI LETT, V328, P150, DOI 10.1016/S0304-3940(02)00469-X; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; UEDA Y, 2001, J NEUROTRAUM, V18, P1179; WATSON D, 1991, J NEUROSCI RES, V30, P226, DOI 10.1002/jnr.490300123; WITGEN BM, 2002, J NEUROTRAUM, V18, P1171	64	63	66	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2006	197	2					353	362		10.1016/j.expneurol.2005.10.003			10	Neurosciences	Neurosciences & Neurology	009RV	WOS:000235131000011	16297913				2021-06-18	
J	Kashluba, S; Casey, JE; Paniak, C				Kashluba, S; Casey, JE; Paniak, C			Evaluating the utility of ICD-10 diagnostic criteria for postconcussion syndrome following mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						longitudinal; control group; symptoms; follow-up; diagnostic criteria; adult	HEAD-INJURY; PATIENT COMPLAINTS; RANDOMIZED-TRIAL; BASE RATES; SYMPTOMS	The present study investigated the utility Of the International Classification of Diseases and Related Health Problems, 10th edition (ICD-10) diagnostic criteria for postconcussion syndrome (PCS) symptoms by comparing symptom endorsement rates in a group of patients with mild traumatic brain injury (MTBT) to those of a noninjured control group at one month and three months post-injury. The 110 MTBI patients and I 18 control participants were group-matched on age, gender, and education level. Seven of the nine self-reported ICD-10 PCS symptoms differentiated the groups at one month post-injury and two symptoms differentiated the groups at three months post-injury: symptom endorsement rates were higher in the MTBI group at both time periods. Fatiguing quickly and dizziness/vertigo best differentiated the groups at both time periods, while depression and anxiety/tension failed to differentiate the groups at either time period. Collectively, the ICD-10 PCS symptoms accurately classified the MTBI patients at one month post-injury, with the optimal positive test threshold of endorsement of five symptoms coinciding with a sensitivity and specificity of 73% and 61%, respectively. The ICD-10 PCS symptoms were unable to accurately classify the MTBI patients at three months post-injury.	Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Glenrose Rehabil Hosp, Dept Psychol Serv, Edmonton, AB, Canada	Casey, JE (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	jecasey@uwindsor.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CARROLL LJ, 1908, J REHABILITATION MED, V43, pS84; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jagoda A, 2000, EMERG MED CLIN N AM, V18, P355, DOI 10.1016/S0733-8627(05)70130-9; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Swets JA, 1996, SIGNAL DETECTION THE; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS	27	63	64	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					111	118		10.1017/S1355617706060036			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800013	16433950				2021-06-18	
J	Stevens, RD; Bhardwaj, A				Stevens, RD; Bhardwaj, A			Approach to the comatose patient	CRITICAL CARE MEDICINE			English	Article						coma; vegetative state; hypoxic-ischemic encephalopathy; traumatic brain injury; neurologic diagnosis; outcome prediction	SEVERE HEAD-INJURY; INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; HERPES-SIMPLEX ENCEPHALITIS; MINIMALLY CONSCIOUS STATES; CHRONIC HEALTH EVALUATION; NEURON-SPECIFIC ENOLASE; ACUTE PHYSIOLOGY SCORE	Background: Coma is a medical emergency and may constitute a diagnostic and therapeutic challenge for the intensivist. Objective: To review currently available data on the etiology, diagnosis, and outcome of coma. To propose an evidence-based approach for the clinical management of the comatose patient. Data Source: Search of Medline and Cochrane databases; manual review of bibliographies from selected articles and monographs. Data Synthesis and Conclusions: Coma and other states of impaired consciousness are signs of extensive dysfunction or injury involving the brainstem, diencephalon, or cerebral cortex and are associated with a substantial risk of death and disability. Management of impaired consciousness includes prompt stabilization of vital physiologic functions to prevent secondary neurologic injury, etiological diagnosis, and the institution of brain-directed therapeutic or preventive measures. Neurologic prognosis is determined by the underlying etiology and may be predicted by the combination of clinical signs and electrophysiological tests.	Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Dept Anesthesiol Crit Care Med Neurol & Neurosurg, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Stevens, RD (corresponding author), Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Dept Anesthesiol Crit Care Med Neurol & Neurosurg, Baltimore, MD 21218 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046379] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 046379] Funding Source: Medline		ACKERMANN H, 1995, FORTSCHR NEUROL PSYC, V63, P59, DOI 10.1055/s-2007-996603; ADAMS HP, 1985, NEUROLOGY, V35, P1263, DOI 10.1212/WNL.35.9.1263; AdelsonMitty J, 1997, INTENS CARE MED, V23, P749, DOI 10.1007/s001340050404; American Psychiatric Association, 1994, TASK FORC DSM 4 DIAG, V4th; American Psychiatric Association, 2000, TASK FORC DSM 4 DIAG; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Bateman DE, 2001, J NEUROL NEUROSUR PS, V71, P13; Bates D, 2001, J NEUROL NEUROSUR PS, V71, P20; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER KJ, 1997, CURRENT THERAPY NEUR; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Burns A, 2004, J NEUROL NEUROSUR PS, V75, P362, DOI 10.1136/jnnp.2003.023366; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; Cartlidge N, 2001, J NEUROL NEUROSUR PS, V71, P18; Chalela JA, 2001, NEUROLOGY, V56, P481, DOI 10.1212/WNL.56.4.481; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHIEN LT, 1977, ARCH NEUROL-CHICAGO, V34, P361, DOI 10.1001/archneur.1977.00500180055011; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Coleman MR, 2005, J NEUROL NEUROSUR PS, V76, P432, DOI 10.1136/jnnp.2004.045930; COLICE GL, 1984, AM REV RESPIR DIS, V130, P941; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; DAUBE JR, 1993, NEUROLOGY, V43, P625; Douglas NJ, 2001, J NEUROL NEUROSUR PS, V71, P3; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Finelli PF, 2004, J NEUROL NEUROSUR PS, V75, P1189, DOI 10.1136/jnnp.2003.030833; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Hasbun R, 2001, NEW ENGL J MED, V345, P1727, DOI 10.1056/NEJMoa010399; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Hollinger P, 2000, J NEUROL, V247, P232, DOI 10.1007/s004150050573; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kaplan PW, 2004, J CLIN NEUROPHYSIOL, V21, P307; Kaplan PW, 1999, CLIN NEUROPHYSIOL, V110, P205, DOI 10.1016/S1388-2457(98)00046-7; KARKELA J, 1992, CRIT CARE MED, V20, P378; Kaye AH, 2000, LANCET, V356, P1540, DOI 10.1016/S0140-6736(00)03121-4; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kunze K, 2002, J NEUROL, V249, P1150, DOI 10.1007/s00415-002-0869-z; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Liu GT, 1999, NEUROSURG CLIN N AM, V10, P579, DOI 10.1016/S1042-3680(18)30159-1; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; McNicoll L, 2003, J AM GERIATR SOC, V51, P591, DOI 10.1034/j.1600-0579.2003.00201.x; Mesulam M., 2000, PRINCIPLES BEHAV COG; Metersky ML, 1997, CLIN INFECT DIS, V25, P285, DOI 10.1086/514531; MORUZZI G, 1995, J NEUROPSYCH CLIN N, V7, P251; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; PLUM F, 1980, CONT NEUROLOGY SERIE, V19; Qureshi AI, 2000, CRIT CARE MED, V28, P984, DOI 10.1097/00003246-200004000-00012; Rafanan AL, 2000, CRIT CARE MED, V28, P1306, DOI 10.1097/00003246-200005000-00008; Restrepo L, 2002, STROKE, V33, P2909, DOI 10.1161/01.STR.0000040408.75704.15; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Rordorf G, 2000, CRIT CARE MED, V28, P1301, DOI 10.1097/00003246-200005000-00007; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; SAMUELS MA, 1993, NEUROL CLIN, V11, P273; SAUNDERS DE, 1995, STROKE, V26, P2272, DOI 10.1161/01.STR.26.12.2272; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SEGATORE M, 1992, HEART LUNG, V21, P548; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smith E, 2005, BMJ-BRIT MED J, V330, P406, DOI 10.1136/bmj.330.7488.406; SMITH JB, 1975, MAYO CLIN PROC, V50, P469; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Sulter G, 2003, STROKE, V34, P101, DOI 10.1161/01.STR.0000048148.09143.6C; Taylor MA, 2003, AM J PSYCHIAT, V160, P1233, DOI 10.1176/appi.ajp.160.7.1233; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thompson BT, 2004, CRIT CARE MED, V32, P1781, DOI 10.1097/01.CCM.0000126895.66850.14; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213; TUHRIM S, 1991, ANN NEUROL, V29, P658, DOI 10.1002/ana.410290614; van de Beek D, 2004, NEW ENGL J MED, V351, P1849, DOI 10.1056/NEJMoa040845; Varelas PN, 2003, NEUROLOGY, V61, P702, DOI 10.1212/01.WNL.0000078812.36581.97; Vargas F, 2000, INTENS CARE MED, V26, P623, DOI 10.1007/s001340051213; Varon J, 2000, CHEST, V118, P214, DOI 10.1378/chest.118.1.214; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; WIJDICKS EFM, 2002, CONT NEUROLOGY SERIE, V64; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6; Wityk RJ, 2001, ARCH NEUROL-CHICAGO, V58, P571, DOI 10.1001/archneur.58.4.571; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; Young GB, 1999, ARCH NEUROL-CHICAGO, V56, P153, DOI 10.1001/archneur.56.2.153; Young GB, 2004, J CLIN NEUROPHYSIOL, V21, P379; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263; ZIAI WC, 2004, HDB NEUROCRITICAL CA; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; 2002, NEUROSURGERY, V50, pS7	122	63	72	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2006	34	1					31	41		10.1097/01.CCM.0000194534.42661.9F			11	Critical Care Medicine	General & Internal Medicine	999IB	WOS:000234381900005	16374153				2021-06-18	
J	Farkas, O; Polgar, B; Szekeres-Bartho, J; Doczi, T; Povlishock, JT; Buki, A				Farkas, O; Polgar, B; Szekeres-Bartho, J; Doczi, T; Povlishock, JT; Buki, A			Spectrin breakdown products in the cerebrospinal fluid in severe head injury - preliminary observations	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; calpain; caspase; spectrin; human; cerebrospinal fluid	TRAUMATIC BRAIN-INJURY; CALPAIN ACTIVATION; ALPHA-SPECTRIN; AXONAL INJURY; II-SPECTRIN; PROTEOLYSIS; CASPASE; RAT; DEGRADATION; CULTURES	Background. Calcium-induced proteolytic processes are considered key players in the progressive pathobiology of traumatic brain injury (TBI). Activation of calpain and caspases after TBI leads to the cleavage of cytoskeletal proteins such as non-erythroid alpha II-spectrin. Recent reports demonstrate that the levels of spectrin and spectrin breakdown products (SBDPs) are elevated in vitro after mechanical injury, in the cerebrospinal fluid (CSF) and brain tissue following experimental TBI, and in human brain tissue after TBI. Methods. This study was initiated to detect spectrin and SBDP accumulation in the ventricular CSF of 12 severe TBI-patients with raised intracranial pressure (ICP). Nine patients with non-traumatically elevated ICP and 5 undergoing diagnostic lumbar puncture (LP) served as controls. Intact spectrin and calpain and caspase specific SBDPs in CSF collected once a day over a several day period were assessed via Western blot analysis. Parameters of severity and outcome such as ICP, Glasgow Coma Scale and Glasgow Outcome Scale were also monitored in order to reveal a potential correlation between these CSF markers and clinical parameters. Results. In control patients undergone LP no immunoreactivity was detected. Non-erythroid alpha-II-spectrin and SBDP occurred more frequently and their level was significantly higher in the CSF of TBI patients than in other pathological conditions associated with raised ICP. Those TBI patients followed for several days post-injury revealed a consistent temporal pattern for protein accumulation with the highest level achieved on the 2(nd)-3(rd) days after TBI. Conclusion. Elevation of calpain and caspase specific SBDPs is a significant finding in TBI patients indicating that intact brain spectrin- and SBDP-levels are closely associated with the specific neurochemical processes evoked by TBI. The results strongly support the potential utility of these surrogate markers in the clinical monitoring of patients with severe TBI and provide further evidence of the role of calcium-induced, calpain- and caspase-mediated structural proteolysis in TBI.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Ctr Med & Hlth Sci, Dept Neurosurg, Pecs, Hungary	Farkas, O (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA.	ofarkas@vcu.edu	Doczi, Tamas/C-5750-2009; Buki, Andras/B-1960-2010				Banik NL, 2000, METH MOL B, V144, P195; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Brana C, 1999, EUR J NEUROSCI, V11, P2375, DOI 10.1046/j.1460-9568.1999.00653.x; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Del Bigio MR, 2000, J NEUROPATH EXP NEUR, V59, P946, DOI 10.1093/jnen/59.11.946; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEWIN ICF, 1992, HEAD INJURIES COST C; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; PIKE BR, 1978, J NEUROCHEM, V78, P1297; RINGGER MC, 2002, J NEUROTRAUM, V19, P1302; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4	21	63	65	0	0	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	AUG	2005	147	8					855	861		10.1007/s00701-005-0559-6			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	950FY	WOS:000230844200014	15924207				2021-06-18	
J	Pelinka, LE; Hertz, H; Mauritz, W; Harada, N; Jafarmadar, M; Albrecht, M; Redl, H; Bahrami, S				Pelinka, LE; Hertz, H; Mauritz, W; Harada, N; Jafarmadar, M; Albrecht, M; Redl, H; Bahrami, S			Nonspecific increase of systemic neuron-specific enolase after trauma: Clinical and experimental findings	SHOCK			English	Article						cerebral trauma; extra-cranial trauma; ischemia; multiple trauma; neuron-specific enolase; reperfusion	BRAIN-DAMAGE; CEREBROSPINAL-FLUID; SERUM S100B; MARKERS; PROTEIN; INJURY; REPERFUSION; CIRCULATION; PREDICTOR; ISCHEMIA	The aim of this clinical and experimental study was to determine whether systemic neuron-specific enolase (NSE) is a useful early marker of traumatic brain injury (TBI) and whether NSE is affected by ischemia/reperfusion damage of abdominal organs. Our study included patients with and without TBI (verified by computerized tomography) admitted within 6 h after trauma and male Sprague-Dawley rats with ischemia and reperfusion of the abdominal organs liver, gut, or kidney. Thirty-eight study patients included 13 with isolated TBI and 18 patients with multiple trauma and TBI. Seven patients had multiple trauma but no TBI. Fifteen rats were anaesthetized and subjected to isolated ischemia of the liver, gut, or kidney (n = 5 each) for 1 h, followed by reperfusion for 3 h. In patients, NSE increased over 2-fold versus the upper normal limit (10 mu g/L) within 6 h after trauma, regardless of whether TBI had occurred or not. In rats, NSE increased over 3-fold versus laboratory controls during ischemia of the liver and kidney (both P < 0.0005), but not of the gut. NSE increased over 2-fold after onset of reperfusion of the liver and kidney (both P < 0.05), but not of the gut and increased over 3-fold after 3 h of reperfusion of the liver, gut (both P < 0.005), and kidney (P < 0.0005). Our data show that systemic NSE increases to similar degrees with and without TBI. Therefore, NSE is not a useful early marker of TBI in multiple trauma.	Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr, Allgemeine Unfallversicherungsanstalt, A-1200 Vienna, Austria; Lorenz Boehler Trauma Ctr, Allgemeine Unfallversicherungsanstalt, A-1200 Vienna, Austria; Fukuoka Univ, Inst Pharmacol, Jonan Ku, Fukuoka 8140180, Japan	Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr, Allgemeine Unfallversicherungsanstalt, Donaueschingenstr 13, A-1200 Vienna, Austria.	lindapel@via.at	Redl, Heinz/AAD-8157-2019	Bahrami, Soheyl/0000-0002-4563-6251; Mauritz, Walter/0000-0001-9043-3712			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Ashburn JH, 2004, SHOCK, V22, P120, DOI 10.1097/01.shk.0000127683.26493.e4; BOCK E, 1975, SCAND J IMMUNOL, P31; BRADLEY HE, 1994, MONITORING CENTRAL N, P26; CHRISTENSEN EI, 1991, SEMIN NEPHROL, V11, P414; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Cucullo L, 2002, BRAIN RES, V951, P243, DOI 10.1016/S0006-8993(02)03167-0; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; FLETCHER L, 1976, BIOCHIM BIOPHYS ACTA, V452, P245, DOI 10.1016/0005-2744(76)90077-2; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; Harada N, 1999, CRIT CARE MED, V27, P1958, DOI 10.1097/00003246-199909000-00040; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; JENNETT B, 1975, LANCET, V1, P480; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Snyder-Ramos SA, 2003, RESTOR NEUROL NEUROS, V21, P123; Sobhian B, 2005, SHOCK, V23, P243, DOI 10.1097/01.shk.0000150775.93741.6f; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378	32	63	66	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	AUG	2005	24	2					119	123		10.1097/01.shk.0000168876.68154.43			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	952SV	WOS:000231026700004	16044081				2021-06-18	
J	Morali, G; Letechipia-Vallejo, G; Lopez-Loeza, E; Montes, P; Hernandez-Morales, L; Cervantes, M				Morali, G; Letechipia-Vallejo, G; Lopez-Loeza, E; Montes, P; Hernandez-Morales, L; Cervantes, M			Post-ischemic administration of progesterone in rats exerts neuroprotective effects on the hippocampus	NEUROSCIENCE LETTERS			English	Article						global cerebral ischemia; hippocampal pyramidal neurons; CA1; neuroprotection; progesterone; 4VO	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; DAMAGE; ISCHEMIA; PROTECTS; STROKE; MODEL; ACID	Progesterone is neuroprotective in models of focal or global ischemia when treatment starts either before the insult or at the onset of reperfusion. In these cases the steroid may act during the occurrence of the early pathophysiological events triggered by ischemia or reperfusion. As opposed to this condition, the aim of the present study was to assess the effect of delayed, post-injury administration of progesterone on the preservation of pyramidal neurons of the hippocampus of rats 21 days after been exposed to global ischemia by the four vessel occlusion model. Progesterone (8 mg/kg, i.v.) or its vehicle, were administered at 20 min, 2, 6, and 24 h after the end of ischemia. At histological examination, brains of the ischemic vehicle-treated rats showed a severe reduction of the population of pyramidal neurons in the CA1 and CA2 subfields (12% and 29% remaining neurons, respectively), and a less severe neuronal loss in the CA3 and CA4 subfields of the hippocampus (68% and 63% remaining neurons, respectively), as compared to rats exposed to sham procedures. They also showed a two-fold enlargement of the lateral ventricles and 33% shrinkage of the cerebral cortex as compared to the sham group. Progesterone treatment resulted in a significant preservation of pyramidal neurons in CA1 and CA2 (40% and 62% remaining neurons), with no ventricular dilation and only a mild (12%) cortical shrinkage. Results suggest that progesterone, is able to interfere with some late pathophysiological mechanisms leading both to selective neuronal damage in the hippocampal CA1 and CA2 subfields, and to shrinkage of the cerebral cortex. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	IMSS, CMN Siglo 21, Unidad Invest Med Farmacol, Mexico City 03100, DF, Mexico; Univ Michoacana, Fac Med, Morelia 58240, Michoacan, Mexico; IMSS, Ctr Invest Biomed Michoacan, Lab Neurofarmacol, Morelia 58240, Michoacan, Mexico	Morali, G (corresponding author), IMSS, CMN Siglo 21, Unidad Invest Med Farmacol, Eugenia 626 Girasol 302,Col Valle, Mexico City 03100, DF, Mexico.	gmorali@hotmail.com	Morali, Gabriela/AAH-8014-2020	Montes, Pedro/0000-0003-1630-5047			Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; DOWNIE MM, 1983, BASIC STAT METHODS; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; GWAG BJ, 2002, METH NE FRO NEUROSCI, P79; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kraemer M, 2004, J NEUROIMAGING, V14, P265, DOI 10.1177/1051228404264950; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LUNA G, 1960, MANUAL HISTOLOGIC ST; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; Roine R.O., 1997, CURRENT REV CEREBROV, P159; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarraf-Yazdi S, 1999, NEUROL DIS, V48, P243; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Siegel S., 1956, NONPARAMETRIC STAT B; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	32	63	66	1	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUL 15	2005	382	3					286	290		10.1016/j.neulet.2005.03.066			5	Neurosciences	Neurosciences & Neurology	939IK	WOS:000230065800017	15885907				2021-06-18	
J	Bennett, PC; Ong, B; Ponsford, J				Bennett, PC; Ong, B; Ponsford, J			Measuring executive dysfunction in an acute rehabilitation setting: Using the Dysexecutive Questionnaire (DEX)	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						dysexecutive questionnaire (DEX); executive dysfunction (ED); behavioral assessment of the dysexecutive syndrome (BADS); clinical neuropsychology	CARD SORTING TEST; FRONTAL-LOBE DAMAGE; HEAD-INJURY; BEHAVIORAL-ASSESSMENT; PERFORMANCE; VALIDITY; DEFICITS; ABILITY; SAMPLE	It is recognized that existing neuropsychological measures of executive dysfunction lack adequate sensitivity and selectivity. While attempts have been made to develop improved measures, these have not yet been of great value to those who need to accurately identify executive deficits in a clinical setting. Several behavioral rating scales have been developed for this reason, including the 20-item Dysexecutive Questionnaire (DEX), which forms part of the Behavioral Assessment of the Dysexecutive Syndrome (BADS) test battery. To investigate the ability of the DEX to identify executive dysfunction in an acute rehabilitation setting, the BADS was administered to 64 persons who had sustained traumatic brain injury. It was found to be almost as sensitive to executive dysfunction, as measured by the total score obtained on the BADS battery, as an extended 65-item version of the scale, when completed by either the occupational therapist or clinical neuropsychologist working with each patient. Family members and the patient themselves provided, as expected, less accurate information. Our results indicate that the DEX can be used with some confidence as a screening instrument to identify executive dysfunction in an acute rehabilitation setting, provided it is completed by professional personnel, trained to be sensitive to the cognitive and behavioral concomitants of this disorder.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Dept Psychol, Caulfield, Vic 3145, Australia; La Trobe Univ, Sch Psychol Sci, Bundoora, Vic, Australia	Bennett, PC (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Dept Psychol, POB 197, Caulfield, Vic 3145, Australia.	p.bennett@med.monash.edu.au	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			ALDERMAN N, 1993, J CLIN EXP NEUROPSYC, V15, P69; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Banich M. T, 1997, NEUROPSYCHOLOGY NEUR; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Bryan J, 2000, J CLIN EXP NEUROPSYC, V22, P40, DOI 10.1076/1380-3395(200002)22:1;1-8;FT040; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P209, DOI 10.1080/713755574; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Greve KW, 1997, BRIT J CLIN PSYCHOL, V36, P283, DOI 10.1111/j.2044-8260.1997.tb01414.x; Handler J., 1994, HANDB NEUR, P125; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Levin HS, 1989, NEUROPSYCHOLOGY, V3, P243, DOI 10.1037//0894-4105.3.4.243; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Nelson HE, 1982, NATL ADULT READING T; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; RICCIO CA, 1994, DEV NEUROPSYCHOL, V10, P215, DOI 10.1080/87565649409540580; ROSENTHAL M, 1992, NEUROREHABILITATION, V2, P1; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tabachnick BG, 2013, USING MULTIVARIATE S; VANDENBROEK MD, 1993, BRIT J CLIN PSYCHOL, V32, P333; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wilson BA, 1996, BEHAV ASSESSMENT DYS; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135	40	63	65	2	19	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2005	11	4					376	385		10.1017/S1355617705050423			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	948UY	WOS:000230742400004	16209417				2021-06-18	
J	Rodriguez-Paez, AC; Brunschwig, JP; Bramlett, HM				Rodriguez-Paez, AC; Brunschwig, JP; Bramlett, HM			Light and electron microscopic assessment of progressive atrophy following moderate traumatic brain injury in the rat	ACTA NEUROPATHOLOGICA			English	Article						progressive atrophy; inflammation; macrophages/microglia; traumatic brain injury; white matter	AMYLOID PRECURSOR PROTEIN; ENDOTHELIAL GROWTH-FACTOR; NONDISRUPTIVE AXONAL INJURY; NITRIC-OXIDE SYNTHASE; CLOSED-HEAD-INJURY; OPTIC-NERVE FIBERS; INFLAMMATORY RESPONSE; STRETCH-INJURY; WHITE-MATTER; POSTTRAUMATIC HYPOTHERMIA	The presence of progressive white matter atrophy following traumatic brain injury (TBI) has been reported in humans as well as in animal models. However, a quantitative analysis of progressive alterations in myelinated axons and other cellular responses to trauma has not been conducted. This study examined quantitative differences in myelinated axons from several white and gray matter structures between non-traumatized and traumatized areas at several time points up to 1 year. We hypothesize that axonal numbers decrease over time within the structures analyzed, based on our previous work demonstrating shrinkage of tissue in these vulnerable areas. Intubated, anesthetized male Sprague-Dawley rats were subjected to moderate (1.8-2.2 atm) parasagittal fluid-percussion brain injury, and perfused at various intervals after surgery. Sections from the fimbria, external capsule, thalamus and cerebral cortex from the ipsilateral hemisphere of traumatized and sham-operated animals were prepared and. estimated total numbers of myelinated axons were determined by systematic random sampling. Electron micrographs were obtained for ultrastructural analysis. A significant (P < 0.05) reduction in the number of myelinated axons in the traumatized hemisphere compared to control in all structures was observed. In addition, thalamic and cortical axonal counts decreased significantly (P < 0.05) over time. Swollen axons and macrophage/microglia infiltration were present as late as 6 months post-TBI in various structures. This study is the first to describe quantitatively chronic axonal changes in vulnerable brains regions after injury. Based on these data, a time-dependent decrease in the number of myelinated axons is seen to occur in vulnerable gray matter regions including the cerebral cortex and thalamus along with distinct morphological changes within white matter tracts after TBI. Although this progressive axonal response to TBI may include Wallerian degeneration, other potential mechanisms underlying this progressive pathological response within the white matter are discussed.	Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Neurosurg, Miami Project Cure Paralysis,Neurotrauma Res Ctr, Miami, FL 33152 USA	Bramlett, HM (corresponding author), Univ Miami, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	hbramlett@miami.edu					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; CRUTCHER KA, 1990, ACTA NEUROBIOL EXP, V50, P115; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; Gahm C, 2000, NEUROSURGERY, V46, P169; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Grad S, 1998, CLIN CHEM LAB MED, V36, P379, DOI 10.1515/CCLM.1998.064; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HUGHES CCW, 1987, J NEUROL SCI, V79, P101, DOI 10.1016/0022-510X(87)90264-4; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KIMBELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Lu J, 2003, NEUROSCI LETT, V339, P147, DOI 10.1016/S0304-3940(03)00003-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MURPHY S, 1987, NEUROSCIENCE, V22, P381, DOI 10.1016/0306-4522(87)90342-3; Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Peters A., 1976, FINE STRUCTURE NERVO; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VEGA JA, 1994, MECH AGEING DEV, V73, P9, DOI 10.1016/0047-6374(94)90033-7; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WEST RW, 1993, CARCINOGENESIS, V14, P285, DOI 10.1093/carcin/14.2.285	86	63	64	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2005	109	6					603	616		10.1007/s00401-005-1010-z			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	940KE	WOS:000230142600007	15877231				2021-06-18	
J	Haley, SM; Raczek, AE; Coster, WJ; Dumas, HM; Fragala-Pinkham, MA				Haley, SM; Raczek, AE; Coster, WJ; Dumas, HM; Fragala-Pinkham, MA			Assessing mobility in children using a computer adaptive testing version of the Pediatric Evaluation of Disability Inventory	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						outcome assessment (health care); pediatrics; rehabilitation	ITEM RESPONSE THEORY; TRAUMATIC BRAIN INJURY; MEASURING OUTCOMES; REHABILITATION; SIMULATION; MODEL	Objective: To assess score agreement, validity, precision, and response burden of a prototype computerized adaptive testing (CAT) version of the Mobility Functional Skills Scale (Mob-CAT) of the Pediatric Evaluation of Disability Inventory (PEDI) as compared with the full 59-item version (Mob-59). Design: Computer simulation analysis of cross-sectional and longitudinal retrospective data; and cross-sectional prospective study. Setting: Pediatric rehabilitation hospital, including inpatient acute rehabilitation, day school program, outpatient clinics, community-based day care, preschool, and children's homes. Participants: Four hundred sixty-nine children with disabilities and 412 children with no disabilities (analytic sample); 41 children without disabilities and 39 with disabilities (cross-validation sample). Interventions: Not applicable. Main Outcome Measures: Summary scores from a prototype Mob-CAT application and versions using 15-, 10-, and 5-item stopping rules; scores from the Mob-59; and number of items and time (in seconds) to administer assessments. Results: Mob-CAT scores from both computer simulations (intraclass correlation coefficient [ICC] range, .94-.99) and field administrations (ICC = .98) were in high agreement with scores from the Mob-59. Using computer simulations of retrospective data, discriminant validity, and sensitivity to change of the Mob-CAT closely approximated that of the Mob-59, especially when using the 15- and 10-item stopping rule versions of the Mob-CAT. The Mob-CAT used no more than 15% of the items for any single administration, and required 20% of the time needed to administer the Mob-59. Conclusions: Comparable score estimates for the PEDI mobility scale can be obtained from CAT administrations, with losses in validity and precision for shorter forms, but with a considerable reduction in administration time.	Boston Univ, Hlth & Disabil Res Inst, Boston, MA 02215 USA; QualityMetr Inc, Lincoln, RI USA; Franciscan Childrens Hosp, Res Ctr Children Special Hlth Care Needs, Boston, MA USA	Haley, SM (corresponding author), Boston Univ, Hlth & Disabil Res Inst, 53 Bay State Rd, Boston, MA 02215 USA.	smhaley@bu.edu	Fragala-Pinkham, Maria/AAY-4354-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD042388, K02HD045354] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02 HD45354-01A1, R43 HD42388-01] Funding Source: Medline		ANDRICH D, 1998, RASCH MODELS MEASURE; Bedell GM, 2002, BRAIN INJURY, V16, P659, DOI 10.1080/02699050210128924; Bjorner JB, 2003, QUAL LIFE RES, V12, P981, DOI 10.1023/A:1026123400242; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P1189, DOI 10.1016/S0895-4356(98)00111-5; Bjorner JB, 2003, QUAL LIFE RES, V12, P913, DOI 10.1023/A:1026163113446; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, P384, DOI 10.1053/apmr.2003.50006; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; Dumas HM, 2001, BRAIN INJURY, V15, P891, DOI 10.1080/02699050110065691; Embretson S. E., 2000, ITEM RESPONSE THEORY, P123; Engelbert RHH, 1997, PEDIAT PHYS THER, V9, P18; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; Fischer GH, 1995, RASCH MODELS FDN REC; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; GOLDBERG MJ, 1991, J PEDIATR ORTHOPED, V11, P682; Granger C., 1996, CHILD SPINAL CORD IN, P709; Haley S.M., 1992, PEDIAT EVALUATION DI; Haley S. M., 1993, PHYS MED REH CLIN N, V4, P529; HALEY SM, 1992, MED SPORT SCI, V36, P278; Haley SM, 2004, ARCH PHYS MED REHAB, V85, P661, DOI 10.1016/j.apmr.2003.08.097; Haley SM, 2001, PHYS THER, V81, P1425, DOI 10.1093/ptj/81.8.1425; HALEY SM, 1991, PHYS MED REH CLIN N, V2, P689; HALEY SM, 2000, ORTHOP PHYS THER CLI, V9, P17; Hambleton R. K., 1991, FUNDAMENTALS ITEM RE; Hays RD, 2000, MED CARE, V38, P28; Iyer LV, 2003, PHYS THER, V83, P888, DOI 10.1093/ptj/83.10.888; Kothari DH, 2003, PHYS THER, V83, P776, DOI 10.1093/ptj/83.9.776; Law M, 1999, ARCH PHYS MED REHAB, V80, P629, DOI 10.1016/S0003-9993(99)90164-8; Lollar DJ, 2000, ARCH PHYS MED REHAB, V81, pS46, DOI 10.1053/apmr.2000.20624; Ludlow L H, 2000, J Outcome Meas, V4, P482; Ludlow LH, 1996, EDUC PSYCHOL MEAS, V56, P122, DOI 10.1177/0013164496056001008; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MISLEVY RJ, 1986, J EDUC STAT, V11, P3, DOI 10.3102/10769986011001003; Msall ME, 2002, PEDIATRICS, V109, P317, DOI 10.1542/peds.109.2.317; MUTHEN S, 1998, MPLUS USERS GUIDE; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; Norrlin S, 2003, ACTA PAEDIATR, V92, P204; Ostensjo S, 2003, DEV MED CHILD NEUROL, V45, P603, DOI 10.1017/S0012162203001105; Ottenbacher KJ, 2000, AM J PHYS MED REHAB, V79, P114, DOI 10.1097/00002060-200003000-00002; Revicki DA, 1997, QUAL LIFE RES, V6, P595, DOI 10.1023/A:1018420418455; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TJUR T, 1982, SCAND J STAT, V9, P23; Tsai PY, 2002, CHILD NERV SYST, V18, P48, DOI 10.1007/s00381-001-0531-6; Turk M., 1997, ASSESSING MED REHABI, P367; van der Linden W.J., 1997, HDB MODERN ITEM RESP; VERHELST ND, 1995, ONEPARAMETER LOGISTI; Wainer H, 2000, COMPUTERIZED ADAPTIV; Ware JE, 2003, QUAL LIFE RES, V12, P935, DOI 10.1023/A:1026115230284; Ware JE, 2003, ARCH PHYS MED REHAB, V84, pS43, DOI 10.1053/apmr.2003.50246; Ware JE, 2000, MED CARE, V38, P73; WARM TA, 1989, PSYCHOMETRIKA, V54, P427, DOI 10.1007/BF02294627; Wright FV, 1993, CAN J REHABIL, V7, P41; YEN WM, 1993, J EDUC MEAS, V30, P187, DOI 10.1111/j.1745-3984.1993.tb00423.x; YOUNG NL, 1995, J PEDIATR ORTHOPED, V15, P244	54	63	63	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					932	939		10.1016/j.apmr.2004.10.032			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	928NM	WOS:000229278500013	15895339				2021-06-18	
J	Neary, JT; Kang, Y; Tran, M; Feld, J				Neary, JT; Kang, Y; Tran, M; Feld, J			Traumatic injury activates protein kinase B/Akt in cultured astrocytes: Role of extracellular ATP and P2 purinergic receptors	JOURNAL OF NEUROTRAUMA			English	Article						Akt; ATP; ERK; gliosis; protein kinases; purinergic receptors; trauma	STRETCH-INDUCED INJURY; DNA-SYNTHESIS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; NEURONAL SURVIVAL; BRAIN-INJURY; RELEASE; CALCIUM; AKT; MECHANISMS	Protein kinase B/Akt is a key signaling molecule that regulates cell survival, growth, and metabolism, and inhibits apoptosis. Traumatic brain injury (TBI) activates Akt, and. Akt has been implicated in neuronal survival after TBI, but little is known about injury-induced Akt activation in astrocytes, cells that exhibit hypertrophic and hyperplastic responses to CNS injury. Here we have investigated the effect of mechanical strain on Akt activation in primary cultures of rat cortical astrocytes growing on deformable Silastic membranes. When astrocytes were subjected to mechanical strain (50 msec; 5-7.5 mm displacement), we observed an increase in phosphorylation of serine 473, a key indicator of Akt activation. Akt phosphorylation was increased at 3 min postinjury, was maximal from 5 to 10 min, and declined gradually thereafter. Akt activation was also dependent on the severity of the injury. Stretch-induced Akt phosphorylation was attenuated by blocking calcium influx and phosphoinositide 3-kinase (PI3K), an upstream activator of Akt. In addition, we found that ATP is rapidly released after mechanical strain and that the P2 purinergic receptor antagonist iso-pyridoxal-5'-phosphate-6-azophenyl-2',5'disulfonate (PPADS) attenuated trauma-induced Akt activation. We conclude that mechanical strain causes activation of Akt in astrocytes via stimulation of P2 receptors. This suggests that P2 receptor/Akt signaling promotes astrocyte survival and growth, and this process may play a role in the generation of reactive gliosis after TBI.	Univ Miami, Sch Med, Res Serv,VA Med Ctr, Dept Pathol, Miami, FL 33125 USA; Univ Miami, Sch Med, Res Serv,VA Med Ctr, Dept Biochem, Miami, FL 33125 USA; Univ Miami, Sch Med, Res Serv,VA Med Ctr, Mol Biol & Neurosci Program, Miami, FL 33125 USA	Neary, JT (corresponding author), Univ Miami, Sch Med, Res Serv,VA Med Ctr, Dept Pathol, 1201 NW 16th St, Miami, FL 33125 USA.	jneary@med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046651] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 46651] Funding Source: Medline		ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; Adam RM, 2003, J UROLOGY, V169, P2388, DOI 10.1097/01.ju.0000063980.99368.35; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Anderson CM, 2004, J NEUROCHEM, V88, P246, DOI 10.1046/j.1471-4159.2003.02204.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; BODIN P, 1992, P ROY SOC B-BIOL SCI, V247, P131, DOI 10.1098/rspb.1992.0019; Bolego C, 1997, BRIT J PHARMACOL, V121, P1692, DOI 10.1038/sj.bjp.0701294; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; CHAN TO, 2001, UNPUB AKT SCI S 0123; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cheng AW, 2003, J BIOL CHEM, V278, P7591, DOI 10.1074/jbc.M207232200; Chorna NE, 2004, J NEUROCHEM, V91, P119, DOI 10.1111/j.1471-4159.2004.02699.x; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014-5793(03)00055-3; Deb TB, 2004, J BIOL CHEM, V279, P38903, DOI 10.1074/jbc.M405314200; Egea J, 2001, J CELL BIOL, V154, P585, DOI 10.1083/jcb.200101023; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frank C, 1999, J Sci Med Sport, V2, P190, DOI 10.1016/S1440-2440(99)80173-X; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Haga M, 2003, ENDOTHELIUM-J ENDOTH, V10, P149, DOI 10.1080/713715223; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jiang LH, 2000, MOL PHARMACOL, V58, P82; Jiang ZJ, 2002, BIOCHEM BIOPH RES CO, V294, P726, DOI 10.1016/S0006-291X(02)00540-5; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Khakh BS, 2001, PHARMACOL REV, V53, P107; Knight GE, 2002, AM J PHYSIOL-RENAL, V282, pF281, DOI 10.1152/ajprenal.00293.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI KM, 1991, J NEUROCHEM, V57, P1510, DOI 10.1111/j.1471-4159.1991.tb06345.x; Lenz G, 2000, BRIT J PHARMACOL, V129, P927, DOI 10.1038/sj.bjp.0703138; Murashov AK, 2001, MOL BRAIN RES, V93, P199, DOI 10.1016/S0169-328X(01)00212-1; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Namikawa K, 2000, J NEUROSCI, V20, P2875; NEARY JT, 1992, PROG BRAIN RES, V94, P145; NEARY JT, 1994, J NEUROCHEM, V63, P490; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Perez-Garcia MJ, 2004, J BIOL CHEM, V279, P6132, DOI 10.1074/jbc.M308367200; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Ralevic V, 1998, PHARMACOL REV, V50, P413; RATHBONE MP, 1992, NEUROSCI RES, V13, P1, DOI 10.1016/0168-0102(92)90030-G; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schwiebert ER, 2001, CLIN EXP PHARMACOL P, V28, P340, DOI 10.1046/j.1440-1681.2001.03451.x; Sedding DG, 2003, CIRCULATION, V108, P616, DOI 10.1161/01.CIR.0000079102.08464.E2; SHREIBER D, 1995, P 1995 INT RES C BIO; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	60	63	63	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2005	22	4					491	500		10.1089/neu.2005.22.491			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	920YM	WOS:000228731400006	15853465				2021-06-18	
J	Knight, RG; Harnett, M; Titov, N				Knight, RG; Harnett, M; Titov, N			The effects of traumatic brain injury on the predicted and actual performance of a test of prospective remembering	BRAIN INJURY			English	Article							PROSPECTIVE MEMORY; SELF-AWARENESS; DEFICITS; ADULTS; EVENT; FAILURE; DAMAGE; TIME	Primary objective: The aim of the present study was to assess prospective memory ( PM) with a video-based task using naturalistic stimuli, in a group with long-term disabilities resulting from traumatic brain injury (TBI). The specific focus of the research was on comparing the accuracy of the TBI and control groups' estimates of successful completion of the prospective memory tasks. Research design: A group of 25 persons with TBI and 20 matched controls were compared on the video-based test of prospective remembering, on a test of retrospective memory ( the Logical Memory sub-test of the Wechsler Memory Scale) and tests of executive dysfunction. Correlations between the neuropsychological and PM test scores were calculated and an item analysis of the PM test was undertaken. Procedures: For the PM test, participants were given a scenario involving a robbery, and a list of tasks to be completed in a nearby city centre. The instructions were given twice and on the second occasion they were asked to rate the likelihood of remembering each item. They then watched a videotaped segment showing the perspective of a person first driving and then walking through an unfamiliar city. Their task was to recall each instruction when a relevant cue appeared. Outcomes and results: The TBI group ratings of likelihood of recalling items were entirely equivalent to those made by the controls. On the PM test, however, their performance was significantly reduced. The performance of the TBI group on the PM test was correlated with scores on the Logical Memory and verbal fluency measures. Conclusions: The results showed that, although the TBI group performed more poorly on the PM task, their expectations about how much they would remember were comparable to those of the controls. The findings suggest that persons with TBI may have unrealistic expectations about how much they will remember in a novel situation. Awareness and acceptance of cognitive changes after TBI can be a significant issue for rehabilitation.	Univ Otago, Dept Psychol, Dunedin, New Zealand	Knight, RG (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin, New Zealand.	rknight@psy.otago.ac.nz		Titov, Nickolai/0000-0002-7268-729X; Fountain, Mairead/0000-0003-0575-5368			Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Cherry KE, 2001, MEMORY, V9, P177, DOI 10.1080/09658210143000092; CICERONE KD, ARCH PHYSL MED REHAB, V81, P1596; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Katai S, 2003, J NEUROL NEUROSUR PS, V74, P704, DOI 10.1136/jnnp.74.6.704; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KRINSKY R, 1985, ACTA PSYCHOL, V58, P141, DOI 10.1016/0001-6918(85)90004-6; Marsh RL, 2000, APPL COGNITIVE PSYCH, V14, pS29, DOI 10.1002/acp.769; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDermott K, 2004, APPL COGNITIVE PSYCH, V18, P349, DOI 10.1002/acp.977; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; NELSON TO, 1984, PSYCHOL BULL, V95, P109, DOI 10.1037/0033-2909.95.1.109; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Perfect TJ, 1999, J EXP PSYCHOL-APPL, V5, P250, DOI 10.1037/1076-898X.5.3.250; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; Titov N, 2000, BRAIN INJURY, V14, P877; Titov N, 2001, APPL COGNITIVE PSYCH, V15, P61, DOI 10.1002/1099-0720(200101/02)15:1<61::AID-ACP689>3.0.CO;2-Y	35	63	70	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2005	19	1					19	27		10.1080/02699050410001720022			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	875AS	WOS:000225392600003	15762098				2021-06-18	
J	Kline, AE; Massucci, JL; Ma, XC; Zafonte, RD; Dixon, CE				Kline, AE; Massucci, JL; Ma, XC; Zafonte, RD; Dixon, CE			Bromocriptine reduces lipid peroxidation and enhances spatial learning and hippocampal neuron survival in a rodent model of focal brain trauma	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; function; learning; memory; MWM; recovery	RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; OXIDATIVE STRESS; COGNITIVE DEFICITS; HEAD-INJURY; STILBAZULENYL NITRONE; CEREBROSPINAL-FLUID; ALPHA-TOCOPHEROL; ANTIOXIDANT	Oxidative stress is a significant contributor to the secondary sequelae of traumatic brain injury (TBI), and may mediate subsequent neurobehavioral deficits and histopathology. The present study examined the neuroprotective effects of bromocriptine (BRO), a dopamine D2 receptor agonist with significant antioxidant properties, on cognition, histopathology, and lipid peroxidation in a rodent model of focal brain trauma. BRO (5 mg/kg) or a comparable volume of vehicle (VEH) was administered intraperitoneally 15 min prior to cortical impact or sham injury. In experiment 1, spatial learning was assessed in an established water maze task on post-surgery days 14-18, followed by quantification of hippocampal cell survival and cortical lesion volume at 4 weeks. In experiment 2, rats were sacrificed 1 hr post-surgery, and malondialdehyde (MDA), the end product of lipid peroxidation, was measured in the frontal cortex, striatum, and substantia nigra using a thiobarbituric acid reactive substances assay. The TBI+BRO group was significantly more adept at locating a hidden platform in the water maze compared to the TBI+VEH group and also exhibited a greater percentage of surviving CA(3) hippocampal neurons. TBI increased MDA in all examined regions of the VEH-treated, but not BRO-treated group versus SHAMS. MDA was significantly decreased in both the striatum (4.22 +/- 0.52 versus 5.60 +/- 0.44 nmol per mg/tissue +/-SEM) and substantia nigra (4.18 +/- 0.35 versus 7.76 +/- 2.05) of the TBI+BRO versus TBI+VEH groups, respectively, while only a trend toward decreased MDA was observed in the frontal cortex (5.44 +/- 0.44 versus 6.96 +/- 0.77). These findings suggest that TBI-induced oxidative stress is attenuated by acute BRO treatment, which may, in part, explain the benefit in cognitive and histological outcome.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Kaufmann Bldg,Ste 201,3471 5th Ave, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD043851] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS033150] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Bozbuga M, 1998, NEUROSURG REV, V21, P36, DOI 10.1007/BF01111483; BRANNAN T, 1993, J NEURAL TRANSM-PARK, V6, P81, DOI 10.1007/BF02261001; Chen YK, 2001, BRAIN RES, V896, P165, DOI 10.1016/S0006-8993(01)02081-9; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Ginsberg MD, 2003, ANN NEUROL, V54, P330, DOI 10.1002/ana.10659; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Golden K. M., 2000, Journal of Neurotrauma, V17, P960; Hall ED, 1996, BRAIN RES, V742, P80, DOI 10.1016/S0006-8993(96)00968-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1996, FREE RADICAL BIO MED, P351; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Iida M, 1999, BRAIN RES, V838, P51, DOI 10.1016/S0006-8993(99)01688-1; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Kato N, 2003, ACTA NEUROCHIR, V145, P489, DOI 10.1007/s00701-003-0036-z; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LIU XH, 1995, J NEUROL SCI, V129, P9, DOI 10.1016/0022-510X(94)00239-K; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Muralikrishnan D, 1998, FASEB J, V12, P905; O'Neill MJ, 1998, EUR J PHARMACOL, V352, P37, DOI 10.1016/S0014-2999(98)00333-1; PALKOVITS M, 1988, MAP GUIDE MICRODISSE; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Powell WC, 1996, CURR TOP MICROBIOL, V213, P1; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; PULASKI KH, 1994, AM J OCCUP THER, V48, P263, DOI 10.5014/ajot.48.3.263; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Tanaka K, 2001, NEUROCHEM RES, V26, P31, DOI 10.1023/A:1007672414239; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; YOSHIKAWA T, 1994, J NEUROCHEM, V62, P1034	63	63	68	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1712	1722		10.1089/0897715042664849			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400003	15684763				2021-06-18	
J	Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D				Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D			Proton MR spectroscopy detected glutamate/glutamine is increased in children with traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						children; glutamate; infants; spectroscopy; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; AMINO-ACID RELEASE; CLOSED-HEAD INJURY; VENTRICULAR CEREBROSPINAL-FLUID; PEDIATRIC INTENSIVE-CARE; CORTICAL IMPACT INJURY; IN-VIVO; METABOLITE CONCENTRATIONS; GLUTAMATE CONCENTRATIONS; RAT-BRAIN	Adults with traumatic brain injury (TBI) have been shown by invasive methods to have increased levels of the excitatory neurotransmitter glutamate. It is unclear whether glutamate release contributes to primary or secondary injury and whether its protracted elevation is predictive of a poor outcome. Preliminary studies at our institution in adults found that early increases in magnetic resonance spectroscopy (MRS)-detected glutamate/glutamine (Glx) were associated with poor outcomes. We therefore studied 38 children (mean age, 11 years; range, 1.6-17 years) who had TBI with quantitative short-echo time (STEAM, TE = 20 msec) proton MRS, a mean of 7 +/- 4 (range, 1-17) days after injury in order to determine if their occipital or parietal Glx levels correlated with the severity of injury or outcome. Occipital Glx was significantly increased in children with TBI compared to controls (13.5 +/- 2.4 vs. 10.7 +/- 1.8; p = 0.002), but there was no difference between children with good compared to poor outcomes as determined by the Pediatric Cerebral Performance Category Scale score at 6-12 months after injury. We also did not find a correlation between the amount of Glx and the initial Glasgow Coma Scale score, duration of coma, nor with changes in spectral metabolites, including N-acetyl aspartate, choline, and myoinositol. In part, this may have occurred because, in this study, most patients with poor outcomes were studied later than patients with good outcomes, potentially beyond the time frame for peak elevation of Glx after injury. Additional early and late studies of patients with varying degrees of injury are required to assess the importance to the pathophysiology of TBI of this excitatory neurotransmitter.	Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92350 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, 11175 Campus St,Rm A1120G, Loma Linda, CA 92350 USA.	sashwal@ahs.ilumc.edu					Alessandri B, 1999, ACT NEUR S, V75, P25; Antuono PG, 2001, NEUROLOGY, V56, P737, DOI 10.1212/WNL.56.6.737; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Auer DP, 2000, BIOL PSYCHIAT, V47, P305, DOI 10.1016/S0006-3223(99)00159-6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARTH TM, 1990, STROKE, V21, P153; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bittigau P, 1997, J CHILD NEUROL, V12, P471, DOI 10.1177/088307389701200802; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Danielsen ER, 1999, MAGNETIC RESONANCE S; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gopinath SP, 2000, ACT NEUR S, V76, P437; Hajek M, 1997, EPILEPSY RES, V28, P245, DOI 10.1016/S0920-1211(97)00050-8; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.0.CO;2-6; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HOLSHOUSER BA, 2003, P INT SOC MAG RESON, V11, P2032; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Koura SS, 1998, ACT NEUR S, V71, P244; Kreis R, 2002, MAGNET RESON MED, V48, P949, DOI 10.1002/mrm.10304; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; Lundbom NMI, 1999, AM J NEURORADIOL, V20, P1543; Malcon C, 2000, BRAIN RES, V860, P195, DOI 10.1016/S0006-8993(00)02038-2; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Miller SP, 2002, NEUROLOGY, V58, P542, DOI 10.1212/WNL.58.4.542; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Petroff O A, 2000, Adv Neurol, V83, P261; Petroff OAC, 1999, SEIZURE-EUR J EPILEP, V8, P120, DOI 10.1053/seiz.1999.0267; Pouwels PJW, 1998, MAGN RESON MED, V39, P53, DOI 10.1002/mrm.1910390110; Pouwels PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Pu YL, 2000, AM J NEURORADIOL, V21, P203; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robertson NJ, 2001, PEDIATR RES, V50, P692, DOI 10.1203/00006450-200112000-00011; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rothman DL, 1999, PHILOS T R SOC B, V354, P1165, DOI 10.1098/rstb.1999.0472; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Savic I, 2000, ACTA NEUROL SCAND, V102, P179, DOI 10.1034/j.1600-0404.2000.102003179.x; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Simister RJ, 2003, NEUROLOGY, V61, P897, DOI 10.1212/01.WNL.0000086903.69738.DC; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; STANLEY JA, 1995, MAGNET RESON MED, V34, P17, DOI 10.1002/mrm.1910340105; Staub F, 1997, BRAIN RES, V766, P285, DOI 10.1016/S0006-8993(97)00751-8; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; TANAKA H, 1994, ACTA NEUROCHIR, P524; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Yamamoto T, 1999, ACT NEUR S, V75, P17; Zhang H, 2001, CLIN CHEM, V47, P1458; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	80	63	67	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1539	1552		10.1089/neu.2004.21.1539			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800002	15684647				2021-06-18	
J	Taub, E				Taub, E			Harnessing brain plasticity through behavioral techniques to produce new treatments in neurorehabilitation	AMERICAN PSYCHOLOGIST			English	Article							INDUCED MOVEMENT THERAPY; CONSTRAINT-INDUCED THERAPY; PHANTOM-LIMB PAIN; CORTICAL REORGANIZATION; SOMATOSENSORY CORTEX; STROKE PATIENTS; MOTOR RECOVERY; LEARNED NONUSE; ADULT; DEAFFERENTATION	Basic behavioral neuroscience research with monkeys has given rise to an efficacious new approach to the rehabilitation of movement after stroke, cerebral palsy, traumatic brain injury, and other types of neurological injury, in humans termed Constraint-Induced Movement therapy or CI therapy. For the upper extremity, the treatment involves intensive training of the more affected arm by "shaping," the application of a number of other behavioral techniques, and prolonged constraint of use of the less affected arm. CI therapy has been shown to produce large changes in the organization and junction of the brain. This result points to the fact that behavior can have a profound effect on the nervous system that is greater than is generally recognized, and harnessing this brain plasticity by behavioral means has promise for the development of new treatments in the field of rehabilitation.	Univ Alabama Birmingham, Vet Affairs Med Ctr, Dept Psychol, Birmingham, AL 35294 USA	Taub, E (corresponding author), Univ Alabama Birmingham, Vet Affairs Med Ctr, Dept Psychol, CPM 712,1530 3rd Ave S, Birmingham, AL 35294 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD034273] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD34273] Funding Source: Medline		Azrin N. H., 1966, OPERANT BEHAVIOR ARE, P380; Bach-y-Rita P, 1992, J NEUROL REHABIL, V6, P191, DOI [10.1177/136140969200600404, DOI 10.1177/136140969200600404]; Bauder H, 1999, PSYCHOPHYSIOLOGY, V36, pS31; Broca P, 1861, B SOC ANATOMIQUE PAR, V36, P398; Candia V, 1999, LANCET, V353, P42, DOI 10.1016/S0140-6736(05)74865-0; Catania A.C., 1998, LEARNING, Vinterim 4th; CHAMBERS W W, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P721; DeLuca SC, 2003, PHYS THER, V83, P1003, DOI 10.1093/ptj/83.11.1003; DETTMERS C, IN PRESS ARCH PHYS M; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; Duncan P W, 1997, Top Stroke Rehabil, V3, P1, DOI 10.1080/10749357.1997.11754126; Elbert T, 1995, SCIENCE, V220, P21; ESTES WK, 1944, PSYCHOL MONOGRAPHS, V57; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Franz S. I., 1915, JAMA-J AM MED ASSOC, V65, P2150, DOI [DOI 10.1001/JAMA.1915.02580250022007, 10.1001/jama.1915.02580250022007]; HALBERSTAM J L, 1971, Archives of Physical Medicine and Rehabilitation, V52, P318; INCE LP, 1969, PSYCHON SCI, V16, P49; JACKSON FL, 1984, BERGEYS MANUAL SYSTE, V1, P591; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; Lashley KS, 1924, ARCH NEURO PSYCHIATR, V12, P249, DOI 10.1001/archneurpsyc.1924.02200030002001; Levy CE, 2001, AM J PHYS MED REHAB, V80, P4, DOI 10.1097/00002060-200101000-00003; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; MARK V, IN PRESS RESTORATIVE; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; MILTNER WHR, 2004, UNPUB CI THERAPY TRE; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Ogden R, 1917, PSYCHOBIOLOGY, V1, P33, DOI [10.1037/h0074814, DOI 10.1037/H0074814]; OSTENDORF CG, 1981, PHYS THER, V61, P1022, DOI 10.1093/ptj/61.7.1022; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Ruch TC, 1960, MED PHYSL BIOPHYSICS, P249; Sherrington CS., 1894, P ROY SOC LONDON, V57, P481, DOI DOI 10.1098/RSP1.1894.0179; Skinner B. F., 1968, TECHNOLOGY TEACHING; Skinner BF, 1938, BEHAV ORGANISMS; Sterr A, 2002, ARCH PHYS MED REHAB, V83, P1374, DOI 10.1053/apmr.2002.35108; Sterr A, 1998, NATURE, V391, P134, DOI 10.1038/34322; Taub E, 2004, PEDIATRICS, V113, P305, DOI 10.1542/peds.113.2.305; Taub E, 2003, J REHABIL MED, V35, P34, DOI 10.1080/16501960310010124; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 1999, J REHABIL RES DEV, V36, P237; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; TAUB E, 1995, SFI STUDIES SCI COMP, P201; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; Taub E, 1968, NEUROPSYCHOL SPATIAL, P173; Tower SS, 1940, BRAIN, V63, P36, DOI 10.1093/brain/63.1.36; USWATTE G, 1999, COGNITIVE NEUROREHAB, P215; Weiss T, 1999, NEUROSCI LETT, V272, P131, DOI 10.1016/S0304-3940(99)00595-9; Wittenberg GF, 2003, NEUROREHAB NEURAL RE, V17, P48, DOI 10.1177/0888439002250456; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; WOLF SL, 1983, PHYS THER, V63, P1448, DOI 10.1093/ptj/63.9.1448	58	63	68	0	10	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0003-066X	1935-990X		AM PSYCHOL	Am. Psychol.	NOV	2004	59	8					692	704		10.1037/0003-066X.59.8.692			13	Psychology, Multidisciplinary	Psychology	869XQ	WOS:000225018300006	15554826				2021-06-18	
J	Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D				Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D			Proton spectroscopy detected myoinositol in children with traumatic brain injury	PEDIATRIC RESEARCH			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; PEDIATRIC INTENSIVE-CARE; AMINO-ACID RELEASE; CLOSED-HEAD INJURY; MR SPECTROSCOPY; INOSITOL; HYPERNATREMIA; INFANTS; ASTROGLIOSIS; SPECTRA	Previous studies have shown that proton magnetic resonance spectroscopy (MRS) is useful in predicting neurologic prognosis in children with traumatic brain injury (TBI). Reductions in N-acetyl derived metabolites and presence of lactate have been predictive of poor outcomes. We examined another spectroscopy metabolite, myoinositol (ml), to determine whether it is altered after TBI. Found primarily in astrocytes, ml functions as an osmolyte and is involved in hormone response pathways and protein-kinase C activation. Myoinositol is elevated in the newborn brain and is increased in a variety of diseases. We studied 38 children (mean age 11 y; range 1.6-17 y) with TBI using quantitative short echo time occipital gray and parietal white matter proton MRS at a mean of 7 d (range 1-17 d) after injury. We found that occipital gray matter ml levels were increased in children with TBI (4.30 +/- 0.73) compared with controls (3.53 +/- 0.48; p = 0.003). We also found that patients with poor outcomes 6-12 mo after injury had higher ml levels (4.78 +/- 0.68) than patients with good outcomes (4.15 +/- 0.69; p < 0.05). Myoinositol is elevated after pediatric TBI and is associated with a poor neurologic outcome. The reasons for its elevation remain unclear but may be due to astrogliosis or to a disturbance in osmotic function.	Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Pediat, Div Crit Care Med, Loma Linda, CA 92350 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, 11175 Campus St,Room A1120G, Loma Linda, CA 92350 USA.	sashwal@ahs.llumc.edu					Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; BATTAGLIA F, 1961, Q J EXP PHYSIOL CMS, V46, P188, DOI 10.1113/expphysiol.1961.sp001532; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chang L, 1999, NEUROLOGY, V53, P782, DOI 10.1212/WNL.53.4.782; Cotran R.S., 1994, ROBBINS PATHOLOGIC B, P1; DANIELSEN ER, 1999, MAGNETIC RESONANCE S, P349; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; FRAHM J, 1997, MAGNETIC RESONANCE S, P329; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; JACKSON PS, 1994, AM J PHYSIOL-CELL PH, V267, pC1203; Koura SS, 1998, ACT NEUR S, V71, P244; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; LOHR JW, 1988, LIFE SCI, V43, P271, DOI 10.1016/0024-3205(88)90317-7; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robertson NJ, 2001, PEDIATR RES, V50, P692, DOI 10.1203/00006450-200112000-00011; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Staub F, 1997, BRAIN RES, V766, P285, DOI 10.1016/S0006-8993(97)00751-8; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; Yamashita T, 1997, MOL BRAIN RES, V46, P236, DOI 10.1016/S0169-328X(97)00020-X	37	63	65	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	OCT	2004	56	4					630	638		10.1203/01.PDR.0000139928.60530.7D			9	Pediatrics	Pediatrics	855WG	WOS:000224005000018	15295080	Bronze			2021-06-18	
J	Clausen, F; Lundqvist, H; Ekmark, S; Lewen, A; Ebendal, T; Hillered, L				Clausen, F; Lundqvist, H; Ekmark, S; Lewen, A; Ebendal, T; Hillered, L			Oxygen free radical-dependent activation of extracellular signal-regulated kinase mediates apoptosis-like cell death after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						ERK; MEK inhibition; neuroprotection; rats; ROS; TUNEL	FOCAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE; NITRIC-OXIDE; C-FOS; OXIDATIVE STRESS; AMINO-ACIDS; S-PBN; RECEPTOR; INHIBITION; EXPRESSION	Mitogen-activated protein kinase (MAPK) cascades are membrane-to-nucleus signaling modules that recently have been implicated as mediators of cellular injury. In this study, we investigated the involvement of the MAP kinase p44/p42 (extracellular signal-regulated kinase [ERK1/2]) in traumatic brain injury (TBI) in rats. There was a strong increase in activated, phosphorylated ERK 1/2 (p-ERK 1/2) protein at 10 min up to 24 h after the injury. Expression of p-ERK occurred in cells identified as neurons, astrocytes, and microglia. Most of the cells expressing p-ERK were TUNEL positive at later time points. Treatment with the MEK inhibitor U0126 or the free radical scavenger S-PBN, both with neuroprotective properties in TBI, attenuated the early activation of ERK and resulted in less activation of caspase-3 and subsequent DNA fragmentation. Post-treatment with U0126 resulted in a significant decrease (-60%) in cortical cavity size and cortical atrophy at 2 weeks after trauma. Overall, the results suggest that ERK activation is initiated by increased oxygen radical activity and that overactivation of ERK sets off secondary cell death mechanisms in TBI. Clinical studies are warranted to evaluate the concept of MEK inhibition in head-injured patients.	Uppsala Univ, Dept Neurosci, Uppsala, Sweden; Uppsala Univ, Dept Neurosurg, Uppsala, Sweden; Uppsala Univ, Dept Dev Neurosci, Uppsala, Sweden	Clausen, F (corresponding author), Univ Uppsala Hosp, Dept Neurosci & Neurosurg, S-75185 Uppsala, Sweden.	fredrik.clausen@neurokir.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Clausen, Fredrik/0000-0003-3592-4417			Abe K, 2001, J NEUROCHEM, V76, P217, DOI 10.1046/j.1471-4159.2001.00062.x; Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Hassan WN, 2002, FREE RADICAL BIO MED, V32, P551, DOI 10.1016/S0891-5849(02)00744-X; Huang CY, 2001, STROKE, V32, P741, DOI 10.1161/01.STR.32.3.741; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KURINO M, 1995, J NEUROCHEM, V65, P1282; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MANTYLA M, 1981, ANN CLIN RES, V13, P5; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Noshita N, 2002, J NEUROSCI, V22, P7923; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Regan RF, 2001, J NEUROCHEM, V79, P545, DOI 10.1046/j.1471-4159.2001.00590.x; Satoh T, 2000, NEUROSCI LETT, V288, P163, DOI 10.1016/S0304-3940(00)01229-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Skaper SD, 2001, ANN NY ACAD SCI, V939, P11; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yu CR, 2002, CANCER RES, V62, P188	59	63	79	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1168	1182		10.1089/neu.2004.21.1168			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900006	15453987				2021-06-18	
J	Lee, CA; Birkedal, JP; Dickerson, EA; Vieta, PA; Webb, LX; Teasdall, RD				Lee, CA; Birkedal, JP; Dickerson, EA; Vieta, PA; Webb, LX; Teasdall, RD			Stabilization of Lisfranc joint injuries: A biomechanical study	FOOT & ANKLE INTERNATIONAL			English	Article						Lisfranc joint; rigid fixation; stabilization	FRACTURE-DISLOCATIONS; TARSOMETATARSAL JOINT; COMPLEX	Background: Lisfranc joint injuries are often misdiagnosed, leading to significant morbidity. Methods for anatomic reduction of the tarsometatarsal joint include closed reduction with casting or surgical stabilization with either Kirschner wires and/or cortical screw fixation. Controversy exists as to which fixation technique offers optimal stability. In the present study, the biomechanical stability of three fixation methods was tested: (1) four Kirschner wires, (2) three cortical screws plus two Kirschner wires, and (3) five cortical screws. Methods: Ten matched pairs of fresh-frozen cadaveric feet were dissected to their ligamentous and capsular elements. The tarsometatarsal ligaments were completely transected to replicate a Lisfranc dislocation; the "injury" was reduced and stabilized using one of the three methods. Biomechanical studies were performed by applying a 100-N cyclic load physiologically distributed to the plantar aspect of the metatarsal heads. Displacement and force measurements were taken from the first and fifth metatarsal heads. Average stiffness of each construct was calculated from the force displacement curves. Results and Conclusions' Method 2 provided significantly more stability than Kirschner wire fixation. Method 3 created more stiffness than method 2 at the medial portion of the foot; no statistical difference between the two methods was evident at the lateral foot. Clinical Relevance: Cortical screw fixation provides a more rigid and stable method of fixation for Lisfranc injuries as compared to Kirschner wire fixation. This fixation method allows maintenance of anatomic reduction and possibly earlier mobilization with a decreased risk of posttraumatic arthrosis.	Wake Forest Univ, Sch Med, Dept Orthopaed Surg, Baptist Med Ctr, Winston Salem, NC 27157 USA; Orthofix Inc, Winston Salem, NC USA	Teasdall, RD (corresponding author), Wake Forest Univ, Sch Med, Dept Orthopaed Surg, Baptist Med Ctr, Med Ctr Blvd,4th Floor,Watlington Hall, Winston Salem, NC 27157 USA.	teasdall@wfubmc.edu					ARNTZ CT, 1987, ORTHOP CLIN N AM, V18, P105; ARNTZ CT, 1988, J BONE JOINT SURG AM, V70A, P173, DOI 10.2106/00004623-198870020-00003; BLANCO RP, 1988, J ORTHOP TRAUMA, V2, P188; BRUNET JA, 1987, J BONE JOINT SURG BR, V69, P437; Buzzard BM, 1998, CLIN ORTHOP RELAT R, P125; CAVANAGH PR, 1987, FOOT ANKLE, V7, P262, DOI 10.1177/107110078700700502; dePalma L, 1997, FOOT ANKLE INT, V18, P356, DOI 10.1177/107110079701800609; FERRIS LR, 1995, ORTHOP CLIN N AM, V26, P393; GOOSENS M, 1983, CLIN ORTHOP RELAT R, V176, P165; HANSEN ST, 1992, SKELETAL TRAUMA; HARDCASTLE PH, 1982, J BONE JOINT SURG BR, V64, P349; JEFFREYS TE, 1963, J BONE JOINT SURG BR, V45, P546; Kuo RS, 2000, J BONE JOINT SURG AM, V82A, P1609, DOI 10.2106/00004623-200011000-00015; LENCZNER EM, 1974, J TRAUMA, V14, P1012, DOI 10.1097/00005373-197412000-00003; MYERSON M, 1989, ORTHOP CLIN N AM, V20, P655; MYERSON MS, 1986, FOOT ANKLE, V6, P225, DOI 10.1177/107110078600600504; RESCH S, 1990, FOOT ANKLE, V11, P117, DOI 10.1177/107110079001100301; Ruedi TP., 2000, AO PRINCIPLES FRACTU; TREVINO SG, 1995, ORTHOP CLIN N AM, V26, P229	19	63	82	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1071-1007	1944-7876		FOOT ANKLE INT	Foot Ankle Int.	MAY	2004	25	5					365	370		10.1177/107110070402500515			6	Orthopedics	Orthopedics	854FD	WOS:000223885800015	15134620				2021-06-18	
J	Espy, KA				Espy, KA			Using developmental, cognitive, and neuroscience approaches to understand executive control in young children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							PREFRONTAL CORTEX; PRESCHOOL-CHILDREN; WORKING-MEMORY; FUNCTIONAL MRI; TASK; PERFORMANCE; BRAIN	The 7 articles in this special issue address the nature of executive control in young children. Executive control is framed in a developmental context, where the unique aspects of cognition in this age range are considered. The set of articles demonstrates the multidisciplinary approaches to study cognition in young children that includes application of cognitive, neuroscience, and developmental paradigms in typically developing youngsters, as well as those affected by clinical conditions, such as traumatic brain injury, exposure to low levels of lead in the environment, and prematurity. Although much work remains to be done, these study results are illustrative of the dynamic work in this exciting developmental period.	So Illinois Univ, Sch Med, Dept Family & Community Med, Carbondale, IL 62901 USA	Espy, KA (corresponding author), So Illinois Univ, Sch Med, Dept Family & Community Med, MC 6503,600 Agr Dr, Carbondale, IL 62901 USA.	kespy@siumed.edu					Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Canfield RL, 2004, DEV NEUROPSYCHOL, V26, P513, DOI 10.1207/s15326942dn2601_8; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Casey BJ, 2001, HUM BRAIN MAPP, V13, P26, DOI 10.1002/hbm.1022; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P723, DOI 10.1080/01688638708405213; DIAMOND A, 1985, CHILD DEV, V56, P868, DOI 10.1111/j.1467-8624.1985.tb00160.x; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P465, DOI 10.1207/s15326942dn2601_6; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Flavell JH, 1999, ANNU REV PSYCHOL, V50, P21, DOI 10.1146/annurev.psych.50.1.21; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P1, DOI 10.1080/87565649609540636; FLETCHER JM, 1984, J CLIN NEUROPSYCHOL, V6, P39, DOI 10.1080/01688638408401195; Goldman PS, 1974, PLASTICITY RECOVERY; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Heaton R., 1993, WISCONSIN CARD SORTI; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; Rennie DAC, 2004, DEV NEUROPSYCHOL, V26, P423, DOI 10.1207/s15326942dn2601_4; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Senn TE, 2004, DEV NEUROPSYCHOL, V26, P445, DOI 10.1207/s15326942dn2601_5; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; ZELAZO PD, 1995, DEV PSYCHOL, V31, P508, DOI 10.1037/0012-1649.31.3.508	25	63	65	4	28	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	26	1					379	384		10.1207/s15326942dn2601_1			6	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	844BO	WOS:000223132300001	15276900				2021-06-18	
J	Schachar, R; Levin, HS; Max, JE; Purvis, K; Chen, S				Schachar, R; Levin, HS; Max, JE; Purvis, K; Chen, S			Attention deficit hyperactivity disorder symptoms and response inhibition after closed head injury in children: Do preinjury behavior and injury severity predict outcome?	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CHOICE REACTION-TIME; DEFICIT/HYPERACTIVITY DISORDER; SUSTAINED ATTENTION; DELAY AVERSION; STOP-SIGNAL; ADOLESCENTS; IMPULSIVITY; SEQUELAE; ADHD	We examined the effect of closed head injury (CHI) on the development of symptoms of secondary attention deficit hyperactivity disorder (SADHD), emotional disturbance, and impaired response inhibition. We also investigated the relation of developmental and recovery variables to SADHD symptoms and inhibition. Participants were 200 children aged 5-17 years, 137 children who had CHI, and 63 children with no history of CHI served as controls. We assessed preinjury behavior problems, head injury variables (severity, age at time of injury, time since injury), postinjury SADHD, and anxiety symptoms at least 2 years following the head injury. Response inhibition was measured with the stop-signal task. CHI predicted the development of SADHD symptoms and anxiety with more severe injury predicting more severe outcomes. Only the combination of severe CHI and a high level of SADHD symptoms predicted poor response inhibition. Postinjury anxiety was not associated with poor inhibition. The consequences of CHI did not vary with age at injury or time since injury, but poorer outcome was predicted by preinjury behavior problems. CHI in children leads to SADHD symptoms and anxiety even after taking preinjury disturbance into account. Poor response inhibition is a consequence of CHI but only when the CHI is severe and the child manifests high levels of SADHD symptoms.	Hosp Sick Children, Brain & Behav Program, Res Inst, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA	Schachar, R (corresponding author), Hosp Sick Children, Brain & Behav Program, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	russell.schachar@sickkids.ca		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH1800-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS 21889-16] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Band GPH, 2003, ACTA PSYCHOL, V112, P105, DOI 10.1016/S0001-6918(02)00079-3; BARKHAM J, 1993, GLOBAL ECOL BIOGEOGR, V3, P92, DOI 10.2307/2997552; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barkley RA, 1996, PEDIATRICS, V98, P1089; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; Boyle MH, 1997, ARCH GEN PSYCHIAT, V54, P793; Boyle MH, 1996, CAN J PSYCHIAT, V41, P549, DOI 10.1177/070674379604100903; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P72; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Crosbie J, 2001, AM J PSYCHIAT, V158, P1884, DOI 10.1176/appi.ajp.158.11.1884; DAUGHERTY TK, 1993, J GENET PSYCHOL, V154, P177, DOI 10.1080/00221325.1993.9914731; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DENNIS M, 1995, TRAUMATIC HEAD INJUR, P1654; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Eaves LJ, 1997, J CHILD PSYCHOL PSYC, V38, P965, DOI 10.1111/j.1469-7610.1997.tb01614.x; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GORDON M, 1988, GORDON DIAGNOSTIC SY; Gordon M., 1983, GORDON DIAGNOSTIC SY; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Jennings JR, 1997, DEV PSYCHOL, V33, P308, DOI 10.1037/0012-1649.33.2.308; JENNINGS JR, 1992, J EXP PSYCHOL HUMAN, V18, P422, DOI 10.1037/0096-1523.18.2.422; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kuntsi J, 2001, J CHILD PSYCHOL PSYC, V42, P199, DOI 10.1111/1469-7610.00711; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; LOGAN GD, 1985, J EXP PSYCHOL LEARN, V11, P675, DOI 10.1037/0278-7393.11.1-4.675; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Logan Gordon D., 1994, P189; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Ollman RT, 1973, ATTENTION PERFORM, V4, P571; Oosterlaan J, 1998, J CHILD PSYCHOL PSYC, V39, P411, DOI 10.1111/1469-7610.00336; OSMAN A, 1986, J EXP PSYCHOL HUMAN, V12, P243, DOI 10.1037/0096-1523.12.3.243; Quay HC, 1997, J ABNORM CHILD PSYCH, V25, P7, DOI 10.1023/A:1025799122529; Quay HC, 1988, ATTENTION DEFICIT DI, V3, P176; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; SCHACHAR R, 1995, J AM ACAD CHILD PSY, V34, P639, DOI 10.1097/00004583-199505000-00016; SCHACHAR R, 1990, DEV PSYCHOL, V26, P710, DOI 10.1037/0012-1649.26.5.710; SCHACHAR RJ, 1993, CLIN PSYCHOL REV, V13, P721, DOI 10.1016/S0272-7358(05)80003-0; SEMRUDCLIKEMAN M, 1994, J AM ACAD CHILD PSY, V33, P875, DOI 10.1097/00004583-199407000-00014; SOLANTO MV, 1990, J CHILD PSYCHOL PSYC, V31, P803, DOI 10.1111/j.1469-7610.1990.tb00819.x; Solanto MV, 2001, J ABNORM CHILD PSYCH, V29, P215, DOI 10.1023/A:1010329714819; TEASDALE G, 1974, LANCET, V2, P81; Thapar A, 1999, BRIT J PSYCHIAT, V174, P105, DOI 10.1192/bjp.174.2.105; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205	62	63	64	0	7	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					179	198		10.1207/s15326942dn2501&2_10			20	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	774CG	WOS:000188961700010	14984334				2021-06-18	
J	Hoane, MR; Akstulewicz, SL; Toppen, J				Hoane, MR; Akstulewicz, SL; Toppen, J			Treatment with vitamin B-3 improves functional recovery and reduces GFAP expression following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						GFAP; niacin; nicotinamide; rat; recovery of function; vitamin B-3	FOCAL CEREBRAL-ISCHEMIA; COGNITIVE DEFICITS; MAGNESIUM THERAPY; WISTAR RATS; FACILITATE RECOVERY; SENSORIMOTOR CORTEX; NMDA ANTAGONISTS; NICOTINAMIDE; LESIONS; INFARCTION	Previous studies have shown that administration of vitamin B-3 (B-3) in animal models of ischemia significantly reduced the size of infarction and improved functional recovery. The present study evaluated the effect of administration of B-3 on recovery of function following traumatic brain injury (TBI), incorporating the bilateral medial frontal cortex contusion injury model. Groups of rats were assigned to B-3 (500 mg/kg) or saline (1.0 ml/kg) treatment conditions and received contusion injuries or sham surgeries. Drug treatment was administered 15 min and 24 h following injury. Rats were examined on a variety of tests to measure sensorimotor performance (bilateral tactile adhesive removal), skilled forelimb use (staircase test), and cognitive ability (reference and working memory) in the Morris Water Maze. Administration of B-3 following injury significantly reduced the behavioral impairments observed on the bilateral tactile removal test, but not on skilled forelimb use. The acquisition of reference and working memory tests were also significantly improved compared to saline-treated rats. Examination of the brains revealed that administration of B-3 significantly reduced the size of the lesion compared to treatment with saline. In addition, examination of glial fibrillary acidic protein (GFAP) expression around the lesion revealed that B-3 significantly reduced the number of GFAP(+) astrocytes. These results indicate that B-3 administration significantly improved behavioral outcome following injury, reduced the size of the lesion, and reduced the expression of GFAP. The current findings suggest that B-3 may have therapeutic potential for the treatment of TBI.	E Carolina Univ, Dept Psychol, Brain Injury Lab, Greenville, NC 27858 USA; E Carolina Univ, Neurosci Program, Greenville, NC 27858 USA; E Carolina Univ, Sch Ind & Technol, Greenville, NC 27858 USA	Hoane, MR (corresponding author), E Carolina Univ, Dept Psychol, Brain Injury Lab, Rawl 218, Greenville, NC 27858 USA.	hoanem@mail.ecu.edu		Hoane, Michael/0000-0001-7779-2657	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 45647] Funding Source: Medline		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BARTH TM, 1990, STROKE, V21, P153; BETZ AL, 1994, ACTA NEUROCHIR, P314; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; GREEN RG, 1970, SCHIZOPHRENIA, V2, P70; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; HOANE MR, 2003, BRAIN RES B, V6586, P1; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Lindner MD, 1997, NEUROBIOL LEARN MEM, V68, P203, DOI 10.1006/nlme.1997.3782; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MODUDAI T, 2000, STROKE, V31, P1679; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; STRATFORD MRL, 1992, RADIOTHER ONCOL, V25, P37, DOI 10.1016/0167-8140(92)90193-X; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vink R, 1990, Magnes Res, V3, P163	38	63	63	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2003	20	11					1189	1199		10.1089/089771503770802871			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	747BE	WOS:000186784600004	14651806				2021-06-18	
J	Luis, CA; Vanderploeg, RD; Curtiss, G				Luis, CA; Vanderploeg, RD; Curtiss, G			Predictors of postconcussion symptom complex in community dwelling male veterans	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain concussion; head injury; minor; neurobehavioral manifestations; mental disorders; social support; sequelae	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; DIAGNOSTIC INTERVIEW SCHEDULE; DIFFUSE AXONAL INJURY; COMPLAINT BASE RATES; UNITED-STATES; CONCUSSION; RECOVERY; STRESS; CONSEQUENCES	The presence of a persistent postconcussion symptom complex (PPCSC) was examined in a non-referred sample of male veterans with a history of mild head injury and a comparison group without a history of head injury., Hierarchical logistic regression procedures were used to determine possible predictors of PPCSC using variables supported by previous research (i.e., preexisting psychiatric difficulties, demographic and social support variables, and history of an accidental injurious event). Although PPCSC was common in all groups (23% of the total sample), a significantly greater proportion of individuals in the mild head injury with loss of consciousness group (37.2%) had PPCSC compared with three other groups (head injury without loss of consciousness = 26.1%; motor vehicle accident without head injury = 23%; and control = 17.3%). However, the most salient predictors of PPCSC were early life psychiatric difficulties such as anxiety or depression, limited social support, lower intelligence, and interactions among these variables. The predictive value of loss of consciousness was significant, but low (1.4% of unique variance). The findings provide support for the premise that PPCSC is mediated in part by individual resilience, preexisting psychological status, and psychosocial support.	James A Haley Vet Hosp, Psychiat Serv 116B, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Def & Vet Brain Injury Ctr, Tampa, FL USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychiat Serv 116B, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				ACCORDINO MP, 2000, J MENTAL HLTH COUNSE, V22, P268; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; [Anonymous], 1988, JAMA, V259, P2701; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BRYANT R, 1999, J NERV MENT DIS, V5, P302; Butcher, 1989, MINNESOTA MULTIPHASI; *CDC, 1989, HLTH STAT VIETN VET, V4; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CURTISS G, 2001, M AM PSYCH ASS SAN F; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DeMaris A, 2002, SOCIOL METHOD RES, V31, P27, DOI 10.1177/0049124102031001002; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GOLDBERG L, 1990, PSYCHOPATHOLOGY, V23, P15, DOI 10.1159/000284632; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; GRONWALL D, 1989, ASSESSMENT BEHAV CON, V7; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; HATHAWAY SR, 1983, MINNESOTA MULTIPHASI; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCKELVEY RD, 1975, J MATH SOCIOL, V4, P103, DOI 10.1080/0022250X.1975.9989847; Miller L, 1996, J COGNITIVE REHABILI, V14, P8; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Timmerman IGH, 1998, BEHAV RES THER, V36, P863, DOI 10.1016/S0005-7967(98)00053-9; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; WOOD F, 1984, INT J PSYCHIAT MED, V14, P277; World Health Organization, 1992, ICD 10 INT STAT CLAS; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	76	63	63	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2003	9	7					1001	1015		10.1017/S1355617703970044			15	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	735RW	WOS:000186129200004	14738282				2021-06-18	
J	Besson, VC; Croci, N; Boulu, RG; Plotkine, M; Marchand-Verrecchia, C				Besson, VC; Croci, N; Boulu, RG; Plotkine, M; Marchand-Verrecchia, C			Deleterious poly (ADP-ribose)polymerase-1 pathway activation in traumatic brain injury in rat	BRAIN RESEARCH			English	Article						3-nitrotyrosine; 3-aminobenzamide; neuroprotection; poly(ADP-ribose)polymerase-1; peroxynitrite; traumatic brain injury	DNA STRAND-BREAKS; MIDDLE CEREBRAL-ARTERY; SPINAL-CORD INJURY; POLY(ADP-RIBOSE) POLYMERASE; NITRIC-OXIDE; OXIDATIVE STRESS; CELL-DEATH; TYROSINE NITRATION; RIBOSE POLYMERASE; ISCHEMIC-INJURY	Traumatic brain injury produces nitric oxide and reactive oxygen species. Peroxynitrite, resulting from the combination of nitric oxide and superoxide anions, triggers DNA strand breaks, leading to the activation of poly(ADP-ribose)polymerase-1. As excessive activation of this enzyme induces cell death, we examined the production of nitrosative stress, the activation of poly(ADP-ribose)polymerase-1, and the role of this enzyme in the outcomes of traumatic brain injury produced by fluid percussion in rats. Immunohistochemistry showed that 3-nitrotyrosine, an indicator of nitrosative stress, and poly(ADP-ribose), a marker of poly(ADP-ribose)polymerase-1 activation, were present as early as 30 min post-injury, and that persisted for 72 h. The poly(ADP-ribose)polymerase inhibitor, 3-aminobenzamide, at 10 and 30 mg/kg, significantly improved the neurological deficit, with a 60% reduction in the brain lesion volume and inhibition of poly(ADP-ribose)polyinerase-1 activation. Thus, poly(ADP-ribose)polyinerase-1 is involved in the neurological consequences of traumatic brain injury and may be a promising therapeutic target in clinical treatment of acute brain trauma. (C) 2003 Elsevier B.V. All rights reserved.	Univ Paris 05, Pharmacol Lab, F-75006 Paris, France	Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, 4 Ave Observ, F-75006 Paris, France.		besson, valerie C/L-7388-2017; MARCHAND-LEROUX, Catherine/L-7453-2017; BESSON, VALERIE/AAZ-9989-2020	besson, valerie C/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380			Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Cookson MR, 1999, BRAIN PATHOL, V9, P165; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Droge W, 2002, PHYSIOL REV, V82, P47; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Love S, 1999, BRAIN PATHOL, V9, P119; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1999, J CEREB BLOOD FLOW M, V19, pS390; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Whalen MJ, 2000, ACT NEUR S, V76, P61; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5	52	63	63	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 31	2003	989	1					58	66		10.1016/S0006-8993(03)03362-6			9	Neurosciences	Neurosciences & Neurology	733GL	WOS:000185991500008	14519512				2021-06-18	
J	Rancan, M; Morganti-Kossmann, MC; Barnum, TR; Saft, T; Schmidt, TOI; Ertel, WG; Stahel, PF				Rancan, M; Morganti-Kossmann, MC; Barnum, TR; Saft, T; Schmidt, TOI; Ertel, WG; Stahel, PF			Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	19th International Complement Workshop Meeting	SEP 22-26, 2002	PALERMO, ITALY			traumatic brain injury; complement; neuroinflammation; blood; brain barrier; transgenic mice	TRAUMATIC BRAIN INJURY; BARRIER DYSFUNCTION; ACTIVATION; PROTEIN; RATS; ACCUMULATION; EXPRESSION; FLUID	The role of intracerebral complement activation after traumatic brain injury remains unclear. In this study, the authors demonstrate that transgenic mice with astrocyte-targeted expression of the soluble complement inhibitor sCrry have a significantly reduced neurologic impairment and improved blood-brain barrier function after closed head injury compared with wild-type C57BL/6 littermates. This work further implicates the complement system as a participant in secondary progression of brain damage after head trauma and provides a strong rationale for future studies of posttraumatic pharmacologic complement inhibition.	Free Univ Berlin, Klinikum Benjamin Franklin, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Alfred Hosp, Dept Trauma Surg, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	Stahel, PF (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Dept Trauma & Reconstruct Surg, Hindenburgdamm 30, D-12200 Berlin, Germany.			Morganti-Kossmann, Cristina/0000-0002-0807-2063	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38901] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038901] Funding Source: NIH RePORTER		Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Davoust N, 1999, J IMMUNOL, V163, P6551; FOLEY S, 1993, EUR J IMMUNOL, V23, P1381, DOI 10.1002/eji.1830230630; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 2002, PRACTICE GEN SURG, P101; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Morganti-Kossmann M.C., 2002, IMMUNE INFLAMMATORY, P106; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	22	63	64	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2003	23	9					1070	1074		10.1097/01.WCB.0000084250.20114.2C			5	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	718KQ	WOS:000185144800008	12973023	Bronze			2021-06-18	
J	Gouvier, WD; Sytsma-Jordan, S; Mayville, S				Gouvier, WD; Sytsma-Jordan, S; Mayville, S			Patterns of discrimination in hiring job applicants with disabilities: The role of disability type, job complexity, and public contact	REHABILITATION PSYCHOLOGY			English	Article							EMPLOYER CONCERNS; BIAS; SELECTION; WORKERS	Objective: To evaluate the effects of disability type, job complexity, and public contact on hiring decisions. Design and Participants: An Americans With Disabilities Act (ADA; 1990) fact sheet and matched resumes with vocational and medical histories including chronic mental illness, developmental disability, closed head injury, and back injury were provided to 295 undergraduate business-related majors, who rated the applicants' suitability for 2 job positions and work shifts. Results: Findings indicated disparities in ratings of employability as a function of disability type. Paired comparisons yielded complementary findings, with effects of disability type and Disability Type X Job Complexity, but no effects of public contact. Conclusions: Stereotyping and discrimination in employment decisions apparently persist, more than 10 years after the ADA.	Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA; Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, University, MS 38677 USA	Gouvier, WD (corresponding author), Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA.						Bell BS, 2001, REHABIL PSYCHOL, V46, P229, DOI 10.1037/0090-5550.46.3.229; BORDIERI JE, 1990, J APPL SOC PSYCHOL, V20, P244, DOI 10.1111/j.1559-1816.1990.tb00409.x; BORDIERI JE, 1988, REHABIL PSYCHOL, V33, P239, DOI 10.1037//0090-5550.33.4.239; Colella A, 1997, HUM RESOUR MANAGE R, V7, P27, DOI 10.1016/S1053-4822(97)90004-8; COMBS IH, 1986, J REHABIL, V52, P42; Diksa E, 1996, REHABIL COUNS BULL, V40, P31; DREHMER DE, 1985, REHABIL PSYCHOL, V30, P157, DOI 10.1037//0090-5550.30.3.157; FARINA A, 1973, J CONSULT CLIN PSYCH, V41, P363, DOI 10.1037/h0035329; GOUVIER WD, 1991, REHABIL PSYCHOL, V36, P121, DOI 10.1037/0090-5550.36.2.121; Guion RM., 1965, PERSONNEL TESTING; Loo R, 2001, REHABIL PSYCHOL, V46, P288, DOI 10.1037/0090-5550.46.3.288; MILLINGTON MJ, 1994, REHABIL COUNS BULL, V38, P27; STONE CI, 1980, J VOCAT BEHAV, V16, P96, DOI 10.1016/0001-8791(80)90041-X; *US BUR CENS, 1993, POV US 1992	14	63	63	1	30	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2003	48	3					175	181		10.1037/0090-5550.48.3.175			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	717FY	WOS:000185077900007					2021-06-18	
J	Faden, AI; Knoblach, SM; Cernak, I; Fan, L; Vink, R; Araldi, GL; Fricke, ST; Roth, BL; Kozikowski, AP				Faden, AI; Knoblach, SM; Cernak, I; Fan, L; Vink, R; Araldi, GL; Fricke, ST; Roth, BL; Kozikowski, AP			Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						TRH analogs; neuroprotection; traumatic brain injury; necrosis; apoptosis	THYROTROPIN-RELEASING-HORMONE; CONTROLLED CORTICAL IMPACT; FREE MAGNESIUM; CELL-DEATH; NEURONAL APOPTOSIS; TRH; CONTRIBUTES; ACTIVATION; DEFICITS; MODEL	The authors developed a novel diketopiperazine that shows neuroprotective activity in a variety of in vitro models, as well as in a clinically relevant experimental model of traumatic brain injury (TBI) in rats. Treatment with 1-ARA-35b (35b), a cyclized dipeptide derived from a modified thyrotropin-releasing hormone (TRH) analog, significantly reduced cell death associated with necrosis (maitotoxin), apoptosis (staurosporine), or mechanical injury in neuronalglial cocultures. Rats subjected to lateral fluid percussion-induced TBI and then treated with 1 mg/kg intravenous 35b thirty minutes after trauma showed significantly improved motor recovery and spatial learning compared with vehicle-treated controls. Treatment also significantly reduced lesion volumes as shown by magnetic resonance imaging, and decreased the number of TUNEL-positive neurons observed in ipsilateral hippocampus. Unlike TRH or traditional TRH analogs, 35b treatment did not change mean arterial pressure, body temperature, or thyroid- stimulating hormone release, and did not have analeptic activity. Moreover, in contrast to TRH or typical TRH analogs, 35b administration after TBI did not alter free-magnesium concentration or cellular bioenergetic state. Receptor-binding studies showed that 35b did not act with high affinity at 50 classical receptors, channels, or transporters. Thus, 35b shows none of the typical physiologic actions associated with TRH, but possesses neuroprotective actions in vivo and in vitro, and appears to attenuate both necrotic and apoptotic cell death.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA; Case Western Reserve Univ, Sch Med, NIMH, Psychoact Drug Screening Program, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44109 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Room Ep-12, Washington, DC 20057 USA.	fadena@georgetown.edu	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008; Roth, Bryan L/F-3928-2010	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K02MH001366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K02 MH 01366] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 41119-01] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allen JW, 1999, FASEB J, V13, P1875; ANDREWS JS, 1984, PHARMACOL BIOCHEM BE, V21, P715, DOI 10.1016/S0091-3057(84)80008-8; ANDREWS JS, 1983, REGUL PEPTIDES, V7, P373, DOI 10.1016/0167-0115(83)90109-X; BASSIRI RM, 1973, J CLIN INVEST, V52, P1616, DOI 10.1172/JCI107339; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1996, NEUROTRAUMA, P1479; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; KIEFFER JD, 1974, ACTA ENDOCRINOL-COP, V76, P495; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KOSKINEN LOD, 1986, BRIT J PHARMACOL, V87, P509, DOI 10.1111/j.1476-5381.1986.tb10193.x; KRAUS JF, 1996, NEUROTRAUMA, P13; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; METCALF G, 1982, BRAIN RES REV, V4, P389, DOI 10.1016/0165-0173(82)90012-1; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; OLSON GL, 1995, J MED CHEM, V38, P2866, DOI 10.1021/jm00015a009; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock JT., 1996, NEUROTRAUMA, P1325; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Shvachkin Iu P, 1989, Biull Eksp Biol Med, V108, P671; SIESJO BK, 1981, EUR NEUROL, V20, P194, DOI 10.1159/000115233; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; Vink R, 1996, J NEUROCHEM, V66, P2477; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	55	63	63	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2003	23	3					342	354		10.1097/01.WCB.0000046143.31247.FD			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	652VH	WOS:000181401200009	12621309	Bronze			2021-06-18	
J	Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V				Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V			Serum S-100B protein as a molecular marker in severe traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	International Symposium on Molecular Markers of Brain Damage - Current State and Future Perspectives	JUN 13-15, 2002	BREMEN, GERMANY			S-100 protein; severe head injury; prognosis; outcome	SEVERE HEAD-INJURY; NEURON-SPECIFIC ENOLASE; CARDIAC-SURGERY; NEUROBIOCHEMICAL MARKERS; OUTCOME PREDICTION; CEREBRAL-ISCHEMIA; DAMAGE MARKERS; S100B PROTEIN; ACUTE STROKE; RELEASE	Purpose: There is growing evidence that S-100B protein may be used as a novel biochemical marker of brain cell damage. measured by a simple blood test. In this paper, we summarize the current knowledge about S-100B serum measurements in severe head injury and address actual controversies. Methods: The material of the present analysis consists of a MEDLINE literature search for S-100 and severe head injury from 1966 to 2003. Studies of S-100B in severe head injury were reviewed for their information about the potential clinical value of this marker. Results: A total of 18 clinical studies were identified and reviewed. Peak values of serum S-100B were demonstrated to have the highest correlation to any endpoint parameter. Admission values also have a significant correlation to injury severity and outcome but show a highly time dependent temporal course. There is extracranial release of S-100B in multitrauma patients in the first 48 hours, but the impact is limited as many studies have found a clear relationship between S-100B and injury severity, imaging findings and outcome. Conclusion: S-100B belongs to a new generation of molecular serum markers of brain damage. These markers will have potential as a surrogate outcome marker or monitoring parameters for both clinical and experimental settings.		Raabe, A (corresponding author), Univ Frankfurt, Dept Neurosurg, Neuroctr, Schleusenweg 2-16, D-60528 Frankfurt, Germany.						Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bertsch T, 2001, CLIN CHEM LAB MED, V39, P319, DOI 10.1515/CCLM.2001.050; Bottiger BW, 2001, CIRCULATION, V103, P2694; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ikeda Y, 2001, NEUROSURG QUART, V11, P173, DOI 10.1097/00013414-200109000-00001; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; INGEBRIGTSEN T, IN PRESS BRAIN INJ; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 2001, ANN THORAC SURG, V71, P1433, DOI 10.1016/S0003-4975(00)02612-6; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; Marmarou A, 2000, ACT NEUR S, V76, P349; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McKeating EG, 1998, ACT NEUR S, V71, P117; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	40	63	69	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2003	21	3-4					159	169					11	Neurosciences	Neurosciences & Neurology	745LV	WOS:000186690900008	14530578				2021-06-18	
J	Webbe, FM; Ochs, SR				Webbe, FM; Ochs, SR			Recency and frequency of soccer heading interact to decrease neurocognitive performance	APPLIED NEUROPSYCHOLOGY			English	Article; Proceedings Paper	20th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 15-18, 2000	ORLANDO, FL	Natl Acad Neuropsychol		soccer; traumatic brain injury; athletic participation; neuropsychology; sport psychology	TRAUMATIC BRAIN-INJURY; CONCUSSION; RECOVERY; SPORT	This study investigated the role of heading recency interacting with heading frequency in determining neuropsychological deficits associated with heading the ball during soccer play. Sixty-four high-ability male soccer players ages 16 to 34 completed the California Verbal Learning Test (CVLT), the Trailmaking Test, the Paced Auditory Serial Addition Test (PASAT), the Facial Recognition Test, the Rey-Osterrieth Complex Figure, and the Shipley Scales. Heading recency interacted with heading frequency, such that players with the highest self-reported estimates of heading who also experienced heading within the previous 7 days scored significantly lower on CVLT, Shipley, Trailmaking, and PASAT than other combinations of heading and recency. Although strict ball-to-head contacts could not be isolated as sufficient to cause this interaction, these results increase the weight of evidence that heading behavior is problematic for causing at least transient cognitive impairment.	Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA	Webbe, FM (corresponding author), Florida Inst Technol, Sch Psychol, 150 W Univ Blvd, Melbourne, FL 32901 USA.	webb@fit.edu	Webbe, Frank/A-8074-2009	Webbe, Frank/0000-0002-4370-5698			Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Almquist J, 2001, ATHLET THER TODAY, V6, P13, DOI 10.1123/att.6.1.13; Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT., 1989, MILD HEAD INJURY, P257; Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Delis DC, 1987, CALIFORNIA VERBAL LE; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ERLANGER D, IN PRESS J NEUROSURG; FRENGUELLI A, 1991, J CRANIO MAXILL SURG, V19, P178, DOI 10.1016/S1010-5182(05)80309-9; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kawanishi A, 1999, NEUROL MED-CHIR, V39, P231, DOI 10.2176/nmc.39.231; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Taylor L B, 1969, Clin Neurosurg, V16, P269; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WITOL AD, IN PRESS ARCH CLIN N; Zachary R., 1986, SHIPLEY I LIVING SCA; 2001, NCAA NEWS       0312, P6	41	63	63	1	14	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					31	41		10.1207/S15324826AN1001_5			11	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900005	12734073				2021-06-18	
J	Jayakumar, AR; Panickar, KS; Norenberg, MD				Jayakumar, AR; Panickar, KS; Norenberg, MD			Effects on free radical generation by ligands of the peripheral benzodiazepine receptor in cultured neural cells	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; free radicals; microglia; mitochondrial permeability transition; neurons; peripheral benzodiazepine receptor	MITOCHONDRIAL PERMEABILITY TRANSITION; GLOBAL FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN INJURY; RAT SCIATIC-NERVE; BINDING-SITES; CYCLOSPORINE-A; OXIDATIVE STRESS; THIAMINE-DEFICIENCY; CONDUCTANCE CHANNEL; LIPID-PEROXIDATION	The effect of peripheral benzodiazepine receptor (PBR) ligands on free radical production was investigated in primary cultures of rat brain astrocytes and neurons as well as in BV-2 microglial cell lines using the fluorescent dye dichlorofluorescein-diacetate. Free radical production was measured at 2, 30, 60 and 120 min of treatment with the PBR ligands 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195), 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one (Ro5-4864) and protoporphyrin IX (PpIX) (all at 10 nm). In astrocytes, all ligands showed a significant increase in free radical production at 2 min. The increase was short-lived with PK11195, whereas with Ro5-4864 it persisted for at least 2 h. PpIX caused an increase at 2 and 30 min, but not at 2 h. Similar results were observed in microglial cells. In neurons, PK11195 and PpIX showed an increase in free radical production only at 2 min; Ro5-4864 had no effect. The central-type benzodiazepine receptor ligand, clonazepam, was ineffective in eliciting free radical production in all cell types. As the PBR may be a component of the mitochondrial permeability transition (MPT) pore, and free radical production may occur following induction of the MPT, we further investigated whether cyclosporin A (CsA), an inhibitor of the MPT, could prevent free radical formation by PBR ligands. CsA (1 muM) completely blocked free radical production following treatment with PK11195 and Ro5-4864 in all cell types. CsA was also effective in blocking free radical production in astrocytes following PpIX treatment, but it failed to do so in neurons and microglia. Our results indicate that exposure of neural cells to PBR ligands generates free radicals, and that the MPT may be involved in this process.	Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034951] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34951] Funding Source: Medline		Afonso S, 1999, FREE RADICAL RES, V31, P161, DOI 10.1080/10715769900300711; ANHOLT RRH, 1986, TRENDS PHARMACOL SCI, V7, P506, DOI 10.1016/0165-6147(86)90438-4; ANHOLT RRH, 1984, J NEUROSCI, V4, P593; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; APRILLE JR, 1977, SCIENCE, V197, P908, DOI 10.1126/science.887930; BASILE AS, 1987, BRAIN RES BULL, V19, P1, DOI 10.1016/0361-9230(87)90158-4; BASILE AS, 1989, J PHARMACOL EXP THER, V248, P463; BENAVIDES J, 1988, ANN NEUROL, V24, P708, DOI 10.1002/ana.410240603; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BERNASSAU JM, 1993, J MOL GRAPHICS, V11, P236, DOI 10.1016/0263-7855(93)80003-A; Berson A, 2001, J PHARMACOL EXP THER, V299, P793; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BETTENDORFF L, 1995, J NEUROCHEM, V64, P2013; BLACK KL, 1990, CANCER, V65, P93, DOI 10.1002/1097-0142(19900101)65:1<93::AID-CNCR2820650120>3.0.CO;2-1; BLOKHUIS GG, 1970, FEBS LETT, V11, P197, DOI 10.1016/0014-5793(70)80527-0; BOLGER GT, 1984, EUR J PHARMACOL, V105, P143, DOI 10.1016/0014-2999(84)90658-7; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; BROADDUS WC, 1990, BRAIN RES, V518, P199, DOI 10.1016/0006-8993(90)90973-F; Chelli B, 2001, BIOCHEM PHARMACOL, V61, P695, DOI 10.1016/S0006-2952(00)00588-8; COMPORTI M, 1985, LAB INVEST, V53, P599; Conway EL, 1998, NEUROSCIENCE, V82, P805; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAVAL JL, 1989, J NEUROCHEM, V52, P110, DOI 10.1111/j.1471-4159.1989.tb10904.x; Decaudin D, 2002, CANCER RES, V62, P1388; Desjardins P, 1999, NEUROCHEM INT, V35, P363, DOI 10.1016/S0197-0186(99)00082-0; DOBLE A, 1987, BRAIN RES BULL, V18, P49, DOI 10.1016/0361-9230(87)90033-5; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; DUCIS I, 1989, BRAIN RES, V493, P362, DOI 10.1016/0006-8993(89)91171-2; ESHLEMAN AJ, 1989, J NEUROCHEM, V53, P494, DOI 10.1111/j.1471-4159.1989.tb07361.x; Fennell DA, 2001, BRIT J CANCER, V84, P1397, DOI 10.1054/bjoc.2001.1788; Friberg H, 1998, J NEUROSCI, V18, P5151; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Gavish M, 1999, PHARMACOL REV, V51, P629; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; ITZHAK Y, 1993, GLIA, V9, P211, DOI 10.1002/glia.440090306; Jayakumar AR, 2001, J NEUROCHEM, V78, P25; JAYAKUMAR AR, 2002, IN PRESS SOC NEUR AB; Kinnally KW, 1996, J BIOENERG BIOMEMBR, V28, P115, DOI 10.1007/BF02110641; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Lacor P, 1996, NEUROSCI LETT, V220, P61, DOI 10.1016/S0304-3940(96)13187-6; LEONG DK, 1994, J CEREBR BLOOD F MET, V14, P100, DOI 10.1038/jcbfm.1994.14; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; MARANGOS PJ, 1982, MOL PHARMACOL, V22, P26; Marino F, 2001, PHARMACOLOGY, V63, P42, DOI 10.1159/000056111; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; McGeer E G, 1988, Alzheimer Dis Assoc Disord, V2, P331, DOI 10.1097/00002093-198802040-00001; McKenna MC, 1995, NEUROCHEM RES, V20, P1491, DOI 10.1007/BF00970599; Messmer K, 1998, NEUROSCI LETT, V241, P53, DOI 10.1016/S0304-3940(97)00967-1; MORENOSANCHEZ R, 1991, BIOCHEM PHARMACOL, V41, P1479, DOI 10.1016/0006-2952(91)90564-L; PANICKAR KS, 2001, J NEUROTRAUM, V18, P1160; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Papadopoulos V, 1998, P SOC EXP BIOL MED, V217, P130; Park CH, 1996, GLIA, V16, P65, DOI 10.1002/(SICI)1098-1136(199601)16:1<65::AID-GLIA7>3.0.CO;2-A; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; RUFF MR, 1985, SCIENCE, V229, P1281, DOI 10.1126/science.2994216; Schousboe A., 1989, DISSECTION TISSUE CU, P203; SONNEWALD U, 1993, DEV NEUROSCI-BASEL, V15, P351, DOI 10.1159/000111355; Sonnewald U, 1998, J CEREBR BLOOD F MET, V18, P231, DOI 10.1097/00004647-199803000-00001; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; TRIBBLE DL, 1987, HEPATOLOGY, V7, P377, DOI 10.1002/hep.1840070227; Veenman L, 2000, DRUG DEVELOP RES, V50, P355, DOI 10.1002/1098-2299(200007/08)50:3/4<355::AID-DDR18>3.0.CO;2-W; Veenman L, 2002, J NEUROCHEM, V80, P917, DOI 10.1046/j.0022-3042.2002.00769.x; VERMA A, 1989, ANNU REV PHARMACOL, V29, P307; VILLIGER JW, 1984, NEUROSCI LETT, V46, P267, DOI 10.1016/0304-3940(84)90110-1; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; Waagepetersen HS, 1999, ANN NY ACAD SCI, V893, P421, DOI 10.1111/j.1749-6632.1999.tb07869.x; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P753, DOI 10.1073/pnas.81.3.753; WEISSMAN BA, 1984, EUR J PHARMACOL, V97, P257; Yokoo H, 1996, J NEUROPATH EXP NEUR, V55, P716, DOI 10.1097/00005072-199606000-00005; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; Zorov DB, 1996, BBA-BIOENERGETICS, V1275, P10, DOI 10.1016/0005-2728(96)00042-4	87	63	63	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	DEC	2002	83	5					1226	1234		10.1046/j.1471-4159.2002.01261.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	621CR	WOS:000179571400022	12437594				2021-06-18	
J	Suhr, JA; Gunstad, J				Suhr, JA; Gunstad, J			Postconcussive symptom report: The relative influence of head injury and depression	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; CHRONIC-FATIGUE-SYNDROME; BASE RATES; SUBJECTIVE COMPLAINTS; COGNITIVE COMPLAINTS; ETIOLOGY; PERFORMANCE; SENSITIVITY; SPECIFICITY; INDIVIDUALS	The present study explored whether any subset of self-reported postconcussion (PCS) symptoms or specific PCS symptom is sensitive and/or specific to head injury in non-self-selected samples of individuals aged 18-21 with head injury and depression (n=32), head injury without depression (n=31), depression without head injury (n=25), and controls (n=50). All participants completed a self-report PCS symptom scale based on their current symptoms. Results showed that depression. not head-injury status, largely accounted for elevation in PCS symptom reports, including cognitive symptoms. Thus, report of cognitive PCS symptoms is not specific to head injury, raising concerns about using such items to screen for head injury in the general population.	Ohio Univ, Dept Psychol, Athens, OH 45701 USA	Suhr, JA (corresponding author), Ohio Univ, Dept Psychol, Porter Hall 200, Athens, OH 45701 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; ERRICO AL, 1990, PSYCHOL ASSESSMENT, V2, P45, DOI DOI 10.1037/1040-3590.2.1.45; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GFELLER J, 1996, ASSESSMENT, V3, P393; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jonker C, 2000, INT J GERIATR PSYCH, V15, P983, DOI 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MANDEL S, 1989, POSTGRAD MED, V85, P213; McClelland RJ, 1996, J PSYCHOSOM RES, V40, P563, DOI 10.1016/0022-3999(95)00616-8; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Schwartz CE, 1996, ANN BEHAV MED, V18, P177, DOI 10.1007/BF02883395; Tabachnick BG, 2013, USING MULTIVARIATE S; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; VINGERHOETS G, 1995, J PSYCHOSOM RES, V39, P843, DOI 10.1016/0022-3999(95)00021-3; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	35	63	64	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2002	24	8					981	993		10.1076/jcen.24.8.981.8372			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	642HA	WOS:000180797100001	12650225				2021-06-18	
J	Hawley, CA; Ward, AB; Magnay, AR; Long, J				Hawley, CA; Ward, AB; Magnay, AR; Long, J			Children's brain injury: a postal follow-up of 525 children from one health region in the UK	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; ADOLESCENTS; MOTOR; AGE; REHABILITATION; CHILDHOOD; INFANTS	Primary objectives: To follow-up a population of children admitted to one Hospital Trust with traumatic brain injury (TBI), and compare outcomes following mild TBI with outcomes following moderate or severe TBI. Research design: Population-based postal questionnaire survey. Methods and procedures: Questionnaires were mailed to parents of all 974 surviving children on a register of paediatric TBI admissions, 525 completed questionnaires were returned (56.2%). Most children (419) had suffered mild TBI, 57 moderate, and 49 severe. Main outcomes and results: Thirty per cent of parents received no information on post-injury symptoms, and clinical follow-up was limited. Statistically significant differences were observed between mild and moderate/severe groups for cognitive, social, emotional, and mobility problems. Nevertheless, similar to20% of the mild group suffered from poor concentration, personality change and educational problems post-injury. Few schools (20%) made special provision for children returning after injury. Conclusions: Children can have long-lasting and wide-ranging sequelae following TBI. Information should be routinely given to parents and schools after brain injury.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent ST6 7AG, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England	Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				*BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; Emanuelson I, 1998, INJURY, V29, P193, DOI 10.1016/S0020-1383(97)00177-0; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; *HOUS COMM SEL COM, 2001, 3 REP HEAD INJ REH; JOHNSON DA, 1998, ED NEEDS HEAD INJURY; JONES GS, 1994, NUCL MED BIOL, V21, P117, DOI 10.1016/0969-8051(94)90138-4; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kennard MA, 1936, AM J PHYSIOL, V115, P138; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; *N STAFF HLTH AUTH, 1994, HLTH N STAFF ANN REP; Norusis M. J, 1998, SPSS 8 0 GUIDE DATA; O'Flaherty SJ, 2000, ARCH PHYS MED REHAB, V81, P723, DOI 10.1053/apmr.2000.4428; Parmelee D X, 1989, Psychiatr Med, V7, P11; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; Schootman M, 1999, BRAIN INJURY, V13, P995; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; STILWELL J, 1998, REPORT NATL TRAUMATI; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO	34	63	66	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2002	16	11					969	985		10.1080/02699050210147239			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	609PQ	WOS:000178914500004	12443547				2021-06-18	
J	Wagner, KR; Packard, BA; Hall, CL; Smulian, AG; Linke, MJ; de Courten-Myers, GM; Packard, LM; Hall, NC				Wagner, KR; Packard, BA; Hall, CL; Smulian, AG; Linke, MJ; de Courten-Myers, GM; Packard, LM; Hall, NC			Protein oxidation and heme oxygenase-1 induction in porcine white matter following intracerebral infusions of whole blood or plasma	DEVELOPMENTAL NEUROSCIENCE			English	Article						intracerebral hemorrhage; white matter; protein oxidation; heme oxygenase; pigs	EDEMA DEVELOPMENT; BRAIN-INJURY; IN-VIVO; HEMORRHAGE; ACCUMULATION; EXPRESSION; SUSCEPTIBILITY; MICROGLIA; CYTOKINE; THROMBIN	Spontaneous or traumatic intracerebral hemorrhage (ICH) in the white matter of neonates, children and adults causes significant mortality and morbidity. The detailed biochemical mechanisms through which blood damages white matter are poorly defined. Presently, we tested the hypothesis that ICH induces rapid oxidative stress in white matter. Also, since clot-derived plasma proteins accumulate in white matter after ICH and these proteins can induce oxidative stress in microglia in vitro, we determined whether the blood's plasma component alone induces oxidative stress. Lastly, since heme oxygenase-1 (HO-1) induction is highly sensitive to oxidative stress, we also examined white matter HO-1 gene expression. We infused either whole blood,or plasma (2.5 ml) into the frontal hemispheric white matter of pentobarbital-anesthetized pigs (similar to1 kg) over 15 min. We monitored and controlled physiologic variables and froze brains in situ between 1 and 24 h after ICH. White matter oxidative stress was determined by measuring protein carbonyl formation and HO-1 gene expression by RT-PCR. Protein carbonyl formation occurred rapidly in the white matter adjacent to both blood and plasma clots with significant elevations (3- to 4-fold) already 1 h after infusion. This increase remained through the first 24 h. HO-1 mRNA was rapidly induced in white matter with either whole blood or plasma infusions. These results demonstrate that not only whole blood but also its plasma component are capable of rapidly inducing oxidative stress in white matter. This rapid response, possibly in microglial cells, may contribute to white matter damage not only following ICH, but also in pathophysiological states in which blood-brain-barrier permeability to plasma proteins is increased. Copyright (C) 2002 S. Karger AG, Basel.	Dept Vet Affairs Med Ctr, Med Res Serv, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Grad Program Neurosci, Cincinnati, OH USA	Wagner, KR (corresponding author), Dept Vet Affairs Med Ctr, Res Serv 151, 3200 Vine St, Cincinnati, OH 45220 USA.	wagnerkr@email.uc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030652] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS30652] Funding Source: Medline		Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P452, DOI 10.1097/00004647-200003000-00002; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Dean RT, 1997, BIOCHEM J, V324, P1; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dozois CM, 1997, VET IMMUNOL IMMUNOP, V58, P287, DOI 10.1016/S0165-2427(97)00039-1; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; Gebel JM, 1998, STROKE, V29, P563, DOI 10.1161/01.STR.29.3.563; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hall N, 1999, J NEUROCHEM, V72, pS33; Hall N, 1998, STROKE, V29, P273; Hall NC, 2000, CELL MOL BIOL, V46, P673; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; IBAS G, 1992, J NEUROTRAUMA S1, V9, pS265; JENKINS A, 1990, British Journal of Neurosurgery, V4, P45, DOI 10.3109/02688699009000681; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Lamb NJ, 1999, BIOCHEM J, V344, P153, DOI 10.1042/0264-6021:3440153; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matsuoka Y, 1999, NEUROPHARMACOLOGY, V38, P825, DOI 10.1016/S0028-3908(99)00020-9; Matz PG, 2001, J CEREBR BLOOD F MET, V21, P921, DOI 10.1097/00004647-200108000-00004; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; McCord JM, 1998, SEMIN HEMATOL, V35, P5; Murakami K, 1998, J NEUROTRAUM, V15, P825, DOI 10.1089/neu.1998.15.825; Nakaso K, 2000, NEUROSCI LETT, V293, P49, DOI 10.1016/S0304-3940(00)01491-9; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Packard B. A., 1999, Society for Neuroscience Abstracts, V25, P1849; Panahian N, 1999, J NEUROCHEM, V72, P1187; Peeling J, 1998, BRAIN RES, V795, P63, DOI 10.1016/S0006-8993(98)00253-4; Perlman JM, 1998, EARLY HUM DEV, V53, P99, DOI 10.1016/S0378-3782(98)00037-1; Richmon JD, 1998, BRAIN RES, V780, P108, DOI 10.1016/S0006-8993(97)01314-0; Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; Si QS, 1997, GLIA, V21, P413, DOI 10.1002/(SICI)1098-1136(199712)21:4<413::AID-GLIA9>3.0.CO;2-3; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Suttner DM, 1999, FASEB J, V13, P1800; Suzuki J, 1980, SPONTANEOUS INTRACER, P121; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Wagner KR, 2001, STROKE, V32, P327; Wagner KR, 1998, J NEUROSURG, V88, P1058, DOI 10.3171/jns.1998.88.6.1058; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; WAGNER KR, 2001, NEUROPROTECTION, P471; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580	49	63	65	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.	MAR-JUN	2002	24	2-3					154	160		10.1159/000065703			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	613QN	WOS:000179143100009	12401953				2021-06-18	
J	Horsfield, SA; Rosse, RB; Tomasino, V; Schwartz, BL; Mastropaolo, J; Deutsch, SI				Horsfield, SA; Rosse, RB; Tomasino, V; Schwartz, BL; Mastropaolo, J; Deutsch, SI			Fluoxetine's effects on cognitive performance in patients with traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						cognition; fluoxetine; neuronal remodeling; traumatic brain injury; SSRI's	RAT	Objective: There are preclinical data showing that fluoxetine stimulated expression of Brain Derived Neurotrophic Factor (BDNF) and its specific tyrosine kinase receptor, and caused neuritic elongation and increased dendritic branching density of CA3 hippocampal pyramidal cell neurons in rodents. The latter effect of fluoxetine has been referred to as neuronal remodeling. In view of this preclinical data, we wondered if specific cognitive measures could serve as novel therapeutic targets for fluoxetine in head-injured patients. Theoretically, fluoxetine-induced "neuronal remodeling" might improve cognition, independently of a primary effect on mood. Method: In an open-label pilot investigation, fluoxetine hydrochloride (Prozac; 20-60 mg/day) was administered to a heterogeneous group of five head-injured patients with either no or moderate depression for a period of eight months. These patients had no histories of prior treatment with antidepressant medications. They were administered cognitive and memory tests at baseline and after eight months of treatment on fluoxetine. Results: The preliminary results showed that fluoxetine improved mood, in addition to improving performance on the Trail Making Test Part A, an attentional-motor speed task, and the letter-number sequencing subtest of the WAIS-III, a measure reflecting "working memory." Conclusions: Although fluoxetine had beneficial effects on some measures of cognition, more work is needed to connect these improvements with neuronal remodeling.	Mental Hlth Serv Line, Dept Vet Affairs, Ctr Med, Washington, DC 20422 USA; Georgetown Univ, Sch Med, Dept Psychiat, Washington, DC USA	Deutsch, SI (corresponding author), Mental Hlth Serv Line, Dept Vet Affairs, Ctr Med, 116A 50 Irving St,NW, Washington, DC 20422 USA.						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P171; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Caine ED, 2000, COMPREHENSIVE TXB PS, P854; Detre JA, 2001, ANN NEUROL, V50, P697, DOI 10.1002/ana.10076; Fava M, 1999, J CLIN PSYCHIAT, V60, P21; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GREBB JA, 2000, COMPREHENSIVE TXB PS, P2235; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Lezak MD, 1983, NEUROPSYCHOLOGICAL A, P533; Morinobu S, 1997, SYNAPSE, V25, P313, DOI 10.1002/(SICI)1098-2396(199704)25:4<313::AID-SYN1>3.3.CO;2-J; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Parker ES, 1995, J CLIN EXP NEUROPSYC, V17, P926, DOI 10.1080/01688639508402441; *SCI RES ASS, 1948, ARM GEN CLASS TEST; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yudofsky SC, 1987, TXB NEUROPSYCHIATRY, P179	15	63	63	0	6	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701 USA	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		2002	32	4					337	344		10.2190/KQ48-XT0L-2H14-5UMV			8	Psychiatry	Psychiatry	680XK	WOS:000183005200002	12779183				2021-06-18	
J	Adelson, PD; Jenkins, LW; Hamilton, RL; Robichaud, P; Tran, MP; Kochanek, PM				Adelson, PD; Jenkins, LW; Hamilton, RL; Robichaud, P; Tran, MP; Kochanek, PM			Histopathologic response of the immature rat to diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; diffuse axonal injury; experimental model; head injury; histopathology; pediatrics; rodent	LONG-TERM POTENTIATION; SEVERE HEAD-INJURY; COMA DATA-BANK; AXONAL INJURY; HIPPOCAMPUS; CHILDREN; MODEL; CA1; SYNAPSES; EDEMA	The purpose of this study was to characterize the histopathologic response of rats at postnatal day (PND) 17 following an impact-acceleration diffuse traumatic brain injury (TBI) using a 150-g/2-meter injury as previously described. This injury produces acute neurologic and physiologic derangements as well as enduring motor and Morris water maze (MWM) functional deficits. Histopathologic studies of perfusion-fixed brains were performed by gross examination and light microscopy using hematoxylin and eosin, Bielschowsky silver stain, and glial fibrillary acidic protein (GFAP) immunohistochemistry at 1, 3, 7, 28, and 90 day after injury. Gross pathologic examination revealed diffuse subarachnoid hemorrhage (SAH) at 1-3 days but minimal supratentorial intraparenchymal hemorrhage. Petechial hemorrhages were noted in ventral brainstem segments and in the cerebellum. After 1-3-day survivals, light microscopy revealed diffuse SAH and intraventricular hemorrhage (IVH), mild edema, significant axonal injury, reactive astrogliosis, and localized midline cerebellar hemorrhage. Axonal injury most commonly occurred in the long ascending and descending fiber tracts of the brainstem and occasionally in the forebrain, and was maximal at 3 days, but present until 7 days after injury. Reactive astrocytes were similarly found both in location and timing, but were also significantly identified in the hippocampus, white matter tracts, and corpus callosum. Typically, TBI produced significant diffuse SAH accompanied by cerebral and brainstem astrogliosis and axonal injury without obvious neuronal loss. Since this injury produces some pathologic changes with sustained functional deficits similar to TBI in infants and children, it should be useful for the further study of the pathophysiology and therapy of diffuse TBI and brainstem injury in the immature brain.	Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Adelson, PD (corresponding author), Childrens Hosp Pittsburgh, Dept Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.	adelsod@chplink.chp.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, K08NS001809, P01NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40049, NS30318, KO8 NS01809] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; ADELSON PD, 1997, J NEUROTRAUM, V14, P787; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BARNES CA, 1994, J NEUROSCI, V14, P5793; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOTHE HW, 1986, STROKE, V17, P1160, DOI 10.1161/01.STR.17.6.1160; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cimadevilla JM, 1997, MECH AGEING DEV, V99, P49, DOI 10.1016/S0047-6374(97)00090-0; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARCIA JH, 1978, ACTA NEUROPATHOL, V43, P85; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, V1, P86; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; IZUMI Y, 1995, SYNAPSE, V20, P19, DOI 10.1002/syn.890200104; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LINDENBERG R, 1955, P 2 INT C NEUR LOND, P477; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Printz J, 1998, AGRO FOOD IND HI TEC, V9, P15; STEWARD O, 1986, J NEUROSCI, V6, P412; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEYLER TJ, 1989, NEUROPSYCHOLOGIA, V27, P31, DOI 10.1016/0028-3932(89)90088-2; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9; Zaidel DW, 1999, ANAT REC, V254, P87, DOI 10.1002/(SICI)1097-0185(19990101)254:1<87::AID-AR11>3.0.CO;2-T	38	63	66	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					967	976		10.1089/08977150152693674			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000001	11686497				2021-06-18	
J	Niskakangas, T; Ohman, J; Niemela, M; Ilveskoski, E; Kunnas, TA; Karhunen, PJ				Niskakangas, T; Ohman, J; Niemela, M; Ilveskoski, E; Kunnas, TA; Karhunen, PJ			Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage - A preliminary study	STROKE			English	Article						apolipoproteins; genetics; outcome; subarachnoid hemorrhage	E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; E IMMUNOREACTIVITY; INTRACEREBRAL HEMORRHAGE; CEREBRAL-ISCHEMIA; TERM SURVIVAL; BRAIN INJURY; BETA-PROTEIN; HEAD-INJURY; POPULATION	Background and Purpose-Variation in the outcome after aneurysmal subarachnoid hemorrhage (SAH) is not fully explained by known prognostic factors. APOE genotype is the most important genetic determinant of susceptibility to Alzheimer's disease, and it is also shown to be associated with the outcome after traumatic brain injury. We studied the association of apolipoprotein E polymorphism with the outcome after aneurysmal SAH. Methods-A total of 160 consecutive patients were admitted after SAH to a neurosurgical unit. The clinical assessment after the SAH was performed with the Hunt and Hess grading scale. The severity of the bleeding as visualized on CT was assessed by Fisher's grading system, Outcome was assessed with the Glasgow Outcome Scale. APOE genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism. Results-126 patients had aneurysmatic SAH, and detailed information on outcome and APOE genotype was available for 108 patients (86%). Sixteen (40%) of 40 patients with APOE epsilon4 had an unfavorable outcome compared with 13 (19%) of 68 without the APOE epsilon4 allele (OR 2.8, 95% CI 1.18 to 6.77). Association was more significant after adjustment for age, rebleeding, clinical status on admission, and CT scan findings (OR 7.1, 95% CI 1.9 to 26.3; P=0.0035). Conclusions-Our findings show a significant genetic association of APOE polymorphism with outcome after spontaneous aneurysmal SAH, Genetic factors thus seem to explain a part of individual differences in the recovery of SAH,	Univ Helsinki, Cent Hosp, Dept Neurosurg, FIN-00260 Helsinki, Finland; Univ Tampere, Dept Forens Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Kuopio, Dept Clin Pathol & Forens Med, Kuopio, Finland	Niskakangas, T (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, Topeliuksenkatu 5, FIN-00260 Helsinki, Finland.		Niemela, Mika R/F-2539-2015	Niemela, Mika R/0000-0003-1526-0684; Ohman, Juha/0000-0002-6592-1367			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; EHNHOLM C, 1986, J LIPID RES, V27, P227; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FOGELHOLM R, 1981, STROKE, V12, P296, DOI 10.1161/01.STR.12.3.296; FOGELHOLM R, 1993, STROKE, V24, P1649, DOI 10.1161/01.STR.24.11.1649; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Ilveskoski E, 1998, J NEUROSCI METH, V79, P5, DOI 10.1016/S0165-0270(97)00157-X; INAGAWA T, 1995, STROKE, V26, P761, DOI 10.1161/01.STR.26.5.761; Jakobsson KE, 1996, J NEUROSURG, V85, P995, DOI 10.3171/jns.1996.85.6.0995; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Neil-Dwyer G, 1998, ACTA NEUROCHIR, V140, P1019, DOI 10.1007/s007010050210; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; Pluta R, 1997, NEUROSCI LETT, V232, P95, DOI 10.1016/S0304-3940(97)00571-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Wijdicks EFM, 1998, MAYO CLIN PROC, V73, P745, DOI 10.4065/73.8.745; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423	42	63	70	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAY	2001	32	5					1181	1184		10.1161/01.STR.32.5.1181			4	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	430MG	WOS:000168577200028	11340230	Bronze			2021-06-18	
J	Hall, CD; Smith, AL; Keele, SW				Hall, CD; Smith, AL; Keele, SW			The impact of aerobic activity on cognitive function in older adults: A new synthesis based on the concept of executive control	EUROPEAN JOURNAL OF COGNITIVE PSYCHOLOGY			English	Article							CEREBRAL BLOOD-FLOW; PHYSICAL-ACTIVITY LEVEL; CLOSED-HEAD INJURY; REACTION-TIME; PREFRONTAL CORTEX; AGE-DIFFERENCES; EXERCISE; PERFORMANCE; FITNESS; HEALTH	Numerous reaction time studies have suggested that age-related declines in cognitive function might be ameliorated by lifestyles involving aerobic activity or by interventionist programmes of aerobic exercise. These studies are far from conclusive, however, reflecting a failure to factor out cognitive from sensory and motor processes. Following a critical review of the literature, we report on recent developments that differentiate cognitive processes involving executive vs non-executive control, the former being associated with frontal lobe function. Three key studies suggest that aerobic exercise primarily improves executive control.	Univ Oregon, Dept Psychol, Eugene, OR 97405 USA; Univ Texas, Austin, TX 78712 USA; Purdue Univ, W Lafayette, IN 47907 USA; Univ Oregon, Eugene, OR 97403 USA	Keele, SW (corresponding author), Univ Oregon, Dept Psychol, Eugene, OR 97405 USA.		Smith, Alan L./I-5124-2015	Smith, Alan L./0000-0003-2267-7293			ABOUREZK T, 1995, J AGING PHYS ACTIV, V3, P251, DOI 10.1123/japa.3.3.251; ALLPORT A, 1994, ATTENTION PERFORM, V15, P421; *AM COLL SPORTS ME, 1986, GUID GRAD EX PRESCR; BAYLOR AM, 1988, J GERONTOL, V43, pP121, DOI 10.1093/geronj/43.5.P121; Birren J. E., 1965, BEHAV AGING NERVOUS, P191; BLUMENTHAL JA, 1991, J GERONTOL, V46, P352; Bouchard C, 1995, RES Q EXERCISE SPORT, V66, P268, DOI 10.1080/02701367.1995.10607911; CERELLA J, 1985, PSYCHOL BULL, V98, P67, DOI 10.1037/0033-2909.98.1.67; CLARKSONSMITH L, 1989, PSYCHOL AGING, V4, P183, DOI 10.1037/0882-7974.4.2.183; DONDERS FC, 1969, ACTA PSYCHOL, V30, P412, DOI 10.1016/0001-6918(69)90065-1; Dustman R. E., 1994, Journal of Aging and Physical Activity, V2, P143; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; EMERY CF, 1995, GERONTOLOGIST, V35, P378, DOI 10.1093/geront/35.3.378; Etnier JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/jsep.19.3.249; Frith CD, 2000, ATTENTION PERFORMANC, VXVIII; Gregoire J, 1997, AGING NEUROPSYCHOL C, V4, P140, DOI 10.1080/13825589708256642; GUR RC, 1987, ARCH GEN PSYCHIAT, V44, P617; HAWKINS HL, 1992, PSYCHOL AGING, V7, P643, DOI 10.1037/0882-7974.7.4.643; Keele S.W., 1973, ATTENTION HUMAN PERF; KEELE SW, 1985, HDB PERCEPTION PERFO; KEELE SW, 2000, ATTENTION PERFORMANC, V18; KERR B, 1993, ANN M PSYCH SOC WASH; Konishi S, 1998, NAT NEUROSCI, V1, P80, DOI 10.1038/283; KRAMER AE, IN PRESS HUMAN FACTO; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Kray J, 2000, PSYCHOL AGING, V15, P126, DOI 10.1037//0882-7974.15.1.126; Lee IM, 1995, RES Q EXERCISE SPORT, V66, P286, DOI 10.1080/02701367.1995.10607913; LINDENBERGER U, 1993, PSYCHOL AGING, V8, P207, DOI 10.1037/0882-7974.8.2.207; LUPINACCI NS, 1993, RES Q EXERCISE SPORT, V64, P144, DOI 10.1080/02701367.1993.10608791; MADDEN DJ, 1989, PSYCHOL AGING, V4, P307, DOI 10.1037/0882-7974.4.3.307; MAYR U, 1993, J EXP PSYCHOL LEARN, V19, P1297, DOI 10.1037/0278-7393.19.6.1297; Mayr U, 1996, COGNITION, V59, P61, DOI 10.1016/0010-0277(95)00689-3; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Meyer DE, 1997, PSYCHOL REV, V104, P3, DOI 10.1037/0033-295X.104.1.3; MEYER DE, 1998, COGN NEUR SOC SAN FR; MEYERSON J, 1990, PSYCHOL REV, V97, P475; Monsell S., 2000, ATTENTION PERFORMANC; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; PANTON LB, 1990, J GERONTOL, V41, P645; PETRIDES M, 2000, ATTENTION PERFORMANC, V18; Posner MI., 1978, CHRONOMETRIC EXPLORA; RIKLI R, 1986, J GERONTOL, V41, P645, DOI 10.1093/geronj/41.5.645; RIKLI RE, 1991, RES Q EXERCISE SPORT, V62, P61, DOI 10.1080/02701367.1991.10607519; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Rogers RD, 1998, BRAIN, V121, P815, DOI 10.1093/brain/121.5.815; SALTHOUSE TA, 1985, THEORY COGNITIVE AGI, P249; SHAW TG, 1984, NEUROLOGY, V34, P855, DOI 10.1212/WNL.34.7.855; SHAY KA, 1992, PSYCHOL AGING, V7, P15, DOI 10.1037/0882-7974.7.1.15; SPECTOR A, 1976, AM J PSYCHOL, V89, P669, DOI 10.2307/1421465; SPIRDUSO WW, 1975, J GERONTOL, V30, P435, DOI 10.1093/geronj/30.4.435; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STERNBERG S, 1969, AM SCI, V57, P521; UMILTA C, 1992, EUR J COGN PSYCHOL, V4, P21, DOI 10.1080/09541449208406241; US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Vuori I, 1995, RES Q EXERCISE SPORT, V66, P276, DOI 10.1080/02701367.1995.10607912; WARREN LR, 1985, J GERONTOL, V40, P53, DOI 10.1093/geronj/40.1.53; WEISS AD, 1965, J GERONTOL, V20, P60, DOI 10.1093/geronj/20.1.60; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; WHITEHURST M, 1991, PERCEPT MOTOR SKILL, V72, P251, DOI 10.2466/PMS.72.1.251-256	61	63	64	0	17	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0954-1446			EUR J COGN PSYCHOL	Eur. J. Cogn. Psychol.	MAR-JUN	2001	13	1-2					279	300		10.1080/09541440042000313			22	Psychology, Experimental	Psychology	425EF	WOS:000168274800014					2021-06-18	
J	Mellman, TA; David, D; Bustamante, V; Fins, AI; Esposito, K				Mellman, TA; David, D; Bustamante, V; Fins, AI; Esposito, K			Predictors of post-traumatic stress disorder following severe injury	DEPRESSION AND ANXIETY			English	Article						stress disorder; post-traumatic; risk factors; injury; dissociation; coping; arousal	VEHICLE ACCIDENT VICTIMS; POSTTRAUMATIC-STRESS; COPING STRATEGIES; FEMALE VICTIMS; RAPE; SURVIVORS; VETERANS; OUTCOMES; ASSAULT; SCALE	The chronicity and morbidity of established post-traumatic stress disorder (PTSD) has stimulated interest in recognizing and understanding the early development of the disorder. Acute stress disorder, a new diagnosis intended to facilitate early case detection, res-ts on the occurrence of dissociative reactions. It remains uncertain whether dissociation is a universal or unique early predictor of subsequent PTSD. Traumatic injury is an important and relatively understudied antecedent of PTSD. The objective of this Study was to preliminarily identify which previously implicated early reactions and risk factors would apply to the prediction of PTSD following severe traumatic injury. Patients admitted to a regional Level I trauma center following life threatening events who bad recall of the incident and did not have signs of traumatic brain injury or recent psychopathology were enrolled. Comprehensive assessments were conducted during hospitalization and after discharge approximately 2 months after the traumatic event. At follow-up, 24% of the available 50 subjects met full criteria for PTSD and an additional 22% met criteria for two of three symptom clusters. Early symptoms of heightened arousal and coping with disengagement were independent predictors of PTSD severity at follow-up. Relationships to initial dissociative reactions and a diagnosis of ASD were not significant. These early predictors found in a setting of severe injury only partially overlap findings front previous PTSD studies. (C) 2001 Wiley-Liss, Inc.	Univ Miami, Sch Med, Dept Psychiat & Behav Sci, Miami, FL USA; Dartmouth Coll Sch Med, Dept Psychiat, Lebanon, NH USA	Mellman, TA (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.		Esposito, Karin/AAG-6878-2019		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH054006] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH54006] Funding Source: Medline		*AM COLL SURG, 1999, REP COMM TRAUM RES O; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blake D. D., 1990, BEHAV THER, V13, P187; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Classen C, 1998, AM J PSYCHIAT, V155, P620, DOI 10.1176/ajp.155.5.620; Dancu CV, 1996, J TRAUMA STRESS, V9, P253, DOI 10.1002/jts.2490090208; FLEMING R, 1992, J HUMAN STRESS, V9, P14; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; MAYOU R, 1993, BRIT MED J, V307, P9; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; North CS, 1997, AM J PSYCHIAT, V154, P1696, DOI 10.1176/ajp.154.12.1696; Resnick H, 1997, NATL CTR PTSD CLIN Q, V7, P41; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Spitzer RL, 1994, INSTRUCTION MANUAL S; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Valentiner DP, 1996, J ABNORM PSYCHOL, V105, P455, DOI 10.1037/0021-843X.105.3.455; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690	30	63	63	0	8	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	1091-4269			DEPRESS ANXIETY	Depress. Anxiety		2001	14	4					226	231		10.1002/da.1071			6	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	504YB	WOS:000172882800005	11754130				2021-06-18	
J	Strauss, DJ; Ashwal, S; Day, SM; Shavelle, RM				Strauss, DJ; Ashwal, S; Day, SM; Shavelle, RM			Life expectancy of children in vegetative and minimally conscious states	PEDIATRIC NEUROLOGY			English	Article							LONG-TERM SURVIVAL; CEREBRAL-PALSY; MENTAL-RETARDATION; NATURAL-HISTORY; CNS INJURIES; BRAIN INJURY; PERSISTENT; SCOLIOSIS; MORTALITY; DIFFICULTIES	We determined estimates of survival in children, 3-15 years of age, in the vegetative state (VS) (n = 564), immobile minimally conscious state (MCS) (n = 705), and mobile MCS (n = 3,806), Data were extracted from the annual Client Development Evaluation Reports of the California Department of Developmental Services between 1988 and 1997 using the operational definitions for these three states on the basis of 15 descriptive behavioral categories. Patients were also categorized according to the following four etiologies: acquired (traumatic and nontraumatic) brain injury; perinatal/genetic; degenerative; and unknown/undetermined, The percentage of patients surviving 8 Sears was 63%, 65%, and 81%, for the VS, immobile MCS, and mobile MCS, respectively. Children in the VS and MCSs with acquired brain injury had lower mortality rates and those with degenerative diseases the highest mortality rates. We observed little difference in survival between patients in the VS and immobile MCS, suggesting that the presence of consciousness is not a critical variable in determining life expectancy. Furthermore, survival was much greater for patients in the mobile MCS than for those in the immobile MCS, suggesting that mobility is more important in predicting survival than the level of consciousness. (C) 2000 by Elsevier Science Inc. All rights reserved.	Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, 11175 Campus St,Coleman Pavil, Loma Linda, CA 92350 USA.		Day, Steven/P-1002-2019	Day, Marc/0000-0002-1711-3963; Day, Steven/0000-0001-8305-5813			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; ASHWAL S, 1994, PEDIATR NEUROL, V10, P27, DOI 10.1016/0887-8994(94)90063-9; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Broder Andrew J, 1995, Univ Detroit Mercy Law Rev, V72, P787; *CAL DEP DEV SERV, 1978, CLIENT DEV EV REP; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Collett D., 1994, MODELLING SURVIVAL D; Cranford RE, 1998, GERIATRICS, V53, pS70; DETOLEDO J, 1994, BRAIN INJURY, V8, P607, DOI 10.3109/02699059409151013; DeToledo JC, 1999, BRAIN INJURY, V13, P39, DOI 10.1080/026990599121863; Eyman RK, 1996, DIAGNOSIS MANAGEMENT, P543; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Gillon R, 1998, J MED ETHICS, V24, P75, DOI 10.1136/jme.24.2.75; HAIG AJ, 1994, NEW ENGL J MED, V331, P1380; HARRIS CW, 1982, INTERRATER RELIABILI; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; Hosmer D, 1989, APPL LOGISTIC REGRES; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; KOHDA E, 1994, ACTA OTO-LARYNGOL, P11; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Majd ME, 1997, SPINE, V22, P1461, DOI 10.1097/00007632-199707010-00007; Martin Bonnie J. W., 1994, Dysphagia, V9, P1; McLean SAM, 1999, J CLIN PATHOL, V52, P490, DOI 10.1136/jcp.52.7.490; MINDERHOUD JM, 1985, NED TIJDSCHR GENEES, V29, P2385; Nelson L J, 1999, J Contemp Health Law Policy, V15, P427; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; Piguet O, 1999, BRAIN INJURY, V13, P829, DOI 10.1080/026990599121223; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; Saito N, 1998, LANCET, V351, P1687, DOI 10.1016/S0140-6736(98)01302-6; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, ACTA NEUROCHIR, V112, P110, DOI 10.1007/BF01405137; Strauss D, 1998, J Insur Med, V30, P96; Strauss D, 1998, DEV MED CHILD NEUROL, V40, P369; Strauss D, 1996, AM J MENT RETARD, V101, P26; Strauss D, 1998, MENT RETARD, V36, P360, DOI 10.1352/0047-6765(1998)036<0360:MOAWDD>2.0.CO;2; Strauss D, 1997, PEDIATRICS, V99, P358, DOI 10.1542/peds.99.3.358; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; WIDAMAN KF, 1984, 92 ANN M AM PSYCH AS; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN; Zafonte RD, 1996, NEUROREHABILITATION, V6, P19, DOI 10.3233/NRE-1996-6104; 1996, ASP CONS C	53	63	64	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	OCT	2000	23	4					312	319		10.1016/S0887-8994(00)00194-6			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	372FQ	WOS:000165224000003	11068163	Green Published			2021-06-18	
J	Mu, XJ; Azbill, RD; Springer, JE				Mu, XJ; Azbill, RD; Springer, JE			Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						excitotoxicity; glucocorticoids; glutamate release; myelin; spinal cord trauma	NEUROPROTECTIVE AGENT RILUZOLE; AMYOTROPHIC-LATERAL-SCLEROSIS; NMDA RECEPTOR ANTAGONISTS; EXCITATORY AMINO-ACIDS; NERVOUS-SYSTEM INJURY; LIPID-PEROXIDATION; SODIUM-CHANNELS; GRANULE CELLS; BRAIN INJURY; TISSUE LOSS	The potential use of riluzole (a glutamate release inhibitor) alone or in combination with methylprednisolone (MP) in treating acute spinal cored injury (SCI) was examined. Rats received a contusion injury to the spinal cord using the NYU impactor and were treated with vehicle, riluzole (8 mg/kg), MP(30 mg/kg), or riluzole + MP at 2 and 4 h following injury. Animals continued to receive riluzole treatment (8 mg/kg) for a period of 1 week. The animals were then tested weekly for functional recovery using the BBB open field locomotor score. At the end of testing (6 weeks after injury), each spinal cord was examined for the amount of remaining tissue at the injury site and a myelination index was used to quantify remaining axons in the ventromedial white matter. In this study, only the combination treatment was found to significantly improve behavioral recovery as assessed using the BBB open field locomotor scale. In addition, the combination treatment promoted tissue sparing at the lesion epicenter, but had no clear effect on the index of myelnation. The results of this study clearly demonstrate the potential beneficial effects of a combination approach in the treatment of traumatic SCI.	Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Ctr Spinal Cord & Brain Injury Res, Lexington, KY 40536 USA	Mu, XJ (corresponding author), Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Ctr Spinal Cord & Brain Injury Res, 800 Rose St, Lexington, KY 40536 USA.			Azbill, David/0000-0001-7989-1771	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040015, R01NS030248] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30248, R01 NS040015, NS40015] Funding Source: Medline		Agrawal SK, 1997, J NEUROSCI, V17, P1055; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BOENING JA, 1989, NEUROSCIENCE, V33, P263, DOI 10.1016/0306-4522(89)90205-4; Bryson HM, 1996, DRUGS, V52, P549, DOI 10.2165/00003495-199652040-00010; CHERAMY A, 1992, NEUROSCI LETT, V147, P209, DOI 10.1016/0304-3940(92)90597-Z; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; COURATIER P, 1994, NEUROREPORT, V5, P1012, DOI 10.1097/00001756-199404000-00040; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; DOBLE A, 1996, NEUROLOGY S4, V47, P233; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Farooque M, 1997, EXP BRAIN RES, V113, P1, DOI 10.1007/BF02454136; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1992, N NEUROTRAUMA S1, V9, pS165; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; Huang CS, 1997, J PHARMACOL EXP THER, V282, P1280; HUBERT JP, 1994, BRIT J PHARMACOL, V113, P261, DOI 10.1111/j.1476-5381.1994.tb16203.x; ILDAN F, 1995, NEUROSURG REV, V18, P35, DOI 10.1007/BF00416476; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; MALGOURIS C, 1994, NEUROSCI LETT, V177, P95, DOI 10.1016/0304-3940(94)90053-1; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Mu XJ, 2000, BRAIN RES, V870, P66, DOI 10.1016/S0006-8993(00)02402-1; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; PRENEN GHM, 1988, EXP NEUROL, V99, P118, DOI 10.1016/0014-4886(88)90132-X; ROMETTINO S, 1991, EUR J PHARMACOL, V199, P371, DOI 10.1016/0014-2999(91)90503-I; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; Song JH, 1997, J PHARMACOL EXP THER, V282, P707; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Springer JE, 1997, J NEUROCHEM, V68, P2469; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teng YD, 1997, J NEUROSCI, V17, P4359; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Watanabe M, 1998, J NEUROTRAUM, V15, P285, DOI 10.1089/neu.1998.15.285; Wokke J, 1996, LANCET, V348, P795, DOI 10.1016/S0140-6736(96)03181-9; Wrathall JR, 1998, J NEUROSCI, V18, P8780; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; YOUNG W, 1994, ANN NY ACAD SCI, V743, P241, DOI 10.1111/j.1749-6632.1994.tb55796.x; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	59	63	66	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2000	17	9					773	780		10.1089/neu.2000.17.773			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	356LM	WOS:000089444800005	11011817				2021-06-18	
J	McGowan, JC; Yang, JH; Plotkin, RC; Grossman, RI; Umile, EM; Cecil, KM; Bagley, LJ				McGowan, JC; Yang, JH; Plotkin, RC; Grossman, RI; Umile, EM; Cecil, KM; Bagley, LJ			Magnetization transfer imaging in the detection of injury associated with mild head trauma	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	6th Annual Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine	APR 17-25, 1998	SYDNEY, AUSTRALIA	Int Soc Magnet Resonance Med			APPEARING WHITE-MATTER; MULTIPLE-SCLEROSIS LESIONS; DIFFUSE AXONAL INJURY; HISTOPATHOLOGIC CORRELATION; BRAIN INJURY; MR; SPECTROSCOPY; PIG	BACKGROUND AND PURPOSE: Most traumatic brain injuries are classified as mild, yet in many instances cognitive deficits result, The purpose of this study was to investigate possible relationships between quantitative magnetization transfer imaging (MTI) and neurocognitive findings in a cohort of patients with mild head trauma but negative findings on conventional MR images. METHODS: We examined 13 patients and 10 healthy volunteers with a standard MR protocol including fast spin-echo and gradient-echo imaging, to which was added quantitative MTI, MTI was performed with a modified gradient-echo sequence incorporating pulsed, off-resonance saturation. Both region-of-interest analysis and contour plots were obtained from the MTI data. A subgroup of nine patients was examined with a battery of neuropsychological tests, comprising 25 measures of neurocognitive ability. RESULTS: The magnetization transfer ratio (MTR) in the splenium of the corpus callosum was lower in the patient group as compared with the control group, but no significant reduction in MTR was found in the pens. Individual regional MTR values were significantly reduced in two cases, and contour plot analysis revealed focal areas of abnormality in the splenium of four patients. All the patients showed impairment on at least three measures of the neuropsychological test battery, and in two cases a significant correlation was found between regional MTR values and neuropsychological performance. CONCLUSION: Our results suggest that MTI and contour plot analysis may add sensitivity to the MR imaging examination of patients with traumatic brain injury.	Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Rehabil Med, Philadelphia, PA 19104 USA	McGowan, JC (corresponding author), Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.			Cecil, Kim/0000-0001-8233-5485	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29029, NS34353, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R37NS029029, P50NS008803, R29NS034353, R55NS034353, R01NS029029] Funding Source: NIH RePORTER		Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; FILIPPI M, 1995, NEUROLOGY, V45, P478, DOI 10.1212/WNL.45.3.478; Filippi M, 1997, J NEUROL SCI, V147, P151, DOI 10.1016/S0022-510X(96)05322-1; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GILROY J, 1982, BASIC NEUROLOGY, P329; GOMORI JM, 1993, AM J NEURORADIOL, V14, P871; HENKELMAN RM, 1993, MAGNET RESON MED, V29, P759, DOI 10.1002/mrm.1910290607; HIEHLE JF, 1995, AM J NEURORADIOL, V16, P69; HIEHLE JF, 1994, MAGNET RESON MED, V32, P285, DOI 10.1002/mrm.1910320303; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Long C. J., 1992, HDB HEAD TRAUMA ACUT; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; MCGOWAN JC, 1994, MAGNET RESON MED, V32, P517, DOI 10.1002/mrm.1910320415; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Petrella JR, 1996, AM J NEURORADIOL, V17, P1041; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; van Buchem MA, 1998, NEUROLOGY, V50, P1609, DOI 10.1212/WNL.50.6.1609; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011	26	63	66	0	0	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2000	21	5					875	880					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	313CU	WOS:000086983400014	10815663				2021-06-18	
J	Chen, T; Qian, YZ; Di, X; Rice, A; Zhu, JP; Bullock, R				Chen, T; Qian, YZ; Di, X; Rice, A; Zhu, JP; Bullock, R			Lactate/glucose dynamics after rat fluid percussion brain injury	JOURNAL OF NEUROTRAUMA			English	Article						glucose; lactate; microdialysate; traumatic brain injury	EXCITATORY AMINO-ACIDS; CORTICAL EXTRACELLULAR LEVELS; CEREBROSPINAL-FLUID; ENERGY-METABOLISM; SYNAPTIC FUNCTION; CONTUSION TRAUMA; HEAD-INJURY; CELL-DAMAGE; LACTATE; GLUCOSE	Traumatic brain injury (TBI) places enormous early energy demand on brain tissue to reinstate normal ionic balance. Clinical studies have demonstrated a decline in extracellular fluid (ECF) glucose and an increase in lactate after TBI. In vitro studies suggest that this increase in lactate is mediated by increased glutamate and may provide a metabolic substrate for neurons, to aid in ionic restoration. This led us to hypothesize that high ECF lactate may be beneficial in recovery following TBI, where major ionic flux has been shown to occur. In this study, we measured cerebral dialysate lactate and glucose, and arterial lactate and glucose, before and after rat lateral fluid percussion brain injury (FPI; 2.06 +/- 0.13 atm) with and without IV lactate infusion (100 mM x 0.65 mL/h X 5 h) to test the hypothesis that arterial lactate can influence ECF lactate. Dialysate lactate increased within 10 min following FPI, with higher values in the lactate infusion group. Following FPI, the dialysate lactate increase was 238% with lactate infusion versus 171% increase with saline infusion. Dialysate glucose fell immediately following FPI, with a more severe decline in the saline group. The glucose decrease was 231% greater in the IV saline group. Furthermore, in the lactate infusion group, the dialysate glucose levels recovered to baseline levels by 4 h after injury, whereas they remained depressed through out the experiment, in the saline infusion group. We conclude that arterial lactate augmentation can increase brain dialysate lactate, and result in more rapid recovery of dialysate glucose after FPI. This may indicate a beneficial role for lactate, that may be potentially useful in the clinical situation, after TBI.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NIH12587] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CROCKARD HA, 1972, EUR NEUROL, V8, P151, DOI 10.1159/000114569; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DREWES LR, 1973, ARCH NEUROL-CHICAGO, V29, P385, DOI 10.1001/archneur.1973.00490300047005; ENEVOLDSEN EM, 1977, CLIN NEUROL NEUROSUR, V80, P213; FERNANDES J, 1982, LANCET, V1, P113; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; IZUMI Y, 1994, NEUROREPORT, V5, P617, DOI 10.1097/00001756-199401000-00021; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KING LR, 1974, J NEUROSURG, V40, P617, DOI 10.3171/jns.1974.40.5.0617; KNUDSEN GM, 1991, J CEREBR BLOOD F MET, V11, P581, DOI 10.1038/jcbfm.1991.107; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; LJUNGGREN B, 1974, BRAIN RES, V77, P173, DOI 10.1016/0006-8993(74)90782-3; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; METZEL E, 1971, ACTA NEUROCHIR, V25, P177, DOI 10.1007/BF01809099; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLDENDORF WH, 1971, EUR NEUROL, V6, P49, DOI 10.1159/000114465; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; SCHURR A, 1987, BRAIN RES, V421, P135, DOI 10.1016/0006-8993(87)91283-2; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SEITZ H D, 1976, Zeitschrift fuer Experimentelle Chirurgie, V9, P341; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SIESJO BK, 1973, ARCH NEUROL-CHICAGO, V29, P400, DOI 10.1001/archneur.1973.00490300062008; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; STITTSWORTH JD, 1993, BRAIN RES, V630, P21, DOI 10.1016/0006-8993(93)90637-3; TUAN XQ, 1993, J NEUROTRAUM, V10, P307; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	44	63	64	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					135	142		10.1089/neu.2000.17.135			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800003	10709871				2021-06-18	
J	Azouvi, P; Jokic, C; Attal, N; Denys, P; Markabi, S; Bussel, B				Azouvi, P; Jokic, C; Attal, N; Denys, P; Markabi, S; Bussel, B			Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial	BRAIN INJURY			English	Article							SCALE; SEQUELAE; PATIENT; CLINICIAN; EFFICACY	Ten patients presenting agitation and anger outbursts at Various stages following a severe closed head injury, were treated in a prospective open trial with carbamazepine, with doses ranging from 400 to 800 mg per day, during 8 weeks. Group analysis demonstrated a statistically significant improvement of a score made up from six target items from the neurobehavioural rating scale. Improvement mainly concerned irritability and disinhibition. A statistically significant improvement was also found with the Agitated Behaviour Scale. Social functioning, as assessed by family or staff ratings of the Katz Adjustment Scale, also significantly improved. No modification of global cognitive functioning was found with the Mini Mental Status Examination. Individual analysis demonstrated that the beneficial effect was important in five cases, moderate in three patients and negligible in two cases. It is concluded that carbamazepine might help to reduce agitated behaviour in brain-injured patients. However, response to treatment demonstrated an important inter-individual variability.	Raymond Poincare Hosp, Dept Neurol Rehabil, F-92380 Garches, France; Ctr Hosp, Dept Neurol Rehabil, Auyay Sur Odon, France; Hop La Pitie Salpetriere, Ctr Marguerite Bottard, Paris, France; Lab Ciba Geigy, Rueil Malmaison, France	Azouvi, P (corresponding author), Raymond Poincare Hosp, Dept Neurol Rehabil, F-92380 Garches, France.						ANTON RF, 1986, J CLIN PSYCHOPHARM, V6, P232; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; ESSA M, 1986, J CLIN PSYCHOPHARM, V6, P234; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GLENN MB, 1989, AM J PHYS MED REHAB, V68, P221, DOI 10.1097/00002060-198910000-00004; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1990, INT DRUG THERAPY NEW, V25, P28; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; NEPPE VM, 1982, LANCET, V2, P334; OKUMA T, 1979, PSYCHOPHARMACOLOGY, V66, P211, DOI 10.1007/BF00428308; POURCHER E, 1994, AM J PSYCHIAT, V151, P150; PRIGATANO GP, 1987, NEUROBEHAVIORAL RECO, P155; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; TEASDALE G, 1974, LANCET, V2, P81	23	63	63	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					797	804		10.1080/026990599121188			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800005	10576463				2021-06-18	
J	Franz, G; Reindl, M; Patel, SC; Beer, R; Unterrichter, I; Berger, T; Schmutzhard, E; Poewe, W; Kampfl, A				Franz, G; Reindl, M; Patel, SC; Beer, R; Unterrichter, I; Berger, T; Schmutzhard, E; Poewe, W; Kampfl, A			Increased expression of apolipoprotein D following experimental traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apolipoprotein D; traumatic brain injury; neurons; glia; cell death	MICROTUBULE-ASSOCIATED PROTEIN-2; CORTICAL IMPACT INJURY; RNA TISSUE DISTRIBUTION; BREAST-CANCER CELLS; PERIPHERAL-NERVE; MESSENGER-RNA; MOLECULAR CHARACTERIZATION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; TRANSGENIC MICE	Increasing evidence suggests that apolipoprotein D (apoD) could play a major role in mediating neuronal degeneration and regeneration in the CNS and the PNS, To investigate further the temporal pattern of apoD expression after experimental traumatic brain injury in the rat, male Sprague-Dawley rats were subjected to unilateral cortical impact injury. The animals were killed and examined for apoD mRNA and protein expression and for immunohistological analysis at intervals from 15 min to 14 days after injury. Increased apoD mRNA and protein levels were seen in the cortex and hippocampus ipsilateral to the injury site from 48 h to 14 days after the trauma. Immunohistological investigation demonstrated a differential pattern of apoD expression in the cortex and hippocampus, respectively: Increased apoD immunoreactivity in glial cells was detected from 2 to 3 days after the injury in cortex and hippocampus. In contrast, increased expression of apoD was seen in cortical and hippocampal neurons at later time points following impact injury. Concurrent histopathological examination using hematoxylin and eosin demonstrated dark, shrunken neurons in the cortex ipsilateral to the injury site. in contrast, no evidence of cell death was observed in the hippocampus ipsilateral to the injury site up to 14 days after the trauma. No evidence of increased apoD mRNA or protein expression or neuronal pathology by hematoxylin and eosin staining was detected in the contralateral cortex and hippocampus. Our results reveal induction of apoD expression in the cortex and hippocampus following traumatic brain injury in the rat. Our data also suggest that increased apoD expression may play an important role in cortical neuronal degeneration after brain injury in vivo. However, increased expression of apoD in the hippocampus may not necessarily be indicative of neuronal death.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; VA Connecticut Healthcare Syst, Neurobiol Res Lab, Newington, CT USA	Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.		Reindl, Markus/ABE-5880-2020	Berger, Thomas/0000-0001-5626-1144; Reindl, Markus/0000-0003-2817-1402	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034339] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-34339] Funding Source: Medline		Bidmon HJ, 1998, NEUROSCIENCE, V82, P377; BOYLES JK, 1990, J LIPID RES, V31, P2243; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CABRAL JHM, 1995, FEBS LETT, V366, P53, DOI 10.1016/0014-5793(95)00484-Q; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chen SF, 1997, PSYCHOL SCI, V8, P80, DOI 10.1111/j.1467-9280.1997.tb00687.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Flower DR, 1996, BIOCHEM J, V318, P1; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HIGASHI Y, 1991, INT CONGR SER, V962, P85; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; Hyman BT, 1996, ANN NY ACAD SCI, V802, P1, DOI 10.1111/j.1749-6632.1996.tb32592.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Keller JN, 1998, J NEUROSCI, V18, P687; LABRIE F, 1990, ANN NY ACAD SCI, V586, P174, DOI 10.1111/j.1749-6632.1990.tb17805.x; Lea O A, 1988, Steroids, V52, P337, DOI 10.1016/0039-128X(88)90135-3; LEBLANC AC, 1990, J NEUROSCI RES, V26, P317, DOI 10.1002/jnr.490260308; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MCCONATH.WJ, 1973, FEBS LETT, V37, P178, DOI 10.1016/0014-5793(73)80453-3; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Navarro A, 1998, NEUROSCI LETT, V254, P17, DOI 10.1016/S0304-3940(98)00639-9; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2; Ong WY, 1999, NEUROSCIENCE, V90, P913, DOI 10.1016/S0306-4522(98)00507-7; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patel RC, 1997, PROTEIN ENG, V10, P621, DOI 10.1093/protein/10.6.621; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; Peitsch M C, 1990, New Biol, V2, P197; POIRIER J, 1990, P NATL ACAD SCI USA, V87, P303, DOI 10.1073/pnas.87.1.303; POIRIER J, 1991, MOL BRAIN RES, V9, P191, DOI 10.1016/0169-328X(91)90002-F; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; PROVOST PR, 1990, J LIPID RES, V31, P2057; REBECK GW, 1993, NEURON, V11, P575; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SEGUIN D, 1995, MOL BRAIN RES, V30, P242, DOI 10.1016/0169-328X(95)00008-G; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; SIMARD J, 1991, CANCER RES, V51, P4336; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SKENE JHP, 1983, P NATL ACAD SCI-BIOL, V80, P4169, DOI 10.1073/pnas.80.13.4169; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Suresh S, 1998, J NEUROCHEM, V70, P242; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Terrisse L, 1998, J NEUROCHEM, V71, P1643; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yoshida K, 1996, DNA CELL BIOL, V15, P873, DOI 10.1089/dna.1996.15.873	70	63	64	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	1999	73	4					1615	1625		10.1046/j.1471-4159.1999.0731615.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	236TZ	WOS:000082616200033	10501208	Bronze			2021-06-18	
J	Madsen, JE; Hukkanen, M; Aune, AK; Basran, I; Moller, JF; Polak, JM; Nordsletten, L				Madsen, JE; Hukkanen, M; Aune, AK; Basran, I; Moller, JF; Polak, JM; Nordsletten, L			Fracture healing and callus innervation after peripheral nerve resection in rats	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							GENE-RELATED PEPTIDE; IMMUNOREACTIVE NERVES; NEURAL INVOLVEMENT; GROWTH-FACTOR; HEAD-INJURY; BONE-CELLS; DENERVATION; IMMOBILIZATION; PROLIFERATION; RECOVERY	The effects of femoral and sciatic nerve resection on fracture healing and innervation of the fracture callus were studied using a stable fracture model, In 34 rats the right tibia was subjected to a standardized closed fracture and stabilized with a modular intramedullary nail, In half of the animals, resection of 1 cm of the femoral and sciatic nerves was performed (nerve resection group), whereas the other animals had sham operations (sham group). To avoid unequal loadbearing between the two groups, all fractured hindlimbs were immobilized in a plaster of Paris cast. The trial was terminated after 5 weeks of fracture healing. Callus size was scored radiographically, and bone mineralization was measured by (85)Strontium incorporation, Seven rats from each group had immunohistochemical examination for neural regeneration and ingrowth, Antisera for protein gene product 9.5, neurofilaments, neural growth associated protein 43/B-50, calcitonin gene related peptide, and substance P were used, The mechanical properties of the healing fractures were recorded in a three-point cantilever bending test, After 5 weeks, the normally innervated, fractured tibias had regained approximately 50% strength compared with the unfractured side, in comparison with only 20% in the animals that had nerve resection, Although the fracture calluses were mechanically weaker, they were significantly larger in the nerve resection group, indicating defects in tissue composition or organization rendered by the nerve injury The mineralization rate, as measured by (85)Strontium incorporation, was the same in the two groups. However, the nerve resection did not provide complete denervation but changed the innervation pattern of the healing fracture, as the density of sensory nerve fibers immunostaining for substance P and neurofilaments was less in the group with femoral and sciatic nerve resection, The results suggest that intact innervation is essential for normal fracture healing because nerve injury induced a large, but mechanically insufficient, fracture callus.	Univ Oslo, Natl Hosp, Rikshosp, Inst Surg Res, N-0316 Oslo, Norway; Martina Hansens Hosp, Sandvika, Norway; Royal Postgrad Med Sch, Dept Histochem, London, England; Univ Aarhus, Inst Expt Clin Res, DK-8000 Aarhus C, Denmark	Madsen, JE (corresponding author), Martina Hansens Hosp, N-1355 Baerum, Norway.			Hukkanen, Mika/0000-0001-9687-9571			ARO H, 1985, J ORTHOPAED RES, V3, P101, DOI 10.1002/jor.1100030113; ARO H, 1981, CLIN ORTHOP RELAT R, P211; ARO H, 1982, CLIN ORTHOP RELAT R, P292; ARO H, 1985, CLIN ORTHOP RELAT R, P292; ARO H, 1985, ACTA ORTHOP SCAND, V56, P233, DOI 10.3109/17453678508993002; Augat P, 1996, CLIN ORTHOP RELAT R, P194; BJURHOLM A, 1992, J BONE MINER RES, V7, P1011; BJURHOLM A, 1988, J AUTONOM NERV SYST, V25, P119, DOI 10.1016/0165-1838(88)90016-1; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CHEN LE, 1992, J ORTHOPAED RES, V10, P657, DOI 10.1002/jor.1100100508; EKELAND A, 1981, ACTA ORTHOP SCAND, V52, P605, DOI 10.3109/17453678108992155; FRENKEL SR, 1990, CELL TISSUE RES, V260, P507, DOI 10.1007/BF00297230; FRENKEL SR, 1990, BIOMATERIALS, V11, P38; FROST HM, 1966, J BONE JOINT SURG AM, VA 48, P1192, DOI 10.2106/00004623-196648060-00018; FRYMOYER JW, 1977, J TRAUMA, V17, P355, DOI 10.1097/00005373-197705000-00004; HAEGERSTRAND A, 1990, P NATL ACAD SCI USA, V87, P3299, DOI 10.1073/pnas.87.9.3299; HUKKANEN M, 1993, NEUROSCIENCE, V54, P969, DOI 10.1016/0306-4522(93)90588-7; HUKKANEN M, 1995, CLIN ORTHOP RELAT R, P247; HUKKANEN M, 1992, INT J TISSUE REACT, V15, P1; Hulth A, 1965, J Trauma, V5, P571, DOI 10.1097/00005373-196509000-00001; KLEIN L, 1977, J BONE JOINT SURG AM, V59, P1065, DOI 10.2106/00004623-197759080-00011; KONTTINEN YT, 1990, J RHEUMATOL, V17, P1586; KONTTINEN YT, 1992, SCAND J RHEUMATOL, V21, P55, DOI 10.3109/03009749209095068; LINDBOE CF, 1985, ACTA NEUROPATHOL, V66, P42, DOI 10.1007/BF00698294; Madsen JE, 1996, BONE, V18, P411, DOI 10.1016/8756-3282(96)00027-0; Madsen JE, 1996, ACTA ORTHOP SCAND, V67, P217, DOI 10.3109/17453679608994676; NORDSLETTEN L, 1994, ACTA ORTHOP SCAND, V65, P299, DOI 10.3109/17453679408995457; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; QUILIS AN, 1974, ACTA ORTHOP SCAND, V45, P820, DOI 10.3109/17453677408989693; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; SANTAVIRTA S, 1992, ACTA ORTHOP SCAND, V63, P579; SARMIENTO A, 1977, J BONE JOINT SURG AM, V59, P369, DOI 10.2106/00004623-197759030-00014; SIEMIONOW M, 1994, MICROSURG, V15, P891, DOI 10.1002/micr.1920151213; SMITH WS, 1955, SURG FORUM, V6, P559; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; TUUKKANEN J, 1992, ACTA PHYSIOL SCAND, V145, P407, DOI 10.1111/j.1748-1716.1992.tb09382.x; VARON SS, 1978, ANNU REV NEUROSCI, V1, P327, DOI 10.1146/annurev.ne.01.030178.001551; WHITESIDE LA, 1978, J BONE JOINT SURG AM, V60, P26, DOI 10.2106/00004623-197860010-00004; WILLIAMS PL, 1980, GRAYS ANATOMY, P1131; ZAIDI M, 1988, Q J EXP PHYSIOL CMS, V73, P471, DOI 10.1113/expphysiol.1988.sp003168; ZAIDI M, 1990, BIOCHEM J, V269, P775, DOI 10.1042/bj2690775	41	63	81	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	JUN	1998		351					230	240					11	Orthopedics; Surgery	Orthopedics; Surgery	ZU050	WOS:000074156200028	9646767				2021-06-18	
J	Naredi, S; Eden, E; Zall, S; Stephensen, H; Rydenhag, B				Naredi, S; Eden, E; Zall, S; Stephensen, H; Rydenhag, B			A standardized neurosurgical/neurointensive therapy directed toward vasogenic edema after severe traumatic brain injury: clinical results	INTENSIVE CARE MEDICINE			English	Article						head injury; cerebral edema; cerebral perfusion pressure; blood-brain barrier	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; DIHYDROERGOTAMINE; CATECHOLAMINES; MANAGEMENT; LESIONS	Objective: Analysis of a standardized therapy focusing on prevention and treatment of vasogenic edema in patients suffering severe traumatic brain injury (TBI). Design: A retrospective analysis. Setting: Neurointensive care unit at Sahlgrenska University Hospital, Goteborg, Sweden. Patients: 38 patients with severe TBI were included. The median Glasgow Coma Score was 5 (range 3-8) and median age 27 years (range 5-70 years). Interventions: Measurement of intracranial pressure (ICP). Surgical evacuation of hematomas and contusions. Volume expansion aiming at normovolemia. Sedation with continuous intravenous infusion of low-dose thiopentone and reduction of stress response by clonidine, Normalization of capillary hydrostatic pressure by metoprolol and clonidine, If ICP and cerebral perfusion pressure (CPP) were not stabilized (ICP < 20 mmHg and CPP > 60 mm Hg), a continuous infusion of dihydroergotamine was added, In 4 patients a craniectomy was performed. Results: Of the 35 patients, 27 (71%) survived with good recovery or moderate disability 5 (13 %) survived with severe disability, 1 (3%) remained in a vegetative state, and 5 (13%) died. The mortality due to intracranial hypertension was 11% (4 patients), Conclusion: A therapy focusing on treatment of the assumed vasogenic edema in combination with aggressive neurosurgery resulted in an outcome as good as the best previously reported.	Univ Hosp No Sweden, Dept Anesthesiol & Intens Care, S-90185 Umea, Sweden; Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Neurosurg, S-41345 Goteborg, Sweden; Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Anesthesiol & Intens Care, S-41345 Goteborg, Sweden	Naredi, S (corresponding author), Univ Hosp No Sweden, Dept Anesthesiol & Intens Care, S-90185 Umea, Sweden.	Peter.Naredi@surgery.umu.se		Naredi, Silvana/0000-0002-4409-6089			ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COOPER KR, 1985, J NEUROSURG, V63, P552, DOI 10.3171/jns.1985.63.4.0552; DIDIER P, 1990, CRIT CARE MED, V18, P392; ELL SR, 1991, INVEST RADIOL, V26, P499, DOI 10.1097/00004424-199105000-00022; Grande PO, 1996, ACTA ANAESTH SCAND, V40, P1255, DOI 10.1111/j.1399-6576.1996.tb05563.x; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; GUIPTA VL, 1996, ACTA ANAESTH SCAND, V40, P389; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; ILLIEVICH UM, 1994, CURR OPIN ANAESTH, V7, P394; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; MILLER JD, 1994, INTENS CARE MED, V20, P249, DOI 10.1007/BF01708957; MILLER JD, 1995, NEUROTRAUMA, P61; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P916, DOI 10.1111/j.1399-6576.1995.tb04198.x; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; STARMARK JE, 1996, TRAUMA CARE; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	29	63	64	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAY	1998	24	5					446	451		10.1007/s001340050594			6	Critical Care Medicine	General & Internal Medicine	ZT544	WOS:000074098500008	9660259				2021-06-18	
J	Forbes, ML; Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Wisniewski, SR; Kelsey, SF; DeKosky, ST; Graham, SH; Marion, DW; Ho, C				Forbes, ML; Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Wisniewski, SR; Kelsey, SF; DeKosky, ST; Graham, SH; Marion, DW; Ho, C			Assessment of cerebral blood flow and CO2 reactivity after controlled cortical impact by perfusion magnetic resonance imaging using arterial spin-labeling in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	4th Scientific Meeting and Exhibition of the International-Society-for-Magnetic-Resonance-in-Medicine	APR 27-MAY 03, 1996	NEW YORK, NY	Int Soc Magnet Resonance Med		traumatic brain injury; magnetic resonance imaging; perfusion; rat; controlled cortical impact	EXPERIMENTAL BRAIN INJURY; CARBON-DIOXIDE; HEAD-INJURY; FOCAL ISCHEMIA; WATER; INVERSION; MODEL; OXIDE	We measured CBF and CO, reactivity after traumatic brain injury (TBI) produced by controlled cortical impact (CCI) using magnetic resonance imaging (MRI) and spin-labeled carotid artery water protons as an endogenous tracer. Fourteen Sprague-Dawley rats divided into TBI (CCI; 4.02 +/- 0.14 m/s velocity; 2.5 mm deformation), sham, and control groups were studied 24 hours after TBI or surgery. Perfusion maps were generated during normocarbia (PaCO2 30 to 40 mm Hg) and hypocarbia (PaCO2 15 to 25 mm Hg). During normocarbia, CBF was reduced within a cortical region of interest (ROI, injured versus contralateral) after TBI (200 +/- 82 versus 296 +/- 65 mL.100 g(-1).min(-1), P < 0.05). Within a contusion-enriched ROI, CBF was reduced after TBI (142 +/- 73 versus 280 +/- 64 mL.100 g(-1).min(-1), P < 0.05). Cerebral blood flow in the sham group was modestly reduced (212 +/- 112 versus 262 +/- 118 mL.100 g(-1).min(-1), P < 0.05). Also, TBI widened the distribution of CBF in injured and contralateral cortex. Hypocarbia reduced cortical CBF in control (48%), sham (45%), and TBI rats (48%) versus normocarbia, P < 0.05. In the contusion-enriched ROI, only controls showed a significant reduction in CBF, suggesting blunted CO2 reactivity in the sham and TBI group. CO2 reactivity was reduced in the sham (13%) and TBI (30%) groups within the cortical ROI (versus contralateral cortex). These values were increased twofold within the contusion-enriched ROI but were not statistically significant. After TBI, hypocarbia narrowed the CBF distribution in the injured cortex. We conclude that perfusion MRI using arterial spin-labeling is feasible for the serial, noninvasive measurement of CBF and CO2 reactivity in rats.	SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT NEUROL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT NEUROSURG, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; CARNEGIE MELLON UNIV, PITTSBURGH NMR CTR BIOMED RES, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT SCI BIOL, PITTSBURGH, PA 15213 USA			Ho, Chien/O-6112-2016; Marion, Donald/AAR-5749-2021; Forbes, MD, FAAP, Michael/C-4110-2009; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Forbes, MD, FAAP, Michael/0000-0002-2612-5392; Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; DeKosky, Steven/0000-0003-3743-2758	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-10962, RR-03631] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR003631, R01RR010962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON WT, 1986, MAGN RESON MED, V3, P454, DOI 10.1002/mrm.1910030311; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; GINSBERG MD, 1987, CEREBRAL BLOOD FLOW, P299; GJEDDE A, 1977, ACTA PHYSIOL SCAND, V100, P273, DOI 10.1111/j.1748-1716.1977.tb05950.x; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HEILAND S, 1995, J CEREB BLOOD FLOW M, V15, pS58; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; JIANG Q, 1994, J CEREBR BLOOD F MET, V14, P732, DOI 10.1038/jcbfm.1994.94; JONES SC, 1982, J COMPUT ASSIST TOMO, V6, P116, DOI 10.1097/00004728-198202000-00020; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEE JG, 1995, ANESTH ANALG, V80, P696, DOI 10.1097/00000539-199504000-00008; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; REITH W, 1994, ACTA NEUROCHIR, V131, P151, DOI 10.1007/BF01401466; SIESJO BK, 1983, J CEREBR BLOOD F MET, V3, P478, DOI 10.1038/jcbfm.1983.74; SMITH DH, 1993, J NEUROSCI, V13, P5383; Strupp JP., 1996, NEUROIMAGE, V3, pS607, DOI DOI 10.1016/S1053-8119(96)80609-4; WALSH EG, 1994, MAGNET RESON MED, V31, P147, DOI 10.1002/mrm.1910310208; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WARNER DS, 1987, CEREBRAL BLOOD FLOW, P288; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P4220; WILLIAMS DS, 1993, MAGNET RESON MED, V30, P361, DOI 10.1002/mrm.1910300314; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; ZHANG WG, 1992, MAGNET RESON MED, V25, P362, DOI 10.1002/mrm.1910250216; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	36	63	64	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	1997	17	8					865	874		10.1097/00004647-199708000-00005			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	XU902	WOS:A1997XU90200005	9290584				2021-06-18	
J	Gabella, B; Hoffman, RE; Marine, WW; Stallones, L				Gabella, B; Hoffman, RE; Marine, WW; Stallones, L			Urban and rural traumatic brain injuries in Colorado	ANNALS OF EPIDEMIOLOGY			English	Article						rural population; urban population; surveillance; head injuries; mortality rates	MOTOR-VEHICLE CRASHES; HEAD-INJURY; EPIDEMIOLOGY; MORTALITY; SEVERITY; TRENDS; POPULATION; COMMUNITY; COUNTY; DEATHS	PURPOSE: The purpose of this study was to compare and contrast the epidemiology of traumatic brain injury among urban and rural residents of Colorado. METHODS: Cases of traumatic brain injury (ICD 800, 801, 803, 804, 850-854) for 1991 and 1992 from the Colorado surveillance system of hospitalized and fatal traumatic brain injuries were used. Urban cases resided in counties designated by the U.S. Census Bureau as metropolitan statistical areas (MSA). Rural cases were divided into two groups: ''rural, nonremote,'' if the country of residence was adjacent to an MSA county or if it had a population of 2500, and ''rural, remote,'' if not. and ''rural, remote,'' if not. RESULTS: Average annual age-adjusted rates of hospitalized and fatal traumatic brain injury varied significantly from 97.8 per 100,000 population for the most urban group to 172.1 per 100,000 population for the residents of rural, remote counties. Similarly, total mortality ranged from 18.1 per 100,000 population among residents of the most urban counties to 33.8 among residents of rural, remote counties. Prehospital mortality ranged from 10.0 to 27.7 traumatic brain injuries per 100,000 population. CONCLUSIONS: These results provide justification for expanding efforts to prevent traumatic brain injury to include the small, but high-risk group of residents in rural areas. (C) 1997 by Elsevier Science Inc.	UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262; COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT ENVIRONM HLTH,FT COLLINS,CO 80523	Gabella, B (corresponding author), COLORADO DEPT PUBL HLTH & ENVIRONM,DCEEDIEA3,4300 CHERRY CREEK DR S,DENVER,CO 80222, USA.		Stallones, Lorann/AAC-6248-2021	Stallones, Lorann/0000-0001-7616-582X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U59/CCU803364] Funding Source: Medline		*AM HOSP ASS, 1994, AHA PROF US HOSP DAT, pR33; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; BAKER SP, 1992, INJURY FACT BOOK, P28; CHEN B, 1995, J TRAUMA, V38, P228, DOI 10.1097/00005373-199502000-00014; CHIANG CL, 1961, VITAL STAT SPECIAL R, V47; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; FIFE D, 1984, J NEUROSURG, V60, P697, DOI 10.3171/jns.1984.60.4.0697; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; *HLTH STAT VIT REC, 1992, RED OCC INJ DEATH RU, P1; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KEEFER S, 1989, INJURY COLORADO BASE, V75, P106; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MACKENZIE EJ, 1990, AM J PUBLIC HEALTH, V80, P217, DOI 10.2105/AJPH.80.2.217; Ricketts TC, 1994, GEOGRAPHIC METHODS H; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STALLONES L, 1990, SUICIDE LIFE-THREAT, V20, P156; STALLONES L, 1992, J RURAL HEALTH, V8, P139; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; *US BUR CENS, 1990, 1990 CENS POP HOUS P; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	27	63	63	0	3	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	1047-2797			ANN EPIDEMIOL	Ann. Epidemiol.	APR	1997	7	3					207	212		10.1016/S1047-2797(96)00150-0			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	WX578	WOS:A1997WX57800008	9141644				2021-06-18	
J	McDermott, KL; Raghupathi, R; Fernandez, SC; Saatman, KE; Protter, AA; Finklestein, SP; Sinson, G; Smith, DH; McIntosh, TK				McDermott, KL; Raghupathi, R; Fernandez, SC; Saatman, KE; Protter, AA; Finklestein, SP; Sinson, G; Smith, DH; McIntosh, TK			Delayed administration of basic fibroblast growth factor (bFGF) attenuates cognitive dysfunction following parasagittal fluid percussion brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						basic fibroblast growth factor; cognition; fluid-percussion injury; neurotrophic factors; traumatic brain injury	CEREBRAL BLOOD-FLOW; FIMBRIA FORNIX TRANSECTION; FACTOR PROMOTES SURVIVAL; CHOLINERGIC NEURONS; HEAD-INJURY; EXCITOTOXIC LESIONS; NERVE; ISCHEMIA; DEATH; HIPPOCAMPUS	The present study evaluates the therapeutic effects of delayed administration of bFGF on cognitive dysfunction and histopathological damage following lateral fluid-percussion (FP) brain injury, Male Sprague-Dawley rats were trained to learn a visuospatial task in a Morris Water Maze (MWM) paradigm and then were anesthetized and subjected to either FP brain injury of moderate severity (2.5-2.8 atm, n = 32) or surgery without brain injury (n = 10), Twenty-four hours postinjury, an infusion cannula connected to a mini-osmotic pump was implanted into the area of maximal cortical injury to continuously infuse either bFGF (2.0 g) or vehicle for 7 days, Treatment with bFGF significantly attenuated posttraumatic memory dysfunction in the MWM at 8 days postinjury when compared to vehicle treatment (p < 0.05). The cortical lesion and significant cell loss in the ipsilateral CA3 region of the hippocampus, produced by FP injury, was not affected by bFGF treatment, However, immunohistochemical evaluation of glial fibrillary acidic protein revealed a trend toward increased astrocytosis in the injured cortex of bFGF-treated animals compared to vehicle-treated animals (p < 0.1). These results indicate that bFGF may be efficacious in attenuating cognitive dysfunction associated with traumatic brain injury.	UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104; MASSACHUSETTS GEN HOSP,DEPT NEUROL,CNS GROWTH FACTOR RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA; SCIOS NOVA INC,MT VIEW,CA 94043			smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline		AKANEYA Y, 1993, J CEREBR BLOOD F MET, V13, P1029, DOI 10.1038/jcbfm.1993.130; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; ARAUJO DM, 1993, J NEUROCHEM, V61, P899, DOI 10.1111/j.1471-4159.1993.tb03601.x; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CASPER D, 1995, J NEUROCHEM, V65, P1016; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIETRICH DW, 1996, J NEUROTRAUM, V13, P309; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HALL ED, 1988, STROKE, V19, P340, DOI 10.1161/01.STR.19.3.340; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Hill S. J., 1994, Society for Neuroscience Abstracts, V20, P424; ISHIHARA A, 1992, JPN J PHARMACOL, V59, P7, DOI 10.1254/jjp.59.7; JIANG N, 1996, IN PRESS J NEUROLOG; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; Kimelberg H.K., 1982, HEAD INJURY BASIC CL, P31; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mair R G, 1994, Rev Neurosci, V5, P105; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OTTO D, 1989, J NEUROSCI RES, V22, P83, DOI 10.1002/jnr.490220111; OTTO D, 1987, NEUROSCI LETT, V83, P156, DOI 10.1016/0304-3940(87)90233-3; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; Pierce JES, 1996, J NEUROSCI, V16, P1083; RAY J, 1994, J NEUROSCI, V14, P3548; REGLI L, 1994, BRAIN RES, V665, P155, DOI 10.1016/0006-8993(94)91167-3; ROSENBLATT S, 1994, J CEREBR BLOOD F MET, V14, P70, DOI 10.1038/jcbfm.1994.11; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROTRAUMA S, V10, pS62; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SWEETNAM PM, 1991, J NEUROCHEM, V57, P237, DOI 10.1111/j.1471-4159.1991.tb02121.x; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YUAN X, 1981, J NEUROTRAUM, V5, P289; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	66	63	64	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1997	14	4					191	200		10.1089/neu.1997.14.191			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WY593	WOS:A1997WY59300002	9151768				2021-06-18	
J	BeitYannai, E; Kohen, R; Horowitz, M; Trembovler, V; Shohami, E				BeitYannai, E; Kohen, R; Horowitz, M; Trembovler, V; Shohami, E			Changes of biological reducing activity in rat brain following closed head injury: A cyclic voltammetry study in normal and heat-acclimated rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						biological oxidation potential; cyclic voltammetry; closed head injury; reactive oxygen species	OXYGEN RADICALS; DAMAGE; ANTIOXIDANT; MECHANISMS; ISCHEMIA; TRAUMA	Reactive oxygen species (ROS) are normally generated in the brain during metabolism, and their production is enhanced by various insults. Low molecular weight antioxidants (LMWA) are one of the defense mechanisms of the living cell against ROS. The reducing capacity of brain tissue (total LMWA) was measured by cyclic vol tammetry (CV), which records biological oxidation potential specific to the type of scavenger(s) present and anodic current intensity (I-a), which depends on scavenger concentration. In the present study, the reducing capacity of rat brain following closed head injury (CHI) was measured. In addition, CV of heat-acclimated traumatized rats was used to correlate endogenous cerebroprotection after CHI with LMWA activity. Sham-injured rat brains displayed two anodic potentials: at 350 +/- 50 mV (I-a = 0.75 +/- 0.06 mu A/mg protein) and at 750 +/- 50 mV (I-a = 1.00 +/- 0.05 mu A/mg protein). Following CHI, the anodic waves appeared at the same potentials as in the sham animals. However, within 5 min of CHI, the total reducing capacity was transiently decreased by 40% (p < 0.01). A second dip was detected at 24 h (60%, p < 0.005). By 48 h and at 7 days, the I-a levels normalized. The acclimated rats displayed anodic potentials identical to those of normothermic rats. However, the I-a of both potentials was lower (60% of control, p < 0.001). The I-a profile after CHI was the direct opposite of the normothermic I,profile: no immediate decrease of I-a and an increase from 4 h and up to 7 days (40-50%, p < 0.001). We suggest that the lowered levels of LMWA in the post-CHI period reflect their consumption due to overproduction of free radicals. The augmented concentration of LMWA found in the brain of the heat-acclimated rats suggests that these rats are better able to cope with these harmful radicals, resulting in a more favorable outcome following CHI.	HEBREW UNIV JERUSALEM, SCH PHARM, DEPT PHARMACOL, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH PHARM, DEPT PHARM, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH PHARM, DEPT PHYSIOL, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH MED, IL-91120 JERUSALEM, ISRAEL			Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			BAETHMANN A, 1989, NEUROSURG ANESTHESIO, V2, P567; Bard A.J., 1980, ELECTROCHEMICAL METH, P316; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; CHAN PH, 1989, CELLULAR ANTIOXIDANT, P89; CHEVION S, 1996, IN PRESS FREE RAD BI; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DIRNAGL U, 1995, J CEREBR BLOOD F MET, V15, P929, DOI 10.1038/jcbfm.1995.118; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GREEF R, 1990, HARWOOD SERIES PHYSI, P183; HADAS H, 1989, INT CONGR SER, V871, P395; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; HIGSON FK, 1988, FREE RADICAL RES COM, V5, P107, DOI 10.3109/10715768809066918; HOROWITZ M, 1985, COMP BIOCHEM PHYS A, V81, P103, DOI 10.1016/0300-9629(85)90274-9; HOROWITZ M, 1986, J MOL CELL CARDIOL, V18, P511, DOI 10.1016/S0022-2828(86)80916-6; HOROWITZ M, 1989, MILESTONES ENV PHYSL, P31; KISSINGER PT, 1973, BRAIN RES, V55, P209, DOI 10.1016/0006-8993(73)90503-9; KOHEN R, 1992, EXP GERONTOL, V27, P161, DOI 10.1016/0531-5565(92)90040-7; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LEVI E, 1993, J APPL PHYSIOL, V75, P833; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PHILLIS JW, 1994, PROG NEUROBIOL, V42, P441, DOI 10.1016/0301-0082(94)90046-9; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHINAR E, 1983, J BIOL CHEM, V258, P4778; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1994, RESTOR NEUROL NEUROS, V6, P107, DOI 10.3233/RNN-1994-6204; SHOHAMI E, 1989, J NEUROCHEM, V53, P541; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Yukido I, 1990, NEUROSURGERY, V27, P1	33	63	63	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1997	17	3					273	279		10.1097/00004647-199703000-00004			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	WQ178	WOS:A1997WQ17800004	9119900	Bronze			2021-06-18	
J	Kreutzer, JS; Witol, AD; Marwitz, JH				Kreutzer, JS; Witol, AD; Marwitz, JH			Alcohol and drug use among young persons with traumatic brain injury	JOURNAL OF LEARNING DISABILITIES			English	Article							HEAD-INJURY; SUBSTANCE USE; FOLLOW-UP; HYPERACTIVE BOYS; ADOLESCENTS; POPULATION; REHABILITATION; DISABILITIES; PREVALENCE; PATTERNS	The pre- and postinjury patterns of alcohol and illicit drug use of 87 persons with traumatic brain injury ages 16 to 20 were examined. Follow-up data were collected at two time intervals averaging 8 and 28 months postinjury. A comparison with large-sample studies revealed that patients had preinjury drinking patterns similar to those in the general population. A review of data provided evidence of a decline in alcohol use at initial follow-up; however, preinjury and second follow-up alcohol use patterns were similar. Analyses suggested that drinking quantity and frequency increased over time, perhaps eventually returning to postinjury levels. A review of the literature and the findings of the present investigation indicate that men and persons with a history of preinjury heavy drinking are at greatest risk for long-term alcohol abuse postinjury. Postinjury illicit drug use rates remained relatively low, falling below 10% at both follow-up intervals. Among persons taking prescribed medications, 17% reported moderate or heavy drinking at second follow-up.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROL SURG,DEPT SURG,RICHMOND,VA 23298							Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; ALLDADI V, 1986, PHARM ALERT, V16, P2; AUGUST GJ, 1983, BRIT J PSYCHIAT, V143, P192, DOI 10.1192/bjp.143.2.192; BECK L, 1975, AM J PSYCHIAT, V132, P436, DOI 10.1176/ajp.132.4.436; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Bruck M., 1985, ADV APPLIED DEV PSYC, P91; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; CLAMPIT MK, 1983, ADOLESCENCE, V18, P811; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Drubach D A, 1993, Md Med J, V42, P989; ENGS RC, 1988, PUBLIC HEALTH REP, V103, P667; GALBRAITH S, 1976, BRIT J SURG, V63, P735; GITTELMAN R, 1985, ARCH GEN PSYCHIAT, V42, P937; GLOW BA, 1989, ALCOHOLISM SUBSTANCE, P65; GOLD MA, 1993, J ADOLESCENT HEALTH, V14, P80, DOI 10.1016/1054-139X(93)90089-8; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HILTON ME, 1987, ALCOHOL CLIN EXP RES, V11, P167, DOI 10.1111/j.1530-0277.1987.tb01283.x; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAAG JW, 1994, J LEARN DISABIL, V27, P223, DOI 10.1177/002221949402700404; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MAISTO SA, 1979, J CONSULT CLIN PSYCH, V47, P106, DOI 10.1037/0022-006X.47.1.106; MEILMAN PW, 1990, J STUD ALCOHOL, V51, P389, DOI 10.15288/jsa.1990.51.389; MILLS CJ, 1984, J CONSULT CLIN PSYCH, V52, P231, DOI 10.1037/0022-006X.52.2.231; MOORE D, 1991, INT J ADDICT, V26, P65, DOI 10.3109/10826089109056240; MOTETGRIGORAS CN, 1986, J CLIN PSYCHIAT, V47, P234; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; National Institute on Drug Abuse, 1991, DHHS PUBL; Newcomb MD, 1987, J APPLIED DEV PSYCHO, V8, P221, DOI DOI 10.1016/0193-3973(87)90001-3; OSHANICK GJ, 1990, COMMUNITY INTEGRATIO, P15; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROBINSON TN, 1987, JAMA-J AM MED ASSOC, V258, P2072, DOI 10.1001/jama.258.15.2072; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SANDER A, 1996, 20 ANN POSTGR COURS; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; *WI DEP HLTH SOC S, 1985, ALC US PERS DIS PREL; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	51	63	63	0	6	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1996	29	6					643	651		10.1177/002221949602900608			9	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	VU234	WOS:A1996VU23400008	8942308				2021-06-18	
J	SCHIFFER, D; GIORDANA, MT; CAVALLA, P; VIGLIANI, MC; ATTANASIO, A				SCHIFFER, D; GIORDANA, MT; CAVALLA, P; VIGLIANI, MC; ATTANASIO, A			IMMUNOHISTOCHEMISTRY OF GLIAL REACTION AFTER INJURY IN THE RAT - DOUBLE STAININGS AND MARKERS OF CELL-PROLIFERATION	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						BRAIN INJURY; GLIAL REACTION; GFAP AND VIMENTIN; BRDU-PCNA	FIBRILLARY ACIDIC PROTEIN; MESSENGER-RNA LEVELS; NERVOUS-SYSTEM; CEREBRAL-CORTEX; BRAIN INJURY; RADIAL GLIA; STAB WOUNDS; ADULT-RATS; ASTROCYTES; EXPRESSION	The astrocytic reaction in the rat after brain injury has been studied immunohistochemically for intermediate filaments (GFAP and vimentin), also with double staining procedures, and for markers of proliferation (BrdU and PCNA). GFAP-positive reactive astrocytes appeared around the lesion, where they were vimentin-positive and at a distance. BrdU and PCNA showed a high labelling index around the wound at day 2 and scattered positive nuclei were also found at a distance in the ipsilateral side. BrdU-positive astrocytes represented a minor fraction of GFAP- and vimentin-positive astrocytes. The expression of vimentin persisted at least 15 days after the lesion. Our results could suggest that distant reactive astrocytes originate through hypertrophy while those close to lesion arise by hyperplasia from mature or immature glial cells. The hypothesis is formulated that cells of the periventricular matrix contribute to the post-traumatic proliferative activity.		SCHIFFER, D (corresponding author), UNIV TURIN,DEPT NEUROL 2,VIA CHERASCO 15,I-10126 TURIN,ITALY.			vigliani, maria claudia/0000-0002-9026-7985; Cavalla, Paola/0000-0003-4589-4864			BIGNAMI A, 1974, NATURE, V252, P55, DOI 10.1038/252055a0; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; FEDOROFF S, 1984, J NEUROSCI RES, V12, P15, DOI 10.1002/jnr.490120103; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; IKUTA F, 1991, NEUROPATHOLOGY BRAIN, P211; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; JANECZKO K, 1991, BRAIN RES, V564, P86, DOI 10.1016/0006-8993(91)91355-5; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEVITT P, 1981, J NEUROSCI, V1, P27; LUDWIN SK, 1985, LAB INVEST, V52, P20; LUDWIN SK, 1984, ACTA NEUROPATHOL, V63, P240, DOI 10.1007/BF00685250; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MILLER RH, 1986, J NEUROSCI, V6, P22; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; REYNERS H, 1986, J NEUROCYTOL, V15, P53, DOI 10.1007/BF02057904; SCHIFFER D, 1991, ACTA NEUROPATHOL, V83, P30, DOI 10.1007/BF00294427; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; STEWARD O, 1990, J NEUROSCI, V10, P2373; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309	28	63	64	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	APR	1993	11	2					269	280		10.1016/0736-5748(93)90085-R			12	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	LD086	WOS:A1993LD08600016	7687086				2021-06-18	
J	TAHA, JM; CRONE, KR; BERGER, TS; BECKET, WW; PRENGER, EC; SCOTT, RM; WALKER, ML				TAHA, JM; CRONE, KR; BERGER, TS; BECKET, WW; PRENGER, EC; SCOTT, RM; WALKER, ML			SIGMOID SINUS THROMBOSIS AFTER CLOSED HEAD-INJURY IN CHILDREN	NEUROSURGERY			English	Article						HEAD INJURY; SIGMOID SINUS; THROMBOSIS; TRAUMA	MR; SIGN	IN THE LITERATURE, clinical descriptions of sigmoid sinus thrombosis occurring after closed head injury in children are rare. One to 5 days after trauma to the back of the head, five children (aged 1 to 7 yr) presented with gait ataxia, vomiting, and headache. Trauma was mild in four children. Computed tomography of all the children, performed within 5 days after the injury, showed focal hyperdensity in the region of the left sigmoid sinus. Four children had extra-axial hyperdense collections along the left transverse sinus, and three had skull fractures adjacent to the left sigmoid sinus. Magnetic resonance imaging (MRI) of all the children, performed 2 to 6 days after injury, showed left sigmoid-sinus thrombosis and decreased flow or thrombosis within the lateral third of the left transverse sinus. All the children had MRI scans 4 to 6 weeks after their diagnosis and were followed up for 1 to 12 months. In four children whose symptoms subsided completely within 2 to 10 weeks, MRI showed recanalization of the sigmoid sinus within 4 to 6 weeks after injury. In one child whose symptoms resolved after 6 months, sigmoid-sinus thrombosis persisted with the formation of collateral flow. We conclude that traumatic sigmoid-sinus thrombosis should be suspected when a child has persistent or delayed gait ataxia and vomiting after injury to the back of the head. Computed tomography characteristically demonstrated focal hyperdensity within the sigmoid sinus that we term the dense sigmoid-sinus sign. Because the sinus recanalized and the symptoms subsided in most children within 6 weeks, we conclude that prophylactic medical or surgical intervention is not indicated.	UNIV CINCINNATI,COLL MED,DEPT NEUROSURG,231 BETHESDA AVE,CINCINNATI,OH 45267; CHILDRENS HOSP,MED CTR,DIV PEDIATR NEUROSURG,CINCINNATI,OH; CHILDRENS HOSP,MED CTR,DEPT RADIOL,CINCINNATI,OH; MAYFIELD NEUROSURG INST,CINCINNATI,OH							ACHIRON A, 1990, STROKE, V21, P817, DOI 10.1161/01.STR.21.5.817; ANDERSON SC, 1987, J COMPUT ASSIST TOMO, V11, P1059, DOI 10.1097/00004728-198711000-00028; BJORNEBRINK J, 1976, ANGIOLOGY, V27, P688, DOI 10.1177/000331977602701203; BRADLEY WG, 1985, RADIOLOGY, V154, P444; BUOANNO F, 1978, J COMPUT ASSIST TOMO, V2, P281; CONVERS P, 1986, NEUROCHIRURGIE, V32, P495; GHORAYEB BY, 1987, ARCH OTOLARYNGOL, V113, P749; GOLDBERG AL, 1986, J COMPUT ASSIST TOMO, V10, P16, DOI 10.1097/00004728-198601000-00003; GOLDENBERG RA, 1985, ARCH OTOLARYNGOL, V111, P56; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HARRIS TM, 1989, J COMPUT ASSIST TOMO, V13, P682, DOI 10.1097/00004728-198907000-00025; HULCELLE PJ, 1989, NEURORADIOLOGY, V31, P217, DOI 10.1007/BF00344346; IMAIZUMI M, 1980, J NEUROL, V22, P215; KAPP J, 1985, NEUROSURGERY, P1300; KINAL ME, 1967, J NEUROSURG, V27, P142, DOI 10.3171/jns.1967.27.2.0142; LENZ R, 1984, LARYNGOSCOPE, V4, P1451; Luerssen T G, 1991, Neurosurg Clin N Am, V2, P399; MAS JL, 1990, STROKE, V21, P1350, DOI 10.1161/01.STR.21.9.1350; McCormick W.F., 1985, NEUROSURGERY, P1544; MITCHELL D, 1986, J NEUROL NEUROSUR PS, V49, P218, DOI 10.1136/jnnp.49.2.218; NISSEN A J, 1980, American Journal of Otology, V2, P164; RENGACHARY SS, 1985, NEUROSURGERY, P50; RIPPE DJ, 1990, AM J NEURORADIOL, V11, P199; SAMUEL J, 1987, J LARYNGOL OTOL, V101, P1227, DOI 10.1017/S0022215100103561; TOVI F, 1988, J LARYNGOL OTOL, V102, P623, DOI 10.1017/S0022215100105900; TSUDA JS, 1991, AJNR, V12, P481; VIRAPONGSE C, 1987, RADIOLOGY, V162, P779, DOI 10.1148/radiology.162.3.3809494	27	63	66	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1993	32	4					541	546		10.1227/00006123-199304000-00008			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KV759	WOS:A1993KV75900008	8474644				2021-06-18	
J	MARTINEZARIZALA, A; GREEN, BA				MARTINEZARIZALA, A; GREEN, BA			HYPOTHERMIA IN SPINAL-CORD INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			BLOOD-FLOW; BRAIN TEMPERATURE; TISSUE OXYGEN; RAT-BRAIN; ISCHEMIA; TRAUMA; PROTECTION; ANESTHESIA; MONKEYS	Early investigations involving central nervous system (CNS) temperature lowering to protect against the detrimental effects of hypoxia and ischemia were based on the observation that hypothermia reduces brain metabolism and energy consumption. The protective effects of hypothermia have been demonstrated in numerous experimental models of cerebral ischemia and recently in models of brain trauma. These observations also led to the application of hypothermia, in the form of local spinal cord cooling (LSCC), in animal models of experimental spinal cord injury (SCI). Although some investigators have reported negative results in studies of LSCC following traumatic SCI, the majority of studies have noted beneficial effects. The favorable results in animal experimentation led to a limited number of cases where LSCC was used in the treatment of human SCI. However, results are difficult to interpret because (1) most investigators report only a small number of cases, (2) the studies lack a control population, (3) the time interval from injury to the application of cooling has been highly variable, and (4) several investigators combined drug treatments with LSCC. In these experiments, LSCC was achieved via perfusion with a cold solution or an epidural heat exchanger and the aim was to lower cord temperatures significantly (about 10-degrees-C). The application of the technique itself is fraught with difficulties. It requires acute surgery in a traumatized patient, a wide multilevel laminectomy, and minimizing the time interval between injury and the application of spinal cord cooling. Recent studies in experimental brain ischemia strongly suggest that a drastic lowering of CNS temperature may be unnecessary to lessen the degree of tissue damage occurring following an ischemic brain injury. It has been documented that modest temperature changes (1-3-degrees-C) can critically alter the extent of neuronal injury and blood-brain barrier alterations that occur in models of experimental brain ischemia. These findings are especially intriguing, since an earlier experimental SCI study showed a beneficial effect for normothermic perfusion of contused spinal cord tissue. If lowering brain temperature 1-3-degrees-C is sufficient to benefit compromised brain tissue, it is quite possible that this modest temperature change could also be beneficial to the injured spinal cord. Current investigations in our laboratories are addressing the applicability of these findings to experimental SCI.	UNIV MIAMI,SCH MED,DEPT NEUROL,MIAMI,FL 33136; UNIV MIAMI,SCH MED,DEPT NEUROL SURG,MIAMI,FL 33136	MARTINEZARIZALA, A (corresponding author), UNIV MIAMI,SCH MED,MIAMI PROJECT CURE PARALYSIS,R-48,1600 NW 10TH AVE,MIAMI,FL 33136, USA.						Albin M S, 1965, Surg Forum, V16, P423; ALBIN MS, 1967, ANESTH ANAL CURR RES, V46, P8; ALBIN MS, 1968, J NEUROSURG, V29, P113, DOI 10.3171/jns.1968.29.2.0113; BEATTIE EJ, 1953, SURG GYNECOL OBSTET, V96, P711; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BLACK P, 1971, Surgical Forum (Chicago), V22, P409; Bricolo A, 1976, Surg Neurol, V6, P101; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Campbell J B, 1973, Surg Neurol, V1, P102; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DUCKER TB, 1978, SURG NEUROL, V10, P60; DUCKER TB, 1978, SURG NEUROL, V10, P64; DUCKER TB, 1969, J NEUROSURG, V30, P693; Eidelberg E, 1976, Surg Neurol, V6, P243; Green B A, 1973, Surg Forum, V24, P436; HAGERDAL M, 1978, ANESTHESIOLOGY, V49, P165, DOI 10.1097/00000542-197809000-00003; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; Hansebout R R, 1975, Surg Neurol, V4, P531; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; HANSEBOUT RR, 1985, CAN J NEUROL SCI, V12, P83, DOI 10.1017/S0317167100046758; HOWITT MM, 1972, CAN J SURG, V15, P179; KELLY DL, 1970, J NEUROSURG, V33, P554, DOI 10.3171/jns.1970.33.5.0554; KOONS D D, 1972, Cleveland Clinic Quarterly, V39, P109; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; Kuchner E F, 1976, Surg Neurol, V6, P371; MARSHALL SB, 1956, ARCH SURG-CHICAGO, V72, P98; MEACHAM WF, 1973, SOUTH MED J, V66, P95, DOI 10.1097/00007611-197301000-00016; MICHENFELDER JD, 1976, ARCH NEUROL-CHICAGO, V33, P345, DOI 10.1001/archneur.1976.00500050031006; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; NEGRIN J, 1975, NEW YORK STATE J MED, V75, P2387; NOBLE LJ, 1987, EXP NEUROL, V95, P530, DOI 10.1016/0014-4886(87)90162-2; PONTIUS R G, 1955, Surg Forum, V5, P224; PONTIUS RG, 1954, SURGERY, V36, P33; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROSOMOFF HL, 1957, ARCH NEURO PSYCHIATR, V78, P454, DOI 10.1001/archneurpsyc.1957.02330410018002; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; ROSOMOFF HL, 1956, J NEUROSURG, V13, P244; SAKAMOTO T, 1989, AM J PHYSIOL, V257, pH785; SAKAMOTO T, 1989, J NEUROSURG, V70, P780, DOI 10.3171/jns.1989.70.5.0780; SAKAMOTO T, 1990, NEUROSURGERY, V26, P958, DOI 10.1227/00006123-199006000-00006; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; SELKER R G, 1971, Surgical Forum (Chicago), V22, P411; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; TATOR CH, 1979, NEURAL TRAUMA, P363; THIENPRASIT P, 1975, J NEUROSURG, V42, P150, DOI 10.3171/jns.1975.42.2.0150; WELLS JD, 1978, SURG NEUROL, V10, P200; ZIELONKA J S, 1974, Surgical Forum (Chicago), V25, P434	50	63	63	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S497	S505					9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900007	1613809				2021-06-18	
J	VINK, R; MCINTOSH, TK; RHOMHANYI, R; FADEN, AI				VINK, R; MCINTOSH, TK; RHOMHANYI, R; FADEN, AI			OPIATE ANTAGONIST NALMEFENE IMPROVES INTRACELLULAR FREE MG-2+, BIOENERGETIC STATE, AND NEUROLOGIC OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROSCIENCE			English	Article									UNIV CONNECTICUT,CTR HLTH,DEPT SURG,FARMINGTON,CT 06032; UNIV CALIF SAN FRANCISCO,SCH MED,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143; VET ADM MED CTR,SAN FRANCISCO,CA 94121	VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT CHEM & BIOCHEM,TOWNSVILLE,QLD 4811,AUSTRALIA.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [902269] Funding Source: Medline		ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; CHANCE B, 1986, FED PROC, V45, P2915; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DAGANI F, 1987, J NEUROCHEM, V49, P1229, DOI 10.1111/j.1471-4159.1987.tb10015.x; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; Faden A I, 1988, Adv Neurol, V47, P531; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1990, IN PRESS J PHARM EXP; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MICHEL ME, 1984, PHARMACOLOGIST, V26, P201; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VELOSO D, 1973, J BIOL CHEM, V248, P4811; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1987, MAGNET RESON MED, V6, P37; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; 1984, NALMEFENE INFORMATIO	45	63	65	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513	0270-6474			J NEUROSCI	J. Neurosci.	NOV	1990	10	11					3524	3530					7	Neurosciences	Neurosciences & Neurology	EG885	WOS:A1990EG88500006	2230942				2021-06-18	
J	Alosco, ML; Mez, J; Tripodis, Y; Kiernan, PT; Abdolmohammadi, B; Murphy, L; Kowall, NW; Stein, TD; Huber, BR; Goldstein, LE; Cantu, RC; Katz, DI; Chaisson, CE; Martin, B; Solomon, TM; McClean, MD; Daneshvar, DH; Nowinski, CJ; Stern, RA; McKee, AC				Alosco, Michael L.; Mez, Jesse; Tripodis, Yorghos; Kiernan, Patrick T.; Abdolmohammadi, Bobak; Murphy, Lauren; Kowall, Neil W.; Stein, Thor D.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Chaisson, Christine E.; Martin, Brett; Solomon, Todd M.; McClean, Michael D.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Stern, Robert A.; McKee, Ann C.			Age of first exposure to tackle football and chronic traumatic encephalopathy	ANNALS OF NEUROLOGY			English	Article							21ST-CENTURY BRAIN BANKING; HEAD IMPACT EXPOSURE; HIGH-SCHOOL FOOTBALL; WHITE-MATTER; COGNITIVE RESERVE; LATER-LIFE; CHILDREN; ADOLESCENCE; CONCUSSION; MATURATION	ObjectiveTo examine the effect of age of first exposure to tackle football on chronic traumatic encephalopathy (CTE) pathological severity and age of neurobehavioral symptom onset in tackle football players with neuropathologically confirmed CTE. MethodsThe sample included 246 tackle football players who donated their brains for neuropathological examination. Two hundred eleven were diagnosed with CTE (126 of 211 were without comorbid neurodegenerative diseases), and 35 were without CTE. Informant interviews ascertained age of first exposure and age of cognitive and behavioral/mood symptom onset. ResultsAnalyses accounted for decade and duration of play. Age of exposure was not associated with CTE pathological severity, or Alzheimer's disease or Lewy body pathology. In the 211 participants with CTE, every 1 year younger participants began to play tackle football predicted earlier reported cognitive symptom onset by 2.44 years (p<0.0001) and behavioral/mood symptoms by 2.50 years (p<0.0001). Age of exposure before 12 predicted earlier cognitive (p<0.0001) and behavioral/mood (p<0.0001) symptom onset by 13.39 and 13.28 years, respectively. In participants with dementia, younger age of exposure corresponded to earlier functional impairment onset. Similar effects were observed in the 126 CTE-only participants. Effect sizes were comparable in participants without CTE. InterpretationIn this sample of deceased tackle football players, younger age of exposure to tackle football was not associated with CTE pathological severity, but predicted earlier neurobehavioral symptom onset. Youth exposure to tackle football may reduce resiliency to late-life neuropathology. These findings may not generalize to the broader tackle football population, and informant-report may have affected the accuracy of the estimated effects. Ann Neurol 2018;83:886-901	[Alosco, Michael L.; Mez, Jesse; Tripodis, Yorghos; Kiernan, Patrick T.; Abdolmohammadi, Bobak; Murphy, Lauren; Kowall, Neil W.; Stein, Thor D.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Chaisson, Christine E.; Martin, Brett; Solomon, Todd M.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Kiernan, Patrick T.] Midwestern Univ, Arizona Coll Osteopath Med, Glendale, AZ USA; [Kowall, Neil W.; Stein, Thor D.; Goldstein, Lee E.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Kowall, Neil W.; Stein, Thor D.; Goldstein, Lee E.; McKee, Ann C.] Boston Univ, Sch Med, Dept Lab Med, Boston, MA 02118 USA; [Kowall, Neil W.; Stein, Thor D.; Huber, Bertrand Russell; McKee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA; [Stein, Thor D.; McKee, Ann C.] US Dept Vet Affairs, Med Ctr, Bedford, MA USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Psychiat, Ophthalmol, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Biomed Engn, Boston, MA 02215 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Elect Engn, Boston, MA 02215 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Comp Engn, Boston, MA 02215 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.; Nowinski, Christopher J.] Concuss Legacy Fdn, Boston, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Boston, MA USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Chaisson, Christine E.; Martin, Brett] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA; [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Daneshvar, Daniel H.] Stanford Univ, Dept Orthopaed, Stanford, CA 94305 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA	McKee, AC (corresponding author), Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B7800, Boston, MA 02118 USA.	amckee@bu.edu	Kowall, Neil/M-5378-2019; , Bob/ABA-8507-2020	Kowall, Neil/0000-0002-6624-0213; Tripodis, Yorghos/0000-0003-2190-7608	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01, U01NS093334, R01NS078337, R56NS078337]; Department of DefenseUnited States Department of Defense [W81XWH-13-2-0064]; Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP) [13267017]; National Institute of Aging Boston University Framingham Heart Study [R01AG1649]; National Operating Committee on Standards for Athletic Equipment; Concussion Legacy Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32NS096803, K23 AG046377]; Boston University Alzheimer's Disease Center [AG013846]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, K23NS102399, F32NS096803, U01NS093334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RF1AG057902, K23AG046377, P30AG013846, R01AG062348] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke (1U01NS086659-01, U01NS093334, R01NS078337, and R56NS078337), Department of Defense (W81XWH-13-2-0064), Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the National Institute of Aging Boston University Alzheimer's Disease Center (P30AG13846; supplement 0572063345-5), Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP #13267017), the National Institute of Aging Boston University Framingham Heart Study (R01AG1649), and the National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation, the WWE, and the NFL. Michael L. Alosco and research reported in this publication is supported by the National Institutes of Health under grant number F32NS096803 and a Pilot Grant from the Boston University Alzheimer's Disease Center (AG013846). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Jesse Mez is supported by the National Institutes of Health under grant number K23 AG046377. Funding sources did not have restrictions on the design and conduct of the study, collection, management, analysis, and interpretation of data, or the preparation, review, or approval of the manuscript, or decision to submit the manuscript for publication.	Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Alosco ML, 2017, J NEUROPSYCH CLIN N, V29, P6, DOI 10.1176/appi.neuropsych.16030043; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Borenstein AR, 2006, ALZ DIS ASSOC DIS, V20, P63, DOI 10.1097/01.wad.0000201854.62116.d7; Caviness VS, 1996, CEREB CORTEX, V6, P726, DOI 10.1093/cercor/6.5.726; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Esopenko C, 2017, J NEUROL NEUROSUR PS, V88, P512, DOI 10.1136/jnnp-2016-315260; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2010, BRAIN COGNITION, V72, P6, DOI 10.1016/j.bandc.2009.08.009; Haneuse S, 2009, NEUROEPIDEMIOLOGY, V32, P229, DOI 10.1159/000197389; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Marek S, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002328; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sherman LE, 2014, DEV COGN NEUROS-NETH, V10, P148, DOI 10.1016/j.dcn.2014.08.002; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; Winship C, 1999, ANNU REV SOCIOL, V25, P659, DOI 10.1146/annurev.soc.25.1.659	47	62	62	6	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAY	2018	83	5					886	901		10.1002/ana.25245			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GK7QH	WOS:000436402600003	29710395	Green Accepted, Bronze			2021-06-18	
J	Scott, G; Zetterberg, H; Jolly, A; Cole, JH; De Simoni, S; Jenkins, PO; Feeney, C; Owen, DR; Lingford-Hughes, A; Howes, O; Patel, MC; Goldstone, AP; Gunn, RN; Blennow, K; Matthews, PM; Sharp, DJ				Scott, Gregory; Zetterberg, Henrik; Jolly, Amy; Cole, James H.; De Simoni, Sara; Jenkins, Peter O.; Feeney, Claire; Owen, David R.; Lingford-Hughes, Anne; Howes, Oliver; Patel, Maneesh C.; Goldstone, Anthony P.; Gunn, Roger N.; Blennow, Kaj; Matthews, Paul M.; Sharp, David J.			Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration	BRAIN			English	Article						traumatic brain injury; microglia; minocycline; neurodegeneration; positron emission tomography	NEUROFILAMENT LIGHT PROTEIN; RHESUS-MONKEY; SPINAL-CORD; INJURY; BINDING; SINGLE; PET; INFLAMMATION; BIOMARKER; EFFICACY	Survivors of a traumatic brain injury can deteriorate years later, developing brain atrophy and dementia. Traumatic brain injury triggers chronic microglial activation, but it is unclear whether this is harmful or beneficial. A successful chronic-phase treatment for traumatic brain injury might be to target microglia. In experimental models, the antibiotic minocycline inhibits microglial activation. We investigated the effect of minocycline on microglial activation and neurodegeneration using PET, MRI, and measurement of the axonal protein neurofilament light in plasma. Microglial activation was assessed using C-11-PBR28 PET. The relationships of microglial activation to measures of brain injury, and the effects of minocycline on disease progression, were assessed using structural and diffusion MRI, plasma neurofilament light, and cognitive assessment. Fifteen patients at least 6 months after a moderate-to-severe traumatic brain injury received either minocycline 100 mg orally twice daily or no drug, for 12 weeks. At baseline, C-11-PBR28 binding in patients was increased compared to controls in cerebral white matter and thalamus, and plasma neurofilament light levels were elevated. MRI measures of white matter damage were highest in areas of greater C-11-PBR28 binding. Minocycline reduced 11 C-PBR28 binding (mean Delta white matter binding = -23.30%, 95% confidence interval -40.9 to -5.64%, P = 0.018), but increased plasma neurofilament light levels. Faster rates of brain atrophy were found in patients with higher baseline neurofilament light levels. In this experimental medicine study, minocycline after traumatic brain injury reduced chronic microglial activation while increasing a marker of neurodegeneration. These findings suggest that microglial activation has a reparative effect in the chronic phase of traumatic brain injury.	[Scott, Gregory; Jolly, Amy; Cole, James H.; De Simoni, Sara; Jenkins, Peter O.; Feeney, Claire; Owen, David R.; Lingford-Hughes, Anne; Howes, Oliver; Goldstone, Anthony P.; Matthews, Paul M.; Sharp, David J.] Imperial Coll London, Div Brain Sci, Dept Med, London, England; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Patel, Maneesh C.] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, London, England; [Gunn, Roger N.] Imanova Ltd, London, England	Sharp, DJ (corresponding author), Imperial Coll London, Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Howes, Oliver/E-7156-2010; Cole, James H/I-5197-2019	Howes, Oliver/0000-0002-2928-1972; Cole, James H/0000-0003-1908-5588; Scott, Gregory/0000-0001-8063-5871; Jolly, Amy/0000-0002-7413-9772; Gunn, Roger/0000-0003-1181-5769; Goldstone, Anthony/0000-0001-8179-7071; Owen, David/0000-0002-1198-7563	Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme; UK National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); MS Society of Great Britain; Progressive MS Alliance; Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); GlaxoSmithKlineGlaxoSmithKline; Imperial College Healthcare Trust Biomedical Research Centre; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; VINNOVAVinnova; Torsten Soderberg foundation; NIHRNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/L022141/1, G0900897, 1116129, G0700995, MR/N026063/1, MR/N008219/1, MC_U120097115, MR/K501013/1, MR/N026934/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0514-10022, NIHR-RP-011-048] Funding Source: researchfish	G.S. was supported by a clinical research fellowship awarded in the Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme. D.R.O. is supported by the UK National Institute for Health Research (NIHR). P.M.M. has research support from the MS Society of Great Britain, the Progressive MS Alliance, the Medical Research Council (MRC) and GlaxoSmithKline and personal support from the Edmund J. Safra Foundation and from Lily Safra. D.J.S. currently holds a National Institute of Health Research Professorship -RP-011-048. K.B. currently holds the Torsten Soderberg Professorship in Medicine. H.Z. is a Wallenberg Academy Fellow. This work was supported by the Imperial College Healthcare Trust Biomedical Research Centre, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, VINNOVA and the Torsten Soderberg foundation. This paper presents independent research funded by the NIHR and carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NIHR, the NHS or the Department of Health.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Ashburner J, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00197; Bacioglu M, 2016, NEURON, V91, P494, DOI 10.1016/j.neuron.2016.07.007; Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Garrido-Mesa N, 2013, PHARMACOL RES, V67, P18, DOI 10.1016/j.phrs.2012.10.006; Gentleman SM, 2013, NEUROPATH APPL NEURO, V39, P45, DOI 10.1111/nan.12017; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Hansson O, 2017, NEUROLOGY, V88, P930, DOI 10.1212/WNL.0000000000003680; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jucaite A, 2015, BRAIN, V138, P2687, DOI 10.1093/brain/awv184; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; Loggia ML, 2015, BRAIN, V138, P604, DOI 10.1093/brain/awu377; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Maas AIR, 2004, ACT NEUR S, V89, P113; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Owen DR, 2014, J CEREBR BLOOD F MET, V34, P989, DOI 10.1038/jcbfm.2014.46; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Srivastava MVP, 2012, NEUROL INDIA, V60, P23, DOI 10.4103/0028-3886.93584; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00351; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784	52	62	62	3	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2018	141		2				459	471		10.1093/brain/awx339			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FV0AI	WOS:000424217900020	29272357	Green Published, Other Gold			2021-06-18	
J	Yip, PK; Carrillo-Jimenez, A; King, P; Vilalta, A; Nomura, K; Chau, CC; Egerton, AMS; Liu, ZH; Shetty, AJ; Tremoleda, JL; Davies, M; Deierborg, T; Priestley, JV; Brown, GC; Michael-Titus, AT; Venero, JL; Burguillos, MA				Yip, Ping Kei; Carrillo-Jimenez, Alejandro; King, Paul; Vilalta, Anna; Nomura, Koji; Chau, Chi Cheng; Egerton, Alexander Michael Scott; Liu, Zhuo-Hao; Shetty, Ashray Jayaram; Tremoleda, Jordi L.; Davies, Meirion; Deierborg, Tomas; Priestley, John V.; Brown, Guy Charles; Michael-Titus, Adina Teodora; Luis Venero, Jose; Burguillos, Miguel Angel			Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration	SCIENTIFIC REPORTS			English	Article							SPINAL-CORD-INJURY; RECEPTOR 4; INFLAMMATORY RESPONSE; GENE-EXPRESSION; MESSENGER-RNA; MICROGLIA; ACTIVATION; NEURONS; MICE; NEUROINFLAMMATION	Traumatic brain injury (TBI) is currently a major cause of morbidity and poor quality of life in Western society, with an estimate of 2.5 million people affected per year in Europe, indicating the need for advances in TBI treatment. Within the first 24 h after TBI, several inflammatory response factors become upregulated, including the lectin galectin-3. In this study, using a controlled cortical impact (CCI) model of head injury, we show a large increase in the expression of galectin-3 in microglia and also an increase in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after head injury. We report that galectin-3 can bind to TLR-4, and that administration of a neutralizing antibody against galectin-3 decreases the expression of IL-1 beta, IL-6, TNF alpha and NOS2 and promotes neuroprotection in the cortical and hippocampal cell populations after head injury. Long-term analysis demonstrated a significant neuroprotection in the cortical region in the galectin-3 knockout animals in response to TBI. These results suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other proteins, to TLR-4 and promoting inflammation and neuronal loss. Taking all together, galectin-3 emerges as a clinically relevant target for TBI therapy.	[Yip, Ping Kei; King, Paul; Chau, Chi Cheng; Egerton, Alexander Michael Scott; Liu, Zhuo-Hao; Shetty, Ashray Jayaram; Tremoleda, Jordi L.; Davies, Meirion; Priestley, John V.; Michael-Titus, Adina Teodora; Burguillos, Miguel Angel] Queen Mary Univ London, Blizard Inst, Ctr Neurosci & Trauma, London E1 2AT, England; [Carrillo-Jimenez, Alejandro] Univ Seville, Fac Farm, Dept Bioquim & Biol Mol, E-41012 Seville, Spain; [Carrillo-Jimenez, Alejandro] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, E-41012 Seville, Spain; [Vilalta, Anna; Nomura, Koji; Brown, Guy Charles] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Liu, Zhuo-Hao] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp, Dept Neurosurg, 5 Fu Shin St, Linkou, Taiwan; [Deierborg, Tomas] Lund Univ, Dept Expt Med Sci, Expt Neuroinflammat Lab, BMC B11, S-22184 Lund, Sweden; [Burguillos, Miguel Angel] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England	Burguillos, MA (corresponding author), Queen Mary Univ London, Blizard Inst, Ctr Neurosci & Trauma, London E1 2AT, England.; Burguillos, MA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England.	m.burguillos@qmul.ac.uk	Burguillos, Miguel Angel/AAF-6802-2021; Garcia, Miguel Angel Burguillos/N-4806-2019; Liu, Zhuo-Hao/C-6758-2011; CARRILLO JIMENEZ, ALEJANDRO/H-9351-2015	Burguillos, Miguel Angel/0000-0002-3165-9997; Nomura, Koji/0000-0002-5912-074X; Brown, Guy/0000-0002-3610-1730; Liu, Zhuo-Hao/0000-0003-4079-8697; Vilalta, Anna/0000-0002-2183-072X; CARRILLO JIMENEZ, ALEJANDRO/0000-0002-3023-4268; Chau, Chi Cheng/0000-0002-3134-6798	Spanish Ministerio de Educacion, Cultura y DeporteSpanish Government; Spanish Ministerio (MINECO/FEDER, UE), Blizard Research Theme grants, Blizard Institute, Queen Mary University of London [SAF2015-64171R]; Barts Charity Centre for Trauma Sciences (C4TS); Wellcome Trust Institutional Strategic Support Fund (ISSF)Wellcome Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/L010593/1] Funding Source: researchfish	We thank Drs B. Joseph, D. Sheer and M. Branco for providing us with reagents. A.C.-J. is supported by a pre-doctoral fellowship from Spanish Ministerio de Educacion, Cultura y Deporte. This work has been supported by grants from the Spanish Ministerio SAF2015-64171R (MINECO/FEDER, UE), Blizard Research Theme grants, Blizard Institute, Queen Mary University of London. M. A. B has been funded by the Barts Charity Centre for Trauma Sciences (C4TS) and the Wellcome Trust Institutional Strategic Support Fund (ISSF).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Boza-Serrano A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0156-0; Brazinova A, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0133-z; Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710; Burguillos MA, 2015, CELL REP, V10, P1626, DOI 10.1016/j.celrep.2015.02.012; Butenschon J, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-015-0268-x; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Colnot C, 1998, DEV DYNAM, V211, P306, DOI 10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Didangelos A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21607; DODD J, 1986, J EXP BIOL, V124, P225; Doverhag C, 2010, NEUROBIOL DIS, V38, P36, DOI 10.1016/j.nbd.2009.12.024; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Ferrini F, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/429815; Fricker M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-196; Funasaka T, 2014, GLYCOBIOLOGY, V24, P886, DOI 10.1093/glycob/cwu086; Hanamsagar R, 2012, TRENDS IMMUNOL, V33, P333, DOI 10.1016/j.it.2012.03.001; Hayward Jin Hee, 2014, Exp Neurobiol, V23, P138, DOI 10.5607/en.2014.23.2.138; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Jeon SB, 2010, J IMMUNOL, V185, P7037, DOI 10.4049/jimmunol.1000154; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Ji XC, 2015, CELL MOL NEUROBIOL, V35, P881, DOI 10.1007/s10571-015-0182-x; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Li Y, 2008, J IMMUNOL, V181, P2781, DOI 10.4049/jimmunol.181.4.2781; Liu ZH, 2015, J NEUROSCI, V35, P12733, DOI 10.1523/JNEUROSCI.0605-15.2015; MacKinnon AC, 2008, J IMMUNOL, V180, P2650, DOI 10.4049/jimmunol.180.4.2650; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Mostacada K, 2015, EXP NEUROL, V271, P390, DOI 10.1016/j.expneurol.2015.07.006; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Neher JJ, 2013, P NATL ACAD SCI USA, V110, pE4098, DOI 10.1073/pnas.1308679110; Newlaczyl AU, 2011, CANCER LETT, V313, P123, DOI 10.1016/j.canlet.2011.09.003; Pajoohesh-Ganji A, 2012, BRAIN RES, V1475, P96, DOI 10.1016/j.brainres.2012.07.058; Park C, 2008, NEUROSCI LETT, V431, P123, DOI 10.1016/j.neulet.2007.11.057; Parpura V, 2010, BRAIN RES REV, V63, P83, DOI 10.1016/j.brainresrev.2009.11.008; Pearce N, 2015, NEUROBIOL AGING, V36, P1383, DOI 10.1016/j.neurobiolaging.2014.12.024; Pesheva P, 2000, NEUROSCI LETT, V293, P37, DOI 10.1016/S0304-3940(00)01499-3; Santos D, 2016, BRAIN RES, V1636, P93, DOI 10.1016/j.brainres.2016.01.051; Shan RZ, 2016, J NEUROTRAUM, V33, P49, DOI 10.1089/neu.2014.3811; Shen YF, 2016, CLIN CHIM ACTA, V456, P75, DOI 10.1016/j.cca.2016.02.029; Shin T, 2013, ACTA HISTOCHEM, V115, P407, DOI 10.1016/j.acthis.2012.11.010; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Sundblad V, 2011, HISTOL HISTOPATHOL, V26, P247, DOI 10.14670/HH-26.247; Taylor SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097096; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Yu ZQ, 2012, ANN CLIN LAB SCI, V42, P26; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	61	62	62	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 27	2017	7								41689	10.1038/srep41689			13	Multidisciplinary Sciences	Science & Technology - Other Topics	EJ2DM	WOS:000393020100001	28128358	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Aziz, O; Musngi, M; Park, EJ; Mori, G; Robinovitch, SN				Aziz, Omar; Musngi, Magnus; Park, Edward J.; Mori, Greg; Robinovitch, Stephen N.			A comparison of accuracy of fall detection algorithms (threshold-based vs. machine learning) using waist-mounted tri-axial accelerometer signals from a comprehensive set of falls and non-fall trials	MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING			English	Article						Older adults; Falls; Wearable sensors; Machine learning; Threshold-based algorithms	DWELLING OLDER PERSONS; PRE-IMPACT DETECTION; WEARABLE SENSORS; PEOPLE; HUMANS; RISK	Falls are the leading cause of injury-related morbidity and mortality among older adults. Over 90 % of hip and wrist fractures and 60 % of traumatic brain injuries in older adults are due to falls. Another serious consequence of falls among older adults is the 'long lie' experienced by individuals who are unable to get up and remain on the ground for an extended period of time after a fall. Considerable research has been conducted over the past decade on the design of wearable sensor systems that can automatically detect falls and send an alert to care providers to reduce the frequency and severity of long lies. While most systems described to date incorporate threshold-based algorithms, machine learning algorithms may offer increased accuracy in detecting falls. In the current study, we compared the accuracy of these two approaches in detecting falls by conducting a comprehensive set of falling experiments with 10 young participants. Participants wore waist-mounted tri-axial accelerometers and simulated the most common causes of falls observed in older adults, along with near-falls and activities of daily living. The overall performance of five machine learning algorithms was greater than the performance of five threshold-based algorithms described in the literature, with support vector machines providing the highest combination of sensitivity and specificity.	[Aziz, Omar; Robinovitch, Stephen N.] Simon Fraser Univ, Injury Prevent & Mobil Lab, Burnaby, BC, Canada; [Robinovitch, Stephen N.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC, Canada; [Aziz, Omar; Robinovitch, Stephen N.] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC, Canada; [Mori, Greg] Simon Fraser Univ, Sch Comp Sci, Burnaby, BC, Canada; [Aziz, Omar; Musngi, Magnus; Park, Edward J.] Simon Fraser Univ, Sch Mech Syst Engn, Surrey, BC, Canada	Aziz, O (corresponding author), Simon Fraser Univ, Injury Prevent & Mobil Lab, Burnaby, BC, Canada.; Aziz, O (corresponding author), Simon Fraser Univ, Sch Engn Sci, Burnaby, BC, Canada.; Aziz, O (corresponding author), Simon Fraser Univ, Sch Mech Syst Engn, Surrey, BC, Canada.	oaziz@sfu.ca		Robinovitch, Stephen/0000-0003-3881-6227	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [AMG-100487, TIR-103945]; Canada Research Chairs programCanada Research Chairs	This work was supported by team grants from the Canadian Institutes of Health Research (Funding Reference Numbers: AMG-100487 and TIR-103945). SNR was also supported by the Canada Research Chairs program. The funding agency had no direct role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.	Albert MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036556; Arnold Catherine M, 2007, BMC Geriatr, V7, P17; Aziz O, 2014, GAIT POSTURE, V39, P506, DOI 10.1016/j.gaitpost.2013.08.034; Aziz O, 2012, IEEE ENG MED BIO, P5837, DOI 10.1109/EMBC.2012.6347321; Aziz O, 2011, IEEE T NEUR SYS REH, V19, P670, DOI 10.1109/TNSRE.2011.2162250; Bagala F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037062; Bourke AK, 2008, MED ENG PHYS, V30, P937, DOI 10.1016/j.medengphy.2007.12.003; Bourke AK, 2007, GAIT POSTURE, V26, P194, DOI 10.1016/j.gaitpost.2006.09.012; Bourke AK, 2010, J BIOMECH, V43, P3051, DOI 10.1016/j.jbiomech.2010.07.005; Bourke A. K., 2006, P 24 IASTED INT C BI; Bourke AK, 2008, IEEE ENG MED BIO, P2844, DOI 10.1109/IEMBS.2008.4649795; Boyle J, 2008, IEEE ENG MED BIO, P1274, DOI 10.1109/IEMBS.2008.4649396; Chao PK, 2009, PHYSIOL MEAS, V30, P1027, DOI 10.1088/0967-3334/30/10/004; Chen J, 2005, P ANN INT IEEE EMBS, P3551, DOI 10.1109/IEMBS.2005.1617246; Diaz A, 2004, Conf Proc IEEE Eng Med Biol Soc, V2004, P2180; Herman M., 2006, EVOLUTION SENIORS FA; Kangas M, 2008, GAIT POSTURE, V28, P285, DOI 10.1016/j.gaitpost.2008.01.003; Kau LJ, 2015, IEEE J BIOMED HEALTH, V19, P44, DOI 10.1109/JBHI.2014.2328593; Kern N, 2007, PERS UBIQUIT COMPUT, V11, P251, DOI 10.1007/s00779-006-0086-3; KING MB, 1995, J AM GERIATR SOC, V43, P1146, DOI 10.1111/j.1532-5415.1995.tb07017.x; Lee JK, 2015, IEEE T NEUR SYS REH, V23, P258, DOI 10.1109/TNSRE.2014.2357806; Lindemann U, 2005, MED BIOL ENG COMPUT, V43, P548, DOI 10.1007/BF02351026; MALLINSON WJW, 1985, AGE AGEING, V14, P174, DOI 10.1093/ageing/14.3.174; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Noury N, 2008, IEEE ENG MED BIO, P2828, DOI 10.1109/IEMBS.2008.4649791; Noury N, 2008, IRBM, V29, P340, DOI 10.1016/j.irbm.2008.08.002; Robinovitch SN, 2013, LANCET, V381, P47, DOI 10.1016/S0140-6736(12)61263-X; Srygley JM, 2009, ARCH PHYS MED REHAB, V90, P786, DOI 10.1016/j.apmr.2008.11.007; Tinetti ME, 1998, J GERONTOL A-BIOL, V53, pM112, DOI 10.1093/gerona/53A.2.M112; VELLAS B, 1987, AGE AGEING, V16, P189, DOI 10.1093/ageing/16.3.189; Weiss Aner, 2010, BMC Res Notes, V3, P62, DOI 10.1186/1756-0500-3-62; Weiss GM, 2003, J ARTIF INTELL RES, V19, P315, DOI 10.1613/jair.1199; WILD D, 1981, BRIT MED J, V282, P266, DOI 10.1136/bmj.282.6260.266	33	62	65	2	42	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0140-0118	1741-0444		MED BIOL ENG COMPUT	Med. Biol. Eng. Comput.	JAN	2017	55	1					45	55		10.1007/s11517-016-1504-y			11	Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Mathematical & Computational Biology; Medical Informatics	Computer Science; Engineering; Mathematical & Computational Biology; Medical Informatics	EK0CH	WOS:000393593600004	27106749				2021-06-18	
J	Shi, W; Huang, CJ; Xu, XD; Jin, GH; Huang, RQ; Huang, JF; Chen, YN; Ju, SQ; Wang, Y; Shi, YW; Qin, JB; Zhang, YQ; Liu, QQ; Wang, XB; Zhang, XH; Chen, J				Shi, W.; Huang, C. J.; Xu, X. D.; Jin, G. H.; Huang, R. Q.; Huang, J. F.; Chen, Y. N.; Ju, S. Q.; Wang, Y.; Shi, Y. W.; Qin, J. B.; Zhang, Y. Q.; Liu, Q. Q.; Wang, X. B.; Zhang, X. H.; Chen, J.			Transplantation of RADA16-BDNF peptide scaffold with human umbilical cord mesenchymal stem cells forced with CXCR4 and activated astrocytes for repair of traumatic brain injury	ACTA BIOMATERIALIA			English	Article						Traumatic brain injury; Transplantation; hUC-MSCs; Astrocytes; CXCR4/SDF-1axis; Neuronal differentiation; Peptide hydrogel	BONE-MARROW; IN-VITRO; REACTIVE ASTROCYTES; ADULT BRAIN; THERAPY; BDNF; RECOVERY; MODEL; DIFFERENTIATION; PROLIFERATION	Due to the poor self-regeneration of brain tissue, stem cell transplantation therapy is purported to enable the replacement of lost neurons after traumatic brain injury (TBI). The main challenge of brain regeneration is whether the transplanted cells can survive and carry out neuronal functions in the lesion area. The brain is a complex neuronal network consisting of various types of cells that significantly influence on each other, and the survival of the implanted stem cells in brain is critically influenced by the surrounding cells. Although stem cell-based therapy is developing rapidly, most previous studies just focus on apply single type of stem cells as cell source. Here, we found that co-culturing human umbilical cord mesenchymal stem cells (hUC-MSCs) directly with the activated astrocytes benefited to the proliferation and neuron differentiation of hUC-MSCs in vitro. In this study, hUC-MSCs and the activated astrocytes were seeded in RADA16-BDNF peptide scaffold (R-B-SPH scaffold), a specifical self-assembling peptide hydrogel, in which the environment promoted the differentiation of typical neuron-like cells with neurites extending in three-dimensional directions. Moreover, the results showed co-culture of hUC-MSCs and activated astrocytes promoted more BDNF secretion which may benefit to both neural differentiation of ectogenic hUC-MSCs and endogenic neurogenesis. In order to promote migration of the transplanted hUC-MSCs to the host brain, the hUC-MSCs were forced with CXC chemokine receptor 4 (CXCR4). We found that the moderate-sized lesion cavity, but not the large cavity caused by TBI was repaired via the transplantation of hUC-MSCscxcR4 and activated astrocytes embedded in R-B-SPH scaffolds. The functional neural repair for TBI demonstrated in this study is mainly due to the transplantation system of double cells, hUC-MSCs and activated astrocytes. We believe that this novel cell transplantation system offers a promising treatment option for cell replacement therapy for TBI. Statement of Significance In this reach, we specifically linked RGIDKRHWNSQ a functional peptide derived from BDNF, to the C-terminal of RADARADARADARADA (RADA16) to structure a functional self-assembling peptide hydro gel scaffold, RADA16-BDNF (R-B-SPH scaffold) for the better transplantation of the double cell unit. Also, the novel scaffold was used as cell-carrier for transplantation double cell unit (hUC-MSCs/astrocyte) for treating traumatic brain injury. The results of this study showing that R-B-SPH scaffold was pliancy and flexibility to fit the brain lesion cavity and promotes the outgrowth of axons and dendrites of the neurons derived from hUC-MSCs in vitro and in vivo, indicating the 3D R-B-SPH scaffold provided a suitable microenvironment for hUC-MSC survival, proliferation and differentiation. Also, our results showing the double-cells transplantation system (hUC-MSC5/astrocyte) may be a novel cell-based therapeutic strategy for neuroregeneration after TBI with potential value for clinical application. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Shi, W.; Xu, X. D.; Chen, Y. N.; Liu, Q. Q.; Chen, J.] Nantong Univ, Dept Neurosurg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China; [Jin, G. H.; Qin, J. B.; Zhang, X. H.] Nantong Univ, Sch Med, Dept Anat & Neurobiol, Nantong 226001, Peoples R China; [Huang, C. J.] First Peoples Hosp Wujiang, Dept Neurosurg, Suzhou 215200, Peoples R China; [Shi, W.] Xinhua Hosp Kazak Autonomous Prefecture Ili, Dept Neurosurg, Sinkiang 835000, Peoples R China; [Shi, W.; Huang, C. J.; Ju, S. Q.] Nantong Univ, Dept Lab Surg, Affiliated Hosp, Nantong 226001, Peoples R China; [Huang, R. Q.] Fudan Univ, Minist Educ, Key Lab Smart Drug Delivery, Shanghai 201203, Peoples R China; [Huang, R. Q.] Fudan Univ, Sch Pharm, Dept Pharmaceut, PLA, Shanghai 201203, Peoples R China; [Wang, Y.] Fudan Univ, Ctr Anal & Measurement, Shanghai 200433, Peoples R China; [Huang, J. F.] Nantong Univ, Affiliated Hosp, Dept Pathol & Clin Biobank, Nantong 226001, Peoples R China; [Shi, Y. W.] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Peoples R China; [Zhang, Y. Q.] Nantong Univ, Affiliated Hosp, Dept Obstet & Gynecol, Nantong 226001, Peoples R China; [Wang, X. B.] Nantong Univ, Affiliated Hosp, Med Image Ctr, Nantong 226001, Peoples R China	Chen, J (corresponding author), Nantong Univ, Dept Neurosurg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.; Zhang, XH (corresponding author), Nantong Univ, Dept Anat & Neurobiol, Nantong 226001, Jiangsu, Peoples R China.	zhangxinhua@ntu.edu.cn; ntfychenjian@126.com	Huang, Rongqin/C-4165-2014	Zhang, Xin-hua/0000-0002-5702-6733	National Natural Science Foundation of China - ChinaNational Natural Science Foundation of China (NSFC) [81271368]; Chinese Projects for Postdoctoral Science Funds - China [2014M561698]; Chinese Special Projects for Postdoctoral Science Funds - China [2015T80573]; Natural Science Foundation of Jiangsu Province - ChinaNatural Science Foundation of Jiangsu Province [BK2012654]; Jiangsu Planned Projects for Postdoctoral Research Funds - China [1401085B]; Application Research Project of Nantong City - China [HS12030]; Grand of Nantong University for innovation talent - China [CXZR201308]	The authors thank the Surgical Comprehensive Laboratory of the Affiliated Hospital of Nantong University for technical assistance and equipment support. This work was supported by the National Natural Science Foundation of China - China (grant no. 81271368); Chinese Projects for Postdoctoral Science Funds - China (No. 2014M561698); Chinese Special Projects for Postdoctoral Science Funds - China (No. 2015T80573); the Natural Science Foundation of Jiangsu Province - China (grant no. BK2012654); Jiangsu Planned Projects for Postdoctoral Research Funds - China (No. 1401085B); Application Research Project of Nantong City - China (Grant No. HS12030) and The Grand of Nantong University for innovation talent - China (Grant No. CXZR201308).	Bara JJ, 2014, STEM CELLS, V32, P1713, DOI 10.1002/stem.1649; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bjorklund A, 2000, NATURE, V405, P892, DOI 10.1038/35016175; Boccazzi M, 2014, GLIA, V62, P428, DOI 10.1002/glia.22614; Bonilla C, 2009, BRAIN INJURY, V23, P760, DOI 10.1080/02699050903133970; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chen LW, 2005, CURR DRUG TARGETS, V6, P821, DOI 10.2174/138945005774574506; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Conti L, 2006, BRAIN PATHOL, V16, P143, DOI 10.1111/j.1750-3639.2006.00009.x; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Dimmeler S, 2014, NAT MED, V20, P814, DOI 10.1038/nm.3627; Du JL, 2004, NATURE, V429, P878, DOI 10.1038/nature02618; England T, 2009, INT J STROKE, V4, P101, DOI 10.1111/j.1747-4949.2009.00253.x; Filous AR, 2010, DEV NEUROBIOL, V70, P826, DOI 10.1002/dneu.20820; Fobian K, 2010, J NEUROSCI RES, V88, P1170, DOI 10.1002/jnr.22285; Forraz N, 2013, J TISSUE ENG REGEN M, V7, P523, DOI 10.1002/term.552; Gonfiotti A, 2014, LANCET, V383, P238, DOI 10.1016/S0140-6736(13)62033-4; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Guzman R, 2008, STROKE, V39, P1300, DOI 10.1161/STROKEAHA.107.500470; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kim SS, 2008, STEM CELLS, V26, P2217, DOI 10.1634/stemcells.2008-0108; Lee J, 2008, TISSUE ENG PART B-RE, V14, P61, DOI 10.1089/teb.2007.0150; Li JY, 2015, J CRANIOFAC SURG, V26, P548, DOI 10.1097/SCS.0000000000001348; Luo ZL, 2012, CHEM SOC REV, V41, P4736, DOI 10.1039/c2cs15360b; Mojsilovic S, 2011, CELL TISSUE RES, V346, P305, DOI 10.1007/s00441-011-1284-5; Nakano M, 2016, SCI REP-UK, V6, DOI 10.1038/srep24805; Park HJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0180-4; Patel K, 2016, BRAIN RES, V1640, P104, DOI 10.1016/j.brainres.2016.01.055; Pelizzoni I, 2013, BBA-MOL BASIS DIS, V1832, P1326, DOI 10.1016/j.bbadis.2013.04.007; Raynald, 2016, BRAIN RES, V1634, P21, DOI 10.1016/j.brainres.2015.10.038; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Saracino GAA, 2013, CHEM SOC REV, V42, P225, DOI 10.1039/c2cs35065c; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Srikanth M, 2012, NAT REV NEUROL, V8, P307, DOI 10.1038/nrneurol.2012.76; Thomaidou D, 2014, METHODS MOL BIOL, V1210, P9, DOI 10.1007/978-1-4939-1435-7_2; Vazey EM, 2006, EXP NEUROL, V199, P384, DOI 10.1016/j.expneurol.2006.01.034; Wang FW, 2011, STEM CELL RES, V7, P41, DOI 10.1016/j.scr.2011.03.004; Yang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6627; Zhu J, 2005, CURR DRUG TARGETS, V6, P97, DOI 10.2174/1389450053345055	45	62	63	5	62	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	NOV	2016	45						247	261		10.1016/j.actbio.2016.09.001			15	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	EB3VZ	WOS:000387298300018	27592818				2021-06-18	
J	Koerte, IK; Mayinger, M; Muehlmann, M; Kaufmann, D; Lin, AP; Steffinger, D; Fisch, B; Rauchmann, BS; Immler, S; Karch, S; Heinen, FR; Ertl-Wagner, B; Reiser, M; Stern, RA; Zafonte, R; Shenton, ME				Koerte, Inga K.; Mayinger, Michael; Muehlmann, Marc; Kaufmann, David; Lin, Alexander P.; Steffinger, Denise; Fisch, Barbara; Rauchmann, Boris-Stephan; Immler, Stefanie; Karch, Susanne; Heinen, Florian R.; Ertl-Wagner, Birgit; Reiser, Maximilian; Stern, Robert A.; Zafonte, Ross; Shenton, Martha E.			Cortical thinning in former professional soccer players	BRAIN IMAGING AND BEHAVIOR			English	Article						Repetitive subconcussive head impact; Soccer; Cortical thickness; Aging; Traumatic brain injury	CONCUSSION; THICKNESS	Soccer is the most popular sport in the world. Soccer players are at high risk for repetitive subconcussive head impact when heading the ball. Whether this leads to long-term alterations of the brain's structure associated with cognitive decline remains unknown. The aim of this study was to evaluate cortical thickness in former professional soccer players using high-resolution structural MR imaging. Fifteen former male professional soccer players (mean age 49.3 [SD 5.1] years) underwent high-resolution structural 3 T MR imaging, as well as cognitive testing. Fifteen male, age-matched former professional non-contact sport athletes (mean age 49.6 [SD 6.4] years) served as controls. Group analyses of cortical thickness were performed using voxel-based statistics. Soccer players demonstrated greater cortical thinning with increasing age compared to controls in the right inferolateral-parietal, temporal, and occipital cortex. Cortical thinning was associated with lower cognitive performance as well as with estimated exposure to repetitive subconcussive head impact. Neurocognitive evaluation revealed decreased memory performance in the soccer players compared to controls. The association of cortical thinning and decreased cognitive performance, as well as exposure to repetitive subconcussive head impact, further supports the hypothesis that repetitive subconcussive head impact may play a role in early cognitive decline in soccer players. Future studies are needed to elucidate the time course of changes in cortical thickness as well as their association with impaired cognitive function and possible underlying neurodegenerative process.	[Koerte, Inga K.; Mayinger, Michael; Muehlmann, Marc; Lin, Alexander P.; Rauchmann, Boris-Stephan; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Koerte, Inga K.; Mayinger, Michael; Muehlmann, Marc; Kaufmann, David; Steffinger, Denise; Fisch, Barbara; Rauchmann, Boris-Stephan; Ertl-Wagner, Birgit; Reiser, Maximilian] Univ Munich, Inst Clin Radiol, Munich, Germany; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Kaufmann, David] Charite, Dept Radiol, Berlin, Germany; [Lin, Alexander P.; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA; [Immler, Stefanie; Heinen, Florian R.] Univ Munich, Dept Pediat Neurol & Dev Med, Dr von Hauner Childrens Hosp, Munich, Germany; [Karch, Susanne] Univ Munich, Dept Psychiat, Munich, Germany; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Zafonte, Ross] Harvard Med Sch, Brigham & Womens Hosp, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp,Massachusetts Gen Hosp, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA	Koerte, IK (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02115 USA.; Koerte, IK (corresponding author), Univ Munich, Inst Clin Radiol, Munich, Germany.; Koerte, IK (corresponding author), Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany.	ikoerte@bwh.harvard.edu	, Bob/ABA-8507-2020; Ertl-Wagner, Birgit/AAD-5708-2020; Heinen, Florian/B-6594-2015; Shenton, Martha/V-8780-2019	Heinen, Florian/0000-0002-3872-6136; Ertl-Wagner, Birgit/0000-0002-7896-7049	Else Kroner-Fresenius Stiftung, Germany; Department of DefenseUnited States Department of Defense [X81XWH-07-CC-CSDoD]; VA Merit AwardUS Department of Veterans Affairs; Petraeic Legate foundation, Germany	This study was supported by the Else Kroner-Fresenius Stiftung, Germany (IK). This work was also partially funded by grants from The Department of Defense (X81XWH-07-CC-CSDoD; RZ, MES) and a VA Merit Award (MES). Michael Mayinger was supported by the Petraeic Legate foundation, Germany.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; EKBLOM B, 1986, SPORTS MED, V3, P50, DOI 10.2165/00007256-198603010-00005; Fjell AM, 2009, CEREB CORTEX, V19, P2001, DOI 10.1093/cercor/bhn232; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Shin MS, 2006, NAT PROTOC, V1, P892, DOI 10.1038/nprot.2006.115; Sowell ER, 2007, CEREB CORTEX, V17, P1550, DOI 10.1093/cercor/bhl066; Storsve AB, 2014, J NEUROSCI, V34, P8488, DOI 10.1523/JNEUROSCI.0391-14.2014; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tysvaer A, 1981, Br J Sports Med, V15, P163; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364	22	62	62	0	25	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2016	10	3					792	798		10.1007/s11682-015-9442-0			7	Neuroimaging	Neurosciences & Neurology	DU7IL	WOS:000382387300018	26286826				2021-06-18	
J	Ojo, JO; Mouzon, B; Algamal, M; Leary, P; Lynch, C; Abdullah, L; Evans, J; Mullan, M; Bachmeier, C; Stewart, W; Crawford, F				Ojo, Joseph O.; Mouzon, Benoit; Algamal, Moustafa; Leary, Paige; Lynch, Cillian; Abdullah, Laila; Evans, James; Mullan, Michael; Bachmeier, Corbin; Stewart, William; Crawford, Fiona			Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal injury; Behavior; Cerebral blood flow; Concussion; Glial activation; hTau mice; Tau	ALZHEIMERS-DISEASE; MOUSE MODEL; HEAD-INJURY; NEUROFIBRILLARY TANGLES; PROFESSIONAL FOOTBALL; DEMENTIA-PUGILISTICA; PHOSPHORYLATED-TAU; RISK-FACTOR; ENCEPHALOPATHY; NEURODEGENERATION	Exposure to repetitive mild traumatic brain injury (mTBI) is a risk factor for chronic traumatic encephalopathy, which is characterized by patchy deposition of hyperphosphorvlated tau aggregates in neurons and astrocytes at the depths of cortical sulci. We developed an mTBI paradigm to explore effects of repetitive concussive-type injury over several months in mice with a human tau genetic background (hTau). Two injuries were induced in the hTau mice weekly over a period of 3 or 4 months and the effects were compared with those in noninjured sham animals. Behavioral and in vivo measures and detailed neuropathological assessments were conducted 6 months after the first injury. Our data confirm impairment in cerebral blood flow and white matter damage. This was accompanied by a 2-fold increase in total tau levels and mild increases in tau oligomers/conformers and pTau (Thr231) species in brain gray matter. There was no evidence of neurofibrillary/astroglial tangles, neuropil threads, or perivascular foci of tau immunoreactivity. There were neurobehavioral deficits (ie, disinhibition and impaired cognitive performance) in the mTBI animals. These data support the relevance of this new mTBI injury model for studying the consequences of chronic repetitive mTBI in humans, and the role of tau in TBI.	[Ojo, Joseph O.; Mouzon, Benoit; Algamal, Moustafa; Leary, Paige; Lynch, Cillian; Abdullah, Laila; Evans, James; Mullan, Michael; Bachmeier, Corbin; Crawford, Fiona] Roskamp Inst, Sarasota, FL USA; [Mouzon, Benoit; Abdullah, Laila; Bachmeier, Corbin; Crawford, Fiona] James A Haley Vet Hosp, Tampa, FL USA; [Mouzon, Benoit; Algamal, Moustafa; Lynch, Cillian; Bachmeier, Corbin; Crawford, Fiona] Open Univ, Milton Keynes, Bucks, England; [Bachmeier, Corbin] Bay Pines VA Healthcare Syst, Bay Pines, FL USA; [Stewart, William] Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland; [Stewart, William] Univ Glasgow, Glasgow, Lanark, Scotland; [Stewart, William] Univ Penn, Philadelphia, PA 19104 USA	Ojo, JO (corresponding author), Roskamp Inst, Neuropathol Core Unit, 2040 Whitfield Ave, Sarasota, FL 34324 USA.	bojo@roskampinstitute.net		Algamal, Moustafa/0000-0002-6215-0122; Stewart, William/0000-0003-2199-2582	Roskamp Foundation	This study was funded by the Roskamp Foundation.	Abdullah L, 2008, NEUROMOL MED, V14, P349; Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Bazan NG, 2006, CELL MOL NEUROBIOL, V26, P901, DOI 10.1007/s10571-006-9064-6; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Braak H, 2012, CURR OPIN NEUROL, V25, P708, DOI 10.1097/WCO.0b013e32835a3432; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Harbuz M, 2002, EXP PHYSIOL, V87, P519, DOI 10.1113/eph8702411; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Kovacech B, 2010, NEURODEGENER DIS, V7, P24, DOI 10.1159/000283478; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Liu YT, 2001, EUR J PHARMACOL, V428, P193, DOI 10.1016/S0014-2999(01)01255-9; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2014, ANN NEUROL, V74, P65; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; McKee A, 2011, J NEUROPATH EXP NEUR, V70, P517; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Millspaugh JA, 2013, US NAVAL MED B, V35, P297; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nakamura K, 2013, PRION, V7, P117, DOI 10.4161/pri.22849; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Ojo JO, 2015, J NEUROPATH EXP NEUR, V74, P1012, DOI 10.1097/NEN.0000000000000247; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Paris D, 2003, NEUROL RES, V25, P642, DOI 10.1179/016164103101201940; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Phillips M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019567; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROBERTS GW, 1988, LANCET, V2, P1456; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shahim P, 2016, J NEUROTRAUMA; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stewart W, 2015, QJM, V109, P11; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Uchihara T, 2001, ACTA NEUROPATHOL, V101, P535; Wohleb ES, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00447; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhang J, 2015, J CEREBR BLOOD F MET, V35, P443, DOI 10.1038/jcbfm.2014.216	91	62	62	0	39	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2016	75	7					636	655		10.1093/jnen/nlw035			20	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DR3BG	WOS:000379777000003	27251042	Green Published, Bronze			2021-06-18	
J	Muccigrosso, MM; Ford, J; Benner, B; Moussa, D; Burnsides, C; Fenn, AM; Popovich, PG; Lifshitz, J; Walker, FR; Eiferman, DS; Godbout, JP				Muccigrosso, Megan M.; Ford, Joni; Benner, Brooke; Moussa, Daniel; Burnsides, Christopher; Fenn, Ashley M.; Popovich, Phillip G.; Lifshitz, Jonathan; Walker, Fredrick Rohan; Eiferman, Daniel S.; Godbout, Jonathan P.			Cognitive deficits develop 1 month after diffuse brain injury and are exaggerated by microglia-associated reactivity to peripheral immune challenge	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Fluid percussion injury; Microglia; Astrocytes; Cognitive decline; Lipopolysaccharide; Neuroinflammation	DEPRESSIVE-LIKE BEHAVIOR; LONG-TERM POTENTIATION; AGED MICE; HIPPOCAMPAL NEUROGENESIS; EXPERIMENTAL-MODELS; SICKNESS BEHAVIOR; NEURONAL LOSS; HEAD-INJURY; ACTIVATION; MEMORY	Traumatic brain injury (TBI) elicits immediate neuroinflammatory events that contribute to acute cognitive, motor, and affective disturbance. Despite resolution of these acute complications, significant neuropsychiatric and cognitive issues can develop and progress after TBI. We and others have provided novel evidence that these complications are potentiated by repeated injuries, immune challenges and stressors. A key component to this may be increased sensitization or priming of glia after TBI. Therefore, our objectives were to determine the degree to which cognitive deterioration occurred after diffuse TBI (moderate midline fluid percussion injury) and ascertain if glial reactivity induced by an acute immune challenge potentiated cognitive decline 30 days post injury (dpi). In post-recovery assessments, hippocampal-dependent learning and memory recall were normal 7 dpi, but anterograde learning was impaired by 30 dpi. Examination of mRNA and morphological profiles of glia 30 dpi indicated a low but persistent level of inflammation with elevated expression of GFAP and IL-1 beta in astrocytes and MHCII and IL-1 beta in microglia. Moreover, an acute immune challenge 30 dpi robustly interrupted memory consolidation specifically in TBI mice. These deficits were associated with exaggerated microglia-mediated inflammation with amplified (IL-1 beta, CCL2, TNF alpha) and prolonged (TNF alpha) cytokine/chemokine expression, and a marked reactive morphological profile of microglia in the CA3 of the hippocampus. Collectively, these data indicate that microglia remain sensitized 30 dpi after moderate TBI and a secondary inflammatory challenge elicits robust microglial reactivity that augments cognitive decline. Statement of Significance: Traumatic brain injury (TBI) is a major risk factor in development of neuropsychiatric problems long after injury, negatively affecting quality of life. Mounting evidence indicates that inflammatory processes worsen with time after a brain injury and are likely mediated by glia. Here, we show that primed microglia and astrocytes developed in mice 1 month following moderate diffuse TBI, coinciding with cognitive deficits that were not initially evident after injury. Additionally, TBI-induced glial priming may adversely affect the ability of glia to appropriately respond to immune challenges, which occur regularly across the lifespan. Indeed, we show that an acute immune challenge augmented microglial reactivity and cognitive deficits. This idea may provide new avenues of clinical assessments and treatments following TBI. (C) 2016 Elsevier Inc. All rights reserved.	[Muccigrosso, Megan M.; Ford, Joni; Benner, Brooke; Moussa, Daniel; Burnsides, Christopher; Fenn, Ashley M.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, 333 W 10th Ave, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, 460 W 12th Ave, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, 460 Med Ctr Dr, Columbus, OH 43210 USA; [Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Barrow Neurol Inst, Phoenix Childrens Hosp,Dept Child Hlth, Phoenix, AZ USA; [Walker, Fredrick Rohan] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Eiferman, Daniel S.] Ohio State Univ, Dept Surg, 395 W 12th Ave, Columbus, OH 43210 USA	Godbout, JP (corresponding author), Ohio State Univ, 231 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA.	jonathan.godbout@osumc.edu			NIA Grant [R01-AG-033028]; College of Medicine Dean's Discovery Grant; Center for Brain and Spinal Cord Repair; American Surgical Society Fellowship; P30 Core Grant [NINDS P30-NS045758]; National Institute of Dental and Craniofacial Research Training Grant [T32-DE-01-4320]; OSU Presidential Fellowship; Ray W. Poppleton Endowment; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE014320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033028] Funding Source: NIH RePORTER	This research was supported by an NIA Grant (R01-AG-033028 to J.P.G.), College of Medicine Dean's Discovery Grant (to J.P.G.), Funding from the Center for Brain and Spinal Cord Repair (to J.P.G), an American Surgical Society Fellowship (to D.S.E). In addition, this work was supported by a P30 Core Grant NINDS P30-NS045758. M.M.M. was supported by a National Institute of Dental and Craniofacial Research Training Grant (T32-DE-01-4320), A.M.F. was supported by the OSU Presidential Fellowship, and P.G.P was supported by a Ray W. Poppleton Endowment.	Almeida O.P., 2015, INT J GERIATR PSYCHI; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barrientos RM, 2010, AGING DIS, V1, P212; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P46, DOI 10.1016/j.bbi.2008.07.002; Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Ben Menachem-Zidon O, 2011, BRAIN BEHAV IMMUN, V25, P1008, DOI 10.1016/j.bbi.2010.11.007; Berg BM, 2004, BRAIN BEHAV IMMUN, V18, P149, DOI 10.1016/S0889-1591(03)00113-2; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hazra A, 2014, J NEUROSCI RES, V92, P1434, DOI 10.1002/jnr.23430; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Jo S, 2014, NAT MED, V20, P886, DOI 10.1038/nm.3639; Johnson SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10607; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kheirbek MA, 2011, NEUROPSYCHOPHARMACOL, V36, P373, DOI 10.1038/npp.2010.148; Kongsui R, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0182-7; Kongsui R, 2014, BRAIN BEHAV IMMUN, V42, P69, DOI 10.1016/j.bbi.2014.05.017; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Molofsky AV, 2012, GENE DEV, V26, P891, DOI 10.1101/gad.188326.112; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; [National Center for Injury Prevention and Control National Institute of Health (NIH) Centers for Disease Control and Prevention C], 2015, TRAUM BRAIN INJ US E; Norden D.M., 2015, GLIA; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Radler ME, 2015, NEUROSCIENCE, V285, P236, DOI 10.1016/j.neuroscience.2014.11.014; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Sahinkaya FR, 2014, EXP NEUROL, V255, P113, DOI 10.1016/j.expneurol.2014.02.025; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Valero J, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00083; Walker FR, 2014, BRAIN BEHAV IMMUN, V37, P1, DOI 10.1016/j.bbi.2013.12.010; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Whiting MD, 2008, BRAIN RES, V1213, P69, DOI 10.1016/j.brainres.2008.01.107; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Wohleb ES, 2014, BIOL PSYCHIAT, V75, P970, DOI 10.1016/j.biopsych.2013.11.029; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	70	62	66	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2016	54						95	109		10.1016/j.bbi.2016.01.009			15	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	DJ4VW	WOS:000374207200010	26774527	Green Accepted			2021-06-18	
J	Johnstone, DM; Moro, C; Stone, J; Benabid, AL; Mitrofanis, J				Johnstone, Daniel M.; Moro, Cecile; Stone, Jonathan; Benabid, Alim-Louis; Mitrofanis, John			Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease	FRONTIERS IN NEUROSCIENCE			English	Article						disease-modifying; neuroprotection; photobiomodulation; amyloid plagues; tau protein	LEVEL LASER THERAPY; TRAUMATIC BRAIN-INJURY; DOPAMINERGIC CELL-SURVIVAL; TERM NEUROLOGICAL DEFICITS; TRANSGENIC MOUSE MODEL; ACUTE ISCHEMIC-STROKE; MPTP-TREATED MICE; MITOCHONDRIAL DYSFUNCTION; INDUCED NEUROTOXICITY; SENILE PLAQUES	Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders. They develop after a progressive death of many neurons in the brain. Although therapies are available to treat the signs and symptoms of both diseases, the progression of neuronal death remains relentless, and it has proved difficult to slow or stop. Hence, there is a need to develop neuroprotective or disease-modifying treatments that stabilize this degeneration. Red to infrared light therapy (lambda =600-1070 nm), and in particular light in the near infrared (NIr) range, is emerging as a safe and effective therapy that is capable of arresting neuronal death. Previous studies have used NIr to treat tissue stressed by hypoxia, toxic insult, genetic mutation and mitochondrial dysfunction with much success. Here we propose NIr therapy as a neuroprotective or disease-modifying treatment for Alzheimer's and Parkinson's patients.	[Johnstone, Daniel M.; Stone, Jonathan] Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; [Moro, Cecile; Benabid, Alim-Louis; Mitrofanis, John] Univ Grenoble Alpes, CEA, LETI, CLINATEC, Grenoble, France; Univ Sydney, Dept Anat, Sydney, NSW 2006, Australia	Mitrofanis, J (corresponding author), Univ Grenoble Alpes, CEA, LETI, CLINATEC, MINATEC Campus, Grenoble, France.	john.mitrofanis@sydney.edu.cn			Tenix corp; Salteri family; Fondation Philanthropique Edmond J. Safra, France Parkinson; Michael J. Fox Foundation; French National Research Agency (ANR Carnot Institute)French National Research Agency (ANR); Foote Foundation; Sir Zelman Cowen Universities Fund	We are forever grateful to Tenix corp, Salteri family, Fondation Philanthropique Edmond J. Safra, France Parkinson, Michael J. Fox Foundation, and the French National Research Agency (ANR Carnot Institute) for funding our work. DJ is an Early Career Fellow of the NHMRC Australia. JS was supported by the Foote Foundation and Sir Zelman Cowen Universities Fund; he is Director of CSCM Ply Ltd.	Abdo A, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.7.075001; Albarracin R, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-125; Alzheimer A, 1911, Z GESAMTE NEUROL PSY, V4, P356, DOI 10.1007/BF02866241; Alzheimer A., 1907, ALLG Z PSYCHIAT, V64, P146, DOI DOI 10.1002/CA.980080612; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828; Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6; Bergman H, 2002, MOVEMENT DISORD, V17, pS28, DOI 10.1002/mds.10140; Bezard E, 2013, MOVEMENT DISORD, V28, P61, DOI 10.1002/mds.25108; Blanco NJ, 2017, J NEUROPSYCHOL, V11, P14, DOI 10.1111/jnp.12074; Blandini F, 2000, PROG NEUROBIOL, V62, P63, DOI 10.1016/S0301-0082(99)00067-2; Blesa J, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/845618; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; BRAVERMAN B, 1989, LASER SURG MED, V9, P50, DOI 10.1002/lsm.1900090111; Brettschneider J, 2015, NAT REV NEUROSCI, V16, P109, DOI 10.1038/nrn3887; Burchman M A, 2011, J LASER DENT, V19, P297; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carvey PM, 2009, J NEUROCHEM, V111, P291, DOI 10.1111/j.1471-4159.2009.06319.x; Chaturvedi RK, 2008, ANN NY ACAD SCI, V1147, P395, DOI 10.1196/annals.1427.027; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Coppede F, 2015, MUTAT RES-FUND MOL M, V776, P84, DOI 10.1016/j.mrfmmm.2014.11.010; Corti O, 2013, CURR OPIN NEUROBIOL, V23, P100, DOI 10.1016/j.conb.2012.11.002; Cosgrove J, 2015, POSTGRAD MED J, V91, P212, DOI 10.1136/postgradmedj-2015-133247; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; Cullen KM, 2005, J CEREBR BLOOD F MET, V25, P1656, DOI 10.1038/sj.jcbfm.9600155; Darlot F, 2016, ANN NEUROL, V79, P59, DOI 10.1002/ana.24542; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Del Tredici K, 2013, J NEUROL NEUROSUR PS, V84, P774, DOI 10.1136/jnnp-2011-301817; DeSmet K, 2009, PROC SPIE, V7165, DOI 10.1117/12.803964; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; El Massri N, 2016, INT J NEUROSCI, V126, P76, DOI 10.3109/00207454.2014.994063; Exner N, 2012, EMBO J, V31, P3038, DOI 10.1038/emboj.2012.170; Farfara D, 2015, J MOL NEUROSCI, V55, P430, DOI 10.1007/s12031-014-0354-z; Farkas E, 2000, ACTA NEUROPATHOL, V100, P395, DOI 10.1007/s004010000195; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fukae J, 2007, MITOCHONDRION, V7, P58, DOI 10.1016/j.mito.2006.12.002; Galluzzi L, 2012, CIRC RES, V111, P1198, DOI 10.1161/CIRCRESAHA.112.268946; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Gitler AD, 2009, NAT GENET, V41, P308, DOI 10.1038/ng.300; Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555; Gonzalez-Lima F, 2014, BIOCHEM PHARMACOL, V88, P584, DOI 10.1016/j.bcp.2013.11.010; Grammas P, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001918; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Hamblin M. R., 2006, P SPIE INT SOC OPTIC; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haslinger B, 2001, BRAIN, V124, P558, DOI 10.1093/brain/124.3.558; Hausenloy DJ, 2008, CARDIOVASC RES, V79, P377, DOI 10.1093/cvr/cvn114; Herrup K, 2015, NAT NEUROSCI, V18, P794, DOI 10.1038/nn.4017; Hou ST, 2008, INT REV CEL MOL BIO, V267, P125, DOI 10.1016/S1937-6448(08)00603-5; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Jankovic J, 2012, CURR OPIN NEUROL, V25, P433, DOI 10.1097/WCO.0b013e3283542fc2; Johnstone DM, 2014, NEUROSCIENCE, V274, P93, DOI 10.1016/j.neuroscience.2014.05.023; Johnstone D. M., 2014, CHRONOPHYSIOL THER, V4, P1, DOI DOI 10.2147/CPT.S57180; Johnstone DM, 2015, NEURAL REGEN RES, V10, P349, DOI 10.4103/1673-5374.153673; Kortekaas R, 2005, ANN NEUROL, V57, P176, DOI 10.1002/ana.20369; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Maloney R., 2010, AM SOC LASER MED SUR, V185; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; MERRY G, 2012, INVEST OPHTH VIS SCI, V53, P2049; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Moges H, 2009, LASER SURG MED, V41, P52, DOI 10.1002/lsm.20732; Moro C, 2014, J NEUROSURG, V120, P670, DOI 10.3171/2013.9.JNS13423; Moro C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-40; Muili KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030655; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Natoli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072135; Natoli R, 2010, MOL VIS, V16, P1801; Nelson L, 2015, AGEING RES REV, V23, P193, DOI 10.1016/j.arr.2015.07.002; Olanow CW, 2008, ANN NEUROL, V64, pS101, DOI 10.1002/ana.21461; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Purushothuman S, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt232; Purushothuman S, 2013, BRAIN RES, V1535, P61, DOI 10.1016/j.brainres.2013.08.047; Purushothurnan S, 2015, NEUROSCI LETT, V591, P155, DOI 10.1016/j.neulet.2015.02.037; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Quirk Brendan J, 2012, Front Biosci (Elite Ed), V4, P818; Recasens A, 2014, ANN NEUROL, V75, P351, DOI 10.1002/ana.24066; Reinhart F, 2016, J NEUROSURG, V124, P1829, DOI 10.3171/2015.5.JNS15735; Reinhart F, 2015, NEUROSCI RES, V92, P86, DOI 10.1016/j.neures.2014.11.005; RINNE JO, 1993, MOVEMENT DISORD, V8, pS31, DOI 10.1002/mds.870080507; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Sabatini U, 2000, BRAIN, V123, P394, DOI 10.1093/brain/123.2.394; Samuel M, 1997, BRAIN, V120, P963, DOI 10.1093/brain/120.6.963; Schapira AHV, 2014, LANCET, V384, P545, DOI 10.1016/S0140-6736(14)61010-2; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Shaw VE, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/296875; Shaw VE, 2010, PARKINSONISM RELAT D, V16, P338, DOI 10.1016/j.parkreldis.2010.02.008; Sommer AP, 2012, PHOTOMED LASER SURG, V30, P54, DOI 10.1089/pho.2011.3073; Stone J, 2013, 9 WALT C GOLD COAST; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Stone J, 2015, J ALZHEIMERS DIS, V44, P355, DOI 10.3233/JAD-141884; Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045; Tang XQ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00175; Tata DB, 2011, LASER PHOTONICS REV, V5, P1, DOI 10.1002/lpor.200900032; Taylor RC, 2014, NAT REV MOL CELL BIO, V15, P211, DOI 10.1038/nrm3752; Tierney Travis S, 2013, Front Biosci (Elite Ed), V5, P490; Trimmer PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-26; Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Vos M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078562; Whelan Harry, 2008, SPIE Newsroom, V2008, P1; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yetgin T, 2012, CARDIOL REV, V20, P279, DOI 10.1097/CRD.0b013e31826c15aa; Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057; ZHAO G, 2003, ACTA ACAD MED QINGDA, V39, P398; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	122	62	62	1	50	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	JAN 11	2016	9								500	10.3389/fninc.2015.00500			15	Neurosciences	Neurosciences & Neurology	DA5LF	WOS:000367843900001	26793049	DOAJ Gold			2021-06-18	
J	Brommeland, T; Rydning, PN; Pripp, AH; Helseth, E				Brommeland, Tor; Rydning, Pal Nicolay; Pripp, Are Hugo; Helseth, Eirik			Cranioplasty complications and risk factors associated with bone flap resorption	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Craniectomy; Cranioplasty; Bone flap resorption; Post-operative complications	DECOMPRESSIVE CRANIECTOMY; AUTOLOGOUS BONE; MULTICENTER; IMPROVEMENT; EXPERIENCE; INFECTION; OUTCOMES; SURGERY	Background: Decompressive craniectomy (DC) may be performed in patients with acutely raised intracranial pressure due to traumatic brain injury or stroke. It is later followed by a cranioplasty procedure (CP) in the surviving patients. This procedure is associated with a high frequency of post-operative complications. Identifying risk factors for these adverse events is important in order to improve the clinical outcome. This study examines possible predictive parameters for post-operative complications in CP. Methods: Retrospective, single institution review of all patients undergoing a DC for acutely raised intracranial pressure over a 10 year period at Oslo University Hospital Ullev, Norway. Subsequent CP using autologous bone flaps or synthetic implants were registered along with all post-operative complications. Predictors of post-operative complications were identified using uni -and multivariable regression analyses. Results: A DC was carried out in 125 patients, of whom 33 died, 4 were lost to follow-up, and 1 (an infant) later underwent cranial remodeling. A CP was performed in the remaining 87 patients. Post-operative complications were recorded in 31 (36 %) patients of whom 22 lost their primary implant. Surgical site infection (SSI) and bone flap resorption (BFR) were the two most common complications, affecting 8 (9.2 %) and 14 (19.7 %) patients, respectively. Only BFR was associated with some of the recorded variables. Using multivariable logistic regression analysis, young age (OR = 0.94, 95 % CI 0.88-1.00, p = 0.04), bone flap fragmentation (OR = 14.3, 95 % CI 2.26-89, p = 0.005), long storage time (OR = 1.03, 95 % CI 1.00-1.04, p = 0.02) and Glasgow Outcome Scale at the time of cranioplasty (OR = 2.55, 95 % CI 1.04-6.23, p = 0.04) were found to be significant risk factors for bone flap resorption. Conclusions: Cranioplasty after decompressive craniectomy carries a high rate of complications. In this study, SSI and BFR were the two most common complications of which predictive clinical parameters could be identified for BFR only. The results indicate that synthetic implants may be considered in pediatric patients and in cases with fragmented bone flaps or delayed time to cranioplasty. Although the rate of complications was high, 73 % had a successful reinsertion of the autologous graft at a low cost. We feel this result justifies the continued use of cryopreserved bone flaps.	[Brommeland, Tor; Rydning, Pal Nicolay; Helseth, Eirik] Univ Oslo, Ulleval Hosp, Dept Neurosurg, Oslo, Norway; [Pripp, Are Hugo] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Res Support Serv, Oslo, Norway; [Helseth, Eirik] Univ Oslo, Fac Med, Oslo, Norway	Brommeland, T (corresponding author), Univ Oslo, Ulleval Hosp, Dept Neurosurg, POB 4950, Oslo, Norway.	torbro@ous-hf.no	Helseth, Eirik/AAH-2466-2020; Brommeland, Tor/AAJ-8483-2020				Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623-200203000-00020; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Gosain AK, 2011, PLAST RECONSTR SURG, V128, P85, DOI 10.1097/PRS.0b013e31821740cc; Harris DA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13560; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Im SH, 2012, J KOREAN NEUROSURG S, V52, P396, DOI 10.3340/jkns.2012.52.4.396; Jelcic N, 2013, ACTA NEUROCHIR, V155, P1597, DOI 10.1007/s00701-012-1519-6; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Reddy S, 2014, PLAST RECONSTR SURG, V133, P864, DOI 10.1097/PRS.0000000000000013; Schoekler B, 2014, CLIN NEUROL NEUROSUR, V120, P64, DOI 10.1016/j.clineuro.2014.02.014; Schuss P, 2013, J NEUROTRAUM, V30, P91, DOI 10.1089/neu.2012.2542; Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Stefini Roberto, 2013, Surg Neurol Int, V4, P12, DOI 10.4103/2152-7806.106290; Sundseth J, 2014, ACTA NEUROCHIR, V156, P805, DOI 10.1007/s00701-013-1992-6; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	31	62	64	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	OCT 6	2015	23								75	10.1186/s13049-015-0155-6			7	Emergency Medicine	Emergency Medicine	CS7SB	WOS:000362284500001	26437934	DOAJ Gold, Green Published			2021-06-18	
J	Pitkanen, A; Lukasiuk, K; Dudek, FE; Staley, KJ				Pitkanen, Asla; Lukasiuk, Katarzyna; Dudek, F. Edward; Staley, Kevin J.			Epileptogenesis	COLD SPRING HARBOR PERSPECTIVES IN MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; SPONTANEOUS RECURRENT SEIZURES; CONTROLLED CORTICAL IMPACT; INDUCED STATUS EPILEPTICUS; FLUID PERCUSSION INJURY; MIDDLE CEREBRAL-ARTERY; SPRAGUE-DAWLEY RATS; TERM VIDEO-EEG	Epileptogenesis is a chronic process that can be triggered by genetic or acquired factors, and that can continue long after epilepsy diagnosis. In 2015, epileptogenesis is not a treatment indication, and there are no therapies available in clinic to treat individuals at risk of epileptogenesis. However, thanks to active research, a large number of animal models have become available for search of molecular mechanisms of epileptogenesis. The first glimpses of treatment targets and biomarkers that could be developed to become useful in clinic are in sight. However, the heterogeneity of the epilepsy condition, and the dynamics of molecular changes over the course of epileptogenesis remain as challenges to overcome.	[Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FI-70211 Kuopio, Finland; [Lukasiuk, Katarzyna] Polish Acad Sci, M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; [Dudek, F. Edward] Univ Utah, Dept Neurosurg, Sch Med, Salt Lake City, UT 84108 USA; [Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland.	asla.pitkanen@uef.fi	Lukasiuk, Katarzyna/F-4636-2010	Lukasiuk, Katarzyna/0000-0002-1582-0920	Academy of FinlandAcademy of FinlandEuropean Commission; UEF Spearhead Project "UEF-Brain"; ERA-NET NEURON II [FA0200006175]; Polish National Research Centre Grant [2011/01/M/NZ3/02139]; Polish Ministry of Science and Education Grant [DNP/N119/ESF-EuroEPINOMICS/2012]; United States National Institutes of Health GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS086364]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086364] Funding Source: NIH RePORTER	This work is supported by the Academy of Finland (A.P.), UEF Spearhead Project "UEF-Brain" (A.P.), ERA-NET NEURON II FA0200006175 (A.P.), Polish National Research Centre Grant 2011/01/M/NZ3/02139 (K.L.), Polish Ministry of Science and Education Grant DNP/N119/ESF-EuroEPINOMICS/2012 (K.L.), and the United States National Institutes of Health Grant R01NS086364 (F.E.D. and K.J.S.).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arntz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055498; Aronica E, 2007, NEUROBIOL DIS, V26, P497, DOI 10.1016/j.nbd.2007.01.015; Aronica E, 2010, EUR J NEUROSCI, V31, P1100, DOI 10.1111/j.1460-9568.2010.07122.x; Avoli M., 2012, JASPERS BASIC MECH E; BABB TL, 1989, J NEUROSCI, V9, P2562; Baulac M., 2009, EPILEPSIA, V50, P571; Bausch SB, 2000, J NEUROPHYSIOL, V84, P2918; Beaumont TL, 2012, J NEUROSCI, V32, P14389, DOI 10.1523/JNEUROSCI.3408-12.2012; Becker AJ, 2003, EUR J NEUROSCI, V18, P2792, DOI 10.1111/j.1460-9568.2003.02993.x; Berdichevsky Y, 2013, J NEUROSCI, V33, P9056, DOI 10.1523/JNEUROSCI.3870-12.2013; Berdichevsky Y, 2012, NEUROBIOL DIS, V45, P774, DOI 10.1016/j.nbd.2011.11.001; Berg AT, 2006, NEUROLOGY, V67, P12, DOI 10.1212/01.wnl.0000227190.64928.67; BERTRAM EH, 1993, BRAIN RES, V625, P295, DOI 10.1016/0006-8993(93)91071-Y; BERTRAM EH, 1994, BRAIN RES, V661, P157, DOI 10.1016/0006-8993(94)91192-4; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bot AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076051; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS., 2012, JASPERS BASIC MECH E; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Casals JB, 2011, COMPARATIVE MED, V61, P305; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Darrah SD, 2013, EPILEPSY RES, V103, P180, DOI 10.1016/j.eplepsyres.2012.07.006; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Dudek FE, 2011, NEUROSCI LETT, V497, P240, DOI 10.1016/j.neulet.2011.03.071; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Elliott RC, 2003, J NEUROSCI, V23, P2218; Engel J, 2005, EPILEPSIA, V46, P1333, DOI 10.1111/j.1528-1167.2005.18505_2.x; Engel J Jr, 1996, Epilepsy Res Suppl, V12, P9; Engel J, 2008, CURR OPIN NEUROL, V21, P150, DOI 10.1097/WCO.0b013e3282f4edc3; Engel J, 2013, EPILEPSIA, V54, P61, DOI 10.1111/epi.12299; Filibian M, 2012, EPILEPSIA, V53, P1907, DOI 10.1111/j.1528-1167.2012.03685.x; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Goffin K, 2007, EXP NEUROL, V205, P501, DOI 10.1016/j.expneurol.2007.03.008; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Gorter JA, 2007, EPILEPSIA, V48, P53, DOI 10.1111/j.1528-1167.2007.01290.x; Gorter JA, 2006, J NEUROSCI, V26, P11083, DOI 10.1523/JNEUROSCI.2766-06.2006; Gorter JA, 2014, NEUROBIOL DIS, V62, P508, DOI 10.1016/j.nbd.2013.10.026; Graham NSN, 2013, STROKE, V44, P605, DOI 10.1161/STROKEAHA.111.000220; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Heinemann U, 2014, ADV EXP MED BIOL, V813, P25, DOI 10.1007/978-94-017-8914-1_2; Hellier JL, 1998, EPILEPSY RES, V31, P73, DOI 10.1016/S0920-1211(98)00017-5; Hendriksen H, 2001, EUR J NEUROSCI, V14, P1475, DOI 10.1046/j.0953-816x.2001.01778.x; Henshall JM, 2014, GENET SEL EVOL, V46, DOI 10.1186/s12711-014-0051-y; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Holtman L, 2013, EPILEPSIA, V54, P589, DOI 10.1111/epi.12112; Hu XL, 2011, CEREB CORTEX, V21, P2158, DOI 10.1093/cercor/bhq284; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Ioannidis JPA, 2009, NAT GENET, V41, P149, DOI 10.1038/ng.295; Iyer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044789; JENNETT B, 1975, EPILEPSIA, V16, P251, DOI 10.1111/j.1528-1157.1975.tb06055.x; Jirsa VK, 2014, BRAIN, V137, P2210, DOI 10.1093/brain/awu133; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kandel ER, 2013, NAT REV NEUROSCI, V14, P659, DOI 10.1038/nrn3578; Kanner AM, 2014, NEUROTHERAPEUTICS, V11, P358, DOI 10.1007/s13311-014-0271-4; Karhunen H, 2007, NEUROSCIENCE, V148, P314, DOI 10.1016/j.neuroscience.2007.05.047; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Karhunen H, 2006, EPILEPSY RES, V72, P25, DOI 10.1016/j.eplepsyres.2006.07.003; Kelley Melinda S, 2009, Epilepsia, V50, P579, DOI 10.1111/j.1528-1167.2008.01813.x; Kelly KM, 2006, EXP NEUROL, V201, P495, DOI 10.1016/j.expneurol.2006.05.006; Kelly Kevin M, 2004, Epilepsy Curr, V4, P176, DOI 10.1111/j.1535-7597.2004.04503.x; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kobow K, 2014, PROG BRAIN RES, V213, P279, DOI 10.1016/B978-0-444-63326-2.00014-4; Kobow K, 2013, ACTA NEUROPATHOL, V126, P741, DOI 10.1007/s00401-013-1168-8; Kojima N, 2008, J NEUROSCI, V28, P6459, DOI 10.1523/JNEUROSCI.0412-08.2008; Lauren HB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010733; Lew FH, 2011, EPILEPSIA, V52, P2326, DOI 10.1111/j.1528-1167.2011.03315.x; Li AQ, 2010, BRAIN PATHOL, V20, P1077, DOI 10.1111/j.1750-3639.2010.00414.x; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu JP, 2002, EPILEPSY RES, V52, P85, DOI 10.1016/S0920-1211(02)00194-8; Lukasiuk K, 2003, EUR J NEUROSCI, V17, P271, DOI 10.1046/j.1460-9568.2003.02461.x; Lukasiuk K, 2006, PROG BRAIN RES, V158, P223, DOI 10.1016/S0079-6123(06)58011-2; Lukasiuk K, 2014, NEUROTHERAPEUTICS, V11, P319, DOI 10.1007/s13311-014-0261-6; MACVICAR BA, 1980, BRAIN RES, V184, P220, DOI 10.1016/0006-8993(80)90602-2; Mateffyova A, 2006, EUR J NEUROSCI, V24, P351, DOI 10.1111/j.1460-9568.2006.04910.x; MCBAIN CJ, 1989, J NEUROSCI METH, V27, P35, DOI 10.1016/0165-0270(89)90051-4; McClelland S, 2014, ELIFE, V3, DOI 10.7554/eLife.01267; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; Miller MA, 2010, BRAIN INJURY, V24, P1468, DOI 10.3109/02699052.2010.520299; Ndode-Ekane XE, 2013, MOL NEUROBIOL, V47, P914, DOI 10.1007/s12035-012-8386-2; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Okamoto OK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-230; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Perin R, 2011, P NATL ACAD SCI USA, V108, P5419, DOI 10.1073/pnas.1016051108; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/14656566.5.4.777; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; Pitkanen A, 2014, NEUROBIOL DIS, V72, P224, DOI 10.1016/j.nbd.2014.05.037; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P231, DOI 10.1007/s13311-014-0257-2; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Porter BE, 2008, NEUROSCIENCE, V152, P829, DOI 10.1016/j.neuroscience.2007.10.064; Rakhade SN, 2009, NAT REV NEUROL, V5, P380, DOI 10.1038/nrneurol.2009.80; Risbud RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053464; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; Shao LR, 2005, J NEUROPHYSIOL, V94, P952, DOI 10.1152/jn.01342.2004; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Simonato M, 2012, EPILEPSIA, V53, P1860, DOI 10.1111/j.1528-1167.2012.03541.x; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Sutula TP, 2007, PROG BRAIN RES, V163, P541, DOI 10.1016/S0079-6123(07)63029-5; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Theilhaber J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074428; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; White A, 2010, EPILEPSIA, V51, P371, DOI 10.1111/j.1528-1167.2009.02339.x; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Winden KD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020763; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang Y, 2011, J CELL BIOCHEM, V112, P2435, DOI 10.1002/jcb.23168	126	62	63	1	20	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	2157-1422			CSH PERSPECT MED	Cold Spring Harb. Perspect. Med.	OCT	2015	5	10							a022822	10.1101/cshperspect.a022822			17	Medicine, Research & Experimental	Research & Experimental Medicine	CZ9WM	WOS:000367448000009	26385090	Green Published, Bronze			2021-06-18	
J	Logsdon, AF; Lucke-Wold, BP; Turner, RC; Huber, JD; Rosen, CL; Simpkins, JW				Logsdon, Aric F.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Huber, Jason D.; Rosen, Charles L.; Simpkins, James W.			Role of Microvascular Disruption in Brain Damage from Traumatic Brain Injury	COMPREHENSIVE PHYSIOLOGY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CAPILLARY ENDOTHELIAL-CELLS; CEREBRAL-BLOOD-FLOW; GLASGOW COMA SCALE; BARRIER DISRUPTION; AXONAL INJURY; HEAD-INJURY; ER STRESS	Traumatic brain injury (TBI) is acquired from an external force, which can inflict devastating effects to the brain vasculature and neighboring neuronal cells. Disruption of vasculature is a primary effect that can lead to a host of secondary injury cascades. The primary effects of TBI are rapidly occurring while secondary effects can be activated at later time points and may be more amenable to targeting. Primary effects of TBI include diffuse axonal shearing, changes in blood-brain barrier (BBB) permeability, and brain contusions. These mechanical events, especially changes to the BBB, can induce calcium perturbations within brain cells producing secondary effects, which include cellular stress, inflammation, and apoptosis. These secondary effects can be potentially targeted to preserve the tissue surviving the initial impact of TBI. In the past, TBI research had focused on neurons without any regard for glial cells and the cerebrovasculature. Now a greater emphasis is being placed on the vasculature and the neurovascular unit following TBI. A paradigm shift in the importance of the vascular response to injury has opened new avenues of drug-treatment strategies for TBI. However, a connection between the vascular response to TBI and the development of chronic disease has yet to be elucidated. Long-term cognitive deficits are common amongst those sustaining severe or multiple mild TBIs. Understanding the mechanisms of cellular responses following TBI is important to prevent the development of neuropsychiatric symptoms. With appropriate intervention following TBI, the vascular network can perhaps be maintained and the cellular repair process possibly improved to aid in the recovery of cellular homeostasis. (C) 2015 American Physiological Society.	[Logsdon, Aric F.; Huber, Jason D.] W Virginia Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Morgantown, WV 26506 USA; [Simpkins, James W.] W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Huber, Jason D.; Rosen, Charles L.; Simpkins, James W.] W Virginia Univ, Hlth Sci Ctr, Ctr Neurosci, Morgantown, WV 26506 USA	Simpkins, JW (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA.	jwsimpkins@hsc.wvu.edu		Turner, Ryan/0000-0001-5523-0645	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 AG022550, P01 AG027956, P20 GM109098, U54GM104942]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942, P20GM109098, T32GM081741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027956, P01AG022550] Funding Source: NIH RePORTER	This review was supported in part by NIH grants P01 AG022550, P01 AG027956, P20 GM109098, and U54GM104942 (J. W. Simpkins).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abdul-Muneer PM, 2014, MOL NEUROBIOL; Adalbert R, 2009, BRAIN, V132, P402, DOI 10.1093/brain/awn312; Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Amantini A, 2012, MINERVA ANESTESIOL, V78, P1067; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Asakuno Keizoh, 2014, Surg Neurol Int, V5, P61, DOI 10.4103/2152-7806.132031; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Badaut J, 2014, TRANSL STROKE RES, V5, P394, DOI 10.1007/s12975-013-0304-z; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bauer AM, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00072; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Biancardi VC, 2014, HYPERTENSION, V63, P572, DOI 10.1161/HYPERTENSIONAHA.113.01743; Bor-Seng-Shu E, 2013, NEUROSURG REV, V36, P361, DOI 10.1007/s10143-013-0453-2; Brandner S, 2015, J NEUROSURG ANESTH, V27, P26, DOI 10.1097/ANA.0000000000000083; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bukovics P, 2014, PEPTIDES, V60, P18, DOI 10.1016/j.peptides.2014.07.001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chalouhi N, 2014, J NEUROSURG, V121, P904, DOI 10.3171/2014.6.JNS132638; Chen B, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-77; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Covey Dana C, 2010, J Surg Orthop Adv, V19, P8; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cui T, 2014, CELL BIOCH BIOPHYS; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Cullen NK, 2009, PM&R, V1, P1069, DOI 10.1016/j.pmrj.2009.09.013; Dagher JH, 2010, BRAIN INJURY, V24, P1389, DOI 10.3109/02699052.2010.523042; Dapul HR, 2013, J NEUROTRAUM, V30, P382, DOI 10.1089/neu.2012.2536; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Dore-Duffy P, 2011, NEUROL RES, V33, P176, DOI 10.1179/016164111X12881719352372; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Faust K, 2014, CLIN NEUROL NEUROSUR, V125, P36, DOI 10.1016/j.clineuro.2014.06.023; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Foster KA, 2014, J NEUROTRAUM, V31, P1625, DOI 10.1089/neu.2014.3372; Fujita M, 2012, J NEUROTRAUM, V29, P1491, DOI 10.1089/neu.2011.2278; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Gurkoff G, 2013, PHARMACEUTICALS, V6, P788, DOI 10.3390/ph6070788; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hartmann DA, 2014, MICROCIRCULATION; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Ho KM, 2014, J NEUROSURG, V121, P674, DOI 10.3171/2014.6.JNS132838; Hochstadter E, 2014, NEUROCRIT CARE, V21, P505, DOI 10.1007/s12028-014-9986-7; Hoozemans JJM, 2007, BIOCHEM BIOPH RES CO, V354, P707, DOI 10.1016/j.bbrc.2007.01.043; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Izzy S, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-013-0278-x; Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kelman Craig, 2014, Neurosurg Focus, V37, P1, DOI 10.3171/2014.V2.FOCUS14172; Kim H, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0186-2; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Korczyn AD, 2012, J ALZHEIMERS DIS, V29, P275, DOI 10.3233/JAD-2011-110359; Kramer AH, 2012, CURRENT TREAT OPTION; Kramer DR, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/415813; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Le Heron CJ, 2014, J CEREBR BLOOD F MET, V34, P964, DOI 10.1038/jcbfm.2014.40; Lee HC, 2010, WORLD NEUROSURG, V74, P654, DOI 10.1016/j.wneu.2010.06.019; Levy AS, 2014, WORLD NEUROSURG, V82, pE319, DOI 10.1016/j.wneu.2013.11.008; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Li SH, 2013, ANN NEUROL, V74, P768, DOI 10.1002/ana.24005; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Liu S, 2014, BRAIN INJURY, V28, P133, DOI 10.3109/02699052.2013.860479; Liu YQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-141; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Mangat Halinder S, 2012, Continuum (Minneap Minn), V18, P532, DOI 10.1212/01.CON.0000415426.76524.e1; Marchesi VT, 2014, CELL MOL LIFE SCI, V71, P949, DOI 10.1007/s00018-013-1542-7; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Mata-Mbemba D, 2014, J NEUROTRAUMA; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; Miyauchi T, 2013, J NEUROTRAUM, V30, P1664, DOI 10.1089/neu.2013.2995; Molino Y, 2014, JOVE-J VIS EXP, V88; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Munoz P, 2006, BIOL RES, V39, P189, DOI 10.4067/S0716-97602006000100021; Munoz P, 2011, J BIOL CHEM, V286, P13382, DOI 10.1074/jbc.M110.213785; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neuhof C, 2014, WORLD J CARDIOL, V6, P638, DOI 10.4330/wjc.v6.i7.638; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; Nirula R, 2014, J TRAUMA ACUTE CARE, V76, P944, DOI 10.1097/TA.0000000000000194; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Padayachy LC, 2012, CHILD NERV SYST, V28, P1911, DOI 10.1007/s00381-012-1837-2; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Paradis A, 2013, CURR VASC PHARMACOL, V11, P594, DOI 10.2174/1570161111311050004; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Qutub AA, 2008, MOL CELL BIOL, V28, P5106, DOI 10.1128/MCB.00060-08; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Razumovsky A, 2013, ACTA NEUROCHIR SUPPL, V115, P87, DOI 10.1007/978-3-7091-1192-5_19; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; RINK A, 1995, AM J PATHOL, V147, P1575; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosenbaum BP, 2014, J CLIN NEUROSCI, V21, P1874, DOI 10.1016/j.jocn.2014.05.006; Rostami E, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00114; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubino S, 2014, J NEUROSURG, V121, P944, DOI 10.3171/2014.6.JNS132204; Rubovitch V, 2011, NEUROCHEM INT, V58, P443, DOI 10.1016/j.neuint.2011.01.009; Ruhe A, 2014, SPORTS HEALTH, V6, P427, DOI 10.1177/1941738114541238; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Saito T, 2011, NEUROSCI LETT, V497, P116, DOI 10.1016/j.neulet.2011.04.043; Salminen A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-41; Sanelli PC, 2014, AM J NEURORADIOL, V35, P1714, DOI 10.3174/ajnr.A3947; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Scheper W, 2011, AUTOPHAGY, V7, P910, DOI 10.4161/auto.7.8.15761; Schiera G, 2003, J CELL MOL MED, V7, P165, DOI 10.1111/j.1582-4934.2003.tb00215.x; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Shin SS, 2014, PROG NEUROL SURG, V28, P86, DOI 10.1159/000358767; Shohami E, 2014, CNS NEUROL DISORD-DR, V13, P567, DOI 10.2174/18715273113126660196; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Turner RC, 2013, J NEUROSURG, V118, P1072, DOI 10.3171/2012.11.JNS12408; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5; van der Eerden AW, 2014, RADIOLOGY, V270, P506, DOI 10.1148/radiol.13122720; Wang Y, 2014, J NEUROTRAUM, V31, P498, DOI [10.1089/neu.2013.3074, 10.1089/NEU.2013.3074]; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wilson CD, 2014, CAN J NEUROL SCI, V41, P314, DOI 10.1017/S031716710001725X; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Xu ZNS, 2014, J ULTRAS MED, V33, P1763, DOI 10.7863/ultra.33.10.1763; Yeh DD, 2012, WORLD J SURG, V36, P966, DOI 10.1007/s00268-012-1500-9; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang YP, 2014, TRANSL STROKE RES, V5, P454, DOI 10.1007/s12975-014-0327-0; Zhong N, 2009, J BIOL CHEM, V284, P27273, DOI 10.1074/jbc.M109.014464	191	62	65	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2040-4603			COMPR PHYSIOL	Compr. Physiol.	JUL	2015	5	3					1147	1160		10.1002/cphy.c140057			14	Physiology	Physiology	CM3PY	WOS:000357596400005	26140712	Green Accepted			2021-06-18	
J	Jonas, JB; Wang, NL; Yang, DY; Ritch, R; Panda-Jonas, S				Jonas, Jost B.; Wang, Ningli; Yang, Diya; Ritch, Robert; Panda-Jonas, Songhomitra			Facts and myths of cerebrospinal fluid pressure for the physiology of the eye	PROGRESS IN RETINAL AND EYE RESEARCH			English	Article						Cerebrospinal fluid pressure; Glaucoma; Open-angle glaucoma; Normal-pressure glaucoma; Diabetic retinopathy; Retinal vein occlusion; Brain pressure	OPTIC-NERVE SHEATH; OPEN-ANGLE GLAUCOMA; CENTRAL RETINAL VEIN; NORMAL-TENSION GLAUCOMA; IDIOPATHIC INTRACRANIAL HYPERTENSION; INCREASED INTRAOCULAR-PRESSURE; ZONE PARAPAPILLARY ATROPHY; DOPPLER PULSATILITY INDEX; VISUAL-FIELD PROGRESSION; TRAUMATIC BRAIN-INJURY	The orbital cerebrospinal fluid pressure (CSFP) represents the true counter-pressure against the intraocular pressure (lOP) across the lamina cribrosa and is, therefore, one of the two determinants of the trans-lamina cribrosa pressure difference (TLPD). From this anatomic point of view, an elevated TLPD could be due to elevated lOP or abnormally low orbital CSFP. Both experimental and clinical studies have suggested that a low CSFP could be associated with glaucomatous optic neuropathy in normal-pressure glaucoma. These included monkey studies with an experimental long-term reduction in CSFP, and clinical retrospective and prospective studies on patients with normal-pressure glaucoma. Since the choroidal blood drains via the vortex veins through the superior ophthalmic vein into the intracranial cavernous sinus, anatomy suggests that the CSFP could influence choroidal thickness. A population-based study revealed that thicker subfoveal choroidal thickness was associated with higher CSFP. Since the central retinal vein passes through the orbital CSF space, anatomy suggests that the retinal venous pressure should be at least as high as the orbital CSFP. Other experimental, clinical or population-based studies suggested an association between higher CSFP and higher retinal venous pressure and wider retinal veins. Consequently, a higher estimated CSFP was associated with arterial hypertensive retinopathy (with respect to the dilated retinal vein diameter and higher arterial-to-venous diameter) and with the prevalence, severity and incidence of diabetic retinopathy. Physiologically, CSFP was related with higher !OP. The influence of the CSFP on the episcleral venous pressure and/or a regulation of both CSFP and lOP by a center in the dorsomedial/perifornical hypothalamus may be responsible for this. In summary, the CSFP may be an overlooked parameter in ocular physiology and pathology. Abnormal changes in the CSFP, in particular in relationship to the RP, may have pathophysiologic importance. (C) 2015 Elsevier Ltd. All rights reserved.	[Jonas, Jost B.; Panda-Jonas, Songhomitra] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Seegartenklin, Heidelberg, Germany; [Jonas, Jost B.; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol,Beijing Ophthalmol & Visu, Beijing 100730, Peoples R China; [Wang, Ningli; Yang, Diya] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China; [Ritch, Robert] New York Ear Eye & Ear Infirm Mt Sinai, Einhorn Clin Res Ctr, New York, NY USA	Wang, NL (corresponding author), Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dongjiaominxiang St, Beijing 100730, Peoples R China.	wningli@vip.163.com		Ritch, Robert/0000-0002-9368-7547; Jonas, Jost/0000-0003-2972-5227			ALBECK MJ, 1991, J NEUROSURG, V74, P597, DOI 10.3171/jns.1991.74.4.0597; ANDERSON DR, 1973, INVEST OPHTH VISUAL, V12, P204; Bauerle J, 2011, J NEUROL, V258, P2014, DOI 10.1007/s00415-011-6059-0; Balaratnasingam C, 2007, BRIT J OPHTHALMOL, V91, P441, DOI 10.1136/bjo.2006.105338; Balaratnasingam C, 2009, EXP EYE RES, V89, P618, DOI 10.1016/j.exer.2009.06.002; Baskaran M, 2006, OPHTHALMOLOGY, V113, P1327, DOI 10.1016/j.ophtha.2006.02.063; Behrens A, 2010, NEUROSURGERY, V66, P1050, DOI 10.1227/01.NEU.0000369519.35932.F2; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Berdahl JP, 2008, OPHTHALMOLOGY, V115, P763, DOI 10.1016/j.ophtha.2008.01.013; Berdahl John P, 2013, J Glaucoma, V22 Suppl 5, pS17, DOI 10.1097/IJG.0b013e31829349fc; Berdahl JP, 2012, INVEST OPHTH VIS SCI, V53, P1422, DOI 10.1167/iovs.11-8220; Berdahl JP, 2008, INVEST OPHTH VIS SCI, V49, P5412, DOI 10.1167/iovs.08-2228; Brandi G, 2010, ACTA NEUROCHIR, V152, P965, DOI 10.1007/s00701-010-0643-4; Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001; Burgoyne CF, 2001, J GLAUCOMA, V10, pS16, DOI 10.1097/00061198-200110001-00007; CARLSON KH, 1987, INVEST OPHTH VIS SCI, V28, P1346; Chacon M, 2010, IEEE ENG MED BIO, P996, DOI 10.1109/IEMBS.2010.5627816; COX SN, 1988, ARCH OPHTHALMOL-CHIC, V106, P1190; CULLEN LK, 1990, AM J VET RES, V51, P300; Czarnik T, 2007, J TRAUMA, V62, P207, DOI 10.1097/01.ta.0000219128.29515.d5; Dai Y, 2013, INVEST OPHTH VIS SCI, V54, P2013, DOI 10.1167/iovs.12-11255; De Moraes CG, 2011, DOC OPHTHALMOL, V123, P43, DOI 10.1007/s10633-011-9280-3; De Moraes CGV, 2011, ARCH OPHTHALMOL-CHIC, V129, P562, DOI 10.1001/archophthalmol.2011.72; Dickerman RD, 1999, NEUROL RES, V21, P243, DOI 10.1080/01616412.1999.11740925; Dubourg J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-62; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Firsching R, 2000, J NEUROSURG, V93, P33, DOI 10.3171/jns.2000.93.1.0033; Firsching R, 2011, J NEUROSURG, V115, P371, DOI 10.3171/2011.3.JNS101275; Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3; Fleischman D., 2014, ACTA OPHTHALMOL; FRISEN L, 1984, OPHTHALMOLOGY, V91, P1342; Gallardo MJ, 2006, ADV THER, V23, P921, DOI 10.1007/BF02850214; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; GILLAND O, 1969, NEW ENGL J MED, V280, P904; Greenfield DS, 1997, ARCH OPHTHALMOL-CHIC, V115, P423, DOI 10.1001/archopht.1997.01100150425022; Gupta A, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-47; Gupta Aditi, 2013, Oman J Ophthalmol, V6, P183, DOI 10.4103/0974-620X.122275; Gupta P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096661; Han Y, 2008, ANN NEUROL, V64, P221, DOI 10.1002/ana.21416; Harder B, 2007, BRIT J OPHTHALMOL, V91, P401, DOI 10.1136/bjo.2006.103341; Hawthorne C, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00121; Hayreh SS, 2009, GRAEF ARCH CLIN EXP, V247, P721, DOI 10.1007/s00417-008-0984-3; Hayreh SS, 2000, AM J OPHTHALMOL, V130, P91, DOI 10.1016/S0002-9394(00)00387-1; HAYREH SS, 1971, BRIT J OPHTHALMOL, V55, P649, DOI 10.1136/bjo.55.10.649; Hayreh SS, 1998, INVEST OPHTH VIS SCI, V39, P2296; HAYREH SS, 1978, SURV OPHTHALMOL, V23, P1, DOI 10.1016/0039-6257(78)90194-7; Hayreh SS, 2001, OPHTHALMOLOGY, V108, P1586, DOI 10.1016/S0161-6420(01)00649-2; HAYREH SS, 1977, ARCH OPHTHALMOL-CHIC, V95, P1553, DOI 10.1001/archopht.1977.04450090075006; Hayreh SS, 2000, AM J OPHTHALMOL, V129, P786, DOI 10.1016/S0002-9394(00)00384-6; HEDGES TR, 1973, AM J OPHTHALMOL, V75, P90, DOI 10.1016/0002-9394(73)90657-0; Hirooka K, 2003, J GLAUCOMA, V12, P379, DOI 10.1097/00061198-200308000-00015; Iwase A, 2004, OPHTHALMOLOGY, V111, P1641, DOI 10.1016/j.ophtha.2004.03.029; Jaggi GP, 2007, EUR J OPHTHALMOL, V17, P454; Jaggi GP, 2010, BRIT J OPHTHALMOL, V94, P1088, DOI 10.1136/bjo.2009.171660; Jaggi GP, 2012, BRIT J OPHTHALMOL, V96, P53, DOI 10.1136/bjo.2010.199224; JAMES CB, 1991, GRAEF ARCH CLIN EXP, V229, P341, DOI 10.1007/BF00170692; Jonas J. B., 2014, ACTA OPHTHALMOL; JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1599; JONAS JB, 1993, INVEST OPHTH VIS SCI, V34, P2260; JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1604; Jonas JB, 1999, AM J OPHTHALMOL, V127, P523, DOI 10.1016/S0002-9394(99)00030-6; JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942; JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P401; Jonas JB, 2006, GRAEF ARCH CLIN EXP, V244, P129, DOI 10.1007/s00417-004-1042-4; Jonas JB, 2000, PROG RETIN EYE RES, V19, P1, DOI 10.1016/S1350-9462(99)00002-6; Jonas JB, 2004, INVEST OPHTH VIS SCI, V45, P2660, DOI 10.1167/iovs.03-1363; Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P501, DOI 10.1136/bjo.2003.030650; Jonas JB, 2003, INVEST OPHTH VIS SCI, V44, P5189, DOI 10.1167/iovs.03-0174; Jonas JB, 2003, ACTA OPHTHALMOL SCAN, V81, P419, DOI 10.1034/j.1600-0420.2003.00110.x; Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P949, DOI 10.1136/bjo.87.8.949; Jonas JB, 2003, GRAEF ARCH CLIN EXP, V241, P367, DOI 10.1007/s00417-003-0643-7; Jonas JB, 2003, J GLAUCOMA, V12, P285, DOI 10.1097/00061198-200306000-00019; Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P577, DOI 10.1136/bjo.87.5.577; Jonas JB, 1999, J GLAUCOMA, V8, P227; Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P361, DOI 10.1136/bjo.87.3.361-a; JONAS JB, 1989, ACTA OPHTHALMOL, V67, P199; Jonas JB, 1999, BRIT J OPHTHALMOL, V83, P1291, DOI 10.1136/bjo.83.11.1291; JONAS JB, 1994, GRAEF ARCH CLIN EXP, V232, P759, DOI 10.1007/BF00184280; Jonas JB, 2008, GRAEF ARCH CLIN EXP, V246, P1059, DOI 10.1007/s00417-008-0780-0; Jonas JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P287, DOI 10.1001/archopht.126.2.287-b; Jonas JB, 2007, OPHTHALMOLOGY, V114, P1791, DOI 10.1016/j.ophtha.2007.04.045; Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100533; Jonas JB, 2014, AM J HYPERTENS, V27, P1170, DOI 10.1093/ajh/hpu037; Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096273; Jonas JB, 2014, ACTA OPHTHALMOL, V92, pe273, DOI 10.1111/aos.12324; Jonas JB, 2014, INVEST OPHTH VIS SCI, V55, P1292, DOI 10.1167/iovs.13-13351; Jonas JB, 2014, ACTA OPHTHALMOL, V92, pE194, DOI 10.1111/aos.12297; Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086678; Jonas JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082284; Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237; Jonas JB, 2012, INVEST OPHTH VIS SCI, V53, P6045, DOI 10.1167/iovs.12-10623; Jonas JB, 2011, AM J OPHTHALMOL, V152, P1021, DOI 10.1016/j.ajo.2011.05.006; Jonas JB, 2011, J GLAUCOMA, V20, P405, DOI 10.1097/IJG.0b013e3181f7af9b; Jonas JB, 2011, ACTA OPHTHALMOL, V89, P505, DOI 10.1111/j.1755-3768.2010.01915.x; Kain S, 2010, BRIT J OPHTHALMOL, V94, P854, DOI 10.1136/bjo.2009.169813; Kaufmann C, 2006, ARCH OPHTHALMOL-CHIC, V124, P1104, DOI 10.1001/archopht.124.8.1104; Kawasaki R, 2013, OPHTHALMOLOGY, V120, P84, DOI 10.1016/j.ophtha.2012.07.007; Killer HE, 2007, BRAIN, V130, P514, DOI 10.1093/brain/awl324; Killer HE, 2008, J HISTOCHEM CYTOCHEM, V56, P1087, DOI 10.1369/jhc.2008.950840; Killer HE, 2008, CLIN EXP OPHTHALMOL, V36, P308, DOI 10.1111/j.1442-9071.2008.01735.x; Killer Hanspeter E, 2013, J Glaucoma, V22 Suppl 5, pS8, DOI 10.1097/IJG.0b013e318293498b; Killer HE, 2012, BRIT J OPHTHALMOL, V96, P544, DOI 10.1136/bjophthalmol-2011-300663; Killer Hanspeter Esriel, 2013, J Glaucoma, V22 Suppl 5, pS19, DOI 10.1097/IJG.0b013e3182934a0f; Killer HE, 2011, BRIT J OPHTHALMOL, V95, P822, DOI 10.1136/bjo.2010.189324; Killer HE, 2006, BRAIN, V129, P1027, DOI 10.1093/brain/awl045; Killer HE, 1999, J NEURO-OPHTHALMOL, V19, P222; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Kirk T, 2011, ANN NEUROL, V70, P323, DOI 10.1002/ana.22414; Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P76, DOI 10.1001/archopht.122.1.76; Klein R, 2007, OPHTHALMOLOGY, V114, P1884, DOI 10.1016/j.ophtha.2007.02.023; Klein R, 2006, OPHTHALMOLOGY, V113, P1488, DOI 10.1016/j.ophtha.2006.03.028; KLINGELHOFER J, 1987, KLIN WOCHENSCHR, V65, P542, DOI 10.1007/BF01727619; Kramer LA, 2012, RADIOLOGY, V263, P819, DOI 10.1148/radiol.12111986; Lang EW, 2003, J NEUROSURG, V98, P214, DOI 10.3171/jns.2003.98.1.0214; Lashutka MK, 2004, ANN EMERG MED, V43, P585, DOI 10.1016/j.annemergmed.2003.12.006; Le A, 2009, ANN EMERG MED, V53, P785, DOI 10.1016/j.annemergmed.2008.11.025; Lenfeldt N, 2007, NEUROLOGY, V68, P155, DOI 10.1212/01.wnl.0000250270.54587.71; Li J, 2013, BIOL CELL, V105, P304, DOI 10.1111/boc.201300013; Li Z, 2013, CHINESE MED J-PEKING, V126, P1588, DOI 10.3760/cma.j.issn.0366-6999.20123186; Li Z, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-66; Mader TH, 2013, J NEURO-OPHTHALMOL, V33, P249, DOI 10.1097/WNO.0b013e31829b41a6; Mader TH, 2011, OPHTHALMOLOGY, V118, P2058, DOI 10.1016/j.ophtha.2011.06.021; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; Mansouri K, 2012, INVEST OPHTH VIS SCI, V53, P8050, DOI 10.1167/iovs.12-10569; Maurel D, 1996, BRAIN RES, V736, P165, DOI 10.1016/S0006-8993(96)00676-2; MINCKLER DS, 1976, AM J OPHTHALMOL, V82, P741, DOI 10.1016/0002-9394(76)90012-X; Mitchell P, 2005, AM J OPHTHALMOL, V140, P131, DOI 10.1016/j.ajo.2004.12.088; MOLLER P M, 1955, Acta Ophthalmol Suppl, P1; MOLLER P M, 1954, Acta Ophthalmol (Copenh), V32, P597; Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; Morgan WH, 2009, BRIT J OPHTHALMOL, V93, P594, DOI 10.1136/bjo.2008.149963; MORGAN WH, 1995, INVEST OPHTH VIS SCI, V36, P1163; Morgan WH, 1998, INVEST OPHTH VIS SCI, V39, P1419; Morgan WH, 2004, OPHTHALMOLOGY, V111, P1489, DOI 10.1016/j.ophtha.2003.12.053; Morgan WH, 2002, INVEST OPHTH VIS SCI, V43, P3236; Morgan WH, 1997, MICROVASC RES, V53, P211, DOI 10.1006/mvre.1997.2010; Morgan W, 2012, INVEST OPHTH VIS SCI, V53, P6880, DOI 10.1167/iovs.12-10943; Morgan WH, 2008, J GLAUCOMA, V17, P408, DOI 10.1097/IJG.0b013e31815c5f7c; Morgan WH, 2012, INVEST OPHTH VIS SCI, V53, P4676, DOI 10.1167/iovs.12-9837; Morgan WH, 2008, CLIN EXP OPHTHALMOL, V36, P802, DOI 10.1111/j.1442-9071.2008.01881.x; Motschmann M, 2001, Strabismus, V9, P13, DOI 10.1076/stra.9.1.13.711; Paques M, 2005, INVEST OPHTH VIS SCI, V46, P4707, DOI 10.1167/iovs.05-0638; PEYMAN GA, 1972, ARCH OPHTHALMOL-CHIC, V88, P650; Pillunat KR, 2014, BRIT J OPHTHALMOL, V98, P1374, DOI 10.1136/bjophthalmol-2014-305126; Pinto LA, 2012, GRAEF ARCH CLIN EXP, V250, P1075, DOI 10.1007/s00417-011-1878-3; Potgieter DW, 2011, ANAESTH INTENS CARE, V39, P95, DOI 10.1177/0310057X1103900116; Qu YZ, 2011, ACTA OPHTHALMOL, V89, pE428, DOI 10.1111/j.1755-3768.2011.02118.x; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; QUIGLEY HA, 1976, INVEST OPHTH VISUAL, V15, P606; Ragauskas A, 2005, ACT NEUR S, V95, P357; Ragauskas A, 2012, NEUROLOGY, V78, P1684, DOI 10.1212/WNL.0b013e3182574f50; Ragauskas A, 2014, NEUROL RES, V36, P607, DOI 10.1179/1743132813Y.0000000308; REID A, 1990, British Journal of Audiology, V24, P123, DOI 10.3109/03005369009077853; Ren RJ, 2012, GRAEF ARCH CLIN EXP, V250, P445, DOI 10.1007/s00417-011-1746-1; Ren RJ, 2011, GRAEF ARCH CLIN EXP, V249, P1057, DOI 10.1007/s00417-011-1657-1; Ren RJ, 2011, ACTA OPHTHALMOL, V89, pE142, DOI 10.1111/j.1755-3768.2010.02015.x; Ren RJ, 2010, OPHTHALMOLOGY, V117, P259, DOI 10.1016/j.ophtha.2009.06.058; Ren RJ, 2009, INVEST OPHTH VIS SCI, V50, P2175, DOI 10.1167/iovs.07-1429; RIOSMONTENEGRO EN, 1973, ARCH OPHTHALMOL-CHIC, V89, P52; RODRIGUE.LA, 1966, J COMP NEUROL, V126, P109, DOI 10.1002/cne.901260109; ROSENBLOOM AL, 1990, DIABETES CARE, V13, P22, DOI 10.2337/diacare.13.1.22; Sajjadi SA, 2006, ANN NEUROL, V59, P867, DOI 10.1002/ana.20856; Salman MS, 1997, LANCET, V350, P1367, DOI 10.1016/S0140-6736(05)65138-0; Samuels BC, 2012, INVEST OPHTH VIS SCI, V53, P7328, DOI 10.1167/iovs.12-10632; Schuman JS, 2000, OPHTHALMOLOGY, V107, P127, DOI 10.1016/S0161-6420(99)00015-9; Sheeran P, 2000, LANCET, V355, P899, DOI 10.1016/S0140-6736(99)02768-3; Shimbles S, 2005, ACTA NEUROCHIR SUPPL, V95, P197; SHIN DH, 1995, INVEST OPHTH VIS SCI, V36, P2163; SHIOSE Y, 1991, JPN J OPHTHALMOL, V35, P133; Siaudvytyte L., 2014, ACTA OPHTHALMOL; Silver DM, 2000, CURR EYE RES, V20, P115, DOI 10.1076/0271-3683(200002)20:2;1-D;FT115; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Spentzas T, 2010, PEDIATR CRIT CARE ME, V11, P593, DOI 10.1097/PCC.0b013e3181ce755c; Srinivasan S, 2012, PEDIATR EMERG CARE, V28, P696, DOI 10.1097/PEC.0b013e31825d2198; Stodtmeister R, 2008, KLIN MONATSBL AUGENH, V225, P632, DOI 10.1055/s-2008-1027233; Stodtmeister R, 2013, INVEST OPHTH VIS SCI, V54, P4698, DOI 10.1167/iovs.12-10607; Stodtmeister R, 2010, INVEST OPHTH VIS SCI, V51, P6620, DOI 10.1167/iovs.09-4594; Strumwasser A, 2011, J SURG RES, V170, P265, DOI 10.1016/j.jss.2011.03.009; Tain RW, 2009, IEEE T BIO-MED ENG, V56, P544, DOI 10.1109/TBME.2008.2006010; Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782; TARKKANEN A, 1967, ACTA OPHTHALMOL, V45, P569; Teng CC, 2011, OPHTHALMOLOGY, V118, P2409, DOI 10.1016/j.ophtha.2011.06.014; Teng CC, 2010, OPHTHALMOLOGY, V117, P909, DOI 10.1016/j.ophtha.2009.10.016; Toyokawa N, 2012, OPHTHAL SURG LAS IM, V43, P109, DOI 10.3928/15428877-20120102-06; TSUKAHARA I, 1975, A GRAEF ARCH KLIN EX, V196, P239, DOI 10.1007/BF00410035; VANDERMEULEN JA, 1987, LANCET, V2, P306; Volkov V V, 1976, Oftalmol Zh, V31, P500; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Wang NL, 2012, OPHTHALMOLOGY, V119, P2065, DOI 10.1016/j.ophtha.2012.03.054; Wang YX, 2013, ACTA OPHTHALMOL, V91, P521, DOI 10.1111/j.1755-3768.2012.02454.x; Wang YX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104267; Wegner W, 1930, ARCH AUGENHEILKD, V102, P1; WEINREB RN, 1984, AM J OPHTHALMOL, V98, P784, DOI 10.1016/0002-9394(84)90698-6; WOOD E G, 1990, Pediatric Emergency Care, V6, P285, DOI 10.1097/00006565-199012000-00009; Wostyn P, 2015, ACTA OPHTHALMOL, V93, pE83, DOI 10.1111/aos.12331; Wostyn P, 2014, PROG RETIN EYE RES, V39, P107, DOI 10.1016/j.preteyeres.2013.12.002; Wostyn P, 2013, AM J OPHTHALMOL, V156, P5, DOI 10.1016/j.ajo.2013.03.003; Wostyn P, 2010, J GLAUCOMA, V19, P225, DOI 10.1097/IJG.0b013e3181c29af4; Xie XB, 2013, CRIT CARE, V17, DOI 10.1186/cc12841; Xin XR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020142; Xu L, 2007, AM J OPHTHALMOL, V144, P541, DOI 10.1016/j.ajo.2007.05.038; Xu L, 2007, AM J OPHTHALMOL, V144, P461, DOI 10.1016/j.ajo.2007.05.013; Xu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030104; Xu P, 2010, IEEE T INF TECHNOL B, V14, P971, DOI 10.1109/TITB.2009.2027317; Yablonski M, 1979, INVEST OPHTHALMOL  S, V18, P165; Yang DY, 2014, INVEST OPHTH VIS SCI, V55, P3067, DOI 10.1167/iovs.13-13657; Yang HL, 2007, INVEST OPHTH VIS SCI, V48, P5068, DOI 10.1167/iovs.07-0790; Zeng T, 2010, CHIN J TRAUMATOL, V13, P146, DOI 10.3760/cma.j.issn.1008-1275.2010.03.003; Zhang Z, 2014, ACTA OPHTHALMOL, V92, pE475, DOI 10.1111/aos.12263	211	62	66	1	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1350-9462	1873-1635		PROG RETIN EYE RES	Prog. Retin. Eye Res.	MAY	2015	46						67	83		10.1016/j.preteyeres.2015.01.002			17	Ophthalmology	Ophthalmology	CI2PZ	WOS:000354590800003	25619727				2021-06-18	
J	King, D; Hume, PA; Brughelli, M; Gissane, C				King, Doug; Hume, Patria A.; Brughelli, Matt; Gissane, Conor			Instrumented Mouthguard Acceleration Analyses for Head Impacts in Amateur Rugby Union Players Over a Season of Matches	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						injury; linear; rotational; impact; instrumented mouthguard	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; BRAIN-INJURY; ICE HOCKEY; CONCUSSION; EXPOSURE; BIOMECHANICS; SPORTS	Background: Direct impacts with the head (linear acceleration or pressure) and inertial loading of the head (rotational acceleration or strain) have been postulated as the 2 major mechanisms of head-related injuries such as concussion. Although data are accumulating for soccer and American football, there are no published data for nonhelmeted collision sports such as rugby union. Purpose: To quantify head impacts via instrumented mouthguard acceleration analyses for rugby union players over a season of matches. Study Design: Descriptive epidemiology study. Methods: Data on impact magnitude and frequency were collected with molded instrumented mouthguards worn by 38 premier amateur senior rugby players participating in the 2013 domestic season of matches. Results: A total of 20,687 impacts >10g (range, 10.0-164.9g) were recorded over the duration of the study. The mean SD number of impacts per player over the duration of the season of matches was 564 +/- 618, resulting in a mean +/- SD of 95 +/- 133 impacts to the head per player, per match over the duration of the season of matches. The impact magnitudes for linear accelerations were skewed to the lower values (S-p = 3.7 +/- 0.02; P < .001), with a mean linear acceleration of 22.2 +/- 16.2g. Rotational accelerations were also skewed to the lower values (S-p = 2.0 +/- 0.02; P < .001), with a mean rotational acceleration of 3902.9 +/- 3948.8 rad/s(2). Conclusion: The acceleration magnitudes and number of head impacts in amateur rugby union players over a season of matches, measured via instrumented mouthguard accelerations, were higher than for most sports previously reported. Mean linear acceleration measured over a season of matches was similar to the mean linear accelerations previously reported for youth, high school, and collegiate American football players but lower than that for female youth soccer players. Mean rotational acceleration measured over a season of matches was similar to mean rotational accelerations for youth, high school, and collegiate American football players but less than those for female youth soccer players, concussed American collegiate players, collegiate American football players, and professional American football players.	[King, Doug; Hume, Patria A.; Brughelli, Matt; Gissane, Conor] Auckland Univ Technol, Auckland, New Zealand	King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Hume, Patria/AAN-5514-2021; Gissane, Conor/I-3661-2019	Hume, Patria/0000-0003-1847-8128; Gissane, Conor/0000-0003-4677-3853			Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco J, 2010, J ATHL TRAINING, V45, P459; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gadd C, 1966, P 10 STAPP CAR RASH; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Hopkins WG, 2007, CLIN J SPORT MED, V17, P208, DOI 10.1097/JSM.0b013e3180592a68; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; King A, 2003, IRCOBI C SEPT 24 LIS; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; Mattson J, 2012, CLIN J SPORT MED, V22, P294; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Moon D W, 1971, Med Sci Sports, V3, P44; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Patton DA, 2012, P I MECH ENG P-J SPO, V226, P177, DOI 10.1177/1754337112438305; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	68	62	62	0	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2015	43	3					614	624		10.1177/0363546514560876			11	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CC6JP	WOS:000350471500014	25535096				2021-06-18	
J	Huusko, N; Romer, C; Ndode-Ekane, XE; Lukasiuk, K; Pitkanen, A				Huusko, Noora; Romer, Christine; Ndode-Ekane, Xavier Ekolle; Lukasiuk, Katarzyna; Pitkanen, Asla			Loss of hippocampal interneurons and epileptogenesis: a comparison of two animal models of acquired epilepsy	BRAIN STRUCTURE & FUNCTION			English	Article						Epileptogenesis; Seizure susceptibility; Status epilepticus; Traumatic brain injury	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; NEUROPEPTIDE-Y; STATUS EPILEPTICUS; INHIBITORY INTERNEURONS; POSTTRAUMATIC EPILEPSY; GABAERGIC INTERNEURONS; RAT HIPPOCAMPUS; ELECTRICAL-STIMULATION	Reduced hippocampal GABAergic inhibition is acknowledged to be associated with epilepsy. However, there are no studies that had quantitatively compared the loss of various interneuron populations in different models of epilepsy. We tested a hypothesis that the more severe the loss of hippocampal interneurons, the more severe was the epilepsy. Epileptogenesis was triggered in adult rats by status epilepticus (SE) (56 SE, 24 controls) or by traumatic brain injury (TBI) (45 TBI, 23 controls). The total number of hippocampal parvalbumin (PARV), cholecystokinin (CCK), calretinin (CR), somatostatin (SOM), or neuropeptide Y (NPY) positive neurons was estimated using unbiased stereology at 1 or 6 months post-insult. The rats with TBI had no spontaneous seizures but showed increased seizure susceptibility. Eleven of the 28 rats (39 %) in the SE group had spontaneous seizures. The most affected hippocampal area after TBI was the ipsilateral dentate gyrus, where 62 % of PARV-immunoreactive (ir) (p < 0.001 compared to controls), 77 % of CR-ir (p < 0.05), 46 % of SOM-ir (p < 0.001), and 59 % of NPY-ir (p < 0.001) cells remained at 1 month after TBI. At 6 months post-TBI, only 35 % of PARV-ir (p < 0.001 compared to controls), 63 % of CCK-ir (p < 0.01), 74 % of CR-ir (p < 0.001), 55 % of SOM-ir (p < 0.001), and 51 % of NPY-ir (p < 0.001) cells were remaining. Moreover, the reduction in PARV-ir, CCK-ir, and CR-ir neurons was bilateral (all p < 0.05). Substantial reductions in different neuronal populations were also found in subfields of the CA3 and CA1. In rats with epilepsy after SE, the number of PARV-ir neurons was reduced in the ipsilateral CA1 (80 % remaining, p < 0.05) and the number of NPY-ir neurons bilaterally in the dentate gyrus (33-37 %, p < 0.01) and the CA3 (54-57 %, p < 0.05). Taken together, interneuron loss was substantially more severe, widespread, progressive, and included more interneuron subclasses after TBI than after SE. Interneurons responsible for perisomatic inhibition were more vulnerable to TBI than those providing dendritic inhibition. Unlike expected, we could not demonstrate any etiology-independent link between the severity of hippocampal interneuron loss and the overall risk of spontaneous seizures.	[Huusko, Noora; Romer, Christine; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Kuopio 70211, Finland; [Lukasiuk, Katarzyna] Polish Acad Sci, Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, Kuopio 70211, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, Kuopio 70211, Finland.	asla.pitkanen@uef.fi	Lukasiuk, Katarzyna/F-4636-2010; Romer, Christine/AAU-9643-2020	Romer, Christine/0000-0002-2592-1071; Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632; Lukasiuk, Katarzyna/0000-0002-1582-0920	FP6 Grant [LSHM-CT-2006-037315]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; North-Savo Regional Fund of The Finnish Cultural FoundationFinnish Cultural Foundation; Finnish Epilepsy Foundation	This study was supported by the FP6 Grant LSHM-CT-2006-037315 (A.P.), Academy of Finland (A.P.), The Sigrid Juselius Foundation (A.P.), The North-Savo Regional Fund of The Finnish Cultural Foundation (N.H.), and The Finnish Epilepsy Foundation (N.H.). We thank Mr Jarmo Hartikainen and Mrs Merja Lukkari for their excellent technical assistance.	Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060.abs; Andrioli A, 2007, NEUROSCIENCE, V149, P131, DOI 10.1016/j.neuroscience.2007.07.029; Arellano JI, 2004, BRAIN, V127, P45, DOI 10.1093/brain/awh004; Bausch SB, 2005, EPILEPSY BEHAV, V7, P390, DOI 10.1016/j.yebeh.2005.07.019; Bering R, 1997, EXP BRAIN RES, V115, P423, DOI 10.1007/PL00005712; Biagini G, 2010, CURR OPIN NEUROL, V23, P170, DOI 10.1097/WCO.0b013e32833735cf; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Czuczwar SJ, 2001, CNS DRUGS, V15, P339, DOI 10.2165/00023210-200115050-00001; DeFelipe J, 1999, BRAIN, V122, P1807, DOI 10.1093/brain/122.10.1807; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Ferrari D, 2008, EPILEPSY BEHAV, V13, P36, DOI 10.1016/j.yebeh.2008.01.001; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Gulyas AI, 1996, J NEUROSCI, V16, P3397; HARTIG W, 1992, NEUROREPORT, V3, P869; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Karetko-Sysa M, 2011, EXP NEUROL, V231, P113, DOI 10.1016/j.expneurol.2011.05.022; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Klausberger T, 2008, SCIENCE, V321, P53, DOI 10.1126/science.1149381; Kuruba R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024493; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; Long LL, 2011, INT J NEUROSCI, V121, P69, DOI 10.3109/00207454.2010.530007; LOSCHER W, 1991, EPILEPSY RES, V9, P1, DOI 10.1016/0920-1211(91)90041-D; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Magloczky Z, 2005, TRENDS NEUROSCI, V28, P334, DOI 10.1016/j.tins.2005.04.002; Magloczky Z, 2000, NEUROSCIENCE, V96, P7, DOI 10.1016/S0306-4522(99)00474-1; Magloczky Z, 2010, EPILEPSY RES, V89, P52, DOI 10.1016/j.eplepsyres.2010.01.002; Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012; Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6; Mathern GW, 1997, NEUROSCIENCE, V77, P1003, DOI 10.1016/S0306-4522(96)00516-7; MATHERN GW, 1995, J NEUROSCI, V15, P3990; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nairismagi J, 2004, EPILEPSIA, V45, P1024, DOI 10.1111/j.0013-9580.2004.08904.x; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Noe F, 2008, BRAIN, V131, P1506, DOI 10.1093/brain/awn079; OJEMANN GA, 1987, J NEUROSURG, V66, P489, DOI 10.3171/jns.1987.66.4.0489; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwaller B, 2004, MOL CELL NEUROSCI, V25, P650, DOI 10.1016/j.mcn.2003.12.006; SCHWARZER C, 1995, NEUROSCIENCE, V69, P831, DOI 10.1016/0306-4522(95)00268-N; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Sloviter RS, 2001, J COMP NEUROL, V430, P283; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; Soderpalm B, 2002, EUR J PAIN-LONDON, V6, P3, DOI 10.1053/eujp.2001.0315; SPERK G, 1992, NEUROSCIENCE, V50, P831, DOI 10.1016/0306-4522(92)90207-I; Sun CS, 2007, J COMP NEUROL, V500, P876, DOI 10.1002/cne.21207; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth K, 2010, BRAIN, V133, P2763, DOI 10.1093/brain/awq149; Toth Z, 1997, J NEUROSCI, V17, P8106; van Vliet EA, 2004, EXP NEUROL, V187, P367, DOI 10.1016/j.expneurol.2004.01.016; Vezzani A, 2004, NEUROPEPTIDES, V38, P245, DOI 10.1016/j.npep.2004.05.004; Vreugdenhil M, 2003, J NEUROPHYSIOL, V89, P1414, DOI 10.1152/jn.00576.2002; Wasterlain CG, 1996, EPILEPSY RES, V26, P255, DOI 10.1016/S0920-1211(96)00058-7; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wittner L, 2001, NEUROSCIENCE, V108, P587, DOI 10.1016/S0306-4522(01)00446-8; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020; Zhang BL, 2011, BRAIN RES, V1382, P165, DOI 10.1016/j.brainres.2011.01.065; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009	70	62	67	0	11	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	JAN	2015	220	1					153	191		10.1007/s00429-013-0644-1			39	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CA5XE	WOS:000348980800013	24096381				2021-06-18	
J	Carney, N; Ghajar, J; Jagoda, A; Bedrick, S; Davis-O'Reilly, C; du Coudray, H; Hack, D; Helfand, N; Huddleston, A; Nettleton, T; Riggio, S				Carney, Nancy; Ghajar, Jamshid; Jagoda, Andy; Bedrick, Steven; Davis-O'Reilly, Cynthia; du Coudray, Hugo; Hack, Dallas; Helfand, Nora; Huddleston, Amy; Nettleton, Tracie; Riggio, Silvana			Concussion Guidelines Step 1: Systematic Review of Prevalent Indicators	NEUROSURGERY			English	Article						Concussion; Indicators of concussion; Systematic review	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; FOOTBALL PLAYERS; MILD; RECOVERY; SPORTS; SYMPTOMS; RETURN	BACKGROUND: Currently, there is no evidence-based definition for concussion that is being uniformly applied in clinical and research settings. OBJECTIVE: To conduct a systematic review of the highest-quality literature about concussion and to assemble evidence about the prevalence and associations of key indicators of concussion. The goal was to establish an evidence-based foundation from which to derive, in future work, a definition, diagnostic criteria, and prognostic indicators for concussion. METHODS: Key questions were developed, and an electronic literature search from 1980 to 2012 was conducted to acquire evidence about the prevalence of and associations among signs, symptoms, and neurologic and cognitive deficits in samples of individuals exposed to potential concussive events. Included studies were assessed for potential for bias and confound and rated as high, medium, or low potential for bias and confound. Those rated as high were excluded from the analysis. Studies were further triaged on the basis of whether the definition of a case of concussion was exclusive or inclusive; only those with wide, inclusive case definitions were used in the analysis. Finally, only studies reporting data collected at fixed time points were used. For a study to be included in the conclusions, it was required that the presence of any particular sign, symptom, or deficit be reported in at least 2 independent samples. RESULTS: From 5437 abstracts, 1362 full-text publications were reviewed, of which 231 studies were included in the final library. Twenty-six met all criteria required to be used in the analysis, and of those, 11 independent samples from 8 publications directly contributed data to conclusions. Prevalent and consistent indicators of concussion are (1) observed and documented disorientation or confusion immediately after the event, (2) impaired balance within 1 day after injury, (3) slower reaction time within 2 days after injury, and/or (4) impaired verbal learning and memory within 2 days after injury. CONCLUSION: The results of this systematic review identify the consistent and prevalent indicators of concussion and their associations, derived from the strongest evidence in the published literature. The product is an evidence-based foundation from which to develop diagnostic criteria and prognostic indicators.	[Carney, Nancy; Davis-O'Reilly, Cynthia; du Coudray, Hugo; Helfand, Nora; Huddleston, Amy; Nettleton, Tracie] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Bedrick, Steven] Oregon Hlth & Sci Univ, Ctr Spoken Language Understanding, Portland, OR 97201 USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Ghajar, Jamshid] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Jagoda, Andy] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA; [Riggio, Silvana] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Riggio, Silvana] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [du Coudray, Hugo] Portland State Univ, Dept Psychol, Portland, OR 97207 USA; [Hack, Dallas] US Army Med Res & Materiel Command, US Army Combat Casualty Care Res Program, Ft Detrick, MD USA	Ghajar, J (corresponding author), Brain Trauma Fdn, 7 World Trade Ctr,34th Floor,250 Greenwich St, New York, NY 10007 USA.	ghajar@braintrauma.org		Bedrick, Steven/0000-0002-0163-9397	US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911QY-11-C-0074]; Brain Trauma Foundation	There are no conflicts of interest. The Brain Trauma Foundation Concussion Guidelines project is supported by the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, under contract No. W911QY-11-C-0074. The Brain Trauma Foundation provided funding for 2 meetings of the Panel of Technical Experts. Dr Jagoda is a consultant for Banyan Biomarkers. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Dutton RP, 2011, J TRAUMA, V70, P554, DOI 10.1097/TA.0b013e31820d1062; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Saadat S, 2009, J NEUROSURG, V111, P688, DOI 10.3171/2009.2.JNS08909; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	31	62	62	0	33	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2014	75			1			S3	S15		10.1227/NEU.0000000000000433			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AL3XC	WOS:000339063600002	25006974				2021-06-18	
J	Cripton, PA; Dressler, DM; Stuart, CA; Dennison, CR; Richards, D				Cripton, Peter A.; Dressler, Daniel M.; Stuart, Cameron A.; Dennison, Christopher R.; Richards, Darrin			Bicycle helmets are highly effective at preventing head injury during head impact: Head-form accelerations and injury criteria for helmeted and unhelmeted impacts	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Brain injury; Concussion; Helmet; Bicycle; Injury prevention	PROFESSIONAL FOOTBALL; HYBRID III; RISK; CONCUSSION; EFFICACY; TRAUMA	Cycling is a popular form of recreation and method of commuting with clear health benefits. However, cycling is not without risk. In Canada, cycling injuries are more common than in any other summer sport; and according to the US National Highway and Traffic Safety Administration, 52,000 cyclists were injured in the US in 2010. Head injuries account for approximately two-thirds of hospital admissions and three-quarters of fatal injuries among injured cyclists. In many jurisdictions and across all age levels, helmets have been adopted to mitigate risk of serious head injuries among cyclists and the majority of epidemiological literature suggests that helmets effectively reduce risk of injury. Critics have raised questions over the actual efficacy of helmets by pointing to weaknesses in existing helmet epidemiology including selection bias and lack of appropriate control for the type of impact sustained by the cyclist and the severity of the head impact. These criticisms demonstrate the difficulty in conducting epidemiology studies that will be regarded as definitive and the need for complementary biomechanical studies where confounding factors can be adequately controlled. In the bicycle helmet context, there is a paucity of biomechanical data comparing helmeted to unhelmeted head impacts and, to our knowledge, there is no data of this type available with contemporary helmets. In this research, our objective was to perform biomechanical testing of paired helmeted and unhelmeted head impacts using a validated anthropomorphic test headform and a range of drop heights between 0.5 m and 3.0 m, while measuring headform acceleration and Head Injury Criterion (HIC). In the 2 m (6.3 m/s) drops, the middle of our drop height range, the helmet reduced peak accelerations from 824 g (unhelmeted) to 181 g (helmeted) and HIC was reduced from 9667 (unhelmeted) to 1250 (helmeted). At realistic impact speeds of 5.4 m/s (1.5 m drop) and 6.3 m/s (2.0 m drop), bicycle helmets changed the probability of severe brain injury from extremely likely (99.9% risk at both 5.4 and 6.3 m/s) to unlikely (9.3% and 30.6% risk at 1.5 m and 2.0 m drops respectively). These biomechanical results for acceleration and HIC, and the corresponding results for reduced risk of severe brain injury show that contemporary bicycle helmets are highly effective at reducing head injury metrics and the risk for severe brain injury in head impacts characteristic of bicycle crashes. (C) 2014 Elsevier Ltd. All rights reserved.	[Cripton, Peter A.; Dressler, Daniel M.; Dennison, Christopher R.] Univ British Columbia, Dept Mech Engn, Vancouver, BC V6T 1Z4, Canada; [Cripton, Peter A.; Dressler, Daniel M.; Dennison, Christopher R.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V6T 1Z4, Canada; [Cripton, Peter A.] Univ British Columbia, Ctr Hip Hlth & Mobil, Vancouver, BC V6T 1Z4, Canada; [Cripton, Peter A.; Dressler, Daniel M.] Univ British Columbia, Orthopaed & Injury Biomech Grp, Vancouver, BC V6T 1Z4, Canada; [Stuart, Cameron A.; Richards, Darrin] Synapt Anal Consulting Grp, Vancouver, BC, Canada	Cripton, PA (corresponding author), Univ British Columbia, Dept Mech Engn, 6250 Appl Sci Lane, Vancouver, BC V6T 1Z4, Canada.	cripton@mech.ubc.ca	Cripton, Peter/AAC-8268-2020	Cripton, Peter/0000-0002-5067-0833			Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; [Anonymous], 2010, BIC OTH CYCL; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; BENZ G, 1993, EUR J PEDIATR SURG, V3, P259, DOI 10.1055/s-2008-1063555; Canadian Institute for Health Information, 2010, CYCL INJ HOSP CAN 20; Curnow WJ, 2006, ACCIDENT ANAL PREV, V38, P833, DOI 10.1016/j.aap.2006.04.007; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; DeMarco AL, 2010, ACCIDENT ANAL PREV, V42, P1778, DOI 10.1016/j.aap.2010.04.019; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Eppinger R., 1999, DEV IMPROVED INJURY; Fahlstedt M, 2012, P INT RES COUNC BIOM, V40, P787; Federal Trade Commission, 1998, FED REG, V63; Foster K.J., 1977, 770938 SAE; Gennarelli TA, 2005, ABBREVIATED INJURY S; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hagel BE, 2006, ACCIDENT ANAL PREV, V38, P277, DOI 10.1016/j.aap.2005.09.004; Hamer M, 2008, PREV MED, V46, P9, DOI 10.1016/j.ypmed.2007.03.006; Heng K. W. J., 2006, SMJ Singapore Medical Journal, V47, P367; Hodgson VR., 1990, IMPACT SKID RETENTIO; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Mattei T.A., 2012, J NEUROSURG PEDIAT, V10, P1; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; Newman J.A., 2002, ACCIDENTAL INJURY, P303; Nightingale RW, 1997, SPINE, V22, P2380, DOI 10.1097/00007632-199710150-00012; Page JL, 2012, INJURY PREV, V18, P94, DOI 10.1136/injuryprev-2011-040029; Pang TY, 2011, INT J CRASHWORTHINES, V16, P297, DOI 10.1080/13588265.2011.559799; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Scher I., 2006, J ASTM INT, V3; Scher IS, 2009, 010248 SAE; Thompson D., 1999, COCHRANE DATABASE SY; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Wen LM, 2008, PREV MED, V46, P29, DOI 10.1016/j.ypmed.2007.08.009	37	62	63	0	103	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	SEP	2014	70						1	7		10.1016/j.aap.2014.02.016			7	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	AJ7CR	WOS:000337855300001	24686160				2021-06-18	
J	Naziroglu, M; Senol, N; Ghazizadeh, V; Yuruker, V				Naziroglu, Mustafa; Senol, Nilgun; Ghazizadeh, Vahid; Yuruker, Vehbi			Neuroprotection Induced by N-acetylcysteine and Selenium Against Traumatic Brain Injury-Induced Apoptosis and Calcium Entry in Hippocampus of Rat	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Apoptosis; Hippocampus; N-acetylcysteine; Oxidative stress; Traumatic brain injury; TRPV1 channels	DORSAL-ROOT GANGLION; OXIDATIVE STRESS; CELL-DEATH; MOLECULAR PATHWAYS; TRPM2 CHANNELS; SPINAL-CORD; IN-VITRO; MITOCHONDRIA; INFLUX; ANTIOXIDANT	Neurodegeneration associated with acute central nervous system injuries and diseases such as spinal cord injury and traumatic brain injury (TBI) are reported to be mediated by the regulation of apoptosis and oxidative stress through Ca2+ influx. The thiol redox system antioxidants, such as N-acetylcysteine (NAC) and selenium (Se), display neuroprotective activities mediated at least in part by their antioxidant and anti-inflammatory properties. However, there are no reports on hippocampal apoptosis, cytosolic reactive oxygen species (ROS), or Ca2+ values in rats with an induced TBI. Therefore, we tested the effects of Se and NAC administration on apoptosis, oxidative stress, and Ca2+ influx through TRPV1 channel activations in the hippocampus of TBI-induced rats. The 32 rats were divided into four groups: control, TBI, TBI + NAC, and TBI + Se groups. Intraperitoneal administrations of NAC and Se were performed at 1, 24, 48, and 72 h after TBI induction. After 3 days, the hippocampal neurons were freshly isolated from the rats. In cytosolic-free Ca2+ analyses, the neurons were stimulated with the TRPV1 channel agonist capsaicin, a pungent compound found in hot chili peppers. Cytosolic-free Ca2+, apoptosis, cytosolic ROS levels, and caspase-3 and -9 activities were higher in the TBI group than control. The values in the hippocampus were decreased by Se and NAC administrations. In conclusion, we observed that NAC and Se have protective effects on oxidative stress, apoptosis, and Ca2+ entry via TRPV1 channel activation in the hippocampus of this TBI model, but the effect of NAC appears to be much greater than that of Se. They are both interesting candidates for studying the amelioration of TBIs. Possible molecular pathways of TBI on oxidative stress, apoptosis and Ca2+ entry through TRPV1 cation channels in hippocampus and DRG neurons. It is likely that TRPV1-mediated Ca2+ entry in the hippocampus of epileptic rats involves accumulation of ROS and opening of mitochondrial membrane pores that consequently leads to mitochondrial dysfunction, substantial swelling of the mitochondria with rupture of the outer membrane and release of apoptosis-inducing factors such as caspase-3 and -9.	[Naziroglu, Mustafa; Ghazizadeh, Vahid] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey; [Senol, Nilgun; Yuruker, Vehbi] Suleyman Demirel Univ, Fac Med, Dept Neurosurg, TR-32260 Isparta, Turkey	Naziroglu, M (corresponding author), Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.	mustafanaziroglu@sdu.edu.tr			Free Oxygen Radical Society, Isparta, Turkey	Dr. Vahid Ghazizadeh was partially supported for the project by Free Oxygen Radical Society, Isparta, Turkey. MN formulated the present hypothesis and was responsible for writing the report. NS, VG, and VY were responsible for the analyses. The authors wish to thank the Research Assistant, Ahmi Oz (Department of Biophysics, Medical Faculty, Suleyman Demirel University, Isparta, Turkey) for preparation of graphical abstract.	Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Arakawa M, 2007, CEREBELLUM, V6, P308, DOI 10.1080/14734220601142878; Celik O, 2012, PHYSIOL BEHAV, V107, P458, DOI 10.1016/j.physbeh.2012.09.013; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Daiber A, 2013, CELL MEMBR FREE RADI, V5, P221; Elphick LM, 2008, TOXICOL APPL PHARM, V232, P258, DOI 10.1016/j.taap.2008.07.008; Englezou PC, 2012, EXP BRAIN RES, V221, P357, DOI 10.1007/s00221-012-3179-4; Espino J, 2011, J PINEAL RES, V51, P195, DOI 10.1111/j.1600-079X.2011.00876.x; Gonzalez A, 2007, BRAIN RES, V1178, P28, DOI 10.1016/j.brainres.2007.08.040; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hallak M, 2008, APOPTOSIS, V13, P147, DOI 10.1007/s10495-007-0156-7; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Karalija A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041086; Kim TS, 2002, BIOCHEM BIOPH RES CO, V294, P1130, DOI 10.1016/S0006-291X(02)00612-5; Limbrick DD, 2003, CELL CALCIUM, V33, P69, DOI 10.1016/S0143-4160(02)00054-4; Liu Y, 2009, CELL ADHES MIGR, V3, P94, DOI 10.4161/cam.3.1.7516; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Naziroglu M, 2013, NEUROSCIENCE, V242, P151, DOI 10.1016/j.neuroscience.2013.03.032; Naziroglu M, 2013, NUTR NEUROS IN PRESS; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2013, MUSCLE NERVE, V48, P945, DOI 10.1002/mus.23844; Naziroglu M, 2013, CELL MOL NEUROBIOL, V33, P589, DOI 10.1007/s10571-013-9936-5; Naziroglu M, 2012, NEUROCHEM RES, V37, P2065, DOI 10.1007/s11064-012-0850-x; Naziroglu M, 2011, NEUROCHEM RES, V36, P355, DOI 10.1007/s11064-010-0347-4; Naziroglu M, 2009, NEUROCHEM RES, V34, P2181, DOI 10.1007/s11064-009-0015-8; Naziroglu M, 2008, J MEMBRANE BIOL, V225, P39, DOI 10.1007/s00232-008-9132-6; Oksay T, 2013, ANDROLOGIA, V45, P171, DOI 10.1111/j.1439-0272.2012.01329.x; Ozgul C, 2012, PHYSIOL BEHAV, V106, P122, DOI 10.1016/j.physbeh.2012.01.014; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Puppa LD, 2007, ANN NY ACAD SCI, V1096, P179, DOI 10.1196/annals.1397.084; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; ROTHE G, 1988, NATURWISSENSCHAFTEN, V75, P354, DOI 10.1007/BF00368326; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Shang DJ, 2011, ONCOL REP, V25, P267, DOI 10.3892/or_00001070; Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006; Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x; Uguz AC, 2012, NEUROCHEM RES, V37, P1631, DOI 10.1007/s11064-012-0758-5; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Yeo JE, 2008, CELL PHYSIOL BIOCHEM, V21, P225, DOI 10.1159/000113764; Yeo JE, 2007, BBA-MOL BASIS DIS, V1772, P1199, DOI 10.1016/j.bbadis.2007.09.004; Zhang YF, 2010, ANTI-CANCER DRUG, V21, P494, DOI 10.1097/CAD.0b013e328336e927; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635	45	62	64	1	23	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	AUG	2014	34	6					895	903		10.1007/s10571-014-0069-2			9	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	AL8IT	WOS:000339382500012	24842665				2021-06-18	
J	Bayley, MT; Tate, R; Douglas, JM; Turkstra, LS; Ponsford, J; Stergiou-Kita, M; Kua, A; Bragge, P				Bayley, Mark Theodore; Tate, Robyn; Douglas, Jacinta Mary; Turkstra, Lyn S.; Ponsford, Jennie; Stergiou-Kita, Mary; Kua, Ailene; Bragge, Peter		INCOG Expert Panel	INCOG Guidelines for Cognitive Rehabilitation Following Traumatic Brain Injury: Methods and Overview	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; guidelines; knowledge translation; neuropsychology; rehabilitation; therapeutic approaches for the treatment of CNS injury; traumatic brain injury		Introduction: Traumatic brain injury results in complex cognitive sequelae. However, clinicians have difficulty implementing the available evidence. An international group of researchers and clinicians (known as INCOG) convened to develop clinical practice guidelines for cognitive rehabilitation posttraumatic brain injury. Methods: The Guidelines Adaptation and Development cycle was used to derive the recommendations. Previously published cognitive rehabilitation recommendations were identified and tabulated. An expert panel met to select appropriate recommendations. Afterward, the team enhanced the recommendations by reviewing available literature. To address shortfalls of previous guidelines, the team developed decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials and expert opinion. The team then prioritized the recommendations for implementation and developed audit criteria to evaluate adherence to best practice. Results: The team recommends that individuals have detailed assessments of cognition after resolution of posttraumatic amnesia. Cognitive assessment and rehabilitation should be tailored to the patient's neuropsychological profile, premorbid cognitive characteristics, and goals for life activities and participation. Clinical algorithms and audit tools to evaluate current practice are provided. Conclusion: Cognitive rehabilitation should be offered to select individuals with traumatic brain injury. These guidelines provide assistance to clinicians who want to provide evidence-based care.	[Bayley, Mark Theodore] Univ Hlth Network, Toronto Rehabil Inst, Brain & Spinal Cord Rehabil Program, Toronto, ON M5G 2C4, Canada; [Kua, Ailene] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5G 2C4, Canada; [Bayley, Mark Theodore] Univ Toronto, Fac Med, Toronto, ON, Canada; [Tate, Robyn] Univ Sydney, Royal Rehabil Ctr, Sydney Med Sch Northern, Ctr Rehabil Res,Kolling Inst, Sydney, NSW 2006, Australia; [Douglas, Jacinta Mary] La Trobe Univ, Dept Human Commun Sci, Melbourne, Vic, Australia; [Turkstra, Lyn S.] Univ Wisconsin Madison, Dept Commun Sci & Disorders, Madison, WI USA; [Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Stergiou-Kita, Mary] Toronto Rehabil Inst, Toronto, ON, Canada; [Stergiou-Kita, Mary] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Bragge, Peter] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Bragge, Peter] Monash Univ, Melbourne, Vic 3004, Australia	Bayley, MT (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, Brain & Spinal Cord Rehabil Program, 190 Elizabeth St, Toronto, ON M5G 2C4, Canada.	mark.bayley@uhn.ca		Bragge, Peter/0000-0003-0745-5131; Bayley, Mark/0000-0001-7860-9463; Douglas, Jacinta/0000-0003-0940-6624	Victorian Neurotrauma Initiative- a research program of the Transport Accident Commission; Monash UniversityMonash University; Ontario Neurotrauma Foundation; Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University	The project described in this article was funded by the Victorian Neurotrauma Initiative- a research program of the Transport Accident Commission and Monash University's Strategic Grants Scheme (Lead CI: Peter Bragge) and the Ontario Neurotrauma Foundation (Lead CI: Mark Bayley). The authors gratefully acknowledge the support of the Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University, and the Ontario Neurotrauma Foundation for their support of this project.	[Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P353; [Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P338; [Anonymous], 1990, CLIN PRACTICE GUIDEL; [Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P321; [Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P307; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P268, DOI 10.1097/HTR.0000000000000053; Bosch M, 2013, J EVAL CLIN PRACT, V19, P763, DOI 10.1111/j.1365-2753.2012.01835.x; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2012, J NEUROTRAUM, V29, P1539, DOI 10.1089/neu.2011.2193; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, PREV MED, V51, P421, DOI 10.1016/j.ypmed.2010.08.005; Ciliska D K, 2001, AACN Clin Issues, V12, P520, DOI 10.1097/00044067-200111000-00008; Davies BL, 2002, JOGNN-J OBST GYN NEO, V31, P558, DOI 10.1111/j.1552-6909.2002.tb00081.x; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Grol R, 2001, MED CARE, V39, pII46; Haskins EC, 2012, AM C REH; Ivers N, 2012, COCHRANE DATABASE SY, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Lindsay M, 2010, CANADIAN BEST PRACTI; *ROYAL COLL PHYS, 2002, NAT CLIN GUID STROK; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; *SCOTT INT GUID NE, 2002, MAN PAT STROK REH PR; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate RL, 2013, NEUROREHABILITATION, V32, P729, DOI 10.3233/NRE-130898; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Velikonja D, 2014, J HEAD TRAUMA REHAB, V29, P369, DOI 10.1097/HTR.0000000000000069; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	28	62	63	2	41	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					290	306		10.1097/HTR.0000000000000070			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300007	24984093				2021-06-18	
J	Orlovska, S; Pedersen, MS; Benros, ME; Mortensen, PB; Agerbo, E; Nordentoft, M				Orlovska, Sonja; Pedersen, Michael Skaarup; Benros, Michael Eriksen; Mortensen, Preben Bo; Agerbo, Esben; Nordentoft, Merete			Head Injury as Risk Factor for Psychiatric Disorders: A Nationwide Register-Based Follow-Up Study of 113,906 Persons With Head Injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; SCHIZOPHRENIA-LIKE PSYCHOSIS; AUTOIMMUNE-DISEASES; SEVERE INFECTIONS; BIPOLAR DISORDER; DEPRESSION; EPILEPSY; CHILDREN; ILLNESS; ASSOCIATION	Objective: Studies investigating the relationship between head injury and subsequent psychiatric disorders often suffer from methodological weaknesses and show conflicting results. The authors investigated the incidence of severe psychiatric disorders following hospital contact for head injury. Method: The authors used linkable Danish nationwide population-based registers to investigate the incidence of schizophrenia spectrum disorders, unipolar depression, bipolar disorder, and organic mental disorders in 113,906 persons who had suffered head injuries. Data were analyzed by survival analysis and adjusted for gender, age, calendar year, presence of a psychiatric family history, epilepsy, infections, autoimmune diseases, and fractures not involving the skull or spine. Results: Head injury was associated with a higher risk of schizophrenia (incidence rate ratio [IRR]=1.65, 95% CI=1.55-1.75), depression (IRR=1.59 95% CI=1.53-1.65), bipolar disorder (IRR=1.28, 95% CI=1.10-1.48), and organic mental disorders (IRR=439, 95% CI=3.86-4.99). This effect was larger than that of fractures not involving the skull or spine for schizophrenia, depression, and organic mental disorders, which suggests that the results were not merely due to accident proneness. Head injury between ages 11 and 15 years was the strongest predictor for subsequent development of schizophrenia, depression, and bipolar disorder. The added risk of mental illness following head injury did not differ between individuals with and without a psychiatric family history. Conclusions: This is the largest study to date investigating head injury and subsequent mental illness. The authors demonstrated an increase in risk for all psychiatric outcomes after head injury. The effect did not seem to be solely due to accident proneness, and the added risk was not more pronounced in persons with a psychiatric family history.	[Orlovska, Sonja] Univ Copenhagen, Fac Hlth Sci, Mental Hlth Ctr Copenhagen, iPSYCH, DK-1168 Copenhagen, Denmark; Aarhus Univ, Natl Ctr Register Based Res, iPSYCH, DK-8000 Aarhus C, Denmark; Aarhus Univ CIRRAU, Ctr Integrated Register Based Res, iPSYCH, Aarhus, Denmark	Orlovska, S (corresponding author), Univ Copenhagen, Fac Hlth Sci, Mental Hlth Ctr Copenhagen, iPSYCH, DK-1168 Copenhagen, Denmark.	sonjaorlovska@gmail.com	Nordentoft, Merete/AAH-3253-2019; Benros, Michael Eriksen/N-5868-2016; Agerbo, Esben/A-2645-2012; Mortensen, Preben B/D-2358-2015; Orlovska-Waast, Sonja/K-3057-2019	Benros, Michael Eriksen/0000-0003-4939-9465; Agerbo, Esben/0000-0002-2849-524X; Mortensen, Preben B/0000-0002-5230-9865; Nordentoft, Merete/0000-0003-4895-7023	Stanley Medical Research Institute; Lundbeck FoundationLundbeckfonden; Lundbeck FoundationLundbeckfonden [R155-2014-1724] Funding Source: researchfish	Supported by a grant from the Stanley Medical Research Institute and an unrestricted grant from the Lundbeck Foundation.	Andersen TF, 1999, DAN MED BULL, V46, P263; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Benros ME, 2013, JAMA PSYCHIAT, V70, P812, DOI 10.1001/jamapsychiatry.2013.1111; Benros ME, 2011, AM J PSYCHIAT, V168, P1303, DOI 10.1176/appi.ajp.2011.11030516; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YH, 2011, PSYCHOL MED, V41, P1271, DOI 10.1017/S0033291710001819; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Coetzer R, 2008, CNS SPECTRUMS, V13, P1022, DOI 10.1017/S1092852900017065; Diamond B, 2009, NAT REV IMMUNOL, V9, P449, DOI 10.1038/nri2529; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Insel TR, 2010, NATURE, V468, P187, DOI 10.1038/nature09552; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Mortensen PB, 2003, J AFFECT DISORDERS, V76, P79, DOI 10.1016/S0165-0327(02)00073-3; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wirrell EC, 2006, EPILEPSIA, V47, P79, DOI 10.1111/j.1528-1167.2006.00666.x; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0; Zhang Y, 2011, DISCOV MED, V11, P395	40	62	65	0	28	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	APR	2014	171	4					463	469		10.1176/appi.ajp.2013.13020190			7	Psychiatry	Psychiatry	AD8FD	WOS:000333501000014	24322397				2021-06-18	
J	McIntosh, AS; Patton, DA; Frechede, B; Pierre, PA; Ferry, E; Barthels, T				McIntosh, Andrew S.; Patton, Declan A.; Frechede, Bertrand; Pierre, Paul-Andre; Ferry, Edouard; Barthels, Tobias			The biomechanics of concussion in unhelmeted football players in Australia: a case-control study	BMJ OPEN			English	Article							TRAUMATIC BRAIN-INJURY; HEAD IMPACTS; RECONSTRUCTION; SPORT; RUGBY	Objective: Concussion is a prevalent brain injury in sport and the wider community. Despite this, little research has been conducted investigating the dynamics of impacts to the unprotected human head and injury causation in vivo, in particular the roles of linear and angular head acceleration. Setting: Professional contact football in Australia. Participants: Adult male professional Australian rules football players participating in 30 games randomly selected from 103 games. Cases selected based on an observable head impact, no observable symptoms (eg, loss-of-consciousness and convulsions), no on-field medical management and no injury recorded at the time. Primary and secondary outcome measures: A data set for no-injury head impact cases comprising head impact locations and head impact dynamic parameters estimated through rigid body simulations using the MAthematical DYnamic MOdels (MADYMO) human facet model. This data set was compared to previously reported concussion case data. Results: Qualitative analysis showed that the head was more vulnerable to lateral impacts. Logistic regression analyses of head acceleration and velocity components revealed that angular acceleration of the head in the coronal plane had the strongest association with concussion; tentative tolerance levels of 1747 rad/s(2) and 2296 rad/s(2) were reported for a 50% and 75% likelihood of concussion, respectively. The mean maximum resultant angular accelerations for the concussion and no-injury cases were 7951 rad/s(2) (SD 3562 rad/s(2)) and 4300 rad/s(2) (SD 3657 rad/s(2)), respectively. Linear acceleration is currently used in the assessment of helmets and padded headgear. The 50% and 75% likelihood of concussion values for resultant linear head acceleration in this study were 65.1 and 88.5 g, respectively. Conclusions: As hypothesised by Holbourn over 70 years ago, angular acceleration plays an important role in the pathomechanics of concussion, which has major ramifications in terms of helmet design and other efforts to prevent and manage concussion.	[McIntosh, Andrew S.] Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia; [McIntosh, Andrew S.] Monash Univ, Monash Injury Res Inst, Melbourne, Vic 3004, Australia; [Patton, Declan A.] Univ New S Wales, Fac Sci, Sydney, NSW, Australia; [Frechede, Bertrand] Univ Lyon, F-69622 Villeurbanne, France; [Frechede, Bertrand] Univ Lyon 1, F-69622 Villeurbanne, France; [Frechede, Bertrand] LBMC, UMR T9406, IFSTTAR, F-69675 Bron, France; [Pierre, Paul-Andre] Techspace Aero, Safran Grp Milmort, Liege, Belgium; [Ferry, Edouard] Ecoparc Affaires Sologne, CEDREM, Neung Sur Beuvron, France; [Barthels, Tobias] Stryker GmbH & Co, Duisburg, Germany	McIntosh, AS (corresponding author), Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia.	as.mcintosh@bigpond.com	FRECHEDE, Bertrand/H-3091-2018	FRECHEDE, Bertrand/0000-0002-9292-3544			[Anonymous], 2009, PASW STAT; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Bewick V, 2005, CRIT CARE, V9, P112, DOI 10.1186/cc3045; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Cheng HM, 1996, PROCEEDINGS OF THE 1996 FIFTEENTH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE, P251, DOI 10.1109/SBEC.1996.493162; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Frechede B, 2007, 20 INT TECHN C ENH S, P1; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Funk J. R., 2006, INJ BIOM RES 34 INT, P1; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy WN, STAPP CAR CRASH J; Holbourn AHS., LANCET; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2001, BRIT J SPORT MED, V35, P146, DOI 10.1136/bjsm.35.3.146; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2011, BRIT J SPORT MED, V45, P1258, DOI 10.1136/bjsports-2011-090509; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 1993, 37 STAPP CAR CRASH C, P43; Menard S., 1995, APPL LOGISTIC REGRES; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Neale M, 2004, INT RES COUNC BIOM I; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J, 1999, INT RES COUNC BIOM I, P17; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Peng CYJ, 2002, J EDUC RES, V96, P3, DOI 10.1080/00220670209598786; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schmitt K-U, 2007, TRAUMA BIOMECHANICS, P55; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	45	62	63	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2014	4	5							e005078	10.1136/bmjopen-2014-005078			9	Medicine, General & Internal	General & Internal Medicine	AI6IQ	WOS:000336976900050	24844272	DOAJ Gold, Green Published			2021-06-18	
J	Dams-O'Connor, K; Spielman, L; Singh, A; Gordon, WA; Lingsma, HF; Maas, AIR; Manley, GT; Mukherjee, P; Okonkwo, DO; Puccio, AM; Schnyer, DM; Valadka, AB; Yue, JK; Yuh, EL; Cooper, SR; Cheong, M; Hricik, AJ; Knight, EE; Menon, DK; Morabito, DJ; Pacheco, JL; Sinha, TK; Vassar, MJ				Dams-O'Connor, Kristen; Spielman, Lisa; Singh, Ayushi; Gordon, Wayne A.; Lingsma, Hester F.; Maas, Andrew I. R.; Manley, Geoffrey T.; Mukherjee, Pratik; Okonkwo, David O.; Puccio, Ava M.; Schnyer, David M.; Valadka, Alex B.; Yue, John K.; Yuh, Esther L.; Cooper, Shelly R.; Cheong, Maxwell; Hricik, Allison J.; Knight, Emily E.; Menon, David K.; Morabito, Diane J.; Pacheco, Jennifer L.; Sinha, Tuhin K.; Vassar, Mary J.		TRACK-TBI Investigators Including	The Impact of Previous Traumatic Brain Injury on Health and Functioning: A TRACK-TBI Study	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; cognitive function; recovery; traumatic brain injury	IDENTIFICATION METHOD; HEAD-INJURY; RELIABILITY; CONCUSSION; SCALE; SATISFACTION; PREDICTORS; VALIDITY; HISTORY	The idea that multiple traumatic brain injury (TBI) can have a cumulative detrimental effect on functioning is widely accepted. Most research supporting this idea comes from athlete samples, and it is not known whether remote history of previous TBI affects functioning after subsequent TBI in community-based samples. This study investigates whether a previous history of TBI with loss of consciousness (LOC) is associated with worse health and functioning in a sample of individuals who require emergency department care for current TBI. Twenty-three percent of the 586 individuals with current TBI in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury study reported having sustained a previous TBI with LOC. Individuals with previous TBI were more likely to be unemployed ((2)=17.86; p=0.000), report a variety of chronic medical and psychiatric conditions (4.75(2)24.16; p<0.05), and report substance use (16.35(2)27.57; p<0.01) before the acute injury, compared to those with no previous TBI history. Those with a previous TBI had less-severe acute injuries, but experienced worse outcomes at 6-month follow-up. Results of a series of regression analyses controlling for demographics and acute injury severity indicated that individuals with previous TBI reported more mood symptoms, more postconcussive symptoms, lower life satisfaction, and had slower processing speed and poorer verbal learning, compared to those with no previous TBI history. These findings suggest that history of TBI with LOC may have important implications for health and psychological functioning after TBI in community-based samples.	[Dams-O'Connor, Kristen; Spielman, Lisa; Singh, Ayushi; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Manley, Geoffrey T.; Yue, John K.; Cooper, Shelly R.; Morabito, Diane J.; Sinha, Tuhin K.; Vassar, Mary J.; TRACK-TBI Investigators Including] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Mukherjee, Pratik; Yuh, Esther L.; Cheong, Maxwell] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Okonkwo, David O.; Puccio, Ava M.; Hricik, Allison J.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Schnyer, David M.; Knight, Emily E.; Pacheco, Jennifer L.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge CB2 2QQ, England	Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240B, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Mukherjee, Pratik/0000-0001-7473-7409; Cooper, Shelly/0000-0003-0026-6688	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RC2NS069409]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER	This work was aupported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (grant no.: 1RC2NS069409). This study is registered with ClinicalTrials.gov (identifier no.: NCT01565551). The authors gratefully acknowledge the contributions of Edwin Kulubya and Kerri Lawless to the implementation of the project and Tausif Billah for technical assistance with the manuscript.	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; Delis DC, 2000, CALIFORNIA VERBAL LE; Derogatis L., 2004, USE PSYCHOL TESTING, V3, P28; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; TEASDALE G, 1974, LANCET, V2, P81; Weathers F.W., 1991, PCL M DSM 4; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327; Yue JK, 2013, J NEUROTRAUM, DOI DOI 10.1089/NEU.2013.2970; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	36	62	62	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2014	2020		10.1089/neu.2013.3049			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500002	23924069	Green Published			2021-06-18	
J	Yang, SH; Gustafson, J; Gangidine, M; Stepien, D; Schuster, R; Pritts, TA; Goodman, MD; Remick, DG; Lentsch, AB				Yang, Sung H.; Gustafson, Josh; Gangidine, Matt; Stepien, David; Schuster, Rebecca; Pritts, Timothy A.; Goodman, Michael D.; Remick, Daniel G.; Lentsch, Alex B.			A murine model of mild traumatic brain injury exhibiting cognitive and motor deficits	JOURNAL OF SURGICAL RESEARCH			English	Article						TBI; Inflammation; Combat casualty care; Trauma; Cytokines; Chemokines	CLOSED-HEAD INJURY; AXONAL INJURY; INTERLEUKIN-6; SEPSIS; MORTALITY; RECOVERY; DISEASE; IMPACT; IL-6	Background: Mild traumatic brain injury (TBI) is a serious public health concern affecting more than 1.7 million people in the United States annually. Mild TBI is difficult to diagnose and is clinically associated with impaired motor coordination and cognition. Methods: We subjected mice to a mild TBI (mTBI-1 or mTBI-2) induced by a weight drop model. We assessed brain injury histologically and biochemically, the latter by serum neuron-specific enolase and glial fibrillary acidic protein. Systemic and brain inflammation were measured by cytokine array. We determined blood-brain barrier integrity by cerebral vascular leakage of micromolecular and macromolecular fluorescent molecules. We evaluated mice using a rotarod device and novel object recognition to measure motor coordination and cognition, respectively. Results: Mice undergoing mTBI-1 or mTBI-2 had significant deficits in motor coordination and cognition for several days after injury compared with controls. Furthermore, both mTBI-1 and mTBI-2 caused micromolecular leakage in the blood-brain barrier, whereas only mTBI-2 caused macromolecular leakage. Serum neuron-specific enolase and glial fibrillary acidic protein were elevated acutely and corresponded to the degree of injury, but returned to baseline within 24 h. Serum cytokines interleukin-6 and keratinocyte-derived chemokine were significantly increased within 90 min of TBI. Interleukin-6 levels correlated with the degree of injury. Conclusions: The current study provides a reproducible model of mild TBI in mice that exhibits pathologic features of mild TBI in humans. Furthermore, our data suggest that serum cytokines, such as IL-6, may be effective biomarkers for severity of head injury. (C) 2013 Elsevier Inc. All rights reserved.	[Yang, Sung H.; Gustafson, Josh; Gangidine, Matt; Schuster, Rebecca; Pritts, Timothy A.; Goodman, Michael D.; Lentsch, Alex B.] Univ Cincinnati, Dept Surg, Inst Mil Med, Cincinnati, OH 45267 USA; [Gustafson, Josh] Boonshoft Sch Med, Dept Surg, Dayton, OH USA; [Stepien, David; Remick, Daniel G.] Boston Univ, Dept Pathol, Boston, MA 02215 USA	Lentsch, AB (corresponding author), Univ Cincinnati, Dept Surg, Inst Mil Med, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA.	alex.lentsch@uc.edu		Pritts, Timothy/0000-0003-2495-3255; Stepien, David/0000-0002-3521-6210	United States Air ForceUnited States Department of Defense [FA8650-10-2-6B01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM08478]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478] Funding Source: NIH RePORTER	Supported by United States Air Force grant FA8650-10-2-6B01 and National Institutes of Health training grant T32 GM08478.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FOEX BA, 1993, INJURY, V24, P373, DOI 10.1016/0020-1383(93)90098-Q; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Michalski D, 2010, BRAIN RES, V1359, P186, DOI 10.1016/j.brainres.2010.08.045; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morey RA, 2012, HUM BRAIN M IN PRESS; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PATEL RT, 1994, BRIT J SURG, V81, P1306, DOI 10.1002/bjs.1800810914; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	29	62	63	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2013	184	2					981	988		10.1016/j.jss.2013.03.075			8	Surgery	Surgery	215XE	WOS:000324243500046	23622728	Green Accepted			2021-06-18	
J	Yeoh, S; Bell, ED; Monson, KL				Yeoh, Stewart; Bell, E. David; Monson, Kenneth L.			Distribution of Blood-Brain Barrier Disruption in Primary Blast Injury	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Vascular dysfunction; Immunohistology; Brain lesion	RATS; PRESSURE; EXPOSURE; MODEL	Traumatic brain injury (TBI) resulting from explosive-related blast overpressure is a topic at the forefront of neurotrauma research. Compromise of the blood-brain barrier (BBB) and other cerebral blood vessel dysfunction is commonly reported in both experimental and clinical studies on blast injury. This study used a rifle primer-driven shock tube to investigate cerebrovascular injury in rats exposed to low-impulse, pure primary blast at three levels of overpressure (145, 232, and 323 kPa) and with three survival times (acute, 24, and 48 h). BBB disruption was quantified immunohistochemically by measuring immunoglobulin G (IgG) extravasation with image analysis techniques. Pure primary blast generated small lesions scattered throughout the brain. The number and size of lesions increased with peak overpressure level, but no significant difference was seen between survival times. Despite laterally directed blast exposure, equal numbers of lesions were found in each hemisphere of the brain. These observations suggest that cerebrovascular injury due to primary blast is distinct from that associated with conventional TBI.	[Yeoh, Stewart; Bell, E. David; Monson, Kenneth L.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; [Monson, Kenneth L.] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA	Monson, KL (corresponding author), Univ Utah, Dept Bioengn, 50 S Cent Campus Dr,MEB 2132, Salt Lake City, UT 84112 USA.	ken.monson@utah.edu	Monson, Ken/L-4702-2019; Bell, E David/K-7196-2013	Monson, Ken/0000-0002-8461-6034	Department of DefenseUnited States Department of Defense [W81XWH-08-1-0295]	Funding for this research was provided by the Department of Defense (W81XWH-08-1-0295). The authors would like to acknowledge Jordan Walker and Louise Butler for assistance with tissue processing, imaging, and data analysis.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Cullis I G, 2001, J R Army Med Corps, V147, P16; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham DI, 1996, NEUROTRAUMA, P43; KLATZO I, 1987, Z KARDIOL, V76, P67; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mouritz A.P., 2001, COMPOS, V32, P431, DOI [DOI 10.1016/S1359-8368(01)00015-4, 10.1016/S1359-8368(01)00015-4]; Ohtake M, 2004, NEUROPATHOLOGY, V24, P219, DOI 10.1111/j.1440-1789.2004.00560.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2012, BLAST INDUCED BRAIN; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; WHITE CS, 1968, ANN NY ACAD SCI, V152, P89, DOI 10.1111/j.1749-6632.1968.tb11969.x	32	62	64	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2013	41	10					2206	2214		10.1007/s10439-013-0805-7			9	Engineering, Biomedical	Engineering	213QM	WOS:000324073200017	23568152				2021-06-18	
J	Kozlowski, KF; Graham, J; Leddy, JJ; Devinney-Boymel, L; Willer, BS				Kozlowski, Karl F.; Graham, James; Leddy, John J.; Devinney-Boymel, Lee; Willer, Barry S.			Exercise Intolerance in Individuals With Postconcussion Syndrome	JOURNAL OF ATHLETIC TRAINING			English	Article						brain injuries; concussions; treadmill test	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; UP-REGULATION; SYMPTOMS; RECOVERY; CHALLENGE; CAPACITY; STRESS	Context: Little is known about exercise intolerance or the utility of an exercise evaluation in patients with postconcussion syndrome (PCS). Objective: To assess exercise intolerance in male and female patients with PCS. Design: Cross-sectional study. Setting: Laboratory setting. Patients or Other Participants: Participants included a convenience sample of 34 patients with PCS (17 males, 17 females; age = 25.9 +/- 10.9 years) and 22 uninjured individuals on whom we gathered historical deidentified laboratory data (control group; 11 males, 11 females; age = 23.3 +/- 6.2 years). Main Outcome Measure(s): Self-reported symptoms, heart rate, systolic and diastolic blood pressures (BPs), and the Borg rating of perceived exertion were measured before, during each minute of, and immediately after a graded treadmill exercise test (Balke protocol). Exercise was stopped when participants could no longer maintain the effort or reported the onset of or increase in PCS symptoms. Results: Exercise test duration (8.5 +/- 4.4 minutes versus 17.9 +/- 3.6 minutes; t(51) = 1.8, P < .001), heart rate (142.8 +/- 24.1 versus 175.2 +/- 17.4; t(54) - -5.5, P < .001), and systolic BP (142.1 +/- 18.3 mm Hg versus 155.5 +/- 24.5 mm Hg; t(53) = 2.3, P = .02) were lower, and diastolic BP (78.4 +/- 10.2 mm Hg versus 73.5 +/- 11.7 mm Hg; t(53) = 2.2, P = .03) was higher at test cessation in the PCS than control group. Cox regression showed the odds of a shorter exercise duration were nearly 8 times greater in the PCS than control group (hazard ratio = 7.93; 95% confidence interval = 3.39, 18.56). In the general linear models that adjusted for differences in test duration, rating of perceived exertion was the only physiologic measure to show an overall difference between groups, with the control group reporting higher ratings than the PCS group (t(53) = -6.0, P < .001). Within the PCS group, systolic BP was the only measure to show a sex effect, with males showing higher pressure readings than females throughout the exercise tests (t(31) = 2.8, P = .009). Conclusions: Patients with PCS had a symptom-limited response to exercise, and the treadmill test was a potentially useful tool to monitor the recovery from PCS.	[Kozlowski, Karl F.] Canisius Coll, Dept Kinesiol, Buffalo, NY 14208 USA; [Graham, James] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Leddy, John J.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14260 USA; [Leddy, John J.] SUNY Buffalo, Sports Med Inst, Buffalo, NY 14260 USA; [Devinney-Boymel, Lee] SUNY Buffalo, Dept Exercise & Nutr Sci, Buffalo, NY 14260 USA; [Willer, Barry S.] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA	Kozlowski, KF (corresponding author), Canisius Coll, Koessler Ctr 173, 2001 Main St, Buffalo, NY 14208 USA.	karl.kozlowski@canisius.edu	Kozlowski, Karl/H-5253-2019				*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P704; American College of Sports Medicine, 2006, ACSMS GUID EX TEST P, P18; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dawes H, 2006, DISABIL REHABIL, V28, P1243, DOI 10.1080/09638280600554595; Dawes HN, 2005, ARCH PHYS MED REHAB, V86, P912, DOI 10.1016/j.apmr.2004.10.043; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Merritta C, 2010, INT J REHABIL RES, V33, P109, DOI 10.1097/MRR.0b013e32832e6b37; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; World Health Organization, 1993, ICD 10 CLASS MENT BE, P63	36	62	63	0	16	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2013	48	5					627	635		10.4085/1062-6050-48.5.02			9	Sport Sciences	Sport Sciences	268AR	WOS:000328140600006	23952041	Green Published, Bronze			2021-06-18	
J	Chamard, E; Lassonde, M; Henry, L; Tremblay, J; Boulanger, Y; De Beaumont, L; Theoret, H				Chamard, Emilie; Lassonde, Maryse; Henry, Luke; Tremblay, Julie; Boulanger, Yvan; De Beaumont, Louis; Theoret, Hugo			Neurometabolic and microstructural alterations following a sports-related concussion in female athletes	BRAIN INJURY			English	Article						Diffusion tensor imaging; magnetic resonance spectroscopy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; GENDER-DIFFERENCES; HEAD ACCELERATION; METABOLIC-CHANGES; SEX-DIFFERENCES; WHITE-MATTER; POSTCONCUSSION SYMPTOMS; DIFFUSION; ABNORMALITIES	Background: Sports-related concussions are a major public health concern affecting millions of individuals annually. Neurometabolic and microstructural alterations have been reported in the chronic phase following a concussion in male athletes, while no study has investigated these alterations in female athletes. Methods: Neurometabolic and microstructural alterations following a concussion were investigated by comparing 10 female athletes with a concussion and 10 control female athletes, using magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI). Athletes with concussion were scanned at least 7 months post-concussion (mean = 18.9 months). Results: MRS revealed a significant lower level of myo-inositol in the hippocampus and the primary motor cortices (M1) bilaterally. DTI analysis using Tract-Based Spatial Statistics (TBSS) showed no difference in fractional anisotropy (FA) while higher level of mean diffusivity (MD) in athletes with concussion was detected in large white matter tracts including the forceps minors, inferior/superior longitudinal fasciculi, inferior fronto-occipital fasciculus, cingulum, uncinate fasciculus, anterior thalamic radiations and corticospinal tract. Moreover, a region of interest approach for the corpus callosum revealed a significant lower level of FA in the segment containing fibres projecting to M1. Conclusions: This study demonstrates persistent neurometabolic and microstructural alterations in female athletes suffering a sports-related concussion.	[Chamard, Emilie; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H2V 2S9, Canada; [Henry, Luke] UPMC Sports Concuss Clin, Pittsburgh, PA USA; [Tremblay, Julie] Hop Ste Justine, Montreal, PQ, Canada; [Boulanger, Yvan] Univ Montreal, Dept Radiol, Montreal, PQ H2V 2S9, Canada; [Boulanger, Yvan] Hop St Luc, Montreal, PQ H2X 1P1, Canada; [De Beaumont, Louis] UQTR, Ctr Rech Neuropsychol & Cognit, Dept Psychol, Montreal, PQ, Canada	Chamard, E (corresponding author), Univ Montreal, Dept Psychol, 90 Ave Vincent DIndy, Montreal, PQ H2V 2S9, Canada.	emilie.chamard@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797			Acosta-Cabronero J, 2010, BRAIN, V133, P529, DOI 10.1093/brain/awp257; Andersson J.L.R., 2007, NONLINEAR REGISTRATI; Andersson JLR, 2007, TR07JA9 FMRIB CTR; BADARGOFFER RS, 1992, BIOCHEM J, V282, P225, DOI 10.1042/bj2820225; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barr M., 2005, HUMAN NERVOS SYSTEM; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bear MF., 2007, NEUROSCIENCE EXPLORI, V3; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Braun CMJ, 2002, LATERALITY, V7, P97, DOI 10.1080/13576500143000212; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Castillo M, 2000, AM J NEURORADIOL, V21, P1645; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cotran R.S., 1994, ROBBINS PATHOLOGIC B, P1; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Esposito G, 1996, J NUCL MED, V37, P559; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Geurts JJG, 2004, J MAGN RESON IMAGING, V20, P366, DOI 10.1002/jmri.20138; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kandel E, 2000, PRINCIPLES NEUROSCIE; King KG, 2008, RADIOLOGY, V249, P242, DOI 10.1148/radiol.2491071500; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Szentkuti A, 2004, J NEUROL, V251, P1345, DOI 10.1007/s00415-004-0540-y; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Toga A.W., 2002, BRAIN MAPPING METHOD; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zimmerman ME, 2008, NEUROLOGY, V70, P1594, DOI 10.1212/01.wnl.0000306314.77311.be	75	62	62	0	40	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1038	1046		10.3109/02699052.2013.794968			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100008	23834633				2021-06-18	
J	Beckwith, JG; Greenwald, RM; Chu, JJ; Crisco, JJ; Rowson, S; Duma, SM; Broglio, SP; Mcallister, TW; Guskiewicz, KM; Mihalik, JP; Anderson, S; Schnebel, B; Brolinson, PG; Collins, MW				Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.; Crisco, Joseph J.; Rowson, Steven; Duma, Stefan M.; Broglio, Steven P.; Mcallister, Thomas W.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Anderson, Scott; Schnebel, Brock; Brolinson, P. Gunnar; Collins, Michael W.			Timing of Concussion Diagnosis Is Related to Head Impact Exposure Prior to Injury	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HIT SYSTEM; IMPACT BIOMECHANICS; MILD TRAUMATIC BRAIN INJURY (mTBI); TRAUMATIC BRAIN INJURY (TBI); INJURY THRESHOLD; SYMPTOMATOLOGY	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL FOOTBALL; ACCELERATION; BIOMECHANICS; KINEMATICS; MAGNITUDE; LOCATION	BECKWITH, J. G., R. M. GREENWALD, J. J. CHU, J. J. CRISCO, S. ROWSON, S. M. DUMA, S. P. BROGLIO, T. W. MCALLISTER, K. M. GUSKIEWICZ, J. P. MIHALIK, S. ANDERSON, B. SCHNEBEL, P. G. BROLINSON, and M. W. COLLINS. Timing of Concussion Diagnosis Is Related to Head Impact Exposure Prior to Injury. Med. Sci. Sports Exerc., Vol. 45, No. 4, pp. 747-754, 2013. Purpose: Concussions are commonly undiagnosed in an athletic environment because the postinjury signs and symptoms may be mild, masked by the subject, or unrecognized. This study compares measures of head impact frequency, location, and kinematic response before cases of immediate and delayed concussion diagnosis. Methods: Football players from eight collegiate and six high school teams wore instrumented helmets during play (n = 1208), of which 95 were diagnosed with concussion (105 total cases). Acceleration data recorded by the instrumented helmets were reduced to five kinematic metrics: peak linear and rotational acceleration, Gadd severity index, head injury criterion, and change in head velocity (Delta v). In addition, each impact was assigned to one of four general location regions (front, back, side, and top), and the number of impacts sustained before injury was calculated over two periods (1 and 7 days). Results: All head kinematic measures associated with injury, except peak rotational acceleration (P = 0.284), were significantly higher for cases of immediate diagnosis than delayed diagnosis (P < 0.05). Players with delayed diagnosis sustained a significantly higher number of head impacts on the day of injury (32.9 +/- 24.9, P < 0.001) and within 7 d of injury (69.7 +/- 43.3, P = 0.006) than players with immediate diagnosis (16.5 +/- 15.1 and 50.2 +/- 43.6). Impacts associated with concussion occurred most frequently to the front of the head (46%) followed by the top (25%), side (16%), and back (13%) with the number of impacts by location independent of temporal diagnosis (chi(2)(3) = 4.72, P = 0.19). Conclusions: Concussions diagnosed immediately after an impact event are associated with the highest kinematic measures, whereas those characterized by delayed diagnosis are preceded by a higher number of impacts.	[Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH 03766 USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, Joseph J.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Broglio, Steven P.] Michigan NeuroSport, Ann Arbor, MI USA; [Mcallister, Thomas W.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Anderson, Scott] Univ Oklahoma, Dept Intercollegiate Athlet, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA	Beckwith, JG (corresponding author), Simbex, 10 Water St,Suite 410, Lebanon, NH 03766 USA.	jbeckwith@simbex.com	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596; Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R01NS055020]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, 5R49CE000196]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000196, R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by award R01HD048638 and R01NS055020 from the National Institute of Health, R01CE001254 and 5R49CE000196 from the Centers for Disease Control and Prevention, and NOCSAE (07-04, 14-19). HIT System technology was developed in part under NIH R44HD40473 and research and development support from Riddell, Inc. (Chicago, IL).	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hodgson VR, 1976, MEASUREMENT PREDICTI, V31, P121; Hodgson VR, 1970, 700901 SAE, DOI [10.4271/700901, DOI 10.4271/700901]; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	32	62	62	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2013	45	4					747	754		10.1249/MSS.0b013e3182793067			8	Sport Sciences	Sport Sciences	109ZK	WOS:000316410600018	23135364	Green Accepted			2021-06-18	
J	Lingsma, H; Andriessen, TMJC; Haitsema, I; Horn, J; van der Naalt, J; Franschman, G; Maas, AIR; Vos, PE; Steyerberg, EW				Lingsma, Hester; Andriessen, Teuntje M. J. C.; Haitsema, Iain; Horn, Janneke; van der Naalt, Joukje; Franschman, Gaby; Maas, Andrew I. R.; Vos, Pieter E.; Steyerberg, Ewout W.			Prognosis in moderate and severe traumatic brain injury: External validation of the IMPACT models and the role of extracranial injuries	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; trauma; prognosis; prognostic model; validation	HEAD-INJURY; PREDICTION	BACKGROUND: Several prognostic models to predict outcome in traumatic brain injury (TBI) have been developed, but few are externally validated. We aimed to validate the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) prognostic models in a recent unselected patient cohort and to assess the additional prognostic value of extracranial injury. METHODS: The Prospective Observational COhort Neurotrauma (POCON) registry contains 508 patients with moderate or severe TBI, who were admitted in 2008 and 2009 to five trauma centers in the Netherlands. We predicted the probability of mortality and unfavorable outcome at 6 months after injury with the IMPACT prognostic models. We studied discrimination (area under the curve [AUC]) and calibration. We added the extracranial component of the Injury Severity Score (ISS) to the models and calculated the increase in AUC. RESULTS: The IMPACT models had an adequate discrimination in the POCON registry, with AUCs in the external validation between 0.85 and 0.90 for mortality and between 0.82 and 0.87 for unfavorable outcome. Observed outcomes agreed well with predicted outcomes. Adding extracranial injury slightly improved predictions in the overall population (unfavorable outcome: AUC increase of 0.002, p = 0.02; mortality: AUC increase of 0.000, p = 0.37) but more clearly in patients with moderate TBI (unfavorable outcome: AUC increase of 0.008, p < 0.01, mortality: AUC increase of 0.012, p = 0.02) and patients with minor computed tomographic result abnormalities (unfavorable outcome: AUC increase of 0.013, p < 0.01; mortality: AUC increase of 0.001, p = 0.08). CONCLUSION: The IMPACT models performed well in a recent series of TBI patients. We found some additional impact of extracranial injury on outcome, specifically in patients with less severe TBI or minor computed tomographic result abnormalities. (J Trauma Acute Care Surg. 2013;74: 639-646. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Lingsma, Hester; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Haitsema, Iain] Erasmus MC, Ctr Med Decis Making, Dept Neurosurg, Rotterdam, Netherlands; [Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Franschman, Gaby] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium	Lingsma, H (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	Steyerberg, Ewout W/C-1509-2018; Maas, Andrew IR/C-5584-2013	Steyerberg, Ewout W/0000-0002-7787-0122; Maas, Andrew IR/0000-0003-1612-1264	Dutch Brain Foundation [HSN-07-01]	The POCON study is funded by the Dutch Brain Foundation (Hersenstichting, HSN-07-01). We thank Dick Drost, Annemiek Coers, Annelou van der Veen, Joshua Field, and Vivian de Ruijter for their help with the data collection. We thank Amon Heijne for his help with the development and maintenance of the POCON database and Carel Gosling (Trauma Unit AMC) for providing us with emergency department admission data.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Roozenbeek B, 2012, J NEUROTRAUM, P133; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek Bob, 2012, Clin Investig (Lond), V2, P153; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223	23	62	63	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					639	646		10.1097/TA.0b013e31827d602e			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	108UH	WOS:000316321200059	23354263	Green Published			2021-06-18	
J	Ponsford, J				Ponsford, Jennie			Factors contributing to outcome following traumatic brain injury	NEUROREHABILITATION			English	Article						Traumatic brain injury; outcome; prediction	POSTTRAUMATIC AMNESIA DURATION; QUALITY-OF-LIFE; HEAD-INJURY; PSYCHOSOCIAL ADJUSTMENT; ALZHEIMERS-DISEASE; GENDER-DIFFERENCES; PSYCHIATRIC-DISORDERS; COGNITIVE RECOVERY; COPING STRATEGIES; PROGNOSTIC VALUE	BACKGROUND: Traumatic brain injury results in some distinctive patterns of cognitive, behavioural and physical impairment which impact significantly on independent living skills and participation in work or study, social and leisure activities and interpersonal relationships. There is, however, still considerable variability in outcome across individuals in each of the reported domains. This has led to a significant body of research examining factors associated with outcome. A range of injury-related, personal and social factors have been shown to influence survival, as well as cognitive, functional and employment outcome. METHODS: This paper reviews the factors associated with each of these aspects of outcome specifically injury-related factors, including neuroimaging findings, GCS and PTA, other injuries, and cognitive and behavioural impairments; demographic factors, including age, gender, genetic status, education, pre-injury IQ and employment status; and social factors including family and other social support, cultural factors, pre-injury psychiatric history and coping style. CONCLUSION: The paper identifies contributions and complex interrelationships of all of these factors to outcome following TBI. It concludes with a brief discussion of the implications of these factors for the rehabilitation process.	Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	Jennie.ponsford@monash.edu					Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Alway Y, 2012, NEUROPSYCHOL REHABIL, V22, P374, DOI 10.1080/09602011.2011.648757; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; CORKIN S, 1989, J NEUROSCI, V9, P3876; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Czosnyka M, 2008, ACTA NEUROCHIR SUPPL, V102, P25, DOI 10.1007/978-3-211-85578-2_5; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Eastvold AD, 2013, J HEAD TRAUMA REHAB, V28, P48, DOI 10.1097/HTR.0b013e31823c9317; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kendall E, 2009, SOC SCI MED, V69, P947, DOI 10.1016/j.socscimed.2009.06.021; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lannsjo M., 2012, EUROPEAN J NEUROLOGY, DOI [10.1111/j.1468-1331.2012.03813x, DOI 10.1111/J.1468-1331.2012.03813X]; Lazarus R.S., 1984, STRESS APPRAISAL COP; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park JE, 2009, J KOREAN NEUROSURG S, V45, P90, DOI 10.3340/jkns.2009.45.2.90; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P1; Ponsford J, 2012, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Ponsford J, 2010, BRAIN IMPAIR, V11, P253, DOI 10.1375/brim.11.3.253; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Poon WS, 2005, ACT NEUR S, V93, P207; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Saltapidas H, 2008, BRAIN IMPAIR, V9, P1, DOI 10.1375/brim.9.1.1; Saltapidas H, 2007, J HEAD TRAUMA REHAB, V22, P132, DOI 10.1097/01.HTR.0000265101.75177.8d; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Senathi-Raja D, 2010, J HEAD TRAUMA REHAB, V25, P330, DOI 10.1097/HTR.0b013e3181ccc893; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Senathi-Raja D, 2009, J REHABIL MED, V41, P666, DOI 10.2340/16501977-0396; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wolters Gregorio G., J HEAD TRAU IN PRESS; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2013, J HEAD TRAUMA REHAB, V28, P98, DOI 10.1097/HTR.0b013e3182426029; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	128	62	63	1	52	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	4					803	815		10.3233/NRE-130904			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	184QF	WOS:000321907100011	23867406				2021-06-18	
J	Quintana, A; Erta, M; Ferrer, B; Comes, G; Giralt, M; Hidalgo, J				Quintana, Albert; Erta, Maria; Ferrer, Beatriz; Comes, Gemma; Giralt, Mercedes; Hidalgo, Juan			Astrocyte-specific deficiency of interleukin-6 and its receptor reveal specific roles in survival, body weight and behavior	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Interleukin-6; Astrocyte; Intrauterine survival; Body weight; Normal behavior	TUMOR-NECROSIS-FACTOR; ELEVATED PLUS-MAZE; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; CYTOKINE RECEPTORS; GENE-EXPRESSION; KNOCKOUT MICE; RAT BEHAVIOR; IL-6	Interleukin-6 (IL-6) is a major cytokine which controls not only the immune system but also exhibits many other functions including effects in the central nervous system (CNS). IL-6 is known to be produced by different cells in the CNS, and all the major CNS do respond to IL-6, which makes it difficult to dissect the specific roles of each cell type when assessing the role of IL-6 in the brain. We have produced for the first time foxed mice for IL-6 and have crossed them with GFAP-Cre mice to delete IL-6 in astrocytes (Ast-IL-6 KO mice), and have compared their phenotype with that of mice with deletion of IL-6 receptor in astrocytes (Ast-IL6R KO mice). Our results indicate a major prosurvival role of the astrocyte IL-6 system at early ages (intrauterine life), which was also involved to various degrees in the control of adult body weight, locomotor activity, anxiety and exploratory behaviors. In some occasions deleting IL-6R in astrocytes mimicked the phenotype of Ast-IL-6 KO mice (i.e. activity), while in others the opposite was observed (i.e. exploration), suggesting autocrine and paracrine (presumably on neurons) roles of astrocyte IL-6. Our results suggest important roles of the astrocyte IL-6 system on normal brain physiology, in some cases totally unexpected from previous results with total IL-6 KO mice. (C) 2012 Elsevier Inc. All rights reserved.	[Quintana, Albert; Erta, Maria; Ferrer, Beatriz; Comes, Gemma; Giralt, Mercedes; Hidalgo, Juan] Univ Autonoma Barcelona, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Fac Biociencias, E-08193 Barcelona, Spain; [Quintana, Albert; Erta, Maria; Ferrer, Beatriz; Comes, Gemma; Giralt, Mercedes; Hidalgo, Juan] Univ Autonoma Barcelona, Inst Neurosci, E-08193 Barcelona, Spain	Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Fac Biociencias, Edificio C, E-08193 Barcelona, Spain.	juan.hidalgo@uab.es	Quintana, Albert/N-5544-2015; Hidalgo, Juan/C-9082-2011; Giralt, Mercedes/K-1626-2014	Quintana, Albert/0000-0003-1674-7160; Hidalgo, Juan/0000-0003-0921-1122; Giralt, Mercedes/0000-0002-1806-1528; COMES, GEMMA/0000-0002-4074-7665	FP6 Integrated Project Exgenesis [LSHM-CT-2004-005272]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission; Ministerio de Ciencia e InnovacionInstituto de Salud Carlos IIISpanish GovernmentEuropean Commission [RETICS (REEM, RD07/0060/0002)]; UAB;  [SAF2008-00435];  [SAF2011-23272]	The authors acknowledge the collaboration of the Unit of Transgenic Animals, CBATEG, from the Universitat Autonoma de Barcelona, for generating the IL-6 floxed mice, and especially the collaboration of Richard Palmiter for the generation of the IL-6 construct. The help of Jordi Mann with the HB and EPM programs is gratefully acknowledged. This work was supported by SAF2008-00435, SAF2011-23272, FP6 Integrated Project Exgenesis (LSHM-CT-2004-005272), and by Instituto de Salud Carlos III and Ministerio de Ciencia e Innovacion-Fondo Europeo de Desarrollo Regional (FEDER), ref. RETICS (REEM, RD07/0060/0002) to JH. Maria Erta gratefully acknowledges a PhD fellowship from UAB.	Alleva E, 1998, EUR J NEUROSCI, V10, P3664, DOI 10.1046/j.1460-9568.1998.00377.x; ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; Armario A, 1998, J NEUROIMMUNOL, V92, P160, DOI 10.1016/S0165-5728(98)00199-4; Baier PC, 2009, BEHAV BRAIN RES, V200, P192, DOI 10.1016/j.bbr.2009.01.013; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054; Benrick A, 2009, J NEUROENDOCRINOL, V21, P620, DOI 10.1111/j.1365-2826.2009.01879.x; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BOISSIER J R, 1962, Therapie, V17, P1225; Braida D, 2004, BEHAV BRAIN RES, V153, P423, DOI 10.1016/j.bbr.2003.12.018; Burton MD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-54; Butterweck V, 2003, BEHAV BRAIN RES, V144, P49, DOI 10.1016/S0166-4328(03)00059-7; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; Chesnokova V, 2002, ENDOCRINOLOGY, V143, P1571, DOI 10.1210/en.143.5.1571; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Chourbaji S, 2006, NEUROBIOL DIS, V23, P587, DOI 10.1016/j.nbd.2006.05.001; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; DALRYMPLE SA, 1995, INFECT IMMUN, V63, P2262, DOI 10.1128/IAI.63.6.2262-2268.1995; Deverman BE, 2009, NEURON, V64, P61, DOI 10.1016/j.neuron.2009.09.002; Di Gregorio GB, 2004, AM J PHYSIOL-ENDOC M, V287, pE182, DOI 10.1152/ajpendo.00189.2003; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Ellingsgaard H, 2008, P NATL ACAD SCI USA, V105, P13163, DOI 10.1073/pnas.0801059105; Faldt J, 2004, ENDOCRINOLOGY, V145, P2680, DOI 10.1210/en.2003-1319; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Fernandes C, 1999, PHARMACOL BIOCHEM BE, V64, P731, DOI 10.1016/S0091-3057(99)00139-2; FILE SE, 1975, PSYCHOPHARMACOLOGIA, V44, P53, DOI 10.1007/BF00421184; Garcia-Oscos F, 2012, BIOL PSYCHIAT, V71, P574, DOI 10.1016/j.biopsych.2011.11.018; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Hidalgo J, 2010, BRAIN BEHAV IMMUN, V24, P119, DOI 10.1016/j.bbi.2009.09.002; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; Kasckow JW, 1997, ENDOCRINOLOGY, V138, P4774, DOI 10.1210/en.138.11.4774; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Marz P, 1999, EUR J NEUROSCI, V11, P2995, DOI 10.1046/j.1460-9568.1999.00755.x; McFarland-Mancini MM, 2010, J IMMUNOL, V184, P7219, DOI 10.4049/jimmunol.0901929; Murphy PG, 1999, EUR J NEUROSCI, V11, P2243, DOI 10.1046/j.1460-9568.1999.00641.x; Nadal R., 2006, TASKS TECHNIQUES SAM, P25; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Quintana A, 2010, P NATL ACAD SCI USA, V107, P10996, DOI 10.1073/pnas.1006214107; RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M; Rose-John S, 2007, EXPERT OPIN THER TAR, V11, P613, DOI 10.1517/14728222.11.5.613; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; Schele E, 2012, J NEUROENDOCRINOL, V24, P930, DOI 10.1111/j.1365-2826.2012.02286.x; SCHINDLER R, 1990, BLOOD, V75, P40; Senaris RM, 2011, J NEUROENDOCRINOL, V23, P675, DOI 10.1111/j.1365-2826.2011.02158.x; SHELLARD SA, 1993, ANTI-CANCER DRUG, V4, P491, DOI 10.1097/00001813-199308000-00011; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Stalder AK, 1998, AM J PATHOL, V153, P767, DOI 10.1016/S0002-9440(10)65620-9; Swiergiel AH, 2006, BEHAV BRAIN RES, V171, P94, DOI 10.1016/j.bbr.2006.03.024; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Vereyken EJF, 2007, EUR J NEUROSCI, V25, P3605, DOI 10.1111/j.1460-9568.2007.05615.x; Vgontzas AN, 1999, J CLIN ENDOCR METAB, V84, P2603, DOI 10.1210/jc.84.8.2603; Wallenius K, 2002, BIOCHEM BIOPH RES CO, V293, P560, DOI 10.1016/S0006-291X(02)00230-9; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wang XQ, 2009, ANNU REV IMMUNOL, V27, P29, DOI 10.1146/annurev.immunol.24.021605.090616; Wernstedt I, 2006, AM J PHYSIOL-REG I, V291, pR551, DOI 10.1152/ajpregu.00514.2005	67	62	64	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591			BRAIN BEHAV IMMUN	Brain Behav. Immun.	JAN	2013	27						162	173		10.1016/j.bbi.2012.10.011			12	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	058JE	WOS:000312629100020	23085146				2021-06-18	
J	Sarkaki, AR; Haddad, MK; Soltani, Z; Shahrokhi, N; Mahmoodi, M				Sarkaki, Ali Reza; Haddad, Mohammad Khaksari; Soltani, Zahra; Shahrokhi, Nader; Mahmoodi, Mehdi			Time- and Dose-Dependent Neuroprotective Effects of Sex Steroid Hormones on Inflammatory Cytokines after a Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; IL-1 beta; IL-6; TNF-alpha; TGF-beta	TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR EXPRESSION; C-REACTIVE PROTEIN; RAT-BRAIN; CEREBROSPINAL-FLUID; CEREBRAL TRAUMA; NERVOUS-SYSTEM; MESSENGER-RNA; PROGESTERONE; RECEPTOR	Following a traumatic brain injury (TBI), excessive release of proinflammatory cytokines is the major cause of cerebral edema and neuronal loss. This study was designed to examine changes in concentrations of some proinflammatory cytokines-including interleukin-1 beta (IL-1 beta), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta)-in a rat model of TBI in which the animals were treated with different doses of estrogen or progesterone 6 and 24 h after the TBI. Adult female rats were divided into 14 groups. Hormones or vehicle were given intraperitoneally 30 min after a moderate TBI was induced by the Marmarou method. The levels of proinflammatory cytokines in brain were measured at 6 and 24 h after the TBI. A high dose of estrogen (E2) or a low dose of progesterone (P1) increased brain levels of IL-1 beta 52.7% and 79.2% respectively at 6 h after the TBI. By 24h, IL-1 beta levels in the brain were 27.5% and 27% lower following administration of estrogen low dose (E1) or E2, respectively. High-dose administration of progesterone reduced brain levels of IL-6 to 45.9% at 6 h after the TBI, and P1 and E1 treatment significantly decreased IL-6 levels at 24 h. Brain levels of TNF-alpha were 72.5% lower at 6 h after the TBI following P2 treatment and 48.5% higher at 24 hrs following treatment with E2. The levels of TGF-beta were also 3.37 times higher 24 h after the TBI following treatment with E1. Both doses of the hormones tested increases TGF-beta levels 6 h after the TBI. Based on our findings, we conclude that progesterone and estrogen influence the levels of proinflammatory cytokines either at the primary or secondary stages after a TBI. Accordingly, this study suggests a mechanism by which hormones reduce cerebral edema.	[Sarkaki, Ali Reza] Ahwaz Univ Med Sci, Physiol Res Ctr, Ahwaz, Iran; [Haddad, Mohammad Khaksari; Shahrokhi, Nader] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Bam Int Unit, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Physiol Res Ctr, Sch Med, Kerman, Iran; [Mahmoodi, Mehdi] Rafsanjan Univ Med Sci, Dept Biochem, Rafsanjan, Iran	Haddad, MK (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Sch Med, Kerman, Iran.	khaksar38@yahoo.co.uk	Soltani, Zahra/AAC-1350-2019; Shahrokhi, Nader/AAV-3747-2020; Sarkaki, Alireza/Q-8363-2017; Mahmoodi, Mehdi/H-2754-2017; Haddad, Mohammad Khaksari/AAB-9025-2019	Soltani, Zahra/0000-0002-8423-6189; Shahrokhi, Nader/0000-0002-0149-7819; Sarkaki, Alireza/0000-0001-9272-6228; Mahmoodi, Mehdi/0000-0002-8463-8364; Haddad, Mohammad Khaksari/0000-0003-0770-4281	Kerman Neuroscience Center; Ahwaz Physiology Research Center	The present study was financially supported by the Kerman Neuroscience and Ahwaz Physiology Research Centers.	Bartfai T, 2007, ANN NY ACAD SCI, V1113, P173, DOI 10.1196/annals.1391.022; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Crandall C, 2006, J WOMENS HEALTH, V15, P14, DOI 10.1089/jwh.2006.15.14; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; Das C, 2002, J REPROD IMMUNOL, V53, P257, DOI 10.1016/S0165-0378(01)00099-7; DOREDUFFY P, 1994, MOL CHEM NEUROPATHOL, V22, P161, DOI 10.1007/BF03160103; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fee DB, 2004, BRAIN RES, V1012, P52, DOI 10.1016/j.brainres.2004.03.028; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hatthachote P, 1999, ENDOCRINOLOGY, V140, P2533, DOI 10.1210/en.140.6.2533; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Hoffman S. W, 2001, ACAD EMERG MED, V8, P496; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Houdeau E, 2007, GASTROENTEROLOGY, V132, P982, DOI 10.1053/j.gastro.2006.12.028; Hrekova S P, 2002, Fiziol Zh, V48, P63; Hussein Mohamed Z, 2004, Egypt J Immunol, V11, P165; Jain SK, 2004, CYTOKINE, V26, P102, DOI 10.1016/j.cyto.2004.01.002; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Jonsson Daniel, 2007, Swed Dent J Suppl, P11; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Lacut K, 2003, THROMB HAEMOSTASIS, V90, P124; LaMarca BD, 2007, AM J HYPERTENS, V20, P1216, DOI 10.1016/j.amjhyper.2007.07.002; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; molaie L Ahmad, 2007, J KERMAN U MED SCI, V15, P47; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rostworowski M, 1997, J NEUROSCI, V17, P3664; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shifren JL, 2008, J CLIN ENDOCR METAB, V93, P1702, DOI 10.1210/jc.2007-2193; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Soltani Z., 2009, Iranian Journal of Endocrinology and Metabolism, V10, P629; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Won CK, 2006, J VET MED SCI, V68, P277, DOI 10.1292/jvms.68.277; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Yuan K, 2002, J PERIODONTOL, V73, P701, DOI 10.1902/jop.2002.73.7.701	58	62	67	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					47	54		10.1089/neu.2010.1686			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300008	21851230	Green Accepted			2021-06-18	
J	Budohoski, KP; Czosnyka, M; de Riva, N; Smielewski, P; Pickard, JD; Menon, DK; Kirkpatrick, PJ; Lavinio, A				Budohoski, Karol P.; Czosnyka, Marek; de Riva, Nicolas; Smielewski, Peter; Pickard, John D.; Menon, David K.; Kirkpatrick, Peter J.; Lavinio, Andrea			The Relationship Between Cerebral Blood Flow Autoregulation and Cerebrovascular Pressure Reactivity After Traumatic Brain Injury	NEUROSURGERY			English	Article						Cerebral autoregulation; Cerebrovascular reactivity; Intracranial pressure; Transcranial Doppler; Traumatic brain injury	HEAD-INJURY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; SUBARACHNOID HEMORRHAGE; VASOMOTOR REACTIVITY; PULSE PRESSURE; HYPERTENSION; OXYGEN; CRANIECTOMY; CIRCULATION	BACKGROUND: Cerebrovascular pressure reactivity is the principal mechanism of cerebral autoregulation. Assessment of cerebral autoregulation can be performed by using the mean flow index (Mx) based on transcranial Doppler ultrasonography. Cerebrovascular pressure reactivity can be monitored by using the pressure reactivity index (PRx), which is based on intracranial pressure monitoring. From a practical point of view, PRx can be monitored continuously, whereas Mx can only be monitored in short periods when transcranial Doppler probes can be applied. OBJECTIVE: To assess to what degree impairment in pressure reactivity (PRx) is associated with impairment in cerebral autoregulation (Mx). METHODS: A database of 345 patients with traumatic brain injury was screened for data availability including simultaneous Mx and PRx monitoring. Absolute differences, temporal changes, and association with outcome of the 2 indices were analyzed. RESULTS: A total of 486 recording sessions obtained from 201 patients were available for analysis. Overall a moderate correlation between Mx and PRx was found (r = 0.58; P < .001). The area under the receiver operator characteristic curve designed to detect the ability of PRx to predict impaired cerebral autoregulation was 0.700 (95% confidence interval: 0.607-0.880). Discrepancies between Mx and PRx were most pronounced at an intracranial pressure of 30 mm Hg and they were significantly larger for patients who died (P = .026). Both Mx and PRx were significantly lower at day 1 postadmission in patients who survived than in those who died (P < .01). CONCLUSION: There is moderate agreement between Mx and PRx. Discrepancies between Mx and PRx are particularly significant in patients with sustained intracranial hypertension. However, for clinical purposes, there is only limited interchangeability between indices.	[Budohoski, Karol P.; Czosnyka, Marek; de Riva, Nicolas; Smielewski, Peter; Pickard, John D.; Kirkpatrick, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 2QQ, England; [de Riva, Nicolas] Univ Barcelona, Dept Anaesthesiol, Hosp Clin Barcelona, Barcelona, Spain; [Pickard, John D.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge CB2 2QQ, England; [Lavinio, Andrea] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Dept Anaesthesia, Cambridge, England	Budohoski, KP (corresponding author), Mazovia Brodnowski Hosp, Med Ctr Postrgrad Training, Dept Neurosurg, Ul Kondratowicza 8, PL-03242 Warsaw, Poland.		de Riva, Nicolas/AAN-3347-2020; Lavinio, Andrea/M-1778-2016	de Riva, Nicolas/0000-0003-2691-5770; Smielewski, Peter/0000-0001-5096-3938	National Institute of Health ResearchNational Institute for Health Research (NIHR); Biomedical Research Centre (Neuroscience Theme); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Clifford and Mary Corbridge Trust of Robinson College, Cambridge, UK; St. Catharine's College, University of Cambridge; Hospital Clinic de Barcelona, Barcelona, Spain; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This work was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (grants G0600986 and G9439390), and National Institute of Health Research Senior Investigator Awards (to J. D. P. and D. K. M.); by the Clifford and Mary Corbridge Trust of Robinson College, Cambridge, UK, and the St. Catharine's College, University of Cambridge Travel and Research Fund (to K. P. B.); by the Hospital Clinic de Barcelona, Barcelona, Spain (NdR). ICM+ software (Cambridge Enterprise, Cambridge, UK http://www.neurosurg.cam.ac.uk/icmplus/) is licensed by the University of Cambridge, Cambridge Enterprise Ltd. P. S. and M. C. have a financial interest in a part of licensing fee. J. D. P. and M. C. are directors of Technicam, UK. The other authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	AVEZAAT CJJ, 1980, J NEUROL NEUROSUR PS, V43, P222, DOI 10.1136/jnnp.43.3.222; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; Bijlenga P, 2010, NEUROCRIT CARE, V13, P17, DOI 10.1007/s12028-010-9362-1; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 1997, NEUROSURGERY, V41, P17; Czosnyka M, 2008, ANESTH ANALG, V106, P234, DOI 10.1213/01.ane.0000295802.89962.13; Eide PK, 2007, NEUROL RES, V29, P578, DOI 10.1179/016164107X172167; HARPER AM, 1966, J NEUROL NEUROSUR PS, V29, P398, DOI 10.1136/jnnp.29.5.398; Haubrich C, 2011, J NEUROTRAUM, V28, P1133, DOI 10.1089/neu.2010.1577; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LASSEN NA, 1959, PHYSIOL REV, V39, P183; LASSEN NA, 1964, CIRC RES, V15, P201; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Ogoh S, 2010, J APPL PHYSIOL, V108, P538, DOI 10.1152/japplphysiol.01235.2009; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 2002, J NEUROTRAUM, V19, P1127, DOI 10.1089/08977150260337949; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	39	62	66	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2012	71	3					652	660		10.1227/NEU.0b013e318260feb1			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	996HB	WOS:000308074400030	22653390				2021-06-18	
J	Karver, CL; Wade, SL; Cassedy, A; Taylor, HG; Stancin, T; Yeates, KO; Walz, NC				Karver, Christine L.; Wade, Shari L.; Cassedy, Amy; Taylor, H. Gerry; Stancin, Terry; Yeates, Keith Owen; Walz, Nicolay C.			Age at Injury and Long-Term Behavior Problems After Traumatic Brain Injury in Young Children	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; long-term behavior problems; young children	SOCIAL-BEHAVIOR; PSYCHIATRIC-DISORDERS; ANTISOCIAL-BEHAVIOR; SUSTAINED ATTENTION; CONSTRUCT-VALIDITY; EXECUTIVE FUNCTION; SELF-REGULATION; EARLY-CHILDHOOD; HEAD-INJURY; OUTCOMES	Objective: This study examined the effects of age at injury on the persistence of behavior problems and social skill deficits in young children with complicated mild to severe traumatic brain injury (TBI). Method: A concurrent cohort/prospective research design was used with repeated assessments of children with TBI (n = 82) or Orthopedic Injury (OI) (n = 114). Parents completed the Child Behavior Checklist, the Behavior Rating Inventory of Executive Functions, and the Preschool and Kindergarten Behavior Scales or the Home and Community Social and Behavior Scales shortly after injury to assess preinjury functioning, and at an extended follow-up an average of 38 months postinjury. Generalized linear modeling was used to examine the relationship of age at injury to the maintenance of behavior problems, and logistic regression was used to examine the persistence of clinically significant behavior problems. Results: At the extended follow-up, severe TBI was associated with significantly greater anxiety problems relative to the Group OI. With increasing time since injury, children who sustained a severe TBI at an earlier age had significantly higher levels of parent-reported symptoms of ADHD and anxiety than children who were older at injury. Conclusions: Findings suggest that longer-term treatment for behavior problems may be needed after severe TBI, particularly for those injured at an earlier age.	[Karver, Christine L.] Univ Cincinnati, Dept Psychol, Edwards Ctr ML 0376 1, Cincinnati, OH 45221 USA; [Karver, Christine L.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA; [Stancin, Terry] MetroHlth Med Ctr, Cleveland, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Walz, Nicolay C.] Cincinnati Childrens Hosp Med Ctr, Dept Behav Med, Cincinnati, OH USA	Karver, CL (corresponding author), Univ Cincinnati, Dept Psychol, Edwards Ctr ML 0376 1, Cincinnati, OH 45221 USA.	karvercl@mail.uc.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000077, 8 UL1 TR000077-04] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 08084, M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02 HD44099, R01 HD42729, R01 HD042729, K02 HD044099] Funding Source: Medline		Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Baum KT, 2010, EPILEPSY BEHAV, V17, P467, DOI 10.1016/j.yebeh.2010.01.010; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Caldarella, 2002, HOME COMMUNITY SOCIA; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Ebesutani C, 2010, J PSYCHOPATHOL BEHAV, V32, P373, DOI 10.1007/s10862-009-9174-9; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gioia G.A., 2000, BEHAV RATING INVENTO; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Hegewald J., 2003, P N E SAS US GROUP W; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Lund J, 2001, J PSYCHOEDUC ASSESS, V19, P112, DOI 10.1177/073428290101900201; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Mccoy H, 2008, CHILD YOUTH SERV REV, V30, P735, DOI 10.1016/j.childyouth.2007.12.003; Merrell K.W., 2002, PRESCHOOL KINDERGART; Merrell KW, 1996, J EARLY INTERVENTION, V20, P132, DOI 10.1177/105381519602000205; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; Merrell KW, 2001, J EMOT BEHAV DISORD, V9, P260, DOI 10.1177/106342660100900406; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Schatz David Beck, 2006, J Atten Disord, V10, P141, DOI 10.1177/1087054706286698; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	50	62	62	0	52	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2012	57	3					256	265		10.1037/a0029522			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	999AM	WOS:000308281500008	22946613	Green Accepted			2021-06-18	
J	Tang, CH; Fu, XJ; Xu, XL; Wei, XJ; Pan, HS				Tang, Chong-Hui; Fu, Xiao-Jun; Xu, Xin-Long; Wei, Xiao-Jie; Pan, Hong-Song			The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain	PEPTIDES			English	Article						Traumatic brain injury; Nesfatin-1; Inflammation; Neuronal cell apoptosis	SATIETY MOLECULE; KAPPA-B; INJURY; BARRIER; IMMUNOREACTIVITY	Nesfatin-1 has been demonstrated to possess anti-inflammatory and anti-apoptotic effects in the rat brain with subarachnoid hemorrhage. The study was designed to investigate the influence of nesfatin-1 on inflammatory responses and neuronal cell apoptosis after traumatic brain injury. Wistar rats were subjected to 5, 10 or 20 mu g/kg of nesfatin-1 at designed time points (0.5, 2, 4 or 8h after head trauma) intraperitoneally. Rats were sacrificed at hours 2, 6 and 12, as well as day 1, 2, 3 and 5 after head trauma. The administration of 10 or 20 mu g/kg of nesfatin-1 at hour 0.5 after head trauma could significantly suppress gene expressions of nuclear factor kappa-B, lessen concentrations of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6, diminish caspase-3 activity as well as reduce number of apoptotic neuronal cells in traumatic rat brain tissues (P < 0.05), but the administration of 5 mu g/kg of nesfatin-1 not (P > 0.05). Moreover, 20 mu g/kg nesfatin-1 also significantly suppressed the inflammation and neuronal cell apoptosis when applied 2, 4 or 8 h after head trauma. However, a clear concentration-response or time-response relationship was not found. These findings suggest that nesfatin-1 may inhibit nuclear factor kappa-B-dependent inflammatory responses, and lessen caspase-3-mediated neuronal cell apoptosis after traumatic brain injury in rats. (C) 2012 Elsevier Inc. All rights reserved.	[Tang, Chong-Hui; Fu, Xiao-Jun; Xu, Xin-Long; Wei, Xiao-Jie; Pan, Hong-Song] Cixi Peoples Hosp, Wenzhou Med Coll, Dept Neurosurg, Hushan Dist 315300, Cixi, Peoples R China	Fu, XJ (corresponding author), Cixi Peoples Hosp, Wenzhou Med Coll, Dept Neurosurg, 999 Nanerhuan E Rd, Hushan Dist 315300, Cixi, Peoples R China.	chonghuitang@126.com			Ningbo Municipal Natural Science Foundation of China [2010A610065]; Cixi Municipal Science and Technology Bureau of China [CN2008032, CN2009022]	This work is financially supported by Ningbo Municipal Natural Science Foundation of China (Grant No. 2010A610065) and Cixi Municipal Science and Technology Bureau of China (Grant Nos. CN2008032, CN2009022).	Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Begley DJ, 2003, PROG DRUG RES, V61, P39; Bonnet MS, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-27; Brailoiu GC, 2007, ENDOCRINOLOGY, V148, P5088, DOI 10.1210/en.2007-0701; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Foo KS, 2008, NEUROSCIENCE, V156, P563, DOI 10.1016/j.neuroscience.2008.07.054; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goebel M, 2009, BRAIN RES, V1300, P114, DOI 10.1016/j.brainres.2009.08.082; Goebel M, 2009, NEUROSCI LETT, V452, P241, DOI 10.1016/j.neulet.2009.01.064; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Merali Z, 2008, PSYCHOPHARMACOLOGY, V201, P115, DOI 10.1007/s00213-008-1252-2; Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162; Ozsavci D, 2011, NEUROSURGERY, V68, P1699, DOI 10.1227/NEU.0b013e318210f258; Pan WH, 2007, PEPTIDES, V28, P2223, DOI 10.1016/j.peptides.2007.09.005; Price TO, 2007, PEPTIDES, V28, P2372, DOI 10.1016/j.peptides.2007.10.008; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Yosten GLC, 2009, AM J PHYSIOL-REG I, V297, pR330, DOI 10.1152/ajpregu.90867.2008	22	62	65	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781			PEPTIDES	Peptides	JUL	2012	36	1					39	45		10.1016/j.peptides.2012.04.014			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	986EH	WOS:000307323400006	22561242				2021-06-18	
J	Gomes, JR; Costa, JT; Melo, CV; Felizzi, F; Monteiro, P; Pinto, MJ; Inacio, AR; Wieloch, T; Almeida, RD; Graos, M; Duarte, CB				Gomes, Joao R.; Costa, Joao T.; Melo, Carlos V.; Felizzi, Federico; Monteiro, Patricia; Pinto, Maria J.; Inacio, Ana R.; Wieloch, Tadeusz; Almeida, Ramiro D.; Graos, Mario; Duarte, Carlos B.			Excitotoxicity Downregulates TrkB.FL Signaling and Upregulates the Neuroprotective Truncated TrkB Receptors in Cultured Hippocampal and Striatal Neurons	JOURNAL OF NEUROSCIENCE			English	Article							IN-VIVO ROLE; CELL-DEATH; NEUROTROPHIN RECEPTORS; CEREBRAL-ISCHEMIA; CALPAIN; EXPRESSION; CASPASE; MICE; BDNF; GENE	Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal survival through activation of TrkB receptors. The trkB gene encodes a full-length receptor tyrosine kinase (TrkB.FL) and its truncated (T1/T2) isoforms. We investigated the changes in TrkB protein levels and signaling activity under excitotoxic conditions, which are characteristic of brain ischemia, traumatic brain injury, and neurodegenerative disorders. Excitotoxic stimulation of cultured rat hippocampal or striatal neurons downregulated TrkB.FL and upregulated a truncated form of the receptor (TrkB.T). Downregulation of TrkB.FL was mediated by calpains, whereas the increase in TrkB.T protein levels required transcription and translation activities. Downregulation of TrkB.FL receptors in hippocampal neurons correlated with a decrease in BDNF-induced activation of the Ras/ERK and PLC gamma pathways. However, calpain inhibition, which prevents TrkB.FL degradation, did not preclude the decrease in signaling activity of these receptors. On the other hand, incubation with anisomycin, to prevent the upregulation of TrkB.T, protected to a large extent the TrkB.FL signaling activity, suggesting that truncated receptors may act as dominant-negatives. The upregulation of TrkB.T under excitotoxic conditions was correlated with an increase in BDNF-induced inhibition of RhoA, a mediator of excitotoxic neuronal death. BDNF fully protected hippocampal neurons transduced with TrkB.T when present during excitotoxic stimulation with glutamate, in contrast with the partial protection observed in cells overexpressing TrkB.FL or expressing GFP. These results indicate that BDNF protects hippocampal neurons by two distinct mechanisms: through the neurotrophic effects of TrkB.FL receptors and by activation of TrkB.T receptors coupled to inhibition of the excitotoxic signaling.	[Gomes, Joao R.; Costa, Joao T.; Melo, Carlos V.; Pinto, Maria J.; Almeida, Ramiro D.; Duarte, Carlos B.] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal; [Felizzi, Federico] ETH, Dept Biosyst Sci & Engn DBSSE, CH-4058 Basel, Switzerland; [Monteiro, Patricia; Graos, Mario; Duarte, Carlos B.] Biocant, P-3060197 Cantanhede, Portugal; [Inacio, Ana R.; Wieloch, Tadeusz] Lund Univ, Wallenberg Neurosci Ctr, S-22184 Lund, Sweden; [Duarte, Carlos B.] Univ Coimbra, Ctr Neurosci & Cell Biol, Dept Life Sci, P-3004517 Coimbra, Portugal	Duarte, CB (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol, Dept Life Sci, P-3004517 Coimbra, Portugal.	cbduarte@ci.uc.pt	Inacio, Ana/M-6905-2016; Duarte, Carlos B/K-6358-2013; Graos, Mario/O-7273-2017; Pinto, Maria Joana MJ Guimaraes/L-8990-2016; Almeida, Ramiro D./J-2656-2013; Monteiro, Patricia/Q-7646-2017; Gomes, Joao/D-5115-2011	Duarte, Carlos B/0000-0002-1474-0208; Graos, Mario/0000-0002-2707-1488; Pinto, Maria Joana MJ Guimaraes/0000-0001-9730-5772; Almeida, Ramiro D./0000-0001-5830-2595; Monteiro, Patricia/0000-0003-3288-4560; Gomes, Joao/0000-0002-5710-8819; Costa, Joao/0000-0003-1018-2875; Wieloch, Tadeusz/0000-0002-7669-2520; Vieira Melo, Carlos/0000-0001-5392-1258	FCT, PortugalPortuguese Foundation for Science and TechnologyEuropean Commission; FCTPortuguese Foundation for Science and TechnologyEuropean Commission; FEDER, PortugalEuropean Commission [PTDC/SAU-NEU/65846/2006]	J.R.G, J.T.C, A. R. I., and C. V. M. were supported by FCT, Portugal. This work was supported by FCT and FEDER, Portugal (PTDC/SAU-NEU/65846/2006). We thank Elisabete Carvalho for the assistance in the preparation of cultured hippocampal neurons and Andrea Lobo for the pull-down of active RhoA optimization.	Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Caldeira MV, 2007, J BIOL CHEM, V282, P12619, DOI 10.1074/jbc.M700607200; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Counts SE, 2010, J NEUROCHEM, V113, P649, DOI 10.1111/j.1471-4159.2010.06622.x; De Wit J, 2006, J NEUROSCI, V26, P1516, DOI 10.1523/JNEUROSCI.4543-05.2006; Dorsey SG, 2006, NEURON, V51, P21, DOI 10.1016/j.neuron.2006.06.009; Dos-Anjos S, 2009, NEUROCHEM INT, V54, P180, DOI 10.1016/j.neuint.2008.09.016; Drukarch B, 2001, EXPERT OPIN INV DRUG, V10, P1855, DOI 10.1517/13543784.10.10.1855; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eide FF, 1996, J NEUROSCI, V16, P3123; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P229; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gomes JR, 2011, J NEUROSCI, V31, P4622, DOI 10.1523/JNEUROSCI.3541-10.2011; Goutan E, 1998, MOL BRAIN RES, V59, P154, DOI 10.1016/S0169-328X(98)00156-9; Grumelli C, 2008, MOL CELL NEUROSCI, V39, P314, DOI 10.1016/j.mcn.2008.07.011; Haacke A, 2007, J BIOL CHEM, V282, P18851, DOI 10.1074/jbc.M611914200; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; Hartmann M, 2004, J CELL SCI, V117, P5803, DOI 10.1242/jcs.01511; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; Li ZK, 2009, CANCER RES, V69, P7851, DOI 10.1158/0008-5472.CAN-08-4002; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Luberg K, 2010, J NEUROCHEM, V113, P952, DOI 10.1111/j.1471-4159.2010.06662.x; Luikart BW, 2003, NEUROSCIENCE, V117, P847, DOI 10.1016/S0306-4522(02)00719-4; Manadas Bruno J., 2007, P137, DOI 10.1007/978-0-387-70830-0_7; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Martin KJ, 2011, NEUROPHARMACOLOGY, V61, P148, DOI 10.1016/j.neuropharm.2011.03.021; Meary F, 2007, J BIOL CHEM, V282, P14226, DOI 10.1074/jbc.M700028200; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; Nygren J, 2005, J CEREBR BLOOD F MET, V25, P1625, DOI 10.1038/sj.jcbfm.9600157; Ohira K, 2006, BIOCHEM BIOPH RES CO, V342, P867, DOI 10.1016/j.bbrc.2006.02.033; Ohira K, 2005, NEUROSCI LETT, V385, P105, DOI 10.1016/j.neulet.2005.05.033; Ohira K, 2005, J NEUROSCI, V25, P1343, DOI 10.1523/JNEUROSCI.4436-04.2005; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Saarelainen T, 2000, MOL CELL NEUROSCI, V16, P87, DOI 10.1006/mcne.2000.0863; Santos ARA, 2008, J NEUROSCI RES, V86, P3684, DOI 10.1002/jnr.21796; Semenova MM, 2007, NAT NEUROSCI, V10, P436, DOI 10.1038/nn1869; Silhol M, 2007, NEUROSCIENCE, V146, P962, DOI 10.1016/j.neuroscience.2007.02.013; Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301; Takai Y, 2001, PHYSIOL REV, V81, P153; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Tolosa L, 2009, NEUROSCIENCE, V158, P1348, DOI 10.1016/j.neuroscience.2008.10.060; Tomioka M, 2002, MOL BRAIN RES, V108, P18, DOI 10.1016/S0169-328X(02)00486-2; Traystman RJ, 2003, ILAR J, V44, P85, DOI 10.1093/ilar.44.2.85; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	60	62	66	1	23	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 28	2012	32	13					4610	4622		10.1523/JNEUROSCI.0374-12.2012			13	Neurosciences	Neurosciences & Neurology	917GA	WOS:000302159400024	22457507	Bronze, Green Published			2021-06-18	
J	Goldman, SM; Kamel, F; Ross, GW; Jewell, SA; Bhudhikanok, GS; Umbach, D; Marras, C; Hauser, RA; Jankovic, J; Factor, SA; Bressman, S; Lyons, KE; Meng, C; Korell, M; Roucoux, DF; Hoppin, JA; Sandler, DP; Langston, JW; Tanner, CM				Goldman, Samuel M.; Kamel, Freya; Ross, G. Webster; Jewell, Sarah A.; Bhudhikanok, Grace S.; Umbach, David; Marras, Connie; Hauser, Robert A.; Jankovic, Joseph; Factor, Stewart A.; Bressman, Susan; Lyons, Kelly E.; Meng, Cheryl; Korell, Monica; Roucoux, Diana F.; Hoppin, Jane A.; Sandler, Dale P.; Langston, J. William; Tanner, Caroline M.			Head injury, alpha-synuclein Rep1, and Parkinson's disease	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL RISK-FACTORS; INFLAMMATORY RESPONSE; AMYLOID-BETA; CELL-DEATH; EXPRESSION; ACCUMULATION; PATHOGENESIS; ASSOCIATION; VARIABILITY	Objective: To test the hypothesis that variability in SNCA Rep1, a polymorphic dinucleotide microsatellite in the promoter region of the gene encoding a-synuclein, modifies the association between head injury and Parkinson's disease (PD) risk. Methods: Participants in the Farming and Movement Evaluation (FAME) and the Study of Environmental Association and Risk of Parkinsonism using Case-Control Historical Interviews (SEARCH), 2 independent case-control studies, were genotyped for Rep1 and interviewed regarding head injuries with loss of consciousness or concussion prior to Parkinson's disease (PD) diagnosis. Logistic regression modeling adjusted for potential confounding variables and tested interaction between Rep1 genotype and head injury. Results: Consistent with prior reports, relative to medium-length Rep1, short Rep1 genotype was associated with reduced PD risk (pooled odds ratio [OR], 0.7; 95% confidence interval [CI], 0.5-0.9), and long Rep1 with increased risk (pooled OR, 1.4; 95% CI, 0.95-2.2). Overall, head injury was not significantly associated with PD (pooled OR, 1.3; 95% CI, 0.9-1.8). However, head injury was strongly associated with PD in those with long Rep1 (FAME OR, 5.4; 95% CI, 1.5-19; SEARCH OR, 2.3; 95% CI, 0.6-9.2; pooled OR, 3.5; 95% CI 1.4-9.2, p-interaction 0.02). Individuals with both head injury and long Rep1 were diagnosed 4.9 years earlier than those with neither risk factor (p 0.03). Interpretation: While head injury alone was not associated with PD risk, our data suggest head injury may initiate and/ or accelerate neurodegeneration when levels of synuclein are high, as in those with Rep1 expansion. Given the high population frequency of head injury, independent verification of these results is essential. ANN NEUROL 2012; 71: 40-48	[Goldman, Samuel M.; Jewell, Sarah A.; Bhudhikanok, Grace S.; Meng, Cheryl; Korell, Monica; Roucoux, Diana F.; Langston, J. William; Tanner, Caroline M.] Parkinsons Inst, Sunnyvale, CA 94085 USA; [Kamel, Freya; Hoppin, Jane A.; Sandler, Dale P.] NIEHS, Epidemiol Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA; [Umbach, David] NIEHS, Biostat Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA; [Ross, G. Webster] Vet Affairs Pacific Isl Hlth Care Syst, Honolulu, HI USA; [Jewell, Sarah A.] German Ctr Neurodegenerat Dis, DZNE, Bonn, Germany; [Marras, Connie] Univ Toronto, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Hauser, Robert A.] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA; [Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Bressman, Susan] Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA; [Lyons, Kelly E.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA	Goldman, SM (corresponding author), Parkinsons Inst, 675 Almanor Ave, Sunnyvale, CA 94085 USA.	sgoldman@thepi.org	Hauser, Robert/I-5372-2012; Goldman, Samuel/A-2225-2014	Jewell, Sarah/0000-0002-9877-2599; Goldman, Samuel/0000-0002-3039-9927; Sandler, Dale/0000-0002-6776-0018; Hoppin, Jane/0000-0001-8456-0969	NIH (National Institute of Environmental Health Sciences [NIEHS])United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01-ES044007, Z01-ES049030, R01-ES10803, U54 ES012077, NCI Z01-CP010119]; Michael J. Fox Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [Z01CP010119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ZIAES049004, ZIAES049030, ZIAES044007] Funding Source: NIH RePORTER	This research was supported in part by the Intramural Research Program of the NIH (National Institute of Environmental Health Sciences [NIEHS] Z01-ES044007, Z01-ES049030, R01-ES10803 (C. M. T.), U54 ES012077 (C. M. T., J.W.L.); NCI Z01-CP010119); Michael J. Fox Foundation (C. M. T., J. W. L.); Parkinson's Unity Walk; James and Sharron Clark. SEARCH was supported by an unrestricted grant from a group of current and former manufacturers of welding consumables awarded to The Parkinson's Institute.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Alavanja MCR, 1996, ENVIRON HEALTH PERSP, V104, P362, DOI 10.2307/3432672; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; BHARUCHA NE, 1986, NEUROLOGY, V36, P284, DOI 10.1212/WNL.36.2.284; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Caudle WM, 2009, EXP NEUROL, V220, P230, DOI 10.1016/j.expneurol.2009.09.027; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; Cronin KD, 2009, HUM MOL GENET, V18, P3274, DOI 10.1093/hmg/ddp265; DeMichele G, 1996, MOVEMENT DISORD, V11, P17, DOI 10.1002/mds.870110105; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dufty BM, 2007, AM J PATHOL, V170, P1725, DOI 10.2353/ajpath.2007.061232; Eriksen JL, 2005, ARCH NEUROL-CHICAGO, V62, P353, DOI 10.1001/archneur.62.3.353; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Fuchs J, 2008, FASEB J, V22, P1327, DOI 10.1096/fj.07-9348com; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kay DM, 2008, AM J MED GENET B, V147B, P1222, DOI 10.1002/ajmg.b.30758; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lee JK, 2009, J NEUROIMMUNE PHARM, V4, P419, DOI 10.1007/s11481-009-9176-0; Linnertz C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007480; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; MARTYN CN, 1995, J NEUROL SCI, V132, P201, DOI 10.1016/0022-510X(95)00148-U; McCann SJ, 1998, NEUROEPIDEMIOLOGY, V17, P310, DOI 10.1159/000026185; McCormack AL, 2009, CURR PROTEIN PEPT SC, V10, P476, DOI 10.2174/138920309789351912; McCulloch CC, 2008, HUM GENET, V123, P257, DOI 10.1007/s00439-008-0466-z; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORANO A, 1994, ACTA NEUROL SCAND, V89, P164; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Norris EH, 2005, ANTIOXID REDOX SIGN, V7, P673; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Ross OA, 2008, ANN NEUROL, V63, P743, DOI 10.1002/ana.21380; Rugbjerg K, 2008, BMJ-BRIT MED J, V337, pa2494, DOI [10.1136/bmj.a2494, DOI 10.1136/BMJ.A2494]; Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Siebert H, 2010, J NEUROCHEM, V114, P1007, DOI 10.1111/j.1471-4159.2010.06832.x; Smargiassi A, 1998, NEUROTOXICOLOGY, V19, P709; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Spangenberg S, 2009, PARKINSONISM RELAT D, V15, P12, DOI 10.1016/j.parkreldis.2008.02.004; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Tanner CM, 2009, ARCH NEUROL-CHICAGO, V66, P1106, DOI 10.1001/archneurol.2009.195; Tanner CM, 2008, PARKINSONS DIS DIAGN, P387; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; Tsai CH, 2002, CLIN NEUROL NEUROSUR, V104, P328, DOI 10.1016/S0303-8467(02)00027-6; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wilms H, 2009, INT J IMMUNOPATH PH, V22, P897, DOI 10.1177/039463200902200405; Yao XL, 2008, J NEUROCHEM, V104, P353, DOI 10.1111/j.1471-4159.2007.04970.x; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	68	62	63	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2012	71	1					40	48		10.1002/ana.22499			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	880MW	WOS:000299412200008	22275250	Green Accepted			2021-06-18	
J	VandeVord, PJ; Bolander, R; Sajja, VSSS; Hay, K; Bir, CA				VandeVord, Pamela J.; Bolander, Richard; Sajja, Venkata Siva Sai Sujith; Hay, Kathryn; Bir, Cynthia A.			Mild Neurotrauma Indicates a Range-Specific Pressure Response to Low Level Shock Wave Exposure	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Blast; Neurotrauma; Injury mechanism; Brain	TRAUMATIC BRAIN-INJURY; SPATIAL WORKING-MEMORY; WATER MAZE PERFORMANCE; DENTATE GYRUS; ADULT NEUROGENESIS; INTRACRANIAL-PRESSURE; CORTICAL-NEURONS; BLAST INJURY; FLUORO-JADE; AMYGDALA	Identifying the level of overpressure required to create physiological deficits is vital to advance prevention, diagnostic, and treatment strategies for individuals exposed to blasts. In this study, a rodent model of primary blast neurotrauma was employed to determine the pressure at which acute neurological alterations occurred. Rats were exposed to a single low intensity shock wave at a pressure of 0, 97, 117, or 153 kPa. Following exposure, rats were assessed for acute cognitive alterations using the Morris water maze and motor dysfunction using the horizontal ladder test. Subsequently, histological analyses of three brain regions ( primary motor cortex, the hippocampal dentate gyrus region, and the posteromedial cortical amygdala) were conducted. Histological parameters included measuring the levels of glial fibrillary acidic protein (GFAP) to identify astrocyte activation, cleaved caspase-3 for early apoptosis identification and Fluoro-Jade B (FJB) which labels degenerating neurons within the brain tissue. The results demonstrated that an exposure to a single 117 kPa shock wave revealed a significant change in overall neurological deficits when compared to controls and the other pressures. The animals showed significant alterations in water maze parameters and a histological increase in the number of GFAP, caspase-3, and FJB-positive cells. It is suggested that when exposed to a low level shock wave, there may be a biomechanical response elicited by a specific pressure range which can cause low level neurological deficits within the rat. These data indicate that neurotrauma induced from a shock wave may lead to cognitive deficits in short-term learning and memory of rats. Additional histological evidence supports significant and diffuse glial activation and cellular damage. Further investigation into the biomechanical aspects of shock wave exposure is required to elucidate this pressure range-specific phenomenon.	[VandeVord, Pamela J.; Bolander, Richard; Sajja, Venkata Siva Sai Sujith; Hay, Kathryn; Bir, Cynthia A.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [VandeVord, Pamela J.] John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI 48201 USA	VandeVord, PJ (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	pvord@wayne.edu; dt8583@wayne.edu; dz2837@wayne.edu; du7030@wayne.edu; cbir@wayne.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501; Bir, Cynthia/0000-0002-0777-0951	United States Office of Naval ResearchOffice of Naval Research [N000140810585]	The authors would like to thank Samantha Staley, James Kopacz, and Drs. Alessandra Dal Cengio Leonardi, Bin Wu, and Li Mao for their technical assistance. This research was partially supported by the United States Office of Naval Research grant Award Number N000140810585.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ang ET, 2006, BRAIN RES, V1113, P186, DOI 10.1016/j.brainres.2006.07.023; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bolander R., 2011, ANN BIOMED ENG  0707; Caberlotto L, 2000, J CHEM NEUROANAT, V20, P327, DOI 10.1016/S0891-0618(00)00107-1; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Ciraulo DL, 2006, J AM COLL SURGEONS, V203, P942, DOI 10.1016/j.jamcollsurg.2006.07.028; CLEMEDSON C.-J., 1957, ACTA PATHOL ET MICROBIOL SCAND, V40, P89; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Davies RR, 2005, BRAIN, V128, P1984, DOI 10.1093/brain/awh582; Duman RS, 2001, J PHARMACOL EXP THER, V299, P401; Fraticelli-Torres Ada I, 2010, Ethn Dis, V20, pS1; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Fuster JM, 2002, J NEUROCYTOL, V31, P373, DOI 10.1023/A:1024190429920; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Hernandez-Rabaza V, 2007, BRAIN RES BULL, V72, P315, DOI 10.1016/j.brainresbull.2007.01.013; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hong Jun, 2002, Chin J Traumatol, V5, P36; Jenkins TA, 2006, NEUROSCIENCE, V137, P747, DOI 10.1016/j.neuroscience.2005.09.034; Kamnaksh A., 2011, J NEUROTRAUMA, V23; Kesner RP, 2007, PROG BRAIN RES, V163, P567, DOI 10.1016/S0079-6123(07)63030-1; Kirby E. D., 2011, MOL PSYCHIAT    0614; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Leong SY, 2011, NEUROCHEM INT, V59, P382, DOI 10.1016/j.neuint.2010.12.024; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Mirescu C, 2004, NAT NEUROSCI, V7, P841, DOI 10.1038/nn1290; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nicolle MM, 2001, NEUROSCIENCE, V107, P415, DOI 10.1016/S0306-4522(01)00374-8; Niewoehner B, 2007, EUR J NEUROSCI, V25, P837, DOI 10.1111/j.1460-9568.2007.05312.x; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Payette DJ, 2008, INT J CLIN EXP PATHO, V1, P44; Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sanes JN, 2000, ANNU REV NEUROSCI, V23, P393, DOI 10.1146/annurev.neuro.23.1.393; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Warren MW, 2007, ACTA NEUROPATHOL, V114, P277, DOI 10.1007/s00401-007-0259-9; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wurm F, 2007, STROKE, V38, P2833, DOI 10.1161/STROKEAHA.107.485524; Zhang L., 2006, J BIOMECH, V39, pS163	63	62	63	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		227	236		10.1007/s10439-011-0420-4			10	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700020	21994066				2021-06-18	
J	Hirschberg, R; Giacino, JT				Hirschberg, Ron; Giacino, Joseph T.			The Vegetative and Minimally Conscious States: Diagnosis, Prognosis and Treatment	NEUROLOGIC CLINICS			English	Article						Consciousness; Vegetative state; Traumatic brain injury; Neuroimaging; Outcomes	ANOXIC BRAIN-INJURY; DISORDERS; RECOVERY; ZOLPIDEM; COMA; SCALE; RECOMMENDATIONS; AMANTADINE; ACCURACY; INSIGHTS	Severe acquired brain injury has profound impact on alertness, cognition, and behavior. Among those who survive the initial injury, a significant minority fail to fully recover self and environmental awareness, and go on to experience prolonged disorders of consciousness (DOC) that can last a lifetime. Although there are no standards of care to guide clinical management, a growing body of empirical evidence is beginning to accrue to inform clinical decision making. In this article, we review the state of the science as it pertains to diagnosis, prognosis, and treatment of patients with DOC.	[Hirschberg, Ron; Giacino, Joseph T.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Hirschberg, Ron; Giacino, Joseph T.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Hirschberg, Ron] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Giacino, Joseph T.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA	Giacino, JT (corresponding author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.	jgiacino@partners.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			American Congress of Rehabilitation Medicine, 2005, ARCH PHYS MED REHAB, V76, P205; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Clauss RP, 2000, S AFR MED J, V90, P68; Cohen SI, 2008, AM J PHYS MED REHAB, V87, P229, DOI 10.1097/PHM.0b013e318161971b; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Giacino J, 2008, HDB CLIN NEUROLOGY, V90, P99; Giacino JT, 2007, CURR OPIN NEUROL, V20, P614, DOI 10.1097/WCO.0b013e3282f189ef; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giacino JT, 2005, REHABILITATION TRAUM, P305; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; James W, 1999, NEW AGE NEW THOUGHT, P51; JENNETT B, 1972, LANCET, V1, P734; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Lombardi F, 2007, COCHRANE DB SYST REV, V2, P1; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; Monti MM, 2009, PROG BRAIN RES, V177, P249, DOI 10.1016/S0079-6123(09)17717-8; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Moreno DR, 2010, NEUROLOGY, V75, P1871, DOI 10.1212/WNL.0b013e3181feb259; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff Nicholas D, 2010, Cleve Clin J Med, V77 Suppl 3, pS27, DOI 10.3949/ccjm.77.s3.05; Schiff Nicholas D., 2002, Thalamus & Related Systems, V2, P55, DOI 10.1017/S1472928802000286; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Smart CM, 2008, NAT CLIN PRACT NEURO, V4, P448, DOI 10.1038/ncpneuro0823; SPUDIS EV, 1991, J NEUROL SCI, V102, P128, DOI 10.1016/0022-510X(91)90060-K; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; TEASDALE G, 1974, LANCET, V2, P81; Vanhaudenhuyes A, 2008, NEUROLOGY, V71, P1; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Whyte J, 2007, AM J PHYS MED REHAB, V86, P86, DOI 10.1097/PHM.0b013e31802f0434; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	51	62	76	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2011	29	4					773	+		10.1016/j.ncl.2011.07.009			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	853BN	WOS:000297401300006	22032660				2021-06-18	
J	Sookplung, P; Siriussawakul, A; Malakouti, A; Sharma, D; Wang, J; Souter, MJ; Chesnut, RM; Vavilala, MS				Sookplung, Pimwan; Siriussawakul, Arunotai; Malakouti, Amin; Sharma, Deepak; Wang, Jin; Souter, Michael J.; Chesnut, Randall M.; Vavilala, Monica S.			Vasopressor Use and Effect on Blood Pressure After Severe Adult Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Vasopressor; Phenylephrine; Norepinephrine; Dopamine; Cerebral perfusion pressure	CEREBRAL PERFUSION-PRESSURE; CORTICAL PERFUSION; TISSUE OXYGENATION; UNITED-STATES; NOREPINEPHRINE; DOPAMINE; MANAGEMENT; AUTOREGULATION; RESUSCITATION; PHENYLEPHRINE	We describe institutional vasopressor usage, and examine the effect of vasopressors on hemodynamics: heart rate (HR), mean arterial blood pressure (MAP), intracranial pressure (ICP), cerebral perfusion pressure (CPP), brain tissue oxygenation (PbtO(2)), and jugular venous oximetry (SjVO(2)) in adults with severe traumatic brain injury (TBI). We performed a retrospective analysis of 114 severely head injured patients who were admitted to the neurocritical care unit of Level 1 trauma center and who received vasopressors (phenylephrine, norepinephrine, dopamine, vasopressin or epinephrine) to increase blood pressure Phenylephrine was the most commonly used vasopressor (43%), followed by norepinephrine (30%), dopamine (22%), and vasopressin (5%). Adjusted for age, gender, injury severity score, vasopressor dose, baseline blood pressure, fluid administration, propofol sedation, and hypertonic saline infusion, phenylephrine use was associated with 8 mmHg higher mean arterial pressure (MAP) than dopamine (P = 0.03), and 12 mmHg higher cerebral perfusion pressure (CPP) than norepinephrine (P = 0.02) during the 3 h after vasopressor start. There was no difference in ICP between the drug groups, either at baseline or after vasopressor treatment. Most severe TBI patients received phenylephrine. Patients who received phenylephrine had higher MAP and CPP than patients who received dopamine and norepinephrine, respectively.	[Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Sookplung, Pimwan; Siriussawakul, Arunotai; Malakouti, Amin; Sharma, Deepak; Souter, Michael J.; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pediat, 325 Ninth Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu	Souter, Michael/ABE-1890-2020	Chesnut, Randall/0000-0001-6377-3666	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS072308, R01 NS072308-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER		Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; BEVAN JA, 1987, FASEB J, V1, P193; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Drummond JC, 1994, ANESTHESIA, P689; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2641, DOI 10.1097/CCM.0b013e3181847af3; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Guimaraes S, 2001, PHARMACOL REV, V53, P319; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; STARKE K, 1981, J CARDIOVASC PHARM, V3, pS14, DOI 10.1097/00005344-198100031-00002; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Stubbe HD, 2006, CRIT CARE MED, V34, P2651, DOI 10.1097/01.CCM.0000239196.17999.B7; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8	28	62	64	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					46	54		10.1007/s12028-010-9448-9			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100008	20878264	Green Accepted			2021-06-18	
J	Washington, CW; Schuerer, DJE; Grubb, RL				Washington, Chad W.; Schuerer, Douglas J. E.; Grubb, Robert L., Jr.			Platelet Transfusion: An Unnecessary Risk for Mild Traumatic Brain Injury Patients on Antiplatelet Therapy	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Platelet transfusion; Antiplatelet therapy	INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; ELDERLY-PATIENTS; HEAD-INJURY; CLOPIDOGREL; MORTALITY; IMPACT; CLASSIFICATION; PREDICTORS; OUTCOMES	Introduction: To determine whether there is a benefit to platelet transfusion in mild traumatic brain injury (MTBI) patients with intracranial hemorrhage (ICH), taking antiplatelet therapy before hospitalization. Materials and Methods: The study design retrospectively reviewed patients admitted to a Level I trauma center during a 2-year period with an isolated MTBI (Glasgow Coma Scale score >= 13, ICH seen on a head computed tomographic scan (head computed tomography [HCT]), and taking an antiplatelet agent before hospitalization. HCT's were categorized based on the Marshall Classification, Rotterdam Score, and ICH volume. Hospital records were reviewed noting neurologic, cardiac, respiratory events, and discharge Glasgow Outcome Scale. Results: There were 1,101 patients with TBI hospitalized during the 2-year study period. Three hundred twenty-one of these patients had an MTBI with ICH at the time of admission, and from this group, 113 were taking an antiplatelet agent. Only 4 (1.2%) of the 321 patients suffered a neurologic decline. All were gradual in nature, and none required emergent intervention. An analysis of the 113 patients taking antiplatelet agents, comparing patients who were not given a platelet transfusion with those who received a platelet transfusion, found no significant difference in the rate of HCT progression, neurologic decline, or Glasgow Outcome Scale at hospital discharge between the two groups. There was a trend, which was not significant, toward more medical declines in patients who received a platelet transfusion. A further review, analyzing all 321 patients with ICH showed receiving a transfusion of any type (i.e., platelets, fresh frozen plasma, or blood) was a strong predictor of medical decline (p < 0.0001). The odds ratio of having a medical decline after transfusion was 5.8 (95% confidence interval, 1.2-28.2). Conclusions: Platelet transfusion did not improve short-term outcomes after MTBI. Further randomized controlled trials need to be done to truly assess if there is no benefit in platelet transfusion in patients taking antiplatelet agents suffering an MTBI. Because the overall outcome in MTBI patients is favorable, platelet transfusion in these patients may not be indicated.	[Washington, Chad W.; Grubb, Robert L., Jr.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; [Schuerer, Douglas J. E.] Washington Univ, Sch Med, Div Gen Surg, Sect Acute & Crit Care Surg, St Louis, MO 63110 USA	Washington, CW (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, 660 S Euclid Ave,Campus Box 8057, St Louis, MO 63110 USA.	washingtonc@wudosis.wustl.edu					Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042; Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Albaladejo P, 2010, BEST PRACT RES-CLIN, V24, P41, DOI 10.1016/j.bpa.2009.09.008; Benson AB, 2009, BRIT J HAEMATOL, V147, P431, DOI 10.1111/j.1365-2141.2009.07840.x; Cesar J, 2009, PLATELETS, V20, P158, DOI 10.1080/09537100902751925; Control NCfIPa, 2003, REP C MILD TRAUM BRA; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Spiess BD, 2010, BEST PRACT RES-CLIN, V24, P65, DOI 10.1016/j.bpa.2009.11.001; TEASDALE G, 1974, LANCET, V2, P81; Vilahur G, 2007, J THROMB HAEMOST, V5, P82, DOI 10.1111/j.1538-7836.2006.02245.x; 2010, 10 LEADING CAUSES DE	25	62	62	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71	2					358	363		10.1097/TA.0b013e318220ad7e			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	806XH	WOS:000293850200031	21825939				2021-06-18	
J	Ghosh, M; Yang, YJ; Rothstein, JD; Robinson, MB				Ghosh, Mausam; Yang, Yongjie; Rothstein, Jeffrey D.; Robinson, Michael B.			Nuclear Factor-kappa B Contributes to Neuron-Dependent Induction of Glutamate Transporter-1 Expression in Astrocytes	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; AMINO-ACID CARRIER-1; UP-REGULATION; NEURON/ASTROCYTE COCULTURES; GLT-1/EAAT2 SUBTYPE; HIPPOCAMPAL-NEURONS; ISCHEMIC TOLERANCE; SIGNALING PATHWAYS; DOWN-REGULATION; MICE LACKING	The glutamate transporter-1 [GLT-1 (excitatory amino acid transporter 2)] subtype of glutamate transporter ensures crisp excitatory signaling and limits excitotoxicity in the CNS. Astrocytic expression of GLT-1 is regulated during development, by neuronal activity, and in neurodegenerative diseases. Although neurons activate astrocytic expression of GLT-1, the mechanisms involved have not been identified. In the present study, astrocytes from transgenic mice that express enhanced green fluorescent protein (eGFP) under the control of a bacterial artificial chromosome (BAC) containing a very large region of DNA surrounding the GLT-1 gene (BAC GLT-1 eGFP mice) were used to assess the role of nuclear factor-kappa B (NF-kappa B) in neuron-dependent activation of the GLT-1 promoter. We provide evidence that neurons activate NF-kappa B signaling in astrocytes. Transduction of astrocytes from the BAC GLT-1 eGFP mice with dominant-negative inhibitors of NF-kappa B signaling completely blocked neuron-dependent activation of a NF-kappa B reporter construct and attenuated induction of eGFP. Exogenous expression of p65 and/or p50 NF-kappa B subunits induced expression of eGFP or GLT-1 and increased GLT-1-mediated transport activity. Using wild-type and mutant GLT-1 promoter reporter constructs, we found that NF-kappa B sites at -583 or -251 relative to the transcription start site were required for neuron-dependent reporter activation. Electrophoretic mobility shift and supershift assays reveal that p65 and p50 interact with these same sites ex vivo. Finally, chromatin immunoprecipitation showed that p65 and p50 interact with these sites in adult cortex, but not in kidney (a tissue that expresses no detectable GLT-1). Together, these studies strongly suggest that NF-kappa B contributes to neuron-dependent regulation of astrocytic GLT-1 transcription.	[Ghosh, Mausam; Robinson, Michael B.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Robinson, Michael B.] Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; [Yang, Yongjie; Rothstein, Jeffrey D.] Johns Hopkins Univ, Dept Neurol & Neurosci, Baltimore, MD 21205 USA	Robinson, MB (corresponding author), 502N Abramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@mail.med.upenn.edu	rothstein, jeffrey d/C-9470-2013		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36465]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036465] Funding Source: NIH RePORTER	This work was supported by NIH Grant NS36465 to M. B. R. and J.D.R. We thank Dr. Dean Ballard (Vanderbilt University School of Medicine) for the dominant-negative constructs of I kappa B alpha; Olga Zelanaia and Janice Watch for subcloning some of these cDNAs into the lentiviral backbone; and Dr. Judy Grinspan (Children's Hospital of Philadelphia) for providing the A2B5 hybridoma supernatant. We thank members of the Robinson laboratory for their advice and suggestion with this project.	Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brooks-Kayal AR, 1998, NEUROCHEM INT, V33, P95, DOI 10.1016/S0197-0186(98)00018-7; Caccamo D, 2005, EXP NEUROL, V193, P377, DOI 10.1016/j.expneurol.2005.01.014; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; Dabir DV, 2006, J NEUROSCI, V26, P644, DOI 10.1523/JNEUROSCI.3861-05.2006; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Denis-Donini S, 2008, J NEUROSCI, V28, P3911, DOI 10.1523/JNEUROSCI.0148-08.2008; Furuta A, 1997, J NEUROSCI, V17, P8363; Ganel R, 2006, NEUROBIOL DIS, V21, P556, DOI 10.1016/j.nbd.2005.08.014; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; Gegelashvili G, 1996, NEUROREPORT, V8, P261, DOI 10.1097/00001756-199612200-00052; Genoud C, 2006, PLOS BIOL, V4, P2057, DOI 10.1371/journal.pbio.0040343; GINSBERG SD, 1995, J NEUROCHEM, V65, P2800; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; Gonzalez MI, 2007, J NEUROCHEM, V103, P1917, DOI 10.1111/j.1471-4159.2007.04881.x; Gonzalez MI, 2007, J BIOL CHEM, V282, P29855, DOI 10.1074/jbc.M704738200; Gutierrez H, 2008, J NEUROSCI, V28, P8246, DOI 10.1523/JNEUROSCI.1941-08.2008; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hein C, 2001, EUR J NEUROSCI, V13, P1839, DOI 10.1046/j.0953-816x.2001.01559.x; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kawahara K, 2005, GLIA, V49, P349, DOI 10.1002/glia.20114; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; Li LB, 2006, J NEUROCHEM, V97, P759, DOI 10.1111/j.1471-4159.2006.03743.x; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li S, 1997, J NEUROPATH EXP NEUR, V56, P901, DOI 10.1097/00005072-199708000-00008; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mathern GW, 1999, NEUROLOGY, V52, P453, DOI 10.1212/WNL.52.3.453; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Mennerick S, 1998, J NEUROSCI, V18, P4490; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Perego C, 2000, J NEUROCHEM, V75, P1076, DOI 10.1046/j.1471-4159.2000.0751076.x; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rawls SM, 2007, BRIT J PHARMACOL, V151, P1095, DOI 10.1038/sj.bjp.0707309; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Rodriguez-Kern A, 2003, NEUROCHEM INT, V43, P363, DOI 10.1016/S0197-0186(03)00023-8; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Saura J, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-26; Schlag BD, 1998, MOL PHARMACOL, V53, P355; Schwaninger M, 1999, J NEUROCHEM, V73, P1461, DOI 10.1046/j.1471-4159.1999.0731461.x; Shayakul C, 1997, AM J PHYSIOL-RENAL, V273, pF1023; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Sheldon AL, 2008, NEUROCHEM INT, V53, P296, DOI 10.1016/j.neuint.2008.07.010; Shin JY, 2005, J CELL BIOL, V171, P1001, DOI 10.1083/jcb.200508072; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Susarla BTS, 2004, J NEUROCHEM, V91, P1151, DOI 10.1111/j.1471-4159.2004.02791.x; Sutherland ML, 1996, J NEUROSCI, V16, P2191; Swanson RA, 1997, J NEUROSCI, V17, P932; Tai YH, 2008, NEUROSCIENCE, V153, P823, DOI 10.1016/j.neuroscience.2008.02.055; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tong X, 2004, MOL CELL BIOCHEM, V265, P171, DOI 10.1023/B:MCBI.0000044394.66951.4d; Watson Deborah J, 2003, Methods Mol Med, V76, P383; Weller ML, 2008, NEUROSCIENCE, V155, P1204, DOI 10.1016/j.neuroscience.2008.05.059; Yamada T, 2006, NEUROCHEM RES, V31, P49, DOI 10.1007/s11064-005-9077-4; Yang YJ, 2009, NEURON, V61, P880, DOI 10.1016/j.neuron.2009.02.010; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zelenaia O, 2000, MOL PHARMACOL, V57, P667	72	62	63	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 22	2011	31	25					9159	9169		10.1523/JNEUROSCI.0302-11.2011			11	Neurosciences	Neurosciences & Neurology	782AT	WOS:000291980500012	21697367	Green Accepted, Green Published, Bronze			2021-06-18	
J	Beauchamp, MH; Ditchfield, M; Maller, JJ; Catroppa, C; Godfrey, C; Rosenfeld, JV; Kean, MJ; Anderson, VA				Beauchamp, M. H.; Ditchfield, M.; Maller, J. J.; Catroppa, C.; Godfrey, C.; Rosenfeld, J. V.; Kean, M. J.; Anderson, V. A.			Hippocampus, amygdala and global brain changes 10 years after childhood traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Brain injury; MRI; Hippocampus; Amygdala; Morphometry; Children	CLOSED-HEAD-INJURY; DIFFUSION-TENSOR; QUANTITATIVE-ANALYSIS; LONGITUDINAL CHANGES; MAJOR DEPRESSION; CORPUS-CALLOSUM; MEMORY FUNCTION; CHILDREN; ATROPHY; MRI	Traumatic brain injury (TBI) in children results in damage to the developing brain, particularly in severely injured individuals. Little is known, however, of the long-term structural aspects of the brain following childhood TBI. This study investigated the integrity of the brain 10 years post-TBI using magnetic resonance imaging volumetrics in a sample of 49 participants with mild, moderate and severe TB!, evaluated against a normative sample of 20 individuals from a pediatric database with comparable age and gender distribution. Structural integrity was investigated in gray and white matter, and by manually segmenting two regions of interest (hippocampus, amygdala), potentially vulnerable to the effects of childhood TBI. The results indicate that more severe injuries caused a reduction in gray and white brain matter, while all TBI severity levels resulted in increased volumes of cerebrospinal fluid and smaller hippocampal volumes. In addition, enlarged amygdala volumes were detected in severely injured patients compared to their mild and moderate counterparts, suggesting that childhood TBI may disrupt the development of certain brain regions through diffuse pathological changes. The findings highlight the lasting impact of childhood TBI on the brain and the importance of monitoring brain structure in the long-term after early injury. (C) 2010 ISDN. Published by Elsevier Ltd. All rights reserved.	[Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, M. H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Beauchamp, M. H.; Ditchfield, M.; Catroppa, C.; Godfrey, C.; Kean, M. J.; Anderson, V. A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Ditchfield, M.] Monash Univ, Dept Med, Clayton, Vic 3800, Australia; [Ditchfield, M.] Monash Med Ctr, Melbourne, Vic, Australia; [Maller, J. J.] Monash Univ, Alfred Psychiat Res Ctr, Clayton, Vic 3800, Australia; [Catroppa, C.; Anderson, V. A.] Univ Melbourne, Melbourne, Vic 3010, Australia; [Catroppa, C.; Kean, M. J.; Anderson, V. A.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Rosenfeld, J. V.] Monash Univ, Dept Surg, Clayton, Vic 3800, Australia; [Rosenfeld, J. V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia	Anderson, VA (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Maller, Jerome J/H-4963-2014; Rosenfeld, Jeffrey V/B-7249-2011	Maller, Jerome J/0000-0003-4685-1508; 	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [284518]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Thrasher Research Fund; Lynne Quayle Charitable Fund; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-HD02-3343, N01-MH9-0002, N01-NS-9-2314, -2315, -2316, -2317, -2319, -2320]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [N01HD023343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [N01MH090002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER	This work was supported by the National Health and Medical Research Council (project grant no. 284518) and by the Canadian Institutes of Health Research, Thrasher Research Fund, and Lynne Quayle Charitable Fund (MHB). The funding sources were not involved in the study design, collection, analysis or interpretation of data or writing of the manuscript.; Comparison group data used in the preparation of this article were obtained from the Pediatric MRI Data Repository (third release, 10/2009) created by the NIH MRI Study of Normal Brain Development. This is a multi-site, longitudinal study of typically developing children, from ages newborn through young adulthood, conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01-HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://www.bic.mni.mcgill.ca/nihpd/info/participating_centers.html.	Adolphs R, 2006, BRAIN RES, V1079, P25, DOI 10.1016/j.brainres.2005.12.127; Adolphs R, 2003, ANN NY ACAD SCI, V985, P326; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Brierley B, 2002, BRAIN RES REV, V39, P84, DOI 10.1016/S0165-0173(02)00160-1; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; COFFEY CE, 1991, PSYCHOPATHOLOGY BRAI; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Daniel A. E., 1983, POWER PRIVILEGE PRES; De Bellis MD, 2000, BIOL PSYCHIAT, V48, P51, DOI 10.1016/S0006-3223(00)00835-0; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DUVERNOY H, 1998, HUMAN HIPPOCAMPUS AT; Duvernoy H.M., 1998, HUMAN HIPPOCAMPUS FU; Evans AC, 2006, NEUROIMAGE, V30, P184, DOI 10.1016/j.neuroimage.2005.09.068; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Frodl T, 2003, BIOL PSYCHIAT, V53, P338, DOI 10.1016/S0006-3223(02)01474-9; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Hajek T, 2009, J AFFECT DISORDERS, V115, P395, DOI 10.1016/j.jad.2008.10.007; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Howard MA, 2000, NEUROREPORT, V11, P2931, DOI 10.1097/00001756-200009110-00020; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Lange C, 2004, PSYCHOL MED, V34, P1059, DOI 10.1017/S0033291703001806; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maller JJ, 2007, PSYCHIAT RES-NEUROIM, V156, P185, DOI 10.1016/j.pscychresns.2007.06.005; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; Schumann CM, 2004, J NEUROSCI, V24, P6392, DOI 10.1523/JNEUROSCI.1297-04.2004; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sisk CL, 2004, NAT NEUROSCI, V7, P1040, DOI 10.1038/nn1326; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tottenham N, 2010, DEVELOPMENTAL SCI, V13, P46, DOI 10.1111/j.1467-7687.2009.00852.x; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Verger K, 2001, BRAIN INJURY, V15, P211; Watson C, 1997, ARCH NEUROL-CHICAGO, V54, P1521, DOI 10.1001/archneur.1997.00550240071015; Weniger G, 2006, J AFFECT DISORDERS, V94, P219, DOI 10.1016/j.jad.2006.04.017; Whitford TJ, 2007, HUM BRAIN MAPP, V28, P228, DOI 10.1002/hbm.20273; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	61	62	63	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	APR	2011	29	2					137	143		10.1016/j.ijdevneu.2010.12.003			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	735IT	WOS:000288408200005	21147212				2021-06-18	
J	Shojo, H; Kaneko, Y; Mabuchi, T; Kibayashi, K; Adachi, N; Borlongan, CV				Shojo, H.; Kaneko, Y.; Mabuchi, T.; Kibayashi, K.; Adachi, N.; Borlongan, C. V.			GENETIC AND HISTOLOGIC EVIDENCE IMPLICATES ROLE OF INFLAMMATION IN TRAUMATIC BRAIN INJURY-INDUCED APOPTOSIS IN THE RAT CEREBRAL CORTEX FOLLOWING MODERATE FLUID PERCUSSION INJURY	NEUROSCIENCE			English	Article						head trauma; brain injury model gene expression; apoptosis related genes; inflammation	MITOCHONDRIAL CYTOCHROME-C; CELL-DEATH; ALTERED EXPRESSION; MESSENGER-RNA; ACTIVATION; DAMAGE; TRANSLOCATION; LOCALIZATION; DYSFUNCTION; CASPASES	Traumatic brain injury (TBI) causes massive brain damage However, the secondary injury and temporal sequence of events with multiple mechanisms after the insult has not been elucidated Here we examined the occurrence of apoptosis and a causal relationship between inflammation and apoptosis in the TBI brain Following a lateral moderate fluid percussion injury model of TBI in adult rats, microarray analyses detected apparent changes in the expression levels of apoptosis related genes which revealed time-dependent expression patterns for 23 genes in the lateral cortex The upregulated 23 genes included inflammatory cytokines such as interleukin 1 (IL 1) alpha, IL 1 beta, and tumor necrotic factor (TNF) which immediately increased at 3 h following the injury Time dependent gene expression profile analyses showed that apoptosis was subsequently induced following inflammation These results taken together suggested changes in expression of apoptosis related genes may be associated with inflammatory response Accompanying this surge of cell death genes after TBI was a neurostructural pathologic hall mark of apoptosis characterized by leakage of cytochrome c into cytoplasm, DNA fragmentation and apoptotic cells in the lateral cortex of the impacted hemisphere Caspase-3 positive cells in the TBI brain were initially sporadic after 3 h, but these apoptotic cells subsequently increased and populated the cerebral cortex at 6 and 12 h, and gradually reached a plateau by 48 h Interestingly, the expression profile of CD68 macrophage labeled cells closely resembled that of apoptotic cells after TBI, including the role of inflammatory signaling pathway in the progression of apoptotic cell death These results taken together suggest that TBI induced upregulation of apoptosis related genes, concomitant with the detection of apoptotic brain pathology during the 3-48 h post-injury period, which may be likely mediated by inflammation Thera pies designed at abrogating apoptosis and/or inflammation may prove effective when initiated at this subacute TBI phase (C) 2010 IBRO Published by Elsevier Ltd All rights reserved	[Shojo, H.; Adachi, N.] Univ Yamanashi, Dept Legal Med, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, Yamanashi 4093898, Japan; [Shojo, H.; Kaneko, Y.; Borlongan, C. V.] Univ S Florida, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Mabuchi, T.] Univ Yamanashi, Dept Biochem, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, Yamanashi 4093898, Japan; [Kibayashi, K.] Tokyo Womens Med Univ, Dept Legal Med, Shinjuku Ku, Tokyo 1628666, Japan	Shojo, H (corresponding author), Univ Yamanashi, Dept Legal Med, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.		Borlongan, Cesar/I-5696-2012; Kazuhiko, Kibayashi/F-5173-2013	Borlongan, Cesar/0000-0002-2966-9782; Kazuhiko, Kibayashi/0000-0001-6510-5215	Ministry of Education Culture Sports Sciences and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17790409, 19689015, 22390141]; James and Esther King Biomedical Research [09KB 01 23123, 1KG01 33966]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22390141, 22330027] Funding Source: KAKEN	This study was supported by grants (17790409 19689015 and 22390141) from the Ministry of Education Culture Sports Sciences and Technology of Japan (Dr Shojo) USF Department of Neurosurgery and Brain Repair funds (Drs Kaneko and Borlongan) Dr Borlongan received funds from James and Esther King Biomedical Research Programs Grant Numbers 09KB 01 23123 and 1KG01 33966	Abbas AK, 2003, EFFECTOR MECH IMMUNE, P243; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Bruce A, 2002, CELL CYCLE PROGRAM 4, P1010; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Cavallaro S, 2001, EUR J NEUROSCI, V13, P1809, DOI 10.1046/j.0953-816x.2001.01543.x; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Crawford FC, 2007, BRAIN RES, V1185, P45, DOI 10.1016/j.brainres.2007.09.042; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Ezcurra ALD, 2010, NEUROBIOL DIS, V37, P630, DOI 10.1016/j.nbd.2009.11.018; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; Eilers A, 1998, J NEUROSCI, V18, P1713; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gown AM, 2002, J HISTOCHEM CYTOCHEM, V50, P449, DOI 10.1177/002215540205000401; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; Manor T, 2008, NEUROL RES, V30, P1075, DOI 10.1179/174313208X346107; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Nagai A, 2005, J NEUROSCI RES, V81, P342, DOI 10.1002/jnr.20478; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Pedersen MO, 2009, BRAIN RES, V1271, P103, DOI 10.1016/j.brainres.2009.03.022; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; RINK A, 1995, AM J PATHOL, V147, P1575; SANES JR, 2000, DEV NERVOUS SYSTEM P, P1087; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	56	62	66	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 29	2010	171	4					1273	1282		10.1016/j.neuroscience.2010.10.018			10	Neurosciences	Neurosciences & Neurology	693NO	WOS:000285231000028	20950674				2021-06-18	
J	Kline, AE; McAloon, RL; Henderson, KA; Bansal, UK; Ganti, BM; Ahmed, RH; Gibbs, RB; Sozda, CN				Kline, Anthony E.; McAloon, Rose L.; Henderson, Kate A.; Bansal, Utsav K.; Ganti, Bhaskar M.; Ahmed, Rashid H.; Gibbs, Robert B.; Sozda, Christopher N.			Evaluation of a Combined Therapeutic Regimen of 8-OH-DPAT and Environmental Enrichment after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						beam-walking; behavior; controlled cortical impact; ChAT; 5-HT1A receptor agonist; functional recovery; hippocampus; learning and memory; Morris water maze; traumatic brain injury	RECEPTOR AGONIST 8-OH-DPAT; CONTROLLED CORTICAL IMPACT; FOREBRAIN CHOLINE-ACETYLTRANSFERASE; COGNITIVE DEFICITS; GROWTH-FACTOR; MODERATE HYPOTHERMIA; UNITED-STATES; NEUROBEHAVIORAL BENEFIT; CONTUSION INJURY; CLINICAL-TRIALS	When provided individually, both the serotonin (5-HT1A)-receptor agonist 8-hydroxy-2-(di-n-propylamino)te-tralin (8-OH-DPAT) and environmental enrichment (EE) enhance behavioral outcome and reduce histopathology after experimental traumatic brain injury (TBI). The aim of this study was to determine whether combining these therapies would yield greater benefit than either used alone. Anesthetized adult male rats received a cortical impact or sham injury and then were randomly assigned to enriched or standard (STD) housing, where either 8-OH-DPAT (0.1 mg/kg) or vehicle (1.0 mL/kg) was administered intraperitoneally once daily for 3 weeks. Motor and cognitive assessments were conducted on post-injury days 1-5 and 14-19, respectively. CA1/CA3 neurons and choline acetyltransferase-positive (ChAT(+)) medial septal cells were quantified at 3 weeks. 8-OH-DPAT and EE attenuated CA3 and ChAT(+) cell loss. Both therapies also enhanced motor recovery, acquisition of spatial learning, and memory retention, as verified by reduced times to traverse the beam and to locate an escape platform in the water maze, and a greater percentage of time spent searching in the target quadrant during a probe trial in the TBI+STD+8-OH-DPAT, TBI+EE+8-OH-DPAT, and TBI+EE+vehicle groups versus the TBI+STD+vehicle group (p <= 0.0016). No statistical distinctions were revealed between the TBI+EE+8-OH-DPAT and TBI+EE+vehicle groups in functional outcome or CA1/CA3 cell survival, but there were significantly more ChAT(+) cells in the former (p=0.003). These data suggest that a combined therapeutic regimen of 8-OH-DPAT and EE reduces TBI-induced ChAT(+) cell loss, but does not enhance hippocampal cell survival or neurobehavioral performance beyond that of either treatment alone. The findings underscore the complexity of combinational therapies and of elucidating potential targets for TBI.	[Kline, Anthony E.; McAloon, Rose L.; Henderson, Kate A.; Bansal, Utsav K.; Ganti, Bhaskar M.; Ahmed, Rashid H.; Sozda, Christopher N.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grants HD046700 and NS060005, awarded to A.E.K.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon C. Edward, 2009, P385, DOI 10.1007/978-1-60327-185-1_33; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fujii T, 1997, BRAIN RES, V761, P244, DOI 10.1016/S0006-8993(97)00325-9; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; Gibbs RB, 2002, HORM BEHAV, V42, P245, DOI 10.1006/hbeh.2002.1825; Gibbs RB, 2000, NEUROSCIENCE, V101, P931, DOI 10.1016/S0306-4522(00)00433-4; Gibbs RB, 2010, ENDOCR REV, V31, P224, DOI 10.1210/er.2009-0036; Gold PE, 2003, NEUROBIOL LEARN MEM, V80, P194, DOI 10.1016/j.nlm.2003.07.003; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Hasselmo ME, 2006, CURR OPIN NEUROBIOL, V16, P710, DOI 10.1016/j.conb.2006.09.002; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Johnson DA, 2002, BRAIN RES, V943, P132, DOI 10.1016/S0006-8993(02)02623-9; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; Lanari A, 2006, MECH AGEING DEV, V127, P158, DOI 10.1016/j.mad.2005.09.016; Lazaris A, 2003, BRAIN RES, V967, P181, DOI 10.1016/S0006-8993(02)04272-5; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Menku A, 2003, NEUROSURG REV, V26, P288, DOI 10.1007/s10143-003-0277-6; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mufson Elliott J, 2008, Expert Rev Neurother, V8, P1703, DOI 10.1586/14737175.8.11.1703; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Oosterink BJ, 2003, NEUROREPORT, V14, P57, DOI 10.1097/00001756-200301200-00011; Paban V, 2005, NEUROSCIENCE, V132, P13, DOI 10.1016/j.neuroscience.2004.11.024; PARK GAS, 1992, NEUROSCI LETT, V143, P259, DOI 10.1016/0304-3940(92)90278-F; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Roloff EV, 1999, CELL MOL LIFE SCI, V55, P601, DOI 10.1007/s000180050318; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; Row BW, 2007, BEHAV BRAIN RES, V177, P308, DOI 10.1016/j.bbr.2006.11.028; RYLETT RJ, 1993, PROG BRAIN RES, V98, P161; Sarter M, 2003, NEUROBIOL LEARN MEM, V80, P245, DOI 10.1016/S1074-7427(03)00070-4; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Segovia G, 2009, J NEURAL TRANSM, V116, P1007, DOI 10.1007/s00702-009-0214-0; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; WU DH, 1994, J NEUROCHEM, V62, P1653; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	91	62	63	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					2021	2032		10.1089/neu.2010.1535			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500009	21028935	Green Published			2021-06-18	
J	Manni, L; Albanesi, M; Guaragna, M; Paparo, SB; Aloe, L				Manni, Luigi; Albanesi, Marcello; Guaragna, Morena; Paparo, Samuele Barbaro; Aloe, Luigi			Neurotrophins and acupuncture	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						Neurotrophin; Nerve growth factor; Acupuncture	NERVE GROWTH-FACTOR; INDUCED POLYCYSTIC OVARIES; LOW-FREQUENCY ELECTROACUPUNCTURE; DORSAL-ROOT GANGLION; FACTOR MESSENGER-RNA; RAT-BRAIN; DIABETIC POLYNEUROPATHY; SEROTONERGIC NEURONS; CLINICAL-APPLICATION; SIGNAL-TRANSDUCTION	The aim of this review is to report recent findings and ongoing studies on the effects of acupuncture on endogenous biological mediators, in particular on neurotrophins such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Acupuncture is a therapeutic technique and is a part of Traditional Chinese Medicine (TCM). Western descriptions of the clinical efficacy of acupuncture on pain, inflammation, motor dysfunction, mood disorders, and seizures are based on the stimulation of several classes of sensory afferent fibers and the consequent activation of physiological processes similar to those resulting from physical exercise or deep massage. The established research on the neuro-physiological correlates of acupuncture has pointed towards endogenous opioids as the principal biological mediators of the therapeutic actions of this ancient technique. More recently, several classes of molecules, such as neurotransmitters, cytokines and growth factors, have also been identified as possible mediators for specific acupuncture effects. This review will focus on the links between acupuncture and a class of growth factors known as neurotrophins (NTs), which are the main mediators of neural activity, plasticity and repair following neurodegeneration and/or traumatic injury. A special emphasis will be placed on the work of our laboratory investigating the role of nerve growth factor (NGF), the prototypical member of the neurotrophin family, as a mediator of acupuncture effects in the central nervous system (CNS) and as a modulator of sensory and autonomic activity. (C) 2010 Elsevier B.V. All rights reserved.	[Manni, Luigi; Aloe, Luigi] CNR, Inst Neurobiol & Mol Med, I-00143 Rome, Italy; [Albanesi, Marcello; Guaragna, Morena; Paparo, Samuele Barbaro] Univ Roma La Sapienza, Fac Med & Chirurg 2, Dip Med Interna, UO Allergol Immunol Clin, Rome, Italy	Manni, L (corresponding author), CNR, Inst Neurobiol & Mol Med, Via Fosso di Fiorano 64, I-00143 Rome, Italy.	luigi.manni@inmm.cnr.it	Manni, Luigi/J-5637-2018	Albanesi, Marcello/0000-0001-7608-9572	Regione LazioRegione Lazio	Luigi Manni's contract is supported by Regione Lazio grant "Sviluppo della Ricerca sul Cervello" to INMM-CNR (Regione Lazio, Legge n.9, 17 febbraio 2005, Art. 41 Comma 2).	Aarts MM, 2005, NEUROSCIENTIST, V11, P116, DOI 10.1177/1073858404272966; Allen SJ, 2006, CLIN SCI, V110, P175, DOI 10.1042/CS20050161; Alleva E, 1993, Rev Neurosci, V4, P41; Aloe L, 1999, MICROSC RES TECHNIQ, V45, P285, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<285::AID-JEMT12>3.0.CO;2-3; Aloe L, 2004, PROG BRAIN RES, V146, P515; Aloe L, 2002, PHARMACOL BIOCHEM BE, V73, P159, DOI 10.1016/S0091-3057(02)00757-8; ALOE L, 1994, BRAIN RES BULL, V33, P173, DOI 10.1016/0361-9230(94)90247-X; Aloe L, 1997, ALLERGY, V52, P883, DOI 10.1111/j.1398-9995.1997.tb01247.x; Aloe L, 2001, Arch Physiol Biochem, V109, P354, DOI 10.1076/apab.109.4.354.4235; Aloe L, 2008, PHARMACOL RES, V57, P253, DOI 10.1016/j.phrs.2008.01.010; Aloe L, 2009, NEUROSCI LETT, V449, P173, DOI 10.1016/j.neulet.2008.11.003; ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5; Angelucci F, 2000, J NEUROSCI RES, V60, P783, DOI 10.1002/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M; APFEL SC, 1995, BAILLIERE CLIN NEUR, V4, P593; Apfel SC, 2000, JAMA-J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; Apfel SC, 2002, INT REV NEUROBIOL, V50, P393; Bai YH, 2004, GYNECOL OBSTET INVES, V57, P80, DOI 10.1159/000075382; BARRIA A, 1993, ENDOCRINOLOGY, V133, P2696, DOI 10.1210/en.133.6.2696; Bartoletti A, 2002, J NEUROSCI, V22, P10072; Bian J T, 1993, Int J Neurosci, V72, P15; Bonini S, 1999, INT ARCH ALLERGY IMM, V118, P159, DOI 10.1159/000024055; Bonini S, 2000, OPHTHALMOLOGY, V107, P1347, DOI 10.1016/S0161-6420(00)00163-9; Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552; Campbell Anthony, 2006, Acupunct Med, V24, P118; CAO XD, 1983, ACUPUNCTURE ELECTRO, V8, P25, DOI 10.3727/036012983816715028; Capsoni S, 2009, J ALZHEIMERS DIS, V16, P371, DOI 10.3233/JAD-2009-0953; Carlsson Christer, 2002, Acupunct Med, V20, P82; Chae Y, 2007, NEUROL RES, V29, pS42, DOI 10.1179/016164107X172284; Chalazonitis A, 2004, PROG BRAIN RES, V146, P243, DOI 10.1016/S0079-6123(03)46016-0; Chao DM, 1999, AM J PHYSIOL-HEART C, V276, pH2127; Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163; Chen J, 2007, NEUROSCI RES, V59, P399, DOI 10.1016/j.neures.2007.08.006; Chen Xue-Qing, 1998, J Alzheimers Dis, V1, P35; Chen YY, 2008, ACUPUNCTURE ELECTRO, V33, P19, DOI 10.3727/036012908803861212; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Colangelo AM, 2004, MOL BRAIN RES, V124, P97, DOI 10.1016/j.molbrainres.2004.01.011; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cowan WM, 2001, ANNU REV NEUROSCI, V24, P551, DOI 10.1146/annurev.neuro.24.1.551; Culmsee C, 1999, EUR J PHARMACOL, V379, P33, DOI 10.1016/S0014-2999(99)00452-5; DayLollini PA, 1997, EXP NEUROL, V145, P24, DOI 10.1006/exnr.1997.6448; Ding Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-35; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Eriksdotter J.M., 1998, DEMENT GERIATR COGN, V9, P246, DOI [DOI 10.1159/000017069, 10.1159/000017069]; Ernfors P, 2001, CELL MOL LIFE SCI, V58, P1036, DOI 10.1007/PL00000918; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; FRIEDMAN WJ, 1993, EXP NEUROL, V119, P72, DOI 10.1006/exnr.1993.1007; Friedman WJ, 1998, NEUROSCIENCE, V84, P101, DOI 10.1016/S0306-4522(97)00526-5; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; Generini S, 2004, EXP CLIN ENDOCR DIAB, V112, P542, DOI 10.1055/s-2004-821313; Guo HF, 1996, MOL BRAIN RES, V43, P157, DOI 10.1016/S0169-328X(96)00170-2; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAN JS, 1986, PAIN, V27, P101, DOI 10.1016/0304-3959(86)90227-7; HE LF, 1992, ACUPUNCTURE ELECTRO, V17, P243, DOI 10.3727/036012992816357620; Hefti FF, 2006, TRENDS PHARMACOL SCI, V27, P85, DOI 10.1016/j.tips.2005.12.001; Hochhaus F, 2001, BMC Pediatr, V1, P2, DOI 10.1186/1471-2431-1-2; Holden JE, 2005, AACN ADV CRIT CARE, V16, P291, DOI 10.1097/00044067-200507000-00003; HOLE K, 1981, CEPHALALGIA, V1, P51, DOI 10.1111/j.1468-2982.1981.tb00008.x; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Ibanez CF, 1996, NEUROCHEM RES, V21, P787, DOI 10.1007/BF02532301; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010; KAUFMAN MP, 1984, CARDIOVASC RES, V18, P663, DOI 10.1093/cvr/18.11.663; Kawakita K, 1996, PROG BRAIN RES, V113, P507, DOI 10.1016/S0079-6123(08)61105-X; Kawakita K., 1991, ADV PHYSL SCI, P731; Kawakita K, 2006, J PHARMACOL SCI, V100, P443, DOI 10.1254/jphs.CRJ06004X; Kennedy AJ, 1998, J NEUROL NEUROSUR PS, V65, P393, DOI 10.1136/jnnp.65.3.393; Kim WS, 2009, BRAIN RES, V1248, P176, DOI 10.1016/j.brainres.2008.11.009; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; KNIFFKI KD, 1981, CIRC RES, V48, P25; KOLIATSOS VE, 1991, ANN NEUROL, V30, P831, DOI 10.1002/ana.410300613; Krzan M, 2001, J NEUROSCI RES, V64, P261, DOI 10.1002/jnr.1074.abs; Kwon YB, 2000, AM J CHINESE MED, V28, P435, DOI 10.1142/S0192415X00000519; Lambiase A, 2003, ARCH ITAL BIOL, V141, P141; Lambiase A, 2000, INVEST OPHTH VIS SCI, V41, P1063; Lambiase A, 2007, BRAIN RES, V1127, P45, DOI 10.1016/j.brainres.2006.09.102; Lara HE, 2000, ENDOCRINOLOGY, V141, P1059, DOI 10.1210/en.141.3.1059; Lara HE, 2002, MICROSC RES TECHNIQ, V59, P495, DOI 10.1002/jemt.10229; LARA HE, 1993, ENDOCRINOLOGY, V133, P2690, DOI 10.1210/en.133.6.2690; Lee E, 2009, BMB REP, V42, P239, DOI 10.5483/BMBRep.2009.42.5.239; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liang XB, 2002, MOL BRAIN RES, V108, P51, DOI 10.1016/S0169-328X(02)00513-2; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; Liu F, 2009, NEUROSCI LETT, V450, P158, DOI 10.1016/j.neulet.2008.09.066; Lu B, 2000, PROG BRAIN RES, V128, P231; MAESTRIPIERI D, 1990, PHYSIOL BEHAV, V47, P161, DOI 10.1016/0031-9384(90)90056-A; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANNERAS L, 2009, AM J PHYSIOL-REG I, V926, pR1124; Manneras L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053; Manni L, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-21; Manni L, 2006, AM J PHYSIOL-REG I, V290, pR826, DOI 10.1152/ajpregu.00078.2005; Manni L, 2005, J NEUROENDOCRINOL, V17, P846, DOI 10.1111/j.1365-2826.2005.01378.x; Manni L, 2005, AUTON NEUROSCI-BASIC, V118, P79, DOI 10.1016/j.autneu.2005.01.004; Manni L, 2000, BRIT J PHARMACOL, V129, P744, DOI 10.1038/sj.bjp.0703088; Manni L, 2002, RHEUMATOLOGY, V41, P787, DOI 10.1093/rheumatology/41.7.787; Manni L, 2001, NEUROREPORT, V12, P1621, DOI 10.1097/00001756-200106130-00022; McAllister AK, 2001, CELL MOL LIFE SCI, V58, P1054, DOI 10.1007/PL00000920; McArthur JC, 2000, NEUROLOGY, V54, P1080, DOI 10.1212/WNL.54.5.1080; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Mufson EJ, 1999, PROG NEUROBIOL, V57, P451, DOI 10.1016/S0301-0082(98)00059-8; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; OLSON L, 1993, ACTA NEUROCHIR, P3; Pagani L, 2006, BRAIN RES, V1092, P198, DOI 10.1016/j.brainres.2006.03.074; Parkman HP, 2003, AM J GASTROENTEROL, V98, P1338, DOI 10.1016/S0002-9270(03)00252-1; Pezet S, 2004, EXPERT OPIN THER TAR, V8, P391, DOI 10.1517/14728222.8.5.391; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Riaz SS, 2000, MOL BRAIN RES, V85, P179; Rush RA, 1997, CLIN EXP PHARMACOL P, V24, P549, DOI 10.1111/j.1440-1681.1997.tb02089.x; Sahenk Z, 2005, NEUROLOGY, V65, P681, DOI 10.1212/01.WNL.0000171978.70849.c5; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; Schor NF, 2005, PROG NEUROBIOL, V77, P201, DOI 10.1016/j.pneurobio.2005.10.006; Schulte-Herbruggen O, 2007, CURR MED CHEM, V14, P2318, DOI 10.2174/092986707781745578; SEIGER A, 1993, BEHAV BRAIN RES, V57, P255, DOI 10.1016/0166-4328(93)90141-C; Semkova I, 1996, BRAIN RES, V717, P44, DOI 10.1016/0006-8993(95)01567-1; SKUP MH, 1994, ACTA NEUROBIOL EXP, V54, P81; Stener-Victorin E, 2000, BIOL REPROD, V63, P1497, DOI 10.1095/biolreprod63.5.1497; Stener-Victorin Elisabet, 2003, Reprod Biol Endocrinol, V1, P33, DOI 10.1186/1477-7827-1-33; Sun N, 2005, BRAIN RES, V1064, P98, DOI 10.1016/j.brainres.2005.09.060; TAGLIALATELA G, 1991, ENDOCRINOLOGY, V129, P2212, DOI 10.1210/endo-129-4-2212; Takagi J, 1998, JPN J PHARMACOL, V78, P511, DOI 10.1254/jjp.78.511; Terenghi G, 1999, J ANAT, V194, P1, DOI 10.1046/j.1469-7580.1999.19410001.x; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Tirassa P, 1998, BRIT J PHARMACOL, V123, P1230, DOI 10.1038/sj.bjp.0701718; Tirassa P, 1999, P NATL ACAD SCI USA, V96, P6473, DOI 10.1073/pnas.96.11.6473; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Tuveri M, 2000, LANCET, V356, P1739, DOI 10.1016/S0140-6736(00)03212-8; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Vassilakopoulos T, 2005, CURR OPIN CRIT CARE, V11, P1, DOI 10.1097/00075198-200502000-00002; Vitalis T, 2002, J NEUROSCI, V22, P4987, DOI 10.1523/JNEUROSCI.22-12-04987.2002; Wang TH, 2007, NEUROCHEM RES, V32, P1415, DOI 10.1007/s11064-007-9326-9; Winkler J, 1997, ANN NEUROL, V41, P82, DOI 10.1002/ana.410410114; Wu HG, 2008, DIGEST DIS SCI, V53, P1644, DOI 10.1007/s10620-007-0062-4; Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133; Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004; Yamada K, 2002, LIFE SCI, V70, P735, DOI 10.1016/S0024-3205(01)01461-8; Yamada K, 2003, J PHARMACOL SCI, V91, P267; Yasuno H, 2000, BRAIN RES, V887, P53, DOI 10.1016/S0006-8993(00)02966-8; Yun SJ, 2002, NEUROSCI LETT, V318, P85, DOI 10.1016/S0304-3940(01)02492-2; Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002; Zhang WT, 2004, NEUROSCI LETT, V354, P50, DOI 10.1016/j.neulet.2003.09.080; ZHAO L, 2005, YI XUE YING DE WEN B, V25, P247; Zhao L, 2007, LIFE SCI, V81, P1211, DOI 10.1016/j.lfs.2007.08.034; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; ZHOU XF, 1994, BRAIN RES, V643, P162, DOI 10.1016/0006-8993(94)90022-1; Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943	148	62	67	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	OCT 28	2010	157	1-2			SI		9	17		10.1016/j.autneu.2010.03.020			9	Neurosciences	Neurosciences & Neurology	679SX	WOS:000284182200003	20451467				2021-06-18	
J	Bennet, L; Booth, L; Gunn, AJ				Bennet, L.; Booth, L.; Gunn, A. J.			Potential biomarkers for hypoxic-ischemic encephalopathy	SEMINARS IN FETAL & NEONATAL MEDICINE			English	Article						Asphyxia; Biomarkers; Brain metabolism; Electroencephalogram; Hypoxic-ischemic encephalopathy; Near-infrared spectroscopy	PRETERM FETAL SHEEP; MAGNETIC-RESONANCE-SPECTROSCOPY; NEAR-INFRARED SPECTROSCOPY; UMBILICAL-CORD OCCLUSION; NEURON-SPECIFIC ENOLASE; AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; TRAUMATIC BRAIN-INJURY; RAT HIPPOCAMPAL SLICES; TERM NEWBORN-INFANTS; NEONATAL ENCEPHALOPATHY	Cerebral hypothermia reduces brain injury and improves behavioral recovery after hypoxia ischemia (HI) at birth. However, using current enrolment criteria many infants are not helped, and conversely, a significant proportion of control infants survive without disability. In order to further improve treatment we need better biomarkers of injury. A 'true' biomarker for the phase of evolving, 'treatable' injury would allow us to identify not only whether infants are at risk of damage, but also whether they are still able to benefit from intervention. Even a less specific measure that allowed either more precise early identification of infants at risk of adverse neurodevelopmental outcome would reduce the variance of outcome of trials, improving trial power while reducing the number of infants unnecessarily treated. Finally, valid short-term surrogates for long term outcome after treatment would allow more rapid completion of preliminary evaluation and thus allow new strategies to be tested more rapidly. Experimental studies have demonstrated that there is a relatively limited 'window of opportunity' for effective treatment (up to about 6-8 h after HI, the 'latent phase'), before secondary cell death begins. We critically evaluate the utility of proposed biochemical, electronic monitoring, and imaging biomarkers against this framework. This review highlights the two central limitations of most presently available biomarkers: that they are most precise for infants with severe injury who are already easily identified, and that their correlation is strongest at times well after the latent phase, when injury is no longer 'treatable'. This is an important area for further research. (c) 2010 Elsevier Ltd. All rights reserved.	[Bennet, L.; Booth, L.; Gunn, A. J.] Univ Auckland, Dept Physiol, Fetal Physiol & Neurosci Grp, Auckland, New Zealand	Bennet, L (corresponding author), Univ Auckland, Dept Physiol, Fetal Physiol & Neurosci Grp, Private Bag 92019, Auckland, New Zealand.	l.bennet@auckland.ac.nz		Booth, Lindsea/0000-0003-3093-5766; Gunn, Alistair/0000-0003-0656-7035; Bennet, Laura/0000-0002-4336-7596	Health Research Council of New ZealandHealth Research Council of New Zealand; Auckland Medical Research Foundation; Lottery Health New Zealand; March of Dimes USAMarch of Dimes; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS063141] Funding Source: NIH RePORTER	The authors gratefully acknowledge funding support from the Health Research Council of New Zealand, The Auckland Medical Research Foundation, Lottery Health New Zealand, March of Dimes USA, and the US National Institutes of Health.	AZZOPARDI D, 1989, PEDIATR RES, V25, P445, DOI 10.1203/00006450-198905000-00004; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bashir Moataza, 2009, Front Biosci (Elite Ed), V1, P560; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; Bennet L, 2007, J NEUROPHYSIOL, V97, P572, DOI 10.1152/jn.00957.2006; Bennet L, 2006, J PHYSIOL-LONDON, V572, P141, DOI 10.1113/jphysiol.2006.105197; Bennet L, 2009, FETAL NEONATAL NEURO, P472; BENNET L, 2009, FETAL NEONATAL BRAIN, P48; Bennet L, 2007, AM J PHYSIOL-REG I, V292, pR1569, DOI 10.1152/ajpregu.00743.2006; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bokesch PM, 2002, ANESTH ANALG, V95, P889, DOI 10.1097/00000539-200210000-00018; Bruschettini M, 2005, DEV BRAIN RES, V159, P113, DOI 10.1016/j.devbrainres.2005.07.003; Cady EB, 2001, CHILD NERV SYST, V17, P145, DOI 10.1007/s003810000391; Cady EB, 2008, J NEUROCHEM, V107, P1027, DOI 10.1111/j.1471-4159.2008.05662.x; Cooper CE, 1999, J CEREBR BLOOD F MET, V19, P27, DOI 10.1097/00004647-199901000-00003; Cowan F, 2003, LANCET, V361, P736, DOI 10.1016/S0140-6736(03)12658-X; DAWES GS, 1959, J PHYSIOL-LONDON, V146, P516, DOI 10.1113/jphysiol.1959.sp006208; Dean JM, 2006, NEUROSCIENCE, V142, P615, DOI 10.1016/j.neuroscience.2006.06.066; Dean JM, 2006, NEUROPHARMACOLOGY, V50, P491, DOI 10.1016/j.neuropharm.2005.10.017; Dean JM, 2006, EXP PHYSIOL, V91, P423, DOI 10.1113/expphysiol.2005.032375; Dean JM, 2008, NEUROPHARMACOLOGY, V55, P166, DOI 10.1016/j.neuropharm.2008.05.009; DeHaan HH, 1997, PEDIATR RES, V41, P96, DOI 10.1203/00006450-199701000-00015; deHaan HH, 1997, AM J OBSTET GYNECOL, V176, P18, DOI 10.1016/S0002-9378(97)80005-1; DOYLE OM, 2007, C P IEEE ENG MED BIO, P717; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Friel LA, 2007, J PERINAT MED, V35, P385, DOI 10.1515/JPM.2007.101; Fujii EY, 2004, BRAIN RES, V1018, P136, DOI 10.1016/j.brainres.2004.05.061; Garnier Y, 2009, REPROD SCI, V16, P758, DOI 10.1177/1933719109335801; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2000, CLIN CHEM, V46, P998; Gazzolo D, 2009, J MATERN-FETAL NEO M, V22, P57, DOI 10.1080/14767050903181468; Geddes R, 2001, DEV NEUROSCI-BASEL, V23, P180, DOI 10.1159/000046140; George S, 2004, AM J PHYSIOL-REG I, V287, pR925, DOI 10.1152/ajpregu.00263.2004; Giuseppe D, 2009, CURR NEUROVASC RES, V6, P110, DOI 10.2174/156720209788185614; Giussani DA, 2005, PEDIATR RES, V58, P179, DOI 10.1203/01.PDR.0000169999.66157.C0; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; Greisen G, 2006, SEMIN FETAL NEONAT M, V11, P498, DOI 10.1016/j.siny.2006.07.010; Gunn A J, 2006, NeuroRx, V3, P154, DOI 10.1007/BF03207046; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 2008, CURR OPIN OBSTET GYN, V20, P175, DOI 10.1097/GCO.0b013e3282f4ef9e; Gunn AJ, 2009, CLIN PERINATOL, V36, P579, DOI 10.1016/j.clp.2009.06.007; Hirst JJ, 2008, NEUROCHEM INT, V52, P602, DOI 10.1016/j.neuint.2007.07.018; HOPE PL, 1984, LANCET, V2, P366; HUGHES JR, 1994, CLIN ELECTROENCEPHAL, V25, P127, DOI 10.1177/155005949402500404; Iwata O, 2007, BRAIN RES, V1154, P173, DOI 10.1016/j.brainres.2007.03.083; Jensen EC, 2006, J PHYSIOL-LONDON, V572, P131, DOI 10.1113/jphysiol.2005.100768; Jensen FE, 1998, J NEUROPHYSIOL, V79, P73; JIANG W, 2009, C P IEEE ENG MED BIO, V1, P2192; Laptook AR, 2009, PEDIATRICS, V124, P1619, DOI 10.1542/peds.2009-0934; Loukovaara M, 2009, EUR J OBSTET GYN R B, V142, P115, DOI 10.1016/j.ejogrb.2008.10.008; Low JA, 1997, AM J OBSTET GYNECOL, V177, P1391, DOI 10.1016/S0002-9378(97)70080-2; MacLennan A, 1999, BMJ-BRIT MED J, V319, P1054, DOI 10.1136/bmj.319.7216.1054; Martin E, 1996, PEDIATR RES, V40, P749, DOI 10.1203/00006450-199611000-00015; Martins RO, 2006, ARQ NEURO-PSIQUIAT, V64, P24, DOI 10.1590/S0004-282X2006000100006; Murabayashi M, 2008, PEDIATR INT, V50, P17, DOI 10.1111/j.1442-200X.2007.02506.x; Murray DM, 2009, PEDIATRICS, V124, pE459, DOI 10.1542/peds.2008-2190; Murray DM, 2009, AM J PERINAT, V26, P605, DOI 10.1055/s-0029-1220774; Nagdyman N, 2003, PEDIATR RES, V54, P270, DOI 10.1203/01.PDR.0000072518.98189.A0; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Nelson KB, 1996, NEW ENGL J MED, V334, P613, DOI 10.1056/NEJM199603073341001; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Okumura A, 2003, J PEDIATR-US, V143, P26, DOI 10.1016/S0022-3476(03)00182-3; PEEBLES DM, 1992, AM J OBSTET GYNECOL, V166, P1369, DOI 10.1016/0002-9378(92)91606-B; Peeters-Scholte C, 2004, EXP BRAIN RES, V156, P20, DOI 10.1007/s00221-003-1761-5; PEZZANI C, 1986, NEUROPEDIATRICS, V17, P11, DOI 10.1055/s-2008-1052492; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; Robertson NJ, 2007, EARLY HUM DEV, V83, P801, DOI 10.1016/j.earlhumdev.2007.09.015; Roth SC, 1997, DEV MED CHILD NEUROL, V39, P718; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Scher MS, 2002, EPILEPTIC DISORD, V4, P139; SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P179, DOI 10.1016/0013-4694(94)90089-2; Schulpis KH, 2006, SCAND J CLIN LAB INV, V66, P733, DOI 10.1080/00365510600977737; Selman WR, 2004, BRAIN RES, V999, P167, DOI 10.1016/j.brainres.2003.11.016; Shalak LF, 2003, PEDIATRICS, V111, P351, DOI 10.1542/peds.111.2.351; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHELLEY HJ, 1961, BRIT MED BULL, V17, P137, DOI 10.1093/oxfordjournals.bmb.a069888; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Szeto HH, 2008, ANTIOXID REDOX SIGN, V10, P601, DOI 10.1089/ars.2007.1892; Thayyil S, 2010, PEDIATRICS, V125, pE382, DOI 10.1542/peds.2009-1046; Thorngren-Jerneck K, 2004, PEDIATR RES, V55, P406, DOI 10.1203/01.PDR.0000106806.75086.D3; Tichauer KM, 2009, J APPL PHYSIOL, V106, P1506, DOI 10.1152/japplphysiol.91156.2008; Toet MC, 2009, EARLY HUM DEV, V85, P77, DOI 10.1016/j.earlhumdev.2008.11.007; VANBE, 2008, NEONATOLOGY, V94, P237; Vannucci RC, 2004, J CEREBR BLOOD F MET, V24, P1090, DOI 10.1097/01.WCB.0000133250.03953.63; VecchieriniBlineau MF, 1996, NEUROPHYSIOL CLIN, V26, P350, DOI 10.1016/S0987-7053(97)89149-6; Vicente E, 2007, CLIN EXP PHARMACOL P, V34, P1126, DOI 10.1111/j.1440-1681.2007.04687.x; Wang C, 1996, EPILEPSY RES, V23, P105, DOI 10.1016/0920-1211(95)00086-0; Wassink G, 2007, J APPL PHYSIOL, V103, P1311, DOI 10.1152/japplphysiol.00396.2007; Wayenberg JL, 2005, J MATERN-FETAL NEO M, V18, P381, DOI 10.1080/14767050500249916; WESTGATE JA, 1997, AM J OBSTET GYNECOL, V236, pE1; Wijnberger LDE, 2002, PEDIATR RES, V51, P492, DOI 10.1203/00006450-200204000-00015; Winter JD, 2009, PEDIATR RES, V65, P181, DOI 10.1203/PDR.0b013e31818f06fb; Wong FY, 2007, EARLY HUM DEV, V83, P379, DOI 10.1016/j.earlhumdev.2006.08.002; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839	97	62	64	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1744-165X	1878-0946		SEMIN FETAL NEONAT M	Semin. Fetal Neonatal Med.	OCT	2010	15	5					253	260		10.1016/j.siny.2010.05.007			8	Pediatrics	Pediatrics	653RZ	WOS:000282115700004	20646975	Green Accepted			2021-06-18	
J	Zweifel, C; Katan, M; Schuetz, P; Siegemund, M; Morgenthaler, NG; Merlo, A; Mueller, B; Christ-Crain, M				Zweifel, Christian; Katan, Mira; Schuetz, Philipp; Siegemund, Martin; Morgenthaler, Nils G.; Merlo, Adrian; Mueller, Beat; Christ-Crain, Mirjam			Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage	BMC NEUROLOGY			English	Article							CORTICOTROPIN-RELEASING HORMONE; TRAUMATIC BRAIN-INJURY; VASOPRESSIN PRECURSOR; STABLE PEPTIDE; REGULATORY MECHANISMS; ANTIDIURETIC-HORMONE; PROGNOSTIC MARKER; CEREBRAL-ISCHEMIA; GRADING SCALE; V-2 RECEPTORS	Background: Spontaneous intracerebral hemorrhage (ICH) accounts for a high mortality and morbidity. Early prediction of outcome is crucial for optimized care and treatment decision. Copeptin, the C-terminal part of provasopressin, has emerged as a new prognostic marker in a variety of diseases, but its prognostic value in ICH is unknown. Methods: In 40 consecutive patients who were admitted to the hospital within 72 hours after a spontaneous ICH, the plasma copeptin level was measured with a sandwich immunoassay upon admission. The prognostic value of copeptin to predict 30 day mortality and functional outcome after 90 days was assessed. A favorable outcome was defined as a Barthel score above 85 and a score below 3 on the Modified Rankin Scale. Results: Copeptin correlated positively with hematoma volume (r = 0.32, p < 0.05) and negatively with the Glasgow Coma Scale (GCS) on admission (r = -0.35, p < 0.05). Copeptin levels were higher in patients who died within 30 days than in 30-day survivors (179.0 pmol/l (IQR 33.7-566.0) vs. 12.9 pmol/l (IQR 5.2-42.8), p = 0.003). Copeptin levels were also higher in patients with an unfavorable functional outcome at 90 days compared to patients with a favorable outcome (32.4 pmol/l (IQR 9.5-97.8) vs. 11.9 pmol/l (IQR 3.2-19.8), p = 0.04). For the prediction of death, receiver-operating-characteristics analysis revealed an area under the curve (AUC) for copeptin of 0.88 (95% CI 0.75-1.00). The predictive value of the copeptin concentration was thus similar to that of GCS (AUC 0.82 (95% CI 0.59-1.00) p = 0.53), of the ICH Score (AUC 0.89, (95% CI 0.76-1.00), p = 0.94) and the ICH Grading Scale (AUC 0.86 (95% CI 0.69-1.00), p = 0.81). Conclusions: Copeptin is a new prognostic marker in patients with an ICH. If this finding can be confirmed in larger studies, copeptin might be an additional valuable tool for risk stratification and decision-making in the acute phase of ICH.	[Katan, Mira; Schuetz, Philipp; Mueller, Beat; Christ-Crain, Mirjam] Univ Basel Hosp, Dept Endocrinol & Clin Nutr, CH-4031 Basel, Switzerland; [Zweifel, Christian; Merlo, Adrian] Univ Basel Hosp, Dept Neurosurg, CH-4031 Basel, Switzerland; [Katan, Mira] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Siegemund, Martin] Univ Basel Hosp, Dept Anesthesia, Operat Intens Care Unit, CH-4031 Basel, Switzerland; [Morgenthaler, Nils G.] Ctr Biotechnol, BRAHMS Aktiengesell, Dept Res, D-16761 Hennigsdorf, Germany; [Mueller, Beat] Dept Internal Med, CH-5001 Aarau, Switzerland	Christ-Crain, M (corresponding author), Univ Basel Hosp, Dept Endocrinol & Clin Nutr, Petersgraben 4, CH-4031 Basel, Switzerland.	Christ-Crain@unibas.ch	Siegemund, Martin/AAM-8929-2020; Mueller, Beat/G-2662-2012	Siegemund, Martin/0000-0002-2013-4140; Katan, Mira/0000-0002-9265-8066; Christ-Crain, Mirjam/0000-0002-6336-0965	Departments of Endocrinology and Neurology of the University Hospital of Basel, Switzerland; University of Basel; Swiss National FoundationSwiss National Science Foundation (SNSF) [PP00P3-123346]	We are grateful to the nurses, ward physicians, and patients who participated in the study, the Departments of Neurosurgery, Neurology, and Anesthesia, the emergency unit. We thank the staff of the central laboratory of the University Hospital Basel, particularly Melanie Wieland and Heike Freidank, for their help and technical support. This study was supported by in-house grants from the Departments of Endocrinology and Neurology of the University Hospital of Basel, Switzerland as well as by a research grant for young scientist from the University of Basel (to MK) and further by research grants from the Swiss National Foundation (PP00P3-123346, to MCC). We thank Dr. Ethan Taub for proof-reading our manuscript.	Alvarez-Sabin J, 2004, STROKE, V35, P1316, DOI 10.1161/01.STR.0000126827.69286.90; Andersen KK, 2009, STROKE, V40, P2068, DOI 10.1161/STROKEAHA.108.540112; Ariesen MJ, 2005, J NEUROL NEUROSUR PS, V76, P839, DOI 10.1136/jnnp.2004.048223; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Delgado P, 2007, NEUROLOGIA, V22, P448; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; Delgado P, 2006, STROKE, V37, P2837, DOI 10.1161/01.STR.0000245085.58807.ad; Fenske W, 2009, J CLIN ENDOCR METAB, V94, P123, DOI 10.1210/jc.2008-1426; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Goldstein LB, 2004, STROKE, V35, P1941, DOI 10.1161/01.STR.0000135225.80898.1c; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Itoi K, 2004, J NEUROENDOCRINOL, V16, P348, DOI 10.1111/j.0953-8194.2004.01172.x; Itoi K, 1998, ENDOCR J, V45, P13, DOI 10.1507/endocrj.45.13; Katan M, 2008, NEUROENDOCRINOL LETT, V29, P341; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Khan SQ, 2007, CIRCULATION, V115, P2103, DOI 10.1161/CIRCULATIONAHA.106.685503; KLEINDIENST A, 2006, ACTA NEUROCHIR SUPP, V221, P224; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; MAHONEY F I, 1965, Md State Med J, V14, P61; Mendelow AD, 2005, LANCET, V365, P387; Molnar AH, 2008, ACTA NEUROCHIR, V150, P265, DOI 10.1007/s00701-007-1400-1; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Morgenthaler NG, 2008, TRENDS ENDOCRIN MET, V19, P43, DOI 10.1016/j.tem.2007.11.001; Morgenthaler NG, 2007, SHOCK, V28, P219, DOI 10.1097/SHK.0b013e318033e5da; Ranger GS, 2002, INT J CLIN PRACT, V56, P777; RANKIN J, 1957, Scott Med J, V2, P200; Robertson GL, 2001, ENDOCRIN METAB CLIN, V30, P671, DOI 10.1016/S0889-8529(05)70207-3; Ruiz-Sandoval JL, 2007, STROKE, V38, P1641, DOI 10.1161/STROKEAHA.106.478222; Sacco RL, 2006, NAT CLIN PRACT NEURO, V2, P577, DOI 10.1038/ncpneuro0345; Stoiser B, 2006, EUR J CLIN INVEST, V36, P771, DOI 10.1111/j.1365-2362.2006.01724.x; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Xu Miao, 2007, Chin J Traumatol, V10, P90	36	62	64	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	MAY 26	2010	10								34	10.1186/1471-2377-10-34			8	Clinical Neurology	Neurosciences & Neurology	626AZ	WOS:000279939400001	20504314	DOAJ Gold, Green Published			2021-06-18	
J	Coester, A; Neumann, CR; Schmidt, MI				Coester, Ariane; Neumann, Cristina Rolim; Schmidt, Maria Ines			Intensive Insulin Therapy in Severe Traumatic Brain Injury: A Randomized Trial	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Intensive insulin infusion; Hyperglycemia; Randomized trial	CRITICALLY-ILL PATIENTS; SEVERE HEAD-INJURY; CARE-UNIT; GLUCOSE CONTROL; GLYCEMIC CONTROL; LACTATE/PYRUVATE RATIO; MANAGEMENT PROTOCOL; MORBIDITY REDUCTION; INFUSION PROTOCOL; PRACTICAL SCALE	Background: Intensive insulin therapy (IIT) has been shown to reduce morbidity and mortality in critically ill patients. Little investigation has been done to find out whether it improves the prognosis of patients with severe traumatic brain injury (STBI). Methods: We conducted a prospective controlled study where adult patients with blunt STBI, with Glasgow Coma Scale <= 8, admitted to the intensive care unit (ICU) were randomly assigned to receive either IIT (maintenance of blood glucose between 80 mg/dL and 110 mg/dL with continuous insulin infusion) or conventional glycemic therapy (CGT) (maintenance of blood glucose below 180 mg/dL with subcutaneous insulin and insulin infusion only if blood glucose levels exceeded 220 mg/dL). The main outcome was Glasgow outcome scale 6 months after trauma. Secondary measures were hypoglycemia, incidence of infections, and days in ICU. Results: Of the 88 patients randomized, 42 were assigned to IIT and 46 to CGT. There was no difference (p = 0.63) in neurologic outcomes between the treatment groups: Glasgow outcome scale > 3 was observed in 16 patients (41%) in the IIT and in 13 patients (32.5%) in the CGT group. More patients in the IIT group had hypoglycemia: 32 (82.1%), compared with 7 (17.5%) in the CGT group (p < 0.001). There were no differences in the number of days spent in the ICU (18.2 +/- 27.6 vs. 12.9 +/- 12.7) or in the sepsis rates (84.6% vs. 80%) between the groups. Conclusion: In our study, IIT did not improve the neurologic outcome of patients with STBI but did increase the risk of hypoglycemia compared with CGT.	Univ Fed Rio Grande do Sul, Programa Posgrad Epidemiol, Porto Alegre, RS, Brazil; Hosp Pronto Socorro Porto Alegre, Porto Alegre, RS, Brazil	Coester, A (corresponding author), Rua David Francisco Mauricio 85, BR-91760220 Porto Alegre, RS, Brazil.	arianecoester@yahoo.com.br	neumann, cristina/K-4692-2012; Iats, Inct/K-2300-2013; Schmidt, Maria/V-3196-2019		Brazilian government; CNPq (National Council for Scientific and Technological Development)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	Supported by the Brazilian government and the CNPq (National Council for Scientific and Technological Development).	ALEXANDER EBB, 2002, J PHARM PRACT, V15, P158; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bellomo R, 2009, MAYO CLIN PROC, V84, P400, DOI 10.1016/S0025-6196(11)60557-0; Biffl W, 2007, J TRAUMA, V62, P1375; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Bochicchio GV, 2007, J TRAUMA, V63, P1353, DOI 10.1097/TA.0b013e31815b83c4; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Clayton SB, 2006, CRIT CARE MED, V34, P2974, DOI 10.1097/01.CCM.0000248906.10399.CF; Collier B, 2005, JPEN-PARENTER ENTER, V29, P353, DOI 10.1177/0148607105029005353; de Azevedo JRA, 2007, ARQ NEURO-PSIQUIAT, V65, P733, DOI 10.1590/S0004-282X2007000500001; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Gawryszewski Vilma Pinheiro, 2006, Sao Paulo Med. J., V124, P208, DOI 10.1590/S1516-31802006000400007; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Krinsley JS, 2007, CRIT CARE MED, V35, P2262, DOI 10.1097/01.CCM.0000282073.98414.4B; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; Lacherade JC, 2007, INTENS CARE MED, V33, P814, DOI 10.1007/s00134-007-0543-0; Langouche L, 2008, CRIT CARE MED, V36, P1475, DOI 10.1097/CCM.0b013e31816f7bae; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Oksanen T, 2007, INTENS CARE MED, V33, P2093, DOI 10.1007/s00134-007-0876-8; *ORG PAN AM SAUD, IND BAS SAUD NO BRAS; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Reed CC, 2007, J AM COLL SURGEONS, V204, P1048, DOI 10.1016/j.jamcollsurg.2006.12.047; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Scalea TM, 2007, ANN SURG, V246, P605, DOI 10.1097/SLA.0b013e318155a789; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Shin S, 2007, AM SURGEON, V73, P769; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; TEASDALE G, 1974, LANCET, V2, P81; Teixeira Paulo José Zimermann, 2004, J. bras. pneumol., V30, P540, DOI 10.1590/S1806-37132004000600009; Toschlog EA, 2007, J TRAUMA, V62, P1370, DOI 10.1097/TA.0b013e318047b7dc; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; Van den Berghe Greet, 2003, Clin Cornerstone, V5, P56, DOI 10.1016/S1098-3597(03)90018-4; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vriesendorp TM, 2008, CURR OPIN CRIT CARE, V14, P397, DOI 10.1097/MCC.0b013e328306c7b1; Vriesendorp TM, 2006, CRIT CARE MED, V34, P2714, DOI 10.1097/01.CCM.0000241155.36689.91; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6	48	62	69	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					904	911		10.1097/TA.0b013e3181c9afc2			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	583GY	WOS:000276663100030	20032790				2021-06-18	
J	McHugh, GS; Butcher, I; Steyerberg, EW; Marmarou, A; Lu, J; Lingsma, HF; Weir, J; Maas, AIR; Murray, GD				McHugh, Gillian S.; Butcher, Isabella; Steyerberg, Ewout W.; Marmarou, Anthony; Lu, Juan; Lingsma, Hester F.; Weir, James; Maas, Andrew I. R.; Murray, Gordon D.			A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project	CLINICAL TRIALS			English	Article							ACUTE STROKE; NEUROPROTECTIVE AGENTS; PROGNOSTIC ANALYSIS; CLINICAL-TRIALS; DESIGN; EFFICACY; SCALES	Background Clinical trials in traumatic brain injury have a disappointing track record, with a long history of 'negative' Phase III trials. One contributor to this lack of success is almost certainly the low efficiency of the conventional approach to the analysis, which discards information by dichotomizing an ordinal outcome scale. Purpose Our goal was to evaluate the potential efficiency gains, which can be achieved by using techniques, which extract additional information from ordinal outcome data - the proportional odds model and the sliding dichotomy. In addition, we evaluated the additional efficiency gains, which can be achieved through covariate adjustment. Methods The study was based on simulations, which were built around a database of patient-level data extracted from eight Phase III trials and three observational studies in traumatic brain injury. Two different putative treatment effects were explored, one which followed the proportional odds model, and the other which assumed that the effect of the intervention was to reduce the risk of death without changing the distribution of outcomes within survivors. The results are expressed as efficiency gains, reported as the percentage reduction in sample size that can be used with the ordinal analyses without loss of statistical power relative to the conventional binary analysis. Results The simulation results show substantial efficiency gains. Use of the sliding dichotomy allows sample sizes to be reduced by up to 40% without loss of statistical power. The proportional odds model gives modest additional gains over and above the gains achieved by use of the sliding dichotomy. Limitations As with any simulation study, it is difficult to know how far the findings may be extrapolated beyond the actual situations that were modeled. Conclusions Both ordinal techniques offer substantial efficiency gains relative to the conventional binary analysis. The choice between the two techniques involves subtle value judgments. In the situations examined, the proportional odds model gave efficiency gains over and above the sliding dichotomy, but arguably, the sliding dichotomy is more intuitive and clinically appealing. Clinical Trials 2010; 7: 44-57. http://ctj.sagepub.com.	[McHugh, Gillian S.; Butcher, Isabella; Weir, James; Murray, Gordon D.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Marmarou, Anthony; Lu, Juan] Virginia Commonwealth Univ, Dept Neurosurg, Med Ctr, Richmond, VA USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium	Murray, GD (corresponding author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	gordon.murray@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	This work was supported by the US National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691).	Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; JENNETT B, 1975, LANCET, V1, P480; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mendelow AD, 2005, LANCET, V365, P387; Miller SW, 2008, STROKE, V39, pE14, DOI 10.1161/STROKEAHA.107.500355; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Optimising Anal Stroke Trials OAST, 2008, INT J STROKE, V3, P78, DOI 10.1111/j.1747-4949.2008.00184.x; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Saver JL, 2009, NEUROLOGY, V72, P1310, DOI 10.1212/01.wnl.0000341308.73506.b7; Steyerberg EW., 2009, CLIN PREDICTION MODE; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young FB, 2005, STROKE, V36, P597, DOI 10.1161/01.STR.0000154856.42135.85	23	62	62	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1740-7745	1740-7753		CLIN TRIALS	Clin. Trials	FEB	2010	7	1					44	57		10.1177/1740774509356580			14	Medicine, Research & Experimental	Research & Experimental Medicine	561VU	WOS:000275008800004	20156956				2021-06-18	
J	Johansson, B; Starmark, A; Berglund, P; Rodholm, M; Ronnback, L				Johansson, Birgitta; Starmark, Anders; Berglund, Peter; Rodholm, Martin; Ronnback, Lars			A self-assessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries	BRAIN INJURY			English	Article						Mental fatigue; self-assessment questionnaire	TRAUMATIC BRAIN-INJURY; COGNITIVE COMPLAINTS; POSTSTROKE FATIGUE; PROCESSING SPEED; MILD; STROKE; DEPRESSION; MEMORY; RELIABILITY; SCALE	Primary objective: The purpose was to evaluate a new self-reporting scale for assessment of mental fatigue and its usefulness in describing mental fatigue after neurological diseases and injuries. Mental fatigue is suggested to comprise a spectrum of items including sensory, emotional and cognitive symptoms. Methods and procedures: Mental fatigue and related symptoms were measured with a self-assessment scale on different diagnostic groups with neurological injuries and diseases as well as healthy controls. The scale covers sleep, sensory, emotional and cognitive domains, mental recovery and 24-hour variation. Results: There were significant correlations between all the questions in the self-assessing scale and also a high internal consistency among items (Cronbach's alpha of 0.944). Despite the different aetiologies of mental fatigue and related symptoms, the individuals rated the questions in a similar way. The total sum of scores, as well as the separate questions showed significantly lower values for healthy controls compared to mental fatigue groups. Conclusion: In spite of the different aetiology of mental fatigue, the items included in the scale were significant for different diseases with co-occurring mental fatigue. The self-reported scale is suggested to be a valuable tool for assessment of mental fatigue in different diagnoses.	[Johansson, Birgitta; Starmark, Anders; Berglund, Peter; Ronnback, Lars] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden; [Rodholm, Martin] Kungalv Hosp, Psychiat Clin, Kungalv, Sweden	Johansson, B (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Dubbsgatan 14, SE-41345 Gothenburg, Sweden.	birgitta.johansson2@vgregion.se		, Birgitta/0000-0003-0240-1142; Berglund, Peter/0000-0003-2367-1686	Health & Medical Care Committee of the Vastra Gotaland Region; Swedish Research CouncilSwedish Research CouncilEuropean Commission [21X-13015]; Fyrbodalinstitutet; Swedish Association of Survivors of Traffic Accidents and Polio	This work was supported by grants from The Health & Medical Care Committee of the Vastra Gotaland Region, The Swedish Research Council (grant no 21X-13015), Fyrbodalinstitutet and The Swedish Association of Survivors of Traffic Accidents and Polio.	ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; BELOMONT A, 2006, ANN READAPTIVE MED P, V49, P283; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carlsson GE, 2003, CEREBROVASC DIS, V16, P383, DOI 10.1159/000072561; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Christodoulou C, 2005, ISS CLIN COGN NEUROP, P19; DELUCA J, 2007, INFORM PROCESSING SP, P265; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Glader EL, 2002, STROKE, V33, P1327, DOI 10.1161/01.STR.0000014248.28711.D6; Hagell P, 2009, J NEUROL NEUROSUR PS, V80, P489, DOI 10.1136/jnnp.2008.159772; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Joy S, 2004, ARCH CLIN NEUROPSYCH, V19, P759, DOI 10.1016/j.acn.2003.09.009; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Lange G, 2005, NEUROIMAGE, V26, P513, DOI 10.1016/j.neuroimage.2005.02.011; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Naess H, 2005, CEREBROVASC DIS, V20, P245, DOI 10.1159/000087706; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Rasquin SMC, 2004, DEMENT GERIATR COGN, V18, P138, DOI 10.1159/000079193; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Shah A, 2009, PHYS MED REH CLIN N, V20, P363, DOI 10.1016/j.pmr.2008.12.003; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; STULEMEIJER M, 2006, J NEUROL, V253, P1432; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D., 2003, WECHSLER ADULT INTEL; Winward C, 2009, STROKE, V40, P757, DOI 10.1161/STROKEAHA.108.527101; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	51	62	65	1	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2010	24	1					2	12		10.3109/02699050903452961			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	554AA	WOS:000274406700001	20001478				2021-06-18	
J	DeJong, G; Horn, SD; Smout, RJ; Tian, WQ; Putman, K; Gassaway, J				DeJong, Gerben; Horn, Susan D.; Smout, Randall J.; Tian, Wenqiang; Putman, Koen; Gassaway, Julie			Joint Replacement Rehabilitation Outcomes on Discharge From Skilled Nursing Facilities and Inpatient Rehabilitation Facilities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	84th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	OCT 03-07, 2007	Washington, DC	Amer Cong Rehabil Med		Arthroplasty, replacement, hip; Arthroplasty, replacement, knee; Rehabilitation; Skilled nursing facilities	FUNCTIONAL ASSESSMENT SCALES; TRAUMATIC BRAIN-INJURY; TOTAL KNEE REPLACEMENT; HOSPITAL VOLUME; HIP FRACTURE; INDEPENDENCE MEASURE; ELECTIVE HIP; CARE; ARTHROPLASTY; OBESITY	DeJong G, Horn SD, Smout RJ, Tian W, Putman K, Gassaway J. Joint replacement rehabilitation outcomes on discharge from skilled nursing facilities and inpatient rehabilitation facilities. Arch Phys Med Rehabil 2009;90: 1284-96. Objective: To compare functional outcomes at discharge across postacute settings. Design: Prospective observational cohort study. Setting: Eleven inpatient rehabilitation facilities (IRFs), 8 freestanding skilled nursing facilities (SNFs), and 1 hospital-based SNF from across the United States. Participants: Consecutively enrolled patients (N=2152): patients with knee replacement (n=1401) and patients with hip replacement (n=751). Interventions: None; examination of existing practice patterns. Main Outcome Measure: FIM discharge motor score. Results: Freestanding SNF patients entered with higher motor FIM scores and left with higher scores than did IRF patients. IRF patients, however, achieved larger motor FIM gains and achieved them in a shorter time. In multivariate models controlling for patient differences and onset days, IRFs were associated with better discharge motor outcomes, but the overall setting effect was not large. The largest motor FIM differences were between medium-volume IRFs and low-volume freestanding SNFs: 4.6 motor FIM points for patients with knee replacement and 7.3 motor FIM points for patients with hip replacement. Other differences between settings were much smaller. Multivariate models explained between a third and a half of the variance in outcome. Conclusions: As a group, IRFs had better motor FIM outcomes than did SNFs, but the size of the IRF advantage was not large. Other important facility and practice characteristics also were associated with discharge outcomes after joint replacement rehabilitation. Earlier and more intensive rehabilitation was associated with better outcomes. The volume of joint replacement patients seen by a facility also plays a part: medium-volume facilities among both SNFs and IRFs had better outcomes.	[DeJong, Gerben; Tian, Wenqiang; Putman, Koen] Natl Rehabil Hosp, Ctr Postacute Studies, Washington, DC 20010 USA; [Horn, Susan D.; Smout, Randall J.; Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT USA; [Putman, Koen] Vrije Univ Brussel, Dept Med Sociol & Hlth Sci, Brussels, Belgium	DeJong, G (corresponding author), Natl Rehabil Hosp, Ctr Postacute Studies, 102 Irving St, Washington, DC 20010 USA.	DeJong@MedStar.net	Putman, Koen/D-4334-2009	Putman, Koen/0000-0002-7235-3759			Amin AK, 2006, J BONE JOINT SURG BR, V88B, P335, DOI 10.1302/0301-620X.88B3.16488; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Battaglia TC, 2006, CLIN ORTHOP RELAT R, P28, DOI 10.1097/01.blo.0000218743.99741.f0; Buntin MB, 2005, COMP MEDICARE SPENDI, P1; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1306, DOI 10.1016/j.apmr.2009.04.003; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1297, DOI 10.1016/j.apmr.2008.12.029; Deutsch A, 2005, MED CARE, V43, P892, DOI 10.1097/01.mlr.0000173591.23310.d5; Deutsch A, 2006, STROKE, V37, P1477, DOI 10.1161/01.STR.0000221172.99375.5a; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; Durairaj L, 2005, CHEST, V128, P1682, DOI 10.1378/chest.128.3.1682; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAMILTON B, 1987, UNIFORM DATA SYSTEM; Hamilton BB, 1999, ARCH PHYS MED REHAB, V80, P385, DOI 10.1016/S0003-9993(99)90274-5; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamoui N, 2006, OBES SURG, V16, P35, DOI 10.1381/096089206775222140; Hervey SL, 2003, J BONE JOINT SURG AM, V85A, P1775, DOI 10.2106/00004623-200309000-00017; Homboe ES, 2006, MED CARE, V44, P1073; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Jette DU, 2005, ARCH PHYS MED REHAB, V86, P373, DOI 10.1016/j.apmr.2004.10.018; Kane RL, 1996, J AM GERIATR SOC, V44, P545, DOI 10.1111/j.1532-5415.1996.tb01440.x; Kane RL, 1998, J AM GERIATR SOC, V46, P1525, DOI 10.1111/j.1532-5415.1998.tb01537.x; Kane RL, 2000, HEALTH SERV RES, V35, P615; Kane RL, 2007, ARCH PHYS MED REHAB, V88, P1500, DOI 10.1016/j.apmr.2007.06.015; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Lyman S, 2005, CLIN ORTHOP RELAT R, P132, DOI 10.1097/01.blo.0000150571.51381.9a; Mahomed NN, 2000, J RHEUMATOL, V27, P1753; *MED PAYM ADV COMM, 2008, C MED PAYM POL, P153; *MED PAYM ADV COMM, 2005, PAYM POST CAR, P105; Merrill C, 2007, HOSP STAYS INVOLVING; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; Munin MC, 2005, ARCH PHYS MED REHAB, V86, P367, DOI 10.1016/j.apmr.2004.10.004; Nallamothu BK, 2005, ARCH INTERN MED, V165, P333, DOI 10.1001/archinte.165.3.333; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Stickles B, 2001, OBES RES, V9, P219, DOI 10.1038/oby.2001.24; Sung VW, 2006, AM J OBSTET GYNECOL, V195, P1778, DOI 10.1016/j.ajog.2006.07.015; Tian WQ, 2009, ARCH PHYS MED REHAB, V90, P1260, DOI 10.1016/j.apmr.2008.10.035; Tribe KL, 2005, CHRONIC ILLN, V1, P289, DOI 10.1179/174239505X72011; *US GEN ACC OFF, 2005, MOR SPEC CRIT NEED C; Vincent HK, 2007, OBESITY, V15, P522, DOI 10.1038/oby.2007.551; Vitale MA, 2005, J PEDIATR ORTHOPED, V25, P393, DOI 10.1097/01.bpo.0000153880.05314.be; Walsh MB, 2006, AM J PHYS MED REHAB, V85, P1, DOI 10.1097/01.phm.0000197538.33707.d9; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007	49	62	64	1	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2009	90	8					1284	1296		10.1016/j.apmr.2009.02.009			13	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	483PY	WOS:000268981000004	19651262				2021-06-18	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			Different gait tasks distinguish immediate vs. long-term effects of concussion on balance control	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; CENTER-OF-MASS; STABILITY FOLLOWING CONCUSSION; HEAD-INJURY; HIGH-SCHOOL; RECOVERY; ATTENTION; DEFICITS; INSTABILITY; COLLEGIATE	The purpose of this study was to longitudinally compare the sensitivity of previously documented paradigms for measuring balance control during gait following a concussion. We hypothesized that gait with a concurrent cognitive task would be most sensitive to the effects of concussion on dynamic balance control. Individuals with concussion (n = 30) and matched controls ( n = 30) performed a single task of level walking, attention divided walking, and an obstacle-crossing task at two heights. Testing occurred four times post-injury. Balance control during gait was assessed with whole-body center of mass and center of pressure motion. The single-task level walking task did not result in any significant differences in balance control between individuals with concussion and control subjects. Within 48 hours post-injury, individuals with concussion walked slower and allowed less motion of their center of mass in the sagittal plane when attention was divided during walking, but there were no group differences by day 6 for this task. Group differences in balance control during obstacle crossing was unremarkable during the first two testing sessions, but by day 14 individuals with concussion displayed less mediolateral motion of their center of mass. Attention divided gait is able to better distinguish gait adaptations immediately following a concussion, but obstacle crossing can be used further along in the recovery process to detect new gait adaptations.	[Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	rcatena@uoregon.edu; paulvd@uoregon.edu; chou@uoregon.edu		Catena, Robert/0000-0001-9128-1343	Center for Disease Control and Prevention [R49/CCR021735, CCR023203]	This study was supported by the Center for Disease Control and Prevention (R49/CCR021735 and CCR023203). The authors would like to thank Tonya Parker for help with data collection.	BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; IVERSON GL, 2002, NAT AC NEUR MIAM FL; Kelly JP, 1997, NEUROLOGY, V48, P581; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Krauss JK, 1997, MOVEMENT DISORD, V12, P428, DOI 10.1002/mds.870120326; Lee HJ, 2006, ARCH PHYS MED REHAB, V87, P569, DOI 10.1016/j.apmr.2005.11.033; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Vallis LA, 2004, EXP BRAIN RES, V157, P94, DOI 10.1007/s00221-003-1824-7; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; Westfall P, 1999, MULTIPLE COMP MULTIP; Winter D.A., 1995, ABC BALANCE STANDING; Winter D.A., 1990, BIOMECHANICS MOTOR C, V2nd; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	32	62	62	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	JUL 7	2009	6								25	10.1186/1743-0003-6-25			7	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	478FZ	WOS:000268574500001	19580680	DOAJ Gold, Green Published			2021-06-18	
J	Ryu, WHA; Feinstein, A; Colantonio, A; Streiner, DL; Dawson, DR				Ryu, Won Hyung A.; Feinstein, Anthony; Colantonio, Angela; Streiner, David L.; Dawson, Deirdre R.			Early Identification and Incidence of Mild TBI in Ontario	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; MANAGEMENT; EMERGENCY; CARE; EPIDEMIOLOGY; CONCUSSION; AGREEMENT; COMMUNITY	Objectives: (1) To examine the variability in diagnosis of mild traumatic brain injury (mTBI) in primary care relative to that of an expert reviewer; and (2) to determine the incidence rate of mTBI in Ontario, Canada. Method: Potential mTBI cases were identified through reviewing three months of Emergency Department (ED) and Family Physician (FP) health records. Potential cases were selected from ED records using the International Classification of Disease, 9th revision, Clinical Modification and External Cause codes and from all FPS records for the time period. Documented diagnoses of mTBI were compared to expert reviewer diagnosis. Incidence of mTBI was determined using the documented diagnoses and data from hospital catchment areas and population census. Results: 876 potential mTBI cases were identified, 25 from FP records. Key indicators of mTBI were missing on many records (e.g., 308/876 records had Glasgow Coma Scale (GCS) scores). The expert reviewer disagreed with the documented diagnosis in 380/876 cases (kappa=0.19). The expert reviewer was more likely to give a diagnosis if the GCS was 13-14, if there was documented loss of consciousness and/or post-traumatic amnesia, and/or if there was pathology found on an acute brain scan. Calculated incidence rates of hospital-treated mTBI were 426 or 535/100,000 (expert review - hospital diagnosis). Including family physician cases increased the rate to 493 or 653/100,000. Conclusion: Health record documentation of key indicators for mTBI is often lacking. Notwithstanding, some patients with mTBI appear to be missed or misdiagnosed by primary care physicians. A more comprehensive case definition resulted in estimated incidence rates higher than previous reports.	[Ryu, Won Hyung A.; Streiner, David L.; Dawson, Deirdre R.] Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; [Ryu, Won Hyung A.; Colantonio, Angela; Streiner, David L.; Dawson, Deirdre R.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Colantonio, Angela; Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Feinstein, Anthony; Streiner, David L.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Feinstein, Anthony] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Ryu, Won Hyung A.; Colantonio, Angela; Dawson, Deirdre R.] Toronto Rehabil Inst, Toronto, ON, Canada	Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Ryu, Won H/AAU-6774-2020; Streiner, David/E-6563-2011; Dawson, Deirdre R/I-8882-2014	Streiner, David/0000-0003-0610-6271; Dawson, Deirdre R/0000-0001-7517-6121; Colantonio, Angela/0000-0003-2094-4765			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM AC NEUR QUAL S, PRACT PAR MAN CONC S; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ANDERSON DW, 1980, J NEUROSURG      NOV, pS11; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Hustey FM, 2002, ANN EMERG MED, V39, P248, DOI 10.1067/mem.2002.122057; Jaakkimainen L., 2006, PRIMARY CARE ONTARIO; Kennedy JE, 2006, MIL MED, V171, P516, DOI 10.7205/MILMED.171.6.516; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KURTZKE JF, 1993, CLIN NEUROL; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Medicode (Firm), 1997, ICD 9 CM INT CLASS D; *MILD TRAUM BRAIN, 2003, 1 NAT CTR INJ PREV C; Norman G.R., 2000, BIOSTATISTICS BARE E, V2nd; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schootman M, 2000, BRAIN INJURY, V14, P373; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Von Wild K, 2001, BRAIN INJURY, V15, P273	35	62	62	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	JUL	2009	36	4					429	435		10.1017/S0317167100007745			7	Clinical Neurology	Neurosciences & Neurology	481VR	WOS:000268840900005	19650352	Bronze			2021-06-18	
J	Viano, DC; Hamberger, A; Bolouri, H; Saljo, A				Viano, David C.; Hamberger, Anders; Bolouri, Hayde; Saljo, Annette			CONCUSSION IN PROFESSIONAL FOOTBALL: ANIMAL MODEL OF BRAIN INJURY-PART 15	NEUROSURGERY			English	Article						Animal models; Brain injury; Concussion; Head impact; Protective headgear; Recreation and sports	CLOSED-HEAD-INJURY; CONTROLLED CORTICAL IMPACT; ROTATIONAL ACCELERATION; AXONAL INJURY; PERCUSSION CONCUSSION; INTRACRANIAL-PRESSURE; SUBDURAL-HEMATOMA; GAME IMPACTS; RAT; BIOMECHANICS	OBJECTIVE: A concussion model was developed to study injury mechanisms, functional effects, treatment, and recovery. Concussions in National Football League football involve high-impact velocity (7.4-11.2 m/s) and rapid change in head velocity (Delta V) (5.4-9.0 m/s). Current animal models do not simulate these head impact conditions. METHODS: One hundred eight adult male Wistar rats weighing 280 to 350 g were used in ballistic impacts simulating 3 collision severities causing National Football League-type concussion. Pneumatic pressure accelerated a 50g impactor to velocities of 7.4, 9.3, and 11.2 m/s at the left side of the helmet-protected head. A thin layer of padding on the helmet controlled head acceleration, which was measured on the opposite side of the head, in line with the impact. Peak head acceleration, AV, impact duration, and energy transfer were determined. Fifty-four animals were exposed to single impact, with 18 each having 1, 4, or 10 days of survival. Similar tests were conducted on another 54 animals, which received 3 impacts at 6-hour intervals. An additional 72 animals were tested with a 100g impactor to study more serious brain injuries. Brains were perfused, and surface injuries were identified. RESULTS: The 50g impactor matches concussion conditions scaled to the rat. Impact velocity and head Delta V were within 1% and 3% of targets on average. Head acceleration reached 450g to 1750g without skull fracture. The test is repeatable and robust. Gross pathology was observed in 11%, 28%, and 33% of animals in the 7.4-, 9.3-, and 11.2-m/s single impacts, respectively. At 7.4 m/s, a single diameter area of less than 0.5 mm of fine petechial hemorrhage occurred on the brain surface in the parenchyma and meninges nearest the point of impact. At higher velocities, there were larger areas of bleeding, sometimes with subdural hemorrhage. When the 50g impactor tests were examined by logistic regression, greater energy transfer increased the probability of injury (odds ratio, 5.83; P = 0.01), as did 3 repeat impacts (odds ratio, 4.72; P = 0.002). The number of survival days decreased the probability of observing injury (odds ratio, 0.25 and 0.11 for 4 and 10 days, respectively, compared with 1 day). The 100g impactor produced more severe brain injuries. CONCLUSION: A concussion model was developed to simulate the high velocity of impact and rapid head Delta Vof concussions in National Football League players. The new procedure can be used to evaluate immediate and latent effects of concussion and more severe injury with greater impact mass.	[Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Viano, David C.] Mild Traumat Brain Injury Comm, New York, NY USA; [Hamberger, Anders; Bolouri, Hayde; Saljo, Annette] Univ Gothenburg, Dept Anat & Cell Biol, Inst Biomed, Gothenburg, Sweden	Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; ARMITAGE P, 1987, STAT METHODS MED RES, P410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ellingson Benjamin M., 2005, V41, P86; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; Gremmelt A, 1995, ANAESTHESIST, V44, pS559; GURDJIAN ES, 1975, SURG GYNECOL OBSTET, V140, P845; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; HAMBERGER A, NEUROSURGERY, V64, P1172; Heath DL, 2001, J NEUROTRAUM, V18, P465, DOI 10.1089/089771501750171074; Holbourn AHS, 1943, LANCET, V2, P438; Hosmer D, 1989, APPL LOGISTIC REGRES; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LINDGREN S, 1967, J TRAUM, V7, P493, DOI 10.1097/00005373-196707000-00001; MARGULIES SS, 1985, P IRCOBI AAAM C GOT, P13; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Rinder L, 1972, Scand J Rehabil Med, V4, P97; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; VIANO DC, 1988, J BIOMECH, V21, P387, DOI 10.1016/0021-9290(88)90145-5; VIANO DC, 1999, CRASH PREV INJ CONTR, V1, P35; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	64	62	63	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2009	64	6					1162	1173		10.1227/01.NEU.0000345863.99099.C7			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	452YE	WOS:000266576300035	19487897				2021-06-18	
J	Orrison, WW; Hanson, EH; Alamo, T; Watson, D; Sharma, M; Perkins, TG; Tandy, RD				Orrison, William W., Jr.; Hanson, Eric H.; Alamo, Tony; Watson, David; Sharma, Mythri; Perkins, Thomas G.; Tandy, Richard D.			Traumatic Brain Injury: A Review and High-Field MRI Findings in 100 Unarmed Combatants Using a Literature-Based Checklist Approach	JOURNAL OF NEUROTRAUMA			English	Article						boxing; checklist; magnetic resonance imaging; traumatic brain injury; unarmed combatants	DIFFUSE AXONAL INJURY; VIRCHOW-ROBIN SPACES; CEREBRAL MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; HEAD TRAUMA; HIPPOCAMPAL VOLUME; ARACHNOID CYSTS; FIBER TRACKING; CELL LOSS; MILD	This study reviewed the literature for the extent of neuroimaging findings in boxers, indicative of traumatic brain injury (TBI) as identified in magnetic resonance imaging (MRI). The study then utilized a systematic checklist approach to assess 100 unselected consecutive 1.5- and 3.0-Tesla MRI examinations of professional unarmed combatants to determine the extent of identifiable TBI findings. The percentage of positive findings and the localization of lesions were quantified using the checklist that included the MRI findings previously reported in the medical literature. Seventy-six percent of the unarmed combatants had at least one finding that may be associated with TBI: 59% hippocampal atrophy, 43% cavum septum pellucidum, 32% dilated perivascular spaces, 29% diffuse axonal injury, 24% cerebral atrophy, 19% increased lateral ventricular size, 14% pituitary gland atrophy, 5% arachnoid cysts, and 2% had contusions. Statistical relationships were found between number of bouts and lateral ventricular size (tau-b=0.149, p = 0.0489), with years of fighting correlating with the presence of dilated perivascular spaces (tau-b = 0.167, p = 0.0388) and diffuse axonal injury (tau-b = 0.287, p = 0.0013) findings. The improved resolution and increased signal-to-noise ratio on 1.5- and 3.0-Tesla high-field MRI systems defines the range of pathological variations that may occur in professional unarmed combatants. Additionally, the use of a systematic checklist approach insures evaluation for all possible TBI-related abnormalities. This knowledge can be used to anticipate the regions of potential brain pathology for radiologists and emergency medicine physicians, and provides important information for evaluating unarmed combatants relative to their safety and long-term neurocognitive outcome.	[Orrison, William W., Jr.; Hanson, Eric H.] Amigenics Inc, Las Vegas, NV 89118 USA; [Orrison, William W., Jr.] Nevada Imaging Ctr, Las Vegas, NV USA; [Orrison, William W., Jr.; Hanson, Eric H.; Sharma, Mythri] Touro Univ, Nevada Coll Osteopath Med, Henderson, NV USA; [Alamo, Tony] Alamo Med Clin, Henderson, NV USA; [Watson, David] Nevada State Athlet Commiss, Las Vegas, NV USA; [Perkins, Thomas G.] Philips Healthcare, Cleveland, OH USA; [Tandy, Richard D.] Univ Nevada, Dept Kinesiol, Las Vegas, NV 89154 USA	Hanson, EH (corresponding author), Amigenics Inc, 5495 S Rainbow Blvd,Suite 102, Las Vegas, NV 89118 USA.	eric.hanson@amigenics.com	Hanson, Eric H/B-7367-2009				Adriani M, 2003, NEUROIMAGE, V20, pS66, DOI 10.1016/j.neuroimage.2003.09.007; Allkemper T, 2004, RADIOLOGY, V232, P874, DOI 10.1148/radiol.2323030322; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Benvenga Salvatore, 2005, Pituitary, V8, P193, DOI 10.1007/s11102-006-6040-6; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BILANIUK LT, 1984, RADIOLOGY, V153, P409, DOI 10.1148/radiology.153.2.6541355; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Eskandary H, 2005, SURG NEUROL, V63, P550, DOI 10.1016/j.surneu.2004.07.049; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gosalakkal JA, 2002, PEDIATR NEUROL, V26, P93, DOI 10.1016/S0887-8994(01)00329-0; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Groeschel S, 2006, NEURORADIOLOGY, V48, P745, DOI 10.1007/s00234-006-0112-1; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; Hesselink John R, 2006, Top Magn Reson Imaging, V17, P243, DOI 10.1097/01.rmr.0000248666.91834.af; Howell D. C., 1997, STAT METHODS PSYCHOL; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2006, BRAIN INJURY, V20, P15, DOI 10.1080/02699050500309593; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2005, AM J NEURORADIOL, V26, P719; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KINARD RE, 1986, AM J ROENTGENOL, V147, P848, DOI 10.2214/ajr.147.4.848; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lidzba K, 2006, NEUROREPORT, V17, P929, DOI 10.1097/01.wnr.0000221841.12632.d6; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2002, BRIT J SPORT MED, V36, P157, DOI 10.1136/bjsm.36.3.157; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; *NAC, 2007, NEV STAT ATHL COMM F; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; ORRISON WW, 1991, RADIOLOGY, V181, P121, DOI 10.1148/radiology.181.1.1887020; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; RODRIGUEZ G, 1983, LANCET, V2, P858; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Tisserand DJ, 2006, BRAIN COGNITION, V60, P216; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; WESTER K, 1992, NEUROSURGERY, V31, P940, DOI 10.1227/00006123-199211000-00018; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321	79	62	62	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					689	701		10.1089/neu.2008.0636			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500005	19335205				2021-06-18	
J	Castriotta, RJ; Atanasov, S; Wilde, MC; Masel, BE; Lai, JM; Kuna, ST				Castriotta, Richard J.; Atanasov, Strahil; Wilde, Mark C.; Masel, Brent E.; Lai, Jenny M.; Kuna, Samuel T.			Treatment of Sleep Disorders after Traumatic Brain Injury	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						Trauma; brain injury; hypersomnia; sleep apnea; narcolepsy; sleep disorders; MSLT; continuous positive airway pressure	EXCESSIVE DAYTIME SLEEPINESS; POSITIVE AIRWAY PRESSURE; APNEA-HYPOPNEA SYNDROME; MILD HEAD-INJURY; QUALITY-OF-LIFE; CPAP TREATMENT; RESIDUAL SLEEPINESS; DOUBLE-BLIND; MODAFINIL; PLACEBO	Study Objectives: Determine whether treatment of sleep disorders identified in brain injured adults would result in resolution of those sleep disorders and improvement of symptoms and daytime function. Methods: Prospective evaluation of unselected traumatic brain injury patients with nocturnal polysomnography (NPSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS), and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ) before and after treatment with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA), modafinil (200 mg) for narcolepsy and posttraumatic hypersomnia (PTH), or pramipexole (0.375 mg) for periodic limb movements in sleep (PLMS). Setting: Three academic medical centers. Participants: Fifty-seven (57) adults >= 3 months post traumatic brain injury (TBI). Measurements And Results: Abnormal sleep studies were found in 22 subjects (39%), of whom 13 (23%) had OSA, 2 (3%) had PTH, 3 (5%) had narcolepsy, 4 (7%) had PLMS, and 12 had objective excessive daytime sleepiness with MSLT score < 10 minutes. Apneas, hypopneas, and snoring were eliminated by CPAP in OSA subjects, but there was no significant change in MSLT scores. Periodic limb movements were eliminated with pramipexole. One of 3 narcolepsy subjects and 1 of 2 PTH subjects had resolution of hypersomnia with modafinil. There was no significant change in FOSQ, POMS, or PVT results after treatment. Conclusions: Treatment of sleep disorders after TBI may result in polysomnographic resolution without change in sleepiness or neuropsychological function.	[Castriotta, Richard J.] Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, Houston, TX 77030 USA; [Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.] Mem Hermann Hosp Sleep Disorders Ctr, Houston, TX USA; [Atanasov, Strahil] Univ Texas Med Branch Galveston, Galveston, TX USA; [Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA; [Kuna, Samuel T.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA	Castriotta, RJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, 6431 Fannin St,MSB 1-274, Houston, TX 77030 USA.	Richard.J.Castriotta@uth.tmc.edu	Sanguansri, Luz/B-6630-2011; Lang, Steven/AAE-8102-2021	Sanguansri, Luz/0000-0003-1908-7604; Lang, Steven/0000-0003-1669-9146; Castriotta, Richard/0000-0003-3502-4558			Agrawal A, 2008, J CLIN SLEEP MED, V4, P177; Aloia MS, 2004, J INT NEUROPSYCH SOC, V10, P772, DOI 10.1017/S1355617704105134; American Sleep Disorders Association, 1997, INT CLASS SLEEP DIS; [Anonymous], 1997, SLEEP, V20, P406; [Anonymous], 1999, SLEEP, V22, P667; Bardwell WA, 2001, SLEEP, V24, P905, DOI 10.1093/sleep/24.8.905; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Black J, 2003, RESP PHYSIOL NEUROBI, V136, P211, DOI 10.1016/S1569-9048(03)00083-1; Bonnet MH, 2006, J CLIN NEUROPHYSIOL, V23, P50, DOI 10.1097/01.wnp.0000190415.83841.17; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chami HA, 2008, CIRCULATION, V117, P2599, DOI 10.1161/CIRCULATIONAHA.107.717892; Coleman R, 1982, SLEEPING WAKING DISO, P265; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dinges DF, 2003, SLEEP MED, V4, P393, DOI 10.1016/S1389-9457(03)00108-4; Dinges DF, 1997, SLEEP, V20, P267; Ellen RLB, 2006, J CLIN SLEEP MED, V2, P193; Gooneratne NS, 2003, J AM GERIATR SOC, V51, P642, DOI 10.1034/j.1600-0579.2003.00208.x; Hia KM, 2008, SLEEP, V31, P795; Hirshkowitz M, 2007, CNS DRUGS, V21, P407, DOI 10.2165/00023210-200721050-00004; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; Kingshott RN, 2001, AM J RESP CRIT CARE, V163, P918, DOI 10.1164/ajrccm.163.4.2005036; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Lenfant C, 2008, AM J THER, V15, P345, DOI 10.1097/MJT.0b013e31815fd0fe; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Macey PM, 2008, SLEEP, V31, P967; Marshall NS, 2008, SLEEP, V31, P1079; Marshall NS, 2006, THORAX, V61, P430, DOI 10.1136/thx.2005.050583; McNair D, 1971, MANUAL PROFILE MOOD; Monasterio C, 2001, AM J RESP CRIT CARE, V164, P939, DOI 10.1164/ajrccm.164.6.2008010; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Ondo WG, 2005, J NEUROL NEUROSUR PS, V76, P1636, DOI 10.1136/jnnp.2005.065870; Pandi-Perumal SR, 2006, BRAZ J MED BIOL RES, V39, P863, DOI 10.1590/S0100-879X2006000700003; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Weaver TE, 2003, SLEEP, V26, P727; Weaver TE, 1997, SLEEP, V20, P835; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Young T, 2008, SLEEP, V31, P1071; Yu BH, 1999, J PSYCHIAT RES, V33, P427, DOI 10.1016/S0022-3956(99)00020-5; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	48	62	62	0	8	AMER ACAD SLEEP MEDICINE	WESTCHESTER	ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA	1550-9389			J CLIN SLEEP MED	J. Clin. Sleep Med.	APR 15	2009	5	2					137	144					8	Clinical Neurology	Neurosciences & Neurology	499YN	WOS:000270262900009	19968047				2021-06-18	
J	Aoshiba, K; Onizawa, S; Tsuji, T; Nagai, A				Aoshiba, Kazutetsu; Onizawa, Shigemitsu; Tsuji, Takao; Nagai, Atsushi			Therapeutic effects of erythropoietin in murine models of endotoxin shock	CRITICAL CARE MEDICINE			English	Article						septic shock; erythropoietin; apoptosis; nitric oxide; hypoxia; mouse	NITRIC-OXIDE SYNTHASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; CRITICALLY-ILL PATIENTS; LUNG INJURY; SEPSIS; EFFICACY; RAT; INHIBITION; EXPRESSION; APOPTOSIS	Objective: Erythropoietin has recently emerged as a cytoprotective cytokine, which possesses the ability to protect many tissues, including the brain, heart, and kidneys, against ischemia or traumatic injury. We investigated the therapeutic effects of erythropoietin in a murine model of endotoxin shock. Design. Prospective, randomized study. Setting: University-based research laboratory. Subjects: Male BALB/c mice. Interventions., Mice intraperitoneally received either lipopolysaccharide (LPS) from Escherichia coli or vehicle. Erythropoietin was administered at a dose of 1000 IU/kg subcutaneously at different time points after LPS administration. We also investigated the effect of erythropoietin on the development of septic shock caused by cecal perforation. Measurements and Main Results: Treatment of mice with erythropoietin, within 2 hours after LPS administration, improved the mortality rate. Treatment of cecal perforated mice with erythropoietin extended survival by 12 hours, but all animals died by 72 hours in both groups. Erythropoietin attenuated apoptosis in the lungs, liver, small intestine, thymus, and spleen, as assessed by terminal deoxynucleotidyl transferase-mediated nucleotide nick-end labeling staining, active caspase-3 immunostaining and immunoblotting, and measurements of caspase-3/7 activity. Erythropoietin also reduced inducible nitric oxide synthase expression, nitric oxide production, peroxynitrite formation, and tissue hypoxia. In contrast, erythropoietin did not affect the degree of LPS-induced inflammation, as assessed by measurements of blood levels of interleukin-1 beta, interleukin-6, tumor necrosis factor-a, growth-related oncogene/keratinocyte-derived cytokine, and high mobility group box 1, the phosphorylation levels of nuclear factor kappa B, and the number of neutrophils infiltrating the lungs and the liver. Conclusions: The results of the study demonstrate that administration of a large dose of erythropoietin after induction of experimental endotoxemia improved survival and that the beneficial effects of erythropoietin were associated with inhibition of apoptosis, nitric oxide production, and tissue hypoxia, without alterations in inflammatory responses. (Crit Care Med 2009; 37: 889-898)	[Aoshiba, Kazutetsu; Onizawa, Shigemitsu; Tsuji, Takao; Nagai, Atsushi] Tokyo Womens Med Univ, Dept Med 1, Tokyo, Japan	Aoshiba, K (corresponding author), Tokyo Womens Med Univ, Dept Med 1, Tokyo, Japan.	kaoshiba@chi.twmu.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21590973, 19590917] Funding Source: KAKEN		Abdelrahman M, 2004, SHOCK, V22, P63, DOI 10.1097/01.shk.00001276869.21260.9d; Akimoto T, 1999, J HYPERTENS, V17, P1249, DOI 10.1097/00004872-199917090-00003; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3; Cauwels A, 2007, KIDNEY INT, V72, P557, DOI 10.1038/sj.ki.5002340; Chandra Abhijit, 2006, Clinics, V61, P71, DOI 10.1590/S1807-59322006000100012; Connelly L, 2005, J BIOL CHEM, V280, P10040, DOI 10.1074/jbc.M411991200; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Cuzzocrea S, 2006, CRIT CARE MED, V34, P1168, DOI 10.1097/01.CCM.0000207346.56477.E8; d'Uscio LV, 2007, HYPERTENSION, V49, P1142, DOI 10.1161/HYPERTENSIONAHA.106.085704; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Farrell F, 2004, ONCOLOGIST, V9, P18, DOI 10.1634/theoncologist.9-90005-18; Foster DJ, 2004, AM J PHYSIOL-LUNG C, V287, pL1107, DOI 10.1152/ajplung.00119.2004; Genc K, 2006, PHYSIOL RES, V55, P33; GHEZZL P, 2003, CELL DEATH DIFFER, V11, pS37; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 2003, SCAND J INFECT DIS, V35, P585, DOI 10.1080/00365540310015692; JELKMANN W, 1992, PHYSIOL REV, V72, P449; Kamolz LP, 2002, J RECONSTR MICROSURG, V18, P487, DOI 10.1055/s-2002-33319; Koroglu TF, 2006, PHYSIOL RES, V55, P309; LEERS MP, 1999, J PATHOL, V5, P562; Lehner MD, 2006, J PHARMACOL EXP THER, V317, P181, DOI 10.1124/jpet.105.098673; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Matejovic M, 2004, SHOCK, V21, P458, DOI 10.1097/00024382-200405000-00010; McGown CC, 2007, BRIT J ANAESTH, V98, P163, DOI 10.1093/bja/ael358; Okamoto I, 2000, AM J RESP CRIT CARE, V162, P716, DOI 10.1164/ajrccm.162.2.9907039; PEARCE ML, 1965, CIRC RES, V16, P482, DOI 10.1161/01.RES.16.5.482; Remick DG, 2007, AM J PATHOL, V170, P1435, DOI 10.2353/ajpath.2007.060872; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Savino R, 2004, CELL DEATH DIFFER, V11, pS2, DOI 10.1038/sj.cdd.4401469; Sharples EJ, 2006, NEPHRON EXP NEPHROL, V104, pE83, DOI 10.1159/000094546; Silver M, 2006, CRIT CARE MED, V34, P2310, DOI 10.1097/01.CCM.0000233873.17954.42; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Strunk V, 2001, ANESTH ANALG, V92, P681, DOI 10.1213/00000539-200103000-00025; WAND H, 2004, NAT MED, V10, P1216; Wang W, 2004, AM J PHYSIOL-RENAL, V287, pF1044, DOI 10.1152/ajprenal.00136.2004; Wang XQ, 1999, HYPERTENSION, V33, P894, DOI 10.1161/01.HYP.33.3.894; WESHCHESOLDATO DE, 2007, CURR DRUG TARGETS, V8, P493; Westenfelder C, 1999, KIDNEY INT, V55, P808, DOI 10.1046/j.1523-1755.1999.055003808.x; Wu HW, 2006, EUR J CARDIO-THORAC, V29, P902, DOI 10.1016/j.ejcts.2006.02.036; Yang CW, 2003, FASEB J, V17, P1754, DOI 10.1096/fj.02-1191fje; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yasuda CL, 2006, SEIZURE-EUR J EPILEP, V15, P35, DOI 10.1016/j.seizure.2005.10.005	52	62	65	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2009	37	3					889	898		10.1097/CCM.0b013e31819b8371			10	Critical Care Medicine	General & Internal Medicine	413FW	WOS:000263779300012	19237893				2021-06-18	
J	Iverson, GL; Langlois, JA; McCrea, MA; Kelly, JP				Iverson, Grant L.; Langlois, Jean A.; McCrea, Michael A.; Kelly, James P.			CHALLENGES ASSOCIATED WITH POST-DEPLOYMENT SCREENING FOR MILD TRAUMATIC BRAIN INJURY IN MILITARY PERSONNEL	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild Traumatic Brain Injury; Military; Screening; Epidemiology	POSTCONCUSSIVE SYMPTOMS; CHRONIC PAIN; CONCUSSION; IRAQ; METAANALYSIS; AFGHANISTAN; DISORDER; CARE	There is ongoing debate regarding the epidemiology of mild traumatic brain injury (MTBI) in military personnel. Accurate and timely estimates of the incidence of brain injury and the prevalence of long-term problems associated with brain injuries among active duty service members and veterans are essential for (a) operational planning, and (b) to allocate sufficient resources for rehabilitation and ongoing services and supports. The purpose of this article is to discuss challenges associated with post-deployment screening for MTBI. Multiple screening methods have been used in military, Veterans Affairs, and independent studies, which complicate cross-study comparisons of the resulting epidemiological data. We believe that post-deployment screening is important and necessary-but no screening methodology will be flawless, and false positives and false negatives are inevitable. Additional research is necessary to refine the sequential screening methodology, with the goal of minimizing false negatives during initial post-deployment screening and minimizing false positives during follow-up evaluations.	[Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Langlois, Jean A.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [McCrea, Michael A.] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Kelly, James P.] Univ Colorado, Dept Neurosurg, Denver Sch Med, Denver, CO 80202 USA; [Kelly, James P.] Univ Colorado, Dept Phys Med & Rehabil, Denver Sch Med, Denver, CO 80202 USA; [Kelly, James P.] Def Ctr Excellence Psychol Hlth, Natl Intrepid Ctr Excellence, Washington, DC USA; [Kelly, James P.] US Dept Def, TBI, Washington, DC 20305 USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Drazen JM, 2005, NEW ENGL J MED, V352, P2121, DOI 10.1056/NEJMe048332; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; General Accounting Office, 2008, GAO08276; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KANG H, 2007, ANAL VA HLTH CARE UT; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; *MENT HLTH ADV TEA, 2008, MHAT V OP IR FREED 0; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604	24	62	62	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	8					1299	1314		10.1080/13854040903153902			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	524KF	WOS:000272141500005	19882473				2021-06-18	
J	Alexanian, AR; Maiman, DJ; Kurpad, SN; Gennarelli, TA				Alexanian, Arshak R.; Maiman, Dennis J.; Kurpad, Shekar N.; Gennarelli, Thomas A.			In Vitro and In Vivo Characterization of Neurally Modified Mesenchymal Stem Cells Induced by Epigenetic Modifiers and Neural Stem Cell Environment	STEM CELLS AND DEVELOPMENT			English	Article							MARROW STROMAL CELLS; ADULT SPINAL-CORD; NEURONAL DIFFERENTIATION; NONHEMATOPOIETIC TISSUES; MUSCLE REGENERATION; PROGENITOR CELLS; BONE; INDUCTION; PHENOTYPE; BRAIN	Mesenchymal stem cell (MSC)-mediated tissue regeneration is a promising strategy to treat several neurodegenerative diseases and traumatic injuries of the central nervous system. Bone marrow MSCs have great potential as therapeutic agents, since they are easy to isolate and expand and are capable of producing various cell types, including neural cells. Recently we developed a highly efficient methodology to produce neural stem-like and neural precursor-like cells from mice bone marrow-derived MSCs that eventually differentiate into neuronaland glial-like cells in vitro. The aim of this study is to further elucidate neural expression profile of neurally induced mesenchymal stem cells (NI-MSCs) and their ability to retain neural differentiation potential when grafted into the intact spinal cord of rats. To this end, we further characterized in vitro and in vivo properties of NI-MSCs by immunocytochemistry, Western blot, ELISA, and immunohistochemistry. Immunocytochemical data demonstrated that NI-MSCs express several mature neural markers such as B3T, GFAP MAP-2, NF-200, and NeuN, which were confirmed through Western blot. ELISA data showed that NI-MSCs release nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). In vivo studies demonstrated that grafted NI-MSCs survived after transplantation into intact spinal cord and produced cells that expressed neural markers. All these data suggest that neurally modified MSCs, induced by recently developed methodology, could be a potential source of cells to replace damaged neurons and glia in injured spinal cord, and/or to promote cell survival and axonal growth of host tissue.	[Alexanian, Arshak R.; Maiman, Dennis J.; Kurpad, Shekar N.; Gennarelli, Thomas A.] Vet Adm Med Ctr, Dept Neurosurg, Neurosci Res Labs, Milwaukee, WI 53295 USA	Alexanian, AR (corresponding author), Vet Adm Med Ctr, Dept Neurosurg, Neurosci Res Labs, Res 151,5000 W Natl Ave, Milwaukee, WI 53295 USA.	aalexan@mcw.edu	Kurpad, Shekar/V-2188-2019		VA Medical Research and the Department of Neurosurgery	This work was supported by VA Medical Research and the Department of Neurosurgery. We thank Christy Stadig for technical assistance.	Alexanian AR, 2006, J NEUROSCI METH, V150, P41, DOI 10.1016/j.jneumeth.2005.05.024; Alexanian AR, 2005, EXP CELL RES, V310, P383, DOI 10.1016/j.yexcr.2005.08.015; Alexanian AR, 2007, J CELL BIOCHEM, V100, P362, DOI 10.1002/jcb.21029; Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Bertani N, 2005, J CELL SCI, V118, P3925, DOI 10.1242/jcs.02511; BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, P287; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Corti S., 2003, Current Gene Therapy, V3, P247, DOI 10.2174/1566523034578375; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dezawa M, 2005, EXPERT OPIN BIOL TH, V5, P427, DOI 10.1517/14712598.5.4.427; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Joannides A, 2003, J HEMATOTH STEM CELL, V12, P681, DOI 10.1089/15258160360732704; KATSETOS CD, 1994, ARCH PATHOL LAB MED, V118, P1002; Kim BJ, 2002, NEUROREPORT, V13, P1185, DOI 10.1097/00001756-200207020-00023; Kim SS, 2005, NEUROREPORT, V16, P1357, DOI 10.1097/01.wnr.0000175243.12966.f5; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kondo T, 2005, P NATL ACAD SCI USA, V102, P4789, DOI 10.1073/pnas.0408239102; Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Levy YS, 2003, J MOL NEUROSCI, V21, P121, DOI 10.1385/JMN:21:2:121; Long XX, 2005, STEM CELLS DEV, V14, P65, DOI 10.1089/scd.2005.14.65; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Mizuno S, 1996, EXP CELL RES, V227, P89, DOI 10.1006/excr.1996.0253; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Padovan CS, 2003, CELL TRANSPLANT, V12, P839, DOI 10.3727/000000003771000183; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qian LC, 2004, BIOMATERIALS, V25, P1331, DOI 10.1016/j.biomaterials.2003.08.013; Qu TY, 2004, RESTOR NEUROL NEUROS, V22, P459; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476-9255-2-8; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tropel P, 2006, STEM CELLS, V24, P2868, DOI 10.1634/stemcells.2005-0636; UMEZAWA A, 1991, MOL CELL BIOL, V11, P920, DOI 10.1128/MCB.11.2.920; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yang Xiao-su, 2005, Zhonghua Yi Xue Za Zhi, V85, P1125; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	54	62	79	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	DEC	2008	17	6					1123	1130		10.1089/scd.2007.0212			8	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	380UL	WOS:000261490700012	18484898				2021-06-18	
J	Haxel, BR; Grant, L; Mackay-Sim, A				Haxel, Boris R.; Grant, Leah; Mackay-Sim, Alan			Olfactory Dysfunction After Head Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brief smell identification tests; chemosensory-evoked potentials; head trauma; olfactometry; sense of smell; Sniffin' Sticks; traumatic brain injury	TRAUMATIC BRAIN-INJURY; OF-PENNSYLVANIA SMELL; DISCRIMINATION; IDENTIFICATION; POTENTIALS; ANOSMIA; TASTE	To determine the incidence of olfactory dysfunction after head trauma using clinical and radiologic findings, quantitative assessment, and electro-physiologic methods. Participants: A total of 190 patients with head trauma of different severity (n = 32 with mild traumatic brain injury (TBI), n = 94 with signs of moderate TBI, and n = 64 with severe TBI) 6 to 32 months prior to the study. Design: Patients were selected retrospectively, surveyed by telephone (n = 190), and screened for olfactory function with Brief Smell Identification Test (n = 82). Those with olfactory dysfunction were assessed as outpatients using the Sniffin' Sticks (n = 19) and olfactory-evoked potential recording (n = 16). Results: Twenty-one participants (11%) reported a decreased sense of smell after trauma. The incidence of olfactory dysfunction after head injury was 12.8%. The results of the odor-evoked potentials were heterogeneous. A significant correlation was found between olfactory dysfunction and the appearance of skull base fractures and intracranial hemorrhage or hematoma. Conclusion: The site of trauma may be more relevant to prognosis than a simple probability (of olfactory loss) based on incidence. Odor-evoked potentials indicate that functional anosmia can occur even when there is some evidence of intact olfactory nerve function.	[Haxel, Boris R.] Johannes Gutenberg Univ Mainz, Sch Med, Dept Otolaryngol Head & Neck Surg, Mainz, Germany; [Haxel, Boris R.; Grant, Leah; Mackay-Sim, Alan] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Nathan, Qld 4111, Australia	Haxel, BR (corresponding author), Mainz Med Sch, Dept Otorhinolaryngol, Langenbeckstr 1, D-55101 Mainz, Germany.	haxel@hno.klinik.uni-mainz.de	Mackay-Sim, Alan/C-3431-2008	Mackay-Sim, Alan/0000-0003-4446-5371			Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Costanzo D, 2003, HDB OLFACTION GESTAT, P1038; COSTANZO R, 1991, SMELL TASTE HLTH DIS; COSTANZO RM, 1987, ANN NY ACAD SCI, V510, P242; Doty R.L., 2001, BRIEF SMELL IDENTIFI; Doty RL, 1997, CHEM SENSES, V22, P565, DOI 10.1093/chemse/22.5.565; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DULFANO MJ, 1981, AM REV RESPIR DIS, V123, P139; Geisler MW, 1999, J CLIN NEUROPHYSIOL, V16, P77, DOI 10.1097/00004691-199901000-00008; GRAZIADEI PPC, 1980, BRAIN RES, V201, P39, DOI 10.1016/0006-8993(80)90773-8; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; Kettenmann B, 1997, CHEM SENSES, V22, P493, DOI 10.1093/chemse/22.5.493; KOBAL G, 1988, ELECTROEN CLIN NEURO, V71, P241, DOI 10.1016/0168-5597(88)90023-8; Kobal G, 2000, EUR ARCH OTO-RHINO-L, V257, P205, DOI 10.1007/s004050050223; Kobal G, 1998, LARYNGOSCOPE, V108, P1033, DOI 10.1097/00005537-199807000-00015; Leigh AD, 1943, LANCET, V1, P38; Mackay-Sim A, 2004, J CLIN NEUROSCI, V11, P874, DOI 10.1016/j.jocn.2003.12.001; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; Murrell W, 1996, NEUROREPORT, V7, P1189, DOI 10.1097/00001756-199604260-00019; Ogawa T, 1999, ACTA OTO-LARYNGOL, P50; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; Wolfensberger M, 2000, ACTA OTO-LARYNGOL, V120, P303, DOI 10.1080/000164800750001134; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	26	62	64	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2008	23	6					407	413		10.1097/01.HTR.0000341437.59627.ec			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	379WZ	WOS:000261428300007	19033834				2021-06-18	
J	Kemp, CD; Johnson, JC; Riordan, WP; Cotton, BA				Kemp, Clinton D.; Johnson, J. Chad; Riordan, William P.; Cotton, Bryan A.			How we die: The impact of nonneurologic organ dysfunction after severe traumatic brain injury	AMERICAN SURGEON			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; HEAD-INJURY; DEATH; COMPLICATIONS; PULMONARY; ABNORMALITIES; EPIDEMIOLOGY; GUIDELINES; SURVIVAL; FAILURE	Although nonneurologic organ dysfunction (NNOD) has been shown to significantly affect mortality in subarachnoid hemorrhage, the contribution of NNOD to mortality after severe traumatic brain injury (TBI) has yet to be defined. We hypothesized that NNOD has a significant impact on mortality after severe TBI. The trauma registry was queried for all patients admitted between January 2004 and December 2004 who died during their initial hospitalization after severe TBI (head Abbreviated Injury Score 3 or greater). Cause of death and contributing factors to mortality were determined by an attending trauma surgeon from the medical record. The data were analyzed using both Fisher's exact and Wilcoxon rank sum. One hundred thirty-five patients met inclusion criteria. Sixty-seven per cent were males, 83 per cent were white, and the mean age was 38.5 years. Mean length of stay was 2.9 days. Fifty-four patients (40%) had isolated TBI (chest Abbreviated Injury Score = 0, abdominal Abbreviated Injury Score = 0). Of the 81 deaths attributed to a single cause, 48 (60%) patients died from nonsurvivable TBI or brain death, whereas 33 (40%) died of a nonneurologic cause. Cardiovascular and respiratory dysfunction (excluding pneumonia) contributed to mortality in 51.1 per cent and 34.1 per cent of patients, respectively. NNOD contributes to approximately two-thirds of all deaths after severe TBI. These complications occur early and are seen even among those with isolated head injuries. These findings demonstrate the impact of the extracranial manifestations of severe TBI on overall mortality and highlight potential areas for future intervention and research.	[Kemp, Clinton D.; Johnson, J. Chad; Riordan, William P.; Cotton, Bryan A.] Vanderbilt Univ, Sch Med, Div Trauma & Surg Crit Care, Dept Surg, Nashville, TN 37212 USA	Cotton, BA (corresponding author), Vanderbilt Univ, Sch Med, Div Trauma & Surg Crit Care, Dept Surg, 121st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	bryan.cotton@vanderbilt.cdu	Cotton, Bryan/A-7107-2009				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Collier BR, 2004, J NEUROSURG ANESTH, V16, P196, DOI 10.1097/00008506-200407000-00003; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Friedman JA, 2003, NEUROSURGERY, V52, P1025, DOI 10.1227/01.NEU.0000058222.59289.F1; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Gilroy D, 2005, INJURY, V36, P47, DOI 10.1016/j.injury.2004.04.015; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Huang CH, 2004, AM J EMERG MED, V22, P141, DOI 10.1016/j.ajem.2004.02.029; Kemp CD, 2008, J TRAUMA, V64, P1573, DOI 10.1097/TA.0b013e318068fc2f; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LANZINO G, 1994, J NEUROSURG ANESTH, V6, P156; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; Macrea LM, 2005, RESUSCITATION, V65, P139, DOI 10.1016/j.resuscitation.2004.11.010; MARION DW, 1986, NEUROSURGERY, V18, P101, DOI 10.1227/00006123-198601000-00019; Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; THURMAN D, 1999, JAMA-J AM MED ASSOC, V282, P989; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; Vespa PM, 2004, NEUROCRIT CARE, V1, P157, DOI 10.1385/NCC:1:2:157; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	33	62	63	0	3	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	SEP	2008	74	9					866	872					7	Surgery	Surgery	344NC	WOS:000258933400021	18807680				2021-06-18	
J	Mothe, AJ; Tator, CH				Mothe, Andrea J.; Tator, Charles H.			Transplanted neural stem/progenitor cells generate myelinating oligodendrocytes and Schwann cells in spinal cord demyelination and dysmyelination	EXPERIMENTAL NEUROLOGY			English	Article						neural stem/progenitor cells; transplantation; spinal cord; myelination; focal demyelination lesions; shiverer mouse	CENTRAL-NERVOUS-SYSTEM; SHIVERER MOUSE-BRAIN; CNS STEM-CELLS; ADULT-RAT; PRECURSOR CELLS; ADHESION MOLECULE; COMPRESSION INJURY; TYPE-1 ASTROCYTES; MUTANT MOUSE; REMYELINATION	Stein cell therapy is a promising approach for remyelination strategies in demyelinating and traumatic disorders of the spinal cord. Self-renewing neural stem/progenitor cells (NSPCs) reside in the adult mammalian brain and spinal cord. We transplanted NSPCs derived from the adult spinal cord of transgenic rats into two models of focal demyelination and congenital dysmyelination. Focal demyelination was induced by X-irradiation and ethidium bromide injection (X-EB); and dysmyelination was in adult shiverer mutant mice, which lack compact CNS myelin. We examined the differentiation potential and myelinogenic capacity of NSPCs transplanted into the spinal cord. In X-EB lesions, the transplanted cells primarily differentiated along an oligodendrocyte lineage but only some of the oligodendrocytic Progeny remyelinated host axons. In this glial-free lesion, NSPCs also differentiated into cells with Schwann-like features based on ultrastructure, expression of Schwann cell markers, and generation of peripheral myelin. in contrast, after transplantation into the spinal cord of adult shiverer mice, the majority of the NSPCs expressed an oligodendrocytic phenotype which myelinated the dysmyelinated CNS axons forming compact myelin, and none had Schwann cell-like features. This is the first Study to examine the differentiation and myelinogenic capacity of adult Spinal Cord stem/progenitors in focal demyelination and dysmyelination of the adult rodent spinal cord. Our findings demonstrate that these NSPCs have the inherent plasticity to differentiate into oligodendrocytes OF Schwann-like cells depending oil the host environment, and that both cell types are capable of myelinating axons in the demyelinated and dysmyelinated adult spinal Cord. (C) 2008 Elsevier Inc. All rights reserved.	[Mothe, Andrea J.; Tator, Charles H.] Toronto Western Res Inst, Krembil Neurosci Ctr, Div Genet & Dev, Toronto, ON M5T 2S8, Canada; [Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A8, Canada	Mothe, AJ (corresponding author), Toronto Western Res Inst, Krembil Neurosci Ctr, Div Genet & Dev, Toronto, ON M5T 2S8, Canada.	amothe@uhnres.utoronto.ca			Christopher Reeve Paralysis Foundation; MS Society of Canada; International Foundation of Research in Paraplegia; CIHR NETCanadian Institutes of Health Research (CIHR); Ontario Neurotrauma Foundation; CIHRCanadian Institutes of Health Research (CIHR)	This work was supported by operating grants to C.H.T from the Christopher Reeve Paralysis Foundation, MS Society of Canada, International Foundation of Research in Paraplegia, and in part by CIHR NET team grant. A. J. M. was supported by fellowships from the Ontario Neurotrauma Foundation and CIHR. We thank Linda Lee and Rita van Bendegem for the technical assistance and Iris Kulbatski for Culturing some of the cells used for the focal demyelination transplantation experiments. We thank Dr. Armand Keating and Dr. Xinghua Wang of the Cell Therapy Program, Princess Margaret Hospital and Ontario Cancer Institute, for maintaining the transgenic rat colony. We thank Bob Kuba and Dr. Richard Hill of the Division of Applied Molecular Oncology, Princess Margaret Hospital and Ontario Cancer Institute, for their help with the X-irradiation of rats. We thank Sheer Ramjohn and Dr. Patrick Shannon of the Department of Cellular and Molecular Pathology, University of Toronto, for their help with the ultrastructural analysis. We thank Stephanie Tung for her assistance with cell Counts and Dr. Juan Archelos for the gift of P0 antibody.	Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Bhat RV, 1996, GLIA, V17, P169; BLAKEMORE WF, 1989, J NEUROCYTOL, V18, P519, DOI 10.1007/BF01474547; Blakemore WF, 2005, NEUROPATH APPL NEURO, V31, P1, DOI 10.1111/j.1365-2990.2005.00637.x; Blakemore WF, 2003, EXP NEUROL, V184, P955, DOI 10.1016/S0014-4886(03)00347-9; BLAKEMORE WF, 1978, NEUROPATH APPL NEURO, V4, P47, DOI 10.1111/j.1365-2990.1978.tb00528.x; BLAKEMORE WF, 1982, NEUROPATH APPL NEURO, V8, P365, DOI 10.1111/j.1365-2990.1982.tb00305.x; BRUNI JE, 1987, ACTA ANAT, V128, P265; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; CHERNOFF GF, 1981, J HERED, V72, P128, DOI 10.1093/oxfordjournals.jhered.a109442; CRANG AJ, 1992, J NEUROIMMUNOL, V40, P243, DOI 10.1016/0165-5728(92)90140-G; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Dervan AG, 2003, J COMP NEUROL, V458, P293, DOI 10.1002/cne.10594; DROMARD C, J NEUROSCI RES; Eftekharpour E, 2007, J NEUROSCI, V27, P3416, DOI 10.1523/JNEUROSCI.0273-07.2007; Franklin RJM, 1996, EXP NEUROL, V137, P263, DOI 10.1006/exnr.1996.0025; FRANKLIN RJM, 1991, J NEUROCYTOL, V20, P420, DOI 10.1007/BF01355538; Gajavelli S, 2004, EXP NEUROL, V188, P205, DOI 10.1016/j.expneurol.2004.03.026; GUMPEL M, 1989, DEV NEUROSCI-BASEL, V11, P132, DOI 10.1159/000111894; Hakamata Y, 2001, BIOCHEM BIOPH RES CO, V286, P779, DOI 10.1006/bbrc.2001.5452; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Horky LL, 2006, J COMP NEUROL, V498, P525, DOI 10.1002/cne.21065; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; KOHSAKA S, 1986, BRAIN RES, V372, P137, DOI 10.1016/0006-8993(86)91466-6; Kulbatski I, 2007, J HISTOCHEM CYTOCHEM, V55, P209, DOI 10.1369/jhc.6A7020.2006; LACHAPELLE F, 1994, EUR J NEUROSCI, V6, P814, DOI 10.1111/j.1460-9568.1994.tb00992.x; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; LUBETZKI C, 1988, J NEUROL SCI, V88, P161, DOI 10.1016/0022-510X(88)90214-6; Martens DJ, 2002, EUR J NEUROSCI, V16, P1045, DOI 10.1046/j.1460-9568.2002.02181.x; McKenzie IA, 2006, J NEUROSCI, V26, P6651, DOI 10.1523/JNEUROSCI.1007-06.2006; Mitome M, 2001, BRAIN, V124, P2147, DOI 10.1093/brain/124.11.2147; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Mothe AJ, 2005, J HISTOCHEM CYTOCHEM, V53, P1215, DOI 10.1369/jhc.5A6639.2005; Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011; MOTHE AJ, CELL TRANSP IN PRESS; Mujtaba T, 1998, DEV BIOL, V200, P1, DOI 10.1006/dbio.1998.8913; Namiki J, 1999, J NEUROPATH EXP NEUR, V58, P489, DOI 10.1097/00005072-199905000-00008; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; NORDLANDER RH, 1978, J COMP NEUROL, V180, P349, DOI 10.1002/cne.901800211; OUMESMAR BN, 1995, EUR J NEUROSCI, V7, P480, DOI 10.1111/j.1460-9568.1995.tb00344.x; Parr AM, 2007, J NEUROTRAUM, V24, P835, DOI 10.1089/neu.2006.3771; Pfeifer K, 2006, REGEN MED, V1, P255, DOI 10.2217/17460751.1.2.255; PRIVAT A, 1979, NEUROSCI LETT, V12, P107, DOI 10.1016/0304-3940(79)91489-7; Radtke C, 2007, INT J DEV NEUROSCI, V25, P149, DOI 10.1016/j.ijdevneu.2007.02.002; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sasaki M, 2006, J NEUROSCI, V26, P1803, DOI 10.1523/JNEUROSCI.3611-05.2006; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Takahashi M, 2003, J NEUROPATH EXP NEUR, V62, P185, DOI 10.1093/jnen/62.2.185; Talbott JF, 2006, GLIA, V54, P147, DOI 10.1002/glia.20369; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Vacanti MP, 2001, TRANSPLANT P, V33, P592, DOI 10.1016/S0041-1345(00)02158-8; VAQUERO J, 1981, ACTA NEUROCHIR, V59, P209, DOI 10.1007/BF01406350; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; WALLACE MC, 1987, SURG NEUROL, V27, P209, DOI 10.1016/0090-3019(87)90031-0; Weiss S, 1996, J NEUROSCI, V16, P7599; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Wu SF, 2002, J NEUROSCI RES, V69, P940, DOI 10.1002/jnr.10346; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3	68	62	70	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2008	213	1					176	190		10.1016/j.expneurol.2008.05.024			15	Neurosciences	Neurosciences & Neurology	344QX	WOS:000258943500022	18586031				2021-06-18	
J	Friedemann-Sanchez, G; Sayer, NA; Pickett, T				Friedemann-Sanchez, Greta; Sayer, Nina A.; Pickett, Treven			Provider perspectives on rehabilitation of patients with polytrauma	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; caregivers; combat disorders; rehabilitation; rehabilitation centers.	TRAUMATIC BRAIN-INJURY; INJECTION-DRUG USE; RAPID ASSESSMENT; IRAQ; CARE; WAR; AFGHANISTAN; SOLDIERS; OUTCOMES; VICTIMS	Objectives: To describe, from the perspective of U.S. Department of Veterans Affairs (VA) polytrauma rehabilitation providers, (1) patients with combat-related polytrauma and their rehabilitation, (2) polytrauma patient family member involvement in rehabilitation, and (3) the impact on providers of providing polytrauma rehabilitation. Design: Qualitative study based on rapid assessment process methodology, which included semistructured interviews, observation, and use of a field liaison. Setting: The 4 VA polytrauma rehabilitation centers (PRCs). Participants: Fifty-six purposefully selected PRC providers and providers from consulting services. Interventions: Not applicable. Main Outcomes Measures: Provider self-report of polytrauma patient characteristics, polytrauma patient family member involvement in rehabilitation, and the impact of polytrauma rehabilitation on providers themselves. Results: According to PRC providers, polytrauma patients are younger than VA rehabilitation patients. Strong military identities affect rehabilitation needs and reactions to severe injury. The public and the media have particular interest in war-injured patients. Patients with blast-related polytrauma have unique constellations of visible (including amputations, craniectomies, and burns) and invisible (including traumatic brain injury, pain, and posttraumatic stress disorder) injuries. Providers have adjusted treatment strategies and involved services outside of rehabilitation because of this clinical complexity. Family members are intensely involved in rehabilitation and have service needs that may surpass those of families of rehabilitation patients without polytrauma. Sources of provider stress include new responsibilities, media attention, increased oversight, and emotional costs associated with treating severely injured young patients and their families. Providers also described the work as deeply rewarding. Conclusions: The VA should prioritize the identification or development and implementation of strategies to address family member needs and to monitor and ensure that PRC providers have access to appropriate resources. Future research should determine whether findings generalize to patients injured in other wars and to people who sustain polytraumatic injuries outside of a war zone, including victims of terrorist attacks.	[Friedemann-Sanchez, Greta] Univ Minnesota, Hubert H Humphrey Inst Publ Affairs, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; [Friedemann-Sanchez, Greta; Sayer, Nina A.] Ctr Chron Dis Outcomes Res VA Med Ctr, Minneapolis, MN USA; [Pickett, Treven] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Pickett, Treven] McGuire VA Med Ctr, Richmond, VA USA; [Pickett, Treven] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA	Friedemann-Sanchez, G (corresponding author), Univ Minnesota, Hubert H Humphrey Inst Publ Affairs, Humphrey Ctr 267, 301-19th Ave S, Minneapolis, MN 55455 USA.	frie0013@umn.edu	Sayer, Nina/E-3249-2016	Friedemann-Sanchez, Greta/0000-0002-0493-7218			Aharonson-Daniel L, 2005, SCAND J SURG, V94, P185, DOI 10.1177/145749690509400302; AMARA J, 2007, WORKING PAPER SERIES; Beach SR, 2005, J AM GERIATR SOC, V53, P255, DOI 10.1111/j.1532-5415.2005.53111.x; Beach SR, 2000, PSYCHOL AGING, V15, P259, DOI 10.1037//0882-7974.15.2.259; Beebe J., 2001, RAPID ASSESSMENT PRO; Burg M. M., 1994, ANN BEHAV MED, V16, P109; CHAMBERS R, 1994, WORLD DEV, V22, P1253, DOI 10.1016/0305-750X(94)90003-5; Chambers R., 1992, RAP RAPID ASSESSMENT, P295; Chatterjee A., 1996, Bulletin on Narcotics, V48, P11; Darkins A, 2008, ARCH PHYS MED REHAB, V89, P182, DOI 10.1016/j.apmr.2007.07.027; de Jong W, 1999, J DRUG ISSUES, V29, P843, DOI 10.1177/002204269902900406; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Eldar R, 2003, DISABIL REHABIL, V25, P1019, DOI 10.1080/0963828031000137739; Fitch, 2000, Int J Drug Policy, V11, P63, DOI 10.1016/S0955-3959(99)00056-0; Fitch C, 2004, SOC SCI MED, V59, P1819, DOI 10.1016/j.socscimed.2004.02.028; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; GITTLESON J, 1998, RAPID ASSESSMENT PRO; Glaser B. G., 1967, DISCOVERY GROUNDED T; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Green J., 2004, QUALITATIVE METHODS; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; GUNTHER MS, 1994, AM J PSYCHOTHER, V48, P208; KLEVEN J, 2004, INJ CONTROL SAF PROM, V11, P1; Kluger Y, 2004, J AM COLL SURGEONS, V199, P875, DOI 10.1016/j.jamcollsurg.2004.09.003; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; MANDERSON L, 1992, SOC SCI MED, V35, P839, DOI 10.1016/0277-9536(92)90098-B; Menetrez Jennifer S, 2002, Phys Med Rehabil Clin N Am, V13, P67, DOI 10.1016/S1047-9651(03)00072-X; Needle RH, 2003, AM J PUBLIC HEALTH, V93, P970, DOI 10.2105/AJPH.93.6.970; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; OSBORN M, 1988, AM J PHYS MED REHAB, V67, P275; Pape TLB, 2006, BRAIN INJURY, V20, P743, DOI 10.1080/02699050600676933; Patton M.Q., 2002, QUALITATIVE RES EVAL; Peake JB, 2005, NEW ENGL J MED, V352, P219, DOI 10.1056/NEJMp048312; Pearson R, 1989, Hygie, V8, P23; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Rusk H A, 1969, Arch Phys Med Rehabil, V50, P463; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SCHLENZ KC, 1995, AM J OCCUP THER, V49, P986, DOI 10.5014/ajot.49.10.986; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Scrimshaw NS., 1992, RAPID ASSESSMENT PRO; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Stimson GV, 2006, AM J PUBLIC HEALTH, V96, P288, DOI 10.2105/AJPH.2003.035899; Strauss A., 1990, BASICS QUALITATIVE R; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; Wittig PG, 2003, DISABIL REHABIL, V25, P97, DOI 10.1080/0963828021000024933	53	62	64	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2008	89	1					171	178		10.1016/j.apmr.2007.10.017			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	249LB	WOS:000252228600029	18164350				2021-06-18	
J	Glang, A; Todis, B; Thomas, C; Hood, D; Bedell, G; Cockrell, J				Glang, Ann; Todis, Bonnie; Thomas, CatherineW.; Hood, Donald; Bedell, Gary; Cockrell, Janice			Return to school following childhood TBI: Who gets services?	NEUROREHABILITATION			English	Article						Special education; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ACADEMIC-ACHIEVEMENT; CHILDREN; ADOLESCENTS; REHABILITATION; INTERVENTIONS; TRANSITION; PLACEMENT; RECOVERY; STUDENTS	Long-term follow-up studies of children conducted during the K-12 school years suggest that problems associated with TBI tend to persist or worsen as children progress through school. A critical issue in service delivery for students with TBI is the significant discrepancy between the incidence of TBI and the identification of children with TBI for special education services. The purpose of this study was to examine factors that influence identification and service practices for students with TBI. Parents of 56 youth with TBI completed a questionnaire and interview about the hospital-school transition and educational services provided within the first year of school re-entry. A subsample participated in a concurrent qualitative study. Results document that 25% of the sample were identified for formal services (via individual education plan or 504 plan) while over 41% received informal supports (e. g., schedule change, extra time on tests). Results from chi-square and logistic regression analyses suggest that injury severity and hospital-school transition services (e. g., written or verbal communication between hospital and school) were related to the provision of formal special education or 504 services. A critical factor contributing to the identification of students with TBI for special education is the link between hospital and school.	[Glang, Ann; Todis, Bonnie; Thomas, CatherineW.; Hood, Donald] Teaching Res Inst Eugene, Eugene, OR 97401 USA; [Hood, Donald] Tufts Univ, Boston, MA 02111 USA; [Cockrell, Janice] Legacy Emanuel Childrens Hosp, Portland, OR USA	Glang, A (corresponding author), Teaching Res Inst Eugene, 99 W 10th Ave,Suite 370, Eugene, OR 97401 USA.	glanga@wou.edu					Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Blosser J, 1997, J HEAD TRAUMA REHAB, V12, P21, DOI 10.1097/00001199-199704000-00004; Dettmer JL, 2007, J HEAD TRAUMA REHAB, V22, P339, DOI 10.1097/01.HTR.0000300229.13490.c7; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; Dishion TJ, 2005, J CLIN CHILD ADOLESC, V34, P62, DOI 10.1207/s15374424jccp3401_6; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Frank EM, 1997, J CHILDRENS COMMUNIC, V18, P49, DOI 10.1177/152574019701800206; FUNK P, 1996, PHYS DISABILITIES ED, V15, P49; Gioia G.A., 2000, BEHAV RATING INVENTO; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; GLANG A, 1996, CHILDREN ACQUIRED BR, P149; GLANG A, 2006, J HEAD TRAUMA REHAB, V21, P408; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; HOLLER RA, 2008, NASSP B, V2; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LANGLOIS JA, 2002, TRAUMATIC BRAIN INJU, P1; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MARINO MJ, 2000, TBI CHALLENGE, V4, P18; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Todis B, 1997, CHILDREN ACQUIRED BR; *US DEP ED, 2003, 21 ANN REP C IMPL IN; van Lier PAC, 2005, J ABNORM CHILD PSYCH, V33, P99, DOI 10.1007/s10802-005-0938-8; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P42, DOI 10.1097/00001199-199512000-00007; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	45	62	64	0	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	6					477	486					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200004	19127001				2021-06-18	
J	Couch, JR; Lipton, RB; Stewart, WF; Scher, AI				Couch, James R.; Lipton, Richard B.; Stewart, Walter F.; Scher, Ann I.			Head or neck injury increases the risk of chronic daily headache - A population-based study	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HEADACHE; MINOR HEAD; FREQUENT HEADACHE; PREVALENCE; CONCUSSION; SEVERITY; MIGRAINE	Objective: To evaluate the extent to which head and neck injury ( HANI) contributes to chronic daily headache ( CDH). Background: In prospective studies, head injury is associated with headache ( HA) that remains a problem at 12 to 24 months post- head injury in 20 to30% of patients. Of these, up to 30 to 50% manifest CDH. The degree to which head injury contributes to CDH has not been evaluated in a non- clinical population. We evaluate the relationship between lifetime occurrence of HANI and CDH in a randomly chosen population sample. Methods: Study participants are from the Frequent Headache Epidemiology Study. Cases with CDH ( >= 180 HA/ year) and a comparison group with episodic headache ( EH, 2 to 102 HA/ year) were identified from the general population. Subjects were asked about lifetime occurrence of HANI. HANI were further classified as potentially precipitating injuries ( PPI) if they occurred within 2 years of CDH onset for cases or in an equivalent 2- year period for EH controls. Results: Lifetime occurrence of HANI was more frequent in cases than controls for men ( adjusted OR = 3.1 [ 1.3 to 7.2]), women ( OR = 1.5 [ 0.97 to 2.3]), and overall ( OR = 1.7 [ 1.1 to 2.4]). The attributable risk was 15% ( 36% men, 11% women). Results were similar for PPI. The odds of CDH increased with the number of lifetime HANI in all groups ( p < 0.05 trend). Conclusions: Results suggest that head and neck injury ( HANI) accounts for approximately 15% of chronic daily headache ( CDH) cases in this non- clinical population. The relationship between HANI and CDH was not limited to injuries proximate to CDH onset. The lifetime risk of CDH increases with increasing number of HANI.	Univ Oklahoma, Sch Med, Dept Neurol, Oklahoma City, OK 73104 USA; Albert Einstein Coll Med, Dept Neurol Epidemiol Populat Hlth, Bronx, NY 10467 USA; Outcomes Res Inst, Danville, PA USA; Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD USA	Couch, JR (corresponding author), Univ Oklahoma, Sch Med, Dept Neurol, 711 SL Yong Blvd,Room 209, Oklahoma City, OK 73104 USA.		Lipton, Richard B/B-5060-2011	Scher, Ann/0000-0003-4599-9834			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Bekkelund SI, 2003, HEADACHE, V43, P59, DOI 10.1046/j.1526-4610.2003.03010.x; Berglund A, 2001, J CLIN EPIDEMIOL, V54, P851, DOI 10.1016/S0895-4356(00)00369-3; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; Cartlidge NEF, 1981, HEAD INJURY, P95; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Guttmann E, 1943, LANCET, V1, P10; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; KAY DWK, 1971, LANCET, V2, P1052; LANZI G, 1985, CEPHALALGIA, V5, P211, DOI 10.1046/j.1468-2982.1985.0504211.x; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Moscato Davide, 2005, J Headache Pain, V6, P284, DOI 10.1007/s10194-005-0208-8; Nestvold K, 2005, ACTA NEUROL SCAND, V112, P13, DOI 10.1111/j.1600-0404.2005.00344.x; Radanov BP, 2001, EUR SPINE J, V10, P403, DOI 10.1007/s005860000227; RASKIN NH, 1987, HEADACHE, V27, P416, DOI 10.1111/j.1526-4610.1987.hed2708416.x; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHECTER AL, 2001, WOLFFS HEADACHE OTHE, P108; Scher AI, 2003, NEUROLOGY, V60, P1366, DOI 10.1212/01.WNL.0000055873.71552.51; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Scher AI, 2003, PAIN, V106, P81, DOI 10.1016/S0304-3959(03)00293-8; Scher AI, 2004, NEUROLOGY, V63, P2022, DOI 10.1212/01.WNL.0000145760.37852.ED; Schrader H, 2006, EUR J NEUROL, V13, P1226, DOI 10.1111/j.1468-1331.2006.01481.x; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0; Symonds CP, 1943, LANCET, V1, P7; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Wiendels NJ, 2006, CEPHALALGIA, V26, P1434, DOI 10.1111/j.1468-2982.2006.01210.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; YOUNG WB, 2005, CHRONIC DAILY HEADAC	42	62	67	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 11	2007	69	11					1169	1177		10.1212/01.wnl.0000276985.07981.0a			9	Clinical Neurology	Neurosciences & Neurology	208VA	WOS:000249346100014	17846416				2021-06-18	
J	Cullen, DK; Lessing, MC; LaPlaca, MC				Cullen, D. Kacy; Lessing, M. Christian; LaPlaca, Michelle C.			Collagen-dependent neurite outgrowth and response to dynamic deformation in three-dimensional neuronal cultures	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						cell biomechanics; neurite outgrowth; hydrogel; in vitro; mechanotransduction; TBI	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; EXTRACELLULAR-MATRIX; MECHANICAL STRETCH; CELL-ADHESION; GEL STIFFNESS; AXONAL INJURY; NEURAL CELLS; 3 DIMENSIONS; INTEGRIN	In vitro models of brain injury that use thick 3-D cultures and control extracellular matrix constituents allow evaluation of cell-matrix interactions in a more physiologically relevant configuration than traditional 2-D cultures. We have developed a 3-D cell culture system consisting of primary rat cortical neurons distributed throughout thick (> 500 mu m) gels consisting of type IV collagen (Col) conjugated to agarose. Neuronal viability and neurite outgrowth were examined for a range of agarose (AG) percentages (1.0-3.0%) and initial collagen concentrations ([Col](i); 0-600 mu g/mL). In unmodified AG, 1.5% gels supported viable cultures with significant neurite outgrowth, which was not found at lower (<= 1.0%) concentrations. Varying [Col](i) in 1.25% AG revealed the formation of dense, 3-D neurite networks at [Col](i) of 300 mu g/mL, while neurons in unmodified AG and at higher [Col](i) (600 mu g/mL) exhibited significantly less neurite outgrowth; although, neuronal survival did not vary with [Col](i). The effect of [Col](i) on acute neuronal response following high magnitude, high rate shear deformation (0.50 strain, 30 s(-1) strain rate) was evaluated in 1.5% AG for [Col](i) of 30, 150, and 300 mu g/mL, which supported cultures with similar baseline viability and neurite outgrowth. Conjugation of Col to AG also increased the complex modulus of the hydrogel. Following high rate deformation, neuronal viability significantly decreased with increasing [Col](i), implicating cell-matrix adhesions in acute mechanotransduction events associated with traumatic loading. These results suggest interrelated roles for matrix mechanical properties and receptor-mediated cell-matrix interactions in neuronal viability, neurite outgrowth, and transduction of high rate deformation. This model system may be further exploited for the elucidation of mechanotransduction mechanisms and cellular pathology following mechanical insult.	Georgia Inst Technol, GT Emory Coulter Dept Biomed Engn, Atlanta, GA 30332 USA	LaPlaca, MC (corresponding author), Georgia Inst Technol, GT Emory Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001014] Funding Source: Medline; NCIPC CDC HHS [R49/CE000191] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6; Anderson KL, 2004, J NEUROSCI RES, V75, P688, DOI 10.1002/jnr.20018; ARREGUI CO, 1994, J NEUROSCI, V14, P6967; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; BELLAMKONDA R, 1995, J NEUROSCI RES, V41, P501, DOI 10.1002/jnr.490410409; BRADSHAW AD, 1995, DEVELOPMENT, V121, P3593; CARMELIET G, 1994, J CELL SCI, V107, P3379; Cavalcanti-Adam Elisabetta Ada, 2005, Prog Orthod, V6, P232; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Danen EHJ, 2003, J PATHOL, V201, P632, DOI 10.1002/path.1472; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Dillon GP, 1998, J BIOMAT SCI-POLYM E, V9, P1049, DOI 10.1163/156856298X00325; Dodla MC, 2006, J BIOMED MATER RES A, V78A, P213, DOI 10.1002/jbm.a.30747; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FAWCETT JW, 1995, EXP BRAIN RES, V106, P275; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Granet C, 1998, MED BIOL ENG COMPUT, V36, P513, DOI 10.1007/BF02523224; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P615, DOI 10.1016/0955-0674(95)80101-4; Hamill OP, 2001, PHYSIOL REV, V81, P685; HOFFMAN RM, 1993, STEM CELLS, V11, P105, DOI 10.1002/stem.5530110205; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Kamm Roger D, 2004, Mech Chem Biosyst, V1, P201; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Ko KS, 2001, BIOCHEM BIOPH RES CO, V285, P1077, DOI 10.1006/bbrc.2001.5177; KREWSON CE, 1994, BIOTECHNOL BIOENG, V43, P555, DOI 10.1002/bit.260430704; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MASI L, 1992, CALCIFIED TISSUE INT, V51, P202, DOI 10.1007/BF00334548; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; O'Connor SM, 2000, BIOSENS BIOELECTRON, V14, P871; O'Connor SM, 2001, NEUROSCI LETT, V304, P189, DOI 10.1016/S0304-3940(01)01769-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Schense JC, 2000, J BIOL CHEM, V275, P6813, DOI 10.1074/jbc.275.10.6813; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; Smith DH, 1999, J NEUROSCI, V19, P4263; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TOMASELLI KJ, 1991, ANN NY ACAD SCI, V633, P100; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wehrle-Haller B, 2003, J PATHOL, V200, P481, DOI 10.1002/path.1399; Willits RK, 2004, J BIOMAT SCI-POLYM E, V15, P1521, DOI 10.1163/1568562042459698; Woerly S, 1996, NEUROSCI LETT, V205, P197, DOI 10.1016/0304-3940(96)12349-1; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; Yu TT, 2005, BIOMATERIALS, V26, P1507, DOI 10.1016/j.biomaterials.2004.05.012; Yu XJ, 2001, J NEUROSCI RES, V66, P303, DOI 10.1002/jnr.1225	63	62	64	0	29	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2007	35	5					835	846		10.1007/s10439-007-9292-z			12	Engineering, Biomedical	Engineering	158TF	WOS:000245816900014	17385044				2021-06-18	
J	Mihalik, JP; McCaffrey, MA; Rivera, EM; Pardini, JE; Guskiewicz, KM; Collins, MW; Lovell, MR				Mihalik, Jason P.; McCaffrey, Meghan A.; Rivera, Eric M.; Pardini, Jamie E.; Guskiewicz, Kevin M.; Collins, Michael W.; Lovell, Mark R.			Effectiveness of mouthguards in reducing neurocognitive deficits following sports-related cerebral concussion	DENTAL TRAUMATOLOGY			English	Article						mild traumatic brain injury; high school athlete; concussion recovery; oral injury	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; NCAA CONCUSSION; ICE HOCKEY; RECOVERY; INJURIES; SOCCER; PERFORMANCE; FRACTURES; TRAUMA	Although it is widely accepted that mouthguards decrease the incidence of dental injuries, there is a controversy among sports medicine professionals as to the effectiveness of mouthguards in decreasing the incidence or severity of sports-related cerebral concussion (SRCC). While some experimental data suggest that this may be the case, there exist a number of reports suggesting that mouthguards do not serve this purpose. These conclusions have been drawn, however, without actually measuring the extent of neurocognitive dysfunction in athletes following sports-related concussion. The purpose of this study was to determine whether mouthguard use reduces the neurocognitive and symptomatic impairments that follow an injurious episode of SRCC. Preseason baseline data were collected as part of an ongoing clinical program that uses a computerized neurocognitive test to assess various faculties of brain function and symptoms reported at the time of testing. Follow-up testing from 180 student-athletes who had sustained an SRCC was analyzed for the purpose of this study. These athletes were separated into one of two groups: those who reported using mouthguards and those who did not. Neurocognitive testing was accomplished using the Immediate Post-Concussion and Assessment Test (ImPACT). Results suggest that neurocognitive deficits at the time of the athletes' first follow-up assessment did not differ between mouthguard users and non-users, suggesting that mouthguard use does little to reduce the severity of neurocognitive dysfunction and onset of symptoms following sports-related head trauma. However, an interesting finding in this study was that athletes experienced significantly lower neurocognitive test scores and reported higher symptom scores following SRCC regardless of mouthguard use. This emphasizes a thorough clinical evaluation of athletes that have sustained an SRCC. Although it was found in this study that mouthguard use does not decrease the severity of concussion, it is important to note that the use of mouthguards is paramount in reducing maxillofacial and dental trauma and their use should continue to be mandated by athletic associations and supported by all dental and sports medicine professionals.	Univ N Carolina, Sports Med Res Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Endodont, Chapel Hill, NC 27599 USA; Univ Pittsburgh, Med Ctr, Sports Med Concuss Program, Pittsburgh, PA USA	Mihalik, JP (corresponding author), Univ N Carolina, Sports Med Res Lab, CB 8700,Fetzer Gymnasium S Rd, Chapel Hill, NC 27599 USA.	jasonm@unc.edu	Mihalik, Jason P/E-7059-2010	Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322			Blignaut J B, 1987, Br J Sports Med, V21, P5; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hawn KL, 2002, J ATHL TRAINING, V37, P204; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JONES NP, 1994, BRIT J SPORT MED, V28, P272, DOI 10.1136/bjsm.28.4.272; Kerr L, 1983, Clin Sports Med, V2, P115; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Levin L, 2003, DENT TRAUMATOL, V19, P237, DOI 10.1034/j.1600-9657.2003.00196.x; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mihalik JP, 2005, J ATHL TRAINING, V40, P116; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Padilla R, 1996, J Calif Dent Assoc, V24, P30; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Woodmansey K F, 1999, Gen Dent, V47, P64; WOODMANSEY KF, 1999, GEN DENT, V47, P70	36	62	66	1	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	FEB	2007	23	1					14	20		10.1111/j.1600-9657.2006.00488.x			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	125LM	WOS:000243443400004	17227375				2021-06-18	
J	Wang, Y; Moges, H; Bharucha, Y; Symes, A				Wang, Yu; Moges, Helina; Bharucha, Yasmin; Symes, Aviva			Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; glial scar; gliosis; transforming growth factor-beta; Smad3	TRANSFORMING-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; CHONDROITIN SULFATE PROTEOGLYCANS; FIBRILLARY ACIDIC PROTEIN; ADULT-RAT BRAIN; TGF-BETA; REACTIVE ASTROCYTES; NG2 PROTEOGLYCAN; GLIAL SCAR; EXTRACELLULAR-MATRIX	Following central nervous system injury, adult mammalian neurons do not regenerate through regions of scar formation. This regenerative failure is due in part to the inhibitory environment of the glial scar at the lesion site. Following injury, transforming growth factor beta (TGF-beta) is strongly induced and is important to many aspects of the response to injury, including deposition of extracellular matrix (ECM) in the glial scar. However, the pathways through which TGF-beta signals to mediate these effects are not known. In order to examine the contribution of the TGF-beta-induced transcription factor, Smad3, to formation of the glial scar after traumatic brain injury, we utilized mice that do not express Smad3. We report that Smad3 null mice heal stab wounds to the cerebral cortex more rapidly than do wild-type mice. In Smad3 null mice many aspects of glial scar formation and the immune response to injury were altered. Fewer neutrophils, macrophages/microglia, NG2-positive cells and GFA-beta-positive cells were detected immediately around the lesion in Smad3 null mice. Expression of fibronectin and laminin was also reduced. Injury-induced cell proliferation was significantly lower in Smad3 null mice around the lesion. There was no overall difference between wild-type and Smad3 null mice in immunoreactivity for TGF-beta(1) after injury. Thus, our experiments suggest that TGF-beta signaling through Smad3 contributes significantly to the immune response and scar formation after cortical stab wound injury, delaying recovery through multiple mechanisms. Published by Elsevier Inc.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Symes, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Asymes@usuhs.mil	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939			Abraham S, 2003, VIROLOGY, V309, P196, DOI 10.1016/S0042-6822(03)00112-0; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CUI W, 1996, GROWTH FACTORS CYTOK, P319; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x; Davies SJA, 1997, NATURE, V390, P680; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; GAGELIN C, 1995, GLIA, V13, P283, DOI 10.1002/glia.440130405; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962; HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; King VR, 2004, NEUROSCIENCE, V126, P173, DOI 10.1016/j.neuroscience.2004.03.035; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; Konig HG, 2005, J CELL BIOL, V168, P1077, DOI 10.1083/jcb.200407027; KRIEGLSTEIN K, 1995, INT J DEV NEUROSCI, V13, P301, DOI 10.1016/0736-5748(94)00062-8; KROHN K, 1995, J NEUROIMMUNOL, V56, P53, DOI 10.1016/0165-5728(94)00133-9; Krohn K, 1999, J NEUROCHEM, V72, P1353, DOI 10.1046/j.1471-4159.1999.721353.x; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2003, GENE DEV, V17, P2993, DOI 10.1101/gad.1167003; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MCKINNON RD, 1993, J CELL BIOL, V121, P1397, DOI 10.1083/jcb.121.6.1397; MCNEILL H, 1994, NEUROREPORT, V5, P901, DOI 10.1097/00001756-199404000-00012; Moon LDF, 2002, NEUROSCIENCE, V109, P101, DOI 10.1016/S0306-4522(01)00457-2; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Moon LDF, 2001, NAT NEUROSCI, V4, P465; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nomura M, 1998, NATURE, V393, P786; Pang L, 2001, STROKE, V32, P544, DOI 10.1161/01.STR.32.2.544; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Sousa VD, 2004, EUR J NEUROSCI, V19, P1721, DOI 10.1111/j.1460.9568.2004.03249.x; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weiss JM, 1998, J NEUROIMMUNOL, V91, P190, DOI 10.1016/S0165-5728(98)00183-0; Wickelgren I, 2002, SCIENCE, V297, P178, DOI 10.1126/science.297.5579.178; WINDLE WF, 1952, J COMP NEUROL, V96, P359, DOI 10.1002/cne.900960207; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; WyssCoray T, 1997, J NEUROIMMUNOL, V77, P45, DOI 10.1016/S0165-5728(97)00049-0; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhu Y, 2000, BRAIN RES, V866, P286, DOI 10.1016/S0006-8993(00)02240-X; Zuo J, 2002, EXP NEUROL, V176, P221, DOI 10.1006/exnr.2002.7922	87	62	69	1	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2007	203	1					168	184		10.1016/j.expneurol.2006.08.006			17	Neurosciences	Neurosciences & Neurology	123NU	WOS:000243303400019	16996058				2021-06-18	
J	Max, JE; Levin, HS; Schachar, RJ; Landis, J; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M				Max, JE; Levin, HS; Schachar, RJ; Landis, J; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M			Predictors of personality change due to traumatic brain injury in children and adolescents six to twenty-four months after injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							FRONTAL-LOBE DAMAGE; PSYCHIATRIC-DISORDERS; RELIABILITY; VALIDITY; BEHAVIOR; SCHEDULE	Phenomenology and predictive factors of personality change due to traumatic brain injury (TBI) 6 to 24 months after injury was investigated in children, ages 5 to 14 years, enrolled from consecutive admissions and followed prospectively for 2 years. Injury and preinjury psychosocial variables were assessed. Personality change occurred in 13% of participants between 6 and 12 months after injury and 12% in the second year after injury. Severity of injury consistently predicted personality change, and preinjury adaptive function predicted personality change only in the second year postinjury. Lesions of the superior frontal gyrus were associated with personality change between 6 and 12 months following injury, after controlling for severity of injury and the presence of other brain lesions. Only lesions in the frontal lobe white matter were significantly related to personality change in the second year after injury. After childhood TBI, neural correlates of personality change evolve between 6 and 12 months and 12 to 24 months after injury. The data implicate the dorsal prefrontal cortex and frontal lobe white matter in the emergence of personality change involving the effortful or conscious regulation of affective states.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA USA; Baylor Coll Med, Dept Neurosurg, Dept Phys Med & Rehabil, Houston, TX USA; Univ Houston, Dept Educ Psychol, Houston, TX USA; Hosp Sick Children, Res Inst, Dept Psyhciat Brain & Behav Program, Toronto, ON, Canada; Univ Texas, Hlth Sci Ctr, Dept Psychiat, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX USA; Univ Texas, Ctr Brain Hlth, Dept Behav & Brain Sci, Dallas, TX USA	Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Biederman J, 1997, J AFFECT DISORDERS, V44, P177, DOI 10.1016/S0165-0327(97)00043-8; Blau A, 1936, ARCH NEURO PSYCHIATR, V35, P723, DOI 10.1001/archneurpsyc.1936.02260040031003; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Drevets WC, 2003, ANN NY ACAD SCI, V985, P420, DOI 10.1111/j.1749-6632.2003.tb07098.x; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; GOODMAN R, 1989, BRIT J PSYCHIAT, V154, P292, DOI 10.1192/bjp.154.3.292; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; LISHMAN WA, 1978, ORGANIC PSYCHIAT; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; MAX JE, 2005, ADOLESCENT PSYCHIAT, V44, P435; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN, P107; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sparrow S., 1984, VINELAND ADAPTIVE BE; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81	35	62	62	0	29	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2006	18	1					21	32		10.1176/appi.neuropsych.18.1.21			12	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	014YU	WOS:000235519900004	16525067				2021-06-18	
J	Dyer, KFW; Bell, R; McCann, J; Rauch, R				Dyer, Kevin F. W.; Bell, Rob; McCann, John; Rauch, Robert			Aggression after traumatic brain injury: Analysing socially desirable responses and the nature of aggressive traits	BRAIN INJURY			English	Article						traumatic brain injury; spinal cord injury; aggression; social desirability	LONG-TERM SURVIVORS; HEAD-INJURY; PERSONALITY; MANAGEMENT; IMPULSIVENESS; QUESTIONNAIRE; BEHAVIOR; ANGER	Primary objective: To compare patients with traumatic brain injury ( TBI) with controls on sub-types of aggression and explore the role of social desirability. Design: Quasi- experimental, matched-participants design. Methods and procedures: Sixty- nine participants were included in the study. The sample comprised a TBI group ( n = 24), a spinal cord injury ( SCI) group (n = 21) and an uninjured (UI) group of matched healthy volunteers ( n = 24). Participants were given self-report measures of aggression, social desirability and impulsivity. Sixty- one independent 'otherraters' were nominated, who rated participant pre-morbid and post- morbid aggression. Main outcomes and results: Using standardized norms, 25 - 39% of participants with TBI were classified as high average - very high on anger and 35 - 38% as high average - very high on verbal aggression. Other- raters rated participants with TBI as significantly higher on verbal aggression than SCI and UI participants. There were no differences between the groups on physical aggression. The TBI group also had higher levels of impulsivity than SCI and UI groups. Social desirability was a highly significant predictor of self- reported aggression for the entire sample. Conclusions: Impulsive verbal aggression and anger are the principal aggressive traits after brain injury. Physical aggression may present in extreme cases after TBI, but appears less prominent overall in this population. Social desirability, previously overlooked in research examining TBI aggression, emerged as an influential variable that should be considered in future TBI research.	Queens Univ Belfast, Sch Psychol, Belfast BT9 5BP, Antrim, North Ireland; Joss Cardwell Ctr, Belfast, Antrim, North Ireland	Dyer, KFW (corresponding author), Queens Univ Belfast, Sch Psychol, Belfast BT9 5BP, Antrim, North Ireland.	kdyer01@qub.ac.uk					Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Archer J, 1995, AGGRESSIVE BEHAV, V21, P371, DOI 10.1002/1098-2337(1995)21:5<371::AID-AB2480210506>3.0.CO;2-P; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; BLAKE JF, 2006, PERSONALITY INDIVIDU, V40, P1625; Bockian NR, 2003, J CLIN PSYCHOL MED S, V10, P307, DOI 10.1023/A:1026309622586; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bowman M. L., 1997, IMPULSIVITY THEORY A, P116; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; Buss A.H., 2000, AGGRESSION QUESTIONN; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Diaz F G, 1995, Med Law, V14, P131; Edwards A., 1957, SOCIAL DESIRABILITY; FISCHER DG, 1993, ED PSYHOL MEASUREMEN, V4, P699; GARCIALEON A, 2004, SPANISH J PSYCHOL, V5, P45; Gisi TM, 2000, INT J NEUROSCI, V105, P121, DOI 10.3109/00207450009003271; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greve KW, 2002, PERS INDIV DIFFER, V32, P639, DOI 10.1016/S0191-8869(01)00066-6; Greve KW, 2001, BRAIN INJURY, V15, P255; Harris JA, 1997, BEHAV RES THER, V35, P1047, DOI 10.1016/S0005-7967(97)00064-8; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Jamner LD, 1999, PSYCHIAT RES, V85, P17, DOI 10.1016/S0165-1781(98)00134-6; JARVIE HF, 1954, J NEUROL NEUROSUR PS, V17, P14, DOI 10.1136/jnnp.17.1.14; Lazaro F, 2000, PSYCHIAT B, V24, P264; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LUENGO MA, 1991, PERS INDIV DIFFER, V12, P657, DOI 10.1016/0191-8869(91)90220-6; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Miller E, 1999, J FORENSIC PSYCHIATR, V10, P157, DOI 10.1080/09585189908402146; NOBLE M, 2001, MEASURES DEPRIVATION; Novaco R.W., 1975, ANGER CONTROL DEV EV; O'Connor DB, 2001, AGGRESSIVE BEHAV, V27, P79, DOI 10.1002/ab.2; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; OWNSWORTH T, 2002, NEUROPSYCHOL REHABIL, V14, P291; OWNSWORTH T, 2004, BRAIN INJURY, V16, P535; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; PAULHUS DL, 1991, ROLE CONSTRUCTS PSYC, P49; Pauls CA, 2004, PERS INDIV DIFFER, V37, P1137, DOI 10.1016/j.paid.2003.11.018; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Swann AC, 2002, BIOL PSYCHIAT, V51, P988, DOI 10.1016/S0006-3223(01)01357-9; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMSEN IV, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P52; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Warnken W J, 1994, Violence Vict, V9, P153; Wolfson AM, 2000, ARCH PHYS MED REHAB, V81, P1567, DOI 10.1053/apmr.2000.16345; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408	54	62	62	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1163	1173		10.1080/02699050601049312			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600007	17123933				2021-06-18	
J	Nott, MT; Chapparo, C; Baguley, IJ				Nott, Melissa T.; Chapparo, Christine; Baguley, Ian J.			Agitation following traumatic brain injury: An Australian sample	BRAIN INJURY			English	Article						traumatic brain injury; agitation; cognition; post-traumatic amnesia; outcomes	CLOSED HEAD-INJURY; SCALE; REHABILITATION; AGGRESSION; RESTLESSNESS; BEHAVIOR	Purpose: Agitation following traumatic brain injury (TBI) is perceived to limit the achievement of rehabilitation goals. The aims of this study were: (1) To examine the nature and incidence of agitation during TBI rehabilitation in an Australian sample; and (2) To explore the relationship between agitation and functional outcomes after TBI. Method: Retrospective medical record review of 80 participants admitted for rehabilitation following TBI. Outcome data collected at discharge, 6 and 24 months post-discharge, included length of stay, duration of post- traumatic amnesia ( PTA), community integration, functional independence and life satisfaction. Results: Seventy per cent of patients demonstrated agitation during rehabilitation for an average of 32 days. Agitated patients experienced longer PTA duration, increased length of stay and reduced functional independence, specifically cognitive function, at discharge. These differences between agitated and non- agitated participants did not appear to persist and were not evident at follow- up 6 and 24 months post- discharge. Longer duration of agitation was associated with delayed PTA emergence, longer rehabilitation stay and reduced functional independence at discharge and follow- up. Conclusions: A large proportion of patients with TBI experience agitation. Presence of agitation seems to limit rehabilitation gains at discharge. Longer duration of agitation is associated with persisting limitations to functional independence.	Univ Sydney, Fac Hlth Sci, Lidcombe, NSW 1825, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia	Nott, MT (corresponding author), Univ Sydney, Fac Hlth Sci, Room J126, Lidcombe, NSW 1825, Australia.	mnot2529@mail.usyd.edu.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021; Nott, Melissa T/M-6778-2018	Baguley, Ian J/0000-0001-5650-3705; Nott, Melissa T/0000-0001-7088-5826			Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleminger S, 2003, BMJ-BRIT MED J, V327, P4, DOI 10.1136/bmj.327.7405.4; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; HAGAN C, 1979, LEVELS COGNITIVE FUN; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Maryniak O, 2001, BRAIN INJURY, V15, P167, DOI 10.1080/026990501458399; Plylar P A, 1989, J Neurosci Nurs, V21, P353; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; van der Naalt J, 2000, BRAIN INJURY, V14, P781; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	26	62	62	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1175	1182		10.1080/02699050601049114			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600008	17123934				2021-06-18	
J	Falo, MC; Fillmore, HL; Reeves, TM; Phillips, LL				Falo, M. C.; Fillmore, H. L.; Reeves, T. M.; Phillips, L. L.			Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						matrix metalloproteinase; synaptogenesis; hippocampus; neurotrauma	COMBINED FLUID PERCUSSION; ENTORHINAL CORTICAL LESION; DENTATE-GYRUS; EXTRACELLULAR-MATRIX; MMP-3 EXPRESSION; PROTEOLYTIC CLEAVAGE; MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; UP-REGULATION; RAT-BRAIN	The interaction between extracellular matrix (ECM) and regulatory matrix metalloproteinases (MMPs) is important in establishing and maintaining synaptic connectivity. By using fluid percussion traumatic brain injury (TBI) and combined TBI and bilateral entorhinal cortical lesion (TBI + BEC), we previously demonstrated that hippocampal stromelysin-1 (MMP-3) expression and activity increased during synaptic plasticity. We now report a temporal analysis of MMP-3 protein and mRNA response to TBI during both degenerative (2 day) and regenerative (7, 15 day) phases of reactive synaptogenesis. MMP-3 expression during successful synaptic reorganization (following unilateral entorhinal cortical lesion; UEC) was compared with MMP-3 expression when normal synaptogenesis fails (after combined TBI + BEC insult). Increased expression of MMP-3 protein and message was observed in both models at 2 days postinjury, and immuohistochemical (IHC) colocalization suggested that reactive astrocytes contribute to that increase. By 7 days postinjury, model differences in MMP-3 were observed. UEC MMP-3 mRNA was equivalent to control, and MMP-3 protein was reduced within the deafferented region. In contrast, enzyme mRNA remained elevated in the maladaptive TBI + BEC model, accompanied by persistent cellular labeling of MMP-3 protein. At 15 days survival, MMP-3 mRNA was normalized in each model, but enzyme protein remained higher than paired controls. When TBI + BEC recovery was enhanced by the N-methyl-D-aspartate antagonist MK-801, 7-day MMP-3 mRNA was significantly reduced. Similarly, MMP inhibition with FN-439 reduced the persistent spatial learning deficits associated with TBI + BEC insult. These results suggest that MMP-3 might differentially affect the sequential phases of reactive synaptogenesis and exhibit an altered pattern when recovery is perturbed. (c) 2006 Wiley-Liss, Inc.	Virginia Commonwealth Univ, Ctr Med, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Sch Med, Dept Neurosurg, Richmond, VA USA	Phillips, LL (corresponding author), Virginia Commonwealth Univ, Ctr Med, Sch Med, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	llphilli@vcu.edu		Fillmore, Helen/0000-0003-4131-579X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044372, R56NS044372] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS044372, NS-44372] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NSO-07288] Funding Source: Medline		Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; BEJARANO PA, 1988, BIOCHEM J, V256, P413, DOI 10.1042/bj2560413; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; Chernoff EAG, 2000, WOUND REPAIR REGEN, V8, P282, DOI 10.1046/j.1524-475x.2000.00282.x; Cuzner ML, 1996, J NEUROPATH EXP NEUR, V55, P1194, DOI 10.1097/00005072-199612000-00002; D'Souza CA, 2002, J BIOL CHEM, V277, P13589, DOI 10.1074/jbc.M108817200; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; Falo MC, 2003, J NEUROTRAUM, V20, P1124; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; Mayer J, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-52; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Mun-Bryce S, 2002, BRAIN RES, V933, P42, DOI 10.1016/S0006-8993(02)02303-X; OKADA Y, 1987, J RHEUMATOL, V14, P41; Phillips LL, 2004, J NEUROTRAUM, V21, P1321; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Reeves TM, 2003, J NEUROSCI, V23, P10182; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Sole S, 2004, J NEUROPATH EXP NEUR, V63, P338, DOI 10.1093/jnen/63.4.338; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Vaillant C, 1999, J NEUROSCI, V19, P4994; VanSaun M, 2000, J NEUROBIOL, V43, P140, DOI 10.1002/(SICI)1097-4695(200005)43:2<140::AID-NEU4>3.0.CO;2-K; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Witek-Zawada B, 2003, J PHYSIOL PHARMACOL, V54, P489; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	47	62	65	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP	2006	84	4					768	781		10.1002/jnr.20986			14	Neurosciences	Neurosciences & Neurology	080YI	WOS:000240284000007	16862547				2021-06-18	
J	Richards, EM; Rosenthal, RE; Kristian, T; Fiskum, G				Richards, Erica M.; Rosenthal, Robert E.; Kristian, Tibor; Fiskum, Gary			Postischemic hyperoxia reduces hippocampal pyruvate dehydrogenase activity	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						mitochondria; hyperoxia; nitrotyrosine; normoxia; oxidative stress; global ischemia; selective vulnerability; free radicals	FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; ALPHA-KETOGLUTARATE DEHYDROGENASE; SELECTIVE NEURONAL VULNERABILITY; MANGANESE SUPEROXIDE-DISMUTASE; TRAUMATIC BRAIN-INJURY; CANINE CARDIAC-ARREST; PROTEIN NITRATION; OXIDATIVE STRESS; MASS-SPECTROMETRY	The pyruvate dehydrogenase complex (PDHC) is a mitochondrial matrix enzyme that catalyzes the oxidative decarboxylation of pyruvate and represents the sole bridge between anaerobic and aerobic cerebral energy metabolism. Previous studies demonstrating loss of PDHC enzyme activity and immunoreactivity during reperfusion after cerebral ischemia suggest that oxidative modifications are involved. This study tested the hypothesis that hyperoxic reperfusion exacerbates loss of PDHC enzyme activity, possibly due to tyrosine nitration or S-nitrosation. We used a clinically relevant canine ventricular fibrillation cardiac arrest model in which, after resuscitation and ventilation on either 100% O-2 (hyperoxic) or 21-30% O-2 (normoxic), animals were sacrificed at 2 h reperfusion and the brains removed for enzyme activity and immunoreactivity measurements. Animals resuscitated under hyperoxic conditions exhibited decreased PDHC activity and elevated 3-nitrotyrosine immunoreactivity in the hippocampus but not the cortex, compared to nonischemic controls. These measures were unchanged in normoxic animals. In vitro exposure of purified PDHC to peroxynitrite resulted in a dose-dependent loss of activity and increased nitrotyrosine immunoreactivity. These results support the hypothesis that oxidative stress contributes to loss of hippocampal PDHC activity during cerebral ischemia and reperfusion and suggest that PDHC is a target of peroxynitrite. (c) 2006 Elsevier Inc. All rights reserved.	Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Program Trauma, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA.	gfisk001@umaryland.edu	Kristian, Tibor/I-5697-2019; Kristian, Tibor/U-6497-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050653, R21 NS050653, U01 NS049425, NS049425, U01 NS049425-03, R01 NS034152-12, R01 NS034152, NS34152] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS050653, R01NS034152, U01NS049425] Funding Source: NIH RePORTER		AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Alonso D, 2002, J COMP NEUROL, V443, P183, DOI 10.1002/cne.10111; Aoyama K, 2000, ANN NEUROL, V47, P524, DOI 10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.3.CO;2-X; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CARDELL M, 1989, J CEREBR BLOOD F MET, V9, P350, DOI 10.1038/jcbfm.1989.53; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Dohi K, 2003, ACT NEUR S, V86, P87; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; ELNAGEH KM, 1988, J NEUROCHEM, V51, P1482, DOI 10.1111/j.1471-4159.1988.tb01115.x; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; FISKUM G, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P487; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gonzalez D, 2004, J BIOL CHEM, V279, P43345, DOI 10.1074/jbc.M401889200; Haga KK, 2003, BRAIN RES, V993, P42, DOI 10.1016/j.brainres.2003.08.063; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HINMAN LM, 1981, J BIOL CHEM, V256, P6583; Hoehn T, 2003, PEDIATR RES, V54, P179, DOI 10.1203/01.PDR.0000075220.17631.F1; Hurtado O, 2003, FASEB J, V17, P2082, DOI 10.1096/fj.02-1086fje; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kanski J, 2005, J BIOL CHEM, V280, P24261, DOI 10.1074/jbc.M501773200; Kim HY, 2005, ANN NEUROL, V57, P571, DOI 10.1002/ana.20430; Krajewska M, 2004, EXP NEUROL, V189, P261, DOI 10.1016/j.expneurol.2004.05.020; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; Kusumoto M, 1996, J NEUROCHEM, V67, P1613; Lei BP, 1999, BRAIN RES PROTOC, V4, P415, DOI 10.1016/S1385-299X(99)00047-1; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; Liu D, 2002, J CEREBR BLOOD F MET, V22, P431, DOI 10.1097/00004647-200204000-00007; Liu SM, 2004, J CEREBR BLOOD F MET, V24, P343, DOI 10.1097/01.WCB.0000110047.43905.01; Liu YB, 1998, STROKE, V29, P1679, DOI 10.1161/01.STR.29.8.1679; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MICKEL HS, 1987, STROKE, V18, P426, DOI 10.1161/01.STR.18.2.426; Murray J, 2003, J BIOL CHEM, V278, P37223, DOI 10.1074/jbc.M305694200; Ohtaki H, 2003, ACT NEUR S, V86, P97; Park LCH, 1999, J NEUROCHEM, V72, P1948, DOI 10.1046/j.1471-4159.1999.0721948.x; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; POON HF, NEUROBIOL AGING; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Rhee KY, 2005, P NATL ACAD SCI USA, V102, P467, DOI 10.1073/pnas.0406133102; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Sasaki T, 2001, Keio J Med, V50, P182; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Shirakura T, 2005, BIOL PHARM BULL, V28, P1658, DOI 10.1248/bpb.28.1658; SIMS NR, 1992, NEUROCHEM RES, V17, P923, DOI 10.1007/BF00993269; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; Takeda Y, 2004, J CEREBR BLOOD F MET, V24, P986, DOI 10.1097/01.WCB.0000127966.84050.61; Takizawa S, 2002, J CEREBR BLOOD F MET, V22, P50, DOI 10.1097/00004647-200201000-00006; Tan S, 2001, FREE RADICAL BIO MED, V30, P1045, DOI 10.1016/S0891-5849(01)00499-3; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VasquezVivar J, 1997, CHEM RES TOXICOL, V10, P786, DOI 10.1021/tx970031g; VERECZKI V, J CEREB BLOOD FLOW M; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Zaidan E, 1998, J NEUROCHEM, V70, P233; ZAIDAN E, 1993, J CEREBR BLOOD F MET, V13, P98, DOI 10.1038/jcbfm.1993.12; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545; ZWEMER CF, 1994, RESUSCITATION, V27, P267; ZWEMER CF, 1994, RESUSCITATION, V27, P159, DOI 10.1016/0300-9572(94)90009-4	78	62	62	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUN 1	2006	40	11					1960	1970		10.1016/j.freeradbiomed.2006.01.022			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	050QP	WOS:000238103300009	16716897	Green Accepted			2021-06-18	
J	Ouellet, MC; Morin, CA				Ouellet, MC; Morin, CA			Fatigue following traumatic brain injury: Frequency, characteristics, and associated factors	REHABILITATION PSYCHOLOGY			English	Article						fatigue; traumatic brain inury	MINOR HEAD-INJURY; COGNITIVE-BEHAVIOR-THERAPY; MULTIPLE-SCLEROSIS; VALIDATION; COMPLAINTS; DISORDERS; INVENTORY; SYMPTOMS; INSOMNIA; IMPACT	Objectives: To document the frequency, characteristics, and factors associated with fatigue following traumatic brain injury (TBI). Design: Survey methodology and multivariate statistical design. Setting: Rehabilitation center and community. Participants: 452 participants aged 16 years and over with minor to severe TBI who answered a questionnaire measuring diverse aspects of fatigue as well as different dimensions of psychological distress, pain, and sleep quality. Measures: Proportion of participants reporting being significantly fatigued. Validated measures of fatigue, sleep quality, and psychological distress. Results of a logistic regression analysis. Results: Significant fatigue was reported by 68.5% of participants. Mental fatigue was the most prominent type of fatigue, followed by physical fatigue. Fatigue was present even several years following the accident and had many perceived impacts on day-to-day function. Factors associated with fatigue were a shorter time since injury; being on long-term disability leave; and higher levels of sleep problems, cognitive disturbances, and anxiety. Conclusion: Fatigue is a prevalent problem after TBI that requires more clinical and scientific attention because it probably has important repercussions on the quality of rehabilitation.	Univ Laval, Ecole Psychol, Quebec City, PQ GK1 7P4, Canada	Ouellet, MC (corresponding author), Univ Laval, Ecole Psychol, Pavilon Felix Antoine Savard, Quebec City, PQ GK1 7P4, Canada.	marie-christine.ouellet.1@ulaval.ca	Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895			Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Blais FC, 1997, ENCEPHALE, V23, P447; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P10; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008; Gervais M, 1999, ETUDE EXPLORATOIRE B; Gibson AS, 2003, SPORTS MED, V33, P167; Holzner B, 2003, CANCER, V97, P1564, DOI 10.1002/cncr.11253; Holzner B, 2002, ANN ONCOL, V13, P965, DOI 10.1093/annonc/mdf122; ILFELD FW, 1976, PSYCHOL REP, V39, P1215, DOI 10.2466/pr0.1976.39.3f.1215; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; KLONOFF DC, 1992, CLIN INFECT DIS, V15, P812, DOI 10.1093/clind/15.5.812; KRAUS F, 1993, HEAD INJURY, P1; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lichstein KL, 1997, BEHAV RES THER, V35, P733, DOI 10.1016/S0005-7967(97)00029-6; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Morin CM., 1993, INSOMNIA PSYCHOL ASS; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; OUELLET MC, IN PRESS J HEAD TRAU; Preville M, 1992, DETRESSE PSYCHOL DET; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Strober LB, 2005, ARCH CLIN NEUROPSYCH, V20, P631, DOI 10.1016/j.acn.2005.04.002; Tabachnick BG, 2013, USING MULTIVARIATE S; van der Werf SP, 1998, J NEUROL SCI, V160, P164, DOI 10.1016/S0022-510X(98)00251-2; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	38	62	62	0	10	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2006	51	2					140	149		10.1037/0090-5550.51.2.140			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	047PO	WOS:000237891400005					2021-06-18	
J	DeRidder, MN; Simon, MJ; Siman, R; Auberson, YP; Raghupathi, R; Meaney, DF				DeRidder, MN; Simon, MJ; Siman, R; Auberson, YP; Raghupathi, R; Meaney, DF			Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition	NEUROBIOLOGY OF DISEASE			English	Article						traumatic brain injury; organotypic; hippocampus; caspase-3; calpain; N-methyl-D-aspartate receptor	METHYL-D-ASPARTATE; EXPERIMENTAL BRAIN-INJURY; CORTICAL IMPACT INJURY; CELL-DEATH; NEURONAL APOPTOSIS; HEAD-INJURY; COGNITIVE DEFICITS; TEMPORAL PROFILE; RAT; NECROSIS	Apoptotic or necrotic cell death in the hippocampus is a major factor underlying the cognitive impairments following traumatic brain injury. In this study, we examined if traumatic mechanical injury would produce regional activation of calpain and caspase-3 in the in vitro hippocampus and studied how the mechanically induced activation of NR2A and NR2B containing N-methyl-D-aspartate receptors (NMDARs) affects the activation of these proteases following mechanical injury. Following a 75% stretch, significant levels of activated caspase-3 and calpain-mediated spectrin breakdown products were evident only in cells within the dentate gyrus, and little co-localization of the markers was identified within individual cells. After 100% stretch, only calpain activation was observed, localized to the CA3 subregion 24 It after stretch. At moderate injury, levels, both caspase-3 and calpain activation was attenuated by blocking NR2B containing NMDARs prior to stretch or by blocking all NMDARs prior to stretch injury. Treatment with an NR2A selective NMDAR antagonist had little effect on either activated caspase-3 or Ab38 immunoreactivity following moderate injury but resulted in the appearance of activated caspase-3 in the dentate gyrus following severe mechanical stretch. Together, these studies suggest that the injury induced activation of NR2A containing NMDARs functions as a pro-survival signal, while the activation of NR2B containing NMDARs is a competing, anti-survival, signal following mechanical injury to the hippocampus. (c) 2005 Elsevier file. All rights reserved.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Novartis Pharma AG, CH-4002 Basel, Switzerland; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk,Room 105E,Hayden Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Auberson, Yves/AAF-6538-2019	Auberson, Yves/0000-0001-5800-4811; Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS35712, R01 NS 41699] Funding Source: Medline		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Auberson YP, 2002, BIOORG MED CHEM LETT, V12, P1099, DOI 10.1016/S0960-894X(02)00074-4; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clouse AK, 2003, J NEUROTRAUM, V20, P1109; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottlieb M, 1997, J CEREBR BLOOD F MET, V17, P290, DOI 10.1097/00004647-199703000-00006; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Krebs C, 2003, J NEUROSCI, V23, P3364; Lesort M, 1997, NEUROSCI LETT, V221, P213, DOI 10.1016/S0304-3940(96)13310-3; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Papachristou GI, 2005, CLIN LAB MED, V25, P17, DOI 10.1016/j.cll.2004.12.003; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sattler R, 1998, J NEUROCHEM, V71, P2349; Schipke CG, 2001, FASEB J, V15, P1270; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tenneti L, 1998, J NEUROCHEM, V71, P946; Teramoto N, 1998, J VIROL METHODS, V73, P89, DOI 10.1016/S0166-0934(98)00048-2; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Tovar KR, 1999, J NEUROSCI, V19, P4180; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	61	62	66	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	APR	2006	22	1					165	176		10.1016/j.nbd.2005.10.011			12	Neurosciences	Neurosciences & Neurology	029WN	WOS:000236595200017	16356733				2021-06-18	
J	Sumanont, Y; Murakami, Y; Tohda, M; Vajragupta, O; Watanabe, H; Matsumoto, K				Sumanont, Y; Murakami, Y; Tohda, M; Vajragupta, O; Watanabe, H; Matsumoto, K			Prevention of kainic acid-induced changes in nitric oxide level and neuronal cell damage in the rat hippocampus by manganese complexes of curcumin and diacetylcurcumin	LIFE SCIENCES			English	Article						curcumin; manganese complex; nitric oxide; kainic acid; neurotoxicity	KAINATE-INDUCED EXCITOTOXICITY; RADICAL SCAVENGING ABILITY; SUPEROXIDE-DISMUTASE; STATUS EPILEPTICUS; GLUTAMATE RELEASE; BRAIN; SEIZURES; NEUROTOXICITY; MECHANISMS; MICRODIALYSIS	Curcumin is a natural antioxidant isolated from the medicinal plant Curcuma longa Linn. We previously reported that manganese complexes of curcumin (Cp-Mn) and diacetylcurcumin (DiAc-Cp-Mn) exhibited potent superoxide dismutase (SOD)-like activity in an in vitro assay. Nitric oxide (NO) is a free radial playing a multifaceted role in the brain and its excessive production is known to induce neurotoxicity. Here, we examined the in vivo effect of Cp-Mn and DiAc-Cp-Mn on NO levels enhanced by kainic acid (KA) and L-arginine (L-Arg) in the hippocampi of awake rats using a microdialysis technique. Injection of KA (10 mg/kg, i.p.) and L-Arg (1000 mg/kg, i.p.) significantly increased the concentration of NO and Cp-Mn and DiAc-Cp-Mn (50 mg/kg, i.p.) significantly reversed the effects of KA and L-Arg without affecting the basal NO concentration. Following KA-induced seizures, severe neuronal cell damage was observed in the CA1 and CA3 subfields of hippocampal 3 days after KA administration. Pretreatment with Cp-Mn and DiAc-Cp-Mn (50 mg/kg, i.p.) significantly attenuated KA-induced neuronal cell death in both CA1 and CA3 regions of rat hippocampus compared with vehicle control, and Cp-Mn and DiAc-Cp-Mn showed more potent neuroprotective effect than their parent compounds, curcumin and diacetylcurcumin. These results suggest that Cp-Mn and DiAc-Cp-Mn protect against KA-induced neuronal cell death by suppression of KA-induced increase in NO levels probably by their NO scavenging activity and antioxidative activity. Cp-Mn and DiAc-Cp-Mn have an advantage to be neuroprotective agents in the treatment of acute brain pathologies associated with NO-induced neurotoxicity and oxidative stress-induced neuronal damage such as epilepsy, stroke and traumatic brain injury. (c) 2005 Elsevier Inc. All rights reserved.	Toyama Med & Pharmaceut Univ, 21st COE Program, Inst Nat Med, Div Med Pharmacol, Toyama 9300194, Japan; Mahidol Univ, Fac Pharm, Dept Pharmaceut Chem, Bangkok 10400, Thailand; Toyama Med & Pharmaceut Univ, 21st COE Program, Toyama 9300194, Japan	Matsumoto, K (corresponding author), Toyama Med & Pharmaceut Univ, 21st COE Program, Inst Nat Med, Div Med Pharmacol, 2630 Sugitani, Toyama 9300194, Japan.	mkinzo@ms.toyama-mpu.ac.jp	vajragupta, opa/R-6616-2019	Vajragupta, Opa/0000-0003-3313-0621			BAGETTA G, 1995, NEURODEGENERATION, V4, P43, DOI 10.1006/neur.1995.0005; Bagetta G, 1995, EUR J PHARMACOL, V294, P341, DOI 10.1016/0014-2999(95)00689-3; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Das KC, 2002, BIOCHEM BIOPH RES CO, V295, P62, DOI 10.1016/S0006-291X(02)00633-2; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Hara S, 2004, NEUROSCI LETT, V366, P302, DOI 10.1016/j.neulet.2004.05.055; Joe B, 2004, CRIT REV FOOD SCI, V44, P97, DOI 10.1080/10408690490424702; Jones PA, 1998, NEUROSCI LETT, V249, P75, DOI 10.1016/S0304-3940(98)00372-3; Kashihara K, 1998, NEUROSCI RES, V32, P189, DOI 10.1016/S0168-0102(98)00086-8; Kim HC, 2000, BRAIN RES, V853, P215, DOI 10.1016/S0006-8993(99)02254-4; Lian XY, 2005, EPILEPSIA, V46, P15, DOI 10.1111/j.0013-9580.2005.40904.x; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Liu Z, 1997, NEUROREPORT, V8, P2019, DOI 10.1097/00001756-199705260-00043; Maj R, 1998, EUR J PHARMACOL, V359, P27, DOI 10.1016/S0014-2999(98)00554-8; Masuda T, 2001, J AGR FOOD CHEM, V49, P2539, DOI 10.1021/jf001442x; Matsumoto K, 1999, BRAIN RES, V839, P74, DOI 10.1016/S0006-8993(99)01715-1; Milatovic D, 2002, BRAIN RES, V957, P330, DOI 10.1016/S0006-8993(02)03669-7; Milatovic D, 2001, BRAIN RES, V912, P67, DOI 10.1016/S0006-8993(01)02657-9; Montecot C, 1998, NEUROSCIENCE, V84, P791, DOI 10.1016/S0306-4522(97)00566-6; Montecot C, 1997, J CEREBR BLOOD F MET, V17, P94, DOI 10.1097/00004647-199701000-00012; Murakami Y, 2000, BEHAV BRAIN RES, V109, P83, DOI 10.1016/S0166-4328(99)00162-X; Najm IM, 1998, BRAIN RES, V810, P72, DOI 10.1016/S0006-8993(98)00886-5; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Paxinos G., 1982, RAT BRAIN STEREOTAXI; REDDY ACP, 1994, MOL CELL BIOCHEM, V137, P1, DOI 10.1007/BF00926033; Shin EJ, 2004, CLIN EXP PHARMACOL P, V31, P320, DOI 10.1111/j.1440-1681.2004.03990.x; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Sumanont Y, 2004, BIOL PHARM BULL, V27, P170, DOI 10.1248/bpb.27.170; UNNIKRISHNAN MK, 1995, MOL CELL BIOCHEM, V146, P35, DOI 10.1007/BF00926878; Vajragupta O, 2004, FREE RADICAL RES, V38, P303, DOI 10.1080/10715760310001643339; Vajragupta O, 2003, FREE RADICAL BIO MED, V35, P1632, DOI 10.1016/j.freeradbiomed.2003.09.011; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I	39	62	69	2	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAR 13	2006	78	16					1884	1891		10.1016/j.lfs.2005.08.028			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	022WC	WOS:000236085800015	16266725				2021-06-18	
J	Cameron, JI; Cheung, AM; Streiner, DL; Coyte, PC; Stewart, DE				Cameron, JI; Cheung, AM; Streiner, DL; Coyte, PC; Stewart, DE			Stroke survivors' behavioral and psychologic symptoms are associated with informal caregivers' experiences of depression	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						behavioral symptoms; caregivers; cerebrovascular accident; depression; quality of life; rehabilitation	TRAUMATIC BRAIN INJURY; FAMILY CAREGIVERS; PSYCHOEDUCATIONAL INTERVENTION; ACTIVITY RESTRICTION; SPOUSAL CAREGIVERS; CANCER-PATIENTS; STRESS PROCESS; MENTAL-HEALTH; DEMENTIA; CARE	Objective: To determine the impact of stroke survivors' behavioral and psychologic symptoms (BPS) on informal caregivers' experience of depression in the context of the caregiving situation. Design: Cross-sectional survey using a structured quantitative interview. Setting: Rehabilitation facility outpatient clinic, tertiary care facility outpatient clinic, and community care organizations. Participants: Ninety-four informal caregivers to stroke survivors completed standardized measurement instruments. Interventions: Not applicable. Main Outcome Measures: Measurement instruments included the Center for Epidemiological Studies Depression Scale, Brain Impairment Behavior Inventory-Revised, Caregiver Assistance Scale, Caregiving Impact Scale, and Mastery scale. Results: A substantial percentage (44.7%) of caregivers were at risk of clinical depression. Caregivers experienced more depression symptoms when they cared for stroke survivors exhibiting more BPS of memory and comprehension difficulties, provided less assistance, experienced more lifestyle interference, and had lower mastery (F-5,F-85=26.02, P<.001, adjusted R-2=.58). Conclusions: BPS exhibited by stroke survivors contribute to informal caregivers' experience of depression. These results can assist rehabilitation professionals to identify informal care providers who are at greater risk of experiencing emotional distress and, therefore, may benefit from intervention.	Univ Toronto, Univ Hlth Network, Womens Hlth Program, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Rehabil Inst, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Baycrest Ctr Geriatr Care, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada	Cheung, AM (corresponding author), Univ Toronto, Univ Hlth Network, Womens Hlth Program, 200 Elizabeth St,7 Eaton N 221, Toronto, ON M5G 2C4, Canada.	angela.cheung@uhn.on.ca	Streiner, David/E-6563-2011; Stewart, Donna Eileen E/J-2844-2016	Streiner, David/0000-0003-0610-6271; Stewart, Donna Eileen E/0000-0002-8157-7746; Cameron, Jill/0000-0003-4161-1572; Cheung, Angela M./0000-0001-8332-0744	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [44917, 52482] Funding Source: Medline		ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Arai Y, 2001, PSYCHIAT CLIN NEUROS, V55, P379, DOI 10.1046/j.1440-1819.2001.00878.x; BibouNakou I, 1997, SOC PSYCH PSYCH EPID, V32, P104, DOI 10.1007/BF00788928; Bloom JR, 1998, PSYCHO-ONCOLOGY, V7, P89, DOI 10.1002/(SICI)1099-1611(199803/04)7:2<89::AID-PON293>3.0.CO;2-E; Bromberger JT, 2004, AM J PUBLIC HEALTH, V94, P1378, DOI 10.2105/AJPH.94.8.1378; Cameron JI, 2006, CRIT CARE MED, V34, P81, DOI 10.1097/01.CCM.0000190428.71765.31; Cameron JI, 2002, CANCER-AM CANCER SOC, V94, P521, DOI 10.1002/cncr.10212; CAMERON JI, 2004, THESIS U TORONTO TOR; Devins G M, 1994, Adv Ren Replace Ther, V1, P251; DEVINS GM, 1984, INT J PSYCHIAT MED, V13, P327, DOI 10.2190/5DCP-25BV-U1G9-9G7C; DRAPER BM, 1992, J AM GERIATR SOC, V40, P896, DOI 10.1111/j.1532-5415.1992.tb01986.x; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P144; Fairclough D., 2002, DESIGN ANAL QUALITY; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; Folkman S, 1997, SOC SCI MED, V45, P1207, DOI 10.1016/S0277-9536(97)00040-3; Garand L, 2002, ARCH PSYCHIAT NURS, V16, P156, DOI 10.1053/apnu.2002.34392; Gaugler JE, 2000, PSYCHOL AGING, V15, P437, DOI 10.1037/0882-7974.15.3.437; Gerdner LA, 2002, NURS RES, V51, P363, DOI 10.1097/00006199-200211000-00004; Goode KT, 1998, HEALTH PSYCHOL, V17, P190, DOI 10.1037/0278-6133.17.2.190; Gresham GE, 1997, STROKE, V28, P1522, DOI 10.1161/01.STR.28.7.1522; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; *HEART STROK FDN O, 2005, BEST PRACT GUID STRO; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; Li LW, 1999, PSYCHOL AGING, V14, P206, DOI 10.1037/0882-7974.14.2.206; Martire LM, 2000, PSYCHOL AGING, V15, P148, DOI 10.1037/0882-7974.15.1.148; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Nieboer AP, 1998, SOC SCI MED, V47, P1361, DOI 10.1016/S0277-9536(98)00214-7; Nijboer C, 1999, SOC SCI MED, V48, P1259, DOI 10.1016/S0277-9536(98)00426-2; OBERST MT, 1989, CANCER NURS, V12, P209; Ostwald SK, 1999, GERONTOLOGIST, V39, P299, DOI 10.1093/geront/39.3.299; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; PERIARD ME, 1993, PUBLIC HEALTH NURS, V10, P252, DOI 10.1111/j.1525-1446.1993.tb00061.x; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Pohjasvaara T, 1998, STROKE, V29, P75, DOI 10.1161/01.STR.29.1.75; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 2004, JAMA-J AM MED ASSOC, V292, P961, DOI 10.1001/jama.292.8.961; SCHULZ R, 1988, PSYCHOL AGING, V3, P131, DOI 10.1037/0882-7974.3.2.131; Stevens J., 1996, APPL MULTIVARIATE ST; Tabachnick B., 2001, USING MULTIVARIATE S; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Wentzel C, 2001, NEUROLOGY, V57, P714, DOI 10.1212/WNL.57.4.714; Williams A, 1994, J Neurosci Nurs, V26, P155; Williamson GA, 2005, REHABIL PSYCHOL, V50, P215, DOI 10.1037/0090-5550.50.3.215; Williamson GM, 1998, HEALTH PSYCHOL, V17, P152, DOI 10.1037/0278-6133.17.2.152; Yamamoto-Mitani N, 2001, Sch Inq Nurs Pract, V15, P113; YAMAMOTOMITANI N, 2001, SCH INQ NURS PRACT, V15, P137; Yates ME, 1999, J GERONTOL B-PSYCHOL, V54, pP12, DOI 10.1093/geronb/54B.1.P12; Yee JL, 2000, GERONTOLOGIST, V40, P147, DOI 10.1093/geront/40.2.147; YOUNG RF, 1989, GERONTOLOGIST, V29, P660, DOI 10.1093/geront/29.5.660	54	62	63	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2006	87	2					177	183		10.1016/j.apmr.2005.10.012			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	013CJ	WOS:000235386900005	16442969				2021-06-18	
J	Mateer, CA; Sira, CS				Mateer, Catherine A.; Sira, Claire S.			Cognitive and emotional consequences of TBI: Intervention strategies for vocational rehabilitation	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			cognitive rehabilitation; vocational outcome; brain injury; rehabilitation; emotion	TRAUMATIC BRAIN-INJURY; MEMORY PERFORMANCE; EMPLOYMENT; AWARENESS; WORK; METAMEMORY; ADJUSTMENT; DEPRESSION; TASK	The effects of a traumatic brain injury on vocational outcome can be predicted on the basis of several factors. Environmental factors such as a supportive work environment, and person specific factors, including the client's age, premorbid occupation, injury variables, level of awareness, psychosocial adjustment, coping skills, and cognitive deficits have all been found to predict return to work following a traumatic brain injury. Some of these factors are amenable to treatment, and clinicians can impact clients' likelihood of returning to work by intervening in various ways. Through case studies and a literature review on the effectiveness of cognitive rehabilitation interventions, we have outlined specific strategies and recommendations for interventions. Cognitive rehabilitation strategies that address attention, memory and executive deficits can improve clients' abilities to manage workplace tasks and demands. Many clients continue to experience problems with social and emotional adjustment following a brain injury that impact return to work. Cognitive behavioural therapy is well suited for improving coping skills, helping clients to manage cognitive difficulties, and addressing more generalized anxiety and depression in the context of a brain injury.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Mateer, CA (corresponding author), Univ Victoria, Dept Psychol, POB 3050,STN CSC, Victoria, BC V8W 3P5, Canada.	cmateer@uvic.ca					BENYISHAY Y, 1989, NEUROPSYHCOLOGICAL T; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; CALLAHAN CD, 2001, REHABILITATION NEURO; Camp C. J., 1998, CLIN GERONTOLOGIST, V19, P51, DOI DOI 10.1300/J018V19N01_; CAVANAUGH JC, 1989, PSYCHOL AGING, V4, P365, DOI 10.1037/0882-7974.4.3.365; ELLIOTT E, 1989, PSYCHOL PERSPECTICES; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Heald Paul, 1998, J INTELL PROP L, V5, P415; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; HERTZOG C, 1990, PSYCHOL AGING, V5, P215, DOI 10.1037/0882-7974.5.2.215; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; HULTSCH DF, 1988, COGNITIVE DEV ADULTH; Jonker C, 1997, EDUC GERONTOL, V23, P115, DOI 10.1080/0360127970230203; KAY T, 1989, ASSESSMENT BEHAV CON; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1995, NEUROPSYCHOLOIGICAL; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; MATEER CA, HDB CLIN NEUROPSYCHO; MCCUE M, 1998, HUMAN BRAIN FUNCT, P113; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1995, HDB MEMORY DISORDERS; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; REICH JH, 1991, J NERV MENT DIS, V179, P74, DOI 10.1097/00005053-199102000-00003; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; ROSENTHAL M, 1990, REHABILITATION ADULT; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sohlberg M. M., 2001, COGNITIVE REHABILITA; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; WILSON BA, 2002, NEUROPSYCHOLOGY MEMO	47	62	64	0	20	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	4					315	326					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700006	17361048				2021-06-18	
J	Ziino, C; Ponsford, J				Ziino, C; Ponsford, J			Vigilance and fatigue following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						fatigue; attention; brain injury; depression	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; MULTIPLE-SCLEROSIS; CANCER-PATIENTS; ATTENTION; DEPRESSION; SCALE; MODERATE; REHABILITATION; IMPAIRMENTS	Research, findings have suggested that individuals with traumatic brain injury (TBI) show greater psychophysiological and subjective costs associated with performing vigilance tasks, but have not examined relationships with fatigue. The present study aimed to investigate vigilance and its relationship with subjective and objective fatigue measures. Forty-six TBI participants and 46 controls completed a 45-minute vigilance task. They also completed a subjective fatigue scale (the VAS-F) and a selective attention task before and after the vigilance task, and had their blood pressure (BP) monitored. TBI participants performed at a lower level on the vigilance task, but performed at a similar level across the duration of the task. Higher subjective fatigue ratings,on the VAS-F were associated with more misses on the vigilance task for TBI participants. TBI participants showed greater increases in diastolic BP, and these were associated with greater increases in subjective fatigue ratings on the VAS-F. A subgroup of TBI participants showed a decline in performance on the vigilance task and also showed disproportionate increases in subjective fatigue. Findings provide support for the coping hypothesis, suggesting that TBI individuals expend greater psychophysiological costs in order to maintain stable performance over time, and that these costs are also associated with subjective increases in fatigue.	Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia	Ziino, C (corresponding author), Monash Univ, Dept Psychol, Clayton Campus,POB 17, Clayton, Vic 3800, Australia.	Carlo.Ziino@med.monash.edu.au					Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Annett J, 2002, ERGONOMICS, V45, P966, DOI 10.1080/00140130210166951; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; COHEN RA, 1993, NEUROPSYCHOLOGY ATTE, P49; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; EVANS RW, 1992, NEUROL CLIN, V10, P815; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Ferraccioli G, 1996, J RHEUMATOL, V23, P1539; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Harter M, 2001, DISABIL REHABIL, V23, P737; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Parasuraman R., 1984, SUSTAINED ATTENTION, P61; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; PRIGITANO GP, 1975, AWARENESS DEFICITS B; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Sturm W, 2001, NEUROIMAGE, V14, pS76, DOI 10.1006/nimg.2001.0839; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wilson, 1991, NATL ADULT READING T; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	56	62	63	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					100	110		10.1017/S1355617706060139			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800012	16433949				2021-06-18	
J	Ponsford, J				Ponsford, J			Rehabilitation interventions after mild head injury	CURRENT OPINION IN NEUROLOGY			English	Article						concussion; intervention; mild head injury; mild traumatic brain injury; rehabilitation	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; ROUTINE FOLLOW-UP; CONCUSSION; ADULTS; IMPACT	Purpose of review This review examines current management and rehabilitation strategies for mild traumatic brain injury, with emphasis on the need to address multiple potential causative factors in order to enhance outcomes and to conduct more controlled efficacy studies. Recent findings Whilst most individuals who sustain mild traumatic brain injury make a good recovery, a proportion experience significant ongoing disability. In some cases this is due to diffuse axonal injury and cognitive impairment, but in others symptoms are exacerbated by factors such as pain,,stress, personality issues or litigation, or in children, previous head injury, behavioural or learning difficulties. Provision of information early after injury results in reduced symptom reporting in adults and children. There is also a need, however, to address these other factors in treatment. Psychological therapy using a cognitive behavioural approach may be helpful, but controlled evaluations of such interventions have been lacking. Recent uncontrolled studies have examined the impact of computer-mediated interventions to remediate visual and verbal processing and oculomotor problems and the impact of quantitative electroencephalog rap by. More rigorous efficacy studies of these approaches are needed. Guidelines for management of sports-related concussion and timing of return to play also require a more solid scientific basis. Summary The evidence base for management of mild traumatic brain injury is still very limited. There is a need to conduct more carefully controlled prospective studies and examine the influence of factors not directly related to the brain injury as a basis for formulating more uniform management guidelines.	Epworth Med Fdn, Dept Psychol, Epworth Rehabil Ctr, Richmond, Vic 3121, Australia; Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3168, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Epworth Rehabil Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au					Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bronfort G, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001878.PUB2; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Friedman Jules M, 2004, Med Health R I, V87, P296; Horton A., 2002, MED SCI SPORTS EXERC, V34, P99; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McKerral M, 2005, J REHABIL MED, V37, P61, DOI 10.1080/16501970510026647; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MOORE C, 2004, NZ MED J, V117, P1046; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J. L., 1999, J HEAD TRAUMA REHAB, V14, P25; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Rose JM, 2005, BRAIN INJURY, V19, P29, DOI 10.1080/02699050310001617361; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	36	62	62	0	36	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2005	18	6					692	697		10.1097/01.wco.0000186840.61431.44			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	989MT	WOS:000233678800011	16280681				2021-06-18	
J	Ward, H; Shum, D; McKinlay, L; Baker-Tweney, S; Wallace, G				Ward, H; Shum, D; McKinlay, L; Baker-Tweney, S; Wallace, G			Development of prospective memory: Tasks based on the prefrontal-lobe model	CHILD NEUROPSYCHOLOGY			English	Article						prospective memory; children; prefrontal-lobe model	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; WORKING-MEMORY; FRONTAL-LOBE; EXPLICIT MEMORY; PERFORMANCE; CHILDREN; EVENT; TIME; DEFICITS	This study investigated the development of prospective memory using tasks based on the prefrontal-lobe model. Three groups each of 30 children, adolescents, and young adults were compared on prospective-memory performance using ongoing tasks with two levels of cognitive demand (low and high), and two levels of importance (unstressed and stressed) of remembering prospective cues. The Self-Ordered Pointing Task (SOPT), Stroop Color Word Interference Test, and Tower of London were also used to assess relationships between prospective memory and prefrontal-lobe functions. The children remembered fewer prospective cues than either the adolescents or adults, but the adolescents and adults remembered equally well. This trend increased significantly as the cognitive demand of the ongoing tasks increased. However, stressing or not stressing the importance of remembering made no difference to prospective-memory performance. Performance on the SOPT and Stroop Colour Word Interference predicted performance on the high- but not on the low-demand condition. These findings implicate the maturation of the brain's prefrontal region in the development of prospective memory.	Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia; Griffith Univ, Appl Cognit Neurosci Res Ctr, Nathan, Qld 4111, Australia; Royal Childrens Hosp, Brisbane, Qld, Australia; Mater Childrens Hosp, Brisbane, Qld, Australia	Ward, H (corresponding author), Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia.	h.ward@griffith.edu.au	Wallace, Geoff/H-1252-2013; Shum, David/A-3914-2008	Wallace, Geoff/0000-0001-9306-3542; Shum, David/0000-0002-4810-9262; McKinlay, Lynne/0000-0002-6677-0628			CECI SJ, 1985, CHILD DEV, V56, P152, DOI 10.2307/1130182; *CEDR CORP, 1996, SUP LAB PRO EXP LAB; CLUTTERBUCK PM, 1990, ART TEACHING SPELLIN; Cohen J.D., 1996, PROSPECTIVE MEMORY T, P267; DAIGNEAULT S, 1993, J CLIN EXP NEUROPSYC, V15, P881, DOI 10.1080/01688639308402605; DEMPSTER FN, 1992, DEV REV, V12, P45, DOI 10.1016/0273-2297(92)90003-K; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; ELLIS JA, 1993, MEMORY, V10, P7; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gevins A, 1998, HUM FACTORS, V40, P79, DOI 10.1518/001872098779480578; Golden C., 1978, STROOP COLOUR WORD T; Golden CJ., 2000, NEUROPSYCHOLOGICAL I; Hanes KR, 1996, ARCH CLIN NEUROPSYCH, V11, P185, DOI 10.1016/0887-6177(95)00034-8; HARRIS JE, 1983, EVERYDAY MEMORY ACTI, P71; HITCH GJ, 1988, MEM COGNITION, V16, P120, DOI 10.3758/BF03213479; HITCH GJ, 1989, MEM COGNITION, V17, P175, DOI 10.3758/BF03197067; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kidder DP, 1997, AGING NEUROPSYCHOL C, V4, P93, DOI 10.1080/13825589708256639; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Kvavilashvili L, 1998, APPL COGNITIVE PSYCH, V12, P533, DOI 10.1002/(SICI)1099-0720(1998120)12:6<533::AID-ACP538>3.0.CO;2-1; Kvavilashvili L, 2001, DEV PSYCHOL, V37, P418, DOI 10.1037//0012-1649.37.3.418; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Leech Geoffrey., 2001, WORD FREQUENCIES WRI; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Mateer C., 1997, CHILDHOOD TRAUMATIC, P153; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; Maylor EA, 2002, MEM COGNITION, V30, P871, DOI 10.3758/BF03195773; McGann D, 2002, MEM COGNITION, V30, P1021, DOI 10.3758/BF03194320; Meier B, 2000, APPL COGNITIVE PSYCH, V14, pS11, DOI 10.1002/acp.768; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Park DC, 1997, PSYCHOL AGING, V12, P314, DOI 10.1037/0882-7974.12.2.314; Passolunghi MC, 1995, INT J BEHAV DEV, V18, P631, DOI 10.1177/016502549501800404; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; RUSSO R, 1995, J EXP CHILD PSYCHOL, V59, P566, DOI 10.1006/jecp.1995.1026; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHALLICE T, 1996, PROSPECTIVE MEMORY T, P319; Shimamura A.P., 1994, NEUROPSYCHOLOGY, V8, P408, DOI DOI 10.1037/0894-4105.8.3.408; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Shum D, 2000, BRAIN COGNITION, V44, P59; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P149, DOI 10.1076/jcen.21.2.149.929; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P141; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; SNODGRASS JG, 1989, IMPLICIT MEMORY, P259; SOMERVILLE SC, 1983, J GENET PSYCHOL, V143, P87, DOI 10.1080/00221325.1983.10533537; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Tunstall J., 1999, THESIS GRIFFITH U BR; Uttl B, 1997, J CLIN EXP NEUROPSYC, V19, P405, DOI 10.1080/01688639708403869; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wilson KM, 2001, J LEARN DISABIL-US, V34, P237, DOI 10.1177/002221940103400304; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3	63	62	63	0	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	2005	11	6					527	549		10.1080/09297040490920186			23	Clinical Neurology	Neurosciences & Neurology	987ZY	WOS:000233557900004	16306026				2021-06-18	
J	Coates, BM; Vavilala, MS; Mack, CD; Muangman, S; Suz, P; Sharar, SR; Bulger, E; Lam, AM				Coates, BM; Vavilala, MS; Mack, CD; Muangman, S; Suz, P; Sharar, SR; Bulger, E; Lam, AM			Influence of definition and location of hypotension on outcome following severe pediatric traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						blood pressure; brain injury; pediatric trauma; children; head trauma; hemodynamics	SEVERE HEAD-INJURY; INTENSIVE-CARE-UNIT; BLOOD-PRESSURE; CEREBRAL AUTOREGULATION; CHILDREN; SURVIVAL; DAMAGE; RAT	Objective: To examine the influence of definition and location (field, emergency department, or pediatric intensive care unit) of hypotension on outcome following severe pediatric traumatic brain injury. Design: Retrospective cohort study. Setting: Harborview Medical Center (level I pediatric trauma center), Seattle, WA, over a 5-yr period between 1998 and 2003. Patients: Ninety-three children <14 yrs of age with traumatic brain injury following injury, head Abbreviated Injury Score >= 3, and pediatric intensive care unit admission Glasgow Coma Scale score <9 formed the analytic sample. Data sources included the Harborview Trauma Registry and hospital records. Interventions: None. Measurements and Main Results: The relationship between hypotension and outcome was examined comparing two definitions of hypotension: a) systolic blood pressure <5th percentile for age; and b) systolic blood pressure <90 mm Hg. Hospital discharge Glasgow Outcome Score <4 or disposition of either death or discharge to a skilled nursing facility was considered a poor outcome. Pediatric intensive care unit and hospital length of stay were also examined. Systolic blood pressure <5th percentile for age was more highly associated with poor hospital discharge Glasgow Outcome Score (p=.001), poor disposition (p=.02), pediatric intensive care unit length of stay (rate ratio 9.5; 95% confidence interval 6.7-12.3), and hospital length of stay (rate ratio 18.8; 95% confidence interval 14.0-23.5) than systolic blood pressure <90 mm Hg. Hypotension occurring in either the field or emergency department, but not in the pediatric intensive care unit, was associated with poor Glasgow Outcome Score (p=.008), poor disposition (p=.03), and hospital length of stay (rate ratio 18.7; 95% confidence interval 13.1-24.2). Conclusions: Early hypotension, defined as systolic blood pressure <5th percentile for age in the field and/or emergency department, was a better predictor of poor outcome than delayed hypotension or the use of systolic blood pressure <90 mm Hg.	Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Harborview Injury Prevent & Res Ctr, Seattle, WA USA	Coates, BM (corresponding author), Univ Washington, Sch Med, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD044632] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [K23044632] Funding Source: Medline		BLUMENTHAL S, 1977, PEDIATRICS, V59, P797; BLUMENTHAL S, 1987, PEDIATRICS, V79, P1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2002, CHILD NERV SYST, V18, P54, DOI 10.1007/s00381-001-0533-4; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DESWIET M, 1980, PEDIATRICS, V65, P1028; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; GENTLEMAN D, 1992, INT SURG, V77, P297; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; HILL DA, 1993, AUST NZ J SURG, V63, P604, DOI 10.1111/j.1445-2197.1993.tb00466.x; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Langlois JA, 2001, TRAUMATIC BRAIN INJU; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RULEY EJ, 1993, TXB CRITICAL CARE, P602; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	27	62	62	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	NOV	2005	33	11					2645	2650		10.1097/01.CCM.0000186417.19199.9B			6	Critical Care Medicine	General & Internal Medicine	999XC	WOS:000234423500028	16276192	Green Accepted			2021-06-18	
J	Emery, DL; Fulp, CT; Saatman, KE; Schutz, C; Neugebauer, E; McIntosh, TK				Emery, DL; Fulp, CT; Saatman, KE; Schutz, C; Neugebauer, E; McIntosh, TK			Newly born granule cells in the dentate gyrus rapidly extend axons into the hippocampal CA3 region following experimental brain injury	JOURNAL OF NEUROTRAUMA			English	Article						BrdU; hippocampus; mossy fiber pathway; neurogenesis; neuronal plasticity; progenitor cells; tract tracing; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; TRANSIENT GLOBAL-ISCHEMIA; NMDA RECEPTOR ACTIVATION; ADULT-RAT; STEM-CELLS; ENHANCED NEUROGENESIS; SPINAL-CORD; PSA-NCAM; PROLIFERATION; NEURONS	We investigated whether new neurons generated in the adult rat brain following lateral fluid percussion traumatic brain injury (TBI) are capable of projecting axons along the mossy fiber pathway to the CA3 region of the hippocampus. Dividing cells were labeled by intraperitoneal injection of bromodeoxyuridine (BrdU) on the day of surgery/injury, and neurons that extended axons to the CA3 region were retrogradely labeled by fluorescent tracers (FluoSpheres(R)), stereotactically injected into the CA3 region of both the ipsi- and contralateral hippocampus at I or 12 days following TBI (n = 12) or sham injury (n = 12) in anaesthetized rats. Animals (11 = 6 injured and n = 6 sham-injured controls per time point) were sacrificed at either 3 or 14 days post-injury. Another group of animals (n = 3) was subjected to experimental TBI and BrdU administration and sacrificed 3 days after TBI to be processed for BrdU and immunohistochemistry for polysialylated neural cell adhesion molecule (PSA-NCAM), a growth-related protein normally observed during CNS development. A fivefold bilateral increase in the number of mitotically active (BrdU+) cells was noted within the dentate gyrus when compared to uninjured controls as early as 3 days following TBI. A subgroup of dividing cells was also immunoreactive for PSA-NCAM at 3 days following TBI. By 2 weeks post-injury the number of BrdU+ cells within the dentate gyrus was increased twofold compared to the uninjured counterparts and a proportion of these newly generated cells showed cytoplasmic staining for the fluorescent tracer. These findings document rapid neurogenesis following TBI and show, for the first time, that newly generated granule neurons are capable of extending projections along the hippocampal mossy fiber pathway in the acute post-traumatic period.	Univ Kentucky, Spinal Cord & Brain Injury Ctr, Lexington, KY 40536 USA; Univ Penn, Sch Med, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; Univ Cologne, Dept Expt Surg, Cologne, Germany	Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Ctr, B367 BB3RB,741 S Limestone St, Lexington, KY 40536 USA.	K.Saatman@uky.edu	Schuetz, Christian/K-5234-2013	Schuetz, Christian/0000-0002-6828-4543	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS40978, P50-NS08803] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-45131] Funding Source: Medline		Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; Bender RA, 2003, HIPPOCAMPUS, V13, P399, DOI 10.1002/hipo.10089; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cameron HA, 1998, CURR OPIN NEUROBIOL, V8, P677, DOI 10.1016/S0959-4388(98)80099-8; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Golarai G, 2001, J NEUROSCI, V21, P8523; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Grados-Munro EM, 2003, J NEUROSCI RES, V74, P479, DOI 10.1002/jnr.10803; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hastings NB, 2002, J COMP NEUROL, V452, P324, DOI 10.1002/cne.10386; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill S. J., 1994, Society for Neuroscience Abstracts, V20, P424; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; HOUSE RM, 1992, PROTEUS, V9, P41; HOUSER CR, 1990, J NEUROSCI, V10, P267; HOUSER CR, 1992, EPILEPSY RES, P223; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KAPLAN SJ, 1984, ACM T DATABASE SYST, V9, P1, DOI 10.1145/348.318584; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Liu JL, 1998, J NEUROSCI, V18, P7768; Markakis EA, 1999, J COMP NEUROL, V406, P449; MATHERN GW, 1994, DEV BRAIN RES, V78, P70, DOI 10.1016/0165-3806(94)90011-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore N, 2002, J NEUROCHEM, V80, P111, DOI 10.1046/j.0022-3042.2001.00680.x; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Nomura T, 2000, J NEUROSCI RES, V61, P588, DOI 10.1002/1097-4547(20000915)61:6<588::AID-JNR2>3.0.CO;2-M; Parent JM, 1999, J NEUROSCI, V19, P4508; Parent JM, 1997, J NEUROSCI, V17, P3727; Pasterkamp RJ, 2001, BRAIN RES REV, V35, P36, DOI 10.1016/S0165-0173(00)00050-3; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Radley JJ, 2003, BRAIN RES, V966, P1, DOI 10.1016/S0006-8993(02)03989-6; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; Scott BW, 1998, NEUROSCI LETT, V248, P73, DOI 10.1016/S0304-3940(98)00355-3; SEKI T, 1993, DEV BRAIN RES, V73, P141, DOI 10.1016/0165-3806(93)90056-G; Seki Tatsunori, 2003, Anatomical Science International, V78, P69, DOI 10.1046/j.0022-7722.2003.00043.x; SERESS L, 1992, EPILEPSY RES, P3; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; SHUMATE M, 1995, EPILEPSIA, V36, P503; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SLOVITER RS, 1991, J COMP NEUROL, V308, P381, DOI 10.1002/cne.903080306; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Soares HD, 1995, J NEUROSCI, V15, P8223; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Steindler DA, 2002, LANCET, V359, P1047, DOI 10.1016/S0140-6736(02)08096-0; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a	83	62	65	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					978	988		10.1089/neu.2005.22.978			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600005	16156713				2021-06-18	
J	Bandak, FA				Bandak, FA			Shaken baby syndrome: A biomechanics analysis of injury mechanisms	FORENSIC SCIENCE INTERNATIONAL			English	Article						injury; infant shaken; baby; rotational; acceleration/deceleration; syndrome; neck	PERMANENT BRAIN-DAMAGE; SUBDURAL HAEMATOMA; MENTAL-RETARDATION; WHIPLASH INJURY; CHILDREN; INFANTS; SHAKING; YOUNGER	Traumatic infant shaking has been associated with the shaken baby syndrome (SBS) diagnosis without verification of the operative mechanisms of injury. Intensities for SBS have been expressed only in qualitative, unsubstantiated terms usually referring to acceleration/deceleration rotational injury and relating to falls from great heights onto hard surfaces or from severe motor vehicle crashes. We conducted an injury biomechanics analysis of the reported SBS levels of rotational velocity and acceleration of the head for their injury effects on the infant head-neck. Resulting forces were compared with experimental data on the structural failure limits of the cervical spine in several animal models as well as human neonate cadaver models. We have determined that an infant head subjected to the levels of rotational velocity and acceleration called for in the SBS literature, would experience forces on the infant neck far exceeding the limits for structural failure of the cervical spine. Furthermore, shaking cervical spine injury can occur at much lower levels of head velocity and acceleration than those reported for the SBS. These findings are consistent with the physical laws of injury biomechanics as well as our collective understanding of the fragile infant cervical spine from (1) clinical obstetric experience, (2) automotive medicine and crash safety experience, and (3) common parental experience. The findings are not, however, consistent with the current clinical SBS experience and are in stark contradiction with the reported rarity of cervical spine injury in children diagnosed with SBS. In light of the implications of these findings on child protection and their social and medico-legal significance, a re-evaluation of the current diagnostic criteria for the SBS and its application is suggested. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med A1036, Bethesda, MD 20814 USA	Bandak, FA (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med A1036, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	fbandak@usuhs.mil					American Academy of Pediatrics, 2001, PEDIATRICS, V108; BANDAK FA, 1996, TRAUMATIC BRAIN INJU, P139; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Ching R P, 2001, Stapp Car Crash J, V45, P329; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUNCAN M, 1874, BRIT MED J, V2, P763; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; JENNY C, 2002, 30 INT WORKSH PONT V, P129; JOHNSON WH, 1961, RADIOGRAPHIC ANATOMY; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Mayer R., 1999, INJ BIOM RES P 27 IN, P87; Nuckley D., 2000, INJ SCI RES P 28 INT, P85; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1969, LANCET, V2, P237; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; QUAYLE K, 1997, PEDIATRICS, V99; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; STERN WE, 1959, AM J OBSTET GYNECOL, V78, P498, DOI 10.1016/0002-9378(59)90520-4	22	62	66	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	JUN 30	2005	151	1					71	79		10.1016/j.forsciint.2005.02.033			9	Medicine, Legal	Legal Medicine	941YV	WOS:000230251000010	15885948				2021-06-18	
J	Martz, E; Livneh, H; Priebe, M; Wuermser, LA; Ottomanelli, L				Martz, E; Livneh, H; Priebe, M; Wuermser, LA; Ottomanelli, L			Predictors of psychosocial adaptation among people with spinal cord injury or disorder	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						coping behavior; rehabilitation; spinal cord injuries; stress disorders post-traumatic	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; LONG-TERM ADJUSTMENT; COPING STRATEGIES; SOCIAL SUPPORT; PSYCHOLOGICAL DISTRESS; POSTTRAUMATIC-STRESS; PHYSICAL-DISABILITY; EMOTIONAL DISTRESS; DEATH ANXIETY	Objective: To examine the influence of disability-related medical and psychologic variables on psychosocial adaptation to spinal cord injury or disorder (SCI/D). Design: A structural equation modeling design linking 3 sets of predictive variables to an outcome measure of adaptation. Setting: Two outpatient SCI clinics (1 veteran, 1 civilian) in Texas. Participants: Veterans (n = 181) and civilians (n = 132) with SCI/D. Interventions: Not applicable. Main Outcome Measures: The adaptation outcome was measured by 2 subscales (acknowledgment, adjustment) of the Reactions to Impairment and Disability Inventory (RIDI) and by the Quality of Life Scale. The predictive variables were measured by a demographic questionnaire, 3 subscales (intrusion, reexperiencing, hyperarousal) of the Purdue Posttraumatic Stress Disorder-Revised scale, the McMordie-Templer Death Anxiety Scale, and 3 subscales (anxiety, depression, denial) of the RIDI. Results: Goodness-of-fit indices suggested that a revised model of adaptation was a moderately good fit to the data. The revised model of adaptation indicated that there were medium total effects (direct plus indirect) on psychosocial adaptation by 2 latent variables (disability severity and impact, negative affectivity) and small total effects on psychosocial adaptation by disengagement coping. The latent factor of disengagement coping had the strongest direct effect on adaptation (although not statistically significant). Disability severity and impact had medium indirect effects and negative affectivity had small indirect effects on psychosocial adaptation. All of the aforementioned effects had a negative coefficient. Conclusions: Negative emotional responses (eg. depression, anxiety) to SCI/D, disengagement-type coping (eg, disability denial, avoidance), and the severity and impact of disability were related to lower levels of adaptation to SCI/D. Key Words: Coping behavior-, Rehabilitation; Spinal cord injuries; Stress disorders post-traumatic.	Univ Missouri, Sch Educ, Columbia, MO 65211 USA; Univ Missouri, Dept Counseling Psychol, Columbia, MO 65211 USA; Portland State Univ, Portland, OR 97207 USA; Edward Hines Jr VA Hosp, Hines, IL USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; VA N Texas Hlth Care Syst, Dallas, TX USA	Martz, E (corresponding author), Univ Missouri, Sch Educ, 4B Hill Hall, Columbia, MO 65211 USA.	martze@missouri.edu					ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; ARBUCKLE JL, 1995, AMOS 4 0 USERS GUIDE; Bergeman CS, 1999, LIFE-SPAN PERSPECTIVES ON HEALTH AND ILLNESS, P207; BRACKEN MB, 1980, SOC PSYCHIATR, V15, P33, DOI 10.1007/BF00577959; BRACKEN MB, 1981, PARAPLEGIA, V19, P271, DOI 10.1038/sc.1981.53; BRESLAU ND, 1991, ARCH GEN PSYCHIAT, V8, P216; Breznitz Shlomo, 1983, DENIAL STRESS, P257; BROWN DJ, 1992, PARAPLEGIA, V30, P77, DOI 10.1038/sc.1992.28; BUCHELEW SP, 1992, SCI PSYCHOSOC PROCES, V5, P99; BUCKELEW SP, 1990, REHABIL PSYCHOL, V35, P101, DOI 10.1037/0090-5550.35.2.101; BYRNE BM, 2001, STRUCTURE EQUATION M; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chase BW, 2000, J REHABIL, V66, P14; Chibnall J.T., 1990, PSYCHOL, V4, P283, DOI [10.1080/08870449008400397, DOI 10.1080/08870449008400397]; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; Cook DW, 1979, REHABIL PSYCHOL, V26, P97; COYLE CP, 1994, REHABIL PSYCHOL, V39, P95, DOI 10.1037/h0080309; CRAIG AR, 1994, PARAPLEGIA, V32, P675, DOI 10.1038/sc.1994.109; CRAIG AR, 1990, AUST NZ J PSYCHIAT, V24, P418, DOI 10.3109/00048679009077711; CRISP R, 1992, AUST PSYCHOL, V27, P43, DOI 10.1080/00050069208257573; DAVIDOFF G, 1990, REHABIL PSYCHOL, V35, P171, DOI 10.1037/h0079060; de Carvalho SAD, 1998, GEN HOSP PSYCHIAT, V20, P353, DOI 10.1016/S0163-8343(98)00047-4; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; Diener E, 1997, SOC INDIC RES, V40, P189, DOI 10.1023/A:1006859511756; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Elliott TR, 1999, J PERS INTERPERS LOS, V4, P361, DOI 10.1080/10811449908409742; Evans R L, 1994, J Am Paraplegia Soc, V17, P60; FABIAN ES, 1991, REHABIL COUNS BULL, V34, P344; FRANK RG, 1987, ARCH PHYS MED REHAB, V68, P344; FUHRER MJ, 1993, ARCH PHYS MED REHAB, V74, P255; Fuhrer MJ, 1996, TOPICS SPINAL CORD I, V4, P56; Go Bette K., 1995, P21; GREEN BC, 1984, ARCH PHYS MED REHAB, V65, P751; HAMMELL KRW, 1992, PARAPLEGIA, V30, P317; HANCOCK KM, 1993, PARAPLEGIA, V31, P349, DOI 10.1038/sc.1993.59; Hansen N, 1994, SCI PSYCHOSOC PROCES, V7, P195; HANSON S, 1993, REHABIL PSYCHOL, V38, P41, DOI 10.1037/0090-5550.38.1.41; HARDY RE, 1999, COUNSELING REHABILIT, P177; HEINEMANN AW, 1988, REHABIL PSYCHOL, V33, P195, DOI 10.1037//0090-5550.33.4.195; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; HU SS, 1995, MED PSYCHOL VOCATION; HUANG DD, 1990, J NEUROL REHABIL, V4, P157; JUDD FK, 1991, PARAPLEGIA, V29, P91, DOI 10.1038/sc.1991.12; Kemp BJ, 1999, DISABIL REHABIL, V21, P241; Kennedy P, 2000, BRIT J HEALTH PSYCH, V5, P157, DOI 10.1348/135910700168838; KENNEDY P, 1995, BRIT J CLIN PSYCHOL, V34, P627, DOI 10.1111/j.2044-8260.1995.tb01496.x; Kline RB., 2016, PRINCIPLES PRACTICE, V4; KRAUSE JS, 1990, PARAPLEGIA, V28, P186, DOI 10.1038/sc.1990.24; KRAUSE JS, 1992, REHABIL PSYCHOL, V37, P49, DOI 10.1037/0090-5550.37.1.49; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LAUTERBACH D, 1996, ASSESSMENT, V3, P17, DOI DOI 10.1177/107319119600300102; LEVIN R, 1989, OMEGA, V20, P341; Livneh H, 2003, INT J REHABIL RES, V26, P191, DOI 10.1097/00004356-200309000-00005; LIVNEH H, 1991, REHABIL COUNS BULL, V34, P298; Livneh H, 2001, REHABIL COUNS BULL, V44, P151, DOI 10.1177/003435520104400305; Livneh H., 1990, J APPL REHABIL COUS, V21, P13, DOI [10.1891/0047-2220.21.4.13, DOI 10.1891/0047-2220.21.4.13]; Livneh H., 1997, PSYCHOSOCIAL ADAPTAT; MacLeod L, 1998, DISABIL REHABIL, V20, P448, DOI 10.3109/09638289809166109; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P359; MARINI I, 1995, REHABIL COUNS BULL, V38, P198; MARINO RJ, 2000, INT STANDARDS NEUROL; McColl MA, 2003, ARCH PHYS MED REHAB, V84, P1137, DOI 10.1016/S0003-9993(03)00138-2; McGrath P, 1999, J REHABIL, V65, P17; McMillen JC, 2003, REHABIL PSYCHOL, V48, P77, DOI 10.1037/0090-5550.48.2.77; MCMORDIE WR, 1979, PSYCHOL REP, V44, P975, DOI 10.2466/pr0.1979.44.3.975; MCNETT SC, 1987, NURS RES, V36, P98; Mertler CA, 2002, ADV MULTIVARIATE STA; MEYER TM, 1999, ANN CONV AM PSYCH AS; Moore A D, 1994, Int J Rehabil Res, V17, P39, DOI 10.1097/00004356-199403000-00004; MOOS RH, 1984, COPING PHYSICAL ILLN, V2, P3; Nielsen MS, 2003, REHABIL PSYCHOL, V48, P289, DOI 10.1037/0090-5550.48.4.289; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; OVERHOLSER JC, 1993, REHABIL PSYCHOL, V38, P187, DOI 10.1037/0090-5550.38.3.187; PEDHAZUR PJ, 1997, MULTIPLE REGRESSION; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; Radnitz CL, 2000, J ANXIETY DISORD, V14, P313, DOI 10.1016/S0887-6185(00)00025-6; Radnitz CL, 1995, SCI PSYCHOSOCIAL PRO, V8, P145; RICHARDS JS, 1986, ARCH PHYS MED REHAB, V67, P362; Richards JS, 1997, REHABIL PSYCHOL, V42, P115, DOI 10.1037/0090-5550.42.2.115; ROSENSTIEL AK, 1981, J HUM STRESS, V7, P35, DOI 10.1080/0097840X.1981.9934542; SCHLOSSBERG NK, 1981, COUNS PSYCHOL, V9, P2, DOI 10.1177/001100008100900202; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; SHADISH WR, 1981, J CONSULT CLIN PSYCH, V49, P297, DOI 10.1037/0022-006X.49.2.297; Tabachnick B., 2001, USING MULTIVARIATE S; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; TATE DG, 1990, REHABIL PSYCHOL, V35, P211, DOI 10.1037/h0079062; TEMPLER DI, 1970, J GEN PSYCHOL, V82, P165, DOI 10.1080/00221309.1970.9920634; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; TRIESCHMANN RB, 1988, SPINE CORD INJURIES; Whalley Hammell K. R., 1994, Paraplegia, V32, P771; WOODRICH F, 1983, J REHABIL, V49, P26	93	62	67	0	12	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2005	86	6					1182	1192		10.1016/j.apmr.2004.11.036			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	934EK	WOS:000229689500017	15954058				2021-06-18	
J	Guo, XL; Meiyu, G; Guanhua, D				Guo, XL; Meiyu, G; Guanhua, D			Glucose transporter 1, distribution in the brain and in neural disorders: Its relationship with transport of neuroactive drugs through the blood-brain barrier	BIOCHEMICAL GENETICS			English	Article						glucose transporter; distribution in brain; expression in brain disease; neuroactive drug; saccharide; blood-brain barrier	GLUT1 GLUCOSE-TRANSPORTER; ELECTRON-MICROSCOPIC IMMUNOGOLD; POSITRON-EMISSION-TOMOGRAPHY; ANALOGS PRODUCE ANALGESIA; ALZHEIMERS-DISEASE; GLYCOPEPTIDE ANALOGS; BIOLOGICAL-ACTIVITY; ENKEPHALIN ANALOGS; MOLECULAR-CLONING; GENE-EXPRESSION	Facilitative glucose transport is mediated by one or more of the members of the closely related glucose transporter ( GLUT) family. Thirteen members of the GLUT family have been described thus far. GLUT1 is a widely expressed isoform that provides many cells with their basic glucose requirement. It is also the primary transporter across the blood-brain barrier. This review describes the distribution and expression of GLUT1 in brain in different pathophysiological conditions including Alzheimer's disease, epilepsy, ischemia, or traumatic brain injury. Recent investigations show that GLUT1 mediates the transport of some neuroactive drugs, such as glycosylated neuropeptides, low molecular weight heparin, and D-glucose derivatives, across the blood-brain barrier as a delivery system. By utilizing such highly specific transport mechanisms, it should be possible to establish strategies to regulate the entry of candidate drugs.	Ocean Univ China, Marine Drug & Food Inst, Dept Pharmacol, Qingdao 266003, Peoples R China; Shandong Univ, Sch Pharm, Dept Pharmacol, Jinan 250012, Peoples R China; Chinese Acad Med Sci, Beijing 100050, Peoples R China; Peking Union Med Coll, Beijing 100050, Peoples R China	Meiyu, G (corresponding author), Ocean Univ China, Marine Drug & Food Inst, Dept Pharmacol, Qingdao 266003, Peoples R China.	gengmy@ouc.edu.cn					Au KK, 1997, J CELL BIOCHEM, V67, P131, DOI 10.1002/(SICI)1097-4644(19971001)67:1<131::AID-JCB13>3.0.CO;2-K; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bilsky EJ, 2000, J MED CHEM, V43, P2586, DOI 10.1021/jm000077y; Boado RJ, 1998, NEUROSCI LETT, V255, P147, DOI 10.1016/S0304-3940(98)00731-9; Boado RJ, 1998, J NEURAL TRANSM-SUPP, P323; Bolz S, 1996, CELL TISSUE RES, V284, P355, DOI 10.1007/s004410050596; Bourasset F, 2003, J NEUROCHEM, V86, P1564, DOI 10.1046/j.1471-4159.2003.01990.x; Chavez JC, 2002, J NEUROSCI, V22, P8922; Cheng CM, 2001, FASEB J, V15, P907, DOI 10.1096/fj.00-0398com; CORNFORD EM, 1995, J NEUROPATH EXP NEUR, V54, P842, DOI 10.1097/00005072-199511000-00011; Cornford EM, 1998, J CEREBR BLOOD F MET, V18, P26, DOI 10.1097/00004647-199801000-00003; CORNFORD EM, 1993, J CEREBR BLOOD F MET, V13, P841, DOI 10.1038/jcbfm.1993.106; Cornford EM, 1998, ANN NEUROL, V43, P801, DOI 10.1002/ana.410430615; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Doege H, 2000, J BIOL CHEM, V275, P16275, DOI 10.1074/jbc.275.21.16275; Doege H, 2001, BIOCHEM J, V358, P791; Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8; Egleton RD, 2000, BRAIN RES, V881, P37, DOI 10.1016/S0006-8993(00)02794-3; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; FILIRA F, 1990, INT J PEPT PROT RES, V36, P86; Halmos T, 1997, CARBOHYD RES, V299, P15, DOI 10.1016/S0008-6215(96)00328-X; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; HARR SD, 1995, J NEUROPATH EXP NEUR, V54, P38, DOI 10.1097/00005072-199501000-00005; HORVAT S, 1993, INT J PEPT PROT RES, V41, P399; Janigro D, 1999, EPILEPSY RES, V37, P223, DOI 10.1016/S0920-1211(99)00074-1; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; KAYANO T, 1990, J BIOL CHEM, V265, P13276; Klepper J, 2004, PROSTAG LEUKOTR ESS, V70, P321, DOI 10.1016/j.plefa.2003.07.004; Kondo F, 2001, NEUROSCI RES, V39, P339, DOI 10.1016/S0168-0102(00)00233-9; Kriss CT, 2000, TETRAHEDRON-ASYMMETR, V11, P9, DOI 10.1016/S0957-4166(99)00544-3; Leino RL, 2001, NEUROCHEM INT, V38, P519, DOI 10.1016/S0197-0186(00)00102-9; Leveugle B, 1998, J NEUROCHEM, V70, P736; Ma Q, 2002, THROMB RES, V105, P447, DOI 10.1016/S0049-3848(02)00050-6; MAHER F, 1991, Molecular and Cellular Neuroscience, V2, P351, DOI 10.1016/1044-7431(91)90066-W; MAHER F, 1994, FASEB J, V8, P1003; MAHER F, 1995, J NEUROSCI RES, V42, P459, DOI 10.1002/jnr.490420404; McVie-Wylie AJ, 2001, GENOMICS, V72, P113, DOI 10.1006/geno.2000.6457; Mitchell SA, 2001, J ORG CHEM, V66, P2327, DOI 10.1021/jo005712m; Mooradian AD, 1997, NEUROBIOL AGING, V18, P469, DOI 10.1016/S0197-4580(97)00111-5; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; PARDRIDGE WM, 2000, BLOOD BRAIN BARRIER, P395; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; POLT R, 1994, P NATL ACAD SCI USA, V91, P7114, DOI 10.1073/pnas.91.15.7114; RICHARD DE, 1997, PEPTIDES, V18, P1431; RODRIGUEZ RE, 1989, NEUROSCI LETT, V101, P89, DOI 10.1016/0304-3940(89)90446-1; Rogers S, 2002, AM J PHYSIOL-ENDOC M, V282, pE733; Sasaki T, 2001, BIOCHEM BIOPH RES CO, V289, P1218, DOI 10.1006/bbrc.2001.6101; Schurmamn A, 2001, DIABETES, V50, pA277; Simpson IA, 2001, J BIOL CHEM, V276, P12725, DOI 10.1074/jbc.M010897200; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; Simpson IA, 1999, J NEUROCHEM, V72, P238, DOI 10.1046/j.1471-4159.1999.0720238.x; Tomatis R, 1997, J MED CHEM, V40, P2948, DOI 10.1021/jm970119r; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; VARGADEFTERDAROVIC L, 1992, INT J PEPT PROT RES, V39, P12; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173	57	62	62	3	22	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0006-2928	1573-4927		BIOCHEM GENET	Biochem. Genet.	APR	2005	43	3-4					175	187		10.1007/s10528-005-1510-5			13	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	910CX	WOS:000227908200008	15932065				2021-06-18	
J	Engstrom, M; Romner, B; Schalen, W; Reinstrup, P				Engstrom, M; Romner, B; Schalen, W; Reinstrup, P			Thrombocytopenia predicts progressive hemorrhage after head trauma	JOURNAL OF NEUROTRAUMA			English	Article						brain; contusion; progressive; TBI; thrombocytopenia; trauma	EARLY HEMOSTATIC THERAPY; INTRACEREBRAL HEMORRHAGE; BRAIN-INJURY; PLATELET-FUNCTION; COAGULOPATHY; COAGULATION; GUIDELINES; EPIDEMIOLOGY; MANAGEMENT; CHILDREN	Patients with traumatic brain injury (TBI) often show progression of hemorrhagic injuries (PHI) after admission to the hospital. This progression is correlated with poor outcome. In this study, we have investigated if thrombocytopenia was a risk factor for PHI. The study was performed on patients admitted to the hospital with severe TBI during year 2000. In total, 50 patients were admitted with severe TBI. Twenty-seven out of these had complete platelet counts at admission and 24 hours thereafter and were included for further study. We found thrombocytopenia at admission to be a risk factor for PHI (p = 0.008). We also found that the platelet count decreased more significantly during the first 24 h after injury in patients with PHI compared to patients without PHI (P = 0.009). A trend towards longer periods of mechanical ventilation in patients with PHI compared to patients without PHI was identified. These findings support a causal relationship between thrombocytopenia and PHI. The findings provide a rationale for future studies of hemostatic agents in the treatment of TBI in order to minimise complications caused by PHI.	Lund Univ Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden	Engstrom, M (corresponding author), Lund Univ Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden.	martin.engstrom@skane.se					Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; BURCH JM, 1992, ANN SURG, V215, P476, DOI 10.1097/00000658-199205000-00010; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LITTLETON JM, 1982, ALCOHOL CLIN EXP RES, V6, P512, DOI 10.1111/j.1530-0277.1982.tb05015.x; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2002, NEUROL RES, V24, P19, DOI 10.1179/016164102101199495; Mayer SA, 2003, STROKE, V34, P224, DOI 10.1161/01.STR.0000046458.67968.E4; Mayer SA, 2002, INTENS CARE MED, V28, pS235, DOI 10.1007/s00134-002-1470-8; Mikhail J, 1999, AACN Clin Issues, V10, P85, DOI 10.1097/00044067-199902000-00008; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Serebruany VL, 2000, J THROMB THROMBOLYS, V9, P229, DOI 10.1023/A:1018762510842; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; ZOUCAS E, 1982, EUR SURG RES, V14, P33, DOI 10.1159/000128220	34	62	73	0	1	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					291	296		10.1089/neu.2005.22.291			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400008	15716634				2021-06-18	
J	Tsung, JW; Blaivas, M; Cooper, A; Levick, NR				Tsung, JW; Blaivas, M; Cooper, A; Levick, NR			A rapid noninvasive method of detecting elevated intracranial pressure using bedside ocular ultrasound - Application to 3 cases of head trauma in the pediatric emergency department	PEDIATRIC EMERGENCY CARE			English	Article						optic nerve sheath diameter; ocular ultrasound; emergency ultrasonography; elevated intracranial pressure; traumatic brain injury	NERVE; ULTRASONOGRAPHY; HEMORRHAGES	Managing pediatric head trauma with elevated intracranial pressure in the acute setting can be challenging. Bedside ocular ultrasound for measuring optic nerve sheath diameters has been recently proposed as a portable noninvasive method to rapidly detect increased intracranial pressure in emergency department patients with head trauma. Prior study data agree that the upper limit of normal optic nerve sheath diameters is 5.0 turn in adults, 4.5 turn in children aged 1 to 15, and 4.0 min in infants up to I year of age. We report the application of this technique to 3 cases of head trauma in the pediatric emergency department.	Columbia Univ, Div Pediat Emergency Med, Dept Pediat, Harlem Hosp,Coll Phys & Surgeons, New York, NY USA; Med Coll Georgia, Dept Emergency Med, Augusta, GA 30912 USA; Columbia Univ, Coll Phys & Surg, Div Pediat Surg, Dept Surg,Harlem Hosp, New York, NY USA	Tsung, JW (corresponding author), NYU, Sch Med, Bellevue Hosp Ctr, 462 1st Ave,Room 1 E 9, New York, NY 10016 USA.	james.tsung@med.nyu.edu	Tsung, James W/I-6343-2019	Tsung, James/0000-0002-4718-8325			Ballantyne J, 1999, CLIN RADIOL, V54, P740, DOI 10.1016/S0009-9260(99)91176-5; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Blaivas M, 2002, ACAD EMERG MED, V9, P791, DOI 10.1197/aemj.9.8.791; Blaivas M, 2001, ACAD EMERG MED, V8, P90, DOI 10.1111/j.1553-2712.2001.tb00563.x; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; *CTR DIS CONTR PRE, 2002, 2000 NAT HOSP AMB ME; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; Foster T, 2003, ACAD EMERG MED, V10, P487; GALETTA S, 1989, J CLIN NEURO-OPHTHAL, V9, P79; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; JOHNSON LN, 1991, J FAM PRACTICE, V33, P4; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; Ma O. J., 2003, EMERGENCY ULTRASOUND; National Center for Injury Prevention and Control, 2002, TRAUM BRAIN INJ US A; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; YEH K, 2002, PEDIATR EMERG CARE, V18, P226	17	62	64	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	2005	21	2					94	98		10.1097/01.pec.0000159052.64930.64			5	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	897ZC	WOS:000227044400004	15699817				2021-06-18	
J	Le, TH; Mukherjee, P; Henry, RG; Berman, JI; Ware, M; Manley, GT				Le, TH; Mukherjee, P; Henry, RG; Berman, JI; Ware, M; Manley, GT			Diffusion tensor imaging with three-dimensional fiber tractography of traumatic axonal shearing injury: An imaging correlate for the posterior callosal "disconnection" syndrome: Case report	NEUROSURGERY			English	Article						corpus callosum; diffuse axonal injury; diffusion tensor imaging; fiber tractography; magnetic resonance imaging; traumatic brain injury; white matter			Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	Le, TH (corresponding author), Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.		Mukherjee, Pratik/A-5446-2008; Ware, Marcus/E-4981-2011	Mukherjee, Pratik/0000-0001-7473-7409				0	62	63	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2005	56	1					189	189		10.1227/01.NEU.0000144846.00569.3A			1	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	884FD	WOS:000226069300057	15617604				2021-06-18	
J	Read, KM; Kufera, JA; Dischinger, PC; Kerns, TJ; Ho, SM; Burgess, AR; Burch, CA				Read, KM; Kufera, JA; Dischinger, PC; Kerns, TJ; Ho, SM; Burgess, AR; Burch, CA			Life-altering outcomes after lower extremity injury sustained in motor vehicle crashes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						lower extremity injury; psychosocial consequences; motor vehicle crash; outcomes; traumatic brain injury	MULTIPLE TRAUMA; DEPRESSION; ALCOHOLISM; RECOVERY; IMPACT; COSTS; SF-36; CAGE	Background. Lower extremity injuries (LEIs) sustained in vehicular crashes result in physical problems and unexpected psychosocial consequences. Their significance is diminished by low Abbreviated Injury Scale scores. Methods:. Drivers who sustained LEIs were identified as part of the Crash Injury Research and Engineering Network (CIREN) and interviewed during hospitalization, at 6 months, and at 1 year. All were occupants of newer vehicles with seatbelts and airbags. Results: Sixty-five patients were followed for 1 year. Injuries included mild brain injury (43%), ankle/foot fractures (55%), and bilateral injuries (37%). One year post-injury, 46% reported limitations in walking and 22% with ankle/foot fractures were unable to return to work. Depression (39%), cognitive problems (32%), and post-traumatic stress disorder (18%) were significant in the mild brain injury group. Conclusions. Long-lasting physical and psychological burdens may impede recovery and alter the lifestyle of patients with LEI. These issues need to be addressed by trauma center personnel.	Univ Maryland, Sch Med, Natl Study Ctr Trauma & Emergency Med Syst, MSW, Baltimore, MD 21201 USA	Read, KM (corresponding author), Univ Maryland, Sch Med, Natl Study Ctr Trauma & Emergency Med Syst, MSW, 701 W Pratt St,5th Floor, Baltimore, MD 21201 USA.	kread@som.umaryland.edu					A PC F, 2000, INT CLASSIFICATION D, P10; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; BLANCHARD EB, 1997, CRASH ASSESSMENT TRE; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; Convit A, 2003, P NATL ACAD SCI USA, V100, P2019, DOI 10.1073/pnas.0336073100; DISCHINGER P, 1994, P INJ PREV BIOM S WA, P29; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; DISCHINGER PC, 1995, ACCIDENT ANAL PREV, V27, P601, DOI 10.1016/0001-4575(95)00002-H; DISCHINGER PC, 1994, SAE INT, P11; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Goldberg R J, 1993, R I Med, V76, P391; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Joint Commission on Accreditation of Health- care Organizations, 2000, PAIN ASS MAN ORG APP; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Loo GT, 1996, J TRAUMA, V41, P935, DOI 10.1097/00005373-199612000-00001; MacKenzie EJ, 2000, J ORTHOP TRAUMA, V14, P455, DOI 10.1097/00005131-200009000-00001; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MCCLURE R, 2000, P 3 INT C MEAS BURD; Nesse RE, 1996, AM FAM PHYSICIAN, V53, P2125; SIEGEL JH, 1993, J TRAUMA, V35, P920, DOI 10.1097/00005373-199312000-00019; Soderstrom CA, 1997, J TRAUMA, V43, P962, DOI 10.1097/00005373-199712000-00017; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; *US DEP TRANSP, 2001, EFF OCC PROT SYSTM T; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; 2000, DIAGNOSTIC STAT MAN, P463	29	62	63	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2004	57	4					815	823		10.1097/01.TA.0000136289.15303.44			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	871EN	WOS:000225112300026	15514536				2021-06-18	
J	Massagli, TL; Fann, JR; Burington, BE; Jaffe, KM; Katon, WJ; Thompson, RS				Massagli, TL; Fann, JR; Burington, BE; Jaffe, KM; Katon, WJ; Thompson, RS			Psychiatric illness after mild traumatic brain injury in children	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; psychiatry; rehabilitation	CLOSED-HEAD-INJURY; DISORDERS; ADOLESCENTS; SEQUELAE; ADJUSTMENT	Objective: To determine the incidence of psychiatric illness 3 years after mild traumatic brain injury (TBI) in children. Design: Prospective cohort study with 3-year follow-up. Setting: Emergency department, hospital, and outpatient clinics in a large health maintenance organization. Participants: Children, 14 years old or less (n=490), who sustained a mild TBI in 1993. Three TBI unexposed subjects per TBI exposed patient were matched by sex, age, and enrollment at the time of injury (n=1470). Interventions: Not applicable. Main Outcome Measures: Computerized records were examined to identify psychiatric diagnoses, psychiatric medication prescription, and utilization of psychiatric services for the year before TBI and 3 years after. Adjusted relative risks for incidence of psychiatric illness were estimated for those with and without a premorbid psychiatric disorder. Results: The cumulative incidence estimates for any psychiatric illness in the 3 years after mild TBI were 30% in children exposed to mild TBI and 20% in unexposed children (P=.0001). Cumulative incidence estimates were particularly high in both TBI exposed (55%) and unexposed children (63%) who had psychiatric illness in the year before the index TBI (psychiatric history). The exposed and unexposed children with psychiatric history did not have significantly different estimates of incidence during follow-up for any of the studied indicators of psychiatric illness. In those with no psychiatric history, 26% of exposed and 16% of unexposed children (P<.0001) had evidence of a psychiatric illness in the 3 years after mild TBI. For those with no psychiatric history, the adjusted relative risk estimate of any psychiatric illness in TBI exposed versus unexposed children, in the first year after TBI, was 2.03 (95% confidence interval [CI], 1.4-2.9). Children with mild TBI but no psychiatric history were at higher risk for hyperactivity (diagnosis of hyperkinetic syndrome of childhood or prescription of psychostimulants) in the first year after injury (incidence, 3%; first year relative risk, 7.59; 95% CI, 2.7-21.6). Conclusions: In the 3 years after mild TBI, children with no evidence of prior-year psychiatric history were at significantly increased risk for psychiatric illness, particularly hyperactivity in the first year after injury. Prior-year psychiatric history conferred a significant independent risk for subsequent psychiatric illness. There was no evidence for an additional increase in risk in the 3-year follow-up that is attributable to mild TBI in children with prior psychiatric history.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98121 USA	Massagli, TL (corresponding author), Childrens Hosp & Med Ctr, POB 5371,Mail Stop 6G3, Seattle, WA 98105 USA.	massagli@u.washington.edu					Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; BIJUR PE, 1990, PEDIATRICS, V86, P337; Black P, 1981, BRAIN DYSFUNCTION CH, P171; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hosmer DW, 1999, APPL SURVIVAL ANAL; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; National Center for Health Statistics, 1991, NAT CTR HLTH STAT PU; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; THRUMAN DJ, 1995, GUIDELINES SURVEILL; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; THURMAN DJ, 1996, PROPOSED CLASIFICATI; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	37	62	62	0	12	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2004	85	9					1428	1434		10.1016/j.apmr.2003.12.036			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	852DW	WOS:000223736400007	15375812				2021-06-18	
J	Ederoth, P; Tunblad, K; Bouw, R; Lundberg, CJF; Ungerstedt, U; Nordstrom, CH; Hammarlund-Udenaes, M				Ederoth, P; Tunblad, K; Bouw, R; Lundberg, CJF; Ungerstedt, U; Nordstrom, CH; Hammarlund-Udenaes, M			Blood-brain barrier transport of morphine in patients with severe brain trauma	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2000	SAN FRANCISCO, CA	Amer Soc Anaesthesiologists		blood-brain barrier; brain injury; human; microdialysis; morphine; pharmacokinetics	IN-VIVO MICRODIALYSIS; P-GLYCOPROTEIN; INTRACEREBRAL MICRODIALYSIS; RESISTANCE; ANESTHESIA; STATE	Aims In experimental studies, morphine pharmacokinetics is different in the brain compared with other tissues due to the properties of the blood-brain barrier, including action of efflux pumps. It was hypothesized in this clinical study that active efflux of morphine occurs also in human brain, and that brain injury would alter cerebral morphine pharmacokinetics. Methods Patients with traumatic brain injury, equipped with one to three microdialysis catheters in the brain and one in abdominal subcutaneous fat for metabolic monitoring, were studied. The cerebral catheter locations were classified as 'better' and 'worse' brain tissue, referring to the degree of injury. Morphine (10 mg) was infused intravenously over a 10-min period in seven patients in the intensive care setting. Tissue and plasma morphine concentrations were obtained during the subsequent 3-h period with microdialysis and regular blood sampling. Results The area under the concentration-time curve (AUC) ratio of unbound morphine in brain tissue to plasma was 0.64 (95% confidence interval 0.40, 0.87) in 'better' brain tissue (P < 0.05 vs. the subcutaneous fat/plasma ratio), 0.78 (0.49, 1.07) in 'worse' brain tissue and 1.00 (0.86, 1.13) in subcutaneous fat. The terminal half-life and T-max were longer in the brain vs. plasma and fat, respectively. The relative recovery for morphine was higher in 'better' than in 'worse' brain tissue. The T-max value tended to be shorter in 'worse' brain tissue. Conclusions The unbound AUC ratio below unity in the 'better' human brain tissue demonstrates an active efflux of morphine across the blood-brain barrier. The 'worse' brain tissue shows a decrease in relative recovery for morphine and in some cases also an increase in permeability for morphine over the blood-brain barrier.	Univ Lund Hosp, Dept Anaesthesiol & Intens Care, SE-22185 Lund, Sweden; Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; Univ Lund Hosp, Dept Clin Neurosci, SE-22185 Lund, Sweden	Ederoth, P (corresponding author), Univ Lund Hosp, Dept Anaesthesiol & Intens Care, SE-22185 Lund, Sweden.	per.ederoth@swipnet.se		Lundberg, Johan/0000-0002-3021-1795			Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; BONICA JJ, 1990, MANAGEMENT PAIN, P368; Bouw MR, 1998, PHARMACEUT RES, V15, P1673, DOI 10.1023/A:1011992125204; Bouw MR, 2000, PHARMACEUT RES, V17, P1220, DOI 10.1023/A:1026414713509; BUNGAY PM, 1990, LIFE SCI, V46, P105, DOI 10.1016/0024-3205(90)90043-Q; Chen KC, 2002, J NEUROCHEM, V81, P108, DOI 10.1046/j.1471-4159.2002.00793.x; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; JOEL SP, 1988, J CHROMATOGR-BIOMED, V430, P394, DOI 10.1016/S0378-4347(00)83176-X; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Letrent SP, 1999, DRUG METAB DISPOS, V27, P827; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stain-Texier F, 1999, BRIT J PHARMACOL, V128, P917, DOI 10.1038/sj.bjp.0702873; STOELTING RK, 1999, PHARM PHYSL ANESTHET, P77; Taylor JC, 2001, J BIOL CHEM, V276, P36075, DOI 10.1074/jbc.C100345200; Tunblad K, 2003, PHARMACEUT RES, V20, P618, DOI 10.1023/A:1023250900462; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; van den Nieuwenhuyzen MCO, 2000, CLIN PHARMACOKINET, V38, P181, DOI 10.2165/00003088-200038020-00003; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Xie RJ, 1999, BRIT J PHARMACOL, V128, P563, DOI 10.1038/sj.bjp.0702804	25	62	63	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	APR	2004	57	4					427	435		10.1046/j.1365-2125.2003.02032.x			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	804AY	WOS:000220272800008	15025740	Green Published, Bronze			2021-06-18	
J	Gates, MA; Coupe, VM; Torres, EM; Fricker-Gates, RA; Dunnett, SB				Gates, MA; Coupe, VM; Torres, EM; Fricker-Gates, RA; Dunnett, SB			Spatially and temporally restricted chemoattractive and chemorepulsive cues direct the formation of the nigro-striatal circuit	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						substantia nigra; dopamine neurons; rat; axon guidance; Parkinson's disease	LATERAL GANGLIONIC EMINENCE; AXON GUIDANCE; C-ELEGANS; DOPAMINE NEURONS; FIBER OUTGROWTH; SONIC HEDGEHOG; OPTIC TECTUM; CELL; MIDLINE; DROSOPHILA	Identifying cellular and molecular mechanisms that direct the formation of circuits during development is thought to be the key to reconstructing circuitry lost in adulthood to neurodegenerative disorders or common traumatic injuries. Here we have tested whether brain regions situated in and around the developing nigro-striatal pathway have particular chemoattractive or chemorepulsive effects on mesencephalic dopamine axons, and whether these effects are temporally restricted. Mesencephalic explants from embryonic day (E)12 rats were either cultured alone or with coexplants from the embryonic, postnatal or adult medial forebrain bundle region (MFB), striatum, cortex, brain stem or thalamus. Statistical analysis of axon growth responses revealed a potent chemoattraction to the early embryonic MFB (i.e. E12-15) that diminished (temporally) in concert with the emergence of chemoattraction to the striatum in the late embryonic period (i.e. E19+). Repulsive responses by dopaminergic axons were obvious in cocultures with embryonic brain stem and cortex, however, there was no effect by the thalamus. Such results suggest that the nigro-striatal circuit is formed via spatially and temporally distributed chemoattractive and chemorepulsive elements that: (i) orientate the circuit in a rostral direction (via brain stem repulsion); (ii) initiate outgrowth (via MFB attraction); (iii) prevent growth beyond the target region (via cortical repulsion); and (iv) facilitate target innervation (via striatal chemoattraction). Subsequent studies will focus on identifying genes responsible for these events so that their products may be exploited to increase the integration of neuronal transplants to the mature brain, or provide a means to (re)establish the nigro-striatal circuit in vivo.	Cardiff univ, Sch Biosci, Brain Repair Grp, Cardiff CF10 3US, S Glam, Wales	Gates, MA (corresponding author), Cardiff univ, Sch Biosci, Brain Repair Grp, Cardiff CF10 3US, S Glam, Wales.	gatesma@cf.ac.uk	Dunnett, Stephen B/A-5869-2010; Fricker, Gert/N-4157-2018	Dunnett, Stephen B/0000-0003-1826-1578; Fricker, Gert/0000-0003-3894-961X			ALTMAN, 1991, NEOCORTICAL DEV; Battye R, 1999, DEVELOPMENT, V126, P2475; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; BRUNDIN P, 1986, DEV BRAIN RES, V24, P77, DOI 10.1016/0165-3806(86)90174-4; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; COSTANTINI LC, 1994, EXP NEUROL, V127, P219, DOI 10.1006/exnr.1994.1098; Coupe VM, 2002, EXP NEUROL, V175, P432; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; EmgardMattson M, 1997, CELL TRANSPLANT, V6, P277, DOI 10.1016/S0963-6897(97)00038-9; Friedman GC, 1996, J NEUROSCI, V16, P5498; Gates M A, 2000, Prog Brain Res, V127, P115; Gates MA, 1998, NEUROSCIENCE, V84, P1013, DOI 10.1016/S0306-4522(97)00512-5; Gates MA, 1996, J NEUROSCI, V16, P8005; Haque NSK, 1996, BRAIN RES, V712, P45, DOI 10.1016/0006-8993(95)01427-6; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Irving C, 2002, DEVELOPMENT, V129, P5389, DOI 10.1242/dev.00117; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; Keleman K, 2002, CELL, V110, P415, DOI 10.1016/S0092-8674(02)00901-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Laywell ED, 1996, J NEUROSCI METH, V66, P99, DOI 10.1016/0165-0270(96)00008-8; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MOLNAR Z, 1995, TRENDS NEUROSCI, V18, P389, DOI 10.1016/0166-2236(95)93935-Q; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Nakamura S, 2000, J NEUROSCI, V20, P4112; Ohtani N, 2003, J NEUROSCI, V23, P2840; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Rosenblad C, 1996, NEUROSCIENCE, V75, P979; SAUER H, 1993, BRAIN RES, V626, P37, DOI 10.1016/0006-8993(93)90560-A; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Sinclair SR, 1996, NEUROREPORT, V7, P2547, DOI 10.1097/00001756-199611040-00029; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Super H, 1998, BRAIN RES REV, V27, P40, DOI 10.1016/S0165-0173(98)00005-8; Tanaka A, 2001, BRAIN RES, V912, P105, DOI 10.1016/S0006-8993(01)02726-3; Trousse F, 2001, DEVELOPMENT, V128, P3927; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011; YUREK DM, 1990, EXP NEUROL, V109, P191, DOI 10.1016/0014-4886(90)90073-2; ZHOU HF, 1990, J COMP NEUROL, V292, P320, DOI 10.1002/cne.902920213; ZHOU HF, 1992, J COMP NEUROL, V317, P145, DOI 10.1002/cne.903170204; Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6	47	62	66	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2004	19	4					831	844		10.1111/j.1460-9568.2004.03213.x			14	Neurosciences	Neurosciences & Neurology	803TE	WOS:000220252600005	15009130				2021-06-18	
J	Pilitsis, JG; Coplin, WM; O'Regan, MH; Wellwood, JM; Diaz, FG; Fairfax, MR; Michael, DB; Phillis, JW				Pilitsis, JG; Coplin, WM; O'Regan, MH; Wellwood, JM; Diaz, FG; Fairfax, MR; Michael, DB; Phillis, JW			Free fatty acids in cerebrospinal fluids from patients with traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						cerebral trauma; free fatty acids; phospholipases; patient outcome	RAT; LACTATE; CORTEX; DAMAGE	Free fatty acid (FFA) concentrations in cerebrospinal fluid (CSF) are recognized as markers of brain damage in animal studies. There is, however, relatively little information regarding FFA concentrations in human CSF in normal and pathological conditions. The present study examined FFA concentrations in CSF from 15 patients with traumatic brain injury (TBI) and compared the data with values obtained from 73 contemporary controls. Concentrations of specific FFAs from TBI patients, obtained within 48 It of the insult were significantly greater than those in the control group (arachidonic, docosahexaenoic and myristic, P < 0.001; oleic, palmitic, P < 0.01; linoleic, P < 0.05). Higher concentrations of total polyunsaturated fatty acids (P < 0.001) and of arachidonic, myristic and palmitic acids measured individually in CSF (P < 0.01) obtained I week after the insult were associated with a worse outcome at the time of hospital discharge using the Glasgow Outcome Scale. This preliminary investigation suggests that CSF FFA concentrations may be useful as a predictive marker of outcome following TBI. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Univ Detroit Mercy, Sch Dent, Dept Biomed Sci, Detroit, MI 48219 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Phillis, JW (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 5374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038905] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS38905] Funding Source: Medline		Carman HM, 1998, BRAIN RES, V808, P116, DOI 10.1016/S0006-8993(98)00824-5; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Pilitsis JG, 2001, NEUROCHEM RES, V26, P1265, DOI 10.1023/A:1014227231130; Saluja I, 1999, NEUROCHEM RES, V24, P669, DOI 10.1023/A:1021004525979; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2	11	62	63	0	5	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 2	2003	349	2					136	138		10.1016/S0304-3940(03)00803-6			3	Neurosciences	Neurosciences & Neurology	720ZT	WOS:000185293100017	12946571				2021-06-18	
J	Cory, CZ; Jones, MD				Cory, CZ; Jones, MD			Can shaking alone cause fatal brain injury? A biomechanical assessment of the Duhaime shaken baby syndrome model	MEDICINE SCIENCE AND THE LAW			English	Article							INFLICTED HEAD-INJURY; DIFFUSE AXONAL INJURY; IMPACT; INFANTS; WHIPLASH; NEUROPATHOLOGY; DAMAGE	A biomechanical model of a one-month old baby was designed and tested by Duhaime and co-workers in 1987 in an attempt to assess the biomechanics of the shaken baby syndrome (SBS). The study implied that pure shaking alone cannot cause fatal head injuries, a factor which has been applied in criminal courts. In an attempt to test the validity of the model a preliminary study was undertaken in which a replica was constructed and tested. The broad description of the design and construction of the Duhaime model allowed for variations and therefore uncertainties in its reproduction. It was postulated therefore that differences in certain parameters may increase angular head accelerations. To further investigate this observation, an adjustable replica model was developed and tested. The results indicated that certain parameter changes in the model did in fact lead to an increase in angular head acceleration. When these parameter changes were combined and an injurious shake pattern was employed, using maximum physical effort, the angular head acceleration results exceeded the original Duhaime et al. (1987) results and spanned two scaled tolerance limits for concussion. Additionally, literature suggests that the tolerance limits used to assess the shaking simulation results in the original study may not be reliable. Results from our study were closer to the internal head injury, subdural haematoma, tolerance limits. A series of end point impacts were identified in the shake cycles, therefore, an impact-based head injury measure (Head Injury Criterion - HIC) was utilized to assess their severity. Seven out of ten tests conducted resulted in HIC values exceeding the tolerance limits (critical load value, Sturtz, 1980) suggested for children. At this present stage the authors conclude that it cannot be categorically stated, from a biomechanical perspective, that pure shaking cannot cause fatal head injuries in an infant. Parameters identified in this study require further investigation to assess the accuracy of simulation and increase the biofidelity of the models before further conclusions can be drawn. There must now be sufficient doubt in the reliability of the Duhaime et al. (1987) biomechanical study to warrant the exclusion of such testimony in cases of suspected shaken baby syndrome.	Univ Wales Coll Cardiff, Cardiff Sch Engn, Med Engn Res Ctr, Cardiff CF24 0YF, S Glam, Wales	Cory, CZ (corresponding author), Univ Wales Coll Cardiff, Cardiff Sch Engn, Med Engn Res Ctr, The Parade,POB 925, Cardiff CF24 0YF, S Glam, Wales.						ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; Beusenberg M., 1993, 933104 SAE; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; BUNDEZ DL, 1994, J FOR SCI, V41, P411; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Cory CZ, 2001, FORENSIC SCI INT, V123, P89, DOI 10.1016/S0379-0738(01)00523-0; CORY CZ, 2001, THESIS U WALES CARDI; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Duhaime AC, 1996, PEDIAT TRAUMA FORENS, V4, P73; DUHAIME AC, 1998, COMMUNICATION; ELNER SG, 1996, J FOR SCI, V41, P114; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1956, P 11 STAPP CAR CRASH; INGRAHAM FD, 1972, AJDC, V124, P161; IRWIN AL, 1972, 973317 SAE; JACOBI G, 1986, J FOR SCI, V41, P114; JANSSEN EG, 1991, 35 STAPP CAR CRASH C; Klinich K.D., 1996, TECHNIQUES DEV CHILD; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MARGULIES SS, 1999, COMMUNICATION; MASSICOTTE SJ, 1991, J FOR SCI, V41, P114; MUNGER CE, 1993, J FOR SCI, V41, P114; Norris Beverley., 1995, CHILDATA HDB CHILD M; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; PHEASANT ST, 1986, CHILDATA HDB CHILD M; PRANGE MT, 1999, P 43 STAPP CAR CRASH, P333; PRASAD P, 1985, 851246 SAE; RAO N, 1988, J FOR SCI, V41, P114; Snyder R. G., 1977, ANTHROPOMETRY INFANT; STEENBEKKERS LPA, 1993, CHILDATA HDB CHILD M; Sturtz G, 1980, 24 STAPP CAR CRASH C; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Thibault LE, 1985, P 4 EXP SAF VEH C NE	44	62	62	1	7	CHILTERN PUBLISHING	BEACONSFIELD	34 AYLESBURY END, BEACONSFIELD HP9 1LW, BUCKS, ENGLAND	0025-8024			MED SCI LAW	Med. Sci. Law	OCT	2003	43	4					317	333		10.1258/rsmmsl.43.4.317			17	Law; Medicine, Legal; Pathology	Government & Law; Legal Medicine; Pathology	752LD	WOS:000187161200006	14655963				2021-06-18	
J	Gilad, GM; Gilad, VH				Gilad, GM; Gilad, VH			Overview of the brain polyamine-stress-response: Regulation, development, and modulation by lithium and role in cell survival	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						behavior; cell death; hypothalamic-pituitary-adrenocortical axis; lithium; neuroprotection; neurotrauma; ornithine decarboxylase; putrescine; spermidine; spermine	ORNITHINE DECARBOXYLASE ACTIVITY; BIPOLAR AFFECTIVE-DISORDER; FOCAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE-C; RAT-BRAIN; NERVOUS-SYSTEM; CORTICOSTERONE TREATMENT; SIGNAL-TRANSDUCTION; CHRONIC EXPOSURE; HEAT-SHOCK	An early transient increase in brain polyamine (PA) metabolism, termed the PA-stress-response (PSR), is a common reaction to stressful stimuli, including physical, emotional, and hormonal stressors, with a magnitude related to the stress intensity. In the extreme, traumatic injury can result in an incomplete PSR, with persistent accumulation of putrescine and eventual reduction in the concentrations of the higher polyamines (PAs), spermidine and spermine. Chronic intermittent application of stressors causes a recurrence of the brain PSR, but, in contrast, it leads to habituation of the response in the periphery ( liver). Severe continuous stress, however, may lead to accumulation of brain PAs. Long-term inhibition of PA synthesis depletes brain PAs and can result in altered emotional reactivity to stressors. Furthermore, the brain PSR, in contrast to the periphery, can be blocked by a long-term, but not by short-term, treatment with lithium, the most efficacious treatment of manic-depressive illness. The brain PSR is developmentally regulated, and the switch to the mature pattern coincides with the cessation of the "stress hyporesponsive period" in the hypothalamic-pituitary-adrenocortical (HPA) system. In contrast to the brain and liver, the PSR in the adrenal and thymus is down-regulated by acute stressors. Transient up-regulation of the PSR, as in the brain and liver, is implicated in cell survival while its down-regulation is implicated in cell death. Taken together, the findings indicate that the PSR is a dynamic process that varies with the type, intensity, and duration of stressors, and implicate this response as an adaptive mechanism in the reaction to stressful events. Under persistent stressful conditions, however, the PSR may be maladaptive as may be reflected by PA accumulation. This raises the hypothesis that proper regulation of brain PSR may be critical for neuronal function and for an appropriate behavioral response to stressors.	Assaf Harofeh Med Ctr, Neurosci Lab, IL-70300 Zerifin, Israel	Gilad, GM (corresponding author), Assaf Harofeh Med Ctr, Neurosci Lab, PO Beer Yaakov, IL-70300 Zerifin, Israel.	gmgilad@asaf.health.gov.il	Gilad, Gad M/E-7193-2010				Abraham I, 1997, J NEUROENDOCRINOL, V9, P713, DOI 10.1046/j.1365-2826.1997.00634.x; Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; ANDERSON TR, 1975, BIOCHEM PHARMACOL, V24, P495, DOI 10.1016/0006-2952(75)90136-7; Anisman H, 1998, INT J DEV NEUROSCI, V16, P149, DOI 10.1016/S0736-5748(98)00025-2; ARMARIO A, 1988, NEUROENDOCRINOLOGY, V47, P263, DOI 10.1159/000124921; AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Bohn M.C., 1984, NEUROBEHAVIORAL TERA, P365; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; BUEB JL, 1992, BIOCHEM J, V282, P545, DOI 10.1042/bj2820545; CALDECOTTHAZARD S, 1991, SYNAPSE, V8, P185, DOI 10.1002/syn.890080306; COTTERRELL M, 1972, J NEUROCHEM, V19, P2151, DOI 10.1111/j.1471-4159.1972.tb05124.x; COUSIN MA, 1982, J NEUROCHEM, V38, P1296, DOI 10.1111/j.1471-4159.1982.tb07904.x; COX RH, 1985, J APPL PHYSIOL, V58, P1207; DANZIN C, 1979, LIFE SCI, V24, P519, DOI 10.1016/0024-3205(79)90173-5; EBSTEIN RP, 1980, J PHARMACOL EXP THER, V213, P161; FERCHMIN PA, 1993, PHARMACOL BIOCHEM BE, V45, P967, DOI 10.1016/0091-3057(93)90149-N; FLAMIGNI F, 1986, J MOL CELL CARDIOL, V18, P3, DOI 10.1016/S0022-2828(86)80977-4; GILAD GM, 1995, MECH AGEING DEV, V78, P75, DOI 10.1016/0047-6374(94)01529-U; Gilad GM, 2002, BRAIN RES, V943, P23, DOI 10.1016/S0006-8993(02)02479-4; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; GILAD GM, 1992, LIFE SCI, V50, pPL149, DOI 10.1016/0024-3205(92)90289-2; Gilad GM, 1998, INT J DEV NEUROSCI, V16, P271, DOI 10.1016/S0736-5748(98)00033-1; Gilad GM, 1996, J NEUROCHEM, V67, P1992; Gilad VH, 2001, BIOCHEM PHARMACOL, V61, P207, DOI 10.1016/S0006-2952(00)00517-7; Gilad VH, 2000, DEV BRAIN RES, V120, P255, DOI 10.1016/S0165-3806(00)00012-2; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; Goodwin FK, 1990, MANIC DEPRESSIVE ILL; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; Heim C, 1997, PSYCHOPHARMACOL BULL, V33, P185; HIETALA OA, 1983, BIOCHEM PHARMACOL, V32, P1581, DOI 10.1016/0006-2952(83)90331-3; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HIRVONEN A, 1988, BIOCHIM BIOPHYS ACTA, V950, P229, DOI 10.1016/0167-4781(88)90015-2; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; JOPE RS, 1994, BIOCHEM PHARMACOL, V47, P429, DOI 10.1016/0006-2952(94)90172-4; KANBA S, 1991, NEUROPHARMACOLOGY, V30, P497, DOI 10.1016/0028-3908(91)90012-Z; Kuhn CM, 1998, INT J DEV NEUROSCI, V16, P261, DOI 10.1016/S0736-5748(98)00034-3; KVETNANKY R, 1979, AM J PHYSIOL, V246, pH457; LACHMAN HM, 1989, LIFE SCI, V45, P1413, DOI 10.1016/0024-3205(89)90031-3; LI PP, 1993, J NEUROCHEM, V61, P1722, DOI 10.1111/j.1471-4159.1993.tb09809.x; LUKKARAINEN J, 1995, EUR J NEUROSCI, V7, P1840, DOI 10.1111/j.1460-9568.1995.tb00704.x; Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811; MANJI HK, 1993, J NEUROCHEM, V61, P2303, DOI 10.1111/j.1471-4159.1993.tb07474.x; MARTIN A, 1994, J CHEM TECHNOL BIOT, V60, P7, DOI 10.1002/jctb.280600103; MARTON LJ, 1986, PHARMACEUT RES, V3, P311, DOI 10.1023/A:1016375705487; MASANA MI, 1992, J NEUROCHEM, V59, P200, DOI 10.1111/j.1471-4159.1992.tb08891.x; MATSUI I, 1980, BIOCHIM BIOPHYS ACTA, V633, P87, DOI 10.1016/0304-4165(80)90040-9; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORUZZI MS, 1993, MOL CELL BIOCHEM, V124, P1, DOI 10.1007/BF01096375; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; NISENBAUM LK, 1991, J NEUROSCI, V11, P1478; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; OBAYASHI M, 1992, BIOCHIM BIOPHYS ACTA, V1131, P41, DOI 10.1016/0167-4781(92)90096-I; PASCHEN W, 1988, NEUROCHEM PATHOL, V9, P1; PEGG AE, 1982, AM J PHYSIOL, V243, pC212; POL O, 1992, PHARMACOL BIOCHEM BE, V42, P407, DOI 10.1016/0091-3057(92)90133-Z; PRINCE CR, 1984, BEHAV NEURAL BIOL, V42, P99, DOI 10.1016/S0163-1047(84)90942-7; RICHARDS JF, 1990, LIFE SCI, V47, P233, DOI 10.1016/0024-3205(90)90325-L; ROSELLINI RA, 1976, B PSYCHONOMIC SOC, V7, P251, DOI 10.3758/BF03337180; RUSSELL DH, 1974, J NEUROBIOL, V5, P349, DOI 10.1002/neu.480050406; Sapolsky, 1996, Stress, V1, P1, DOI 10.3109/10253899609001092; SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X; SCHLESINGER MJ, 1994, PEDIATR RES, V36, P1; SCHUBER F, 1989, BIOCHEM J, V260, P1; SCHUBERT T, 1991, PSYCHOPHARMACOLOGY, V104, P45, DOI 10.1007/BF02244552; SEILER N, 1985, NEUROCHEM RES, V10, P529, DOI 10.1007/BF00964656; Seiler N, 1991, Prog Drug Res, V37, P107; Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SINGH SS, 1995, LIFE SCI, V57, P685, DOI 10.1016/0024-3205(95)00320-6; Soliman KFA, 1997, LIFE SCI, V60, P2383, DOI 10.1016/S0024-3205(97)00298-1; Sparapani M, 1997, BRAIN RES, V765, P164, DOI 10.1016/S0006-8993(97)00656-2; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TIZABI Y, 1989, NEUROSCI LETT, V105, P177, DOI 10.1016/0304-3940(89)90033-5; UMEMOTO S, 1994, NEUROSCI LETT, V167, P101, DOI 10.1016/0304-3940(94)91037-5; Wang SY, 1996, J NEUROSCI, V16, P836; WEISS JM, 1981, BRAIN RES REV, V3, P167, DOI 10.1016/0165-0173(81)90005-9; WEISS JM, 1975, PSYCHOSOM MED, V37, P522, DOI 10.1097/00006842-197511000-00006; WILLNER P, 1990, PHARMACOL THERAPEUT, V45, P425, DOI 10.1016/0163-7258(90)90076-E; WSTRARKMAN MN, 1999, BIOL PSYCHOL, V45, P1595; YOUNG LT, 1991, BRAIN RES, V553, P323, DOI 10.1016/0006-8993(91)90843-K; ZOLI M, 1991, NEUROSCI LETT, V132, P225, DOI 10.1016/0304-3940(91)90307-F	84	62	64	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	OCT	2003	23	4-5					637	649		10.1023/A:1025036532672			13	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	708UX	WOS:000184589000017	14514021				2021-06-18	
J	Tuzson, AE; Granata, KP; Abel, MF				Tuzson, AE; Granata, KP; Abel, MF			Spastic velocity threshold constrains functional performance in cerebral palsy	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	7th Annual Meeting of the Gait-and-Clinical-Movement-Analysis-Society	APR 17-20, 2002	CHATTANOOGA, TENNESSEE	Gait & Clin Movement Anal Soc		cerebral palsy; gait; muscle spasticity; rehabilitation	MODIFIED ASHWORTH SCALE; STRETCH REFLEX THRESHOLD; TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; MUSCLE SPASTICITY; MOVEMENT; RELIABILITY; EXCITABILITY; CHILDREN; ELBOW	Objectives: To evaluate a quantitative, velocity-based assessment of spasticity in the quadriceps and hamstrings muscles of children with cerebral palsy (CP) and to show the effects of spasticity in constraining knee velocities during fast gait. Design: A quantitative comparison of neuromuscular and biomechanical performance in patients with CP and controls without CP. Setting: Movement analysis laboratory within a university clinical referral center. Participants: A convenience sample of 18 ambulatory patients with CP and 11 control subjects without CP. Interventions: Not applicable. Main Outcome Measures: Spastic threshold velocity recorded from electromyographic response during passive isovelocity knee movement was compared with knee angular velocity during fast walking, Gross Motor Function Measure (GMFM) scores. and Ashworth Scale score. Results: Patients with measurable spasticity showed slower peak knee angular velocity during walking than patients without spasticity (P<.005). A significant correlation existed between spastic threshold velocity and peak knee angular velocity during fast walking (r=.85, P<.001). Spastic threshold velocity correlated significantly with GMFM (r=.58, P<.05) but not with Ashworth score. Conclusions: The velocity dependency of spasticity can be measured by electromyograph and dynamometer to determine spastic threshold velocity. Spastic threshold velocity correlated with limitations in joint angular velocity during walking and functional performance.	Univ Virginia, Kluge Childrens Rehabil Ctr, Mot Anal & Motor Performance Lab, Charlottesville, VA USA	Granata, KP (corresponding author), Virginia Polytech Inst & State Univ, Dept Engn Sci & Mech, Musculoskeletal Biomech Lab, 219 Norris Hall 0219, Blacksburg, VA 24061 USA.				NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA092680] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD039631-050001, HD-99-006-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039631] Funding Source: NIH RePORTER		Abel MF, 1996, J PEDIATR ORTHOPED, V16, P753, DOI 10.1097/01241398-199611000-00010; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; ALLISON SC, 1995, J NEUROL, V242, P699, DOI 10.1007/BF00866923; BERMAN B, 1990, AM J OCCUP THER, V44, P511, DOI 10.5014/ajot.44.6.511; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; CAMPBELL SK, 1992, DIPLEGIC CHILD : EVALUATION AND MANAGEMENT, P221; CORCOS DM, 1986, BRAIN, V109, P1043, DOI 10.1093/brain/109.5.1043; Damiano DL, 2002, DEV MED CHILD NEUROL, V44, P112, DOI 10.1017/S0012162201001761; Engsberg JR, 1996, ARCH PHYS MED REHAB, V77, P594, DOI 10.1016/S0003-9993(96)90301-9; FELLOWS SJ, 1994, ANN NEUROL, V36, P397, DOI 10.1002/ana.410360311; GOLDKAMP O, 1984, ARCH PHYS MED REHAB, V65, P232; Haas BM, 1996, SPINAL CORD, V34, P560, DOI 10.1038/sc.1996.100; Jobin A, 2000, DEV MED CHILD NEUROL, V42, P531, DOI 10.1017/S0012162200001018; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; KNUTSSON E, 1980, SCAND J REHABIL MED, V12, P93; KUMAN KC, 1994, NEW ENGL J MED, V330, P188; LANCE JW, 1980, NEUROLOGY, V30, P1303, DOI 10.1212/WNL.30.12.1303; LEVIN MF, 1994, BRAIN RES, V657, P23, DOI 10.1016/0006-8993(94)90949-0; LIN JP, 1994, DEV MED CHILD NEUROL, V36, P116; LIN JP, 1994, DEV MED CHILD NEUROL, V36, P290; Malouin F, 1997, SCAND J REHABIL MED, V29, P147; McGeer T., 1990, INT J ROBOT RES, V9, P68, DOI DOI 10.1177/027836499000900206); Pandyan AD, 2001, CLIN BIOMECH, V16, P859, DOI 10.1016/S0268-0033(01)00084-5; PARK TS, 1992, NEW ENGL J MED, V326, P745; Phillips CA, 1997, COMPUT BIOL MED, V27, P309, DOI 10.1016/S0010-4825(97)00007-3; Priebe MM, 1996, ARCH PHYS MED REHAB, V77, P713, DOI 10.1016/S0003-9993(96)90014-3; ROSEN MG, 1992, AM J OBSTET GYNECOL, V167, P417, DOI 10.1016/S0002-9378(11)91422-7; Russell D., 1993, GROSS MOTOR FUNCTION; THILMANN AF, 1991, BRAIN, V114, P233	30	62	63	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2003	84	9					1363	1368		10.1016/S0003-9993(03)00199-0			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	718WT	WOS:000185170000017	13680575	Green Accepted			2021-06-18	
J	Francisco, GE; Boake, C				Francisco, GE; Boake, C			Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: A preliminary study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	North American Stroke Meeting	AUG 15-18, 2001	SAN DIEGO, CA			cerebrovascular accident; drug therapy; muscle spasticity; rehabilitation; walking	UPPER EXTREMITY SPASTICITY; TRAUMATIC BRAIN-INJURY; BOTULINUM TOXIN; MOTOR CONTROL; STROKE; GAIT; HYPERTONIA; RECOVERY; INFUSION; TIZANIDINE	Objective: To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors. Design: Case series. Setting: Tertiary care center. Participants: Ten adults with poststroke hemiparesis who were ambulatory at the time of pump implantation. Interventions: Implantation of ITB pump after inadequate control of spasticity with other interventions. Time from stroke onset to implantation averaged 28.6 months (range, 9-55mo). Main Outcome Measures: Customary walking speed was measured from the time required to walk 50ft (15m) at a self-selected pace. Evaluators rated spastic hypertonia and functional mobility. Results: Statistically significant improvements occurred in walking speed, functional mobility ratings, and spasticity (P<.05) at a follow-up interval that averaged 8.9 months. Mean walking speed over 50ft improved from 36.6 to 52cm/s. Mean Modified Ashworth Scale scores in the muscles of the affected lower limb improved from 2.0 to 0.4. Normal muscle strength (5/5) was preserved in the unaffected limbs. Conclusions: This preliminary study suggests that ITB therapy, in combination with physical therapy, may improve walking speed and functional mobility in ambulatory individuals with poststroke spastic hemiplegia. (C) 2003 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Houston, TX USA; Inst Rehabil & Res, Houston, TX USA	Francisco, GE (corresponding author), 1333 Moursund, Houston, TX 77030 USA.	francg@tirr.tmc.edu					ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; [Anonymous], 1997, GUID UN DAT SET MED; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BORENSTEIN M, 1997, POWER PRECISION; BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Francisco GE, 2002, AM J PHYS MED REHAB, V81, P355, DOI 10.1097/00002060-200205000-00007; FRANCISCO GE, 2001, ARCH PHYS MED REHAB, V82, pA1335; Gelber DA, 2001, STROKE, V32, P1841, DOI 10.1161/01.STR.32.8.1841; Gerszten PC, 1997, PEDIATR NEUROSURG, V27, P40, DOI 10.1159/000121223; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; Hesse S, 1996, STROKE, V27, P455, DOI 10.1161/01.STR.27.3.455; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; KNUTSSON E, 1979, BRAIN, V102, P405, DOI 10.1093/brain/102.2.405; Lamontagne A, 2001, ARCH PHYS MED REHAB, V82, P1696, DOI 10.1053/apmr.2001.26810; LATASH ML, 1990, J NEUROSURG, V72, P388, DOI 10.3171/jns.1990.72.3.0388; Meythaler JA, 2001, ARCH PHYS MED REHAB, V82, P1155, DOI 10.1053/apmr.2001.25141; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; PARKE B, 1989, ARCH PHYS MED REHAB, V70, P30; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; RICHARDS CL, 1996, GAIT POSTURE, V4, P149; RICHARDS CL, 1995, GAIT ANAL THEORY APP, P355; SAHRMANN SA, 1977, ANN NEUROL, V2, P460, DOI 10.1002/ana.410020604; Shiavi R, 1987, J Rehabil Res Dev, V24, P24; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Sylvester A, 2001, NEUROLOGY, V56, pA26; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; YOUNG RR, 1981, NEW ENGL J MED, V304, P28	34	62	65	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2003	84	8					1194	1199		10.1016/S0003-9993(03)00134-5			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	709LQ	WOS:000184627000015	12917859				2021-06-18	
J	Cross, NE; Glantz, MJ				Cross, NE; Glantz, MJ			Neurologic complications of radiation therapy	NEUROLOGIC CLINICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TEMPORAL-LOBE NECROSIS; INDUCED BRAIN-INJURY; INDUCED OPTIC NEUROPATHY; LONG-TERM SURVIVORS; BREAST-CANCER; MALIGNANT GLIOMAS; CEREBRAL NECROSIS; BRACHIAL-PLEXUS; NERVOUS-SYSTEM	Radiation therapy is a mainstay of cancer treatment, particularly for patients with nervous system tumors. Like most cancer treatments, radiation is nonspecifically cytotoxic. As a result, when radiation therapy is used to treat primary or metastatic nervous system cancers or non-nervous system malignancies located close to neural structures (eg, head and neck cancers or mediastinal Hodgkin disease), treatment must be carefully crafted and doses and fraction sizes curtailed to prevent injury to the adjacent normal nervous system. A dramatic example of radiation-related nervous system injury, cerebral radionecrosis, was originally described in 1930, soon after radiation was first used therapeutically for brain tumors [1]. Since that time, a spectrum of injuries involving central and peripheral nervous system structures has been identified. Despite this heightened awareness, the neurologic complications of radiation therapy continue to occur because individual tolerances to radiation are variable, safe radiation thresholds are not precisely known (and may be altered by concurrent chemotherapy, pre-existing disease, and variations in tumor anatomy), and intentional "overdoses" may be given with curative or long-term palliative intent. The incidence of radiation-related nervous system injury seems to be increasing as conventional radiation therapy techniques are being applied more aggressively, new approaches (such as hyperfractionated radiation therapy, concurrent chemo- and radiotherapy, and radiosurgery) are becoming commonplace, and patients are surviving longer. Accurate diagnosis based on clinical manifestations is critical to exclude other potentially treatable total doses, higher fraction size, and larger volumes of treated nervous system [2]. Among the acute complications, acute radiation encephalopathy is now uncommon because of careful radiation treatment planning and the judicious use of corticosteroids. In contrast, fatigue and other nonspecific side effects associated with conventional and stereotactic cranial irradiation (Box 1) occur in the majority of patients. Except for subacute myelopathy, which is seen in up to 15% of patients treated with mantle irradiation for Hodgkin disease, the subacute complications of nervous system irradiation are also uncommon. In contrast to the acute and subacute complications of radiation, late radiation effects are relatively common. Delayed cerebral radionecrosis occurs in approximately 5% of patients receiving more than 5000 cGy of cranial irradiation, although the actual incidence is dose and fraction size dependent (Fig. 1A, B; Fig. 2A, B). Hypertension, diabetes, concomitant chemotherapy (particularly with known radiosensitizing agents) [3-7], accelerated hyperfractionated radiation [8], stereotactic radiosurgery, and interstitial brachytherapy increase the frequency and accelerate the time course of this form of late-radiation-related injury. Up to 20% of patients receiving stereotactic radiosurgery [9] and as many as 80% of patients undergoing interstitial brachytherapy develop symptomatic radionecrosis, usually 3 to 12 months after treatment [10]. Radiation-related white matter changes are extremely common on CT and MRI scans [11,12], and as many as 20% of patients with these radiographic correlates of diffuse late brain injury develop frank radiation-induced dementia [ 13] (Fig. 3A-D). The incidence is greatest in patients receiving whole-brain radiation therapy with fractions greater than 200 cGy and in patients surviving more than I year. Concurrent methotrexate or nitrosourea chemotherapy may increase the risk. Subtle, nonprogressive personality and cognitive changes are even more frequent and are more pronounced in children and in those over 60 years of age. The manifestations of radiation-induced endocrine dysfunction are often subtle and difficult to distinguish from other treatment- and tumor-related with regard to prognosis and therapeutic options, and competing diagnoses with very different natural histories and therapies often mask or mimic the signs and symptoms of radiation-related nervous system injury. The ability to efficiently negotiate this complicated differential diagnostic landscape allows for early diagnosis of tumor recurrence or an alternative etiology, prompt institution of appropriate therapy, avoidance of unnecessary diagnostic studies, and confident prognostication for patients and families. Even after the diagnosis of a radiation-related complication is made, continued vigilance for additional sites or manifestations of radiation injury is mandatory. Meanwhile, further research into treatment, prevention, and the causes of individual susceptibility to radiation injury are essential.	Univ Massachusetts, Dept Med, Berkshire Med Ctr, Pittsfield, MA 01201 USA; Stiefel Res Inst, Oak Hill, NY 12460 USA	Glantz, MJ (corresponding author), Univ Massachusetts, Dept Med, Berkshire Med Ctr, 725 N St, Pittsfield, MA 01201 USA.	mjg@massmed.org					Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Akiyama K, 2001, NEUROL MED-CHIR, V41, P590, DOI 10.2176/nmc.41.590; Arlt W, 1997, NEUROLOGY, V49, P498, DOI 10.1212/WNL.49.2.498; ARMSTRONG C, 1995, J CLIN ONCOL, V13, P2263, DOI 10.1200/JCO.1995.13.9.2263; ARONEN HJ, 1995, ACTA RADIOL, V36, P520; ATKINSON JLD, 1989, NEUROSURGERY, V24, P171, DOI 10.1227/00006123-198902000-00004; Belka C, 2001, BRIT J CANCER, V85, P1233, DOI 10.1054/bjoc.2001.2100; BERGER PS, 1977, CANCER, V40, P152, DOI 10.1002/1097-0142(197707)40:1<152::AID-CNCR2820400125>3.0.CO;2-E; BEYER RA, 1986, NEUROLOGY, V36, P1173, DOI 10.1212/WNL.36.9.1173; BURGER PC, 1979, CANCER, V44, P1256, DOI 10.1002/1097-0142(197910)44:4<1256::AID-CNCR2820440415>3.0.CO;2-T; CHANG SM, 1995, NEUROSURGERY, V36, P685, DOI 10.1227/00006123-199504000-00007; Cheng KM, 2001, J NEURO-ONCOL, V51, P143, DOI 10.1023/A:1010631112015; Chong VFH, 2001, EUR RADIOL, V11, P317, DOI 10.1007/s003300000548; Chuba PJ, 1997, CANCER-AM CANCER SOC, V80, P2005, DOI 10.1002/(SICI)1097-0142(19971115)80:10<2005::AID-CNCR19>3.0.CO;2-0; CONSTINE LS, 1993, NEW ENGL J MED, V328, P87, DOI 10.1056/NEJM199301143280203; CORN BW, 1994, CANCER, V74, P2828, DOI 10.1002/1097-0142(19941115)74:10<2828::AID-CNCR2820741014>3.0.CO;2-K; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; DICHIRO G, 1988, AM J ROENTGENOL, V150, P189, DOI 10.2214/ajr.150.1.189; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; FELDMANN E, 1986, ARCH NEUROL-CHICAGO, V43, P1227, DOI 10.1001/archneur.1986.00520120011009; FENKETASUBRAMAN.N, 2001, NEUROLOGY S3, V56, pA37; FIKE JR, 1995, INT J RADIAT ONCOL, V32, P1035, DOI 10.1016/0360-3016(95)00030-3; FISHER AW, 1930, DTSCH Z CHIR, V227, P475; Fouladi M, 2000, J CLIN ONCOL, V18, P824, DOI 10.1200/JCO.2000.18.4.824; Gavazzi C, 2001, LANCET, V357, P1410, DOI 10.1016/S0140-6736(00)04565-7; GERARD JM, 1989, NEUROLOGY, V39, P450, DOI 10.1212/WNL.39.3.450; GLANTZ MJ, 1994, NEUROLOGY, V44, P2020, DOI 10.1212/WNL.44.11.2020; GOLDWEIN JW, 1987, MED PEDIATR ONCOL, V15, P89, DOI 10.1002/mpo.2950150208; GROSSMAN H, 1994, NEUROPSY NEUROPSY BE, V7, P125; GUTIN PH, 1991, INT J RADIAT ONCOL, V21, P601, DOI 10.1016/0360-3016(91)90676-U; GUY J, 1991, J NEUROSURG, V74, P426, DOI 10.3171/jns.1991.74.3.0426; Hallahan DE, 1999, ONCOLOGY-NY, V13, P71; Hill JM, 1998, CANCER-AM CANCER SOC, V82, P208; HOCHBERG FH, 1980, NEUROLOGY, V30, P172, DOI 10.1212/WNL.30.2.172; HOROWITZ SL, 1983, CAN J NEUROL SCI, V10, P56, DOI 10.1017/S0317167100044589; HUDGINS PA, 1992, AM J NEURORADIOL, V13, P235; Jenkin D, 1998, MED PEDIATR ONCOL, V31, P506, DOI 10.1002/(SICI)1096-911X(199812)31:6<506::AID-MPO7>3.3.CO;2-O; Karlsson P, 1998, RADIAT RES, V150, P357, DOI 10.2307/3579984; Kilgore S, 2001, NEUROLOGY, V56, pA409; KIMURA H, 1995, INT J RADIAT ONCOL, V33, P627, DOI 10.1016/0360-3016(95)00205-D; KLINE LB, 1985, OPHTHALMOLOGY, V92, P1118; KORI SH, 1981, NEUROLOGY, V31, P45, DOI 10.1212/WNL.31.1.45; Kumar AJ, 2000, RADIOLOGY, V217, P377, DOI 10.1148/radiology.217.2.r00nv36377; Larson JJ, 1998, J NEUROSURG, V88, P51, DOI 10.3171/jns.1998.88.1.0051; LASKIN WB, 1988, CANCER-AM CANCER SOC, V62, P2330, DOI 10.1002/1097-0142(19881201)62:11<2330::AID-CNCR2820621113>3.0.CO;2-2; LEE AWM, 1988, CANCER-AM CANCER SOC, V61, P1535, DOI 10.1002/1097-0142(19880415)61:8<1535::AID-CNCR2820610809>3.0.CO;2-E; Lee AWM, 2002, INT J RADIAT ONCOL, V53, P75, DOI 10.1016/S0360-3016(02)02711-6; LEQUANG C, 1989, HAND CLIN, V5, P23; Levin N, 2001, NEUROLOGY, V56, pA476; Little MP, 1998, INT J CANCER, V78, P269, DOI 10.1002/(SICI)1097-0215(19981029)78:3<269::AID-IJC1>3.0.CO;2-T; LOFTUS CM, 1987, ARCH NEUROL-CHICAGO, V44, P711, DOI 10.1001/archneur.1987.00520190023011; Loning L, 2000, BLOOD, V95, P2770, DOI 10.1182/blood.V95.9.2770.009k16_2770_2775; MACK EE, 1993, J NEUROSURG, V79, P28, DOI 10.3171/jns.1993.79.1.0028; Malone S, 2000, INT J RADIAT ONCOL, V47, P185, DOI 10.1016/S0360-3016(99)00554-4; MARKS JE, 1985, PROG EXP TUMOR RES, V29, P210; Meyers CA, 2000, ONCOLOGY-NY, V14, P75; MURROS KE, 1989, ARCH NEUROL-CHICAGO, V46, P449, DOI 10.1001/archneur.1989.00520400109029; MUSA BS, 1995, BRIT J NEUROSURG, V9, P629, DOI 10.1080/02688699550040918; O'Connor MM, 2000, NEUROSURGERY, V46, P138; OLDFIELD EH, 1990, J NEUROSURG, V72, P737, DOI 10.3171/jns.1990.72.5.0737; OLSEN NK, 1993, INT J RADIAT ONCOL, V26, P43, DOI 10.1016/0360-3016(93)90171-Q; PAYNE R, 1986, NEUROLOGY, V36, P329; Peacock J, 2000, RADIOTHER ONCOL, V55, P173, DOI 10.1016/S0167-8140(00)00173-0; Peters LJ, 1996, CANCER, V77, P2379, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2379::AID-CNCR29>3.3.CO;2-6; PRATT RA, 1977, SURG NEUROL, V7, P117; Rauhut F, 2002, ACTA NEUROCHIR, V144, P37, DOI 10.1007/s701-002-8272-8; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; Rose SR, 1999, J CLIN ENDOCR METAB, V84, P4472, DOI 10.1210/jc.84.12.4472; ROSENBLUM MK, 1989, J NEURO-ONCOL, V7, P269; ROTTENBERG DA, 1977, ANN NEUROL, V1, P339, DOI 10.1002/ana.410010406; Russo C, 1999, INT J RADIAT ONCOL, V44, P85, DOI 10.1016/S0360-3016(98)00514-8; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; Schagen SB, 2001, J NEURO-ONCOL, V51, P159, DOI 10.1023/A:1010635229762; SCHULTHEISS TE, 1988, INT J RADIAT ONCOL, V14, P27, DOI 10.1016/0360-3016(88)90046-6; SCHULTHEISS TE, 1992, BRIT J RADIOL, V65, P737, DOI 10.1259/0007-1285-65-777-737; SCHWARTZ RB, 1991, AM J NEURORADIOL, V12, P1187; SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Thiessen B, 1998, ARCH NEUROL-CHICAGO, V55, P705, DOI 10.1001/archneur.55.5.705; THOMAS JE, 1985, NEUROLOGY, V35, P1; Tikka T, 2001, J NEUROCHEM, V78, P1409, DOI 10.1046/j.1471-4159.2001.00543.x; TSANG RW, 1993, CANCER-AM CANCER SOC, V72, P2227, DOI 10.1002/1097-0142(19931001)72:7<2227::AID-CNCR2820720727>3.0.CO;2-I; Tsui EYK, 2001, EUR J RADIOL, V39, P133, DOI 10.1016/S0720-048X(01)00328-X; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Walter AW, 1998, J CLIN ONCOL, V16, P3761, DOI 10.1200/JCO.1998.16.12.3761; WALTHER PJ, 1987, CANCER, V60, P2170, DOI 10.1002/1097-0142(19871101)60:9<2170::AID-CNCR2820600909>3.0.CO;2-N; Wehbe T, 1998, J NEURO-ONCOL, V39, P245, DOI 10.1023/A:1005710710418; WEN PY, 1994, CANCER-AM CANCER SOC, V73, P3029, DOI 10.1002/1097-0142(19940615)73:12<3029::AID-CNCR2820731222>3.0.CO;2-4; WILSON CB, 1992, CLIN NEUR, V38, P49; ZIMMERMAN CF, 1990, AM J OPHTHALMOL, V110, P389, DOI 10.1016/S0002-9394(14)77019-9	92	62	65	0	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2003	21	1					249	+	PII S0733-8619(02)00031-2	10.1016/S0733-8619(02)00031-2			31	Clinical Neurology; Neurosciences	Neurosciences & Neurology	641EK	WOS:000180731700011	12690652				2021-06-18	
J	Beghi, E				Beghi, E			Overview of studies to prevent posttraumatic epilepsy	EPILEPSIA			English	Article						epilepsy; prophylaxis; brain injury; anticonvulsant drug; clinical trial	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC EPILEPSY; ANTIEPILEPTIC DRUGS; BRAIN INJURY; HEAD-INJURY; SEIZURES; CARBAMAZEPINE; PROPHYLAXIS; FAILURE; TRIALS	Purpose: Prevention of posttraumatic epilepsy (PTE) is of primary importance to reduce the degree of functional morbidity following traumatic brain injury (TBI). However, the effects of antiepileptic drugs (AEDs) in patients with TBI must be assessed separately in terms of prevention and control of provoked seizures (which include immediate and early posttraumatic seizures) and prevention of subsequent unprovoked seizures (late posttraumatic seizures or PTE). Methods: Potential mechanisms for prevention of epileptogenesis as well as reports and systematic reviews were evaluated to determine strategies and results of attempts to reduce or prevent the development of epilepsy following TBI. Results: In observational studies, after a period ranging from 6 months to 13 years, the proportion of cases developing seizures was 0-10% in patients receiving treatment compared to 2-50% in those who were left untreated. In randomized clinical trials, the difference between active treatment [phenytoin (PHT), phenobarbital, or carbamazepine (CBZ)} and placebo was less remarkable after a follow-up ranging from 3 to 60 months and was virtually lacking for the prevention of PTE. In a Cochrane systematic review of 890 patients from 10 RCTs assessing PHT or CBZ, the pooled relative risk (RR) for prevention of early seizures was 0.33 (95% Cl 0.21-0.52). By contrast, the RR for prevention of late seizures was 1.28 (95% Cl 0.90-1.81). Mortality and neurological disability were similar in the two treatment groups. The use of PHT was followed by an increased (nonsignificant) risk of skin rashes. In addition, cognitive performance was significantly affected by PHT in severely injured patients at 1 month and treatment withdrawal was followed by improvement in cognitive function. Conclusions: The failure to influence the risk of PTE in studies of patients with TBI are similar to findings of meta-analysis of randomized clinical trials on seizure prevention in other conditions, such as febrile seizures, cerebral malaria, craniotomy, and excessive alcohol intake. For these reasons, the prophylactic use of AEDs should be short-lasting and limited to the prevention of immediate and early seizures. Chronic treatment should be considered only after a diagnosis of PTE.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Milano Bicocca, Epilepsy Ctr, Monza, Italy	Beghi, E (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	beghi@marionegri.it	Beghi, Ettore/AAA-7426-2020	Beghi, Ettore/0000-0003-2542-0469			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1993, EPILEPSIA, V34, P592; BIRKMAYER W, 1951, WIEN KLIN WOCHENSCHR, V63, P603; Brunbech L, 2002, DRUGS, V62, P593, DOI 10.2165/00003495-200262040-00004; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; COLLINS MA, 1986, ALKALOIDS, V27, P323; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Hernandez TD, 1997, TRENDS PHARMACOL SCI, V18, P59, DOI 10.1016/S0165-6147(96)01027-9; Hoff H, 1947, MON PSYCHIATR NEUROL, V114, P105; HOMAN RW, 1987, NEUROLOGY, V37, P1620, DOI 10.1212/WNL.37.10.1620; Jennett B, 1975, EPILEPSY NONMISSILE; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; MURRI L, 1992, ITAL J NEUROL SCI, V13, P755, DOI 10.1007/BF02229161; MURRI L, 1980, ITAL J NEUROL SCI, V1, P225; MUSICCO M, 1993, NEUROLOGY, V43, P478; PECHADRE JC, 1991, PRESSE MED, V20, P841; PRICE D, 1980, ROYAL SOC MED INT C, P23; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; Schiller NG, 1997, IDENTITIES-GLOB STUD, V4, P1; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; SMITH DB, 1987, EPILEPSIA, V28, pS50, DOI 10.1111/j.1528-1157.1987.tb05778.x; Temkin Nancy R., 1998, V76, P179; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; TEMKIN NR, EPILEPSIA S10, V44, P18; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	41	62	66	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2003	44			10			21	26		10.1046/j.1528-1157.44.s10.1.x			6	Clinical Neurology	Neurosciences & Neurology	733YK	WOS:000186028100005	14511391	Bronze			2021-06-18	
J	McMillan, T; Robertson, IH; Brock, D; Chorlton, L				McMillan, T; Robertson, IH; Brock, D; Chorlton, L			Brief mindfulness training for attentional problems after traumatic brain injury: A randomised control treatment trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEVERE HEAD-INJURY; REHABILITATION; FAILURES; QUESTIONNAIRE; DEFICITS; WORK	A mindfulness meditation technique has been shown to be effective in reducing self-reports of pain and mood disorder in chronic pain patients. Although a pilot study on traumatic brain injury patients showed improvement in self-report of cognitive impairment, a larger scale randomised control treatment trial found no differences on objective or self-report measures of cognitive function, mood or symptom reporting. Brief exposure to mindfulness meditation cannot be recommended as a treatment technique for traumatic brain injury cases.	Univ Glasgow, Glasgow, Lanark, Scotland; Trinity Coll Dublin, Dublin, Ireland; St Georges Healthcare, Wolfson Neurorehabil Ctr, London, England	McMillan, T (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Dept Psychol Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.			Robertson, Ian H/0000-0001-8637-561X			BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; COUGHLAN AK, 1985, ADULT MEMORY INFORMA; Goldberg D, 1988, USERS GUIDE GEN HLTH; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; Kabat-Zinn J, 1987, CLIN J PAIN, V3, P159, DOI [10.1097/00002508-198703010-00010, DOI 10.1097/00002508-198602030-00004]; KABATZINN J, 1993, MINDFULNESS MEDITA 2; KABATZINN J, 1988, J BEHAV MED, V11, P335; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; McMillan TM, 2001, NEUROBEHAVIOURAL DIS; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Robertson I. H., 1994, TEST EVERYDAY ATTENT; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WILSON C, 1992, NEUROPSYCHOL REHABIL, V2, P193; Wood R L, 1987, Int Disabil Stud, V9, P149; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21	28	62	64	1	32	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR	2002	12	2					117	125		10.1080/09602010143000202			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	535RQ	WOS:000174660400003					2021-06-18	
J	Carnevale, GJ; Anselmi, V; Busichio, K; Millis, SR				Carnevale, GJ; Anselmi, V; Busichio, K; Millis, SR			Changes in ratings of caregiver burden following a community-based behavior management program for persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregiver burden; community-based behavior management program; traumatic brain injury	PERCEIVED STRESS; HEAD-INJURY; DISTRESS; INDIVIDUALS; HEALTH; NEEDS	Objective: This study examines the use of a community-delivered behavior management program for persons with traumatic brain injury and their caregivers and its effect on reduction of ratings of caregiver burden. Design: A control group was compared with an education only and education plus behavior management group with random assignment to conditions. Participants: Total number of participants was 27 persons with brain injury and their caregivers. Main Outcome Measures: Dependent measures were subscales of the Questionnaire on Resources and Stress (QRS) and an adapted version of the Maslach Burnout Inventory (MBI). Results: An analysis of covariance adjusting for baseline burden and stress ratings showed no significant change in these measures associated with treatment. Conclusions: The results are discussed in terms of the potential modifiability of caregiver burden, the small sample size, and the sensitivity of current measures of caregiver stress and burden to detect clinically meaningful change.	Kaiser Inst Rehabil, Dept Psychol Neuropsychol, E Orange, NJ 07018 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA	Carnevale, GJ (corresponding author), Kaiser Inst Rehabil, Dept Psychol Neuropsychol, 240 Cent Ave, E Orange, NJ 07018 USA.						Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; CARNEVALE GJ, 1995, NATURAL SETTING BEHA; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Holroyd J., 1987, MANUAL QUESTIONNAIRE; KAUSAR R, 1996, CLIN REHABIL, V10, P159; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Maslach C., 1996, MASLACH BURNOUT INVE, V3rd ed.; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Moules S, 1999, BRAIN INJURY, V13, P983; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751	25	62	63	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					83	95		10.1097/00001199-200204000-00002			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500002	11909508				2021-06-18	
J	Fujii, D; Ahmed, I				Fujii, D; Ahmed, I			Characteristics of psychotic disorder due to traumatic brain injury: An analysis of case studies in the literature	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; REDUPLICATIVE PARAMNESIA; COMPUTERIZED-TOMOGRAPHY; CHRONIC-SCHIZOPHRENIA; CAPGRAS SYNDROME; SEX-DIFFERENCES; EPILEPSY; DAMAGE; MISIDENTIFICATION; PREVALENCE	The authors analyzed data from 69 published case studies of Psychotic Disorder Due to Traumatic Brain Injury (PDTBI) in order to describe its common characteristics and assist in its diagnosis and differentiation from schizophrenia. The majority of these PDTBI patients were males with onset of symptoms occurring within the first 2 years after moderate to severe head injury. A majority showed abnormalities on MRI/CT and EEG with localization in the frontal and temporal areas. The general presentation included delusions and hallucinations without co-occurring negative symptoms. The findings demonstrate that patients with PDTBI have a profile that distinguishes itself front schizophrenia.	Hawaii State Hosp, Dept Neuropsychol, Kaneohe, HI 96744 USA	Fujii, D (corresponding author), Hawaii State Hosp, Dept Neuropsychol, Kaneohe, HI 96744 USA.	defujii@hsh.health.state.hi.us					ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Ahmed II, 1998, SEMIN CLIN NEUROPSYC, V3, P23; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAMRAH JS, 1991, BRIT J PSYCHIAT, V158, P117, DOI 10.1192/bjp.158.1.117; BARNHILL LJ, 1989, NEUROPSY NEUROPSY BE, V2, P211; BASSO A, 1982, CORTEX, V18, P469, DOI 10.1016/S0010-9452(82)80044-0; BENSON DF, 1990, SCHIZOPHRENIA BULL, V16, P403, DOI 10.1093/schbul/16.3.403; BIENENFELD D, 1989, J CLIN PSYCHIAT, V50, P68; BOUVY PF, 1988, ACTA PSYCHIAT SCAND, V77, P361, DOI 10.1111/j.1600-0447.1988.tb05136.x; BREIER A, 1991, ARCH GEN PSYCHIAT, V48, P239; BUCKLEY P, 1993, AM J PSYCHIAT, V150, P146; Burg JS, 1996, J CLIN PSYCHOL MED S, V3, P243, DOI 10.1007/BF01993910; CAZZULLO CL, 1989, PSYCHIAT RES, V29, P257, DOI 10.1016/0165-1781(89)90055-3; COHEN MAA, 1994, GEN HOSP PSYCHIAT, V16, P141, DOI 10.1016/0163-8343(94)90060-4; Cummings JL, 1985, CLIN NEUROPSYCHIATRY; DALBY JT, 1989, NEUROPSY NEUROPSY BE, V2, P306; DAVISON K, 1969, BRIT J PSYCHIAT, V114, P113; DOLINAR LJ, 1991, PSYCHOSOMATICS, V32, P460, DOI 10.1016/S0033-3182(91)72054-9; DRAKE ME, 1988, PSYCHIAT J U OTTAWA, V13, P36; FEINSTEIN A, 1990, PSYCHOL MED, V20, P793, DOI 10.1017/S0033291700036485; FENTON WS, 1996, HDB MENTAL HLTH EC H, V1, P79; FILLEY CM, 1987, NEUROLOGY, V37, P701, DOI 10.1212/WNL.37.4.701; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; GEREZ M, 1995, BIOL PSYCHIAT, V38, P34, DOI 10.1016/0006-3223(94)00205-H; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GUR RC, 1982, SCIENCE, V217, P659, DOI 10.1126/science.7089587; HAYMAN MA, 1977, BRIT J PSYCHIAT, V130, P68, DOI 10.1192/bjp.130.1.68; Hillbom E., 1960, ACTA PSYCHIATRICA S, VS142, P1; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; IKEMURA Y, 1987, FUNCT NEUROL, V11, P87; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; KENDLER KS, 1982, AM J PSYCHIAT, V139, P1557; KOUFEN DI, 1987, EUR ARCH PSY NEUR SC, V237, P2; LEVINE DN, 1982, NEUROLOGY, V32, P267, DOI 10.1212/WNL.32.3.267; Levy J., 1992, HDB BEHAVIORAL NEURO, P245; LEWIS SW, 1990, BRIT J PSYCHIAT, V157, P16, DOI 10.1192/S0007125000291824; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LOYD DW, 1981, J CLIN PSYCHIAT, V42, P246; MARSHALL JC, 1995, CORTEX, V31, P183, DOI 10.1016/S0010-9452(13)80116-5; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; MCKENNA PJ, 1985, AM J PSYCHIAT, V142, P895; Murai T, 1997, NEUROPSY NEUROPSY BE, V10, P190; NASRALLAH HA, 1983, J CLIN PSYCHIAT, V44, P407; NASRALLAH HA, 1981, PSYCHOSOMATICS, V22, P359; NASRALLAH HA, 1992, TXB NEUROPSYCHIATRY, P621; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; OConnor M, 1996, NEUROPSY NEUROPSY BE, V9, P265; OWENS DGC, 1980, J NEUROL NEUROSUR PS, V43, P1065, DOI 10.1136/jnnp.43.12.1065; Pearlson GD, 1999, BIOL PSYCHIAT, V46, P627, DOI 10.1016/S0006-3223(99)00071-2; PIZZAMIGLIO L, 1985, BRAIN LANG, V25, P213, DOI 10.1016/0093-934X(85)90081-1; PRIGATANO GP, 1988, J HEAD TRAUMA REHAB, V3, P23; PURI BK, 1994, BRIT J PSYCHIAT, V164, P841, DOI 10.1192/bjp.164.6.841; ROGERS M J C, 1992, Brain Injury, V6, P469, DOI 10.3109/02699059209008142; Sabhesan S, 1988, Indian J Psychiatry, V30, P39; Sabhesan S, 1988, Indian J Psychiatry, V30, P177; Sabhesan S, 1990, Indian J Psychiatry, V32, P180; SACCHETTI E, 1992, BRIT J PSYCHIAT, V160, P390, DOI 10.1192/bjp.160.3.390; SANDEL ME, 1993, BRAIN INJURY, V7, P77, DOI 10.3109/02699059309008159; SIGNER SF, 1987, BRIT J PSYCHIAT, V151, P402, DOI 10.1192/bjp.151.3.402; SILVA JA, 1993, CAN J PSYCHIAT, V38, P239, DOI 10.1177/070674379303800401; SILVA JA, 1989, CAN J PSYCHIAT, V34, P728, DOI 10.1177/070674378903400719; STATON RD, 1982, CORTEX, V18, P23, DOI 10.1016/S0010-9452(82)80016-6; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; TISHER PW, 1993, HARVARD REV PSYCHIAT, V1, P219, DOI 10.3109/10673229309017082; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; VITA A, 1991, AM J PSYCHIAT, V148, P1577; VITA A, 1988, SCHIZOPHR RES, V1, P329, DOI 10.1016/0920-9964(88)90046-1; WALDFOGEL S, 1994, BRAIN INJURY, V8, P377, DOI 10.3109/02699059409150988; WESTON MJ, 1971, BRIT J PSYCHIAT, V119, P25, DOI 10.1192/bjp.119.548.25; WHITE AC, 1987, BRIT J PSYCHIAT, V150, P692, DOI 10.1192/bjp.150.5.692; WILL RG, 1988, BRIT J PSYCHIAT, V152, P410, DOI 10.1192/bjp.152.3.410; YOUNG AW, 1992, PSYCHOL MED, V22, P799, DOI 10.1017/S003329170003823X	74	62	64	0	5	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2002	14	2					130	140		10.1176/appi.neuropsych.14.2.130			11	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	555JB	WOS:000175790000002	11983787				2021-06-18	
J	Wade, SL; Borawski, EA; Taylor, HG; Drotar, D; Yeates, KO; Stancin, T				Wade, SL; Borawski, EA; Taylor, HG; Drotar, D; Yeates, KO; Stancin, T			The relationship of caregiver coping to family outcomes during the initial year following pediatric traumatic injury	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Developmental-and-Behavioral-Pediatrics	SEP, 1998	CLEVELAND, OHIO	Soc Dev & Behav Pediat			BRAIN INJURY; PSYCHOLOGICAL ADJUSTMENT; STRESSFUL EVENTS; BREAST-CANCER; HEAD-INJURY; CHILDREN; PREDICTORS; ADAPTATION; RESOURCES; STRATEGIES	This study identified coping strategies associated with caregiver outcomes following pediatric injury and examined injury type as a moderator of coping efficacy. Families of 103 children with traumatic brain injury (TBI) and 71 children with orthopedic injuries were followed prospectively during the initial year postinjury. The groups had comparable preinjury characteristics and hospitalization experiences but differed on neurological insult. In hierarchical regression analyses, acceptance was associated with lower burden and denial was associated with greater distress in both groups. Active coping resulted in higher distress following TBI but not orthopedic injuries. Conversely. the use of humor was related to diminishing distress following TBI but unrelated to distress following orthopedic injuries. Results are discussed in terms of the implications for intervention following TBI.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Case Western Reserve Univ, Dept Epidemiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Ohio State Univ, Columbus Childrens Hosp, Columbus, OH 43210 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH 44106 USA	Wade, SL (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Stancin, Terry/L-7993-2019; Borawski, Elaine/R-9959-2019; Yeates, Keith/AAJ-4223-2020	Borawski, Elaine/0000-0001-7629-6889; Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 R01 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline		Aiken L.S., 1991, MULTIPLE REGRESSION; Aldwin C. M., 1987, J PERS SOC PSYCHOL, V53, P237; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BERESFORD BA, 1994, J CHILD PSYCHOL PSYC, V35, P171, DOI 10.1111/j.1469-7610.1994.tb01136.x; BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877, DOI 10.1037/0022-3514.46.4.877; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Compas BE, 1999, SOOTHING AND STRESS, P229; COMPAS BE, 1997, PL S STRESS, P105; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; FELTON BJ, 1984, J CONSULT CLIN PSYCH, V52, P343, DOI 10.1037/0022-006X.52.3.343; FELTON BJ, 1984, SOC SCI MED, V18, P889, DOI 10.1016/0277-9536(84)90158-8; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FORSYTHE CJ, 1987, COGNITIVE THER RES, V11, P473, DOI 10.1007/BF01175357; HOLAHAN CJ, 1985, J PERS SOC PSYCHOL, V49, P739, DOI 10.1037/0022-3514.49.3.739; JENNETT B, 1975, LANCET, V1, P480; Lazarus R.S., 1984, STRESS APPRAISAL COP; Marks M, 1993, NeuroRehabilitation, V3, P1, DOI 10.3233/NRE-1993-3303; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS RH, 1988, SOC SCI MED, V27, P999, DOI 10.1016/0277-9536(88)90291-2; NEZU AM, 1988, J PERS SOC PSYCHOL, V54, P520, DOI 10.1037/0022-3514.54.3.520; NEZU AM, 1998, HELPING CANC PATIENT; Osowiecki D, 1998, COGNITIVE THER RES, V22, P483, DOI 10.1023/A:1018725716620; Osowiecki DM, 1999, COGNITIVE THER RES, V23, P169, DOI 10.1023/A:1018779228432; PARK C, 1990, J PERS SOC PSYCHOL, V59, P562, DOI 10.1037/0022-3514.59.3.562; PARK CL, 1993, COGNITIVE THER RES, V17, P561, DOI 10.1007/BF01176079; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROEMER L, 1994, J ABNORM PSYCHOL, V103, P467, DOI 10.1037/0021-843X.103.3.467; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V11, P345; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TERRY DJ, 1991, PERS INDIV DIFFER, V12, P1031, DOI 10.1016/0191-8869(91)90033-8; TERRY DJ, 1998, J PERS SOC PSYCHOL, V64, P293; VITALIANO PP, 1990, J PERS SOC PSYCHOL, V59, P582, DOI 10.1037/0022-3514.59.3.582; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Walker LS, 1997, PSYCHOL ASSESSMENT, V9, P392, DOI 10.1037/1040-3590.9.4.392; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	51	62	63	0	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	JUN	2001	69	3					406	415		10.1037//0022-006X.69.3.406			10	Psychology, Clinical	Psychology	470LB	WOS:000170872500006	11495170				2021-06-18	
J	McCrory, P				McCrory, P			Do mouthguards prevent concussion?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							OROFACIAL INJURIES; PREVALENCE; MANAGEMENT; ATTITUDES; WORLD; TEAM		Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia; Univ Melbourne, Inst Brain Res, Parkville, Vic 3052, Australia	McCrory, P (corresponding author), Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019				Banky J, 1999, J Sci Med Sport, V2, P20, DOI 10.1016/S1440-2440(99)80181-9; Blignaut J B, 1987, Br J Sports Med, V21, P5; CARLOS TA, 1938, ORAL HYG, V28, P1580; CHAPMAN P, 1991, AUST J SCI MED SPORT, V22, P113; Chapman P, 1985, AUST J SCI MED SPORT, V3, P170; Chapman P J, 1990, Br J Sports Med, V24, P156; Chapman P J, 1985, Br J Sports Med, V19, P93; Chapman P J, 1988, Br J Sports Med, V22, P98; Chapman P J, 1985, Br J Sports Med, V19, P34; CHAPMAN PJ, 1993, BRIT J SPORT MED, V27, P197, DOI 10.1136/bjsm.27.3.197; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; CHAPMAN PJ, 1989, AUST DENT J, V34, P36, DOI 10.1111/j.1834-7819.1989.tb03003.x; CHAPMAN PJ, 1985, AUST DENT J, V30, P364, DOI 10.1111/j.1834-7819.1985.tb02533.x; CHAPMAN PJ, 1986, AUST J SCI MED SPORT, V18, P3; Chapman PJ, 1985, AUST J SCI MED SPORT, V17, P15; CHAPMAN PJ, 1983, SPORT HLTH, V1, P13; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GENNARELLI TA, 1993, J EMERG MED, V1, P5; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; JACOBS WH, 1938, ORAL HYGIENE, V28, P1152; Jennings D C, 1990, Br J Sports Med, V24, P159; Kay E J, 1990, Br J Sports Med, V24, P271; KERR IL, 1986, SPORTS MED, V3, P415, DOI 10.2165/00007256-198603060-00003; MAESTRELLODEMOYA MG, 1989, J DENT CHILD, V56, P36; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1990, SPORTS NEUROLOGY; REED RV, 1994, BRIT DENT J, V176, P478, DOI 10.1038/sj.bdj.4808485; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; STOKES AN, 1991, NZ J SPORTS MED, V19, P66; WEHNER PJ, 1965, DENT CLIN N AM, P493	32	62	64	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2001	35	2					81	82		10.1136/bjsm.35.2.81			2	Sport Sciences	Sport Sciences	418GC	WOS:000167881700003	11273965	Bronze, Green Published			2021-06-18	
J	Garnett, MR; Corkill, RG; Blamire, AM; Rajagopalan, B; Manners, DN; Young, JD; Styles, P; Cadoux-Hudson, TAD				Garnett, MR; Corkill, RG; Blamire, AM; Rajagopalan, B; Manners, DN; Young, JD; Styles, P; Cadoux-Hudson, TAD			Altered cellular metabolism following traumatic brain injury: A magnetic resonance spectroscopy study	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; magnesium; magnetic resonance spectroscopy; metabolism; phosphorus; proton; traumatic brain injury	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; FREE MAGNESIUM CONCENTRATION; FOCAL CEREBRAL-ISCHEMIA; P-31 NMR-SPECTROSCOPY; MR SPECTROSCOPY; PHOSPHATE-METABOLISM; INTRACRANIAL TUMORS; INITIAL EXPERIENCE; ENERGY-METABOLISM	Experimental studies have reported early reductions in pH, phosphocreatine, and free intracellular magnesium following traumatic brain injury using phosphorus magnetic resonance spectroscopy. Paradoxically, in clinical studies there is some evidence for an increase in the pH in the subacute stage following traumatic brain injury. We therefore performed phosphorus magnetic resonance spectroscopy on seven patients in the subacute stage (mean 9 days postinjury) following traumatic brain injury to assess cellular metabolism. In areas of normal-appearing white matter, the pH was significantly alkaline (patients 7.09 +/- 0.04 [mean +/- SD], controls 7.01 +/- 0.04, p = 0.008), the phosphocreatine to inorganic phosphate ratio (PCr/Pi) was significantly increased (patients 4.03 +/- 1.18, controls 2.64 +/- 0.71, p = 0.03), the inorganic phosphate to adenosine triphosphate ratio (Pi/ATP) was significantly reduced (patients 0.37 +/- 0.10, controls 0.56 +/- 0.19, p = 0.04), and the PCr/ATP ratio was nonsignificantly increased (patients 1.53 +/- 0.29, controls 1.34 +/- 0.19, p = 0.14) in patients compared to controls. Furthermore, the calculated free intracellular magnesium was significantly increased in the patients compared to the controls (patients 0.33 +/- 0.09 mM, controls 0.22 +/- 0.09 mM, p = 0.03). Proton spectra, acquired from similar regions showed a significant reduction in N-acetylaspartate (patients 9.64 +/- 2.49 units, controls 12.84 +/- 2.35 units, p = 0.03) and a significant increase in choline compounds (patients 7.96 +/- 1.02, controls 6.67 +/- 1.01 units, p = 0.03). No lactate was visible in any patient or control spectrum. The alterations in metabolism observed in these patients could not be explained by ongoing ischemia but might be secondary to a loss of normal cellular homeostasis or a relative alteration in the cellular population, in particular an increase in the glial cell density, in these regions.	John Radcliffe Hosp, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Neurosurg, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Neurol, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Anaesthet, Oxford OX3 9DU, England	Garnett, MR (corresponding author), John Radcliffe Hosp, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England.	Mg@bioch.ox.ac.uk	Manners, David N/J-2415-2012; Young, John D/M-9756-2016	Manners, David N/0000-0002-2404-1101; Blamire, Andrew/0000-0002-8749-1257; Young, John Duncan/0000-0002-6838-4835			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; BOTTOMLEY PA, 1986, RADIOLOGY, V160, P763, DOI 10.1148/radiology.160.3.3737915; BOTTOMLEY PA, 1987, ANN NY ACAD SCI, V508, P333, DOI 10.1111/j.1749-6632.1987.tb32915.x; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROWN TR, 1982, P NATL ACAD SCI-BIOL, V79, P3523, DOI 10.1073/pnas.79.11.3523; BRUHN H, 1989, RADIOLOGY, V172, P541, DOI 10.1148/radiology.172.2.2748837; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; CADOUXHUDSON TAD, 1989, BRIT J CANCER, V60, P430, DOI 10.1038/bjc.1989.300; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gillard JH, 1996, AM J NEURORADIOL, V17, P873; GUNTHER T, 1981, ARTERY, V9, P167; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAASE A, 1985, PHYS MED BIOL, V30, P341, DOI 10.1088/0031-9155/30/4/008; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HEINDEL W, 1988, J COMPUT ASSIST TOMO, V12, P907, DOI 10.1097/00004728-198811000-00001; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HUBESCH B, 1990, RADIOLOGY, V174, P401, DOI 10.1148/radiology.174.2.2296651; HUGG JW, 1992, MAGN RESON IMAGING, V10, P227, DOI 10.1016/0730-725X(92)90483-G; HUGG JW, 1992, J CEREBR BLOOD F MET, V12, P734, DOI 10.1038/jcbfm.1992.104; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENNETT B, 1975, LANCET, V1, P480; LANFERMANN H, 1995, RADIOLOGY, V196, P203, DOI 10.1148/radiology.196.1.7784568; LEVINE SR, 1992, RADIOLOGY, V185, P537, DOI 10.1148/radiology.185.2.1410369; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MINTOSH TK, 1988, J NEUROTRAUM, V5, P17; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOON RB, 1973, J BIOL CHEM, V248, P7276; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; NOAT G, 1970, EUR J BIOCHEM, V13, P347, DOI 10.1111/j.1432-1033.1970.tb00937.x; OTTO M, 1974, EUR J BIOCHEM, V49, P169, DOI 10.1111/j.1432-1033.1974.tb03822.x; Pearl GS, 1998, CLIN LAB MED, V18, P39; RANGO M, 1990, ANN NEUROL, V28, P661, DOI 10.1002/ana.410280510; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SAPPEYMARINIER D, 1992, RADIOLOGY, V182, P29, DOI 10.1148/radiology.182.1.1727305; SEGEBARTH CM, 1990, MAGN RESON MED, V13, P62, DOI 10.1002/mrm.1910130108; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; van den Boogaart A, 1997, MAGN RESON CHEM, V35, pS146, DOI 10.1002/(SICI)1097-458X(199712)35:13<S146::AID-OMR196>3.0.CO;2-X; VANDENBOOGART A, 1997, USERS GUIDE MAGNETIC; VANDERVEEN JWC, 1988, MAGNET RESON MED, V6, P92, DOI 10.1002/mrm.1910060111; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Welch K M, 1990, Funct Neurol, V5, P21; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	59	62	64	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					231	240		10.1089/08977150151070838			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000001	11284544				2021-06-18	
J	Yeates, KO; Taylor, HG; Barry, CT; Drotar, D; Wade, SL; Stancin, T				Yeates, KO; Taylor, HG; Barry, CT; Drotar, D; Wade, SL; Stancin, T			Neurobehavioral symptoms in childhood closed-head injuries: Changes in prevalence and correlates during the first year postinjury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						closed-head injury; children; neurobehavioral symptoms	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; FAMILY BURDEN; CHILDREN; RELIABILITY; PREDICTORS; SEVERITY; ADOLESCENTS; RECOVERY; VALIDITY	Objective: To examine changes in the prevalence and correlates of neurobehavioral symptoms during the first year following childhood closed-head injuries (CHIs). Methods: Participants included 31 children with severe CHIs, 38 with moderate CHIs, and 53 with orthopedic injuries (Ols). Children and their families were assessed shortly after injury and at 6- and 12-month follow-ups. Parents rated 15 symptoms classified as either cognitive/somatic (C/S) or emotional/behavioral (E/B). Results: Both kinds of symptoms were more common in the CHI groups than in the OI group. C/S symptoms declined in the CHI groups over time, whereas E/B symptoms became relatively more common. Measures of injury severity, children's premorbid behavioral adjustment, and concurrent cognitive functioning predicted C/S symptoms. E/B symptoms were predicted by injury severity, concurrent cognitive functioning soon after the injury, and concurrent parent and family functioning later in time. Both types of symptoms contributed to the prediction of perceived family burden, with the relationships strengthening over time. Conclusions: The findings indicate that the prevalence and correlates of,neurobehavioral symptoms in childhood CHIs vary as a function of symptom type and time since injury.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Univ Cincinnati, Cincinnati, OH 45221 USA; Metrohlth Med Ctr, Cleveland, OH USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 RO1 NS36335] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Delis D, 1994, MANUAL CALIFORNIA VE; Demellweek C, 1998, OX MED PUBL, P207; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DROTAR D, 1995, J CLIN CHILD PSYCHOL, V24, P184, DOI 10.1207/s15374424jccp2402_6; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; JENNETT B, 1975, LANCET, V1, P480; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; MOOS R, 1988, LIFE STRESSORS SOCIA; Moos RH, 1988, J SUBSTANCE ABUSE, V1, P135, DOI DOI 10.1016/S0899-3289(88)80017-8; MYERS JL, 1982, PSYCHOL BULL, V92, P517, DOI 10.1037/0033-2909.92.2.517; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; Sattler J. M., 1992, ASSESSMENT CHILDREN; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wechsler D., 1991, MANUAL WECHSLER INTE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	42	62	62	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	MAR	2001	26	2					79	91		10.1093/jpepsy/26.2.79			13	Psychology, Developmental	Psychology	408KZ	WOS:000167326500002	11181884	Bronze			2021-06-18	
J	Zhang, LY; Yang, KH; King, AI				Zhang, LY; Yang, KH; King, AI			Biomechanics of neurotrauma	NEUROLOGICAL RESEARCH			English	Article						biomechanics; head impact; finite element modeling; traumatic minor brain injury	DIFFUSE AXONAL INJURY; CEREBRAL CONCUSSION; SUBDURAL-HEMATOMA; HEAD-INJURY; PRIMATE; IMPACT; MODEL	This paper reviews the traditional areas of impact biomechanics as they relate to brain injury caused by blunt impact. These areas are injury mechanisms, human response to impact, human tolerance to impact and the use of human surrogates. With the advent of high-speed computers, it is now possible to add computer models to the list of human surrogates that used to be limited to animals and human cadavers. The advantages and shortcomings of current computer models are discussed One of the computer models was used to predict the pressures and shear stresses developed in the brain and the extent of stretch of the bridging veins in the brains of American football players who sustained severe helmet-to-helmet head impact during the game. It was found that increases in intracranial pressure were more dependent on translational acceleration while the primary determinant for the development of shear stresses in the brain is rotational acceleration. Although the current head injury criterion is based almost entirely on translational acceleration, it is recommended that any new criterion should reflect the contribution of both translational and rotational acceleration.	Wayne State Univ, Bioengn Ctr, Detroit, MI 48202 USA	King, AI (corresponding author), Wayne State Univ, Bioengn Ctr, 818 W Hancock, Detroit, MI 48202 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR503534-09] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; BYCROFT GN, 1973, J BIOMECH, V6, P487, DOI 10.1016/0021-9290(73)90007-9; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Ewing C. L., 1975, P 19 STAPP CAR CRASH; Gadd CW, 1966, P 10 STAPP CAR CRASH; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, P 16 STAPP CAR CRASH; Goldsmith W, 1989, P IRCOBI C 1989 SEPT, P1; GRONWALL D, 1975, LANCET, V2, P995; GROSS A G, 1958, J Aviat Med, V29, P725; GURDJIAN ES, 1961, J NEUROSURG, V18, P58, DOI 10.3171/jns.1961.18.1.0058; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Gurdjian ES, 1945, MENT ADV DIS, V24, P28; GURDJIAN ES, 1963, P 7 STAPP CAR CRASH, V35, P470; Hardy CH, 1971, ELASTIC ANAL SKULL; HODGSON VR, 1973, 002 HS801 DOT NAT TE; HODGSON VR, 1969, P 13 STAPP CAR CRASH; Holbourn AHS, 1943, LANCET, V2, P438; Hosey R. R., 1982, FINITE ELEMENTS BIOM, P379; Huston J, 1975, P INT IRCOBI C BIOM, P153; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Lighthall J.W., 1989, P 12 INT TECHN C EXP, P627; LINDENBERG R, 1955, AM J PATHOL, V31, P297; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; LOWENHIELM P, 1975, J BIOMECH, V8, P351, DOI 10.1016/0021-9290(75)90069-X; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Newman J. A., 1999, P INT RESEAR C BIOME, P17; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; OMMAYA AK, 1966, P 10 STAPP CAR CRASH; Ono K., 1980, P 24 STAPP CAR CRASH; Patrick LM, 1963, P 7 STAPP CAR CRASH, V36, P483; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; PRINCERNAILLE Y, 1989, P 33 STAPP CAR CRASH; PUDENZ RH, 1946, J NEUROSURG, V3, P87; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; RUAN J, 1991, P 1 INJ PREV BIOM S, P97; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shelden CH, 1944, J NEUROSURG, V1, P67, DOI 10.3171/jns.1944.1.1.0067; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; STRICH SJ, 1961, LANCET, V2, P443; Tarriere C, 1987, HEAD INJURY MECHANIS, P47; THIBAULT LE, 1989, P 10 INT TECH C EXP; THIBAULT LE, 1985, P 29 STAPP CAR CRASH; Trosseille X., 1992, P 36 STAPP CAR CRASH; UNTERHARNSCHEID.FJ, 1971, P 15 STAPP CAR CRASH; Ward C, 1975, P 19 STAPP CAR CRASH; Ward C, 1980, P 24 STAPP CAR CRASH; Zhou C, 1995, P 39 STAPP CAR CRASH	56	62	63	0	12	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					144	156		10.1179/016164101101198488			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	422DX	WOS:000168104200006	11320593				2021-06-18	
J	Mayer, SA; Commichau, C; Scarmeas, N; Presciutti, M; Bates, J; Copeland, D				Mayer, SA; Commichau, C; Scarmeas, N; Presciutti, M; Bates, J; Copeland, D			Clinical trial of an air-circulating cooling blanket for fever control in critically ill neurologic patients	NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; ACUTE STROKE; BODY-TEMPERATURE; HYPERTHERMIA; WORSENS; CARE; UNIT	Objective: To evaluate the efficacy of an air-circulating cooling blanket for reducing body temperature in febrile neuro-ICU patients treated with acetaminophen. Methods: Two-hundred twenty consecutively admitted neuro-ICU patients whose tympanic membrane temperature reached or exceeded 101 degreesF (38.3 degreesC) were randomly assigned to receive acetaminophen (650 mg every 4 hours) alone (n = 107) or acetaminophen plus air blanket therapy (n = 113). After 24 hours of treatment, the authors compared the proportion of subjects who attained treatment success (T less than or equal to 99 degreesF) or treatment failure (T greater than or equal to 101 degreesF for 2 consecutive hours) using the chi (2) test and the time to reach these endpoints using Kaplan-Meier survival analysis. Main Results: Air blanket therapy resulted in a small increase in the proportion of subjects with treatment success (44% versus 36%, chi (2) p = 0.19, log rank p = 0.10) and a similar small reduction in the proportion of patients with treatment failure (42% versus 53%, chi (2) p = 0.11, log-rank p = 0.21), compared with treatment with acetaminophen alone. Approximately one third of patients in both groups remained febrile after randomization and "failed" after the first 2 hours of treatment. Twelve percent of patients assigned to air blanket therapy refused or were unable to tolerate treatment, compared with 2% of patients treated with acetaminophen alone (p = 0.005). Conclusions: Treatment with an air-circulating cooling blanket did not effectively reduce body temperature in febrile neuro-ICU patients treated with acetaminophen. More effective interventions are needed to maintain normothermia in patients at risk for fever-related brain damage.	Columbia Univ Coll Phys & Surg, Dept Neurol, Div Crit Care Neurol, New York, NY 10032 USA; New York Presbyterian Hosp, Columbia Presbyterian Med Ctr, Dept Nursing, New York, NY USA	Mayer, SA (corresponding author), Neurol Inst, 710 W 168th St,Unit 39, New York, NY 10032 USA.						Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AMEER B, 1977, ANN INTERN MED, V87, P202, DOI 10.7326/0003-4819-87-2-202; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BUSTO R, 1987, J CEREB BLOOD FLOW M, V7, P129; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CLASEN RA, 1974, J NEUROSURG, V41, P576, DOI 10.3171/jns.1974.41.5.0576; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; DONE AK, 1983, AM J MED, V74, P27, DOI 10.1016/0002-9343(83)90525-9; ERICKSON RS, 1993, CRIT CARE MED, V21, P1528, DOI 10.1097/00003246-199310000-00022; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Guyton A. C, 1991, TXB MED PHYSL, P797; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; HOLTZCLAW BJ, 1992, HEART LUNG, V21, P482; ISAACS SN, 1990, AM J MED, V88, P31, DOI 10.1016/0002-9343(90)90124-V; KIELBLOCK AJ, 1986, S AFR MED J, V69, P378; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Klein NC, 1996, INFECT DIS CLIN N AM, V10, P211, DOI 10.1016/S0891-5520(05)70295-6; LEBOVITZ RM, 1975, EPILEPSIA, V16, P215, DOI 10.1111/j.1528-1157.1975.tb06050.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Morgan S P, 1990, J Neurosci Nurs, V22, P19; NEWMAN J, 1985, CAN MED ASSOC J, V132, P641; O'Grady NP, 1998, CRIT CARE MED, V26, P392, DOI 10.1097/00003246-199802000-00046; ODonnell J, 1997, CLIN INFECT DIS, V24, P1208, DOI 10.1086/513660; Poblete B, 1997, BRIT J ANAESTH, V78, P123; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Schmitz T, 1995, Am J Crit Care, V4, P286; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; STEELE RW, 1970, J PEDIATR-US, V77, P824, DOI 10.1016/S0022-3476(70)80242-6; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WEINER JS, 1980, LANCET, V1, P507; WYNDHAM CH, 1959, J APPL PHYSIOL, V14, P771	33	62	67	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 13	2001	56	3					292	298		10.1212/WNL.56.3.292			7	Clinical Neurology	Neurosciences & Neurology	401DK	WOS:000166911700004	11171891				2021-06-18	
J	Bareyre, FM; Saatman, KE; Raghupathi, R; McIntosh, TK				Bareyre, FM; Saatman, KE; Raghupathi, R; McIntosh, TK			Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						fluid-percussion; lesion volume; magnesium chloride; neuroprotection; head injury	SODIUM-CHANNEL BLOCKER; CEREBRAL EDEMA; NEURONAL LOSS; HEAD TRAUMA; CALCIUM; NEUROTOXICITY; ACTIVATION; ANTAGONISM; EFFICACY; DECLINE	The neuroprotective effect of magnesium chloride (MgCl2), a compound previously demonstrated to improve behavioral and neurochemical outcome in several models of experimental brain injury, was evaluated in the present study. Male Sprague-Dawley rats were anesthetized and subjected to lateral fluid-percussion brain injury of moderate severity (2.5-2.8 atm), A cannula was implanted in the left femoral vein and at 1 h following injury, animals randomly received a 15 min i.v. infusion of either MgCl2 (125 mu mol/rat) or saline. A second group of animals received anesthesia, surgery, and either MgCl2 or vehicle to serve as uninjured (sham) controls, Two weeks following brain injury, animals were sacrificed, brains removed, and coronal sections were taken for quantitative analysis of cortical lesion volume and hippocampal CA(3) cell counts. Traumatic brain injury resulted in a lesion in the ipsilateral cortex and loss of pyramidal neurons in the CA3 region of the hippocampus in vehicle-treated animals (p < 0.01 vs. uninjured animals). Administration of MgCl2 significantly reduced the injury-induced damage in the cortex (p < 0.01) but did not alter posttraumatic cell loss in the CA(3) region of the ipsilateral hippocampus, The present study demonstrates that, in addition to its beneficial effects on behavioral outcome, MgCl2 treatment attenuates cortical histological damage when administered following traumatic brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS08803] Funding Source: Medline		Aikawa J., 1981, MAGNESIUM ITS BIOL S; ALTURA B M, 1985, Magnesium, V4, P245; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; CHOI DW, 1987, J NEUROSCI, V7, P357; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GIBSON BL, 1985, NEUROSCI LETT, V57, P13, DOI 10.1016/0304-3940(85)90033-3; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEALTH DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Regan RF, 1998, J NEUROCHEM, V70, P77; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TASSANI V, 1995, BIOCHEM BIOPH RES CO, V207, P661, DOI 10.1006/bbrc.1995.1238; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; Vink R, 1990, Magnes Res, V3, P163; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	64	62	63	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2000	17	11					1029	1039		10.1089/neu.2000.17.1029			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	374KY	WOS:000165345400003	11101206				2021-06-18	
J	Reinert, M; Khaldi, A; Zauner, A; Doppenberg, E; Choi, S; Bullock, R				Reinert, M; Khaldi, A; Zauner, A; Doppenberg, E; Choi, S; Bullock, R			High level of extracellular potassium and its correlates after severe head injury: relationship to high intracranial pressure	JOURNAL OF NEUROSURGERY			English	Article						potassium; glutamate; lactate; cerebral blood flow; severe head injury; intracranial pressure	TRAUMATIC BRAIN INJURY; CORTICAL SPREADING DEPRESSION; NEUROPIL GLIAL-CELLS; CEREBRAL-ISCHEMIA; MITOCHONDRIAL DYSFUNCTION; GLUTAMATE UPTAKE; NEURAL TISSUE; LACTATE; GLUCOSE; RAT	Object. Disturbed ionic and neurotransmitter homeostasis are now recognized as probably the most important mechanisms contributing to the development of secondary brain swelling after traumatic brain injury (TBI). Evidence obtained in animal models indicates that posttraumatic neuronal excitation by excitatory amino acids leads to an increase in extracellular potassium, probably due to ion channel activation. The purpose of this study was therefore to measure dialysate potassium in severely head injured patients and to correlate these results with measurements of intracranial pressure (ICP), patient outcome, and levels of dialysate glutamate and lactate, and cerebral blood flow (CBF) to determine the role of ischemia in this posttraumatic ion dysfunction. Methods. Eighty-five patients with severe TBI (Glasgow Coma Scale Score < 8) were treated according to an intensive ICP management-focused protocol. All patients underwent intracerebral microdialyis. Dialysate potassium levels were analyzed using flame photometry, and dialysate glutamate and dialysate lactate levels were measured using high-performance liquid chromatography and an enzyme-linked amperometric method in 72 and 84 patients, respectively. Cerebral blood flow studies (stable xenon computerized tomography scanning) were performed in 59 patients. In approximately 20% of the patients, dialysate potassium values were increased (dialysate potassium > 1.8 mM) for 3 hours or more. A mean amount of dialysate potassium greater than 2 mM throughout the entire monitoring period was associated with ICP above 30 mm Hg and fatal outcome, as were progressively rising levels of dialysate potassium. The presence of dialysate potassium correlated positively with dialysate glutamate (p < 00001) and lactate (p < 0.0001) levels. Dialysate potassium was significantly inversely correlated with reduced CBF (p = 0.019). Conclusions. Dialysate potassium was increased after TBI in 20% of measurements. High levels of dialysate potassium were associated with increased ICP and poor outcome. The simultaneous increase in dialysate potassium, together with dialysate glutamate and lactate, supports the concept that glutamate induces ionic flux and consequently increases ICP, which the authors speculate may be due to astrocytic swelling. Reduced CBF was also significantly correlated with increased levels of dialysate potassium. This may be due to either cell swelling or altered vasoreactivity in cerebral blood vessels caused by higher levels of potassium after trauma. Additional studies in which potassium-sensitive microelectrodes are used are needed to validate these ionic events more clearly.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.	mreinert@insel.ch	Reinert, Michael/E-4964-2011; Reinert, Michael/AAA-3929-2019	Reinert, Michael/0000-0002-0971-9543	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P012587] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Armstead WM, 1998, AM J PHYSIOL-HEART C, V274, pH1674; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; BALLANYI K, 1990, GLIA, V3, P151, DOI 10.1002/glia.440030302; BALLANYI K, 1987, J PHYSIOL-LONDON, V382, P159, DOI 10.1113/jphysiol.1987.sp016361; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1995, NEUROCHEMICAL MONITO; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; Forsyth R, 1996, DEV NEUROSCI-BASEL, V18, P360, DOI 10.1159/000111429; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HIROTA H, 1995, NEUROL RES, V17, P94, DOI 10.1080/01616412.1995.11740294; HOSSMAN K, 1977, ACTA PHYSL SCAND, V113, P437; JENNETT B, 1975, LANCET, V1, P480; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMPSKI O, 1991, ANN NY ACAD SCI, V633, P306; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; KUFFLER SW, 1967, PROC R SOC SER B-BIO, V168, P1, DOI 10.1098/rspb.1967.0047; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; NICHOLLS JG, 1992, NEURON BRAIN CELLULA; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Schousboe A, 1997, GLIA, V21, P99; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schurr A, 1999, J NEUROSCI, V19, P34; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Sykova E, 1999, GLIA, V25, P56, DOI 10.1002/(SICI)1098-1136(19990101)25:1<56::AID-GLIA6>3.0.CO;2-4; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; TEASDALE G, 1974, LANCET, V2, P81; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WUTTKE WA, 1990, J NEUROPHYSIOL, V63, P1089; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	45	62	65	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2000	93	5					800	807		10.3171/jns.2000.93.5.0800			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	366YL	WOS:000090033800011	11059661				2021-06-18	
J	Painter, TJ; Chaljub, G; Sethi, R; Singh, H; Gelman, B				Painter, TJ; Chaljub, G; Sethi, R; Singh, H; Gelman, B			Intracranial and intraspinal meningeal melanocytosis	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							NEUROCUTANEOUS MELANOSIS; DIAGNOSTIC-CRITERIA; FEATURES; MR	We describe a 35-year-old man with a history of remote closed head injury who presented with new neurologic deficits. A noncontrast head CT scan showed hyperattenuation involving both temporal lobes, frontal lobes, basal meninges, and cerebellum. A subsequent contrast-enhanced MR examination of the brain showed enhancement in the basal cisterns extending into the upper cervical spine and throughout the spinal canal. Gross, histologic, and immunohistochemical analysis revealed meningeal melanocytoma.	Univ Texas, Med Branch, Dept Radiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77550 USA	Chaljub, G (corresponding author), Univ Texas, Med Branch, Dept Radiol, 301 Univ Blvd, Galveston, TX 77555 USA.						AICHNER F, 1982, CANCER-AM CANCER SOC, V50, P1751, DOI 10.1002/1097-0142(19821101)50:9<1751::AID-CNCR2820500918>3.0.CO;2-Q; Alwatban J, 1997, J COMPUT ASSIST TOMO, V21, P38, DOI 10.1097/00004728-199701000-00008; DEMIRCI A, 1995, AM J NEURORADIOL, V16, P603; FAILLACE WJ, 1984, J NEUROSURG, V61, P782, DOI 10.3171/jns.1984.61.4.0782; FOX H, 1964, ARCH DIS CHILD, V39, P508, DOI 10.1136/adc.39.207.508; JELLINGER K, 1988, ACTA NEUROCHIR, V94, P78, DOI 10.1007/BF01406621; LACH B, 1988, NEUROSURGERY, V22, P773, DOI 10.1227/00006123-198804000-00030; LEANEY BJ, 1985, J NEUROSURG, V62, P148, DOI 10.3171/jns.1985.62.1.0148; LITOFSKY NS, 1992, NEUROSURGERY, V31, P945, DOI 10.1227/00006123-199211000-00019; NAUL LG, 1991, AM J NEURORADIOL, V12, P315; Ruelle A, 1996, NEUROSURG REV, V19, P39, DOI 10.1007/BF00346608; TATAGIBA M, 1992, NEUROSURGERY, V31, P958, DOI 10.1227/00006123-199211000-00023; UEMATSU Y, 1992, J NEUROSURG, V76, P705, DOI 10.3171/jns.1992.76.4.0705; Vanzieleghem BD, 1999, AM J NEURORADIOL, V20, P457	14	62	69	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	AUG	2000	21	7					1349	1353					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	369FG	WOS:000165054800033	10954294				2021-06-18	
J	Novack, TA; Dowler, RN; Bush, BA; Glen, T; Schneider, JJ				Novack, TA; Dowler, RN; Bush, BA; Glen, T; Schneider, JJ			Validity of the Orientation Log, relative to the Galveston Orientation and Amnesia Test	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article								Objective: To establish the validity of the Orientation Log (O-Log) by comparison with the Galveston Orientation and Amnesia Test (GOAT). Design: Correlation of daily measures of orientation. Setting: Acute rehabilitation hospital. Subjects: Sixty-eight inpatients receiving rehabilitation following traumatic brain injury (TBI). Primary measures: The O-Log and GOAT. Results: There was a significant correlation between the GOAT and O-Log (r = .901, P < .001). A cutoff of 25 on the O-Log was found to be comparable with the 75 cutoff on the GOAT. The scales were equivalent in measuring duration of posttraumatic amnesia. Conclusions: The O-Log is a valid measure of orientation for people with TBI and offers some advantages in administration over the GOAT.	Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL 35233 USA	Novack, TA (corresponding author), Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, 1717 6th Ave S, Birmingham, AL 35233 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR40364] Funding Source: Medline		Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004	3	62	63	0	2	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2000	15	3					957	961		10.1097/00001199-200006000-00008			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	321FL	WOS:000087445400008	10785625				2021-06-18	
J	Ng, I; Yeo, TT; Tang, WY; Soong, R; Ng, PY; Smith, DR				Ng, I; Yeo, TT; Tang, WY; Soong, R; Ng, PY; Smith, DR			Apoptosis occurs after cerebral contusions in humans	NEUROSURGERY			English	Article						apoptosis; bax; bcl-2; cerebral contusions	TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; SPINAL-CORD INJURY; SEVERE HEAD-INJURY; NEURONAL APOPTOSIS; FRAGMENTED DNA; BCL-2 GENE; IN-VIVO; C-MYC; HYPOTHERMIA	OBJECTIVE: Animal model systems have shown that head trauma can induce cell death in regions of the brain away from the site of the impact via a process of apoptosis. We sought to determine whether there was evidence of cellular apoptosis in clinically collected materials from human head trauma patients, as well as to attempt to determine the pathway by which it may occur. METHODS: Thirty-one sequential specimens of brain tissue excised during emergency craniotomy for evacuation of cerebral contusions with mass effect were examined. Non-necrotic pericontusional tissues were detected in 11 samples. These were examined for the presence of apoptotic cells by the terminal deoxynucleotide transferase-mediated nick end labeling method as well as by immunohistochemistry to detect possible expression of the apoptosis-related genes p53, bcl-2, and bax. RESULTS: Bax expression was detected in all patients, whereas bcl-2 expression was noted in six patients, Terminal deoxynucleotide transferase-mediated nick end labeling-positive cells were noted in eight patients. One instance of p53-positive immunostaining was observed. Patients with bcl-2 expression had a better survival rate than patients in whom no bcl-2 expression was noted (P = 0.01). CONCLUSION: Although necrosis seemed to be the main finding in cerebral contusions, these results support the hypothesis that apoptosis does occur in patients after traumatic brain injury, and this may contribute to the secondary injury processes that are seen with head injury. Patients in whom anti-apoptotic bcl-2 is induced seem to have a better prognosis. This may have important clinical significance in the development of bcl-2 homologs or bax inhibitors to prevent apoptosis.	Tan Tock Seng Hosp, Brain & Spine Ctr, Mol Biol Lab, Singapore 308433, Singapore; Tan Tock Seng Hosp, Dept Neurosurg, Singapore 308433, Singapore	Smith, DR (corresponding author), Tan Tock Seng Hosp, Brain & Spine Ctr, Mol Biol Lab, Singapore 308433, Singapore.		Yeo, Tseng Tsai/U-8864-2017; Smith, Duncan R/C-6891-2011	Smith, Duncan R/0000-0002-6592-9852; Soong, Richie/0000-0002-0152-1225			ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Bauer J, 1995, CURR OPIN IMMUNOL, V7, P839, DOI 10.1016/0952-7915(95)80057-3; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DURE LS, 1995, EXP NEUROL, V133, P207, DOI 10.1006/exnr.1995.1023; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GAVNELI Y, 1992, J CELL BIOL, V119, P493; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Johnstone SA, 1998, ANN ONCOL, V9, P36; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Katoh K, 1996, NEUROSCI LETT, V216, P9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LINDENBERG R, 1971, PATHOLOGY NERVOUS SY, V2, P705; Liu XZ, 1997, J NEUROSCI, V17, P5395; MAJNO G, 1995, AM J PATHOL, V146, P3; MCCORMICK WF, 1983, CLIN NEUROSCIENCES, V3, P241; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1994, CANCER RES, V54, P3131; Moss SF, 1996, DIGEST DIS SCI, V41, P2238, DOI 10.1007/BF02071407; Namura S, 1998, J NEUROSCI, V18, P3659; NEMOTO EM, 1994, J NEUROSURG ANESTH, V6, P220; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; Ogura E, 1999, ONCOL REP, V6, P365; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; RINK A, 1995, AM J PATHOL, V147, P1575; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; SEARLE J, 1982, PATHOL ANNU, V17, P229; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DR, 1996, BRIT J CANCER, V74, P216, DOI 10.1038/bjc.1996.340; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	65	62	80	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2000	46	4					949	956		10.1097/00006123-200004000-00034			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	302HR	WOS:000086360100101	10764270				2021-06-18	
J	Michaels, AJ; Michaels, CE; Zimmerman, MA; Smith, JS; Moon, CH; Peterson, C				Michaels, AJ; Michaels, CE; Zimmerman, MA; Smith, JS; Moon, CH; Peterson, C			Posttraumatic stress disorder in injured adults: Etiology by path analysis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	29th Annual Meeting of the Western-Trauma-Association	FEB 28-MAR 06, 1999	CRESTED BUTTE, COLORADO	Western Trauma Asso			MOTOR-VEHICLE ACCIDENTS; ROAD TRAFFIC ACCIDENTS; TRAUMA PATIENTS; PERITRAUMATIC DISSOCIATION; PSYCHIATRIC CONSEQUENCES; PREDICTORS; PTSD; VETERANS; RECOVERY; EVENTS	Objective: Posttraumatic Stress Disorder (PTSD) impairs outcome from injury. We present a path analysis of factors related to the development of PTSD in injured adults. Methods: A prospective cohort of 250 patients without severe neurotrauma was evaluated by interview during admission and by mailed self-report 6 months later. Data were gathered from the trauma registry (age, injury mechanism, and Injury Severity Score), social history (gender, income, education, and social support), and survey instruments. Baseline assessment used the Michigan Critical Events Perception Scale (peritraumatic dissociation and subjective threat to life), the Life Experience Survey (stressful exposure history), and the SF36 (general and mental health). PTSD at 6 months was identified with the civilian Mississippi Scale for PTSD. Data are listed as mean +/- SEM or percent (%). Path analysis was conducted by linear regression and significant (p < 0.05) variables are shown. Factors are listed with the standardized beta. A negative beta suggests a protective effect. Results: The 176 patients (72%) who completed the 6-month follow-up were 37.7 +/- 0.88 years old; 75% were men; and blunt (70%), penetrating (13.5%), and burn (16.4%) mechanisms caused the injuries. Assault was involved in 14.5% of the cases. Average income was $44,300 +/- 2,700/yr, education was 13.0 +/- 0.15 years, and Injury Severity Score was 13.9 +/- 0.50. A total of 42.3% of the patients developed PTSD. The 39.7% of the variance in PTSD explained by the model was due to intentional injury (beta = 0.27), male gender (beta = -0.21), age (beta = -0.20), peritraumatic dissociation (beta = 0.174), baseline mental health (beta = -0.21), and prior life-threatening illness (beta = -0.29). Peritraumatic dissociation was due to the patient's sense of threat to life (beta = -0.47), and threat was related to Injury Severity Score (beta = 0.2), assault(beta = 0.14), education (beta = -0.15), and age (beta = -0.19). Baseline SF36 mental health was related to social support (beta = 0.27) and income (beta = 0.21). Income was contingent on education (beta = 0.21). Conclusion: PTSD occurred in 42.3% of injured adults 6 months after trauma and was related to assault, dissociation, female gender, youth, poor mental health, and prior illness. By modeling PTSD, we may learn more of the etiology, risk stratification, and potentials for the treatment of this common and important morbidity of injury.	Legacy Emanuel Hosp, Dept Surg, Portland, OR USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Publ Hlth, Ann Arbor, MI 48109 USA	Michaels, AJ (corresponding author), Emanuel Hosp, Trauma Serv, 2801 Gantenbien Ave, Portland, OR 97227 USA.						American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BREMNER JD, 1992, AM J PSYCHIAT, V149, P328; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; DEROGATIS LR, 1993, BSI BRIEF SYMPTOM IN; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; EPSTEIN RS, 1993, J TRAUMA STRESS, V6, P451, DOI 10.1002/jts.2490060404; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; GLANCY KE, 1992, J TRAUMA, V33, P602, DOI 10.1097/00005373-199210000-00017; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; LANDSMAN IS, 1990, J BEHAV MED, V13, P561, DOI 10.1007/BF00844735; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Marmar CR, 1996, AM J PSYCHIAT, V153, P94; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; MICHAELS AJ, 1998, SURG FORUM, V49, P534; MICHAELS CE, 1997, ANN M INT SOC TRAUM; Mirza KAH, 1998, BRIT J PSYCHIAT, V172, P443, DOI 10.1192/bjp.172.5.443; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; PERRY S, 1992, AM J PSYCHIAT, V149, P931; Prigerson HG, 1999, J NERV MENT DIS, V187, P23, DOI 10.1097/00005053-199901000-00005; Richmond TS, 1998, J TRAUMA, V44, P635, DOI 10.1097/00005373-199804000-00012; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Taal LA, 1998, BURNS, V24, P285, DOI 10.1016/S0305-4179(98)00030-8; Taft CT, 1999, J TRAUMA STRESS, V12, P3, DOI 10.1023/A:1024786030358; vanderKolk BA, 1996, AM J PSYCHIAT, V153, P83; VREVEN DL, 1995, J TRAUMA STRESS, V8, P91, DOI 10.1007/BF02105409; Ware JE., 1993, SF 36 HLTH SURVEY MA	44	62	65	2	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	1999	47	5					867	873		10.1097/00005373-199911000-00009			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	254QM	WOS:000083623700008	10568714				2021-06-18	
J	Voller, B; Benke, T; Benedetto, K; Schnider, P; Auff, E; Aichner, F				Voller, B; Benke, T; Benedetto, K; Schnider, P; Auff, E; Aichner, F			Neuropsychological, MRI and EEG findings alter very mild traumatic brain injury	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; PRACTICAL SCALE; TOMOGRAPHY; DEFICITS; CT	Neuropsychological performance, magnetic resonance imaging (MRI) and electroencephalography (EEG) were investigated in 12 consecutive patients with very mild traumatic brain injury (MTBI) (Glasgow coma score 15) within 24 hours and 6 weeks after injury. The data were compared to 14 control subjects. There was a significant impairment in neuropsychological performance (verbal memory, arithmetic abilities and psychomotor reaction time) at onset and after 6 weeks, whereas verbal fluency and non-verbal memory lest revealed no significant differences matching the control values. In MRI scans, three patients showed traumatic lesions (slight epidural haematoma, haemorrhagic contusions and white matter lesions indicating diffuse axonal injury). In the EEG recordings, no generalized slowing or focal changes were found. Structural and functional impairment can be identified using neuroimaging and neuropsychological examination, even in very MTBI patients.	Univ Vienna, Dept Neurol, Div Neurorehabil, A-1090 Vienna, Austria; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Trauma Surg, A-6020 Innsbruck, Austria; Landesnervenklin Linz, Dept Neurol, Linz, Austria	Voller, B (corresponding author), Univ Vienna, Dept Neurol, Div Neurorehabil, Wahringergurtel 18-20, A-1090 Vienna, Austria.	bernhard.voller@akh-wien.ac.at		Voller, Bernhard/0000-0001-5809-874X			Adams J.H., 1990, HDB CLIN NEUROLOGY, V13, P43; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BENZER A, 1987, NOTFALLMEDIZIN, V13, P41; Delis DC, 1987, CALIFORNIA VERBAL LE; DENMAN SB, 1984, CLIN ASSESMENT IMMED; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; GEETS W, 1985, ACTA NEUROL BELG, V85, P277; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; ILMBGER J, 1992, MUNCHNER GEDACHTNIST; JENKINS A, 1986, LANCET, V2, P445; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	25	62	62	0	5	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					821	827		10.1080/026990599121214			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800008	10576466				2021-06-18	
J	Wada, K; Chatzipanteli, K; Busto, R; Dietrich, WD				Wada, K; Chatzipanteli, K; Busto, R; Dietrich, WD			Effects of L-NAME and 7-NI on NOS catalytic activity and behavioral outcome after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						behavior; 3-bromo-' 7-nitro indazole; fluid percussion brain injury; nitric oxide synthase; nitro-L-arginine-methyl ester; rat	NITRIC-OXIDE SYNTHASE; CEREBRAL BLOOD-FLOW; L-ARGININE; MODERATE HYPOTHERMIA; RELAXING FACTOR; HEAD-INJURY; GLUTAMATE NEUROTOXICITY; NMDA RECEPTORS; INFARCT VOLUME; ISCHEMIA	Traumatic brain injury (TBI) produces transient increases in constitutive nitric oxide synthase (cNOS) activity and prolonged behavioral abnormalities. This study investigated the effects of nitro-L-arginine-methyl ester (L-NAME) and 3-bromo-7-nitroindazole (7-NI) treatment on cNOS catalytic activity and sensorimotor behavioral outcome after TBI, Rats underwent moderate (1.8-2.2 atm) parasagittal fluid percussion brain injury (FPI). At 5 min after FPI, cNOS activity was significantly increased within the damaged cerebral cortex of vehicle-treated rats compared to the noninjured contralateral cortex (206.7 +/- 150.5% of contralateral,p < 0.01). Pretreatment with L-NAME and 7-NI significantly reduced injury-induced cNOS activation (47.7 +/- 42.6%,p < 0.05, and 96.16 +/- 12.76, p < 0.05, respectively). Pretreatment with L-NAME and 7-NI also inhibited cNOS activity within the contralateral noninjured cerebral cortex compared to vehicle-treated rats (L-NAME 43.7 +/- 12.47%,p < 0.05; 7-NI 36.8 +/- 7.47%,p < 0.05), Furthermore, pretreatment with 7-NI, but not L-NAME, significantly reduced forelimb placing sensorimotor deficits (3.14 +/- 1.07, p < 0.05) at 1 day after TBI compared to vehicle-treated rats (5.38 +/- 0.42), These data indicate that inhibition of injury-induced elevations in neuronal NOS activity has a beneficial effect on neurological outcome after parasagittal FPI brain injury.	Univ Miami, Sch Med, Dept Neurol D45, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Miami, FL 33101 USA; Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 359, Japan; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol D45, POB 016960, Miami, FL 33101 USA.	dalton@stroke.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1995, ANN NEUROL, V37, P115, DOI 10.1002/ana.410370122; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DERYCK M, 1992, BRAIN RES, V573, P44; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARACI FM, 1991, AM J PHYSIOL, V261, pH1038; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; GREENBERG RS, 1995, AM J PHYSIOL-HEART C, V269, pH341; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HE Z, 1995, BRAIN RES, V699, P208, DOI 10.1016/0006-8993(95)00907-8; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUMURA E, 1994, J CEREBR BLOOD F MET, V14, P487, DOI 10.1038/jcbfm.1994.60; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MACKENZIE GM, 1994, NEUROREPORT, V5, P1993, DOI 10.1097/00001756-199410000-00039; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1989, NEUROSCI LETT, V126, P83; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; NAGAFUJI T, 1995, MOL CHEM NEUROPATHOL, V26, P107, DOI 10.1007/BF02815009; NATHAN C, 1992, FASEB J, V6, P3051; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PAAKKARI I, 1995, ANN MED, V27, P369, DOI 10.3109/07853899509002590; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PRADO R, 1992, STROKE, V23, P1118, DOI 10.1161/01.STR.23.8.1118; PRADO R, 1993, J CEREBR BLOOD F MET, V13, P720, DOI 10.1038/jcbfm.1993.91; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Sadoshima S, 1997, BRAIN RES, V744, P246, DOI 10.1016/S0006-8993(96)01063-3; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stagliano NE, 1997, BRAIN RES, V759, P32, DOI 10.1016/S0006-8993(97)00200-X; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P217, DOI 10.1038/jcbfm.1994.28; ZILLES L, 1985, CORTEX RAT STEREOTAX; ZORUMSKI CF, 1992, PROG NEUROBIOL, V39, P295, DOI 10.1016/0301-0082(92)90020-F	78	62	63	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1999	16	3					203	212		10.1089/neu.1999.16.203			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	178QQ	WOS:000079277800002	10195468				2021-06-18	
J	Gordon, WA; Sliwinski, M; Echo, J; McLoughlin, M; Sheerer, M; Meili, TE				Gordon, WA; Sliwinski, M; Echo, J; McLoughlin, M; Sheerer, M; Meili, TE			The benefits of exercise in individuals with traumatic brain injury: A retrospective study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							BETA-ENDORPHIN; AEROBIC EXERCISE; DEPRESSION; FITNESS; STATES; MOOD	Objective: This study examined the benefits of exercise. Design: A retrospective study. Setting: A community-based sample. Participants: A sample of 240 individuals with traumatic brain injury (TBI) (64 exercisers and 176 nonexercisers) and 139 individuals without a disability (66 exercisers and 73 nonexercisers). Main Outcome Measures: Scales measuring disability and handicap. Results: It was found that the TBI exercisers were less depressed than nonexercising individuals with TDI, TDI exercisers reported fewer symptoms, and their self-reported health status was better th:ln the nonexercising individuals with TBI. There were no differences between the two groups of individuals with TBI on measures of disability and handicap. Conclusions: The findings suggest that exercise improves mood and aspects of health status but does affect aspects of disability and handicap.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Salomon Brothers, New York, NY USA	Gordon, WA (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.						ANTHONY J, 1991, CLIN SPORT MED, V10, P171; Beck A.T., 1987, BECK DEPRESSION INVE; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; BLAIR S, 1989, JAMA-J AM MED ASSOC, V262, P395; Brown R S, 1978, Phys Sportsmed, V6, P34, DOI 10.1080/00913847.1978.11710794; BROWN RS, 1978, PHYSICIAN SPORTSMED, V6, P44; BYRNE A, 1993, J PSYCHOSOM RES, V37, P565, DOI 10.1016/0022-3999(93)90050-P; CARR DB, 1981, NEW ENGL J MED, V305, P560, DOI 10.1056/NEJM198109033051006; COLT EWD, 1981, LIFE SCI, V28, P1637, DOI 10.1016/0024-3205(81)90319-2; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; GREIST JH, 1979, COMPR PSYCHIAT, V20, P41, DOI 10.1016/0010-440X(79)90058-0; GREIST JH, 1979, PSYCHIAT ANN, V9, P23; HOWARD R, 1988, PHYSIOTHER CAN, V8, P4; JANOWSKI L, 1990, ARCH PHYS MED REHAB, V71, P500; KELEMEN MH, 1990, JAMA-J AM MED ASSOC, V263, P2766, DOI 10.1001/jama.263.20.2766; LAFONTAINE TP, 1992, SPORTS MED, V13, P160, DOI 10.2165/00007256-199213030-00002; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; *MED OUTC TRUST, 1992, SF 36 HLTH SURV; MORAN AJ, 1976, MED J AUSTRALIA, V1, P396, DOI 10.5694/j.1326-5377.1976.tb140699.x; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P533; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SIMON HB, 1992, STAYING WELL YOUR CO; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; TWIST DJ, 1992, AM J PHYS MED REHAB, V71, P156, DOI 10.1097/00002060-199206000-00006; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILDMANN J, 1986, LIFE SCI, V38, P997, DOI 10.1016/0024-3205(86)90233-X; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA	32	62	64	0	18	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					58	67		10.1097/00001199-199808000-00006			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000006	9651240				2021-06-18	
J	Fujiki, M; Zhang, ZY; Guth, L; Steward, O				Fujiki, M; Zhang, ZY; Guth, L; Steward, O			Genetic influences on cellular reactions to spinal cord injury: Activation of macrophages/microglia and astrocytes is delayed in mice carrying a mutation (Wld(s)) that causes delayed wallerian degeneration	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						inflammation; trauma; cytotoxicity; immunocytochemistry; regeneration; wound healing; scar	CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; MONONUCLEAR PHAGOCYTES; ASTROGLIAL PROLIFERATION; AMEBOID MICROGLIA; TRAUMATIC INJURY; MAMMALIAN BRAIN; MESSENGER-RNA; ADULT-RATS; CNS	Reactive changes in macrophages/microglia and astrocytes were evaluated following spinal cord injury in normal mice of the C57BL/6J strain and in mice carrying a mutation (Wld(s)) which delays the onset of Wallerian degeneration in damaged axons. Crush injuries were produced at the T8 level by using an extradural approach; animals were allowed to survive for 2 days to 12 weeks, and spinal cords were prepared for immunocytochemistry using antibodies against Mad and glial fibrillary acidid protein (GFAP). In normal mice, Mad-positive macrophages accumulated at the injury site by 4 days and immunostaining of these cells peaked at 6-8 days. Cells in the gray matter near the crush site and in the ascending dorsal column also exhibited increased Mad staining that was prominent at 1 week and remained high at 2-4 weeks. In mice carrying the Wld(s) mutation, the accumulation of macrophages at the injury site and the increase in immunostaining of these cells were delayed, as were the increases in immunostaining in the gray matter and dorsal columns. Both normal and mutant mice exhibited pronounced increases in glial fibrillary acidic protein immunostaining at the edge of the crush site and for some distance both rostral and caudal to the injury; increased immunostaining was also prominent along the ascending dorsal columns. The center of the crush site, which contained connective tissue, remained completely unstained for GFAP. In normal mice, immunostaining for GFAP reached a peak at 1 week postinjury and then declined. In mice carrying the Wld(s) mutation, increases in GFAP immunostaining did not reach a peak until 2-3 weeks postinjury. These results indicate that activation of macrophages, microglia, and astrocytes is delayed and prolonged in mice carrying the Wld(s) mutation. (C) 1996 Wiley-Liss, Inc.	UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22908; COLL WILLIAM & MARY,DEPT BIOL,WILLIAMSBURG,VA 23185				Steward, Oswald/0000-0001-7069-8756	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS032280, R01NS021460] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 32280, NS 21460] Funding Source: Medline		AGUAYO AJ, 1979, SOC NEUROSCI S, V4, P361; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1985, J CELL BIOL, V101, P2411, DOI 10.1083/jcb.101.6.2411; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1985, CELLULAR MOL BIOL LY, P815; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; GUTH L, 1994, EXP NEUROL, V126, P76, DOI 10.1006/exnr.1994.1043; GUTH L, 1985, EXP NEUROL, V88, P1, DOI 10.1016/0014-4886(85)90109-8; HOULGATTE R, 1989, J NEUROSCI RES, V24, P143, DOI 10.1002/jnr.490240204; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; MOULIN V, 1995, EUR J CELL BIOL, V68, P1; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; PERRY VH, 1990, EUR J NEUROSCI, V2, P408, DOI 10.1111/j.1460-9568.1990.tb00433.x; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; Ramo<prime>n y Cajal S., 1913, DEGENERATION REGENER; Reier P., 1983, SPINAL CORD RECONSTR; REIER PJ, 1985, NEUROPATH APPL NEURO, V11, P81, DOI 10.1111/j.1365-2990.1985.tb00007.x; Reier PJ, 1986, ASTROCYTES, V3, P263; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STEWARD O, 1992, EXP NEUROL, V118, P340, DOI 10.1016/0014-4886(92)90192-S; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; WINDLE WF, 1952, J COMP NEUROL, V96, P359, DOI 10.1002/cne.900960207; Zhang ZY, 1996, J COMP NEUROL, V371, P485	46	62	62	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0021-9967			J COMP NEUROL	J. Comp. Neurol.	JUL 29	1996	371	3					469	484					16	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	UZ738	WOS:A1996UZ73800009	8842900				2021-06-18	
J	Bryant, RA				Bryant, RA			Posttraumatic stress disorder, flashbacks, and pseudomemories in closed head injury	JOURNAL OF TRAUMATIC STRESS			English	Article						posttraumatic stress; motor vehicle accidents; traumatic brain injury; flashbacks; pseudomemories	IMPLICIT MEMORY; FOLLOW-UP; ACCIDENTS; ANXIETY; IMPACT; ADULTS	Posttraumatic stress disorder (PTSD) is rarely diagnosed in patients with significant head injury. This paper reviews two patients who were amnesic for events surrounding their motor vehicle accidents (MVAs) but developed delayed-onset PTSD. Symptoms included vivid images of the MVAs that were based on information learnt following the trauma. These cases indicate that amnesic head injured patients can suffer pseudomemories that are phenomenologically similar to flashback observed in PTSD. Implications for understanding the nature of flashbacks are discussed.		Bryant, RA (corresponding author), UNIV NEW S WALES, SCH PSYCHOL, SYDNEY, NSW 2052, AUSTRALIA.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BROM D, 1993, J CLIN PSYCHOL, V49, P131, DOI 10.1002/1097-4679(199303)49:2<131::AID-JCLP2270490202>3.0.CO;2-2; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BULL JP, 1979, EPIDEMIOLOGICAL FEAT; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; FRANKEL FH, 1994, INT J CLIN EXP HYP, V42, P321, DOI 10.1080/00207149408409362; HICKLING EJ, 1992, J ANXIETY DISORD, V6, P285, DOI 10.1016/0887-6185(92)90040-E; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Horowitz M.J., 1983, IMAGE FORMATION PSYC; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Johnson M. K., 1988, DELUSIONAL BELIEFS I, P34; JOHNSON MK, 1988, J EXP PSYCHOL GEN, V117, P371, DOI 10.1037/0096-3445.117.4.371; Jurado M A, 1993, Neurologia, V8, P91; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LITZ BT, 1989, CLIN PSYCHOL REV, V9, P243, DOI 10.1016/0272-7358(89)90030-5; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Malt U F, 1992, Psychiatr Med, V10, P117; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; SCHACTER DL, 1992, AM PSYCHOL, V47, P559, DOI 10.1037/0003-066X.47.4.559; SCHACTER DL, 1990, ANN NY ACAD SCI, V608, P543, DOI 10.1111/j.1749-6632.1990.tb48909.x; SCHWARZ ED, 1993, J TRAUMA STRESS, V6, P545, DOI 10.1002/jts.2490060410; STRAUMAN TJ, 1992, J ABNORM PSYCHOL, V101, P87, DOI 10.1037/0021-843X.101.1.87; WATSON IPB, 1988, BRIT J PSYCHIAT, V152, P164	26	62	62	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	JUL	1996	9	3					621	629					9	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	UW921	WOS:A1996UW92100017	8827662				2021-06-18	
J	Raskin, SA; Rearick, E				Raskin, SA; Rearick, E			Verbal fluency in individuals with mild traumatic brain injury	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	International-Neuropsychological-Society Annual Meeting	1994	ANGERS, FRANCE	Int Neuropsychol Soc			MINOR HEAD-INJURY; FRONTAL-LOBE; INTELLIGENCE	Tests of verbal fluency that require either retrieval by semantic category or retrieval by initial letter were presented to 19 participants with mild traumatic brain injury (MTBI) and 24 control (NC) participants. Performance on these tasks was analyzed for total number of words produced, the presence of semantic clusters in the order of words produced, the presence of phonemic clusters in the order of word, produced, and number of errors (i.e., perseverations, words out of category). Individuals with MTBI produced fewer words and made more errors than NCs, but their production contained an equal proportion of semantic and phonemic clusters. These data are discussed in relation to a previous study in patients with Parkinson's disease (PD). FD participants did not make more errors than age-matched NCs despite reduced production. Implications for memory and executive function deficits following MTBI are discussed.	TRINITY COLL,PROGRAM NEUROSCI,HARTFORD,CT 06106; NEUROPSYCHOL SERV,PUYALLUP,WA	Raskin, SA (corresponding author), TRINITY COLL,DEPT PSYCHOL,HARTFORD,CT 06106, USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALVES W, 1992, REHABILITATION POSTC; AUERBACH S, 1989, TRAUMATIC BRAIN INJU, V3, P1; Beck A. T., 1993, BECK DEPRESSION INVE; Benton AL, 1983, MULTILINGUAL APHASIA; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; DRACHMAN DA, 1972, J EXP PSYCHOL, V93, P302, DOI 10.1037/h0032489; ESTES WK, 1974, AM PSYCHOL, V29, P740, DOI 10.1037/h0037458; FURRY CA, 1973, J GERONTOL, V28, P73, DOI 10.1093/geronj/28.1.73; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goodglass H., 1972, ASSESSMENT APHASIA R; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Heaton R., 1993, WISCONSIN CARD SORTI; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HOLLINGSHEAD AB, 1977, 4 FACTOR INDEX SOCIA; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LAINE M, 1988, J CLIN EXPT NEUROPSY, V10; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; Mateer C.A., 1992, REHABILITATION POSTC; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; MILLER E, 1975, PSYCHOL MED, V5, P255, DOI 10.1017/S0033291700056610; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Milner B., 1964, FRONTAL GRANULAR COR; MONTGOMERY K, 1982, THESIS U VICTORIA VI; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RAMIER AM, 1970, REV NEUROL, V123, P17; RASKIN SA, 1992, NEUROPSYCHOLOGIA, V30, P95, DOI 10.1016/0028-3932(92)90018-H; Ruff R. M., 1989, MILD HEAD INJURY; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; WILSON BA, 1992, NEUROPSYCHOLOGY MEMO	36	62	62	1	6	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1996	10	3					416	422		10.1037/0894-4105.10.3.416			7	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	UY062	WOS:A1996UY06200013					2021-06-18	
J	Fukuda, K; Aihara, N; Sagar, SM; Sharp, FR; Pitts, LH; Honkaniemi, J; Noble, LJ				Fukuda, K; Aihara, N; Sagar, SM; Sharp, FR; Pitts, LH; Honkaniemi, J; Noble, LJ			Purkinje cell vulnerability to mild traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						microglia; OX-42; PEP-19; Purkinje cell; traumatic brain injury	CEREBRAL-ISCHEMIA; C-FOS; PARASAGITTAL ZONES; MESSENGER-RNA; HEAD-INJURIES; RAT; PROTEIN; CEREBELLUM; MICROGLIA; MACROPHAGES	In this study we examined the cerebellar response to mild traumatic brain injury by assessing microglial activation and Purkinje cell loss, Activated microglia were identified using the antibodies OX-42 and ED-1 as well as isolectin B4. The anti-Purkinje cell antibody PEP-19 was used to evaluate Purkinje cell loss after injury, The mechanism of cell injury was examined using a monoclonal antibody to the inducible 72-kDa heat shock protein, A monoclonal antibody to the N-terminal sequence of Fos was used as a marker for neuronal activation, There was progressive activation of microglia in the cerebellar vermis within a few days after forebrain injury. In coronal sections the processes of activated microglia were oriented in ''stripes'' perpendicular to the cortical surface, In sagittal sections the activated microglia were in irregularly shaped clusters or in a fan-like distribution that radiated from the Purkinje cell layer toward the cortical surface. There was a significant loss of Purkinje cells 7 days postinjury as compared to the control group, There was no evidence of induction of heat shock protein in the cerebellum, In addition, there was no evidence of induction of c-Fos protein in either the cerebellar cortex or inferior olivary nuclei within the first 3 h after injury, These studies demonstrate that a fluid percussive impact to the forebrain results in cerebellar damage, The close anatomical association between activated microglia and Purkinje cells suggests that Purkinje cell injury is the cause of the microglial activation, The mechanism of Purkinje cell death, however, remains unclear.	UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94110					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ANDERSON G, 1978, EXP BRAIN RES, V35, P565; Brodal A, 1980, ADV ANAT EMBRYOL CEL, V64, P1, DOI DOI 10.1007/978-3-642-67775-5; BURT AM, 1993, TXB NEUROANATOMY, P349; CAVANAGH JB, 1994, NEUROPATH APPL NEURO, V20, P599, DOI 10.1111/j.1365-2990.1994.tb01014.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; GILMAN S, 1994, ANN NEUROL, V35, P3, DOI 10.1002/ana.410350103; Glickstein M, 1992, Curr Opin Neurobiol, V2, P802, DOI 10.1016/0959-4388(92)90137-A; GOENEWEGEN HJ, 1977, J COMP NEUROL, V174, P417; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GRAFMAN J, 1992, NEUROLOGY, V42, P1493, DOI 10.1212/WNL.42.8.1493; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS A, 1986, LANCET, V2, P445; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P209, DOI 10.1007/BF00691854; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Llinas R, 1993, Curr Opin Neurobiol, V3, P958, DOI 10.1016/0959-4388(93)90168-X; MARTY S, 1991, NEUROSCIENCE, V45, P529, DOI 10.1016/0306-4522(91)90268-S; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; MOLCHAN SE, 1994, P NATL ACAD SCI USA, V91, P8122, DOI 10.1073/pnas.91.17.8122; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NAKKI R, 1995, J NEUROSCI, V15, P2097; OHEARN E, 1993, NEUROREPORT, V4, P299, DOI 10.1097/00001756-199303000-00018; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; OLSON JMM, 1987, NEUROSCIENCE, V22, P913, DOI 10.1016/0306-4522(87)92969-1; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; ROSS CA, 1990, TRENDS NEUROSCI, V13, P216, DOI 10.1016/0166-2236(90)90163-5; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; THOMAS WE, 1992, BRAIN RES REV, V17, P61; VONLUBITZ DKJE, 1983, ACTA NEUROPATHOL, V61, P52, DOI 10.1007/BF00688386; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YAMAMOTO K, 1986, BRAIN RES, V384, P1, DOI 10.1016/0006-8993(86)91212-6; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; ZIAI MR, 1988, J NEUROCHEM, V51, P1771, DOI 10.1111/j.1471-4159.1988.tb01158.x; ZIAI R, 1986, P NATL ACAD SCI USA, V83, P8420, DOI 10.1073/pnas.83.21.8420	49	62	62	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1996	13	5					255	266		10.1089/neu.1996.13.255			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UT295	WOS:A1996UT29500003	8797175				2021-06-18	
J	Heindl, UT; Laub, MC				Heindl, UT; Laub, MC			Outcome of persistent vegetative state following hypoxic or traumatic brain injury in children and adolescents	NEUROPEDIATRICS			English	Article						brain injury; children; epilepsy; cerebral hypoxia; ischemia; persistent vegetative state	CLOSED-HEAD-INJURY; PROLONGED POSTTRAUMATIC UNAWARENESS; COMA; UNCONSCIOUSNESS; CONSCIOUSNESS; PARAMETERS; RECOVERY	Persistent vegetative state (PVS, apallic syndrome) has become a significant medical and social problem. The outcome of young people with PVS is a matter of great interest. Therefore, we analysed the outcome of 127 children and adolescents who were in PVS for at least 30 days following traumatic (n = 82) or hypoxic (n = 45) brain injury. After 19 months of follow-up, 84% of the patients of the traumatic brain injury (TBI) group, but only 55% of the hypoxic brain injury (HBI) group had left PVS (p<0.001). The TBI patients regained consciousness earlier. Later than 9 months post trauma less than 5% of the patients of both groups left PVS. Hypoxic brain injury patients had a higher incidence of seizures (p = 0.01) and a higher seizure frequency. They had significantly more com plications like pneumonia, gastrointestinal disturbance or myositis ossificans (= heterotopic ossification). Posttraumatic hyperthermia and autonomic dysfunctions were correlated with worse outcome in the TBI group, but not in the HBI group. Thirteen patients (16%) with TBI became independent in everyday life versus only two (4 %) with HBI. These results underline the important contribution of hypoxia in severe and permanent brain impairment. They also may help to establish the prognosis of children in PVS.	BEHANDLUNGSZENTRUM VOGTAREUTH,ABT NEUROPADIATR,D-83569 VOGTAREUTH,GERMANY							ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ANDREWS K, 1993, BRIT MED J, V306, P1600, DOI 10.1136/bmj.306.6892.1600; [Anonymous], 1995, NEUROLOGY, V45, P1015; [Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1993, ANN NEUROL, V33, P386; Ashwal S, 1994, Adv Pediatr, V41, P195; ASHWAL S, 1992, ANN NEUROL, V32, P454; BARTKOWSKI HM, 1986, HEAD TRAUMA REHABIL, V1, P1; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BERNEY J, 1995, CHILD NERV SYST, V11, P256, DOI 10.1007/BF00301755; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; CELESIA GG, 1993, NEUROLOGY, V43, P1457, DOI 10.1212/WNL.43.8.1457; CHILDERS MK, 1994, BRAIN INJURY, V8, P335, DOI 10.3109/02699059409150984; CHU HS, 1993, J FORMOS MED ASSOC, V92, P697; COLE G, 1984, BRIT MED J, V289, P1620, DOI 10.1136/bmj.289.6458.1620-c; D'Aleo G, 1994, Funct Neurol, V9, P189; FIELDS AI, 1993, CRIT CARE MED, V21, P1890, DOI 10.1097/00003246-199312000-00016; FREEMAN EA, 1993, MED J AUSTRALIA, V159, P428, DOI 10.5694/j.1326-5377.1993.tb137943.x; GARNER C, 1994, PHYS MED REHAB KUROR, V4, P220; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; GROTE EH, 1993, UNFALLCHIRURG, V96, P609; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; HOWARD RS, 1995, BRIT MED J, V310, P341, DOI 10.1136/bmj.310.6976.341; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; KALLERT TW, 1994, FORTSCHR NEUROL PSYC, V62, P241, DOI 10.1055/s-2007-996674; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRETSCHMER E, 1940, NEUROL PSYCHIAT, V169, P576; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; KRIEL RL, 1994, PEDIATR NEUROL, V10, P207, DOI 10.1016/0887-8994(94)90024-8; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LAVELLE JM, 1993, CRIT CARE MED, V21, P368, DOI 10.1097/00003246-199303000-00013; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; MAGUN JG, EPILEPSIESYNDROME TH; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARGOLIS LH, 1980, PEDIATRICS, V65, P477; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; RUIJS MBM, 1994, CLIN NEUROL NEUROSUR, V96, P273, DOI 10.1016/0303-8467(94)90114-7; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; SOUSTIEL JF, 1993, ELECTROEN CLIN NEURO, V87, P277, DOI 10.1016/0013-4694(93)90180-4; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; TURKSTRA LS, 1995, BRAIN INJURY, V9, P61, DOI 10.3109/02699059509004573; 1995, ARCH PHYS MED REHAB, V76, P205; 1994, NEW ENGL J MED, V330, P1499; 1990, JAMA-J AM MED ASSOC, V263, P426; 1994, NEW ENGL J MED, V330, P1572	55	62	64	0	1	HIPPOKRATES VERLAG GMBH	STITTGART	PO BOX 30 05 04 RUDIGERSTRASSE 14, 70469 STITTGART, GERMANY	0174-304X			NEUROPEDIATRICS	Neuropediatrics	APR	1996	27	2					94	100		10.1055/s-2007-973756			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	UN784	WOS:A1996UN78400007	8737825				2021-06-18	
J	Korteling, JE; Kaptein, NA				Korteling, JE; Kaptein, NA			Neuropsychological driving fitness tests for brain-damaged subjects	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CEREBRAL-DAMAGE	Objective: The study was carried out to evaluate and develop simple tools to assess the driving fitness of brain-damaged patients. Design: Four neuropsychological tests (predictors) were validated against an open-road driving test (criterion standard), which is used by the Department of Adaptations of the Dutch Driving Licensing Agency for assessing disabled drivers. Setting: The predictor tests were conducted in the involved scientific institute; the criterion standard involved participation in normal traffic. Patients: The subject group consisted of 33 men and 5 women who had recovered to a stabilized level from traumatic brain injuries. All had valid driving licenses when they were injured and they were considered to be potentially able to recommence driving. The subjects had a mean reported driving experience of 109.200km (SD = 86.300km). All subjects were recovered from a brain trauma with an average coma duration of 33 days (SD = 51 days). They were tested at least 1 year after the accident. All subjects had normal or corrected-to-normal vision and none used medications that, according to existing medical criteria, interfere with normal psychomotor or cognitive functioning. Ages at the time of the injury were between 17 and 55 years (mean, 29.8; SD, 10.9). Main Outcome Measures: Pearson product moment correlations (and explained variances) were calculated between the four predictor tests (a Perceptual Speed test, the WAIS Symbol-Digit Substitution subtest, a Tracking-Reaction dual task, and a Time Estimation task) and the open-road criterion standard. Results: The results indicated that performance on both the Perceptual Speed task and the Time Estimation task were significantly correlated with driving performance (p < .05). When combined with coma duration and driving experience, the Perceptual Speed and Tracking-Reaction tests together explained 35.3% (r = .59) of the variance in on-road driving performance. Conclusion: The amount of variance in open-road driving performance that could be accounted for by these tests was insufficient to completely replace an open-road driving fitness assessment. Also, based on other experimental documentation, it is concluded that more integral, domain-specific tests leg, based on driving simulation) need to be developed. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.		Korteling, JE (corresponding author), TNO,HUMAN FACTORS RES INST,POB 23,3769 ZG SOESTERBERG,NETHERLANDS.						BROUWER W, 1992, 2ND INT C OBJ EV REH; Caroll J. B., 1993, HUMAN COGNITIVE ABIL; Deelman B. G., 1980, NEUROPSYCHOLOGIE NED, P253; DUNCAN J, 1990, ERGONOMICS, V33, P1265, DOI 10.1080/00140139008925331; FOX G, 1993, SEP ASTB C, P1; Fox G K, 1992, Disabil Rehabil, V14, P140; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1993, ARCH PHYS MED REHAB, V70, P745; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; KEMA GN, 1972, PRIMARY MENTAL ABILI; KORTELING JE, 1990, HUM FACTORS, V32, P95, DOI 10.1177/001872089003200107; KORTELING JE, 1994, THESIS GRONINGEN STA; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; RAVESTEIN R, 1982, DRIVING SKILL REHABI; SAAN RJ, 1981, PSYCHOLOOG, V16, P739; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STINISSEN J, 1970, HANDLEIDING NEDERLAN; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	25	62	63	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1996	77	2					138	146		10.1016/S0003-9993(96)90158-6			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TU541	WOS:A1996TU54100005	8607737				2021-06-18	
J	BECA, J; COX, PN; TAYLOR, MJ; BOHN, D; BUTT, W; LOGAN, WJ; RUTKA, JT; BARKER, G				BECA, J; COX, PN; TAYLOR, MJ; BOHN, D; BUTT, W; LOGAN, WJ; RUTKA, JT; BARKER, G			SOMATOSENSORY-EVOKED POTENTIALS FOR PREDICTION OF OUTCOME IN ACUTE SEVERE BRAIN INJURY	JOURNAL OF PEDIATRICS			English	Article							SEVERE HEAD-INJURY; COMATOSE CHILDREN; PROGNOSTIC UTILITY; NORMATIVE DATA; INFANTS; SEPS; RELIABILITY; RESPONSES; STATE	The purpose of this study was to evaluate prospectively short-latency somatosensory evoked potentials (SEPs) as a predictor of outcome in acute, severe brain injury, and to compare this with the predictive power of the motor component of the Glasgow Coma Scale score and computed tomographic scan. Outcome was measured with the Glasgow Outcome Scale at a minimum of 6 months after injury. We studied 109 patients (aged 0.1 to 16.8 years) with SEPs within 4 days of the onset of coma. Four patients had absent SEPs and a favorable outcome by the Glasgow Outcome Scale (full recovery or moderate disability); two of these patients had meningitis with bilateral subdural effusions, one had a mid-brain hemorrhage, and one had a decompressive craniectomy for uncontrolled intracranial hypertension. Normal SEPs had a positive predictive value for favorable outcome of 93% (95% confidence interval (Cl), 77% to 99%), and absent SEPs had a positive predictive value for unfavorable outcome by the Glasgow Outcome Scale (severe disability, survival in a persistent vegetative state, or death) of 92% (95% Cl, 80% to 98%). If the above identifiable clinical situations in which a physical barrier existed to impede cutaneous reception of the electrical impulse were excluded, the positive predictive value of absent SEPs for poor outcome reached 100% (95% Cl, 92% to 100%). An absent motor response to painful stimulus also had 100% positive predictive value (95% Cl, 84% to 100%) for unfavorable outcome; however, 23% of patients could not be evaluated because of the effects of muscle relaxants or sedatives. In patients with traumatic brain injury, results of computed tomography did not reliably predict outcome. Of the 59 patients with unfavorable outcome, 76% could be identified with SEPs compared with 36% with examination of motor function. We suggest that SEPs be performed in children with acute severe brain injury because they add an important tool to the physician's prognostic armamentarium. We conclude that in the absence of the above mentioned identifiable clinical situations, absent SEPs predict 100% unfavorable outcome, and this finding may warrant consideration of withdrawal of treatment in children with brain injuries.	HOSP SICK CHILDREN, DEPT CRIT CARE, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT NEUROL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT NEUROSURG, TORONTO, ON M5G 1X8, CANADA; ROYAL CHILDRENS HOSP, DEPT CRIT CARE, MELBOURNE, VIC, AUSTRALIA							ALTMAN DG, 1990, PRACTICAL STATISTICS, P409; BATES D, 1991, J NEUROL NEUROSUR PS, V54, P569, DOI 10.1136/jnnp.54.7.569; BONGERSSCHOKKING CJ, 1989, BRAIN DEV-JPN, V11, P33, DOI 10.1016/S0387-7604(89)80006-3; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; De Meirleir L J, 1986, Pediatr Neurol, V2, P31, DOI 10.1016/0887-8994(86)90036-6; DEMEIRLEIR LJ, 1987, PEDIATR NEUROL, V3, P78, DOI 10.1016/0887-8994(87)90031-2; FRANK LM, 1985, NEUROLOGY, V35, P931, DOI 10.1212/WNL.35.6.931; GANES T, 1983, J NEUROL NEUROSUR PS, V46, P509, DOI 10.1136/jnnp.46.6.509; GEORGE SR, 1991, ELECTROEN CLIN NEURO, V80, P94, DOI 10.1016/0168-5597(91)90146-O; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GREENBERG RP, 1982, ANN NY ACAD SCI, V388, P683, DOI 10.1111/j.1749-6632.1982.tb50835.x; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; LAUREAU E, 1988, ELECTROEN CLIN NEURO, V71, P100, DOI 10.1016/0168-5597(88)90011-1; LENTER C, 1982, GEIGY SCI TABLES, P89; LUTSCHG J, 1983, AM J DIS CHILD, V137, P421; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; SUTTON LN, 1982, J NEUROSURG, V57, P178, DOI 10.3171/jns.1982.57.2.0178; TAYLOR MJ, 1988, ELECTROEN CLIN NEURO, V71, P323, DOI 10.1016/0168-5597(88)90034-2; TAYLOR MJ, 1992, DEV MED CHILD NEUROL, V34, P507; TAYLOR MJ, 1989, PEDIATR NEUROL, V5, P145, DOI 10.1016/0887-8994(89)90063-5; WILLIS J, 1984, ELECTROEN CLIN NEURO, V59, P366, DOI 10.1016/0168-5597(84)90038-8	28	62	65	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JAN	1995	126	1					44	49		10.1016/S0022-3476(95)70498-1			6	Pediatrics	Pediatrics	QB184	WOS:A1995QB18400008	7815222				2021-06-18	
J	WEBB, PM; GLUECKAUF, RL				WEBB, PM; GLUECKAUF, RL			THE EFFECTS OF DIRECT INVOLVEMENT IN GOAL-SETTING ON REHABILITATION OUTCOME FOR PERSONS WITH TRAUMATIC BRAIN INJURIES	REHABILITATION PSYCHOLOGY			English	Article								Sixteen adults with traumatic brain injuries participated in an eight-week goal setting training program designed to assess the effects of direct involvement in goal-setting on treatment outcome. Participants were randomly assigned to either a condition designed to facilitate high involvement (HI) in goal setting or to a low involvement (LI) condition. From pretesting to posttesting, both HI and LI participants significantly improved in attaining their goals. However, at the two-month follow-up, HI participants maintained gains from pretesting, whereas LI participants regressed to their pretesting level.		WEBB, PM (corresponding author), INDIANA UNIV PURDUE UNIV,PURDUE SCH SCI,DEPT PSYCHOL,402 N BLACKFORD ST,LD 3124,INDIANAPOLIS,IN 46202, USA.						CARLSON P, 1980, 88TH ANN M AM PSYCH; DUBBERT PM, 1984, BEHAV RES THER, V22, P227, DOI 10.1016/0005-7967(84)90003-2; EMMERSON GJ, 1988, COUNS PSYCHOL, V16, P261, DOI 10.1177/0011000088162007; EREZ M, 1985, ACAD MANAGE J, V28, P50, DOI 10.2307/256061; EREZ M, 1986, J APPL PSYCHOL, V71, P591, DOI 10.1037/0021-9010.71.4.591; FRANCE K, 1985, CRISIS INTERVENTION, V14, P11; GLUECKAUF RL, 1992, REHABIL PSYCHOL, V37, P291, DOI 10.1037/0090-5550.37.4.291; GLUECKAUF RL, 1992, J CONSULT CLIN PSYCH, V60, P419, DOI 10.1037/0022-006X.60.3.419; GOLDSTEIN G, 1983, REHABILITATION BRAIN; GUARE JC, 1989, DIABETES CARE, V12, P500, DOI 10.2337/diacare.12.7.500; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; KOVICH K, 1988, HEAD INJURY GUIDE FU, P27; LAFERRIERE L, 1978, AM J COMMUN PSYCHOL, V6, P271, DOI 10.1007/BF00894357; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LLOYD C, 1986, Occupational Therapy in Mental Health, V6, P19; LYNCH WJ, 1981, ARCH PHYS MED REHAB, V62, P223; Priddy D A, 1988, Brain Inj, V2, P249, DOI 10.3109/02699058809150949; ROESSLER R, 1976, PERSONAL ACHIEVEMENT; TREISCHMANN RB, 1974, ARCH PHYSICAL MED RE, V55, P556; TREXLER LE, 1994, BRAIN INJURY NEUROPS; WILLER B, 1976, J CLIN PSYCHOL, V32, P687, DOI 10.1002/1097-4679(197607)32:3<687::AID-JCLP2270320343>3.0.CO;2-V; ZAHARA DJ, 1984, CLIN PSYCHOL REV, V4, P477, DOI 10.1016/0272-7358(84)90022-9	23	62	64	0	8	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FAL	1994	39	3					179	188		10.1037/h0080321			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	PR338	WOS:A1994PR33800003					2021-06-18	
J	LINN, RT; ALLEN, K; WILLER, BS				LINN, RT; ALLEN, K; WILLER, BS			AFFECTIVE SYMPTOMS IN THE CHRONIC STAGE OF TRAUMATIC BRAIN INJURY - A STUDY OF MARRIED-COUPLES	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; RELATIVES; SEQUELAE; MOOD	A convenient sample of 60 brain-injured subjects and their spouses was evaluated cross-sectionally in the chronic stage of recovery on self-rated measures of sensory, motor, cognitive and behavioural disability and on the SCL-90 - R depression and anxiety subscales. A majority of the brain-injured subjects, who were on average almost 6 years post-injury, demonstrated elevations on the affective symptom scales, with almost 70% showing depression and 50% showing anxiety. The spouses of the brain-injured individuals also demonstrated significantly elevated affective symptom scales, with 73% acknowledging symptoms of depression and 55% demonstrating symptoms of anxiety. For the individuals with brain injury, those with higher self-ratings of cognitive disability and social aggression had higher self-ratings of depression and anxiety. In contrast, spouse gender appeared to have the greatest association with the presence of elevation affective responses, with female spouses having higher levels of depression and anxiety than male spouses. These findings are discussed in terms of the reactionary nature of affective disturbances in the chronic stage of recovery.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT PSYCHIAT,BUFFALO,NY 14260; SUNY BUFFALO,HLTH SCI LIB,DEPT MED REFERENCE,BUFFALO,NY 14260	LINN, RT (corresponding author), SUNY BUFFALO,BUFFALO,NY 14214, USA.						BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Caplan B., 1992, J CLIN EXPT NEUROPSY, V14, P78; Derogatis LR, 1983, SCL 90 R ADM SCORING; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Hays W. L., 1988, STATISTICS; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LIVINGSTON MG, 1985, BMJ-BRIT MED J, V291, P919, DOI 10.1136/bmj.291.6500.919; LIVINGSTON MG, 1987, BRAIN INJURY, V1, P333; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PRIGATANO GP, 1981, S REHABILITATION POS; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; ROBINSON RG, 1986, AM J PSYCHIAT, V143, P1238; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTHERFORD WH, 1989, MILD HEAD INJURY, P21; SBORDONE RJ, 1984, INT J CLIN NEUROPSYC, V6, P183; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; WOOD RL, 1987, BRAIN INJURY REHABIL, P179; 1990, SPSS PC PLUS 4 0; 1989, USERS MANUAL NONCATA	25	62	63	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1994	8	2					135	147		10.3109/02699059409150965			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NA029	WOS:A1994NA02900003	8193633				2021-06-18	
J	HELLMANN, JR; SHOTT, SR; GOOTEE, MJ				HELLMANN, JR; SHOTT, SR; GOOTEE, MJ			IMPALEMENT INJURIES OF THE PALATE IN CHILDREN - REVIEW OF 131 CASES	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						PALATE; IMPALEMENT; NEUROLOGIC	INTERNAL CAROTID-ARTERY; THROMBOSIS; TRAUMA	Impalement injuries of the soft palate and oropharynx are common injuries especially in children. Devastating neurologic sequelae secondary to thrombus propagation in the internal carotid artery are rare but well-documented complications of these innocuous appearing injuries. Neurologic sequelae have been reported anywhere from 3 to 60 hours after the injury. Protocols that include hospitalization up to 72 hours have been advocated. In order to evaluate the effectiveness and practicality of such protocols, all hospital admissions for palate injuries in the past 17 years were reviewed. Of the 131 cases reviewed, no complications were discovered during hospitalization, nor were there any complications in these patients seen in follow up. Based on this review, the majority of soft plate and oropharyngeal impalement injuries can be managed on an outpatient basis. Parental counseling, similar to instructions given in instances of mild head trauma, as well as close follow up in the office are felt to be a more reasonable and as well as a safe treatment plan. A suggested instruction form is presented.	CHILDRENS HOSP MED CTR,DEPT PEDIAT OTOLARYNGOL & MAXILLOFACIAL SURG,BETHESDA & ELLAND AVE,CINCINNATI,OH 45229							ALPERS BJ, 1959, ARCH NEURO PSYCHIATR, V81, P409, DOI 10.1001/archneurpsyc.1959.02340160007002; BICKERSTAFF ER, 1964, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.5401.82; BRAUDO M, 1956, BRIT MED J, V1, P665, DOI 10.1136/bmj.1.4968.665; Caldwell JA, 1936, AM J SURG, V32, P522; CRAWFORD B S, 1970, British Journal of Plastic Surgery, V23, P262, DOI 10.1016/S0007-1226(70)80052-2; FAIRBURN B, 1957, BRIT MED J, V2, P750, DOI 10.1136/bmj.2.5047.750; HELMUT D, 1983, PLAST RECONSTR SURG, V72, P656; HENGERER AS, 1984, LARYNGOSCOPE, V94, P1571; HOLYST J, 1976, ACTA NEUROCHIR, V33, P325, DOI 10.1007/BF01886680; MAINS B, 1989, J LARYNGOL OTOL, V103, P796, DOI 10.1017/S0022215100110126; MARTIN N, 1969, SOUTHERN MED J, V62, P103, DOI 10.1097/00007611-196901000-00023; MEYER JS, 1958, NEW ENGL J MED, V258, P151, DOI 10.1056/NEJM195801232580401; PITNER SE, 1966, NEW ENGL J MED, V274, P764, DOI 10.1056/NEJM196604072741403; SHANON E, 1972, ARCHIV OTOLARYNGOL, V96, P256; SHILLITO J, 1964, J NEUROSURG, V21, P540, DOI 10.3171/jns.1964.21.7.0540; TOWNE JB, 1972, ARCH SURG-CHICAGO, V104, P565; WOODHURST WB, 1980, NEUROSURGERY, V6, P559, DOI 10.1227/00006123-198005000-00012	17	62	64	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0165-5876			INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	MAR	1993	26	2					157	163		10.1016/0165-5876(93)90021-T			7	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	KP241	WOS:A1993KP24100007	8444557				2021-06-18	
J	GAINOTTI, G				GAINOTTI, G			EMOTIONAL AND PSYCHOSOCIAL PROBLEMS AFTER BRAIN INJURY	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							BLUNT HEAD-INJURY; FOLLOW-UP; STROKE PATIENTS; RELATIVES VIEW; MOOD DISORDERS; REHABILITATION; UNAWARENESS; DEPRESSION; DETERMINANTS; ANOSOGNOSIA	Emotional and psychosocial disorders of brain-damaged patients have a strong impact upon the outcome of the rehabilitation. However, owing to methodological difficulties, and to the intrinsic complexity of such disorders, these issues have received only a limited amount of interest. The aim of this paper is to try to disentangle some of the major factors underlying these disturbances, making a schematic distinction between three main categories: (1) neurological factors; (2) psychological (or psychodynamic) factors; (3) psychosocial factors. Emotional disorders stem directly from neurological factors when they result from the disruption of specific neural mechanisms subserving the modulation and control of emotional and social behaviour. Patients with severe traumatic head injury are, in general, the more prototypical instances of this category, as in them the lesion usually involves some of the most important cortical components of the limbic system. According to some authors, poststroke depression should also be included in this category. Psychological or psychodynamic factors, on the other hand, consist of those personal attitudes towards the disability that result from an implicit or explicit awareness of the defect and of its implications as to the future quality of life of the patient. These factors are linked to the personality of the patient, to their life-style and to their whole system of values. Finally, psychosocial factors can be considered as the interconnected set of consequences that the handicap, resulting from the functional impairment, will produce on the patient's social activities and on their network of social relationships. An important component of this category consists of the burden that the cognitive and personality change produced by the lesion represents for the close relatives of the patient, of their reaction to this burden, and of the influence that these reactions can have on the process of recovery.	CATHOLIC UNIV SACRED HEART,POLICLIN GEMELLI,INST NEUROL,I-00168 ROME,ITALY							ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALAJOUANINE T, 1956, BRAIN, V79, P1, DOI 10.1093/brain/79.1.1; ALAJOUANINE T, 1964, DISORDERS COMMUNICAT, P204; ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; ANTON G, 1899, ARCH PSYCHIAT NERVEN, V32, P86, DOI DOI 10.1007/BF02126945; BABINSKI MJ, 1914, REV NEUROL, V12, P845; BARRE JA, 1923, REV NEUROL, V29, P500; Ben-Yishay Y, 1990, REHABILITATION ADULT; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brown J. W., 1977, MIND BRAIN CONSCIOUS; Critchley M., 1949, T OPHTHALMOLOGICAL S, V69, P95; CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; FEIBEL JH, 1982, ARCH PHYS MED REHAB, V63, P276; FINSET A, 1988, CEREBRAL HEMISPHERE, P51; FOLSTEIN MF, 1977, J NEUROL NEUROSUR PS, V40, P1018, DOI 10.1136/jnnp.40.10.1018; Gainotti G, 1972, Cortex, V8, P41; GAINOTTI G, 1969, NEUROPSYCHOLOGIA, V7, P195, DOI 10.1016/0028-3932(69)90017-7; Gainotti G, 1992, NEUROPSYCHOLOGICAL R; GAINOTTI G, 1968, ANN NEUROLOGIA PSICH, V62, P1; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GJONE R, 1972, BRIT MED J, V4, P2; GOLDSTEIN K, 1948, LANGUAGE LANGUAGE DI; GRCEVIC N, 1988, SCAND J REHAB MED S, V17, P25; Hackett T P, 1969, Ann N Y Acad Sci, V164, P802, DOI 10.1111/j.1749-6632.1969.tb14095.x; Hamburg DA, 1953, PSYCHIATR, V16, P1; HURWITZ LJ, 1972, BRIT MED J, V1, P94; HYMAN MD, 1972, ARCH PHYS MED REHAB, V53, P217; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KERTESZ A, 1985, SPEECH LANGUAGE EVAL, P83; Kinsbourne M, 1989, EMOTIONS DUAL BRAIN, P248; KINSELLA G, 1978, MANAGEMENT APHASIA, P26; KINSELLA GJ, 1979, SCAND J REHABIL MED, V11, P129; KOEHLER PJ, 1986, J NEUROL SCI, V75, P255, DOI 10.1016/0022-510X(86)90073-0; Korsakoff S., 1889, REV PHILOS, V5, P501; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; LEWIN W, 1976, BRIT MED J, V2, P1533; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LIPSEY JR, 1984, LANCET, V1, P297; LIPSEY JR, 1986, AM J PSYCHIAT, V143, P527; LIPSEY JR, 1985, AM J PSYCHIAT, V142, P527; MALONE RL, 1970, BRIT J DISORD COMMUN, V5, P174; MALONE RL, 1969, J SPEECH HEAR DISORD, V34, P146, DOI 10.1044/jshd.3402.146; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Moore R. Y., 1984, HDB CHEM NEUROANAT 1, V2, P123; NATHANSON M, 1952, AMA ARCH NEUROL PSY, V68, P380, DOI 10.1001/archneurpsyc.1952.02320210090010; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Prigatano G. P, 1988, BRAIN INJURY RECOVER, P335; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1; ROBINSON R G, 1989, Journal of Geriatric Psychiatry, V22, P1; ROBINSON RG, 1984, STROKE, V15, P510, DOI 10.1161/01.STR.15.3.510; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; ROBINSON RG, 1982, STROKE, V13, P635, DOI 10.1161/01.STR.13.5.635; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Schilder P, 1934, AM J PSYCHIAT, V91, P155, DOI 10.1176/ajp.91.1.155; SMITH BH, 1978, NEUROSURGERY, V3, P257; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; Starkstein S. E., 1988, APHASIOLOGY, V2, P1, DOI DOI 10.1080/02687038808248883; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARKSTEIN SE, 1989, BRIT J PSYCHIAT, V154, P170, DOI 10.1192/bjp.154.2.170; TANNER DC, 1988, APHASIOLOGY, V2, P79; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TRIESCHMANN RB, 1980, SPINAL CORD INJURIES; von Monakow A., 1885, ARCH PSYCHIAT, V16, P151, DOI [10.1007/BF02227304, DOI 10.1007/BF02227304]; VONHAGEN KO, 1937, B LOS ANGELES NEUROL, V4, P41; WAHRBORG P, 1988, GOTEBORG PSYCHOL REP, V18, P1; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEDDELL RA, 1987, SCAND J REHABIL MED, V19, P93; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; 1980, STATISTICAL MANUAL M	84	62	63	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		1993	3	3					259	277		10.1080/09602019308401440			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	MC377	WOS:A1993MC37700004					2021-06-18	
J	ODER, W; GOLDENBERG, G; SPATT, J; PODREKA, I; BINDER, H; DEECKE, L				ODER, W; GOLDENBERG, G; SPATT, J; PODREKA, I; BINDER, H; DEECKE, L			BEHAVIORAL AND PSYCHOSOCIAL SEQUELAE OF SEVERE CLOSED HEAD-INJURY AND REGIONAL CEREBRAL BLOOD-FLOW - A SPECT STUDY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SOCIAL RECOVERY; RELATIVES VIEW; FOLLOW-UP; TRAUMA	Thirty six patients (31 male, 5 female) who had suffered severe closed head injury were re-examined at an average of 39.3 (SD 12.8, range 7-66) months after the injury. Behavioural symptoms were measured using the Giessen test. The relatives' reports were used for data analysis to ensure that results were valid. The neurophysical impairment subscale of the Glasgow assessment schedule was completed by two neurologists, and the number connection test was completed by each patient. The adjective mood scale was completed by each relative. All patients were investigated by single photon emission computerised tomography (SPECT). Exploratory factor analysis using the principal components method was carried out separately for SPECT results and psychological measures and correlations were sought between the resulting factors. Factor analysis of the data from the Giessen test identified social isolation, disinhibition, and aggressive behaviour as major components of post-traumatic personality changes; it indicates that these behavioural features are independent of the level of neurological and neuropsychological impairment, which loaded on a single independent factor. Relatives' psychic health seemed to be relatively resistant to physical and cognitive disability and was mainly affected by disinhibitive behaviour. The highest correlation was between frontal flow indices and disinhibitive behaviour (p < 0.01): the severity of disinhibition increased with lower frontal flow rates. There was a significant but somewhat weaker correlation (p < 0.05) between flow indices of the left cerebral hemisphere and social isolation. Low flow values of the right brain regions were related to aggressive behaviour (p < 0.05). Neurological and cognitive impairment correlated negatively with the thalamus; worse neurological and cognitive performance indicated by raised scores on the neurophysical scale and on the number connection test was associated with low thalamic flow values. The results support the importance of lesion location in the production of post traumatic behavioural disorders.		ODER, W (corresponding author), UNIV VIENNA, NEUROL KLIN, DEPT NEUROL, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BECKMANN D, 1979, ERFAHRUNGEN GIESSEN; BEFCKMANN D, 1983, TEST INDIVIDUAL GRUP; BELLINI S, 1979, IEEE T ACOUST SPEECH, V27, P213, DOI 10.1109/TASSP.1979.1163232; Bond M. R., 1990, REHABILITATION ADULT, P179; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BROOKS N, 1990, TRAUMATIC BRAIN INJU, P77; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; Conn HO, 1979, HEPATIC COMA SYNDROM; FAHY TJ, 1967, LANCET, V2, P475; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GOLDENBERG G, 1992, J NEUROL NEUROSURG P; HELL D, 1982, ARCH PSYCHIAT NERVEN, V232, P167, DOI 10.1007/BF00343697; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1990, REHABILITATION ADULT, P3; KING MA, 1984, J NUCL MED, V25, P1234; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Livingston M G, 1985, Int Rehabil Med, V7, P145; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MICHAEL C, 1987, UNTERSUCHUNG PERSONO; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PIGATRANO GP, 1986, NEUROPSYCHOL REHABIL, P29; PODREKA I, 1989, STROKE, V20, P183, DOI 10.1161/01.STR.20.2.183; PODREKA I, 1987, J NUCL MED, V28, P1657; Poewe W, 1983, J Neural Transm Suppl, V19, P215; POPROPEK AT, 1982, IEEE T NUCL SCI, V21, P1299; RICHTER J, 1991, PSYCHOPATHOLOGY, V24, P25, DOI 10.1159/000284693; Rimel RW, 1990, REHABILITATION ADULT, P8; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SNOEK J, 1990, TRAUMATIC BRAIN INJU, P9; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stuss D.T., 1986, FRONTAL LOBES; TASDALE G, 1984, CLOSED HEAD NIJURY P, P4; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VONZERSSEN D, 1976, KLINISCHE BEURTEILUN; VONZERSSEN D, 1986, ASSESSMENT DEPRESSIO, P270; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wood R., 1984, CLOSED HEAD INJURY P, P195; 1986, SPSSX USERS GUIDE	56	62	62	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1992	55	6					475	480		10.1136/jnnp.55.6.475			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	HZ150	WOS:A1992HZ15000012	1619415	Green Published, Bronze			2021-06-18	
J	DUHAYLONGSOD, FG; GLOWER, DD; WOLFE, WG				DUHAYLONGSOD, FG; GLOWER, DD; WOLFE, WG			ACUTE TRAUMATIC AORTIC-ANEURYSM - THE DUKE EXPERIENCE FORM 1970 TO 1990	JOURNAL OF VASCULAR SURGERY			English	Article; Proceedings Paper	45TH ANNUAL MEETING OF THE SOC FOR VASCULAR SURGERY	JUN 04-05, 1991	BOSTON, MA	SOC VASC SURG			THORACIC AORTA; 15-YEAR EXPERIENCE; BLUNT TRAUMA; RISK-FACTORS; RUPTURE; TRANSECTION	Improvements in the operative management of acute traumatic thoracic aortic aneurysm have resulted in safe and expeditious repair. Nonetheless, multisystem injuries continue to inflict significant numbers of deaths. From 1970 to 1990, 108 patients with acute traumatic thoracic aortic aneurysm were evaluated. Mean injury severity score, excluding aortic injury, was 17.5. Ninety-three patients (86%) survived beyond initial resuscitation and came to operation. Median interval from injury to aortic repair was 8 hours (range, 2 hours to 19 days); there were five operative deaths. Lethal nonaortic injuries included 18 closed head injuries, four myocardial contusions, two intraabdominal vascular injuries, and one pulmonary contusion. The overall mortality rate was 39% of total admissions (42 of 108), and 29% of survivors of resuscitation (27 of 93). It is significant that only 11 of the 42 deaths (26%) were directly attributable to thoracic aortic aneurysm. Adjuncts to prevent spinal cord ischemia (shunt/bypass) were used in 76 patients, whereas 12 underwent clamp/repair. Postoperative paraplegia developed in 5 of 79 patients (6.8%, including 4 of 68 (5.9%) repaired with shunt/bypass and 1 of 11 (9.1%) repaired with clamp/repair (p = NS). Among those who developed paraplegia, the injury severity score was 27.0, and the median interval from injury to repair was 4.9 hours (range, 2 to 6.5). Intraoperative hypotension occurred in three of five patients with paraplegia. Death in patients with thoracic aortic aneurysm is due primarily to associated injuries and has remained relatively constant over the 20-year period of review. Overall injury severity, intraoperative hypotension, and extensive aortic tissue destruction may correlate with the development of postoperative paraplegia; however, a larger population sample is required to confirm this conclusion. A plea is made for standardized reporting of all patients with thoracic aortic aneurysm.	DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710							AKINS CW, 1981, ANN THORAC SURG, V31, P305, DOI 10.1016/S0003-4975(10)60955-1; CHAMPION HR, 1991, TRAUMA, P47; COWLEY RA, 1990, J THORAC CARDIOV SUR, V100, P652; EDDY AC, 1990, ARCH SURG-CHICAGO, V125, P1351; KATZ NM, 1981, J THORAC CARDIOV SUR, V81, P669; MURRAY GF, 1976, ANN THORAC SURG, V21, P26, DOI 10.1016/S0003-4975(10)64883-7; PASSARO E, 1959, SURGERY, V46, P787; PICKARD LR, 1977, J TRAUMA, V17, P749, DOI 10.1097/00005373-197710000-00001; STILES QR, 1985, AM J SURG, V150, P132, DOI 10.1016/0002-9610(85)90022-4; STURM JT, 1985, ANN THORAC SURG, V39, P418, DOI 10.1016/S0003-4975(10)61947-9	10	62	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0741-5214			J VASC SURG	J. Vasc. Surg.	FEB	1992	15	2					331	343		10.1016/0741-5214(92)90255-7			13	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	HD471	WOS:A1992HD47100009	1735894	Bronze			2021-06-18	
J	HACKL, JM; GOTTARDIS, M; WIESER, C; RUMPL, E; STADLER, C; SCHWARZ, S; MONKAYO, R				HACKL, JM; GOTTARDIS, M; WIESER, C; RUMPL, E; STADLER, C; SCHWARZ, S; MONKAYO, R			ENDOCRINE ABNORMALITIES IN SEVERE TRAUMATIC BRAIN INJURY - A CUE TO PROGNOSIS IN SEVERE CRANIOCEREBRAL TRAUMA	INTENSIVE CARE MEDICINE			English	Article						SEVERE CRANIOCEREBRAL TRAUMA; ADRENAL SYSTEM; GONADAL SYSTEM; THYROIDAL SYSTEM; HUMAN GROWTH HORMONE; INSULIN SYSTEM	CENTRAL NERVOUS-SYSTEM; LOW-THYROXINE STATE; GROWTH-HORMONE; HEAD-TRAUMA; SOMATOMEDIN ACTIVITY; PLASMA-CORTISOL; SOMATOSTATIN; SUPPRESSION; THYROTROPIN; METABOLISM	Patients with severe craniocerebral trauma (sCCT) display metabolic and endocrine changes. The question is raised whether hormonal patterns give cues to the prognosis of outcome or not. In 21 patients the function of the adrenocortical, gonadal, thyroid and human growth hormone (hGH)-insulin system was assessed. LH, FSH, TSH, prolactin and hGH were stimulated. 3 groups of patients were formed. Group I: patients in acute phase with a Glasgow Coma Score (GCS) more than 6 (group Ia) and less than 6 (group Ib). Group II: patients in transition to traumatic apallic syndrome (TAS). Group III: patients with full-blown or resolving TAS. The values of group Ia comprised low T3, T4 and testosterone, elevated insulin, normal hGH. Group Ib had hypothyroid T3 and T4 and an attenuated response of LH, TSH, prolactin and hGH to stimulation. Group III: there was seen an endocrine normalisation with elevated T4 and TBG and an altered response of hGH and prolactin to stimulation. Endocrine abnormalities were not helpful in predicting which course, either to better or to worse, a given patient would follow.	UNIV HOSP INNSBRUCK,DEPT ANAESTHESIA & GEN INTENS CARE MED,INNSBRUCK,AUSTRIA; UNIV HOSP INNSBRUCK,INST EXPTL PATHOL,INNSBRUCK,AUSTRIA; GEN HOSP KLAGENFURT,DEPT NEUROL,KLAGENFURT,AUSTRIA							BAES M, 1987, ENDOCRINOLOGY, V120, P280, DOI 10.1210/endo-120-1-280; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BRATUSCHMARREIN PR, 1987, J CLIN ENDOCR METAB, V55, P973; COATES CL, 1981, INJURY, V13, P100, DOI 10.1016/0020-1383(81)90042-5; DANIEL PM, 1959, LANCET, V2, P927; EVERSMANN I, 1978, ASIAT SPACE ENV MED, V49, P234; FISHER DA, 1980, ENDOCRINOLOGY, V107, P714, DOI 10.1210/endo-107-3-714; GERSTENBRAND F, 1967, TRAUMATISCHE APALLIS, P9; GNEHM H E, 1979, Helvetica Paediatrica Acta, V34, P529; GOBIET W, 1976, NEUROGENER SCHOCK, P91; GOTTARDIS M, 1988, INFUSIONSTHERAPIE, V15, P112; HACKL JM, 1986, ANAESTHESIST, V35, P171; HANSEN AP, 1975, SCAND J CLIN LAB INV, V35, P205; HARTIG W, 1986, J CLIN NUTR GASTROEN, V1, P255; HESCH RD, 1982, ACTA ENDOKRINOL STOF, V3, P24; HOEFFLER JP, 1987, ENDOCRINOLOGY, V120, P791, DOI 10.1210/endo-120-2-791; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HUME DM, 1974, PRINCIPLES SURGERY, P1; JAMBART S, 1980, ACTA ENDOCRINOL-COP, V93, P264, DOI 10.1530/acta.0.0930264; JENNETT B, 1975, LANCET, V1, P480; Josten K U, 1980, Anasth Intensivther Notfallmed, V15, P213, DOI 10.1055/s-2007-1005141; KAPTEIN EM, 1981, J CLIN ENDOCR METAB, V53, P764, DOI 10.1210/jcem-53-4-764; KIRKPATRICK JR, 1987, NUTRITION, V3, P221; KIRVELA O, 1985, CLIN NUTR, V4, P39, DOI 10.1016/0261-5614(85)90036-6; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; MAREK J, 1981, ACTA ENDOCRINOL-COP, V96, P491, DOI 10.1530/acta.0.0960491; MARTIN JB, 1980, FED PROC, V39, P2902; Pentelenyi T, 1979, Acta Neurochir Suppl (Wien), V28, P103; PHILLIPS LS, 1986, METABOLISM, V35, P78, DOI 10.1016/0026-0495(86)90100-9; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; RUMPL E, 1987, NEUROLOGISCHE PSYCHI, P563; SHAMOON H, 1981, J CLIN ENDOCR METAB, V52, P1235, DOI 10.1210/jcem-52-6-1235; SILER TM, 1974, J CLIN ENDOCR METAB, V38, P742, DOI 10.1210/jcem-38-5-742; STAUB JJ, 1978, SCHWEIZ MED WSCHR, V108, P1909; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904	35	62	65	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0342-4642			INTENS CARE MED	Intensive Care Med.		1991	17	1					25	29		10.1007/BF01708405			5	Critical Care Medicine	General & Internal Medicine	FB204	WOS:A1991FB20400006	2037721				2021-06-18	
J	JANKOWSKI, LW; SULLIVAN, SJ				JANKOWSKI, LW; SULLIVAN, SJ			AEROBIC AND NEUROMUSCULAR TRAINING - EFFECT ON THE CAPACITY, EFFICIENCY, AND FATIGABILITY OF PATIENTS WITH TRAUMATIC BRAIN INJURIES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									INST READAPTAT MONTREAL,CTR RECH,MONTREAL,QUEBEC,CANADA	JANKOWSKI, LW (corresponding author), CONCORDIA UNIV,DEPT EXERCISE SCI,7141 SHERBROOKE ST W,MONTREAL H4B 1R6,QUEBEC,CANADA.						ALLEN TH, 1956, METABOLISM, V5, P346; ASTRAND PO, 1987, ARCH PHYS MED REHAB, V68, P305; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Berger M, 1976, Fortschr Med, V94, P1553; BLACKBURN H, 1988, NEW ENGL J MED, V319, P1217, DOI 10.1056/NEJM198811033191808; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FINDLEY TW, 1988, ARCH PHYS MED REHAB, V69, P855; FISHER SV, 1978, ARCH PHYS MED REHAB, V59, P124; GASS GC, 1984, MED SCI SPORT EXER, V16, P355; HARKCOM TM, 1985, ARTHRITIS RHEUM, V28, P32, DOI 10.1002/art.1780280106; HJELTNES N, 1986, SCAND J REHABIL MED, V18, P65; HOOK O, 1988, SCAND J REHABIL MED, V17, P65; JANKOWSKI LW, 1976, SCAND J REHABIL MED, V8, P135; MAGNUS BC, 1988, ADAPTED PHYSICAL ACT, V5, P90; NORDEMAR R, 1981, SCAND J RHEUMATOL, V10, P17; OLGIATI R, 1988, ARCH PHYS MED REHAB, V69, P846; PITETTI KH, 1987, J BONE JOINT SURG AM, V69A, P914, DOI 10.2106/00004623-198769060-00018; 1986, GUIDELINES EXERCISE	18	62	62	0	9	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1990	71	7					500	504					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DH157	WOS:A1990DH15700011	2350220				2021-06-18	
J	GORDON, E				GORDON, E			CONTROLLED RESPIRATION IN MANAGEMENT OF PATIENTS WITH TRAUMATIC BRAIN INJURIES	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article																ALEXANDER SC, 1970, ANESTHESIOLOGY, V32, P60, DOI 10.1097/00000542-197001000-00013; Bottistini N, 1969, CEREBRAL BLOOD FLOW, P249; BOZZMARRUBINI M, 1965, AUG S AN INT PRAG; BRAWLEY BW, 1968, SCAND J CLIN LA S102; BROCK M, 1970, 1970 P PRINC C CER D; CAMPAN L, 1968, ANN ANESTH FRANC, V9, P4; CHAMBERLAIN JH, 1970, BRIT J ANAESTH, V42, P32, DOI 10.1093/bja/42.1.32; COTEV S, 1968, SCAND J CLIN LA S102, P111; GORDON E, 1970, ACTA ANAESTH SCAND, V14, P97, DOI 10.1111/j.1399-6576.1970.tb00763.x; GORDON E, 1968, ACTA ANAESTH SCAND, V12, P51, DOI 10.1111/j.1399-6576.1968.tb00411.x; GOTOH F, 1965, ARCH NEUROL-CHICAGO, V12, P410, DOI 10.1001/archneur.1965.00460280080008; GRANHOLM L, 1969, ACTA PHYSIOL SCAND, V77, P179, DOI 10.1111/j.1748-1716.1969.tb04562.x; GRANHOLM L, 1968, EXPERIENTIA, V24, P337, DOI 10.1007/BF02140806; HOEDTRASMUSSEN K, 1967, ARCH NEUROL-CHICAGO, V17, P271, DOI 10.1001/archneur.1967.00470270049007; HUANG CT, 1963, ARCH NEUROL-CHICAGO, V9, P545, DOI 10.1001/archneur.1963.00460110113012; HUNTER AR, 1964, LANCET, V1, P279; KIENLE G, 1969, CEREBRAL BLOOD FLOW, P132; KJALLQUI.A, 1969, ACTA PHYSIOL SCAND, V75, P267, DOI 10.1111/j.1748-1716.1969.tb04380.x; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LUNDBERG L, 1959, ACTA PSYCH NEUR S139, P34; MEYER JS, 1960, ARCH NEUROL-CHICAGO, V3, P539, DOI 10.1001/archneur.1960.00450050059007; MEYER JS, 1969, CEREBRAL BLOOD FLOW, P199; PLUM F, 1968, AM J PHYSIOL, V215, P1240; ROSSANDA M, 1970, ACTA ANAESTH SCAND, V14, P173, DOI 10.1111/j.1399-6576.1970.tb00963.x; ROSSANDA M, 1966, ACTA ANAESTH SC  S23, P766; SOLOWAY M, 1968, ANESTHESIOLOGY, V29, P975, DOI 10.1097/00000542-196809000-00022; SUGIOKA K, 1960, ANESTHESIOLOGY, V21, P135, DOI 10.1097/00000542-196003000-00001; Symon L., 1968, SCAND J CLIN LA S102, V102, pXIII; THORN W, 1954, PFLUG ARCH GES PHYS, V258, P501, DOI 10.1007/BF00363713; VAPALATHI M, 1969, CEREBRAL BLOOD FLOW, P249	30	62	63	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.		1971	15	3					193	&		10.1111/j.1399-6576.1971.tb05461.x			0	Anesthesiology	Anesthesiology	K5975	WOS:A1971K597500005	5120955				2021-06-18	
J	YARNELL, PR; LYNCH, S				YARNELL, PR; LYNCH, S			RETROGRADE MEMORY IMMEDIATELY AFTER CONCUSSION	LANCET			English	Article																BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P539, DOI 10.1136/jnnp.30.6.539; MAZZIA VDB, 1966, ARCH NEUROL-CHICAGO, V14, P522, DOI 10.1001/archneur.1966.00470110066008; MCGAUGH TL, 1966, SCIENCE, V153, P1351; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; THOMPSON RF, 1967, FOUNDATIONS PHYSIOLO; WILLIAMS M, 1952, J NEUROL NEUROSUR PS, V15, P54, DOI 10.1136/jnnp.15.1.54; WILLIAMS M, 1969, PATHOLOGY MEMORY	8	62	62	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet		1970	1	7652					863	&					0	Medicine, General & Internal	General & Internal Medicine	G0871	WOS:A1970G087100005	4191508				2021-06-18	
J	Meyfroidt, G; Baguley, IJ; Menon, DK				Meyfroidt, Geert; Baguley, Ian J.; Menon, David K.			Paroxysmal sympathetic hyperactivity: the storm after acute brain injury	LANCET NEUROLOGY			English	Article							ALLEVIATES AUTONOMIC DYSFUNCTION; INTRATHECAL BACLOFEN THERAPY; INTENSIVE-CARE-UNIT; PHARMACOLOGICAL MANAGEMENT; DIAGNOSTIC-CRITERIA; VEGETATIVE STATE; AFFERENT STIMULI; METABOLIC-RATE; DYSAUTONOMIA; OVERRESPONSIVENESS	A substantial minority of patients who survive an acquired brain injury develop a state of sympathetic hyperactivity that can persist for weeks or months, consisting of periodic episodes of increased heart rate and blood pressure, sweating, hyperthermia, and motor posturing, often in response to external stimuli. The unifying term for the syndrome-paroxysmal sympathetic hyperactivity (PSH)-and clear diagnostic criteria defined by expert consensus were only recently established. PSH has predominantly been described after traumatic brain injury (TBI), in which it is associated with worse outcomes. The pathophysiology of the condition is not completely understood, although most researchers consider it to be a disconnection syndrome with paroxysms driven by a loss of inhibitory control over excitatory autonomic centres. Although therapeutic strategies to alleviate sympathetic outbursts have been proposed, their effects on PSH are inconsistent between patients and their influence on outcome is unknown. Combinations of drugs are frequently used and are chosen on the basis of local custom, rather than on objective evidence. New rigorous tools for diagnosis could allow better characterisation of PSH to enable stratification of patients for future therapeutic trials	[Meyfroidt, Geert] Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium; [Baguley, Ian J.] Westmead Hosp, Westmead, NSW, Australia; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England	Menon, DK (corresponding author), Addenbrookes Hosp, Box 93, Cambridge CB2 2QQ, England.	dkm13@cam.ac.uk	Baguley, Ian/AAM-5828-2021		Research Foundation, FlandersFWO; National Institute for Healthcare Research (NIHR), UK, through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre; NIHR Senior Investigator Award; European UnionEuropean Commission [602150]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	GM is funded by the Research Foundation, Flanders as senior clinical investigator. DKM is supported by the National Institute for Healthcare Research (NIHR), UK, through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre and a NIHR Senior Investigator Award, and is supported by a European Union Framework Program 7 grant (CENTER-TBI; grant agreement no. 602150). The funders had no role in the preparation, editing, or submission of the manuscript.	Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Baguley IJ, 2009, AM J PHYS MED REHAB, V88, P615, DOI 10.1097/PHM.0b013e3181aeab96; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Becker R, 1999, J NEUROL NEUROSUR PS, V66, P114, DOI 10.1136/jnnp.66.1.114; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Bhatnagar S, 2016, BRAIN RES, V1640, P164, DOI 10.1016/j.brainres.2016.01.021; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Bower RS, 2010, NEUROCRIT CARE, V13, P233, DOI 10.1007/s12028-010-9381-y; Brown A, 2012, EXP NEUROL, V235, P133, DOI 10.1016/j.expneurol.2011.11.004; Caldwell SB, 2014, BRAIN INJURY, V28, P370, DOI 10.3109/02699052.2013.865265; Choi HA, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0370-3; CHRISTIN L, 1989, METABOLISM, V38, P439, DOI 10.1016/0026-0495(89)90195-9; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Farias-Moeller R, 2015, NEUROCRIT CARE, V23, P380, DOI 10.1007/s12028-015-0124-y; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2012, J NEUROTRAUMA; Fernandez-Ortega JF, 2017, J NEUROTRAUM, V34, P109, DOI 10.1089/neu.2015.4364; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Gao B, 2014, ANN CLIN TRANSL NEUR, V1, P215, DOI 10.1002/acn3.44; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hinson HE, 2015, BRAIN INJURY, V29, P455, DOI 10.3109/02699052.2014.995229; Hoarau X, 2012, BRAIN INJURY, V26, P927, DOI 10.3109/02699052.2012.661913; Kirk KA, 2012, DEV MED CHILD NEUROL, V54, P759, DOI 10.1111/j.1469-8749.2012.04322.x; Krach LE, 1997, J NEUROL REHABIL, V11, P41; Laxe S, 2013, BRAIN INJURY, V27, P1383, DOI 10.3109/02699052.2013.823648; Lee S.-C., 2016, SPRINGERPLUS, V5; Levy ER, 2011, J PALLIAT MED, V14, P1355, DOI 10.1089/jpm.2010.0444; Lv LQ, 2011, ARCH PHYS MED REHAB, V92, P1515, DOI 10.1016/j.apmr.2011.01.014; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Mathew MJ, 2016, ACTA NEUROCHIR, V158, P2047, DOI 10.1007/s00701-016-2934-x; May CC, RECTAL PROPRANOLOL C; Mehta NM, 2008, JPEN-PARENTER ENTER, V32, P281, DOI 10.1177/0148607108316196; Mrkobrada S, 2016, CHILD NERV SYST, V32, P1299, DOI 10.1007/s00381-015-2931-z; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Pattoneri Paolo, 2005, J Clin Hypertens (Greenwich), V7, P734, DOI 10.1111/j.1524-6175.2005.04780.x; Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; Penfield W, 1954, EPILEPSY FUNCTIONAL, P412; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Pignolo L, 2012, J REHABIL MED, V44, P502, DOI 10.2340/16501977-0981; Pozzi M, 2015, J HEAD TRAUMA REHAB, V30, P357, DOI 10.1097/HTR.0000000000000084; Pozzi M, 2014, J NEUROTRAUM, V31, P1897, DOI 10.1089/neu.2014.3540; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Samuel S, 2016, J NEUROSCI NURS, V48, P82, DOI 10.1097/JNN.0000000000000207; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Tang JS, 2009, PROG NEUROBIOL, V89, P383, DOI 10.1016/j.pneurobio.2009.10.002; Verma R, 2015, INDIAN J CRIT CARE M, V19, P34, DOI 10.4103/0972-5229.148638; WELLE S, 1991, METABOLISM, V40, P619, DOI 10.1016/0026-0495(91)90053-Y	60	61	68	3	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2017	16	9					721	729		10.1016/S1474-4422(17)30259-4			9	Clinical Neurology	Neurosciences & Neurology	FC8ZW	WOS:000407131400013	28816118				2021-06-18	
J	Sun, W; Incitti, T; Migliaresi, C; Quattrone, A; Casarosa, S; Motta, A				Sun, Wei; Incitti, Tania; Migliaresi, Claudio; Quattrone, Alessandro; Casarosa, Simona; Motta, Antonella			Viability and neuronal differentiation of neural stem cells encapsulated in silk fibroin hydrogel functionalized with an IKVAV peptide	JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE			English	Article						silk fibroin; hydrogel; sonication; encapsulation; neural stem cells; differentiation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NEURITE OUTGROWTH; GROWTH-FACTOR; SCAFFOLDS; ADHESION; LAMININ; MATRIX; REGENERATION; CHALLENGES	Three-dimensional (3D) porous scaffolds combined with therapeutic stem cells play vital roles in tissue engineering. The adult brain has very limited regeneration ability after injuries such as trauma and stroke. In this study, injectable 3D silk fibroin-based hydrogel scaffolds with encapsulated neural stem cells were developed, aiming at supporting brain regeneration. To improve the function of the hydrogel towards neural stem cells, silk fibroin was modified by an IKVAV peptide through covalent binding. Both unmodified and modified silk fibroin hydrogels were obtained, through sonication, with mechanical stiffness comparable to that of brain tissue. Human neural stem cells were encapsulated in both hydrogels and the effects of IKVAV peptide conjugation on cell viability and neural differentiation were assessed. The silk fibroin hydrogel modified by IKVAV peptide showed increased cell viability and an enhanced neuronal differentiation capability, which contributed to understanding the effects of IKVAV peptide on the behaviour of neural stem cells. For these reasons, IKVAV-modified silk fibroin is a promising material for brain tissue engineering. Copyright (C) 2015 John Wiley & Sons, Ltd.	[Sun, Wei; Migliaresi, Claudio; Motta, Antonella] Univ Trento, Dept Ind Engn, Via Regole 101, I-38123 Mattarello, Trento, Italy; [Sun, Wei; Migliaresi, Claudio; Motta, Antonella] Univ Trento, Biotech Res Ctr, Via Regole 101, I-38123 Mattarello, Trento, Italy; [Sun, Wei; Migliaresi, Claudio; Motta, Antonella] European Inst Excellence Tissue Engn & Regenerat, Trento, Italy; [Sun, Wei; Incitti, Tania; Quattrone, Alessandro; Casarosa, Simona] Univ Trento, Ctr Integrat Biol, Trento, Italy; [Casarosa, Simona] CNR Neurosci Inst, Pisa, Italy	Motta, A (corresponding author), Univ Trento, Dept Ind Engn, Via Regole 101, I-38123 Mattarello, Trento, Italy.; Motta, A (corresponding author), Univ Trento, Biotech Res Ctr, Via Regole 101, I-38123 Mattarello, Trento, Italy.	antonella.motta@ing.unitn.it	; Motta, Antonella/E-2554-2014	Incitti, Tania/0000-0002-5573-1914; Motta, Antonella/0000-0003-4893-6863	Bridging the Gap Erasmus Mundus Project	We thank Professor Riccardo Ceccato for help in rheological testing. We also thank Valentina Adami and Pamela Gatto for their help with Columbus software. Partial financial support from the Bridging the Gap Erasmus Mundus Project is gratefully acknowledged.	Aurand ER, 2012, J FUNCT BIOMATER, V3, P839, DOI 10.3390/jfb3040839; Banerjee A, 2009, BIOMATERIALS, V30, P4695, DOI 10.1016/j.biomaterials.2009.05.050; Barinaga M, 1998, SCIENCE, V281, P1302, DOI 10.1126/science.281.5381.1302; Chen JP, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-170; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fico A, 2008, STEM CELLS DEV, V17, P573, DOI 10.1089/scd.2007.0130; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Foss C, 2013, BIOMACROMOLECULES, V14, P38, DOI 10.1021/bm301174x; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119; Hall PE, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-71; Hopkins AM, 2013, ADV FUNCT MATER, V23, P5140, DOI 10.1002/adfm.201300435; Hosseinkhani H, 2013, ACS CHEM NEUROSCI, V4, P1229, DOI 10.1021/cn400075h; Hu Y., 2012, ADV MATER SCI ENG, V2012, P5; Jiang FX, 2008, ANN BIOMED ENG, V36, P1565, DOI 10.1007/s10439-008-9530-z; Jin HJ, 2005, ADV FUNCT MATER, V15, P1241, DOI 10.1002/adfm.200400405; Jin K, 2007, J NEUROIMMUNE PHARM, V2, P236, DOI 10.1007/s11481-007-9076-0; Kikuchi K, 2012, INT J MOL SCI, V13, P7739, DOI 10.3390/ijms13067739; Koh HS, 2008, BIOMATERIALS, V29, P3574, DOI 10.1016/j.biomaterials.2008.05.014; Kubinova S, 2010, BIOMATERIALS, V31, P5966, DOI 10.1016/j.biomaterials.2010.04.040; Li J, 2013, BIOMED RES INT, V2013, P32; Li QQ, 2014, J BIOMED MATER RES A, V102, P1991, DOI 10.1002/jbm.a.34876; Li XW, 2012, PROG POLYM SCI, V37, P1105, DOI 10.1016/j.progpolymsci.2012.02.004; Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012; Meinel L, 2004, J BIOMED MATER RES A, V71A, P25, DOI 10.1002/jbm.a.30117; MILLARUELO AI, 1988, DEV BRAIN RES, V38, P219, DOI 10.1016/0165-3806(88)90047-8; Motta A, 2004, J BIOMAT SCI-POLYM E, V15, P851, DOI 10.1163/1568562041271075; NOMIZU M, 1995, FEBS LETT, V365, P227, DOI 10.1016/0014-5793(95)00475-O; Pakulska MM, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/2/024101; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; RUTKA JT, 1988, J NEUROSURG, V69, P155, DOI 10.3171/jns.1988.69.2.0155; Santin M, 1999, J BIOMED MATER RES, V46, P382, DOI 10.1002/(SICI)1097-4636(19990905)46:3<382::AID-JBM11>3.0.CO;2-R; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Silva SS, 2008, BIOMACROMOLECULES, V9, P2764, DOI 10.1021/bm800874q; Srikanth M, 2013, NEURO-ONCOLOGY, V15, P319, DOI 10.1093/neuonc/nos316; Sun W, 2016, J TISSUE ENG REGEN M, V10, P876, DOI 10.1002/term.1868; Sun Y, 2008, MOL CELL NEUROSCI, V38, P245, DOI 10.1016/j.mcn.2008.02.014; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Uludag H, 2000, ADV DRUG DELIVER REV, V42, P29, DOI 10.1016/S0169-409X(00)00053-3; Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013; Vidal G, 2013, ACTA BIOMATER, V9, P4935, DOI 10.1016/j.actbio.2012.09.003; Villard V, 2006, J PEPT SCI, V12, P206, DOI 10.1002/psc.707; Vink R, 2010, NEUROTHERAPEUTICS, V7, P1, DOI 10.1016/j.nurt.2009.12.001; Wang XQ, 2008, BIOMATERIALS, V29, P1054, DOI 10.1016/j.biomaterials.2007.11.003; Zhu HL, 2012, MAT SCI ENG C-MATER, V32, P822, DOI 10.1016/j.msec.2012.01.033	47	61	62	6	62	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-6254	1932-7005		J TISSUE ENG REGEN M	J. Tissue Eng. Regen. Med.	MAY	2017	11	5					1532	1541		10.1002/term.2053			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Engineering, Biomedical	Cell Biology; Biotechnology & Applied Microbiology; Engineering	EX1MJ	WOS:000402987500020	26053955				2021-06-18	
J	Spaite, DW; Hu, CC; Bobrow, BJ; Chikani, V; Barnhart, B; Gaither, JB; Denninghoff, KR; Adelson, PD; Keim, SM; Viscusi, C; Mullins, T; Sherrill, D				Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Adelson, P. David; Keim, Samuel M.; Viscusi, Chad; Mullins, Terry; Sherrill, Duane			The Effect of Combined Out-of-Hospital Hypotension and Hypoxia on Mortality in Major Traumatic Brain Injury	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Scientific Sessions of the American-Heart-Association and American-Stroke-Association / Resuscitation Science Symposium	NOV 15-19, 2014	Chicago, IL	Amer Heart Assoc, Amer Stroke Assoc			SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; SECONDARY INSULTS; PROGNOSTIC VALUE; MANAGEMENT; HYPOXEMIA; CHILDREN; IMPACT; DEATH	Study objective: Survival is significantly reduced by either hypotension or hypoxia during the out-of-hospital management of major traumatic brain injury. However, only a handful of small studies have investigated the influence of the combination of both hypotension and hypoxia occurring together. In patients with major traumatic brain injury, we evaluate the associations between mortality and out-of-hospital hypotension and hypoxia separately and in combination. Methods: All moderate or severe traumatic brain injury cases in the preimplementation cohort of the Excellence in Prehospital Injury Care study (a statewide, before/after, controlled study of the effect of implementing the out-of-hospital traumatic brain injury treatment guidelines) from January 1, 2007, to March 31, 2014, were evaluated (exclusions: <10 years, out-of-hospital oxygen saturation <= 10%, and out-of-hospital systolic blood pressure <40 or >200 mm Hg). The relationship between mortality and hypotension (systolic blood pressure <90 mm Hg) or hypoxia (saturation <90%) was assessed with multivariable logistic regression, controlling for Injury Severity Score, head region severity, injury type (blunt versus penetrating), age, sex, race, ethnicity, payer, interhospital transfer, and trauma center. Results: Among the 13,151 patients who met inclusion criteria (median age 45 years; 68.6% men), 11,545 (87.8%) had neither hypotension nor hypoxia, 604 (4.6%) had hypotension only, 790 (6.0%) had hypoxia only, and 212 (1.6%) had both hypotension and hypoxia. Mortality for the 4 study cohorts was 5.6%, 20.7%, 28.1%, and 43.9%, respectively. The crude and adjusted odds ratios for death within the cohorts, using the patients with neither hypotension nor hypoxia as the reference, were 4.4 and 2.5, 6.6 and 3.0, and 13.2 and 6.1, respectively. Evaluation for an interaction between hypotension and hypoxia revealed that the effects were additive on the log odds of death. Conclusion: In this statewide analysis of major traumatic brain injury, combined out-of-hospital hypotension and hypoxia were associated with significantly increased mortality. This effect on survival persisted even after controlling for multiple potential confounders. In fact, the adjusted odds of death for patients with both hypotension and hypoxia were more than 2 times greater than for those with either hypotension or hypoxia alone. These findings seem supportive of the emphasis on aggressive prevention and treatment of hypotension and hypoxia reflected in the current emergency medical services traumatic brain injury treatment guidelines but clearly reveal the need for further study to determine their influence on outcome.	[Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad] Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA; [Adelson, P. David] Univ Arizona, Coll Med, Barrow Neurol Inst, Phoenix Childrens Hosp, Phoenix, AZ USA; [Adelson, P. David] Univ Arizona, Coll Med, Dept Child Hlth Neurosurg, Phoenix, AZ USA; [Spaite, Daniel W.; Bobrow, Bentley J.; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad] Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ 85721 USA; [Hu, Chengcheng; Sherrill, Duane] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA; [Bobrow, Bentley J.; Chikani, Vatsal; Mullins, Terry] Arizona Dept Hlth Serv, Bur EMS & Trauma Syst, Phoenix, AZ USA	Spaite, DW (corresponding author), Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA.; Spaite, DW (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ 85721 USA.	dan@aemrc.arizona.edu	Adelson, David/W-2083-2019	Spaite, Daniel/0000-0003-2601-6476; Chikani, Vatsal/0000-0003-0904-7887	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS071049] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049] Funding Source: NIH RePORTER		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chesnut RM, 2000, J NEUROTRAUM, V17, P199; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; Davis DP, 2007, PREHOSP EMERG CARE, V11, P1, DOI 10.1080/10903120601021093; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Frieden TR., 2015, CDC NIH REP CONGRESS, DOI [10.3171/2009.10.JNS091500, DOI 10.3171/2009.10.JNS091500]; GENTLEMAN D, 1992, INT SURG, V77, P297; Glance LG, 2001, J TRAUMA, V51, P725, DOI 10.1097/00005373-200110000-00017; Haddad Samir, 2005, Middle East Journal of Anesthesiology, V18, P45; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JEFFREYS RV, 1981, LANCET, V2, P459; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie EJ, 2010, J TRAUMA, V69, P1, DOI 10.1097/TA.0b013e3181e03a21; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MAYER TA, 1985, ANN EMERG MED, V14, P1178, DOI 10.1016/S0196-0644(85)81025-8; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McSwain NE, 2004, J TRAUMA, V57, P8; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; R Foundation, R LANG ENV STAT COMP; Ringdal KG, 2007, SCAND J SURG, V96, P325, DOI 10.1177/145749690709600412; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SEELIG JM, 1986, INTRACRANIAL PRESSUR, P675; Shutter LA, 2008, ANN EMERG MED, V51, pS37, DOI 10.1016/j.annemergmed.2007.11.013; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Spaite DW, 2014, ACAD EMERG MED, V21, P818, DOI 10.1111/acem.12411; Spaite DW, 1993, PREHOSP DISASTER MED, V8, pS35; Stassen W, 2014, SAMJ S AFR MED J, V104, P424, DOI [10.7196/SAMJ.7494, 10.7196/samj.7494]; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WARDROPE J, 1992, BRIT MED J, V305, P1016, DOI 10.1136/bmj.305.6860.1016; Wood S., 2017, GEN ADDITIVE MODELS, V2nd ed.; Wood SN, 2013, BIOMETRIKA, V100, P221, DOI 10.1093/biomet/ass048; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x	58	61	61	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2017	69	1					62	72		10.1016/j.annemergmed.2016.08.007			11	Emergency Medicine	Emergency Medicine	EG3XQ	WOS:000390978400014	27692683	Green Accepted, Bronze			2021-06-18	
J	Novak, Z; Aglipay, M; Barrowman, N; Yeates, K; Beauchamp, MH; Gravel, J; Freedman, SB; Gagnon, I; Gioia, G; Boutis, K; Burns, E; Ledoux, AA; Osmond, MH; Zemek, RL				Novak, Zuzana; Aglipay, Mary; Barrowman, Nick; Yeates, Keith O.; Beauchamp, Miriam H.; Gravel, Jocelyn; Freedman, Stephen B.; Gagnon, Isabelle; Gioia, Gerard; Boutis, Kathy; Burns, Emma; Ledoux, Andree-Anne; Osmond, Martin H.; Zemek, Roger L.		Pediat Emergency Res Canada	Association of Persistent Postconcussion Symptoms With Pediatric Quality of Life	JAMA PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; ACUTE CONCUSSION; RISK-FACTORS; 1ST YEAR; CHILDREN; MILD; ADOLESCENTS; MODERATE; INVENTORY; VALIDITY	IMPORTANCE Persistent postconcussion symptoms (PPCS) pose long-term challenges and can negatively affect patients' health-related quality of life (HRQoL). To date, no large comprehensive study has addressed the association between PPCS and HRQoL. OBJECTIVES To determine the association between HRQoL and PPCS at 4 weeks after concussion and assess the degree of impairment of HRQoL in the subsequent 12 weeks. DESIGN, SETTING, AND PARTICIPANTS In a prospective, multicenter cohort study (Predicting Persistent Postconcussive Problems in Pediatrics [5P]) from August 14, 2013, to September 30, 2014, children aged 5 to 18 years who presented to the emergency department within 48 hours after head injury and were considered to have an acute concussion were enrolled across 9 pediatric emergency departments within the Pediatric Emergency Research Canada Network. Persistent postconcussion symptoms were defined as 3 or more persistent symptoms on the validated Post-Concussion Symptom Inventory at 4 weeks. Linear mixed effects random coefficients models evaluated the association between PPCS and HRQoL, adjusting for potential confounders including age, sex, prior concussions, migraine, anxiety, learning disability, depression, and sleep disorder. MAIN OUTCOMES AND MEASURES The primary outcomewas HRQoL assessed with the validated Pediatric Quality of Life Inventory version 4.0 (PedsQL-4.0) at 4, 8, and 12 weeks after head injury. RESULTS Of 2006 children enrolled (median age, 11.8 years [interquartile range, 8.9-14.6 years]; 1241 boys and 765 girls), 1667 (83.1%) completed the PedsQL-4.0 at all 3 time points. Of these 1667 children, the 510 with PPCS (30.6%) had lower total PedsQL-4.0 scores (mean, 70.0) than did those without PPCS (mean, 80.3; mean difference, -10.3; 95% CI, -9.4 to -11.2). Patients with PPCS also had significantly lower physical, emotional, social, and school PedsQL-4.0 subscores at 4, 8, and 12 weeks. Patients with PPCS had lower HRQoL than published healthy norms at 4 weeks (mean difference, 13.89; 95% CI, 11.55-16.23), 8 weeks (mean difference, 11.63; 95% CI, 9.34-13.93), and 12 weeks (mean difference, 9.38; 95% CI, 7.01-11.75; P<.001). Patients who recovered from concussion also had lower HRQoL than norms at 4 weeks (mean difference, 3.56; 95% CI, 1.28-5.85) and 8 weeks (mean difference, 2.75; 95% CI, 0.48-5.02; P<.05). School functioning PedsQL-4.0 subscores were significantly lower for all children regardless of PPCS status at all time points. CONCLUSIONS AND RELEVANCE Children with PPCS have lower HRQoL compared with those who have recovered from concussion, yet deficits in HRQoL are pervasive across all domains and may persist for months even in children whose symptoms have resolved. Future interventional research should target the effect of concussion on HRQoL.	[Aglipay, Mary; Barrowman, Nick; Ledoux, Andree-Anne; Osmond, Martin H.; Zemek, Roger L.] Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada; [Novak, Zuzana] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Yeates, Keith O.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith O.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Beauchamp, Miriam H.; Gravel, Jocelyn] Univ Montreal, Ste Justine Res Ctr, Montreal, PQ, Canada; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Gravel, Jocelyn] Hosp Ste Justine, Dept Pediat, Montreal, PQ, Canada; [Freedman, Stephen B.] Alberta Childrens Prov Gen Hosp, Dept Pediat, Calgary, AB, Canada; [Gagnon, Isabelle] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Gioia, Gerard] George Washington Univ, Sch Med, Childrens Natl Hlth Syst, Dept Neuropsychol, Rockville, MD USA; [Boutis, Kathy] Hosp Sick Children, Dept Pediat, Toronto, ON, Canada; [Burns, Emma] Izaak Walton Killam Hlth Ctr, Dept Pediat, Halifax, NS, Canada; [Osmond, Martin H.; Zemek, Roger L.] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON, Canada	Zemek, RL (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	rzernek@crieo.on.ca	Yeates, Keith/AAJ-4223-2020; Barrowman, Nick/AAL-3166-2020; Zemek, Roger/H-1039-2018; Freedman, Stephen/H-9102-2012	Barrowman, Nick/0000-0002-4704-9595; Freedman, Stephen/0000-0003-2319-6192; Yeates, Keith/0000-0001-7680-2892; Osmond, Martin/0000-0001-8275-8381; Gravel, Jocelyn/0000-0001-5901-4990	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TM1 127047, MRP 119829]; Canadian Institutes of Health Research-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury Team [126197]	This study was supported by operating grant TM1 127047 from the Canadian Institutes of Health Research and grant 126197 from the Canadian Institutes of Health Research-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury Team. Preliminary work was funded by planning grant MRP 119829 from the Canadian Institutes of Health Research.	Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Carroll L J, 2011, CONCUSSION CRISIS AN; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Desai AD, 2014, JAMA PEDIATR, V168, P1114, DOI 10.1001/jamapediatrics.2014.1600; Erickson SJ, 2010, DEV NEUROREHABIL, V13, P175, DOI 10.3109/17518420903479867; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; GRONWALL D, 1975, LANCET, V2, P995; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Naughton MJ, 2014, J PEDIAT, V164; Pieper P, 2014, BRAIN INJURY, V28, P105, DOI 10.3109/02699052.2013.847208; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rodgers C, 2015, J PEDIATR ONCOL NURS, V32, P329, DOI 10.1177/1043454214563413; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 2015, J HEAD TRAUMA REHAB, V30, P302, DOI 10.1097/HTR.0000000000000106; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; World Health Organization, 1992, INT STAT CLASS DIS; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550corr1; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088	37	61	61	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	DEC 1	2016	170	12							e162900	10.1001/jamapediatrics.2016.2900			8	Pediatrics	Pediatrics	EF3WZ	WOS:000390256900002	27775762	Bronze			2021-06-18	
J	Wang, XT; Gao, X; Michalski, S; Zhao, S; Chen, JH				Wang, Xiaoting; Gao, Xiang; Michalski, Stephanie; Zhao, Shu; Chen, Jinhui			Traumatic Brain Injury Severity Affects Neurogenesis in Adult Mouse Hippocampus	JOURNAL OF NEUROTRAUMA			English	Article						neural stem cell proliferation; injury severity; traumatic brain injury; neurogenesis	CONTROLLED CORTICAL IMPACT; DENTATE GYRUS; NEURAL STEM; NEURONAL DIFFERENTIATION; ENHANCED NEUROGENESIS; CELL-PROLIFERATION; COGNITIVE RECOVERY; GRANULE CELLS; RATS; MICE	Traumatic brain injury (TBI) has been proven to enhance neural stem cell (NSC) proliferation in the hippocampal dentate gyrus. However, various groups have reported contradictory results on whether TBI increases neurogenesis, partially due to a wide range in the severities of injuries seen with different TBI models. To address whether the severity of TBI affects neurogenesis in the injured brain, we assessed neurogenesis in mouse brains receiving different severities of controlled cortical impact (CCI) with the same injury device. The mice were subjected to mild, moderate, or severe TBI by a CCI device. The effects of TBI severity on neurogenesis were evaluated at three stages: NSC proliferation, immature neurons, and newly-generated mature neurons. The results showed that mild TBI did not affect neurogenesis at any of the three stages. Moderate TBI promoted NSC proliferation without increasing neurogenesis. Severe TBI increased neurogenesis at all three stages. Our data suggest that the severity of injury affects adult neurogenesis in the hippocampus, and thus it may partially explain the inconsistent results of different groups regarding neurogenesis following TBI. Further understanding the mechanism of TBI-induced neurogenesis may provide a potential approach for using endogenous NSCs to protect against neuronal loss after trauma.	[Wang, Xiaoting; Gao, Xiang; Zhao, Shu; Chen, Jinhui] Indiana Univ, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA; [Wang, Xiaoting; Gao, Xiang; Zhao, Shu; Chen, Jinhui] Indiana Univ, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Wang, Xiaoting; Gao, Xiang; Michalski, Stephanie; Zhao, Shu; Chen, Jinhui] Indiana Univ, Dept Neurol Surg, Indianapolis, IN 46202 USA	Chen, JH (corresponding author), Indiana Univ, 320 W 15th St, Indianapolis, IN 46202 USA.	chen204@iupui.edu			NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001108] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR025761, UL1 RR025761] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R21NS072631-01A, 1R21NS075733-01A1] Funding Source: Medline		Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Belarbi K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00145; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Christian KM, 2014, ANNU REV NEUROSCI, V37, P243, DOI 10.1146/annurev-neuro-071013-014134; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faigle R, 2013, BBA-GEN SUBJECTS, V1830, P2435, DOI 10.1016/j.bbagen.2012.09.002; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Prigatano GP, 2005, ACT NEUR S, V93, P39; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Thomas R., 2013, REPORT C TRAUMATIC B; Trotter J, 2010, BRAIN RES REV, V63, P72, DOI 10.1016/j.brainresrev.2009.12.006; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	48	61	62	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					721	733		10.1089/neu.2015.4097			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900002	26414411	Green Published			2021-06-18	
J	Ponsford, J; Lee, NK; Wong, D; Mckay, A; Haines, K; Alway, Y; Downing, M; Furtado, C; O'Donnell, ML				Ponsford, J.; Lee, N. K.; Wong, D.; McKay, A.; Haines, K.; Alway, Y.; Downing, M.; Furtado, C.; O'Donnell, M. L.			Efficacy of motivational interviewing and cognitive behavioral therapy for anxiety and depression symptoms following traumatic brain injury	PSYCHOLOGICAL MEDICINE			English	Article						Anxiety; cognitive behavioral therapy; depression; motivational interviewing; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; PSYCHIATRIC-DISORDERS; STRESS-DISORDER; INDIVIDUALS; CBT; REHABILITATION; PSYCHOTHERAPY; ENGAGEMENT; FREQUENCY; PROGRAM	Background Anxiety and depression are common following traumatic brain injury (TBI), often co-occurring. This study evaluated the efficacy of a 9-week cognitive behavioral therapy (CBT) program in reducing anxiety and depression and whether a three-session motivational interviewing (MI) preparatory intervention increased treatment response. Method A randomized parallel three-group design was employed. Following diagnosis of anxiety and/or depression using the Structured Clinical Interview for DSM-IV, 75 participants with mild-severe TBI (mean age 42.2 years, mean post-traumatic amnesia 22 days) were randomly assigned to an Adapted CBT group: (1) MI + CBT (n = 26), or (2) non-directive counseling (NDC) + CBT (n = 26); or a (3) waitlist control (WC, n = 23) group. Groups did not differ in baseline demographics, injury severity, anxiety or depression. MI and CBT interventions were guided by manuals adapted for individuals with TBI. Three CBT booster sessions were provided at week 21 to intervention groups. Results Using intention-to-treat analyses, random-effects regressions controlling for baseline scores revealed that Adapted CBT groups (MI + CBT and NDC + CBT) showed significantly greater reduction in anxiety on the Hospital Anxiety and Depression Scale [95% confidence interval (CI) -2.07 to -0.06] and depression on the Depression Anxiety and Stress Scale (95% CI -5.61 to -0.12) (primary outcomes), and greater gains in psychosocial functioning on Sydney Psychosocial Reintegration Scale (95% CI 0.04-3.69) (secondary outcome) over 30 weeks post-baseline relative to WC. The group receiving MI + CBT did not show greater gains than the group receiving NDC + CBT. Conclusions Findings suggest that modified CBT with booster sessions over extended periods may alleviate anxiety and depression following TBI.	[Ponsford, J.; Wong, D.; McKay, A.; Haines, K.; Alway, Y.; Downing, M.; Furtado, C.] Monash Univ, Sch Psychol Sci, Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia; [Lee, N. K.] Flinders Univ S Australia, Natl Ctr Educ & Training Addict, Adelaide, SA, Australia; [Lee, N. K.] Curtin Univ, Natl Drug Res Inst, Perth, WA, Australia; [O'Donnell, M. L.] Univ Melbourne, Phoenix Australia, Melbourne, Vic 3010, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Downing, Marina/AAX-2380-2020; McKay, Adam/M-6003-2017	Downing, Marina/0000-0002-3126-6632; Wong, Dana/0000-0001-9619-1929; McKay, Adam/0000-0002-0479-7681; O'Donnell, Meaghan/0000-0003-4349-0022	NHMRCNational Health and Medical Research Council of Australia [606432]	This study was funded by NHMRC grant No 606432. The authors thank Ming-Yun Hsieh for work in developing and piloting the manualized intervention.	Arkowitz H., 2008, MOTIVATIONAL INTERVI; Ashman T, 2014, J HEAD TRAUMA REHAB, V29, P467, DOI 10.1097/HTR.0000000000000098; Baker A, 2005, ADDICTION, V100, P367, DOI 10.1111/j.1360-0443.2005.01002.x; Beck A. T., 1979, COGNITIVE THERAPY DE; Beck J.S., 1995, COGNITIVE THERAPY BA; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Carroll KM, 2006, DRUG ALCOHOL DEPEN, V81, P301, DOI 10.1016/j.drugalcdep.2005.08.002; Coughlin A, 2007, MEMORY INFORM PROCES; Cuijpers P, 2008, J CONSULT CLIN PSYCH, V76, P909, DOI 10.1037/a0013075; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Dugas MJ, 2005, COGNITIVE BEHAV TREA; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; First M.B., 2007, STRUCTURED CLIN INTE; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P585, DOI 10.1080/09602011.2012.678860; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P563, DOI 10.1080/09602011.2012.676284; Hsieh MY, 2012, BRAIN INJURY, V26, P126, DOI 10.3109/02699052.2011.635365; Hsieh MY, 2012, DISABIL REHABIL, V34, P408, DOI 10.3109/09638288.2011.607219; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Medley AR, 2010, NEUROPSYCHOL REHABIL, V20, P481, DOI 10.1080/09602010903529610; O'Donnell ML, 2012, J TRAUMA STRESS, V25, P125, DOI 10.1002/jts.21677; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P1, DOI [10.1017/S135561771000111621083962, DOI 10.1017/S1355617710001116]; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Soo C, 2007, COCHRANE DB SYST REV, V3; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; van den Broek MD, 2005, J HEAD TRAUMA REHAB, V20, P464, DOI 10.1097/00001199-200509000-00007; Waldron B, 2013, NEUROPSYCHOL REHABIL, V23, P64, DOI 10.1080/09602011.2012.724196; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Watkins CL, 2007, STROKE, V38, P1004, DOI 10.1161/01.STR.0000258114.28006.d7; Westra H. A., 2003, MOTIVATIONAL INTERVI; Westra HA, 2007, J CONSULT CLIN PSYCH, V75, P363, DOI 10.1037/0022-006X.75.3.363; Westra HA, 2006, COGNITIVE THER RES, V30, P481, DOI 10.1007/s10608-006-9016-y; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Wilson, 1991, NATL ADULT READING T; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662	49	61	61	0	39	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	APR	2016	46	5					1079	1090		10.1017/S0033291715002640			12	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	DF8PQ	WOS:000371620700016	26708017				2021-06-18	
J	Zhang, L; Ding, K; Wang, HD; Wu, Y; Xu, JG				Zhang, Li; Ding, Ke; Wang, Handong; Wu, Yong; Xu, Jianguo			Traumatic Brain Injury-Induced Neuronal Apoptosis is Reduced Through Modulation of PI3K and Autophagy Pathways in Mouse by FTY720	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						FTY720; Traumatic brain injury; Apoptosis; PI3K/AKT signaling pathway; Autophagy	OXIDATIVE STRESS; CELL-DEATH; N-ACETYLCYSTEINE; CALCIUM-ENTRY; MODEL; NEUROPROTECTION; HIPPOCAMPUS; SURVIVAL; INVOLVEMENT; PROTECTION	FTY720 is a synthetic compound produced by modification of metabolite from Isaria sinclairii. It is a novel type of immunosuppressive agent inhibiting lymphocyte egress from secondary lymphoid tissues, thereby causing peripheral lymphopenia. Growing evidences have suggested that apoptosis and autophagy were involved in the secondary brain injury after traumatic brain injury (TBI) although FTY720 exerted neuroprotective effects in a variety of neurological diseases except TBI. The present study was aimed to investigate the role of FTY720 in a mouse model of TBI. In experiment 1, ICR mice were divided into four groups: sham group, TBI group, TBI + vehicle group, and TBI + FTY720 group. And the injured cerebral cortex (including both contused and penumbra) was used for analysis. We found that FTY720 administration after TBI improved neurobehavioral function, alleviated brain edema, accompanied by modulation of apoptotic indicators such as Bcl-2, Bcl-xL, Bax, and cytochrome c. In experiment 2, ICR mice were also divided into four groups: sham group, TBI + vehicle group, TBI + FTY720 group, and TBI + FTY720 + inhibitors group. And the injured cerebral cortex (including both contused and penumbra) was used for analysis. We found that FTY720 increased the expression of phospho-protein kinase B (AKT) and some autophagy markers such as LC3 and Beclin 1. In addition, the apoptosis inhibition effect of FTY720 was partly abrogated by the phosphatidylinositide 3-kinases (PI3K)/AKT pathway inhibitor LY294002 and autophagy inhibitor 3-methyladenine. Collectively, our data provide the first evidence that FTY720 exerted neuroprotective effects after TBI, at least in part, through the activation of PI3K/AKT pathway and autophagy.	[Zhang, Li; Ding, Ke; Wang, Handong; Wu, Yong; Xu, Jianguo] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81401026]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M562665]	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81371357 & 81401026) and the China Postdoctoral Science Foundation funded project under Grant (No. 2014M562665).	Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Campos F, 2013, STROKE, V44, P505, DOI 10.1161/STROKEAHA.112.679043; Chen SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036784; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Cox-Limpens KEM, 2014, BRAIN RES, V1564, P85, DOI 10.1016/j.brainres.2014.04.001; Czech B, 2009, BIOCHEM BIOPH RES CO, V389, P251, DOI 10.1016/j.bbrc.2009.08.142; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hasegawa Y, 2010, STROKE, V41, P368, DOI 10.1161/STROKEAHA.109.568899; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Kitagishi Y, 2013, ALZHEIMERS RES THER, V5, DOI [10.1186/1758-9193-5-42, 10.1186/alzrt208]; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Lu L, 2014, BRAIN RES, V1555, P89, DOI 10.1016/j.brainres.2014.01.048; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, BRAIN RES, V1502, P1, DOI 10.1016/j.brainres.2013.01.037; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Naziroglu M, 2014, CELL MOL NEUROBIOL, V34, P895, DOI 10.1007/s10571-014-0069-2; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ovey IS, 2015, NEUROSCIENCE, V284, P225, DOI 10.1016/j.neuroscience.2014.09.078; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; RINK A, 1995, AM J PATHOL, V147, P1575; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Sun YX, 2013, NEUROL SCI, V34, P345, DOI 10.1007/s10072-012-1007-z; Walker Chandler L, 2013, Front Biol (Beijing), V8, DOI 10.1007/s11515-013-1255-1; Wang JW, 2014, J SURG RES, V186, P328, DOI 10.1016/j.jss.2013.08.027; Wang LT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079814; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Wei Y, 2011, ANN NEUROL, V69, P119, DOI 10.1002/ana.22186; Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yeh EA, 2011, ADV THER, V28, P270, DOI 10.1007/s12325-011-0004-6; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zhang L, 2013, ONCOL REP, V30, P2571, DOI 10.3892/or.2013.2765; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	41	61	66	2	34	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2016	36	1					131	142		10.1007/s10571-015-0227-1			12	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	DA3KF	WOS:000367694900013	27348907				2021-06-18	
J	Zhao, H; Garton, T; Keep, RF; Hua, Y; Xi, GH				Zhao, Hao; Garton, Thomas; Keep, Richard F.; Hua, Ya; Xi, Guohua			Microglia/Macrophage Polarization After Experimental Intracerebral Hemorrhage	TRANSLATIONAL STROKE RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; NADPH OXIDASE; IN-VIVO; MICROGLIA; ACTIVATION; MECHANISMS; ROLES; INFLAMMATION; PLASTICITY; PATHOLOGY		[Zhao, Hao; Garton, Thomas; Keep, Richard F.; Hua, Ya; Xi, Guohua] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA	Xi, GH (corresponding author), Univ Michigan, Dept Neurosurg, R5018 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	guohuaxi@umich.edu		Garton, Thomas/0000-0001-9352-8530; Keep, Richard/0000-0001-6441-5334	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS091545, R01 NS073595, R21 NS084049, NS-090925, NS-091545, R01 NS090925, NS-079157, R01 NS079157, NS-084049, NS-073595] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079157, R21NS091545, R01NS073595, R21NS084049, R01NS090925] Funding Source: NIH RePORTER		Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Benton RL, 2011, TRANSL STROKE RES, V2, P556, DOI 10.1007/s12975-011-0128-7; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Boscia F, 2013, ADV EXP MED BIOL, V961, P307, DOI 10.1007/978-1-4614-4756-6_26; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; del Zoppo GJ, 2010, ANN NY ACAD SCI, V1207, P46, DOI 10.1111/j.1749-6632.2010.05760.x; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Gao HM, 2003, J NEUROSCI, V23, P6181; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jin H, 2013, TRANSL STROKE RES, V4, P130, DOI 10.1007/s12975-012-0232-3; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Pennypacker KR, 2014, TRANSL STROKE RES, V5, P635, DOI 10.1007/s12975-014-0372-8; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhao JB, 2014, TRANSL STROKE RES, V5, P586, DOI 10.1007/s12975-014-0353-y; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	34	61	62	1	22	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2015	6	6					407	409		10.1007/s12975-015-0428-4			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CV3JE	WOS:000364154700001	26446073	Green Accepted			2021-06-18	
J	Hellyer, PJ; Scott, G; Shanahan, M; Sharp, DJ; Leech, R				Hellyer, Peter J.; Scott, Gregory; Shanahan, Murray; Sharp, David J.; Leech, Robert			Cognitive Flexibility through Metastable Neural Dynamics Is Disrupted by Damage to the Structural Connectome	JOURNAL OF NEUROSCIENCE			English	Article						cognitive flexibility; computational modeling; connectome; metastability; traumatic brain injury	RICH-CLUB ORGANIZATION; DIFFUSE AXONAL INJURY; RESPONSE-INHIBITION; SALIENCE NETWORK; BRAIN; CONNECTIVITY; CRITICALITY; MODEL; SYNCHRONIZATION; DIAGNOSIS	Current theory proposes that healthy neural dynamics operate in a metastable regime, where brain regions interact to simultaneously maximize integration and segregation. Metastability may confer important behavioral properties, such as cognitive flexibility. It is increasingly recognized that neural dynamics are constrained by the underlying structural connections between brain regions. An important challenge is, therefore, to relate structural connectivity, neural dynamics, and behavior. Traumatic brain injury (TBI) is a pre-eminent structural disconnection disorder whereby traumatic axonal injury damages large-scale connectivity, producing characteristic cognitive impairments, including slowed information processing speed and reduced cognitive flexibility, that may be a result of disrupted metastable dynamics. Therefore, TBI provides an experimental and theoretical model to examine how metastable dynamics relate to structural connectivity and cognition. Here, we use complementary empirical and computational approaches to investigate how metastability arises from the healthy structural connectome and relates to cognitive performance. We found reduced metastability in large-scale neural dynamics after TBI, measured with resting-state functional MRI. This reduction in metastability was associated with damage to the connectome, measured using diffusion MRI. Furthermore, decreased metastability was associated with reduced cognitive flexibility and information processing. A computational model, defined by empirically derived connectivity data, demonstrates how behaviorally relevant changes in neural dynamics result from structural disconnection. Our findings suggest how metastable dynamics are important for normal brain function and contingent on the structure of the human connectome.	[Hellyer, Peter J.; Scott, Gregory; Sharp, David J.; Leech, Robert] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England; [Hellyer, Peter J.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Neuroimaging Sci, London SE5 8AF, England; [Shanahan, Murray] Univ London Imperial Coll Sci Technol & Med, Dept Comp, London SW7 2RH, England	Leech, R (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes,Du Cane Rd, London W12 0NN, England.	r.leech@imperial.ac.uk	Sharp, David J/A-2119-2013; Hellyer, Peter J/F-7112-2013; Leech, Robert/AAE-8254-2019	Hellyer, Peter J/0000-0002-5139-3401; Leech, Robert/0000-0002-5801-6318; Scott, Gregory/0000-0001-8063-5871	Medical Research Council Doctoral Training AwardUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	P.J.H. was supported by a Medical Research Council Doctoral Training Award. G.S. was supported by a clinical research fellowship awarded in the Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme. We thank Frantisek Vasa for useful conversations on comparing simulated and empirical networks. We also thank the participants who were involved in this research.	Acebron JA, 2005, REV MOD PHYS, V77, P137, DOI 10.1103/RevModPhys.77.137; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baddeley A. D., 1986, WORKING MEMORY; Baddeley AD, 1994, DOORS PEOPLE TEST VI; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Bassett DS, 2006, NEUROSCIENTIST, V12, P512, DOI 10.1177/1073858406293182; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Beggs JM, 2003, J NEUROSCI, V23, P11167; Beggs JM, 2008, PHILOS T R SOC A, V366, P329, DOI 10.1098/rsta.2007.2092; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bhowmik D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062234; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Cabral J, 2012, NEUROIMAGE, V62, P1342, DOI 10.1016/j.neuroimage.2012.06.007; Cabral J, 2011, NEUROIMAGE, V57, P130, DOI 10.1016/j.neuroimage.2011.04.010; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Chang C, 2010, NEUROIMAGE, V50, P81, DOI 10.1016/j.neuroimage.2009.12.011; Chialvo DR, 2010, NAT PHYS, V6, P744, DOI 10.1038/NPHYS1803; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Deco G, 2009, PROG NEUROBIOL, V88, P1, DOI 10.1016/j.pneurobio.2009.01.006; Deco G, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000092; Erika-Florence M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5073; Fagerholm ED, 2015, J NEUROSCI, V35, P4626, DOI 10.1523/JNEUROSCI.3694-14.2015; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; FREEMAN LC, 1978, SOCIOL METHOD RES, V6, P411, DOI 10.1177/004912417800600401; Friston Karl J, 2002, World Psychiatry, V1, P66; Friston KJ, 2000, NEUROIMAGE, V12, P466, DOI 10.1006/nimg.2000.0630; Friston KJ, 1997, NEUROIMAGE, V5, P164, DOI 10.1006/nimg.1997.0259; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gigandet X, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004006; Glerean E, 2012, BRAIN CONNECT, V2, P91, DOI 10.1089/brain.2011.0068; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Haldeman C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.058101; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Humphries MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002051; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones D. K., 2010, IMAGING MED, V2, P341; Jones Derek K, 2010, Top Magn Reson Imaging, V21, P87, DOI 10.1097/RMR.0b013e31821e56ac; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kitzbichler MG, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000314; Kuramoto Y., 1984, CHEM OSCILLATIONS WA; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Messe A, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003530; Niazy RK, 2011, PROG BRAIN RES, V193, P259, DOI 10.1016/B978-0-444-53839-0.00017-X; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Scott G, 2014, J NEUROSCI, V34, P16611, DOI 10.1523/JNEUROSCI.3474-14.2014; Senden M, 2014, NEUROIMAGE, V96, P174, DOI 10.1016/j.neuroimage.2014.03.066; Shanahan M, 2010, CHAOS, V20, DOI 10.1063/1.3305451; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sharp DJ, 2010, ANN NEUROL, V68, P753, DOI 10.1002/ana.21866; Shew WL, 2013, NEUROSCIENTIST, V19, P88, DOI 10.1177/1073858412445487; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sporns O, 2006, BIOSYSTEMS, V85, P55, DOI 10.1016/j.biosystems.2006.02.008; Spreng RN, 2010, J COGNITIVE NEUROSCI, V22, P1112, DOI 10.1162/jocn.2009.21282; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Tagliazucchi E, 2014, NEURON, V82, P695, DOI 10.1016/j.neuron.2014.03.020; Tognoli E, 2014, NEURON, V81, P35, DOI 10.1016/j.neuron.2013.12.022; Uhhaas PJ, 2006, NEURON, V52, P155, DOI 10.1016/j.neuron.2006.09.020; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Warren DE, 2014, P NATL ACAD SCI USA, V111, P14247, DOI 10.1073/pnas.1322173111; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Werner G, 2007, BIOSYSTEMS, V90, P496, DOI 10.1016/j.biosystems.2006.12.001; Wildie M, 2012, CHAOS, V22, DOI 10.1063/1.4766592; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060	82	61	62	2	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 17	2015	35	24					9050	9063		10.1523/JNEUROSCI.4648-14.2015			14	Neurosciences	Neurosciences & Neurology	CN2KU	WOS:000358250700010	26085630	Green Published, Bronze			2021-06-18	
J	Grandhi, R; Harrison, G; Voronovich, Z; Bauer, J; Chen, SH; Nicholas, D; Alarcon, LH; Okonkwo, DO				Grandhi, Ramesh; Harrison, Gillian; Voronovich, Zoya; Bauer, Joshua; Chen, Stephanie H.; Nicholas, Dederia; Alarcon, Louis H.; Okonkwo, David O.			Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; aspirin; clopidogrel; warfarin; mortality	INTRACRANIAL HEMORRHAGE; HEAD-INJURY; ANTICOAGULATED PATIENTS; PLATELET TRANSFUSION; IMPACT; OUTCOMES; RISK; CLOPIDOGREL; ASPIRIN; AGENTS	BACKGROUND: Previous studies of traumatic brain injury ( TBI) outcomes in elderly patients on oral antithrombotic ( OAT) therapies have yielded conflicting results. Our objective was to examine the effect of premorbid OAT medications on outcomes among elderly TBI patients with intracranial hemorrhage. METHODS: We performed a retrospective analysis of elderly TBI patients ( >= 65 years) with closed head injury and evidence of brain hemorrhage on computed tomography scan from 2006 to 2010. Patient demographics, injury severity, clinical course, hospital and intensive care unit length of stay, and disposition were collected. Comparison of patients stratified by premorbid OAT use was performed using nonparametric Kruskal-Wallis and Fisher's exact tests. Multivariable logistic regression was used to compare groups and identify predictors of primary outcomes, including mortality, neurosurgical intervention, hemorrhage progression, complications, and infection. RESULTS: A total of 1,552 patients were identified: 543 on aspirin only, 97 on clopidogrel only, 218 on warfarin only, 193 on clopidogrel and aspirin, and 501 on no antithrombotic agent. Blood products were administered to reverse coagulopathy in 77.3% of patients on antithrombotic medications. After adjusting for covariates, including medication reversal, OAT use was associated with increased mortality ( p = 0.04). Warfarin use was identified as a key predictor ( odds ratio, 2.27; p = 0.05), in contrast to the preinjury use of antiplatelet medications, which was not associated with increased risk of in-hospital death. Rates of neurosurgical intervention differed between groups, with patients on warfarin undergoing intervention more frequently. Survivor subset analysis demonstrated that hemorrhage progression was not associated with preinjury antithrombotic therapy, nor were rates of complication or infection, hospital and intensive care unit lengths of stay, or ventilator days. CONCLUSION: Preinjury use of warfarin, but not antiplatelet medications, influences survival and need for neurosurgical intervention in elderly TBI patients with intracranial hemorrhage; hemorrhage progression and morbidity are not affected. The importance of antithrombotic therapy may lie in its impact on initial injury severity. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)	[Grandhi, Ramesh; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Nicholas, Dederia; Alarcon, Louis H.] Univ Pittsburgh, Med Ctr, Div Trauma & Gen Surg, Dept Surg, Pittsburgh, PA 15213 USA; [Bauer, Joshua; Chen, Stephanie H.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; [Voronovich, Zoya] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Harrison, Gillian] NYU Langone Med Ctr, Dept Neurosurg, New York, NY USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu		Alarcon, Louis/0000-0001-6994-8412			Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; [Anonymous], 2005, J TRAUMA; [Anonymous], 2008, J TRAUMA; [Anonymous], 2008, SURGERY; Bonville DJ, 2011, SURGERY, V150, P861, DOI 10.1016/j.surg.2011.07.070; Centers for Disease Control and Prevention (CDC), 2012, MMWR-MORBID MORTAL W, V61, P11; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Depreitere B, 2012, Acta Neurochir Suppl, V114, P289, DOI 10.1007/978-3-7091-0956-4_56; Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313; Downey DM, 2009, AM SURGEON, V75, P1100; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gangavati AS, 2009, J AM GERIATR SOC, V57, P1470, DOI 10.1111/j.1532-5415.2009.02344.x; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Grandhi R, 2008, AM SURGEON, V74, P802; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirley K, 2012, CIRC-CARDIOVASC QUAL, V5, P615, DOI 10.1161/CIRCOUTCOMES.112.967299; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Ott MM, 2010, J TRAUMA, V68, P560, DOI 10.1097/TA.0b013e3181ad6600; Peck KA, 2011, J TRAUMA, V71, P1600, DOI 10.1097/TA.0b013e31823b9ce1; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Vincent GK, NEXT 4 DECADES OLDER; Wahl WL, 2001, J TRAUMA, V51, P1151; Warkentin AE, 2012, J THROMB HAEMOST, V10, P512, DOI 10.1111/j.1538-7836.2012.04635.x; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Werner C, 2010, OLDER POPULATION 201; Williams TM, 2008, J TRAUMA, V65, P772, DOI 10.1097/TA.0b013e3181877ff7; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	41	61	63	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2015	78	3					614	621		10.1097/TA.0000000000000542			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CE8DQ	WOS:000352072000030	25710435				2021-06-18	
J	Linam, WM; Ahmed, M; Cope, JR; Chu, C; Visvesvara, GS; da Silva, AJ; Qvarnstrom, Y; Green, J				Linam, W. Matthew; Ahmed, Mubbasheer; Cope, Jennifer R.; Chu, Craig; Visvesvara, Govinda S.; da Silva, Alexandre J.; Qvarnstrom, Yvonne; Green, Jerril			Successful Treatment of an Adolescent With Naegleria fowleri Primary Amebic Meningoencephalitis	PEDIATRICS			English	Article							SEVERE BACTERIAL-MENINGITIS; FREE-LIVING AMEBAS; IN-VITRO; BALAMUTHIA-MANDRILLARIS; AMPHOTERICIN-B; ACANTHAMOEBA SPP.; BRAIN-INJURY; MOUSE MODEL; HYPOTHERMIA; INFECTION	Naegleria fowleri is a thermophilic, free-living ameba that causes primary amebic meningoencephalitis. The infections are nearly always fatal. We present the third well-documented survivor of this infection in North America. The patient's survival most likely resulted from a variety of factors: early identification and treatment, use of a combination of antimicrobial agents (including miltefosine), and management of elevated intracranial pressure based on the principles of traumatic brain injury.	[Linam, W. Matthew] Arkansas Childrens Hosp, Pediat Infect Dis Sect, Little Rock, AR 72202 USA; [Ahmed, Mubbasheer; Chu, Craig; Green, Jerril] Arkansas Childrens Hosp, Pediat Crit Care Sect, Little Rock, AR 72202 USA; [Cope, Jennifer R.; Visvesvara, Govinda S.; da Silva, Alexandre J.; Qvarnstrom, Yvonne] Ctr Dis Control & Prevent, Atlanta, GA USA	Linam, WM (corresponding author), Arkansas Childrens Hosp, Pediat Infect Dis Sect, 1 Childrens Way,Slot 512-11, Little Rock, AR 72202 USA.	wlinam@uams.edu			Intramural CDC HHS [CC999999] Funding Source: Medline		Aichelburg AC, 2008, EMERG INFECT DIS, V14, P1743, DOI 10.3201/eid1411.070854; Centers for Disease Control and Prevention, NAEGL FOWL PRIM AM M; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cope JR, 2013, MMWR-MORBID MORTAL W, V62, P666; Goswick SM, 2003, ANTIMICROB AGENTS CH, V47, P524, DOI 10.1128/AAC.47.2.524-528.2003; Hunte T, 2013, MMWR-MORBID MORTAL W, V62, P903; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; Kemble SK, 2012, CLIN INFECT DIS, V54, P805, DOI 10.1093/cid/cir961; Lepur D, 2011, J INFECTION, V62, P172, DOI 10.1016/j.jinf.2010.10.001; Martinez DY, 2010, CLIN INFECT DIS, V51, pE7, DOI 10.1086/653609; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Rojas-Hernandez S, 2004, PARASITOL RES, V94, P31, DOI 10.1007/s00436-004-1177-6; Schuster FL, 2006, J EUKARYOT MICROBIOL, V53, P121, DOI 10.1111/j.1550-7408.2005.00082.x; SEIDEL JS, 1982, NEW ENGL J MED, V306, P346, DOI 10.1056/NEJM198202113060607; Soltow SM, 2007, ANTIMICROB AGENTS CH, V51, P23, DOI 10.1128/AAC.00788-06; Tiewcharoen Supathra, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P38; van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2; Vargas-Zepeda J, 2005, ARCH MED RES, V36, P83, DOI 10.1016/j.arcmed.2004.11.003; Visvesvara GS, 2007, FEMS IMMUNOL MED MIC, V50, P1, DOI 10.1111/j.1574-695X.2007.00232.x; Xu LJ, 2002, J CEREBR BLOOD F MET, V22, P21, DOI 10.1097/00004647-200201000-00003; Yoder JS, 2010, EPIDEMIOL INFECT, V138, P968, DOI 10.1017/S0950268809991014; Yoder JS, 2012, CLIN INFECT DIS, V55, pE79, DOI 10.1093/cid/cis626	24	61	62	1	24	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2015	135	3					E744	E748		10.1542/peds.2014-2292			5	Pediatrics	Pediatrics	CF0BD	WOS:000352206600027	25667249	Green Accepted			2021-06-18	
J	Hartings, JA; Wilson, JA; Hinzman, JM; Pollandt, S; Dreier, JP; DiNapoli, V; Ficker, DM; Shutter, LA; Andaluz, N				Hartings, Jed A.; Wilson, J. Adam; Hinzman, Jason M.; Pollandt, Sebastian; Dreier, Jens P.; DiNapoli, Vince; Ficker, David M.; Shutter, Lori A.; Andaluz, Norberto			Spreading Depression in Continuous Electroencephalography of Brain Trauma	ANNALS OF NEUROLOGY			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; FOCAL CEREBRAL-ISCHEMIA; INJURED HUMAN BRAIN; PERIINFARCT DEPOLARIZATIONS; MALIGNANT STROKE; BREACH RHYTHM; EEG; CORTEX; SEIZURES; SPIKES	ObjectiveCortical spreading depolarizations are a pathophysiological mechanism and candidate target for advanced monitoring in acute brain injury. Here we investigated manifestations of spreading depolarization in continuous electroencephalography (EEG) as a broadly applicable, noninvasive method for neuromonitoring. MethodsEighteen patients requiring surgical treatment of traumatic brain injury were monitored by invasive electrocorticography (ECoG; subdural electrodes) and noninvasive scalp EEG during intensive care. Spreading depolarizations were first identified in subdural recordings, and EEG was then examined visually and quantitatively to identify correlates. ResultsA total of 455 spreading depolarizations occurred during 65.9 days of simultaneous ECoG/EEG monitoring. For 179 of 455 events (39%), depolarizations caused temporally isolated, transient depressions of spontaneous EEG amplitudes to 57% (median) of baseline power. Depressions lasted 21 minutes (median) and occurred as suppressions of high-amplitude delta activity present as a baseline pattern in the injured hemisphere. For 62 of 179 (35%) events, isolated depressions showed a clear spread of depression between EEG channels with delays of 17 minutes (median), sometimes spanning the entire hemisphere. A further 188 of 455 (41%) depolarizations were associated with continuous EEG depression that lasted hours to days due to ongoing depolarizations. Depolarizations were also evidenced in EEG as shifts in direct current potentials. InterpretationLeAo's spreading depression can be observed in clinically standard, continuous scalp EEG, and underlying depolarizations can spread widely across the injured cerebral hemisphere. These results open the possibility of monitoring noninvasively a neuronal pathophysiological mechanism in a wide range of disorders including ischemic stroke, subarachnoid hemorrhage, and brain trauma, and suggest a novel application for continuous EEG. Ann Neurol 2014;76:681-694	[Hartings, Jed A.; Wilson, J. Adam; Hinzman, Jason M.; DiNapoli, Vince; Shutter, Lori A.; Andaluz, Norberto] Univ Cincinnati, Dept Neurosurg, Coll Med, Cincinnati, OH 45267 USA; [Hartings, Jed A.; Shutter, Lori A.; Andaluz, Norberto] Univ Cincinnati, Neurosci Inst, Neurotrauma Ctr, Cincinnati, OH 45267 USA; [Hartings, Jed A.; DiNapoli, Vince; Shutter, Lori A.; Andaluz, Norberto] Mayfield Clin, Cincinnati, OH USA; [Pollandt, Sebastian; Ficker, David M.; Shutter, Lori A.] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA; [Dreier, Jens P.] Charite, Dept Expt Neurol, Ctr Stroke Res, D-13353 Berlin, Germany; [Dreier, Jens P.] Charite, Ctr Stroke Res, Dept Neurol, D-13353 Berlin, Germany	Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, 231 Albert Sabin Way,ML0517, Cincinnati, OH 45267 USA.	jed.hartings@uc.edu	Pollandt, Sebastian/I-8055-2019; Shutter, Lori A/G-2957-2013	Pollandt, Sebastian/0000-0003-1540-7439; Hartings, Jed/0000-0001-8583-3471; Dreier, Jens/0000-0001-7459-2828; Shutter, Lori/0000-0002-1390-0628	US Army CDMRP PH/TBI Research Program [W81XWH-08-2-0016]; Mayfield Education and Research Foundation; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG DR323/5-1]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 0801]; Bundesministerium fur Bildung und Forschung (Bernstein Center for Computational Neuroscience Berlin)Federal Ministry of Education & Research (BMBF) [01GQ1001C B2]	This work was funded by the US Army CDMRP PH/TBI Research Program (Contract No. W81XWH-08-2-0016) and the Mayfield Education and Research Foundation. J.P.D. acknowledges support from the Deutsche Forschungsgemeinschaft (DFG DR323/5-1) and the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801; Bernstein Center for Computational Neuroscience Berlin 01GQ1001C B2).	[Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Brigo F, 2011, CLIN NEUROPHYSIOL, V122, P2116, DOI 10.1016/j.clinph.2011.07.024; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; COBB WA, 1979, ELECTROEN CLIN NEURO, V47, P251, DOI 10.1016/0013-4694(79)90278-5; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FAUGHT E, 1993, STROKE, V24, P609, DOI 10.1161/01.STR.24.4.609; Foreman B, 2012, CRIT CARE, V16, DOI 10.1186/cc11230; Gorji A, 2004, EUR J NEUROSCI, V19, P3371, DOI 10.1111/j.0953-816X.2004.03436.x; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2006, J CEREBR BLOOD F MET, V26, P696, DOI 10.1038/sj.jcbfm.9600223; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; Kobayashi K, 2005, EPILEPSIA, V46, P397, DOI 10.1111/j.0013-9580.2005.31404.x; Kruger H, 1996, NEUROREPORT, V7, P2733; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Tao JX, 2005, EPILEPSIA, V46, P669, DOI 10.1111/j.1528-1167.2005.11404.x; Vanhatalo S, 2005, CLIN NEUROPHYSIOL, V116, P1, DOI 10.1016/j.clinph.2004.09.015; VansHarreveld A, 1953, J NEUROPHYSIOL, V16, P352; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Voytek B, 2010, J COGNITIVE NEUROSCI, V22, P2491, DOI 10.1162/jocn.2009.21384; Wilson JA, 2013, ACTA NEUROCHIR SUPPL, V115, P67, DOI 10.1007/978-3-7091-1192-5_15; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932	40	61	61	0	18	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	NOV	2014	76	5					681	694		10.1002/ana.24256			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AS9ZE	WOS:000344596000006	25154587				2021-06-18	
J	Pandya, JD; Readnower, RD; Patel, SP; Yonutas, HM; Pauly, JR; Goldstein, GA; Rabchevsky, AG; Sullivan, PG				Pandya, Jignesh D.; Readnower, Ryan D.; Patel, Samir P.; Yonutas, Heather M.; Pauly, James R.; Goldstein, Glenn A.; Rabchevsky, Alexander G.; Sullivan, Patrick G.			N-acetylcysteine amide confers neuroprotection, improves bioenergetics and behavioral outcome following TBI	EXPERIMENTAL NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; CONTROLLED CORTICAL IMPACT; CELL-DEATH; OXIDATIVE STRESS; PROTEOMIC IDENTIFICATION; SYNAPTIC PROTEINS; TIME-COURSE; RAT MODEL; ANTIOXIDANT	Traumatic brain injury (TBI) has become a growing epidemic but no approved pharmacological treatment has been identified. Our previous work indicates that mitochondrial oxidative stress/damage and loss of bioenergetics play a pivotal role in neuronal cell death and behavioral outcome following experimental TBI. One tactic that has had some experimental success is to target glutathione using its precursor N-acetylcysteine (NAC). However, this approach has been hindered by the low CNS bioavailability of NAC. The current study evaluated a novel, cell permeant amide form of N-acetylcysteine (NACA), which has high permeability through cellular and mitochondrial membranes resulting in increased CNS bioavailability. Cortical tissue sparing, cognitive function and oxidative stress markers were assessed in rats treated with NACA, NAC, or vehicle following a TBI. At 15 days post-injury, animals treated with NACA demonstrated significant improvements in cognitive function and cortical tissue sparing compared to NAC or vehicle treated animals. NACA treatment also was shown to reduce oxidative damage (HNE levels) at 7 days post-injury. Mechanistically, post-injury NACA administration was demonstrated to maintain levels of mitochondrial glutathione and mitochondrial bioenergetics comparable to sham animals. Collectively these data provide a basic platform to consider NACA as a novel therapeutic agent for treatment of TBI. (C) 2014 Elsevier Inc All rights reserved.	[Pandya, Jignesh D.; Readnower, Ryan D.; Patel, Samir P.; Yonutas, Heather M.; Pauly, James R.; Rabchevsky, Alexander G.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Readnower, Ryan D.; Yonutas, Heather M.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Patel, Samir P.; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA; [Goldstein, Glenn A.] Karolinska Inst, Pediat Endocrinol Dept Womens & Childrens Hlth, Stockholm, Sweden	Sullivan, PG (corresponding author), Univ Kentucky, Chandler Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Anat & Neurobiol,Endowed Chair, 475 BBSRB,741 South Limestone St, Lexington, KY 40536 USA.	Patsull@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS062993, R01NS069633, P30NS051220]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS062993, F31NS086395, R01NS069633] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS R01 NS062993 (JWG and PGS), R01NS069633 (AGR and PGS), NIH/NINDS P30NS051220 and funding from the Kentucky Spinal Cord and Head Injury Research Trust. We would like to thank Andrea Sebastian for expert technical assistance.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Avery MA, 2012, CURR BIOL, V22, P596, DOI 10.1016/j.cub.2012.02.043; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bartov O, 2006, BRAIN RES, V1069, P198, DOI 10.1016/j.brainres.2005.10.079; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; CHOI DW, 1987, J NEUROSCI, V7, P357; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Dykens J.A., 1994, J NEUROCHEM, V63, P584; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Grinberg L, 2005, FREE RADICAL BIO MED, V38, P136, DOI 10.1016/j.freeradbiomed.2004.09.025; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HALLIWELL B, 1991, DRUGS, V42, P569, DOI 10.2165/00003495-199142040-00003; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Offen D, 2004, J NEUROCHEM, V89, P1241, DOI 10.1111/j.1471-4159.2004.02428.x; Offen D., 1999, BRAIN TARGETED LOW M; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Penugonda S, 2005, BRAIN RES, V1056, P132, DOI 10.1016/j.brainres.2005.07.032; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sims NR, 2004, J BIOENERG BIOMEMBR, V36, P329, DOI 10.1023/B:JOBB.0000041763.63958.e7; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Stelmasiak Z, 2000, Med Sci Monit, V6, P426; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sunitha K, 2013, FREE RADICAL RES, V47, P357, DOI 10.3109/10715762.2013.781595; Thomale UW, 2005, ACT NEUR S, V95, P429; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	59	61	61	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2014	257						106	113		10.1016/j.expneurol.2014.04.020			8	Neurosciences	Neurosciences & Neurology	AK1MU	WOS:000338180000012	24792639	Green Accepted			2021-06-18	
J	Plumb, TR; Peachey, JT; Zelman, DC				Plumb, Taylor R.; Peachey, John T.; Zelman, Diane C.			Sleep Disturbance Is Common Among Servicemembers and Veterans of Operations Enduring Freedom and Iraqi Freedom	PSYCHOLOGICAL SERVICES			English	Article						veterans; military service; sleep; insomnia; nightmares; PTSD	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; COGNITIVE-BEHAVIOR THERAPY; TRAUMATIC BRAIN-INJURY; QUALITY INDEX ADDENDUM; PSYCHIATRIC-DISORDERS; CHRONIC INSOMNIA; COMBAT VETERANS; AFGHANISTAN; WAR	Sleep routines that develop as an adaptation or reaction to deployment can persist upon return stateside. Sleep problems intensify and are intensified by psychiatric distress. This research presents the findings of a comprehensive survey of sleep impairment in relation to demographic data, military history, combat exposure, and mental illness symptoms among a general sample of 375 servicemembers and veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) at a wide range of times postdeployment. Sleep impairment was assessed with the Pittsburgh Sleep Quality Index (PSQI) and the Addendum for PTSD. Posttraumatic stress disorder (PTSD), depression, and anxiety symptoms were evaluated, with the PTSD Checklist-Military, the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder-7. Sleep problems were common across the sample, with 45.4% of participants reporting sleep onset greater than 30 minutes, 21.4% typically achieving less than 4.5 hours of total sleep time, and 56% reporting being awake in bed more than 15% of the night. Global PSQI scores classified 89% of the sample as "poor sleepers." Sleep problems were more severe among servicemembers with less education, from lower ranks (E1-E3), with greater combat exposure, and greater depression, anxiety, and PTSD symptoms. These findings suggest the need for routine screening of sleep problems among veterans and increased professional training in interventions for insomnia and nightmares. For individuals experiencing sleep problems with concurrent psychiatric symptoms, addressing sleep concerns may be one less-stigmatizing way to transition servicemembers and veterans into needed mental health services.	[Plumb, Taylor R.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; [Peachey, John T.; Zelman, Diane C.] Alliant Int Univ, Calif Sch Profess Psychol, Clin Psychol Program, San Francisco, CA 94133 USA	Zelman, DC (corresponding author), Alliant Int Univ, Calif Sch Profess Psychol, One Beach St, San Francisco, CA 94133 USA.	dzelman@alliant.edu		Zelman, Diane/0000-0003-3061-5228			Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Baker DG, 2009, MIL MED, V174, P773; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Caldwell Barbara A, 2005, Issues Ment Health Nurs, V26, P721, DOI 10.1080/01612840591008294; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; Collier E, 2003, J Psychiatr Ment Health Nurs, V10, P697, DOI 10.1046/j.1365-2850.2003.00654.x; Cukrowicz KC, 2006, DREAMING, V16, P1, DOI DOI 10.1037/1053-0797.16.1.1; ESPIE CA, 1989, J BEHAV THER EXP PSY, V20, P143, DOI 10.1016/0005-7916(89)90047-5; Espie CA, 2001, J CONSULT CLIN PSYCH, V69, P58, DOI 10.1037//0022-006X.69.1.58; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Friedman MJ, 2006, AM J PSYCHIAT, V163, P586, DOI 10.1176/appi.ajp.163.4.586; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Gorman LA, 2011, PSYCHIAT SERV, V62, P28, DOI 10.1176/ps.62.1.pss6201_0028; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Haimov I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061390; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2003, CLIN PSYCHOL REV, V23, P377, DOI 10.1016/S0272-7358(03)00032-1; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Insana SP, 2013, J TRAUMA STRESS, V26, P192, DOI 10.1002/jts.21793; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Manber R., 2012, OXFORD HDB SLEEP SLE, P471, DOI DOI 10.1093/OXFORDHB/9780195376203.013.0024; Manber R, 2012, J CLIN SLEEP MED, V8, P209, DOI 10.5664/jcsm.1786; Margolies SO, 2013, J CLIN PSYCHOL, V69, P1026, DOI 10.1002/jclp.21970; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Neylan T. C., 2013, COGNITIVE BEHA UNPUB; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Peachey JT, 2012, TRAIN EDUC PROF PSYC, V6, P18, DOI 10.1037/a0026793; Perlis ML, 2010, J SLEEP RES, V19, P31, DOI 10.1111/j.1365-2869.2009.00768.x; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Pietrzak RH, 2010, J PSYCHOSOM RES, V69, P441, DOI 10.1016/j.jpsychores.2010.07.002; Plumb T., 2008, INT SOC TRAUM STRESS; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Reeves RR, 2005, J PSYCHOSOC NURS MEN, V43, P18, DOI 10.3928/02793695-20050701-06; Reite M., 2009, CLIN MANUAL EVALUATI, P1; ROSZELL DK, 1991, HOSP COMMUNITY PSYCH, V42, P293; Rudd MD, 2011, PROF PSYCHOL-RES PR, V42, P354, DOI 10.1037/a0025164; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sharafkhaneh A, 2004, SLEEP MED, V5, P345, DOI 10.1016/j.sleep.2004.01.019; Sher L, 2011, MIL MED, V176, P601, DOI 10.7205/MILMED-D-11-00026; Skinner KM, 2000, J INTERPERS VIOLENCE, V15, P291, DOI 10.1177/088626000015003005; Smith MT, 2005, CLIN PSYCHOL REV, V25, P559, DOI 10.1016/j.cpr.2005.04.004; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tan M., 2013, ARMY TIMES      0201; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; U. S. Department of Veterans Affairs, 2012, COMB EXP SCAL CES; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Weathers F. W., 1993, ANN M INT SOC TRAUM; WEBB WB, 1974, PSYCHOPHYSIOLOGY, V11, P265, DOI 10.1111/j.1469-8986.1974.tb00543.x; Woodward SH, 1996, J TRAUMA STRESS, V9, P137, DOI 10.1007/BF02116839	56	61	61	0	17	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1541-1559	1939-148X		PSYCHOL SERV	Psychol. Serv.	MAY	2014	11	2					209	219		10.1037/a0034958			11	Psychology, Clinical	Psychology	AI3TC	WOS:000336784900011	24274111				2021-06-18	
J	Rowson, S; Duma, SM; Greenwald, RM; Beckwith, JG; Chu, JJ; Guskiewicz, KM; Mihalik, JP; Crisco, JJ; Wilcox, BJ; McAllister, TW; Maerlender, AC; Broglio, SP; Schnebel, B; Anderson, S; Brolinson, PG				Rowson, Steven; Duma, Stefan M.; Greenwald, Richard M.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Crisco, Joseph J.; Wilcox, Bethany J.; McAllister, Thomas W.; Maerlender, Arthur C.; Broglio, Steven P.; Schnebel, Brock; Anderson, Scott; Brolinson, P. Gunnar			Can helmet design reduce the risk of concussion in football?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; sports; concussion incidence; football; exposure; prevention	CHRONIC TRAUMATIC ENCEPHALOPATHY; LEAGUE PLAYER; HEAD; IMPACT; INJURY	Of all sports, football accounts for the highest incidence of concussion in the US due to the large number of athletes participating and the nature of the sport. While there is general agreement that concussion incidence can be reduced through rule changes and teaching proper tackling technique, there remains debate as to whether helmet design may also reduce the incidence of concussion. A retrospective analysis was performed of head impact data collected from 1833 collegiate football players who were instrumented with helmet-mounted accelerometer arrays for games and practices. Data were collected between 2005 and 2010 from 8 collegiate football teams: Virginia Tech, University of North Carolina, University of Oklahoma, Dartmouth College, Brown University, University of Minnesota, Indiana University, and University of Illinois. Concussion rates were compared between players wearing Riddell VSR4 and Riddell Revolution helmets while controlling for the head impact exposure of each player. A total of 1,281,444 head impacts were recorded, from which 64 concussions were diagnosed. The relative risk of sustaining a concussion in a Revolution helmet compared with a VSR4 helmet was 46.1% (95% CI 28.1%-75.8%). When controlling for each player's exposure to head impact, a significant difference was found between concussion rates for players in VSR4 and Revolution helmets (chi(2) = 4.68, p = 0.0305). This study illustrates that differences in the ability to reduce concussion risk exist between helmet models in football. Although helmet design may never prevent all concussions from occurring in football, evidence illustrates that it can reduce the incidence of this injury.	[Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA USA; [Greenwald, Richard M.; Beckwith, Jonathan G.; Chu, Jeffrey J.] Simbex, Lebanon, NH USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Crisco, Joseph J.; Wilcox, Bethany J.] Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA; [Crisco, Joseph J.; Wilcox, Bethany J.] Rhode Isl Hosp, Providence, RI USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Maerlender, Arthur C.] Geisel Sch Med Dartmouth, Pediat Neuropsychol Serv, Dartmouth, NS, Canada; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Schnebel, Brock] Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; [Anderson, Scott] Univ Oklahoma, Dept Intercollegiate Athlet, Norman, OK 73019 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA	Rowson, S (corresponding author), 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	srowson@vt.edu	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R01NS055020, R44HD40473]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, 5R49CE000196]; National Operating Committee on Standards for Athletic Equipment (NOCSAE) [07-04, 14-19]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000196, R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by grant nos. R01HD048638 and R01NS055020 from the NIH, grant nos. R01CE001254 and 5R49CE000196 from the Centers for Disease Control and Prevention, and grant nos. 07-04 and 14-19 from the National Operating Committee on Standards for Athletic Equipment (NOCSAE). The HIT System technology was developed in part under NIH grant no. R44HD40473. Joseph J. Crisco, Richard M. Greenwald, Jeffrey J. Chu, Jonathan G. Beckwith, and Simbex have a financial interest in the instruments (HIT System, Sideline Response System [Riddell]) that were used to collect the biomechanical data reported in this study. The remaining authors have no financial interests associated with this study.	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P2512, DOI 10.1007/s10439-012-0660-y; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4	17	61	61	0	76	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					919	922		10.3171/2014.1.JNS13916			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800017	24484225	Bronze, Green Published			2021-06-18	
J	Peck, KA; Calvo, RY; Schechter, MS; Sise, CB; Kahl, JE; Shackford, MC; Shackford, SR; Sise, MJ; Blaskiewicz, DJ				Peck, Kimberly A.; Calvo, Richard Y.; Schechter, Mark S.; Sise, C. Beth; Kahl, Jessica E.; Shackford, Meghan C.; Shackford, Steven R.; Sise, Michael J.; Blaskiewicz, Donald J.			The impact of preinjury anticoagulants and prescription antiplatelet agents on outcomes in older patients with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Anticoagulant; antiplatelet; older adult; elderly; traumatic brain injury	ELDERLY-PATIENTS; INTRACRANIAL HEMORRHAGE; MORTALITY; CLOPIDOGREL	BACKGROUND: Anticoagulants and prescription antiplatelet (ACAP) agents widely used by older adults have the potential to adversely affect traumatic brain injury (TBI) outcomes. We hypothesized that TBI patients on preinjury ACAP agents would have worse outcomes than non-ACAP patients. METHODS: This was a 5.5-year retrospective review of patients 55 years and older admitted to a Level I trauma center with blunt force TBI. Patients were categorized as ACAP (warfarin, clopidogrel, dipyridamole/aspirin, enoxaparin, subcutaneous heparin, or multiple agents) or non-ACAP. ACAP patients were further stratified by class of agent (anticoagulant or antiplatelet). Initial and subsequent head computerized tomographic results were examined for type and progression of TBI. Patient preadmission living status and discharge destination were identified. Primary outcome was in-hospital mortality. Secondary outcomes were progression of initial TBI, development of new intracranial hemorrhage (remote from initial), and the need for an increased level of care at discharge. RESULTS: A total of 353 patients met inclusion criteria: 273 non-ACAP (77%) and 80 ACAP (23%). Upon exclusion of three patients taking a combination of agents, 350 were available for advanced analyses. ACAP status was significantly related to in-hospital mortality. After adjustment for patient and injury characteristics, anticoagulant users were more likely than non-ACAP patients to show progression of initial hemorrhage and develop a new hemorrhagic focus. However, compared with non-ACAP users, antiplatelet users were more likely to die in the hospital. Among survivors to discharge, anticoagulant users were more likely to be discharged to a care facility, but this finding was not robust to adjustment. CONCLUSION: Older TBI patients on preinjury ACAP agents experience a comparatively higher rate of inpatient mortality and other adverse outcomes caused by the effects of antiplatelet agents. Our findings should inform decision making regarding prognosis and caution against grouping anticoagulant and antiplatelet users together in considering outcomes. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Peck, Kimberly A.; Calvo, Richard Y.; Schechter, Mark S.; Sise, C. Beth; Kahl, Jessica E.; Shackford, Meghan C.; Shackford, Steven R.; Sise, Michael J.; Blaskiewicz, Donald J.] Scripps Mercy Hosp, Trauma Serv, San Diego, CA 92103 USA	Peck, KA (corresponding author), Scripps Mercy Hosp, Trauma Serv MER 62, 4077 5th Ave, San Diego, CA 92103 USA.	peck.kimberly@scrippshealth.org		Calvo, Richard/0000-0001-9147-2668			Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferraris VA, 2012, J TRAUMA ACUTE CARE, V73, P492, DOI 10.1097/TA.0b013e31825b85f1; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	14	61	63	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2014	76	2					431	436		10.1097/TA.0000000000000107			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AH8KG	WOS:000336386100025	24458049				2021-06-18	
J	Taccone, FS; Su, FH; De Deyne, C; Abdellhai, A; Pierrakos, C; He, XR; Donadello, K; Dewitte, O; Vincent, JL; De Backer, D				Taccone, Fabio Silvio; Su, Fuhong; De Deyne, Cathy; Abdellhai, Ali; Pierrakos, Charalampos; He, Xinrong; Donadello, Katia; Dewitte, Olivier; Vincent, Jean-Louis; De Backer, Daniel			Sepsis Is Associated With Altered Cerebral Microcirculation and Tissue Hypoxia in Experimental Peritonitis	CRITICAL CARE MEDICINE			English	Article						brain oxygenation; cerebral microcirculation; microdialysis; sepsis; sidestream dark-field videomicroscopy	TRAUMATIC BRAIN-INJURY; PERFUSION-PRESSURE; OXYGEN-TENSION; ORGAN FAILURE; BLOOD-FLOW; METABOLISM; DYSFUNCTION; AUTOREGULATION; HETEROGENEITY; REACTIVITY	Objective: Alterations in cerebral microvascular blood flow may develop during sepsis, but the consequences of these abnormalities on tissue oxygenation and metabolism are not well defined. We studied the evolution of microvascular blood flow, brain oxygen tension (Pbo(2)), and metabolism in a clinically relevant animal model of septic shock. Design: Prospective randomized animal study. Setting: University hospital research laboratory. Subjects: Fifteen invasively monitored and mechanically ventilated female sheep. Interventions: The sheep were randomized to fecal peritonitis (n = 10) or a sham procedure (n = 5), and craniectomies were performed to enable evaluation of cerebral microvascular blood flow, Pbo(2), and metabolism. The microvascular network of the left frontal cortex was evaluated (at baseline, 6, 12, and 18 hr) using sidestream dark-field videomicroscopy. Using an off-line semiquantitative method, functional capillary density and the proportion of small perfused vessels were calculated. Pbo(2) was measured hourly by a parenchymal Clark electrode, and cerebral metabolism was assessed by the lactate/pyruvate ratio using brain microdialysis; both these systems were placed in the right frontal cortex. Measurement and Main Results: In septic animals, cerebral functional capillary density (from 3.1 0.5 to 1.9 +/- 0.4 n/mm, p < 0.001) and proportion of small perfused vessels (from 98% +/- 2% to 84% +/- 7%, p = 0.004) decreased over the 18-hour study period. Concomitantly, Pbo(2) decreased (61 +/- 5 to 41 +/- 7 mm Hg, p < 0.001) and lactate/pyruvate ratio increased (23 +/- 5 to 36 +/- 19, p < 0.001). At 18 hours, when shock was present, animals with a mean arterial pressure less than 65 mm Hg (n = 6) had similar functional capillary density, proportion of small perfused vessels, and Pbo(2) values but significantly higher lactate/pyruvate ratio (46 +/- 18 vs 20 +/- 4, p = 0.009) compared with animals with an mean arterial pressure of 65-70 mm Hg (n = 4). Conclusions: Impaired cerebral microcirculation during sepsis is associated with progressive impairment in Pbo(2) and brain metabolism. Development of severe hypotension was responsible for a further increase in anaerobic metabolism. These alterations may play an important role in the pathogenesis of brain dysfunction during sepsis.	[Taccone, Fabio Silvio; Su, Fuhong; Abdellhai, Ali; Pierrakos, Charalampos; He, Xinrong; Donadello, Katia; Vincent, Jean-Louis; De Backer, Daniel] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [De Deyne, Cathy] ZOL St Jan, Dept Anesthesia & Intens Care, Genk, Belgium; [Dewitte, Olivier] Univ Libre Bruxelles, Erasme Hosp, Dept Neurosurg, Brussels, Belgium	Taccone, FS (corresponding author), Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium.	ftaccone@ulb.ac.be	De Backer, Daniel/AAF-4177-2020; DONADELLO, KATIA/R-9442-2018	De Backer, Daniel/0000-0001-9841-5762; DONADELLO, KATIA/0000-0002-7053-8434; Su, Fuhong/0000-0003-4962-7907; Vincent, Jean-Louis/0000-0001-6011-6951; He, Xinrong/0000-0003-3426-1420	Fondation Erasme (Bourse de Recherche); Integra Lifesciences Service SAS; European Critical Care Research Network (ECCRN)	Supported, in part, by grants from Fondation Erasme (Bourse de Recherche 2008-2011) and Integra Lifesciences Service SAS.; Dr. Taccone received the Basic Science Research Award from the European Critical Care Research Network (ECCRN; October 2009). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Awan ZA, 2011, MICROVASC RES, V81, P245, DOI 10.1016/j.mvr.2011.02.004; Bateman RM, 2007, AM J PHYSIOL-HEART C, V293, pH448, DOI 10.1152/ajpheart.00035.2007; Cardoso FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035919; Comim CM, 2011, INTENS CARE MED, V37, P711, DOI 10.1007/s00134-011-2151-2; De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC; Diller R, 2008, J SURG RES, V150, P3, DOI 10.1016/j.jss.2007.12.795; Doerschug KC, 2007, AM J PHYSIOL-HEART C, V293, pH1065, DOI 10.1152/ajpheart.01237.2006; Frykholm P, 2005, J NEUROSURG, V102, P1076, DOI 10.3171/jns.2005.102.6.1076; Goldman D, 2004, AM J PHYSIOL-HEART C, V287, pH2535, DOI 10.1152/ajpheart.00889.2003; Humer MF, 1996, J APPL PHYSIOL, V81, P895; Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58; Klaus S, 2003, CARDIOVASC RES, V59, P105, DOI 10.1016/S0008-6363(03)00347-X; Knotzer H, 2006, INTENS CARE MED, V32, P170, DOI 10.1007/s00134-005-2858-z; Lawerenz J, 2010, J NEUROCHEM, V113, P502, DOI 10.1111/j.1471-4159.2010.06621.x; Legrand M, 2011, INTENS CARE MED, V37, P1534, DOI 10.1007/s00134-011-2267-4; Levy B, 2010, INTENS CARE MED, V36, P1703, DOI 10.1007/s00134-010-1938-x; MAEKAWA T, 1991, AM J EMERG MED, V9, P139, DOI 10.1016/0735-6757(91)90175-J; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Papadopoulos MC, 1999, CLIN SCI, V96, P461, DOI 10.1042/CS19980327; Pfister D, 2008, CRIT CARE, V12, DOI 10.1186/cc6891; Rosengarten B, 2007, CEREBROVASC DIS, V23, P140, DOI 10.1159/000097051; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sair M, 2001, CRIT CARE MED, V29, P1343, DOI 10.1097/00003246-200107000-00008; Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Taccone FS, 2013, CURR VASC PHARMACOL, V11, P170; Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205; Taccone FS, 2010, NEUROCRIT CARE, V12, P35, DOI 10.1007/s12028-009-9289-6; Thees C, 2007, CRIT CARE, V11, DOI 10.1186/cc6185; Vachharjani V, 2005, MICROCIRCULATION, V12, P183, DOI 10.1080/10739680590904982; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Wang NS, 2013, AM J PHYSIOL-ENDOC M, V304, pE538, DOI 10.1152/ajpendo.00537.2012; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	39	61	64	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2014	42	2					E114	E122		10.1097/CCM.0b013e3182a641b8			9	Critical Care Medicine	General & Internal Medicine	291WS	WOS:000329863400004	24196192				2021-06-18	
J	Zhang, MY; Shan, HY; Chang, P; Wang, T; Dong, WW; Chen, XP; Tao, LY				Zhang, Mingyang; Shan, Haiyan; Chang, Pan; Wang, Tao; Dong, Wenwen; Chen, Xiping; Tao, Luyang			Hydrogen Sulfide Offers Neuroprotection on Traumatic Brain Injury in Parallel with Reduced Apoptosis and Autophagy in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; CYSTATHIONINE-BETA-SYNTHASE; CENTRAL-NERVOUS-SYSTEM; INDUCED CELL-DEATH; ALZHEIMERS-DISEASE; HEAD-INJURY; RAT MODEL; CONTRIBUTES; MECHANISMS; STRATEGIES	Hydrogen sulfide (H2S), a novel gaseous mediator, has been recognized as an important neuromodulator and neuroprotective agent in the central nervous system. The present study was undertaken to study the effects of exogenous H2S on traumatic brain injury (TBI) and the underlying mechanisms. The effects of exogenous H2S on TBI were examined by using measurement of brain edema, behavior assessment, propidium iodide (PI) staining, and Western blotting, respectively. Compared to TBI groups, H2S pretreatment had reduced brain edema, improved motor performance and ameliorated performance in Morris water maze test after TBI. Immunoblotting results showed that H2S pretreatment reversed TBI-induced cleavage of caspase-3 and decline of Bcl-2, suppressed LC3-II, Beclin-1 and Vps34 activation and maintained p62 level in injured cortex and hippocampus post TBI. The results suggest a protective effect and therapeutic potential of H2S in the treatment of brain injury and the protective effect against TBI may be associated with regulating apoptosis and autophagy.	[Zhang, Mingyang; Chang, Pan; Wang, Tao; Dong, Wenwen; Chen, Xiping; Tao, Luyang] Soochow Univ, Coll Med, Dept Forens Sci, Suzhou, Peoples R China; [Zhang, Mingyang; Chang, Pan; Wang, Tao; Dong, Wenwen; Chen, Xiping; Tao, Luyang] Soochow Univ, Coll Med, Lab Brain Injury, Suzhou, Peoples R China; [Zhang, Mingyang] Nantong Univ, Coll Med, Dept Forens Sci, Nantong, Peoples R China; [Shan, Haiyan] North Dist Suzhou Municipal Hosp, Dept Obstet & Gynecol, Suzhou, Peoples R China	Chen, XP (corresponding author), Soochow Univ, Coll Med, Dept Forens Sci, Suzhou, Peoples R China.	xiping.chen@163.com; luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Zhang, Mingyang/0000-0003-1612-0763	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872666, 81172911, 81301039]	This study was supported by grants 30872666, 81172911 and 81301039 from the National Natural Science Foundation of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe K, 1996, J NEUROSCI, V16, P1066; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bierbach B, 2008, STROKE, V39, P213, DOI 10.1161/STROKEAHA.107.496620; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Enokido Y, 2005, FASEB J, V19, P1854, DOI 10.1096/fj.05-3724fje; Eto K, 2002, BIOCHEM BIOPH RES CO, V293, P1485, DOI 10.1016/S0006-291X(02)00422-9; Florian B, 2008, NEUROSCI LETT, V438, P180, DOI 10.1016/j.neulet.2008.04.020; Francis RC, 2011, ANESTHESIOLOGY, V115, P1012, DOI 10.1097/ALN.0b013e31823306cf; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kajta M, 2004, POL J PHARMACOL, V56, P689; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Karlsson O, 2011, BEHAV BRAIN RES, V219, P310, DOI 10.1016/j.bbr.2011.01.056; Kimura H, 2010, ANTIOXID REDOX SIGN, V12, P1111, DOI 10.1089/ars.2009.2919; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu YH, 2012, ANTIOXID REDOX SIGN, V17, P141, DOI 10.1089/ars.2011.4005; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Martelli A, 2012, MED RES REV, V32, P1093, DOI 10.1002/med.20234; Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03-1052fje; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Qu K, 2006, STROKE, V37, P889, DOI 10.1161/01.STR.0000204184.34946.41; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Tan BH, 2010, NEUROCHEM INT, V56, P3, DOI 10.1016/j.neuint.2009.08.008; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wong PTH, 2006, J NEUROPATH EXP NEUR, V65, P109, DOI 10.1097/01.jnen.0000199571.96472.c7; Xuan AG, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-202; Yin J, 2013, BRAIN RES, V1491, P188, DOI 10.1016/j.brainres.2012.10.046; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5; Zhang MY, 2013, NEUROCHEM RES, V38, P714, DOI 10.1007/s11064-013-0969-4; Zhang MY, 2012, J MOL NEUROSCI, V46, P631, DOI 10.1007/s12031-011-9651-y; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	46	61	65	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2014	9	1							e87241	10.1371/journal.pone.0087241			11	Multidisciplinary Sciences	Science & Technology - Other Topics	297XI	WOS:000330288000203	24466346	DOAJ Gold, Green Published			2021-06-18	
J	Iverson, GL				Iverson, Grant L.			Chronic traumatic encephalopathy and risk of suicide in former athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Sporting injuries	CHRONIC PAIN; LIFE EVENTS; BEHAVIOR; DISEASE; ASSOCIATION; AGGRESSION; DEPRESSION; MORTALITY; DEMENTIA; ADULTS	Background In the initial autopsy case studies of chronic traumatic encephalopathy (CTE), some researchers have concluded that the proteinopathy associated with CTE is the underlying cause of suicidality and completed suicide in former athletes. Methods A review of the literature on contact sports and risk of completed suicide revealed only one epidemiological study with direct relevant data. Results There are no published cross-sectional, epidemiological or prospective studies showing a relation between contact sports and risk of suicide. One published epidemiological study suggests that retired National Football League players have lower rates of death by suicide than the general population. Outside of sports, there is a mature body of evidence suggesting that the causes of suicide are complex, multifactorial and difficult to predict in individual cases. Conclusions Future research might establish a clear causal connection between the proteinopathy of CTE and suicide. At present, however, there is insufficient scientific evidence to conclude that there is a strong causal relationship between the presence of these proteinopathies and suicide in former athletes. Additional research is needed to determine the extent to which the neuropathology of CTE is a possible mediator or moderator variable associated with suicide.	[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA	Iverson, GL (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, 79-96 13th St, Charlestown, MA 02129 USA.	giverson@partners.org		Iverson, Grant/0000-0001-7348-9570	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Alcohol Beverage Medical Research Council; Rehabilitation Research and Development (RR&D) Service of the US Department of Veterans Affairs; Vancouver Coastal Health Research Institute; Roche Diagnostics Canada	GLI has been reimbursed by the government, professional scientific bodies and commercial organisations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences and symposiums. He has received research funding from several test publishing companies, including ImPACT Applications, Inc, CNS Vital Signs, and Psychological Assessment Resources (PAR, Inc). He is a co-investigator, collaborator or consultant on grants relating to mild TBI funded by several organisations, including, but not limited to, the Canadian Institute of Health Research, Alcohol Beverage Medical Research Council, Rehabilitation Research and Development (RR&D) Service of the US Department of Veterans Affairs, Vancouver Coastal Health Research Institute and Roche Diagnostics Canada.	Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Arsenault-Lapierre G, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-37; Banks SM, 1996, PSYCHOL BULL, V119, P95, DOI 10.1037/0033-2909.119.1.95; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Barr B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5142; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beghi M, 2010, CURR OPIN PSYCHIATR, V23, P349, DOI 10.1097/YCO.0b013e32833ad783; Bruffaerts R, 2010, BRIT J PSYCHIAT, V197, P20, DOI 10.1192/bjp.bp.109.074716; Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P321; Chang SS, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5239; Chang SS, 2009, SOC SCI MED, V68, P1322, DOI 10.1016/j.socscimed.2009.01.010; Conner KR, 2012, DRUG ALCOHOL DEPEN, V120, P155, DOI 10.1016/j.drugalcdep.2011.07.013; Conner KR, 2004, AM J GERIAT PSYCHIAT, V12, P37, DOI 10.1176/appi.ajgp.12.1.37; Conner KR, 2001, SUICIDE LIFE-THREAT, V31, P367, DOI 10.1521/suli.31.4.367.22048; Conwell Y, 2002, BIOL PSYCHIAT, V52, P193, DOI 10.1016/S0006-3223(02)01347-1; Conwell Y, 2010, INT J GERIATR PSYCH, V25, P371, DOI 10.1002/gps.2348; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Fassberg MM, 2012, INT J ENV RES PUB HE, V9, P722, DOI 10.3390/ijerph9030722; Foster T, 2011, ARCH SUICIDE RES, V15, P1, DOI 10.1080/13811118.2011.540213; Frith D., 2001, SILENCE HEART CRICKE; Gardner A., 2013, BRIT J SPORT MED; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gelber RP, 2012, CURR ALZHEIMER RES, V9, P664; Gonzalez HM, 2010, J PSYCHIATR RES, V44, P1043, DOI 10.1016/j.jpsychires.2010.03.017; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Horn S, 2009, AM J PHYS MED REHAB, V88, P192, DOI 10.1097/PHM.0b013e318198b622; Hundertmark J, 2007, AUSTRALAS PSYCHIATRY, V15, P509, DOI 10.1080/10398560701458210; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Lindqvist AS, 2013, SCAND J MED SCI SPOR, DOI [10.1111/sms.12122., DOI 10.1111/SMS.12122.[]; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McGirr Alexander, 2007, Curr Psychiatry Rep, V9, P460, DOI 10.1007/s11920-007-0062-2; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McWilliams LA, 2003, PAIN, V106, P127, DOI 10.1016/S0304-3959(03)00301-4; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Ohayon MM, 2010, J PSYCHIATR RES, V44, P454, DOI 10.1016/j.jpsychires.2009.10.013; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parssinen M, 2000, INT J SPORTS MED, V21, P225, DOI 10.1055/s-2000-304; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Rockett Ian R H, 2012, Am J Public Health, V102, pe84, DOI 10.2105/AJPH.2012.300960; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Scott KM, 2010, PSYCHOSOM MED, V72, P712, DOI 10.1097/PSY.0b013e3181e3333d; Smith G, 2011, PERCEPT MOTOR SKILL, V112, P55, DOI 10.2466/07.PMS.112.1.55-60; Snowdon DA, 2003, ANN INTERN MED, V139, P450, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00014; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859; Von Korff M, 2005, PAIN, V113, P331, DOI 10.1016/j.pain.2004.11.010; White L, 2009, J ALZHEIMERS DIS, V18, P713, DOI 10.3233/JAD-2009-1178	56	61	61	2	41	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					162	U174		10.1136/bjsports-2013-092935			4	Sport Sciences	Sport Sciences	276KK	WOS:000328749000021	24178363				2021-06-18	
J	Prathep, S; Sharma, D; Hallman, M; Joffe, A; Krishnamoorthy, V; Mackensen, GB; Vavilala, MS				Prathep, Sumidtra; Sharma, Deepak; Hallman, Matthew; Joffe, Aaron; Krishnamoorthy, Vijay; Mackensen, G. Burkhard; Vavilala, Monica S.			Preliminary Report on Cardiac Dysfunction After Isolated Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						cardiac function; echocardiography; traumatic brain injury	LEFT-VENTRICULAR DYSFUNCTION; WALL-MOTION ABNORMALITIES; TROPONIN-I; ECHOCARDIOGRAPHIC EVALUATION; INTRACRANIAL-PRESSURE; MYOCARDIAL DAMAGE; INFARCTION; STRESS; STROKE	Objective: The aim of this study was to examine cardiac dysfunction during the first 2 weeks after isolated traumatic brain injury and its association with in-hospital mortality. Design Retrospective. Setting Level 1 regional trauma center. Patients Adult patients with severe traumatic brain injury. Methods: After institutional review board approval, data from adult patients with isolated traumatic brain injury who underwent echocardiography during the first 2 weeks after traumatic brain injury between 2003 and 2010 were examined. Patients with preexisting cardiac disease were excluded. Clinical characteristics and echocardiogram reports were abstracted. Cardiac dysfunction was defined as left ventricular ejection fraction less than 50% or presence of regional wall motion abnormality. Interventions: None. Measurement and Main Results: We examined data from 139 patients with isolated traumatic brain injury who underwent echocardiographic evaluation. Patients were 5820 years old, 66% were male patients, and 62.6% had subdural hematoma; admission Glasgow Coma Scale score was 3 +/- 1 (3-15) and head Abbreviated Injury Scale was 4 +/- 1 (2-5). Of this cohort, 22.3% had abnormal echocardiogram: reduced left ventricular ejection fraction was documented in 12% (left ventricular ejection fraction, 43% +/- 8%) and 17.5% of patients had a regional wall motion abnormality. Hospital day 1 was the most common day of echocardiographic exam. Abnormal echocardiogram was independently associated with all cause in-hospital mortality (9.6 [2.3-40.2]; p = 0.002). Conclusions: Cardiac dysfunction in the setting of isolated traumatic brain injury occurs and is associated with increased in-hospital mortality. This finding raises the question as to whether there are uncharted opportunities for a more timely recognition of cardiac dysfunction and subsequent optimization of the hemodynamic management of these patients.	[Prathep, Sumidtra; Sharma, Deepak; Hallman, Matthew; Joffe, Aaron; Krishnamoorthy, Vijay; Mackensen, G. Burkhard; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Prathep, Sumidtra; Sharma, Deepak; Hallman, Matthew; Joffe, Aaron; Krishnamoorthy, Vijay; Mackensen, G. Burkhard; Vavilala, Monica S.] Univ Washington, Dept Pain Med, Seattle, WA 98195 USA; [Sharma, Deepak; Vavilala, Monica S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA	Vavilala, MS (corresponding author), Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.	vavilala@uw.edu	Mackensen, G. Burkhard/AAJ-3951-2021		National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [3R01NS072308-03]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER	Supported, in part, by grant 3R01NS072308-03 from National Institute of Neurological Diseases and Stroke.; Drs. Krishnamoorthy and Vavilala received funding support from the National Institutes of Health. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Ako J, 2006, AM J MED, V119, P10, DOI 10.1016/j.amjmed.2005.08.022; Bahloul M, 2006, AM J CRIT CARE, V15, P462; Berman M, 2010, J HEART LUNG TRANSPL, V29, P957, DOI 10.1016/j.healun.2010.04.008; Brain Trauma Foundation, 2007, J NEUROTRAUMA S, V24, pS1; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Bulsara KR, 2003, J NEUROSURG, V98, P524, DOI 10.3171/jns.2003.98.3.0524; Davison DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11226; Di Angelantonio E, 2005, J NEUROL NEUROSUR PS, V76, P76, DOI 10.1136/jnnp.2004.041491; Dupuis M, 2012, SEIZURE-EUR J EPILEP, V21, P51, DOI 10.1016/j.seizure.2011.09.006; Flynn M, 2009, J THORAC CARDIOV SUR, V137, P1063, DOI 10.1016/j.jtcvs.2008.12.023; GILBERT EM, 1988, J THORAC CARDIOV SUR, V95, P1003; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; Horowitz MB, 1998, ACTA NEUROCHIR, V140, P87, DOI 10.1007/s007010050063; James P, 2000, BRIT MED J, V320, P1502, DOI 10.1136/bmj.320.7248.1502; KOLIN A, 1984, STROKE, V15, P990, DOI 10.1161/01.STR.15.6.990; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Mashaly Hazem Antar, 2008, Cleve Clin J Med, V75 Suppl 2, pS26; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; Moussouttas M, 2012, NEUROCRIT CARE, V16, P381, DOI 10.1007/s12028-012-9673-5; MYERS MG, 1982, STROKE, V13, P838, DOI 10.1161/01.STR.13.6.838; Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3; Parr MJA, 1996, BRIT MED J, V313, P681; Richard C, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-39; Riera Maria, 2010, J Trauma, V68, pE13, DOI 10.1097/TA.0b013e3181469d5b; Samuels MA, 2007, CIRCULATION, V116, P77, DOI 10.1161/CIRCULATIONAHA.106.678995; SCHRADER H, 1985, ACTA NEUROL SCAND, V72, P283; SEILER C, 1992, J HEART LUNG TRANSPL, V11, P867; SHANLIN RJ, 1988, J AM COLL CARDIOL, V12, P727, DOI 10.1016/S0735-1097(88)80065-2; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Song HS, 2008, J CLIN NEUROL, V4, P75, DOI 10.3988/jcn.2008.4.2.75; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Sosin DM, 1995, JAMA-J AM MED ASSOC, V273, P1778; Temes RE, 2010, NEUROCRIT CARE, V13, P359, DOI 10.1007/s12028-010-9447-x; Tung P, 2004, STROKE, V35, P548, DOI 10.1161/01.STR.0000114874.96688.54; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046	35	61	64	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2014	42	1					142	147		10.1097/CCM.0b013e318298a890			6	Critical Care Medicine	General & Internal Medicine	274OK	WOS:000328615600036	23963125	Green Accepted			2021-06-18	
J	Watanabe, J; Shetty, AK; Hattiangady, B; Kim, DK; Foraker, JE; Nishida, H; Prockop, DJ				Watanabe, Jun; Shetty, Ashok K.; Hattiangady, Bharathi; Kim, Dong-Ki; Foraker, Jessica E.; Nishida, Hidetaka; Prockop, Darwin J.			Administration of TSG-6 improves memory after traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article						TSG-6; Mesenchymal stem cells; Traumatic brain injury; Blood brain barrier; Neutrophils; Matrix metalloproteinase	INTER-ALPHA-INHIBITOR; FACTOR-STIMULATED GENE-6; STEM-CELLS; STROMAL CELLS; LINK MODULE; STEM/PROGENITOR CELLS; INFLAMMATORY DAMAGE; INNATE IMMUNITY; HEAVY-CHAINS; PROTEIN	Traumatic brain injury (TBI) causes multiple long-term defects including a loss of working memory that is frequently incapacitating. Administrations of mesenchymal stem/stromal cells (MSCs) previously produced beneficial effects in models of TBI as well as other disease models. In several models, the beneficial effects were explained by the MSCs being activated to express TSG-6, a multifunctional protein that modulates inflammation. In a mouse model of TB!, we found the initial mild phase of the inflammatory response persisted for at least 24 h and was followed by secondary severe response that peaked at 3 days. Intravenous human MSCs or TSG-6 during initial mild phase decreased neutrophil extravasation, expression of matrix metalloproteinase 9 by endothelial cells and neutrophils, and the subsequent blood brain barrier leakage in secondary phase. Administration of TSG-6 also decreased the lesion size at 2 weeks. Importantly, the acute administration of TSG-6 within 24 h of TBI was followed 6 to 10 weeks later by improvements in memory, depressive-like behavior and the number of newly born-neurons. The data suggested that acute administration of TSG-6 may be an effective therapy for decreasing some of the long-term consequences of TBI. (C) 2013 Elsevier Inc. All rights reserved.	[Watanabe, Jun; Shetty, Ashok K.; Hattiangady, Bharathi; Kim, Dong-Ki; Foraker, Jessica E.; Nishida, Hidetaka; Prockop, Darwin J.] Scott & White Mem Hosp & Clin, Texas A&M Hlth Sci Ctr, Coll Med, Inst Regenerat Med, Temple, TX 76502 USA	Prockop, DJ (corresponding author), Scott & White Mem Hosp & Clin, Texas A&M Hlth Sci Ctr, Coll Med, Inst Regenerat Med, 5701 Airport Rd, Temple, TX 76502 USA.	Prockop@medicine.tamhsc.edu	Shetty, Ashok/AAT-7273-2020; Shetty, Ashok K/A-2428-2008	Shetty, Ashok/0000-0001-5049-6671; Shetty, Ashok K/0000-0001-5049-6671; Tulloch, Jessica/0000-0002-6737-2525; Hattiangady, Bharathi/0000-0002-0432-1894	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P40OD011050]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P40OD011050] Funding Source: NIH RePORTER	This study is supported in part by NIH grant P40OD011050.	Baranova NS, 2011, J BIOL CHEM, V286, P25675, DOI 10.1074/jbc.M111.247395; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Cao TV, 2004, MICROCIRCULATION, V11, P615, DOI 10.1080/10739680490503438; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Edwards P, 2005, LANCET, V365, P1957; Flach A, 2000, OPHTHALMOLOGY, V107, P1224, DOI 10.1016/S0161-6420(00)00223-2; Foraker JE, 2011, J NEUROCHEM, V119, P1052, DOI 10.1111/j.1471-4159.2011.07511.x; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Kohman RA, 2013, BRAIN BEHAV IMMUN, V27, P22, DOI 10.1016/j.bbi.2012.09.003; Kovesdi E., 2012, FRONT NEUROL, V3, P1; Kuznetsova SA, 2005, J BIOL CHEM, V280, P30899, DOI 10.1074/jbc.M500701200; Kuznetsova SA, 2008, MATRIX BIOL, V27, P201, DOI 10.1016/j.matbio.2007.10.003; Leali D, 2012, ARTERIOSCL THROM VAS, V32, P696, DOI 10.1161/ATVBAHA.111.243998; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Lin JC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1129; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Mihara Y, 2011, J MOL NEUROSCI, V43, P162, DOI 10.1007/s12031-010-9438-6; Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nagyeri G, 2011, J BIOL CHEM, V286, P23559, DOI 10.1074/jbc.M111.222026; Oh JY, 2010, P NATL ACAD SCI USA, V107, P16875, DOI 10.1073/pnas.1012451107; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Parihar VK, 2011, MOL PSYCHIATR, V16, P171, DOI 10.1038/mp.2009.130; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Prockop DJ, 2007, CLIN PHARMACOL THER, V82, P241, DOI 10.1038/sj.clpt.6100313; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Rao MS, 2005, EUR J NEUROSCI, V21, P464, DOI 10.1111/j.1460-9568.2005.03853.x; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rawson RA, 1943, AM J PHYSIOL, V138, P0708; Rivest Serge, 2011, Expert Rev Neurother, V11, P783, DOI 10.1586/ern.11.64; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Russo I, 2011, J NEUROCHEM, V116, P947, DOI 10.1111/j.1471-4159.2010.07168.x; Scavenius C, 2011, BBA-PROTEINS PROTEOM, V1814, P1624, DOI 10.1016/j.bbapap.2011.08.017; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; Uccelli A, 2010, CURR OPIN IMMUNOL, V22, P768, DOI 10.1016/j.coi.2010.10.012; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Wolfe Margaret, 2008, V449, P3, DOI 10.1007/978-1-60327-169-1_1; Zhang SZ, 2012, J BIOL CHEM, V287, P12433, DOI 10.1074/jbc.M112.342873; Zietlow R, 2008, CELL TISSUE RES, V331, P301, DOI 10.1007/s00441-007-0488-1	64	61	67	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2013	59						86	99		10.1016/j.nbd.2013.06.017			14	Neurosciences	Neurosciences & Neurology	221MV	WOS:000324663900009	23851308	Green Accepted			2021-06-18	
J	Berthelson, L; Mulchan, SS; Odland, AP; Miller, LJ; Mittenberg, W				Berthelson, Lena; Mulchan, Siddika S.; Odland, Anthony P.; Miller, Lori J.; Mittenberg, Wiley			False positive diagnosis of malingering due to the use of multiple effort tests	BRAIN INJURY			English	Article						Base rate; effort tests; malingering; medicolegal; symptom exaggeration; symptom validity	VALIDITY TEST-PERFORMANCE; NEUROPSYCHOLOGICAL TEST BATTERIES; ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; RELIABLE DIGIT SPAN; 15-ITEM MEMORY TEST; BASE RATES; NEUROCOGNITIVE DYSFUNCTION; HEALTHY-ADULTS; RESPONSE BIAS	Objective: Effort indicators are used to determine if neuropsychological test results are valid measures of a patient's cognitive abilities. The use of multiple effort measures is often advocated, but the false positive rate for multiple indicators depends on the number of measures used and the correlation among indicators. This study presents a meta-analysis of correlations among effort measures. False positive rates for multiple correlated indicators are then estimated using Monte Carlo simulations. Methods: a literature search of published studies identified 22 independent samples in which 407 correlations among 31 effort measures were available in 3564 participants with normal effort. Participants were patients with neurological or psychiatric disorders and healthy volunteers. Results: Meta-analysis showed a mean correlation among effort indicators of 0.31. Monte Carlo simulation based on a 15% false positive rate for individual indicators showed that, when 10 effort indicators are used together, 38% of patients with valid performance will be incorrectly identified as malingering if two failures is the diagnostic standard. Failure on five of 10 measures is required for a false positive rate of 10% or less. If five effort indicators are interpreted, a false positive rate of 19% results when two test failures are assumed to characterize poor effort and failure on three measures is required to maintain 90% specificity. Conclusions: False positive rates for effort tests increase significantly as the number of indicators that are administered is increased.	[Berthelson, Lena; Mulchan, Siddika S.; Mittenberg, Wiley] Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA; [Odland, Anthony P.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA; [Miller, Lori J.] Eastern Washington Univ, Belmont, WA USA	Mittenberg, W (corresponding author), Nova SE Univ, Ctr Psychol Studies, 3301 Coll Ave, Ft Lauderdale, FL 33314 USA.	wiley@nova.edu					AEgisdottir S, 2006, COUNS PSYCHOL, V34, P341, DOI 10.1177/0011000005285875; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P725, DOI 10.1093/arclin/acs071; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Decker SL, 2012, ARCH CLIN NEUROPSYCH, V27, P69, DOI 10.1093/arclin/acr088; Ferguson GA, 1971, STAT ANAL PSYCHOL ED, P81; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Grove WM, 2000, PSYCHOL ASSESSMENT, V12, P19, DOI 10.1037/1040-3590.12.1.19; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry M, 2010, J CLIN EXP NEUROPSYC, V32, P19, DOI 10.1080/13803390902791653; Holdnack J, 2009, ADV CLIN SOLUTIONS C; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Macciocchi SN, 2006, ARCH CLIN NEUROPSYCH, V21, P395, DOI 10.1016/j.acn.2006.06.003; McGlinchey R, REDUCED EFFORT UNPUB; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Metropolis Nick., 1987, SPECIAL ISSUE DEDICA, V15, P125, DOI DOI 10.1128/JCM.05092-11; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Pella RD, 2012, ARCH CLIN NEUROPSYCH, V27, P45, DOI 10.1093/arclin/acr090; Perna R, 2013, APPL NEUROP IN PRESS; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Rienstra A, 2010, ARCH CLIN NEUROPSYCH, V25, P371, DOI 10.1093/arclin/acq035; Rosenfeld B., 2010, INT J FORENSIC MENT, V9, P63, DOI DOI 10.1080/14999013.2010.499559; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Strutt AM, 2011, CLIN NEUROPSYCHOL, V25, P1253, DOI 10.1080/13854046.2011.609839; Sweet JJ, 2009, NEUROPSYCHOLOGY MALI, P568; Welsh AJ, 2012, ARCH CLIN NEUROPSYCH, V27, P735, DOI 10.1093/arclin/acs063	43	61	62	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					909	916		10.3109/02699052.2013.793400			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200019	23782260				2021-06-18	
J	Mannix, R; O'Brien, MJ; Meehan, WP				Mannix, Rebekah; O'Brien, Michael J.; Meehan, William P., III			The Epidemiology of Outpatient Visits for Minor Head Injury: 2005 to 2009	NEUROSURGERY			English	Article						Concussion; Epidemiology; Traumatic brain injury	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; 3RD INTERNATIONAL-CONFERENCE; UNITED-STATES; EMERGENCY-DEPARTMENTS; HIGH-SCHOOL; COMPUTED-TOMOGRAPHY; CONSENSUS STATEMENT; FOOTBALL PLAYERS; MANAGEMENT	BACKGROUND: The Centers for Disease Control and Prevention have called for studies detailing the prevalence and burden of mild traumatic brain injury (mTBI) in the outpatient clinical setting. OBJECTIVE: The aim of this study was to describe the prevalence of outpatient visits for minor head injury and compare the number of outpatient visits for minor head injury with the number of emergency department (ED) visits. METHODS: This was a cross-sectional study of outpatient visits for minor head injuries from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS). We examined outpatient visits for minor head injury between 2005 and 2009 and compared them with visits in the ED for the same diagnoses using simple survey-weighted descriptive statistics. RESULTS: In the 5-year study period, there were 4 146 777 outpatient visits for minor head injury and 6 077 147 ED visits for minor head injury. In the outpatient setting, 14% of office-based visits and 21% of hospital-based visits referred patients for advanced imaging, whereas 63% of minor head injury patients in the ED underwent imaging. A return visit was arranged for 54% of minor head injury patients in office-based practices and 29% of patients in hospital-based clinics, while 67% of minor head injury patients were given instructions to follow-up after an ED visit. CONCLUSION: More than 800 000 outpatient visits for minor head injury occur each year. The diagnostics and management associated with these visits differ from those seen in the ED setting.	[Mannix, Rebekah; Meehan, William P., III] Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Mannix, Rebekah; Meehan, William P., III] Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA; [O'Brien, Michael J.; Meehan, William P., III] Childrens Hosp, Sports Concuss Clin, Div Sports Med, Boston, MA 02115 USA; [O'Brien, Michael J.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA	Mannix, R (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020				Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sue Binder, 2003, MILD TRAUMATIC BRAIN; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	40	61	61	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2013	73	1					129	134		10.1227/01.neu.0000429846.14579.41			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	299FJ	WOS:000330380900038	23615100				2021-06-18	
J	Mihalik, JP; Register-Mihalik, J; Kerr, ZY; Marshall, SW; McCrea, MC; Guskiewicz, KM				Mihalik, Jason P.; Register-Mihalik, Johna; Kerr, Zachary Y.; Marshall, Stephen W.; McCrea, Michael C.; Guskiewicz, Kevin M.			Recovery of Posttraumatic Migraine Characteristics in Patients After Mild Traumatic Brain Injury	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						athlete; concussion; evaluation; headache; return-to-participation	COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; HEAD-INJURY; POSTURAL STABILITY; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; STANDARDIZED ASSESSMENT; NCAA CONCUSSION; EPIDEMIOLOGY; MANAGEMENT	Background: Headache-related symptoms may be predictive of delayed recovery in student athletes after sport-related concussion. Purpose and Hypothesis: To compare balance performance, cognitive function, and symptom recovery in concussed student athletes with no headache, those with posttraumatic headache, and those with characteristics of posttraumatic migraine following a sport-related concussion. It was hypothesized that those with posttraumatic migraine would take longer to recover on all clinical measures. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: A total of 296 student athletes who sustained sport-related concussions (migraine, 52; headache, 176; no headache, 68) were evaluated on measures of balance performance, cognition, and symptoms. Patients were categorized into posttraumatic migraine, posttraumatic headache, and no headache groups based on symptoms reported 1 day after injury. Serial testing was conducted with the Balance Error Scoring System, the Standardized Assessment of Concussion, and a graded symptom checklist to evaluate balance performance, cognition, and symptoms, respectively, at baseline, at the time of injury, after the event, and at days 1, 2, 3, 5, 7, and 90. Results: Student athletes with posttraumatic migraine experienced greater symptom severity scores than did those with posttraumatic headache and no headache at the time of injury, after the event, and through day 7 (P < .001 for all). By day 7, symptom severity scores reported by patients with posttraumatic migraine still demonstrated deficits relative to baseline (Delta = 5.6 +/- 1.2) compared with patients with headache (D = 20.8 +/- 0.7) and those with no headache (Delta = -1.4 +/- 1.1). Patients with headache experienced greater symptom severity scores than patients with no headache at the time of injury (P < . 001), after the event (P < .001), and at day 1 (P <. 001), day 2 (P = .005), and day 3 (P = .038). Much smaller differences were observed between the headache and no headache groups beyond day 3 (P > .05). There were no group differences on balance performance (P = .439) and cognitive testing (P = .200) over time. Female patients were 2.13 times more likely than males to report posttraumatic migraine characteristics after concussion. Conclusion: Posttraumatic migraine characteristics are related to prolonged symptom recovery after sport-related concussion. Clinicians should exercise caution in making decisions about return to participation for athletes with migraine-like symptoms given the increased short-term impairments and delayed symptom recovery we observed.	[Mihalik, Jason P.; Register-Mihalik, Johna; Kerr, Zachary Y.; Marshall, Stephen W.; McCrea, Michael C.; Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC 27599 USA	Mihalik, JP (corresponding author), 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Mihalik, Jason/0000-0001-6085-8322; Register-Mihalik, Johna/0000-0002-4229-4743; Marshall, Stephen/0000-0002-2664-9233; Kerr, Zachary/0000-0003-1423-1259; Guskiewicz, Kevin/0000-0002-8682-2130	National Collegiate Athletic Association (NCAA); National Operating Committee on Standards for Athletic Equipment (NOCSAE); National Centers for Injury Prevention and Control (NCIPC); University of North Carolina Injury Prevention Research Center	This research was funded in part by the National Collegiate Athletic Association (NCAA) and the National Operating Committee on Standards for Athletic Equipment (NOCSAE). Major funding came from the National Centers for Injury Prevention and Control (NCIPC) for the Concussion Prevention Initiative Study, and the University of North Carolina Injury Prevention Research Center contributed to the execution and success of this project.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Couch JR, 2011, HEADACHE, V51, P33, DOI 10.1111/j.1526-4610.2010.01800.x; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Jackson JL, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5222; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MANDEL S, 1989, POSTGRAD MED, V85, P213; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Patel AV, 2007, J ATHL TRAINING, V42, P66; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Triplett G, 1996, PERCEPT MOTOR SKILL, V83, P1344, DOI 10.2466/pms.1996.83.3f.1344	45	61	61	1	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2013	41	7					1490	1496		10.1177/0363546513487982			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	301HS	WOS:000330524000009	23696213				2021-06-18	
J	Tweedie, D; Rachmany, L; Rubovitch, V; Zhang, YQ; Becker, KG; Perez, E; Hoffer, BJ; Pick, CG; Greig, NH				Tweedie, David; Rachmany, Lital; Rubovitch, Vardit; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Hoffer, Barry J.; Pick, Chaim G.; Greig, Nigel H.			Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Physical-traumatic brain injury; Blast-traumatic brain injury; Cognitive dysfunction; Gene expression; Molecular pathway(s); Neurodegeneration; Stem cells; Alzheimer's disease	IMPAIRED RECOGNITION MEMORY; DIFFUSE AXONAL INJURY; ELEVATED PLUS-MAZE; ALPHA SYNTHESIS INHIBITOR; FLUID-PERCUSSION INJURY; OBJECT-RECOGNITION; HEAD-INJURY; BARRIER PERMEABILITY; SPATIAL MEMORY; CORTEX DAMAGE	Warfare has long been associated with traumatic brain injury (TBI) in militarized zones. Common forms of TBI can be caused by a physical insult to the head brain or by the effects of a high velocity blast shock wave generated by the detonation of an explosive device. While both forms of trauma are distinctly different regarding the mechanism of trauma induction, there are striking similarities in the cognitive and emotional status of survivors. Presently, proven effective therapeutics for the treatment of either form of TBI are unavailable. To be able to develop efficacious therapies, studies involving animal models of physical- and blast-TBI are required to identify possible novel or existing medicines that may be of value in the management of clinical events. We examined indices of cognition and anxiety-like behavior and the hippocampal gene transcriptome of mice subjected to both forms of TBI. We identified common behavioral deficits and gene expression regulations, in addition to unique injury-specific forms of gene regulation. Molecular pathways presented a pattern similar to that seen in gene expression. Interestingly, pathways connected to Alzheimer's disease displayed a markedly different form of regulation depending on the type of TBI. While these data highlight similarities in behavioral outcomes after trauma, the divergence in hippocampal transcriptome observed between models suggests that, at the molecular level, the TBIs are quite different. These models may provide tools to help define therapeutic approaches for the treatment of physical- and blast-TBIs. Based upon observations of increasing numbers of personnel displaying TBI related emotional and behavioral changes in militarized zones, the development of efficacious therapies will become a national if not a global priority. (C) 2013 Elsevier Inc. All rights reserved.	[Tweedie, David; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Zhang, Yongqing; Becker, Kevin G.] NIA, Gene Express & Genom Unit, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Expt Gerontol, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA	Tweedie, D (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program, BRC Room 05B121,251 Bayview Blvd, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov; litalrac@post.tau.ac.il; rubovitc@post.tau.ac.il; zhangyon@grc.nia.nih.gov; BeckerK@grc.nia.nih.gov; perezev@grc.nia.nih.gov; bjh82@case.edu; pickc@post.tau.ac.il; greign@grc.nia.nih.gov		Becker, Kevin/0000-0002-6794-6656	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute on Drug Abuse, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); Sackler School of Medicine, Tel-Aviv University; Israeli science foundationIsrael Science Foundation [108/09]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24790295, 24791291] Funding Source: KAKEN; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311, ZICAG000616, ZIAAG000350, ZIAAG000333] Funding Source: NIH RePORTER	The authors wish to acknowledge Dr. Henriette van Pragg as well as William Wood III and Elin Lehrmann for their help in the preparation of this manuscript. This research was supported in part by the Intramural Research Programs of both the National Institute on Aging and National Institute on Drug Abuse, National Institutes of Health, and by the Sackler School of Medicine, Tel-Aviv University, and in part by a grant from the Israeli science foundation, grant no. 108/09.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Aston C, 2005, MOL PSYCHIATR, V10, P309, DOI 10.1038/sj.mp.4001565; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bandres E, 2005, J NEURO-ONCOL, V73, P189, DOI 10.1007/s11060-004-5174-5; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Baxter MG, 2001, HIPPOCAMPUS, V11, P61, DOI 10.1002/1098-1063(2001)11:1<61::AID-HIPO1021>3.0.CO;2-Z; Beason-Held LL, 1999, HIPPOCAMPUS, V9, P562, DOI 10.1002/(SICI)1098-1063(1999)9:5<562::AID-HIPO10>3.0.CO;2-X; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bryan C, 2012, J HEAD TRAUMA REHAB, V27, P45, DOI 10.1097/HTR.0b013e318238f146; Burton GR, 2004, GENE, V329, P167, DOI 10.1016/j.gene.2003.12.012; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Campdelacreu J., 2012, NEUROLOGIA; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Clark RE, 2000, J NEUROSCI, V20, P8853; COLE JC, 1993, BEHAV PHARMACOL, V4, P573; COLE JC, 1995, PHARMACOL BIOCHEM BE, V52, P473, DOI 10.1016/0091-3057(95)00163-Q; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Deacon RMJ, 2002, BEHAV BRAIN RES, V133, P57, DOI 10.1016/S0166-4328(01)00451-X; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Falk A.C., 2012, SCAND J CARING SCI; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gilbert PE, 2003, LEARN MEMORY, V10, P525, DOI 10.1101/lm.64503; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Hattori Y, 1997, MOL BRAIN RES, V47, P139, DOI 10.1016/S0169-328X(97)00044-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hunt MC, 2012, BBA-MOL BASIS DIS, V1822, P1397, DOI 10.1016/j.bbadis.2012.03.009; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang CH, 2001, P NATL ACAD SCI USA, V98, P1930, DOI 10.1073/pnas.98.4.1930; Johnson VE, 2012, EXP NEUROL; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Lee WH, 2012, INT J RADIAT ONCOL, V82, P1559, DOI 10.1016/j.ijrobp.2010.12.032; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Lorenzini CGA, 1997, BRAIN RES, V768, P242, DOI 10.1016/S0006-8993(97)00651-3; Luukkainen S., 2012, PSYCHIAT RES; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mody M, 2001, P NATL ACAD SCI USA, V98, P8862, DOI 10.1073/pnas.141244998; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mumby DG, 2001, BEHAV BRAIN RES, V127, P159, DOI 10.1016/S0166-4328(01)00367-9; Mumby DG, 1999, BEHAV BRAIN RES, V106, P97, DOI 10.1016/S0166-4328(99)00097-2; Murray EA, 2000, ANN NY ACAD SCI, V911, P166; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Rachmany L., 2012, AGE DORDR; Rachmany L., 2012, EXP NEUROL; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Reed JM, 1997, BEHAV NEUROSCI, V111, P667, DOI 10.1037/0735-7044.111.4.667; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Russo I, 2012, J NEUROCHEM, V122, P1181, DOI 10.1111/j.1471-4159.2012.07846.x; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Sajja V.S., 2012, NMR BIOMED; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Seo JH, 2012, CURR PHARM DESIGN, V18, P3645; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Squire LR, 1996, P NATL ACAD SCI USA, V93, P13515, DOI 10.1073/pnas.93.24.13515; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Takahashi N, 2011, PROG NEUROBIOL, V93, P13, DOI 10.1016/j.pneurobio.2010.09.004; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Van Hove I, 2012, MOL NEUROBIOL, V45, P17, DOI 10.1007/s12035-011-8215-z; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Wada K., 1999, J NEUROTRAUM, V16, P203; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Yang CC, 2012, BRAIN INJURY, V26, P1185, DOI 10.3109/02699052.2012.666374; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zola SM, 2001, HIPPOCAMPUS, V11, P92, DOI 10.1002/hipo.1027	99	61	62	0	28	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JUN	2013	54						1	11		10.1016/j.nbd.2013.02.006			11	Neurosciences	Neurosciences & Neurology	132EZ	WOS:000318052000001	23454194	Green Accepted			2021-06-18	
J	Baalman, KL; Cotton, RJ; Rasband, SN; Rasband, MN				Baalman, Kelli L.; Cotton, R. James; Rasband, S. Neil; Rasband, Matthew N.			Blast Wave Exposure Impairs Memory and Decreases Axon Initial Segment Length	JOURNAL OF NEUROTRAUMA			English	Article						axon initial segment; ion channel; traumatic brain injury	TRAUMATIC BRAIN-INJURY; RECOGNITION MEMORY; NEURONAL INJURY; SODIUM-CHANNELS; RATS; OVERPRESSURE; CYTOSKELETON; NEUROTRAUMA; TETRODOTOXIN; MAINTENANCE	Exposure to a blast wave has been proposed to cause mild traumatic brain injury (mTBI), with symptoms including altered cognition, memory, and behavior. This idea, however, remains controversial, and the mechanisms of blast-induced brain injury remain unknown. To begin to resolve these questions, we constructed a simple compressed air shock tube, placed rats inside the tube, and exposed them to a highly reproducible and controlled blast wave. Consistent with the generation of a mild injury, 2 weeks after exposure to the blast, we found that motor performance was unaffected, and a panel of common injury markers showed little or no significant changes in expression in the cortex, corpus callosum, or hippocampus. Similarly, we were unable to detect elevated spectrin breakdown products in brains collected from blast-exposed rats. Using an object recognition task, however, we found that rats exposed to a blast wave spent significantly less time exploring a novel object when compared with control rats. Intriguingly, we also observed a significant shortening of the axon initial segment (AIS) in both the cortex and hippocampus of blast-exposed rats, suggesting altered neuronal excitability after exposure to a blast. A computational model showed that shortening the AIS increased both threshold and the interspike interval of repetitively firing neurons. These results support the conclusion that exposure to a single blast wave can lead to mTBI with accompanying cognitive impairment and subcellular changes in the molecular organization of neurons.	[Baalman, Kelli L.; Cotton, R. James; Rasband, Matthew N.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Rasband, S. Neil] Brigham Young Univ, Dept Phys & Astron, Provo, UT 84602 USA	Rasband, MN (corresponding author), Baylor Coll Med, Dept Neurosci, 1 Baylor Plaza, Houston, TX 77030 USA.	rasband@bcm.edu		Rasband, Matthew/0000-0001-8184-2477	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0145]	We thank Ms. Eva Ng and Yanhong Liu for technical help. We thank Cameron Cowan for help measuring the optokinetic response of rats. This work was supported by grant W81XWH-08-2-0145 from the Department of Defense.	Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Buffington SA, 2011, EUR J NEUROSCI, V34, P1609, DOI 10.1111/j.1460-9568.2011.07875.x; Burggraf D, 2008, BRAIN RES, V1189, P189, DOI 10.1016/j.brainres.2007.10.085; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Delcour M, 2012, BEHAV BRAIN RES, V232, P233, DOI 10.1016/j.bbr.2012.03.029; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Galiano MR, 2012, CELL, V149, P1125, DOI 10.1016/j.cell.2012.03.039; Gerstner W, 1997, P NATL ACAD SCI USA, V94, P12740, DOI 10.1073/pnas.94.24.12740; Grubb MS, 2011, J NEUROSCI, V31, P16049, DOI 10.1523/JNEUROSCI.4064-11.2011; Grubb MS, 2010, NATURE, V465, P1070, DOI 10.1038/nature09160; Hedstrom KL, 2008, J CELL BIOL, V183, P635, DOI 10.1083/jcb.200806112; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jeong H.K., 2011, PLOS ONE, V5; Kaphzan H, 2011, J NEUROSCI, V31, P17637, DOI 10.1523/JNEUROSCI.4162-11.2011; Kole MHP, 2008, NAT NEUROSCI, V11, P178, DOI 10.1038/nn2040; Kuba H, 2010, NATURE, V465, P1075, DOI 10.1038/nature09087; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Li XY, 2011, EMBO J, V30, P4825, DOI 10.1038/emboj.2011.376; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Ogawa Y, 2006, J NEUROSCI, V26, P5230, DOI 10.1523/JNEUROSCI.0425-06.2006; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Rasband MN, 2010, NAT REV NEUROSCI; Rathbun DL, 2007, J NEUROPHYSIOL, V98, P911, DOI 10.1152/jn.00802.2006; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schafer DP, 2004, J NEUROSCI, V24, P3176, DOI 10.1523/JNEUROSCI.5427-03.2004; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wimmer VC, 2010, J PHYSIOL-LONDON, V588, P1829, DOI 10.1113/jphysiol.2010.188417; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yang Y, 2007, J CELL BIOL, V176, P509, DOI 10.1083/jcb.200610128	50	61	61	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		741	751		10.1089/neu.2012.2478			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600006	23025758	Green Published			2021-06-18	
J	Miller, DM; Singh, IN; Wang, JA; Hall, ED				Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Nrf2; Mitochondria; Oxidative damage; Lipid peroxidation; 4-Hydroxy-2-nonenal; Free radicals	TRAUMATIC BRAIN-INJURY; TRANSCRIPTION FACTOR NRF2; COMPLEX-II INHIBITION; SPINAL-CORD-INJURY; OXIDATIVE STRESS; NITRIC-OXIDE; ALKENAL/ONE OXIDOREDUCTASE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; IN-VITRO	The transcription factor NF-E2-related factor 2 (Nrf2) mediates transcription of antioxidant/cytoprotective genes by binding to the antioxidant-response element (ARE) within DNA. Upregulation of these genes constitutes a pleiotropic cytoprotective defense pathway, which has been shown to produce neuroprotection in numerous models by decreasing lipid peroxidation (LP) as measured by the neurotoxic LP by-product 4-hydroxynonenal (4-HNE). As neuronal mitochondria have previously been shown to be susceptible to insult-induced LP-mediated oxidative damage, we sought to mechanistically investigate whether Nrf2-ARE activation in vivo could protect mitochondria from subsequent 4-HNE exposure ex vivo. Young adult male CF-1 mice were administered one of two known Nrf2-ARE activators as single intraperitoneal doses-sulforaphane (SFP; 5.0 mg/kg) or carnosic acid (CA; 1.0 mg/kg)-or their respective vehicles 48 h before Ficoll isolation of rat cerebral cortical mitochondria. Purified mitochondria were then exposed ex vivo to 4-HNE for 15 min. at 37 degrees C which we showed to cause a concentration-related inhibition of mitochondrial respiration together with covalent binding of 4-HNE to mitochondrial proteins. We chose a 30 mu M concentration of 4-HNE, which produced an approximately 50% inhibition of complex I- or complex II-driven respiration, to assess whether prior in vivo Nrf2-ARE-activating compounds would increase the resistance of the isolated, cortical mitochondria to 4-HNE's mitotoxic effects. Administration of either compound significantly increased (p < 0.05) expression of heme oxygenase-1 mRNA in cortical tissue 48 h postadministration, verifying that both compounds were capable of inducing the Nrf2-ARE pathway. Moreover, the prior in vivo administration of SFP and CA significantly (p < 0.05) attenuated 4-HNE-induced inhibition of mitochondrial respiration for complex I, but only carnosic acid acted to protect complex II. Furthermore, both CA and SFP significantly (p < 0.05) reduced the amount of 4-HNE bound to mitochondrial proteins as determined by Western blot. These results demonstrate the capability of in vivo Nrf2-ARE induction to protect from 4-HNE toxicity to cortical mitochondria ex vivo. Ongoing studies will determine the therapeutic efficacy of Nrf2-ARE activators to attenuate traumatic brain injury-induced pathophysiology. (C) 2013 Elsevier Inc. All rights reserved.	[Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St BBSRB Room B477, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		Kentucky Spinal Cord 82 Head Injury Research Trust;  [NIH-NIDA 1T32 DA022738];  [NIH-NINDS 2P30 NS051220-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS077889, P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by Grants NIH-NIDA 1T32 DA022738 and NIH-NINDS 2P30 NS051220-01 and funds from the Kentucky Spinal Cord 82 Head Injury Research Trust.	Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bosken J.M., 2012, ANIMAL MODELS NEUROL, P347; Calkins MJ, 2010, TOXICOL SCI, V115, P557, DOI 10.1093/toxsci/kfq072; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Denicola A, 2005, TOXICOLOGY, V208, P273, DOI 10.1016/j.tox.2004.11.023; Dick RA, 2001, J BIOL CHEM, V276, P40803, DOI 10.1074/jbc.M105487200; Greco T, 2011, FREE RADICAL BIO MED, V51, P2164, DOI 10.1016/j.freeradbiomed.2011.09.017; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; Hall E. D, 1996, NEUROSURGERY, P505; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Innamorato NG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011838; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2009, EXP BIOL MED, V234, P181, DOI 10.3181/0807-RM-232; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; KOCHANEK PM, 2007, BRAIN INJURY MED PRI, P81; Kraft AD, 2007, EXP NEUROL, V207, P107, DOI 10.1016/j.expneurol.2007.05.026; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Matsushita M, 1997, J COMP NEUROL, V377, P251, DOI 10.1002/(SICI)1096-9861(19970113)377:2<251::AID-CNE7>3.0.CO;2-2; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pettazzoni P, 2011, FREE RADICAL BIO MED, V51, P1610, DOI 10.1016/j.freeradbiomed.2011.07.009; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Son TG, 2010, J NEUROCHEM, V112, P1316, DOI 10.1111/j.1471-4159.2009.06552.x; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Yu X, 2006, J BIOL CHEM, V281, P26245, DOI 10.1074/jbc.M604620200; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	51	61	62	0	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	APR	2013	57						1	9		10.1016/j.freeradbiomed.2012.12.011			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	105AC	WOS:000316037000001	23275005	Green Accepted			2021-06-18	
J	Simpson, G; Jones, K				Simpson, Grahame; Jones, Kate			How important is resilience among family members supporting relatives with traumatic brain injury or spinal cord injury?	CLINICAL REHABILITATION			English	Article						Traumatic brain injury; spinal cord injury; family adaptation; caregiver; resilience	PSYCHOLOGICAL DISTRESS; LIFE SATISFACTION; HEAD-INJURY; REHABILITATION; SPOUSES; PEOPLE; IMPACT; ADJUSTMENT; ADAPTATION; STRESS	Objective: To investigate the relationship between resilience and affective state, caregiver burden and caregiving strategies among family members of people with traumatic brain or spinal cord injury. Design: An observational prospective cross-sectional study. Setting: Inpatient and community rehabilitation services. Subjects: Convenience sample of 61 family respondents aged 18 years or older at the time of the study and supporting a relative with severe traumatic brain injury (n = 30) or spinal cord injury (n = 31). Main measures: Resilience Scale, Positive And Negative Affect Schedule, Caregiver Burden Scale, Functional Independence Measure, Carer's Assessment of Managing Index. Results: Correlational analyses found a significant positive association between family resilience scores and positive affect (r(s) = 0.67), and a significant negative association with negative affect (r(s) = -0.47) and caregiver burden scores (r(s) = -0.47). No association was found between family resilience scores and their relative's severity of functional impairment. Family members with high resilience scores rated four carer strategies as significantly more helpful than family members with low resilience scores. Between-groups analyses (families supporting relative with traumatic brain injury vs. spinal cord injury) found no significant differences in ratings of the perceived helpfulness of carer strategies once Bonferroni correction for multiple tests was applied. Conclusions: Self-rated resilience correlated positively with positive affect, and negatively with negative affect and caregiver burden. These results are consistent with resilience theories which propose that people with high resilience are more likely to display positive adaptation when faced by significant adversity.	[Simpson, Grahame; Jones, Kate] Liverpool Hosp, Sydney, NSW, Australia	Simpson, G (corresponding author), Liverpool Hlth Serv, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool Bc, NSW 1871, Australia.	grahame.simpson@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Jones, Kate/0000-0002-5964-3479	NSW Life Time Care and Support Authority [08/210]	This work was supported by the NSW Life Time Care and Support Authority (08/210).	Alfano D P, 1994, Appl Neuropsychol, V1, P57, DOI 10.1207/s15324826an0101&2_10; Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; Campbell-Sills L, 2006, BEHAV RES THER, V44, P585, DOI 10.1016/j.brat.2005.05.001; Chan RCK, 2000, CLIN REHABIL, V14, P137, DOI 10.1191/026921500675826560; Earvolino-Ramirez M, 2007, NURS FORUM, V42, P73, DOI 10.1111/j.1744-6198.2007.00070.x; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Friborg O, 2003, INT J METH PSYCH RES, V12, P65, DOI 10.1002/mpr.143; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Kolakowsky-Hayner SA, 1999, NEUROREHABILITATION, V13, P27; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; KOSCIULEK JF, 1993, J REHABIL, V59, P40; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; Lopez J, 2005, ARCH GERONTOL GERIAT, V41, P81, DOI 10.1016/j.archger.2004.12.001; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Mancini AD, 2006, J CLIN PSYCHOL, V62, P971, DOI 10.1002/jclp.20283; Mckee K, 2009, AGING MENT HEALTH, V13, P255, DOI 10.1080/13607860802342219; Meade MA, 2004, REHABIL PSYCHOL, V49, P150, DOI 10.1037/0090-5550.49.2.150; Newman R, 2005, PROF PSYCHOL-RES PR, V36, P227, DOI 10.1037/0735-7028.36.3.227; NOLAN M, 1996, UNDERSTANDING FAMILY; Nolan M., 1998, ASSESSING NEEDS FAMI; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; Ponsford J, 2002, TRAUMATIC BRAIN INJU; Post MWM, 2005, SPINAL CORD, V43, P311, DOI 10.1038/sj.sc.3101704; Richardson GE, 2002, J CLIN PSYCHOL, V58, P307, DOI 10.1002/jclp.10020; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SPINA S, 2005, BRAIN IMPAIR, V6, P33, DOI DOI 10.1375/BRIM.6.1.33.65478; Uniform Data System for Medical Rehabilitation, 1997, GUID UN DAT SET MED; Wagnild G M, 1993, J Nurs Meas, V1, P165; Watson D., 1994, PANAS 10 MAN POS NEG; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001	36	61	61	0	46	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	APR	2013	27	4					367	377		10.1177/0269215512457961			11	Rehabilitation	Rehabilitation	140FN	WOS:000318639900010	23012693				2021-06-18	
J	Cavaco, S; Goncalves, A; Pinto, C; Almeida, E; Gomes, F; Moreira, I; Fernandes, J; Teixeira-Pinto, A				Cavaco, Sara; Goncalves, Alexandra; Pinto, Claudia; Almeida, Eduarda; Gomes, Filomena; Moreira, Ines; Fernandes, Joana; Teixeira-Pinto, Armando			Trail Making Test: Regression-based Norms for the Portuguese Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Cognition; Neuropsychological tests; Standardization; Executive functions; Educational achievement	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ORAL WORD-ASSOCIATION; EXECUTIVE FUNCTION; FRONTAL-LOBE; STROOP TEST; NEUROPSYCHOLOGICAL TESTS; ALZHEIMER-DISEASE; TEST INDEXES; TEST-A	The main goal of this study was to produce normative data for the Portuguese population on the Trail Making Test (TMT). The study included 1,038 community-dwelling individuals aged between 18 and 93 years, who had educational backgrounds ranging from 3 to 22 years. The results showed that sex, age, and education were significantly associated with TMT performance. These demographic characteristics accounted for 57 of the performance variance at part A and 50 at part B. The normative data are presented as regression-based algorithms to adjust direct and derived test scores for sex, age, and education. The adjusted scores percentile distributions and their correspondence with scaled scores are also provided.	[Cavaco, Sara; Goncalves, Alexandra; Pinto, Claudia; Almeida, Eduarda; Gomes, Filomena; Moreira, Ines; Fernandes, Joana] Ctr Hosp Porto, Lab Neurobiol Comportamento Humano, P-4099001 Oporto, Portugal; [Cavaco, Sara; Goncalves, Alexandra; Pinto, Claudia; Almeida, Eduarda; Gomes, Filomena; Moreira, Ines; Fernandes, Joana] Univ Porto, Unidade Multidisciplinar Invest Biomed, P-4100 Oporto, Portugal; [Cavaco, Sara] Univ Iowa Carver Coll Med, Div Behav Neurol & Cognit Neurosci, Iowa City, IA USA; [Teixeira-Pinto, Armando] Univ Porto, CIDES, CINTESIS, Fac Med, P-4100 Oporto, Portugal; [Teixeira-Pinto, Armando] Univ Sydney, Screening & Test Evaluat Program, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia	Cavaco, S (corresponding author), Ctr Hosp Porto, Serv Neurol, P-4099001 Oporto, Portugal.	saramscavaco@gmail.com	Teixeira-Pinto, Armando/H-7947-2013; , CINTESIS/C-6631-2014	Teixeira-Pinto, Armando/0000-0002-9389-2516; Cavaco, Sara/0000-0001-7428-2854; , CINTESIS/0000-0001-7248-2086; Goncalves, Alexandra/0000-0001-9030-3686	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [402764]	This research received no specific grant from any funding agency, commercial or not-for-profit sectors. Armando Teixeira-Pinto was supported by the Australian National Health and Medical Research Council Grant 402764 to the Screening and Test Evaluation Program.	Amieva H, 1998, J CLIN EXP NEUROPSYC, V20, P280, DOI 10.1076/jcen.20.2.280.1161; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Armitage S. G., 1946, PSYCHOL MONOGRAPHS, V60; Army Individual Test Battery, 1944, MAN DIR SCOR; Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Atkinson TM, 2011, CLIN NEUROPSYCHOL, V25, P1193, DOI 10.1080/13854046.2011.589410; Axelrod B N, 2000, Appl Neuropsychol, V7, P186; Bell-McGinty S, 2002, INT J GERIATR PSYCH, V17, P828, DOI 10.1002/gps.646; Cangoz B, 2009, J NEUROL SCI, V283, P73, DOI 10.1016/j.jns.2009.02.313; Chapman RM, 2011, J CLIN EXP NEUROPSYC, V33, P187, DOI 10.1080/13803395.2010.499356; Chen PJ, 2001, ARCH GEN PSYCHIAT, V58, P853, DOI 10.1001/archpsyc.58.9.853; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Dawson JD, 2009, NEUROLOGY, V72, P521, DOI 10.1212/01.wnl.0000341931.35870.49; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Drane DL, 2002, NEUROPSY NEUROPSY BE, V15, P39; Emerson JL, 2012, PSYCHOL AGING, V27, P550, DOI 10.1037/a0026359; Ewers M, 2012, NEUROBIOL AGING, V33, P1203, DOI 10.1016/j.neurobiolaging.2010.10.019; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; Ferman TJ, 2006, CLIN NEUROPSYCHOL, V20, P623, DOI 10.1080/13854040500376831; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Gomar JJ, 2011, ARCH GEN PSYCHIAT, V68, P961, DOI 10.1001/archgenpsychiatry.2011.96; GOUL WR, 1970, PERCEPT MOTOR SKILL, V30, P319, DOI 10.2466/pms.1970.30.1.319; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; Heidler-Gary J, 2007, DEMENT GERIATR COGN, V23, P184, DOI 10.1159/000098562; Heled E, 2012, J CLIN EXP NEUROPSYC, V34, P151, DOI 10.1080/13803395.2011.625351; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Horton AM, 2001, INT J NEUROSCI, V111, P123, DOI 10.3109/00207450108986557; Instituto Nacional de Estatistica, 2001, CENS 2011 RES PROV; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Johnson JK, 2007, J GERONTOL A-BIOL, V62, P1134, DOI 10.1093/gerona/62.10.1134; Kaleita TA, 2004, J NEURO-ONCOL, V67, P245, DOI 10.1023/B:NEON.0000021900.29176.58; KENNEDY KJ, 1981, PERCEPT MOTOR SKILL, V52, P671, DOI 10.2466/pms.1981.52.2.671; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P813, DOI 10.1080/13854040701625846; Lemiere J, 2004, J NEUROL, V251, P935, DOI 10.1007/s00415-004-0461-9; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lucas JA, 2005, CLIN NEUROPSYCHOL, V19, P243, DOI 10.1080/13854040590945337; McDonald CR, 2005, J INT NEUROPSYCH SOC, V11, P477, DOI 10.1017/S1355617705050484; Mitchell M, 2008, J CLIN EXP NEUROPSYC, V30, P683, DOI 10.1080/13803390701679893; Mitrushina M., 1999, HDB NORMATIVE DATA N; O'Rourke JJF, 2011, J CLIN EXP NEUROPSYC, V33, P567, DOI 10.1080/13803395.2010.541228; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038; Potter G. G., AM J GERIAT IN PRESS; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Salthouse TA, 2000, NEUROPSYCHOLOGY, V14, P102, DOI 10.1037/0894-4105.14.1.102; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Seo EH, 2006, INT J GERIATR PSYCH, V21, P844, DOI 10.1002/gps.1570; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Vazzana R, 2010, J AM GERIATR SOC, V58, P719, DOI 10.1111/j.1532-5415.2010.02780.x; Wiberg B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000458; Wolfson D., 1993, HALSTEAD REITAN NEUR; Zalonis I, 2008, CLIN NEUROPSYCHOL, V22, P842, DOI 10.1080/13854040701629301	59	61	62	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2013	28	2					189	198		10.1093/arclin/acs115			10	Psychology, Clinical; Psychology	Psychology	092YS	WOS:000315159500011	23299183	Bronze			2021-06-18	
J	Chrisman, SP; Rivara, FP; Schiff, MA; Zhou, C; Comstock, RD				Chrisman, Sara P.; Rivara, Frederick P.; Schiff, Melissa A.; Zhou, Chuan; Comstock, R. Dawn			Risk factors for concussive symptoms 1 week or longer in high school athletes	BRAIN INJURY			English	Article						Brain concussion; adolescent; recovery of function; athletic injuries; athletic trainer; return to play	SEX-DIFFERENCES; PLAY GUIDELINES; RECOVERY; PREDICTORS; SEVERITY; FOOTBALL; INJURY; RETURN	Objective: To identify risk factors for concussive symptoms >= 1 week. Methods: Retrospective cohort study of concussions in the RIO (TM) database 2006-2009 (n=1412) analysing risk factors for concussive symptoms >= 1 week. This study examined athlete's age, sex, weight, history of concussion, number of symptoms and specific symptoms. Data were stratified by football vs. non-football and analysed using Poisson regression to calculate relative risks and 95% confidence intervals. Results: Presenting with four or more symptoms was associated with double the risk for concussive symptoms >= 1 week for both football (95% CI=1.3-3.5) and non-football players (95% CI=1.4-4.6). History of prior concussion was associated with double the risk for concussive symptoms >= 1 week in football players only (95% CI=1.3-3.5). Several symptoms were associated with concussive symptoms >= 1 week in all athletes: drowsiness, nausea and concentration difficulties. Sensitivity to light and noise was associated with concussive symptoms >= 1 week in non-football players only. Amnesia was associated with concussive symptoms >= 1 week in males, but not females. Loss of consciousness was not significant. Conclusions: Risk factors for concussive symptoms >= 1 week are identifiable and can potentially be used to prognosticate for athletes and design evidence-based return-to-play guidelines.	[Chrisman, Sara P.] Univ Washington, Div Adolescent Med, Seattle, WA 98195 USA; [Rivara, Frederick P.; Schiff, Melissa A.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Rivara, Frederick P.; Zhou, Chuan] Univ Washington, Div Gen Pediat, Seattle, WA 98195 USA; [Schiff, Melissa A.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Zhou, Chuan] Ctr Child Hlth Behav & Dev, Seattle Childrens Res Inst, Seattle, WA USA; [Comstock, R. Dawn] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Columbus, OH USA; [Comstock, R. Dawn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	Chrisman, SP (corresponding author), POB 5371,M-S CW8-6, Seattle, WA 98145 USA.	sara.chrisman@seattlechildrens.org	Zhou, Chuan/AAJ-1935-2020	Chrisman, Sara/0000-0001-5373-7223	Ruth L. Kirschstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	The authors report no conflicts of interest. This research was supported in part by a fellowship from the Ruth L. Kirschstein National Research Service Award.	Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hershey AD, 2007, JAMA-J AM MED ASSOC, V19, p[663, 2549]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	26	61	61	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					1	9		10.3109/02699052.2012.722251			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300001	23252433				2021-06-18	
J	Sosa, MAG; De Gasperi, R; Paulino, AJ; Pricop, PE; Shaughness, MC; Maudlin-Jeronimo, E; Hall, AA; Janssen, WGM; Yuk, FJ; Dorr, NP; Dickstein, DL; McCarron, RM; Chavko, M; Hof, PR; Ahlers, ST; Elder, GA				Sosa, Miguel A. Gama; De Gasperi, Rita; Paulino, Alejandro J.; Pricop, Paul E.; Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; Janssen, William G. M.; Yuk, Frank J.; Dorr, Nathan P.; Dickstein, Dara L.; McCarron, Richard M.; Chavko, Mikulas; Hof, Patrick R.; Ahlers, Stephen T.; Elder, Gregory A.			Blast overpressure induces shear-related injuries in the brain of rats exposed to a mild traumatic brain injury	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Blast overpressure injury; Neuropathology; Shear injury; Traumatic brain injury		Background: Blast-related traumatic brain injury (TBI) has been a significant cause of injury in the military operations of Iraq and Afghanistan, affecting as many as 10-20% of returning veterans. However, how blast waves affect the brain is poorly understood. To understand their effects, we analyzed the brains of rats exposed to single or multiple (three) 74.5 kPa blast exposures, conditions that mimic a mild TBI. Results: Rats were sacrificed 24 hours or between 4 and 10 months after exposure. Intraventricular hemorrhages were commonly observed after 24 hrs. A screen for neuropathology did not reveal any generalized histopathology. However, focal lesions resembling rips or tears in the tissue were found in many brains. These lesions disrupted cortical organization resulting in some cases in unusual tissue realignments. The lesions frequently appeared to follow the lines of penetrating cortical vessels and microhemorrhages were found within some but not most acute lesions. Conclusions: These lesions likely represent a type of shear injury that is unique to blast trauma. The observation that lesions often appeared to follow penetrating cortical vessels suggests a vascular mechanism of injury and that blood vessels may represent the fault lines along which the most damaging effect of the blast pressure is transmitted.	[Sosa, Miguel A. Gama] Vet Affairs Med Ctr, Dept Vet, Gen Med Res Serv, Bronx, NY 10468 USA; [De Gasperi, Rita; Paulino, Alejandro J.; Pricop, Paul E.; Dorr, Nathan P.] Vet Affairs Med Ctr, Dept Vet, Res & Dev Serv, Bronx, NY 10468 USA; [Elder, Gregory A.] Vet Affairs Med Ctr, Dept Vet, Neurol Serv, Bronx, NY 10468 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Paulino, Alejandro J.; Pricop, Paul E.; Dorr, Nathan P.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Janssen, William G. M.; Yuk, Frank J.; Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Dickstein, Dara L.; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; McCarron, Richard M.; Chavko, Mikulas; Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD USA	Sosa, MAG (corresponding author), Vet Affairs Med Ctr, Dept Vet, Gen Med Res Serv, Bronx, NY 10468 USA.	miguel.gama-sosa@mssm.edu	Dickstein, Dara/AAH-6603-2020		Department of Veterans AffairsUS Department of Veterans Affairs [1I01RX000179-01]; General Medical Research Service, James J. Peters VA Medical Center	We thank Bridget Wicinski for expert technical assistance. We thank Drs. Peter Davies, and Robert Lazzarini for gifts of antibodies. This work was supported by grant 1I01RX000179-01 from the Department of Veterans Affairs. MAGS is supported by the General Medical Research Service, James J. Peters VA Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense nor the U.S. Government.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Assari S, 2013, 9 ANN INJ BIOM S COL; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2011, NATO S SURV BLAST IN; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Romba JJ, 1961, ECHNICAL MEMORANDUM, P1; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Yarnell AM, 2013, CURR PROTOC NEUROSCI, V9, P9, DOI DOI 10.1002/0471142301.NS0941S62; Zhu Feng, 2010, Stapp Car Crash J, V54, P211	34	61	62	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2013	1								51	10.1186/2051-5960-1-51			15	Neurosciences	Neurosciences & Neurology	V9K2F	WOS:000422387200041	24252601	DOAJ Gold, Green Published			2021-06-18	
J	Chatelle, C; Majerus, S; Whyte, J; Laureys, S; Schnakers, C				Chatelle, Camille; Majerus, Steve; Whyte, John; Laureys, Steven; Schnakers, Caroline			A sensitive scale to assess nociceptive pain in patients with disorders of consciousness	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							STATE; STIMULI; COMA	Objective To determine the sensitivity of the Nociception Coma Scale (NCS), the first scale developed to assess nociceptive pain in vegetative state and minimally conscious state patients, in comparing behavioural changes in response to noxious versus non-noxious stimulation. Methods The NCS was administered to assess patients' responses in three conditions: (1) baseline (observation of spontaneous behaviours), (2) non-noxious/tactile stimulation (taps on the patient's shoulder), and (3) noxious stimulation (pressure on the nail bed). Results We included 64 patients (27 vegetative state and 37 minimally conscious state; age range 20-82 years; 22 traumatic brain injury; 21 in the acute stage). The NCS total scores and subscores (motor, verbal and facial) were higher for the noxious versus the non-noxious stimulation conditions. We did not observe a difference between the non-noxious and the noxious stimulation conditions for the visual subscale. We also found a NCS cut-off value of 4 differentiating the patients receiving a noxious stimulation from patients receiving a non-noxious stimulation. The exclusion of the visual subscale increased the cut-off sensitivity (from 46% to 73%; specificity of 97% and accuracy of 85%). Conclusion We propose a new version of the NCS excluding the visual subscale, the NCS-R, which constitutes a highly sensitive tool to assess responses to nociceptive pain in severely brain injured patients.	[Chatelle, Camille; Laureys, Steven; Schnakers, Caroline] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Chatelle, Camille; Laureys, Steven; Schnakers, Caroline] Univ Hosp Liege, Dept Neurol, Liege, Belgium; [Majerus, Steve; Schnakers, Caroline] Univ Liege, Dept Cognit Sci, B-4000 Liege, Belgium; [Whyte, John] Moss Rehabil Res Inst, Philadelphia, PA USA	Schnakers, C (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B30, B-4000 Liege, Belgium.	c.schnakers@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Majerus, Steve/D-4678-2009; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Whyte, John/0000-0002-4381-1474; Chatelle, Camille/0000-0002-7526-2107; Majerus, Steve/0000-0002-8206-8097	Belgian Federal Public Health; National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; James S. McDonnell Foundation; Mind Science Foundation; European Commission (Mindbridge, DISCOS, DECODER & COST), Concerted Research Action [ARC 06/11-340]; Public Utility Foundation 'Universite Europeenne du Travail', 'Fondazione Europea di Ricerca Biomedica'; University of LiegeUniversity of Liege	This study was supported by the Belgian Federal Public Health, the National Funds for Scientific Research (FNRS), James S. McDonnell Foundation, Mind Science Foundation, European Commission (Mindbridge, DISCOS, DECODER & COST), Concerted Research Action (ARC 06/11-340), Public Utility Foundation 'Universite Europeenne du Travail', 'Fondazione Europea di Ricerca Biomedica' and the University of Liege. CS is postdoctoral researcher, CC is research fellow, and SM and SL are senior research associates at FNRS.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Hummel P, 2006, SEMIN FETAL NEONAT M, V11, P237, DOI 10.1016/j.siny.2006.02.004; IASP, 1994, CLASS CHRON PAIN S3; Kupers R, 2006, LANCET NEUROL, V5, P1033, DOI 10.1016/S1474-4422(06)70624-X; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Lawrence J, 1993, Neonatal Netw, V12, P59; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Merkel S I, 1997, Pediatr Nurs, V23, P293; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Schnakers C, 2010, EXPERT REV NEUROTHER, V10, P1725, DOI 10.1586/ERN.10.148; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; TEASDALE G, 1974, LANCET, V2, P81; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1016/S1525-8610(04)70258-3	20	61	67	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2012	83	12					1233	1237		10.1136/jnnp-2012-302987			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	037IU	WOS:000311097700024	22906615				2021-06-18	
J	Leopold, A; Krueger, F; dal Monte, O; Pardini, M; Pulaski, SJ; Solomon, J; Grafman, J				Leopold, Anne; Krueger, Frank; dal Monte, Olga; Pardini, Matteo; Pulaski, Sarah J.; Solomon, Jeffrey; Grafman, Jordan			Damage to the left ventromedial prefrontal cortex impacts affective theory of mind	SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE			English	Article						affective theory of mind; ventromedial prefrontal cortex; traumatic brain injury; emotional intelligence; empathy	EMOTIONAL INTELLIGENCE; BRAIN-LESIONS; RHESUS-MONKEY; FALSE BELIEF; HEAD-INJURY; DISSOCIATION; IMPAIRMENTS; EMPATHY; DEPRESSION; AUTISM	Studies investigating theory of mind (ToM) abilities (i.e. ability to understand and predict others' mental states) have revealed that affective and cognitive functions play a significant role and that each of those functions are associated with distinct neural networks. Cognitive facets of ToM have implicated the medial prefrontal cortex, temporo-parietal junction and the anterior paracingulate cortex, whereas affective facets have implicated the ventromedial prefrontal cortex (vmPFC). Although the vmPFC has repeatedly shown to be critical for affective functions, knowledge regarding the exact role of the left and right vmPFC in affective ToM is still obscure. Here, we compared performances of 30 patients with left, right and bilateral vmPFC lesions to two comparison groups (one without and one with brain injuries) on the Faux Pas Recognition task measuring the facets of ToM. We also investigated whether any deficits may be associated with other emotional measures, namely emotional empathy and emotional intelligence. Our results extend earlier findings by showing that the vmPFC is associated with abilities in affective ToM. More importantly, our results revealed that the left, and not the right vmPFC as indicated previously, is involved in affective ToM and that this deficit is associated with emotional intelligence.	[Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Grafman, Jordan] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ 07052 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [dal Monte, Olga] Univ Turin, Dept Neuropsychol, Turin, Italy; [dal Monte, Olga] Henry M Jackson Fdn, Rockville, MD USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; [Solomon, Jeffrey] Med Numer, Germantown, MD USA; [Leopold, Anne; dal Monte, Olga; Pulaski, Sarah J.] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Leopold, Anne] Univ Utrecht, Dept Social & Hlth Psychol, Utrecht, Netherlands	Krueger, F (corresponding author), George Mason Univ, Dept Mol Neurosci, 4400 Univ Dr,Mail Stop 2A1, Fairfax, VA 22030 USA.	FKrueger@gmu.edu; jgrafman@kesslerfoundation.org	Dal Monte, Olga/P-3759-2018; Pardini, Matteo/F-8414-2010	Dal Monte, Olga/0000-0002-7823-4769; Pardini, Matteo/0000-0002-4740-1982; Grafman, Jordan H./0000-0001-8645-4457	National Naval Medical Center; U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]	The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U. S. Government. The authors are grateful to all the Vietnam veterans who participated in this study. Without their long-term commitment to improving the health care of veterans, this study could not have been completed. We thank the National Naval Medical Center for their support and provision of their facilities. We are grateful to S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding and G. Tasick for their invaluable help with the testing of participants and organization of this study. The work was supported by the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the U.S. Army Medical Research and Material Command administrated by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study), grant number: DAMD17-01-1-0675.	Acuna BD, 2002, CEREB CORTEX, V12, P1312, DOI 10.1093/cercor/12.12.1312; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; [Anonymous], 2006, SPSS WIND REL 14 0 1; [Anonymous], 1960, ARMED FORCES QUALIFI; Bar-On R, 2003, BRAIN, V126, P1790, DOI 10.1093/brain/awg177; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Beck AT., 1996, BECK DEPRESSION INVE, V2; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; Critchley HD, 2000, J NEUROSCI, V20, P3033; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Dimitrov M, 1999, NEUROCASE, V5, P345, DOI 10.1080/13554799908411987; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; Goel V, 2004, BRAIN, V127, P783, DOI 10.1093/brain/awh086; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Goel V, 2003, NEUROIMAGE, V20, P2314, DOI 10.1016/j.neuroimage.2003.07.027; Goel V, 2000, NEUROIMAGE, V12, P504, DOI 10.1006/nimg.2000.0636; Goel V, 2007, CEREB CORTEX, V17, P2245, DOI 10.1093/cercor/bhl132; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Kalbe E, 2010, CORTEX, V46, P769, DOI 10.1016/j.cortex.2009.07.010; KAPLAN E, 1976, BOSTON NAMING TEST; Knauff M, 2003, J COGNITIVE NEUROSCI, V15, P559, DOI 10.1162/089892903321662949; Koenigs M, 2007, J NEUROSCI, V27, P951, DOI 10.1523/JNEUROSCI.4606-06.2007; Koenigs M, 2009, BEHAV BRAIN RES, V201, P239, DOI 10.1016/j.bbr.2009.03.004; Koenigs M, 2009, NEUROSCI LETT, V459, P88, DOI 10.1016/j.neulet.2009.04.063; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Krueger F, 2009, P NATL ACAD SCI USA, V106, P22486, DOI 10.1073/pnas.0912568106; Krueger F, 2009, TRENDS COGN SCI, V13, P103, DOI 10.1016/j.tics.2008.12.005; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mayer J.D., 2002, TEST VERSION 2 0 USE; Mayer JD, 2004, PSYCHOL INQ, V15, P197, DOI 10.1207/s15327965pli1503_02; Mayer JD, 2008, AM PSYCHOL, V63, P503, DOI 10.1037/0003-066X.63.6.503; Mayer JD, 2001, EMOTION, V1, P232, DOI 10.1037//1528-3542.1.3.232; Miller SA, 2009, PSYCHOL BULL, V135, P749, DOI 10.1037/a0016854; PANDYA DN, 1969, BRAIN RES, V15, P594, DOI 10.1016/0006-8993(69)90193-0; PERNER J, 1987, BRIT J DEV PSYCHOL, V5, P125, DOI 10.1111/j.2044-835X.1987.tb01048.x; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Reverberi C, 2005, NEUROPSYCHOLOGIA, V43, P460, DOI 10.1016/j.neuropsychologia.2004.06.008; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Sabbagh MA, 2004, BRAIN COGNITION, V55, P209, DOI 10.1016/j.bandc.2003.04.002; Sabbagh MA, 1999, BRAIN LANG, V70, P29, DOI 10.1006/brln.1999.2139; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2006, SOC NEUROSCI-UK, V1, P149, DOI 10.1080/17470910600985589; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shamay-Tsoory SG, 2007, PSYCHIAT RES, V149, P11, DOI 10.1016/j.psychres.2005.10.018; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Shaw P, 2007, NEUROPSYCHOLOGIA, V45, P2783, DOI 10.1016/j.neuropsychologia.2007.04.020; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Singer T, 2006, NEUROSCI BIOBEHAV R, V30, P855, DOI 10.1016/j.neubiorev.2006.06.011; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Strenziok M, 2011, SOC COGN AFFECT NEUR, V6, P2, DOI 10.1093/scan/nsp036; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; VANHOESEN GW, 1975, BRAIN RES, V95, P25, DOI 10.1016/0006-8993(75)90205-X; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 1997, MEASUREMENT ADULT IN; Wellman H. M., 1990, CHILDS THEORY MIND; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004	72	61	62	0	55	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1749-5016	1749-5024		SOC COGN AFFECT NEUR	Soc. Cogn. Affect. Neurosci.	NOV	2012	7	8					871	880		10.1093/scan/nsr071			10	Neurosciences; Psychology; Psychology, Experimental	Neurosciences & Neurology; Psychology	045BZ	WOS:000311671100001	22021651	Green Published, Bronze			2021-06-18	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Incidence and Risk Factors for Post-Traumatic Hydrocephalus following Decompressive Craniectomy for Intractable Intracranial Hypertension and Evacuation of Mass Lesions	JOURNAL OF NEUROTRAUMA			English	Article						complications; decompressive craniectomy; neurotrauma	TRAUMATIC BRAIN-INJURY; VENTRICULAR ENLARGEMENT; HEAD-INJURY; COMPLICATIONS; PATHOGENESIS; HYGROMA	There continues to be a considerable interest in decompressive craniectomy in the management of severe traumatic brain injury (TBI). Though technically straightforward, the procedure is not without significant complications. In this study we assessed the incidence and risk factors for the development of subdural hygroma and hydrocephalus after decompressive craniectomy. A total of 195 patients who had had a decompressive craniectomy for severe TBI between 2004 and 2010 at the two major trauma centers in Western Australia were considered. Of the 166 patients who survived after the acute hospital stay, 93 (56%; 95% confidence interval [CI] 48,63%) developed subdural hygroma; 45 patients (48%) had unilateral and 48 patients (52%) had bilateral subdural hygromas. Of the 159 patients who survived more than 6 months after surgery, 72 (45%; 95% CI 38,53%) developed radiological evidence of ventriculomegaly, and 26 of these 72 patients (36%; 95% CI 26,48%) developed clinical evidence of hydrocephalus and required a ventriculoperitoneal (VP) shunt. Maximum intracranial pressure prior to decompression (p = 0.005), subdural hygroma (p = 0.012), and a lower admission Glasgow Coma Scale score (p = 0.009), were significant risk factors for hydrocephalus after decompressive craniectomy. Hydrocephalus requiring a VP shunt was associated with a higher risk of unfavorable neurological outcomes at 18 months (odds ratio 7.46; 95% CI 1.17,47.4; p = 0.033), after adjusting for other factors. Our results showed a clear association between injury severity, subdural hygroma, and hydrocephalus, suggesting that damage to the cerebrospinal fluid drainage pathways contributes to the primary brain injury rather than the margin of the craniectomy as the factor responsible for these complications.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6019, Australia; [Ho, Kwok M.] Univ Western Australia, Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6019, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dandy WE, 1932, PRACTICE SURG, P306; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; KAUFMAN HH, 1984, ACTA NEUROCHIR, V72, P197, DOI 10.1007/BF01406870; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Licata C, 2001, J Neurosurg Sci, V45, P141; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Munch E, 2000, NEUROSURGERY, V47, P315; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	32	61	76	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1872	1878		10.1089/neu.2012.2356			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400391	22583391				2021-06-18	
J	Shultz, SR; MacFabe, DF; Foley, KA; Taylor, R; Cain, DP				Shultz, Sandy R.; MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy; Cain, Donald P.			Sub-concussive brain injury in the Long-Evans rat induces acute neuroinflammation in the absence of behavioral impairments	BEHAVIOURAL BRAIN RESEARCH			English	Article						Mild traumatic brain injury; Sub-concussive brain injury; Fluid percussion injury; Animal model; Neuroinflammation; Learning and memory	CHRONIC TRAUMATIC ENCEPHALOPATHY; 3RD INTERNATIONAL-CONFERENCE; FLUID PERCUSSION INJURY; ELEVATED PLUS-MAZE; MILD HEAD-INJURY; ANIMAL-MODEL; AXONAL INJURY; SYNAPTIC PLASTICITY; CONSENSUS STATEMENT; PROPIONIC-ACID	Sub-concussive brain injuries may result in neurophysiological changes, cumulative effects, and neurodegeneration. The current study investigated the effects of a mild lateral fluid percussion injury (0.50-0.99 atm) on rat behavior and neuropathology to address the need to better understand sub-concussive brain injury. Male Long-Evans rats received either a single mild lateral fluid percussion injury or a sham-injury, followed by either a short (24 h) or long (4 weeks) recovery period. After recovery, rats underwent extensive behavioral testing consisting of tasks for rodent cognition, anxiety- and depression-like behaviors, social behavior, and sensorimotor function. At the completion of behavioral testing rats were sacrificed and brains were examined immunohistochemically with markers for neuroinflammation and axonal injury. No significant group differences were found on behavioral and axonal injury measures. However, rats given one mild fluid percussion injury displayed an acute neuroinflammatory response, consisting of increased microglia/macrophages and reactive astrogliosis, at 4 days post-injury. Neuroinflammation is a mechanism with the potential to contribute to the cumulative and neurodegenerative effects of repeated sub-concussive injuries. The current findings are consistent with findings in humans experiencing a sub-concussive blow, and provide support for the use of mild lateral fluid percussion injury in the rat as a model of sub-concussive brain injury. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.	[Shultz, Sandy R.; Foley, Kelly A.; Cain, Donald P.] Univ Western Ontario, Dept Psychol, Grad Program Neurosci, London, ON, Canada; [MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy] Univ Western Ontario, Dept Psychiat, Kilee Patchell Evans Autism Res Grp, London, ON N6A 3K7, Canada; [MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy] Univ Western Ontario, Dept Psychol, Kilee Patchell Evans Autism Res Grp, London, ON, Canada	Shultz, SR (corresponding author), Univ Melbourne, Melbourne Brain Ctr, Bldg 144, Melbourne, Vic 3010, Australia.	sshultz@unimelb.edu.au		Shultz, Sandy/0000-0002-2525-8775	Natural Science and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by a grant from the Natural Science and Engineering Research Council (NSERC) to Dr. Donald P. Cain, a scholarship from NSERC to Dr. Sandy R. Shultz, and contributions from Good Life Childrens's Foundation and Round for a Reason Charities to Dr. Derrick F. MacFabe. We thank Drs. Richard Sutton and David Hovda from the UCLA Brain Injury Research Center for their help in LFP training. Additional thanks go to Lisa Tichenoff, Francis Boon, and Acia Blank for their assistance in the research project. Dr. Sandy Shultz now at: Department of Medicine (Royal Melbourne Hospital), Melbourne Brain Centre, University of Melbourne, Parkville, VIC, Australia.	ADAMS FS, 1994, PHYSIOL BEHAV, V55, P947, DOI 10.1016/0031-9384(94)90084-1; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2011, J NEUROTRAUMA; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gerber J, 2009, CLIN NEUROPATHOL, V28, P33; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kadhim HJ, 2009, J INTENSIVE CARE MED, V23, P236; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mochizuki A, 1996, EXP NEUROL, V142, P89, DOI 10.1006/exnr.1996.0181; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Talavage T. M., 2010, J NEUROTRAUMA; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318	59	61	62	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	APR 1	2012	229	1					145	152		10.1016/j.bbr.2011.12.015			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	915SL	WOS:000302047600018	22245525				2021-06-18	
J	Dean, PJA; O'Neill, D; Sterr, A				Dean, Philip J. A.; O'Neill, Darragh; Sterr, Annette			Post-concussion syndrome: Prevalence after mild traumatic brain injury in comparison with a sample without head injury	BRAIN INJURY			English	Article						Mild traumatic brain injury; persistent post-concussion syndrome; Rivermead post-concussion symptoms questionnaire; base rates	POSTCONCUSSION-LIKE SYMPTOMS; DIAGNOSTIC-CRITERIA; UNITED-STATES; TASK-FORCE; ANXIETY; QUESTIONNAIRE; DEPRESSION; COMPLAINTS; DISORDER; STRESS	Primary objective: To compare the prevalence of persistent post-concussion syndrome (PCS; >1 year post-injury) in participants with mild traumatic brain injury (mTBI) and those without head injury. Research design: A cross-sectional sample of 119 participants with mTBI and 246 without previous head injury. Methods: Online questionnaires collected data about post-concussion symptoms, cognitive failures, anxiety, depression, sleep behaviour and post-traumatic stress disorder. Variability within the sample was addressed by splitting by PCS diagnosis to create four groups: mTBI + PCS, mTBI-PCS, Control + PCS and Control-PCS. PCS was diagnosed using ICD-10 criteria in all groups, with controls not requiring previous head injury. Main outcomes and results: PCS was present to a similar extent in participants with no head injury (34%) compared to those with mTBI (31%). Only report of headaches, which could be caused by expectation bias, distinguished between mTBI + PCS and Control + PCS groups. In addition, significantly higher cognitive problems were observed in participants with mTBI compared with the control group. Conclusions: Persistent PCS, as currently defined, is not specific to mTBI. These data suggest that somatic and cognitive symptoms are most likely to be able to distinguish PCS after mTBI from that present in the general population. Further research is necessary into these factors in order to create more specific PCS diagnostic criteria.	[Dean, Philip J. A.; O'Neill, Darragh; Sterr, Annette] Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England	Dean, PJA (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.	p.dean@surrey.ac.uk		Dean, Philip/0000-0002-2362-513X; O'Neill, Dara/0000-0002-8830-0264	Wingate Foundation, UK	This study was supported by a Wingate Foundation Scholarship, UK.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baumert J, 2004, J AFFECT DISORDERS, V82, P29, DOI 10.1016/j.jad.2003.09.006; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chan RCK, 2005, BRAIN INJURY, V19, P1117, DOI 10.1080/026990500150088; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Miletin MS, 2003, SLEEP MED, V4, P195, DOI 10.1016/S1389-9457(03)00031-5; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; *OFF NAT SAT, 2004, CENS 2001 KEY STAT R; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; World Health Organization, 1992, ICD 10 INT STAT CLAS; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543	85	61	62	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					14	26		10.3109/02699052.2011.635354			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900002	22107176	Green Accepted			2021-06-18	
J	McCoy, B; Sharma, R; Ochi, A; Go, C; Otsubo, H; Hutchison, JS; Atenafu, EG; Hahn, CD				McCoy, Blathnaid; Sharma, Rohit; Ochi, Ayako; Go, Cristina; Otsubo, Hiroshi; Hutchison, James S.; Atenafu, Eshetu G.; Hahn, Cecil D.			Predictors of nonconvulsive seizures among critically ill children	EPILEPSIA			English	Article						Continuous EEG monitoring; Intensive care; Pediatrics	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; CONTINUOUS EEG; ELECTROGRAPHIC SEIZURES; PRESSURE; PATTERNS; INCREASE	Purpose: Continuous electroencephalography (EEG) monitoring is a valuable tool for the detection of seizures among critically ill children, in particular when these seizures occur without clinical signs: termed nonconvulsive seizures. Continuous EEG monitoring is a limited resource in many centers. We sought to identify which critically ill children most frequently experience nonconvulsive seizures, and thus may particularly benefit from continuous EEG monitoring. Methods: Single-center review was undertaken of consecutive diagnostic continuous EEG (cEEG) recordings performed in our pediatric and neonatal intensive care units (ICUs). We examined the indications for monitoring, the clinical characteristics of monitored patients, the occurrence and timing of seizures, and clinical and EEG characteristics associated with nonconvulsive seizures. Key Findings: One hundred twenty-one patients underwent diagnostic continuous EEG monitoring, for a mean duration of 26 h. Seizures were detected in 32% of these patients, of which 90% experienced some nonconvulsive seizures, and 72% experienced exclusively nonconvulsive seizures. Patients with nonconvulsive seizures had significantly greater odds of having acute epilepsy, acute structural brain injury, prior in-hospital convulsive seizures, and the presence of interictal epileptiform abnormalities on EEG. Significance: Seizures are common among critically ill children undergoing diagnostic cEEG monitoring. The great majority of these seizures are nonconvulsive, requiring EEG for their detection. Predictors of nonconvulsive seizures include acute epilepsy, acute structural brain injury, prior in-hospital convulsive seizures, and interictal epileptiform abnormalities on EEG. These findings can help inform future allocation of limited cEEG monitoring resources to those patients at greatest risk for nonconvulsive seizures.	[McCoy, Blathnaid; Sharma, Rohit; Ochi, Ayako; Go, Cristina; Otsubo, Hiroshi; Hahn, Cecil D.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; [McCoy, Blathnaid; Sharma, Rohit; Ochi, Ayako; Go, Cristina; Otsubo, Hiroshi; Hutchison, James S.; Hahn, Cecil D.] Univ Toronto, Toronto, ON, Canada; [Hutchison, James S.] Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Atenafu, Eshetu G.] Univ Hlth Network, Princess Margaret Hosp, Dept Biostat, Toronto, ON, Canada	Hahn, CD (corresponding author), Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	cecil.hahn@sickkids.ca	Atenafu, Eshetu G./H-7520-2019; Hahn, Cecil D./F-6218-2011; Hahn, Cecil/J-3372-2016	Atenafu, Eshetu G./0000-0002-4613-3680; Hahn, Cecil D./0000-0002-0887-8761; Hahn, Cecil/0000-0002-0887-8761	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Hospital for Sick Children Foundation; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Ontario Neurotrauma Foundation; Physicians Services Incorporated Foundation; Victoria Neurotrauma Initiative; Hospital for Sick Children Research Institute	Dr Hutchison has received research support from the National Institutes of Health, The Hospital for Sick Children Foundation, the Canada Foundation for Innovation, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Ontario Neurotrauma Foundation, the Physicians Services Incorporated Foundation, and the Victoria Neurotrauma Initiative. Dr Hahn has received research support from The Hospital for Sick Children Research Institute, The Hospital for Sick Children Foundation, the Canadian Institutes of Health Research, and the Physicians Services Incorporated Foundation.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Ronner HE, 2009, SEIZURE-EUR J EPILEP, V18, P257, DOI 10.1016/j.seizure.2008.10.010; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WERTHEIM D, 1994, ARCH DIS CHILD-FETAL, V71, pF97, DOI 10.1136/fn.71.2.F97; Young GB, 1996, NEUROLOGY, V47, P83	22	61	62	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2011	52	11					1973	1978		10.1111/j.1528-1167.2011.03291.x			6	Clinical Neurology	Neurosciences & Neurology	848KE	WOS:000297049700011	22003955				2021-06-18	
J	Ding, MC; Wang, Q; Lo, EH; Stanley, GB				Ding, Ming-Chieh; Wang, Qi; Lo, Eng H.; Stanley, Garrett B.			Cortical Excitation and Inhibition following Focal Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							RECEPTIVE-FIELD PROPERTIES; MOUSE BARREL CORTEX; SPREADING DEPRESSION; SOMATOSENSORY CORTEX; FUNCTIONAL RECOVERY; CEREBRAL-ISCHEMIA; IN-VIVO; MOLECULAR-MECHANISMS; SENSORY RESPONSES; NEURONAL-ACTIVITY	Cortical compression can be a significant problem in many types of brain injuries, such as brain trauma, localized brain edema, hematoma, focal cerebral ischemia, or brain tumors. Mechanical and cellular alterations can result in global changes in excitation and inhibition on the neuronal network level even in the absence of histologically significant cell injury, often manifesting clinically as seizures. Despite the importance and prevalence of this problem, however, the precise electrophysiological effects of brain injury have not been well characterized. In this study, the changes in electrophysiology were characterized following sustained cortical compression using large-scale, multielectrode measurement of multiunit activity in primary somatosensory cortex in a sensory-evoked, in vivo animal model. Immediately following the initiation of injury at a distal site, there was a period of suppression of the evoked response in the rat somatosensory cortex, followed by hyper-excitability that was accompanied by an increase in the spatial extent of cortical activation. Paired-pulse tactile stimulation revealed a dramatic shift in the excitatory/inhibitory dynamics, suggesting a longer term hyperexcitability of the cortical circuit following the initial suppression that could be linked to the disruption of one or more inhibitory mechanisms of the thalamocortical circuit. Together, our results showed that the use of a sensory-evoked response provided a robust and repeatable functional marker of the evolution of the consequences of mild injury, serving as an important step toward in vivo quantification of alterations in excitation and inhibition in the cortex in the setting of traumatic brain injury.	[Wang, Qi; Stanley, Garrett B.] Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Wang, Qi; Stanley, Garrett B.] Emory Univ, Atlanta, GA 30332 USA; [Ding, Ming-Chieh] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Ding, Ming-Chieh] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Neuroprotect Res Lab, Charlestown, MA 02129 USA	Stanley, GB (corresponding author), Georgia Inst Technol, Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	garrett.stanley@bme.gatech.edu	Wang, Qi/D-6997-2012	Ding, Ming-Chieh/0000-0002-2278-5326	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS48285]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048285] Funding Source: NIH RePORTER	This work was supported by NINDS Grant R01 NS48285.	Adamo PF, 2005, J AM ANIM HOSP ASSOC, V41, P400, DOI 10.5326/0410400; Ahissar E, 2001, Prog Brain Res, V130, P75; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Andermann ML, 2006, NAT NEUROSCI, V9, P543, DOI 10.1038/nn1671; ARMSTRONGJAMES M, 1992, J NEUROPHYSIOL, V68, P1345; Aronoff R, 2010, EUR J NEUROSCI, V31, P2221, DOI 10.1111/j.1460-9568.2010.07264.x; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Baker AJ, 2008, J TRAUMA, V64, P348, DOI 10.1097/01.ta.0000245973.71929.db; Berger M, 2008, CEPHALALGIA, V28, P558, DOI 10.1111/j.1468-2982.2008.01556.x; Boloori AR, 2010, J NEUROSCI, V30, P9990, DOI 10.1523/JNEUROSCI.0807-10.2010; Boloori AR, 2006, J NEUROSCI, V26, P3767, DOI 10.1523/JNEUROSCI.4056-05.2006; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Chen JR, 2004, J NEUROTRAUM, V21, P1640, DOI 10.1089/0897715042441729; Chung S, 2002, NEURON, V34, P437, DOI 10.1016/S0896-6273(02)00659-1; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; David-Jurgens M, 2010, CEREB CORTEX, V20, P1208, DOI 10.1093/cercor/bhp185; Desilets-Roy B, 2002, J NEUROSCI, V22; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; Ding MC, 2008, NEUROSCIENCE, V154, P551, DOI 10.1016/j.neuroscience.2008.03.088; EBNER FF, 1990, PROG BRAIN RES, V86, P129; Eikermann-Haerter K, 2008, CURR OPIN NEUROL, V21, P294, DOI 10.1097/WCO.0b013e3282fc25de; Fanselow EE, 1999, J NEUROSCI, V19, P7603, DOI 10.1523/JNEUROSCI.19-17-07603.1999; Fox K, 2003, J NEUROSCI, V23, P8380; Fox K, 2002, NEUROSCIENCE, V111, P799, DOI 10.1016/S0306-4522(02)00027-1; Fujioka H, 2004, STROKE, V35, pE346, DOI 10.1161/01.STR.0000130990.28734.9c; Gil Z, 1997, NEURON, V19, P679, DOI 10.1016/S0896-6273(00)80380-3; Glass TF, 2004, NEUROBIOL DIS, V17, P378, DOI 10.1016/j.nbd.2004.07.017; HARRIS RM, 1987, NEUROSCIENCE, V21, P229, DOI 10.1016/0306-4522(87)90335-6; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Higley MJ, 2006, J NEUROSCI, V26, P448, DOI 10.1523/JNEUROSCI.3506-05.2006; Higley MJ, 2003, J NEUROSCI, V23, P10190; Jefferys JGR, 2003, EPILEPSIA, V44, P44, DOI 10.1111/j.0013-9580.2003.12004.x; Kim DS, 2004, NEUROIMAGE, V21, P876, DOI 10.1016/j.neuroimage.2003.10.018; Kim YR, 2005, J CEREBR BLOOD F MET, V25, P820, DOI 10.1038/sj.jcbfm.9600084; Koistinaho J, 2000, NEUROCHEM RES, V25, P645, DOI 10.1023/A:1007559003261; Kwegyir-Afful EE, 2009, J NEUROSCI, V29, P964, DOI 10.1523/JNEUROSCI.3924-08.2009; Kyriazi H, 1998, SOMATOSENS MOT RES, V15, P146, DOI 10.1080/08990229870871; Kyriazi HT, 1996, J NEUROPHYSIOL, V75, P547; Larrosa B, 2006, NEUROSCIENCE, V141, P1057, DOI 10.1016/j.neuroscience.2006.04.005; Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073; Longoni M, 2006, NEUROL SCI, V27, pS107, DOI 10.1007/s10072-006-0582-2; Maeda M, 1998, ACT NEUR S, V71, P293; Manor T, 2008, NEUROL RES, V30, P1075, DOI 10.1179/174313208X346107; Marino R, 2006, NEUROLOGY, V67, P1165, DOI 10.1212/01.wnl.0000238081.35281.b5; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Miller KD, 2001, CURR OPIN NEUROBIOL, V11, P488, DOI 10.1016/S0959-4388(00)00239-7; Misonou H, 2005, J NEUROSCI, V25, P11184, DOI 10.1523/JNEUROSCI.3370-05.2005; Moore CI, 1998, J NEUROPHYSIOL, V80, P2882; Moreira T, 2007, NEUROSCIENCE, V144, P1169, DOI 10.1016/j.neuroscience.2006.10.054; Petersen CCH, 2007, NEURON, V56, P339, DOI 10.1016/j.neuron.2007.09.017; PINAULT D, 1995, EUR J NEUROSCI, V7, P31, DOI 10.1111/j.1460-9568.1995.tb01017.x; Porter JT, 2004, J NEUROPHYSIOL, V92, P2762, DOI 10.1152/jn.00196.2004; Reinert M, 2000, Neurosurg Focus, V8, pe10; Salci K, 2006, NEUROSURGERY, V59, P367, DOI 10.1227/01.NEU.0000222648.61065.38; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Sato TR, 2010, J NEUROSCI, V30, P4256, DOI 10.1523/JNEUROSCI.3774-09.2010; SILVER IA, 1994, J NEUROSCI, V14, P5068; SIMONS DJ, 1979, BRAIN RES, V165, P327, DOI 10.1016/0006-8993(79)90564-X; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311; SIMONS DJ, 1985, J NEUROPHYSIOL, V54, P615; Smith JM, 2006, BIOL REV, V81, P457, DOI 10.1017/S1464793106007081; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Sosnik R, 2001, J NEUROPHYSIOL, V86, P339; SPACEK J, 1974, J ANAT, V117, P487; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Takatsuru Y, 2009, J NEUROSCI, V29, P10081, DOI 10.1523/JNEUROSCI.1638-09.2009; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Urbain N, 2007, J NEUROSCI, V27, P12407, DOI 10.1523/JNEUROSCI.2914-07.2007; Voronin LL, 2003, NEUROPHARMACOLOGY, V45, P439, DOI 10.1016/S0028-3908(03)00173-4; Voronin LL, 2004, J PHYSIOL-LONDON, V557, P3, DOI 10.1113/jphysiol.2003.058966; Wang JH, 2003, BRAIN RES BULL, V60, P53, DOI 10.1016/S0361-9230(03)00026-1; Watanabe S, 2001, STROKE, V32, P2615, DOI 10.1161/hs1101.097384; Webber RM, 2004, J NEUROPHYSIOL, V91, P2010, DOI 10.1152/jn.00906.2003; Welch KM, 2005, HEADACHE, V45, pS25, DOI 10.1111/j.1526-4610.2005.4501008.x; WELKER C, 1976, J COMP NEUROL, V166, P173, DOI 10.1002/cne.901660205; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Yang HY, 2006, BEHAV BRAIN RES, V172, P80, DOI 10.1016/j.bbr.2006.04.023; Yang HY, 2006, EXP NEUROL, V200, P262, DOI 10.1016/j.expneurol.2006.02.007; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yu Z, 2009, C P IEEE ENG MED BIO, P1135; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158	89	61	62	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 5	2011	31	40					14085	14094		10.1523/JNEUROSCI.3572-11.2011			10	Neurosciences	Neurosciences & Neurology	832LD	WOS:000295805500005	21976493	Green Accepted, Green Published, Bronze			2021-06-18	
J	Thiele, RH; Nemergut, EC; Lynch, C				Thiele, Robert H.; Nemergut, Edward C.; Lynch, Carl, III			The Clinical Implications of Isolated Alpha(1) Adrenergic Stimulation	ANESTHESIA AND ANALGESIA			English	Article							LEFT-VENTRICULAR FUNCTION; INHALED NITRIC-OXIDE; REGIONAL BLOOD-FLOW; ANEURYSMAL SUBARACHNOID HEMORRHAGE; SYSTEMIC VASCULAR-RESISTANCE; CEREBRAL PERFUSION-PRESSURE; INDUCED HYPERTENSION; SPINAL-ANESTHESIA; SEPTIC SHOCK; PHENYLEPHRINE INFUSIONS	Phenylephrine is a direct-acting, predominantly alpha(1) adrenergic receptor agonist used by anesthesiologists and intensivists to treat hypotension. A variety of physiologic studies suggest that alpha-agonists increase cardiac afterload, reduce venous compliance, and reduce renal bloodflow. The effects on gastrointestinal and cerebral perfusion are controversial. To better understand the effects of phenylephrine in a variety of clinical settings, we screened 463 articles on the basis of PubMed searches of "methoxamine," a long-acting alpha agonist, and "phenylephrine" (limited to human, randomized studies published in English), as well as citations found therein. Relevant articles, as well as those discovered in the peer-review process, were incorporated into this review. Phenylephrine has been studied as an antihypotensive drug in patients with severe aortic stenosis, as a treatment for decompensated tetralogy of Fallot and hypoxemia during 1-lung ventilation, as well as for the treatment of septic shock, traumatic brain injury, vasospasm status-postsubarachnoid hemorrhage, and hypotension during cesarean delivery. In specific instances (critical aortic stenosis, tetralogy of Fallot, hypotension during cesarean delivery) in which the regional effects of phenylephrine (e.g., decreased heart rate, favorable alterations in Q(p):Q(s) ratio, improved fetal oxygen supply: demand ratio) outweigh its global effects (e.g., decreased cardiac output), phenylephrine may be a rational pharmacologic choice. In pathophysiologic states in which no regional advantages are gained by using an alpha(1) agonist, alternative vasopressors should be sought. (Anesth Analg 2011;113:297-304)	[Thiele, Robert H.; Nemergut, Edward C.; Lynch, Carl, III] Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA 22908 USA	Thiele, RH (corresponding author), Univ Virginia Hlth Syst, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA.	rht7w@virginia.edu		Thiele, Robert/0000-0001-7262-0653			Alspaugh DM, 2000, J TRAUMA, V48, P851, DOI 10.1097/00005373-200005000-00008; Antonopoulos A, 2002, INT J CARDIOL, V84, P201, DOI 10.1016/S0167-5273(02)00146-8; APPLETON C, 1985, J PHARMACOL EXP THER, V233, P729; AWAD IA, 1987, STROKE, V18, P365, DOI 10.1161/01.STR.18.2.365; AWAN N, 1977, BRIT HEART J, V39, P651; BIGATELLO LM, 1994, ANESTHESIOLOGY, V80, P761, DOI 10.1097/00000542-199404000-00007; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brooker RF, 1997, ANESTHESIOLOGY, V86, P797, DOI 10.1097/00000542-199704000-00009; BUCKLAND MR, 1988, ANESTHESIOLOGY, V69, P116, DOI 10.1097/00000542-198807000-00021; Butterworth J, 2004, ANESTHESIOLOGY, V101, P1038, DOI 10.1097/00000542-200410000-00040; Charls LM, 2003, HEART LUNG, V32, P402, DOI 10.1016/j.hrtlng.2003.07.004; CHARLSON ME, 1989, ANN SURG, V210, P637, DOI 10.1097/00000658-198911000-00012; Cho S, 1996, ANESTHESIOLOGY, V85, P755, DOI 10.1097/00000542-199610000-00010; Cooper DW, 2002, ANESTHESIOLOGY, V97, P1582, DOI 10.1097/00000542-200212000-00034; CRYSTAL GJ, 1991, ANESTH ANALG, V73, P283; CURIEL R, 1989, J CARDIOVASC PHARM, V14, P603, DOI 10.1097/00005344-198910000-00012; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Doering EB, 1997, ANESTHESIOLOGY, V87, P18, DOI 10.1097/00000542-199707000-00004; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2641, DOI 10.1097/CCM.0b013e3181847af3; Egge A, 2001, NEUROSURGERY, V49, P593, DOI 10.1097/00006123-200109000-00012; EICHLER HG, 1989, J CLIN INVEST, V83, P108, DOI 10.1172/JCI113845; FLAMM SD, 1990, CIRCULATION, V81, P1550, DOI 10.1161/01.CIR.81.5.1550; Funk DJ, 2009, ANESTH ANALG, V108, P887, DOI 10.1213/ane.0b013e31818ffd99; Glantz S. A., 2005, PRIMER BIOSTATISTICS; GOERTZ AW, 1993, ANESTH ANALG, V77, P227, DOI 10.1213/00000539-199377020-00004; GOERTZ AW, 1993, ANESTHESIOLOGY, V78, P834, DOI 10.1097/00000542-199305000-00005; GRANGSJO G, 1971, ACTA ANAESTH SCAND, V15, P71, DOI 10.1111/j.1399-6576.1971.tb00822.x; Greenberg M., 2005, HDB NEUROSURGERY, V6th; HAMID SK, 1992, ANAESTHESIA, V47, P490, DOI 10.1111/j.1365-2044.1992.tb02272.x; HARIK SI, 1981, J CEREBR BLOOD F MET, V1, P329, DOI 10.1038/jcbfm.1981.36; HEATH P, 1949, ARCH OPHTHALMOL-CHIC, V41, P172; HEYNDRICKX GR, 1976, AM J PHYSIOL, V231, P1579; HIRAKAWA S, 1984, JPN CIRC J, V48, P620, DOI 10.1253/jcj.48.620; HOFFBRAND BI, 1973, J PHARMACOL EXP THER, V184, P656; Holdcroft A, 2000, BRIT J ANAESTH, V85, P58, DOI 10.1093/bja/85.1.58; Joffe II, 1997, J AM SOC ECHOCARDIOG, V10, P717, DOI 10.1016/S0894-7317(97)70114-7; Kaplan J.A., 2008, ESSENTIALS CARDIAC A; Khaw KS, 2006, FETAL MATERNAL MED R, V17, P157; Kim DH, 2003, NEUROSURGERY, V53, P1044, DOI 10.1227/01.NEU.0000088567.59324.78; KITAGUCHI K, 1993, ANESTHESIOLOGY, V79, P704, DOI 10.1097/00000542-199310000-00011; KOBAYASHI H, 1985, CIRC RES, V56, P402, DOI 10.1161/01.RES.56.3.402; KOSNIK EJ, 1976, J NEUROSURG, V45, P148, DOI 10.3171/jns.1976.45.2.0148; LANDZBERG JS, 1991, CIRCULATION, V84, P1608, DOI 10.1161/01.CIR.84.4.1608; LANG RM, 1986, CIRCULATION, V74, P1114, DOI 10.1161/01.CIR.74.5.1114; Langesaeter E, 2008, ANESTHESIOLOGY, V109, P856, DOI 10.1097/ALN.0b013e31818a401f; Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; LOEB HS, 1978, CIRCULATION, V57, P41, DOI 10.1161/01.CIR.57.1.41; MacDonald R Loch, 2006, Clin Neurosurg, V53, P257; MARINO RJ, 1975, ANESTHESIOLOGY, V43, P570, DOI 10.1097/00000542-197511000-00016; Miller R, 2010, MILLERS ANESTHESIA; MILLER RR, 1977, AM J CARDIOL, V40, P504, DOI 10.1016/0002-9149(77)90063-7; MIZUKI T, 1995, STROKE, V26, P2333, DOI 10.1161/01.STR.26.12.2333; Morelli A, 2008, SHOCK, V29, P446, DOI 10.1097/SHK.0b013e31815810ff; Morelli A, 2008, CRIT CARE, V12, DOI 10.1186/cc7121; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; MUIZELAAR JP, 1986, SURG NEUROL, V25, P317, DOI 10.1016/0090-3019(86)90205-3; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Myburgh J A, 2005, Crit Care Resusc, V7, P200; Ngan Kee WD, 2008, ANESTH ANALG, V107, P1295, DOI 10.1213/ane.0b013e31818065bc; NUDEL DB, 1976, PEDIATRICS, V58, P248; Nygren A, 2006, CRIT CARE MED, V34, P722, DOI 10.1097/01.CCM.0000201879.20281.C6; Oba Y, 2000, NEW ENGL J MED, V343, P813; ONEILL C, 1989, J NEURAL TRANSM-PARK, V1, P303, DOI 10.1007/BF02263484; Pang CCY, 2001, PHARMACOL THERAPEUT, V90, P179, DOI 10.1016/S0163-7258(01)00138-3; Pfister D, 2008, EUR J ANAESTH, V25, P98, DOI 10.1017/S0265021507003407; PROST JF, 1991, EUR RESPIR J, V4, P683; PUYBASSET L, 1994, INTENS CARE MED, V20, P319, DOI 10.1007/BF01720903; RALSTON DH, 1974, ANESTHESIOLOGY, V40, P354, DOI 10.1097/00000542-197404000-00009; Reich DL, 2002, ANESTH ANALG, V95, P273, DOI 10.1097/00000539-200208000-00003; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; ROSSAINT R, 1995, CHEST, V107, P1107, DOI 10.1378/chest.107.4.1107; Saager L, 2009, AM SOC AN ANN M 2009; SHARROCK NE, 1992, THROMB HAEMOSTASIS, V68, P436; Shinomiya Kayo, 2003, Journal of Medical Investigation, V50, P203; Smrcka M, 1998, NEUROSURGERY, V42, P617, DOI 10.1097/00006123-199803000-00032; SNELL RE, 1965, AM HEART J, V69, P529, DOI 10.1016/0002-8703(65)90424-2; Stevens RD, 2009, INTENS CARE MED, V35, P1556, DOI 10.1007/s00134-009-1533-1; Thiele RH, 2011, ANESTH ANALG, V113, P284, DOI 10.1213/ANE.0b013e3182124c0e; Townsend CM., 2007, SABISTON TXB SURG; Treggiari MM, 2009, CURR OPIN CRIT CARE, V15, P83, DOI 10.1097/MCC.0b013e32832922d1; TUMAN KJ, 1995, J CARDIOTHOR VASC AN, V9, P2, DOI 10.1016/S1053-0770(05)80048-5; Varpula M, 2005, INTENS CARE MED, V31, P1066, DOI 10.1007/s00134-005-2688-z; WOODMAN OL, 1987, AM J PHYSIOL, V253, pH388; YANG HT, 1994, J PHARMACOL EXP THER, V269, P732; ZIMMERMAN BG, 1963, J PHARMACOL EXP THER, V139, P290	89	61	63	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2011	113	2					297	304		10.1213/ANE.0b013e3182120ca5			8	Anesthesiology	Anesthesiology	796PQ	WOS:000293064500016	21519053				2021-06-18	
J	Work, SS; Colamonico, JA; Bradley, WG; Kaye, RE				Work, Susan S.; Colamonico, Jennifer A.; Bradley, Walter G.; Kaye, Randall E.			Pseudobulbar affect: an under-recognized and under-treated neurological disorder	ADVANCES IN THERAPY			English	Article						Alzheimer's disease; amyotrophic lateral sclerosis; diagnosis; multiple sclerosis; Parkinson's disease; prevalence; pseudobulbar affect; stroke; traumatic brain injury; treatment	AMYOTROPHIC-LATERAL-SCLEROSIS; EMOTIONAL EXPRESSION DISORDER; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; POSTSTROKE DEPRESSION; MOVEMENT-DISORDERS; ALZHEIMERS-DISEASE; LESION LOCATION; DOUBLE-BLIND; STROKE	Pseudobulbar affect (PBA) is a neurologic syndrome of emotional affect disinhibition, characterized by uncontrollable, exaggerated, and often inappropriate emotional outbursts, which may cause severe distress, embarrassment, and social dysfunction. However, the US prevalence of PBA remains unknown. An online survey was conducted primarily to estimate the US prevalence of PBA in patients with the six most commonly associated conditions: Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury. Invitations to participate were randomly sent online to adults (aged a parts per thousand yen18 years) registered in the Harris Poll Online Panel who were patients or belonged to a household with a patient diagnosed with one of the six conditions (identified through previous screening by Harris Interactive). Participants were screened for PBA using the Pathological Laughing and Crying Scale (PLACS) and the Center for Neurologic Study-Lability Scale (CNS-LS). PBA estimates were made using a cut-off score of a parts per thousand yen13 on the PLACS and two different cut-off thresholds on the CNS-LS, a lower one of a parts per thousand yen13 and a more rigorous one of a parts per thousand yen21. Existing US prevalence data for the six underlying conditions were used to estimate US prevalence of PBA. Of 38,000 individuals invited to participate, 8876 responded (23%) and 2318 (26%) completed the questionnaire. Mean prevalence of PBA across all six conditions was 10.1%, 9.4%, and 37.5% with the PLACS a parts per thousand yen13, CNS-LS a parts per thousand yen21, and CNS-LS a parts per thousand yen13 thresholds, respectively. Using disease population estimates from government agencies and professional organizations, the estimated US population with PBA ranged from 1.8 to 7.1 million. Among patients who discussed their laughing and/or crying episodes with a physician, 41% were diagnosed, and about half received a medication for their episodes. The overall prevalence of PBA was estimated to be about 10% across these commonly associated underlying neurological conditions and appears to be under-recognized.	[Work, Susan S.; Kaye, Randall E.] Avanir Pharmaceut Inc, Aliso Viejo, CA 92656 USA; [Colamonico, Jennifer A.] Harris Interact, Healthcare & Policy Res, New York, NY 10013 USA; [Bradley, Walter G.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA	Work, SS (corresponding author), Avanir Pharmaceut Inc, 101 Enterprise,Suite 300, Aliso Viejo, CA 92656 USA.	SWork@avanir.com			Avanir Pharmaceuticals	Avanir Pharmaceuticals commissioned this survey from Harris Interactive. Walter Bradley is Professor and Chairman Emeritus of the Department of Neurology, Miller School of Medicine, University of Miami. Susan Work and Randall Kaye are employees of Avanir Pharmaceuticals. Susan Work is Senior Director, Market Research and Analytics. Randall Kaye is the Senior Vice President of Medical Affairs. Jennifer A. Colamonico is Senior Vice President of Healthcare Research at Harris Interactive. The authors would like to thank Shawn Wade, Vice President of Market Strategies International, for his assistance with this manuscript when he was still employed by Harris Interactive. Editorial assistance in the preparation of the manuscript was provided by the Curry Rockefeller Group, LLC. Support for this assistance was funded by Avanir Pharmaceuticals.	ALS Association, WHO GETS ALS; American Stroke Association American Heart Association, HEART DIS STROK STAT; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; *AV PHARM INC, 2010, NEUD DEXTR HYDR QUIN; *AV PHARM INC, 2006, DAT FIL; BARNES R, 1982, AM J PSYCHIAT, V139, P1170; Brooks BR, 2004, NEUROLOGY, V63, P1364; Calvert T, 1998, J NEUROL NEUROSUR PS, V65, P928, DOI 10.1136/jnnp.65.6.928; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; *CDC, 2006, WHAT AR LONG TERM OU; Choi-Kwon S, 2002, CEREBROVASC DIS, V13, P31, DOI 10.1159/000047743; Cottrell SS, 1926, J NEUROL PSYCHOPATHO, V7, P1; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; Dark FL, 1996, AUST NZ J PSYCHIAT, V30, P472, DOI 10.3109/00048679609065020; Deming WE, 1940, ANN MATH STAT, V11, P427, DOI 10.1214/aoms/1177731829; Duda JE, 2007, CNS SPECTRUMS, V12, P6, DOI 10.1017/S1092852900025955; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fava M, 1997, PSYCHIAT CLIN N AM, V20, P427, DOI 10.1016/S0193-953X(05)70321-X; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; GREEN RL, 1987, AM J PSYCHIAT, V144, P442; GUBBAY SS, 1985, J NEUROL, V232, P295, DOI 10.1007/BF00313868; Haupt M, 1996, Int Psychogeriatr, V8 Suppl 3, P409; HIER DB, NEUROLOGY CLIN PRACT; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; Kim JS, 2002, J NEUROL, V249, P805, DOI 10.1007/s00415-002-0714-4; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langworthy OR, 1941, AM J PSYCHIAT, V98, P243, DOI 10.1176/ajp.98.2.243; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Miller RG, 2009, ANN NEUROL, V65, pS24, DOI 10.1002/ana.21556; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Muller U, 1999, BRAIN INJURY, V13, P805, DOI 10.1080/026990599121197; National Institute of Neurological Disorders and Stroke (NINDS) NIH, DEM HOP RES; National MS Society, MS WHO GETS MS; Panitch HS, 2006, ANN NEUROL, V59, P780, DOI 10.1002/ana.20828; *PARK DIS FDN, FREQ ASK QUEST PARK; Parvizi J, 2009, J NEUROPSYCH CLIN N, V21, P75, DOI 10.1176/appi.neuropsych.21.1.75; Petracca GM, 2009, J NEUROPSYCH CLIN N, V21, P406, DOI 10.1176/appi.neuropsych.21.4.406; Phuong L, 2009, PARKINSONISM RELAT D, V15, P511, DOI 10.1016/j.parkreldis.2009.01.001; Pioro EP, 2010, ANN NEUROL, V68, P693, DOI 10.1002/ana.22093; Pleis John R, 2003, Vital Health Stat 10, P1; Poeck K, 1969, Ger Med Mon, V14, P394; POECK K, 1985, HDB CLIN NEUROLOGY, V45; PRATT RTC, 1951, J NEUROL NEUROSUR PS, V14, P326, DOI 10.1136/jnnp.14.4.326; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Rosen H, 2008, DRUG TODAY, V44, P661, DOI 10.1358/dot.2008.44.9.1258664; ROWLAND LP, 2000, ARCH NEUROL-CHICAGO, V57, P1084; Sato T, 2002, AM J PSYCHIAT, V159, P968, DOI 10.1176/appi.ajp.159.6.968; Schafer JL., 1997, ANAL INCOMPLETE MULT; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; Siddiqui MS, 2009, WORLD J BIOL PSYCHIA, V10, P234, DOI 10.1080/15622970701639445; Smi CK, 2006, STROKE, V37, P156, DOI 10.1161/01.STR.0000190892.93663.e2; Smith RA, 2004, MULT SCLER, V10, P1; Smith RA, 2006, ANN NEUROL, V60, pS50; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; Strowd RE, 2010, J NEUROL, V257, P1382, DOI 10.1007/s00415-010-5550-3; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Tang WK, 2009, J INT NEUROPSYCH SOC, V15, P62, DOI 10.1017/S1355617708090061; Tang WK, 2004, J NEUROL, V251, P865, DOI 10.1007/s00415-004-0450-z; TARIOT PN, 1995, AM J PSYCHIAT, V152, P1349; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; *US CENS BUR POP D, US POPCLOCK PROJ; WALLIN MT, 2004, NEUROLOGY CLIN PRACT, P776; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Wortzel HS, 2008, CNS DRUGS, V22, P531, DOI 10.2165/00023210-200822070-00001; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160; Ziegler LH, 1930, ARCH NEURO PSYCHIATR, V24, P930, DOI 10.1001/archneurpsyc.1930.02220170050006; Zimmerman EK, 2007, COGN BEHAV NEUROL, V20, P79, DOI 10.1097/WNN.0b013e31804c700b	70	61	65	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0741-238X			ADV THER	Adv. Ther.	JUL	2011	28	7					586	601		10.1007/s12325-011-0031-3			16	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	799KP	WOS:000293285900006	21660634	Bronze			2021-06-18	
J	Zhao, QJ; Zhang, XG; Wang, LX				Zhao, Qing-Jv; Zhang, Xue-Guang; Wang, Le-Xin			Mild hypothermia therapy reduces blood glucose and lactate and improves neurologic outcomes in patients with severe traumatic brain injury	JOURNAL OF CRITICAL CARE			English	Article						Mild hypothermia; Traumatic brain injury; Lactate; Glucose; Neurologic outcome	MODERATE HYPOTHERMIA; HEAD-INJURY; PHASE-II; CHILDREN; PREDICTORS; MANAGEMENT; MORTALITY	Purpose: The study aimed to investigate the association between blood glucose or lactate and the outcomes of severe traumatic brain injury (TBI), and to evaluate the effect of mild hypothermia therapy on glucose and lactate levels. Methods: Eighty-one patients with TBI were randomly divided into normothermia (n = 41) and mild hypothermia (n = 40) group. Body temperature of hypothermia group was maintained at 32.7 degrees C for 72 hours. Arterial blood glucose and lactic acid were determined before and after hypothermia therapy. Glasgow Outcome Scale (GOS) score was assessed 3 months after the treatment. Results: The mean glucose (7.04 +/- 0.51 vs 9.71 +/- 1.63 mmol/L, P < .05) in the hypothermia group was lower than in the normothermia group after hypothermia therapy. There were more patients with good neurologic function (GOS 4-5) in the hypothermia group than in the normothermia group (75.0% vs 51.2%, P = .038). Multivariate regression analysis showed that blood glucose greater than 10 mmol/L (adjusted risk ratio, 5.7; 95% confidence interval, 1.4-13.2; P < .05) was an independent predictor for poor neurologic outcomes in these patients, and hypothermia therapy was an independent predictor for favorable outcomes (risk ratio, 4.9; 95% confidence interval, 1.0-15.6; P < .05). No significant association between lactate and GOS scores was identified in the multivariate analysis. Conclusion: Hyperglycemia after TBI was associated with poor clinical outcomes, but the predictive value of blood lactate level requires further investigation. Hypothermia therapy improves neurologic outcomes in patients with severe TBI, and reduction in blood glucose may be partially responsible for the improved outcomes. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.	[Wang, Le-Xin] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2650, Australia; [Zhao, Qing-Jv; Zhang, Xue-Guang] Taishan Med Univ, Liaocheng Peoples Hosp, Dept Neurosurg, Tai An, Shandong, Peoples R China; [Zhao, Qing-Jv; Zhang, Xue-Guang] Taishan Med Univ, Liaocheng Clin Sch, Tai An, Shandong, Peoples R China	Wang, LX (corresponding author), Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2650, Australia.	lwang@csu.edu.au					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Duke TD, 1997, INTENS CARE MED, V23, P684, DOI 10.1007/s001340050394; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Hatherill M, 2000, INTENS CARE MED, V26, P314, DOI 10.1007/s001340051155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jansen TC, 2009, CRIT CARE MED, V37, P2827, DOI 10.1097/CCM.0b013e3181a98899; Jansen TC, 2009, J TRAUMA, V66, P377, DOI 10.1097/TA.0b013e3181648e2f; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARGULIES DR, 1994, AM SURGEON, V60, P387; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Pittard AJ, 1999, ANN CLIN BIOCHEM, V36, P401, DOI 10.1177/000456329903600402; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Yatsushige H, 2010, ACTA NEUROCHIR SUPPL, V106, P265, DOI 10.1007/978-3-211-98811-4_50	21	61	67	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441			J CRIT CARE	J. Crit. Care	JUN	2011	26	3					311	315		10.1016/j.jcrc.2010.08.014			5	Critical Care Medicine	General & Internal Medicine	774MH	WOS:000291390200014	20889287				2021-06-18	
J	Hua, F; Wang, J; Ishrat, T; Wei, WJ; Atif, F; Sayeed, I; Stein, DG				Hua, Fang; Wang, Jun; Ishrat, Tauheed; Wei, Wenjing; Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.			Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: effect of exogenous progesterone	JOURNAL OF NEUROINFLAMMATION			English	Article						Toll-like receptors progesterone; traumatic brain injury; inflammation; mouse	INTESTINAL INFLAMMATORY RESPONSE; MUCOSA STRUCTURE ALTERATIONS; CEREBRAL EDEMA; INNATE; ACTIVATION; MECHANISMS; CYTOKINES; SIGNAL	Background: Traumatic brain injury (TBI) causes acute inflammatory responses that result in an enduring cascade of secondary neuronal loss and behavioral impairments. It has been reported that progesterone (PROG) can inhibit the increase of some inflammatory cytokines and inflammation-related factors induced by TBI. Toll-like receptors (TLRs) play a critical role in the induction and regulation of immune/inflammatory responses. Therefore, in the present study, we examined the genomic profiles of TLR-mediated pathways in traumatically injured brain and PROG's effects on these genes. Methods: Bilateral cortical impact injury to the medial frontal cortex was induced in C57BL/6J mice. PROG was injected (i.p., 16 mg/kg body weight) at 1 and 6 h after surgery. Twenty-four hours post-surgery, mice were killed and peri-contusional brain tissue was harvested for genomic detection and protein measurement. RT-PCR arrays were used to measure the mRNA of 84 genes in TLR-mediated pathways. Western blot, ELISA and immunohistochemistry were used to confirm the protein expression of genes of interest. Results: We found that 2 TLRs (TLR1 and 2), 5 adaptor/interacting proteins (CD14, MD-1, HSPA1a, PGRP and Ticam2) and 13 target genes (Ccl2, Csf3, IL1a, IL1b, IL1r1, IL6, IL-10, TNFa, Tnfrsf1a, Cebpb, Clec4e, Ptgs2 and Cxcl10) were significantly up-regulated after injury. Administration of PROG significantly down-regulated three of the 13 increased target genes after TBI (Ccl-2, IL-1b and Cxcl-10), but did not inhibit the expression of any of the detected TLRs and adaptor/interacting proteins. Rather, PROG up-regulated the expression of one TLR (TLR9), 5 adaptor/interacting proteins, 5 effectors and 10 downstream target genes. We confirmed that Ccl-2, Cxcl-10, TLR2 and TLR9 proteins were expressed in brain tissue, a finding consistent with our observations of mRNA expression. Conclusion: The results demonstrate that TBI can increase gene expression in TLR-mediated pathways. PROG does not down-regulate the increased TLRs or their adaptor proteins in traumatically injured brain. Reduction of the observed inflammatory cytokines by PROG does not appear to be the result of inhibiting TLRs or their adaptors in the acute stage of TBI.	[Hua, Fang; Wang, Jun; Ishrat, Tauheed; Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Brain Res Lab, Sch Med, Atlanta, GA 30322 USA; [Wei, Wenjing] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Hua, F (corresponding author), Emory Univ, Dept Emergency Med, Brain Res Lab, Sch Med, 1365B Clifton Rd, Atlanta, GA 30322 USA.	fhua2@emory.edu	Stein, Donald/AAJ-5139-2020		AHA National Program SDG [0830481N]; Emory University URC [2009-002]; Department of Pediatric Cardiovascular Surgery at the Children's Hospital of Atlanta; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS048451, 1R01HD061971]; Emory Biomarker Service Center; Neuronal Imaging Core of the Emory Neuroscience NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS055077]; BHR Pharma; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS055077, R01NS048451] Funding Source: NIH RePORTER	This work was supported by AHA National Program SDG 0830481N to FH, Emory University URC Grant (2009-002) to FH, research funding from the Department of Pediatric Cardiovascular Surgery at the Children's Hospital of Atlanta and NIH 5R01NS048451 and 1R01HD061971 to DGS. This research was also supported in part by the Emory Biomarker Service Center and the Neuronal Imaging Core of the Emory Neuroscience NINDS core facilities grant (P30NS055077). A portion of this research was supported by a gift from BHR Pharma.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; Brightbill HD, 2000, IMMUNOLOGY, V101, P1, DOI 10.1046/j.1365-2567.2000.00093.x; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Casanova JL, 2011, ANNU REV IMMUNOL, V29, P447, DOI 10.1146/annurev-immunol-030409-101335; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Chase MA, 2007, J IMMUNOL, V179, P6318, DOI 10.4049/jimmunol.179.9.6318; Chen G, 2008, J SURG RES, V147, P92, DOI 10.1016/j.jss.2007.05.029; Crack PJ, 2007, IMMUNOL CELL BIOL, V85, P476, DOI 10.1038/sj.icb.7100103; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Feng D, 2007, J INT MED RES, V35, P644, DOI 10.1177/147323000703500509; Gao Y, 2009, BIOMED PHARMACOTHER, V63, P442, DOI 10.1016/j.biopha.2008.06.028; Harburger LL, 2009, NEUROSCIENCE, V160, P6, DOI 10.1016/j.neuroscience.2009.02.024; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hua F, 2007, J NEUROIMMUNOL, V190, P101, DOI 10.1016/j.jneuroim.2007.08.014; Hua F, 2009, BRAIN RES, V1262, P100, DOI 10.1016/j.brainres.2009.01.018; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Jenkins KA, 2010, CYTOKINE, V49, P237, DOI 10.1016/j.cyto.2009.01.009; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kimoto M, 2003, SCAND J INFECT DIS, V35, P568, DOI 10.1080/00365540310015700; Leonhardt SA, 2003, STEROIDS, V68, P761, DOI 10.1016/S0039-128X(03)00129-6; Letiembre M, 2009, NEUROBIOL AGING, V30, P759, DOI 10.1016/j.neurobiolaging.2007.08.018; Marsh BJ, 2009, NEUROSCIENCE, V158, P1007, DOI 10.1016/j.neuroscience.2008.07.067; Mishra BB, 2006, J NEUROIMMUNOL, V181, P46, DOI 10.1016/j.jneuroim.2006.07.019; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Naert G, 2009, J INNATE IMMUN, V1, P480, DOI 10.1159/000225990; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Prat A, 2005, CURR OPIN NEUROL, V18, P225, DOI 10.1097/01.wco.0000169737.99040.31; Rohe HJ, 2009, PHARMACOL THERAPEUT, V121, P14, DOI 10.1016/j.pharmthera.2008.09.006; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shimada M, 2008, DEVELOPMENT, V135, P2001, DOI 10.1242/dev.020461; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; Stevens SL, 2008, J CEREBR BLOOD F MET, V28, P1040, DOI 10.1038/sj.jcbfm.9600606; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Wang JY, 2007, INT J IMMUNOGENET, V34, P407, DOI 10.1111/j.1744-313X.2007.00711.x; Wright DW, 2008, BRAIN INJURY, V22, P107, DOI 10.1080/02699050701867399; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	61	63	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAY 8	2011	8								42	10.1186/1742-2094-8-42			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	767MH	WOS:000290860200001	21549006	DOAJ Gold, Green Published			2021-06-18	
J	de Sousa, A; McDonald, S; Rushby, J; Li, S; Dimoska, A; James, C				de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte			Understanding deficits in empathy after traumatic brain injury: The role of affective responsivity	CORTEX			English	Article						Emotional empathy; Emotional responsivity; Traumatic brain injury; Facial mimicry; Skin conductance	SKIN-CONDUCTANCE RESPONSES; ANXIETY STRESS SCALES; FACIAL REACTIONS; EMOTIONAL EMPATHY; MIMICRY REACTIONS; MIRROR-NEURON; EXPRESSION; DEPRESSION; FACES; FEAR	People with traumatic brain injury (TBI) often find social situations challenging because they can no longer respond to the emotional state of the people they are with. Many also lack emotional empathy in their social interactions. But are these problems related? The present study addressed this question by examining psychophysiological indices of emotional responding, including facial electromyography (EMG) and skin conductance during exposure to happy and angry facial expressions, in addition to self-rated emotional empathy in 21 adults with severe TBI and 22 control participants. In comparison to control participants, those in the TBI group displayed a reduction in the ability to empathize emotionally, and showed reduced physiological responding to the emotional expression of anger. By contrast, the control group spontaneously mimicked the emotional expressions they were exposed to, regardless of affective valence, and also demonstrated higher skin conductance responsivity to angry faces. The data further suggested that a loss of emotional empathy plays a role in the emotional response deficits to angry facial expressions following TBI. The results have implications for understanding the impaired social functioning and poor quality of interpersonal relationships commonly seen as a consequence of TBI. (C) 2010 Elsevier Srl. All rights reserved.	[de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	de Sousa, A (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	adesousa@psy.unsw.edu.au	Rushby, Jacqueline/D-1820-2010; McDonald, Skye/G-4118-2014	Rushby, Jacqueline/0000-0002-5018-638X; McDonald, Skye/0000-0003-0723-6094			Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; BAVELAS JB, 1986, J NONVERBAL BEHAV, V10, P102, DOI 10.1007/BF01000007; BAVELAS JB, 1988, HUM COMMUN RES, V14, P275, DOI 10.1111/j.1468-2958.1988.tb00158.x; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blair RJR, 2005, CONSCIOUS COGN, V14, P698, DOI 10.1016/j.concog.2005.06.004; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; de Wied M, 2006, J PSYCHIAT RES, V40, P112, DOI 10.1016/j.jpsychires.2005.08.003; Dimberg U, 2000, PSYCHOL SCI, V11, P86, DOI 10.1111/1467-9280.00221; Dimberg U, 1998, SCAND J PSYCHOL, V39, P39, DOI 10.1111/1467-9450.00054; DIMBERG U, 1990, BIOL PSYCHOL, V30, P151, DOI 10.1016/0301-0511(90)90024-Q; DIMBERG U, 1982, PSYCHOPHYSIOLOGY, V19, P643, DOI 10.1111/j.1469-8986.1982.tb02516.x; DIMBERG U, 1990, PSYCHOPHYSIOLOGY, V27, P481, DOI 10.1111/j.1469-8986.1990.tb01962.x; Dimberg U, 1996, PSYCHOPHYSIOLOGY, V33, pS34; Dimberg U, 2002, COGNITION EMOTION, V16, P449, DOI 10.1080/02699930143000356; Dimberg U., 1988, J PSYCHOPHYSIOL, V2, P277; Ekman P., 1976, PICTURES FACIAL AFFE; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; ESTEVES F, 1994, PSYCHOPHYSIOLOGY, V31, P375, DOI 10.1111/j.1469-8986.1994.tb02446.x; ESTEVES F, 1994, COGNITION EMOTION, V8, P393, DOI 10.1080/02699939408408949; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; FRIDLUND AJ, 1986, PSYCHOPHYSIOLOGY, V23, P567, DOI 10.1111/j.1469-8986.1986.tb00676.x; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Hatfield E., 1994, EMOTION CONTAGION; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hoffman ML, 1984, EMOTIONS COGNITION B, P103; hoffman ML, 2000, EMPATHY MORAL DEV; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Kaplan JT, 2006, SOC NEUROSCI-UK, V1, P175, DOI 10.1080/17470910600985605; Long C. J., 1992, HDB HEAD TRAUMA ACUT; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Marks I. M., 1987, FEARS PHOBIAS RITUAL; Martin I, 1980, TECHNIQUES PSYCHOPHY, P4; McDonald S., 1999, J HEAD TRAUMA REHAB, V16, P612; McDonald S, 2011, J CLIN EXP NEUROPSYC, V33, P17, DOI 10.1080/13803391003761967; McHugo GJ, 1996, MOTIV EMOTION, V20, P85, DOI 10.1007/BF02253867; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Mehrabian A, 1997, AGGRESSIVE BEHAV, V23, P433, DOI 10.1002/(SICI)1098-2337(1997)23:6<433::AID-AB3>3.0.CO;2-H; MEHRABIAN A, 1988, CURR PSYCHOL RES REV, V7, P221, DOI 10.1007/BF02686670; Mehrabian A., 2000, MANUAL BALANCED EMOT; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Nummenmaa L, 2008, NEUROIMAGE, V43, P571, DOI 10.1016/j.neuroimage.2008.08.014; Oddy M, 2003, HDB NEUROLOGICAL REH, P453; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Sanchez-Navarro JP, 2005, BEHAV NEUROSCI, V119, P87, DOI 10.1037/0735-7044.119.1.87; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Shamay-Tsoory SG, 2007, BRAIN, V130, P1663, DOI 10.1093/brain/awm093; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Sonnby-Borgstrom M, 2002, SCAND J PSYCHOL, V43, P433, DOI 10.1111/1467-9450.00312; Sonnby-Borgstrom M, 2003, J NONVERBAL BEHAV, V27, P3, DOI 10.1023/A:1023608506243; Sweeny TD, 2009, J VISION, V9, DOI 10.1167/9.3.2; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tyler CW, 2006, J VISION, V6, P1117, DOI 10.1167/6.10.11; Westbury HR, 2008, BIOL PSYCHOL, V78, P66, DOI 10.1016/j.biopsycho.2007.12.009; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326	59	61	62	0	22	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	MAY	2011	47	5					526	535		10.1016/j.cortex.2010.02.004			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	754BW	WOS:000289827700004	20334857				2021-06-18	
J	Castellanos, NP; Leyva, I; Buldu, JM; Bajo, R; Paul, N; Cuesta, P; Ordonez, VE; Pascua, CL; Boccaletti, S; Maestu, F; del-Pozo, F				Castellanos, Nazareth P.; Leyva, Inmaculada; Buldu, Javier M.; Bajo, Ricardo; Paul, Nuria; Cuesta, Pablo; Ordonez, Victoria E.; Pascua, Cristina L.; Boccaletti, Stefano; Maestu, Fernando; del-Pozo, Francisco			Principles of recovery from traumatic brain injury: Reorganization of functional networks	NEUROIMAGE			English	Article						Magnetoencephalography (MEG); Functional connectivity; Graph theory; Traumatic brain injury (TBI); Plasticity	GRAPH-THEORETICAL ANALYSIS; COGNITIVE REHABILITATION; QUANTITATIVE-ANALYSIS; NEURONAL SYNCHRONY; TUMOR PATIENTS; CONNECTIVITY; OPTIMIZATION; DYNAMICS; COMMUNICATION; COMPLEXITY	Recovery after brain injury is an excellent platform to study the mechanism underlying brain plasticity, the reorganization of networks. Do complex network measures capture the physiological and cognitive alterations that occurred after a traumatic brain injury and its recovery? Patients as well as control subjects underwent resting-state MEG recording following injury and after neurorehabilitation. Next, network measures such as network strength, path length, efficiency, clustering and energetic cost were calculated. We show that these parameters restore, in many cases, to control ones after recovery, specifically in delta and alpha bands, and we design a model that gives some hints about how the functional networks modify their weights in the recovery process. Positive correlations between complex network measures and some of the general index of the WAIS-III test were found: changes in delta-based path-length and those in Performance IQ score, and alpha-based normalized global efficiency and Perceptual Organization Index. These results indicate that: 1) the principle of recovery depends on the spectral band, 2) the structure of the functional networks evolves in parallel to brain recovery with correlations with neuropsychological scales, and 3) energetic cost reveals an optimal principle of recovery. (C) 2010 Elsevier Inc. All rights reserved.	[Castellanos, Nazareth P.; Bajo, Ricardo; Cuesta, Pablo; Ordonez, Victoria E.; Maestu, Fernando; del-Pozo, Francisco] Tech Univ Madrid, Ctr Biomed Technol, Cognit & Computat Neurosci Lab, Madrid, Spain; [Leyva, Inmaculada; Buldu, Javier M.] Univ Rey Juan Carlos, Complex Syst Grp, Fuenlabrada, Spain; [Leyva, Inmaculada; Buldu, Javier M.] Tech Univ Madrid, Ctr Biomed Technol, Lab Biol Networks, Madrid, Spain; [Paul, Nuria] Univ Complutense Madrid, Sch Med, Dept Psychiat & Med Psychol, E-28040 Madrid, Spain; [Pascua, Cristina L.] Ctr Brain Injury Treatment LESCER, Madrid, Spain; [Boccaletti, Stefano] CNR, Inst Complex Syst, Florence, Italy	Castellanos, NP (corresponding author), Univ Politecn Madrid, Ctr Biomed Technol, Lab Cognit & Computat Neurosci, Campus Montegancedo, E-28660 Madrid, Spain.	nazareth@pluri.ucm.es	Boccaletti, Stefano/U-7603-2019; Bajo, Ricardo/AAA-5541-2019; Maestu, Fernando/E-3213-2012; Buldu, Javier/N-5422-2014; Leyva, I./M-1820-2013; Castellanos, Nazareth/AAA-8812-2020; maestu, fernando/M-7480-2019; Buldu, Javier Martin/R-8167-2018; POZO GUERRERO, FRANCISCO DEL/H-6668-2015	Boccaletti, Stefano/0000-0002-5758-7012; Maestu, Fernando/0000-0002-3195-0071; Buldu, Javier/0000-0002-9345-599X; Leyva, I./0000-0001-9634-5385; maestu, fernando/0000-0002-3195-0071; Paul, Nuria/0000-0001-5462-6138; POZO GUERRERO, FRANCISCO DEL/0000-0001-9919-9125; Cuesta Prieto, Pablo/0000-0002-8459-3354; Castellanos, Nazareth/0000-0002-3508-7316	MADRI.B; Obra Social CajaMadrid; MAPFRE; IMSERSO; Spanish Ministry of Science and TechnologySpanish Government [FIS2009-07072]; Community of MadridComunidad de Madrid [MODELICO-CM/S2009ESP-1691]	This work was supported by MADRI.B (CAMi+d+I project), Obra Social CajaMadrid, MAPFRE 2008 and IMSERSO (07-2008), the Spanish Ministry of Science and Technology (FIS2009-07072), and by the Community of Madrid under the R&D Program of activities MODELICO-CM/S2009ESP-1691. We are grateful to S. Aurtenetxe, O. Demuynck, J. Garcia-Pacios, and D. del Rio for their generous help. We would like to thank Dr. Juan Manuel Munoz Cespedes, who led this study. His ideas and personality will always be with us.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900; ALSTOTT J, 2009, PLOS COMPUT BIOL, P5; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Bassett DS, 2009, P NATL ACAD SCI USA, V106, P11747, DOI 10.1073/pnas.0903641106; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; Beason-Held LL, 2009, BRAIN IMAGING BEHAV, V3, P123, DOI 10.1007/s11682-008-9054-z; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; Braitenberg V., 1998, CORTEX STAT GEOMETRY; Bressler SL, 2002, CURR DIR PSYCHOL SCI, V11, P58, DOI 10.1111/1467-8721.00168; Brookes MJ, 2005, NEUROIMAGE, V26, P302, DOI 10.1016/j.neuroimage.2005.01.050; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Butz M, 2009, FRONT COMPUT NEUROSC, V3, DOI 10.3389/neuro.10.010.2009; Buzsaki G, 2004, TRENDS NEUROSCI, V27, P186, DOI 10.1016/j.tins.2004.02.007; Buzsaki G., 2006, RHYTHMS BRAIN; Campo P, 2010, NEUROIMAGE, V49, P2807, DOI 10.1016/j.neuroimage.2009.10.024; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; CHERNIAK C, 1994, J NEUROSCI, V14, P2418; Cherniak C, 2004, P NATL ACAD SCI USA, V101, P1081, DOI 10.1073/pnas.0305212101; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Dall'Asta L, 2006, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2006/P04006; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Deuker L, 2009, NEUROIMAGE, V47, P1460, DOI 10.1016/j.neuroimage.2009.05.035; Dijkstra E.W., 1959, NUMER MATH, V1, P269, DOI [DOI 10.1007/BF01386390, 10.1007/bf01386390]; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011; Fries P, 2009, NEURON, V64, P601, DOI 10.1016/j.neuron.2009.11.024; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GASSER T, 1982, ELECTROEN CLIN NEURO, V53, P119, DOI 10.1016/0013-4694(82)90112-2; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Gong YC, 2009, ANN NY ACAD SCI, V1158, P82, DOI 10.1111/j.1749-6632.2008.03752.x; Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Guimera R, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/02/P02001; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Hellwig B, 2000, BIOL CYBERN, V82, P111, DOI 10.1007/PL00007964; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; Klyachko VA, 2003, P NATL ACAD SCI USA, V100, P7937, DOI 10.1073/pnas.0932745100; Korzeniewska A, 2003, J NEUROSCI METH, V125, P195, DOI 10.1016/S0165-0270(03)00052-9; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Li YH, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000395; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Micheloyannis S, 2006, NEUROSCI LETT, V402, P273, DOI 10.1016/j.neulet.2006.04.006; NAKAMURA T, 2009, PLOS ONE, V14, P4; Palva JM, 2010, P NATL ACAD SCI USA, V107, P7580, DOI 10.1073/pnas.0913113107; Palva S, 2010, NEUROIMAGE, V49, P3257, DOI 10.1016/j.neuroimage.2009.11.031; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PIVIK RT, 1993, PSYCHOPHYSIOLOGY, V30, P547, DOI 10.1111/j.1469-8986.1993.tb02081.x; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schnitzler A, 2005, NAT REV NEUROSCI, V6, P285, DOI 10.1038/nrn1650; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Singer W, 2009, COGN NEURODYNAMICS, V3, P189, DOI 10.1007/s11571-009-9087-z; Stam CJ, 2010, INT J PSYCHOPHYSIOL, V77, P186, DOI 10.1016/j.ijpsycho.2010.06.024; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; van den Heuvel MP, 2009, J NEUROSCI, V29, P7619, DOI 10.1523/JNEUROSCI.1443-09.2009; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	71	61	65	0	30	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 1	2011	55	3					1189	1199		10.1016/j.neuroimage.2010.12.046			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	734DQ	WOS:000288313800032	21195199				2021-06-18	
J	Liu, JH				Liu, Jianghong			Early health risk factors for violence: Conceptualization, evidence, and implications	AGGRESSION AND VIOLENT BEHAVIOR			English	Article						Health risk factors; Alcohol during pregnancy; Tobacco during pregnancy; Toxicity and drugs during pregnancy; Head injury during early childhood; Teenage pregnancy; Birth complications; Malnutrition of the pregnant mother; Malnutrition during early postnatal years; Brain dysfunction; Aggression; Child behavior problems; Violence prevention; Protective factors; Mediating factors; Biosocial interaction	LIFE-COURSE-PERSISTENT; AGE 3 YEARS; DEFICIT HYPERACTIVITY DISORDER; LIMITED ANTISOCIAL PATHWAYS; PRENATAL NICOTINE EXPOSURE; TRAUMATIC BRAIN-INJURY; ONSET CONDUCT PROBLEMS; SHAKEN BABY SYNDROME; MATERNAL DEPRESSION; DISRUPTIVE BEHAVIOR	Violence and aggression are public health problems that can benefit from ongoing research into risk reduction and prevention. Current developmental theories of violence and aggression emphasize biological and psychosocial factors, particularly during adolescence. However, there has been less focus on understanding the interactive, multiplicative effects of these processes. Furthermore, little attention has been given to the pre-, peri-, and postnatal periods, where prevention and intervention may yield effective results. Early health risk factors that influence negative behavioral outcomes include prenatal and postnatal nutrition, tobacco use during pregnancy, maternal depression, birth complications, traumatic brain injury, lead exposure, and child abuse. There is an ample literature to suggest that these early health risk factors may increase the likelihood of childhood externalizing behaviors, aggression, juvenile delinquency, adult criminal behavior, and/or violence. This paper proposes an early health risk factors framework for violence prediction, built on existing developmental theories of criminal behavior and supported by empirical findings. This framework addresses gaps in the adolescent psychopathology literature and presents a novel conceptualization of behavioral disturbance that emphasizes the pre-, peri-, and post-natal periods, when a child's development is critical and the opportunity for behavioral and environmental modification is high. Implications for such a framework on violence prevention programs are discussed. (C) 2010 Elsevier Ltd. All rights reserved.	[Liu, Jianghong] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; [Liu, Jianghong] Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Liu, JH (corresponding author), Univ Penn, Sch Nursing, 418 Curie Blvd,Room 426,Claire M Fagin Hall, Philadelphia, PA 19104 USA.	jhliu@nursing.upenn.edu			NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01 ES018858-01, K01 ES015877-04, K02 ES019878, R01 ES018858, K01 ES015877] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES018858, K01ES015877, K02ES019878] Funding Source: NIH RePORTER		Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Arseneault L, 2002, CHILD DEV, V73, P496, DOI 10.1111/1467-8624.00420; Ashford J, 2008, J AM ACAD CHILD PSY, V47, P779, DOI 10.1097/CHI.0b013e318172eefb; Ashton R, 2010, J CHILD PSYCHOL PSYC, V51, P967, DOI 10.1111/j.1469-7610.2010.02272.x; Baker LA, 2008, J ABNORM CHILD PSYCH, V36, P1265, DOI 10.1007/s10802-008-9249-1; Bellinger DC, 2008, PLOS MED, V5, P690, DOI 10.1371/journal.pmed.0050115; Bellinger DC, 2005, INT J OCCUP ENV HEAL, V11, P138, DOI 10.1179/oeh.2005.11.2.138; BETHEA L, 1999, AM FAMILY PHYS  0315; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bishop D. V., 2009, RUTTERS CHILD ADOLES; Bjork JM, 1999, PSYCHOPHARMACOLOGY, V142, P24, DOI 10.1007/s002130050858; Blair RJR, 2004, BRAIN COGNITION, V55, P198, DOI 10.1016/s0278-2626(03)00276-8; Blatt-Eisengart I, 2009, DEV PSYCHOL, V45, P491, DOI 10.1037/a0014942; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Breakey J, 1997, J PAEDIATR CHILD H, V33, P190, DOI 10.1111/j.1440-1754.1997.tb01578.x; Brennan PA, 1999, ARCH GEN PSYCHIAT, V56, P215, DOI 10.1001/archpsyc.56.3.215; Brennan PA, 2002, AM J PSYCHIAT, V159, P48, DOI 10.1176/appi.ajp.159.1.48; BROPHY MH, 1986, BIOL PSYCHIAT, V21, P704, DOI 10.1016/0006-3223(86)90137-X; Burns JM, 1999, AM J EPIDEMIOL, V149, P740, DOI 10.1093/oxfordjournals.aje.a009883; Burt KB, 2005, J CHILD PSYCHOL PSYC, V46, P490, DOI 10.1111/j.1469-7610.2004.00367.x; Campbell JC, 2007, TRAUMA VIOLENCE ABUS, V8, P246, DOI 10.1177/1524838007303505; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; *CDCP, 2006, PRACT GUID WORK HLTH; Cecil KM, 2008, PLOS MED, V5, P741, DOI 10.1371/journal.pmed.0050112; Chen AM, 2005, J PEDIATR-US, V147, P570, DOI 10.1016/j.jpeds.2005.08.044; Coccaro EF, 1997, BIOL PSYCHIAT, V42, P546, DOI 10.1016/S0006-3223(97)00309-0; Curran GM, 2000, J DRUG ISSUES, V30, P375, DOI 10.1177/002204260003000208; D'Onofrio BM, 2010, ARCH GEN PSYCHIAT, V67, P529, DOI 10.1001/archgenpsychiatry.2010.33; de Haan M, 2006, DEVELOPMENTAL SCI, V9, P350, DOI 10.1111/j.1467-7687.2006.00499.x; Delville Y, 1999, NEUROTOXICOL TERATOL, V21, P445, DOI 10.1016/S0892-0362(98)00062-2; Department of Health and Human Services (DHHS), 2001, YOUTH VIOL REP SURG; Dietrich KN, 2001, NEUROTOXICOL TERATOL, V23, P511, DOI 10.1016/S0892-0362(01)00184-2; Donnellan MB, 2005, PSYCHOL SCI, V16, P328, DOI 10.1111/j.0956-7976.2005.01535.x; Eckstein LW, 1997, DEV BRAIN RES, V103, P59, DOI 10.1016/S0165-3806(97)00117-X; English D., 2002, CHILDHOOD VICTIMIZAT; Entringer S, 2009, HORM BEHAV, V55, P292, DOI 10.1016/j.yhbeh.2008.11.006; Evans LM, 2008, ARCH WOMEN MENT HLTH, V11, P239, DOI 10.1007/s00737-008-0019-4; Ezzati M., 2004, COMP QUANTIFICATION, V1; Farrington D., 2007, SAVING CHILDREN LIFE; Farrington D P, 1989, Violence Vict, V4, P79; Farrington DP, 2005, ADV CRIM THEOR, V14, P73; Farrington DP, 2001, CLINICAL ASSESSMENT OF DANGEROUSNESS, P66; FARRINGTON DP, 1995, J CHILD PSYCHOL PSYC, V36, P929, DOI 10.1111/j.1469-7610.1995.tb01342.x; Farrington DP, 2000, BEHAV SCI LAW, V18, P605, DOI 10.1002/1099-0798(200010)18:5<605::AID-BSL406>3.0.CO;2-0; FERGUSSON DM, 1994, J CHILD PSYCHOL PSYC, V35, P1123, DOI 10.1111/j.1469-7610.1994.tb01813.x; FERGUSSON DM, 1995, J ABNORM CHILD PSYCH, V23, P183, DOI 10.1007/BF01447088; Fergusson DM, 2002, DEV PSYCHOPATHOL, V14, P159, DOI 10.1017/S0954579402001098; Fergusson DM, 2001, AUST NZ J PSYCHIAT, V35, P287, DOI 10.1046/j.1440-1614.2001.00902.x; Ferris C, 1996, UNDERSTANDING AGGRES; Fishbein D., 2001, BIOBEHAVIORAL PERSPE; Fushiki S., 2009, No To Hattatsu, V41, P219; Gatzke-Kopp LM, 2007, CHILD PSYCHIAT HUM D, V38, P255, DOI 10.1007/s10578-007-0059-4; GELFAND DM, 1990, CLIN PSYCHOL REV, V10, P329, DOI 10.1016/0272-7358(90)90065-I; Gibson CL, 2000, PSYCHOL REP, V86, P509, DOI 10.2466/PR0.86.2.509-518; Glover V, 2009, PSYCHONEUROENDOCRINO, V34, P430, DOI 10.1016/j.psyneuen.2008.10.005; HATZITASKOS P, 1994, JUVENILE FAM COURT J, V45, P29; Hawkins JD, 1999, ARCH PEDIAT ADOL MED, V153, P226, DOI 10.1001/archpedi.153.3.226; HIRSCHI T, 1977, AM SOCIOL REV, V42, P571, DOI 10.2307/2094556; Hodgins S, 2001, ARCH GEN PSYCHIAT, V58, P746, DOI 10.1001/archpsyc.58.8.746; Hoffman C, 2006, PARENT-SCI PRACT, V6, P271, DOI 10.1207/s15327922par0604_1; Hubbs-Tait Laura, 2005, Psychol Sci Public Interest, V6, P57, DOI 10.1111/j.1529-1006.2005.00024.x; Kairys SW, 2001, PEDIATRICS, V108, P206; Kaufman A, 2006, ASSESSING ADOLESCENT, V3rd; Kelly TP, 1997, IRISH J PSYCHOL MED, V14, P136, DOI 10.1017/S0790966700003359; Kemppainen L, 2001, AM J PSYCHIAT, V158, P960, DOI 10.1176/appi.ajp.158.6.960; Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851; Koller K, 2004, ENVIRON HEALTH PERSP, V112, P987, DOI 10.1289/ehp.6941; Korkman M, 2003, CHILD NEUROPSYCHOL, V9, P117, DOI 10.1076/chin.9.2.117.14503; Lester BM, 2010, J PEDIATR-US, V157, P288, DOI 10.1016/j.jpeds.2010.02.039; Lister JP, 2005, HIPPOCAMPUS, V15, P393, DOI 10.1002/hipo.20065; LIU J, 2010, INT J NURSING STUDIE; Liu JH, 2005, INT J NURS STUD, V42, P229, DOI 10.1016/j.ijnurstu.2004.06.007; Liu JH, 2004, AM J PSYCHIAT, V161, P2005, DOI 10.1176/appi.ajp.161.11.2005; Liu JH, 2003, ARCH PEDIAT ADOL MED, V157, P593, DOI 10.1001/archpedi.157.6.593; Liu Jianghong, 2004, J Child Adolesc Psychiatr Nurs, V17, P93, DOI 10.1111/j.1744-6171.2004.tb00003.x; Liu JH, 2006, CURR OPIN PEDIATR, V18, P565, DOI 10.1007/0-387-29026-5_20; Liu JH, 2009, J RES ADOLESCENCE, V19, P93, DOI 10.1111/j.1532-7795.2009.00583.x; Mairesse J, 2007, AM J PHYSIOL-ENDOC M, V292, pE1526, DOI 10.1152/ajpendo.00574.2006; Malik NM, 2007, INFANT MENT HEALTH J, V28, P171, DOI 10.1002/imhj.20128; Marchand JF, 2002, PARENT-SCI PRACT, V2, P335, DOI 10.1207/S15327922PAR0204_01; MARGOLIN G, 1988, J CONSULT CLIN PSYCH, V56, P24, DOI 10.1037/0022-006X.56.1.24; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; McCarthy S, 2008, J HUM NUTR DIET, V21, P547, DOI 10.1111/j.1365-277X.2008.00913.x; Moffitt TE, 2002, DEV PSYCHOPATHOL, V14, P179, DOI 10.1017/S0954579402001104; MOFFITT TE, 1990, CRIME JUSTICE, V12, P99, DOI 10.1086/449165; Moffitt TE, 2001, DEV PSYCHOPATHOL, V13, P355, DOI 10.1017/S0954579401002097; MOFFITT TE, 1994, CRIMINOLOGY, V32, P277, DOI 10.1111/j.1745-9125.1994.tb01155.x; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Mohan D, 1998, IRISH J PSYCHOL MED, V15, P10, DOI 10.1017/S0790966700004602; Moore Colleen F, 2005, Psychol Sci Public Interest, V6, pi, DOI 10.1111/j.1529-1006.2005.00023.x; Muneoka K, 1997, DEV BRAIN RES, V102, P117, DOI 10.1016/S0165-3806(97)00092-8; National Institute on Drug Abuse, 2009, PRINC DRUG ADD TREAT; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; NEUGEBAUER R, 1999, JAMA-J AM MED ASSOC, V282, P479; O'Donnell K, 2009, DEV NEUROSCI-BASEL, V31, P285, DOI 10.1159/000216539; Olds D, 1997, MENT RETARD DEV D R, V3, P257, DOI 10.1002/(SICI)1098-2779(1997)3:3<257::AID-MRDD6>3.3.CO;2-7; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Phelan K, 2007, INJURY PREV, V13, P403, DOI 10.1136/ip.2006.014571; PIQUERO AR, 1999, STUDIES CRIME CRIME, V8, P52; Raine A, 1997, J AM ACAD CHILD PSY, V36, P1457, DOI 10.1097/00004583-199710000-00029; Raine A, 2005, J ABNORM PSYCHOL, V114, P38, DOI 10.1037/0021-843X.114.1.38; RAINE A, 1994, ARCH GEN PSYCHIAT, V51, P984; Raine A, 2003, ARCH GEN PSYCHIAT, V60, P1134, DOI 10.1001/archpsyc.60.11.1134; Raine A, 2002, DEV PSYCHOPATHOL, V14, P25, DOI 10.1017/S0954579402001025; Raine A, 2002, J CHILD PSYCHOL PSYC, V43, P417, DOI 10.1111/1469-7610.00034; RAINE A, 1997, BIOSOCIAL BASIS VIOL; Rasanen P, 1999, AM J PSYCHIAT, V156, P857; Rice DC, 2000, ENVIRON HEALTH PERSP, V108, P405, DOI 10.2307/3454528; ROBERTSON CM, 1989, J PEDIAT, V114, P343; ROSEN GM, 1985, J ADOLESCENT HEALTH, V6, P419, DOI 10.1016/S0197-0070(85)80045-0; Royal College of Nursing, 2006, MALN WHAT NURS WORK; Scarpa A, 2006, AGGRESSIVE BEHAV, V32, P502, DOI 10.1002/ab.20151; SCHUTZMAN S, 2008, PATIENT INFORM HEAD; SCIARILLO WG, 1992, AM J PUBLIC HEALTH, V82, P1356, DOI 10.2105/AJPH.82.10.1356; Sever Y, 1997, NEUROPSYCHOBIOLOGY, V35, P178, DOI 10.1159/000119341; Sie LTL, 2000, NEUROPEDIATRICS, V31, P128, DOI 10.1055/s-2000-7496; Sjostrom K, 1997, EUR J OBSTET GYN R B, V74, P149, DOI 10.1016/S0301-2115(97)00100-0; Sowell ER, 2007, NEUROREPORT, V18, P635, DOI 10.1097/WNR.0b013e3280bad8dc; Speltz ML, 1999, J ABNORM PSYCHOL, V108, P315, DOI 10.1037/0021-843X.108.2.315; STOFF DM, 1997, HDB ANTISOCIAL BEHAV; Susman EJ, 2010, PSYCHONEUROENDOCRINO, V35, P557, DOI 10.1016/j.psyneuen.2009.09.004; Teicher, 2000, CEREBRUM, V2, P50; Tremblay RE, 2002, ENCY EARLY CHILDHOOD, P1; TREMBLAY RE, 1995, BUILDING SAFER SOC S, P151; Tremblay RE, 2010, J CHILD PSYCHOL PSYC, V51, P341, DOI 10.1111/j.1469-7610.2010.02211.x; U.S. DEP'T OF HEALTH & HUMAN SERVS, 2008, LONG TERM CONS CHILD; United States Department of Health and Human Services, 2001, YOUTH VIOL REP SURG; *US DEP HHS, 1992, ATSDR IMP LEAD CONT; VIRKKUNEN M, 1995, J PSYCHIATR NEUROSCI, V20, P271; Wadhwa P D, 2001, Prog Brain Res, V133, P131; WAKSCHLAG LS, 2009, MOL PSYCHIAT; WALL JE, 1994, J CLIN CHILD PSYCHOL, V23, P382, DOI 10.1207/s15374424jccp2304_4; WATTS DL, 1990, J ORTHOMOL MED, V5, P159; Webster-Stratton C, 1999, J CHILD PSYCHOL PSYC, V40, P917, DOI 10.1111/1469-7610.00509; WebsterStratton C, 1997, J CONSULT CLIN PSYCH, V65, P93, DOI 10.1037/0022-006X.65.1.93; Weitzman M, 2002, NEUROTOXICOL TERATOL, V24, P397, DOI 10.1016/S0892-0362(02)00201-5; WERBACH M, 1992, J ORTHOMOL MED, V7, P45; WERBACH M, 1995, J ORTHOMOLECULAR MED, V7, P45; WIDOM CS, 1989, PSYCHOL BULL, V106, P3, DOI 10.1037/0033-2909.106.1.3; *WISC COUNC FAM CH, 2000, ASS INT CHILD LEAD P, pCH8; WRIGHT JP, 2009, PLOS MED, V5, P101	142	61	61	1	89	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-1789	1873-6335		AGGRESS VIOLENT BEH	Aggress. Violent Behav.	JAN-FEB	2011	16	1					63	73		10.1016/j.avb.2010.12.003			11	Criminology & Penology; Psychology, Multidisciplinary	Criminology & Penology; Psychology	739NY	WOS:000288726100007	21399727	Green Accepted			2021-06-18	
J	Wells, TS; Miller, SC; Adler, AB; Engel, CC; Smith, TC; Fairbank, JA				Wells, Timothy S.; Miller, Shannon C.; Adler, Amy B.; Engel, Charles C.; Smith, Tyler C.; Fairbank, John A.			Mental health impact of the Iraq and Afghanistan conflicts: A review of US research, service provision, and programmatic responses	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; NATIONAL-GUARD SOLDIERS; D-CYCLOSERINE; WAR VETERANS; PRIMARY-CARE; LONGITUDINAL ASSESSMENT; MILITARY PERSONNEL; GENDER-DIFFERENCES; EXPOSURE THERAPY	Although documentation that war inflicts psychological casualties dates back to the American Civil War and earlier, most research began after the Vietnam conflict, when studies focused on post-traumatic stress disorder (PTSD). With ongoing conflicts in Iraq and Afghanistan, there has been significant research to illuminate the epidemiology of war-related psychological casualties. Significant findings include an appreciation for the role combat plays in the development of mental disorders, including PTSD and traumatic brain injury (TBI). Recent research has endeavoured to understand and improve psychological resilience to temper potentially adverse mental health effects of military service in the theatre of combat operations. Over 2 million US service members have now deployed and returned over 3 million times to the Iraq and Afghanistan conflicts. Mental health providers in the Departments of Defense and Veterans Affairs healthcare systems have consequently observed steep increases in mental health service use among these personnel. The Departments have responded aggressively to bolster staffing levels, increase capacity, improve available services, and anticipate future needs. Scientists and clinicians continue efforts to understand the determinants, prevention, recognition, and treatment of combat-related mental disorders.	[Wells, Timothy S.; Smith, Tyler C.] USN, Ctr Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92106 USA; [Miller, Shannon C.] USAF, Vulnerabil Anal Branch, Res Lab, Wright Patterson AFB, OH 45433 USA; [Miller, Shannon C.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; [Miller, Shannon C.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Ctr Treatment Res & Educ Addict Disorders, Cincinnati, OH USA; [Adler, Amy B.] USA, Med Res Unit Europe, Walter Reed Army Inst Res, Heidelberg, Germany; [Engel, Charles C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD USA; [Engel, Charles C.] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Deployment Hlth Clin Ctr, Washington, DC 20307 USA; [Fairbank, John A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Fairbank, John A.] Mid Atlantic VISN 6 Mental Illness Res Educ & Cli, Durham, NC USA	Wells, TS (corresponding author), USN, Ctr Deployment Hlth Res, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	timothy.wells@med.navy.mil	Fairbank, John/F-8972-2013	Fairbank, John/0000-0003-2604-7256			ADLER AB, 2007, BATTL TRAIN SYST SUP; Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; *ASS SECR DEF HLTH, 2010, MENT HLTH ASS MEMB A; BILMES LJ, 2010, TRUE COST WAR; Bliese PD, 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; BLIESE PD, 2006, MILITARY LIFE PSYCHO, V2, P213; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804; Bowles SV, 2010, MIL MED, V175, P382, DOI 10.7205/MILMED-D-10-00099; Britt TW, 2004, MIL MED, V169, P541, DOI 10.7205/MILMED.169.7.541; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Casey GW, 2011, AM PSYCHOL, V66, P1, DOI 10.1037/a0021930; Castro, 2011, DEPLOYMENT PSYCHOL E, P103, DOI 10.1037/12300-004; Chwastiak LA, 2010, PSYCHOSOM MED, V72, P817, DOI 10.1097/PSY.0b013e3181eb33e9; Cornum R, 2011, AM PSYCHOL, V66, P4, DOI 10.1037/a0021420; COZZA SJ, 2005, PTSD RES Q, V16, P1; *DEP VET AFF, 2010, MENT HLTH EFF SERV A; Dickstein BD, 2010, MIL MED, V175, P482, DOI 10.7205/MILMED-D-09-00178; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Engel CC, 2005, GEN HOSP PSYCHIAT, V27, P158, DOI 10.1016/j.genhosppsych.2005.01.001; ENGEL CC, 2009, S 6 TEL MENT HLTH RE; Engel CC, 2008, MIL MED, V173, P935, DOI 10.7205/MILMED.173.10.935; Felker B, 2008, MIL MED, V173, P155, DOI 10.7205/MILMED.173.2.155; French LM, 2009, J HEAD TRAUMA REHAB, V24, P1, DOI 10.1097/HTR.0b013e318197a14c; Gillham JE, 2007, J CONSULT CLIN PSYCH, V75, P9, DOI 10.1037/0022-006x.75.1.9; GIWERTZ AH, 2010, J CONSULT CLIN PSYCH, V78, P599; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guastella AJ, 2008, BIOL PSYCHIAT, V63, P544, DOI 10.1016/j.biopsych.2007.11.011; Haskell SG, 2010, J WOMENS HEALTH, V19, P267, DOI 10.1089/jwh.2008.1262; Hofmann SG, 2006, ARCH GEN PSYCHIAT, V63, P298, DOI 10.1001/archpsyc.63.3.298; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, INT J EPIDEMIOL, V36, P327, DOI 10.1093/ije/dym013; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, LANCET, V368, P837, DOI 10.1016/S0140-6736(06)69315-X; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; INSEL TR, 2010, RES ACTIVITIES NATL; *IOM, 2010, RET HOM IR AFGH PREL, P94; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jacobson IG, 2009, AM J EPIDEMIOL, V169, P415, DOI 10.1093/aje/kwn366; Kang H. K., 2008, ANAL VA HLTH CARE UT; Kang HK, 2009, J OCCUP ENVIRON MED, V51, P401, DOI 10.1097/JOM.0b013e3181a2feeb; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Kline A, 2010, AM J PUBLIC HEALTH, V100, P276, DOI 10.2105/AJPH.2009.162925; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; LeardMann CA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-437; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; LEEDHAM CS, 1993, MIL MED, V158, P508; Lester PB, 2011, AM PSYCHOL, V66, P77, DOI 10.1037/a0022083; Litz BT, 2007, AM J PSYCHIAT, V164, P1676, DOI 10.1176/appi.ajp.2007.06122057; Magruder KM, 2005, GEN HOSP PSYCHIAT, V27, P169, DOI 10.1016/j.genhosppsych.2004.11.001; MAGUEN S, 2006, MILITARY LIFE PSYCHO, V2, P141; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Maguen S, 2010, J TRAUMA STRESS, V23, P86, DOI 10.1002/jts.20434; MANSFIELD AJ, 2010, ANN M SOC EP RES SEA; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; McHugh RK, 2010, AM PSYCHOL, V65, P73, DOI 10.1037/a0018121; *MHAT 2, 2005, OP IR FREED OIF 2 ME; *MHAT 5, 2008, MENT HLTH ADV TEAM M; Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; MUNSEY C, 2009, MONITOR PSYCHOL, V40, P13; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ouimette P., 2010, MEASURING PTSD COURS, V16, P19, DOI DOI 10.1177/1534765610368570; Phillips CJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-52; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; Rundell JR, 2006, GEN HOSP PSYCHIAT, V28, P352, DOI 10.1016/j.genhosppsych.2006.04.006; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; SCHWAB KA, 2003, ENCY NEUROLOGICAL SC, P438; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI 10.1097/EDE.0b013e31816a9dff; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Stiglitz J.E., 2008, 3 TRILLION DOLLAR WA; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; THOMAS JL, 2007, 2007 AM PSYCH ASS AN; Unutzer J, 2002, PSYCHIATR SERV, V53, P671, DOI 10.1176/appi.ps.53.6.671; *USA, 2008, REP SURG GEN TRAUM B; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P603, DOI 10.1001/archpsyc.62.6.603; Warner CH, 2011, DEPLOYMENT PSYCHOL E, P35, DOI DOI 10.1037/12300-002; WEATHERS R, 2009, EFFECTIVE TREATMENTS, P23; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432; Wojcik BE, 2009, MIL MED, V174, P1010, DOI 10.7205/MILMED-D-01-6108; Zeiss AM, 2008, J CLIN PSYCHOL MED S, V15, P73, DOI 10.1007/s10880-008-9100-4; 2010, MED SURVEILLANCE MON, V17, P18	91	61	62	1	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0954-0261	1369-1627		INT REV PSYCHIATR	Int. Rev. Psych.		2011	23	2					144	152		10.3109/09540261.2011.558833			9	Psychiatry	Psychiatry	755PO	WOS:000289946800004	21521083				2021-06-18	
J	Lustenberger, T; Talving, P; Kobayashi, L; Barmparas, G; Inaba, K; Lam, L; Branco, BC; Demetriades, D				Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Barmparas, Galinos; Inaba, Kenji; Lam, Lydia; Branco, Bernardino Castelo; Demetriades, Demetrios			Early Coagulopathy After Isolated Severe Traumatic Brain Injury: Relationship With Hypoperfusion Challenged	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Severe head injury; Traumatic brain injury; Early coagulopathy; Hypoperfusion; Base deficit; Lactate; Mortality	PROTEIN-C PATHWAY; HEAD-INJURY; COAGULATION DISORDERS; BASE DEFICIT	Introduction: The purpose of this study was to examine the incidence of tissue hypoperfusion in victims of severe traumatic brain injury (sTBI) and to determine the associations between hypoperfusion and TBI coagulopathy. Methods: This is a retrospective analysis of a prospectively collected cohort admitted to the surgical intensive care unit from June 2005 to December 2007 sustaining isolated sTBI, defined as sTBI [head Abbreviated Injury Scale (AIS) >= 3] with chest, abdomen, and extremity AIS <3. Criteria for TBI-associated early coagulopathy included isolated sTBI in conjunction with thrombocytopenia (platelet count <100,000 per mm(3)) or elevated international normalized ratio >1.2 or prolonged activated partial thromboplastin time >36 seconds at admission. Hypoperfusion was defined by the presence of an arterial base deficit (BD) >6 mmol/L. Univariate and multivariate analysis was performed to identify associations among hypoperfusion, coagulopathy, and mortality. Results: A total of 132 patients met the study criteria. TBI-associated early coagulopathy occurred in 48 patients (36.4%). With increasing head injury severity, the incidence of coagulopathy increased in a stepwise fashion. Mean BD values and mean lactate values were significantly higher among patients with coagulopathy compared with their noncoagulopathic counterparts at hospital admission. The coagulopathic cohort presented more frequently with a BD >6 mmol/L at admission (39.6% vs. 20.2%, p = 0.016). In the stepwise logistic regression analysis, head AIS = 5 and an admission BD >6 mmol/L were independently associated with early coagulopathy. Coagulopathy was associated with increased mortality in patients after blunt head trauma, adjusted odds ratio (95% confidence interval): 3.79 (1.06-13.51); adjusted p = 0.04. Conclusion: Hypoperfusion is an independent risk factor for the development of early coagulopathy in patients with isolated sTBI. Nevertheless, early coagulopathy after sTBI does not occur exclusively in patients experiencing tissue hypoperfusion.	[Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Barmparas, Galinos; Inaba, Kenji; Lam, Lydia; Branco, Bernardino Castelo; Demetriades, Demetrios] Los Angeles Cty Univ So Calif Med Ctr, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA USA	Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles Cty Gen Hosp LAC USC,FACS, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St,C4E100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Barmparas, Galinos/L-6530-2019; Talving, Peep/G-8621-2015; INABA, KENJI/AAC-8532-2020; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Martin MJ, 2006, AM J SURG, V191, P625, DOI 10.1016/j.amjsurg.2006.02.014; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Schrieber M, 2007, J TRAUMA, V63, P1261; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	15	61	63	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2010	69	6					1410	1414		10.1097/TA.0b013e3181cdae81			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	695RT	WOS:000285391000028	20404754				2021-06-18	
J	Nishibe, M; Barbay, S; Guggenmos, D; Nudo, RJ				Nishibe, Mariko; Barbay, Scott; Guggenmos, David; Nudo, Randolph J.			Reorganization of Motor Cortex after Controlled Cortical Impact in Rats and Implications for Functional Recovery	JOURNAL OF NEUROTRAUMA			English	Article						behavioral recovery; cortical plasticity; intracortical microstimulation; motor impairment; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ADULT SQUIRREL-MONKEYS; SENSORIMOTOR CORTEX; ISCHEMIC LESIONS; MOVEMENT REPRESENTATIONS; FORELIMB REPRESENTATION; STRUCTURAL PLASTICITY; STROKE; AREAS; PREMOTOR	We report the results of controlled cortical impact (CCI) centered on the caudal forelimb area (CFA) of rat motor cortex to determine the feasibility of examining cortical plasticity in a spared cortical motor area (rostral forelimb area, RFA). We compared the effects of three CCI parameter sets (groups CCI-1, CCI-2, and CCI-3) that differed in impactor surface shape, size, and location, on behavioral recovery and RFA structural and functional integrity. Forelimb deficits in the limb contralateral to the injury were evident in all three CCI groups assessed by skilled reach and footfault tasks that persisted throughout the 35-day post-CCI assessment period. Nissl-stained coronal sections revealed that the RFA was structurally intact. Intracortical microstimulation experiments conducted at 7 weeks post-CCI demonstrated that RFA was functionally viable. However, the size of the forelimb representation decreased significantly in CCI-1 compared to the control group. Subdivided into component movement categories, there was a significant group effect for proximal forelimb movements. The RFA area reduction and reorganization are discussed in relation to possible diaschisis, and to compensatory functional behavior, respectively. Also, an inverse correlation between the anterior extent of the lesion and the size of the RFA was identified and is discussed in relation to corticocortical connectivity. The results suggest that CCI can be applied to rat CFA while sparing RFA. This CCI model can contribute to our understanding of neural plasticity in premotor cortex as a substrate for functional motor recovery.	[Nishibe, Mariko; Barbay, Scott; Guggenmos, David; Nudo, Randolph J.] Univ Kansas, Med Ctr, Landon Ctr Aging, Kansas City, KS 66103 USA; [Barbay, Scott; Guggenmos, David; Nudo, Randolph J.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA; [Nishibe, Mariko] Univ Kansas, Med Ctr, Dept Phys Therapy & Rehabil Sci, Kansas City, KS 66103 USA	Nudo, RJ (corresponding author), Univ Kansas, Med Ctr, Landon Ctr Aging, 3599 W 36th Ave,MS1005, Kansas City, KS 66103 USA.	rnudo@kumc.edu	Nishibe, Mariko/AAP-2226-2020		Department of DefenseUnited States Department of Defense [W81XWH-08-1-0168]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030853]; University of Kansas; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS030853, R01NS030853] Funding Source: NIH RePORTER	We thank Dr. Yong-yue He for performing the CCI surgical procedures, and Dr. Pei-chun Beard for her technical assistance in histology. The work was supported by Department of Defense-Army Research Grant W81XWH-08-1-0168 (to R.J.N.), National Institutes of Health Grant NS030853 (to R.J.N.), and the University of Kansas Summer Research Fellowship (to M.N.).	Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Alaverdashvili M, 2008, BEHAV BRAIN RES, V188, P281, DOI 10.1016/j.bbr.2007.11.007; Alaverdashvili M, 2007, EUR J NEUROSCI, V25, P3442, DOI 10.1111/j.1460-9568.2007.05594.x; Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Boyeson MG, 1991, J NEUROTRAUM, V8, P205, DOI 10.1089/neu.1991.8.205; Bury SD, 2002, J NEUROSCI, V22, P8597; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chu CJ, 2000, EXP NEUROL, V166, P403, DOI 10.1006/exnr.2000.7509; Cirstea MC, 2000, BRAIN, V123, P940, DOI 10.1093/brain/123.5.940; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dancause N, 2006, J NEUROPHYSIOL, V96, P3506, DOI 10.1152/jn.00792.2006; Dancause N, 2006, CEREB CORTEX, V16, P1057; Dancause N, 2006, NEUROSCIENTIST, V12, P489, DOI 10.1177/1073858406292782; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eisner-Janowicz I, 2008, J NEUROPHYSIOL, V100, P1498, DOI 10.1152/jn.90447.2008; Fang PC, 2005, J COMP NEUROL, V490, P305, DOI 10.1002/cne.20665; Fang PC, 2010, STROKE, V41, P544, DOI 10.1161/STROKEAHA.109.572073; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Finger S, 2009, HDB CLIN NEUROL, V95, P833; FINGER S, 1982, BRAIN DAMAGE RECOVER; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gilmour G, 2005, BEHAV BRAIN RES, V165, P98, DOI 10.1016/j.bbr.2005.06.027; GLEES P, 1949, J PHYSIOL-LONDON, V108, pP33; GOLDSTEIN LB, 1993, J NEUROSCI METH, V48, P35, DOI 10.1016/S0165-0270(05)80005-6; Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KELLER A, 1993, CEREB CORTEX, V3, P430, DOI 10.1093/cercor/3.5.430; Kleim JA, 2003, NEURON, V40, P167, DOI 10.1016/S0896-6273(03)00592-0; Kleim JA, 2002, NEUROBIOL LEARN MEM, V77, P63, DOI 10.1006/nlme.2000.4004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Liu Y, 1999, EXP BRAIN RES, V128, P149, DOI 10.1007/s002210050830; Maldonado MA, 2008, NEUROREHAB NEURAL RE, V22, P250, DOI 10.1177/1545968307308551; MAO H, 2010, BIOMECH MODEL MECHAN; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Nowak DA, 2009, NEUROREHAB NEURAL RE, V23, P641, DOI 10.1177/1545968309336661; NUDO RJ, 1990, SOMATOSENS MOT RES, V7, P463, DOI 10.3109/08990229009144720; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Nudo RJ, 2006, EVOLUTION NERVOUS SY, P373; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Reinecke S, 2003, EUR J NEUROSCI, V17, P623, DOI 10.1046/j.1460-9568.2003.02459.x; Rema V, 2003, J NEUROSCI, V23, P10378; ROUILLER EM, 1993, SOMATOSENS MOT RES, V10, P269, DOI 10.3109/08990229309028837; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SLAVIN MD, 1988, BRAIN INJURY RECOVER, P165; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stepniewska I, 2006, J COMP NEUROL, V495, P691, DOI 10.1002/cne.20906; Tennant KA, 2009, J NEUROSCI METH, V181, P18, DOI 10.1016/j.jneumeth.2009.04.009; von Monakow C., 1914, LOKALISATION GROSSHI; Voorhies AC, 2002, BEHAV BRAIN RES, V133, P237, DOI 10.1016/S0166-4328(02)00029-3; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1991, BEHAV BRAIN RES, V42, P77, DOI 10.1016/S0166-4328(05)80042-7; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	72	61	62	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2221	2232		10.1089/neu.2010.1456			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400011	20873958	Green Published			2021-06-18	
J	Wakade, C; Sukumari-Ramesh, S; Laird, MD; Dhandapani, KM; Vender, JR				Wakade, Chandramohan; Sukumari-Ramesh, Sangeetha; Laird, Melissa D.; Dhandapani, Krishnan M.; Vender, John R.			Delayed reduction in hippocampal postsynaptic density protein-95 expression temporally correlates with cognitive dysfunction following controlled cortical impact in mice	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; glutamate; synaptic plasticity; hippocampus	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; MEMORY; ACTIVATION; HEMORRHAGE; CONTUSION; PATHOLOGY; MODERATE; NEURONS; ADULTS	Object. Traumatic brain injury (TBI) induces significant neurological damage, including deficits in learning and memory, which contribute to a poor clinical prognosis. Treatment options to limit cognitive decline and promote neurological recovery are lacking, in part due to a poor understanding of the secondary or delayed processes that contribute to brain injury. In the present study, the authors characterized the temporal and spatial changes in the expression of postsynaptic density protein-95 (PSD-95), a key scaffolding protein implicated in excitatory synaptic signaling, after controlled cortical impacts in mice. Neurological injury, as assessed by the open-field activity test and the novel object recognition test, was compared with changes in PSD-95 expression. Methods. Adult male CD-1 mice were subjected to controlled cortical impacts to simulate moderate TBI in humans. The spatial and temporal expression of PSD-95 was analyzed in the cerebral cortex and hippocampus at various time points following injury and sham operations. Neurological assessments were performed to compare changes in PSD-95 with cognitive deficits. Results. A significant decrease in PSD-95 expression was observed in the ipsilateral hippocampus beginning on Day 7 postinjury. The loss of PSD-95 corresponded with a concomitant reduction in immunoreactivity for NeuN (neuronal nuclei), a neuron-specific marker. Aside from the contused cortex, a significant loss of PSD-95 immunore-activity was not observed in the cerebral cortex. The delayed loss of hippocampal PSD-95 directly correlated with the onset of behavioral deficits, suggesting a possible causative role for PSD-95 in behavioral abnormalities following head trauma. Conclusions. A delayed loss of hippocampal synapses was observed following head trauma in mice. These data may suggest a cellular mechanism to explain the delayed learning and memory deficits in humans after TBI and provide a potential framework for further testing to implicate PSD-95 as a clinically relevant therapeutic target. (DOI: 10.3171/2010.3.JNS091212)	[Wakade, Chandramohan; Sukumari-Ramesh, Sangeetha; Laird, Melissa D.; Dhandapani, Krishnan M.; Vender, John R.] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA	Vender, JR (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.	jvender@mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; American Heart AssociationAmerican Heart Association [BGIA2300135, PRE2250690]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	This work was supported in part by Grant No. NS065172 from the National Institutes of Health (NS065172) and Grant No. BGIA2300135 from the American Heart Association (K.M.D.) and by Fellowship No. PRE2250690 from the American Heart Association (M.D.L.).	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Cheng DM, 2006, MOL CELL PROTEOMICS, V5, P1158, DOI 10.1074/mcp.D500009-MCP200; Christoforidis GA, 2007, STROKE, V38, P1799, DOI 10.1161/STROKEAHA.106.472282; Dhandapani KM, 2003, J BIOL CHEM, V278, P43329, DOI 10.1074/jbc.M305835200; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; Elias GM, 2006, NEURON, V52, P307, DOI 10.1016/j.neuron.2006.09.012; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fukaya M, 2000, J COMP NEUROL, V426, P572; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kingston PA, 1999, SYNAPSE, V32, P1, DOI 10.1002/(SICI)1098-2396(199904)32:1<1::AID-SYN1>3.0.CO;2-M; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Laird MD, 2010, J NEUROCHEM; Lin Y, 2004, J NEUROSCI, V24, P10138, DOI 10.1523/JNEUROSCI.3159-04.2004; Lin Y, 2006, P NATL ACAD SCI USA, V103, P19902, DOI 10.1073/pnas.0609924104; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sangeetha SR, 2009, ENDOCRINE, V35, P389, DOI 10.1007/s12020-009-9159-1; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410	41	61	62	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2010	113	6					1195	1201		10.3171/2010.3.JNS091212			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	684QX	WOS:000284565500011	20397893	Green Accepted			2021-06-18	
J	Gioia, GA; Kenworthy, L; Isquith, PK				Gioia, Gerard A.; Kenworthy, Lauren; Isquith, Peter K.			Executive Function in the Real World: BRIEF Lessons From Mark Ylvisaker	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; executive function; traumatic brain injury; TBI; Ylvisaker	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; NEUROPSYCHOLOGICAL ASSESSMENT; ECOLOGICAL VALIDITY; EARLY-CHILDHOOD; YOUNG-CHILDREN; TBI; PERFORMANCE; ADOLESCENTS; IMPAIRMENT	It is well established that brain injuries adversely affect the executive functions and their development. Mark Ylvisaker had a substantial impact on how we assess and treat children and adolescents with disrupted executive functions secondary to traumatic brain injury. He articulated core principles for effective assessment and intervention that emphasized the importance of real-world meaning and application. He taught us that assessment that captures a child's everyday functioning in the context of real-world demands is often more informative than traditional neuropsychological measures alone and that interventions that improve functioning in the real-world environment are most useful. His pragmatic model influenced our own efforts to measure executive function and to develop intervention systems for children with executive function deficits. This article reviews the development of the Behavior Rating Inventory for Executive Function as an approach to ecological assessment of children and adolescents with traumatic brain injury. As we take what we learned from Mark Ylvisaker, it becomes increasingly apparent that our assessment and intervention methods, especially as related to the executive functions, demand an everyday, real-world context.	[Gioia, Gerard A.; Kenworthy, Lauren] Childrens Natl Med Ctr, Div Pediat Neuropsychol, Rockville, MD 20850 USA; [Gioia, Gerard A.; Kenworthy, Lauren] George Washington Univ, Sch Med, Washington, DC USA; [Isquith, Peter K.] Dartmouth Med Sch, Lebanon, NH USA	Gioia, GA (corresponding author), Childrens Natl Med Ctr, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Ste 350, Rockville, MD 20850 USA.	ggioia@cnmc.org	Kenworthy, Lauren/AAI-7572-2020; Isquith, Peter/AAY-4851-2020		Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352]; National Center for Research Resources, a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359]; Gudelsky Family Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30/HDO40677-07]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	This publication was made possible in part by Centers for Disease Control and Prevention award U17/CCU323352 and grant M01RR020359 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and the Gudelsky Family Foundation. Other grant support included NIH P30/HDO40677-07.	Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Antshel KM, 2005, PSYCHIAT RES-NEUROIM, V138, P235, DOI 10.1016/j.pscychresns.2005.02.003; Antshel KM, 2003, NEUROPSYCHOLOGY, V17, P458, DOI 10.1037/0894-4105.17.3.458; Barkley RA, 2010, ARCH CLIN NEUROPSYCH, V25, P157, DOI 10.1093/arclin/acq014; Beebe DW, 2004, J INT NEUROPSYCH SOC, V10, P962, DOI 10.1017/S135561770410708X; Bernstein J, 2007, EXECUTIVE FUNCTION E, P39; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Dise-Lewis JE, 2009, J HEAD TRAUMA REHAB, V24, P166, DOI 10.1097/HTR.0b013e3181a7ecb0; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Feeney T, 2006, BRAIN INJURY, V20, P629, DOI 10.1080/02699050600744194; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Roth R.M., 2005, BEHAV RATING INVENTO; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	43	61	62	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					433	439		10.1097/HTR.0b013e3181fbc272			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300005	21076244				2021-06-18	
